The	O
isolation	O
of	O
fMHV	O
allowed	O
the	O
localization	O
of	O
the	O
region	O
responsible	O
for	O
S	O
protein	B-CHED
incorporation	O
into	O
virions	O
to	O
the	O
carboxy	B-CHED
-	O
terminal	O
64	O
of	O
the	O
1	O
,	O
324	O
residues	O
of	O
this	O
protein	B-CHED
.	O

Our	O
modified	O
saline	O
solution	O
lavage	O
induced	O
atelectasis	O
and	O
hemorrhage	O
confined	O
to	O
the	O
dependent	O
lung	O
with	O
severe	O
hypoxia	O
(	O
PaO	B-CHED
(	O
2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
=	O
37	O
+/-	O

Together	O
these	O
data	O
demonstrate	O
a	O
high	O
-	O
affinity	O
,	O
specific	O
interaction	O
between	O
the	O
N	O
protein	B-CHED
and	O
a	O
conserved	O
RNA	O
sequence	O
present	O
at	O
the	O
5	O
'-	O
ends	O
of	O
MHV	O
mRNA	B-CHED
.	O

In	O
contrast	O
to	O
the	O
parental	O
virus	O
,	O
the	O
mutants	O
were	O
unable	O
to	O
bind	O
to	O
porcine	O
submandibulary	O
mucin	O
,	O
a	O
substrate	O
rich	O
in	O
sialic	B-CHED
acid	I-CHED
.	O

Each	O
of	O
the	O
mutants	O
was	O
found	O
to	O
contain	O
a	O
single	O
point	O
mutation	O
in	O
the	O
S	O
protein	B-CHED
(	O
Cys155Phe	O
,	O
Met195Val	O
,	O
Arg196Ser	O
,	O
Asp208Asn	O
or	O
Leu209Pro	O
),	O
indicating	O
that	O
these	O
amino	B-CHED
acids	I-CHED
are	O
affecting	O
the	O
sialic	B-CHED
acid	I-CHED
binding	O
site	O
.	O

The	O
parental	O
virus	O
was	O
found	O
to	O
have	O
an	O
increased	O
resistance	O
to	O
the	O
detergent	B-CHED
octylglucoside	O
compared	O
to	O
the	O
HAD	O
mutants	O
.	O

We	O
believe	O
that	O
the	O
efficacy	O
and	O
safety	O
of	O
chelation	O
therapy	O
in	O
severe	O
acute	O
iron	O
poisoning	O
may	O
be	O
improved	O
by	O
targeting	O
the	O
initial	O
high	O
levels	O
of	O
readily	O
chelatable	O
serum	O
iron	O
with	O
adequate	O
doses	O
of	O
desferrioxamine	B-CHED
without	O
prolonging	O
its	O
use	O
unnecessarily	O
.	O

CONCLUSIONS	O
:	O
We	O
believe	O
that	O
the	O
efficacy	O
and	O
safety	O
of	O
chelation	O
therapy	O
in	O
severe	O
acute	O
iron	O
poisoning	O
may	O
be	O
improved	O
by	O
targeting	O
the	O
initial	O
high	O
levels	O
of	O
readily	O
chelatable	O
serum	O
iron	O
with	O
adequate	O
doses	O
of	O
desferrioxamine	B-CHED
without	O
prolonging	O
its	O
use	O
unnecessarily	O
.	O

This	O
anti	O
-	O
body	O
-	O
dependent	O
enhancement	O
(	O
ADE	B-CHED
)	O
of	O
FIPV	O
infection	O
is	O
dependent	O
on	O
mouse	O
MAb	O
subclass	O
,	O
and	O
MAb	O
of	O
IgG2a	O
subclass	O
has	O
a	O
strong	O
ADE	B-CHED
activity	O
.	O

This	O
reaction	O
disappeared	O
after	O
treatment	O
of	O
FK50	O
-	O
4	O
with	O
protein	B-CHED
A	O
.	O
The	O
neutralizing	O
activity	O
of	O
FK50	O
-	O
4	O
was	O
also	O
effective	O
on	O
feline	O
macrophages	O
after	O
the	O
cells	O
were	O
inoculated	O
with	O
FIPV	O
.	O

Since	O
little	O
is	O
known	O
about	O
this	O
generally	O
low	O
-	O
abundance	O
virion	O
component	O
,	O
we	O
have	O
characterized	O
the	O
E	O
protein	B-CHED
of	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
(	O
MHV	O
-	O
A59	O
),	O
an	O
83	O
-	O
residue	O
polypeptide	B-CHED
.	O

Immunofluorescence	O
analysis	O
of	O
cells	O
expressing	O
the	O
E	O
protein	B-CHED
demonstrated	O
that	O
the	O
hydrophilic	O
tail	O
is	O
exposed	O
on	O
the	O
cytoplasmic	O
side	O
.	O

Protein	B-CHED
carbonyl	B-CHED
concentrations	O
were	O
initially	O
highly	O
elevated	O
compared	O
with	O
those	O
in	O
healthy	O
adults	O
in	O
the	O
plasma	O
of	O
both	O
patient	O
groups	O
.	O

Protein	B-CHED
carbonyl	B-CHED
concentrations	O
were	O
also	O
high	O
initially	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
and	O
fell	O
significantly	O
with	O
time	O
.	O

Our	O
results	O
provide	O
evidence	O
of	O
oxidation	O
occurring	O
early	O
in	O
severe	O
sepsis	O
and	O
major	O
trauma	O
patients	O
,	O
with	O
protein	B-CHED
carbonyl	B-CHED
measurements	O
providing	O
a	O
sensitive	O
index	O
of	O
this	O
process	O
.	O

TITLE	O
:	O
[	O
Nitric	B-CHED
oxide	I-CHED
inhalation	O
therapy	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
Cocaine	B-CHED
has	O
been	O
demonstrated	O
to	O
have	O
a	O
number	O
of	O
different	O
effects	O
on	O
immune	O
cell	O
functions	O
.	O

Here	O
,	O
we	O
present	O
evidence	O
that	O
cocaine	B-CHED
stimulates	O
the	O
secretion	O
of	O
an	O
antiviral	B-CHED
product	O
that	O
is	O
neutralized	O
by	O
anti	O
-	O
interferon	O
(	O
anti	O
-	O
IFN	O
).	O

These	O
findings	O
further	O
support	O
our	O
previous	O
research	O
demonstrating	O
an	O
antiviral	B-CHED
activity	O
of	O
cocaine	B-CHED
in	O
vitro	O
.	O

Two	O
clones	O
,	O
8B4	O
(	O
immunoglobulin	O
G2a	O
[	O
IgG2a	O
])	O
and	O
2B11	O
(	O
IgG1	O
),	O
were	O
found	O
suitable	O
for	O
use	O
in	O
an	O
antigen	B-CHED
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
detecting	O
BRV	O
in	O
bovine	O
fecal	O
samples	O
.	O

Antigens	B-CHED
from	O
all	O
three	O
transgenic	O
plant	O
lines	O
induced	O
TGEV	O
-	O
specific	O
immune	O
responses	O
in	O
pigs	O
as	O
determined	O
by	O
virus	O
neutralization	O
and	O
ELISA	O
,	O
and	O
the	O
resultant	O
antibody	O
titers	O
for	O
all	O
three	O
constructs	O
were	O
similar	O
.	O

However	O
,	O
in	O
perinuclear	O
regions	O
the	O
gene	O
1	O
proteins	B-CHED
and	O
nucleocapsid	O
were	O
intercalated	O
with	O
sites	O
of	O
M	O
protein	B-CHED
localization	O
.	O

450	O
pM	O
/	O
mg	O
of	O
protein	B-CHED
)	O
and	O
,	O
conversely	O
,	O
more	O
of	O
the	O
antioxidant	B-CHED
alpha	B-CHED
-	I-CHED
tocopherol	I-CHED
(	O
136	O
+/-	O
22	O
versus	O
40	O
+/-	O

The	O
kinetics	O
of	O
viral	O
load	O
observed	O
in	O
the	O
lungs	O
and	O
kidneys	O
correlated	O
with	O
the	O
level	O
of	O
IBV	O
-	O
specific	O
CTL	O
activity	O
of	O
effector	B-CHED
cells	O
prepared	O
from	O
spleens	O
of	O
infected	O
chicks	O
.	O

ORF	O
3b	O
begins	O
at	O
base	O
432	O
on	O
mRNA	B-CHED
3	O
in	O
Purdue	O
strain	O
.	O

TITLE	O
:	O
Coronavirus	O
-	O
induced	O
membrane	O
fusion	O
requires	O
the	O
cysteine	B-CHED
-	O
rich	O
domain	O
in	O
the	O
spike	O
protein	B-CHED
.	O

However	O
,	O
addition	O
of	O
the	O
cys	B-CHED
domain	O
to	O
fusion	O
-	O
defective	O
chimeric	O
proteins	B-CHED
was	O
unable	O
to	O
restore	O
fusion	O
activity	O
.	O

Thus	O
,	O
the	O
cys	B-CHED
domain	O
is	O
necessary	O
but	O
is	O
not	O
sufficient	O
to	O
complement	O
the	O
gD	O
-	O
1	O
anchor	O
and	O
allow	O
for	O
membrane	O
fusion	O
.	O

The	O
predicted	O
O	O
-	O
glycosylation	O
site	O
consisting	O
of	O
four	O
amino	B-CHED
acid	I-CHED
residues	O
of	O
Ser	B-CHED
-	O
Ser	B-CHED
-	O
Thr	B-CHED
-	O
Thr	B-CHED
is	O
located	O
immediately	O
adjacent	O
to	O
the	O
initiator	O
Met	B-CHED
and	O
is	O
well	O
conserved	O
among	O
MHV	O
strains	O
investigated	O
so	O
far	O
.	O

TITLE	O
:	O
[	O
Two	O
cases	O
of	O
acute	O
myelogenous	O
leukemia	O
complicated	O
with	O
fatal	O
gastrointestinal	O
tract	O
bleeding	O
after	O
treatment	O
with	O
idarubicin	B-CHED
and	O
cytarabine	B-CHED
].	O

ABSTRACT	O
:	O
We	O
describe	O
herein	O
two	O
newly	O
diagnosed	O
patients	O
with	O
acute	O
myelogenous	O
leukemia	O
(	O
AML	O
),	O
who	O
were	O
treated	O
twice	O
with	O
an	O
idarubicin	B-CHED
hydrochloride	B-CHED
(	O
IDR	O
)-	O
containing	O
regimen	O
as	O
a	O
response	O
-	O
orientated	O
induction	O
therapy	O
.	O

ABSTRACT	O
:	O
To	O
group	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
isolates	O
,	O
a	O
genetic	O
grouping	O
method	O
based	O
on	O
hypervariable	O
region	O
1	O
(	O
HVR	O
1	O
,	O
nucleotides	B-CHED
168	O
to	O
197	O
)	O
was	O
compared	O
with	O
that	O
based	O
on	O
the	O
whole	O
S1	O
gene	O
.	O

The	O
change	O
in	O
cardiac	O
index	O
from	O
0	O
to	O
30	O
cm	O
H2O	B-CHED
Paw	O
correlated	O
with	O
baseline	O
values	O
for	O
RAP	O
,	O
PAOP	O
,	O
and	O
right	O
ventricular	O
EDVI	O
(	O
r2	O
=	O
.	O
68	O
,	O
.	O
43	O
,	O
and	O
.	O
34	O
,	O
respectively	O
,	O
p	O
<	O
0	O
.	O
01	O
).	O

By	O
1	O
week	O
after	O
birth	O
patients	O
who	O
had	O
early	O
neutropenia	O
were	O
more	O
likely	O
to	O
require	O
mechanical	O
ventilation	O
and	O
supplemental	O
oxygen	B-CHED
.	O

The	O
present	O
data	O
thus	O
indicate	O
that	O
in	O
immunocompetent	O
mice	O
,	O
effector	B-CHED
CD8	O
+	O
T	O
cells	O
control	O
infection	O
without	O
mediating	O
either	O
clinical	O
disease	O
or	O
demyelination	O
.	O

Rapid	O
viral	O
spread	O
,	O
attributed	O
to	O
determinants	O
within	O
the	O
spike	O
protein	B-CHED
and	O
possibly	O
perpetuated	O
by	O
suboptimal	O
CD8	O
+	O
T	O
cell	O
effector	B-CHED
function	O
,	O
thus	O
ultimately	O
leads	O
to	O
the	O
process	O
of	O
immune	O
-	O
mediated	O
demyelination	O
.	O

TITLE	O
:	O
The	O
viral	O
nucleocapsid	O
protein	B-CHED
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
is	O
cleaved	O
by	O
caspase	O
-	O
6	O
and	O
-	O
7	O
during	O
TGEV	O
-	O
induced	O
apoptosis	O
.	O

These	O
data	O
demonstrate	O
that	O
viral	O
proteins	B-CHED
can	O
be	O
targeted	O
for	O
destruction	O
by	O
the	O
host	O
cell	O
death	O
machinery	O
.	O

TITLE	O
:	O
Infectious	O
bronchitis	O
virus	O
E	O
protein	B-CHED
is	O
targeted	O
to	O
the	O
Golgi	O
complex	O
and	O
directs	O
release	O
of	O
virus	O
-	O
like	O
particles	O
.	O

The	O
short	O
luminal	B-CHED
N	O
terminus	O
of	O
IBV	O
E	O
contains	O
a	O
consensus	O
site	O
for	O
N	O
-	O
linked	O
glycosylation	O
,	O
but	O
the	O
site	O
is	O
not	O
used	O
.	O

When	O
expressed	O
using	O
recombinant	O
vaccinia	O
virus	O
,	O
the	O
IBV	O
E	O
protein	B-CHED
is	O
released	O
from	O
cells	O
at	O
low	O
levels	O
in	O
sedimentable	O
particles	O
that	O
have	O
a	O
density	O
similar	O
to	O
that	O
of	O
coronavirus	O
virions	O
.	O

Electron	O
microscopy	O
revealed	O
corona	B-CHED
-	O
like	O
virus	O
particles	O
in	O
these	O
necrotic	O
cells	O
.	O

In	O
order	O
to	O
identify	O
domains	O
in	O
the	O
N	O
protein	B-CHED
that	O
bind	O
to	O
RNA	O
,	O
the	O
whole	O
protein	B-CHED
(	O
409	O
amino	B-CHED
acids	I-CHED
)	O
and	O
six	O
overlapping	O
fragments	O
were	O
expressed	O
as	O
fusion	O
polypeptides	B-CHED
with	O
six	O
histidine	B-CHED
-	O
tags	O
.	O

Using	O
gel	O
shift	O
assays	O
,	O
the	O
intact	O
N	O
protein	B-CHED
and	O
amino	O
polypeptides	B-CHED
,	O
from	O
residues	O
1	O
to	O
171	O
and	O
residues	O
1	O
to	O
274	O
,	O
and	O
carboxyl	O
polypeptides	B-CHED
,	O
extending	O
from	O
residues	O
203	O
to	O
409	O
and	O
residues	O
268	O
to	O
407	O
,	O
were	O
found	O
to	O
interact	O
with	O
positive	O
-	O
stranded	O
IBV	O
RNA	O
representing	O
the	O
3	O
'	O
end	O
of	O
the	O
genome	O
.	O

Elastase	O
-	O
treated	O
animals	O
with	O
mediator	O
production	O
inhibited	O
(	O
CNI	O
-	O
1493	O
)	O
had	O
attenuated	O
hepatic	O
enzymes	O
,	O
MPO	O
activity	O
,	O
TNF	O
protein	B-CHED
,	O
and	O
TNF	O
mRNA	B-CHED
.	O

HFOV	O
results	O
in	O
a	O
small	O
increase	O
in	O
any	O
air	B-CHED
leak	O
syndrome	O
(	O
ALS	O
),	O
[	O
summary	O
RR	O
1	O
.	O
20	O
(	O
1	O
.	O
03	O
,	O
1	O
.	O
39	O
)].	O

Since	O
the	O
E	O
protein	B-CHED
occurs	O
in	O
particles	O
only	O
in	O
trace	O
amounts	O
,	O
the	O
lateral	O
interactions	O
between	O
the	O
M	O
proteins	B-CHED
apparently	O
generate	O
the	O
major	O
driving	O
force	O
for	O
envelope	O
formation	O
.	O

Mutant	O
M	O
proteins	B-CHED
which	O
were	O
not	O
able	O
to	O
assemble	O
into	O
viruslike	O
particles	O
(	O
VLPs	O
)	O
by	O
themselves	O
(	O
C	O
.	O
A	O
.	O
M	O
.	O
de	O
Haan	O
,	O
L	O
.	O
Kuo	O
,	O
P	O
.	O
S	O
.	O
Masters	O
,	O
H	O
.	O
Vennema	O
,	O
and	O
P	O
.	O
J	O
.	O
M	O
.	O
Rottier	O
,	O
J	O
.	O
Virol	O
.	O

We	O
found	O
that	O
M	O
proteins	B-CHED
lacking	O
parts	O
of	O
the	O
transmembrane	O
cluster	O
,	O
of	O
the	O
amphipathic	O
domain	O
,	O
or	O
of	O
the	O
hydrophilic	O
carboxy	B-CHED
-	O
terminal	O
tail	O
,	O
or	O
M	O
proteins	B-CHED
that	O
had	O
their	O
luminal	B-CHED
domain	O
replaced	O
by	O
heterologous	O
ectodomains	O
,	O
were	O
still	O
able	O
to	O
associate	O
with	O
assembly	O
-	O
competent	O
M	O
proteins	B-CHED
,	O
resulting	O
in	O
their	O
coincorporation	O
into	O
VLPs	O
.	O

The	O
coronavirus	O
genome	O
is	O
capped	O
at	O
the	O
5	O
'	O
end	O
and	O
has	O
a	O
3	O
'	O
UTR	O
that	O
consists	O
of	O
300	O
to	O
500	O
nucleotides	B-CHED
(	O
nt	O
)	O
plus	O
a	O
poly	O
(	O
A	O
)	O
tail	O
.	O

The	O
groups	O
immunized	O
with	O
the	O
CL	O
antigen	B-CHED
having	O
an	O
HA	O
titer	O
of	O
4000	O
or	O
16	O
000	O
produced	O
hemagglutination	O
inhibition	O
(	O
HI	O
)	O
antibody	O
titers	O
of	O
>	O
320	O
and	O
serum	O
neutralizing	O
(	O
SN	O
)	O
antibody	O
titers	O
of	O
>	O
1280	O
.	O

These	O
results	O
indicate	O
that	O
CL	O
antigen	B-CHED
with	O
high	O
HA	O
titer	O
induces	O
antibody	O
production	O
in	O
cattle	O
that	O
provides	O
effective	O
protection	O
against	O
winter	O
dysentery	O
.	O

During	O
infection	O
,	O
the	O
bacteria	O
produce	O
leukotoxin	O
(	O
LKT	O
)	O
and	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
),	O
both	O
potent	O
inducers	O
of	O
inflammation	O
.	O

Protection	O
correlated	O
with	O
the	O
presence	O
of	O
sufficient	O
levels	O
of	O
specific	O
antiviral	B-CHED
antibodies	O
recognizing	O
the	O
same	O
immunodominant	O
domain	O
and	O
13	O
-	O
mer	O
peptide	B-CHED
,	O
located	O
within	O
the	O
C	O
-	O
terminal	O
S2	O
subunit	O
,	O
as	O
the	O
selecting	O
mAb	O
.	O

This	O
is	O
the	O
first	O
evaluation	O
of	O
protective	O
immunization	O
induced	O
by	O
mAb	O
-	O
selected	O
phage	O
-	O
displayed	O
peptides	B-CHED
.	O

Following	O
differential	O
centrifugation	O
of	O
lysates	O
of	O
MHV	O
-	O
infected	O
DBT	B-CHED
cells	O
,	O
gene	O
1	O
proteins	B-CHED
as	O
well	O
as	O
the	O
structural	O
N	O
and	O
M	O
proteins	B-CHED
were	O
detected	O
almost	O
exclusively	O
in	O
a	O
high	O
-	O
speed	O
small	O
membrane	O
pellet	O
.	O

Upon	O
admission	O
to	O
the	O
PICU	O
,	O
patients	O
were	O
initially	O
managed	O
with	O
lung	O
protective	O
strategies	O
using	O
Pressure	O
Controlled	O
Ventilation	O
(	O
PCV	B-CHED
)	O
or	O
Pressure	O
Regulated	O
Volume	O
Control	O
(	O
PRVC	O
)	O
modes	O
with	O
limited	O
peak	O
inspiratory	O
pressure	O
,	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
and	O
permissive	O
hypercapnia	O
.	O

TITLE	O
:	O
Sleep	O
laboratory	O
studies	O
in	O
restless	O
legs	O
syndrome	O
patients	O
as	O
compared	O
with	O
normals	O
and	O
acute	O
effects	O
of	O
ropinirole	B-CHED
.	O

These	O
hemostasis	O
changes	O
lead	O
to	O
inadequate	O
oxygen	B-CHED
delivery	O
and	O
metabolic	O
requirement	O
of	O
oxygen	B-CHED
and	O
are	O
associated	O
with	O
development	O
of	O
oxygen	B-CHED
deficiency	O
in	O
tissues	O
.	O

Both	O
groups	O
with	O
pancreatitis	O
showed	O
an	O
increase	O
in	O
alveolar	O
distention	O
and	O
collapse	O
on	O
day	O
1	O
that	O
persisted	O
only	O
in	O
the	O
TAU	B-CHED
group	O
on	O
days	O
3	O
and	O
8	O
.	O

TITLE	O
:	O
Fludrocortisone	B-CHED
for	O
the	O
treatment	O
of	O
heparin	B-CHED
-	O
induced	O
hyperkalemia	O
.	O

Fludrocortisone	B-CHED
promotes	O
potassium	B-CHED
excretion	O
by	O
its	O
direct	O
actions	O
on	O
the	O
renal	O
distal	O
tubules	O
.	O

ABSTRACT	O
:	O
Disinfectants	B-CHED
for	O
medical	O
devices	O
are	O
uncommonly	O
a	O
cause	O
of	O
iatrogenic	O
adverse	O
effects	O
.	O

Sera	O
against	O
Australia	O
T	O
,	O
China	O
Ch5	O
,	O
Singapore	O
P4	O
,	O
USA	O
M41	O
and	O
China	O
T3	O
isolates	O
were	O
used	O
to	O
study	O
the	O
conservation	O
and	O
localization	O
of	O
the	O
antigenic	O
region	O
on	O
the	O
IBV	O
nucleocapsid	O
protein	B-CHED
.	O

Neither	O
cardiomyopathic	O
or	O
control	O
cats	O
tested	O
positive	O
by	O
PCR	O
for	O
herpes	O
virus	O
,	O
calici	O
virus	O
,	O
and	O
corona	B-CHED
virus	O
.	O

The	O
S	O
-	O
1	O
nucleotide	B-CHED
sequences	O
generated	O
by	O
DACS	O
were	O
aligned	O
and	O
analyzed	O
with	O
commercial	O
software	O
to	O
determine	O
their	O
relationship	O
to	O
the	O
S	O
-	O
1	O
nucleotide	B-CHED
sequences	O
of	O
IBV	O
strains	O
on	O
deposit	O
in	O
the	O
GenBank	O
and	O
EMBL	O
databases	O
.	O

In	O
contrast	O
,	O
the	O
nucleotide	B-CHED
identities	O
of	O
S	O
-	O
1	O
sequences	O
of	O
variant	O
serotypes	O
37	O
,	O
3330	O
,	O
and	O
PA	O
/	O
1220	O
/	O
98	O
and	O
reference	O
strain	O
Clark	O
333	O
,	O
for	O
which	O
database	O
sequences	O
were	O
not	O
available	O
,	O
ranged	O
from	O
27	O
.	O
7	O
%	O
to	O
73	O
.	O
8	O
%,	O
well	O
below	O
the	O
identity	O
values	O
for	O
a	O
homologous	O
serotype	O
.	O

This	O
review	O
details	O
our	O
knowledge	O
of	O
the	O
involvement	O
of	O
MMPs	O
,	O
namely	O
MMP	B-CHED
-	O
2	O
and	O
MMP	B-CHED
-	O
9	O
,	O
in	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

All	O
six	O
patients	O
were	O
treated	O
with	O
quinine	B-CHED
and	O
doxycycline	B-CHED
intravenously	O
.	O

The	O
fusion	O
activity	O
of	O
srr	O
S	O
proteins	B-CHED
as	O
examined	O
by	O
the	O
expression	O
with	O
recombinant	O
vaccinia	O
virus	O
was	O
apparently	O
lower	O
than	O
that	O
of	O
the	O
wt	O
S	O
protein	B-CHED
in	O
BHK	O
-	O
R2	O
cells	O
,	O
while	O
there	O
was	O
not	O
such	O
a	O
remarkable	O
difference	O
in	O
BHK	O
-	O
R1	O
cells	O
.	O

This	O
virus	O
also	O
modulated	O
the	O
activity	O
of	O
matrix	O
metalloproteinases	O
-	O
2	O
and	O
-	O
9	O
and	O
augmented	O
nitric	B-CHED
oxide	I-CHED
production	O
in	O
both	O
U	O
-	O
373MG	O
cells	O
and	O
the	O
human	O
microglial	O
cell	O
line	O
CHME	O
-	O
5	O
.	O

Pulmonary	O
artery	O
pressure	O
(	O
PAP	B-CHED
)	O
and	O
pulmonary	O
capillary	O
wedge	O
pressure	O
(	O
PCWP	O
)	O
were	O
monitored	O
.	O

In	O
addition	O
,	O
an	O
overproduction	O
of	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	O
,	O
examined	O
by	O
its	O
metabolites	B-CHED
nitrite	B-CHED
/	O
nitrate	B-CHED
)	O
by	O
inducible	O
NO	O
synthase	O
(	O
iNOS	O
,	O
examined	O
by	O
western	O
blot	O
analysis	O
)	O
is	O
attenuated	O
by	O
pretreatment	O
of	O
LPS	B-CHED
rats	O
with	O
terbutaline	B-CHED
.	O

Animals	O
were	O
intubated	O
,	O
treated	O
with	O
surfactant	B-CHED
and	O
ventilated	O
with	O
1	O
.	O
00	O
FIO2	O
for	O
4	O
hrs	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
p38	O
mitogen	B-CHED
activate	O
kinase	O
attenuates	O
the	O
severity	O
of	O
pancreatitis	O
-	O
induced	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

Pulmonary	O
TNF	O
-	O
alpha	O
protein	B-CHED
and	O
serum	O
nitrites	B-CHED
were	O
decreased	O
with	O
the	O
administration	O
of	O
CNI	O
-	O
1493	O
(	O
p	O
<	O
.	O
005	O
vs	O
.	O
vehicle	O
).	O

This	O
study	O
explores	O
the	O
effect	O
of	O
systemic	O
pancreatic	O
enzymes	O
on	O
pulmonary	O
NF	O
-	O
kappaB	O
and	O
inhibitory	O
kappa	O
B	O
(	O
IkappaB	O
)	O
proteins	B-CHED
and	O
their	O
role	O
in	O
enzyme	O
-	O
induced	O
pulmonary	O
injury	O
.	O

Patients	O
with	O
pneumonia	O
and	O
pleural	O
effusion	O
should	O
undergo	O
therapeutic	O
thoracentesis	O
;	O
the	O
pleural	O
fluid	O
should	O
be	O
Gram	O
-	O
stained	O
and	O
cultured	O
,	O
and	O
the	O
differential	O
cell	O
count	O
,	O
glucose	B-CHED
and	O
LDH	O
concentration	O
,	O
and	O
pH	O
should	O
be	O
determined	O
.	O

However	O
,	O
on	O
day	O
4	O
she	O
developed	O
respiratory	O
distress	O
,	O
bronchospasm	O
and	O
visible	O
cyanosis	O
with	O
oxygen	B-CHED
saturation	O
of	O
88	O
%	O
while	O
on	O
2	O
L	O
oxygen	B-CHED
.	O

The	O
data	O
indicate	O
that	O
residual	O
virus	O
from	O
a	O
primary	O
CNS	B-CHED
infection	O
is	O
a	O
vital	O
component	O
in	O
mediating	O
local	O
retention	O
of	O
both	O
CD8	O
(+)	O
and	O
CD4	O
(+)	O
T	O
cells	O
and	O
that	O
once	O
minimal	O
thresholds	O
of	O
stimuli	O
are	O
lost	B-CHED
,	O
T	O
cells	O
within	O
the	O
CNS	B-CHED
cannot	O
survive	O
in	O
an	O
autonomous	O
fashion	O
.	O

Protease	B-CHED
inhibitor	I-CHED
studies	O
revealed	O
that	O
unlike	O
3CLpro	O
activity	O
,	O
PLP2	O
activity	O
is	O
not	O
sensitive	O
to	O
cysteine	B-CHED
protease	I-CHED
inhibitor	I-CHED
E64d	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
contains	O
three	O
envelope	O
proteins	B-CHED
,	O
M	O
,	O
E	O
and	O
S	O
,	O
and	O
a	O
nucleocapsid	O
,	O
which	O
consists	O
of	O
genomic	O
RNA	O
and	O
N	O
protein	B-CHED
,	O
within	O
the	O
viral	O
envelope	O
.	O

These	O
data	O
indicated	O
that	O
M	O
protein	B-CHED
interacted	O
with	O
the	O
nucleocapsid	O
,	O
consisting	O
of	O
N	O
protein	B-CHED
and	O
mRNA	B-CHED
1	O
,	O
in	O
infected	O
cells	O
.	O

These	O
data	O
indicated	O
that	O
while	O
the	O
M	O
protein	B-CHED
-	O
N	O
protein	B-CHED
interaction	O
,	O
which	O
is	O
independent	O
of	O
viral	O
RNA	O
,	O
occurred	O
in	O
the	O
M	O
protein	B-CHED
-	O
nucleocapsid	O
complex	O
,	O
some	O
MHV	O
function	O
(	O
s	O
)	O
was	O
necessary	O
for	O
the	O
initiation	O
of	O
M	O
protein	B-CHED
-	O
nucleocapsid	O
interaction	O
.	O

Pasteurella	O
multocida	O
occurs	O
but	O
is	O
easily	O
contained	O
with	O
antibiotics	B-CHED
.	O

The	O
fragments	O
of	O
amplified	O
genetic	O
material	O
were	O
visualized	O
with	O
the	O
use	O
of	O
agarose	B-CHED
gel	O
electrophoresis	O
.	O

Oral	B-CHED
contraceptives	I-CHED
may	O
produce	O
asthma	O
exacerbation	O
,	O
while	O
long	O
term	O
use	O
and	O
/	O
or	O
high	O
doses	O
of	O
postmenopausal	O
hormone	B-CHED
replacement	O
therapy	O
increase	O
the	O
risk	O
of	O
asthma	O
.	O

Antigen	B-CHED
staining	O
was	O
not	O
detected	O
in	O
healthy	O
ferrets	O
or	O
ferrets	O
with	O
other	O
gastrointestinal	O
tract	O
diseases	O
.	O

It	O
is	O
also	O
used	O
in	O
medicine	B-CHED
for	O
treatment	O
of	O
some	O
conditions	O
.	O

ABSTRACT	O
:	O
Together	O
with	O
the	O
evidence	O
that	O
the	O
reduced	O
virus	O
growth	O
and	O
the	O
antiviral	B-CHED
state	O
induced	O
by	O
interferon	O
(	O
IFN	O
)-	O
gamma	O
,	O
occurring	O
only	O
in	O
macrophages	O
from	O
resistant	O
animals	O
,	O
correlated	O
with	O
the	O
decrease	O
of	O
MHV3	O
binding	O
to	O
macrophage	O
membrane	O
proteins	B-CHED
,	O
we	O
show	O
here	O
the	O
expression	O
of	O
cellular	O
and	O
viral	O
genes	O
in	O
resistant	O
(	O
A	O
/	O
J	O
)	O
and	O
susceptible	O
(	O
BALB	O
/	O
c	O
)	O
mouse	O
macrophages	O
after	O
IFN	O
-	O
gamma	O
activation	O
/	O
infection	O
.	O

Furthermore	O
,	O
MHV	O
-	O
induced	O
28S	O
rRNA	B-CHED
cleavage	O
occurred	O
in	O
MHV	O
-	O
infected	O
DBT	B-CHED
cells	O
that	O
do	O
not	O
show	O
apoptotic	O
signs	O
,	O
including	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
DNA	O
fragmentation	O
.	O

Thus	O
,	O
MHV	O
-	O
induced	O
28S	O
rRNA	B-CHED
cleavage	O
appeared	O
to	O
differ	O
from	O
any	O
rRNA	B-CHED
degradation	O
mechanism	O
described	O
previously	O
.	O

Instead	O
,	O
at	O
high	O
levels	O
of	O
expression	O
,	O
a	O
helicase	O
mutant	O
dominantly	O
interfered	O
with	O
the	O
function	O
of	O
the	O
wild	O
-	O
type	O
protein	B-CHED
.	O

Sequencing	O
of	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
)	O
gene	O
amplicons	O
revealed	O
point	O
mutations	O
in	O
OC43	O
,	O
some	O
consistently	O
found	O
in	O
three	O
MS	O
patient	O
brains	O
and	O
one	O
normal	O
control	O
but	O
never	O
observed	O
in	O
laboratory	O
viruses	O
.	O

To	O
identify	O
new	O
receptor	O
-	O
ligand	B-CHED
interactions	O
that	O
might	O
be	O
used	O
to	O
redirect	O
vectors	O
to	O
the	O
apical	O
surface	O
,	O
we	O
investigated	O
the	O
process	O
of	O
infection	O
of	O
airway	O
epithelial	O
cells	O
by	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
),	O
a	O
common	O
cause	O
of	O
respiratory	O
tract	O
infections	O
.	O

The	O
spike	O
glycoprotein	B-CHED
that	O
mediates	O
HCoV	O
-	O
229E	O
binding	O
and	O
fusion	O
to	O
CD13	O
is	O
a	O
candidate	O
for	O
pseudotyping	O
retroviral	O
envelopes	O
or	O
modifying	O
other	O
viral	O
vectors	O
.	O

For	O
the	O
related	O
mouse	O
hepatitis	O
coronavirus	O
(	O
MHV	O
),	O
it	O
has	O
been	O
suggested	O
that	O
the	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
)	O
is	O
involved	O
in	O
viral	O
RNA	O
synthesis	O
.	O

All	O
structural	O
proteins	B-CHED
,	O
including	O
N	O
,	O
were	O
found	O
to	O
be	O
dispensable	O
for	O
genome	O
replication	O
and	O
subgenomic	O
mRNA	B-CHED
transcription	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
changes	O
in	O
the	O
urgent	O
visits	O
made	O
by	O
HIV	O
+	O
patients	O
after	O
generalisation	O
of	O
the	O
protease	B-CHED
inhibitors	I-CHED
.	O

The	O
present	O
study	O
examined	O
whether	O
the	O
genome	O
-	O
length	O
negative	O
-	O
strand	O
RNA	O
serves	O
as	O
a	O
template	O
for	O
subgenomic	O
mRNA	B-CHED
synthesis	O
.	O

Ibuprofen	B-CHED
in	O
Sepsis	O
Study	O
Group	O
.	O

Logistic	O
and	O
multiple	O
regression	O
analyses	O
confirmed	O
that	O
of	O
18	O
clinical	O
variables	O
,	O
initial	O
serum	O
total	O
protein	B-CHED
level	O
and	O
protein	B-CHED
change	O
over	O
time	O
were	O
the	O
most	O
statistically	O
significant	O
predictors	O
of	O
weight	O
gain	O
,	O
prolonged	O
mechanical	O
ventilation	O
,	O
ARDS	O
development	O
,	O
and	O
mortality	O
in	O
the	O
study	O
population	O
.	O

ABSTRACT	O
:	O
A	O
54	O
-	O
year	O
-	O
old	O
man	B-CHED
with	O
acute	O
respiratory	O
failure	O
underwent	O
emergency	O
admission	O
to	O
our	O
hospital	O
.	O

ABSTRACT	O
:	O
Several	O
studies	O
have	O
established	O
that	O
transport	O
of	O
sodium	O
from	O
the	O
air	B-CHED
spaces	O
to	O
the	O
lung	O
interstitium	O
is	O
a	O
primary	O
mechanism	O
driving	O
alveolar	O
fluid	O
clearance	O
,	O
although	O
further	O
work	O
is	O
needed	O
to	O
determine	O
the	O
role	O
of	O
chloride	B-CHED
in	O
vectorial	O
fluid	O
transport	O
across	O
the	O
alveolar	O
epithelium	O
.	O

The	O
application	O
of	O
this	O
new	O
knowledge	O
regarding	O
salt	B-CHED
and	O
water	B-CHED
transport	O
in	O
alveolar	O
epithelium	O
in	O
relation	O
to	O
pathologic	O
conditions	O
has	O
been	O
successful	O
in	O
clinically	O
relevant	O
experimental	O
studies	O
,	O
as	O
well	O
as	O
in	O
a	O
few	O
clinical	O
studies	O
.	O

It	O
is	O
possible	O
that	O
therapy	O
with	O
beta	B-CHED
-	I-CHED
adrenergic	I-CHED
agonists	I-CHED
might	O
be	O
useful	O
to	O
accelerate	O
the	O
resolution	O
of	O
alveolar	O
edema	O
in	O
some	O
patients	O
.	O

In	O
some	O
patients	O
,	O
the	O
extent	O
of	O
injury	O
to	O
the	O
alveolar	O
epithelial	O
barrier	O
may	O
be	O
too	O
severe	O
for	O
beta	B-CHED
-	I-CHED
adrenergic	I-CHED
agonists	I-CHED
to	O
enhance	O
the	O
resolution	O
of	O
alveolar	O
edema	O
,	O
although	O
some	O
experimental	O
studies	O
indicate	O
that	O
alveolar	O
fluid	O
clearance	O
can	O
be	O
augmented	O
in	O
the	O
presence	O
of	O
moderately	O
severe	O
lung	O
injury	O
.	O

Continuous	O
therapies	O
incorporate	O
several	O
advantages	O
including	O
improved	O
hemodynamic	O
stability	O
,	O
optimal	O
fluid	O
balance	B-CHED
,	O
gradual	O
urea	B-CHED
removal	O
,	O
elimination	O
of	O
septic	O
mediators	O
,	O
and	O
the	O
possibility	O
of	O
unlimited	O
parenteral	O
nutrition	O
.	O

TITLE	O
:	O
Severe	O
asthma	O
and	O
ARDS	O
triggered	O
by	O
acute	O
short	O
-	O
term	O
exposure	O
to	O
commonly	O
used	O
cleaning	O
detergents	B-CHED
.	O

Experimental	O
and	O
clinical	O
research	O
supports	O
the	O
hypothesis	O
of	O
involvement	O
of	O
the	O
hormone	B-CHED
leptin	O
in	O
body	O
weight	O
and	O
energy	O
balance	B-CHED
homeostasis	O
.	O

In	O
the	O
steroid	B-CHED
group	O
,	O
each	O
patient	O
was	O
given	O
250	O
mg	O
of	O
methylprednisolone	B-CHED
intravenously	O
before	O
operation	O
followed	O
by	O
125	O
mg	O
on	O
postoperative	O
days	O
1	O
and	O
2	O
.	O

Days	O
until	O
extubation	O
and	O
hospital	O
stay	O
were	O
significantly	O
shorter	O
for	O
the	O
steroid	B-CHED
group	O
.	O

Inflammatory	O
mediators	O
,	O
body	O
temperature	O
,	O
heart	O
rate	O
,	O
and	O
respiratory	O
index	O
after	O
the	O
surgical	O
procedure	O
were	O
significantly	O
lower	O
in	O
the	O
steroid	B-CHED
group	O
.	O

Adverse	O
effects	O
possibly	O
caused	O
by	O
steroid	B-CHED
therapy	O
were	O
not	O
observed	O
.	O

Perioperative	O
steroid	B-CHED
therapy	O
was	O
safe	O
and	O
effective	O
for	O
the	O
inhibition	O
of	O
inflammatory	O
mediators	O
and	O
the	O
improvement	O
of	O
the	O
postoperative	O
clinical	O
course	O
of	O
patients	O
with	O
esophageal	O
cancer	O
.	O

TITLE	O
:	O
Vitamin	B-CHED
A	I-CHED
supplements	O
and	O
diarrheal	O
and	O
respiratory	O
tract	O
infections	O
among	O
children	O
in	O
Dar	O
es	O
Salaam	O
,	O
Tanzania	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
effect	O
of	O
vitamin	B-CHED
A	I-CHED
supplementation	O
on	O
the	O
risk	O
of	O
diarrhea	O
and	O
of	O
acute	O
respiratory	O
infection	O
.	O

Serious	O
complications	O
associated	O
with	O
VSB	O
occur	O
mainly	O
in	O
patients	O
receiving	O
high	O
-	O
dose	O
chemotherapy	O
with	O
cyclophosphamide	B-CHED
before	O
allogeneic	O
bone	O
marrow	O
transplantation	O
who	O
develop	O
severe	O
oral	O
mucositis	O
;	O
these	O
complications	O
are	O
associated	O
with	O
a	O
high	O
mortality	O
rate	O
.	O

TITLE	O
:	O
Optimization	O
of	O
bovine	O
coronavirus	O
hemagglutinin	O
-	O
estrase	O
glycoprotein	B-CHED
expression	O
in	O
E3	O
deleted	O
bovine	O
adenovirus	O
-	O
3	O
.	O

The	O
results	O
show	O
that	O
feeding	O
milk	O
which	O
contains	O
hydrolysed	O
lactose	B-CHED
does	O
not	O
significantly	O
improve	O
lactose	B-CHED
utilization	O
in	O
calves	O
that	O
are	O
suffering	O
from	O
benign	O
infectious	O
diarrhoea	O
.	O

Using	O
previously	O
described	O
BCV	O
primers	O
,	O
the	O
N	O
protein	B-CHED
gene	O
of	O
isolate	O
NC99	O
was	O
amplified	O
by	O
a	O
reverse	O
transcriptase	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
procedure	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
noncanonical	O
signal	O
for	O
transcription	O
of	O
a	O
novel	O
subgenomic	O
mRNA	B-CHED
of	O
mouse	O
hepatitis	O
virus	O
:	O
implication	O
for	O
the	O
mechanism	O
of	O
coronavirus	O
RNA	O
transcription	O
.	O

Transfection	O
of	O
the	O
reporter	O
RNA	O
into	O
MHV	O
-	O
infected	O
cells	O
resulted	O
in	O
synthesis	O
of	O
a	O
CAT	O
-	O
specific	O
subgenomic	O
mRNA	B-CHED
detected	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

The	O
strength	O
of	O
this	O
promoter	O
was	O
similar	O
to	O
that	O
of	O
the	O
IG7	O
(	O
for	O
mRNA	B-CHED
7	O
)	O
as	O
measured	O
by	O
the	O
CAT	O
activity	O
.	O

In	O
vitro	O
translation	O
study	O
confirmed	O
that	O
the	O
envelope	O
(	O
E	O
)	O
protein	B-CHED
was	O
translated	O
from	O
mRNA5	O
-	O
1	O
,	O
which	O
encodes	O
the	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
5b	O
at	O
its	O
5	O
'-	O
end	O
,	O
indicating	O
that	O
mRNA5	O
-	O
1	O
is	O
a	O
functional	O
message	O
.	O

ABSTRACT	O
:	O
The	O
parts	O
of	O
the	O
RNA	O
genome	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
required	O
for	O
replication	O
and	O
packaging	O
of	O
the	O
RNA	O
were	O
investigated	O
using	O
deletion	O
mutagenesis	O
of	O
a	O
defective	O
RNA	O
(	O
D	O
-	O
RNA	O
)	O
CD	O
-	O
61	O
(	O
6	O
.	O
1	O
kb	O
)	O
containing	O
a	O
chloramphenicol	B-CHED
acetyltransferase	O
reporter	O
gene	O
.	O

Region	O
I	O
of	O
the	O
3	O
'	O
UTR	O
,	O
adjacent	O
to	O
the	O
nucleocapsid	O
protein	B-CHED
gene	O
,	O
comprised	O
212	O
nt	O
and	O
could	O
be	O
removed	O
without	O
impairment	O
of	O
replication	O
or	O
packaging	O
of	O
D	O
-	O
RNAs	O
.	O

Animals	O
underwent	O
35	O
%	O
hepatic	O
resection	O
or	O
a	O
similar	O
volume	O
hepatic	O
cryo	O
and	O
were	O
sacrificed	O
at	O
1	O
,	O
2	O
,	O
6	O
,	O
and	O
24	O
h	O
.	O
Pulmonary	O
histologic	O
features	O
were	O
assessed	O
using	O
hematoxylin	B-CHED
and	O
eosin	O
and	O
immunoperoxidase	O
staining	O
with	O
a	O
macrophage	O
-	O
specific	O
antibody	O
(	O
anti	O
-	O
lysozyme	O
,	O
1	O
:	O
200	O
dilution	O
,	O
Dako	O
,	O
Carpinteria	O
,	O
CA	O
).	O

The	O
enzymic	O
properties	O
of	O
HE	O
proteins	B-CHED
in	O
COS	B-CHED
-	O
7	O
cellular	O
extracts	O
and	O
in	O
purified	O
virus	O
preparations	O
were	O
assayed	O
at	O
room	O
temperature	O
,	O
37	O
degrees	O
C	O
and	O
39	O
degrees	O
C	O
by	O
two	O
different	O
assays	O
.	O

The	O
PNPA	O
tests	O
confirmed	O
that	O
HE	O
proteins	B-CHED
of	O
EBCV	O
and	O
RBCV	O
were	O
functionally	O
expressed	O
in	O
transfected	O
COS	B-CHED
-	O
7	O
cells	O
.	O

TITLE	O
:	O
Plasma	O
cGMP	B-CHED
levels	O
in	O
air	B-CHED
embolism	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
An	O
impaired	O
generation	O
of	O
cGMP	B-CHED
may	O
account	O
for	O
the	O
pulmonary	O
hypertension	O
seen	O
in	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

The	O
VAI	O
increased	O
the	O
pulmonary	O
artery	O
pressure	O
(	O
by	O
181	O
%,	O
P	O
<.	O
05	O
)	O
after	O
15	O
minutes	O
of	O
air	B-CHED
infusion	O
without	O
changing	O
the	O
cardiac	O
index	O
.	O

The	O
cores	O
were	O
stabilized	O
at	O
basic	O
pH	O
and	O
by	O
the	O
presence	O
of	O
divalent	O
cations	B-CHED
,	O
with	O
Mg	O
(	O
2	O
+)	O
ions	B-CHED
more	O
effectively	O
contributing	O
to	O
core	O
stability	O
.	O

Only	O
the	O
C	O
region	O
of	O
the	O
M	O
protein	B-CHED
is	O
part	O
of	O
the	O
core	O
.	O

ABSTRACT	O
:	O
The	O
specific	O
endothelial	O
cell	O
product	O
von	O
Willebrand	O
factor	O
antigen	B-CHED
(	O
vWf	O
:	O
Ag	O
)	O
was	O
measured	O
in	O
plasma	O
and	O
lung	O
function	O
tests	O
were	O
carried	O
out	O
and	O
the	O
following	O
lung	O
injury	O
parameters	O
measured	O
:	O
P	O
(	O
a	O
)	O
O2	O
/	O
F	O
(	O
i	O
)	O
O2	O
ratio	O
,	O
static	O
respiratory	O
compliance	O
and	O
Murray	O
'	O
s	O
lung	O
injury	O
score	O
(	O
LIS	O
)	O
in	O
a	O
follow	O
-	O
up	O
study	O
of	O
36	O
severely	O
traumatized	O
patients	O
.	O

ABSTRACT	O
:	O
Recombinant	O
mouse	O
hepatitis	O
viruses	O
(	O
MHV	O
)	O
differing	O
only	O
in	O
the	O
spike	O
gene	O
,	O
containing	O
A59	O
,	O
MHV	O
-	O
4	O
,	O
and	O
MHV	O
-	O
2	O
spike	O
genes	O
in	O
the	O
background	O
of	O
the	O
A59	O
genome	O
,	O
were	O
compared	O
for	O
their	O
ability	O
to	O
replicate	O
in	O
the	O
liver	O
and	O
induce	O
hepatitis	O
in	O
weanling	O
C57BL	O
/	O
6	O
mice	O
infected	O
with	O
500	O
PFU	B-CHED
of	O
each	O
virus	O
by	O
intrahepatic	O
injection	O
.	O

Almitrine	B-CHED
increased	O
mean	O
pulmonary	O
arterial	O
pressure	O
(	O
MPAP	O
)	O
from	O
31	O
+/-	O

In	O
patients	O
with	O
severe	O
hypoxemia	O
related	O
to	O
ARDS	O
,	O
high	O
-	O
dose	O
almitrine	B-CHED
infusion	O
did	O
not	O
improve	O
arterial	O
oxygenation	O
and	O
impaired	O
the	O
loading	O
conditions	O
of	O
the	O
right	O
ventricle	O
.	O

Blood	O
gas	O
,	O
gas	O
exchange	O
,	O
and	O
hemodynamic	O
measurements	O
were	O
performed	O
at	O
the	O
following	O
time	O
points	O
:	O
a	O
)	O
baseline	O
;	O
b	O
)	O
during	O
the	O
optimal	O
or	O
maximum	O
dose	O
of	O
PGI2	B-CHED
;	O
and	O
c	O
)	O
1	O
hr	O
after	O
withdrawal	O
of	O
the	O
drug	O
.	O

ABSTRACT	O
:	O
Structure	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
product	O
-	O
based	O
inhibitors	B-CHED
of	O
hepatitis	O
C	O
virus	O
NS3	O
protease	O
were	O
evaluated	O
using	O
an	O
in	O
vitro	O
assay	O
system	O
comprising	O
the	O
native	O
bifunctional	O
full	O
-	O
length	O
NS3	O
(	O
protease	O
-	O
helicase	O
/	O
NTPase	O
).	O

Taken	O
together	O
,	O
the	O
results	O
suggest	O
that	O
the	O
impact	O
of	O
the	O
helicase	O
domain	O
upon	O
protease	B-CHED
inhibitor	I-CHED
binding	O
is	O
substantial	O
.	O

ABSTRACT	O
:	O
Impairment	O
of	O
alveolar	O
surfactant	B-CHED
function	O
has	O
been	O
documented	O
in	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
in	O
severe	O
pneumonia	O
(	O
PNEU	O
);	O
however	O
,	O
the	O
underlying	O
mechanisms	O
are	O
not	O
completely	O
understood	O
.	O

In	O
the	O
current	O
report	O
we	O
present	O
a	O
detailed	O
analysis	O
of	O
fatty	B-CHED
acid	I-CHED
(	O
FA	O
)	O
profiles	O
of	O
different	O
surfactant	B-CHED
phospholipid	B-CHED
(	O
PL	O
)	O
classes	O
isolated	O
from	O
bronchoalveolar	O
lavage	O
fluids	O
(	O
BALF	O
)	O
and	O
large	O
surfactant	B-CHED
aggregates	O
(	O
LSA	O
)	O
from	O
mechanically	O
ventilated	O
patients	O
with	O
ARDS	O
(	O
n	O
=	O
8	O
),	O
ARDS	O
associated	O
with	O
lung	O
infection	O
(	O
ARDS	O
+	O
PNEU	O
,	O
n	O
=	O
9	O
),	O
and	O
PNEU	O
(	O
n	O
=	O
22	O
).	O

Phosphatidylglycerol	B-CHED
(	O
PG	O
)	O
and	O
phosphatidylinositol	B-CHED
(	O
PI	O
)	O
presented	O
similar	O
FA	O
profiles	O
in	O
control	O
subjects	O
,	O
but	O
differed	O
in	O
the	O
patients	O
.	O

TITLE	O
:	O
Elevated	O
levels	O
of	O
interleukin	O
-	O
8	O
in	O
donor	B-CHED
lungs	O
is	O
associated	O
with	O
early	O
graft	O
failure	O
after	O
lung	O
transplantation	O
.	O

VI	O
,	O
FAT	O
,	O
and	O
TEM	B-CHED
were	O
tested	O
over	O
a	O
course	O
of	O
time	O
before	O
the	O
in	O
situ	O
hybridization	O
was	O
performed	O
.	O

Of	O
these	O
21	O
samples	O
,	O
5	O
(	O
24	O
%)	O
were	O
positive	O
for	O
TGEV	O
by	O
all	O
4	O
tests	O
,	O
15	O
(	O
71	O
%)	O
were	O
positive	O
by	O
FAT	O
,	O
14	O
(	O
67	O
%)	O
were	O
positive	O
by	O
VI	O
,	O
and	O
6	O
(	O
29	O
%)	O
were	O
positive	O
by	O
TEM	B-CHED
.	O

Sequence	O
analysis	O
of	O
the	O
spike	O
protein	B-CHED
genes	O
of	O
the	O
escape	O
mutants	O
identified	O
a	O
single	O
nucleotide	B-CHED
substitution	O
of	O
C	O
to	O
T	O
at	O
position	O
1583	O
,	O
resulting	O
in	O
the	O
change	O
of	O
alanine	B-CHED
to	O
valine	B-CHED
at	O
amino	B-CHED
acid	I-CHED
position	O
528	O
(	O
A528V	O
).	O

A	O
cis	O
-	O
acting	O
element	O
previously	O
identified	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
binds	O
to	O
trans	O
-	O
acting	O
host	O
factors	O
from	O
mouse	O
fibroblasts	O
and	O
forms	O
at	O
least	O
three	O
RNA	O
-	O
protein	B-CHED
complexes	O
.	O

These	O
results	O
show	O
for	O
the	O
first	O
time	O
the	O
presence	O
of	O
IPC	B-CHED
in	O
gut	O
mucosa	O
and	O
gut	O
-	O
associated	O
lymphoid	O
tissues	O
in	O
response	O
to	O
an	O
enteropathogenic	O
virus	O
.	O

MHC	O
class	O
II	O
molecule	O
expression	O
by	O
gut	O
-	O
associated	O
IPC	B-CHED
suggests	O
that	O
these	O
cells	O
may	O
be	O
the	O
in	O
vivo	O
mucosal	O
counterparts	O
of	O
the	O
dendritic	O
cells	O
recently	O
shown	O
to	O
produce	O
IFN	O
-	O
alpha	O
after	O
in	O
vitro	O
viral	O
induction	O
.	O

TITLE	O
:	O
MHV	O
infection	O
of	O
the	O
CNS	B-CHED
:	O
mechanisms	O
of	O
immune	O
-	O
mediated	O
control	O
.	O

Clearance	O
of	O
infectious	O
virus	O
is	O
associated	O
with	O
a	O
gradual	O
decline	O
of	O
CNS	B-CHED
T	O
cells	O
;	O
nevertheless	O
,	O
activated	O
T	O
cells	O
are	O
retained	O
within	O
the	O
CNS	B-CHED
.	O

Although	O
acute	O
JHMV	O
infection	O
is	O
thus	O
primarily	O
controlled	O
by	O
CD8	O
+	O
T	O
cells	O
,	O
both	O
CD4	O
+	O
T	O
cells	O
and	O
B	O
cells	O
make	O
significant	O
contributions	O
in	O
maintaining	O
the	O
balance	B-CHED
between	O
viral	O
replication	O
and	O
immune	O
control	O
,	O
thus	O
allowing	O
host	O
and	O
pathogen	O
survival	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
small	O
envelope	O
protein	B-CHED
E	O
has	O
two	O
known	O
biological	O
functions	O
:	O
it	O
plays	O
a	O
pivotal	O
role	O
in	O
virus	O
envelope	O
formation	O
,	O
and	O
the	O
murine	O
coronavirus	O
E	O
protein	B-CHED
induces	O
apoptosis	O
in	O
E	O
protein	B-CHED
-	O
expressing	O
cultured	O
cells	O
.	O

The	O
constitutive	O
tetA	B-CHED
promoter	O
and	O
the	O
in	O
vivo	O
activated	O
nirB	O
and	O
pagC	O
promoters	O
were	O
evaluated	O
for	O
their	O
use	O
to	O
express	O
two	O
epitopes	O
of	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
spike	O
protein	B-CHED
carried	O
by	O
fimbriae	O
which	O
were	O
displayed	O
on	O
a	O
Salmonella	O
vaccine	O
strain	O
.	O

Further	O
treatment	O
,	O
including	O
gastric	O
decompression	O
,	O
irrigation	O
via	O
the	O
drainage	O
tubes	O
,	O
antibiotics	B-CHED
,	O
somatostatin	B-CHED
,	O
and	O
parenteral	O
nutrition	O
,	O
was	O
continued	O
in	O
all	O
patients	O
following	O
the	O
laparoscopic	O
procedures	O
.	O

From	O
1993	O
to	O
1998	O
,	O
we	O
prospectively	O
evaluated	O
57	O
HIV	O
patients	O
(	O
mean	O
+/-	O
SEM	B-CHED
age	O
36	O
.	O
5	O
+/-	O
1	O
.	O
3	O
yrs	O
)	O
admitted	O
to	O
the	O
ICU	O
showing	O
pulmonary	O
infiltrates	O
and	O
acute	O
respiratory	O
failure	O
.	O

A	O
strong	O
hnRNP	O
A1	O
-	O
binding	O
site	O
was	O
located	O
90	O
to	O
170	O
nucleotides	B-CHED
from	O
the	O
3	O
'	O
end	O
of	O
MHV	O
RNA	O
,	O
and	O
a	O
weak	O
binding	O
site	O
was	O
mapped	O
at	O
nucleotides	B-CHED
260	O
to	O
350	O
from	O
the	O
3	O
'	O
end	O
.	O

These	O
binding	O
sites	O
are	O
complementary	O
to	O
the	O
sites	O
on	O
the	O
negative	O
-	O
strand	O
RNA	O
that	O
bind	O
another	O
cellular	O
protein	B-CHED
,	O
polypyrimidine	O
tract	O
-	O
binding	O
protein	B-CHED
(	O
PTB	O
).	O

Anorexia	O
in	O
response	O
to	O
bacterial	O
lipopolysaccharide	B-CHED
administration	O
,	O
which	O
is	O
also	O
linked	O
to	O
plasma	O
TNF	O
-	O
alpha	O
,	O
is	O
however	O
,	O
caused	O
only	O
via	O
a	O
decrease	O
in	O
meal	O
number	O
.	O

It	O
is	O
also	O
remarkable	O
in	O
that	O
more	O
than	O
two	O
-	O
thirds	O
of	O
the	O
genome	O
is	O
devoted	O
to	O
encoding	O
proteins	B-CHED
involved	O
in	O
the	O
replication	O
and	O
transcription	O
of	O
viral	O
RNA	O
.	O

The	O
mean	O
ventral	O
density	O
index	O
was	O
affected	O
by	O
rotating	O
position	O
and	O
HFOV	O
mode	O
of	O
ventilation	O
after	O
10	O
mL	O
/	O
kg	O
of	O
perflubron	B-CHED
,	O
and	O
rotating	O
position	O
was	O
affected	O
only	O
after	O
15	O
mL	O
/	O
kg	O
of	O
perflubron	B-CHED
.	O

A	O
specific	O
non	O
-	O
sense	O
mutation	O
was	O
identified	O
for	O
the	O
nucleotide	B-CHED
at	O
position	O
88	O
of	O
the	O
putative	O
4	O
.	O
9	O
kDa	O
protein	B-CHED
gene	O
of	O
RBCoV	O
isolates	O
resulting	O
in	O
29	O
rather	O
that	O
43	O
aa	O
residues	O
.	O

In	O
broad	O
-	O
spectrum	O
antiviral	B-CHED
assays	O
,	O
the	O
3	O
-	O
arylsulfonyl	O
-	O
2	O
-(	O
trifluoroacetamido	O
)	O
thiophenes	B-CHED
(	O
8c	O
-	O
g	O
)	O
and	O
2	O
-	O
acetamido	B-CHED
-	O
3	O
-	O
arylsulfonyl	O
-	O
5	O
-	O
nitrothiophenes	O
(	O
9f	O
-	O
g	O
)	O
proved	O
considerably	O
active	O
(	O
IC	O
(	O
50	O
)=	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
mL	O
)	O
against	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
and	O
/	O
or	O
varicella	O
zoster	O
virus	O
(	O
VZV	O
).	O

Iron	O
toxicity	O
,	O
leading	O
to	O
iron	O
-	O
overload	O
,	O
is	O
often	O
treated	O
in	O
humans	O
with	O
the	O
iron	B-CHED
chelator	I-CHED
desferrioxamine	B-CHED
mesylate	I-CHED
.	O

With	O
diazepam	B-CHED
anesthesia	O
,	O
Rint	O
,	O
L	O
decreased	O
linearly	O
,	O
with	O
increasing	O
PaCO2	O
,	O
from	O
2	O
.	O
3	O
to	O
1	O
.	O
4	O
cm	O
H2O	B-CHED
.	O
s	O
.	O
l	O
(-	O
1	O
),	O
whereas	O
deltaR	O
,	O
L	O
decreased	O
from	O
2	O
to	O
1	O
.	O
7	O
cm	O
H2O	B-CHED
.	O
s	O
.	O
l	O
(-	O
1	O
),	O
though	O
not	O
significantly	O
.	O

With	O
diazepam	B-CHED
,	O
Rint	O
,	O
L	O
was	O
45	O
(	O
hypercapnia	O
)	O
to	O
110	O
%	O
(	O
hypocapnia	O
)	O
greater	O
than	O
with	O
isoflurane	B-CHED
.	O

Changes	O
of	O
PaCO2	O
from	O
20	O
-	O
65	O
mmHg	O
cause	O
increasing	O
bronchodilation	O
in	O
anesthetized	O
,	O
paralyzed	O
subjects	O
,	O
this	O
effect	O
being	O
attenuated	O
or	O
abolished	O
by	O
drugs	O
(	O
e	O
.	O
g	O
.,	O
halogenated	O
anesthetics	B-CHED
)	O
that	O
depress	O
smooth	O
muscle	O
tone	O
substantially	O
.	O

The	O
pathologic	O
findings	O
of	O
subdural	O
hemorrhage	O
,	O
subarachnoid	O
hemorrhage	O
,	O
and	O
retinal	B-CHED
hemorrhages	O
are	O
offered	O
as	O
""""	O
markers	O
""""	O
to	O
assist	O
in	O
the	O
recognition	O
of	O
the	O
presence	O
of	O
shearing	O
brain	O
injury	O
in	O
young	O
children	O
.	O

Viral	O
RNA	O
was	O
detected	O
in	O
faeces	O
by	O
reverse	O
-	O
transcriptase	O
PCR	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
plasma	O
antiviral	B-CHED
antibodies	O
by	O
immunofluorescence	O
.	O

TITLE	O
:	O
[	O
Acute	O
respiratory	O
distress	O
syndrome	O
after	O
antineoplastic	B-CHED
chemotherapy	O
.	O

Corticosteroid	B-CHED
therapy	O
,	O
whether	O
given	O
for	O
prevention	O
or	O
cure	O
,	O
is	O
not	O
always	O
effective	O
.	O

Such	O
integration	O
is	O
essential	O
for	O
the	O
production	O
of	O
progeny	O
viruses	O
,	O
and	O
therefore	O
therapeutic	O
agents	O
that	O
can	O
inhibit	O
this	O
process	O
should	O
be	O
effective	O
anti	B-CHED
-	I-CHED
HIV	I-CHED
agents	I-CHED
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
synthesized	O
and	O
tested	O
dicaffeoyl	O
or	O
digalloyl	O
compounds	O
joined	O
through	O
a	O
five	O
-	O
membered	O
heterocyclic	O
ring	O
as	O
HIV	O
IN	O
inhibitors	B-CHED
to	O
explore	O
the	O
SARs	O
of	O
this	O
family	O
of	O
compounds	O
.	O

These	O
data	O
show	O
that	O
the	O
coronavirus	O
replicase	O
gene	O
products	O
suffice	O
for	O
discontinuous	O
subgenomic	O
mRNA	B-CHED
transcription	O
.	O

The	O
N	O
protein	B-CHED
was	O
expressed	O
under	O
control	O
of	O
the	O
vaccinia	O
virus	O
promoter	O
P7	O
.	O
5	O
in	O
chicken	O
embryo	O
fibroblast	O
cell	O
cultures	O
as	O
seen	O
in	O
immunofluorescence	O
assay	O
and	O
in	O
rFPV	O
-	O
inoculated	O
specific	O
-	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
chickens	O
by	O
detecting	O
antibodies	O
with	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

Our	O
results	O
suggest	O
that	O
the	O
C	O
-	O
terminal	O
119	O
amino	B-CHED
acid	I-CHED
of	O
the	O
nucleocapsid	O
expressed	O
by	O
FPV	O
is	O
a	O
host	O
-	O
protective	O
antigen	B-CHED
and	O
may	O
induce	O
cross	O
-	O
protective	O
immunity	O
against	O
illness	O
among	O
some	O
IBV	O
strains	O
.	O

Sequence	O
data	O
demonstrated	O
the	O
complete	O
S1	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
these	O
isolates	O
were	O
almost	O
identical	O
despite	O
recovery	O
from	O
geographically	O
different	O
areas	O
in	O
China	O
and	O
had	O
47	O
.	O
3	O
%-	O
82	O
.	O
3	O
%	O
similarity	O
in	O
comparison	O
with	O
the	O
47	O
published	O
S1	O
sequences	O
.	O

In	O
three	O
relatively	O
older	O
NICU	O
-	O
patients	O
RML	O
was	O
due	O
to	O
lipid	B-CHED
lowering	O
drugs	O
assumption	O
.	O

Pre	O
-	O
operatively	O
,	O
predicted	O
mean	O
of	O
PaO	B-CHED
(	O
2	O
),	O
PaCO	O
(	O
2	O
)	O
and	O
%	O
FEV1	O
were	O
72	O
mmHg	O
(	O
57	O
--	O
86	O
),	O
37	O
mmHg	O
(	O
33	O
--	O
42	O
)	O
and	O
80	O
%	O
(	O
37	O
--	O
114	O
),	O
respectively	O
.	O

This	O
panda	O
most	O
likely	O
contracted	O
Tyzzer	O
'	O
s	O
disease	O
subsequent	O
to	O
having	O
a	O
compromised	O
immune	O
system	O
after	O
corticosteroid	B-CHED
administration	O
and	O
concurrent	O
disease	O
.	O

It	O
is	O
autocatalytically	O
released	O
from	O
the	O
precursors	O
pp1a	O
and	O
pp1ab	O
by	O
one	O
zinc	B-CHED
finger	O
-	O
containing	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
in	O
IBV	O
and	O
by	O
two	O
paralogous	O
PLpros	O
,	O
PL1pro	O
and	O
PL2pro	O
,	O
in	O
mouse	O
hepatitis	O
virus	O
.	O

The	O
PLpro	O
-	O
containing	O
proteins	B-CHED
have	O
been	O
recently	O
implicated	O
in	O
the	O
control	O
of	O
coronavirus	O
subgenomic	O
mRNA	B-CHED
synthesis	O
(	O
transcription	O
).	O

The	O
viral	O
titres	O
in	O
both	O
tissues	O
reached	O
a	O
plateau	O
of	O
10	O
(	O
7	O
)	O
plaque	O
-	O
forming	O
units	O
(	O
PFU	B-CHED
)/	O
0	O
.	O
2	O
g	O
by	O
day	O
4	O
,	O
at	O
which	O
time	O
clinical	O
signs	O
had	O
developed	O
.	O

By	O
immunohistochemical	O
analysis	O
,	O
virus	O
-	O
specific	O
antigen	B-CHED
was	O
found	O
first	O
in	O
the	O
pyramidal	O
cells	O
of	O
the	O
hippocampus	O
and	O
cerebral	O
cortex	O
,	O
and	O
later	O
in	O
the	O
large	O
-	O
sized	O
neurons	O
of	O
the	O
pons	O
and	O
spinal	O
cord	O
.	O

ABSTRACT	O
:	O
Amiodarone	B-CHED
is	O
a	O
commonly	O
used	O
anti	O
-	O
arrhythmic	O
agent	O
,	O
with	O
well	O
-	O
recognized	O
chronic	O
toxicity	O
.	O

Unfortunately	O
,	O
cardiac	O
surgery	O
is	O
one	O
of	O
the	O
clinical	O
scenarios	O
in	O
which	O
amiodarone	B-CHED
is	O
most	O
commonly	O
used	O
.	O

TITLE	O
:	O
Downstream	O
sequences	O
influence	O
the	O
choice	O
between	O
a	O
naturally	O
occurring	O
noncanonical	O
and	O
closely	O
positioned	O
upstream	O
canonical	O
heptameric	O
fusion	O
motif	O
during	O
bovine	O
coronavirus	O
subgenomic	O
mRNA	B-CHED
synthesis	O
.	O

The	O
Ab	O
cross	O
-	O
reacted	O
with	O
a	O
40	O
-	O
kDa	O
protein	B-CHED
from	O
human	O
,	O
rat	O
and	O
sheep	O
liver	O
,	O
but	O
not	O
with	O
liver	O
extracts	O
from	O
the	O
silver	B-CHED
side	O
fish	O
(	O
Odontesthes	O
bonariensis	O
).	O

Although	O
overall	O
T	O
cell	O
recruitment	O
into	O
the	O
CNS	B-CHED
of	O
muMT	O
mice	O
was	O
not	O
impaired	O
,	O
discrepancies	O
in	O
frequencies	O
of	O
virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	O
were	O
most	O
severe	O
during	O
acute	O
infection	O
.	O

Reduced	O
virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cell	O
responses	O
in	O
the	O
CNS	B-CHED
coincided	O
with	O
poor	O
peripheral	O
expansion	O
and	O
diminished	O
CD4	O
(+)	O
T	O
cell	O
help	O
.	O

Most	O
occurrences	O
of	O
angioedema	O
respond	O
to	O
treatment	O
with	O
a	O
histamine	B-CHED
H1	O
receptor	O
blocker	O
(	O
antihistamine	B-CHED
)	O
because	O
they	O
are	O
an	O
allergic	O
or	O
parallergic	O
reaction	O
.	O

Estrogen	B-CHED
and	O
ACE	O
inhibitors	B-CHED
should	O
be	O
avoided	O
in	O
a	O
patient	O
with	O
congenital	O
or	O
acquired	O
C1	O
-	O
INH	O
deficiency	O
.	O

In	O
response	O
to	O
E	O
.	O
coli	O
,	O
the	O
lpr	O
mice	O
had	O
significantly	O
more	O
polymorphonuclear	O
leukocytes	O
(	O
PMN	O
)	O
and	O
macrophage	O
inflammatory	O
protein	B-CHED
2	O
in	O
the	O
lungs	O
,	O
whereas	O
histopathologic	O
changes	O
were	O
less	O
severe	O
.	O

Attempts	O
to	O
define	O
sequence	O
differences	O
in	O
the	O
HE	O
genes	O
of	O
the	O
WD	O
and	O
NCD	O
strains	O
revealed	O
high	O
nucleotide	B-CHED
(	O
NT	O
)	O
identities	O
with	O
only	O
scattered	O
amino	B-CHED
acid	I-CHED
differences	O
,	O
seemingly	O
unrelated	O
to	O
the	O
clinical	O
origin	O
of	O
the	O
isolates	O
or	O
HAI	O
MAb	O
reactivities	O
.	O

ABSTRACT	O
:	O
The	O
incidence	O
of	O
acute	O
cor	O
pulmonale	O
(	O
ACP	B-CHED
),	O
a	O
frequent	O
and	O
usually	O
lethal	O
complication	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
during	O
traditional	O
respiratory	O
support	O
,	O
has	O
never	O
been	O
re	O
-	O
evaluated	O
since	O
protective	O
ventilation	O
gained	O
acceptance	O
.	O

Seventy	O
-	O
five	O
consecutive	O
ARDS	O
patients	O
given	O
respiratory	O
support	O
with	O
airway	O
pressure	O
limitation	O
(	O
plateau	O
pressure	O
<	O
or	O
=	O
30	O
cm	O
H2O	B-CHED
).	O

ACP	B-CHED
was	O
defined	O
as	O
a	O
ratio	O
of	O
right	O
ventricular	O
end	O
-	O
diastolic	O
area	O
to	O
left	O
ventricular	O
end	O
-	O
diastolic	O
area	O
in	O
the	O
long	O
axis	O
>	O
0	O
.	O
6	O
associated	O
with	O
septal	O
dyskinesia	O
in	O
the	O
short	O
axis	O
during	O
TEE	O
examination	O
.	O

However	O
,	O
ACP	B-CHED
patients	O
who	O
recovered	O
required	O
a	O
longer	O
period	O
of	O
respiratory	O
support	O
.	O

Evaluation	O
of	O
right	O
ventricular	O
function	O
by	O
TEE	O
in	O
a	O
group	O
of	O
75	O
ARDS	O
patients	O
submitted	O
to	O
protective	O
ventilation	O
revealed	O
the	O
persistence	O
of	O
a	O
25	O
%	O
incidence	O
of	O
ACP	B-CHED
,	O
resulting	O
in	O
detrimental	O
hemodynamic	O
consequences	O
associated	O
with	O
tachycardia	O
.	O

The	O
inhibition	O
of	O
acetylcholinesterase	O
causes	O
accumulation	O
of	O
acetylcholine	B-CHED
at	O
synapses	O
,	O
and	O
overstimulation	O
of	O
neurotransmission	O
occurs	O
as	O
a	O
result	O
of	O
this	O
accumulation	O
.	O

Treatment	O
of	O
OP	O
poisoning	O
consists	O
of	O
intravenous	O
atropine	B-CHED
and	O
oximes	B-CHED
.	O

108	O
for	O
PCV	B-CHED
to	O
1409	O
+/-	O

4	O
for	O
PCV	B-CHED
to	O
12	O
+/-	O

TITLE	O
:	O
Variation	O
of	O
the	O
sequence	O
in	O
the	O
gene	O
encoding	O
for	O
transmembrane	O
protein	B-CHED
M	O
of	O
canine	O
coronavirus	O
(	O
CCV	O
).	O

Sequence	O
analysis	O
of	O
the	O
samples	O
revealed	O
silent	O
nucleotide	B-CHED
substitutions	O
in	O
the	O
binding	O
site	O
of	O
the	O
internal	O
primer	O
used	O
for	O
the	O
n	O
-	O
PCR	O
.	O

The	O
present	O
study	O
tested	O
the	O
possibility	O
that	O
the	O
selective	O
M	O
protein	B-CHED
-	O
mRNA	B-CHED
1	O
interaction	O
is	O
due	O
to	O
the	O
packaging	O
signal	O
in	O
mRNA	B-CHED
1	O
.	O

Moreover	O
,	O
only	O
the	O
RNA	O
that	O
interacted	O
selectively	O
with	O
M	O
protein	B-CHED
was	O
efficiently	O
packaged	O
into	O
MHV	O
particles	O
.	O

In	O
addition	O
,	O
our	O
results	O
suggest	O
that	O
the	O
N	O
protein	B-CHED
might	O
function	O
to	O
disrupt	O
cell	O
division	O
.	O

Surfactant	B-CHED
replacement	O
combined	O
with	O
early	O
HFOV	O
using	O
a	O
lung	O
recruitment	O
strategy	O
ameliorates	O
the	O
acute	O
lung	O
injury	O
in	O
respiratory	O
distress	O
syndrome	O
that	O
predisposes	O
some	O
preterm	O
infants	O
to	O
develop	O
chronic	O
lung	O
disease	O
.	O

Future	O
studies	O
will	O
build	O
on	O
these	O
observations	O
to	O
expand	O
the	O
list	O
of	O
pro	B-CHED
-	O
and	O
anti	O
-	O
inflammatory	O
coupling	O
factors	O
and	O
explore	O
the	O
mechanisms	O
by	O
which	O
they	O
act	O
to	O
cause	O
or	O
prevent	O
lung	O
injury	O
in	O
acute	O
pancreatitis	O
.	O

These	O
data	O
indicate	O
that	O
CCR5	O
contributes	O
to	O
MHV	O
-	O
induced	O
demyelination	O
by	O
allowing	O
macrophages	O
to	O
traffic	O
into	O
the	O
CNS	B-CHED
.	O

PCT	O
was	O
detectable	O
in	O
BAL	B-CHED
fluids	O
of	O
all	O
14	O
patients	O
.	O

In	O
four	O
cases	O
,	O
a	O
partial	O
or	O
total	O
necrosis	O
of	O
a	O
fillet	O
flap	O
occurred	O
(	O
one	O
patient	O
with	O
diabetic	O
vascular	O
disease	O
,	O
one	O
with	O
Dupuytren	O
'	O
s	O
contracture	O
,	O
and	O
two	O
with	O
high	O
-	O
voltage	B-CHED
electrical	O
injuries	O
).	O
Thirty	O
-	O
six	O
pedicled	O
limb	O
fillet	O
flaps	O
were	O
used	O
in	O
35	O
cases	O
.	O

A	O
therapeutic	O
approach	O
with	O
intravenous	O
immunoglobulins	O
(	O
IVIG	O
)	O
associated	O
with	O
pulse	O
methylprednisolone	B-CHED
,	O
based	O
on	O
the	O
inhibition	O
of	O
Fas	O
-	O
mediated	O
keratinocyte	O
death	O
by	O
naturally	O
occurring	O
Fas	O
-	O
blocking	O
antibodies	O
included	O
in	O
human	O
immunoglobulin	O
preparations	O
,	O
has	O
produced	O
good	O
preliminary	O
results	O
.	O

2	O
.	O
8	O
cm	O
H2O	B-CHED
;	O
and	O
mean	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
,	O
20	O
+/-	O

Most	O
of	O
the	O
amino	B-CHED
acid	I-CHED
substitutions	O
locate	O
in	O
the	O
putative	O
signal	O
sequence	O
and	O
two	O
short	O
hypervariable	O
regions	O
at	O
the	O
amino	O
terminus	O
.	O

The	O
ORF5	O
gene	O
sequence	O
of	O
the	O
acute	O
PRRSV	O
isolate	O
98	O
-	O
37120	O
-	O
2	O
from	O
a	O
non	O
-	O
vaccinated	O
swine	O
herd	O
in	O
Iowa	O
is	O
very	O
closely	O
related	O
to	O
that	O
of	O
the	O
RespPRRS	O
MLV	O
,	O
with	O
97	O
%	O
nucleotide	B-CHED
and	O
96	O
%	O
amino	B-CHED
acid	I-CHED
sequence	O
identities	O
.	O

A	O
59	O
-	O
year	O
-	O
old	O
man	B-CHED
with	O
mild	O
pulmonary	O
emphysema	O
had	O
been	O
followed	O
for	O
two	O
years	O
.	O

PCP	B-CHED
was	O
diagnosed	O
by	O
examination	O
of	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
),	O
and	O
the	O
patient	O
was	O
treated	O
with	O
intravenously	O
administered	O
trimethoprim	B-CHED
-	O
sulphamethoxazole	O
(	O
TMP	B-CHED
-	O
SMX	B-CHED
)	O
and	O
methylprednisolone	B-CHED
.	O

Staphylococcal	O
scarlet	O
fever	O
is	O
not	O
related	O
to	O
exfoliatin	O
as	O
previously	O
believed	O
,	O
but	O
to	O
enterotoxins	O
or	O
TSST	B-CHED
-	O
1	O
,	O
so	O
it	O
seems	O
to	O
be	O
an	O
abortive	O
form	O
of	O
toxic	O
shock	O
syndrome	O
.	O

Erythrogenic	O
toxins	B-CHED
produced	O
by	O
Streptococcus	O
pyogenes	O
are	O
involved	O
in	O
a	O
streptococcal	O
form	O
of	O
toxic	O
shock	O
syndrome	O
with	O
a	O
quite	O
similar	O
presentation	O
.	O

Eighteen	O
showed	O
severe	O
ARF	O
(	O
Serum	O
creatinine	B-CHED
>	O
5	O
mg	O
%).	O

Further	O
,	O
peripheral	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
cells	O
from	O
immunized	O
CCR2	O
(-/-)	O
mice	O
displayed	O
a	O
marked	O
reduction	O
in	O
IFN	O
-	O
gamma	O
production	O
in	O
response	O
to	O
viral	O
Ag	O
and	O
did	O
not	O
migrate	O
into	O
the	O
CNS	B-CHED
of	O
MHV	O
-	O
infected	O
recombination	O
-	O
activating	O
gene	O
(	O
RAG	O
)	O
1	O
(-/-)	O
mice	O
following	O
adoptive	O
transfer	O
.	O

In	O
addition	O
,	O
macrophage	O
/	O
microglial	O
infiltration	O
into	O
the	O
CNS	B-CHED
of	O
RAG1	O
(-/-)	O
mice	O
receiving	O
CCR2	O
(-/-)	O
splenocytes	O
was	O
reduced	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
05	O
),	O
which	O
correlated	O
with	O
a	O
reduction	O
in	O
the	O
severity	O
of	O
demyelination	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
as	O
compared	O
with	O
RAG1	O
(-/-)	O
mice	O
receiving	O
splenocytes	O
from	O
CCR2	O
(+/+)	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
immune	O
response	O
to	O
a	O
naked	O
plasmid	O
DNA	O
encoding	O
the	O
nucleoprotein	O
(	O
N	O
protein	B-CHED
)	O
of	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
was	O
investigated	O
in	O
this	O
study	O
.	O

ABSTRACT	O
:	O
Three	O
soluble	O
receptor	O
-	O
resistant	O
(	O
srr	O
)	O
mutants	O
,	O
srr7	O
,	O
srr11	O
and	O
srr18	O
,	O
derived	O
from	O
a	O
highly	O
neurotropic	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
JHMV	O
have	O
a	O
single	O
amino	B-CHED
acid	I-CHED
mutation	O
in	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
.	O

Twelve	O
animals	O
had	O
moderate	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
50	O
%	O
to	O
70	O
%	O
FiO2	O
at	O
sea	O
level	O
to	O
maintain	O
PaO2	O
of	O
50	O
-	O
70	O
torr	O
[	O
6	O
.	O
65	O
-	O
9	O
.	O
31kPa	O
])	O
induced	O
by	O
intravenous	O
oleic	B-CHED
acid	I-CHED
.	O

The	O
existence	O
of	O
a	O
population	O
of	O
M	O
molecules	O
adopting	O
a	O
Nexo	O
-	O
Cexo	O
topology	O
in	O
the	O
virion	O
envelope	O
was	O
demonstrated	O
by	O
(	O
i	O
)	O
immunopurification	O
of	O
(	O
35	O
)	O
S	O
-	O
labeled	O
TGEV	O
virions	O
using	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
specific	O
for	O
the	O
M	O
protein	B-CHED
carboxy	B-CHED
terminus	O
(	O
this	O
immunopurification	O
was	O
inhibited	O
only	O
by	O
deletion	O
mutant	O
M	O
proteins	B-CHED
that	O
maintained	O
an	O
intact	O
carboxy	B-CHED
terminus	O
),	O
(	O
ii	O
)	O
direct	O
binding	O
of	O
M	O
-	O
specific	O
MAbs	O
to	O
the	O
virus	O
surface	O
,	O
and	O
(	O
iii	O
)	O
mass	O
spectrometry	O
analysis	O
of	O
peptides	B-CHED
released	O
from	O
trypsin	O
-	O
treated	O
virions	O
.	O

Patients	O
with	O
major	O
trauma	O
underwent	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
and	O
IL	O
-	O
8	O
levels	O
were	O
measured	O
in	O
BAL	B-CHED
fluid	O
by	O
ELISA	O
.	O

Hypoxia	O
downregulated	O
a	O
range	O
of	O
other	O
proinflammatory	O
mediators	O
,	O
including	O
MCP	B-CHED
-	O
1	O
and	O
TNF	O
-	O
alpha	O
.	O

The	O
buoyant	O
density	O
of	O
the	O
virus	O
determined	O
in	O
sucrose	B-CHED
was	O
1	O
.	O
17	O
-	O
1	O
.	O
19	O
g	O
/	O
ml	O
.	O

In	O
summary	O
,	O
the	O
first	O
characterization	O
of	O
a	O
new	O
virus	O
that	O
might	O
represent	O
a	O
member	O
of	O
a	O
novel	O
virus	O
family	O
that	O
has	O
morphological	O
features	O
resembling	O
those	O
found	O
in	O
rhabdo	O
-,	O
corona	B-CHED
-	O
and	O
baculoviruses	O
is	O
presented	O
.	O

Vascular	O
catheters	O
were	O
placed	O
in	O
the	O
femoral	O
artery	O
and	O
vein	O
and	O
a	O
Swan	O
-	O
Ganz	O
catheter	O
in	O
the	O
external	O
jugular	O
vein	O
under	O
general	B-CHED
anaesthetic	I-CHED
.	O

The	O
use	O
of	O
urea	B-CHED
for	O
the	O
management	O
of	O
hyponatremia	O
could	O
represent	O
a	O
good	O
alternative	O
to	O
hypertonic	O
saline	O
.	O

Coronaviral	O
particles	O
from	O
intestinal	O
contents	O
or	O
the	O
sucrose	B-CHED
density	O
gradient	O
preparation	O
were	O
mainly	O
spherical	O
in	O
shape	O
and	O
had	O
envelope	O
and	O
central	O
depression	O
.	O

Unlike	O
any	O
other	O
,	O
the	O
BMV	O
-	O
based	O
system	O
enables	O
homologous	O
and	O
nonhomologous	O
recombination	O
studies	O
at	O
both	O
the	O
protein	B-CHED
and	O
RNA	O
levels	O
.	O

No	O
interactions	O
occurred	O
between	O
dietary	O
Lys	B-CHED
and	O
Arg	B-CHED
in	O
Experiment	O
1	O
.	O

Antibody	O
production	O
in	O
response	O
to	O
BA	O
antigens	B-CHED
was	O
not	O
influenced	O
by	O
VE	O
.	O

Similarly	O
,	O
PEEP	B-CHED
set	O
at	O
25	O
cmH2O	O
did	O
not	O
improve	O
oxygenation	O
or	O
compliance	O
.	O

Recently	O
,	O
cDNA	O
microarray	O
analyses	O
were	O
performed	O
that	O
indicated	O
several	O
pathogenic	O
responses	O
during	O
nickel	B-CHED
-	O
induced	O
ALI	O
,	O
including	O
marked	O
macrophage	O
activation	O
.	O

Macrophage	O
activation	O
is	O
mediated	O
,	O
in	O
part	O
,	O
via	O
the	O
receptor	O
tyrosine	B-CHED
kinase	O
Ron	O
.	O

Ron	O
tk	O
-/-	O
mice	O
succumb	O
to	O
nickel	B-CHED
-	O
induced	O
ALI	O
earlier	O
,	O
express	O
larger	O
,	O
early	O
increases	O
in	O
interleukin	O
-	O
6	O
,	O
monocyte	O
chemoattractant	O
protein	B-CHED
-	O
1	O
,	O
and	O
macrophage	O
inflammatory	O
protein	B-CHED
-	O
2	O
,	O
display	O
greater	O
serum	O
nitrite	B-CHED
levels	O
,	O
and	O
exhibit	O
earlier	O
onset	O
of	O
pulmonary	O
pathology	O
and	O
augmented	O
pulmonary	O
tyrosine	B-CHED
nitrosylation	O
.	O

TITLE	O
:	O
VirOligo	O
:	O
a	O
database	O
of	O
virus	O
-	O
specific	O
oligonucleotides	B-CHED
.	O

ABSTRACT	O
:	O
VirOligo	O
is	O
a	O
database	O
of	O
virus	O
-	O
specific	O
oligonucleotides	B-CHED
.	O

Each	O
oligonucleotide	B-CHED
entry	O
contains	O
links	O
to	O
PubMed	O
,	O
GenBank	O
,	O
NCBI	O
Taxonomy	O
databases	O
and	O
BLAST	O
.	O

However	O
,	O
vaccination	O
by	O
repeated	O
injections	O
of	O
plasmids	O
encoding	O
these	O
proteins	B-CHED
did	O
not	O
protect	O
kittens	O
against	O
challenge	O
infection	O
with	O
FIPV	O
.	O

for	O
30	O
min	O
before	O
the	O
oleic	B-CHED
acid	I-CHED
and	O
then	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
h	O
,	O
i	O
.	O
v	O
.	O

At	O
40	O
-	O
48	O
h	O
post	O
-	O
injury	O
,	O
animals	O
underwent	O
cannulation	O
of	O
the	O
carotid	O
artery	O
and	O
jugular	O
vein	O
and	O
were	O
then	O
randomized	O
to	O
HD	O
heparin	B-CHED
(	O
activated	O
clotting	O
time	O
,	O
ACT	O
>	O
300s	O
,	O
n	O
=	O
6	O
)	O
and	O
LD	O
heparin	B-CHED
(	O
ACT	O
<	O
200s	O
,	O
n	O
=	O
7	O
)	O
and	O
placed	O
on	O
AVCO2R	O
for	O
approximately	O
72	O
h	O
using	O
an	O
oxygenator	O
with	O
the	O
Trillium	O
Bio	O
-	O
Passive	O
Surface	O
.	O

In	O
conclusion	O
,	O
LD	O
systemic	O
heparin	B-CHED
(	O
ACT	O
<	O
200s	O
)	O
with	O
a	O
heparin	B-CHED
-	O
coated	O
oxygenator	O
does	O
not	O
increase	O
thrombogenicity	O
during	O
AVCO2R	O
for	O
smoke	O
/	O
burn	O
-	O
induced	O
severe	O
lung	O
injury	O
in	O
sheep	O
.	O

Concomitantly	O
,	O
surfactant	B-CHED
proteins	B-CHED
and	O
Clara	O
cell	O
secretory	O
protein	B-CHED
mRNA	B-CHED
expression	O
decreased	O
.	O

The	O
rnELISA	O
can	O
be	O
an	O
alternative	O
for	O
the	O
diagnosis	O
of	O
TGE	O
with	O
a	O
great	O
advantage	O
in	O
antigen	B-CHED
preparation	O
.	O

Results	O
to	O
date	O
have	O
shown	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	O
)	O
to	O
improve	O
oxygenation	O
in	O
the	O
majority	O
of	O
patients	O
but	O
fail	O
to	O
improve	O
mortality	O
.	O

Among	O
these	O
,	O
neutrophil	B-CHED
elastase	I-CHED
inhibitors	I-CHED
have	O
shown	O
the	O
most	O
promise	O
and	O
are	O
currently	O
undergoing	O
Phase	O
III	O
trials	O
.	O

Furthermore	O
,	O
fusion	O
of	O
BHK	O
cells	O
expressing	O
the	O
JHMV	O
srr7	O
S	O
protein	B-CHED
was	O
also	O
induced	O
by	O
soMHVR	O
.	O

We	O
conclude	O
that	O
the	O
binding	O
of	O
soMHVR	O
to	O
the	O
S	O
protein	B-CHED
converts	O
the	O
S	O
protein	B-CHED
to	O
a	O
fusion	O
-	O
active	O
form	O
competent	O
to	O
mediate	O
cell	O
-	O
cell	O
fusion	O
,	O
in	O
a	O
fashion	O
similar	O
to	O
the	O
fusion	O
of	O
virus	O
and	O
cell	O
membranes	O
.	O

Upon	O
treatment	O
with	O
brefeldin	B-CHED
A	I-CHED
,	O
both	O
the	O
E	O
and	O
CTE	O
proteins	B-CHED
redistributed	O
to	O
punctate	O
structures	O
that	O
colocalized	O
with	O
the	O
Golgi	O
matrix	O
proteins	B-CHED
GM130	O
and	O
p115	O
instead	O
of	O
being	O
localized	O
to	O
the	O
endoplasmic	O
reticulum	O
like	O
Golgi	O
glycosylation	O
enzymes	O
.	O

TITLE	O
:	O
Transcription	O
regulatory	O
sequences	O
and	O
mRNA	B-CHED
expression	O
levels	O
in	O
the	O
coronavirus	O
transmissible	O
gastroenteritis	O
virus	O
.	O

Virus	O
protein	B-CHED
levels	O
were	O
shown	O
to	O
be	O
dependent	O
on	O
transcription	O
and	O
translation	O
regulation	O
.	O

The	O
TOCVs	O
also	O
cross	O
-	O
reacted	O
in	O
an	O
AC	O
-	O
ELISA	O
with	O
MAbs	O
against	O
the	O
M	O
and	O
subunit	O
2	O
of	O
spike	O
glycoprotein	B-CHED
of	O
IBV	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
roles	O
of	O
peroxynitrite	B-CHED
(	O
ONOO	O
(-))	O
in	O
acute	O
lung	O
injury	O
induced	O
by	O
lipopolysaccharides	B-CHED
(	O
LPS	B-CHED
).	O

TITLE	O
:	O
The	O
controversy	O
of	O
the	O
treatment	O
of	O
critically	O
ill	O
patients	O
with	O
thyroid	B-CHED
hormone	I-CHED
.	O

The	O
changes	O
include	O
low	O
levels	O
of	O
thyroxine	B-CHED
and	O
very	O
low	O
levels	O
of	O
tri	O
-	O
iodothyronine	B-CHED
,	O
which	O
would	O
,	O
on	O
the	O
surface	O
,	O
appear	O
to	O
indicate	O
hypothyroidism	O
.	O

In	O
spite	O
of	O
a	O
very	O
large	O
number	O
of	O
published	O
studies	O
,	O
it	O
is	O
very	O
difficult	O
to	O
form	O
clear	O
recommendations	O
for	O
treatment	O
with	O
thyroid	B-CHED
hormone	I-CHED
in	O
the	O
intensive	O
care	O
unit	O
.	O

ABSTRACT	O
:	O
Contributions	O
of	O
humoral	O
and	O
cellular	O
immunity	O
in	O
controlling	O
neurotropic	O
mouse	O
hepatitis	O
virus	O
persistence	O
within	O
the	O
CNS	B-CHED
were	O
determined	O
in	O
B	O
cell	O
-	O
deficient	O
J	O
(	O
H	O
)	O
D	O
and	O
syngeneic	O
H	O
-	O
2	O
(	O
d	O
)	O
B	O
cell	O
+	O
Ab	O
-	O
deficient	O
mice	O
.	O

Increasing	O
viral	O
load	O
did	O
not	O
enhance	O
frequencies	O
or	O
effector	B-CHED
function	O
of	O
virus	O
-	O
specific	O
T	O
cells	O
within	O
the	O
CNS	B-CHED
,	O
indicating	O
down	O
-	O
regulation	O
of	O
T	O
cell	O
responses	O
.	O

The	O
K	O
(	O
m	O
)	O
values	O
of	O
the	O
MHV	O
-	O
like	O
esterases	O
for	O
the	O
latter	O
substrates	O
were	O
two	O
-	O
to	O
tenfold	O
lower	O
than	O
those	O
of	O
the	O
sialate	B-CHED
-	O
9	O
-	O
O	O
-	O
acetylesterases	O
of	O
influenza	O
C	O
viruses	O
.	O

The	O
lowest	O
detection	O
limit	O
of	O
the	O
antigen	B-CHED
-	O
capture	O
ELISA	O
as	O
determined	O
by	O
using	O
the	O
same	O
serially	O
diluted	O
samples	O
was	O
1	O
x	O
10	O
(	O
6	O
)	O
TCID50	O
/	O
0	O
.	O
1	O
ml	O
for	O
each	O
strain	O
.	O

TGEV	O
nucleic	B-CHED
acid	I-CHED
was	O
detected	O
in	O
the	O
duodenum	O
,	O
jejunum	O
and	O
ileum	O
of	O
pigs	O
inoculated	O
with	O
the	O
Purdue	O
or	O
Miller	O
strain	O
but	O
only	O
in	O
the	O
jejunum	O
and	O
ileum	O
of	O
those	O
inoculated	O
with	O
the	O
Korean	O
strain	O
.	O

Diarrhea	O
was	O
observed	O
in	O
32	O
%	O
of	O
the	O
pigs	O
and	O
virus	O
shedding	O
was	O
demonstrated	O
in	O
100	O
%	O
between	O
postinoculation	O
day	O
(	O
PID	B-CHED
)	O
1	O
and	O
8	O
.	O

IgA	O
and	O
IgG	O
ASC	O
responses	O
were	O
evident	O
in	O
the	O
intestinal	O
lymphoid	O
tissues	O
from	O
PID	B-CHED
21	O
,	O
the	O
highest	O
number	O
of	O
specific	O
ASC	O
corresponded	O
to	O
the	O
duodenum	O
lamina	O
propria	O
.	O

The	O
data	O
strongly	O
suggest	O
that	O
,	O
first	O
,	O
the	O
FIPV	O
3CL	O
(	O
pro	B-CHED
)	O
catalytic	O
system	O
employs	O
His	O
(	O
41	O
)	O
and	O
Cys	B-CHED
(	O
144	O
)	O
as	O
the	O
principal	O
catalytic	O
residues	O
.	O

Surprisingly	O
,	O
some	O
of	O
the	O
Asn	B-CHED
(	O
64	O
)	O
mutants	O
even	O
exhibited	O
strongly	O
increased	O
activities	O
.	O

ABSTRACT	O
:	O
The	O
key	O
enzyme	O
in	O
coronavirus	O
replicase	O
polyprotein	O
processing	O
is	O
the	O
coronavirus	O
main	O
protease	O
,	O
3CL	O
(	O
pro	B-CHED
).	O

Combined	O
treatment	O
with	O
methylprednisolone	B-CHED
and	O
erythromycin	B-CHED
was	O
successful	O
and	O
led	O
to	O
a	O
favorable	O
outcome	O
.	O

TITLE	O
:	O
Lack	O
of	O
nitric	B-CHED
oxide	I-CHED
synthase	O
type	O
2	O
(	O
NOS2	O
)	O
results	O
in	O
reduced	O
neuronal	O
apoptosis	O
and	O
mortality	O
following	O
mouse	O
hepatitis	O
virus	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
.	O

The	O
results	O
show	O
that	O
the	O
S	O
-	O
fg	O
fusion	O
protein	B-CHED
is	O
highly	O
cross	O
-	O
reactive	O
among	O
different	O
IBV	O
serotypes	O
,	O
and	O
the	O
S	O
-	O
fg	O
ELISA	O
is	O
found	O
to	O
be	O
a	O
convenient	O
,	O
economical	O
,	O
and	O
efficient	O
method	O
for	O
antibody	O
detection	O
against	O
IBV	O
.	O

PROM20	O
infants	O
had	O
an	O
increased	O
acute	O
respiratory	O
morbidity	O
(	O
higher	O
ventilator	O
settings	O
and	O
increased	O
incidence	O
of	O
hypoxemia	O
,	O
hypercapnia	O
,	O
and	O
pulmonary	O
hypertension	O
)	O
and	O
a	O
trend	O
to	O
more	O
air	B-CHED
leaks	O
.	O

RESULTS	O
:	O
PROM20	O
infants	O
had	O
an	O
increased	O
acute	O
respiratory	O
morbidity	O
(	O
higher	O
ventilator	O
settings	O
and	O
increased	O
incidence	O
of	O
hypoxemia	O
,	O
hypercapnia	O
,	O
and	O
pulmonary	O
hypertension	O
)	O
and	O
a	O
trend	O
to	O
more	O
air	B-CHED
leaks	O
.	O

Only	O
a	O
small	O
response	O
was	O
detected	O
in	O
the	O
groups	O
inoculated	O
with	O
attenuated	O
PEDV	O
,	O
whereas	O
in	O
the	O
group	O
previously	O
exposed	O
to	O
the	O
virulent	O
virus	O
on	O
PID	B-CHED
21	O
a	O
large	O
number	O
of	O
IgG	O
and	O
IgA	O
ASC	O
was	O
detected	O
.	O

ABSTRACT	O
:	O
Blood	O
was	O
collected	O
from	O
55	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
and	O
from	O
50	O
control	O
cats	O
in	O
order	O
to	O
define	O
whether	O
differences	O
in	O
pathological	O
findings	O
and	O
in	O
distribution	O
of	O
feline	O
coronaviruses	O
(	O
FCoV	O
)	O
can	O
be	O
associated	O
with	O
changes	O
in	O
haemograms	O
,	O
serum	O
protein	B-CHED
electrophoresis	O
,	O
and	O
antibody	O
titres	O
.	O

While	O
cellular	O
immunity	O
initially	O
eliminates	O
infectious	O
virus	O
,	O
CNS	B-CHED
viral	O
persistence	O
is	O
predominantly	O
controlled	O
by	O
humoral	O
immunity	O
.	O

Rapid	O
recruitment	O
of	O
B	O
cells	O
in	O
the	O
absence	O
of	O
specific	O
Ab	O
secretion	O
supports	O
a	O
potential	O
Ab	O
-	O
independent	O
effector	B-CHED
function	O
involving	O
lysis	O
of	O
virus	O
-	O
infected	O
cells	O
.	O

However	O
,	O
the	O
precise	O
and	O
relative	O
roles	O
of	O
the	O
two	O
proteins	B-CHED
in	O
BCV	O
infectivity	O
remain	O
elusive	O
.	O

In	O
contrast	O
,	O
chimeric	O
viruses	O
that	O
contain	O
biologically	O
active	O
and	O
functional	O
BCV	O
HE	O
protein	B-CHED
on	O
the	O
surface	O
failed	O
to	O
enter	O
HRT	O
-	O
18	O
cells	O
,	O
indicating	O
that	O
the	O
BCV	O
HE	O
protein	B-CHED
alone	O
is	O
not	O
sufficient	O
for	O
BCV	O
infection	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
evaluate	O
the	O
effects	O
of	O
nitric	B-CHED
oxide	I-CHED
inhalation	O
on	O
bacterial	O
clearance	O
during	O
bacterial	O
pneumonia	O
and	O
on	O
alveolar	O
neutrophil	O
functions	O
.	O

After	O
instillation	O
,	O
rats	O
were	O
exposed	O
to	O
oxygen	B-CHED
alone	O
(	O
FIO	O
(	O
2	O
)	O
100	O
%)	O
or	O
to	O
oxygen	B-CHED
(	O
FIO	O
(	O
2	O
)	O
approximately	O
100	O
%)	O
plus	O
nitric	B-CHED
oxide	I-CHED
(	O
10	O
ppm	O
)	O
during	O
24	O
hrs	O
.	O

However	O
,	O
neither	O
protein	B-CHED
concentration	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
nor	O
mortality	O
rates	O
were	O
modified	O
by	O
nitric	B-CHED
oxide	I-CHED
inhalation	O
.	O

Vascular	O
immunotargeting	O
of	O
the	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)-	O
generating	O
enzyme	O
glucose	B-CHED
oxidase	O
(	O
GOX	O
)	O
to	O
the	O
pulmonary	O
endothelium	O
causes	O
an	O
acute	O
oxidative	O
lung	O
injury	O
in	O
mice	O
.(	O
1	O
)	O
In	O
the	O
present	O
study	O
we	O
compared	O
the	O
pulmonary	O
thrombosis	O
and	O
leukocyte	O
transmigration	O
caused	O
by	O
GOX	O
targeting	O
to	O
the	O
endothelial	O
antigens	B-CHED
platelet	O
-	O
endothelial	O
cell	O
adhesion	O
molecule	O
(	O
PECAM	O
)	O
and	O
thrombomodulin	O
(	O
TM	O
).	O

Although	O
,	O
there	O
were	O
only	O
a	O
few	O
amino	B-CHED
acid	I-CHED
changes	O
between	O
the	O
respiratory	O
and	O
enteric	O
paired	O
isolates	O
,	O
the	O
other	O
two	O
respiratory	O
isolates	O
,	O
one	O
isolated	O
from	O
the	O
same	O
farm	O
as	O
a	O
paired	O
strain	O
and	O
the	O
other	O
from	O
a	O
different	O
farm	O
,	O
showed	O
more	O
sequence	O
diversity	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
a	O
role	O
for	O
IP	O
-	O
10	O
in	O
both	O
effector	B-CHED
T	O
cell	O
generation	O
and	O
trafficking	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
pharmacodynamics	O
and	O
pharmacokinetics	O
of	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
(	O
iNO	O
)	O
in	O
dogs	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Twenty	O
patients	O
with	O
severe	O
ARDS	O
were	O
switched	O
from	O
VC	O
-	O
CRV	O
to	O
PC	O
-	O
IRV	O
if	O
they	O
failed	O
to	O
maintain	O
SaO	O
(	O
2	O
)	O
>	O
90	O
%	O
by	O
the	O
following	O
criteria	O
:	O
peak	O
inspiratory	O
pressure	O
(	O
PIP	B-CHED
)	O
>	O
35	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
FIO	O
(	O
2	O
)	O
=	O
60	O
%,	O
and	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
10	O
cm	O
H	O
(	O
2	O
)	O
O	O
.	O
The	O
values	O
of	O
PIP	B-CHED
,	O
mean	O
airway	O
pressure	O
,	O
minute	O
volumes	O
,	O
and	O
lung	O
injury	O
score	O
in	O
VC	O
-	O
CRV	O
were	O
43	O
.	O
9	O
+/-	O

Sorbent	O
columns	O
of	O
charcoal	O
and	O
an	O
anion	B-CHED
exchanger	O
remove	O
hepatic	O
toxins	B-CHED
from	O
the	O
albumin	O
dialysate	O
,	O
and	O
a	O
second	O
dialyzer	O
removes	O
water	B-CHED
-	O
soluble	O
toxins	B-CHED
,	O
such	O
as	O
ammonium	B-CHED
.	O

The	O
PF	O
add	B-CHED
-	O
on	O
module	O
adds	O
the	O
capability	O
to	O
Liver	O
Dialysis	O
to	O
remove	O
bilirubin	B-CHED
,	O
bile	B-CHED
acids	I-CHED
,	O
and	O
other	O
strongly	O
protein	B-CHED
-	O
bound	O
toxins	B-CHED
from	O
treated	O
patients	O
and	O
may	O
be	O
of	O
clinical	O
benefit	O
in	O
management	O
of	O
patients	O
with	O
the	O
most	O
severe	O
hepatic	O
failure	O
and	O
encephalopathy	O
,	O
including	O
patients	O
with	O
FHF	O
or	O
concomitant	O
sepsis	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
role	O
of	O
sPLA	O
(	O
2	O
)	O
in	O
chemokine	O
production	O
in	O
human	O
lung	O
microvascular	O
endothelial	O
cells	O
(	O
LMVEC	O
)	O
stimulated	O
with	O
the	O
endotoxins	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)	O
and	O
lipoteichoic	B-CHED
acid	I-CHED
(	O
LTA	O
).	O

ABSTRACT	O
:	O
Orthoesterol	O
B	O
,	O
a	O
marine	O
natural	B-CHED
product	I-CHED
exhibiting	O
antiviral	B-CHED
activities	O
,	O
contains	O
a	O
[	O
3	O
.	O
2	O
.	O
1	O
]-	O
bicyclic	O
orthobutyrate	O
bridging	O
the	O
steroid	B-CHED
side	O
chain	O
and	O
ring	O
D	O
.	O
A	O
biosynthetic	O
reaction	O
was	O
proposed	O
by	O
which	O
rearrangement	O
of	O
an	O
epoxy	B-CHED
ester	B-CHED
results	O
in	O
the	O
formation	O
of	O
the	O
orthoester	O
moiety	O
.	O

We	O
have	O
constructed	O
a	O
mutant	O
,	O
M	O
(	O
Delta	O
)	O
2	O
,	O
containing	O
a	O
two	O
-	O
amino	O
-	O
acid	O
truncation	O
of	O
the	O
M	O
protein	B-CHED
that	O
was	O
previously	O
thought	O
to	O
be	O
lethal	O
.	O

Comparison	O
of	O
cells	O
expressing	O
IBV	O
N	O
protein	B-CHED
with	O
controls	O
indicated	O
that	O
cells	O
expressing	O
N	O
protein	B-CHED
had	O
delayed	O
cellular	O
growth	O
.	O

Antigen	B-CHED
and	O
nucleic	B-CHED
acid	I-CHED
of	O
PEDV	O
were	O
detected	O
in	O
15	O
/	O
15	O
,	O
13	O
/	O
15	O
,	O
and	O
14	O
/	O
15	O
of	O
the	O
intestinal	O
and	O
fecal	O
samples	O
from	O
the	O
PEDV	O
-	O
inoculated	O
pigs	O
by	O
RT	O
-	O
PCR	O
,	O
immunohistochemistry	O
,	O
and	O
in	O
situ	O
hybridization	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Analyses	O
of	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinases	O
(	O
MAPKs	O
)	O
in	O
a	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)-	O
infected	O
macrophage	O
-	O
derived	O
J774	O
.	O
1	O
cell	O
line	O
showed	O
activation	O
of	O
two	O
MAPKs	O
,	O
p38	O
MAPK	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
),	O
but	O
not	O
of	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
).	O

By	O
comparing	O
parental	O
TGEV	O
with	O
mutant	O
viruses	O
deficient	O
in	O
the	O
sialic	B-CHED
acid	I-CHED
binding	O
activity	O
,	O
we	O
determined	O
the	O
contributions	O
of	O
both	O
binding	O
activities	O
to	O
the	O
attachment	O
of	O
TGEV	O
to	O
cultured	O
cells	O
.	O

In	O
virus	O
overlay	O
binding	O
assays	O
with	O
immobilized	O
cell	O
surface	O
proteins	B-CHED
,	O
the	O
mutant	O
virus	O
only	O
recognized	O
pAPN	O
.	O

ABSTRACT	O
:	O
More	O
than	O
10	O
mature	O
proteins	B-CHED
processed	O
from	O
coronavirus	O
gene	O
1	O
-	O
encoded	O
polyproteins	O
have	O
been	O
identified	O
in	O
virus	O
-	O
infected	O
cells	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
the	O
most	O
C	O
-	O
terminal	O
cleavage	O
product	O
of	O
the	O
1a	O
polyprotein	O
as	O
a	O
16	O
-	O
kDa	O
protein	B-CHED
in	O
infectious	O
bronchitis	O
virus	O
-	O
infected	O
Vero	O
cells	O
.	O

ABSTRACT	O
:	O
As	O
bolus	O
instillation	O
of	O
surfactant	B-CHED
can	O
lead	O
to	O
acute	O
pulmonary	O
,	O
hemodynamic	O
and	O
cerebral	O
side	O
effects	O
,	O
we	O
tested	O
whether	O
pulmonary	O
mechanics	O
and	O
gas	O
exchange	O
differ	O
between	O
slow	O
surfactant	B-CHED
infusion	O
and	O
bolus	O
administration	O
.	O

Far	O
-	O
reaching	O
or	O
even	O
complete	O
normalization	O
of	O
the	O
PL	O
profile	O
,	O
the	O
LA	O
fraction	O
and	O
its	O
SP	O
-	O
B	O
and	O
SP	O
-	O
C	O
(	O
but	O
not	O
SP	O
-	O
A	O
)	O
content	O
as	O
well	O
as	O
the	O
fatty	B-CHED
acid	I-CHED
composition	O
of	O
the	O
phosphatidylcholine	B-CHED
class	O
was	O
noted	O
.	O

Bronchoscopic	O
administration	O
of	O
large	O
quantities	O
of	O
natural	O
bovine	O
surfactant	B-CHED
in	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
causes	O
far	O
-	O
reaching	O
restoration	O
of	O
biochemical	O
surfactant	B-CHED
properties	O
and	O
significant	O
improvement	O
,	O
however	O
not	O
full	O
normalization	O
,	O
of	O
biophysical	O
surfactant	B-CHED
function	O
.	O

A	O
natural	O
bovine	O
surfactant	B-CHED
extract	O
(	O
300	O
mg	O
x	O
kg	O
(-	O
1	O
)	O
bw	O
Alveofact	O
;	O
mean	O
total	O
volume	O
378	O
mL	O
)	O
was	O
delivered	O
in	O
divided	O
doses	O
to	O
each	O
segment	O
of	O
the	O
lungs	O
via	O
flexible	O
bronchoscope	O
within	O
approximately	O
45	O
min	O
.	O

ABSTRACT	O
:	O
The	O
soluble	O
receptor	O
-	O
resistant	O
(	O
srr	O
)	O
mutants	O
,	O
srr7	O
and	O
srr11	O
,	O
isolated	O
from	O
a	O
murine	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
JHMV	O
,	O
have	O
an	O
amino	B-CHED
acid	I-CHED
mutation	O
at	O
positions	O
1114	O
(	O
Leu	B-CHED
to	O
Phe	B-CHED
)	O
and	O
65	O
(	O
Leu	B-CHED
to	O
His	O
),	O
respectively	O
,	O
in	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
.	O

Srr7A	O
and	O
srr7B	O
S	O
proteins	B-CHED
showed	O
high	O
fusogenicity	O
in	O
both	O
BHK	O
-	O
R1	O
and	O
BHK	O
-	O
R2	O
cells	O
,	O
like	O
the	O
wt	O
virus	O
,	O
while	O
srr7Aa	O
and	O
srr7Ba	O
S	O
proteins	B-CHED
,	O
which	O
had	O
mutations	O
in	O
S1N330	O
-	O
III	O
but	O
not	O
at	O
amino	B-CHED
acid	I-CHED
1114	O
,	O
exhibited	O
profoundly	O
reduced	O
fusion	O
activity	O
in	O
these	O
cell	O
lines	O
.	O

IPP	O
and	O
best	O
-	O
PEEP	B-CHED
therapy	O
enabled	O
us	O
to	O
wean	O
all	O
of	O
our	O
patients	O
'	O
Fio2	O
to	O
<	O
or	O
=	O
0	O
.	O
50	O
within	O
48	O
hours	O
of	O
ARDS	O
onset	O
.	O

Ergotamine	B-CHED
reduced	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
plasma	O
LH	O
and	O
increased	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
growth	B-CHED
hormone	I-CHED
concentrations	O
in	O
Brahman	O
.	O

The	O
triiodothyronine	B-CHED
and	O
respiratory	O
comparisons	O
revealed	O
modified	O
responses	O
in	O
Brahman	O
that	O
suggest	O
a	O
potential	O
benefit	O
of	O
using	O
heat	O
-	O
tolerant	O
genetics	O
to	O
reduce	O
the	O
adverse	O
effects	O
of	O
fescue	O
toxicosis	O
in	O
cattle	O
.	O

This	O
corroborates	O
our	O
previous	O
conclusion	O
that	O
sufficient	O
amounts	O
of	O
eukaryotic	O
protein	B-CHED
co	O
-	O
factors	O
,	O
which	O
could	O
functionally	O
replace	O
IHF	O
,	O
are	O
not	O
present	O
in	O
human	O
cells	O
.	O

We	O
showed	O
previously	O
that	O
the	O
process	O
of	O
CD8	O
T	O
-	O
cell	O
-	O
mediated	O
demyelination	O
was	O
strongly	O
dependent	O
on	O
the	O
expression	O
of	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
by	O
donor	B-CHED
cells	O
.	O

ABSTRACT	O
:	O
Although	O
dietary	O
arginine	B-CHED
is	O
a	O
factor	O
in	O
immune	O
function	O
and	O
disease	O
resistance	O
,	O
the	O
full	O
range	O
of	O
effects	O
has	O
yet	O
to	O
be	O
described	O
.	O

This	O
article	O
will	O
provide	O
an	O
overview	O
on	O
how	O
these	O
molecules	O
regulate	O
T	O
cell	O
and	O
macrophage	O
trafficking	O
into	O
the	O
CNS	B-CHED
of	O
MHV	O
-	O
infected	O
mice	O
and	O
illustrate	O
the	O
delicate	O
balance	B-CHED
that	O
exists	O
with	O
regards	O
to	O
expression	O
of	O
chemokines	O
and	O
their	O
receptors	O
as	O
it	O
relates	O
to	O
both	O
host	O
defense	O
and	O
disease	O
development	O
.	O

The	O
objective	O
of	O
this	O
experiment	O
was	O
to	O
investigate	O
the	O
therapeutic	O
efficacy	O
of	O
a	O
supplemental	O
bovine	O
serum	O
protein	B-CHED
blend	O
fed	O
to	O
calves	O
challenged	O
with	O
virulent	O
coronavirus	O
.	O

Recently	O
several	O
congeners	O
of	O
GHB	B-CHED
,	O
gamma	O
butyrolactone	B-CHED
and	O
1	B-CHED
,	I-CHED
4	I-CHED
-	I-CHED
butanediol	I-CHED
,	O
have	O
emerged	O
as	O
drugs	O
of	O
abuse	O
and	O
show	O
toxidromes	O
similar	O
to	O
GHB	B-CHED
.	O

Molecular	O
modelling	O
and	O
mutagenesis	O
data	O
implicate	O
the	O
loop	O
in	O
substrate	O
binding	O
and	O
elucidate	O
S1	O
and	O
S2	O
subsites	O
suitable	O
to	O
accommodate	O
the	O
side	O
chains	O
of	O
the	O
P1	O
glutamine	B-CHED
and	O
P2	O
leucine	B-CHED
residues	O
of	O
M	O
(	O
pro	B-CHED
)	O
substrates	O
.	O

ABSTRACT	O
:	O
Granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
stimulates	O
hemopoiesis	O
and	O
effector	B-CHED
functions	O
of	O
granulocytes	O
and	O
macrophages	O
and	O
is	O
involved	O
in	O
pulmonary	O
surfactant	B-CHED
homeostasis	O
.	O

The	O
expression	O
of	O
MIF	O
mRNA	B-CHED
and	O
protein	B-CHED
in	O
the	O
lung	O
tissues	O
were	O
detected	O
by	O
using	O
double	O
immuno	O
histochemistry	O
labeling	O
and	O
in	O
situ	O
hybridization	O
.	O

In	O
the	O
intensive	O
care	O
unit	O
the	O
patient	O
received	O
the	O
same	O
drug	O
support	O
,	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
and	O
two	O
bronchoscopic	O
applications	O
of	O
bovine	O
surfactant	B-CHED
.	O

RESULTS	O
:	O
A	O
rapid	O
improvement	O
in	O
PaO2	O
/	O
FiO2	O
within	O
2	O
-	O
3	O
hours	O
of	O
administration	O
of	O
surfactant	B-CHED
was	O
seen	O
.	O

Using	O
transgenic	O
TCR	O
/	O
recombination	O
activation	O
gene	O
2	O
(-/-)	O
mice	O
with	O
only	O
non	O
-	O
mouse	O
hepatitis	O
virus	O
-	O
specific	O
T	O
cells	O
,	O
we	O
show	O
that	O
CD8	O
T	O
cells	O
are	O
able	O
to	O
cause	O
demyelination	O
in	O
the	O
absence	O
of	O
cognate	O
Ag	O
in	O
the	O
CNS	B-CHED
,	O
but	O
only	O
if	O
specifically	O
activated	O
.	O

ABSTRACT	O
:	O
Chlorine	B-CHED
gas	O
exposure	O
is	O
uncommon	O
in	O
children	O
and	O
when	O
it	O
occurs	O
usually	O
results	O
in	O
mild	O
ocular	O
,	O
oropharyngeal	O
,	O
or	O
respiratory	O
symptoms	O
.	O

An	O
antigen	B-CHED
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
used	O
to	O
detect	O
concurrent	O
shedding	O
of	O
BCV	O
in	O
fecal	O
and	O
nasal	O
samples	O
.	O

A	O
pool	O
of	O
Elisa	O
positive	O
sera	O
were	O
also	O
tested	O
to	O
clearly	O
identify	O
the	O
binding	O
profiles	O
of	O
CCoV	O
proteins	B-CHED
.	O

We	O
report	O
the	O
first	O
use	O
of	O
aerosolized	O
diethylenetriamine	B-CHED
nitric	B-CHED
oxide	I-CHED
adduct	O
(	O
DETA	O
/	O
NO	O
),	O
a	O
NONOate	B-CHED
,	O
in	O
a	O
patient	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

External	O
PEEP	B-CHED
needed	O
to	O
be	O
reduced	O
from	O
11	O
.	O
9	O
+/-	O
3	O
.	O
4	O
to	O
9	O
.	O
7	O
+/-	O
2	O
.	O
9	O
cmH	B-CHED
(	O
2	O
)	O
O	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

PaO	B-CHED
(	O
2	O
)	O
was	O
not	O
affected	O
but	O
the	O
alveolar	O
-	O
arterial	O
oxygen	B-CHED
tension	O
difference	O
slightly	O
worsened	O
with	O
the	O
high	O
respiratory	O
rate	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

The	O
ratio	O
of	O
arterial	O
blood	O
PaO	B-CHED
(	O
2	O
)	O
and	O
the	O
fraction	O
of	O
oxygen	B-CHED
in	O
the	O
ventilator	O
was	O
8	O
.	O
5	O
+/-	O
2	O
.	O
7	O
kPa	O
(	O
64	O
+/-	O
20	O
mmHg	O
)	O
before	O
transfer	O
and	O
9	O
.	O
7	O
+/-	O
3	O
.	O
6	O
kPa	O
(	O
73	O
+/-	O
27	O
mmHg	O
)	O
after	O
transfer	O
.	O

Molecular	O
analysis	O
showed	O
a	O
nucleotide	B-CHED
insertion	O
in	O
hypervariable	O
region	O
one	O
(	O
HVR	O
-	O
1	O
)	O
of	O
S1	O
gene	O
of	O
only	O
Quebec	O
isolates	O
(	O
Qu16	O
,	O
Qu_mv	O
and	O
Q_37zm	O
).	O

Donor	B-CHED
/	O
recipient	O
mixed	O
chimerism	O
was	O
attained	O
;	O
thereafter	O
rapid	O
autologous	O
hematopoietic	O
recovery	O
was	O
achieved	O
in	O
concordance	O
with	O
the	O
termination	O
of	O
immunosuppressants	O
.	O

Potential	O
mechanisms	O
of	O
lactate	B-CHED
production	O
by	O
the	O
injured	O
lung	O
may	O
include	O
not	O
only	O
the	O
onset	O
of	O
anaerobic	O
metabolism	O
in	O
hypoxic	O
zones	O
,	O
but	O
also	O
direct	O
cytokine	O
effects	O
on	O
pulmonary	O
cells	O
and	O
an	O
accelerated	O
glucose	B-CHED
metabolism	O
in	O
both	O
the	O
parenchymal	O
and	O
the	O
inflammatory	O
cells	O
infiltrating	O
lung	O
tissue	O
.	O

Prospective	O
randomized	O
trials	O
show	O
that	O
maintaining	O
gut	O
integrity	O
is	O
equally	O
as	O
important	O
as	O
placing	O
the	O
pancreas	O
at	O
rest	B-CHED
while	O
inflammation	O
within	O
the	O
gland	O
resolves	O
.	O

In	O
addition	O
,	O
a	O
B	O
-	O
cell	O
epitope	B-CHED
of	O
the	O
S2	O
glycoprotein	B-CHED
of	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
was	O
inserted	O
in	O
-	O
frame	O
to	O
replace	O
the	O
NP	O
-	O
IDE	B-CHED
.	O

Positioning	O
the	O
patient	O
prone	O
,	O
we	O
observed	O
a	O
prompt	O
increase	O
in	O
intracranial	O
pressure	O
,	O
which	O
resulted	O
in	O
pharmacological	O
intervention	O
(	O
mannitol	B-CHED
).	O

TITLE	O
:	O
Tissue	O
distribution	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
following	O
in	O
ovo	O
inoculation	O
of	O
chicken	O
embryos	O
examined	O
by	O
in	O
situ	O
hybridization	O
with	O
antisense	O
digoxigenin	B-CHED
-	O
labeled	O
universal	O
riboprobe	O
.	O

Extensive	O
antigen	B-CHED
staining	O
in	O
the	O
cytoplasm	O
of	O
epithelial	O
cells	O
in	O
the	O
trachea	O
,	O
lung	O
,	O
bursa	O
,	O
and	O
intestine	O
was	O
detected	O
at	O
2	O
dpi	O
with	O
all	O
8	O
strains	O
of	O
IBV	O
.	O

The	O
sheep	O
developed	O
a	O
hyperkinetic	O
cardiovascular	O
response	O
concomitant	O
with	O
a	O
decrease	O
in	O
Pao	B-CHED
similar	O
to	O
severe	O
sepsis	O
in	O
human	O
patients	O
who	O
meet	O
the	O
criteria	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
PaO2	O
/	O
FIO2	O
<	O
200	O
).	O

The	O
method	O
has	O
the	O
potential	O
to	O
be	O
used	O
to	O
construct	O
viral	O
,	O
microbial	O
,	O
or	O
eukaryotic	O
genomes	O
approaching	O
several	O
million	O
base	O
pairs	O
in	O
length	O
and	O
used	O
to	O
insert	O
restriction	O
sites	O
at	O
any	O
given	O
nucleotide	B-CHED
in	O
a	O
microbial	O
genome	O
.	O

TITLE	O
:	O
Early	O
versus	O
delayed	O
surfactant	B-CHED
administration	O
in	O
extremely	O
premature	O
neonates	O
with	O
respiratory	O
distress	O
syndrome	O
ventilated	O
by	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
.	O

Fewer	O
infants	O
randomized	O
to	O
the	O
EARL	O
group	O
required	O
oxygen	B-CHED
use	O
or	O
died	O
at	O
36	O
weeks	O
(	O
combined	O
outcome	O
29	O
%	O
vs	O
64	O
%,	O
p	O
=	O
0	O
.	O
021	O
),	O
and	O
there	O
was	O
a	O
lower	O
incidence	O
of	O
any	O
intraventricular	O
hemorrhage	O
in	O
this	O
group	O
(	O
43	O
vs	O
82	O
%,	O
p	O
=	O
0	O
.	O
008	O
).	O

In	O
several	O
postmortem	O
lungs	O
,	O
the	O
ELS	O
also	O
displayed	O
apple	O
-	O
green	O
birefringence	O
after	O
staining	O
with	O
Congo	B-CHED
red	I-CHED
,	O
suggesting	O
the	O
presence	O
of	O
amyloid	O
.	O

ABSTRACT	O
:	O
A	O
segment	O
of	O
genomic	O
RNA	O
extending	O
from	O
the	O
3	O
'-	O
end	O
of	O
the	O
membrane	O
(	O
M	O
)	O
protein	B-CHED
gene	O
to	O
the	O
5	O
'-	O
end	O
of	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
gene	O
of	O
Turkey	O
coronavirus	O
(	O
TCV	O
)	O
was	O
amplified	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

The	O
consensus	O
transcription	O
-	O
associated	O
sequence	O
of	O
IBV	O
,	O
CTTAACAA	O
,	O
was	O
highly	O
conserved	O
in	O
the	O
TCV	O
genome	O
with	O
regard	O
to	O
nucleotide	B-CHED
sequence	O
and	O
location	O
in	O
terms	O
of	O
the	O
initiation	O
codons	O
of	O
the	O
genes	O
5	O
and	O
N	O
.	O
The	O
similarities	O
between	O
the	O
predicted	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
ORFs	O
5a	O
and	O
5b	O
of	O
TCV	O
isolates	O
and	O
the	O
homologous	O
genes	O
of	O
IBV	O
strains	O
were	O
85	O
.	O
4	O
%	O
to	O
94	O
.	O
0	O
%.	O

Furthermore	O
,	O
since	O
sera	O
from	O
mice	O
immunized	O
with	O
a	O
purified	O
fraction	O
of	O
the	O
rat	O
liver	O
enzyme	O
do	O
react	O
with	O
its	O
homologous	O
protein	B-CHED
,	O
this	O
antiserum	O
can	O
be	O
used	O
as	O
a	O
positive	O
control	O
avoiding	O
the	O
manipulation	O
of	O
samples	O
from	O
MHV	O
-	O
infected	O
animals	O
.	O

TITLE	O
:	O
Systemic	O
inflammatory	O
response	O
induced	O
by	O
particulate	O
matter	O
air	B-CHED
pollution	O
:	O
the	O
importance	O
of	O
bone	O
-	O
marrow	O
stimulation	O
.	O

TITLE	O
:	O
The	O
virulence	O
of	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
is	O
not	O
dependent	O
on	O
efficient	O
spike	O
protein	B-CHED
cleavage	O
and	O
cell	O
-	O
to	O
-	O
cell	O
fusion	O
.	O

Targeted	O
recombination	O
was	O
used	O
to	O
introduce	O
amino	B-CHED
acid	I-CHED
substitutions	O
into	O
the	O
cleavage	O
signal	O
of	O
the	O
fusion	O
glycoprotein	B-CHED
(	O
spike	O
or	O
S	O
protein	B-CHED
)	O
of	O
MHV	O
strain	O
A59	O
.	O

The	O
recombinants	O
were	O
then	O
used	O
to	O
address	O
the	O
question	O
of	O
the	O
importance	O
of	O
S	O
protein	B-CHED
cleavage	O
and	O
viral	O
-	O
mediated	O
cell	O
-	O
to	O
-	O
cell	O
fusion	O
on	O
pathogenicity	O
.	O

Our	O
data	O
indicate	O
that	O
cleavage	O
of	O
spike	O
is	O
not	O
solely	O
determined	O
by	O
the	O
amino	B-CHED
acid	I-CHED
sequence	O
at	O
the	O
cleavage	O
site	O
,	O
but	O
may	O
also	O
depend	O
on	O
sequences	O
removed	O
from	O
the	O
cleavage	O
site	O
.	O

TITLE	O
:	O
Inhaled	O
nitric	B-CHED
oxide	I-CHED
therapy	O
in	O
premature	O
infants	O
with	O
mild	O
to	O
moderate	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
conclude	O
that	O
:	O
(	O
1	O
)	O
diagnostic	O
criteria	O
of	O
IAEP	O
are	O
compatible	O
with	O
a	O
duration	O
of	O
symptoms	O
for	O
up	O
to	O
1	O
month	O
,	O
but	O
the	O
response	O
to	O
corticosteroid	B-CHED
treatment	O
is	O
not	O
diagnostic	O
because	O
of	O
possible	O
spontaneous	O
recovery	O
;	O
(	O
2	O
)	O
IAEP	O
should	O
be	O
considered	O
as	O
differential	O
diagnosis	O
of	O
acute	O
lung	O
injury	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
(	O
3	O
)	O
bronchoalveolar	O
lavage	O
eosinophilia	O
obviates	O
the	O
need	O
for	O
lung	O
biopsy	O
in	O
IAEP	O
.	O

The	O
findings	O
that	O
in	O
this	O
model	O
of	O
ventilation	O
-	O
induced	O
lung	O
injury	O
exogenous	O
surfactant	B-CHED
at	O
the	O
same	O
time	O
improved	O
lung	O
functions	O
and	O
enhanced	O
mediator	O
release	O
suggest	O
that	O
surfactant	B-CHED
treatment	O
may	O
prevent	O
barotrauma	O
and	O
augment	O
biotrauma	O
.	O

TITLE	O
:	O
Receptor	O
-	O
induced	O
conformational	O
changes	O
of	O
murine	O
coronavirus	O
spike	O
protein	B-CHED
.	O

Subsequently	O
,	O
they	O
instituted	O
studies	O
of	O
neurotransmitter	B-CHED
systems	O
in	O
the	O
brainstem	O
,	O
particularly	O
the	O
muscarinic	O
(	O
1995	O
)	O
and	O
serotenergic	O
systems	O
(	O
2001	O
).	O

The	O
nucleotide	B-CHED
sequences	O
of	O
genes	O
3	O
and	O
5	O
of	O
the	O
pheasant	O
virus	O
had	O
a	O
similar	O
degree	O
of	O
identity	O
(	O
approximately	O
90	O
%)	O
with	O
those	O
of	O
coronaviruses	O
from	O
turkeys	O
and	O
chickens	O
,	O
as	O
is	O
observed	O
when	O
different	O
serotypes	O
of	O
IBV	O
are	O
compared	O
.	O

Variety	O
of	O
antiviral	B-CHED
drugs	I-CHED
with	O
controversial	O
effects	O
have	O
been	O
reported	O
in	O
management	O
of	O
adenoviral	O
infections	O
in	O
immunocompromised	O
persons	O
.	O

Therefore	O
,	O
the	O
present	O
study	O
investigated	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
manner	O
the	O
effect	O
of	O
severe	O
trauma	O
on	O
the	O
alveolar	O
fibrinolytic	O
/	O
coagulation	O
balance	B-CHED
,	O
and	O
the	O
effect	O
here	O
-	O
upon	O
of	O
inhalation	O
of	O
single	O
-	O
chain	O
urokinase	O
plasminogen	O
activator	O
(	O
scu	O
-	O
PA	O
)	O
in	O
pigs	O
.	O

Analyses	O
of	O
the	O
subcellular	O
distribution	O
of	O
cytochrome	B-CHED
c	I-CHED
,	O
procaspase	O
-	O
9	O
,	O
and	O
Apaf	O
-	O
1	O
suggested	O
an	O
aberrant	O
apoptosome	O
formation	O
in	O
the	O
vicinity	O
of	O
the	O
mitochondria	O
,	O
which	O
could	O
be	O
a	O
cell	O
type	O
-	O
specific	O
event	O
.	O

This	O
was	O
based	O
on	O
the	O
sequence	O
information	O
for	O
the	O
neutralizing	O
epitope	B-CHED
of	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
).	O

In	O
addition	O
,	O
the	O
region	O
that	O
corresponds	O
to	O
the	O
neutralizing	O
epitope	B-CHED
of	O
TGEV	O
may	O
also	O
be	O
involved	O
in	O
neutralizing	O
PEDV	O
,	O
although	O
the	O
two	O
viruses	O
are	O
serologically	O
quite	O
distinct	O
.	O

Finally	O
,	O
the	O
amino	B-CHED
acid	I-CHED
sequences	O
that	O
are	O
deduced	O
from	O
the	O
genes	O
for	O
the	O
determined	O
-	O
neutralizing	O
epitope	B-CHED
were	O
highly	O
homologous	O
among	O
the	O
PEDV	O
strains	O
that	O
were	O
isolated	O
from	O
different	O
geographical	O
areas	O
,	O
which	O
suggests	O
conservation	O
of	O
the	O
antigen	B-CHED
gene	O
.	O

Their	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
dropped	O
from	O
109	O
+/-	O
37	O
to	O
94	O
+/-	O
36	O
,	O
P	O
=	O
0	O
.	O
011	O
,	O
when	O
changed	O
from	O
the	O
prone	O
to	O
supine	O
position	O
.	O

Median	O
paO2	O
/	O
FiO2	O
increased	O
from	O
66	O
to	O
140	O
mmHg	O
(	O
8	O
.	O
8	O
-	O
18	O
.	O
7	O
kPa	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
within	O
1	O
h	O
of	O
surfactant	B-CHED
treatment	O
.	O

Surfactant	B-CHED
dysfunction	O
probably	O
plays	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
severe	O
paediatric	O
ARDS	O
triggered	O
by	O
pneumonia	O
,	O
as	O
it	O
was	O
found	O
that	O
surfactant	B-CHED
instillation	O
rapidly	O
improved	O
gas	O
exchange	O
in	O
the	O
majority	O
of	O
the	O
affected	O
infants	O
in	O
our	O
study	O
.	O

Larger	O
randomized	O
controlled	O
studies	O
are	O
necessary	O
to	O
evaluate	O
the	O
effects	O
of	O
surfactant	B-CHED
treatment	O
on	O
morbidity	O
and	O
mortality	O
.	O

However	O
,	O
the	O
truncated	O
form	O
exhibited	O
more	O
severe	O
effects	O
on	O
syncytia	O
formation	O
,	O
virus	O
production	O
,	O
and	O
synthesis	O
of	O
viral	O
RNA	O
and	O
viral	O
proteins	B-CHED
.	O

IgY	O
is	O
also	O
an	O
alternative	O
to	O
antibiotics	B-CHED
for	O
treatment	O
of	O
enteric	O
antibiotic	B-CHED
-	O
resistant	O
pathogens	O
.	O

N	O
-	O
terminal	O
sequence	O
analysis	O
of	O
the	O
processed	O
protein	B-CHED
revealed	O
that	O
cleavage	O
occurred	O
at	O
the	O
location	O
(	O
2827	O
)	O
LVTHE	O
downward	O
arrow	O
VRTGN	O
(	O
2836	O
).	O

Taken	O
together	O
,	O
the	O
data	O
tentatively	O
identify	O
VxHE	O
downward	O
arrow	O
(	O
L	O
,	O
V	O
)	O
as	O
the	O
substrate	O
consensus	O
sequence	O
for	O
the	O
GAV	O
3CL	O
(	O
pro	B-CHED
).	O

The	O
study	O
revealed	O
that	O
the	O
GAV	O
and	O
potyvirus	O
3CL	O
(	O
pro	B-CHED
)	O
s	O
possess	O
similar	O
substrate	O
specificities	O
which	O
correlate	O
with	O
structural	O
similarities	O
in	O
their	O
respective	O
substrate	O
-	O
binding	O
sites	O
,	O
identified	O
in	O
sequence	O
comparisons	O
.	O

The	O
properties	O
of	O
the	O
GAV	O
3CL	O
(	O
pro	B-CHED
)	O
define	O
a	O
novel	O
RNA	O
virus	O
proteinase	O
variant	O
that	O
bridges	O
the	O
gap	O
between	O
the	O
distantly	O
related	O
chymotrypsin	O
-	O
like	O
cysteine	B-CHED
proteinases	O
of	O
coronaviruses	O
and	O
potyviruses	O
.	O

TITLE	O
:	O
A	O
protocol	O
for	O
improved	O
glycaemic	O
control	O
following	O
corticosteroid	B-CHED
therapy	O
in	O
diabetic	O
pregnancies	O
.	O

Seventy	O
-	O
five	O
percent	O
of	O
glucose	B-CHED
measurements	O
were	O
within	O
an	O
acceptable	O
range	O
of	O
4	O
-	O
10	O
mmol	O
/	O
l	O
.	O

Large	O
amounts	O
of	O
supplementary	O
intravenous	O
insulin	B-CHED
are	O
needed	O
to	O
achieve	O
even	O
moderate	O
glycaemic	O
control	O
.	O

In	O
the	O
present	O
prospective	O
randomized	O
study	O
,	O
we	O
compared	O
the	O
effectiveness	O
of	O
oxygen	B-CHED
treatment	O
administered	O
by	O
a	O
face	O
mask	O
vs	O
.	O
nasal	O
continuous	O
positive	O
airway	O
pressure	O
(	O
NCPAP	O
).	O

In	O
the	O
DIC	B-CHED
patients	O
,	O
higher	O
DIC	B-CHED
scores	O
,	O
lower	O
platelet	O
counts	O
,	O
and	O
a	O
longer	O
duration	O
of	O
SIRS	O
were	O
found	O
compared	O
with	O
the	O
non	O
-	O
DIC	B-CHED
patients	O
.	O

Highly	O
activated	O
and	O
sustained	O
inflammation	O
caused	O
by	O
neutrophil	O
-	O
endothelium	O
interaction	O
in	O
DIC	B-CHED
gives	O
rise	O
to	O
MODS	O
and	O
poor	O
outcome	O
in	O
patients	O
with	O
severe	O
trauma	O
.	O

Hyperinflated	O
tissue	O
increased	O
up	O
to	O
2	O
.	O
9	O
+/-	O
4	O
.	O
0	O
%	O
with	O
PEEP	B-CHED
30	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
and	O
to	O
a	O
lesser	O
degree	O
with	O
inspiration	O
.	O

ABSTRACT	O
:	O
Twenty	O
-	O
nine	O
isolates	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
recovered	O
from	O
commercial	O
chicken	O
flocks	O
in	O
California	O
between	O
1988	O
and	O
2001	O
and	O
identified	O
as	O
California	O
variants	O
by	O
serotype	O
and	O
direct	O
automated	O
cycle	O
sequencing	O
of	O
the	O
IBV	O
spike	O
glycoprotein	B-CHED
S1	O
subunit	O
,	O
were	O
further	O
characterized	O
phylogenetically	O
and	O
by	O
nucleotide	B-CHED
sequence	O
comparison	O
.	O

A	O
51Cr	B-CHED
-	O
cytolytic	O
release	O
assay	O
was	O
used	O
to	O
determine	O
the	O
activity	O
of	O
the	O
NK	O
cells	O
harvested	O
via	O
lung	O
lavage	O
from	O
the	O
respiratory	O
tracts	O
of	O
infected	O
chickens	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
in	O
patients	O
intubated	O
for	O
acute	O
lung	O
injury	O
,	O
lower	O
concentrations	O
of	O
surfactant	B-CHED
proteins	B-CHED
A	O
and	O
D	O
in	O
the	O
pulmonary	O
edema	O
fluid	O
and	O
higher	O
concentrations	O
in	O
the	O
plasma	O
are	O
associated	O
with	O
more	O
severe	O
lung	O
injury	O
and	O
worse	O
clinical	O
outcomes	O
.	O

In	O
contrast	O
,	O
pulmonary	O
edema	O
fluid	O
surfactant	B-CHED
protein	B-CHED
D	O
,	O
but	O
not	O
surfactant	B-CHED
protein	B-CHED
A	O
,	O
was	O
lower	O
in	O
patients	O
with	O
worse	O
oxygenation	O
,	O
as	O
measured	O
by	O
the	O
alveolar	O
-	O
arterial	O
oxygen	B-CHED
difference	O
(	O
p	O
=	O
.	O
01	O
)	O
and	O
was	O
lower	O
in	O
the	O
patients	O
who	O
died	O
(	O
2646	O
ng	O
/	O
mL	O
)	O
compared	O
with	O
those	O
who	O
survived	O
(	O
5503	O
ng	O
/	O
mL	O
;	O
p	O
=	O
.	O
02	O
).	O

Truncated	O
S	O
proteins	B-CHED
purified	O
by	O
nickel	B-CHED
affinity	O
chromatography	O
were	O
shown	O
to	O
be	O
glycosylated	O
and	O
to	O
react	O
with	O
polyclonal	O
anti	O
-	O
HCoV	O
-	O
229E	O
antibodies	O
and	O
monoclonal	O
antibodies	O
to	O
the	O
viral	O
S	O
protein	B-CHED
.	O

Antibody	O
to	O
the	O
region	O
from	O
amino	B-CHED
acid	I-CHED
417	O
to	O
the	O
C	O
terminus	O
of	O
S	O
blocked	O
binding	O
of	O
S	O
(	O
547	O
)	O
to	O
hAPN	O
-	O
3T3	O
cells	O
.	O

Relative	O
adrenal	O
insufficiency	O
and	O
peripheral	O
glucocorticoid	B-CHED
resistance	O
syndrome	O
are	O
the	O
two	O
main	O
features	O
of	O
the	O
inappropriate	O
hormonal	O
response	O
and	O
provide	O
the	O
grounds	O
for	O
cortisol	B-CHED
replacement	O
in	O
these	O
diseases	O
.	O

In	O
practice	O
,	O
a	O
high	O
dose	O
of	O
corticosteroids	B-CHED
(	O
i	O
.	O
e	O
.	O
one	O
to	O
four	O
boluses	O
of	O
30	O
mg	O
/	O
kg	O
of	O
methylprednisolone	B-CHED
,	O
or	O
equivalent	O
)	O
had	O
no	O
effects	O
on	O
survival	O
in	O
severe	O
sepsis	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

There	O
are	O
at	O
least	O
seven	O
randomised	O
controlled	O
trials	O
reporting	O
the	O
benefits	O
and	O
risks	O
of	O
low	O
dose	O
corticosteroids	B-CHED
(	O
i	O
.	O
e	O
.	O
200	O
to	O
300	O
mg	O
daily	O
of	O
hydrocortisone	B-CHED
or	O
equivalent	O
)	O
given	O
for	O
a	O
prolonged	O
period	O
in	O
severe	O
sepsis	O
or	O
in	O
the	O
late	O
phase	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

At	O
30	O
mins	O
after	O
INO	O
initiation	O
,	O
83	O
%	O
of	O
patients	O
had	O
a	O
significant	O
increase	O
in	O
blood	O
oxygen	B-CHED
tension	O
,	O
defined	O
as	O
>	O
or	O
=	O
20	O
%	O
increase	O
in	O
Pao2	O
/	O
Fio2	O
.	O

TITLE	O
:	O
Nucleocapsid	O
-	O
independent	O
specific	O
viral	O
RNA	O
packaging	O
via	O
viral	O
envelope	O
protein	B-CHED
and	O
viral	O
RNA	O
signal	O
.	O

In	O
the	O
multicenter	O
study	O
35	O
patients	O
were	O
recruited	O
;	O
20	O
were	O
randomized	O
to	O
the	O
surfactant	B-CHED
group	O
and	O
15	O
to	O
the	O
nonsurfactant	O
group	O
.	O

Outcome	O
criteria	O
were	O
not	O
affected	O
by	O
a	O
second	O
surfactant	B-CHED
dose	O
(	O
n	O
=	O
11	O
).	O

This	O
improvement	O
is	O
sustained	O
only	O
in	O
the	O
subgroup	O
of	O
patients	O
without	O
pneumonia	O
and	O
that	O
with	O
an	O
initial	O
PaO	B-CHED
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
higher	O
than	O
65	O
RESULTS	O
:	O
In	O
the	O
pilot	O
study	O
the	O
PaO	B-CHED
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
increased	O
by	O
a	O
mean	O
of	O
100	O
at	O
48	O
h	O
(	O
n	O
=	O
19	O
).	O

This	O
improvement	O
is	O
sustained	O
only	O
in	O
the	O
subgroup	O
of	O
patients	O
without	O
pneumonia	O
and	O
that	O
with	O
an	O
initial	O
PaO	B-CHED
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
higher	O
than	O
65	O

TITLE	O
:	O
Safety	O
of	O
percutaneous	O
dilational	O
tracheostomy	O
in	O
patients	O
ventilated	O
with	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
).	O

Furthermore	O
,	O
oxygenation	O
did	O
not	O
deteriorate	O
with	O
PDT	B-CHED
even	O
in	O
patients	O
with	O
gravely	O
impaired	O
gas	O
exchange	O
(	O
lowest	O
quartile	O
)	O
with	O
a	O
PaO	B-CHED
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
averaging	O
130	O
+/-	O
42	O
mmHg	O
(	O
range	O
45	O
-	O
192	O
mmHg	O
)	O
at	O
a	O
PEEP	B-CHED
of	O
17	O
+/-	O
4	O
mbar	O
.	O

The	O
immunoglobulins	O
are	O
chicken	O
N	O
-	O
terminal	O
S2	O
peplomeric	O
protein	B-CHED
-	O
specific	O
IgG	O
isolated	O
by	O
immunoaffinity	O
chromatography	O
on	O
synthetic	O
peptide	B-CHED
coupled	O
to	O
CNBr	O
-	O
activated	O
Sepharose	B-CHED
4B	O
or	O
rabbit	O
polyclonal	O
IgG	O
purified	O
from	O
the	O
serum	O
using	O
Protein	B-CHED
A	O
Sepharose	B-CHED
4B	O
.	O

In	O
this	O
study	O
,	O
108	O
episodes	O
of	O
severe	O
anemia	O
were	O
prospectively	O
evaluated	O
in	O
108	O
patients	O
with	O
hemoglobin	B-CHED
SS	O
disease	O
attending	O
the	O
pediatric	O
sickle	O
cell	O
clinic	O
of	O
the	O
University	O
of	O
Nigeria	O
Teaching	O
Hospital	O
,	O
Enugu	O
,	O
Nigeria	O
.	O

She	O
was	O
diagnosed	O
as	O
M	O
.	O
pneumoniae	O
pneumonia	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
treated	O
with	O
clarithromycin	B-CHED
and	O
methylprednisolone	B-CHED
.	O

Pretreatment	O
with	O
PEP	B-CHED
at	O
a	O
dose	O
of	O
2	O
,	O
20	O
,	O
or	O
200	O
micromol	O
/	O
kg	O
attenuated	O
the	O
oleic	B-CHED
acid	I-CHED
-	O
induced	O
decrease	O
in	O
the	O
arterial	O
partial	O
pressure	O
of	O
oxygen	B-CHED
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Patient	O
plasma	O
inhibited	O
LPS	B-CHED
-	O
induced	O
stimulation	O
of	O
a	O
monocyte	O
cell	O
line	O
,	O
and	O
this	O
inhibition	O
was	O
accentuated	O
by	O
complicated	O
disease	O
.	O

The	O
MBL	O
exerts	O
its	O
function	O
by	O
directly	O
binding	O
to	O
microbial	O
surfaces	O
through	O
its	O
carbohydrate	B-CHED
recognition	O
domains	O
,	O
followed	O
by	O
direct	O
opsonization	O
or	O
complement	O
activation	O
via	O
MBL	O
-	O
associated	O
serine	B-CHED
proteases	O
(	O
MASP	O
)-	O
1	O
and	O
-	O
2	O
.	O

Differential	O
susceptibility	O
of	O
infected	O
cell	O
types	O
to	O
clearance	O
by	O
perforin	O
or	O
IFN	O
-	O
gamma	O
uncovered	O
distinct	O
,	O
nonredundant	O
roles	O
for	O
these	O
antiviral	B-CHED
mechanisms	O
.	O

Untreated	O
PKO	O
/	O
GKO	O
mice	O
were	O
unable	O
to	O
control	O
the	O
infection	O
and	O
died	O
of	O
lethal	O
encephalomyelitis	O
within	O
16	O
days	O
,	O
despite	O
substantially	O
higher	O
CD8	O
(+)	O
T	O
cell	O
accumulation	O
in	O
the	O
CNS	B-CHED
compared	O
with	O
controls	O
.	O

Uncontrolled	O
infection	O
was	O
associated	O
with	O
limited	O
MHC	O
class	O
I	O
up	O
-	O
regulation	O
and	O
an	O
absence	O
of	O
class	O
II	O
expression	O
on	O
microglia	O
,	O
coinciding	O
with	O
decreased	O
CD4	O
(+)	O
T	O
cells	O
in	O
CNS	B-CHED
infiltrates	O
.	O

ABSTRACT	O
:	O
An	O
excessive	O
base	O
deficit	O
(	O
BD	O
)	O
and	O
elevated	O
serum	O
lactate	B-CHED
are	O
increasingly	O
recognized	O
as	O
important	O
markers	O
of	O
a	O
malperfusion	O
state	O
during	O
the	O
resuscitation	O
of	O
thermally	O
injured	O
patients	O
.	O

This	O
model	O
of	O
lethal	O
systemic	O
capillary	O
leak	O
syndrome	O
with	O
multiple	O
system	O
organ	O
failure	O
differs	O
greatly	O
from	O
our	O
previous	O
sheep	O
model	O
of	O
acute	O
ventilator	O
-	O
induced	O
lung	O
injury	O
in	O
which	O
sheep	O
were	O
ventilated	O
with	O
a	O
peak	O
inspiratory	O
pressure	O
of	O
50	O
cm	O
H2O	B-CHED
,	O
a	O
respiratory	O
rate	O
of	O
4	O
breaths	O
x	O
min	O
(-	O
1	O
),	O
and	O
an	O
inspiratory	O
time	O
of	O
1	O
.	O
35	O
secs	O
,	O
without	O
inducing	O
capillary	O
leak	O
syndrome	O
.	O

We	O
report	O
here	O
a	O
29	O
-	O
year	O
-	O
old	O
man	B-CHED
with	O
chronic	O
pulmonary	O
thromboembolism	O
(	O
CPTE	O
).	O

In	O
the	O
present	O
study	O
,	O
the	O
contributions	O
of	O
the	O
CC	O
chemokine	O
ligand	B-CHED
3	O
(	O
CCL3	B-CHED
)	O
to	O
the	O
differentiation	O
and	O
migration	O
of	O
effector	B-CHED
T	O
cells	O
in	O
response	O
to	O
viral	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
were	O
analyzed	O
.	O

The	O
vector	O
led	O
to	O
the	O
efficient	O
(>	O
40	O
micro	O
g	O
/	O
10	O
(	O
6	O
)	O
cells	O
)	O
and	O
stable	O
(>	O
20	O
passages	O
)	O
expression	O
of	O
a	O
heterologous	O
gene	O
(	O
green	O
fluorescent	O
protein	B-CHED
[	O
GFP	O
]),	O
driven	O
by	O
the	O
transcription	O
-	O
regulating	O
sequences	O
(	O
TRS	O
)	O
of	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
3a	O
inserted	O
in	O
the	O
site	O
previously	O
occupied	O
by	O
the	O
nonessential	O
ORFs	O
3a	O
and	O
3b	O
.	O

As	O
a	O
consequence	O
,	O
a	O
major	O
species	O
of	O
subgenomic	O
mRNA	B-CHED
was	O
generated	O
from	O
a	O
TRS	O
with	O
the	O
noncanonical	O
core	O
sequence	O
5	O
'-	O
CUAAAA	O
-	O
3	O
'.	O

TITLE	O
:	O
Experimental	O
evaluation	O
of	O
cross	O
-	O
contamination	O
between	O
cryotubes	O
containing	O
mouse	O
2	O
-	O
cell	O
embryos	O
and	O
murine	O
pathogens	O
in	O
liquid	O
nitrogen	B-CHED
tanks	O
.	O

We	O
could	O
not	O
detect	O
serum	O
antibodies	O
to	O
MHV	O
and	O
isolate	O
Pasteurella	O
pneumotropica	O
in	O
the	O
progeny	O
mice	O
,	O
suggesting	O
that	O
cross	O
-	O
contamination	O
between	O
tubes	O
in	O
a	O
liquid	O
nitrogen	B-CHED
tank	O
scarcely	O
occurs	O
.	O

Bronchial	O
microscope	O
in	O
group	O
D	O
presented	O
the	O
bronchus	O
filled	O
with	O
bronchoalveolar	O
fluid	O
,	O
and	O
blood	O
LDH	O
-	O
L	O
and	O
ALP	B-CHED
levels	O
kept	O
rising	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
Inhaled	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	O
)	O
improves	O
systemic	O
oxygenation	O
(	O
PaO2	O
/	O
FIO2	O
)	O
in	O
adult	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Despite	O
two	O
major	O
advances	O
in	O
treatment	O
,	O
low	O
VT	O
ventilation	O
for	O
ALI	O
/	O
ARDS	O
and	O
activated	O
protein	B-CHED
C	O
for	O
severe	O
sepsis	O
(	O
the	O
leading	O
cause	O
of	O
ALI	O
/	O
ARDS	O
),	O
additional	O
research	O
is	O
needed	O
to	O
develop	O
specific	O
treatments	O
and	O
improve	O
understanding	O
of	O
the	O
pathogenesis	O
of	O
these	O
syndromes	O
.	O

The	O
properties	O
of	O
this	O
mutant	O
provide	O
further	O
support	O
for	O
the	O
importance	O
of	O
E	O
protein	B-CHED
in	O
MHV	O
replication	O
,	O
but	O
surprisingly	O
,	O
they	O
also	O
show	O
that	O
E	O
protein	B-CHED
is	O
not	O
essential	O
.	O

Interestingly	O
,	O
expression	O
of	O
the	O
A59	O
spike	O
glycoprotein	B-CHED
within	O
the	O
background	O
of	O
the	O
neurotropic	O
JHM	O
strain	O
does	O
not	O
reproduce	O
the	O
A59	O
hepatotropic	O
phenotype	O
.	O

The	O
clinical	O
significance	O
and	O
success	O
of	O
these	O
therapies	O
is	O
variable	O
with	O
respect	O
to	O
evidence	O
based	O
medicine	B-CHED
.	O

Recommended	O
drug	O
therapy	O
is	O
limited	O
to	O
the	O
administration	O
of	O
stress	O
doses	O
of	O
corticosteroids	B-CHED
and	O
a	O
special	O
anti	O
-	O
inflammatory	O
enteral	O
diet	O
.	O

By	O
using	O
animal	O
models	O
of	O
chronic	O
ethanol	B-CHED
ingestion	O
,	O
researchers	O
have	O
identified	O
alcohol	O
-	O
mediated	O
alterations	O
in	O
epithelial	O
and	O
endothelial	O
cell	O
function	O
,	O
surfactant	B-CHED
synthesis	O
and	O
secretion	O
,	O
alveolar	O
-	O
capillary	O
barrier	O
function	O
,	O
and	O
lung	O
matrix	O
content	O
and	O
composition	O
.	O

However	O
,	O
a	O
meta	O
-	O
analysis	O
of	O
high	O
-	O
dose	O
,	O
short	O
-	O
course	O
glucocorticoid	B-CHED
treatment	O
involving	O
1	O
,	O
297	O
patients	O
with	O
sepsis	O
enrolled	O
in	O
nine	O
trials	O
showed	O
a	O
trend	O
toward	O
harm	O
,	O
and	O
four	O
trials	O
in	O
patients	O
with	O
,	O
or	O
at	O
risk	O
for	O
,	O
ARDS	O
showed	O
no	O
benefit	O
or	O
a	O
greater	O
likelihood	O
of	O
progression	O
to	O
ARDS	O
.	O

One	O
small	O
randomized	O
,	O
controlled	O
trial	O
suggests	O
that	O
moderate	O
doses	O
of	O
glucocorticoids	B-CHED
may	O
be	O
beneficial	O
for	O
patients	O
with	O
late	O
ARDS	O
;	O
a	O
much	O
larger	O
randomized	O
controlled	O
trial	O
is	O
ongoing	O
.	O

A	O
recently	O
published	O
randomized	O
,	O
controlled	O
trial	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
(	O
n	O
=	O
148	O
)	O
comparing	O
HFOV	O
with	O
a	O
pressure	O
-	O
control	O
ventilation	O
strategy	O
(	O
Pao	B-CHED
(	O
2	O
)/	O
Fio	O
(	O
2	O
)	O
ratio	O
of	O
<	O
or	O
=	O
200	O
mm	O
Hg	O
on	O
positive	O
end	O
-	O
expiratory	O
pressure	O
of	O
>	O
10	O
cm	O
H	O
(	O
2	O
)	O
O	O
)	O
demonstrated	O
early	O
(<	O
16	O
hrs	O
)	O
improvement	O
in	O
Pao	B-CHED
(	O
2	O
)/	O
Fio	O
(	O
2	O
)	O
(	O
p	O
=.	O
008	O
)	O
in	O
the	O
HFOV	O
group	O
but	O
no	O
significant	O
difference	O
in	O
oxygenation	O
index	O
between	O
the	O
two	O
groups	O
during	O
the	O
initial	O
72	O
hrs	O
of	O
treatment	O
.	O

Increased	O
pulmonary	O
vascular	O
permeability	O
and	O
leukocyte	O
accumulation	O
have	O
been	O
successfully	O
prevented	O
in	O
animals	O
treated	O
with	O
tissue	O
factor	O
/	O
activated	O
factor	O
VII	O
pathway	O
inhibitor	B-CHED
.	O

Activated	O
protein	B-CHED
C	O
administration	O
has	O
been	O
shown	O
to	O
improve	O
survival	O
and	O
lung	O
function	O
in	O
both	O
animal	O
and	O
clinical	O
studies	O
.	O

After	O
smoke	O
inhalation	O
,	O
all	O
four	O
groups	O
displayed	O
similar	O
high	O
arterial	O
carboxyhemoglobin	O
levels	O
,	O
low	O
Pao	B-CHED
(	O
2	O
)	O
(<	O
150	O
mm	O
Hg	O
),	O
and	O
low	O
dynamic	O
lung	O
compliance	O
(<	O
66	O
%	O
of	O
its	O
baseline	O
).	O

The	O
current	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
combined	O
antiviral	B-CHED
effect	O
in	O
a	O
model	O
of	O
mouse	O
hepatitis	O
virus	O
Type	O
2	O
(	O
MHV	O
-	O
2	O
)	O
infection	O
,	O
in	O
which	O
fulminant	O
hepatitis	O
is	O
developed	O
.	O

This	O
is	O
consistent	O
with	O
the	O
lower	O
levels	O
of	O
hepatocellular	O
necrosis	O
and	O
serum	O
ALT	B-CHED
and	O
the	O
decreased	O
titers	O
of	O
MHV	O
-	O
2	O
virus	O
in	O
the	O
liver	O
tissues	O
(	O
48	O
hr	O
,	O
P	O
<	O
0	O
.	O
001	O
;	O
72	O
hr	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

ABSTRACT	O
:	O
This	O
article	O
describes	O
a	O
rare	O
case	O
of	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
from	O
an	O
unrelated	O
donor	B-CHED
(	O
URD	B-CHED
)	O
in	O
an	O
adult	O
Japanese	O
male	O
with	O
Down	O
syndrome	O
(	O
DS	O
)	O
diagnosed	O
as	O
having	O
acute	O
mixed	O
lineage	O
leukemia	O
.	O

We	O
tested	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
samples	O
obtained	O
from	O
HSCT	O
recipients	O
with	O
acute	O
pulmonary	O
infiltrates	O
for	O
HRV	O
(	O
n	O
=	O
122	O
)	O
and	O
coronavirus	O
(	O
n	O
=	O
46	O
)	O
by	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
.	O

The	O
fatality	O
rate	O
in	O
HRV	O
-	O
infected	O
patients	O
was	O
high	O
(	O
83	O
%),	O
but	O
all	O
patients	O
had	O
significant	O
coinfections	O
,	O
and	O
the	O
overall	O
mortality	O
rate	O
was	O
not	O
different	O
from	O
that	O
of	O
patients	O
who	O
were	O
negative	O
for	O
HRV	O
in	O
BAL	B-CHED
samples	O
.	O

Common	O
laboratory	O
features	O
included	O
elevated	O
lactate	B-CHED
dehydrogenase	O
(	O
87	O
%),	O
hypocalcemia	O
(	O
60	O
%),	O
and	O
lymphopenia	O
(	O
54	O
%).	O

ABSTRACT	O
:	O
Transfusion	O
-	O
related	O
acute	O
lung	O
injury	O
(	O
TRALI	O
)	O
is	O
a	O
severe	O
reaction	O
between	O
leukocyte	O
antigen	B-CHED
and	O
antibody	O
during	O
transfusion	O
of	O
plasma	O
-	O
containing	O
components	O
.	O

The	O
BNI109	O
fragment	O
showed	O
75	O
%	O
homology	O
with	O
BCV	O
and	O
MHV	O
at	O
amino	B-CHED
acid	I-CHED
level	O
.	O

Initial	O
focal	O
air	B-CHED
-	O
space	O
opacity	O
in	O
44	O
of	O
59	O
patients	O
(	O
74	O
.	O
6	O
%)	O
progressed	O
to	O
unilateral	O
multifocal	O
or	O
bilateral	O
involvement	O
during	O
treatment	O
.	O

By	O
fitting	O
a	O
stochastic	O
model	O
to	O
data	O
on	O
1512	O
cases	O
,	O
including	O
these	O
clusters	B-CHED
,	O
we	O
show	O
that	O
the	O
etiological	O
agent	O
of	O
SARS	O
is	O
moderately	O
transmissible	O
.	O

Stem	O
-	O
loop	O
III	O
maps	O
at	O
nt	O
97	O
through	O
116	O
,	O
has	O
a	O
calculated	O
free	O
energy	O
of	O
-	O
9	O
.	O
1	O
kcal	O
/	O
mol	O
in	O
the	O
positive	O
strand	O
and	O
-	O
3	O
.	O
0	O
kcal	O
/	O
mol	O
in	O
the	O
negative	O
strand	O
,	O
and	O
has	O
associated	O
with	O
it	O
beginning	O
at	O
nt	O
100	O
an	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
potentially	O
encoding	O
an	O
8	O
-	O
amino	O
-	O
acid	O
peptide	B-CHED
.	O

Increased	O
use	O
of	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
in	O
patients	O
receiving	O
chemotherapy	O
has	O
been	O
paralleled	O
by	O
an	O
increased	O
incidence	O
of	O
bleomycin	B-CHED
-	O
induced	O
pulmonary	O
toxicity	O
.	O

Mortality	O
was	O
25	O
%	O
with	O
bleomycin	B-CHED
only	O
and	O
50	O
%	O
with	O
bleomycin	B-CHED
+	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
.	O

TITLE	O
:	O
Mass	O
spectrometric	O
characterization	O
of	O
proteins	B-CHED
from	O
the	O
SARS	O
virus	O
:	O
a	O
preliminary	O
report	O
.	O

His	O
chest	O
condition	O
gradually	O
responded	O
to	O
ribavirin	B-CHED
and	O
corticosteroids	B-CHED
,	O
and	O
serial	O
chest	O
X	O
-	O
ray	O
showed	O
resolving	O
pulmonary	O
infiltrates	O
.	O

Case	O
clusters	B-CHED
have	O
played	O
an	O
important	O
part	O
in	O
the	O
course	O
of	O
the	O
epidemic	O
.	O

We	O
followed	O
up	O
75	O
patients	O
for	O
3	O
weeks	O
managed	O
with	O
a	O
standard	O
treatment	O
protocol	O
of	O
ribavirin	B-CHED
and	O
corticosteroids	B-CHED
,	O
and	O
assessed	O
the	O
pattern	O
of	O
clinical	O
disease	O
,	O
viral	O
load	O
,	O
risk	O
factors	O
for	O
poor	O
clinical	O
outcome	O
,	O
and	O
the	O
usefulness	O
of	O
virological	O
diagnostic	O
methods	O
.	O

Case	O
report	O
of	O
a	O
patient	O
with	O
severe	O
inhalation	O
injury	O
and	O
burns	O
in	O
an	O
intensive	O
care	O
unit	O
setting	O
,	O
undergoing	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	O
),	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	O
)-	O
inhalation	O
,	O
surfactant	B-CHED
-,	O
kinetic	O
-,	O
and	O
urodilatin	O
-	O
therapy	O
.	O

TITLE	O
:	O
Putative	O
hAPN	O
receptor	O
binding	O
sites	O
in	O
SARS_CoV	O
spike	O
protein	B-CHED
.	O

The	O
tested	O
virtual	O
screening	O
indicated	O
that	O
73	O
available	O
proteinase	O
inhibitors	B-CHED
in	O
the	O
MDDR	O
database	O
might	O
dock	O
into	O
both	O
the	O
binding	O
pockets	O
of	O
the	O
TGEV	O
Mpro	O
and	O
the	O
SARS	O
-	O
CoV	O
3CL	O
proteinase	O
.	O

The	O
pure	O
sample	O
of	O
SARS	O
E	O
protein	B-CHED
was	O
obtained	O
.	O

Bioinformatics	O
analysis	O
indicated	O
that	O
the	O
key	O
residues	O
of	O
SARS	O
E	O
protein	B-CHED
were	O
much	O
conserved	O
compared	O
to	O
the	O
E	O
proteins	B-CHED
of	O
other	O
coronaviruses	O
.	O

The	O
SARS	O
E	O
protein	B-CHED
may	O
fold	O
in	O
water	B-CHED
solution	O
in	O
a	O
similar	O
way	O
as	O
it	O
in	O
membrane	O
-	O
water	B-CHED
mixed	O
environment	O
.	O

TITLE	O
:	O
Recombinant	O
platelet	B-CHED
-	I-CHED
activating	I-CHED
factor	I-CHED
acetylhydrolase	O
to	O
prevent	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
mortality	O
in	O
severe	O
sepsis	O
:	O
Phase	O
IIb	O
,	O
multicenter	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
clinical	O
trial	O
.	O

The	O
Chinju99	O
N	O
protein	B-CHED
revealed	O
96	O
.	O
8	O
%	O
amino	B-CHED
acid	I-CHED
identity	O
with	O
that	O
of	O
Brl	O
/	O
87	O
and	O
CV777	O
,	O
respectively	O
.	O

Patient	O
demographics	O
,	O
length	O
of	O
hospital	O
stay	O
,	O
rate	O
of	O
intensive	O
care	O
unit	O
admission	O
,	O
peak	O
lactate	B-CHED
dehydrogenase	O
level	O
,	O
pulsed	O
intravenous	O
methylprednisolone	B-CHED
therapy	O
,	O
and	O
peak	O
opacification	O
on	O
chest	O
radiographs	O
were	O
compared	O
between	O
the	O
two	O
groups	O
.	O

Our	O
findings	O
suggest	O
that	O
glycyrrhizin	B-CHED
should	O
be	O
assessed	O
for	O
treatment	O
of	O
SARS	O
.	O

In	O
this	O
study	O
,	O
the	O
nucleotide	B-CHED
and	O
deduced	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
the	O
amino	O
terminal	O
half	O
of	O
the	O
S	O
glycoprotein	B-CHED
gene	O
of	O
one	O
Korean	O
field	O
TGEV	O
strain	O
(	O
133	O
)	O
isolated	O
in	O
1997	O
and	O
three	O
Korean	O
field	O
TGEV	O
strains	O
(	O
KT2	O
,	O
KT3	O
and	O
KT4	O
)	O
isolated	O
in	O
2000	O
and	O
HKT2	O
strain	O
,	O
KT2	O
passaged	O
104	O
times	O
in	O
ST	O
cells	O
,	O
were	O
determined	O
.	O

TITLE	O
:	O
Prophylactic	O
protection	O
by	O
N	B-CHED
-	I-CHED
acetylcysteine	I-CHED
against	O
the	O
pulmonary	O
injury	O
induced	O
by	O
2	B-CHED
-	I-CHED
chloroethyl	I-CHED
ethyl	B-CHED
sulfide	I-CHED
,	O
a	O
mustard	O
analogue	O
.	O

Guinea	O
pigs	O
were	O
given	O
single	O
exposure	O
(	O
0	O
.	O
5	O
-	O
6	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
of	O
2	B-CHED
-	I-CHED
chloroethyl	I-CHED
ethyl	B-CHED
sulfide	I-CHED
(	O
CEES	O
)	O
as	O
a	O
mustard	O
analogue	O
intratracheally	O
and	O
maintained	O
for	O
various	O
lengths	O
of	O
time	O
(	O
1	O
h	O
to	O
21	O
days	O
).	O

Within	O
1	O
h	O
of	O
CEES	O
infusion	O
at	O
4	O
mg	O
/	O
kg	O
,	O
high	O
levels	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
),	O
ceramides	B-CHED
,	O
and	O
nuclear	O
factor	O
kappaB	O
accumulated	O
in	O
lung	O
and	O
alveolar	O
macrophages	O
.	O

Relevant	O
research	O
also	O
indicated	O
that	O
SARS	O
could	O
be	O
classified	O
as	O
an	O
air	B-CHED
-	O
borne	O
infectious	O
disease	O
,	O
transmitted	O
through	O
aerosol	O
and	O
droplets	O
,	O
but	O
close	O
contact	O
also	O
played	O
an	O
important	O
role	O
in	O
the	O
mode	O
of	O
transmission	O
.	O

Dyspnea	O
was	O
present	O
in	O
12	O
patients	O
during	O
their	O
stay	O
in	O
hospital	O
,	O
and	O
all	O
developed	O
abnormalities	O
on	O
chest	O
radiograph	O
;	O
3	O
patients	O
developed	O
severe	O
hypoxemia	O
(	O
PaO	B-CHED
(	O
2	O
)	O
<	O
50	O
mm	O
Hg	O
).	O

Clinical	O
laboratory	O
features	O
of	O
SARS	O
include	O
lymphopenia	O
,	O
thrombocytopenia	O
,	O
and	O
elevated	O
lactate	B-CHED
dehydrogenase	O
levels	O
.	O

Current	O
treatment	O
of	O
SARS	O
with	O
antiviral	B-CHED
agents	I-CHED
such	O
as	O
ribavirin	B-CHED
and	O
corticosteroids	B-CHED
have	O
not	O
achieved	O
very	O
satisfactory	O
results	O
.	O

When	O
compared	O
with	O
the	O
younger	O
age	O
group	O
,	O
the	O
adolescents	O
had	O
significantly	O
higher	O
temperatures	O
,	O
more	O
constitutional	O
upset	O
,	O
and	O
a	O
greater	O
need	O
for	O
steroid	B-CHED
treatment	O
.	O

To	O
explore	O
if	O
the	O
least	O
expressed	O
ORF	O
,	O
ORF	O
3b	O
,	O
which	O
encodes	O
a	O
nonstructural	O
protein	B-CHED
,	O
is	O
evolutionarily	O
conserved	O
and	O
functionally	O
indispensable	O
for	O
viral	O
propagation	O
in	O
cultured	O
cells	O
,	O
the	O
Beaudette	O
strain	O
of	O
IBV	O
was	O
propagated	O
in	O
chicken	O
embryonated	O
eggs	O
for	O
three	O
passages	O
and	O
then	O
adapted	O
to	O
a	O
monkey	O
kidney	O
cell	O
line	O
,	O
Vero	O
.	O

Comparison	O
of	O
the	O
complete	O
genome	O
sequences	O
(	O
27	O
.	O
6	O
kb	O
)	O
of	O
isolates	O
p20c22	O
and	O
p36c12	O
(	O
from	O
passages	O
20	O
and	O
36	O
,	O
respectively	O
)	O
revealed	O
that	O
p36c12	O
contains	O
three	O
amino	B-CHED
acid	I-CHED
substitutions	O
,	O
two	O
in	O
the	O
195	O
-	O
kDa	O
protein	B-CHED
(	O
encoded	O
by	O
gene	O
1	O
)	O
and	O
one	O
in	O
the	O
S	O
protein	B-CHED
,	O
in	O
addition	O
to	O
the	O
frameshifting	O
3b	O
product	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
targeted	O
chemical	O
modification	O
of	O
some	O
natural	B-CHED
products	I-CHED
might	O
provide	O
compounds	O
effective	O
against	O
HSV	O
-	O
1	O
infection	O
.	O

RESULTS	O
:	O
The	O
following	O
factors	O
were	O
associated	O
with	O
a	O
significantly	O
higher	O
mortality	O
rate	O
in	O
the	O
SARS	O
with	O
ARDS	O
patients	O
,	O
including	O
age	O
increase	O
(	O
OR	O
=	O
1	O
.	O
203	O
,	O
CI	O
=	O
1	O
.	O
036	O
to	O
1	O
.	O
396	O
,	O
P	O
=	O
0	O
.	O
016	O
),	O
long	O
-	O
time	O
hypoxia	O
(	O
OR	O
=	O
1	O
.	O
067	O
,	O
CI	O
=	O
1	O
.	O
014	O
to	O
1	O
.	O
122	O
,	O
P	O
=	O
0	O
.	O
013	O
),	O
thrombocytopenia	O
(	O
OR	O
=	O
111	O
.	O
932	O
,	O
CI	O
=	O
6	O
.	O
096	O
to	O
2	O
055	O
.	O
252	O
,	O
P	O
=	O
0	O
.	O
001	O
),	O
hypernatremia	O
(	O
OR	O
=	O
26	O
.	O
667	O
,	O
CI	O
=	O
2	O
.	O
242	O
to	O
317	O
.	O
147	O
,	O
P	O
=	O
0	O
.	O
009	O
),	O
and	O
elevation	O
of	O
serum	O
creatinine	B-CHED
levels	O
(	O
OR	O
=	O
111	O
.	O
932	O
,	O
CI	O
=	O
6	O
.	O
096	O
to	O
2	O
055	O
.	O
252	O
,	O
P	O
=	O
0	O
.	O
001	O
).	O

RESULTS	O
:	O
Chest	O
X	O
-	O
rays	O
radiogram	O
showed	O
significant	O
changes	O
until	O
peak	O
stage	O
(	O
4	O
-	O
12	O
days	O
)	O
with	O
the	O
same	O
doses	O
of	O
methylprednisolone	B-CHED
,	O
but	O
it	O
was	O
dissolved	O
consistently	O
afterwards	O
.	O

TITLE	O
:	O
[	O
Evaluation	O
of	O
glucocorticoid	B-CHED
in	O
treatment	O
for	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
].	O

Their	O
age	O
,	O
sex	O
,	O
APACHE	O
II	O
score	O
,	O
PaO2	O
/	O
FiO2	O
,	O
Qs	O
/	O
Qt	O
,	O
use	O
of	O
artificial	O
ventilation	O
and	O
its	O
duration	O
,	O
level	O
of	O
PEEP	B-CHED
,	O
and	O
the	O
extent	O
of	O
relief	O
from	O
hypoxemia	O
showed	O
no	O
significant	O
differences	O
between	O
two	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
In	O
vivo	O
(	O
lung	O
resistive	O
and	O
viscoelastic	O
pressures	O
and	O
static	O
elastance	O
)	O
and	O
in	O
vitro	O
(	O
tissue	O
resistance	O
,	O
elastance	O
,	O
and	O
hysteresivity	O
)	O
respiratory	O
mechanics	O
were	O
analyzed	O
1	O
and	O
30	O
days	O
after	O
saline	O
(	O
control	O
)	O
or	O
paraquat	B-CHED
(	O
P	O
[	O
10	O
and	O
25	O
mg	O
/	O
kg	O
intraperitoneally	O
])	O
injection	O
in	O
rats	O
.	O

The	O
lung	O
tissue	O
specimens	O
were	O
studied	O
further	O
with	O
Macchiavello	O
staining	O
,	O
viral	O
inclusion	O
body	O
staining	O
,	O
reticulin	B-CHED
staining	O
,	O
PAS	B-CHED
staining	O
,	O
immunohistochemistry	O
,	O
ultrathin	O
sectioning	O
and	O
staining	O
,	O
light	O
microscopy	O
,	O
and	O
transmission	O
electron	O
microscopy	O
.	O

Differential	O
cell	O
counts	O
were	O
performed	O
and	O
supernatant	O
was	O
assayed	O
for	O
IL	O
-	O
8	O
,	O
IL	O
-	O
5	O
,	O
IFN	O
-	O
gamma	O
,	O
and	O
eosinophilic	O
cationic	O
protein	B-CHED
(	O
ECP	O
).	O

TITLE	O
:	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
in	O
a	O
liver	O
transplant	O
recipient	O
and	O
guidelines	O
for	O
donor	B-CHED
SARS	O
screening	O
.	O

Due	O
to	O
the	O
potential	O
severity	O
of	O
SARS	O
in	O
transplant	O
recipients	O
and	O
the	O
large	O
number	O
of	O
cases	O
of	O
SARS	O
in	O
the	O
community	O
,	O
in	O
order	O
to	O
avoid	O
transmission	O
of	O
SARS	O
from	O
a	O
donor	B-CHED
,	O
we	O
developed	O
guidelines	O
for	O
SARS	O
screening	O
of	O
organ	O
donors	O
.	O

The	O
serum	O
levels	O
of	O
IgM	O
and	O
IgG	O
antibodies	O
to	O
N	O
antigen	B-CHED
were	O
measured	O
in	O
200	O
healthy	O
blood	O
donors	O
and	O
13	O
SARS	O
patients	O
at	O
different	O
time	O
points	O
of	O
acute	O
and	O
convalescent	O
phases	O
using	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
N	O
fusion	O
proteins	B-CHED
of	O
SARS	O
-	O
associated	O
coronaviruses	O
.	O

Cases	O
appeared	O
throughout	O
South	O
-	O
East	O
Asia	O
and	O
in	O
Toronto	O
,	O
the	O
spread	O
of	O
SARS	O
being	O
accelerated	O
by	O
international	O
air	B-CHED
travel	O
.	O

The	O
empirical	O
therapy	O
is	O
based	O
on	O
broad	O
-	O
spectrum	O
antibiotics	B-CHED
,	O
steroids	B-CHED
and	O
ribavirin	B-CHED
,	O
but	O
susceptibility	O
testing	O
have	O
failed	O
to	O
demonstrate	O
direct	O
anti	O
-	O
viral	O
activity	O
of	O
ribavirin	B-CHED
against	O
SARS	O
-	O
related	O
coronavirus	O
in	O
vitro	O
.	O

Treatment	O
of	O
SARS	O
includes	O
supportive	O
measures	O
and	O
the	O
empiric	O
use	O
of	O
ribavirin	B-CHED
.	O

(	O
7	O
)	O
Antibiotical	O
therapies	O
included	O
tetracyclines	B-CHED
(	O
91	O
.	O
0	O
%),	O
aminoglycosides	B-CHED
(	O
83	O
.	O
3	O
%),	O
quinolones	B-CHED
(	O
79	O
.	O
2	O
%);	O
18	O
.	O
8	O
%	O
of	O
the	O
patients	O
received	O
a	O
combination	O
of	O
tetracyclines	B-CHED
and	O
aminoglycosides	B-CHED
,	O
while	O
11	O
.	O
5	O
%	O
received	O
a	O
combination	O
of	O
tetracyclines	B-CHED
and	O
quinolones	B-CHED
,	O
and	O
63	O
.	O
5	O
%	O
received	O
a	O
combination	O
of	O
tetracyclines	B-CHED
,	O
aminoglycosides	B-CHED
and	O
quinolones	B-CHED
.	O

ABSTRACT	O
:	O
Gefitinib	B-CHED
is	O
a	O
potent	O
drug	O
used	O
in	O
the	O
treatment	O
of	O
nonsmall	O
-	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
).	O

Gefitinib	B-CHED
acts	O
by	O
inhibition	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	B-CHED
kinase	O
.	O

Heptad	O
repeat	O
(	O
HR	O
)	O
regions	O
are	O
found	O
in	O
fusion	O
proteins	B-CHED
of	O
many	O
different	O
viruses	O
and	O
form	O
an	O
important	O
characteristic	O
of	O
class	O
I	O
viral	O
fusion	O
proteins	B-CHED
.	O

Both	O
on	O
their	O
own	O
and	O
within	O
the	O
complex	O
,	O
the	O
peptides	B-CHED
were	O
highly	O
alpha	O
helical	O
.	O

Using	O
biological	O
assays	O
,	O
the	O
HR2	O
peptide	B-CHED
was	O
shown	O
to	O
be	O
a	O
potent	O
inhibitor	B-CHED
of	O
virus	O
entry	O
into	O
the	O
cell	O
,	O
as	O
well	O
as	O
of	O
cell	O
-	O
cell	O
fusion	O
.	O

BeauR	O
-	O
M41	O
(	O
S	O
)	O
acquired	O
the	O
same	O
cell	O
tropism	O
phenotype	O
as	O
IBV	O
M41	O
-	O
CK	O
in	O
four	O
different	O
cell	O
types	O
,	O
demonstrating	O
that	O
the	O
IBV	O
spike	O
glycoprotein	B-CHED
is	O
a	O
determinant	O
of	O
cell	O
tropism	O
.	O

ABSTRACT	O
:	O
The	O
expression	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
S1	O
glycoprotein	B-CHED
in	O
potatoes	O
and	O
its	O
immunogenicity	O
in	O
mice	O
and	O
chickens	O
were	O
investigated	O
.	O

These	O
results	O
demonstrate	O
that	O
transgenic	O
potatoes	O
expressing	O
IBV	O
S1	O
glycoprotein	B-CHED
can	O
be	O
used	O
as	O
a	O
source	O
of	O
recombinant	O
antigen	B-CHED
for	O
vaccine	O
production	O
.	O

Confocus	O
microscope	O
immunofluorescence	O
was	O
performed	O
to	O
show	O
whether	O
N	O
protein	B-CHED
of	O
MHV	O
enters	O
into	O
the	O
nucleus	B-CHED
of	O
infected	O
cells	O
,	O
which	O
is	O
a	O
critical	O
step	O
for	O
the	O
N	O
protein	B-CHED
to	O
facilitate	O
its	O
transactivation	O
property	O
.	O

ABSTRACT	O
:	O
Inhaled	O
vasodilators	O
such	O
as	O
nitric	B-CHED
oxide	I-CHED
and	O
aerosolized	O
prostacyclin	B-CHED
(	O
PGI	B-CHED
(	O
2	O
))	O
are	O
used	O
to	O
treat	O
severe	O
hypoxemia	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

17	O
mm	O
Hg	O
,	O
p	O
=	O
0	O
.	O
003	O
)	O
and	O
arterial	O
oxygen	B-CHED
saturation	O
measured	O
via	O
pulse	O
oximetry	O
(	O
86	O
+/-	O

It	O
has	O
been	O
observed	O
that	O
both	O
the	O
above	O
compounds	O
interact	O
with	O
the	O
active	O
site	O
of	O
the	O
SARS	O
enzyme	O
through	O
six	O
hydrogen	B-CHED
bonds	O
.	O

Meanwhile	O
,	O
the	O
idea	O
of	O
how	O
to	O
develop	O
inhibitors	B-CHED
of	O
the	O
SARS	O
enzyme	O
based	O
on	O
the	O
knowledge	O
of	O
its	O
own	O
peptide	B-CHED
substrates	O
(	O
the	O
so	O
-	O
called	O
""""	O
distorted	O
key	O
""""	O
approach	O
)	O
was	O
also	O
briefly	O
elucidated	O
.	O

The	O
cytoplasmic	O
tails	O
of	O
both	O
proteins	B-CHED
are	O
important	O
for	O
this	O
interaction	O
.	O

ABSTRACT	O
:	O
Effective	O
antiviral	B-CHED
agents	I-CHED
are	O
needed	O
to	O
treat	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
.	O

Treatment	O
regimens	O
included	O
small	O
doses	O
of	O
steroids	B-CHED
(	O
methylprednisolone	B-CHED
40	O
-	O
80	O
mg	O
,	O
q12	O
h	O
recommended	O
)	O
accompanied	O
with	O
broad	O
-	O
spectrum	O
antibiotics	B-CHED
such	O
as	O
the	O
second	O
generation	O
of	O
cephalosporins	B-CHED
and	O
macrolides	B-CHED
and	O
some	O
other	O
antiviral	B-CHED
drugs	I-CHED
.	O

A	O
large	O
dose	O
of	O
glucocorticoid	B-CHED
may	O
aggravate	O
the	O
suppression	O
and	O
make	O
the	O
body	O
in	O
an	O
active	O
metabolic	O
state	O
(	O
the	O
increase	O
of	O
blood	O
glucose	B-CHED
and	O
the	O
decrease	O
of	O
sera	O
albumin	O
).	O

Thus	O
,	O
to	O
develop	O
and	O
expression	O
protein	B-CHED
fragment	O
from	O
spike	O
protein	B-CHED
gene	O
are	O
the	O
purposes	O
of	O
this	O
experiment	O
.	O

The	O
possible	O
death	O
-	O
related	O
risk	O
factors	O
including	O
age	O
,	O
underlying	O
diseases	O
,	O
leucocytosis	O
,	O
thrombocytopenia	O
,	O
and	O
lymphopenia	O
were	O
analyzed	O
by	O
the	O
Mantel	O
-	O
Haenszel	O
chi	B-CHED
(	O
2	O
)	O
test	O
.	O

Noninvasive	O
ventilation	O
relieves	O
dyspnea	O
and	O
SpO	O
(	O
2	O
)	O
in	O
patients	O
with	O
critical	O
SARS	O
,	O
and	O
should	O
also	O
be	O
employed	O
in	O
those	O
with	O
SpO	O
(	O
2	O
)	O
of	O
90	O
%	O
-	O
93	O
%	O
at	O
rest	B-CHED
under	O
O	O
(	O
2	O
)	O
inhalation	O
5	O
L	O
/	O
min	O
.	O

At	O
the	O
progressive	O
stage	O
application	O
of	O
adrenocortical	O
hormones	B-CHED
and	O
non	O
-	O
invasive	O
mechanical	O
ventilation	O
helped	O
stop	O
the	O
progress	O
of	O
disease	O
.	O

Traditional	O
Chinese	O
medicine	B-CHED
(	O
TCM	O
)	O
regards	O
SARS	O
as	O
one	O
of	O
epidemic	O
febrile	O
diseases	O
.	O

ABSTRACT	O
:	O
SARS	O
virus	O
is	O
a	O
recently	O
found	O
coronavirus	O
,	O
which	O
cause	O
human	O
atypical	O
pneumonia	O
through	O
the	O
binding	O
of	O
its	O
spike	O
protein	B-CHED
to	O
the	O
receptor	O
on	O
human	O
cells	O
.	O

The	O
main	O
treatments	O
include	O
corticosteroid	B-CHED
therapy	O
,	O
anti	B-CHED
-	I-CHED
viral	I-CHED
agents	I-CHED
,	O
anti	O
-	O
infection	O
,	O
mechanical	O
ventilation	O
and	O
isolation	O
.	O

TITLE	O
:	O
Amino	B-CHED
acid	I-CHED
substitutions	O
within	O
the	O
heptad	O
repeat	O
domain	O
1	O
of	O
murine	O
coronavirus	O
spike	O
protein	B-CHED
restrict	O
viral	O
antigen	B-CHED
spread	O
in	O
the	O
central	O
nervous	O
system	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
M	O
protein	B-CHED
,	O
the	O
most	O
abundant	O
coronaviral	O
envelope	O
component	O
,	O
is	O
invariably	O
glycosylated	O
,	O
which	O
provides	O
the	O
virion	O
with	O
a	O
diffuse	O
,	O
hydrophilic	O
cover	O
on	O
its	O
outer	O
surface	O
.	O

In	O
order	O
to	O
investigate	O
the	O
role	O
of	O
the	O
M	O
protein	B-CHED
glycosylation	O
in	O
the	O
host	O
,	O
two	O
genetically	O
modified	O
MHVs	O
were	O
generated	O
by	O
using	O
targeted	O
RNA	O
recombination	O
.	O

MHV	O
with	O
unglycosylated	O
M	O
proteins	B-CHED
appeared	O
to	O
be	O
a	O
poor	O
interferon	B-CHED
inducer	I-CHED
.	O

The	O
mean	O
lowest	O
oxygen	B-CHED
saturation	O
was	O
(	O
94	O
.	O
8	O
+/-	O

3	O
.	O
1	O
)%	O
with	O
supplementary	O
oxygen	B-CHED
through	O
a	O
nasal	O
cannula	O
.	O

The	O
functions	O
of	O
many	O
of	O
these	O
polypeptides	B-CHED
,	O
including	O
the	O
Nsp9	O
-	O
Nsp10	O
replicase	O
-	O
cleavage	O
products	O
,	O
are	O
still	O
unknown	O
.	O

The	O
4382	O
-	O
and	O
7073	O
amino	B-CHED
acid	I-CHED
residue	I-CHED
SARS	O
-	O
CoV	O
replicase	O
polyproteins	O
are	O
predicted	O
to	O
be	O
cleaved	O
into	O
16	O
subunits	O
by	O
two	O
viral	O
proteinases	O
(	O
bringing	O
the	O
total	O
number	O
of	O
SARS	O
-	O
CoV	O
proteins	B-CHED
to	O
28	O
).	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
effect	O
of	O
glucocorticoid	B-CHED
in	O
the	O
treatment	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

(	O
4	O
)	O
Average	O
hospital	O
stay	O
was	O
15	O
days	O
for	O
the	O
23	O
cases	O
with	O
lower	O
dose	O
of	O
40	O
mg	O
to	O
80	O
mg	O
methylprednisolone	B-CHED
daily	O
,	O
18	O
.	O
5	O
days	O
for	O
the	O
27	O
cases	O
with	O
medium	O
dose	O
of	O
120	O
mg	O
to	O
240	O
mg	O
daily	O
,	O
and	O
17	O
.	O
9	O
days	O
for	O
the	O
nine	O
cases	O
with	O
higher	O
dose	O
of	O
320	O
mg	O
to	O
640	O
mg	O
daily	O
(	O
F	O
=	O
1	O
.	O
018	O
,	O
P	O
=	O
0	O
.	O
39	O
).	O

The	O
medicine	B-CHED
associated	O
toxicities	O
may	O
be	O
the	O
main	O
reason	O
of	O
liver	O
lesions	O
.	O

Hence	O
,	O
scIHF2	O
may	O
be	O
used	O
as	O
a	O
novel	O
regulatory	O
cofactor	B-CHED
for	O
recombination	O
or	O
other	O
DNA	O
transactions	O
in	O
mammalian	O
cells	O
that	O
require	O
or	O
benefit	O
from	O
sequence	O
-	O
specific	O
high	O
precision	O
DNA	O
bending	O
.	O

Serum	O
total	O
bilirubin	B-CHED
values	O
elevated	O
in	O
8	O
.	O
4	O
%	O
patients	O
.	O

We	O
have	O
constructed	O
a	O
prototype	O
RNA	O
vector	O
containing	O
the	O
5	O
'	O
and	O
3	O
'	O
ends	O
of	O
the	O
human	O
coronavirus	O
genome	O
,	O
the	O
entire	O
human	O
coronavirus	O
replicase	O
gene	O
,	O
and	O
three	O
reporter	O
genes	O
(	O
i	O
.	O
e	O
.,	O
the	O
chloramphenicol	B-CHED
acetyltransferase	O
[	O
CAT	O
]	O
gene	O
,	O
the	O
firefly	O
luciferase	O
[	O
LUC	O
]	O
gene	O
,	O
and	O
the	O
green	O
fluorescent	O
protein	B-CHED
[	O
GFP	O
]	O
gene	O
).	O

The	O
transfection	O
of	O
vector	O
RNA	O
and	O
human	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
mRNA	B-CHED
into	O
BHK	O
-	O
21	O
cells	O
resulted	O
in	O
the	O
expression	O
of	O
the	O
CAT	O
,	O
LUC	O
,	O
and	O
GFP	O
reporter	O
proteins	B-CHED
.	O

TITLE	O
:	O
High	O
-	O
dose	O
pulse	O
versus	O
nonpulse	O
corticosteroid	B-CHED
regimens	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Initial	O
use	O
of	O
pulse	O
methylprednisolone	B-CHED
therapy	O
appears	O
to	O
be	O
a	O
more	O
efficacious	O
and	O
an	O
equally	O
safe	O
steroid	B-CHED
regimen	O
when	O
compared	O
with	O
regimens	O
with	O
lower	O
dosage	O
and	O
should	O
be	O
considered	O
as	O
the	O
preferred	O
steroid	B-CHED
regimen	O
in	O
the	O
treatment	O
of	O
SARS	O
,	O
pending	O
data	O
from	O
future	O
randomized	O
controlled	O
trials	O
.	O

RESULTS	O
:	O
The	O
MARS	O
therapy	O
was	O
associated	O
with	O
a	O
significant	O
removal	O
of	O
NO	O
and	O
certain	O
cytokines	O
such	O
as	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
INF	O
-	O
gamma	O
,	O
together	O
with	O
marked	O
reduction	O
of	O
other	O
non	O
-	O
water	B-CHED
-	O
soluble	O
albumin	O
bound	O
toxins	B-CHED
and	O
water	B-CHED
-	O
soluble	O
toxins	B-CHED
,	O
these	O
were	O
associated	O
with	O
a	O
improvement	O
of	O
the	O
patients	O
'	O
clinical	O
conditions	O
including	O
hepatic	O
encephalopathy	O
,	O
deranged	O
hemodynamic	O
situation	O
and	O
as	O
well	O
as	O
renal	O
and	O
respiratory	O
function	O
,	O
thus	O
resulted	O
into	O
marked	O
decrease	O
of	O
Sequential	O
Organ	O
Failure	O
Assessment	O
(	O
SOFA	O
)	O
score	O
and	O
improved	O
outcome	O
:	O
nine	O
patients	O
were	O
able	O
to	O
be	O
discharged	O
from	O
the	O
hospital	O
or	O
bridged	O
to	O
successful	O
liver	O
transplantation	O
,	O
the	O
overall	O
survival	O
of	O
24	O
patients	O
was	O
37	O
.	O
5	O
%.	O

A	O
preliminary	O
review	O
of	O
SARS	O
in	O
Singapore	O
shows	O
chest	O
radiographic	O
findings	O
of	O
patchy	O
airspace	O
shadowing	O
with	O
severe	O
cases	O
progressing	O
to	O
diffuse	O
air	B-CHED
-	O
space	O
shadowing	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
the	O
impact	O
of	O
aerosolised	O
prostacyclin	B-CHED
(	O
PGI2	B-CHED
)	O
and	O
iloprost	B-CHED
in	O
the	O
absence	O
or	O
presence	O
of	O
subthreshold	O
intravascular	O
doses	O
of	O
the	O
dual	O
-	O
selective	O
phosphodiesterase	O
-	O
3	O
/	O
4	O
inhibitor	B-CHED
zardaverine	B-CHED
was	O
investigated	O
in	O
an	O
experimental	O
model	O
of	O
acute	O
respiratory	O
failure	O
.	O

Aerosolisation	O
of	O
PGI2	B-CHED
(	O
in	O
total	O
1	O
.	O
05	O
microg	O
x	O
kg	O
(-	O
1	O
)	O
for	O
15	O
min	O
caused	O
a	O
decrease	O
in	O
pulmonary	O
artery	O
pressure	O
(	O
Ppa	O
)	O
and	O
a	O
limitation	O
of	O
maximum	O
shunt	O
flow	O
to	O
approximately	O
37	O
%.	O

Aerosolisation	O
of	O
iloprost	B-CHED
(	O
in	O
total	O
0	O
.	O
7	O
microg	O
x	O
kg	O
(-	O
1	O
))	O
for	O
15	O
min	O
caused	O
a	O
more	O
sustained	O
decrease	O
in	O
Ppa	O
,	O
some	O
enhanced	O
reduction	O
of	O
oedema	O
formation	O
as	O
compared	O
with	O
PGI2	B-CHED
and	O
a	O
decrease	O
in	O
shunt	O
flow	O
to	O
approximately	O
32	O
%.	O

All	O
the	O
animal	O
isolates	O
retain	O
a	O
29	O
-	O
nucleotide	B-CHED
sequence	O
that	O
is	O
not	O
found	O
in	O
most	O
human	O
isolates	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
role	O
of	O
HO	O
-	O
1	O
induction	O
in	O
a	O
rat	O
model	O
of	O
CCl	B-CHED
(	O
4	O
)-	O
induced	O
acute	O
liver	O
injury	O
.	O

The	O
patient	O
was	O
treated	O
with	O
supplemental	O
oxygen	B-CHED
,	O
levofloxacin	B-CHED
,	O
oseltamivir	B-CHED
,	O
ribavirin	B-CHED
and	O
methylprednisolone	B-CHED
.	O

TITLE	O
:	O
Enhanced	O
virulence	O
mediated	O
by	O
the	O
murine	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
strain	O
JHM	O
,	O
is	O
associated	O
with	O
a	O
glycine	B-CHED
at	O
residue	O
310	O
of	O
the	O
spike	O
glycoprotein	B-CHED
.	O

In	O
this	O
study	O
,	O
we	O
set	O
out	O
to	O
identify	O
these	O
proteins	B-CHED
.	O

hnRNP	O
A2	O
/	O
B1	O
,	O
which	O
is	O
predominantly	O
localized	O
to	O
the	O
nucleus	B-CHED
and	O
shuttles	O
between	O
the	O
nucleus	B-CHED
and	O
the	O
cytoplasm	O
,	O
was	O
shown	O
to	O
relocalize	O
to	O
the	O
cytoplasm	O
in	O
MHV	O
-	O
infected	O
CB3	O
cells	O
.	O

Strategies	O
that	O
maximize	O
the	O
benefit	O
and	O
minimize	O
the	O
risks	O
of	O
PN	O
(	O
hypocaloric	O
dose	O
,	O
withholding	O
lipids	B-CHED
,	O
and	O
the	O
use	O
of	O
intensive	O
insulin	B-CHED
therapy	O
to	O
achieve	O
tight	O
glycemic	O
control	O
)	O
should	O
be	O
considered	O
.	O

There	O
are	O
insufficient	O
data	O
to	O
generate	O
recommendations	O
in	O
the	O
following	O
areas	O
:	O
use	O
of	O
indirect	O
calorimetry	O
;	O
optimal	O
pH	O
of	O
EN	O
;	O
supplementation	O
with	O
trace	O
elements	O
,	O
antioxidants	B-CHED
,	O
or	O
fiber	O
;	O
optimal	O
mix	O
of	O
fats	O
and	O
carbohydrates	B-CHED
;	O
use	O
of	O
closed	O
feeding	O
systems	O
;	O
continuous	O
versus	O
bolus	O
feedings	O
;	O
use	O
of	O
probiotics	O
;	O
type	O
of	O
lipids	B-CHED
;	O
and	O
mode	O
of	O
lipid	B-CHED
delivery	O
.	O

The	O
lower	O
partical	O
pressure	O
of	O
carbon	B-CHED
dioxide	I-CHED
in	O
artery	O
(	O
PaCO2	O
),	O
partical	O
pressure	O
of	O
oxygen	B-CHED
in	O
artery	O
(	O
PaO2	O
)	O
in	O
blood	O
was	O
,	O
the	O
higher	O
death	O
rate	O
was	O
.	O

The	O
sensitive	O
rate	O
of	O
vancomycin	B-CHED
to	O
GPC	O
was	O
100	O
.	O
0	O
percent	O
.	O

Among	O
the	O
10	O
index	O
cases	O
,	O
only	O
the	O
super	O
spreader	O
and	O
another	O
one	O
index	O
case	O
transmitted	O
the	O
virus	O
to	O
their	O
contacts	O
but	O
the	O
rest	B-CHED
of	O
index	O
cases	O
did	O
not	O
cause	O
any	O
secondary	O
infection	O
.	O

The	O
congruence	O
of	O
the	O
relationship	O
outcomes	O
with	O
the	O
known	O
classification	O
indicates	O
that	O
there	O
exist	O
phylogenetic	O
signals	O
in	O
the	O
tetra	B-CHED
-	O
nucleotide	B-CHED
usage	O
patterns	O
,	O
that	O
is	O
most	O
prominent	O
in	O
the	O
replicase	O
open	O
reading	O
frames	O
.	O

The	O
vectors	O
were	O
injected	O
into	O
the	O
cerebral	O
cortex	O
,	O
caudate	O
nucleus	B-CHED
,	O
thalamus	O
,	O
corona	B-CHED
radiata	O
,	O
internal	O
capsule	O
,	O
and	O
centrum	O
semiovale	O
of	O
8	O
-	O
week	O
-	O
old	O
cats	O
.	O

SARS	O
-	O
specific	O
research	O
reagents	B-CHED
should	O
also	O
be	O
collected	O
and	O
shared	O
.	O

These	O
would	O
include	O
SARS	O
peptides	B-CHED
,	O
adjuvants	B-CHED
,	O
DNA	O
vaccine	O
vectors	O
and	O
clinical	O
grade	O
viral	O
vectors	O
.	O

SARS	O
-	O
CoV	O
RNA	O
was	O
identified	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
in	O
7	O
of	O
8	O
cases	O
in	O
fresh	O
autopsy	O
tissue	O
and	O
in	O
8	O
of	O
8	O
cases	O
in	O
formalin	B-CHED
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
lung	O
tissue	O
,	O
including	O
the	O
1	O
negative	O
case	O
in	O
fresh	O
tissue	O
.	O

ABSTRACT	O
:	O
Over	O
15	O
years	O
ago	O
,	O
the	O
Benner	O
group	O
noticed	O
that	O
the	O
DNA	O
alphabet	O
need	O
not	O
be	O
limited	O
to	O
the	O
four	O
standard	O
nucleotides	B-CHED
known	O
in	O
natural	O
DNA	O
.	O

ABSTRACT	O
:	O
Fas	O
ligand	B-CHED
(	O
FasL	O
)-	O
induced	O
lung	O
inflammation	O
has	O
recently	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
acute	O
respiratory	O
disease	O
syndrome	O
(	O
ARDS	O
).	O

We	O
used	O
a	O
Bayesian	O
phylogenetic	O
inference	O
approach	O
with	O
sliding	O
window	O
analyses	O
of	O
three	O
SARS	O
-	O
CoV	O
proteins	B-CHED
:	O
RNA	O
dependent	O
RNA	O
polymerase	O
(	O
RDRP	O
),	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
).	O

Maximal	O
and	O
treatment	O
radiographic	O
scores	O
were	O
inversely	O
related	O
to	O
oxygen	B-CHED
saturation	O
(	O
r	O
=	O
-	O
0	O
.	O
67	O
,	O
P	O
<.	O
001	O
;	O
r	O
=	O
-	O
0	O
.	O
35	O
,	O
P	O
=.	O
03	O
).	O

Phylogenetic	O
analysis	O
of	O
the	O
spike	O
protein	B-CHED
gene	O
fragments	O
of	O
these	O
SARS	O
-	O
associated	O
coronavirus	O
strains	O
showed	O
that	O
the	O
GZ01	O
isolate	O
was	O
phylogenetically	O
distinct	O
from	O
other	O
isolates	O
,	O
and	O
compared	O
with	O
groups	O
F1	O
and	O
F2	O
of	O
the	O
T	O
genotype	O
,	O
the	O
isolates	O
of	O
BJ01	O
and	O
CUHK	O
-	O
W1	O
were	O
more	O
closely	O
related	O
to	O
the	O
GZ01	O
isolate	O
.	O

Air	B-CHED
oxidation	O
subsequently	O
forms	O
BN	O
in	O
the	O
heat	O
which	O
immediately	O
yields	O
orange	O
-	O
yellow	O
(	O
4	O
'	O
RS	O
)-	O
4	O
'-	O
chloro	B-CHED
-	O
1	O
',	O
4	O
'-	O
dihydrobananin	O
by	O
1	O
,	O
4	O
-	O
addition	O
of	O
hydrogen	B-CHED
chloride	I-CHED
.	O

Furthermore	O
,	O
theoretical	O
and	O
structural	O
considerations	O
propose	O
that	O
BN	O
is	O
converted	O
into	O
bananin	O
5	O
'-	O
monophosphate	O
(	O
BNP	O
)	O
by	O
the	O
cell	O
type	O
-	O
ubiquitous	O
human	O
enzyme	O
pyridoxal	B-CHED
kinase	O
(	O
EC	O
2	O
.	O
7	O
.	O
1	O
.	O
35	O
).	O

Together	O
with	O
the	O
putative	O
antilentiviral	O
retinoid	B-CHED
vitamin	B-CHED
A	I-CHED
-	O
vitamin	B-CHED
B6	I-CHED
conjugate	O
analogue	O
B6RA	O
(	O
Kesel	O
,	O
A	O
.	O
J	O
.	O
Biochem	O
.	O

Moreover	O
,	O
acute	O
pancreatitis	O
increased	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	B-CHED
-	O
biotin	B-CHED
nick	O
end	O
labeling	O
-	O
positive	O
alveolar	O
and	O
bronchiolar	O
cells	O
in	O
the	O
lung	O
.	O

ABSTRACT	O
:	O
To	O
obtain	O
the	O
information	O
of	O
protein	B-CHED
-	O
protein	B-CHED
interaction	O
between	O
the	O
SARS	O
-	O
CoV	O
proteins	B-CHED
and	O
caveolin	O
-	O
1	O
,	O
identify	O
the	O
possible	O
caveolin	O
-	O
binding	O
sites	O
in	O
SARS	O
-	O
CoV	O
proteins	B-CHED
.	O

Thirty	O
six	O
caveolin	O
-	O
binding	O
motifs	O
in	O
the	O
SARS	O
-	O
CoV	O
proteins	B-CHED
have	O
been	O
mapped	O
out	O
using	O
bioinformatics	O
analysis	O
tools	O
.	O

These	O
caveolin	O
-	O
binding	O
sites	O
located	O
in	O
replicase	O
1AB	O
,	O
spike	O
protein	B-CHED
,	O
orf3	O
protein	B-CHED
,	O
and	O
M	O
protein	B-CHED
,	O
respectively	O
.	O

All	O
the	O
serum	O
samples	O
from	O
the	O
1	O
,	O
060	O
non	O
-	O
SARS	O
children	O
were	O
negative	O
for	O
both	O
IgG	O
and	O
IgM	O
antibodies	O
against	O
SARS	O
coronavirus	O
as	O
determined	O
by	O
indirect	O
immunofluorescent	O
assay	O
,	O
with	O
only	O
two	O
serum	O
samples	O
showing	O
weak	O
positivity	O
for	O
SARS	O
coronavirus	O
-	O
specific	O
antibodies	O
identified	O
by	O
double	O
-	O
antigen	B-CHED
sandwich	O
ELISA	O
.	O

Serologic	O
prevalence	O
in	O
wildcats	O
,	O
sand	O
cats	O
,	O
and	O
feral	O
domestic	O
cats	O
were	O
respectively	O
:	O
6	O
%,	O
0	O
%,	O
8	O
%	O
for	O
FIV	O
/	O
PLV	O
;	O
3	O
%,	O
8	O
%,	O
0	O
%	O
for	O
FeLV	O
;	O
5	O
%,	O
0	O
%,	O
15	O
%	O
for	O
FHV	O
-	O
1	O
;	O
25	O
%,	O
0	O
%,	O
39	O
%	O
for	O
FCV	B-CHED
;	O
10	O
%,	O
0	O
%,	O
0	O
%	O
for	O
FCoV	O
;	O
and	O
5	O
%,	O
0	O
%,	O
8	O
%	O
for	O
FPLV	O
.	O

In	O
patients	O
without	O
a	O
history	O
of	O
close	O
contact	O
with	O
SARS	O
cases	O
,	O
antibiotic	B-CHED
effect	O
was	O
a	O
major	O
factor	O
influencing	O
doctors	O
'	O
diagnosis	O
.	O

No	O
homologs	O
of	O
the	O
N	O
and	O
E	O
proteins	B-CHED
have	O
been	O
found	O
outside	O
coronaviruses	O
,	O
and	O
the	O
only	O
(	O
very	O
)	O
distant	O
homologs	O
of	O
S	O
and	O
M	O
proteins	B-CHED
were	O
identified	O
in	O
toroviruses	O
.	O

ABSTRACT	O
:	O
Aminopeptidase	O
N	O
has	O
been	O
identified	O
as	O
the	O
cellular	O
receptor	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
and	O
was	O
a	O
putative	O
receptor	O
for	O
the	O
spike	O
glycoprotein	B-CHED
encoded	O
by	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Despite	O
being	O
banned	O
in	O
many	O
countries	O
and	O
having	O
its	O
use	O
severely	O
restricted	O
in	O
others	O
,	O
pentachlorophenol	B-CHED
(	O
PCP	B-CHED
)	O
remains	O
an	O
important	O
pesticide	B-CHED
from	O
a	O
toxicological	O
perspective	O
.	O

Assessment	O
of	O
the	O
toxicity	O
of	O
PCP	B-CHED
is	O
confounded	O
by	O
the	O
presence	O
of	O
contaminants	O
known	O
to	O
cause	O
effects	O
identical	O
to	O
those	O
attributed	O
to	O
PCP	B-CHED
.	O

Despite	O
worsening	O
the	O
anemia	O
in	O
renal	O
failure	O
patients	O
by	O
causing	O
hemolysis	O
,	O
ribavirin	B-CHED
is	O
well	O
tolerated	O
after	O
dosage	O
adjustment	O
.	O

Thereafter	O
,	O
severe	O
vitamin	B-CHED
B1	I-CHED
deficiency	O
in	O
infants	O
was	O
diagnosed	O
and	O
treated	O
promptly	O
.	O

The	O
protease	O
structure	O
has	O
a	O
fold	O
that	O
can	O
be	O
described	O
as	O
an	O
augmented	O
serine	B-CHED
-	O
protease	O
,	O
but	O
with	O
a	O
Cys	B-CHED
-	O
His	O
at	O
the	O
active	O
site	O
.	O

To	O
control	O
the	O
epidemic	O
,	O
public	O
health	O
officials	O
initiated	O
enhanced	O
surveillance	O
,	O
isolation	O
of	O
SARS	O
patients	O
,	O
use	O
of	O
personal	O
protective	O
equipment	O
(	O
PPE	B-CHED
)	O
by	O
health	O
-	O
care	O
workers	O
,	O
and	O
quarantine	O
of	O
contacts	O
of	O
known	O
SARS	O
patients	O
.	O

Virus	O
inoculation	O
of	O
21	O
-	O
day	O
postnatal	O
C57BL	O
/	O
6	O
and	O
BALB	O
/	O
c	O
mice	O
led	O
to	O
a	O
generalized	O
infection	O
of	O
the	O
whole	O
CNS	B-CHED
,	O
demonstrating	O
HCoV	O
-	O
OC43	O
neuroinvasiveness	O
and	O
neurovirulence	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
relationship	O
among	O
chest	O
radiographs	O
,	O
oxygen	B-CHED
supplementation	O
requirement	O
,	O
and	O
treatment	O
response	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Laboratory	O
findings	O
included	O
lymphopenia	O
(	O
73	O
%),	O
thrombocytopenia	O
(	O
50	O
%),	O
hyponatremia	O
(	O
60	O
%),	O
and	O
elevated	O
levels	O
of	O
lactate	B-CHED
dehydrogenase	O
(	O
47	O
%)	O
and	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
75	O
%).	O

These	O
patients	O
were	O
treated	O
with	O
glucocorticoids	B-CHED
.	O

TITLE	O
:	O
[	O
Rational	O
therapeutic	O
regime	O
of	O
glucocorticoid	B-CHED
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
its	O
receptor	O
mechanism	O
].	O

The	O
proposed	O
usage	O
of	O
GC	O
according	O
to	O
the	O
levels	O
of	O
GR	O
,	O
cortisol	B-CHED
and	O
clinical	O
indices	O
in	O
the	O
treatment	O
of	O
ARDS	O
was	O
shown	O
to	O
be	O
rational	O
.	O

ABSTRACT	O
:	O
The	O
specificities	O
and	O
sensitivities	O
of	O
five	O
recombinant	O
proteins	B-CHED
of	O
the	O
surface	O
protective	O
antigen	B-CHED
(	O
SpaA	O
)	O
of	O
Erysipelothrix	O
rhusiopathiae	O
were	O
examined	O
by	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
the	O
aim	O
of	O
developing	O
a	O
reliable	O
serological	O
test	O
for	O
the	O
detection	O
of	O
protective	O
antibody	O
against	O
E	O
.	O
rhusiopathiae	O
.	O

Fully	O
mature	O
protein	B-CHED
and	O
the	O
N	O
-	O
terminal	O
416	O
amino	B-CHED
acids	I-CHED
(	O
SpaA416	O
)	O
showed	O
sufficient	O
antigenicities	O
,	O
and	O
further	O
examination	O
was	O
done	O
with	O
SpaA416	O
because	O
of	O
its	O
higher	O
yield	O
.	O

Common	O
laboratory	O
abnormalities	O
included	O
mild	O
leukopenia	O
,	O
lymphopenia	O
,	O
and	O
increased	O
aspartate	B-CHED
transaminase	O
,	O
alanine	B-CHED
transaminase	O
,	O
lactic	O
dehydrogenase	O
,	O
and	O
creatine	B-CHED
kinase	O
.	O

Management	O
consisted	O
of	O
isolation	O
,	O
strict	O
respiratory	O
and	O
contact	O
precautions	O
,	O
ventilatory	O
support	O
as	O
needed	O
,	O
empiric	O
broad	O
-	O
spectrum	O
antibiotics	B-CHED
,	O
ribavirin	B-CHED
,	O
and	O
corticosteroids	B-CHED
.	O

ABSTRACT	O
:	O
A	O
transformation	O
analogous	O
to	O
the	O
well	O
-	O
known	O
conversion	O
of	O
an	O
N	O
-	O
terminal	O
glutamine	B-CHED
residue	I-CHED
to	O
pyroglutamic	B-CHED
acid	I-CHED
is	O
the	O
cyclization	O
of	O
an	O
N	O
-	O
terminal	O
carboxyamidomethylated	O
cysteine	B-CHED
residue	I-CHED
(	O
the	O
normal	O
product	O
of	O
alkylation	O
with	O
iodoacetamide	O
).	O

With	O
regard	O
to	O
blockade	O
,	O
combination	O
antiviral	B-CHED
/	O
antichemokine	O
therapy	O
is	O
a	O
new	O
strategy	O
worth	O
considering	O
as	O
a	O
general	O
therapeutic	O
approach	O
to	O
viral	O
infections	O
,	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

TITLE	O
:	O
Changes	O
in	O
some	O
acute	O
phase	O
protein	B-CHED
and	O
immunoglobulin	O
concentrations	O
in	O
cats	O
affected	O
by	O
feline	O
infectious	O
peritonitis	O
or	O
exposed	O
to	O
feline	O
coronavirus	O
infection	O
.	O

Serum	O
protein	B-CHED
electrophoresis	O
and	O
the	O
concentration	O
of	O
haptoglobin	O
(	O
Hp	O
),	O
serum	O
amyloid	O
A	O
(	O
SAA	O
),	O
alpha	O
(	O
1	O
)-	O
acid	O
glycoprotein	B-CHED
(	O
AGP	O
),	O
IgG	O
and	O
IgM	O
were	O
evaluated	O
in	O
cats	O
exposed	O
to	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
and	O
in	O
cats	O
with	O
FIP	O
.	O

Ecologic	O
analysis	O
was	O
conducted	O
to	O
explore	O
the	O
association	O
and	O
correlation	O
between	O
air	B-CHED
pollution	O
and	O
SARS	O
case	O
fatality	O
via	O
model	O
fitting	O
.	O

Notably	O
,	O
N371	O
and	O
N385	O
,	O
located	O
at	O
the	O
COOH	O
terminus	O
of	O
the	O
N	O
protein	B-CHED
,	O
inhibited	O
binding	O
of	O
antibodies	O
to	O
SARS	O
-	O
coronavirus	O
lysate	O
and	O
bound	O
to	O
antibodies	O
in	O
>	O
94	O
%	O
of	O
samples	O
from	O
SARS	O
study	O
patients	O
.	O

This	O
antibody	O
-	O
dependent	O
enhancement	O
(	O
ADE	B-CHED
)	O
activity	O
increased	O
with	O
the	O
MAb	O
that	O
showed	O
a	O
neutralizing	O
activity	O
with	O
feline	O
kidney	O
cells	O
,	O
suggesting	O
that	O
there	O
was	O
a	O
distinct	O
correlation	O
between	O
ADE	B-CHED
activity	O
and	O
the	O
neutralizing	O
activity	O
.	O

Mechanically	O
-	O
ventilated	O
children	O
with	O
peak	O
inspiratory	O
pressure	O
greater	O
than	O
or	O
equal	O
to	O
30	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
FiO	O
(	O
2	O
)	O
greater	O
than	O
or	O
equal	O
to	O
0	O
.	O
5	O
,	O
and	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
less	O
than	O
or	O
equal	O
to	O
200	O
were	O
included	O
in	O
the	O
study	O
.	O

Patients	O
who	O
presented	O
an	O
increase	O
of	O
at	O
least	O
20	O
in	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
were	O
considered	O
responsive	O
.	O

TITLE	O
:	O
[	O
Cloning	O
,	O
expression	O
and	O
purification	O
of	O
SARS	O
coronavirus	O
PUMC2	O
strain	O
nucleocapsid	O
protein	B-CHED
].	O

Diffusing	O
capacity	O
for	O
carbon	B-CHED
monoxide	I-CHED
(	O
DLco	O
%)	O
of	O
level	O
2	O
and	O
3	O
were	O
statistically	O
lower	O
than	O
that	O
of	O
level	O
0	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

They	O
ran	O
at	O
about	O
180	O
-	O
200kDa	O
in	O
SDS	B-CHED
gels	O
suggesting	O
post	O
-	O
translational	O
modifications	O
as	O
predicted	O
by	O
previous	O
computer	O
analysis	O
and	O
observed	O
for	O
other	O
coronaviruses	O
.	O

The	O
structural	O
model	O
permits	O
us	O
to	O
discuss	O
the	O
potential	O
functional	O
roles	O
of	O
the	O
conserved	O
motifs	O
and	O
residues	O
in	O
replication	O
and	O
their	O
potential	O
interactions	O
with	O
inhibitors	B-CHED
of	O
related	O
enzymes	O
.	O

In	O
addition	O
N	O
protein	B-CHED
binds	O
the	O
intracellular	O
form	O
of	O
the	O
genomic	O
RNA	O
,	O
all	O
of	O
the	O
MHV	O
subgenomic	O
mRNAs	O
,	O
and	O
expressed	O
non	O
-	O
MHV	O
RNA	O
transcripts	O
to	O
form	O
ribonucleoprotein	O
(	O
RNP	O
)	O
complexes	O
in	O
infected	O
cells	O
.	O

TITLE	O
:	O
Diagnosis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
by	O
detection	O
of	O
SARS	O
coronavirus	O
nucleocapsid	O
antibodies	O
in	O
an	O
antigen	B-CHED
-	O
capturing	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

The	O
vaccinated	O
animals	O
all	O
had	O
antibody	O
responses	O
against	O
spike	O
protein	B-CHED
S1	O
fragment	O
and	O
T	O
-	O
cell	O
responses	O
against	O
the	O
nucleocapsid	O
protein	B-CHED
.	O

Common	O
laboratory	O
features	O
included	O
lymphopenia	O
(	O
72	O
.	O
4	O
%),	O
thrombocytopenia	O
(	O
34	O
.	O
5	O
%)	O
and	O
elevated	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
),	O
lactate	B-CHED
dehydrogenase	O
(	O
LDH	O
),	O
and	O
aspartate	B-CHED
aminotransferase	O
(	O
AST	O
)	O
(	O
93	O
.	O
1	O
,	O
62	O
.	O
1	O
,	O
44	O
.	O
8	O
%,	O
respectively	O
).	O

The	O
risk	O
factors	O
associated	O
with	O
severe	O
disease	O
were	O
presence	O
of	O
diarrhoea	O
,	O
high	O
peak	O
LDH	O
and	O
CRP	O
,	O
high	O
AST	O
and	O
creatine	B-CHED
kinase	O
on	O
admission	O
and	O
high	O
peak	O
values	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
spike	O
(	O
S	O
)	O
protein	B-CHED
mediates	O
infection	O
of	O
receptor	O
-	O
expressing	O
host	O
cells	O
and	O
is	O
a	O
critical	O
target	O
for	O
antiviral	B-CHED
neutralizing	O
antibodies	O
.	O

ABSTRACT	O
:	O
The	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
receptor	O
(	O
MHVR	O
),	O
CEACAM1	O
,	O
has	O
two	O
different	O
functions	O
for	O
MHV	O
entry	O
into	O
cells	O
:	O
binding	O
to	O
MHV	O
spike	O
protein	B-CHED
(	O
S	O
protein	B-CHED
)	O
and	O
activation	O
of	O
the	O
S	O
protein	B-CHED
to	O
execute	O
virus	O
-	O
cell	O
membrane	O
fusion	O
,	O
the	O
latter	O
of	O
which	O
is	O
accompanied	O
by	O
conformational	O
changes	O
of	O
the	O
S	O
protein	B-CHED
.	O

Luciferase	O
expression	O
,	O
which	O
is	O
dependent	O
on	O
viral	O
RNA	O
replication	O
and	O
RNA	O
-	O
dependent	O
mRNA	B-CHED
synthesis	O
,	O
was	O
measured	O
in	O
intact	O
yeast	O
cells	O
.	O

Newly	O
identified	O
genes	O
include	O
some	O
in	O
RNA	O
,	O
protein	B-CHED
,	O
or	O
membrane	O
modification	O
pathways	O
and	O
genes	O
of	O
unknown	O
function	O
.	O

According	O
to	O
studies	O
with	O
other	O
coronaviruses	O
,	O
the	O
membrane	O
protein	B-CHED
(	O
M	O
protein	B-CHED
)	O
is	O
the	O
main	O
structural	O
protein	B-CHED
and	O
the	O
recombinant	O
M	O
protein	B-CHED
may	O
be	O
useful	O
as	O
an	O
antigen	B-CHED
for	O
detecting	O
antibodies	O
against	O
coronavirus	O
and	O
for	O
preparing	O
vaccine	O
.	O

ABSTRACT	O
:	O
The	O
membrane	O
-	O
associated	O
carboxypeptidase	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
an	O
essential	O
regulator	O
of	O
heart	O
function	O
.	O

Now	O
,	O
Li	O
at	O
al	O
.	O
identify	O
and	O
characterize	O
an	O
unexpected	O
second	O
function	O
of	O
ACE2	O
as	O
a	O
partner	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
glycoprotein	B-CHED
in	O
mediating	O
virus	O
entry	O
and	O
cell	O
fusion	O
.	O

Postoperative	O
complications	O
,	O
metabolic	O
studies	O
,	O
insulin	B-CHED
usage	O
,	O
pain	O
scores	O
,	O
and	O
quality	O
of	O
life	O
were	O
recorded	O
for	O
all	O
of	O
these	O
patients	O
.	O

Forty	O
-	O
one	O
percent	O
are	O
insulin	B-CHED
independent	O
,	O
and	O
27	O
%	O
required	O
minimal	O
amount	O
of	O
insulin	B-CHED
or	O
a	O
sliding	O
scale	O
.	O

RESULTS	O
:	O
In	O
all	O
three	O
SARS	O
clusters	B-CHED
,	O
the	O
index	O
cases	O
all	O
had	O
chronic	O
disease	O
and	O
played	O
the	O
role	O
of	O
infection	O
source	O
that	O
transmitted	O
the	O
virus	O
to	O
the	O
patients	O
'	O
family	O
members	O
,	O
attending	O
medical	O
staff	O
as	O
well	O
as	O
other	O
non	O
-	O
SARS	O
patients	O
sharing	O
the	O
same	O
ward	O
with	O
them	O
.	O

CONCLUSIONS	O
:	O
The	O
index	O
cases	O
played	O
an	O
important	O
role	O
in	O
transmission	O
of	O
SARS	O
virus	O
among	O
the	O
case	O
clusters	B-CHED
,	O
and	O
their	O
infective	O
stages	O
are	O
confined	O
within	O
certain	O
phases	O
of	O
the	O
disease	O
course	O
.	O

NCBI	O
resources	O
include	O
Entrez	O
,	O
PubMed	O
,	O
PubMed	O
Central	O
,	O
LocusLink	O
,	O
the	O
NCBI	O
Taxonomy	O
Browser	O
,	O
BLAST	O
,	O
BLAST	O
Link	O
(	O
BLink	O
),	O
Electronic	O
PCR	O
,	O
OrfFinder	O
,	O
Spidey	O
,	O
RefSeq	O
,	O
UniGene	O
,	O
HomoloGene	O
,	O
ProtEST	O
,	O
dbMHC	O
,	O
dbSNP	O
,	O
Cancer	O
Chromosome	O
Aberration	O
Project	O
(	O
CCAP	O
),	O
Entrez	O
Genomes	O
and	O
related	O
tools	O
,	O
the	O
Map	O
Viewer	O
,	O
Model	O
Maker	O
,	O
Evidence	O
Viewer	O
,	O
Clusters	B-CHED
of	O
Orthologous	O
Groups	O
(	O
COGs	O
)	O
database	O
,	O
Retroviral	O
Genotyping	O
Tools	O
,	O
SARS	O
Coronavirus	O
Resource	O
,	O
SAGEmap	O
,	O
Gene	O
Expression	O
Omnibus	O
(	O
GEO	O
),	O
Online	O
Mendelian	O
Inheritance	O
in	O
Man	B-CHED
(	O
OMIM	O
),	O
the	O
Molecular	O
Modeling	O
Database	O
(	O
MMDB	O
),	O
the	O
Conserved	O
Domain	O
Database	O
(	O
CDD	O
)	O
and	O
the	O
Conserved	O
Domain	O
Architecture	O
Retrieval	O
Tool	O
(	O
CDART	O
).	O

The	O
two	O
drugs	O
could	O
be	O
stockpiled	O
to	O
prepare	O
for	O
an	O
influenza	O
pandemic	O
but	O
,	O
importantly	O
,	O
clinical	O
and	O
scientific	O
experience	O
need	O
to	O
be	O
gained	O
by	O
using	O
these	O
inhibitors	B-CHED
in	O
the	O
yearly	O
conflagrations	O
of	O
epidemic	O
influenza	O
,	O
which	O
unchecked	O
do	O
great	O
harm	O
to	O
our	O
communities	O
.	O

A	O
series	O
of	O
co	O
-	O
immunoprecipitation	O
assays	O
have	O
established	O
that	O
these	O
four	O
MHV	O
RNA	O
binding	O
proteins	B-CHED
are	O
associated	O
,	O
even	O
in	O
the	O
absence	O
of	O
MHV	O
RNA	O
.	O

We	O
have	O
provided	O
evidence	O
for	O
the	O
interaction	O
of	O
these	O
four	O
proteins	B-CHED
with	O
the	O
3	O
'	O
end	O
region	O
of	O
MHV	O
RNA	O
in	O
infected	O
cells	O
by	O
a	O
series	O
of	O
immunoprecipitation	O
RT	O
-	O
PCR	O
assays	O
.	O

ABSTRACT	O
:	O
Paroxetine	B-CHED
,	O
a	O
selective	O
serotonin	B-CHED
reuptake	I-CHED
inhibitor	I-CHED
(	O
SSRI	B-CHED
)	O
may	O
be	O
given	O
in	O
severe	O
cases	O
of	O
maternal	O
depression	O
and	O
panic	O
disorders	O
during	O
pregnancy	O
.	O

The	O
patient	O
recovered	O
after	O
two	O
days	O
of	O
ventilation	O
and	O
anticonvulsive	O
medication	O
with	O
phenobarbital	B-CHED
.	O

Clinical	O
parameters	O
,	O
including	O
oxygen	B-CHED
saturation	O
and	O
requirement	O
,	O
laboratory	O
measures	O
,	O
and	O
serial	O
chest	O
radiography	O
results	O
.	O

In	O
this	O
preliminary	O
,	O
uncontrolled	O
study	O
of	O
patients	O
with	O
SARS	O
,	O
use	O
of	O
interferon	O
alfacon	O
-	O
1	O
plus	O
corticosteroids	B-CHED
was	O
associated	O
with	O
reduced	O
disease	O
-	O
associated	O
impaired	O
oxygen	B-CHED
saturation	O
,	O
more	O
rapid	O
resolution	O
of	O
radiographic	O
lung	O
abnormalities	O
,	O
and	O
lower	O
levels	O
of	O
creatine	B-CHED
kinase	O
.	O

The	O
mRNAs	O
are	O
produced	O
by	O
a	O
discontinuous	O
transcription	O
in	O
which	O
the	O
leader	O
is	O
linked	O
to	O
the	O
mRNA	B-CHED
coding	O
sequences	O
.	O

We	O
recently	O
reported	O
that	O
certain	O
N	O
-	O
methylthio	B-CHED
-	O
substituted	O
beta	B-CHED
-	I-CHED
lactam	I-CHED
antibiotics	I-CHED
had	O
DNA	O
-	O
damaging	O
and	O
apoptosis	O
-	O
inducing	O
activities	O
in	O
various	O
tumor	O
cells	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
first	O
show	O
that	O
a	O
lead	O
compound	O
(	O
lactam	B-CHED
1	O
)	O
selectively	O
induces	O
apoptosis	O
in	O
human	O
leukemic	O
Jurkat	O
T	O
,	O
but	O
not	O
in	O
the	O
nontransformed	O
,	O
immortalized	O
human	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

Additionally	O
,	O
we	O
screened	O
a	O
library	O
of	O
other	O
N	O
-	O
methylthiolated	O
beta	B-CHED
-	I-CHED
lactams	I-CHED
to	O
determine	O
their	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
),	O
and	O
found	O
lactam	B-CHED
12	O
to	O
have	O
the	O
highest	O
apoptosis	O
-	O
inducing	O
activity	O
against	O
human	O
leukemic	O
Jurkat	O
T	O
cells	O
,	O
associated	O
with	O
increased	O
DNA	O
-	O
damaging	O
potency	O
.	O

Plasma	O
inflammatory	O
cytokine	O
concentrations	O
(	O
interleukin	O
[	O
IL	O
]-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
10	O
,	O
IL	O
-	O
12p70	O
,	O
and	O
TNF	O
-	O
alpha	O
)	O
were	O
monitored	O
longitudinally	O
on	O
admission	O
,	O
immediately	O
before	O
corticosteroids	B-CHED
,	O
and	O
1	O
to	O
2	O
days	O
and	O
7	O
to	O
10	O
days	O
after	O
the	O
drug	O
treatment	O
in	O
a	O
cohort	O
of	O
pediatric	O
patients	O
(	O
n	O
=	O
8	O
)	O
with	O
virologic	O
confirmed	O
SARS	O
-	O
associated	O
coronavirus	O
infection	O
.	O

RESULTS	O
:	O
Plasma	O
IL	O
-	O
1beta	O
levels	O
(	O
excluding	O
patient	O
3	O
)	O
were	O
substantially	O
elevated	O
immediately	O
before	O
(	O
range	O
:	O
7	O
-	O
721	O
ng	O
/	O
L	O
)	O
and	O
7	O
to	O
10	O
days	O
after	O
(	O
range	O
:	O
7	O
-	O
664	O
ng	O
/	O
L	O
)	O
corticosteroid	B-CHED
treatment	O
.	O

General	O
combination	O
therapy	O
including	O
antibiotics	B-CHED
,	O
anti	B-CHED
-	I-CHED
viral	I-CHED
agents	I-CHED
,	O
glucocorticoids	B-CHED
and	O
immunity	O
-	O
enhancing	O
agents	O
,	O
was	O
used	O
.	O

The	O
S	O
protein	B-CHED
was	O
recognized	O
by	O
sera	O
from	O
SARS	O
patients	O
by	O
ELISA	O
and	O
Western	O
blot	O
,	O
which	O
indicated	O
that	O
recombinant	O
S	O
protein	B-CHED
retained	O
its	O
antigenicity	O
.	O

We	O
examined	O
the	O
results	O
of	O
all	O
diagnostic	O
laboratory	O
tests	O
used	O
in	O
117	O
patients	O
admitted	O
to	O
hospitals	O
in	O
Toronto	O
who	O
met	B-CHED
the	O
Health	O
Canada	O
criteria	O
for	O
suspect	O
or	O
probable	O
SARS	O
.	O

The	O
scoring	O
system	O
for	O
SARS	O
was	O
defined	O
as	O
radiographic	O
findings	O
of	O
multilobar	O
or	O
bilateral	O
infiltrates	O
(	O
3	O
points	O
),	O
sputum	O
monocyte	O
predominance	O
(	O
3	O
points	O
),	O
lymphocytopenia	O
(	O
2	O
points	O
),	O
history	O
of	O
exposure	O
(	O
1	O
point	O
),	O
lactate	B-CHED
dehydrogenase	O
more	O
than	O
450	O
U	O
/	O
L	O
(	O
1	O
point	O
),	O
C	O
-	O
reactive	O
protein	B-CHED
more	O
than	O
5	O
.	O
0	O
mg	O
/	O
dL	O
(	O
1	O
point	O
),	O
and	O
activated	O
partial	O
prothrombin	O
time	O
more	O
than	O
40	O
seconds	O
(	O
1	O
point	O
).	O

This	O
was	O
a	O
three	O
and	O
a	O
half	O
year	O
retrospective	O
study	O
comprising	O
of	O
98	O
patients	O
who	O
died	O
of	O
ARDS	O
in	O
the	O
intensive	O
care	O
unit	O
of	O
Apollo	B-CHED
Hospital	O
,	O
a	O
tertiary	O
care	O
referral	O
centre	O
between	O
January	O
1999	O
to	O
June	O
2002	O
.	O

Management	O
required	O
corticosteroid	B-CHED
pulse	O
therapy	O
and	O
plasma	O
exchange	O
.	O

TITLE	O
:	O
Hericium	O
erinaceum	O
(	O
yamabushitake	O
)	O
extract	O
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
monitored	O
by	O
serum	O
surfactant	B-CHED
proteins	B-CHED
.	O

He	O
recovered	O
with	O
successful	O
steroid	B-CHED
pulse	O
therapy	O
under	O
mechanical	O
ventilation	O
.	O

Mice	O
with	O
CD8	O
(+)	O
T	O
cells	O
specific	O
for	O
gp33	O
-	O
41	O
(	O
an	O
H	O
-	O
2D	O
(	O
b	O
)-	O
restricted	O
CD8	O
(+)	O
T	O
-	O
cell	O
epitope	B-CHED
derived	O
from	O
lymphocytic	O
choriomeningitis	O
glycoprotein	B-CHED
)	O
were	O
infected	O
with	O
a	O
recombinant	O
MHV	O
-	O
A59	O
,	O
also	O
expressing	O
gp33	O
-	O
41	O
,	O
as	O
a	O
fusion	O
protein	B-CHED
with	O
enhanced	O
green	O
fluorescent	O
protein	B-CHED
(	O
EGFP	O
).	O

More	O
than	O
90	O
%	O
of	O
the	O
viruses	O
recovered	O
from	O
brain	O
lysates	O
of	O
such	O
protected	O
mice	O
,	O
at	O
5	O
days	O
postinfection	O
,	O
had	O
lost	B-CHED
the	O
ability	O
to	O
express	O
EGFP	O
and	O
had	O
deletions	O
in	O
their	O
genomes	O
encompassing	O
EGFP	O
and	O
gp33	O
-	O
41	O
.	O

Virus	O
recovered	O
from	O
perforin	O
-	O
deficient	O
mice	O
did	O
not	O
exhibit	O
loss	O
of	O
EGFP	O
expression	O
and	O
the	O
gp33	O
-	O
41	O
epitope	B-CHED
.	O

ABSTRACT	O
:	O
To	O
prepare	O
and	O
characterize	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
against	O
S1	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

CONCLUSIONS	O
:	O
The	O
successful	O
amplification	O
and	O
cloning	O
of	O
N	O
gene	O
facilitates	O
further	O
investigation	O
of	O
the	O
expression	O
of	O
the	O
N	O
protein	B-CHED
and	O
study	O
of	O
its	O
structure	O
and	O
functions	O
.	O

For	O
this	O
need	O
,	O
we	O
purified	O
recombinant	O
proteins	B-CHED
including	O
the	O
nucleocapsid	O
(	O
N	O
),	O
envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
),	O
and	O
truncated	O
forms	O
of	O
the	O
spike	O
protein	B-CHED
(	O
S1	O
-	O
S7	O
)	O
of	O
SARS	O
-	O
CoV	O
in	O
Escherichia	O
coli	O
.	O

The	O
blood	O
gas	O
and	O
lung	O
mechanics	O
were	O
measured	O
during	O
the	O
experiments	O
every	O
2	O
h	O
.	O
(	O
1	O
)	O
Meconium	O
aspiration	O
induced	O
ALI	O
and	O
severe	O
HRF	O
(	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
<	O
200	O
mmHg	O
)	O
and	O
depressed	O
dynamic	O
compliance	O
of	O
respiratory	O
system	O
(	O
Cdyn	O
)	O
and	O
airway	O
resistance	O
(	O
Raw	O
).	O

No	O
statistical	O
differences	O
were	O
found	O
in	O
modes	O
of	O
oxygen	B-CHED
therapy	O
and	O
sorts	O
of	O
antibiotics	B-CHED
prescribed	O
among	O
the	O
various	O
transmission	O
generations	O
(	O
P	O
>	O
0	O
.	O
05	O
);	O
however	O
,	O
as	O
with	O
the	O
advanced	O
transmission	O
generations	O
,	O
the	O
number	O
of	O
cases	O
prescribed	O
with	O
methylprednisolone	B-CHED
,	O
human	O
gamma	O
-	O
globulin	O
,	O
interferon	O
-	O
alpha	O
,	O
antiviral	B-CHED
drugs	I-CHED
(	O
oral	O
ribavirin	B-CHED
or	O
oseltamivir	B-CHED
)	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
time	O
from	O
admission	O
to	O
starting	O
these	O
medication	O
shortened	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

By	O
bioinformatics	O
processing	O
and	O
analysis	O
,	O
the	O
nucleotides	B-CHED
at	O
7	O
loci	O
of	O
genome	O
(	O
T	O
:	O
T	O
:	O
A	O
:	O
G	O
:	O
T	O
:	O
C	O
:	O
T	O
/	O
C	O
:	O
G	O
:	O
G	O
:	O
A	O
:	O
C	O
:	O
T	O
:	O
C	O
)	O
can	O
classify	O
SARS	O
-	O
CoV	O
into	O
two	O
types	O
.	O

ABSTRACT	O
:	O
Purification	O
of	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
,	O
expressed	O
in	O
a	O
prokaryotic	O
expression	O
system	O
as	O
histidine	B-CHED
-	O
tagged	O
fusion	O
protein	B-CHED
is	O
demonstrated	O
in	O
the	O
present	O
study	O
.	O

These	O
results	O
indicated	O
that	O
the	O
expressed	O
N	O
protein	B-CHED
is	O
a	O
superior	O
source	O
of	O
TCoV	O
antigen	B-CHED
for	O
development	O
of	O
antibody	O
-	O
capture	O
ELISA	O
for	O
detection	O
of	O
antibodies	O
to	O
TCoV	O
.	O

After	O
the	O
rats	O
were	O
killed	O
,	O
lung	O
tissue	O
was	O
sampled	O
to	O
measured	O
expression	O
of	O
inducible	O
nitric	B-CHED
oxide	I-CHED
synthase	O
(	O
iNOS	O
),	O
nitrotyrosine	O
(	O
NT	O
),	O
myeloperoxidase	O
(	O
MPO	O
)	O
activity	O
,	O
malondialdehyde	B-CHED
(	O
MDA	B-CHED
),	O
wet	O
-	O
to	O
-	O
dry	O
lung	O
weight	O
ratio	O
(	O
W	O
/	O
D	O
),	O
and	O
pulmonary	O
permeability	O
index	O
(	O
PPI	B-CHED
).	O

Compared	O
with	O
the	O
endotoxemic	O
group	O
,	O
both	O
the	O
pretreatment	O
and	O
simultaneously	O
treatment	O
groups	O
,	O
significantly	O
improved	O
PaO2	O
,	O
pH	O
,	O
MAP	O
and	O
5th	O
hour	O
survival	O
rate	O
of	O
rats	O
,	O
and	O
attenuated	O
endotoxin	O
-	O
induced	O
increased	O
iNOSmRNA	O
,	O
NT	O
expression	O
,	O
MPO	O
activity	O
and	O
MDA	B-CHED
level	O
in	O
lung	O
tissue	O
,	O
and	O
decreased	O
pulmonary	O
microvascular	O
permeability	O
,	O
TNF	O
-	O
alpha	O
,	O
NO	O
in	O
plasma	O
.	O

This	O
review	O
summarizes	O
recent	O
studies	O
that	O
demonstrate	O
the	O
critical	O
role	O
played	O
by	O
inflammatory	O
mediators	O
such	O
as	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
platelet	B-CHED
activating	I-CHED
factor	I-CHED
(	O
PAF	B-CHED
),	O
IL	O
-	O
10	O
,	O
granulocyte	O
macrophage	O
-	O
colony	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
),	O
C5a	O
,	O
intercellular	O
adhesion	O
molecule	O
(	O
ICAM	O
)-	O
1	O
,	O
substance	O
P	O
,	O
chemokines	O
,	O
VEGF	O
,	O
IGF	O
-	O
I	O
,	O
KGF	O
,	O
reactive	B-CHED
oxygen	I-CHED
species	I-CHED
(	O
ROS	B-CHED
),	O
and	O
reactive	B-CHED
nitrogen	I-CHED
species	I-CHED
(	O
RNS	B-CHED
)	O
in	O
the	O
pathogenesis	O
of	O
ARDS	O
.	O

TITLE	O
:	O
Case	O
report	O
:	O
requirement	O
of	O
supplemental	O
morphine	B-CHED
during	O
sedation	O
with	O
propofol	B-CHED
in	O
a	O
critically	O
ill	O
patient	O
undergoing	O
hemodiafiltration	O
.	O

Although	O
CD8	O
(+)	O
T	O
cells	O
from	O
all	O
three	O
donors	O
suppressed	O
virus	O
replication	O
in	O
the	O
CNS	B-CHED
,	O
GKO	O
CD8	O
(+)	O
T	O
cells	O
expressed	O
the	O
least	O
antiviral	B-CHED
activity	O
.	O

While	O
wt	O
CD8	O
(+)	O
T	O
cells	O
inhibited	O
virus	O
replication	O
in	O
all	O
CNS	B-CHED
cell	O
types	O
,	O
cytolytic	O
activity	O
in	O
the	O
absence	O
of	O
IFN	O
-	O
gamma	O
suppressed	O
the	O
infection	O
of	O
astrocytes	O
,	O
but	O
not	O
oligodendroglia	O
.	O

TITLE	O
:	O
ACE2	O
X	O
-	O
ray	O
structures	O
reveal	O
a	O
large	O
hinge	O
-	O
bending	O
motion	O
important	O
for	O
inhibitor	B-CHED
binding	O
and	O
catalysis	O
.	O

Then	O
,	O
sodium	B-CHED
dodecyl	I-CHED
sulfate	I-CHED
-	O
polyacrylamide	B-CHED
gel	O
electrophoresis	O
(	O
SDS	B-CHED
-	O
PAGE	O
)	O
was	O
used	O
to	O
separate	O
the	O
complex	B-CHED
protein	I-CHED
constituents	O
,	O
and	O
the	O
strategy	O
of	O
continuous	O
slicing	O
from	O
loading	O
well	O
to	O
the	O
bottom	O
of	O
the	O
gels	O
was	O
utilized	O
to	O
search	O
thoroughly	O
the	O
structural	O
proteins	B-CHED
of	O
the	O
virus	O
.	O

For	O
further	O
confirmation	O
of	O
this	O
phenomenon	O
and	O
its	O
related	O
mechanism	O
,	O
recombinant	O
N	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
was	O
cleaved	O
in	O
vitro	O
by	O
caspase	O
-	O
3	O
and	O
-	O
6	O
respectively	O
.	O

Our	O
method	O
also	O
suggests	O
that	O
polyprotein	O
1ab	O
,	O
polyprotein	O
1a	O
,	O
S	O
,	O
M	O
and	O
N	O
are	O
proteins	B-CHED
of	O
viral	O
origin	O
and	O
others	O
are	O
of	O
prokaryotic	O
.	O

Further	O
studies	O
showed	O
the	O
susceptibility	O
of	O
this	O
cell	O
was	O
due	O
to	O
the	O
expression	O
of	O
endogenous	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
which	O
was	O
activated	O
by	O
inserted	O
LTR	O
from	O
retroviral	O
vector	O
used	O
for	O
expression	O
cloning	O
.	O

Three	O
patients	O
who	O
fulfilled	O
the	O
World	O
Health	O
Organization	O
case	O
definition	O
of	O
probable	O
SARS	O
and	O
developed	O
marked	O
elevation	O
of	O
alanine	B-CHED
aminotransferase	O
were	O
included	O
.	O

Moreover	O
,	O
feline	O
calicivirus	O
(	O
FCV	B-CHED
)-	O
specific	O
CD4	O
+	O
T	O
cells	O
were	O
detected	O
in	O
the	O
spleens	O
of	O
FCV	B-CHED
-	O
vaccinated	O
cats	O
.	O

A	O
straightforward	O
protocol	O
,	O
in	O
which	O
splenocyte	O
preparations	O
served	O
both	O
as	O
APCs	O
and	O
effector	B-CHED
cells	O
,	O
consistently	O
yielded	O
best	O
results	O
.	O

Furthermore	O
,	O
the	O
assay	O
will	O
add	B-CHED
to	O
the	O
value	O
of	O
those	O
systems	O
in	O
which	O
viral	O
infections	O
of	O
the	O
cat	O
serve	O
as	O
models	O
for	O
human	O
disease	O
.	O

ABSTRACT	O
:	O
As	O
part	O
of	O
a	O
high	O
-	O
throughput	O
structural	O
analysis	O
of	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
proteins	B-CHED
,	O
we	O
have	O
solved	O
the	O
structure	O
of	O
the	O
non	O
-	O
structural	O
protein	B-CHED
9	O
(	O
nsp9	O
).	O

The	O
joining	O
of	O
this	O
leader	O
sequence	O
to	O
different	O
segments	O
(	O
mRNA	B-CHED
bodies	O
)	O
from	O
the	O
genomic	O
3	O
'-	O
proximal	O
region	O
presumably	O
involves	O
a	O
unique	O
mechanism	O
of	O
discontinuous	O
minus	O
-	O
strand	O
RNA	O
synthesis	O
.	O

TITLE	O
:	O
[	O
Expression	O
and	O
purification	O
of	O
recombinant	O
N	O
-	O
terminal	O
protein	B-CHED
of	O
SARS	O
S1	O
subunit	O
expressed	O
in	O
E	O
.	O
Coli	O
].	O

The	O
recombinant	O
S1	O
protein	B-CHED
could	O
react	O
with	O
three	O
antibody	O
positive	O
samples	O
from	O
recovered	O
SARS	O
patients	O
,	O
which	O
showed	O
specific	O
bands	O
at	O
64	O
000	O
,	O
but	O
not	O
with	O
the	O
control	O
samples	O
according	O
to	O
results	O
of	O
western	O
blot	O
.	O

We	O
have	O
employed	O
molecular	O
docking	O
of	O
a	O
chemical	O
database	O
into	O
the	O
active	O
site	O
of	O
3CLpro	O
to	O
search	O
for	O
non	O
-	O
peptidyl	O
inhibitors	B-CHED
.	O

One	O
compound	O
was	O
identified	O
to	O
be	O
the	O
natural	B-CHED
product	I-CHED
sabadinine	B-CHED
,	O
isolated	O
from	O
a	O
historical	O
herbal	O
remedy	O
.	O

Unlike	O
unresolving	O
MHV	O
-	O
JHM	O
infections	O
,	O
the	O
clearance	O
of	O
WTR13	O
and	O
S4R22	O
infections	O
coincided	O
with	O
strong	O
IFN	O
-	O
gamma	O
transcription	O
and	O
an	O
increase	O
in	O
the	O
number	O
of	O
CD8	O
T	O
cells	O
infiltrating	O
into	O
the	O
CNS	B-CHED
.	O

Instead	O
,	O
similar	O
to	O
the	O
MHV	O
-	O
JHM	O
infection	O
,	O
reduced	O
survival	O
following	O
S4R22	O
infection	O
was	O
observed	O
in	O
the	O
presence	O
of	O
elevated	O
MIP	O
-	O
1alpha	O
and	O
MIP	O
-	O
1beta	O
mRNA	B-CHED
accumulation	O
and	O
enhanced	O
macrophage	O
numbers	O
within	O
infected	O
brains	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
S	O
protein	B-CHED
of	O
MHV	O
-	O
JHM	O
influences	O
neurovirulence	O
through	O
the	O
induction	O
of	O
MIP	O
-	O
1alpha	O
-	O
and	O
MIP	O
-	O
1beta	O
-	O
driven	O
macrophage	O
immunopathology	O
.	O

In	O
the	O
brain	O
,	O
MHV	O
-	O
JHM	O
infection	O
induced	O
strong	O
accumulation	O
of	O
IFNbeta	O
mRNA	B-CHED
relative	O
to	O
IFNgamma	O
mRNA	B-CHED
.	O

Further	O
ongoing	O
requirements	O
for	O
successful	O
management	O
include	O
research	O
on	O
the	O
immunopathogenesis	O
of	O
SARS	O
and	O
the	O
development	O
of	O
timely	O
and	O
reliable	O
diagnostic	O
tests	O
,	O
effective	O
antiviral	B-CHED
and	O
immunomodulatory	O
agents	O
,	O
and	O
vaccines	O
for	O
the	O
disease	O
.	O

The	O
differences	O
between	O
the	O
two	O
groups	O
were	O
compared	O
in	O
terms	O
of	O
development	O
of	O
illness	O
,	O
time	O
of	O
using	O
corticosteroid	B-CHED
and	O
absorption	O
time	O
of	O
pulmonary	O
inflammatory	O
lesion	O
,	O
etc	O
.	O

We	O
isolated	O
epitope	B-CHED
-	O
specific	O
T	O
cells	O
with	O
an	O
IFN	O
-	O
gamma	O
capture	O
assay	O
or	O
MHC	O
class	O
I	O
/	O
peptide	B-CHED
tetramers	O
and	O
identified	O
different	O
clonotypes	O
by	O
Vbeta	O
chain	O
sequence	O
analysis	O
.	O

We	O
found	O
significantly	O
higher	O
frequencies	O
of	O
SNV	O
-	O
specific	O
T	O
cells	O
in	O
patients	O
with	O
severe	O
HPS	B-CHED
requiring	O
mechanical	O
ventilation	O
(	O
up	O
to	O
44	O
.	O
2	O
%	O
of	O
CD8	O
(+)	O
T	O
cells	O
)	O
than	O
in	O
moderately	O
ill	O
HPS	B-CHED
patients	O
hospitalized	O
but	O
not	O
requiring	O
mechanical	O
ventilation	O
(	O
up	O
to	O
9	O
.	O
8	O
%	O
of	O
CD8	O
(+)	O
T	O
cells	O
).	O

Physicians	O
must	O
establish	O
reasonable	O
therapeutic	O
goals	O
based	O
on	O
oxygen	B-CHED
delivery	O
rather	O
than	O
arbitrary	O
normal	O
values	O
of	O
blood	O
gas	O
measurement	O
.	O

Eight	O
patients	O
with	O
ARDS	O
ventilated	O
with	O
lung	O
-	O
protective	O
strategy	O
and	O
an	O
arterial	O
partial	O
pressure	O
of	O
oxygen	B-CHED
to	O
inspired	O
oxygen	B-CHED
fraction	O
ratio	O
(	O
PaO2	O
/	O
FIO2	O
)	O
<	O
or	O
=	O
100	O
mmHg	O
regardless	O
of	O
PEEP	B-CHED
were	O
prospectively	O
studied	O
.	O

The	O
RM	O
was	O
performed	O
with	O
stepwise	O
increases	O
of	O
5	O
cmH2O	O
of	O
PEEP	B-CHED
every	O
2	O
min	O
and	O
thereafter	O
with	O
stepwise	O
decreases	O
of	O
2	O
cmH2O	O
of	O
PEEP	B-CHED
every	O
2	O
min	O
until	O
a	O
drop	O
in	O
PaO2	O
>	O
10	O
%	O
below	O
the	O
recruitment	O
PEEP	B-CHED
level	O
.	O

Placing	O
the	O
patient	O
in	O
prone	O
position	O
immediately	O
and	O
persistently	O
improved	O
oxygenation	O
:	O
the	O
ratio	O
of	O
P	O
(	O
aO	O
(	O
2	O
))	O
to	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
rose	O
from	O
47	O
to	O
180	O
mm	O
Hg	O
and	O
the	O
oxygenation	O
index	O
decreased	O
from	O
40	O
to	O
11	O
.	O

The	O
antiviral	B-CHED
mechanism	O
of	O
GA	O
appears	O
to	O
be	O
associated	O
with	O
Hsp90	O
inactivation	O
and	O
cell	O
cycle	O
restoration	O
,	O
which	O
indicates	O
that	O
GA	O
exhibits	O
broad	O
-	O
spectrum	O
antiviral	B-CHED
activity	O
.	O

ABSTRACT	O
:	O
The	O
clinical	O
response	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
to	O
a	O
combination	O
of	O
lopinavir	O
/	O
ritonavir	B-CHED
and	O
ribavirin	B-CHED
was	O
examined	O
after	O
establishing	O
the	O
in	O
vitro	O
antiviral	B-CHED
susceptibility	O
of	O
the	O
SARS	O
associated	O
coronavirus	O
to	O
a	O
panel	O
of	O
antiviral	B-CHED
agents	I-CHED
.	O

The	O
apparent	O
favourable	O
clinical	O
response	O
with	O
lopinavir	O
/	O
ritonavir	B-CHED
and	O
ribavirin	B-CHED
supports	O
further	O
randomised	O
placebo	O
controlled	O
trials	O
in	O
patients	O
with	O
SARS	O
.	O

ABSTRACT	O
:	O
Previous	O
reports	O
have	O
documented	O
that	O
cholesterol	B-CHED
supplementations	O
increase	O
cytopathic	O
effects	O
in	O
tissue	O
culture	O
and	O
also	O
intensify	O
in	O
vivo	O
pathogenicities	O
during	O
infection	O
by	O
the	O
enveloped	O
coronavirus	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

Cholesterol	B-CHED
depletions	O
reduced	O
plaque	O
development	O
2	O
-	O
to	O
20	O
-	O
fold	O
,	O
depending	O
on	O
the	O
infecting	O
MHV	O
strain	O
,	O
while	O
supplementations	O
increased	O
susceptibility	O
2	O
-	O
to	O
10	O
-	O
fold	O
.	O

These	O
findings	O
argued	O
against	O
the	O
importance	O
of	O
cholesterol	B-CHED
-	O
dependent	O
CEACAM	O
localizations	O
into	O
membrane	O
microdomains	O
for	O
MHV	O
entry	O
,	O
instead	O
suggesting	O
that	O
cholesterol	B-CHED
had	O
a	O
more	O
direct	O
role	O
.	O

The	O
heterologous	O
genes	O
were	O
expressed	O
under	O
the	O
control	O
of	O
an	O
IBV	O
transcription	O
-	O
associated	O
sequence	O
(	O
TAS	B-CHED
)	O
derived	O
from	O
gene	O
5	O
of	O
IBV	O
Beaudette	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
ISAV	O
specifically	O
binds	O
to	O
glycoproteins	B-CHED
containing	O
4	O
-	O
O	O
-	O
acetylated	O
sialic	B-CHED
acids	I-CHED
.	O

Besides	O
infectious	O
causes	O
and	O
drug	O
hypersensitivity	O
to	O
methotrexate	B-CHED
or	O
acitretin	B-CHED
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
sometimes	O
due	O
to	O
a	O
pulmonary	O
capillary	O
leak	O
syndrome	O
,	O
is	O
a	O
rare	O
cause	O
of	O
pneumonitis	O
in	O
the	O
course	O
of	O
psoriasis	O
,	O
and	O
may	O
be	O
fatal	O
.	O

Here	O
we	O
describe	O
the	O
biophysical	O
analysis	O
of	O
the	O
two	O
predicted	O
heptad	O
repeat	O
regions	O
within	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
S	O
protein	B-CHED
.	O

The	O
presence	O
of	O
this	O
type	O
of	O
protein	B-CHED
has	O
not	O
been	O
detected	O
in	O
the	O
replicative	O
complexes	O
of	O
RNA	O
viruses	O
,	O
and	O
its	O
presence	O
may	O
reflect	O
the	O
unique	O
and	O
complex	O
CoV	O
viral	O
replication	O
/	O
transcription	O
machinery	O
.	O

TITLE	O
:	O
Prolonged	O
disturbances	O
of	O
in	O
vitro	O
cytokine	O
production	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
treated	O
with	O
ribavirin	B-CHED
and	O
steroids	B-CHED
.	O

We	O
found	O
that	O
although	O
some	O
primate	O
cell	O
lines	O
,	O
including	O
Vero	O
E6	O
,	O
293T	O
and	O
Huh	O
-	O
7	O
cells	O
,	O
could	O
be	O
efficiently	O
transduced	O
by	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	B-CHED
pseudoviruses	O
,	O
other	O
cells	O
lines	O
were	O
either	O
resistant	O
or	O
very	O
poorly	O
permissive	O
to	O
virus	O
entry	O
.	O

Together	O
,	O
these	O
studies	O
describe	O
important	O
tools	O
that	O
can	O
be	O
used	O
to	O
study	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	B-CHED
structure	O
and	O
function	O
,	O
including	O
approaches	O
that	O
can	O
be	O
used	O
to	O
identify	O
inhibitors	B-CHED
of	O
the	O
entry	O
of	O
SARS	O
-	O
CoV	O
into	O
target	O
cells	O
.	O

TITLE	O
:	O
Effects	O
of	O
infection	O
with	O
transmissible	O
gastroenteritis	O
virus	O
on	O
concomitant	O
immune	O
responses	O
to	O
dietary	O
and	O
injected	O
antigens	B-CHED
.	O

For	O
determination	O
of	O
which	O
of	O
the	O
viral	O
proteins	B-CHED
encoded	O
by	O
the	O
SARS	O
-	O
CoV	O
genome	O
may	O
be	O
exploited	O
as	O
diagnostic	O
antigens	B-CHED
for	O
serological	O
assays	O
,	O
the	O
viral	O
proteins	B-CHED
were	O
expressed	O
individually	O
in	O
mammalian	O
and	O
/	O
or	O
bacterial	O
cells	O
and	O
tested	O
for	O
reactivity	O
with	O
sera	O
from	O
SARS	O
-	O
CoV	O
-	O
infected	O
patients	O
by	O
Western	O
blot	O
analysis	O
.	O

Sera	O
from	O
some	O
of	O
the	O
patients	O
also	O
showed	O
immunoreactivity	O
to	O
U274	O
(	O
59	O
of	O
81	O
[	O
73	O
%]),	O
a	O
protein	B-CHED
that	O
is	O
unique	O
to	O
SARS	O
-	O
CoV	O
.	O
In	O
addition	O
,	O
all	O
of	O
the	O
convalescent	O
-	O
phase	O
sera	O
showed	O
immunoreactivity	O
to	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
when	O
analyzed	O
by	O
an	O
immunofluorescence	O
method	O
utilizing	O
mammalian	O
cells	O
stably	O
expressing	O
S	O
.	O
However	O
,	O
samples	O
from	O
the	O
acute	O
phase	O
(	O
2	O
to	O
9	O
days	O
after	O
the	O
onset	O
of	O
illness	O
)	O
did	O
not	O
react	O
with	O
S	O
,	O
suggesting	O
that	O
antibodies	O
to	O
N	O
may	O
appear	O
earlier	O
than	O
antibodies	O
to	O
S	O
.	O
Alternatively	O
,	O
this	O
could	O
be	O
due	O
to	O
the	O
difference	O
in	O
the	O
sensitivities	O
of	O
the	O
two	O
methods	O
.	O

TITLE	O
:	O
[	O
Some	O
research	O
clues	O
on	O
Chinese	O
herbal	O
medicine	B-CHED
for	O
SARS	O
prevention	O
and	O
treatment	O
].	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
integrative	O
Chinese	O
and	O
western	O
medicine	B-CHED
(	O
ICWM	O
)	O
in	O
treating	O
severe	O
a	O
cute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

A	O
panel	O
of	O
S	O
protein	B-CHED
-	O
derived	O
peptides	B-CHED
was	O
tested	O
for	O
their	O
binding	O
affinity	O
to	O
HLA	O
-	O
A	O
*	O
0201	O
molecules	O
.	O

Viral	O
antigen	B-CHED
and	O
nucleic	B-CHED
acid	I-CHED
were	O
detected	O
in	O
bronchiolar	O
epithelial	O
cells	O
during	O
peak	O
viral	O
replication	O
.	O

No	O
proof	O
exists	O
that	O
antihypertensive	B-CHED
drugs	I-CHED
reduce	O
perinatal	O
mortality	O
or	O
development	O
of	O
preeclampsia	O
,	O
and	O
such	O
drugs	O
have	O
not	O
been	O
associated	O
with	O
improved	O
fetal	O
growth	O
.	O

Recent	O
findings	O
indicate	O
that	O
the	O
calcium	B-CHED
antagonist	B-CHED
nifedipine	B-CHED
might	O
be	O
a	O
better	O
alternative	O
.	O

CDC	O
staff	O
will	O
work	O
with	O
state	O
and	O
local	O
health	O
departments	O
to	O
investigate	O
reported	O
clusters	B-CHED
of	O
cases	O
of	O
AIPH	O
among	O
infants	O
.	O

Within	O
the	O
first	O
10	O
days	O
the	O
histological	O
picture	O
is	O
that	O
of	O
acute	O
phase	O
diffuse	O
alveolar	O
damage	O
(	O
DAD	O
)	O
with	O
a	O
mixture	B-CHED
of	O
inflammatory	O
infiltrate	O
,	O
oedema	O
and	O
hyaline	O
membrane	O
formation	O
.	O

PCR	O
assays	O
have	O
been	O
developed	O
amplifying	O
parts	O
of	O
the	O
spike	O
protein	B-CHED
gene	O
.	O

TITLE	O
:	O
Cloning	O
and	O
expression	O
of	O
two	O
fragments	O
of	O
the	O
S	O
gene	O
of	O
canine	O
coronavirus	O
type	O
I	O
.	O
ABSTRACT	O
:	O
Two	O
fragments	O
,	O
S66	O
and	O
S55	O
,	O
of	O
the	O
S	O
glycoprotein	B-CHED
of	O
the	O
newly	O
identified	O
canine	O
coronavirus	O
type	O
I	O
(	O
CCoV	O
type	O
I	O
),	O
were	O
expressed	O
in	O
a	O
procariotic	O
system	O
.	O

As	O
CCoV	O
type	O
I	O
seems	O
to	O
be	O
not	O
cultivable	O
in	O
cell	O
cultures	O
,	O
the	O
recombinant	O
fragments	O
of	O
the	O
S	O
protein	B-CHED
represent	O
a	O
unique	O
method	O
to	O
study	O
,	O
preliminarily	O
,	O
the	O
immunological	O
and	O
the	O
pathogenetic	O
characteristics	O
of	O
this	O
new	O
virus	O
.	O

Furthermore	O
,	O
mutational	O
analyses	O
characterized	O
that	O
a	O
serine	B-CHED
/	O
arginine	B-CHED
-	O
rich	O
motif	O
(	O
SSRSSSRSRGNSR	O
)	O
between	O
amino	B-CHED
acids	I-CHED
184	O
and	O
196	O
is	O
crucial	O
for	O
N	O
protein	B-CHED
oligomerization	O
,	O
since	O
deletion	O
of	O
this	O
region	O
completely	O
abolished	O
the	O
N	O
protein	B-CHED
self	O
-	O
multimerization	O
.	O

N	O
-	O
acetyl	B-CHED
cysteine	B-CHED
,	O
if	O
given	O
after	O
skeletal	O
trauma	O
,	O
is	O
of	O
potential	O
therapeutic	O
benefit	O
,	O
in	O
preventing	O
SIRS	O
,	O
ARDS	O
and	O
MOF	O
.	O

The	O
patient	O
recovered	O
after	O
conventional	O
antimicrobial	B-CHED
therapy	O
.	O

ABSTRACT	O
:	O
Current	O
treatment	O
schemes	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
include	O
broad	O
-	O
spectrum	O
antibiotics	B-CHED
,	O
glucocorticoids	B-CHED
,	O
and	O
ribavirin	B-CHED
.	O

ABSTRACT	O
:	O
The	O
human	O
genome	O
and	O
other	O
genome	O
sequencing	O
projects	O
have	O
generated	O
huge	O
amounts	O
of	O
protein	B-CHED
sequence	O
information	O
.	O

The	O
present	O
paper	O
discusses	O
the	O
prediction	O
of	O
protein	B-CHED
-	O
protein	B-CHED
interaction	O
using	O
normal	O
mode	O
analysis	O
and	O
examples	O
of	O
applications	O
are	O
given	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
severity	O
of	O
CNS	B-CHED
disease	O
can	O
be	O
reduced	O
through	O
the	O
use	O
of	O
a	O
neutralizing	O
mAb	O
directed	O
against	O
CCL5	O
in	O
a	O
viral	O
model	O
of	O
demyelination	O
.	O

Lung	O
injury	O
was	O
quantified	O
in	O
terms	O
of	O
lung	O
microvascular	O
permeability	O
(	O
Evans	O
blue	O
dye	B-CHED
extravasation	O
),	O
tissue	O
lipid	B-CHED
peroxidation	O
(	O
thiobarbituric	B-CHED
acid	I-CHED
reactive	O
substances	O
),	O
and	O
tissue	O
polymorphonuclear	O
leukocyte	O
accumulation	O
(	O
myeloperoxidase	O
activity	O
).	O

TITLE	O
:	O
[	O
Severe	O
acute	O
respiratory	O
syndrome	O
:	O
a	O
singular	B-CHED
epidemic	O
of	O
viral	O
pneumonia	O
].	O

We	O
focused	O
on	O
using	O
synthetic	O
peptides	B-CHED
for	O
developing	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
,	O
which	O
aimed	O
to	O
block	O
viral	O
invasion	O
by	O
eliciting	O
an	O
immune	O
response	O
specific	O
to	O
the	O
native	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
.	O

Among	O
the	O
changes	O
in	O
the	O
recommendations	O
to	O
prevent	O
bacterial	O
pneumonia	O
,	O
especially	O
ventilator	O
-	O
associated	O
pneumonia	O
,	O
are	O
the	O
preferential	O
use	O
of	O
oro	B-CHED
-	O
tracheal	O
rather	O
than	O
naso	O
-	O
tracheal	O
tubes	O
in	O
patients	O
who	O
receive	O
mechanically	O
assisted	O
ventilation	O
,	O
the	O
use	O
of	O
noninvasive	O
ventilation	O
to	O
reduce	O
the	O
need	O
for	O
and	O
duration	O
of	O
endotracheal	O
intubation	O
,	O
changing	O
the	O
breathing	O
circuits	O
of	O
ventilators	O
when	O
they	O
malfunction	O
or	O
are	O
visibly	O
contaminated	O
,	O
and	O
(	O
when	O
feasible	O
)	O
the	O
use	O
of	O
an	O
endotracheal	O
tube	O
with	O
a	O
dorsal	O
lumen	O
to	O
allow	O
drainage	O
of	O
respiratory	O
secretions	O
;	O
no	O
recommendations	O
were	O
made	O
about	O
the	O
use	O
of	O
sucralfate	O
,	O
histamine	B-CHED
-	O
2	O
receptor	O
antagonists	B-CHED
,	O
or	O
antacids	B-CHED
for	O
stress	O
-	O
bleeding	O
prophylaxis	O
.	O

For	O
this	O
purpose	O
,	O
we	O
investigated	O
the	O
antigenicity	O
of	O
different	O
regions	O
of	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
.	O

Four	O
important	O
regions	O
with	O
possible	O
epitopes	O
were	O
identified	O
and	O
named	O
as	O
EP1	O
(	O
amino	B-CHED
acids	I-CHED
51	O
-	O
71	O
),	O
EP2	O
(	O
134	O
-	O
208	O
),	O
EP3	O
(	O
249	O
-	O
273	O
),	O
and	O
EP4	O
(	O
349	O
-	O
422	O
),	O
respectively	O
.	O

The	O
N	O
protein	B-CHED
is	O
a	O
potential	O
diagnostic	O
antigen	B-CHED
and	O
vaccine	O
candidate	O
for	O
SARS	O
-	O
CoV	O
.	O

RESULTS	O
:	O
Four	O
types	O
were	O
identified	O
:	O
good	O
water	B-CHED
repellency	O
and	O
water	B-CHED
resistance	O
,	O
poor	O
air	B-CHED
permeability	O
(	O
Type	O
A	O
PPC	O
);	O
good	O
water	B-CHED
repellency	O
and	O
air	B-CHED
permeability	O
,	O
poor	O
water	B-CHED
resistance	O
(	O
Type	O
B	O
PPC	O
);	O
poor	O
water	B-CHED
repellency	O
,	O
poor	O
water	B-CHED
resistance	O
,	O
and	O
fair	O
air	B-CHED
permeability	O
(	O
Type	O
C	O
PPC	O
);	O
and	O
good	O
water	B-CHED
repellency	O
,	O
poor	O
air	B-CHED
permeability	O
,	O
and	O
fair	O
water	B-CHED
resistance	O
(	O
Type	O
D	O
PPC	O
).	O

TITLE	O
:	O
Bioterrorism	O
and	O
emerging	O
infectious	O
disease	O
-	O
antimicrobials	B-CHED
,	O
therapeutics	O
and	O
immune	O
-	O
modulators	O
.	O

We	O
studied	O
serum	O
level	O
of	O
luteinizing	O
hormone	B-CHED
(	O
LH	O
),	O
testosterone	B-CHED
(	O
T	O
)	O
and	O
prolactin	O
(	O
PRL	O
)	O
in	O
20	O
patients	O
with	O
septic	O
shock	O
and	O
in	O
healthy	O
male	O
volunteers	O
(	O
n	O
=	O
20	O
).	O

Our	O
study	O
showed	O
that	O
sex	O
steroid	B-CHED
hormones	I-CHED
can	O
be	O
good	O
prognostic	O
factors	O
of	O
survival	O
and	O
complications	O
of	O
septic	O
shock	O
.	O

After	O
adjusting	O
age	O
and	O
sex	O
,	O
the	O
daily	O
maximal	O
dosage	O
of	O
methylprednisolone	B-CHED
was	O
the	O
only	O
factor	O
that	O
might	O
predict	O
the	O
occurrence	O
of	O
diabetes	O
.	O

The	O
center	O
continues	O
to	O
operate	O
as	O
a	O
part	O
of	O
Ontario	O
'	O
s	O
commitment	O
as	O
a	O
result	O
of	O
diligence	O
in	O
transport	O
medicine	B-CHED
and	O
infection	O
control	O
,	O
even	O
though	O
no	O
new	O
cases	O
of	O
SARS	O
were	O
reported	O
since	O
June	O
12	O
,	O
2003	O
.	O

It	O
is	O
against	O
this	O
background	O
that	O
a	O
review	O
of	O
recent	O
developments	O
in	O
respiratory	O
antivirals	B-CHED
has	O
been	O
undertaken	O
.	O

The	O
late	O
1990s	O
were	O
a	O
period	O
of	O
unprecedented	O
activity	O
in	O
the	O
development	O
of	O
new	O
and	O
much	O
superior	O
antivirals	B-CHED
for	O
the	O
treatment	O
of	O
influenza	O
infections	O
.	O

TITLE	O
:	O
Preparative	O
purification	O
of	O
glycyrrhizin	B-CHED
extracted	O
from	O
the	O
root	O
of	O
liquorice	O
using	O
high	O
-	O
speed	O
counter	B-CHED
-	O
current	O
chromatography	O
.	O

The	O
present	O
method	O
yielded	O
42	O
.	O
2	O
mg	O
glycyrrhizin	B-CHED
at	O
96	O
.	O
8	O
%	O
purity	O
from	O
130	O
mg	O
of	O
the	O
crude	O
exact	O
with	O
95	O
.	O
2	O
%	O
recovery	O
as	O
determined	O
by	O
HPLC	O
analysis	O
.	O

Whereas	O
in	O
the	O
past	O
,	O
reactive	O
oxygen	B-CHED
and	O
reactive	B-CHED
nitrogen	I-CHED
species	I-CHED
were	O
mainly	O
known	O
as	O
harmful	O
agents	O
,	O
recent	O
investigations	O
have	O
given	O
a	O
new	O
insight	O
into	O
the	O
(	O
patho	O
)	O
physiological	O
importance	O
of	O
these	O
substances	O
as	O
powerful	O
messenger	O
molecules	O
involved	O
in	O
gene	O
regulation	O
,	O
thereby	O
enabling	O
the	O
synthesis	O
of	O
cytokines	O
or	O
adhesion	O
molecules	O
necessary	O
for	O
defending	O
inflammatory	O
processes	O
.	O

It	O
is	O
known	O
for	O
other	O
coronaviruses	O
that	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
is	O
required	O
for	O
both	O
viral	O
attachment	O
to	O
permissive	O
cells	O
and	O
for	O
fusion	O
of	O
the	O
viral	O
envelope	O
with	O
the	O
host	O
cell	O
membrane	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
employed	O
this	O
CRT	B-CHED
-	O
based	O
enhancement	O
strategy	O
to	O
create	O
effective	O
DNA	O
vaccines	O
using	O
SARS	O
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
as	O
a	O
target	O
antigen	B-CHED
.	O

To	O
determine	O
the	O
ability	O
of	O
SARS	O
-	O
Cov	O
nucleoprotein	O
(	O
N	O
protein	B-CHED
)	O
to	O
induce	O
antiviral	B-CHED
immunity	O
,	O
in	O
this	O
report	O
,	O
we	O
established	O
a	O
stable	O
C2C12	O
line	O
expressing	O
SARS	O
-	O
Cov	O
N	O
protein	B-CHED
,	O
which	O
was	O
used	O
as	O
a	O
target	O
for	O
specific	O
CTL	O
assay	O
.	O

TITLE	O
:	O
Relation	O
between	O
pesticide	B-CHED
exposure	O
and	O
intrauterine	O
growth	O
retardation	O
.	O

A	O
significant	O
association	O
between	O
the	O
history	O
of	O
positive	O
exposure	O
to	O
pesticides	B-CHED
(	O
i	O
.	O
e	O
.	O
the	O
women	O
themselves	O
or	O
their	O
newborns	O
who	O
showed	O
acetylcholinesterase	O
activity	O
levels	O
lower	O
than	O
20	O
%)	O
and	O
the	O
presence	O
of	O
IUGR	O
was	O
found	O
.	O

Spinal	O
fluid	O
protein	B-CHED
in	O
them	O
is	O
often	O
elevated	O
,	O
higher	O
values	O
seeming	O
to	O
auger	O
a	O
better	O
intravenous	O
immunoglobulin	O
-	O
G	O
response	O
.	O

RESULTS	O
:	O
Key	O
recommendations	O
,	O
listed	O
by	O
category	O
and	O
not	O
by	O
hierarchy	O
,	O
include	O
early	O
goal	O
-	O
directed	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
hrs	O
after	O
recognition	O
;	O
appropriate	O
diagnostic	O
studies	O
to	O
ascertain	O
causative	O
organisms	O
before	O
starting	O
antibiotics	B-CHED
;	O
early	O
administration	O
of	O
broad	O
-	O
spectrum	O
antibiotic	B-CHED
therapy	O
;	O
reassessment	O
of	O
antibiotic	B-CHED
therapy	O
with	O
microbiology	O
and	O
clinical	O
data	O
to	O
narrow	O
coverage	O
,	O
when	O
appropriate	O
;	O
a	O
usual	O
7	O
-	O
10	O
days	O
of	O
antibiotic	B-CHED
therapy	O
guided	O
by	O
clinical	O
response	O
;	O
source	O
control	O
with	O
attention	O
to	O
the	O
method	O
that	O
balances	O
risks	O
and	O
benefits	O
;	O
equivalence	O
of	O
crystalloid	O
and	O
colloid	O
resuscitation	O
;	O
aggressive	O
fluid	O
challenge	O
to	O
restore	O
mean	O
circulating	O
filling	O
pressure	O
;	O
vasopressor	O
preference	O
for	O
norepinephrine	B-CHED
and	O
dopamine	B-CHED
;	O
cautious	O
use	O
of	O
vasopressin	B-CHED
pending	O
further	O
studies	O
;	O
avoiding	O
low	O
-	O
dose	O
dopamine	B-CHED
administration	O
for	O
renal	O
protection	O
;	O
consideration	O
of	O
dobutamine	B-CHED
inotropic	O
therapy	O
in	O
some	O
clinical	O
situations	O
;	O
avoidance	O
of	O
supranormal	O
oxygen	B-CHED
delivery	O
as	O
a	O
goal	O
of	O
therapy	O
;	O
stress	O
-	O
dose	O
steroid	B-CHED
therapy	O
for	O
septic	O
shock	O
;	O
use	O
of	O
recombinant	O
activated	O
protein	B-CHED
C	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
high	O
risk	O
for	O
death	O
;	O
with	O
resolution	O
of	O
tissue	O
hypoperfusion	O
and	O
in	O
the	O
absence	O
of	O
coronary	O
artery	O
disease	O
or	O
acute	O
hemorrhage	O
,	O
targeting	O
a	O
hemoglobin	B-CHED
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
;	O
appropriate	O
use	O
of	O
fresh	O
frozen	O
plasma	O
and	O
platelets	O
;	O
a	O
low	O
tidal	O
volume	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
strategy	O
for	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
application	O
of	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
in	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
a	O
semirecumbent	O
bed	O
position	O
unless	O
contraindicated	O
;	O
protocols	O
for	O
weaning	O
and	O
sedation	O
/	O
analgesia	O
,	O
using	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
with	O
daily	O
interruptions	O
/	O
lightening	O
;	O
avoidance	O
of	O
neuromuscular	O
blockers	O
,	O
if	O
at	O
all	O
possible	O
;	O
maintenance	O
of	O
blood	O
glucose	B-CHED
<	O
150	O
mg	O
/	O
dL	O
after	O
initial	O
stabilization	O
;	O
equivalence	O
of	O
continuous	O
veno	O
-	O
veno	O
hemofiltration	O
and	O
intermittent	O
hemodialysis	O
;	O
lack	O
of	O
utility	O
of	O
bicarbonate	B-CHED
use	O
for	O
pH	O
>	O
or	O
=	O
7	O
.	O
15	O
;	O
use	O
of	O
deep	O
vein	O
thrombosis	O
/	O
stress	O
ulcer	O
prophylaxis	O
;	O
and	O
consideration	O
of	O
limitation	O
of	O
support	O
where	O
appropriate	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	B-CHED
of	O
the	O
SARS	O
coronavirus	O
is	O
capable	O
of	O
self	O
-	O
association	O
through	O
a	O
C	O
-	O
terminal	O
209	O
amino	B-CHED
acid	I-CHED
interaction	O
domain	O
.	O

A	O
short	O
serine	B-CHED
-	O
rich	O
stretch	O
,	O
and	O
a	O
putative	O
bipartite	O
nuclear	O
localization	O
signal	O
are	O
unique	O
to	O
it	O
,	O
thus	O
suggesting	O
its	O
involvement	O
in	O
many	O
important	O
functions	O
during	O
the	O
viral	O
life	O
cycle	O
.	O

The	O
attenuated	O
nature	O
of	O
MVA	B-CHED
and	O
the	O
ability	O
of	O
MVA	B-CHED
/	O
S	O
to	O
induce	O
neutralizing	O
antibody	O
that	O
protects	O
mice	O
support	O
further	O
development	O
of	O
this	O
candidate	O
vaccine	O
.	O

All	O
but	O
5	O
patients	O
lived	O
in	O
seven	O
buildings	O
(	O
A	O
to	O
G	O
),	O
and	O
the	O
index	O
patient	O
and	O
more	O
than	O
half	O
the	O
other	O
patients	O
with	O
SARS	O
(	O
99	O
patients	O
)	O
lived	O
in	O
building	O
E	O
.	O
Residents	O
of	O
the	O
floors	O
at	O
the	O
middle	O
and	O
upper	O
levels	O
in	O
building	O
E	O
were	O
at	O
a	O
significantly	O
higher	O
risk	O
than	O
residents	O
on	O
lower	O
floors	O
;	O
this	O
finding	O
is	O
consistent	O
with	O
a	O
rising	O
plume	O
of	O
contaminated	O
warm	O
air	B-CHED
in	O
the	O
air	B-CHED
shaft	O
generated	O
from	O
a	O
middle	O
-	O
level	O
apartment	O
unit	O
.	O

Exact	O
knowledge	O
of	O
how	O
the	O
immune	O
system	O
handles	O
protein	B-CHED
antigens	B-CHED
would	O
allow	O
for	O
the	O
identification	O
of	O
such	O
linear	O
sequences	O
directly	O
from	O
genomic	O
/	O
proteomic	O
sequence	O
information	O
(	O
Lauemoller	O
et	O
al	O
.,	O
Rev	O
Immunogenet	O
2001	O
:	O
2	O
:	O
477	O
-	O
91	O
).	O

In	O
particular	O
,	O
a	O
cluster	O
of	O
serine	B-CHED
residues	O
(	O
Ser139	O
,	O
Ser144	O
,	O
and	O
Ser147	O
)	O
was	O
identified	O
near	O
the	O
active	O
site	O
cavity	O
and	O
was	O
susceptible	O
to	O
being	O
targeted	O
by	O
compounds	O
containing	O
boronic	B-CHED
acid	I-CHED
.	O

We	O
draw	O
upon	O
our	O
own	O
experience	O
in	O
attempting	O
to	O
conduct	O
a	O
randomized	O
controlled	O
trial	O
(	O
trial	O
)	O
of	O
ribavirin	B-CHED
therapy	O
for	O
SARS	O
and	O
discuss	O
the	O
lessons	O
learned	O
.	O

One	O
hundred	O
and	O
thirty	O
eight	O
patients	O
were	O
treated	O
with	O
broad	O
spectrum	O
antibiotics	B-CHED
,	O
a	O
combination	O
of	O
ribavirin	B-CHED
and	O
low	O
dose	O
corticosteroid	B-CHED
,	O
and	O
then	O
intravenous	O
high	O
dose	O
methylprednisolone	B-CHED
according	O
to	O
responses	O
.	O

FCV	B-CHED
was	O
isolated	O
from	O
the	O
oral	O
fauces	O
of	O
11	O
%	O
of	O
healthy	O
cats	O
upon	O
entry	O
,	O
and	O
isolation	O
rates	O
were	O
highest	O
for	O
kittens	O
(	O
33	O
%).	O

Fifteen	O
percent	O
of	O
cats	O
were	O
shedding	O
FCV	B-CHED
,	O
52	O
%	O
FHV	O
,	O
and	O
60	O
%	O
FECV	O
after	O
1	O
week	O
.	O

In	O
our	O
study	O
,	O
we	O
report	O
the	O
construction	O
of	O
another	O
poxvirus	O
,	O
the	O
modified	O
vaccinia	O
virus	O
Ankara	O
(	O
MVA	B-CHED
),	O
as	O
an	O
expression	O
vector	O
for	O
the	O
FIPV	O
M	O
protein	B-CHED
.	O

Highly	O
conserved	O
heptad	O
repeat	O
1	O
(	O
HR1	O
)	O
and	O
HR2	O
regions	O
in	O
coronavirus	O
spike	O
proteins	B-CHED
indicate	O
a	O
similar	O
three	O
-	O
dimensional	O
structure	O
among	O
these	O
fusion	O
cores	O
and	O
common	O
mechanisms	O
for	O
the	O
viral	O
fusion	O
.	O

RESULTS	O
:	O
80	O
.	O
6	O
%	O
patients	O
(	O
208	O
of	O
258	O
patients	O
)	O
were	O
positive	O
for	O
SARS	O
-	O
Co	O
virus	O
IgG	O
.	O
21	O
.	O
3	O
%	O
patients	O
(	O
55	O
of	O
258	O
patients	O
)	O
showed	O
lung	O
diffusion	O
abnormity	O
(	O
D	O
(	O
LCO	B-CHED
)	O
<	O
80	O
%	O
pred	O
).	O

The	O
specificity	O
of	O
the	O
RT	O
-	O
LAMP	O
assay	O
was	O
further	O
validated	O
by	O
restriction	O
analysis	O
as	O
well	O
as	O
nucleotide	B-CHED
sequencing	O
of	O
the	O
amplified	O
product	O
.	O

The	O
concentration	O
of	O
virus	O
in	O
most	O
of	O
the	O
clinical	O
samples	O
was	O
0	O
.	O
1	O
PFU	B-CHED
(	O
0	O
.	O
1	O
to	O
10	O
(	O
2	O
)	O
PFU	B-CHED
),	O
as	O
determined	O
from	O
the	O
standard	O
curve	O
of	O
SARS	O
RT	O
-	O
LAMP	O
and	O
based	O
on	O
the	O
time	O
of	O
positivity	O
.	O

The	O
ratio	O
of	O
abnormality	O
of	O
ALT	B-CHED
,	O
AST	O
and	O
PAB	O
were	O
more	O
than	O
80	O
.	O
0	O
percent	O
,	O
the	O
ratio	O
of	O
abnormality	O
of	O
ALB	O
was	O
42	O
.	O
7	O
percent	O
,	O
and	O
less	O
than	O
30	O
.	O
0	O
percent	O
for	O
other	O
indexes	O
.	O

RESULTS	O
:	O
Alanine	B-CHED
aminotransferase	O
(	O
ALT	B-CHED
),	O
aspartate	B-CHED
aminotransferase	O
(	O
AST	O
),	O
lactate	B-CHED
dehydrogenase	O
(	O
LDH	O
),	O
total	O
bilirubin	B-CHED
(	O
TBil	O
)	O
of	O
patients	O
with	O
SARS	O
were	O
higher	O
than	O
those	O
of	O
controls	O
,	O
they	O
were	O
(	O
91	O
.	O
61	O
+/-	O
50	O
.	O
53	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
32	O
.	O
91	O
+/-	O
10	O
.	O
56	O
)	O
U	O
/	O
L	O
,	O
(	O
78	O
.	O
68	O
+/-	O
33	O
.	O
32	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
29	O
.	O
43	O
+/-	O
8	O
.	O
89	O
)	O
U	O
/	O
L	O
,	O
(	O
429	O
.	O
95	O
+/-	O
188	O
.	O
94	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
200	O
.	O
83	O
+/-	O
44	O
.	O
86	O
)	O
U	O
/	O
L	O
,	O
(	O
11	O
.	O
67	O
+/-	O
4	O
.	O
26	O
)	O
micromol	O
/	O
L	O
vs	O
.	O
(	O
8	O
.	O
44	O
+/-	O
3	O
.	O
86	O
)	O
micromol	O
/	O
L	O
,	O
all	O
P	O
<	O
0	O
.	O
001	O
.	O

Clinical	O
date	O
of	O
30	O
SARS	O
patients	O
without	O
other	O
diseases	O
in	O
whom	O
corticosteroid	B-CHED
was	O
used	O
were	O
reviewed	O
including	O
total	O
dosage	O
,	O
duration	O
of	O
use	O
,	O
the	O
highest	O
dosage	O
and	O
its	O
duration	O
,	O
and	O
speed	O
of	O
reduction	O
in	O
dosage	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
a	O
dosage	O
-	O
effect	O
relation	O
between	O
the	O
degree	O
of	O
arthralgia	O
and	O
the	O
total	O
dosage	O
of	O
corticosteroid	B-CHED
,	O
and	O
a	O
time	O
-	O
effect	O
relation	O
between	O
the	O
duration	O
of	O
arthralgia	O
and	O
length	O
of	O
the	O
use	O
of	O
corticosteroids	B-CHED
.	O

Respiratory	O
rate	O
decreased	O
from	O
29	O
-	O
49	O
breath	O
/	O
min	O
to	O
18	O
-	O
22	O
breath	O
/	O
min	O
,	O
heart	O
rate	O
decreased	O
from	O
89	O
-	O
145	O
beats	O
/	O
min	O
to	O
60	O
-	O
79	O
beats	O
/	O
min	O
,	O
two	O
faint	O
patients	O
regained	O
consciousness	O
,	O
hypoxemia	O
was	O
redressed	O
,	O
partial	O
pressure	O
of	O
oxygen	B-CHED
in	O
artery	O
increased	O
from	O
56	O
mm	O
Hg	O
(	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
)	O
to	O
87	O
mm	O
Hg	O
,	O
saturation	O
of	O
oxygen	B-CHED
increased	O
from	O
0	O
.	O
89	O
to	O
0	O
.	O
96	O
.	O

CONCLUSIONS	O
:	O
Intravenous	O
drip	O
of	O
the	O
oxygen	B-CHED
-	O
enriched	O
liquid	O
effectively	O
helped	O
correct	O
the	O
hypoxemia	O
of	O
SARS	O
and	O
other	O
infectious	O
diseases	O
cases	O
by	O
bypassing	O
the	O
diseased	O
alveoli	O
through	O
which	O
oxygen	B-CHED
would	O
not	O
pass	O
into	O
the	O
blood	O
by	O
conventional	O
oxygen	B-CHED
inhalation	O
.	O

Chi	B-CHED
-	O
square	O
for	O
trend	O
test	O
was	O
performed	O
to	O
study	O
the	O
correlation	O
between	O
positive	O
rates	O
of	O
RT	O
-	O
PCR	O
and	O
at	O
different	O
periods	O
after	O
the	O
onset	O
of	O
the	O
disease	O
.	O

Chi	B-CHED
-	O
square	O
for	O
trend	O
test	O
revealed	O
that	O
the	O
positive	O
rates	O
of	O
stools	O
and	O
sputa	O
of	O
SARS	O
patients	O
decreased	O
with	O
the	O
development	O
of	O
the	O
disease	O
(	O
chi	B-CHED
(	O
2	O
)	O
for	O
trend	O
=	O
12	O
.	O
55	O
and	O
16	O
.	O
408	O
,	O
P	O
=	O
0	O
.	O
0004	O
and	O
P	O
=	O
0	O
.	O
000	O
05	O
respectively	O
).	O

Expression	O
of	O
SARS	O
protein	B-CHED
3a	O
was	O
detected	O
at	O
8	O
-	O
12	O
h	O
after	O
infection	O
and	O
reached	O
a	O
higher	O
level	O
after	O
approximately	O
24	O
h	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

TITLE	O
:	O
Decreased	O
sialylation	O
of	O
the	O
acute	O
phase	O
protein	B-CHED
alpha1	O
-	O
acid	O
glycoprotein	B-CHED
in	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

ABSTRACT	O
:	O
This	O
study	O
adopts	O
the	O
concept	O
of	O
the	O
three	O
levels	O
of	O
prevention	O
from	O
traditional	O
Chinese	O
medicine	B-CHED
to	O
discuss	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
prevention	O
and	O
nursing	O
.	O

In	O
addition	O
,	O
radio	B-CHED
-	O
tracking	O
of	O
gray	O
foxes	O
in	O
the	O
rural	O
zone	O
indicated	O
that	O
all	O
three	O
of	O
the	O
rural	O
CPV	O
-	O
seropositive	O
foxes	O
had	O
traveled	O
into	O
adjoining	O
small	O
towns	O
,	O
whereas	O
only	O
one	O
of	O
the	O
11	O
seronegative	O
animals	O
had	O
done	O
so	O
.	O

Neither	O
FIV	O
antibodies	O
nor	O
FeLV	O
antigens	B-CHED
were	O
present	O
in	O
any	O
free	O
-	O
ranging	O
cheetah	O
tested	O
.	O

Among	O
the	O
peptides	B-CHED
used	O
in	O
the	O
study	O
,	O
the	O
affinity	O
of	O
peptides	B-CHED
from	O
HCoV	O
-	O
229e	O
(	O
H77	O
and	O
H881	O
)	O
and	O
peptides	B-CHED
from	O
SARS	O
-	O
CoV	O
(	O
S978	O
and	O
S1203	O
)	O
for	O
binding	O
to	O
HLA	O
-	O
A2	O
was	O
higher	O
than	O
that	O
of	O
other	O
sequences	O
.	O

Although	O
these	O
proteins	B-CHED
likely	O
are	O
essential	O
for	O
viral	O
replication	O
,	O
their	O
specific	O
roles	O
in	O
SARS	O
-	O
CoV	O
entry	O
have	O
not	O
been	O
defined	O
.	O

While	O
the	O
amounts	O
of	O
the	O
cellular	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
Cdk	O
)	O
inhibitors	B-CHED
p21	O
(	O
Cip1	O
),	O
p27	O
(	O
Kip1	O
),	O
and	O
p16	O
(	O
INK4a	O
)	O
did	O
not	O
change	O
in	O
infected	O
cells	O
,	O
MHV	O
infection	O
in	O
asynchronous	O
cultures	O
induced	O
a	O
clear	O
reduction	O
in	O
the	O
amounts	O
of	O
Cdk4	O
and	O
G	O
(	O
1	O
)	O
cyclins	O
(	O
cyclins	O
D1	O
,	O
D2	O
,	O
D3	O
,	O
and	O
E	O
)	O
in	O
both	O
DBT	B-CHED
and	O
17Cl	B-CHED
-	O
1	O
cells	O
and	O
a	O
reduction	O
in	O
Cdk6	O
levels	O
in	O
17Cl	B-CHED
-	O
1	O
cells	O
.	O

MHV	O
infection	O
in	O
quiescent	O
17Cl	B-CHED
-	O
1	O
cells	O
prevented	O
normal	O
increases	O
in	O
Cdk4	O
,	O
Cdk6	O
,	O
cyclin	O
D1	O
,	O
and	O
cyclin	O
D3	O
levels	O
after	O
serum	O
stimulation	O
.	O

In	O
addition	O
,	O
targeted	O
viral	O
protein	B-CHED
synthesis	O
,	O
plaque	O
diameter	O
,	O
and	O
cytopathic	O
effect	O
were	O
significantly	O
reduced	O
.	O

TITLE	O
:	O
Cleavage	O
between	O
replicase	O
proteins	B-CHED
p28	O
and	O
p65	O
of	O
mouse	O
hepatitis	O
virus	O
is	O
not	O
required	O
for	O
virus	O
replication	O
.	O

Recently	O
,	O
a	O
metallopeptidase	O
named	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
has	O
been	O
identified	O
as	O
the	O
functional	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
Although	O
ACE2	O
mRNA	B-CHED
is	O
known	O
to	O
be	O
present	O
in	O
virtually	O
all	O
organs	O
,	O
its	O
protein	B-CHED
expression	O
is	O
largely	O
unknown	O
.	O

TITLE	O
:	O
Structure	O
of	O
the	O
N	O
-	O
terminal	O
RNA	O
-	O
binding	O
domain	O
of	O
the	O
SARS	O
CoV	O
nucleocapsid	O
protein	B-CHED
.	O

This	O
enzyme	O
in	O
conjunction	O
with	O
fluorogenic	O
peptide	B-CHED
substrate	O
provides	O
us	O
a	O
suitable	O
tool	O
for	O
identifying	O
potent	O
inhibitors	B-CHED
of	O
SARS	O
protease	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
inhibition	O
using	O
spike	O
protein	B-CHED
heptad	O
repeat	O
-	O
derived	O
peptides	B-CHED
.	O

With	O
the	O
aim	O
of	O
developing	O
therapeutic	O
agents	O
,	O
we	O
have	O
tested	O
peptides	B-CHED
derived	O
from	O
the	O
membrane	O
-	O
proximal	O
(	O
HR2	O
)	O
and	O
membrane	O
-	O
distal	O
(	O
HR1	O
)	O
heptad	O
repeat	O
region	O
of	O
the	O
spike	O
protein	B-CHED
as	O
inhibitors	B-CHED
of	O
SARS	O
-	O
CoV	O
infection	O
of	O
Vero	O
cells	O
.	O

The	O
resulting	O
close	O
apposition	O
of	O
fusion	O
peptide	B-CHED
and	O
spike	O
transmembrane	O
domain	O
facilitates	O
membrane	O
fusion	O
.	O

In	O
this	O
issue	O
of	O
Critical	O
Care	O
,	O
two	O
experts	O
face	O
off	O
over	O
the	O
need	O
to	O
isolate	O
patients	O
infected	O
with	O
methicillin	B-CHED
-	O
resistant	O
Staphylococcus	O
aureus	O
.	O

hCMV	O
/	O
beta	O
-	O
actin	O
-	O
eGFP	O
-	O
3	O
'	O
UTR	O
t	O
-	O
PA	O
transgenic	O
mice	O
express	O
eGFP	O
mRNA	B-CHED
in	O
all	O
brain	O
structures	O
analyzed	O
but	O
lack	O
eGFP	O
fluorescence	O
,	O
with	O
the	O
exception	O
of	O
blood	O
vessels	O
,	O
choroid	O
plexus	O
,	O
and	O
Purkinje	O
cells	O
.	O

This	O
increased	O
fluorescence	O
is	O
correlated	O
with	O
an	O
increased	O
transcription	O
of	O
eGFP	O
in	O
lesioned	O
cells	O
,	O
presumably	O
enhanced	O
by	O
a	O
release	O
of	O
the	O
translational	O
silencing	O
mediated	O
by	O
the	O
3	O
'	O
UTR	O
region	O
of	O
the	O
t	O
-	O
PA	O
mRNA	B-CHED
.	O

This	O
observation	O
provides	O
important	O
clues	O
for	O
the	O
selection	O
of	O
specific	O
immunologic	O
probes	O
to	O
examine	O
whether	O
SARS	O
-	O
CoV	O
expresses	O
antigenic	O
structures	O
that	O
mimic	O
the	O
host	O
glycan	B-CHED
.	O

Fusion	O
of	O
coronaviruses	O
with	O
the	O
host	O
cell	O
is	O
mediated	O
by	O
the	O
envelope	O
spike	O
protein	B-CHED
.	O

Of	O
the	O
182	O
patients	O
,	O
128	O
(	O
70	O
.	O
3	O
%)	O
had	O
abnormal	O
ALT	B-CHED
activity	O
,	O
57	O
(	O
31	O
.	O
3	O
%)	O
had	O
abnormal	O
AST	O
activity	O
and	O
87	O
(	O
47	O
.	O
8	O
%)	O
had	O
abnormal	O
LDH	O
activity	O
.	O

Of	O
the	O
182	O
patients	O
,	O
160	O
(	O
87	O
.	O
9	O
%)	O
had	O
been	O
treated	O
with	O
antibiotics	B-CHED
,	O
137	O
(	O
75	O
.	O
2	O
%)	O
with	O
Ribavirin	B-CHED
,	O
and	O
115	O
(	O
63	O
.	O
2	O
%)	O
with	O
methylpredisolone	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
correlation	O
between	O
the	O
duration	O
of	O
Ribavirin	B-CHED
treatment	O
and	O
hepatic	O
dysfunction	O
.	O

Entry	O
of	O
coronaviruses	O
into	O
target	O
cells	O
is	O
mediated	O
by	O
the	O
viral	O
S	O
protein	B-CHED
.	O

Indeed	O
these	O
molecular	O
markers	O
are	O
very	O
useful	O
for	O
diagnosing	O
thrombus	O
formation	O
,	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	B-CHED
),	O
and	O
the	O
indicator	B-CHED
of	O
treatment	O
of	O
DIC	B-CHED
.	O

Thus	O
such	O
a	O
molecular	O
complex	O
is	O
expected	O
to	O
serve	O
as	O
a	O
parameter	O
for	O
the	O
diagnosis	O
of	O
thrombus	O
formation	O
and	O
DIC	B-CHED
,	O
in	O
particular	O
its	O
early	O
stage	O
.	O

The	O
diagnosis	O
of	O
SIRS	O
was	O
based	O
on	O
the	O
criteria	O
established	O
by	O
American	O
College	O
of	O
Chest	O
Physicians	O
(	O
ACCP	O
)/	O
Society	O
of	O
Critical	O
Care	O
Medicine	B-CHED
(	O
SCCM	O
)	O
Consensus	O
Conference	O
held	O
in	O
August	O
of	O
1991	O
in	O
Northbrook	O
,	O
IL	O
(	O
USA	O
).	O

Smears	O
from	O
the	O
brain	O
and	O
the	O
conjunctiva	O
of	O
both	O
dogs	O
tested	O
positive	O
for	O
canine	O
distemper	O
virus	O
(	O
CDV	B-CHED
)	O
by	O
an	O
immunofluorescent	O
assay	O
,	O
confirmed	O
by	O
the	O
identification	O
of	O
viral	O
RNA	O
using	O
RT	O
-	O
PCR	O
.	O

It	O
would	O
use	O
clusters	B-CHED
of	O
symptoms	O
tied	O
to	O
temporal	O
,	O
demographic	O
and	O
spatial	O
data	O
to	O
increase	O
sensitivity	O
and	O
specificity	O
.	O

It	O
would	O
use	O
clusters	B-CHED
of	O
symptoms	O
tied	O
to	O
temporal	O
,	O
demographic	O
and	O
spatial	O
data	O
to	O
increase	O
sensitivity	O
and	O
specificity	O
.	O

Calpain	O
I	O
inhibitor	B-CHED
is	O
a	O
potent	O
antioxidant	B-CHED
which	O
is	O
an	O
effective	O
inhibitor	B-CHED
of	O
NF	O
-	O
kappaB	O
.	O
This	O
study	O
examined	O
whether	O
the	O
postulate	O
that	O
calpain	O
I	O
inhibitor	B-CHED
attenuates	O
experimental	O
acute	O
pancreatitis	O
.	O

Radiographic	O
findings	O
were	O
nonspecific	O
,	O
but	O
high	O
-	O
resolution	O
computed	O
tomography	O
of	O
the	O
thorax	O
was	O
an	O
early	O
diagnostic	B-CHED
aid	I-CHED
.	O

Although	O
effective	O
in	O
experimental	O
studies	O
no	O
clear	O
recommendation	O
can	O
be	O
made	O
in	O
view	O
to	O
the	O
use	O
of	O
other	O
vasodilators	O
such	O
as	O
phosphodiesterase	B-CHED
inhibitors	I-CHED
or	O
endothelin	O
antagonists	B-CHED
.	O

This	O
review	O
summarises	O
antiviral	B-CHED
activities	O
of	O
IFNs	O
with	O
special	O
regard	O
to	O
SARS	O
,	O
and	O
reviews	O
the	O
published	O
clinical	O
and	O
experimental	O
data	O
describing	O
the	O
use	O
of	O
IFNs	O
for	O
SARS	O
.	O

The	O
most	O
frequent	O
neurological	O
complication	O
of	O
inorganic	O
arsenic	B-CHED
intoxication	O
is	O
a	O
distal	O
symmetrical	O
polyneuropathy	O
.	O

The	O
exact	O
pathophysiology	O
of	O
arsenic	B-CHED
polyneuropathy	O
remains	O
unclear	O
and	O
a	O
interference	O
with	O
pyruvate	B-CHED
oxidation	O
has	O
been	O
postulated	O
.	O

A	O
method	O
for	O
defining	O
and	O
measuring	O
similarity	O
between	O
pairs	O
of	O
biological	O
samples	O
and	O
between	O
sets	O
of	O
biological	O
samples	O
in	O
the	O
context	O
of	O
the	O
set	O
of	O
N	O
reagent	B-CHED
pairs	O
is	O
described	O
.	O

TITLE	O
:	O
Use	O
of	O
recombinant	O
cytokines	O
for	O
optimized	O
induction	O
of	O
antiviral	B-CHED
immunity	O
against	O
SIV	O
in	O
the	O
nonhuman	O
primate	O
model	O
of	O
human	O
AIDS	O
.	O

None	O
of	O
the	O
discharged	O
survivors	O
required	O
continuation	O
of	O
oxygen	B-CHED
therapy	O
.	O

We	O
have	O
sequenced	O
four	O
regions	O
of	O
the	O
replicase	O
genes	O
corresponding	O
to	O
the	O
5	O
'-	O
terminal	O
sequence	O
,	O
PL	O
(	O
pro	B-CHED
),	O
M	O
(	O
pro	B-CHED
),	O
and	O
RdRp	O
domains	O
from	O
20	O
heterologous	O
IBV	O
strains	O
,	O
and	O
compared	O
them	O
with	O
previously	O
published	O
coronavirus	O
sequences	O
.	O

Among	O
IBV	O
strains	O
,	O
the	O
5	O
'	O
untranslated	O
region	O
including	O
the	O
leader	O
sequence	O
was	O
highly	O
conserved	O
(>	O
94	O
%	O
identical	O
);	O
whereas	O
,	O
the	O
N	O
-	O
terminal	O
coding	O
region	O
and	O
the	O
PL	O
(	O
pro	B-CHED
)	O
domains	O
were	O
highly	O
variable	O
ranging	O
from	O
84	O
.	O
6	O
%	O
to	O
100	O
%,	O
and	O
77	O
.	O
6	O
%	O
to	O
100	O
%	O
identity	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Heptad	O
repeat	O
regions	O
(	O
HR1	O
and	O
HR2	O
)	O
are	O
highly	O
conserved	O
sequences	O
located	O
in	O
the	O
glycoproteins	B-CHED
of	O
enveloped	O
viruses	O
.	O

The	O
Western	O
blotting	O
demonstrated	O
that	O
SARS	O
patient	O
convalescent	O
serum	O
could	O
recognize	O
the	O
recombinant	O
fusion	O
protein	B-CHED
.	O

A	O
number	O
of	O
monoclonal	O
antibodies	O
were	O
developed	O
against	O
the	O
fusion	O
protein	B-CHED
.	O

Identification	O
of	O
antigenic	O
epitope	B-CHED
of	O
spike	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
could	O
provide	O
the	O
basis	O
for	O
the	O
development	O
of	O
immunity	O
-	O
based	O
prophylactic	O
,	O
therapeutic	O
,	O
and	O
diagnostic	O
techniques	O
for	O
the	O
control	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

After	O
purification	O
,	O
the	O
Trx	O
-	O
S2	O
fusion	O
protein	B-CHED
was	O
detected	O
by	O
Western	O
blot	O
with	O
6	O
serum	O
samples	O
of	O
convalescent	O
SARS	O
patients	O
and	O
6	O
serum	O
samples	O
of	O
healthy	O
donors	O
.	O

The	O
Trx	O
-	O
S2	O
fusion	O
protein	B-CHED
provides	O
a	O
basis	O
for	O
the	O
research	O
on	O
its	O
role	O
in	O
the	O
course	O
of	O
SARS	O
virus	O
infection	O
of	O
host	O
cells	O
and	O
preparation	O
of	O
recombinant	O
vaccine	O
against	O
SARS	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
angiotensin	B-CHED
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
has	O
been	O
identified	O
as	O
a	O
receptor	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

The	O
downstream	O
targets	O
of	O
p38	O
MAPK	O
,	O
MAPKAPK	O
-	O
2	O
,	O
HSP	B-CHED
-	O
27	O
,	O
CREB	O
,	O
and	O
eIF4E	O
were	O
phosphorylated	O
in	O
virus	O
-	O
infected	O
cells	O
.	O

However	O
,	O
viral	O
protein	B-CHED
synthesis	O
was	O
not	O
affected	O
by	O
treatment	O
of	O
SB203580	O
.	O

TITLE	O
:	O
A	O
novel	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
protein	B-CHED
,	O
U274	O
,	O
is	O
transported	O
to	O
the	O
cell	O
surface	O
and	O
undergoes	O
endocytosis	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
genome	O
contains	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
that	O
encode	O
for	O
several	O
genes	O
that	O
are	O
homologous	O
to	O
proteins	B-CHED
found	O
in	O
all	O
known	O
coronaviruses	O
.	O

Monoclonal	O
antibodies	O
raised	O
against	O
this	O
fragment	O
recognized	O
the	O
native	O
spike	O
protein	B-CHED
of	O
SARS	O
CoV	O
in	O
both	O
monomeric	O
and	O
trimeric	O
forms	O
.	O

S	O
protein	B-CHED
could	O
be	O
cleaved	O
by	O
exogenous	O
trypsin	O
but	O
not	O
by	O
coexpressed	O
furin	O
,	O
suggesting	O
that	O
the	O
protein	B-CHED
is	O
not	O
normally	O
processed	O
during	O
infection	O
.	O

TITLE	O
:	O
Porcine	O
surfactant	B-CHED
(	O
Curosurf	O
)	O
for	O
acute	O
respiratory	O
failure	O
after	O
near	O
-	O
drowning	O
in	O
12	O
year	O
old	O
.	O

ABSTRACT	O
:	O
This	O
case	O
report	O
describes	O
rapid	O
and	O
persistent	O
improvement	O
after	O
one	O
single	O
dose	O
of	O
porcine	O
surfactant	B-CHED
(	O
Curosurf	O
)	O
0	O
.	O
5	O
ml	O
/	O
kg	O
(-	O
1	O
)	O
(	O
40	O
mg	O
/	O
kg	O
)	O
intratracheally	O
for	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
with	O
severe	O
oxygenation	O
failure	O
8	O
h	O
after	O
freshwater	O
near	O
-	O
drowning	O
in	O
a	O
12	O
-	O
year	O
-	O
old	O
girl	O
.	O

Other	O
common	O
abnormal	O
laboratory	O
findings	O
included	O
leukopenia	O
,	O
thrombocytopenia	O
,	O
and	O
elevated	O
levels	O
of	O
aminotransferase	O
,	O
lactate	B-CHED
dehydrogenase	O
,	O
and	O
creatine	B-CHED
kinase	O
.	O

From	O
a	O
probabilistic	O
viewpoint	O
,	O
we	O
can	O
theoretically	O
select	O
the	O
amino	B-CHED
acid	I-CHED
pairs	O
as	O
potential	O
candidates	O
for	O
anti	O
-	O
SARS	O
drugs	O
.	O

(	O
2	O
)	O
The	O
fusion	O
protein	B-CHED
GST	O
-	O
N	O
was	O
soluble	O
.	O

The	O
patient	O
was	O
returned	O
to	O
the	O
supine	O
position	O
,	O
but	O
despite	O
maneuvers	O
to	O
improve	O
oxygen	B-CHED
saturation	O
,	O
the	O
patient	O
'	O
s	O
saturation	O
remained	O
below	O
87	O
%	O
and	O
pulmonary	O
thromboembolism	O
was	O
suspected	O
.	O

A	O
single	O
intranasal	O
administration	O
of	O
BHPIV3	O
expressing	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
(	O
S	O
)	O
induced	O
a	O
high	O
titer	O
of	O
SARS	O
-	O
CoV	O
-	O
neutralizing	O
serum	O
antibodies	O
,	O
only	O
2	O
-	O
fold	O
less	O
than	O
that	O
induced	O
by	O
SARS	O
-	O
CoV	O
infection	O
.	O

An	O
hour	O
of	O
NPPV	O
therapy	O
led	O
to	O
significant	O
increases	O
in	O
PaO	B-CHED
(	O
2	O
)	O
and	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
and	O
a	O
decrease	O
in	O
respiratory	O
rate	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

The	O
case	O
presented	O
here	O
is	O
of	O
severe	O
acute	O
respiratory	O
failure	O
and	O
cardiogenic	O
shock	O
in	O
a	O
44	O
-	O
year	O
-	O
old	O
female	O
patient	O
with	O
severe	O
protein	B-CHED
and	O
calorie	O
malnutrition	O
associated	O
with	O
the	O
start	O
of	O
hyperproteic	O
nutritional	O
support	O
.	O

Treatment	O
with	O
inotropic	O
-	O
vasoactive	O
drugs	O
and	O
diuretics	B-CHED
together	O
with	O
a	O
progressive	O
nutritional	O
programme	O
brought	O
about	O
the	O
complete	O
reversal	O
of	O
her	O
heart	O
failure	O
and	O
the	O
concomitant	O
endocrine	B-CHED
-	O
metabolic	O
syndrome	O
.	O

We	O
examined	O
serum	O
samples	O
obtained	O
from	O
46	O
patients	O
with	O
SARS	O
,	O
40	O
patients	O
with	O
non	O
-	O
SARS	O
pneumonia	O
,	O
and	O
38	O
healthy	O
individuals	O
,	O
by	O
use	O
of	O
Western	O
blotting	O
(	O
WB	O
),	O
enzyme	O
-	O
linked	O
immunoassay	O
(	O
ELISA	O
),	O
and	O
immunofluorescence	O
assay	O
,	O
using	O
both	O
native	O
and	O
bacterially	O
produced	O
antigens	B-CHED
of	O
the	O
virus	O
.	O

Mutational	O
analyses	O
showed	O
that	O
both	O
the	O
signal	O
peptide	B-CHED
sequence	O
and	O
ER	O
retrieval	O
motif	O
were	O
functional	O
.	O

TITLE	O
:	O
Coronavirus	O
spike	O
glycoprotein	B-CHED
,	O
extended	O
at	O
the	O
carboxy	B-CHED
terminus	O
with	O
green	O
fluorescent	O
protein	B-CHED
,	O
is	O
assembly	O
competent	O
.	O

Incorporation	O
into	O
virus	O
-	O
like	O
particles	O
demonstrated	O
the	O
assembly	O
competence	O
of	O
the	O
chimeric	O
spike	O
protein	B-CHED
.	O

In	O
addition	O
to	O
demonstrating	O
receptor	O
expression	O
on	O
CNS	B-CHED
resident	O
cells	O
,	O
these	O
data	O
suggest	O
that	O
transient	O
receptor	O
down	O
regulation	O
on	O
microglia	O
aids	O
in	O
establishing	O
persistence	O
in	O
the	O
CNS	B-CHED
by	O
assisting	O
virus	O
infection	O
of	O
other	O
glial	O
cell	O
types	O
.	O

ABSTRACT	O
:	O
The	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
replicase	O
gene	O
-	O
encoded	O
nonstructural	O
protein	B-CHED
13	O
(	O
nsp13	O
)	O
contains	O
an	O
N	O
-	O
terminal	O
zinc	B-CHED
-	O
binding	O
domain	O
and	O
a	O
C	O
-	O
terminal	O
superfamily	O
1	O
helicase	O
domain	O
.	O

RESULTS	O
:	O
Arterial	O
oxygenation	O
was	O
acutely	O
and	O
significantly	O
increased	O
by	O
pECLA	O
(	O
p	O
(	O
a	O
)	O
O	O
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)=	O
103	O
+/-	O
56	O
mmHg	O
2	O
h	O
after	O
begin	O
)	O
and	O
carbon	B-CHED
dioxide	I-CHED
removal	O
was	O
markedly	O
enhanced	O
in	O
25	O
out	O
of	O
30	O
patients	O
(	O
87	O
%)	O
allowing	O
a	O
lung	O
protective	O
ventilation	O
strategy	O
.	O

Methylprednisolone	B-CHED
therapy	O
caused	O
a	O
dramatic	O
improvement	O
of	O
pulmonary	O
and	O
systemic	O
organ	O
function	O
.	O

A	O
cell	O
-	O
based	O
assay	O
,	O
with	O
SARS	O
virus	O
and	O
Vero	O
E6	O
cells	O
,	O
was	O
developed	O
to	O
screen	O
existing	O
drugs	O
,	O
natural	B-CHED
products	I-CHED
,	O
and	O
synthetic	O
compounds	O
to	O
identify	O
effective	O
anti	O
-	O
SARS	O
agents	O
.	O

A	O
frequency	O
counter	B-CHED
was	O
employed	O
to	O
record	O
the	O
admittance	O
frequency	O
,	O
and	O
the	O
plot	O
of	O
changed	O
frequency	O
was	O
displayed	O
on	O
the	O
computer	O
.	O

Under	O
the	O
optimized	O
conditions	O
,	O
the	O
frequency	O
shifts	O
were	O
linearly	O
dependent	O
on	O
antigen	B-CHED
concentration	O
in	O
the	O
range	O
of	O
0	O
.	O
6	O
-	O
4	O
microg	O
/	O
mL	O
.	O
The	O
device	O
has	O
good	O
reproducibility	O
(	O
could	O
be	O
reused	O
100	O
times	O
without	O
detectable	O
loss	O
of	O
activity	O
),	O
stability	O
(	O
the	O
immunosensor	O
was	O
stable	O
for	O
more	O
than	O
two	O
months	O
when	O
stored	O
over	O
silica	B-CHED
gel	O
blue	O
at	O
4	O
-	O
6	O
degrees	O
C	O
),	O
short	O
analyzing	O
time	O
(	O
less	O
than	O
2	O
min	O
),	O
and	O
specificity	O
.	O

RESULTS	O
:	O
Two	O
organic	O
NO	O
donor	B-CHED
compounds	O
,	O
S	O
-	O
nitroso	B-CHED
-	O
N	B-CHED
-	I-CHED
acetylpenicillamine	I-CHED
(	O
SNAP	O
)	O
and	O
sodium	B-CHED
nitroprusside	I-CHED
(	O
SNP	O
),	O
were	O
tested	O
in	O
a	O
broad	O
range	O
of	O
concentrations	O
.	O

There	O
is	O
a	O
global	O
need	O
to	O
elucidate	O
protective	O
antigens	B-CHED
expressed	O
by	O
the	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

A	O
single	O
mAb	O
,	O
F26G15	O
,	O
is	O
specific	O
for	O
the	O
nucleoprotein	O
as	O
seen	O
in	O
Western	O
immunoblot	O
while	O
five	O
other	O
mAbs	O
react	O
with	O
the	O
Spike	O
protein	B-CHED
.	O

TITLE	O
:	O
Longitudinal	O
profile	O
of	O
immunoglobulin	O
G	O
(	O
IgG	O
),	O
IgM	O
,	O
and	O
IgA	O
antibodies	O
against	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
in	O
patients	O
with	O
pneumonia	O
due	O
to	O
the	O
SARS	O
coronavirus	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
development	O
of	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
the	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
nucleocapsid	O
protein	B-CHED
.	O

Moreover	O
,	O
the	O
protein	B-CHED
could	O
be	O
detected	O
in	O
25	O
(	O
83	O
%)	O
of	O
30	O
nasopharyngeal	O
aspirate	O
specimens	O
obtained	O
from	O
days	O
11	O
to	O
15	O
and	O
in	O
all	O
7	O
fecal	O
specimens	O
obtained	O
from	O
days	O
21	O
to	O
32	O
.	O

TITLE	O
:	O
Association	O
of	O
human	O
-	O
leukocyte	O
-	O
antigen	B-CHED
class	O
I	O
(	O
B	O
*	O
0703	O
)	O
and	O
class	O
II	O
(	O
DRB1	O
*	O
0301	O
)	O
genotypes	O
with	O
susceptibility	O
and	O
resistance	O
to	O
the	O
development	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

TITLE	O
:	O
Proteomic	O
analysis	O
of	O
SARS	O
associated	O
coronavirus	O
using	O
two	O
-	O
dimensional	O
liquid	O
chromatography	O
mass	O
spectrometry	O
and	O
one	O
-	O
dimensional	O
sodium	B-CHED
dodecyl	I-CHED
sulfate	I-CHED
-	O
polyacrylamide	B-CHED
gel	O
electrophoresis	O
followed	O
by	O
mass	O
spectroemtric	O
analysis	O
.	O

For	O
the	O
first	O
time	O
,	O
all	O
of	O
the	O
four	O
predicted	O
structural	O
proteins	B-CHED
of	O
SARS	O
-	O
CoV	O
were	O
identified	O
,	O
including	O
S	O
(	O
Spike	O
),	O
M	O
(	O
Membrane	O
),	O
N	O
(	O
Nucleocapsid	O
),	O
and	O
E	O
(	O
Envolope	O
)	O
proteins	B-CHED
.	O

TITLE	O
:	O
High	O
dose	O
intravenous	O
methylprednisolone	B-CHED
in	O
the	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Pulse	O
dose	O
intravenous	O
corticosteroids	B-CHED
were	O
used	O
in	O
an	O
unsuccessful	O
attempt	O
to	O
treat	O
the	O
inflammatory	O
component	O
of	O
this	O
respiratory	O
illness	O
.	O

48	O
siRNA	O
sequences	O
were	O
designed	O
for	O
targeting	O
regions	O
throughout	O
entire	O
SARS	O
-	O
CoV	O
genome	O
RNA	O
including	O
open	O
-	O
reading	O
frames	O
for	O
several	O
key	O
proteins	B-CHED
.	O

The	O
rapid	O
development	O
of	O
siRNA	O
-	O
based	O
SARS	O
-	O
CoV	O
inhibitors	B-CHED
marked	O
a	O
novel	O
approach	O
for	O
combating	O
newly	O
emergent	O
infectious	O
diseases	O
.	O

Accordingly	O
,	O
S	O
-	O
protein	B-CHED
plays	O
an	O
important	O
role	O
in	O
virus	O
infection	O
cycle	O
and	O
is	O
the	O
primary	O
target	O
of	O
neutralizing	O
antibodies	O
.	O

We	O
were	O
able	O
to	O
pseudotype	O
murine	O
leukemia	O
virus	O
particles	O
with	O
S	O
-	O
protein	B-CHED
and	O
produce	O
SARS	O
pseudoviruses	O
.	O

TITLE	O
:	O
Prediction	O
of	O
class	O
I	O
T	O
-	O
cell	O
epitopes	O
:	O
evidence	O
of	O
presence	O
of	O
immunological	O
hot	O
spots	O
inside	O
antigens	B-CHED
.	O

Anaesthetists	O
were	O
at	O
risk	O
and	O
anaesthetic	B-CHED
practice	O
had	O
to	O
change	O
in	O
view	O
of	O
strict	O
infection	O
control	O
provisions	O
.	O

TITLE	O
:	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
and	O
the	O
GDP	B-CHED
.	O

These	O
phageborne	O
peptides	B-CHED
had	O
4	O
consensus	O
motifs	O
,	O
of	O
which	O
2	O
corresponded	O
to	O
amino	B-CHED
acid	I-CHED
sequences	O
reported	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Three	O
nucleotide	B-CHED
substitutions	O
determining	O
two	O
amino	B-CHED
acid	I-CHED
substitutions	O
were	O
detected	O
.	O

Cg	O
-	O
Foxn1	O
(	O
nu	O
)/	O
Foxn1	O
(	O
nu	O
)	O
mice	O
and	O
M	O
.	O
pulmonis	O
antigen	B-CHED
in	O
Wistar	O
rats	O
were	O
immunolabelled	O
in	O
tissue	O
sections	O
.	O

Both	O
genomes	O
are	O
30	O
,	O
713	O
nucleotides	B-CHED
long	O
,	O
excluding	O
the	O
poly	O
(	O
A	O
)	O
tail	O
,	O
and	O
only	O
differ	O
by	O
6	O
nucleotides	B-CHED
.	O

Elevated	O
stress	O
in	O
the	O
population	O
may	O
be	O
an	O
important	O
indicator	B-CHED
of	O
future	O
psychiatric	O
morbidity	O
.	O

Antiviral	B-CHED
activity	O
varied	O
with	O
the	O
use	O
of	O
different	O
cell	O
lines	O
.	O

We	O
conclusively	O
show	O
that	O
SCoV	O
E	O
protein	B-CHED
contains	O
an	O
unusually	O
short	O
,	O
palindromic	O
transmembrane	O
helical	O
hairpin	O
around	O
a	O
previously	O
unidentified	O
pseudo	O
-	O
center	O
of	O
symmetry	O
,	O
a	O
structural	O
feature	O
which	O
seems	O
to	O
be	O
unique	O
to	O
SCoV	O
.	O
The	O
hairpin	O
deforms	O
lipid	B-CHED
bilayers	O
by	O
way	O
of	O
increasing	O
their	O
curvature	O
,	O
providing	O
for	O
the	O
first	O
time	O
a	O
molecular	O
explanation	O
of	O
E	O
protein	B-CHED
'	O
s	O
pivotal	O
role	O
in	O
viral	O
budding	O
.	O

Sequencing	O
of	O
two	O
amplified	O
products	O
from	O
the	O
S	O
protein	B-CHED
gene	O
of	O
a	O
positive	O
sample	O
revealed	O
the	O
presence	O
of	O
coronavirus	O
specific	O
RNA	O
with	O
a	O
sequence	O
homology	O
to	O
canine	O
coronavirus	O
of	O
76	O
and	O
78	O
%	O
and	O
to	O
feline	O
coronavirus	O
type	O
II	O
of	O
80	O
and	O
84	O
%,	O
respectively	O
.	O

So	O
far	O
,	O
five	O
specific	O
therapies	O
have	O
proven	O
their	O
efficacy	O
to	O
achieve	O
such	O
goal	O
in	O
large	O
randomised	O
controlled	O
trials	O
:	O
early	O
goal	O
-	O
directed	O
therapy	O
,	O
recombinant	O
activated	O
protein	B-CHED
C	O
,	O
moderate	O
doses	O
of	O
steroids	B-CHED
,	O
low	O
tidal	O
volume	O
ventilation	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
intensive	O
insulin	B-CHED
therapy	O
to	O
control	O
hyperglycemia	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
show	O
that	O
SARS	O
-	O
CoV	O
N	O
is	O
capable	O
of	O
inducing	O
apoptosis	O
of	O
COS	B-CHED
-	O
1	O
monkey	O
kidney	O
cells	O
in	O
the	O
absence	O
of	O
growth	O
factors	O
by	O
down	O
-	O
regulating	O
ERK	O
(	O
extracellular	O
-	O
signal	O
-	O
regulated	O
kinase	O
),	O
up	O
-	O
regulating	O
JNK	O
(	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
)	O
and	O
p38	O
MAPK	O
(	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinase	O
)	O
pathways	O
,	O
and	O
affecting	O
their	O
downstream	O
effectors	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
changes	O
in	O
alveolar	O
epithelial	O
liquid	O
clearance	O
during	O
lung	O
edema	O
following	O
acute	O
lung	O
injury	O
induced	O
by	O
oleic	B-CHED
acid	I-CHED
.	O

Two	O
of	O
them	O
,	O
B10	O
and	O
C20	B-CHED
,	O
could	O
recognize	O
non	O
-	O
overlapping	O
epitopes	O
of	O
the	O
E	O
protein	B-CHED
according	O
to	O
the	O
two	O
-	O
site	O
binding	O
test	O
result	O
.	O

The	O
affinity	O
of	O
A17	O
for	O
N	O
protein	B-CHED
was	O
2	O
.	O
1	O
x	O
10	O
(-	O
6	O
)	O
M	O
.	O
All	O
three	O
scFv	O
antibodies	O
were	O
purified	O
with	O
affinity	O
chromatography	O
and	O
determined	O
by	O
Western	O
blot	O
.	O

TITLE	O
:	O
A	O
single	O
amino	B-CHED
acid	I-CHED
mutation	O
in	O
the	O
spike	O
protein	B-CHED
of	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
hampers	O
its	O
maturation	O
and	O
incorporation	O
into	O
virions	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

Common	O
laboratory	O
findings	O
included	O
lymphopenia	O
(	O
on	O
hospital	O
admission	O
,	O
70	O
%;	O
during	O
hospitalization	O
,	O
95	O
%),	O
thrombocytopenia	O
(	O
on	O
hospital	O
admission	O
,	O
28	O
%;	O
during	O
hospitalization	O
,	O
40	O
%),	O
elevated	O
lactate	B-CHED
dehydrogenase	O
(	O
on	O
hospital	O
admission	O
,	O
58	O
%;	O
during	O
hospitalization	O
,	O
88	O
%),	O
creatine	B-CHED
kinase	O
(	O
on	O
hospital	O
admission	O
,	O
18	O
%;	O
during	O
hospitalization	O
,	O
32	O
%),	O
and	O
aspartate	B-CHED
aminotransferase	O
or	O
alanine	B-CHED
aminotransferase	O
levels	O
(	O
on	O
hospital	O
admission	O
,	O
27	O
%;	O
during	O
hospitalization	O
,	O
62	O
%).	O

In	O
the	O
recent	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
outbreak	O
,	O
ribavirin	B-CHED
was	O
used	O
in	O
various	O
countries	O
against	O
this	O
novel	O
coronavirus	O
.	O

We	O
conducted	O
a	O
retrospective	O
analysis	O
to	O
assess	O
the	O
efficacy	O
of	O
ribavirin	B-CHED
in	O
the	O
treatment	O
of	O
SARS	O
in	O
Singapore	O
.	O

Ninety	O
-	O
seven	O
(	O
42	O
.	O
4	O
%)	O
patients	O
received	O
ribavirin	B-CHED
at	O
a	O
mean	O
of	O
6	O
.	O
4	O
days	O
of	O
illness	O
.	O

Substitution	O
of	O
D6408	O
by	O
Ala	B-CHED
was	O
shown	O
to	O
abolish	O
viral	O
RNA	O
synthesis	O
,	O
demonstrating	O
that	O
NendoU	O
has	O
critical	O
functions	O
in	O
viral	O
replication	O
and	O
transcription	O
.	O

TITLE	O
:	O
SARS	O
preventive	O
and	O
risk	O
behaviours	O
of	O
Hong	O
Kong	O
air	B-CHED
travellers	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aims	O
to	O
investigate	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)-	O
related	O
behaviours	O
of	O
travellers	O
returning	O
to	O
Hong	O
Kong	O
by	O
air	B-CHED
.	O

ARDS	O
rabbit	O
models	O
were	O
established	O
by	O
injecting	O
oleic	B-CHED
acid	I-CHED
through	O
central	O
vein	O
,	O
and	O
the	O
results	O
of	O
effective	O
local	O
blood	O
perfusion	O
in	O
different	O
areas	O
of	O
rabbit	O
lung	O
(	O
upper	O
area	O
,	O
abdominal	O
area	O
,	O
and	O
dorsal	O
area	O
of	O
right	O
lung	O
)	O
with	O
PIM	B-CHED
-	O
II	O
laser	O
perfusion	O
imager	O
and	O
arterial	O
blood	O
gas	O
under	O
different	O
ventilation	O
modes	O
[	O
large	O
tidal	O
volume	O
ventilation	O
,	O
low	O
tidal	O
volume	O
ventilation	O
+	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
),	O
prone	O
position	O
+	O
large	O
tidal	O
volume	O
ventilation	O
,	O
and	O
prone	O
position	O
+	O
low	O
tidal	O
volume	O
ventilation	O
+	O
PEEP	B-CHED
]	O
were	O
measured	O
.	O

RESULTS	O
:	O
The	O
results	O
of	O
oxygenation	O
index	O
were	O
significantly	O
getting	O
worsen	O
after	O
lung	O
injury	O
,	O
and	O
after	O
receiving	O
lung	O
protective	O
ventilation	O
(	O
including	O
low	O
tidal	O
volume	O
+	O
PEEP	B-CHED
,	O
prone	O
position	O
+	O
low	O
tidal	O
volume	O
+	O
PEEP	B-CHED
),	O
the	O
indexes	O
were	O
taking	O
a	O
turn	O
to	O
the	O
better	O
.	O

These	O
results	O
are	O
concordant	O
with	O
that	O
of	O
a	O
spike	O
protein	B-CHED
-	O
derived	O
peptide	B-CHED
.	O

The	O
serum	O
samples	O
could	O
neutralize	O
the	O
pseudotype	O
particles	O
bearing	O
the	O
spike	O
glycoproteins	B-CHED
from	O
different	O
SARS	O
-	O
CoV	O
strains	O
,	O
suggesting	O
that	O
the	O
NAbs	O
to	O
SARS	O
-	O
CoV	O
were	O
broadly	O
reactive	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
protein	B-CHED
)	O
is	O
one	O
of	O
the	O
major	O
virion	O
structural	O
proteins	B-CHED
of	O
a	O
newly	O
identified	O
coronavirus	O
,	O
which	O
has	O
been	O
confirmed	O
as	O
the	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

N	O
protein	B-CHED
is	O
denatured	O
reversibly	O
at	O
pH	O
7	O
.	O
4	O
either	O
by	O
urea	B-CHED
(	O
with	O
C	O
(	O
m	O
)	O
of	O
2	O
.	O
77	O
M	O
and	O
m	O
value	O
of	O
2	O
.	O
74	O
kcal	O
mol	O
(-	O
1	O
)	O
M	O
(-	O
1	O
))	O
or	O
GdmCl	O
(	O
with	O
C	O
(	O
m	O
)	O
of	O
1	O
.	O
46	O
M	O
and	O
m	O
value	O
of	O
4	O
.	O
50	O
kcal	O
mol	O
(-	O
1	O
)	O
M	O
(-	O
1	O
)).	O

We	O
propose	O
that	O
the	O
low	O
stability	O
of	O
N	O
protein	B-CHED
may	O
be	O
critical	O
for	O
the	O
stability	O
and	O
function	O
of	O
SARS	O
virus	O
.	O

TITLE	O
:	O
The	O
CC	O
chemokine	O
ligand	B-CHED
3	O
regulates	O
CD11c	O
+	O
CD11b	O
+	O
CD8alpha	O
-	O
dendritic	O
cell	O
maturation	O
and	O
activation	O
following	O
viral	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
:	O
implications	O
for	O
a	O
role	O
in	O
T	O
cell	O
activation	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
CC	O
chemokine	O
ligand	B-CHED
3	O
(	O
CCL3	B-CHED
)	O
in	O
activation	O
of	O
dendritic	O
cells	O
(	O
DCs	O
)	O
following	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
was	O
examined	O
.	O

A	O
72	O
-	O
year	O
-	O
old	O
African	O
American	O
man	B-CHED
developed	O
an	O
acute	O
confusional	O
state	O
(	O
ACS	O
)	O
one	O
month	O
after	O
receiving	O
celecoxib	B-CHED
for	O
osteoarthritis	O
of	O
his	O
knee	O
joints	O
.	O

For	O
the	O
prototype	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
it	O
has	O
previously	O
been	O
established	O
that	O
S	O
protein	B-CHED
assembly	O
into	O
virions	O
is	O
specified	O
by	O
the	O
carboxy	B-CHED
-	O
terminal	O
segment	O
,	O
which	O
comprises	O
the	O
transmembrane	O
domain	O
and	O
the	O
endodomain	O
.	O

In	O
particular	O
,	O
mutational	O
analysis	O
indicated	O
a	O
major	O
role	O
for	O
the	O
charge	O
-	O
rich	O
carboxy	B-CHED
-	O
terminal	O
region	O
of	O
the	O
endodomain	O
.	O

TITLE	O
:	O
Syndromic	O
surveillance	O
using	O
regional	O
emergency	O
medicine	B-CHED
internet	O
.	O

Therefore	O
,	O
we	O
must	O
adhere	O
to	O
the	O
principles	O
of	O
the	O
evidence	O
-	O
based	O
medicine	B-CHED
,	O
strengthen	O
the	O
integrated	O
study	O
on	O
""""	O
disease	O
""""	O
of	O
western	O
medicine	B-CHED
and	O
""""	O
syndrome	O
""""	O
of	O
TCM	O
,	O
insist	O
on	O
""""	O
materialism	O
""""	O
and	O
improve	O
the	O
understanding	O
of	O
the	O
mechanism	O
of	O
Chinese	O
herb	O
formula	O
,	O
pay	O
efforts	O
on	O
the	O
clinical	O
study	O
of	O
difficult	O
and	O
common	O
hepatic	O
diseases	O
,	O
in	O
order	O
to	O
develop	O
the	O
integrated	O
traditional	O
and	O
western	O
medicine	B-CHED
on	O
liver	O
diseases	O
.	O

TITLE	O
:	O
Preventive	O
effect	O
of	O
tranilast	O
on	O
oleic	B-CHED
acid	I-CHED
-	O
induced	O
lung	O
injury	O
in	O
guinea	O
pigs	O
.	O

Totally	O
100	O
patients	O
hospitalized	O
in	O
Beijing	O
Ditan	B-CHED
Hospital	O
since	O
March	O
to	O
June	O
2003	O
with	O
clinical	O
diagnosis	O
of	O
SARS	O
were	O
involved	O
in	O
this	O
study	O
.	O

The	O
production	O
of	O
SARS	O
IgG	O
is	O
not	O
notably	O
correlated	O
with	O
sex	O
,	O
age	O
,	O
seriousness	O
of	O
symptoms	O
,	O
and	O
steroid	B-CHED
treatment	O
.	O

The	O
decrease	O
of	O
arterial	O
partial	O
pressure	O
of	O
oxygen	B-CHED
occurred	O
in	O
26	O
patients	O
(	O
49	O
.	O
1	O
%).	O

Lung	O
wet	O
-	O
to	O
-	O
dry	O
weight	O
ratio	O
and	O
lung	O
vascular	O
permeability	O
were	O
also	O
measured	O
in	O
the	O
AQP1	O
knockout	O
mice	O
(	O
n	O
=	O
9	O
)	O
that	O
received	O
IT	O
LPS	B-CHED
(	O
5	O
mg	O
/	O
kg	O
)	O
at	O
2	O
days	O
.	O

Intratracheal	O
instillation	O
of	O
LPS	B-CHED
produced	O
a	O
severe	O
lung	O
injury	O
at	O
2	O
days	O
,	O
characterized	O
by	O
elevation	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
in	O
the	O
BAL	B-CHED
fluid	O
,	O
and	O
by	O
histological	O
changes	O
consistent	O
with	O
increased	O
lung	O
vascular	O
permeability	O
and	O
neutrophil	O
infiltration	O
.	O

The	O
results	O
suggest	O
that	O
although	O
AQP1	O
expression	O
is	O
decreased	O
after	O
lung	O
injury	O
,	O
depletion	O
of	O
AQP1	O
does	O
not	O
alter	O
lung	O
inflammation	O
and	O
lung	O
edema	O
induced	O
by	O
LPS	B-CHED
.	O

Sequence	O
analysis	O
of	O
the	O
virus	O
indicates	O
that	O
there	O
is	O
only	O
20	O
%	O
amino	B-CHED
acid	I-CHED
(	O
aa	O
)	O
identity	O
with	O
known	O
coronaviruses	O
.	O

Previous	O
studies	O
indicate	O
that	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
amongst	O
various	O
coronavirus	O
proteins	B-CHED
are	O
critical	O
for	O
viral	O
assembly	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
mammalian	O
two	O
-	O
hybrid	O
system	O
to	O
investigate	O
possible	O
interactions	O
between	O
SARS	O
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
and	O
the	O
membrane	O
(	O
M	O
)	O
proteins	B-CHED
.	O

Chloroquine	B-CHED
,	O
an	O
old	O
antimalarial	B-CHED
drug	O
,	O
may	O
be	O
considered	O
for	O
immediate	O
use	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
SARS	O
-	O
CoV	O
infections	O
.	O

(	O
1	O
)	O
The	O
amplitude	O
of	O
air	B-CHED
temperature	O
,	O
air	B-CHED
pressure	O
and	O
diurnal	O
temperature	O
difference	O
were	O
greater	O
around	O
SARS	O
outbreaks	O
in	O
most	O
of	O
the	O
cities	O
.	O

Influenza	O
A	O
(	O
H1N1	O
and	O
H3N2	B-CHED
)	O
and	O
B	O
viruses	O
were	O
detected	O
at	O
all	O
sites	O
.	O

In	O
February	O
2004	O
,	O
Fujisawa	O
Deutschland	O
GmbH	O
,	O
a	O
subsidiary	O
of	O
Fujisawa	O
Pharmaceutical	B-CHED
Co	O
.,	O
entered	O
into	O
an	O
option	O
agreement	O
with	O
Hemispherx	O
Biopharma	O
with	O
the	O
intent	O
of	O
becoming	O
a	O
distributor	O
for	O
Ampligen	O
for	O
the	O
potential	O
treatment	O
of	O
chronic	O
fatigue	O
syndrome	O
in	O
Germany	O
,	O
Switzerland	O
and	O
Austria	O
.	O

Hemispherx	O
and	O
AOP	O
Orphan	O
Pharmaceuticals	B-CHED
have	O
signed	O
a	O
marketing	O
agreement	O
for	O
Ampligen	O
for	O
the	O
treatment	O
of	O
chronic	O
fatigue	O
syndrome	O
for	O
Austria	O
,	O
the	O
Czech	O
Republic	O
,	O
Poland	O
and	O
Hungary	O
.	O

SARS	O
-	O
CoV	O
specific	O
gene	O
expression	O
changes	O
were	O
examined	O
by	O
high	O
-	O
density	O
oligonucleotide	B-CHED
array	O
analysis	O
.	O

Among	O
these	O
biomarkers	O
,	O
one	O
(	O
11	O
,	O
695	O
Da	O
)	O
was	O
identified	O
to	O
be	O
serum	O
amyloid	O
A	O
(	O
SAA	O
)	O
protein	B-CHED
by	O
peptide	B-CHED
mapping	O
and	O
tandem	O
mass	O
spectrometric	O
analysis	O
.	O

ABSTRACT	O
:	O
We	O
have	O
expressed	O
and	O
characterized	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	B-CHED
in	O
cDNA	O
-	O
transfected	O
mammalian	O
cells	O
.	O

ABSTRACT	O
:	O
Infection	O
of	O
receptor	O
-	O
bearing	O
cells	O
by	O
coronaviruses	O
is	O
mediated	O
by	O
their	O
spike	O
(	O
S	O
)	O
proteins	B-CHED
.	O

Patients	O
were	O
ventilated	O
in	O
assist	O
/	O
control	O
mode	O
with	O
a	O
ventilatory	O
strategy	O
providing	O
adequate	O
oxygenation	O
(	O
PaO	B-CHED
(	O
2	O
)	O
>	O
70	O
mmHg	O
)	O
and	O
normocapnia	O
(	O
PaCO	O
(	O
2	O
)	O
between	O
35	O
-	O
40	O
mmHg	O
).	O

Furthermore	O
,	O
the	O
levels	O
of	O
these	O
proteins	B-CHED
significantly	O
correlated	O
with	O
certain	O
clinico	O
-	O
pathological	O
parameters	O
.	O

TITLE	O
:	O
The	O
central	O
role	O
of	O
angiotensin	B-CHED
I	O
-	O
converting	O
enzyme	O
in	O
vertebrate	O
pathophysiology	O
.	O

ABSTRACT	O
:	O
Genomic	O
epidemiologic	O
data	O
,	O
increasingly	O
supported	O
by	O
clinical	O
outcomes	O
results	O
,	O
strongly	O
suggest	O
that	O
overactivity	O
of	O
angiotensin	B-CHED
I	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
may	O
underlie	O
most	O
age	O
-	O
related	O
diseases	O
.	O

In	O
a	O
preliminary	O
study	O
,	O
angiotensin	B-CHED
II	I-CHED
blockade	O
appeared	O
to	O
hasten	O
recovery	O
from	O
West	O
Nile	O
virus	O
encephalitis	O
;	O
it	O
may	O
be	O
equally	O
useful	O
in	O
SARS	O
.	O

The	O
technique	O
of	O
ECLS	O
included	O
veno	O
-	O
venous	O
or	O
veno	O
-	O
arterial	O
vascular	O
access	O
,	O
lung	O
""""	O
rest	B-CHED
""""	O
at	O
low	O
FiO2	O
and	O
inspiratory	O
pressure	O
,	O
minimal	O
anticoagulation	O
,	O
and	O
optimization	O
of	O
systemic	O
oxygen	B-CHED
delivery	O
.	O

TITLE	O
:	O
Protective	O
humoral	O
responses	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
:	O
implications	O
for	O
the	O
design	O
of	O
an	O
effective	O
protein	B-CHED
-	O
based	O
vaccine	O
.	O

Antisera	O
to	O
S	O
and	O
M	O
proteins	B-CHED
were	O
found	O
to	O
have	O
different	O
neutralizing	O
titres	O
towards	O
SARS	O
-	O
CoV	O
infection	O
in	O
vivo	O
,	O
ranging	O
from	O
1	O
:	O
35	O
to	O
1	O
:	O
128	O
.	O

The	O
data	O
demonstrated	O
that	O
the	O
cleavage	O
of	O
S	O
protein	B-CHED
was	O
observed	O
in	O
the	O
lysate	O
,	O
indicating	O
that	O
proteolytic	O
processing	O
of	O
S	O
protein	B-CHED
is	O
present	O
in	O
host	O
cells	O
.	O

While	O
previous	O
studies	O
demonstrated	O
that	O
effector	B-CHED
and	O
memory	O
CD8	O
(+)	O
T	O
lymphocytes	O
are	O
critical	O
in	O
controlling	O
acute	O
IBV	O
infection	O
and	O
disease	O
in	O
chickens	O
,	O
here	O
chicken	O
anti	O
-	O
IBV	O
antibody	O
(	O
IgG	O
)	O
secreting	O
cells	O
(	O
ASC	O
)	O
in	O
both	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
spleens	O
collected	O
following	O
IBV	O
Gray	O
infection	O
were	O
evaluated	O
using	O
an	O
ELISPOT	O
assay	O
.	O

The	O
analogues	O
contained	O
either	O
dinitrile	B-CHED
or	O
diester	B-CHED
groups	O
at	O
the	O
imidazole	B-CHED
4	O
,	O
5	O
-	O
positions	O
,	O
and	O
many	O
of	O
which	O
possessed	O
an	O
acyclic	O
sugar	O
or	O
sugar	O
phosphonate	B-CHED
moiety	O
at	O
the	O
imidazole	B-CHED
1	O
-	O
position	O
.	O

TITLE	O
:	O
Detecting	O
specific	O
cytotoxic	O
T	O
lymphocytes	O
against	O
SARS	O
-	O
coronavirus	O
with	O
DimerX	O
HLA	O
-	O
A2	O
:	O
Ig	O
fusion	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Rhesus	O
and	O
cynomolgus	O
macaques	O
were	O
challenged	O
with	O
10	O
(	O
7	O
)	O
PFU	B-CHED
of	O
a	O
clinical	O
isolate	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
.	O

The	O
coronavirus	O
that	O
causes	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
)	O
utilizes	O
the	O
receptor	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
to	O
infect	O
cells	O
.	O

These	O
enzymes	O
were	O
secreted	O
from	O
Sf9	O
insect	O
cells	O
as	O
chimeric	O
proteins	B-CHED
fused	O
to	O
eGFP	O
.	O

For	O
NV	O
,	O
one	O
of	O
the	O
most	O
important	O
foodborne	O
(	O
live	O
bivalve	O
molluscs	O
)	O
viral	O
pathogens	O
,	O
indicator	B-CHED
organisms	O
are	O
in	O
use	O
.	O

ABSTRACT	O
:	O
Virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
produced	O
by	O
recombinant	O
expression	O
of	O
the	O
major	O
viral	O
structural	O
proteins	B-CHED
could	O
be	O
an	O
attractive	O
method	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
control	O
.	O

The	O
data	O
supported	O
the	O
proposition	O
unequivocally	O
that	O
SARS	O
-	O
CoV	O
3CLpro	O
was	O
a	O
member	O
of	O
serine	B-CHED
proteases	O
involving	O
His41	O
and	O
Cys145	O
residues	O
at	O
the	O
active	O
site	O
.	O

The	O
polyclonal	O
antibodies	O
produced	O
by	O
recombinant	O
S2	O
protein	B-CHED
were	O
tested	O
for	O
antigenicity	O
of	O
the	O
two	O
heptad	O
repeats	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
),	O
a	O
type	O
I	O
transmembrane	O
envelope	O
glycoprotein	B-CHED
,	O
consists	O
of	O
S1	O
and	O
S2	O
domains	O
responsible	O
for	O
virus	O
binding	O
and	O
fusion	O
,	O
respectively	O
.	O

Combination	O
of	O
interferon	O
alfacon	O
-	O
1	O
plus	O
steroid	B-CHED
,	O
or	O
lopinavir	O
/	O
ritonavir	B-CHED
,	O
ribavirin	B-CHED
plus	O
steroid	B-CHED
were	O
associated	O
with	O
a	O
better	O
outcome	O
than	O
ribavirin	B-CHED
plus	O
steroid	B-CHED
(	O
0	O
%	O
vs	O
.	O
2	O
.	O
3	O
%	O
vs	O
.	O
7	O
.	O
7	O
%,	O
respectively	O
).	O

Those	O
who	O
received	O
formal	B-CHED
education	O
demonstrated	O
that	O
they	O
acquired	O
greater	O
knowledge	O
of	O
the	O
sources	O
and	O
precautionary	O
measures	O
for	O
SARS	O
.	O

However	O
,	O
the	O
functions	O
of	O
only	O
a	O
few	O
of	O
these	O
proteins	B-CHED
are	O
known	O
.	O

This	O
is	O
accomplished	O
by	O
viral	O
expression	O
of	O
amino	B-CHED
acid	I-CHED
sequences	O
that	O
are	O
molecular	O
mimics	O
of	O
the	O
host	O
'	O
s	O
adrenocorticotropin	B-CHED
hormone	B-CHED
(	O
ACTH	B-CHED
).	O

These	O
antibodies	O
are	O
specific	O
for	O
numerous	O
viral	O
protein	B-CHED
targets	O
,	O
and	O
six	O
of	O
them	O
are	O
able	O
to	O
effectively	O
neutralize	O
SARS	O
-	O
CoV	O
in	O
vitro	O
,	O
including	O
one	O
with	O
a	O
neutralizing	O
titre	O
of	O
0	O
.	O
075	O
nM	O
.	O
A	O
phylogenetic	O
analysis	O
of	O
the	O
heavy	O
and	O
light	O
chain	O
sequences	O
reveals	O
that	O
the	O
mAbs	O
share	O
considerable	O
homology	O
.	O

TITLE	O
:	O
High	O
-	O
throughput	O
screening	O
identifies	O
inhibitors	B-CHED
of	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	O
.	O

The	O
blood	O
glucose	B-CHED
grew	O
up	O
significantly	O
in	O
the	O
first	O
and	O
the	O
second	O
weeks	O
in	O
the	O
treatment	O
with	O
GCS	O
,	O
and	O
then	O
returned	O
to	O
normal	O
level	O
gradually	O
.	O

Serum	O
potassium	B-CHED
reached	O
its	O
nadir	O
in	O
the	O
first	O
week	O
of	O
GCS	O
treatment	O
and	O
then	O
grew	O
up	O
in	O
the	O
second	O
week	O
.	O

TITLE	O
:	O
Assessment	O
of	O
synthetic	O
peptides	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
recognized	O
by	O
long	O
-	O
lasting	O
immunity	O
.	O

These	O
three	O
peptides	B-CHED
,	O
recognized	O
by	O
their	O
long	O
-	O
lasting	O
immunity	O
,	O
may	O
provide	O
a	O
better	O
understanding	O
of	O
the	O
immunogenicity	O
of	O
SARS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
A	O
peptide	B-CHED
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
can	O
be	O
used	O
for	O
retrospective	O
serosurveillance	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
by	O
helping	O
identify	O
undetected	O
chains	O
of	O
disease	O
transmission	O
.	O

The	O
new	O
peptide	B-CHED
ELISA	O
consistently	O
detected	O
seroconversion	O
by	O
week	O
2	O
of	O
onset	O
of	O
fever	O
,	O
and	O
seropositivity	O
remained	O
through	O
day	O
100	O
.	O

At	O
various	O
time	O
points	O
of	O
posttransfection	O
,	O
the	O
levels	O
of	O
S	O
-	O
EGFP	O
expression	O
and	O
amounts	O
of	O
spike	O
mRNA	B-CHED
transcript	O
were	O
detected	O
by	O
fluorescence	O
microscopy	O
,	O
flow	O
cytometry	O
,	O
Western	O
blot	O
,	O
and	O
real	O
-	O
time	O
quantitative	O
PCR	O
,	O
respectively	O
.	O

The	O
green	O
fluorescence	O
,	O
mean	O
fluorescence	O
intensity	O
,	O
and	O
SARS	O
-	O
CoV	O
S	O
RNA	O
transcripts	O
were	O
found	O
significantly	O
reduced	O
,	O
and	O
the	O
expression	O
of	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	B-CHED
was	O
strongly	O
inhibited	O
in	O
those	O
cells	O
co	O
-	O
transfected	O
with	O
either	O
EGFP	O
-	O
or	O
S	O
-	O
specific	O
siRNAs	O
.	O

For	O
some	O
coronaviruses	O
,	O
the	O
mRNA	B-CHED
cis	O
-	O
acting	O
stimulatory	O
structures	O
involved	O
in	O
this	O
process	O
have	O
been	O
characterized	O
,	O
but	O
their	O
precise	O
contribution	O
to	O
ribosomal	O
frameshifting	O
is	O
not	O
completely	O
understood	O
.	O

TITLE	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
Nsp15	O
protein	B-CHED
is	O
an	O
endoribonuclease	O
that	O
prefers	O
manganese	B-CHED
as	O
a	O
cofactor	B-CHED
.	O

Expression	O
vectors	O
encoding	O
these	O
two	O
proteins	B-CHED
were	O
synthesized	O
by	O
using	O
preferred	O
human	O
codons	O
.	O

The	O
addition	O
of	O
a	O
third	O
gene	O
,	O
encoding	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
,	O
facilitated	O
budding	O
of	O
particles	O
that	O
contained	O
a	O
corona	B-CHED
-	O
like	O
halo	O
resembling	O
SARS	O
-	O
CoV	O
when	O
examined	O
by	O
transmission	O
electron	O
microscopy	O
,	O
with	O
a	O
buoyant	O
density	O
characteristic	O
of	O
coronaviruses	O
.	O

In	O
this	O
report	O
,	O
we	O
immunized	O
ferrets	O
(	O
Mustela	O
putorius	O
furo	O
)	O
with	O
recombinant	O
modified	O
vaccinia	O
virus	O
Ankara	O
(	O
rMVA	O
)	O
expressing	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
.	O

Together	O
,	O
these	O
data	O
demonstrate	O
that	O
CCR2	O
,	O
but	O
not	O
CCL2	B-CHED
,	O
is	O
important	O
in	O
host	O
defense	O
following	O
viral	O
infection	O
of	O
the	O
CNS	B-CHED
,	O
and	O
CCR2	O
ligand	B-CHED
(	O
s	O
),	O
other	O
than	O
CCL2	B-CHED
,	O
participates	O
in	O
generating	O
a	O
protective	O
response	O
.	O

The	O
PCR	O
products	O
were	O
cloned	O
and	O
sequenced	O
and	O
their	O
nucleic	B-CHED
acid	I-CHED
structure	O
and	O
similarity	O
to	O
published	O
sequences	O
of	O
other	O
coronaviruses	O
were	O
analyzed	O
.	O

The	O
consensus	O
transcription	O
-	O
regulating	O
sequence	O
(	O
TRS	O
)	O
of	O
IBV	O
,	O
CT	O
(	O
T	O
/	O
G	O
)	O
AACAA	O
,	O
was	O
highly	O
conserved	O
in	O
TCoV	O
genome	O
at	O
the	O
levels	O
of	O
nucleotide	B-CHED
sequence	O
and	O
location	O
in	O
regarding	O
to	O
the	O
initiation	O
codon	O
of	O
individual	O
genes	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
the	O
deduced	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
S	O
,	O
M	O
,	O
or	O
N	O
protein	B-CHED
demonstrated	O
that	O
TCoV	O
was	O
clustered	O
within	O
the	O
same	O
genomic	O
lineage	O
as	O
the	O
IBV	O
strains	O
while	O
all	O
the	O
other	O
mammalian	O
coronaviruses	O
were	O
grouped	O
into	O
separate	O
clusters	B-CHED
corresponding	O
to	O
antigenic	O
groups	O
I	O
or	O
II	O
.	O

Facilities	O
ranged	O
from	O
urban	O
hospitals	O
with	O
negative	O
-	O
pressure	O
isolation	O
rooms	O
and	O
high	O
-	O
efficiency	O
particulate	O
air	B-CHED
filtration	O
to	O
rural	O
hospitals	O
with	O
patient	O
rooms	O
open	O
to	O
outside	O
air	B-CHED
circulation	O
and	O
intermittent	O
running	O
water	B-CHED
.	O

It	O
is	O
also	O
a	O
major	O
immunogen	B-CHED
and	O
a	O
target	O
for	O
entry	O
inhibitors	B-CHED
.	O

3	O
.	O
4	O
in	O
combination	O
with	O
Western	O
medicine	B-CHED
(	O
RR	O
5	O
.	O
45	O
,	O
95	O
%	O
CI	O
(	O
1	O
.	O
54	O
,	O
19	O
.	O
26	O
)),	O
compound	O
formulas	O
NO	O
.	O

Kangfeidian	O
No	O
.	O
4	O
in	O
combination	O
with	O
Western	O
medicine	B-CHED
had	O
no	O
significant	O
effect	O
on	O
symptom	O
improvement	O
such	O
as	O
loss	O
of	O
dyspnea	O
and	O
cough	O
(	O
RR	O
1	O
.	O
50	O
,	O
95	O
%	O
CI	O
(	O
0	O
.	O
41	O
,	O
5	O
.	O
43	O
))	O
and	O
(	O
RR	O
1	O
.	O
29	O
,	O
95	O
%	O
CI	O
(	O
0	O
.	O
30	O
,	O
5	O
.	O
43	O
)).	O

Similarly	O
,	O
there	O
was	O
significant	O
improvement	O
in	O
oxygen	B-CHED
requirement	O
,	O
when	O
compared	O
with	O
day	O
1	O
,	O
on	O
days	O
6	O
and	O
7	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
after	O
commencement	O
of	O
pentaglobin	O
treatment	O
.	O

TITLE	O
:	O
Tyrosine	B-CHED
dephosphorylation	O
of	O
STAT3	O
in	O
SARS	O
coronavirus	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
E	O
protein	B-CHED
forms	O
cation	B-CHED
-	O
selective	O
ion	O
channels	O
.	O

Coronaviruses	O
including	O
SARS	O
-	O
CoV	O
encode	O
an	O
envelope	O
(	O
E	O
)	O
protein	B-CHED
,	O
a	O
small	O
,	O
hydrophobic	O
membrane	O
protein	B-CHED
.	O

We	O
report	O
that	O
,	O
in	O
planar	O
lipid	B-CHED
bilayers	O
,	O
synthetic	O
peptides	B-CHED
corresponding	O
to	O
the	O
SARS	O
-	O
CoV	O
E	O
protein	B-CHED
forms	O
ion	O
channels	O
that	O
are	O
more	O
permeable	O
to	O
monovalent	O
cations	B-CHED
than	O
to	O
monovalent	O
anions	B-CHED
.	O

CNS	B-CHED
-	O
derived	O
secondary	O
CD8	O
+	O
T	O
cells	O
exhibited	O
increased	O
cytolytic	O
activity	O
and	O
IFN	O
-	O
gamma	O
expression	O
per	O
cell	O
compared	O
with	O
primary	O
CD8	O
+	O
T	O
cells	O
.	O

TITLE	O
:	O
Mapping	O
of	O
antigenic	O
sites	O
on	O
the	O
nucleocapsid	O
protein	B-CHED
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Two	O
major	O
immunodominant	O
epitopes	O
located	O
in	O
the	O
C	O
-	O
terminal	O
region	O
(	O
amino	B-CHED
acids	I-CHED
[	O
aa	O
]	O
362	O
to	O
412	O
)	O
and	O
middle	O
region	O
(	O
aa	O
153	O
to	O
178	O
)	O
reacted	O
with	O
more	O
than	O
75	O
%	O
of	O
sera	O
from	O
SARS	O
patients	O
.	O

TITLE	O
:	O
Inactivated	O
SARS	O
-	O
CoV	O
vaccine	O
elicits	O
high	O
titers	O
of	O
spike	O
protein	B-CHED
-	O
specific	O
antibodies	O
that	O
block	O
receptor	O
binding	O
and	O
virus	O
entry	O
.	O

Both	O
patients	O
with	O
myopathy	O
had	O
elevated	O
serum	O
creatine	B-CHED
kinase	O
levels	O
.	O

The	O
final	O
optimal	O
concentration	O
of	O
methanol	B-CHED
was	O
20	O
mL	O
/	O
L	O
,	O
the	O
DO	O
had	O
a	O
significant	O
effect	O
on	O
rSCoVN	O
protein	B-CHED
expression	O
and	O
growth	O
of	O
recombinant	O
strains	O
.	O

But	O
serum	O
total	O
protein	B-CHED
remained	O
normal	O
during	O
the	O
whole	O
clinical	O
course	O
.	O

Here	O
,	O
we	O
identified	O
another	O
cellular	O
protein	B-CHED
,	O
p70	O
,	O
which	O
has	O
been	O
shown	O
by	O
UV	O
cross	O
-	O
linking	O
to	O
bind	O
both	O
the	O
positive	O
-	O
and	O
negative	O
-	O
strand	O
UTRs	O
of	O
MHV	O
RNA	O
specifically	O
.	O

Matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
(	O
MALDI	O
)-	O
mass	O
spectrometry	O
identified	O
it	O
as	O
synaptotagmin	O
-	O
binding	O
cytoplasmic	O
RNA	O
-	O
interacting	O
protein	B-CHED
(	O
SYNCRIP	O
).	O

The	O
structural	O
proteins	B-CHED
E	O
,	O
M	O
and	O
N	O
of	O
SARS	O
-	O
CoV	O
play	O
important	O
roles	O
during	O
host	O
cell	O
entry	O
and	O
viral	O
morphogenesis	O
and	O
release	O
.	O

Remotely	O
sensed	O
IRT	O
readings	O
were	O
obtained	O
from	O
various	O
parts	O
of	O
the	O
front	O
and	O
side	O
of	O
the	O
face	O
(	O
at	O
distances	O
of	O
1	O
.	O
5	O
and	O
0	O
.	O
5	O
m	O
),	O
and	O
compared	O
to	O
concurrently	O
determined	O
body	O
temperature	O
measurements	O
using	O
conventional	O
means	O
(	O
aural	O
tympanic	O
IRT	O
and	O
oral	O
mercury	B-CHED
thermometry	O
).	O

We	O
used	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
conventional	O
methods	O
of	O
cell	O
culture	O
and	O
antigen	B-CHED
detection	O
to	O
establish	O
the	O
viral	O
etiology	O
of	O
acute	O
respiratory	O
tract	O
infections	O
in	O
75	O
hospitalized	O
children	O
.	O

ABSTRACT	O
:	O
Angiotensin	B-CHED
-	O
converting	O
enzyme	O
-	O
2	O
(	O
ACE2	O
)	O
is	O
the	O
first	O
human	O
homologue	O
of	O
ACE	O
to	O
be	O
described	O
.	O

The	O
role	O
of	O
ACE2	O
in	O
these	O
peptide	B-CHED
systems	O
has	O
yet	O
to	O
be	O
revealed	O
.	O

The	O
use	O
of	O
respiratory	O
masks	O
may	O
be	O
suggested	O
in	O
hospitals	O
or	O
in	O
restricted	O
ventilated	O
areas	O
where	O
,	O
even	O
if	O
coronavirus	O
variant	O
is	O
considered	O
an	O
environmental	O
contaminant	O
more	O
than	O
a	O
respiratory	O
risk	O
,	O
droplets	O
nuclei	B-CHED
may	O
persist	O
in	O
the	O
air	B-CHED
and	O
add	B-CHED
consistent	O
dangers	O
to	O
the	O
heath	O
-	O
care	O
givers	O
.	O

Disinfection	O
of	O
floors	O
or	O
larger	O
surfaces	O
may	O
be	O
obtained	O
with	O
chlorine	B-CHED
compounds	O
solutions	O
,	O
after	O
an	O
accurate	O
pre	O
-	O
cleaning	O
.	O

The	O
effect	O
of	O
ionic	O
strength	O
on	O
the	O
protease	O
molecule	O
was	O
reflected	O
by	O
the	O
drastic	O
change	O
of	O
electrostatic	O
potential	O
contour	O
of	O
the	O
enzyme	O
in	O
the	O
presence	O
of	O
NaCl	B-CHED
.	O

Analysis	O
of	O
the	O
crystal	O
structures	O
indicated	O
that	O
the	O
interfacial	O
ionic	O
interaction	O
was	O
attributed	O
to	O
the	O
Arg	B-CHED
-	O
4	O
...	O

When	O
the	O
scores	O
of	O
APACHE	O
III	O
was	O
higher	O
than	O
60	O
,	O
the	O
mortality	O
increased	O
obviously	O
(	O
chi	B-CHED
(	O
2	O
)	O
=	O
3	O
.	O
886	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

Elderly	O
patients	O
with	O
SARS	O
who	O
were	O
over	O
60	O
years	O
old	O
had	O
a	O
high	O
mortality	O
(	O
chi	B-CHED
(	O
2	O
)	O
=	O
8	O
.	O
660	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
The	O
tertiary	O
structures	O
of	O
the	O
S1	O
and	O
S2	O
domains	O
of	O
the	O
spike	O
protein	B-CHED
of	O
the	O
coronavirus	O
which	O
is	O
responsible	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
have	O
been	O
recently	O
predicted	O
.	O

Macrophages	O
from	O
mice	O
with	O
different	O
genetic	O
backgrounds	O
behave	O
differently	O
at	O
the	O
molecular	O
level	O
and	O
comparison	O
of	O
the	O
patterns	O
of	O
non	O
-	O
activated	O
and	O
IFN	O
-	O
gamma	O
-	O
activated	O
A	O
/	O
J	O
or	O
BALB	O
/	O
c	O
mouse	O
macrophages	O
revealed	O
,	O
for	O
instance	O
,	O
an	O
up	O
-	O
regulation	O
and	O
a	O
down	O
-	O
regulation	O
of	O
genes	O
coding	O
for	O
biological	O
functions	O
such	O
as	O
enzymatic	O
reactions	O
,	O
nucleic	B-CHED
acid	I-CHED
synthesis	O
and	O
transport	O
,	O
protein	B-CHED
synthesis	O
,	O
transport	O
and	O
metabolism	O
,	O
cytoskeleton	O
arrangement	O
and	O
extracellular	O
matrix	O
,	O
phagocytosis	O
,	O
resistance	O
and	O
susceptibility	O
to	O
infection	O
and	O
tumors	O
,	O
inflammation	O
,	O
and	O
cell	O
differentiation	O
or	O
activation	O
.	O

ABSTRACT	O
:	O
A	O
88	O
year	O
old	O
female	O
with	O
active	O
rheumatoid	O
arthritis	O
treated	O
by	O
low	O
dose	O
of	O
prednisolone	B-CHED
and	O
methotrexate	B-CHED
was	O
admitted	O
to	O
our	O
hospital	O
because	O
of	O
severe	O
bilateral	O
pulmonary	O
infiltration	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
versatility	O
of	O
the	O
vector	O
system	O
was	O
recently	O
demonstrated	O
by	O
the	O
rapid	O
production	O
of	O
experimental	O
MVA	B-CHED
vaccines	O
for	O
immunization	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
associated	O
coronavirus	O
.	O

There	O
were	O
no	O
consistent	O
differences	O
in	O
pathogenicity	O
between	O
the	O
recombinant	O
BeauR	O
-	O
M41	O
(	O
S	O
)	O
and	O
its	O
apathogenic	O
parent	O
Beau	O
-	O
R	O
(	O
based	O
on	O
snicking	O
,	O
nasal	O
discharge	O
,	O
wheezing	O
,	O
watery	O
eyes	O
,	O
rales	O
,	O
and	O
ciliostasis	O
in	O
trachea	O
),	O
and	O
both	O
replicated	O
poorly	O
in	O
trachea	O
and	O
nose	O
compared	O
to	O
M41	O
;	O
the	O
S	O
protein	B-CHED
from	O
the	O
pathogenic	O
M41	O
had	O
not	O
altered	O
the	O
apathogenic	O
nature	O
of	O
Beau	O
-	O
R	O
.	O
Both	O
Beau	O
-	O
R	O
and	O
BeauR	O
-	O
M41	O
(	O
S	O
)	O
induced	O
protection	O
against	O
challenge	O
with	O
M41	O
as	O
assessed	O
by	O
absence	O
of	O
recovery	O
of	O
challenge	O
virus	O
and	O
nasal	O
exudate	O
.	O

The	O
greater	O
protection	O
induced	O
by	O
BeauR	O
-	O
M41	O
(	O
S	O
)	O
against	O
M41	O
may	O
be	O
related	O
to	O
the	O
ectodomain	O
of	O
the	O
spike	O
protein	B-CHED
of	O
Beau	O
-	O
R	O
differing	O
from	O
that	O
of	O
M41	O
by	O
4	O
.	O
1	O
%;	O
a	O
small	O
number	O
of	O
epitopes	O
on	O
the	O
S	O
protein	B-CHED
may	O
play	O
a	O
disproportionate	O
role	O
in	O
the	O
induction	O
of	O
immunity	O
.	O

Previously	O
,	O
we	O
have	O
characterized	O
the	O
expression	O
and	O
cellular	O
localization	O
of	O
two	O
of	O
these	O
""""	O
accessory	O
""""	O
viral	O
proteins	B-CHED
,	O
3a	O
(	O
previously	O
termed	O
U274	O
)	O
and	O
7a	O
(	O
previously	O
termed	O
U122	O
).	O

We	O
showed	O
that	O
the	O
overexpression	O
of	O
7a	O
,	O
but	O
not	O
of	O
3a	O
or	O
the	O
viral	O
structural	O
proteins	B-CHED
,	O
nucleocapsid	O
,	O
membrane	O
,	O
and	O
envelope	O
,	O
induces	O
apoptosis	O
.	O

Activation	O
of	O
circulating	O
neutrophils	O
and	O
transmigration	O
into	O
the	O
alveolar	O
airspace	O
are	O
associated	O
with	O
development	O
of	O
acute	O
lung	O
injury	O
,	O
and	O
inhibitors	B-CHED
of	O
neutrophil	O
recruitment	O
attenuate	O
lung	O
damage	O
in	O
many	O
experimental	O
models	O
.	O

There	O
are	O
several	O
proteins	B-CHED
that	O
have	O
never	O
been	O
identified	O
in	O
plasma	O
before	O
using	O
2D	O
gel	O
electrophoresis	O
,	O
among	O
which	O
peroxiredoxin	O
II	O
was	O
chosen	O
for	O
further	O
study	O
by	O
analyzing	O
additional	O
20	O
plasma	O
samples	O
from	O
patients	O
with	O
probable	O
and	O
suspected	O
SARS	O
and	O
patients	O
with	O
fever	O
,	O
respectively	O
.	O

The	O
latest	O
guidelines	O
and	O
publications	O
on	O
antimicrobial	B-CHED
resistance	O
,	O
nursing	O
or	O
infection	O
control	O
professional	O
staffing	O
,	O
West	O
Nile	O
virus	O
,	O
and	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
are	O
included	O
.	O

Although	O
a	O
specific	O
antiviral	B-CHED
agent	I-CHED
and	O
vaccines	O
for	O
SARS	O
are	O
not	O
available	O
at	O
the	O
time	O
of	O
writing	O
,	O
a	O
standard	O
treatment	O
protocol	O
for	O
SARS	O
has	O
been	O
developed	O
.	O

Numerous	O
approaches	O
to	O
the	O
development	O
of	O
SARS	O
-	O
CoV	O
vaccines	O
have	O
been	O
undertaken	O
,	O
and	O
there	O
is	O
evidence	O
that	O
antibodies	O
to	O
the	O
spike	O
protein	B-CHED
may	O
be	O
protective	O
from	O
replication	O
and	O
pathology	O
in	O
animal	O
models	O
.	O

Six	O
groups	O
of	O
animals	O
were	O
included	O
in	O
this	O
study	O
(	O
12	O
per	O
group	O
):	O
sham	O
-	O
saline	O
,	O
sham	O
-	O
NP	O
,	O
shock	O
-	O
saline	O
,	O
shock	O
-	O
NP	O
,	O
shock	O
-	O
L	B-CHED
-	I-CHED
arginine	I-CHED
,	O
and	O
shock	O
-	O
L	O
-	O
N6	O
-(	O
1	O
-	O
iminoethyl	O
)	O
lysine	B-CHED
.	O

This	O
protein	B-CHED
is	O
believed	O
to	O
be	O
more	O
conserved	O
than	O
other	O
proteins	B-CHED
of	O
the	O
virus	O
,	O
such	O
as	O
spike	O
and	O
membrane	O
glycoprotein	B-CHED
.	O

The	O
incidence	O
of	O
respiratory	O
failure	O
,	O
heart	O
injury	O
,	O
brain	O
injury	O
,	O
and	O
atropine	B-CHED
poisoning	O
were	O
also	O
lower	O
in	O
pre	O
-	O
hospital	O
group	O
compared	O
with	O
in	O
-	O
patient	O
group	O
(	O
all	O
P	O
<	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
Small	O
animal	O
models	O
are	O
needed	O
in	O
order	O
to	O
evaluate	O
the	O
efficacy	O
of	O
candidate	O
vaccines	O
and	O
antivirals	B-CHED
directed	O
against	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
).	O

The	O
hamster	O
,	O
therefore	O
,	O
is	O
superior	O
to	O
the	O
mouse	O
as	O
a	O
model	O
for	O
the	O
evaluation	O
of	O
antiviral	B-CHED
agents	I-CHED
and	O
candidate	O
vaccines	O
against	O
SARS	O
CoV	O
replication	O
.	O

IFN	O
-	O
gamma	O
,	O
IL	O
-	O
18	O
,	O
MCP	B-CHED
-	O
1	O
,	O
MIG	O
,	O
and	O
IP	O
-	O
10	O
were	O
already	O
elevated	O
at	O
early	O
days	O
post	O
fever	O
onset	O
.	O

CoVs	O
enter	O
target	O
cells	O
through	O
fusion	O
of	O
viral	O
and	O
cellular	O
membranes	O
mediated	O
by	O
the	O
viral	O
envelope	O
glycoprotein	B-CHED
S	O
.	O
We	O
have	O
determined	O
by	O
x	O
-	O
ray	O
crystallography	O
the	O
structure	O
of	O
a	O
proteolytically	O
stable	O
core	O
fragment	O
from	O
the	O
heptad	O
repeat	O
(	O
HR	O
)	O
regions	O
HR1	O
and	O
HR2	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Monoclonal	O
antibodies	O
to	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
membrane	O
protein	B-CHED
M	O
were	O
prepared	O
and	O
used	O
for	O
the	O
comparative	O
assessment	O
of	O
three	O
blocking	O
ELISA	O
variants	O
to	O
detect	O
PEDV	O
.	O

Since	O
clinical	O
anti	O
-	O
SARS	O
-	O
CoV	O
activity	O
of	O
type	O
I	O
interferons	O
or	O
ribavirin	B-CHED
is	O
limited	O
,	O
we	O
investigated	O
the	O
combination	O
of	O
IFN	O
-	O
beta	O
and	O
ribavirin	B-CHED
.	O

Determination	O
of	O
the	O
virus	O
yield	O
indicated	O
highly	O
synergistic	O
anti	O
-	O
SARS	O
-	O
CoV	O
action	O
of	O
the	O
combination	O
suggesting	O
the	O
consideration	O
of	O
ribavirin	B-CHED
plus	O
IFN	O
-	O
beta	O
for	O
the	O
treatment	O
of	O
SARS	O
.	O

The	O
basic	O
organization	O
of	O
the	O
coronavirus	O
genome	O
is	O
shared	O
with	O
other	O
members	O
of	O
the	O
Nidovirus	O
order	O
(	O
the	O
torovirus	O
genus	O
,	O
also	O
in	O
the	O
family	O
Coronaviridae	O
,	O
and	O
members	O
of	O
the	O
family	O
Arteriviridae	O
)	O
in	O
that	O
the	O
nonstructural	O
proteins	B-CHED
involved	O
in	O
proteolytic	O
processing	O
,	O
genome	O
replication	O
,	O
and	O
subgenomic	O
mRNA	B-CHED
synthesis	O
(	O
transcription	O
)	O
(	O
an	O
estimated	O
14	O
-	O
16	O
end	O
products	O
for	O
coronaviruses	O
)	O
are	O
encoded	O
within	O
the	O
5	O
'-	O
proximal	O
two	O
-	O
thirds	O
of	O
the	O
genome	O
on	O
gene	O
1	O
and	O
the	O
(	O
mostly	O
)	O
structural	O
proteins	B-CHED
are	O
encoded	O
within	O
the	O
3	O
'-	O
proximal	O
one	O
-	O
third	O
of	O
the	O
genome	O
(	O
8	O
-	O
9	O
genes	O
for	O
coronaviruses	O
).	O

The	O
old	O
model	O
explaining	O
subgenomic	O
mRNA	B-CHED
synthesis	O
,	O
which	O
was	O
called	O
leader	O
-	O
primed	O
transcription	O
,	O
was	O
based	O
on	O
erroneous	O
evidence	O
that	O
only	O
genome	O
-	O
length	O
negative	O
strands	O
were	O
present	O
in	O
replicative	O
intermediates	O
.	O

This	O
chapter	O
reviews	O
(	O
1	O
)	O
the	O
organization	O
of	O
the	O
coronavirus	O
replicase	O
gene	O
,	O
(	O
2	O
)	O
the	O
proteolytic	O
processing	O
of	O
the	O
replicase	O
by	O
viral	O
proteases	O
,	O
(	O
3	O
)	O
the	O
available	O
functional	O
and	O
structural	O
information	O
on	O
individual	O
subunits	O
of	O
the	O
replicase	O
,	O
such	O
as	O
proteases	O
,	O
RNA	O
helicase	O
,	O
and	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
,	O
and	O
(	O
4	O
)	O
the	O
subcellular	O
localization	O
of	O
coronavirus	O
proteins	B-CHED
involved	O
in	O
RNA	O
synthesis	O
.	O

ABSTRACT	O
:	O
As	O
the	O
largest	O
RNA	O
virus	O
,	O
coronavirus	O
replication	O
employs	O
complex	O
mechanisms	O
and	O
involves	O
various	O
viral	O
and	O
cellular	O
proteins	B-CHED
.	O

ABSTRACT	O
:	O
Bioprocess	O
oxidative	O
stress	O
caused	O
by	O
many	O
reactive	B-CHED
oxygen	I-CHED
species	I-CHED
(	O
ROS	B-CHED
)	O
can	O
lead	O
to	O
largely	O
irreversible	O
perturbation	O
of	O
yeast	O
bioprocesses	O
.	O

In	O
addition	O
,	O
there	O
may	O
be	O
a	O
demand	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
antigens	B-CHED
,	O
hepatitis	O
A	O
,	O
B	O
and	O
C	O
viral	O
-	O
selected	O
antigens	B-CHED
,	O
HIV	O
retroviral	O
antigens	B-CHED
,	O
influenza	O
antigens	B-CHED
,	O
trypanosomal	O
antigens	B-CHED
,	O
and	O
foot	O
and	O
mouth	O
disease	O
antigens	B-CHED
.	O

Moreover	O
,	O
proteins	B-CHED
/	O
protein	B-CHED
chaperone	O
couples	O
can	O
recycle	O
electrons	O
,	O
often	O
where	O
futile	O
-	O
recycling	O
systems	O
have	O
been	O
instigated	O
.	O

ABSTRACT	O
:	O
Nidoviruses	O
(	O
Coronaviridae	O
,	O
Arteriviridae	O
,	O
and	O
Roniviridae	O
)	O
encode	O
a	O
nonstructural	O
protein	B-CHED
,	O
called	O
nsp10	O
in	O
arteriviruses	O
and	O
nsp13	O
in	O
coronaviruses	O
,	O
that	O
is	O
comprised	O
of	O
a	O
C	O
-	O
terminal	O
superfamily	O
1	O
helicase	O
domain	O
and	O
an	O
N	O
-	O
terminal	O
,	O
putative	O
zinc	B-CHED
-	O
binding	O
domain	O
(	O
ZBD	O
).	O

Replacement	O
of	O
conserved	O
Cys	B-CHED
or	O
His	O
residues	O
with	O
Ala	B-CHED
proved	O
to	O
be	O
more	O
deleterious	O
than	O
Cys	B-CHED
-	O
for	O
-	O
His	O
or	O
His	O
-	O
for	O
-	O
Cys	B-CHED
replacements	O
.	O

Here	O
we	O
report	O
the	O
discovery	O
of	O
another	O
novel	O
coronavirus	O
,	O
coronavirus	O
HKU1	O
(	O
CoV	O
-	O
HKU1	O
),	O
from	O
a	O
71	O
-	O
year	O
-	O
old	O
man	B-CHED
with	O
pneumonia	O
who	O
had	O
just	O
returned	O
from	O
Shenzhen	O
,	O
China	O
.	O

Mass	O
spectroscopic	O
analysis	O
of	O
N	O
protein	B-CHED
identified	O
phosphorylation	O
sites	O
that	O
were	O
proximal	O
to	O
RNA	O
binding	O
domains	O
.	O

However	O
,	O
phosphorylated	O
N	O
protein	B-CHED
bound	O
to	O
viral	O
RNA	O
with	O
a	O
higher	O
binding	O
affinity	O
than	O
nonviral	O
RNA	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
N	O
protein	B-CHED
determined	O
the	O
recognition	O
of	O
virus	O
RNA	O
.	O

Continuously	O
high	O
SOFA	O
score	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
more	O
significant	O
circulatory	O
instability	O
during	O
the	O
first	O
days	O
of	O
the	O
treatment	O
,	O
expressed	O
by	O
a	O
higher	O
need	O
for	O
the	O
adrenaline	B-CHED
use	O
,	O
and	O
continuously	O
increased	O
CRP	O
values	O
during	O
the	O
follow	O
-	O
up	O
treatment	O
(	O
day	O
7	O
-	O
14	O
,	O
p	O
<	O
0	O
.	O
05	O
),	O
all	O
of	O
it	O
signalized	O
unfavourable	O
results	O
.	O

PIT	O
(	O
50	O
)	O
was	O
dependent	O
on	O
disease	O
severity	O
,	O
showing	O
a	O
strong	O
linear	O
correlation	O
with	O
the	O
clinical	O
parameter	O
duration	O
of	O
oxygen	B-CHED
supplementation	O
(	O
r	O
=	O
0	O
.	O
44	O
,	O
p	O
=	O
0	O
.	O
0015	O
).	O

These	O
infections	O
concern	O
human	O
but	O
also	O
animal	O
viruses	O
affecting	O
wild	O
or	O
tame	B-CHED
animals	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
antibiotic	B-CHED
prescriptions	O
made	O
by	O
general	O
practitioners	O
to	O
French	O
recommendations	O
for	O
the	O
management	O
of	O
Acute	O
Exacerbation	O
of	O
Chronic	O
Bronchitis	O
(	O
AECB	O
)	O
referring	O
to	O
the	O
patient	O
'	O
s	O
socio	O
-	O
demographic	O
data	O
,	O
history	O
of	O
Chronic	O
Bronchitis	O
(	O
CB	O
),	O
current	O
episode	O
management	O
,	O
and	O
quality	O
of	O
life	O
.	O

The	O
antibiotic	B-CHED
(	O
AB	O
)	O
prescriptions	O
concerned	O
mostly	O
group	O
2	O
.	O

In	O
addition	O
,	O
5	O
out	O
of	O
10	O
fecal	O
samples	O
which	O
were	O
negative	O
for	O
PEDV	O
by	O
RT	O
-	O
PCR	O
-	O
based	O
agarose	B-CHED
gel	O
electrophoresis	O
were	O
positive	O
for	O
PEDV	O
by	O
RT	O
-	O
PCR	O
-	O
based	O
dot	O
blot	O
hybridization	O
.	O

Three	O
epidemiologically	O
relevant	O
microbes	O
are	O
the	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)-	O
associated	O
coronavirus	O
,	O
methicillin	B-CHED
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
and	O
Clostridium	O
difficile	O
(	O
C	O
.	O
difficile	O
).	O

In	O
SARS	O
patients	O
with	O
persistent	O
pulmonary	O
fibrosis	O
and	O
under	O
prolonged	O
corticosteroid	B-CHED
treatment	O
,	O
special	O
care	O
should	O
be	O
given	O
to	O
avoid	O
intubation	O
-	O
related	O
tracheal	O
injury	O
during	O
the	O
period	O
of	O
ventilatory	O
support	O
.	O

The	O
M	O
protein	B-CHED
is	O
predicted	O
to	O
contain	O
a	O
triple	O
-	O
spanning	O
transmembrane	O
(	O
TM	O
)	O
region	O
,	O
a	O
single	O
N	O
-	O
glycosylation	O
site	O
near	O
its	O
N	O
-	O
terminus	O
that	O
is	O
in	O
the	O
exterior	O
of	O
the	O
virion	O
,	O
and	O
a	O
long	O
C	O
-	O
terminal	O
region	O
in	O
the	O
interior	O
.	O

TITLE	O
:	O
The	O
structure	O
analysis	O
and	O
antigenicity	O
study	O
of	O
the	O
N	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
The	O
Coronaviridae	O
family	O
is	O
characterized	O
by	O
a	O
nucleocapsid	O
that	O
is	O
composed	O
of	O
the	O
genome	O
RNA	O
molecule	O
in	O
combination	O
with	O
the	O
nucleoprotein	O
(	O
N	O
protein	B-CHED
)	O
within	O
a	O
virion	O
.	O

The	O
abundant	O
antigenic	O
sites	O
predicted	O
in	O
the	O
N	O
protein	B-CHED
,	O
as	O
well	O
as	O
experimental	O
evidence	O
with	O
synthesized	O
polypeptides	B-CHED
,	O
indicate	O
that	O
the	O
N	O
protein	B-CHED
is	O
one	O
of	O
the	O
major	O
antigens	B-CHED
of	O
the	O
SARS	O
-	O
CoV	O
.	O
Compared	O
with	O
other	O
viral	O
structural	O
proteins	B-CHED
,	O
the	O
low	O
variation	O
rate	O
of	O
the	O
N	O
protein	B-CHED
with	O
regards	O
to	O
its	O
size	O
suggests	O
its	O
importance	O
to	O
the	O
survival	O
of	O
the	O
virus	O
.	O

TITLE	O
:	O
The	O
R	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
:	O
analyses	O
of	O
structure	O
and	O
function	O
based	O
on	O
four	O
complete	O
genome	O
sequences	O
of	O
isolates	O
BJ01	O
-	O
BJ04	O
.	O

Western	O
analysis	O
on	O
the	O
purified	O
protein	B-CHED
confirmed	O
the	O
expression	O
and	O
purification	O
of	O
the	O
NC	O
fusion	O
proteins	B-CHED
from	O
yeast	O
.	O

TITLE	O
:	O
The	O
epitope	B-CHED
study	O
on	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
protein	B-CHED
)	O
has	O
been	O
found	O
to	O
be	O
an	O
antigenic	O
protein	B-CHED
in	O
a	O
number	O
of	O
coronaviruses	O
.	O

Whether	O
the	O
N	O
protein	B-CHED
in	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
antigenic	O
remains	O
to	O
be	O
elucidated	O
.	O

A	O
detailed	O
screening	O
of	O
peptide	B-CHED
with	O
ELISA	O
demonstrated	O
that	O
the	O
amino	O
sequence	O
from	O
Codons	O
371	O
to	O
407	O
was	O
the	O
epitope	B-CHED
site	O
at	O
the	O
C	O
-	O
terminus	O
of	O
the	O
N	O
protein	B-CHED
.	O

Antibodies	O
against	O
SARS	O
virus	O
were	O
screened	O
by	O
biopanning	O
with	O
immobilized	O
virus	O
antigen	B-CHED
.	O

The	O
prepared	O
recombinant	O
N	O
protein	B-CHED
and	O
mAbs	O
against	O
N	O
protein	B-CHED
lay	O
the	O
foundation	O
for	O
further	O
development	O
of	O
early	O
diagnosis	O
assays	O
for	O
SARS	O
coronavirus	O
infection	O
.	O

CONCLUSIONS	O
:	O
The	O
prepared	O
recombinant	O
N	O
protein	B-CHED
and	O
mAbs	O
against	O
N	O
protein	B-CHED
lay	O
the	O
foundation	O
for	O
further	O
development	O
of	O
early	O
diagnosis	O
assays	O
for	O
SARS	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
function	O
of	O
lymphocytes	O
and	O
the	O
expression	O
pattern	O
of	O
24	O
repertoire	O
TCR	O
Vbeta	O
in	O
the	O
convalescent	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
after	O
treatment	O
by	O
combination	O
of	O
traditional	O
Chinese	O
and	O
Western	O
medicine	B-CHED
.	O

And	O
the	O
expressions	O
of	O
TCR	O
Vbeta4	O
,	O
Vbeta22	O
and	O
Vbeta23	O
in	O
SARS	O
patients	O
treated	O
with	O
glucocorticoid	B-CHED
(>	O
1	O
000	O
U	O
)	O
were	O
higher	O
than	O
those	O
in	O
SARS	O
patients	O
without	O
treatment	O
.	O

Based	O
on	O
tertiary	O
structural	O
comparisons	O
,	O
we	O
propose	O
the	O
s2m	O
RNA	O
binds	O
one	O
or	O
more	O
proteins	B-CHED
possessing	O
an	O
oligomer	O
-	O
binding	O
-	O
like	O
fold	O
,	O
and	O
we	O
suggest	O
a	O
possible	O
mechanism	O
for	O
SARS	O
viral	O
RNA	O
hijacking	O
of	O
host	O
protein	B-CHED
synthesis	O
,	O
both	O
based	O
upon	O
observed	O
s2m	O
RNA	O
macromolecular	O
mimicry	O
of	O
a	O
relevant	O
ribosomal	B-CHED
RNA	I-CHED
fold	O
.	O

SARS	O
-	O
CoV	O
existed	O
in	O
the	O
air	B-CHED
hospital	O
,	O
where	O
SARS	O
patients	O
were	O
admitted	O
to	O
,	O
but	O
the	O
activity	O
of	O
SARS	O
-	O
CoV	O
in	O
air	B-CHED
samples	O
was	O
rather	O
low	O
.	O

CONCLUSIONS	O
:	O
SARS	O
-	O
CoV	O
existed	O
in	O
the	O
air	B-CHED
hospital	O
,	O
where	O
SARS	O
patients	O
were	O
admitted	O
to	O
,	O
but	O
the	O
activity	O
of	O
SARS	O
-	O
CoV	O
in	O
air	B-CHED
samples	O
was	O
rather	O
low	O
.	O

Western	O
blotting	O
showed	O
that	O
one	O
strain	O
(	O
M2	O
)	O
reacted	O
with	O
68000	O
-	O
Dalton	O
(	O
68KD	O
)	O
protein	B-CHED
and	O
four	O
strains	O
with	O
27000	O
-	O
dalton	O
(	O
27KD	O
)	O
protein	B-CHED
.	O

The	O
full	O
examination	O
was	O
defined	O
as	O
images	O
from	O
the	O
screening	O
examination	O
plus	O
three	O
additional	O
imaging	O
sequences	O
:	O
transverse	O
and	O
coronal	O
T2	O
-	O
weighted	O
imaging	O
and	O
short	O
tau	B-CHED
inversion	O
recovery	O
sequence	O
.	O

Osteonecrosis	O
definitely	O
exists	O
in	O
the	O
minority	O
of	O
health	O
care	O
workers	O
with	O
recovered	O
SARS	O
in	O
Guangzhou	O
,	O
who	O
had	O
treated	O
with	O
steroid	B-CHED
.	O

Dynamic	O
hyperinflation	O
affects	O
tidal	O
ventilation	O
,	O
increases	O
airways	O
resistance	O
,	O
and	O
causes	O
intrinsic	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
auto	O
-	O
PEEP	B-CHED
).	O

Higher	O
arginine	B-CHED
consumption	O
was	O
observed	O
in	O
BMMphi	O
from	O
both	O
strains	O
upon	O
activation	O
with	O
IL	O
-	O
4	O
or	O
IFNgamma	O
which	O
further	O
increased	O
,	O
in	O
this	O
case	O
,	O
when	O
the	O
cells	O
were	O
infected	O
with	O
MHV3	O
.	O

High	O
levels	O
of	O
ornithine	B-CHED
were	O
induced	O
only	O
upon	O
IL	O
-	O
4	O
activation	O
.	O

Upon	O
infection	O
with	O
MHV3	O
,	O
we	O
observed	O
a	O
higher	O
synthesis	O
of	O
spermine	B-CHED
.	O

Altogether	O
these	O
data	O
show	O
the	O
relevance	O
of	O
IFNgamma	O
,	O
from	O
the	O
autocrine	O
or	O
paracrine	O
pathway	O
,	O
and	O
arginine	B-CHED
metabolism	O
for	O
the	O
control	O
of	O
MHV3	O
replication	O
in	O
Mphi	O
of	O
a	O
resistant	O
mouse	O
strain	O
.	O

The	O
treatment	O
regiments	O
included	O
oxygen	B-CHED
,	O
small	O
dosage	O
and	O
short	O
period	O
of	O
methylprednisolone	B-CHED
(	O
1	O
to	O
2	O
mg	O
/	O
kg	O
),	O
use	O
of	O
ventilator	O
,	O
psychological	O
intervention	O
,	O
and	O
treatment	O
of	O
underlying	O
diseases	O
,	O
after	O
which	O
,	O
all	O
the	O
7	O
patients	O
recovered	O
.	O

The	O
monoclonal	O
antibody	O
has	O
good	O
specificity	O
and	O
may	O
be	O
used	O
to	O
detect	O
SARS	O
virus	O
antigen	B-CHED
.	O

CONCLUSIONS	O
:	O
S1	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
,	O
which	O
is	O
responsible	O
for	O
receptor	O
binding	O
,	O
can	O
efficiently	O
and	O
sufficiently	O
induce	O
highly	O
potent	O
neutralizing	O
antibody	O
in	O
mice	O
.	O

Confocal	O
microscopy	O
studies	O
using	O
orf7a	O
and	O
orf7a	O
/	O
CD4	O
chimeras	O
implicate	O
the	O
short	O
cytoplasmic	O
tail	O
and	O
transmembrane	O
domain	O
in	O
trafficking	O
of	O
the	O
protein	B-CHED
within	O
the	O
endoplasmic	O
reticulum	O
and	O
Golgi	O
network	O
.	O

Unexpectedly	O
,	O
Abs	O
that	O
neutralized	O
most	O
human	O
S	O
glycoproteins	B-CHED
enhanced	O
entry	O
mediated	O
by	O
the	O
civet	O
virus	O
S	O
glycoproteins	B-CHED
.	O

In	O
this	O
study	O
,	O
829	O
serum	O
specimens	O
were	O
collected	O
from	O
643	O
patients	O
initially	O
reported	O
to	O
be	O
infected	O
with	O
SARS	O
-	O
CoV	O
.	O
The	O
sera	O
were	O
tested	O
for	O
the	O
N	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
by	O
using	O
an	O
antigen	B-CHED
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
based	O
on	O
monoclonal	O
antibodies	O
against	O
the	O
N	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
and	O
compared	O
to	O
197	O
control	O
serum	O
samples	O
from	O
healthy	O
donors	O
and	O
non	O
-	O
SARS	O
febrile	O
patients	O
.	O

The	O
positive	O
rates	O
of	O
N	O
protein	B-CHED
for	O
sera	O
collected	O
at	O
1	O
to	O
5	O
,	O
6	O
to	O
10	O
,	O
11	O
to	O
15	O
,	O
and	O
16	O
to	O
20	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
for	O
414	O
samples	O
from	O
298	O
serologically	O
confirmed	O
patients	O
were	O
92	O
.	O
9	O
,	O
69	O
.	O
8	O
,	O
36	O
.	O
4	O
,	O
and	O
21	O
.	O
1	O
%,	O
respectively	O
.	O

In	O
conclusion	O
,	O
an	O
antigen	B-CHED
capture	O
ELISA	O
reveals	O
a	O
high	O
N	O
protein	B-CHED
detection	O
rate	O
in	O
acute	O
-	O
phase	O
sera	O
of	O
patients	O
with	O
SARS	O
,	O
which	O
makes	O
it	O
useful	O
for	O
early	O
diagnosis	O
of	O
SARS	O
.	O

We	O
describe	O
a	O
case	O
of	O
varicella	O
infection	O
in	O
a	O
previously	O
healthy	O
young	O
adult	O
complicated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
rhabdomyolysis	O
,	O
acute	O
hepatitis	O
and	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	B-CHED
).	O

Acyclovir	B-CHED
was	O
administered	O
for	O
varicella	O
infection	O
and	O
the	O
ARDS	O
was	O
successfully	O
treated	O
with	O
steroidpulse	O
therapy	O
,	O
hemofiltration	O
and	O
a	O
mechanical	O
respiratory	O
support	O
with	O
a	O
positive	O
end	O
-	O
expiratory	O
pressure	O
.	O

Electric	O
mobility	O
shift	O
assay	O
revealed	O
increased	O
DNA	O
binding	O
activity	O
of	O
the	O
cellular	O
transcription	O
factors	O
activator	O
protein	B-CHED
1	O
(	O
AP	O
-	O
1	O
)	O
and	O
nuclear	O
factor	O
(	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
in	O
SARS	O
-	O
CoV	O
infected	O
cells	O
.	O

Sequencing	O
of	O
amplicon	O
from	O
gene	O
1b	O
revealed	O
more	O
than	O
99	O
%	O
nucleotide	B-CHED
homology	O
with	O
the	O
viral	O
type	O
strains	O
while	O
sequencing	O
amplicon	O
from	O
gene	O
1a	O
permitted	O
the	O
grouping	O
of	O
viral	O
strains	O
.	O

These	O
two	O
N	O
MAbs	O
did	O
not	O
compete	O
for	O
binding	O
to	O
SARS	O
-	O
CoV	O
.	O
Four	O
MAbs	O
reacted	O
with	O
the	O
S	O
glycoprotein	B-CHED
,	O
and	O
three	O
of	O
these	O
MAbs	O
neutralized	O
SARS	O
-	O
CoV	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Nitric	B-CHED
oxide	I-CHED
(	O
NO	O
)	O
is	O
an	O
important	O
signaling	B-CHED
molecule	I-CHED
between	O
cells	O
which	O
has	O
been	O
shown	O
to	O
have	O
an	O
inhibitory	O
effect	O
on	O
some	O
virus	O
infections	O
.	O

TITLE	O
:	O
[	O
Preparation	O
and	O
characterization	O
of	O
monoclonal	O
antibodies	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
].	O

ABSTRACT	O
:	O
To	O
obtain	O
monoclonal	O
antibodies	O
(	O
McAbs	O
)	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
to	O
develop	O
diagnostic	O
test	O
for	O
SARS	O
and	O
study	O
the	O
pathogenesis	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
A	O
64	O
-	O
year	O
-	O
old	O
man	B-CHED
was	O
referred	O
to	O
us	O
because	O
of	O
pneumonia	O
refractory	O
to	O
panipenem	O
/	O
betamipron	O
.	O

It	O
is	O
suggested	O
that	O
administration	O
of	O
methylprednisolone	B-CHED
and	O
sivelestat	O
sodium	O
in	O
combination	O
with	O
intravenous	O
erythromycin	B-CHED
and	O
ciprofloxacin	B-CHED
in	O
a	O
case	O
of	O
severe	O
Legionella	O
pneumonia	O
complicated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
is	O
effective	O
,	O
and	O
may	O
be	O
of	O
use	O
in	O
similar	O
cases	O
.	O

The	O
IFN	O
-	O
induced	O
MxA	O
protein	B-CHED
was	O
detected	O
in	O
the	O
IFN	O
-	O
treated	O
Vero	O
cells	O
.	O

A	O
total	O
of	O
73	O
.	O
3	O
%	O
of	O
patients	O
with	O
PGF	B-CHED
died	O
during	O
hospitalization	O
vs	O
14	O
.	O
2	O
%	O
of	O
patients	O
without	O
PGF	B-CHED
(	O
RR	O
,	O
5	O
.	O
18	O
%;	O
95	O
%	O
CI	O
,	O
3	O
.	O
51	O
to	O
7	O
.	O
63	O
;	O
p	O
<	O
0	O
.	O
001	O
).	O

The	O
median	O
best	O
6MWT	O
distance	O
achieved	O
within	O
the	O
first	O
12	O
months	O
was	O
1	O
,	O
196	O
feet	O
in	O
patients	O
with	O
PGF	B-CHED
vs	O
1	O
,	O
546	O
feet	O
in	O
those	O
without	O
PGF	B-CHED
(	O
p	O
=	O
0	O
.	O
009	O
).	O

Interferon	O
-	O
inducible	O
protein	B-CHED
-	O
10	O
(	O
IP	O
-	O
10	O
)	O
was	O
markedly	O
elevated	O
in	O
the	O
blood	O
during	O
the	O
early	O
stage	O
of	O
SARS	O
,	O
and	O
remained	O
at	O
a	O
high	O
level	O
until	O
convalescence	O
.	O

The	O
prompt	O
elevation	O
of	O
interleukin	O
-	O
6	O
,	O
interleukin	O
-	O
8	O
,	O
and	O
monocyte	O
chemoattractant	O
protein	B-CHED
-	O
1	O
is	O
a	O
sign	O
of	O
superinfection	O
,	O
indicating	O
a	O
high	O
risk	O
of	O
death	O
.	O

Based	O
on	O
the	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
principle	O
using	O
5	O
-[(	O
2	O
'-	O
aminoethyl	O
)-	O
amino	O
]	O
naphthelenesulfonic	O
acid	O
(	O
EDANS	O
)	O
and	O
4	O
-[[	O
4	O
-(	O
dimethylamino	O
)	O
phenyl	B-CHED
]	O
azo	B-CHED
]	O
benzoic	B-CHED
acid	I-CHED
(	O
Dabcyl	O
)	O
as	O
the	O
energy	O
transfer	O
pair	O
,	O
one	O
fluorogenic	O
substrate	O
was	O
designed	O
for	O
the	O
evaluation	O
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
proteolytic	O
activity	O
.	O

For	O
this	O
array	O
system	O
,	O
molecular	O
beacons	O
were	O
conjugated	O
with	O
microspheres	O
using	O
a	O
biotin	B-CHED
-	O
streptavidin	O
linkage	O
.	O

Specific	O
antibody	O
response	O
to	O
this	O
purified	O
recombinant	O
N	O
protein	B-CHED
was	O
100	O
%	O
positive	O
in	O
the	O
SARS	O
patients	O
'	O
sera	O
,	O
while	O
none	O
of	O
the	O
control	O
sera	O
from	O
30	O
healthy	O
people	O
gave	O
a	O
positive	O
reaction	O
in	O
the	O
same	O
assay	O
.	O

Oral	O
immunization	O
of	O
BALB	O
/	O
c	O
mice	O
with	O
recombinant	O
LcS	O
that	O
constitutively	O
expresses	O
the	O
75	O
kDa	O
fragment	O
of	O
the	O
glycoprotein	B-CHED
S	O
,	O
induced	O
both	O
local	O
mucosal	O
and	O
systemic	O
immune	O
responses	O
against	O
TGEV	O
.	O

ABSTRACT	O
:	O
A	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
the	O
detection	O
of	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
messenger	B-CHED
RNA	I-CHED
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
is	O
described	O
.	O

To	O
detect	O
most	O
feline	O
coronavirus	O
field	O
strains	O
,	O
the	O
test	O
was	O
designed	O
to	O
amplify	O
subgenomic	O
mRNA	B-CHED
of	O
the	O
highly	O
conserved	O
M	O
gene	O
.	O

In	O
view	O
of	O
the	O
low	O
rate	O
of	O
false	O
-	O
positive	O
results	O
(	O
high	O
specificity	O
)	O
the	O
mRNA	B-CHED
RT	O
-	O
PCR	O
may	O
be	O
a	O
valuable	O
addition	O
to	O
the	O
diagnostic	O
arsenal	O
for	O
FIP	O
.	O

In	O
recruiters	O
(=	O
6	O
patients	O
),	O
elastance	O
decreased	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
PaO	B-CHED
(	O
2	O
)	O
increased	O
(	O
P	O
<	O
0	O
.	O
005	O
),	O
while	O
in	O
non	O
-	O
recruiters	O
(=	O
6	O
patients	O
)	O
elastance	O
and	O
PaCO	O
(	O
2	O
)	O
significantly	O
increased	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

The	O
development	O
of	O
acute	O
renal	O
impairment	O
is	O
an	O
important	O
negative	O
prognostic	O
indicator	B-CHED
for	O
survival	O
with	O
SARS	O
.	O

TITLE	O
:	O
Chinese	O
herbal	O
medicine	B-CHED
for	O
severe	O
acute	O
respiratory	O
syndrome	O
:	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O

TITLE	O
:	O
Surviving	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
utility	O
of	O
open	O
-	O
lung	O
biopsy	O
and	O
large	O
doses	O
of	O
dexamethasone	B-CHED
.	O

By	O
contrast	O
,	O
IRF	O
-	O
3	O
remained	O
in	O
the	O
nucleus	B-CHED
of	O
cells	O
infected	O
with	O
the	O
IFN	O
-	O
inducing	O
control	O
virus	O
Bunyamwera	O
delNSs	O
.	O

METHODS	O
:	O
Twelve	O
TCM	O
prescriptions	O
of	O
herbal	O
drugs	O
(	O
orally	O
or	O
i	O
.	O
v	O
.)	O
were	O
used	O
to	O
treat	O
16	O
cases	O
of	O
SARS	O
without	O
using	O
glucocorticoids	B-CHED
,	O
anti	B-CHED
-	I-CHED
viral	I-CHED
agents	I-CHED
,	O
immune	O
-	O
regulators	O
or	O
antibiotics	B-CHED
(	O
in	O
case	O
there	O
was	O
no	O
definite	O
bacterial	O
infections	O
).	O

The	O
protein	B-CHED
sequence	O
of	O
the	O
chymotrypsin	O
-	O
like	O
cysteine	B-CHED
proteinase	O
(	O
CCP	B-CHED
)	O
responsible	O
for	O
SARS	O
viral	O
replication	O
has	O
been	O
identified	O
as	O
a	O
target	O
for	O
developing	O
anti	O
-	O
SARS	O
drugs	O
.	O

Ndelta1	O
on	O
the	O
imidazole	B-CHED
ring	O
plays	O
the	O
acid	O
-	O
base	O
catalytic	O
role	O
.	O

The	O
octapeptide	O
thus	O
modified	O
might	O
become	O
an	O
effective	O
inhibitor	B-CHED
or	O
a	O
potential	O
drug	O
candidate	O
against	O
SARS	O
.	O

The	O
ratio	O
of	O
nonsynonymous	O
/	O
synonymous	O
nucleotide	B-CHED
substitution	O
in	O
palm	O
civets	O
collected	O
1	O
yr	O
apart	O
from	O
different	O
geographic	O
locations	O
is	O
very	O
high	O
,	O
suggesting	O
a	O
rapid	O
evolving	O
process	O
of	O
viral	O
proteins	B-CHED
in	O
civet	O
as	O
well	O
,	O
much	O
like	O
their	O
adaptation	O
in	O
the	O
human	O
host	O
in	O
the	O
early	O
2002	O
-	O
2003	O
epidemic	O
.	O

Urine	O
UA	O
and	O
creatinine	B-CHED
levels	O
were	O
available	O
for	O
43	O
patients	O
;	O
the	O
serum	O
cytokines	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
),	O
IL	O
-	O
8	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
were	O
measured	O
in	O
16	O
patients	O
.	O

Measures	O
to	O
prevent	O
nosocomial	O
infection	O
included	O
establishing	O
isolation	O
wards	O
for	O
triage	O
,	O
SARS	O
patients	O
,	O
and	O
step	O
-	O
down	O
;	O
training	O
and	O
monitoring	O
hospital	O
staff	O
in	O
infection	O
-	O
control	O
procedures	O
;	O
active	O
and	O
passive	O
screening	O
of	O
HCWs	O
;	O
enforcement	O
of	O
droplet	O
and	O
contact	O
precautions	O
;	O
and	O
compliance	O
with	O
the	O
use	O
of	O
PPE	B-CHED
.	O

TITLE	O
:	O
The	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
3a	O
protein	B-CHED
may	O
function	O
as	O
a	O
modulator	O
of	O
the	O
trafficking	O
properties	O
of	O
the	O
spike	O
protein	B-CHED
.	O

If	O
this	O
hypothesis	O
is	O
proven	O
,	O
it	O
will	O
indicate	O
that	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
modulates	O
the	O
surface	O
expression	O
of	O
the	O
spike	O
protein	B-CHED
via	O
a	O
different	O
mechanism	O
from	O
other	O
coronaviruses	O
.	O

An	O
appreciable	O
dose	O
-	O
related	O
risk	O
was	O
found	O
for	O
osteonecrosis	O
in	O
patients	O
receiving	O
steroid	B-CHED
therapy	O
for	O
SARS	O
.	O

ABSTRACT	O
:	O
Ten	O
potential	O
reference	O
genes	O
were	O
compared	O
for	O
their	O
use	O
in	O
experiments	O
investigating	O
cellular	O
mRNA	B-CHED
expression	O
of	O
virus	O
infected	O
cells	O
.	O

Peripheral	O
blood	O
microscopy	O
,	O
parasite	O
antigen	B-CHED
-	O
based	O
assays	O
,	O
and	O
parasite	O
18s	O
rRNA	B-CHED
gene	O
-	O
based	O
polymerase	O
chain	O
reaction	O
showed	O
the	O
presence	O
of	O
P	O
.	O
vivax	O
and	O
absence	O
of	O
P	O
.	O
falciparum	O
.	O

To	O
avoid	O
the	O
enhancement	O
antibody	O
issue	O
,	O
genes	O
encoding	O
the	O
nucleocapsid	O
,	O
membrane	O
,	O
and	O
envelope	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
were	O
cloned	O
and	O
their	O
expressions	O
in	O
mammalian	O
cells	O
were	O
determined	O
.	O

The	O
newly	O
generated	O
recombinant	O
MVA	B-CHED
,	O
ADS	O
-	O
MVA	B-CHED
,	O
is	O
replication	O
incompetent	O
in	O
mammalian	O
cells	O
and	O
highly	O
immunogenic	O
in	O
terms	O
of	O
inducing	O
potent	O
neutralizing	O
antibodies	O
in	O
mice	O
,	O
rabbits	O
,	O
and	O
monkeys	O
.	O

Histopathology	O
suggests	O
that	O
acid	O
aspiration	O
induced	O
acute	O
lung	O
injury	O
can	O
be	O
effectively	O
treated	O
by	O
lidocaine	B-CHED
and	O
methylprednisolone	B-CHED
,	O
if	O
applied	O
early	O
.	O

Methylprednisolone	B-CHED
was	O
more	O
effective	O
than	O
lidocaine	B-CHED
at	O
reducing	O
lung	O
damage	O
.	O

TITLE	O
:	O
The	O
transmembrane	O
oligomers	O
of	O
coronavirus	O
protein	B-CHED
E	O
.	O
ABSTRACT	O
:	O
We	O
have	O
tested	O
the	O
hypothesis	O
that	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
protein	B-CHED
E	O
(	O
SCoVE	O
)	O
and	O
its	O
homologs	O
in	O
other	O
coronaviruses	O
associate	O
through	O
their	O
putative	O
transmembrane	O
domain	O
to	O
form	O
homooligomeric	O
alpha	O
-	O
helical	O
bundles	O
in	O
vivo	O
.	O

The	O
second	O
is	O
that	O
protein	B-CHED
E	O
forms	O
the	O
same	O
type	O
of	O
transmembrane	O
oligomer	O
and	O
with	O
identical	O
backbone	O
structure	O
in	O
different	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Glycyrrhizin	B-CHED
(	O
GL	O
)	O
was	O
shown	O
to	O
inhibit	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
replication	O
in	O
vitro	O
.	O

Changes	O
in	O
the	O
lungs	O
may	O
be	O
detected	O
by	O
bronchoscopy	O
with	O
biopsy	O
,	O
xenon	B-CHED
imaging	O
,	O
or	O
measurement	O
of	O
pulmonary	O
extracellular	O
fluid	O
(	O
4	O
,	O
5	O
,	O
8	O
).	O

The	O
objectives	O
of	O
SARS	O
-	O
SP	O
were	O
to	O
1	O
)	O
disseminate	O
and	O
update	O
SARS	O
screening	O
forms	O
for	O
ED	O
triage	O
,	O
2	O
)	O
establish	O
surveillance	O
for	O
SARS	O
syndrome	O
elements	O
by	O
using	O
Regional	O
Emergency	O
Medicine	B-CHED
Internet	O
(	O
REMI	O
),	O
3	O
)	O
expand	O
surveillance	O
to	O
multiple	O
regions	O
,	O
and	O
4	O
)	O
evaluate	O
the	O
usefulness	O
of	O
Internet	O
tools	O
for	O
agile	O
surveillance	O
during	O
a	O
rapidly	O
emerging	O
global	O
epidemic	O
.	O

The	O
patients	O
were	O
placed	O
in	O
prone	O
position	O
for	O
2	O
h	O
.	O
The	O
effect	O
of	O
different	O
time	O
(	O
pre	O
-	O
PPV	B-CHED
,	O
PPV	B-CHED
0	O
.	O
5	O
h	O
,	O
PPV	B-CHED
2	O
h	O
)	O
on	O
oxygenation	O
,	O
respiratory	O
mechanics	O
and	O
hemodynamics	O
were	O
observed	O
.	O

When	O
the	O
antibodies	O
were	O
tested	O
for	O
their	O
ability	O
to	O
inhibit	O
SARS	O
-	O
CoV	O
propagation	O
in	O
Vero	O
E6	O
culture	O
,	O
it	O
was	O
found	O
that	O
the	O
anti	O
-	O
SDelta10	O
antibody	O
,	O
which	O
was	O
targeted	O
to	O
amino	B-CHED
acid	I-CHED
residues	O
1029	O
to	O
1192	O
of	O
S	O
,	O
which	O
include	O
heptad	O
repeat	O
2	O
,	O
has	O
strong	O
neutralizing	O
activities	O
,	O
suggesting	O
that	O
this	O
region	O
of	O
S	O
carries	O
neutralizing	O
epitopes	O
and	O
is	O
very	O
important	O
for	O
virus	O
entry	O
into	O
cells	O
.	O

Immunoassays	O
found	O
that	O
most	O
of	O
the	O
patients	O
who	O
had	O
recovered	O
from	O
SARS	O
developed	O
complementary	O
antibodies	O
to	O
the	O
epitope	B-CHED
-	O
rich	O
region	O
on	O
the	O
spike	O
S2	O
protein	B-CHED
,	O
indicating	O
that	O
this	O
is	O
an	O
immunodominant	O
site	O
on	O
the	O
viral	O
envelope	O
comprising	O
the	O
spike	O
,	O
matrix	O
,	O
and	O
small	O
envelope	O
glycoproteins	B-CHED
.	O

We	O
attempted	O
to	O
predict	O
the	O
air	B-CHED
distribution	O
during	O
the	O
time	O
of	O
measurement	O
in	O
July	O
2003	O
and	O
the	O
time	O
of	O
exposure	O
in	O
March	O
2003	O
.	O

Possible	O
improvement	O
to	O
air	B-CHED
distribution	O
in	O
the	O
hospital	O
ward	O
was	O
also	O
considered	O
.	O

Mycoplasmas	O
were	O
isolated	O
from	O
tracheal	O
rings	O
cultured	O
for	O
several	O
days	O
,	O
suggesting	O
that	O
M	O
.	O
gallisepticum	O
persisted	O
in	O
the	O
trachea	O
despite	O
the	O
enrofloxacin	B-CHED
treatment	O
.	O

Nucleotide	B-CHED
and	O
protein	B-CHED
sequence	O
comparisons	O
suggested	O
that	O
all	O
SCoVs	O
of	O
late	O
epidemic	O
came	O
from	O
human	O
-	O
to	O
-	O
human	O
transmission	O
,	O
while	O
certain	O
SCoVs	O
of	O
early	O
epidemic	O
might	O
have	O
originated	O
in	O
animals	O
.	O

The	O
authors	O
sought	O
to	O
determine	O
whether	O
potential	O
pronation	O
benefits	O
are	O
maintained	O
in	O
post	O
-	O
prone	O
semirecumbent	O
(	O
SR	O
(	O
PP	O
))	O
posture	O
under	O
pressure	O
-	O
volume	O
curve	O
-	O
dependent	O
optimisation	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
).	O

The	O
broad	O
-	O
spectrum	O
molecule	O
ribavirin	B-CHED
was	O
used	O
in	O
SE	O
Asia	O
in	O
infected	O
patients	O
alongside	O
corticosteroids	B-CHED
.	O

This	O
study	O
was	O
conducted	O
to	O
demonstrate	O
whether	O
the	O
protein	B-CHED
X4	O
was	O
expressed	O
and	O
its	O
essential	O
function	O
in	O
the	O
process	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

Western	O
blot	O
was	O
employed	O
to	O
evaluate	O
the	O
expression	O
of	O
protein	B-CHED
X4	O
in	O
SARS	O
-	O
CoV	O
particles	O
.	O

The	O
encoded	O
protein	B-CHED
shared	O
97	O
.	O
79	O
%	O
amino	B-CHED
acid	I-CHED
identities	O
compared	O
with	O
CV777	O
,	O
97	O
.	O
35	O
%	O
with	O
Br1	O
/	O
87	O
,	O
97	O
.	O
79	O
%	O
with	O
JMe2	O
,	O
96	O
.	O
90	O
%	O
with	O
KPEDV	O
-	O
9	O
(	O
Korean	O
field	O
isolate	O
),	O
96	O
.	O
46	O
%	O
with	O
KPEDV	O
-	O
9	O
(	O
Korean	O
).	O

Seven	O
of	O
them	O
were	O
mapped	O
to	O
the	O
specific	O
segments	O
of	O
recombinant	O
spike	O
(	O
S	O
)	O
protein	B-CHED
:	O
six	O
on	O
S1	O
subunit	O
(	O
aa	O
12	O
-	O
798	O
)	O
and	O
one	O
on	O
S2	O
subunit	O
(	O
aa	O
797	O
-	O
1192	O
).	O

ABSTRACT	O
:	O
To	O
provide	O
a	O
comprehensive	O
review	O
of	O
the	O
issue	O
related	O
to	O
the	O
administration	O
of	O
sedative	B-CHED
,	O
analgesic	B-CHED
,	O
and	O
neuromuscular	O
blocking	O
agents	O
(	O
NMBA	O
)	O
to	O
patients	O
who	O
are	O
receiving	O
ventilatory	O
support	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
with	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
.	O

Sedative	B-CHED
,	O
analgesic	B-CHED
,	O
and	O
NMBA	O
are	O
used	O
with	O
great	O
frequency	O
in	O
patients	O
with	O
severe	O
ARDS	O
who	O
are	O
undergoing	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
.	O

In	O
this	O
communication	O
,	O
we	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
two	O
SARS	O
vaccine	O
candidates	O
based	O
on	O
the	O
recombinant	O
modified	O
vaccinia	O
Ankara	O
(	O
MVA	B-CHED
)	O
expressing	O
SARS	O
-	O
CoV	O
spike	O
or	O
nucleocapsid	O
proteins	B-CHED
in	O
ferrets	O
.	O

We	O
show	O
that	O
this	O
method	O
could	O
identify	O
and	O
distinguish	O
between	O
SARS	O
and	O
other	O
known	O
CoV	O
,	O
including	O
the	O
human	O
CoV	O
229E	O
and	O
OC43	O
,	O
individually	O
and	O
in	O
a	O
mixture	B-CHED
of	O
all	O
3	O
human	O
viruses	O
.	O

Toward	O
this	O
goal	O
,	O
we	O
have	O
prepared	O
and	O
characterized	O
soluble	O
full	O
-	O
length	O
nucleocapsid	O
proteins	B-CHED
(	O
N	O
protein	B-CHED
)	O
from	O
SARS	O
and	O
229E	O
human	O
coronaviruses	O
.	O

N	O
proteins	B-CHED
form	O
oligomers	O
,	O
mostly	O
as	O
dimers	O
at	O
low	O
concentration	O
.	O

ABSTRACT	O
:	O
Traditional	O
infection	O
control	O
policies	O
have	O
focused	O
on	O
engineering	O
controls	O
,	O
specific	O
protocols	O
,	O
and	O
personal	O
protective	O
equipment	O
(	O
PPE	B-CHED
).	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
oxymatrine	O
on	O
ALI	O
was	O
investigated	O
using	O
an	O
oleic	B-CHED
acid	I-CHED
-	O
induced	O
ALI	O
mouse	O
model	O
.	O

Morphological	O
findings	O
showed	O
that	O
the	O
oleic	B-CHED
acid	I-CHED
group	O
demonstrated	O
a	O
marked	O
lung	O
injury	O
represented	O
by	O
prominent	O
atelectasis	O
,	O
intraalveolar	O
and	O
interstitial	O
patchy	O
hemorrhage	O
,	O
edema	O
,	O
thickened	O
alveolar	O
septum	O
,	O
formation	O
of	O
hyaline	O
membranes	O
and	O
the	O
existence	O
of	O
inflammatory	O
cells	O
in	O
alveolar	O
spaces	O
.	O

The	O
S1	O
part	O
(	O
1644	O
nucleotides	B-CHED
)	O
of	O
the	O
spike	O
protein	B-CHED
gene	O
of	O
the	O
first	O
known	O
isolate	O
of	O
this	O
serotype	O
,	O
FR	O
/	O
CR85131	O
/	O
85	O
,	O
had	O
95	O
.	O
9	O
%	O
to	O
97	O
%	O
nucleotide	B-CHED
identity	O
with	O
the	O
other	O
isolates	O
.	O

SS2	O
is	O
significantly	O
different	O
from	O
SS1	O
:	O
older	O
age	O
,	O
more	O
surgical	O
stays	O
and	O
admission	O
from	O
external	O
transfer	O
,	O
greater	O
number	O
of	O
organ	O
supports	O
,	O
site	O
of	O
infection	O
(	O
less	O
pulmonary	O
and	O
urinary	O
tract	O
infections	O
,	O
and	O
more	O
abdominal	O
and	O
cardiovascular	O
infections	O
),	O
type	O
of	O
bacteria	O
(	O
more	O
methicillin	B-CHED
-	O
resistant	O
Staphylococcus	O
aureus	O
,	O
Pseudomonas	O
,	O
and	O
fungus	O
),	O
ICU	O
length	O
of	O
stay	O
(	O
20	O
.	O
4	O
d	O
vs	O
11	O
.	O
6	O
d	O
),	O
hospital	O
length	O
of	O
stay	O
(	O
33	O
d	O
vs	O
27	O
.	O
9	O
d	O
),	O
ICU	O
mortality	O
(	O
42	O
.	O
7	O
%	O
vs	O
5	O
.	O
5	O
%),	O
and	O
hospital	O
mortality	O
(	O
49	O
%	O
vs	O
11	O
.	O
3	O
%).	O

Further	O
understanding	O
of	O
how	O
these	O
innate	O
responses	O
participate	O
in	O
immune	O
protection	O
or	O
immunopathology	O
in	O
the	O
CNS	B-CHED
will	O
be	O
critical	O
in	O
efforts	O
to	O
intervene	O
in	O
severe	O
encephalitis	O
.	O

Antigenic	O
screening	O
indicated	O
that	O
recombinant	O
GST	O
-	O
N2	O
fusion	O
protein	B-CHED
,	O
the	O
carboxy	B-CHED
-	O
terminus	O
213aa	O
-	O
423aa	O
of	O
N	O
protein	B-CHED
,	O
was	O
strongest	O
positive	O
and	O
weakest	O
non	O
-	O
specific	O
compared	O
with	O
others	O
.	O

Serum	O
TAC	B-CHED
and	O
lung	O
tissue	O
Na	O
+-	O
K	O
+	O
ATPase	O
activity	O
levels	O
were	O
found	O
to	O
be	O
increased	O
in	O
ILO	O
group	O
compared	O
to	O
IR	O
group	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
).	O

Mice	O
received	O
the	O
affinity	O
-	O
purified	O
protein	B-CHED
with	O
either	O
a	O
saponin	B-CHED
(	O
QS21	O
)	O
or	O
a	O
Ribi	O
(	O
MPL	O
+	O
TDM	O
)	O
adjuvant	B-CHED
subcutaneously	O
and	O
were	O
challenged	O
intranasally	O
with	O
SARS	O
-	O
CoV	O
.	O
Both	O
regimens	O
induced	O
binding	O
and	O
neutralizing	O
antibodies	O
and	O
protection	O
against	O
SARS	O
-	O
CoV	O
intranasal	O
infection	O
.	O

However	O
,	O
the	O
best	O
results	O
were	O
obtained	O
with	O
QS21	O
and	O
protein	B-CHED
,	O
which	O
provided	O
the	O
highest	O
antibody	O
as	O
well	O
as	O
complete	O
protection	O
of	O
the	O
upper	O
and	O
lower	O
respiratory	O
tract	O
.	O

3a	O
was	O
detected	O
in	O
virions	O
purified	O
from	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
E6	O
cells	O
although	O
two	O
truncated	O
products	O
were	O
present	O
predominantly	O
instead	O
of	O
the	O
full	O
-	O
length	O
protein	B-CHED
.	O

In	O
this	O
regard	O
,	O
it	O
is	O
very	O
important	O
to	O
know	O
the	O
epidemic	O
bases	B-CHED
of	O
morbid	O
-	O
mortality	O
of	O
SARS	O
and	O
to	O
keep	O
a	O
world	O
wide	O
surveillance	O
in	O
order	O
to	O
detect	O
possible	O
further	O
cases	O
.	O

Regulated	O
on	O
activation	O
normally	O
T	O
cell	O
-	O
expressed	O
and	O
secreted	O
(	O
RANTES	O
)	O
levels	O
were	O
decreased	O
,	O
while	O
monocyte	O
chemoattractant	O
protein	B-CHED
-	O
1	O
(	O
MCP	B-CHED
-	O
1	O
)	O
was	O
elevated	O
in	O
acute	O
patients	O
.	O

Thus	O
,	O
the	O
present	O
work	O
provides	O
large	O
scale	O
protein	B-CHED
-	O
related	O
information	O
to	O
investigate	O
the	O
mechanism	O
of	O
SARS	O
-	O
CoV	O
infection	O
and	O
pathogenesis	O
.	O

We	O
report	O
here	O
that	O
the	O
3CL	O
(	O
pro	B-CHED
)	O
containing	O
additional	O
N	O
-	O
and	O
/	O
or	O
C	O
-	O
terminal	O
segments	O
of	O
the	O
polyprotein	O
sequences	O
undergoes	O
autoprocessing	O
and	O
yields	O
the	O
mature	O
protease	O
in	O
vitro	O
.	O

The	O
dimeric	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
C145A	O
mutant	O
protease	O
shows	O
that	O
the	O
active	O
site	O
of	O
one	O
protomer	O
binds	O
with	O
the	O
C	O
-	O
terminal	O
six	O
amino	B-CHED
acids	I-CHED
of	O
the	O
protomer	O
from	O
another	O
asymmetric	O
unit	O
,	O
mimicking	O
the	O
product	O
-	O
bound	O
form	O
and	O
suggesting	O
a	O
possible	O
mechanism	O
for	O
maturation	O
.	O

The	O
lower	O
affinity	O
of	O
these	O
S	O
proteins	B-CHED
could	O
be	O
complemented	O
by	O
altering	O
specific	O
residues	O
within	O
the	O
S	O
-	O
protein	B-CHED
-	O
binding	O
site	O
of	O
human	O
ACE2	O
to	O
those	O
of	O
civet	O
ACE2	O
,	O
or	O
by	O
altering	O
S	O
-	O
protein	B-CHED
residues	O
479	O
and	O
487	O
to	O
residues	O
conserved	O
during	O
the	O
2002	O
-	O
2003	O
outbreak	O
.	O

With	O
the	O
use	O
of	O
2	O
databases	O
,	O
we	O
compared	O
the	O
ability	O
of	O
the	O
absolute	O
lymphocyte	O
count	O
,	O
absolute	O
neutrophil	O
count	O
,	O
lactate	B-CHED
dehydrogenase	O
level	O
,	O
creatine	B-CHED
kinase	O
level	O
,	O
alanine	B-CHED
aminotransferase	O
level	O
,	O
and	O
serum	O
calcium	B-CHED
level	O
at	O
hospital	O
admission	O
to	O
discriminate	O
between	O
cases	O
of	O
SARS	O
and	O
cases	O
of	O
community	O
-	O
acquired	O
pneumonia	O
.	O

The	O
purified	O
SARS	O
-	O
CoV	O
rNP	O
was	O
used	O
as	O
an	O
antigen	B-CHED
for	O
detection	O
of	O
SARS	O
-	O
CoV	O
antibodies	O
in	O
IgG	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

CD4	O
+	O
T	O
cells	O
which	O
localize	O
to	O
the	O
perivascular	O
and	O
subarachnoid	O
spaces	O
were	O
identified	O
as	O
the	O
primary	O
source	O
of	O
TIMP	O
-	O
1	O
protein	B-CHED
.	O

Specificity	O
was	O
clearly	O
enhanced	O
when	O
interaction	O
time	O
and	O
stringency	O
(	O
in	O
the	O
form	O
of	O
formamide	B-CHED
percentage	O
)	O
were	O
increased	O
.	O

Some	O
of	O
them	O
produced	O
anti	O
-	O
S	O
Abs	O
early	O
during	O
their	O
infection	O
,	O
while	O
others	O
failed	O
to	O
make	O
IgG	O
Abs	O
against	O
the	O
S450	O
-	O
650	O
polypeptide	B-CHED
.	O

In	O
the	O
absence	O
of	O
CD4	O
(+)	O
T	O
cells	O
,	O
fewer	O
CD8	O
(+)	O
T	O
cells	O
are	O
found	O
within	O
the	O
CNS	B-CHED
in	O
association	O
with	O
a	O
coordinate	O
increase	O
in	O
apoptotic	O
lymphocytes	O
.	O

These	O
data	O
suggest	O
that	O
the	O
cellular	O
immune	O
response	O
to	O
acute	O
neurotropic	O
JHMV	O
infection	O
requires	O
a	O
distinct	O
CD4	O
(+)	O
T	O
cell	O
component	O
,	O
but	O
is	O
independent	O
of	O
a	O
requirement	O
for	O
IL	O
-	O
2	O
for	O
induction	O
,	O
activation	O
,	O
recruitment	O
,	O
and	O
/	O
or	O
maintenance	O
of	O
CD8	O
(+)	O
T	O
cells	O
within	O
the	O
CNS	B-CHED
during	O
acute	O
infection	O
.	O

CONCLUSIONS	O
:	O
These	O
themes	O
,	O
when	O
taken	O
together	O
,	O
describe	O
the	O
essence	B-CHED
of	O
the	O
voyage	O
undertaken	O
by	O
nurses	O
who	O
cared	O
for	O
SARS	O
patients	O
during	O
the	O
outbreak	O
.	O

A	O
phylogenetic	O
analytical	O
tool	O
for	O
combining	O
nucleotide	B-CHED
sequences	O
from	O
6	O
variable	O
regions	O
of	O
a	O
SARS	O
-	O
CoV	O
genome	O
was	O
developed	O
by	O
use	O
of	O
20	O
published	O
SARS	O
-	O
CoV	O
sequences	O
;	O
and	O
this	O
method	O
was	O
validated	O
by	O
use	O
of	O
80	O
published	O
SARS	O
-	O
CoV	O
sequences	O
.	O

Using	O
peak	O
ALT	B-CHED
>	O
5XULN	O
as	O
a	O
cut	O
-	O
off	O
and	O
after	O
adjusting	O
for	O
potential	O
confounding	O
factors	O
,	O
the	O
odds	O
ratio	O
of	O
peak	O
ALT	B-CHED
>	O
5X	O
ULN	O
for	O
oxygen	B-CHED
desaturation	O
was	O
3	O
.	O
24	O
(	O
95	O
%	O
CI	O
1	O
.	O
23	O
-	O
8	O
.	O
59	O
,	O
P	O
=	O
0	O
.	O
018	O
),	O
ICU	O
care	O
was	O
3	O
.	O
70	O
(	O
95	O
%	O
CI	O
1	O
.	O
38	O
-	O
9	O
.	O
89	O
,	O
P	O
=	O
0	O
.	O
009	O
),	O
mechanical	O
ventilation	O
was	O
6	O
.	O
64	O
(	O
95	O
%	O
CI	O
2	O
.	O
22	O
-	O
19	O
.	O
81	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
death	O
was	O
7	O
.	O
34	O
(	O
95	O
%	O
CI	O
2	O
.	O
28	O
-	O
24	O
.	O
89	O
,	O
P	O
=	O
0	O
.	O
001	O
).	O

Ninety	O
-	O
three	O
percent	O
of	O
the	O
survived	O
patients	O
had	O
ALT	B-CHED
levels	O
normalized	O
or	O
were	O
on	O
the	O
improving	O
trend	O
during	O
follow	O
-	O
up	O
.	O

TITLE	O
:	O
Synthetic	O
peptides	B-CHED
derived	O
from	O
SARS	O
coronavirus	O
S	O
protein	B-CHED
with	O
diagnostic	O
and	O
therapeutic	O
potential	O
.	O

The	O
antigenicity	O
and	O
immunoreactivity	O
of	O
all	O
the	O
peptides	B-CHED
were	O
tested	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

By	O
using	O
a	O
syncytia	O
formation	O
model	O
,	O
we	O
tested	O
the	O
neutralization	O
ability	O
of	O
all	O
10	O
peptides	B-CHED
and	O
their	O
corresponding	O
antibodies	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
peak	O
level	O
of	O
C	O
-	O
reactive	O
protein	B-CHED
was	O
the	O
only	O
independent	O
predictor	O
of	O
respiratory	O
failure	O
and	O
intubation	O
(	O
odds	O
ratio	O
for	O
every	O
increment	O
of	O
1	O
mg	O
/	O
dL	O
=	O
1	O
.	O
45	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
1	O
.	O
003	O
,	O
2	O
.	O
097	O
;	O
p	O
=	O
0	O
.	O
048	O
).	O

In	O
one	O
child	O
synthetic	O
ACTH	B-CHED
was	O
stopped	O
because	O
of	O
arterial	O
hypertension	O
.	O

Most	O
patients	O
have	O
been	O
treated	O
throughout	O
the	O
illness	O
with	O
broad	O
-	O
spectrum	O
antimicrobials	B-CHED
,	O
supplemental	O
oxygen	B-CHED
,	O
intravenous	O
fluids	O
,	O
and	O
other	O
supportive	O
measures	O
.	O

Therefore	O
,	O
the	O
RBD	O
of	O
SARS	O
S	O
protein	B-CHED
contains	O
multiple	O
conformational	O
epitopes	O
capable	O
of	O
inducing	O
potent	O
neutralizing	O
Ab	O
responses	O
,	O
and	O
is	O
an	O
important	O
target	O
site	O
for	O
developing	O
vaccines	O
and	O
immunotherapeutics	O
.	O

We	O
constructed	O
primers	O
for	O
inefficient	O
reverse	O
transcription	O
of	O
ribosomal	O
sequences	O
based	O
on	O
the	O
distribution	O
analysis	O
of	O
hexanucleotide	O
patterns	O
in	O
ribosomal	B-CHED
RNA	I-CHED
.	O

The	O
results	O
demonstrated	O
that	O
the	O
subjects	O
either	O
had	O
rarely	O
been	O
exposed	O
to	O
the	O
virus	O
before	O
the	O
2003	O
SARS	O
outbreak	O
or	O
had	O
not	O
been	O
exposed	O
but	O
the	O
nucleocapsid	O
protein	B-CHED
cross	O
-	O
reacted	O
with	O
other	O
antibodies	O
in	O
humans	O
.	O

New	O
studies	O
will	O
be	O
reviewed	O
that	O
have	O
identified	O
some	O
of	O
the	O
causes	O
for	O
treatment	O
failures	O
including	O
the	O
type	O
of	O
pathogen	O
and	O
discordant	O
antimicrobial	B-CHED
therapy	O
.	O

A	O
photochemical	O
treatment	O
(	O
PCT	O
)	O
process	O
with	O
amotosalen	O
-	O
HCl	B-CHED
and	O
long	O
-	O
wavelength	O
ultraviolet	O
light	O
(	O
UVA	O
),	O
which	O
cross	O
-	O
links	O
nucleic	B-CHED
acids	I-CHED
,	O
was	O
developed	O
to	O
inactivate	O
viruses	O
and	O
other	O
pathogens	O
in	O
PLT	O
concentrates	O
.	O

The	O
ACE	O
I	O
/	O
D	O
genotypes	O
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
and	O
agarose	B-CHED
gel	O
electrophoresis	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
validate	O
the	O
Impact	O
of	O
Events	O
Scale	O
(	O
IES	B-CHED
)	O
in	O
a	O
sample	O
of	O
nurses	O
working	O
under	O
threat	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Correlation	O
with	O
the	O
Symptoms	O
Checklist	O
90	O
-	O
R	O
demonstrated	O
the	O
convergent	O
validity	O
of	O
the	O
IES	B-CHED
.	O

The	O
optimized	O
recombinant	O
adenoviral	O
vaccine	O
vectors	O
encoding	O
spike	O
can	O
generate	O
robust	O
antigen	B-CHED
-	O
specific	O
cellular	O
immunity	O
in	O
mice	O
and	O
may	O
potentially	O
be	O
useful	O
for	O
control	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

Surprisingly	O
,	O
one	O
new	O
sgRNA	O
could	O
lead	O
to	O
production	O
of	O
a	O
truncated	O
spike	O
protein	B-CHED
.	O

In	O
addition	O
,	O
tissue	O
samples	O
from	O
22	O
lynx	O
submitted	O
in	O
1999	O
were	O
analyzed	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
to	O
detect	O
nucleic	B-CHED
acids	I-CHED
specific	O
for	O
viral	O
agents	O
and	O
A	O
.	O
phagocytophila	O
.	O

All	O
single	O
and	O
double	O
rooms	O
of	O
INMI	O
are	O
equipped	O
with	O
negative	O
air	B-CHED
pressure	O
,	O
sealed	O
doors	O
,	O
high	O
efficiency	O
particulate	O
air	B-CHED
(	O
HEPA	O
)	O
filters	O
and	O
a	O
fully	O
-	O
equipped	O
anteroom	O
;	O
moreover	O
,	O
a	O
dedicated	O
high	O
isolation	O
unit	O
with	O
a	O
laboratory	O
next	O
door	O
for	O
the	O
initial	O
diagnostic	O
assays	O
is	O
available	O
for	O
admission	O
of	O
sporadic	O
patients	O
requiring	O
high	O
isolation	O
.	O

MDA	B-CHED
levels	O
of	O
the	O
plasma	O
,	O
neutrophil	O
and	O
platelet	O
counts	O
,	O
and	O
arterial	O
blood	O
gases	O
were	O
recorded	O
at	O
the	O
beginning	O
of	O
the	O
study	O
and	O
then	O
at	O
two	O
and	O
five	O
hours	O
.	O

Like	O
S	O
,	O
M	O
acquires	O
high	O
-	O
mannose	B-CHED
N	B-CHED
-	I-CHED
glycans	I-CHED
that	O
are	O
subsequently	O
modified	O
into	O
complex	O
N	B-CHED
-	I-CHED
glycans	I-CHED
in	O
the	O
Golgi	O
.	O

A	O
single	O
inoculation	O
with	O
the	O
RV	O
-	O
based	O
vaccine	O
expressing	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
induced	O
a	O
strong	O
SARS	O
-	O
CoV	O
-	O
neutralizing	O
antibody	O
response	O
.	O

ABSTRACT	O
:	O
In	O
the	O
aftermath	O
of	O
the	O
SARS	O
epidemic	O
,	O
there	O
has	O
been	O
significant	O
progress	O
in	O
understanding	O
the	O
molecular	O
and	O
cell	O
biology	O
of	O
SARS	O
-	O
CoV	O
.	O
Some	O
of	O
the	O
milestones	O
are	O
the	O
availability	O
of	O
viral	O
genome	O
sequence	O
,	O
identification	O
of	O
the	O
viral	O
receptor	O
,	O
development	O
of	O
an	O
infectious	O
cDNA	O
clone	O
,	O
and	O
the	O
identification	O
of	O
viral	O
antigens	B-CHED
that	O
elicit	O
neutralizing	O
antibodies	O
.	O

The	O
primary	O
determinant	O
of	O
the	O
pantropism	O
is	O
the	O
enhanced	O
proteolytic	O
cleavability	O
of	O
the	O
fusion	O
(	O
F	O
)	O
protein	B-CHED
of	O
F1	O
-	O
R	O
,	O
which	O
allows	O
the	O
virus	O
to	O
undergo	O
multiple	O
rounds	O
of	O
replication	O
in	O
many	O
different	O
organs	O
,	O
whereas	O
wild	O
-	O
type	O
virus	O
can	O
only	O
undergo	O
multiple	O
rounds	O
of	O
replication	O
in	O
the	O
lungs	O
.	O

The	O
enhanced	O
cleavability	O
of	O
F1	O
-	O
R	O
F	O
was	O
previously	O
attributed	O
to	O
an	O
amino	B-CHED
acid	I-CHED
change	O
at	O
F115	O
that	O
is	O
adjacent	O
to	O
the	O
cleavage	O
site	O
at	O
amino	B-CHED
acid	I-CHED
116	O
.	O

The	O
microtubule	O
disruption	O
is	O
attributed	O
to	O
two	O
amino	B-CHED
acid	I-CHED
differences	O
in	O
M	O
protein	B-CHED
.	O

TITLE	O
:	O
Recombinant	O
protein	B-CHED
-	O
based	O
ELISA	O
and	O
immuno	O
-	O
cytochemical	O
assay	O
for	O
the	O
diagnosis	O
of	O
SARS	O
.	O

The	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
),	O
three	O
N	O
fragments	O
(	O
N1	O
,	O
N2	O
,	O
and	O
N3	O
)	O
and	O
the	O
intraviral	O
domain	O
of	O
the	O
membrane	O
protein	B-CHED
(	O
M2	O
)	O
were	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
as	O
histidine	B-CHED
-	O
tagged	O
proteins	B-CHED
.	O

Specific	O
hyper	O
-	O
immune	O
sera	O
to	O
SARS	O
-	O
CoV	O
and	O
the	O
recombinant	O
proteins	B-CHED
,	O
N	O
,	O
N1	O
,	O
N2	O
,	O
N3	O
,	O
and	O
M2	O
were	O
also	O
generated	O
in	O
mice	O
and	O
rabbits	O
.	O

Detailed	O
examinations	O
,	O
including	O
the	O
measurement	O
of	O
anti	O
-	O
ganglioside	B-CHED
antibodies	O
and	O
anti	O
-	O
glycoprotein	B-CHED
-	O
IIb	O
-	O
IIIa	O
-	O
IgG	O
-	O
producing	O
B	O
-	O
cells	O
,	O
revealed	O
that	O
he	O
developed	O
AIP	O
and	O
ITP	B-CHED
.	O

ABSTRACT	O
:	O
We	O
studied	O
the	O
adjuvanticity	O
of	O
recombinant	O
Onchocerca	O
volvulus	O
activation	O
associated	O
protein	B-CHED
-	O
1	O
(	O
rOv	O
-	O
ASP	B-CHED
-	O
1	O
)	O
for	O
ovalbumin	O
(	O
OVA	O
)	O
in	O
mice	O
.	O

TITLE	O
:	O
[	O
Detection	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
N	O
protein	B-CHED
by	O
time	O
-	O
resolved	O
fluoroimmunoassay	O
].	O

TITLE	O
:	O
In	O
vitro	O
analysis	O
of	O
a	O
hammerhead	O
ribozyme	O
targeted	O
to	O
infectious	O
bronchitis	O
virus	O
nucleocapsid	O
mRNA	B-CHED
.	O

hAPN	O
-	O
transgenic	O
mice	O
expressed	O
hAPN	O
mRNA	B-CHED
in	O
the	O
kidney	O
,	O
small	O
intestine	O
,	O
liver	O
,	O
and	O
lung	O
.	O

Primary	O
embryonic	O
cells	O
and	O
bone	O
marrow	O
dendritic	O
cells	O
derived	O
from	O
hAPN	O
-	O
transgenic	O
mice	O
also	O
expressed	O
hAPN	O
protein	B-CHED
.	O

The	O
RT	O
-	O
PCR	O
multiplex	O
1	O
and	O
the	O
hemi	O
-	O
nested	O
multiplex	O
1	O
detected	O
1	O
and	O
0	O
.	O
1	O
TCID50	O
of	O
RSV	O
A	O
,	O
respectively	O
,	O
and	O
0	O
.	O
01	O
and	O
0	O
.	O
001	O
TCID50	O
of	O
influenza	O
virus	O
A	O
/	O
H3N2	B-CHED
,	O
respectively	O
.	O

In	O
addition	O
,	O
the	O
inactivation	O
of	O
SARS	O
-	O
CoV	O
in	O
wastewater	O
with	O
sodium	O
hypochlorite	B-CHED
and	O
chlorine	B-CHED
dioxide	I-CHED
was	O
also	O
studied	O
.	O

Free	O
chlorine	B-CHED
was	O
found	O
to	O
inactivate	O
SARS	O
-	O
CoV	O
better	O
than	O
chlorine	B-CHED
dioxide	I-CHED
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
protein	B-CHED
is	O
posttranslationally	O
modified	O
by	O
covalent	O
attachment	O
to	O
the	O
small	O
ubiquitin	O
-	O
like	O
modifier	O
.	O

The	O
major	O
sumoylation	O
site	O
was	O
mapped	O
to	O
the	O
(	O
62	O
)	O
lysine	B-CHED
residue	I-CHED
of	O
the	O
N	O
protein	B-CHED
.	O

Further	O
expression	O
and	O
characterization	O
of	O
wild	O
type	O
N	O
protein	B-CHED
and	O
K62A	O
mutant	O
reveal	O
that	O
sumoylation	O
of	O
the	O
N	O
protein	B-CHED
drastically	O
promotes	O
its	O
homo	O
-	O
oligomerization	O
,	O
and	O
plays	O
certain	O
roles	O
in	O
the	O
N	O
protein	B-CHED
-	O
mediated	O
interference	O
of	O
host	O
cell	O
division	O
.	O

TITLE	O
:	O
Recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
forms	O
a	O
dimer	O
through	O
its	O
C	O
-	O
terminal	O
domain	O
.	O

However	O
,	O
seven	O
years	O
after	O
the	O
onset	O
of	O
the	O
disease	O
and	O
four	O
months	O
after	O
the	O
termination	O
of	O
imatinib	B-CHED
treatment	O
the	O
patient	O
died	O
of	O
a	O
cerebral	O
hemorrhage	O
that	O
occurred	O
during	O
an	O
episode	O
of	O
acute	O
respiratory	O
sepsis	O
.	O

Imatinib	B-CHED
has	O
been	O
previously	O
reported	O
to	O
be	O
effective	O
in	O
some	O
hematological	O
conditions	O
with	O
no	O
evidence	O
of	O
the	O
BCR	O
/	O
ABL	B-CHED
transcript	O
.	O

In	O
present	O
work	O
,	O
we	O
sought	O
to	O
characterize	O
the	O
replication	O
of	O
SARS	O
-	O
CoV	O
at	O
the	O
presence	O
of	O
RANTES	O
in	O
THP	B-CHED
-	O
1	O
cells	O
.	O

Macrophages	O
,	O
induced	O
by	O
THP	B-CHED
-	O
1	O
cells	O
,	O
were	O
used	O
as	O
cell	O
model	O
.	O

Sequence	O
analysis	O
predicted	O
that	O
IBV	O
3a	O
was	O
a	O
membrane	O
protein	B-CHED
;	O
however	O
,	O
only	O
a	O
fraction	O
behaved	O
like	O
an	O
integral	O
membrane	O
protein	B-CHED
.	O

These	O
findings	O
were	O
confirmed	O
by	O
semiquantitative	O
reverse	O
transcription	O
-	O
PCR	O
,	O
reverse	O
transcription	O
-	O
quantitative	O
PCR	O
for	O
mRNA	B-CHED
of	O
genes	O
,	O
and	O
immunoassays	O
for	O
some	O
encoded	O
proteins	B-CHED
.	O

Hydrogen	B-CHED
cyanamide	B-CHED
is	O
highly	O
toxic	O
,	O
and	O
adverse	O
health	O
effects	O
from	O
contact	O
include	O
severe	O
irritation	O
and	O
ulceration	O
of	O
the	O
eyes	O
,	O
skin	O
,	O
and	O
respiratory	O
tract	O
.	O

RESULTS	O
:	O
An	O
increase	O
of	O
each	O
10	O
microg	O
/	O
m3	O
over	O
a	O
5	O
-	O
day	O
moving	O
average	O
of	O
PM10	O
,	O
SO2	B-CHED
and	O
NO2	B-CHED
corresponded	O
to	O
1	O
.	O
06	O
(	O
1	O
.	O
00	O
-	O
1	O
.	O
12	O
),	O
0	O
.	O
74	O
(	O
0	O
.	O
48	O
-	O
1	O
.	O
13	O
)	O
and	O
1	O
.	O
22	O
(	O
1	O
.	O
01	O
-	O
1	O
.	O
48	O
)	O
relative	O
risks	O
(	O
RRs	O
)	O
of	O
daily	O
SARS	O
mortality	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
of	O
SARS	O
coronavirus	O
(	O
SARS_CoV	O
)	O
is	O
a	O
major	O
structural	O
component	O
of	O
virions	O
,	O
which	O
appears	O
to	O
be	O
a	O
multifunctional	O
protein	B-CHED
involved	O
in	O
viral	O
RNA	O
replication	O
and	O
translation	O
.	O

GST	O
pull	O
-	O
down	O
results	O
clearly	O
demonstrated	O
that	O
SARS_N	O
protein	B-CHED
could	O
directly	O
and	O
specifically	O
bind	O
to	O
human	O
hnRNP	O
A1	O
in	O
vitro	O
.	O

TITLE	O
:	O
Dynamic	O
changes	O
in	O
clinical	O
features	O
and	O
cytokine	O
/	O
chemokine	O
responses	O
in	O
SARS	O
patients	O
treated	O
with	O
interferon	O
alfacon	O
-	O
1	O
plus	O
corticosteroids	B-CHED
.	O

We	O
report	O
on	O
serum	O
cytokine	O
levels	O
,	O
viral	O
load	O
and	O
clinical	O
parameters	O
over	O
the	O
course	O
of	O
the	O
disease	O
in	O
a	O
cohort	O
of	O
nine	O
adult	O
SARS	O
patients	O
treated	O
with	O
steroids	B-CHED
and	O
interferon	O
alfacon	O
-	O
1	O
at	O
North	O
York	O
General	O
Hospital	O
in	O
Toronto	O
,	O
Ontario	O
.	O

We	O
report	O
the	O
personal	O
respiratory	O
protection	O
and	O
environmental	O
control	O
measures	O
implemented	O
to	O
minimize	O
the	O
risk	O
of	O
droplets	O
spread	O
during	O
these	O
procedures	O
,	O
including	O
re	O
-	O
engineering	O
of	O
the	O
ventilation	O
system	O
of	O
the	O
cardiac	O
catheterization	O
laboratory	O
(	O
CCL	B-CHED
).	O

ABSTRACT	O
:	O
This	O
paper	O
describes	O
mapping	O
of	O
antigenic	O
and	O
host	O
-	O
protective	O
epitopes	O
of	O
infectious	O
bronchitis	O
virus	O
proteins	B-CHED
by	O
assessing	O
the	O
ability	O
of	O
defined	O
peptide	B-CHED
regions	O
within	O
the	O
S1	O
,	O
S2	O
and	O
N	O
proteins	B-CHED
to	O
elicit	O
humoral	O
,	O
cell	O
-	O
mediated	O
and	O
protective	O
immune	O
responses	O
.	O

Hemodynamic	O
stabilization	O
and	O
resuscitation	O
required	O
low	O
doses	O
of	O
epinephrine	B-CHED
,	O
diuretics	B-CHED
,	O
and	O
a	O
high	O
concentration	O
of	O
inspired	O
oxygen	B-CHED
in	O
combination	O
with	O
bronchodilators	O
.	O

ABSTRACT	O
:	O
Monoclonal	O
antibodies	O
(	O
mAb	O
)	O
to	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
nucleoprotein	O
(	O
N	O
)	O
and	O
membrane	O
protein	B-CHED
(	O
M	O
)	O
were	O
prepared	O
and	O
used	O
for	O
the	O
comparative	O
assessment	O
of	O
three	O
blocking	O
ELISA	O
variants	O
to	O
detect	O
TGEV	O
.	O

Among	O
the	O
rabbit	O
antisera	O
to	O
recombinant	O
proteins	B-CHED
S3	O
,	O
N	O
,	O
3a	O
and	O
9b	O
,	O
only	O
anti	O
-	O
S3	O
serum	O
showed	O
significant	O
neutralizing	O
activity	O
to	O
the	O
SARS	O
-	O
CoV	O
infection	O
in	O
Vero	O
E6	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	B-CHED
))	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
plays	O
key	O
roles	O
in	O
viral	O
replication	O
and	O
is	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
SARS	O
drug	O
discovery	O
.	O

In	O
this	O
report	O
,	O
a	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)-	O
based	O
method	O
was	O
developed	O
to	O
assess	O
the	O
proteolytic	O
activity	O
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
).	O

SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
seemed	O
to	O
work	O
more	O
efficiently	O
on	O
1NC	O
than	O
on	O
2NC	O
in	O
trans	O
-	O
cleavage	O
assay	O
.	O

Antibodies	O
recognizing	O
domain	O
III	O
could	O
significantly	O
inhibit	O
the	O
enzymatic	O
activity	O
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
).	O

Inspection	O
of	O
the	O
overlap	O
regions	O
between	O
ORF1a	O
and	O
ORF1b	O
of	O
the	O
SARS	O
-	O
CoV	O
genome	O
revealed	O
that	O
,	O
similar	O
to	O
all	O
coronaviruses	O
,	O
a	O
programmed	O
-	O
1	O
ribosomal	O
frameshift	O
could	O
be	O
used	O
by	O
the	O
virus	O
to	O
produce	O
a	O
fusion	O
protein	B-CHED
.	O

Five	O
mAbs	O
reacted	O
against	O
the	O
S	O
protein	B-CHED
,	O
two	O
against	O
the	O
M	O
protein	B-CHED
,	O
and	O
one	O
each	O
against	O
the	O
N	O
and	O
E	O
proteins	B-CHED
.	O

Based	O
on	O
the	O
activity	O
of	O
SARS	O
(	O
WW	O
-	O
I	O
),	O
we	O
propose	O
that	O
the	O
hydrophobic	O
stretch	O
of	O
19	O
aa	O
corresponding	O
to	O
residues	O
770	O
to	O
788	O
is	O
a	O
fusion	O
peptide	B-CHED
of	O
the	O
SARS	O
-	O
CoV	O
S2	O
subunit	O
.	O

Triterpene	B-CHED
glycyrrhizic	B-CHED
acid	I-CHED
(	O
GL	O
)	O
inhibits	O
SARS	O
-	O
CoV	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
associated	O
coronavirus	O
)	O
replication	O
.	O

CDV	B-CHED
,	O
may	O
be	O
useful	O
against	O
orthopoxvirus	O
infections	O
in	O
humans	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
evaluation	O
of	O
isatin	B-CHED
derivatives	O
as	O
effective	O
SARS	O
coronavirus	O
3CL	O
protease	B-CHED
inhibitors	I-CHED
.	O

An	O
analysis	O
of	O
receptor	O
engagement	O
revealed	O
that	O
NL63	O
-	O
S	O
binds	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
2	O
,	O
the	O
receptor	O
for	O
SARS	O
-	O
CoV	O
,	O
and	O
HCoV	O
-	O
NL63	O
uses	O
ACE2	O
as	O
a	O
receptor	O
for	O
infection	O
of	O
target	O
cells	O
.	O

The	O
result	O
of	O
sequencing	O
and	O
sequence	O
comparison	O
with	O
other	O
SARS	O
-	O
CoV	O
strains	O
showed	O
that	O
nsp2	O
gene	O
was	O
relatively	O
conservative	O
during	O
the	O
transmission	O
and	O
total	O
five	O
base	O
sites	O
mutated	O
in	O
about	O
100	O
strains	O
investigated	O
,	O
three	O
of	O
which	O
in	O
the	O
early	O
and	O
middle	O
phases	O
caused	O
synonymous	O
mutation	O
,	O
and	O
another	O
two	O
base	O
sites	O
variation	O
in	O
the	O
late	O
phase	O
resulted	O
in	O
the	O
amino	B-CHED
acid	I-CHED
substitutions	O
and	O
secondary	O
structure	O
changes	O
.	O

The	O
introduction	O
of	O
RNAi	O
plasmid	O
efficiently	O
and	O
specifically	O
inhibited	O
the	O
synthesis	O
of	O
protein	B-CHED
N	O
.	O
RT	O
-	O
PCR	O
showed	O
that	O
RNAs	O
of	O
N	O
gene	O
were	O
clearly	O
reduced	O
when	O
the	O
pEGFP	O
-	O
C1	O
-	O
N	O
was	O
cotransfected	O
with	O
pshRNA	O
-	O
N	O
,	O
whereas	O
the	O
control	O
vector	O
did	O
not	O
exhibit	O
inhibitory	O
effect	O
on	O
N	O
gene	O
transcription	O
.	O

The	O
introduction	O
of	O
RNAi	O
plasmid	O
efficiently	O
and	O
specifically	O
inhibited	O
the	O
synthesis	O
of	O
protein	B-CHED
N	O
.	O
RT	O
-	O
PCR	O
showed	O
that	O
RNAs	O
of	O
N	O
gene	O
were	O
clearly	O
reduced	O
when	O
the	O
pEGFP	O
-	O
C1	O
-	O
N	O
was	O
cotransfected	O
with	O
pshRNA	O
-	O
N	O
,	O
whereas	O
the	O
control	O
vector	O
did	O
not	O
exhibit	O
inhibitory	O
effect	O
on	O
N	O
gene	O
transcription	O
.	O

ABSTRACT	O
:	O
The	O
activity	O
of	O
inosine	B-CHED
-	O
5	O
'-	O
monophosphate	O
dehydrogenase	O
(	O
IMPDH	O
)	O
inhibitors	B-CHED
,	O
mizoribine	O
and	O
ribavirin	B-CHED
,	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
was	O
determined	O
by	O
plaque	O
reduction	O
and	O
yield	O
reduction	O
assays	O
.	O

Mizoribine	O
inhibited	O
replication	O
of	O
SARS	O
-	O
CoV	O
more	O
strongly	O
than	O
ribavirin	B-CHED
.	O

The	O
current	O
study	O
was	O
undertaken	O
to	O
clarify	O
whether	O
furosemide	B-CHED
attenuates	O
the	O
inflammatory	O
response	O
by	O
changing	O
the	O
epidermal	O
growth	O
factor	O
level	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
.	O

Hospital	O
water	B-CHED
should	O
be	O
Legionella	O
-	O
free	O
,	O
and	O
high	O
-	O
risk	O
patients	O
,	O
especially	O
those	O
with	O
prolonged	O
granulocytopenia	O
or	O
organ	O
transplants	O
,	O
should	O
be	O
cared	O
for	O
in	O
hospital	O
units	O
with	O
high	O
-	O
efficiency	O
-	O
particulate	O
-	O
arrestor	O
(	O
HEPA	O
)	O
filtered	O
air	B-CHED
.	O

SARS	O
-	O
CoV	O
diluted	O
to	O
2	O
PFU	B-CHED
failed	O
to	O
establish	O
persistence	O
,	O
suggesting	O
that	O
some	O
particular	O
viruses	O
in	O
the	O
seed	O
virus	O
did	O
not	O
induce	O
persistent	O
infection	O
.	O

Our	O
previous	O
studies	O
demonstrated	O
that	O
signaling	O
pathways	O
of	O
extracellular	O
signal	O
-	O
related	O
kinase	O
(	O
ERK1	O
/	O
2	O
),	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
protein	B-CHED
kinase	O
(	O
JNK	O
),	O
p38	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinase	O
(	O
MAPK	O
),	O
and	O
phosphatidylinositol	B-CHED
3	O
'-	O
kinase	O
(	O
PI3K	O
)/	O
Akt	O
were	O
activated	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

Molecular	O
modelling	O
of	O
the	O
SARS	O
-	O
CoV	O
peplomer	O
suggests	O
that	O
three	O
of	O
these	O
antiviral	B-CHED
peptides	B-CHED
map	O
to	O
the	O
interfaces	O
between	O
the	O
three	O
monomers	O
of	O
the	O
trimeric	O
peplomer	O
rather	O
than	O
the	O
heptad	O
repeat	O
region	O
from	O
which	O
short	O
peptides	B-CHED
are	O
known	O
to	O
inhibit	O
viral	O
entry	O
.	O

Thus	O
the	O
existence	O
of	O
ARDS	O
in	O
the	O
context	O
of	O
an	O
APS	B-CHED
makes	O
it	O
necessary	O
to	O
rule	O
out	O
the	O
presence	O
of	O
the	O
catastrophic	O
variant	O
of	O
this	O
syndrome	O
.	O

There	O
were	O
no	O
differences	O
in	O
age	O
,	O
sex	O
,	O
precipitating	O
factors	O
,	O
clinical	O
manifestations	O
,	O
or	O
mortality	O
between	O
catastrophic	O
APS	B-CHED
patients	O
with	O
and	O
without	O
ARDS	O
.	O

SARS	O
-	O
CoV	O
initiated	O
viral	O
gene	O
transcription	O
and	O
protein	B-CHED
synthesis	O
in	O
macrophages	O
,	O
but	O
replication	O
was	O
abortive	O
and	O
no	O
infectious	O
virus	O
was	O
produced	O
.	O

Antibodies	O
against	O
the	O
hypothetical	O
(	O
SARS	O
3a	O
,	O
3b	O
,	O
6	O
,	O
7a	O
and	O
9b	O
)	O
and	O
structural	O
proteins	B-CHED
(	O
envelope	O
,	O
membrane	O
,	O
nucleocapsid	O
and	O
spike	O
)	O
of	O
the	O
coronavirus	O
were	O
generated	O
from	O
predicted	O
antigenic	O
epitopes	O
of	O
each	O
protein	B-CHED
.	O

The	O
concentration	O
of	O
perfume	B-CHED
was	O
separately	O
measured	O
by	O
4	O
groups	O
of	O
lab	O
workers	O
and	O
recorded	O
blindly	O
by	O
the	O
scores	O
of	O
""""	O
tenth	O
degree	O
"""."	O

Tracer	B-CHED
gas	O
was	O
detected	O
from	O
the	O
wards	O
of	O
8th	O
to	O
13th	O
floor	O
.	O

TITLE	O
:	O
Withdrawal	O
of	O
fluticasone	B-CHED
propionate	I-CHED
from	O
combined	O
salmeterol	B-CHED
/	O
fluticasone	O
treatment	O
in	O
patients	O
with	O
COPD	O
causes	O
immediate	O
and	O
sustained	O
disease	O
deterioration	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

Combined	O
treatment	O
with	O
ICS	O
and	O
long	O
acting	O
beta2	O
agonists	B-CHED
(	O
LABA	O
)	O
may	O
provide	O
benefit	O
to	O
the	O
stability	O
of	O
COPD	O
,	O
but	O
it	O
is	O
unknown	O
if	O
withdrawal	O
of	O
ICS	O
will	O
result	O
in	O
disease	O
deterioration	O
.	O

METHODS	O
:	O
Hematoxylin	B-CHED
and	O
eosin	O
staining	O
and	O
light	O
microscopy	O
were	O
used	O
to	O
examine	O
the	O
histology	O
of	O
the	O
thyroid	O
tissues	O
from	O
4	O
dead	O
SARS	O
patients	O
and	O
5	O
healthy	O
thyroid	O
samples	O
used	O
as	O
negative	O
controls	O
.	O

The	O
virally	O
encoded	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
Pro	B-CHED
))	O
has	O
been	O
presumed	O
critical	O
for	O
the	O
viral	O
replication	O
of	O
SARS	O
-	O
CoV	O
in	O
infected	O
host	O
cells	O
.	O

CONCLUSIONS	O
:	O
The	O
greater	O
serum	O
CRP	O
elevation	O
after	O
distal	O
type	O
AAD	B-CHED
was	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
oxygenation	O
impairment	O
and	O
poor	O
clinical	O
outcome	O
.	O

The	O
SD	O
treatment	O
irreversibly	O
disrupts	O
the	O
lipid	B-CHED
envelope	O
of	O
viruses	O
such	O
as	O
HIV	O
,	O
HBV	O
,	O
HCV	O
,	O
HGV	O
and	O
CMV	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
proteins	B-CHED
belong	O
to	O
a	O
large	O
group	O
of	O
proteins	B-CHED
that	O
is	O
difficult	O
to	O
express	O
in	O
traditional	O
expression	O
systems	O
.	O

We	O
have	O
exploited	O
the	O
natural	O
chaperoning	O
properties	O
of	O
SUMO	O
to	O
develop	O
an	O
expression	O
system	O
suitable	O
for	O
proteins	B-CHED
that	O
cannot	O
be	O
expressed	O
by	O
traditional	O
methodologies	O
.	O

Our	O
study	O
suggests	O
that	O
the	O
SUMO	O
-	O
fusion	O
technology	O
will	O
be	O
useful	O
for	O
enhancing	O
expression	O
and	O
purification	O
of	O
the	O
viral	O
proteins	B-CHED
for	O
structural	O
and	O
functional	O
studies	O
as	O
well	O
as	O
for	O
therapeutic	O
uses	O
.	O

BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
purified	O
recombinant	O
N	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
for	O
producing	O
mAbs	O
,	O
and	O
New	O
Zealand	O
white	O
rabbits	O
were	O
immunized	O
for	O
producing	O
polyclonal	O
antibodies	O
.	O

Using	O
paired	O
ELISA	O
assay	O
,	O
three	O
mAbs	O
N1E8	O
,	O
N8E1	O
and	O
N10E4	O
were	O
selected	O
as	O
capturing	O
antibody	O
and	O
rabbit	O
polyclonal	O
antibodies	O
as	O
detecting	O
antibody	O
then	O
triple	O
antibodies	O
-	O
based	O
sandwich	O
ELISA	O
was	O
established	O
following	O
horseradish	O
peroxidase	O
(	O
HRP	O
)-	O
conjugated	O
goat	O
anti	O
-	O
rabbit	O
immunoglobulin	O
G	O
.	O
The	O
recombinant	O
N	O
protein	B-CHED
was	O
used	O
as	O
a	O
standard	O
to	O
establish	O
a	O
detection	O
sensitivity	O
of	O
approximated	O
50	O
pg	O
/	O
ml	O
with	O
this	O
assay	O
.	O

By	O
paired	O
and	O
optimized	O
sandwich	O
ELISA	O
,	O
a	O
sensitive	O
and	O
specific	O
antigen	B-CHED
capture	O
ELISA	O
was	O
established	O
for	O
detecting	O
N	O
antigen	B-CHED
of	O
SARS	O
-	O
CoV	O
,	O
which	O
might	O
apply	O
to	O
early	O
diagnosis	O
,	O
source	O
tracing	O
and	O
epidemiological	O
studies	O
of	O
SARS	O
.	O

RESULTS	O
:	O
Nine	O
mAbs	O
and	O
hyperimmune	O
rabbit	O
polyclonal	O
antibodies	O
,	O
specifically	O
against	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
were	O
obtained	O
.	O

ABSTRACT	O
:	O
Two	O
kinds	O
of	O
FeIFN	O
-	O
alpha	O
consisting	O
of	O
166	O
amino	B-CHED
acids	I-CHED
(	O
aa	O
)	O
and	O
171	O
aa	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
and	O
the	O
purified	O
proteins	B-CHED
were	O
tested	O
for	O
antiviral	B-CHED
activity	O
on	O
homologous	O
and	O
heterologous	O
animal	O
cells	O
.	O

One	O
group	O
of	O
piglets	O
served	O
as	O
a	O
control	O
(	O
n	O
=	O
8	O
),	O
a	O
second	O
group	O
(	O
S	O
,	O
n	O
=	O
8	O
)	O
received	O
a	O
porcine	O
surfactant	B-CHED
preparation	O
(	O
Curosurf	O
),	O
and	O
a	O
third	O
group	O
received	O
IKK	O
-	O
NBD	O
peptide	B-CHED
admixed	O
to	O
surfactant	B-CHED
(	O
S	O
+	O
IN	O
,	O
n	O
=	O
8	O
).	O

After	O
6	O
hrs	O
of	O
mechanical	O
ventilation	O
after	O
intervention	O
,	O
S	O
+	O
IN	O
group	O
piglets	O
showed	O
decreased	O
extravascular	O
lung	O
water	B-CHED
(	O
S	O
+	O
IN	O
vs	O
.	O
S	O
,	O
20	O
+/-	O
3	O
vs	O
.	O
28	O
+/-	O

10	O
mL	O
/	O
kg	O
;	O
p	O
<	O
.	O
05	O
)	O
and	O
a	O
lesser	O
protein	B-CHED
content	O
in	O
the	O
epithelial	O
lining	O
fluid	O
(	O
S	O
+	O
IN	O
vs	O
.	O
S	O
,	O
38	O
+/-	O
5	O
vs	O
.	O
50	O
+/-	O

Strikingly	O
,	O
live	O
SARS	O
-	O
CoV	O
could	O
further	O
prime	O
cell	O
types	O
to	O
respond	O
to	O
a	O
suboptimal	O
dose	O
of	O
bacterial	O
LPS	B-CHED
(	O
100	O
ng	O
/	O
ml	O
),	O
resulting	O
in	O
massive	O
release	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
12	O
.	O

Positive	O
SARS	O
-	O
Co	O
virus	O
IgG	O
antibody	O
results	O
were	O
seen	O
in	O
208	O
of	O
258	O
patients	O
,	O
with	O
21	O
.	O
3	O
%	O
(	O
55	O
of	O
258	O
patients	O
)	O
still	O
having	O
a	O
pulmonary	O
diffusion	O
abnormality	O
(	O
D	O
(	O
LCO	B-CHED
)	O
<	O
80	O
%	O
of	O
predicted	O
).	O

RESULTS	O
:	O
Positive	O
SARS	O
-	O
Co	O
virus	O
IgG	O
antibody	O
results	O
were	O
seen	O
in	O
208	O
of	O
258	O
patients	O
,	O
with	O
21	O
.	O
3	O
%	O
(	O
55	O
of	O
258	O
patients	O
)	O
still	O
having	O
a	O
pulmonary	O
diffusion	O
abnormality	O
(	O
D	O
(	O
LCO	B-CHED
)	O
<	O
80	O
%	O
of	O
predicted	O
).	O

In	O
view	O
of	O
studying	O
the	O
MHV3	O
binding	O
to	O
cells	O
or	O
cell	O
extracts	O
,	O
we	O
performed	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
-	O
like	O
virus	O
-	O
binding	O
assay	O
,	O
preparing	O
microplates	O
with	O
L929	O
cells	O
,	O
A	O
/	O
J	O
or	O
BALB	O
/	O
c	O
mouse	O
macrophages	O
and	O
also	O
with	O
proteins	B-CHED
extracted	O
from	O
these	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
severity	O
and	O
global	O
spread	O
of	O
the	O
2003	O
outbreak	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
highlighted	O
the	O
risks	O
to	O
human	O
health	O
posed	O
by	O
emerging	O
viral	O
diseases	O
and	O
emphasized	O
the	O
need	O
for	O
specific	O
therapeutic	O
agents	O
instead	O
of	O
relying	O
on	O
existing	O
broadly	O
active	O
antiviral	B-CHED
compounds	O
.	O

ABSTRACT	O
:	O
The	O
viroporin	O
activity	O
of	O
the	O
E	O
protein	B-CHED
from	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
a	O
member	O
of	O
the	O
coronaviruses	O
,	O
was	O
analyzed	O
.	O

Mammalian	O
cells	O
are	O
also	O
readily	O
permeabilized	O
by	O
the	O
expression	O
of	O
MHV	O
E	O
protein	B-CHED
.	O

TITLE	O
:	O
Longitudinal	O
alteration	O
of	O
circulating	O
dendritic	O
cell	O
subsets	O
and	O
its	O
correlation	O
with	O
steroid	B-CHED
treatment	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

A	O
significant	O
inverse	O
correlation	O
was	O
found	O
between	O
numbers	O
of	O
DC	O
and	O
T	O
-	O
cell	O
subsets	O
and	O
high	O
-	O
dose	O
steroid	B-CHED
treatment	O
.	O

RNA	O
interference	O
(	O
RNAi	O
)	O
is	O
a	O
process	O
in	O
cell	O
to	O
degradation	O
specific	O
target	O
mRNA	B-CHED
by	O
double	O
-	O
stranded	O
RNA	O
.	O

The	O
recombinant	O
N	O
protein	B-CHED
was	O
demonstrated	O
highly	O
antigenic	O
and	O
could	O
be	O
employed	O
as	O
antigen	B-CHED
to	O
detect	O
SARS	O
antibodies	O
in	O
ELISA	O
system	O
for	O
SARS	O
diagnosis	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
heat	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
elicited	O
recall	O
CTL	O
responses	O
to	O
newly	O
identified	O
spike	O
protein	B-CHED
-	O
derived	O
epitopes	O
(	O
SSp	O
-	O
1	O
,	O
S978	O
,	O
and	O
S1202	O
)	O
in	O
peripheral	O
blood	O
of	O
all	O
HLA	O
-	O
A	O
*	O
0201	O
(+)	O
recovered	O
SARS	O
patients	O
over	O
1	O
year	O
postinfection	O
.	O

Intriguingly	O
,	O
heat	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
elicited	O
recall	O
-	O
like	O
CTL	O
responses	O
to	O
SSp	O
-	O
1	O
but	O
not	O
to	O
S978	O
,	O
S1202	O
,	O
or	O
dominant	O
epitopes	O
from	O
several	O
other	O
human	O
viruses	O
in	O
5	O
of	O
36	O
(	O
13	O
.	O
8	O
%)	O
HLA	O
-	O
A	O
*	O
0201	O
(+)	O
healthy	O
donors	O
without	O
any	O
contact	O
history	O
with	O
SARS	O
-	O
CoV	O
.	O
SSp	O
-	O
1	O
-	O
specific	O
CTLs	O
expanded	O
from	O
memory	O
T	O
cells	O
of	O
both	O
recovered	O
SARS	O
patients	O
,	O
and	O
the	O
five	O
exceptional	O
healthy	O
donors	O
shared	O
a	O
differentiated	O
effector	B-CHED
CTL	O
phenotype	O
,	O
CD45RA	O
(+)	O
CCR7	O
(-)	O
CD62L	O
(-),	O
and	O
expressed	O
CCR5	O
and	O
CD44	O
.	O

TITLE	O
:	O
Comprehensive	O
antibody	O
epitope	B-CHED
mapping	O
of	O
the	O
nucleocapsid	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
:	O
insight	O
into	O
the	O
humoral	O
immunity	O
of	O
SARS	O
.	O

This	O
inhibition	O
suggested	O
that	O
ATA	O
could	O
be	O
developed	O
as	O
potent	O
anti	B-CHED
-	I-CHED
viral	I-CHED
drug	I-CHED
.	O

Here	O
,	O
to	O
extend	O
our	O
experimental	O
observation	O
,	O
we	O
have	O
incorporated	O
protein	B-CHED
structural	O
studies	O
(	O
with	O
positive	O
/	O
negative	O
controls	O
)	O
to	O
investigate	O
the	O
potential	O
binding	O
modes	O
/	O
sites	O
of	O
ATA	O
onto	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
from	O
SARS	O
-	O
CoV	O
and	O
other	O
pathogenic	O
positive	O
-	O
strand	O
RNA	O
-	O
viruses	O
,	O
as	O
well	O
as	O
other	O
proteins	B-CHED
in	O
SARS	O
-	O
CoV	O
based	O
on	O
the	O
fact	O
that	O
ATA	O
binds	O
to	O
Ca2	O
+-	O
activated	O
neutral	O
protease	O
(	O
m	O
-	O
calpain	O
),	O
the	O
protein	B-CHED
tyrosine	B-CHED
phosphatase	O
(	O
PTP	B-CHED
)	O
and	O
HIV	O
integrase	O
which	O
have	O
existing	O
crystal	O
structures	O
.	O

The	O
existence	O
of	O
this	O
strictly	O
conserved	O
region	O
that	O
incorporated	O
catalytic	O
residues	O
,	O
coupled	O
with	O
the	O
homologous	O
ATA	O
binding	O
pockets	O
and	O
their	O
consistent	O
DeltaG	O
values	O
,	O
suggested	O
strongly	O
ATA	O
may	O
be	O
involved	O
in	O
an	O
analogous	O
inhibition	O
mechanism	O
of	O
SARS	O
-	O
COV	O
'	O
s	O
RdRp	O
in	O
concomitant	O
to	O
the	O
case	O
in	O
m	O
-	O
calpain	O
,	O
PTP	B-CHED
and	O
HIV	O
integrase	O
.	O

ABSTRACT	O
:	O
The	O
exact	O
residues	O
within	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
S1	O
protein	B-CHED
and	O
its	O
receptor	O
,	O
human	O
ACE2	O
,	O
involved	O
in	O
their	O
interaction	O
still	O
remain	O
largely	O
undetermined	O
.	O

Pulse	O
labeling	O
with	O
32P	O
-	O
orthophosphate	B-CHED
indicated	O
that	O
the	O
IBV	O
N	O
protein	B-CHED
was	O
phosphorylated	O
in	O
the	O
virion	O
,	O
as	O
well	O
as	O
at	O
all	O
times	O
during	O
infection	O
in	O
either	O
chicken	O
embryo	O
kidney	O
cells	O
or	O
Vero	O
cells	O
.	O

Pulse	O
-	O
chase	O
analyses	O
followed	O
by	O
immunoprecipitation	O
of	O
IBV	O
N	O
proteins	B-CHED
using	O
rabbit	O
anti	O
-	O
IBV	O
N	O
polyclonal	O
antibody	O
demonstrated	O
that	O
the	O
phosphate	B-CHED
on	O
the	O
N	O
protein	B-CHED
was	O
stable	O
for	O
at	O
least	O
1	O
h	O
.	O
Simultaneous	O
labeling	O
with	O
32P	O
-	O
orthophosphate	B-CHED
and	O
3H	O
-	O
leucine	B-CHED
identified	O
a	O
3	O
.	O
5	O
-	O
fold	O
increase	O
in	O
the	O
32P	O
:	O
3H	O
counts	O
per	O
minute	O
(	O
cpm	O
)	O
ratio	O
of	O
N	O
in	O
the	O
virion	O
as	O
compared	O
to	O
the	O
32P	O
:	O
3H	O
cpm	O
ratio	O
of	O
N	O
in	O
the	O
cell	O
lysates	O
from	O
chicken	O
embryo	O
kidney	O
cells	O
,	O
whereas	O
in	O
Vero	O
cells	O
the	O
32P	O
:	O
3H	O
cpm	O
ratio	O
of	O
N	O
from	O
the	O
virion	O
was	O
10	O
.	O
5	O
-	O
fold	O
greater	O
than	O
the	O
32P	O
:	O
3H	O
cpm	O
ratio	O
of	O
N	O
from	O
the	O
cell	O
lysates	O
.	O

On	O
the	O
contrary	O
,	O
substitution	O
of	O
these	O
two	O
amino	B-CHED
acid	I-CHED
residues	O
of	O
pcSARS	O
-	O
CoV	O
for	O
those	O
of	O
huSRAS	O
-	O
CoV	O
made	O
pcSARS	O
-	O
CoV	O
capable	O
of	O
infecting	O
human	O
ACE2	O
-	O
expressing	O
cells	O
.	O

ABSTRACT	O
:	O
Angiotensin	B-CHED
-	O
converting	O
enzyme	O
-	O
2	O
(	O
ACE2	O
)	O
is	O
a	O
critical	O
regulator	O
of	O
heart	O
function	O
and	O
a	O
cellular	O
receptor	O
for	O
the	O
causative	O
agent	O
of	O
severe	O
-	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
SARS	O
-	O
CoV	O
(	O
coronavirus	O
).	O

Expression	O
of	O
SP	O
-	O
B	O
,	O
-	O
C	O
,	O
and	O
ABCA3	O
are	O
coregulated	O
during	O
late	O
gestation	O
by	O
transcriptional	O
programs	O
influenced	O
by	O
thyroid	O
transcription	O
factor	O
-	O
1	O
and	O
forkhead	O
box	O
a2	O
,	O
transcription	O
factors	O
that	O
regulate	O
both	O
differentiation	O
of	O
the	O
respiratory	O
epithelium	O
and	O
transcription	O
of	O
genes	O
required	O
for	O
perinatal	O
adaptation	O
to	O
air	B-CHED
breathing	O
.	O

TITLE	O
:	O
History	O
of	O
surfactant	B-CHED
from	O
1980	O
.	O

Eighteen	O
hours	O
later	O
,	O
all	O
animals	O
received	O
a	O
'	O
second	O
hit	O
'	O
of	O
portal	O
LPS	B-CHED
in	O
an	O
isolated	O
liver	O
perfusion	O
system	O
.	O

Interestingly	O
,	O
the	O
sequence	O
at	O
several	O
nucleic	B-CHED
acid	I-CHED
sites	O
of	O
CCV	O
type	O
II	O
differed	O
between	O
foxes	O
and	O
raccoon	O
dogs	O
.	O

The	O
deletion	O
of	O
two	O
hydrophobic	O
regions	O
that	O
flanked	O
the	O
NLS3	O
recovered	O
its	O
activity	O
and	O
localized	O
to	O
the	O
nucleus	B-CHED
.	O

The	O
bone	O
mineral	B-CHED
density	O
of	O
224	O
patients	O
with	O
SARS	O
,	O
who	O
were	O
treated	O
with	O
an	O
average	O
of	O
2753	O
mg	O
(	O
SD	O
=	O
2152	O
mg	O
)	O
prednisolone	B-CHED
and	O
29	O
,	O
344	O
mg	O
(	O
SD	O
=	O
15	O
,	O
849	O
mg	O
)	O
of	O
ribavirin	B-CHED
was	O
compared	O
to	O
normal	O
data	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
spike	O
polypeptide	B-CHED
DNA	O
vaccine	O
priming	O
with	O
recombinant	O
spike	O
polypeptide	B-CHED
from	O
Escherichia	O
coli	O
as	O
booster	O
induces	O
high	O
titer	O
of	O
neutralizing	O
antibody	O
against	O
SARS	O
coronavirus	O
.	O

S	O
-	O
peptide	B-CHED
,	O
mice	O
primed	O
with	O
i	O
.	O
m	O
.	O

tPA	B-CHED
-	O
S	O
-	O
DNA	O
,	O
i	O
.	O
m	O
.	O

The	O
present	O
observation	O
may	O
have	O
major	O
practical	O
value	O
,	O
such	O
as	O
immunization	O
of	O
civet	O
cats	O
,	O
since	O
production	O
of	O
recombinant	O
proteins	B-CHED
from	O
E	O
.	O
coli	O
is	O
far	O
less	O
expensive	O
than	O
production	O
of	O
recombinant	O
proteins	B-CHED
using	O
eukaryotic	O
systems	O
.	O

A	O
series	O
of	O
tripeptide	B-CHED
alpha	O
,	O
beta	O
-	O
unsaturated	O
esters	B-CHED
and	O
ketomethylene	O
isosteres	O
,	O
including	O
AG7088	O
,	O
are	O
synthesized	O
and	O
assayed	O
to	O
target	O
the	O
3CL	O
protease	O
.	O

All	O
patients	O
received	O
etoposide	B-CHED
and	O
/	O
or	O
vinblastine	B-CHED
,	O
and	O
improved	O
after	O
2	O
-	O
4	O
days	O
.	O

ABSTRACT	O
:	O
The	O
non	O
-	O
structural	O
proteins	B-CHED
(	O
nsp	O
or	O
replicase	O
proteins	B-CHED
)	O
of	O
coronaviruses	O
are	O
relatively	O
conserved	O
and	O
can	O
be	O
effective	O
targets	O
for	O
drugs	O
.	O

This	O
study	O
provided	O
the	O
foundation	O
for	O
further	O
exploration	O
of	O
the	O
protein	B-CHED
'	O
s	O
biological	B-CHED
function	I-CHED
,	O
and	O
contributed	O
to	O
the	O
search	O
for	O
anti	O
-	O
SARS	O
-	O
CoV	O
drugs	O
.	O

However	O
,	O
no	O
recombinant	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
(	O
S	O
)-	O
based	O
ELISA	O
is	O
currently	O
available	O
.	O

Angiotensin	B-CHED
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
and	O
ACE2	O
are	O
homologues	O
with	O
different	O
key	O
functions	O
in	O
the	O
renin	O
-	O
angiotensin	B-CHED
system	O
.	O

The	O
N	O
'	O
protein	B-CHED
-	O
based	O
ELISA	O
showed	O
a	O
highly	O
nonspecific	O
reaction	O
.	O

The	O
(	O
N	O
)	O
Delta	O
(	O
121	O
)	O
protein	B-CHED
-	O
based	O
ELISA	O
,	O
with	O
a	O
nonspecific	O
reaction	O
drastically	O
reduced	O
compared	O
to	O
that	O
of	O
the	O
nearly	O
-	O
whole	O
-	O
length	O
N	O
'	O
protein	B-CHED
-	O
based	O
ELISA	O
,	O
resulted	O
in	O
higher	O
rates	O
of	O
positive	O
reactions	O
,	O
higher	O
titers	O
,	O
and	O
earlier	O
detection	O
than	O
the	O
SARS	O
-	O
CoV	O
-	O
infected	O
cell	O
lysate	O
-	O
based	O
ELISA	O
.	O

Eventually	O
,	O
5	O
of	O
17	O
hypoxemic	O
and	O
anemic	O
SARS	O
patients	O
(	O
29	O
%)	O
who	O
were	O
receiving	O
ribavirin	B-CHED
died	O
.	O

The	O
DNA	O
vaccine	O
contained	O
a	O
plasmid	O
encoding	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
S	O
protein	B-CHED
under	O
the	O
control	O
of	O
the	O
human	O
CMV	O
promoter	O
and	O
intron	O
A	O
.	O
The	O
whole	O
killed	O
virus	O
vaccine	O
was	O
comprised	O
of	O
SARS	O
-	O
CoV	O
,	O
propagated	O
in	O
Vero	O
-	O
E6	O
cells	O
,	O
with	O
subsequent	O
beta	O
-	O
propilactone	O
inactivation	O
and	O
formulated	O
with	O
aluminum	B-CHED
hydroxide	I-CHED
adjuvant	B-CHED
.	O

We	O
monitored	O
pulmonary	O
vascular	O
resistance	O
,	O
oxygenation	O
,	O
neutrophil	O
count	O
,	O
lung	O
edema	O
as	O
reflected	O
by	O
wet	O
-	O
dry	O
weights	O
of	O
lung	O
tissue	O
,	O
perfusate	O
concentrations	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
,	O
and	O
8	B-CHED
-	I-CHED
isoprostane	I-CHED
(	O
a	O
marker	O
of	O
oxidative	O
stress	O
),	O
and	O
activation	O
of	O
the	O
transcription	O
factor	O
(	O
NF	O
-	O
kappaB	O
)	O
in	O
lung	O
tissue	O
before	O
and	O
for	O
2	O
h	O
after	O
endotoxin	O
.	O

SARS	O
-	O
CoV	O
infections	O
and	O
the	O
Spike	O
protein	B-CHED
of	O
the	O
SARS	O
-	O
CoV	O
reduce	O
ACE2	O
expression	O
.	O

Many	O
human	O
and	O
animal	O
lives	O
were	O
lost	B-CHED
.	O

Primary	O
immunodeficiency	O
disorders	O
of	O
these	O
patients	O
were	O
as	O
follows	O
:	O
cyclic	O
neutropenia	O
(	O
8	O
patients	O
),	O
Shwachman	O
-	O
Diamond	B-CHED
syndrome	O
(	O
7	O
patients	O
),	O
Kostmann	O
syndrome	O
(	O
6	O
patients	O
),	O
and	O
Chediak	O
-	O
Higashi	O
syndrome	O
(	O
5	O
patients	O
).	O

Many	O
cases	O
are	O
mild	O
to	O
moderate	O
and	O
patients	O
are	O
successfully	O
treated	O
with	O
antibiotics	B-CHED
at	O
home	O
and	O
with	O
no	O
lasting	O
damage	O
to	O
the	O
lungs	O
.	O

The	O
specificity	O
of	O
monoclonal	O
antibodies	O
were	O
tested	O
with	O
a	O
commercial	O
ELISA	O
kit	O
for	O
detecting	O
antibody	O
against	O
SARS	O
-	O
CoV	O
.	O
The	O
results	O
showed	O
that	O
two	O
peptides	B-CHED
with	O
molecular	O
weights	O
of	O
34kD	O
and	O
35kD	O
expressed	O
by	O
the	O
two	O
chimeric	O
genes	O
could	O
be	O
recognized	O
by	O
SARS	O
patient	O
convalescent	O
serum	O
in	O
Western	O
blot	O
.	O

Furthermore	O
,	O
MHV	O
spike	O
protein	B-CHED
bound	O
to	O
nonraftraft	O
membrane	O
at	O
4	O
degrees	O
C	O
but	O
shifted	O
to	O
lipid	B-CHED
rafts	O
at	O
37	O
degrees	O
C	O
,	O
indicating	O
a	O
redistribution	O
of	O
membrane	O
following	O
virus	O
binding	O
.	O

TITLE	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3a	O
protein	B-CHED
up	O
-	O
regulates	O
expression	O
of	O
fibrinogen	O
in	O
lung	O
epithelial	O
cells	O
.	O

The	O
study	O
shows	O
that	O
hemofiltration	O
is	O
an	O
effective	O
and	O
pathogenetic	O
method	O
of	O
complex	O
treatment	O
of	O
MOFS	O
,	O
which	O
has	O
a	O
positive	O
effect	O
on	O
the	O
main	O
pathogenetic	O
mechanisms	O
in	O
ARDS	O
,	O
thus	O
allowing	O
improvement	O
of	O
oxygen	B-CHED
transport	O
in	O
blood	O
.	O

Most	O
emergency	O
departments	O
provided	O
PPE	B-CHED
(	O
80	O
%)	O
and	O
implemented	O
ICMs	O
(	O
66	O
%)	O
at	O
late	O
stages	O
of	O
the	O
outbreak	O
.	O

Instructions	O
to	O
use	O
PPE	B-CHED
or	O
ICMs	O
more	O
frequently	O
originated	O
by	O
emergency	O
department	O
administrators	O
.	O

We	O
constructed	O
a	O
recombinant	O
adenovirus	O
containing	O
a	O
truncated	O
N	O
-	O
terminal	O
fragment	O
of	O
the	O
SARS	O
-	O
CoV	O
Spike	O
(	O
S	O
)	O
gene	O
(	O
from	O
--	O
45	O
to	O
1469	O
,	O
designated	O
Ad	O
-	O
S	O
(	O
N	O
)),	O
which	O
encoded	O
a	O
truncated	O
S	O
protein	B-CHED
(	O
490	O
amino	B-CHED
-	I-CHED
acid	I-CHED
residues	I-CHED
,	O
a	O
part	O
of	O
672	O
amino	O
-	O
acid	O
S1	O
subunit	O
),	O
and	O
investigated	O
whether	O
this	O
construct	O
could	O
induce	O
effective	O
immunity	O
against	O
SARS	O
-	O
CoV	O
in	O
Wistar	O
rats	O
.	O

Our	O
results	O
showed	O
that	O
all	O
of	O
the	O
immunized	O
animals	O
generated	O
humoral	O
immunity	O
against	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
,	O
and	O
the	O
sera	O
of	O
immunized	O
rats	O
showed	O
strong	O
capable	O
of	O
protecting	O
from	O
SARS	O
-	O
CoV	O
infection	O
in	O
vitro	O
.	O

Clinically	O
,	O
human	O
metapneumovirus	O
was	O
found	O
to	O
be	O
second	O
to	O
human	O
respiratory	O
syncytial	O
virus	O
alone	O
,	O
as	O
a	O
cause	O
of	O
respiratory	O
tract	O
infections	O
,	O
while	O
duration	O
of	O
virus	O
excretion	O
appeared	O
to	O
correlate	O
with	O
severity	O
of	O
infection	O
,	O
and	O
virus	O
load	O
in	O
NPA	B-CHED
with	O
the	O
stage	O
of	O
respiratory	O
infection	O
.	O

However	O
,	O
SARS	O
-	O
CoV	O
membrane	O
protein	B-CHED
seems	O
to	O
be	O
more	O
sensitive	O
to	O
heat	O
treatment	O
,	O
since	O
the	O
membrane	O
protein	B-CHED
of	O
MHV	O
-	O
JHM	O
,	O
another	O
member	O
of	O
the	O
Coronaviridae	O
,	O
would	O
not	O
aggregate	O
after	O
the	O
same	O
treatment	O
.	O

ABSTRACT	O
:	O
A	O
capture	O
enzyme	O
-	O
enhanced	O
chemiluminescence	O
immunoassay	O
(	O
ECLIA	O
)	O
based	O
on	O
three	O
specific	O
monoclonal	O
antibodies	O
to	O
detect	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
the	O
serial	O
serum	O
samples	O
from	O
SARS	O
patients	O
was	O
developed	O
.	O

TITLE	O
:	O
Variations	O
in	O
the	O
nucleocapsid	O
protein	B-CHED
gene	O
of	O
infectious	O
bronchitis	O
viruses	O
isolated	O
in	O
Korea	O
.	O

TITLE	O
:	O
Novel	O
rapid	O
immunochromatographic	O
test	O
based	O
on	O
an	O
enzyme	O
immunoassay	O
for	O
detecting	O
nucleocapsid	O
antigen	B-CHED
in	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

The	O
N	O
protein	B-CHED
gene	O
has	O
been	O
cloned	O
into	O
a	O
yeast	O
expression	O
vector	O
pPIC9	O
,	O
transformed	O
into	O
Pichia	O
pastoris	O
strain	O
GS115	O
and	O
induced	O
for	O
expression	O
by	O
methanol	B-CHED
.	O

If	O
bronchoscopy	O
fails	O
to	O
confirm	O
an	O
infectious	O
cause	O
,	O
a	O
short	O
course	O
of	O
steroids	B-CHED
must	O
be	O
tried	O
,	O
which	O
probably	O
leads	O
to	O
a	O
favorable	O
outcome	O
.	O

RESULTS	O
:	O
Vero	O
and	O
Vero	O
-	O
E6	O
cell	O
lines	O
were	O
sensitive	O
to	O
SARS	O
-	O
CoV	O
.	O
The	O
cytopathic	O
changes	O
of	O
the	O
cells	O
were	O
75	O
%	O
at	O
37	O
degrees	O
C	O
in	O
5	O
percent	O
CO2	B-CHED
incubator	O
after	O
infection	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
contains	O
a	O
single	O
spike	O
(	O
S	O
)	O
protein	B-CHED
,	O
which	O
binds	O
to	O
its	O
receptor	O
,	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
induces	O
membrane	O
fusion	O
and	O
serves	O
as	O
a	O
neutralizing	O
antigen	B-CHED
.	O

VSV	O
-	O
SARS	O
-	O
St19	O
will	O
be	O
useful	O
for	O
analysing	O
the	O
function	O
of	O
SARS	O
-	O
CoV	O
-	O
S	O
protein	B-CHED
and	O
for	O
developing	O
rapid	O
methods	O
of	O
detecting	O
neutralizing	O
antibodies	O
specific	O
for	O
SARS	O
-	O
CoV	O
infection	O
.	O

Nucleic	B-CHED
acid	I-CHED
of	O
SARS	O
-	O
CoV	O
can	O
be	O
excreted	O
through	O
the	O
stool	O
of	O
patients	O
into	O
sewage	O
system	O
,	O
and	O
the	O
possibility	O
of	O
SARS	O
-	O
CoV	O
transmitting	O
through	O
digestive	O
system	O
cannot	O
be	O
excluded	O
.	O

The	O
expression	O
of	O
the	O
Spike	O
and	O
Nucleoprotein	O
genes	O
of	O
SARS	O
-	O
CoV	O
at	O
mRNA	B-CHED
and	O
protein	B-CHED
levels	O
in	O
small	O
interfering	O
(	O
si	O
)	O
RNA	O
-	O
expressing	O
cells	O
was	O
significantly	O
less	O
than	O
that	O
in	O
controls	O
when	O
analysed	O
with	O
PCR	O
and	O
Western	O
-	O
blot	O
assays	O
,	O
3	O
days	O
post	O
SARS	O
-	O
CoV	O
infection	O
.	O

They	O
were	O
categorized	O
according	O
to	O
whether	O
or	O
not	O
corticosteroid	B-CHED
therapy	O
was	O
given	O
,	O
and	O
compared	O
in	O
terms	O
of	O
demographic	O
characteristics	O
,	O
comorbidities	O
,	O
peak	O
lactate	B-CHED
dehydrogenase	O
(	O
LDH	O
)	O
levels	O
and	O
clinical	O
outcomes	O
.	O

While	O
concentrations	O
of	O
sTNFR2	O
proteins	B-CHED
were	O
elevated	O
in	O
both	O
BALB	O
/	O
c	O
(	O
p	O
<	O
0	O
.	O
00005	O
)	O
and	O
CD	O
-	O
1	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
mice	O
compared	O
to	O
controls	O
,	O
concentrations	O
were	O
higher	O
in	O
BALB	O
/	O
c	O
mice	O
(	O
p	O
<	O
0	O
.	O
0005	O
).	O

ABSTRACT	O
:	O
The	O
structure	O
of	O
the	O
human	O
MHC	O
-	O
I	O
molecule	O
HLA	O
-	O
A	O
*	O
1101	O
in	O
complex	O
with	O
a	O
nonameric	O
peptide	B-CHED
(	O
KTFPPTEPK	O
)	O
has	O
been	O
determined	O
by	O
X	O
-	O
ray	O
crystallography	O
to	O
1	O
.	O
45	O
A	O
resolution	O
.	O

The	O
SNP362	O
-	O
370	O
peptide	B-CHED
is	O
held	O
in	O
place	O
by	O
17	O
hydrogen	B-CHED
bonds	O
to	O
the	O
alpha	O
-	O
chain	O
residues	O
and	O
by	O
nine	O
water	B-CHED
molecules	O
which	O
are	O
also	O
tightly	O
bound	O
in	O
the	O
peptide	B-CHED
-	O
binding	O
groove	O
.	O

Thr6	O
of	O
the	O
peptide	B-CHED
(	O
Thr6p	O
)	O
does	O
not	O
make	O
efficient	O
use	O
of	O
the	O
middle	O
(	O
E	O
)	O
pocket	O
.	O

We	O
demonstrate	O
that	O
SARS	O
-	O
CoV	O
PLP2	O
by	O
itself	O
differentially	O
cleaves	O
between	O
the	O
amino	B-CHED
acids	I-CHED
Gly180	O
and	O
Ala181	O
,	O
Gly818	O
and	O
Ala819	O
,	O
and	O
Gly2740	O
and	O
Lys2741	O
of	O
the	O
viral	O
polypeptide	B-CHED
pp1a	O
,	O
as	O
determined	O
by	O
reversed	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
analysis	O
coupled	O
with	O
mass	O
spectrometry	O
.	O

With	O
a	O
fluorogenic	O
inhibitor	B-CHED
-	O
screening	O
platform	O
,	O
we	O
show	O
that	O
zinc	B-CHED
ion	I-CHED
and	O
its	O
conjugates	O
potently	O
inhibit	O
the	O
enzymatic	O
activity	O
of	O
SARS	O
-	O
CoV	O
PLP2	O
.	O

TITLE	O
:	O
Antibody	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
spike	O
protein	B-CHED
domain	O
2	O
cross	O
-	O
reacts	O
with	O
lung	O
epithelial	O
cells	O
and	O
causes	O
cytotoxicity	O
.	O

Preabsorption	O
and	O
binding	O
assays	O
indicated	O
the	O
existence	O
of	O
cross	O
-	O
reactive	O
epitopes	O
on	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
domain	O
2	O
(	O
S2	O
).	O

ABSTRACT	O
:	O
The	O
open	O
reading	O
frame	O
3	O
(	O
ORF3	O
)	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
genome	O
encodes	O
a	O
predicted	O
154	O
-	O
amino	B-CHED
acid	I-CHED
protein	B-CHED
,	O
which	O
lacks	O
similarities	O
to	O
any	O
known	O
protein	B-CHED
,	O
and	O
is	O
named	O
3b	O
.	O

Immediately	O
after	O
the	O
diagnosis	O
of	O
DNM	O
,	O
broad	O
-	O
spectrum	O
antibiotics	B-CHED
were	O
administered	O
empirically	O
,	O
and	O
surgical	O
treatments	O
consisting	O
of	O
cervical	O
drainage	O
,	O
thoracotomy	O
with	O
radical	B-CHED
surgical	O
debridement	O
of	O
the	O
mediastinum	O
and	O
excision	O
of	O
necrotic	O
tissue	O
,	O
decortication	O
,	O
and	O
irrigation	O
were	O
performed	O
in	O
all	O
cases	O
.	O

However	O
,	O
apoptosis	O
was	O
inhibited	O
by	O
overexpressed	O
antiapoptotic	O
protein	B-CHED
Bcl	O
-	O
xL	O
.	O
Moreover	O
,	O
we	O
found	O
that	O
SARS	O
-	O
CoV	O
E	O
protein	B-CHED
interacted	O
with	O
Bcl	O
-	O
xL	O
in	O
vitro	O
and	O
endogenous	O
Bcl	O
-	O
xL	O
in	O
vivo	O
and	O
that	O
Bcl	O
-	O
xL	O
interaction	O
with	O
SARS	O
-	O
CoV	O
E	O
protein	B-CHED
was	O
mediated	O
by	O
BH3	B-CHED
(	O
Bcl	O
-	O
2	O
homology	O
domain	O
3	O
)	O
of	O
Bcl	O
-	O
xL	O
.	O
Finally	O
,	O
we	O
identified	O
a	O
novel	O
BH3	B-CHED
-	O
like	O
region	O
located	O
in	O
the	O
C	O
-	O
terminal	O
cytosolic	O
domain	O
of	O
SARS	O
-	O
CoV	O
E	O
protein	B-CHED
,	O
which	O
mediates	O
its	O
binding	O
to	O
Bcl	O
-	O
xL	O
.	O
These	O
results	O
demonstrate	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
novel	O
molecular	O
mechanism	O
of	O
T	O
-	O
cell	O
apoptosis	O
that	O
contributes	O
to	O
the	O
SARS	O
-	O
CoV	O
-	O
induced	O
lymphopenia	O
observed	O
in	O
most	O
SARS	O
patients	O
.	O

These	O
and	O
other	O
emerging	O
agents	O
have	O
arisen	O
or	O
have	O
been	O
introduced	O
partly	O
through	O
changes	O
in	O
donor	B-CHED
demographics	O
,	O
international	O
travel	O
,	O
microbial	O
adaptations	O
,	O
land	O
use	O
,	O
and	O
human	O
behaviour	O
.	O

This	O
study	O
identifies	O
nsp1	O
residues	O
important	O
for	O
protein	B-CHED
processing	O
,	O
viral	O
RNA	O
synthesis	O
,	O
and	O
viral	O
replication	O
.	O

Therefore	O
,	O
further	O
studies	O
are	O
necessary	O
to	O
address	O
this	O
acute	O
and	O
growing	O
problem	O
in	O
intensive	O
medicine	B-CHED
.	O

Synthetic	O
peptides	B-CHED
M1	O
-	O
31	O
derived	O
from	O
the	O
N	O
-	O
terminal	O
epitope	B-CHED
and	O
M132	O
-	O
161	O
derived	O
from	O
the	O
C	O
-	O
terminal	O
epitope	B-CHED
were	O
highly	O
reactive	O
with	O
all	O
of	O
the	O
convalescent	O
-	O
phase	O
sera	O
from	O
40	O
SARS	O
patients	O
but	O
not	O
with	O
30	O
control	O
serum	O
samples	O
from	O
healthy	O
blood	O
donors	O
,	O
suggesting	O
their	O
potential	O
application	O
for	O
serologic	O
diagnosis	O
of	O
SARS	O
.	O

Such	O
a	O
relationship	O
was	O
not	O
found	O
with	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
).	O

The	O
time	O
course	O
curve	O
indicated	O
that	O
IFN	O
-	O
alpha	O
mRNA	B-CHED
induction	O
peaked	O
at	O
24	O
h	O
.	O
p	O
.	O
i	O
,.	O
whereas	O
IFN	O
-	O
gamma	O
mRNA	B-CHED
was	O
still	O
increasing	O
at	O
48	O
h	O
.	O
p	O
.	O
i	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
a	O
neutrophil	B-CHED
elastase	I-CHED
inhibitor	I-CHED
,	O
sivelestat	O
,	O
on	O
lipopolysaccharide	B-CHED
-	O
induced	O
acute	O
lung	O
injury	O
through	O
analysis	O
of	O
hemodynamic	O
changes	O
in	O
the	O
pulmonary	O
microcirculation	O
.	O

Rats	O
were	O
divided	O
into	O
three	O
groups	O
(	O
n	O
=	O
5	O
each	O
groups	O
)	O
on	O
the	O
basis	O
of	O
the	O
reagent	B-CHED
used	O
:	O
lipopolysaccharide	B-CHED
group	O
(	O
100	O
microg	O
/	O
kg	O
lipopolysaccharide	B-CHED
intravenously	O
),	O
sivelestat	O
group	O
(	O
10	O
mg	O
/	O
kg	O
sivelestat	O
;	O
100	O
microg	O
/	O
kg	O
lipopolysaccharide	B-CHED
intravenously	O
),	O
and	O
control	O
group	O
(	O
saline	O
only	O
,	O
intravenously	O
).	O

Sixty	O
minutes	O
after	O
lipopolysaccharide	B-CHED
administration	O
,	O
severe	O
thickening	O
of	O
the	O
interalveolar	O
septa	O
was	O
observed	O
in	O
the	O
lipopolysaccharide	B-CHED
but	O
not	O
the	O
sivelestat	O
group	O
.	O

RESULTS	O
:	O
Nine	O
thousand	O
one	O
hundred	O
twenty	O
-	O
six	O
with	O
blunt	O
injury	O
were	O
ICU	O
admissions	O
,	O
and	O
5	O
,	O
260	O
(	O
58	O
%)	O
met	B-CHED
study	O
criteria	O
(	O
72	O
%	O
male	O
).	O

This	O
approach	O
takes	O
advantage	O
of	O
the	O
cooperative	O
interaction	O
between	O
adjacently	O
hybridized	O
oligonucleotides	B-CHED
.	O

It	O
was	O
shown	O
that	O
,	O
when	O
applied	O
to	O
SARS	O
RNA	O
samples	O
,	O
the	O
sensitivity	O
of	O
nucleic	B-CHED
acid	I-CHED
capture	O
RTPCR	O
was	O
about	O
10	O
-	O
fold	O
greater	O
than	O
routine	O
RT	O
-	O
PCR	O
.	O

The	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
is	O
a	O
major	O
virion	O
structural	O
protein	B-CHED
.	O

Western	O
blotting	O
results	O
demonstrated	O
that	O
100	O
%	O
of	O
the	O
SARS	O
patients	O
tested	O
positive	O
for	O
N	O
protein	B-CHED
-	O
specific	O
antibodies	O
,	O
50	O
%	O
for	O
S1	O
protein	B-CHED
-	O
specific	O
antibodies	O
,	O
30	O
%	O
for	O
S2	O
protein	B-CHED
-	O
specific	O
antibodies	O
,	O
and	O
70	O
%	O
for	O
S3	O
protein	B-CHED
-	O
specific	O
antibodies	O
.	O

These	O
results	O
suggest	O
that	O
the	O
recombinant	O
proteins	B-CHED
N	O
and	O
S3	O
are	O
potentially	O
useful	O
antigens	B-CHED
for	O
a	O
serological	O
diagnosis	O
of	O
SARS	O
.	O

In	O
consideration	O
of	O
possible	O
cross	O
-	O
reactivity	O
among	O
N	O
proteins	B-CHED
of	O
SARS	O
-	O
CoV	O
and	O
other	O
coronaviruses	O
,	O
immunoassays	O
using	O
recombinant	O
N	O
protein	B-CHED
in	O
combination	O
with	O
S3	O
as	O
antigens	B-CHED
might	O
improve	O
the	O
specificity	O
of	O
SARS	O
diagnoses	O
.	O

ABSTRACT	O
:	O
This	O
contribution	O
reviews	O
the	O
synthesis	O
of	O
a	O
range	O
of	O
experimental	O
drugs	O
designed	O
for	O
and	O
aiming	O
at	O
antiviral	B-CHED
chemotherapy	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)-	O
induced	O
human	O
disease	O
conditions	O
.	O

Bananin	O
(	O
BN	O
)	O
was	O
an	O
effective	O
inhibitor	B-CHED
of	O
both	O
SARS	O
-	O
CoV	O
RNA	O
/	O
DNA	O
helicase	O
nucleic	B-CHED
acid	I-CHED
unwinding	O
function	O
and	O
SARS	O
-	O
CoV	O
(	O
Coronaviridae	O
,	O
Coronavirus	O
)	O
RNA	O
-	O
viral	O
replication	O
in	O
cell	O
culture	O
.	O

Thus	O
,	O
the	O
data	O
presented	O
here	O
provide	O
a	O
possible	O
mechanism	O
for	O
phosphorylation	O
-	O
dependent	O
nucleocytoplasmic	O
shuttling	O
of	O
the	O
N	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
of	O
several	O
members	O
within	O
the	O
order	O
Nidovirales	O
localizes	O
to	O
the	O
nucleolus	O
during	O
infection	O
and	O
after	O
transfection	O
of	O
cells	O
with	O
N	O
genes	O
.	O

Till	O
now	O
,	O
there	O
is	O
no	O
report	O
about	O
the	O
function	O
of	O
3b	O
protein	B-CHED
.	O

Higher	O
IgG	O
levels	O
were	O
detected	O
in	O
patients	O
who	O
required	O
supplemental	O
oxygen	B-CHED
(	O
Mann	O
-	O
Whitney	O
;	O
p	O
=	O
0	O
.	O
002	O
),	O
ICU	O
-	O
admission	O
(	O
p	O
=	O
0	O
.	O
001	O
),	O
had	O
negative	O
pre	O
-	O
discharge	O
fecal	O
RT	O
-	O
PCR	O
results	O
(	O
p	O
=	O
0	O
.	O
004	O
),	O
and	O
lymphopenia	O
at	O
presentation	O
(	O
p	O
=	O
0	O
.	O
028	O
).	O

One	O
pair	O
-	O
Abs	O
,	O
consisting	O
of	O
N	O
protein	B-CHED
-	O
specific	O
rabbit	O
polyclonal	O
antibody	O
and	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
-	O
specific	O
mAb	O
,	O
was	O
selected	O
to	O
construct	O
a	O
sandwich	O
ELISA	O
-	O
kit	O
.	O

In	O
addition	O
to	O
the	O
well	O
-	O
known	O
functions	O
of	O
chloroquine	B-CHED
such	O
as	O
elevations	O
of	O
endosomal	O
pH	O
,	O
the	O
drug	O
appears	O
to	O
interfere	O
with	O
terminal	O
glycosylation	O
of	O
the	O
cellular	O
receptor	O
,	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
.	O

Sinigrin	B-CHED
(	O
IC50	O
:	O
217	O
microM	O
)	O
was	O
more	O
efficient	O
in	O
blocking	O
the	O
cleavage	O
processing	O
of	O
the	O
3CLpro	O
than	O
indigo	O
(	O
IC50	O
:	O
752	O
microM	O
)	O
and	O
beta	B-CHED
-	I-CHED
sitosterol	I-CHED
(	O
IC50	O
:	O
1210	O
microM	O
)	O
in	O
the	O
cell	O
-	O
based	O
assay	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
the	O
encoding	O
sequences	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
were	O
analyzed	O
by	O
bioinformatics	O
methods	O
,	O
the	O
structural	O
characteristics	O
and	O
functions	O
were	O
forecasted	O
based	O
on	O
available	O
data	O
.	O

It	O
suggests	O
that	O
the	O
fragment	O
of	O
spike	O
glycoprotein	B-CHED
(	O
S401	O
-	O
659	O
)	O
may	O
be	O
crucial	O
for	O
viral	O
attachment	O
and	O
may	O
be	O
a	O
major	O
immunodominant	O
epitope	B-CHED
.	O

The	O
denatured	O
inclusion	O
bodies	O
were	O
purified	O
with	O
Ni	O
-	O
NTA	B-CHED
chelate	O
agarose	B-CHED
and	O
its	O
purity	O
can	O
reach	O
90	O
%.	O

Alanine	B-CHED
scanning	O
mutagenesis	O
of	O
the	O
fragment	O
S319	O
-	O
518	O
resulted	O
in	O
the	O
identification	O
of	O
ten	O
residues	O
(	O
K390	O
,	O
R426	O
,	O
D429	O
,	O
T431	O
,	O
I455	O
,	O
N473	O
,	O
F483	O
,	O
Q492	O
,	O
Y494	O
,	O
R495	O
)	O
that	O
significantly	O
reduced	O
binding	O
to	O
ACE2	O
,	O
and	O
one	O
residue	O
(	O
D393	O
)	O
that	O
appears	O
to	O
increase	O
binding	O
.	O

Only	O
one	O
patient	O
developed	O
an	O
air	B-CHED
leak	O
complication	O
.	O

It	O
is	O
characterized	O
by	O
the	O
acute	O
onset	O
of	O
dyspnea	O
refractory	O
to	O
oxygen	B-CHED
therapy	O
,	O
and	O
diffuse	O
lung	O
infiltrates	O
.	O

ABSTRACT	O
:	O
Twenty	O
antiviral	B-CHED
drugs	I-CHED
,	O
that	O
is	O
about	O
half	O
of	O
those	O
that	O
are	O
currently	O
approved	O
,	O
are	O
formally	O
licensed	O
for	O
clinical	O
use	O
in	O
the	O
treatment	O
of	O
human	O
immunodeficiency	O
virus	O
infections	O
(	O
acquired	O
immune	O
deficiency	O
syndrome	O
).	O

Recent	O
endeavours	O
have	O
focussed	O
on	O
the	O
development	O
of	O
improved	O
antiviral	B-CHED
therapies	O
for	O
virus	O
infections	O
that	O
have	O
already	O
proved	O
amenable	O
to	O
antiviral	B-CHED
drug	I-CHED
treatment	O
,	O
as	O
well	O
as	O
for	O
virus	O
infections	O
for	O
which	O
,	O
at	O
present	O
,	O
no	O
antiviral	B-CHED
drugs	I-CHED
have	O
been	O
formally	O
approved	O
(	O
i	O
.	O
e	O
.	O
human	O
papilloma	O
viruses	O
,	O
adenoviruses	O
,	O
human	O
herpesvirus	O
type	O
6	O
,	O
poxviruses	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
hemorrhagic	O
fever	O
viruses	O
).	O

TITLE	O
:	O
Rational	O
monoclonal	O
antibody	O
development	O
to	O
emerging	O
pathogens	O
,	O
biothreat	O
agents	O
and	O
agents	O
of	O
foreign	O
animal	O
disease	O
:	O
The	O
antigen	B-CHED
scale	O
.	O

Systematic	O
epitope	B-CHED
mapping	O
showed	O
that	O
all	O
these	O
neutralizing	O
mAbs	O
recognized	O
a	O
15	O
-	O
residues	O
peptide	B-CHED
(	O
CB	O
-	O
119	O
)	O
corresponding	O
to	O
residues	O
1143	O
-	O
1157	O
(	O
SPDVDLGDISGINAS	O
)	O
that	O
was	O
located	O
to	O
the	O
second	O
heptad	O
repeat	O
(	O
HR2	O
)	O
region	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
.	O

Results	O
implicated	O
that	O
the	O
second	O
heptad	O
repeat	O
region	O
of	O
spike	O
protein	B-CHED
could	O
be	O
a	O
good	O
target	O
for	O
vaccine	O
development	O
against	O
SARS	O
-	O
CoV	O
.	O

A	O
recombinant	O
partial	O
nucleocapsid	O
protein	B-CHED
of	O
SARS	O
-	O
associated	O
coronavirus	O
was	O
used	O
as	O
a	O
serodiagnostic	O
antigen	B-CHED
in	O
the	O
ELISA	O
.	O

The	O
scoring	O
system	O
of	O
attributing	O
11	O
,	O
10	O
,	O
3	O
,	O
3	O
and	O
3	O
points	O
to	O
the	O
presence	O
of	O
independent	O
risk	O
factors	O
,	O
namely	O
:	O
epidemiological	O
link	O
,	O
radiographical	O
deterioration	O
,	O
myalgia	O
,	O
lymphopenia	O
and	O
elevated	O
ALT	B-CHED
respectively	O
,	O
generated	O
high	O
and	O
low	O
-	O
risk	O
(	O
total	O
score	O
11	O
-	O
30	O
and	O
0	O
-	O
10	O
,	O
respectively	O
)	O
groups	O
for	O
SARS	O
.	O

Primers	O
were	O
designed	O
from	O
conserved	O
or	O
variable	O
regions	O
of	O
nucleocapsid	O
(	O
N	O
)	O
or	O
spike	O
(	O
S	O
)	O
protein	B-CHED
gene	O
among	O
TCoV	O
,	O
IBV	O
,	O
and	O
BCoV	O
and	O
used	O
in	O
the	O
same	O
PCR	O
reaction	O
.	O

TITLE	O
:	O
Single	O
amino	B-CHED
acid	I-CHED
substitutions	O
in	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
glycoprotein	B-CHED
determine	O
viral	O
entry	O
and	O
immunogenicity	O
of	O
a	O
major	O
neutralizing	O
domain	O
.	O

ABSTRACT	O
:	O
Neutralizing	O
antibodies	O
(	O
NAbs	O
)	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
confer	O
protection	O
to	O
animals	O
experimentally	O
infected	O
with	O
the	O
pathogenic	O
virus	O
.	O

To	O
determine	O
the	O
specific	O
residues	O
that	O
contribute	O
to	O
related	O
phenotypes	O
,	O
we	O
replaced	O
eight	O
basic	O
amino	B-CHED
acids	I-CHED
with	O
alanine	B-CHED
.	O

Finally	O
,	O
the	O
remaining	O
six	O
SNVs	O
caused	O
four	O
amino	B-CHED
acid	I-CHED
changes	O
,	O
at	O
positions	O
227	O
,	O
244	O
,	O
344	O
,	O
and	O
778	O
,	O
which	O
resulted	O
in	O
the	O
group	O
of	O
viruses	O
responsible	O
for	O
the	O
global	O
epidemic	O
.	O

TITLE	O
:	O
Activation	O
of	O
NF	O
-	O
kappaB	O
by	O
the	O
full	O
-	O
length	O
nucleocapsid	O
protein	B-CHED
of	O
the	O
SARS	O
coronavirus	O
.	O

The	O
number	O
and	O
the	O
distribution	O
of	O
single	O
nucleotide	B-CHED
variations	O
(	O
SNVs	O
)	O
and	O
insertions	O
and	O
deletions	O
,	O
with	O
respect	O
to	O
a	O
""""	O
profile	O
""","	O
were	O
determined	O
and	O
discussed	O
"("""	O
profile	O
""""	O
being	O
a	O
sequence	O
containing	O
the	O
most	O
represented	O
letter	O
per	O
position	O
).	O

The	O
protective	O
effect	O
of	O
the	O
F	O
(	O
ab	O
')	O
2	O
fragments	O
against	O
SARS	O
-	O
CoV	O
infection	O
was	O
determined	O
in	O
cultured	O
Vero	O
E6	O
cells	O
by	O
cytopathic	O
effect	O
(	O
CPE	O
),	O
MTT	B-CHED
and	O
plaque	O
-	O
forming	O
assays	O
and	O
in	O
a	O
Balb	O
/	O
c	O
mouse	O
model	O
by	O
CPE	O
and	O
quantitative	O
RT	O
-	O
PCR	O
.	O

Five	O
of	O
these	O
peptides	B-CHED
showed	O
high	O
cross	O
-	O
immunoreactivities	O
(	O
approximately	O
66	O
.	O
7	O
to	O
90	O
.	O
5	O
%)	O
to	O
SARS	O
convalescent	O
patients	O
'	O
sera	O
from	O
the	O
severest	O
epidemic	O
regions	O
of	O
the	O
China	O
mainland	O
.	O

The	O
application	O
of	O
PEEP	B-CHED
resulted	O
in	O
a	O
decrease	O
in	O
venous	O
admixture	O
,	O
increase	O
in	O
respiratory	O
system	O
compliance	O
,	O
and	O
return	O
of	O
the	O
sound	O
transmission	O
to	O
preinjury	O
levels	O
.	O

Second	O
,	O
the	O
6	O
-	O
carboxytetramethylrhodamine	O
(	O
TAMRA	B-CHED
)-	O
labeled	O
PCR	O
products	O
were	O
hybridized	O
specifically	O
with	O
oligonucleotide	B-CHED
microarrays	O
.	O

The	O
TEM	B-CHED
image	O
for	O
our	O
purposes	O
is	O
defined	O
on	O
2	O
-	O
D	O
information	O
,	O
such	O
as	O
the	O
membrane	O
having	O
undergone	O
proliferation	O
and	O
from	O
pattern	O
recognition	O
suggesting	O
that	O
the	O
membrane	O
-	O
described	O
pattern	O
is	O
possibly	O
a	O
gyroid	O
type	O
of	O
membrane	O
.	O

RESULTS	O
:	O
Both	O
hospital	O
groups	O
had	O
comparable	O
demographics	O
and	O
clinical	O
profiles	O
,	O
but	O
NIV	O
Hospital	O
(	O
42	O
patients	O
)	O
had	O
higher	O
lactate	B-CHED
dehydrogenase	O
ratio	O
and	O
worse	O
radiographic	O
score	O
on	O
admission	O
and	O
ribavirin	B-CHED
-	O
corticosteroid	B-CHED
commencement	O
.	O

Her	O
renal	O
function	O
remained	O
stable	O
for	O
a	O
time	O
(	O
serum	O
creatinine	B-CHED
0	O
.	O
5	O
mg	O
/	O
dL	O
,	O
blood	O
urea	B-CHED
nitrogen	B-CHED
10	O
mg	O
/	O
dL	O
,	O
urine	O
output	O
100	O
-	O
200	O
mL	O
/	O
h	O
).	O

Since	O
this	O
case	O
occurred	O
,	O
our	O
intensive	O
care	O
unit	O
has	O
instituted	O
recommendations	O
for	O
the	O
prevention	O
of	O
lorazepam	B-CHED
-	O
associated	O
propylene	B-CHED
glycol	I-CHED
toxicity	O
.	O

ABSTRACT	O
:	O
The	O
210	O
-	O
nucleotide	B-CHED
(	O
nt	O
)	O
5	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
in	O
the	O
positive	O
-	O
strand	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
genome	O
is	O
predicted	O
to	O
contain	O
four	O
higher	O
-	O
order	O
structures	O
identified	O
as	O
stem	O
-	O
loops	O
I	O
to	O
IV	O
,	O
which	O
may	O
function	O
as	O
cis	O
-	O
acting	O
elements	O
in	O
genomic	O
RNA	O
replication	O
.	O

The	O
study	O
included	O
the	O
measurement	O
of	O
static	O
and	O
dynamic	O
lung	O
volumes	O
,	O
the	O
determination	O
of	O
the	O
diffusing	O
capacity	O
of	O
the	O
lung	O
for	O
carbon	B-CHED
monoxide	I-CHED
(	O
D	O
(	O
LCO	B-CHED
)),	O
and	O
a	O
health	O
status	O
evaluation	O
using	O
the	O
St	O
.	O
George	O
Respiratory	O
Questionnaire	O
(	O
SGRQ	O
).	O

The	O
atomic	O
details	O
at	O
the	O
interface	O
between	O
the	O
two	O
proteins	B-CHED
clarify	O
the	O
importance	O
of	O
residue	O
changes	O
that	O
facilitate	O
efficient	O
cross	O
-	O
species	O
infection	O
and	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

These	O
in	O
vitro	O
selected	O
human	O
scFvs	O
specifically	O
recognize	O
in	O
ELISA	O
and	O
western	O
blotting	O
studies	O
distinct	O
epitopes	O
in	O
N	O
protein	B-CHED
domains	O
and	O
detect	O
in	O
immunohistochemistry	O
investigations	O
SARS	O
-	O
CoV	O
particles	O
in	O
infected	O
Vero	O
cells	O
.	O

When	O
patients	O
deteriorate	O
clinically	O
despite	O
treatment	O
with	O
ribavirin	B-CHED
and	O
corticosteroids	B-CHED
,	O
rescue	O
treatment	O
with	O
convalescent	O
plasma	O
and	O
immunoglobulin	O
may	O
be	O
beneficial	O
.	O

The	O
experience	O
with	O
traditional	O
Chinese	O
medicine	B-CHED
is	O
encouraging	O
,	O
and	O
its	O
use	O
as	O
an	O
adjuvant	B-CHED
should	O
be	O
further	O
investigated	O
.	O

For	O
the	O
discovery	O
of	O
a	O
novel	O
efficient	O
way	O
to	O
modify	O
oligonucleotides	B-CHED
,	O
a	O
series	O
of	O
single	O
isonucleotide	O
-	O
incorporated	O
antisense	O
oligodeoxynucleotides	O
have	O
been	O
synthesized	O
,	O
in	O
which	O
an	O
isonucleotide	O
was	O
introduced	O
at	O
different	O
positions	O
of	O
the	O
sequences	O
.	O

This	O
paper	O
reports	O
the	O
ability	O
of	O
transgenic	O
tobacco	O
plants	O
to	O
express	O
a	O
fusion	O
protein	B-CHED
consisting	O
of	O
the	O
synthetic	O
LTB	O
and	O
a	O
synthetic	O
neutralizing	O
epitope	B-CHED
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
causing	O
an	O
enteric	O
disease	O
that	O
is	O
especially	O
severe	O
in	O
piglets	O
.	O

According	O
to	O
different	O
treatment	O
regimens	O
,	O
the	O
patients	O
were	O
divided	O
into	O
hormone	B-CHED
group	O
(	O
n	O
=	O
35	O
)	O
and	O
non	O
-	O
hormone	B-CHED
group	O
(	O
n	O
=	O
59	O
).	O

The	O
results	O
showed	O
that	O
the	O
FBS	O
medium	O
was	O
optimal	O
for	O
recombinant	O
N	O
protein	B-CHED
expression	O
and	O
growth	O
of	O
the	O
recombinant	O
strain	O
.	O

The	O
optimal	O
final	O
concentration	O
of	O
methanol	B-CHED
is	O
1	O
%	O
(	O
V	O
/	O
V	O
),	O
and	O
the	O
DO	O
has	O
a	O
significant	O
effect	O
on	O
recombinant	O
N	O
protein	B-CHED
expression	O
and	O
growth	O
of	O
recombinant	O
strain	O
.	O

The	O
recombinant	O
N	O
protein	B-CHED
expressed	O
was	O
about	O
6	O
%	O
of	O
the	O
total	O
cell	O
proteins	B-CHED
,	O
410	O
mg	O
/	O
L	O
of	O
recombinant	O
N	O
protein	B-CHED
and	O
45	O
OD600	O
were	O
achieved	O
in	O
shake	O
flask	O
.	O

SDS	B-CHED
-	O
PAGE	O
or	O
Western	O
blot	O
analysis	O
of	O
the	O
induced	O
expression	O
products	O
demonstrated	O
that	O
the	O
5	O
recombinant	O
proteins	B-CHED
were	O
expressed	O
in	O
the	O
fission	O
yeast	O
respectively	O
.	O

Immobilisation	O
under	O
paralytic	O
therapy	O
and	O
steroids	B-CHED
may	O
also	O
be	O
important	O
in	O
developing	O
rhabdomyolysis	O
.	O

The	O
major	O
risk	O
factors	O
for	O
withdrawal	O
seizures	O
were	O
symptomatic	O
etiologies	O
,	O
polytherapy	O
and	O
non	O
-	O
seizure	O
free	O
before	O
AED	B-CHED
withdrawal	O
.	O

The	O
enzyme	O
had	O
no	O
detectable	O
activity	O
on	O
several	O
other	O
nucleoside	B-CHED
phosphates	I-CHED
.	O

The	O
mean	O
ADC	B-CHED
was	O
markedly	O
greater	O
in	O
the	O
AVN	O
femoral	O
head	O
(	O
1	O
.	O
66	O
x	O
10	O
(-	O
3	O
)	O
mm	O
(	O
2	O
)/	O
second	O
+/-	O
0	O
.	O
20	O
)	O
than	O
in	O
the	O
normal	O
femoral	O
head	O
(	O
0	O
.	O
47	O
x	O
10	O
(-	O
3	O
)	O
mm	O
(	O
2	O
)/	O
second	O
+/-	O
0	O
.	O
082	O
;	O
P	O
<	O
0	O
.	O
0001	O
).	O

The	O
dosage	O
of	O
corticosteroid	B-CHED
was	O
(	O
5842	O
+/-	O

About	O
one	O
-	O
third	O
patients	O
with	O
SARS	O
who	O
were	O
treated	O
with	O
a	O
high	O
dose	O
of	O
corticosteroid	B-CHED
occurred	O
osteonecrosis	O
.	O

The	O
actual	O
time	O
of	O
onset	O
of	O
ON	O
is	O
early	O
of	O
steroid	B-CHED
used	O
.	O

RESULTS	O
:	O
No	O
osteonecrosis	O
was	O
detected	O
in	O
12	O
patients	O
without	O
corticosteroid	B-CHED
.	O

The	O
chemokines	O
interferon	O
-	O
inducible	O
protein	B-CHED
-	O
10	O
(	O
IP	O
-	O
10	O
),	O
monokine	O
induced	O
by	O
interferon	O
-	O
gamma	O
(	O
MIG	O
),	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
),	O
monocyte	O
chemoattractant	O
protein	B-CHED
-	O
1	O
(	O
MCP	B-CHED
-	O
1	O
),	O
and	O
regulated	O
upon	O
activation	O
normal	O
T	O
cell	O
expressed	O
and	O
secreted	O
(	O
RANTES	O
)	O
were	O
measured	O
by	O
cytometric	O
bead	O
array	O
with	O
a	O
4	O
-	O
color	O
FACSCalibur	O
flow	O
cytometer	O
.	O

SARS	O
-	O
associated	O
coronavirus	O
N	O
protein	B-CHED
gene	O
was	O
amplified	O
from	O
its	O
genomic	O
RNA	O
by	O
reverse	O
transcript	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
nested	O
-	O
PCR	O
)	O
and	O
cloned	O
into	O
pBAD	O
/	O
Thio	B-CHED
-	O
TOPO	O
prokaryotic	O
expression	O
vector	O
.	O

The	O
recombinant	O
expression	O
vector	O
produced	O
high	O
level	O
of	O
the	O
N	O
fusion	O
protein	B-CHED
after	O
induction	O
,	O
and	O
that	O
protein	B-CHED
was	O
purified	O
successfully	O
by	O
affinity	O
chromatography	O
and	O
displayed	O
higher	O
antigenicity	O
and	O
specificity	O
as	O
compared	O
with	O
whole	O
virus	O
lysates	O
.	O

This	O
is	O
likely	O
to	O
result	O
in	O
a	O
fragmentation	O
of	O
intellectual	O
property	O
(	O
IP	O
)	O
rights	O
which	O
in	O
turn	O
may	O
adversely	O
affect	O
the	O
development	O
of	O
products	O
,	O
such	O
as	O
vaccines	O
,	O
to	O
combat	B-CHED
SARS	O
.	O

Therefore	O
to	O
efficiently	O
express	O
difficult	O
membrane	O
proteins	B-CHED
,	O
molecular	O
biologists	O
will	O
have	O
to	O
develop	O
novel	O
or	O
innovative	O
expression	O
systems	O
.	O

In	O
addition	O
to	O
these	O
advantages	O
,	O
we	O
found	O
that	O
SUMO	O
Protease	O
1	O
,	O
can	O
cleave	O
the	O
SUMO	O
fusion	O
high	O
specificity	O
to	O
generate	O
native	O
protein	B-CHED
.	O

A	O
combination	O
of	O
the	O
sequence	O
comparison	O
method	O
BLAST	O
and	O
SVMProt	O
can	O
further	O
improve	O
the	O
prediction	O
accuracy	O
of	O
SMVProt	O
such	O
that	O
the	O
functional	O
class	O
of	O
two	O
additional	O
SARS	O
-	O
CoV	O
proteins	B-CHED
is	O
correctly	O
predicted	O
.	O

The	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
)	O
proteins	B-CHED
of	O
SARS	O
-	O
CoV	O
appear	O
to	O
be	O
the	O
dominant	O
antigens	B-CHED
recognized	O
by	O
serum	O
Abs	O
.	O

Using	O
a	O
specific	O
monoclonal	O
antibody	O
,	O
we	O
demonstrated	O
that	O
the	O
3a	O
protein	B-CHED
displayed	O
a	O
punctate	O
cytoplasmic	O
localization	O
in	O
Drosophila	O
as	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
Houttuynia	O
cordata	O
(	O
Saururaceae	O
)	O
injection	O
(	O
HCI	O
)	O
is	O
a	O
traditional	O
Chinese	O
medicine	B-CHED
used	O
in	O
China	O
.	O

It	O
was	O
chosen	O
as	O
one	O
of	O
eight	O
types	O
of	O
traditional	O
Chinese	O
medicine	B-CHED
that	O
play	O
a	O
unique	O
role	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
owing	O
to	O
the	O
effect	O
of	O
curbing	O
inflammation	O
.	O

Extensive	O
hydrogen	B-CHED
bond	O
formation	O
between	O
the	O
two	O
hairpins	O
and	O
hydrophobic	O
interactions	O
between	O
the	O
beta	O
-	O
sheet	O
and	O
the	O
alpha	O
helices	O
render	O
the	O
interface	O
highly	O
stable	O
.	O

Moreover	O
,	O
the	O
vaccine	O
confers	O
protective	O
immunity	O
as	O
demonstrated	O
by	O
prevention	O
of	O
SARS	O
-	O
CoV	O
replication	O
in	O
the	O
respiratory	O
tract	O
of	O
mice	O
after	O
intranasal	O
challenge	O
with	O
SARS	O
-	O
CoV	O
.	O
Protection	O
of	O
mice	O
was	O
correlated	O
to	O
antibody	O
titre	O
against	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
and	O
neutralising	O
antibody	O
titre	O
.	O

Beta	B-CHED
-	I-CHED
lactam	I-CHED
and	O
macrolide	B-CHED
antibiotics	I-CHED
are	O
considered	O
safe	O
in	O
pregnancy	O
and	O
are	O
effective	O
for	O
most	O
community	O
-	O
acquired	O
pneumonia	O
in	O
pregnancy	O
.	O

Prompt	O
diagnosis	O
and	O
treatment	O
with	O
contemporary	O
antimicrobial	B-CHED
therapy	O
and	O
intensive	O
care	O
unit	O
management	O
of	O
respiratory	O
compromise	O
has	O
reduced	O
the	O
maternal	O
morbidity	O
and	O
mortality	O
due	O
to	O
pneumonia	O
in	O
pregnancy	O
.	O

Prevention	O
and	O
treatment	O
of	O
Pneumocystis	O
pneumonia	O
with	O
trimethoprim	B-CHED
/	I-CHED
sulfamethoxazole	I-CHED
is	O
effective	O
in	O
reducing	O
this	O
risk	O
.	O

Gel	O
-	O
filtration	O
analysis	O
,	O
velocity	O
sedimentation	O
ultracentrifugation	O
,	O
and	O
native	O
gradient	O
pore	O
electrophoresis	O
all	O
showed	O
that	O
the	O
wild	O
-	O
type	O
protein	B-CHED
exists	O
in	O
an	O
equilibrium	O
between	O
hexamers	O
and	O
monomers	O
in	O
solution	O
,	O
with	O
hexamers	O
dominating	O
at	O
micromolar	O
protein	B-CHED
concentration	O
,	O
while	O
native	O
gradient	O
pore	O
electrophoresis	O
also	O
revealed	O
the	O
presence	O
of	O
trimers	O
.	O

TITLE	O
:	O
Screening	O
of	O
electrophilic	O
compounds	O
yields	O
an	O
aziridinyl	O
peptide	B-CHED
as	O
new	O
active	O
-	O
site	O
directed	O
SARS	O
-	O
CoV	O
main	O
protease	B-CHED
inhibitor	I-CHED
.	O

ABSTRACT	O
:	O
Infection	O
control	O
faces	O
radical	B-CHED
changes	O
at	O
the	O
beginning	O
of	O
the	O
third	O
millennium	O
.	O

TITLE	O
:	O
Crystal	O
structures	O
of	O
the	O
main	O
peptidase	O
from	O
the	O
SARS	O
coronavirus	O
inhibited	O
by	O
a	O
substrate	O
-	O
like	O
aza	O
-	O
peptide	B-CHED
epoxide	B-CHED
.	O

Balb	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
recombinant	O
Protein	B-CHED
X4	O
,	O
hybridoma	O
cell	O
lines	O
secreting	O
monoclonal	O
antibodies	O
against	O
protein	B-CHED
X4	O
were	O
screened	O
by	O
regular	O
cell	O
fusion	O
and	O
subcloning	O
approach	O
.	O

In	O
this	O
study	O
,	O
we	O
intended	O
to	O
identify	O
potential	O
3CL	O
(	O
pro	B-CHED
)-	O
interacting	O
cellular	O
protein	B-CHED
(	O
s	O
)	O
using	O
the	O
phage	O
-	O
displayed	O
human	O
lung	O
cDNA	O
library	O
.	O

TITLE	O
:	O
A	O
major	O
determinant	O
for	O
membrane	O
protein	B-CHED
interaction	O
localizes	O
to	O
the	O
carboxy	B-CHED
-	O
terminal	O
domain	O
of	O
the	O
mouse	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
.	O

In	O
previous	O
work	O
with	O
the	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
a	O
highly	O
defective	O
M	O
protein	B-CHED
mutant	O
,	O
MDelta2	O
,	O
was	O
constructed	O
.	O

TITLE	O
:	O
The	O
nsp2	O
replicase	O
proteins	B-CHED
of	O
murine	O
hepatitis	O
virus	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
are	O
dispensable	O
for	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
is	O
a	O
major	O
antigen	B-CHED
in	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
Single	O
nucleotide	B-CHED
variations	O
(	O
SNVs	O
)	O
at	O
5	O
loci	O
(	O
17564	O
,	O
21721	O
,	O
22222	O
,	O
23823	O
,	O
and	O
27827	O
)	O
were	O
used	O
to	O
define	O
the	O
molecular	O
epidemiologic	O
characteristics	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
from	O
Beijing	O
patients	O
.	O

Four	O
patients	O
(	O
4	O
.	O
1	O
%),	O
5	O
patients	O
(	O
5	O
.	O
2	O
%),	O
and	O
23	O
patients	O
(	O
23	O
.	O
7	O
%)	O
had	O
FVC	O
,	O
TLC	O
,	O
and	O
D	O
(	O
LCO	B-CHED
)	O
values	O
<	O
80	O
%	O
of	O
predicted	O
values	O
,	O
respectively	O
.	O

In	O
this	O
study	O
,	O
a	O
detailed	O
in	O
silico	O
analysis	O
of	O
the	O
ORF1ab	O
,	O
encoding	O
the	O
7	O
,	O
182	O
-	O
amino	B-CHED
acid	I-CHED
replicase	O
polyprotein	O
in	O
the	O
CoV	O
-	O
HKU1	O
genome	O
showed	O
that	O
the	O
replicase	O
polyprotein	O
of	O
CoV	O
-	O
HKU1	O
is	O
cleaved	O
by	O
its	O
papain	O
-	O
like	O
proteases	O
and	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	B-CHED
))	O
into	O
16	O
polypeptides	B-CHED
homologous	O
to	O
the	O
corresponding	O
polypeptides	B-CHED
in	O
other	O
coronaviruses	O
.	O

This	O
probably	O
represents	O
a	O
novel	O
cleavage	O
site	O
because	O
the	O
same	O
mutation	O
was	O
consistently	O
observed	O
in	O
CoV	O
-	O
HKU1	O
sequences	O
from	O
multiple	O
specimens	O
of	O
different	O
patients	O
;	O
the	O
P2	O
and	O
P1	O
'-	O
P12	O
'	O
positions	O
of	O
this	O
cleavage	O
site	O
are	O
consistent	O
between	O
CoV	O
-	O
HKU1	O
and	O
other	O
coronaviruses	O
;	O
and	O
as	O
the	O
helicase	O
is	O
one	O
of	O
the	O
most	O
conserved	O
proteins	B-CHED
in	O
coronaviruses	O
,	O
cleavage	O
between	O
nsp10	O
and	O
nsp11	O
should	O
be	O
an	O
essential	O
step	O
for	O
the	O
generation	O
of	O
the	O
mature	O
functional	O
helicase	O
.	O

The	O
MD	O
simulations	O
take	O
into	O
account	O
the	O
different	O
protonation	O
states	O
of	O
two	O
histidine	B-CHED
residues	O
in	O
the	O
substrate	O
-	O
binding	O
site	O
and	O
explain	O
the	O
pH	O
-	O
activity	O
profile	O
of	O
the	O
enzyme	O
.	O

We	O
conducted	O
a	O
prospective	O
cohort	O
study	O
at	O
the	O
respiratory	O
medicine	B-CHED
ward	O
of	O
a	O
university	O
hospital	O
to	O
study	O
the	O
success	O
rate	O
of	O
the	O
use	O
of	O
continuous	O
noninvasive	O
mechanical	O
ventilation	O
and	O
manually	O
and	O
mechanically	O
(	O
CoughAssist	O
)	O
assisted	O
coughing	O
to	O
avert	O
endotracheal	O
intubation	O
in	O
24	O
consecutive	O
episodes	O
of	O
acute	O
respiratory	O
failure	O
for	O
17	O
patients	O
with	O
neuromuscular	O
disease	O
.	O

EICAR	O
,	O
one	O
of	O
the	O
most	O
potent	O
congeners	O
of	O
ribavirin	B-CHED
,	O
has	O
10	O
to	O
100	O
times	O
greater	O
antiviral	B-CHED
potency	O
than	O
ribavirin	B-CHED
.	O

ABSTRACT	O
:	O
Analysis	O
of	O
the	O
sequence	O
of	O
a	O
number	O
of	O
proteins	B-CHED
of	O
the	O
virus	O
causing	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
)	O
was	O
used	O
to	O
theoretically	O
predict	O
antigenic	O
epitopes	O
.	O

Nine	O
sequences	O
,	O
encoding	O
for	O
the	O
predicted	O
epitopes	O
in	O
spike	O
,	O
nucleocapside	O
,	O
and	O
membranous	O
SARS	O
CoV	O
proteins	B-CHED
,	O
were	O
synthesized	O
by	O
polymyrase	O
chain	O
reaction	O
and	O
cloned	O
into	O
the	O
pGEX	O
4	O
-	O
T2	O
vector	O
.	O

Recognition	O
of	O
a	O
specific	O
sequence	O
,	O
termed	O
the	O
packaging	O
signal	O
(	O
PS	O
),	O
by	O
a	O
virus	O
N	O
protein	B-CHED
is	O
often	O
the	O
first	O
step	O
in	O
the	O
assembly	O
of	O
viral	O
RNA	O
,	O
but	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
assembly	O
of	O
SARS	O
-	O
CoV	O
RNA	O
are	O
not	O
clear	O
.	O

The	O
humoral	O
immune	O
response	O
was	O
enhanced	O
most	O
effectively	O
through	O
the	O
use	O
of	O
inactivated	O
virus	O
with	O
adjuvants	B-CHED
,	O
either	O
MF59	O
or	O
alum	O
,	O
and	O
was	O
associated	O
with	O
stimulation	O
of	O
the	O
CD4	O
but	O
not	O
the	O
CD8	O
response	O
.	O

TITLE	O
:	O
[	O
Expression	O
of	O
SARS	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
and	O
construction	O
of	O
its	O
DNA	O
vaccine	O
].	O

ABSTRACT	O
:	O
To	O
express	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
E	O
.	O
coli	O
and	O
construct	O
its	O
DNA	O
vaccine	O
.	O

RESULTS	O
:	O
Recombinant	O
N	O
protein	B-CHED
reacted	O
strongly	O
and	O
specifically	O
with	O
the	O
sera	O
from	O
immunized	O
mice	O
and	O
SARS	O
patients	O
.	O

The	O
recombinant	O
plasmid	O
pcDNA4	O
/	O
ACE	O
-	O
2	O
could	O
express	O
ACE	O
-	O
2	O
protein	B-CHED
in	O
eukaryotic	O
cells	O
and	O
induce	O
cell	O
-	O
cell	O
fusion	O
between	O
S	O
protein	B-CHED
-	O
and	O
ACE2	O
-	O
expressing	O
cells	O
.	O

There	O
are	O
also	O
many	O
opportunities	O
in	O
academia	O
,	O
certainly	O
in	O
colleges	O
of	O
veterinary	O
medicine	B-CHED
but	O
,	O
beyond	O
that	O
,	O
also	O
in	O
human	O
medicine	B-CHED
and	O
in	O
the	O
biology	O
disciplines	O
.	O

The	O
structures	O
and	O
functions	O
of	O
most	O
SARS	O
proteins	B-CHED
remain	O
unknown	O
,	O
and	O
further	O
structural	O
studies	O
will	O
be	O
important	O
for	O
revealing	O
their	O
functions	O
and	O
for	O
designing	O
potential	O
anti	O
-	O
SARS	O
therapeutics	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
if	O
the	O
duration	O
from	O
poisoning	O
to	O
treatment	O
(	O
no	O
treatment	O
period	O
)	O
is	O
related	O
to	O
the	O
prognosis	O
of	O
patients	O
with	O
severe	O
acute	O
organophosphorus	B-CHED
pesticide	I-CHED
poisoning	O
(	O
SAOPP	O
).	O

The	O
time	O
of	O
symptoms	O
disappearance	O
,	O
the	O
recovery	O
time	O
of	O
AChE	O
,	O
atropinization	O
time	O
,	O
atropine	B-CHED
dosage	O
,	O
pralidoxime	B-CHED
chloride	I-CHED
dosage	O
,	O
naloxone	B-CHED
dosage	O
,	O
hospitalization	O
days	O
in	O
treatment	O
group	O
were	O
significantly	O
superior	O
to	O
those	O
in	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

Levels	O
of	O
antimyeloperoxidase	O
-	O
antineutrophil	O
cytoplasmic	O
antibodies	O
,	O
soluble	O
thrombomodulin	O
,	O
soluble	O
interleukin	O
-	O
2	O
receptor	O
,	O
eosinophil	O
cationic	O
protein	B-CHED
were	O
elevated	O
and	O
returned	O
to	O
the	O
normal	O
range	O
in	O
remission	O
.	O

ABSTRACT	O
:	O
Alpha	O
-	O
1	O
-	O
acid	O
glycoprotein	B-CHED
(	O
AGP	O
)	O
is	O
an	O
acute	O
phase	O
protein	B-CHED
that	O
increases	O
in	O
concentration	O
in	O
infectious	O
and	O
inflammatory	O
conditions	O
.	O

Its	O
sequence	O
is	O
similar	O
to	O
yeast	O
YBR022W	O
(	O
also	O
known	O
as	O
Poa1P	O
),	O
a	O
known	O
phosphatase	O
that	O
acts	O
on	O
ADP	B-CHED
-	O
ribose	B-CHED
-	O
1	O
''-	O
phosphate	B-CHED
(	O
Appr	O
-	O
1	O
''-	O
p	O
).	O

ABSTRACT	O
:	O
Spike	O
protein	B-CHED
of	O
coronavirus	O
is	O
responsible	O
for	O
virus	O
binding	O
,	O
fusion	O
and	O
entry	O
,	O
and	O
is	O
a	O
major	O
inducer	O
of	O
neutralizing	O
antibodies	O
.	O

The	O
receptor	O
binding	O
ability	O
of	O
the	O
purified	O
soluble	O
RBD	O
protein	B-CHED
was	O
then	O
detected	O
by	O
ELISA	O
and	O
flow	O
cytometry	O
assay	O
.	O

Endothelial	O
injury	O
bio	O
-	O
markers	O
tPA	B-CHED
and	O
sTM	O
were	O
detected	O
by	O
commercial	O
ELISA	O
-	O
methods	O
.	O

Data	O
on	O
annual	O
patient	O
-	O
days	O
and	O
annual	O
consumption	O
(	O
defined	O
daily	O
dose	O
(	O
DDD	B-CHED
)	O
per	O
1000	O
patient	O
-	O
days	O
)	O
of	O
extended	O
-	O
spectrum	O
cephalosporins	B-CHED
(	O
cefotaxime	B-CHED
,	O
ceftriaxone	B-CHED
,	O
ceftazidime	B-CHED
,	O
flumoxef	O
,	O
cefepime	B-CHED
and	O
cefpirome	B-CHED
),	O
beta	B-CHED
-	I-CHED
lactam	I-CHED
-	O
beta	B-CHED
-	I-CHED
lactamase	I-CHED
inhibitor	I-CHED
combinations	O
(	O
ticarcillin	B-CHED
/	O
clavulanic	B-CHED
acid	I-CHED
and	O
piperacillin	B-CHED
/	O
tazobactam	O
),	O
carbapenems	B-CHED
(	O
imipenem	B-CHED
and	O
meropenem	B-CHED
),	O
aminoglycosides	B-CHED
(	O
amikacin	B-CHED
,	O
gentamicin	B-CHED
and	O
tobramycin	B-CHED
),	O
fluoroquinolones	O
(	O
ciprofloxacin	B-CHED
(	O
oral	O
and	O
injectable	O
)	O
and	O
oral	O
levofloxacin	B-CHED
and	O
moxifloxacin	B-CHED
)	O
from	O
1991	O
to	O
2003	O
were	O
analysed	O
.	O

was	O
significantly	O
associated	O
with	O
the	O
increased	O
usage	O
of	O
extended	O
-	O
spectrum	O
cephalosporins	B-CHED
but	O
not	O
with	O
the	O
other	O
four	O
classes	O
of	O
antibiotics	B-CHED
.	O

Additionally	O
we	O
have	O
identified	O
a	O
role	O
for	O
the	O
3	O
'-	O
terminal	O
42	O
-	O
nucleotide	B-CHED
host	O
protein	B-CHED
binding	O
element	O
in	O
RNA	O
replication	O
and	O
transcription	O
using	O
DI	O
RNA	O
replication	O
assays	O
and	O
targeted	O
recombination	O
and	O
by	O
directly	O
constructing	O
mutants	O
in	O
this	O
protein	B-CHED
binding	O
element	O
using	O
a	O
recently	O
described	O
MHV	O
reverse	O
genetic	O
system	O
.	O

Expression	O
of	O
ACE2	O
in	O
poorly	O
differentiated	O
epithelia	O
facilitated	O
SARS	O
spike	O
(	O
S	O
)	O
protein	B-CHED
-	O
pseudotyped	O
virus	O
entry	O
.	O

ABSTRACT	O
:	O
The	O
envelope	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
mediates	O
the	O
entry	O
of	O
the	O
virus	O
into	O
target	O
cells	O
.	O

Model	O
predictions	O
accounting	O
for	O
this	O
variation	O
differ	O
sharply	O
from	O
average	O
-	O
based	O
approaches	O
,	O
with	O
disease	O
extinction	O
more	O
likely	O
and	O
outbreaks	O
rarer	O
but	O
more	O
explosive	B-CHED
.	O

The	O
subcellular	O
localization	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
N	O
protein	B-CHED
was	O
studied	O
.	O

In	O
contrast	O
to	O
the	O
avian	O
coronavirus	O
N	O
protein	B-CHED
,	O
overexpressed	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
remained	O
principally	O
localized	O
to	O
the	O
cytoplasm	O
,	O
with	O
very	O
few	O
cells	O
exhibiting	O
nucleolar	O
localization	O
.	O

However	O
,	O
cytoplasmic	O
localization	O
was	O
directed	O
by	O
region	O
III	O
and	O
was	O
the	O
dominant	O
localization	O
signal	O
in	O
the	O
protein	B-CHED
.	O

RESULTS	O
:	O
After	O
implementation	O
of	O
iLA	O
,	O
a	O
rapid	O
increase	O
in	O
CO2	B-CHED
-	O
elimination	O
(	O
Pa	O
(	O
CO2	B-CHED
)	O
before	O
iLA	O
:	O
8	O
.	O
92	O
+/-	O
2	O
.	O
9	O
kPa	O
,	O
immediately	O
after	O
implementation	O
:	O
5	O
.	O
06	O
+/-	O
0	O
.	O
93	O
kPa	O
,	O
24	O
h	O
after	O
implementation	O
:	O
4	O
.	O
53	O
+/-	O
1	O
.	O
20	O
kPa	O
[	O
mean	O
+/-	O
SD	O
],	O
P	O
<	O
0	O
.	O
05	O
)	O
was	O
observed	O
and	O
a	O
significant	O
improvement	O
in	O
oxygenation	O
(	O
Pa	O
(	O
O2	O
)	O
before	O
iLA	O
:	O
6	O
.	O
66	O
+/-	O
2	O
.	O
26	O
kPa	O
,	O
immediately	O
after	O
implementation	O
:	O
10	O
.	O
39	O
+/-	O
3	O
.	O
33	O
kPa	O
,	O
24	O
h	O
after	O
implementation	O
:	O
10	O
.	O
25	O
+/-	O
5	O
.	O
46	O
kPa	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
was	O
noted	O
.	O

Scoring	O
was	O
based	O
on	O
the	O
area	O
and	O
location	O
of	O
lung	O
opacification	O
on	O
radiographs	O
obtained	O
at	O
each	O
of	O
five	O
milestones	O
(	O
presentation	O
,	O
beginning	O
of	O
ribavirin	B-CHED
therapy	O
,	O
beginning	O
of	O
corticosteroid	B-CHED
therapy	O
,	O
time	O
of	O
most	O
severe	O
radiographic	O
appearance	O
of	O
disease	O
,	O
and	O
before	O
discharge	O
or	O
death	O
).	O

Recombinant	O
mouse	O
hepatitis	O
viruses	O
expressing	O
the	O
accessory	O
hemagglutinin	O
esterase	O
protein	B-CHED
display	O
reduced	O
fitness	O
in	O
vitro	O
.	O

While	O
HE	O
may	O
provide	O
a	O
strong	O
selective	O
advantage	O
during	O
natural	O
infection	O
,	O
many	O
laboratory	O
strains	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
fail	O
to	O
produce	O
the	O
protein	B-CHED
.	O

However	O
,	O
viral	O
proteins	B-CHED
other	O
than	O
S	O
also	O
contribute	O
to	O
pathogenicity	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
a	O
316	O
-	O
amino	O
-	O
acid	O
catalytic	O
core	O
domain	O
of	O
PLpro	O
that	O
can	O
efficiently	O
cleave	O
replicase	O
substrates	O
in	O
trans	O
-	O
cleavage	O
assays	O
and	O
peptide	B-CHED
substrates	O
in	O
fluorescent	O
resonance	O
energy	O
transfer	O
-	O
based	O
protease	O
assays	O
.	O

In	O
addition	O
,	O
SARS	O
-	O
CoV	O
PLpro	O
was	O
inhibited	O
by	O
the	O
specific	O
deubiquitinating	O
enzyme	B-CHED
inhibitor	I-CHED
ubiquitin	O
aldehyde	B-CHED
,	O
with	O
an	O
inhibition	O
constant	O
of	O
210	O
nM	O
.	O
The	O
purified	O
SARS	O
-	O
CoV	O
PLpro	O
disassembles	O
branched	O
polyubiquitin	O
chains	O
with	O
lengths	O
of	O
two	O
to	O
seven	O
(	O
Ub2	O
-	O
7	O
)	O
or	O
four	O
(	O
Ub4	O
)	O
units	O
,	O
which	O
involves	O
isopeptide	O
bond	O
cleavage	O
.	O

To	O
this	O
end	O
,	O
the	O
soR	O
domain	O
was	O
coupled	O
to	O
single	O
-	O
chain	O
monoclonal	O
antibody	O
425	O
,	O
which	O
is	O
directed	O
against	O
the	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
),	O
resulting	O
in	O
a	O
bispecific	O
adapter	O
protein	B-CHED
(	O
soR	O
-	O
425	O
).	O

The	O
SARS	O
-	O
CoV	O
receptor	O
,	O
human	O
angiotensin	B-CHED
1	O
-	O
converting	O
enzyme	O
2	O
(	O
hACE2	O
),	O
was	O
detected	O
in	O
ciliated	O
airway	O
epithelial	O
cells	O
of	O
human	O
airway	O
tissues	O
derived	O
from	O
nasal	O
or	O
tracheobronchial	O
regions	O
,	O
suggesting	O
that	O
SARS	O
-	O
CoV	O
may	O
infect	O
the	O
proximal	O
airways	O
.	O

SARS	O
-	O
CoV	O
structural	O
proteins	B-CHED
and	O
virions	O
localized	O
to	O
ciliated	O
epithelial	O
cells	O
.	O

HO	O
-	O
1	O
null	O
(	O
HO	O
-	O
1	O
(-/-))	O
mice	O
exhibited	O
severe	O
physiologic	O
lung	O
dysfunction	O
following	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)	O
nebulization	O
,	O
but	O
had	O
similar	O
inflammatory	O
responses	O
as	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
.	O

By	O
monitoring	O
apoptosis	O
indicators	O
including	O
chromatin	O
condensation	O
,	O
cellular	O
DNA	O
fragmentation	O
and	O
cell	O
membrane	O
asymmetry	O
,	O
we	O
demonstrated	O
that	O
the	O
adenovirus	O
-	O
mediated	O
over	O
-	O
expression	O
of	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
and	O
its	O
C	O
-	O
terminal	O
domain	O
(	O
S2	O
)	O
induce	O
apoptosis	O
in	O
Vero	O
E6	O
cells	O
in	O
a	O
time	O
-	O
and	O
dosage	O
-	O
dependent	O
manner	O
,	O
whereas	O
the	O
expression	O
of	O
its	O
N	O
-	O
terminal	O
domain	O
(	O
S1	O
)	O
and	O
other	O
structural	O
proteins	B-CHED
,	O
including	O
envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
do	O
not	O
.	O

Elevated	O
levels	O
of	O
lactate	B-CHED
in	O
brain	O
,	O
blood	O
,	O
and	O
cerebrospinal	O
fluid	O
,	O
abnormal	O
urine	O
organic	B-CHED
acids	I-CHED
,	O
and	O
changes	O
in	O
muscle	O
respiratory	O
chain	O
enzymes	O
are	O
present	O
but	O
inconsistent	O
,	O
without	O
identifiable	O
mitochondrial	O
DNA	O
mutations	O
or	O
deletions	O
.	O

Pooled	O
tissue	O
samples	O
(	O
trachea	O
,	O
kidney	O
,	O
caecal	O
tonsils	O
and	O
cloacal	O
swabs	O
)	O
from	O
164	O
broiler	O
and	O
53	O
layer	O
flocks	O
located	O
throughout	O
New	O
Zealand	O
were	O
collected	O
in	O
transport	O
medium	O
containing	O
antibiotics	B-CHED
.	O

Addressing	O
concerns	O
about	O
lost	B-CHED
income	O
by	O
residents	O
in	O
quarantine	O
was	O
particularly	O
challenging	O
.	O

Yolk	O
immunoglobulin	O
(	O
IgY	O
)	O
was	O
extracted	O
using	O
the	O
water	B-CHED
dilution	O
method	O
,	O
followed	O
by	O
further	O
purification	O
on	O
a	O
Sephadex	O
G	O
-	O
75	O
column	O
.	O

Rev	O
.	O
Drug	O
Disc	O
.	O
2002	O
,	O
1	O
220	O
],	O
is	O
limited	O
by	O
a	O
known	O
challenge	O
in	O
crystallographically	O
determining	O
flexible	O
regions	O
of	O
proteins	B-CHED
.	O

A	O
small	O
-	O
molecule	O
inhibitor	B-CHED
of	O
SARS	O
-	O
CoV	O
,	O
exhibiting	O
an	O
effective	O
concentration	O
(	O
EC50	O
)	O
of	O
23	O
microM	O
in	O
cell	O
-	O
based	O
assays	O
,	O
was	O
identified	O
through	O
virtual	O
screening	O
against	O
a	O
computer	O
-	O
predicted	O
model	O
of	O
the	O
cysteine	B-CHED
proteinase	O
.	O

the	O
rapid	O
development	O
of	O
multiorgan	O
failure	O
following	O
the	O
above	O
-	O
mentioned	O
identifiable	O
precipitating	O
factors	O
,	O
the	O
involvement	O
of	O
unusual	O
organs	O
such	O
as	O
bowel	O
,	O
reproductive	O
organs	O
,	O
and	O
bone	O
marrow	O
,	O
complicating	O
features	O
of	O
disseminated	O
intravascular	O
coagulation	O
in	O
20	O
%	O
of	O
cases	O
,	O
the	O
acute	O
(	O
adult	O
)	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
one	O
third	O
of	O
patients	O
,	O
and	O
severe	O
thrombocytopenia	O
;	O
these	O
not	O
being	O
encountered	O
in	O
the	O
simple	O
/	O
classic	O
APS	B-CHED
.	O

Antifungal	B-CHED
therapy	O
may	O
also	O
be	O
indicated	O
with	O
prolonged	O
treatment	O
and	O
the	O
use	O
of	O
the	O
monoclonal	O
anti	O
-	O
CD20	O
molecule	O
,	O
Rituximab	O
,	O
has	O
proven	O
useful	O
in	O
those	O
patients	O
where	O
thrombocytopenia	O
poses	O
a	O
major	O
risk	O
of	O
hemorrhage	O
.	O

The	O
N	O
-	O
terminal	O
octapeptide	O
N8	O
and	O
its	O
mutants	O
were	O
also	O
synthesized	O
and	O
tested	O
for	O
their	O
potency	O
as	O
dimerization	O
inhibitors	B-CHED
.	O

Peptide	B-CHED
cleavage	O
assay	O
confirms	O
that	O
peptide	B-CHED
N8	O
is	O
a	O
dimerization	O
inhibitor	B-CHED
with	O
a	O
K	O
(	O
i	O
)	O
of	O
2	O
.	O
20mM	O
.	O
The	O
comparison	O
of	O
the	O
inhibitory	O
activities	O
of	O
N8	O
and	O
its	O
mutants	O
indicates	O
that	O
the	O
hydrophobic	O
interaction	O
of	O
Met	B-CHED
-	O
6	O
and	O
the	O
electrostatic	O
interaction	O
of	O
Arg	B-CHED
-	O
4	O
contribute	O
most	O
for	O
inhibitor	B-CHED
binding	O
.	O

This	O
study	O
describes	O
the	O
first	O
example	O
of	O
inhibitors	B-CHED
targeting	O
the	O
dimeric	O
interface	O
of	O
SARS	O
3CL	O
proteinase	O
,	O
providing	O
a	O
novel	O
strategy	O
for	O
drug	O
design	O
against	O
SARS	O
and	O
other	O
coronaviruses	O
.	O

This	O
rapid	O
viral	O
diagnosis	O
will	O
be	O
further	O
confirmed	O
in	O
post	O
mortem	O
by	O
the	O
positive	O
Influenza	O
strain	O
isolation	O
onto	O
lung	O
tissues	O
by	O
classical	O
cell	O
culture	O
techniques	O
(	O
Influenzavirus	O
A	O
strain	O
,	O
H3N2	B-CHED
).	O

ABSTRACT	O
:	O
Autocleavage	O
assay	O
and	O
peptide	B-CHED
-	O
based	O
cleavage	O
assay	O
were	O
used	O
to	O
study	O
the	O
substrate	O
specificity	O
of	O
3CL	O
protease	O
from	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

The	O
binding	O
of	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
to	O
cellular	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
the	O
first	O
step	O
in	O
SARS	O
-	O
CoV	O
infection	O
.	O

Angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
a	O
cellular	O
receptor	O
for	O
two	O
divergent	O
coronaviruses	O
,	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
).	O

ABSTRACT	O
:	O
Chronic	O
ethanol	B-CHED
(	O
EtOH	B-CHED
)	O
ingestion	O
increases	O
the	O
incidence	O
of	O
the	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
),	O
a	O
severe	O
form	O
of	O
acute	O
lung	O
injury	O
characterized	O
by	O
endothelial	O
and	O
epithelial	O
barrier	O
dysfunction	O
.	O

These	O
findings	O
clarify	O
mechanisms	O
by	O
which	O
chronic	O
EtOH	B-CHED
stimulation	O
modulates	O
vascular	O
endothelial	O
function	O
and	O
suggest	O
new	O
targets	O
for	O
investigation	O
and	O
intervention	O
in	O
EtOH	B-CHED
-	O
induced	O
alterations	O
in	O
susceptibility	O
to	O
lung	O
injury	O
.	O

A	O
set	O
of	O
methods	O
for	O
surface	O
modification	O
of	O
micro	O
-	O
channels	O
on	O
such	O
materials	O
have	O
been	O
developed	O
,	O
which	O
results	O
in	O
better	O
reproducibility	O
and	O
higher	O
efficiency	O
in	O
protein	B-CHED
and	O
peptide	B-CHED
analysis	O
.	O

However	O
,	O
treatment	O
with	O
a	O
caspase	O
-	O
8	O
inhibitor	B-CHED
only	O
slightly	O
blocked	O
cytochrome	B-CHED
c	I-CHED
release	O
from	O
the	O
mitochondria	O
.	O

TITLE	O
:	O
Effects	O
of	O
additional	O
milk	O
replacer	O
feeding	O
on	O
calf	O
health	O
,	O
growth	O
,	O
and	O
selected	O
blood	O
metabolites	B-CHED
in	O
calves	O
.	O

In	O
particular	O
,	O
we	O
used	O
x	O
-	O
ray	O
reflectivity	O
to	O
study	O
the	O
location	O
of	O
an	O
iodine	B-CHED
-	O
labeled	O
residue	O
within	O
the	O
lipid	B-CHED
bilayer	O
.	O

These	O
organisms	O
are	O
often	O
identified	O
in	O
immunosuppressed	O
patients	O
,	O
either	O
due	O
to	O
human	O
immunodeficiency	O
virus	O
or	O
from	O
immunosuppressant	B-CHED
medications	O
post	O
-	O
transplantation	O
.	O

Her	O
postoperative	O
course	O
was	O
complicated	O
by	O
severe	O
sepsis	O
syndrome	O
with	O
respiratory	O
failure	O
,	O
hypotension	O
,	O
leukocytosis	O
,	O
and	O
DIC	B-CHED
.	O

Variability	O
was	O
more	O
pronounced	O
for	O
the	O
spike	O
gene	O
,	O
with	O
2	O
clusters	B-CHED
of	O
strains	O
.	O

TITLE	O
:	O
7a	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
inhibits	O
cellular	O
protein	B-CHED
synthesis	O
and	O
activates	O
p38	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinase	O
.	O

The	O
7a	O
protein	B-CHED
was	O
tested	O
for	O
the	O
ability	O
to	O
inhibit	O
cellular	O
gene	O
expression	O
because	O
several	O
proapoptotic	O
viral	O
proteins	B-CHED
with	O
this	O
function	O
have	O
previously	O
been	O
identified	O
.	O

Western	O
blot	O
analysis	O
using	O
phosphospecific	O
antibodies	O
indicated	O
that	O
7a	O
protein	B-CHED
activated	O
p38	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinase	O
(	O
MAPK	O
),	O
but	O
not	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
protein	B-CHED
kinase	O
/	O
stress	O
-	O
activated	O
protein	B-CHED
kinase	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
an	O
Escherichia	O
coli	O
-	O
expressed	O
,	O
denatured	O
spike	O
(	O
S	O
)	O
protein	B-CHED
fragment	O
of	O
the	O
severe	O
acute	O
respiratory	O
coronavirus	O
,	O
containing	O
residues	O
1029	O
to	O
1192	O
which	O
include	O
the	O
heptad	O
repeat	O
2	O
(	O
HR2	O
)	O
domain	O
,	O
was	O
able	O
to	O
induce	O
neutralizing	O
polyclonal	O
antibodies	O
(	O
C	O
.	O
T	O
.	O
Keng	O
,	O
A	O
.	O
Zhang	O
,	O
S	O
.	O
Shen	O
,	O
K	O
.	O
M	O
.	O
Lip	O
,	O
B	O
.	O
C	O
.	O
Fielding	O
,	O
T	O
.	O
H	O
.	O
Tan	O
,	O
C	O
.	O
F	O
.	O
Chou	O
,	O
C	O
.	O
B	O
.	O
Loh	O
,	O
S	O
.	O
Wang	O
,	O
J	O
.	O
Fu	O
,	O
X	O
.	O
Yang	O
,	O
S	O
.	O
G	O
.	O
Lim	O
,	O
W	O
.	O
Hong	O
,	O
and	O
Y	O
.	O
J	O
.	O
Tan	O
,	O
J	O
.	O
Virol	O
.	O

These	O
results	O
provide	O
evidence	O
of	O
novel	O
neutralizing	O
epitopes	O
that	O
are	O
located	O
in	O
the	O
HR2	O
domain	O
and	O
the	O
spacer	O
region	O
immediately	O
upstream	O
of	O
the	O
HR2	O
of	O
the	O
S	O
protein	B-CHED
.	O

Studies	O
on	O
proteins	B-CHED
in	O
SARS	O
-	O
CoV	O
are	O
shown	O
as	O
an	O
example	O
for	O
remote	O
homolog	O
identification	O
application	O
.	O

TITLE	O
:	O
Spectral	O
quality	O
and	O
UV	O
-	O
B	O
stress	O
stimulate	O
glycyrrhizin	B-CHED
concentration	O
of	O
Glycyrrhiza	O
uralensis	O
in	O
hydroponic	O
and	O
pot	O
system	O
.	O

The	O
concentrations	O
of	O
glycyrrhizin	B-CHED
quantified	O
in	O
the	O
root	O
tissues	O
were	O
highest	O
in	O
the	O
plants	O
grown	O
under	O
red	O
light	O
in	O
both	O
hydroponic	O
and	O
pot	O
systems	O
and	O
the	O
concentration	O
increased	O
linearly	O
from	O
1	O
-	O
to	O
3	O
-	O
month	O
-	O
old	O
pot	O
plants	O
.	O

Both	O
the	O
low	O
and	O
high	O
intensity	O
of	O
UV	O
-	O
B	O
exposure	O
increased	O
the	O
concentration	O
of	O
glycyrrhizin	B-CHED
in	O
the	O
root	O
tissues	O
of	O
3	O
-	O
month	O
-	O
old	O
pot	O
plants	O
,	O
the	O
values	O
being	O
nearly	O
X1	O
.	O
5	O
those	O
of	O
the	O
control	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
nucleocapsid	O
immunodominant	O
T	O
-	O
cell	O
epitope	B-CHED
cluster	O
is	O
common	O
to	O
both	O
exogenous	O
recombinant	O
and	O
endogenous	O
DNA	O
-	O
encoded	O
immunogens	O
.	O

A	O
wide	O
variety	O
of	O
pyridine	B-CHED
N	I-CHED
-	I-CHED
oxide	I-CHED
derivatives	O
have	O
been	O
found	O
to	O
be	O
inhibitory	O
against	O
feline	O
coronavirus	O
(	O
FIPV	O
strain	O
)	O
and	O
human	O
SARS	O
-	O
CoV	O
(	O
Frankfurt	O
strain	O
-	O
1	O
)	O
in	O
CRFK	O
and	O
simian	O
kidney	O
(	O
Vero	O
)	O
cell	O
cultures	O
,	O
respectively	O
.	O

The	O
worst	O
-	O
case	O
scenario	O
would	O
be	O
the	O
emergence	O
of	O
a	O
transmissible	O
,	O
small	O
,	O
nonenveloped	O
virus	O
in	O
the	O
blood	O
donor	B-CHED
population	O
.	O

But	O
it	O
showed	O
no	O
significant	O
difference	O
on	O
quality	O
of	O
life	O
or	O
glucocorticoid	B-CHED
dosage	O
.	O

Because	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	O
)	O
has	O
been	O
reported	O
to	O
play	O
roles	O
in	O
the	O
pathogenesis	O
of	O
acute	O
lung	O
injury	O
,	O
the	O
present	O
study	O
explores	O
the	O
effects	O
on	O
VILI	O
of	O
NO	O
derived	O
from	O
chronically	O
overexpressed	O
endothelial	O
nitric	B-CHED
oxide	I-CHED
synthase	O
(	O
eNOS	O
).	O

The	O
lung	O
tissue	O
is	O
very	O
rich	O
in	O
this	O
protein	B-CHED
;	O
many	O
different	O
lung	O
cells	O
produce	O
VEGF	O
and	O
also	O
respond	O
to	O
VEGF	O
.	O

The	O
pulmonary	O
inflammatory	O
reaction	O
in	O
rat	O
models	O
were	O
induced	O
by	O
intratracheal	O
instillation	O
of	O
N	O
-	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
with	O
a	O
dose	O
of	O
0	O
.	O
2	O
mg	O
/	O
kg	O
.	O

The	O
surface	O
glycoprotein	B-CHED
is	O
a	O
major	O
virulence	O
factor	O
in	O
most	O
coronavirus	O
infections	O
.	O

This	O
is	O
achieved	O
by	O
cellular	O
palmitoyl	B-CHED
acyltransferases	O
(	O
PATs	O
),	O
which	O
can	O
modify	O
newly	O
synthesized	O
S	O
proteins	B-CHED
before	O
they	O
are	O
assembled	O
into	O
virion	O
envelopes	O
at	O
the	O
intermediate	O
compartment	O
of	O
the	O
exocytic	O
pathway	O
.	O

At	O
defined	O
2	O
-	O
BP	O
doses	O
,	O
underpalmitoylated	O
S	O
proteins	B-CHED
instead	O
trafficked	O
to	O
infected	O
cell	O
surfaces	O
and	O
elicited	O
cell	O
-	O
cell	O
membrane	O
fusions	O
,	O
suggesting	O
that	O
the	O
acyl	O
chain	O
adducts	O
are	O
more	O
critical	O
to	O
virion	O
assembly	O
than	O
to	O
S	O
-	O
induced	O
syncytial	O
developments	O
.	O

Our	O
collective	O
results	O
indicate	O
that	O
the	O
palmitate	B-CHED
adducts	O
on	O
coronavirus	O
S	O
proteins	B-CHED
are	O
necessary	O
in	O
assembly	O
and	O
also	O
in	O
positioning	O
the	O
assembled	O
envelope	O
proteins	B-CHED
for	O
maximal	O
infectivity	O
.	O

S	O
(	O
VSV	O
-	O
Cyt	B-CHED
),	O
an	O
S	O
chimera	O
with	O
a	O
cytoplasmic	O
tail	O
derived	O
from	O
vesicular	O
stomatitis	O
virus	O
G	O
protein	B-CHED
(	O
VSV	O
-	O
G	O
),	O
and	O
S	O
(	O
MHV	O
-	O
TMDCyt	O
),	O
an	O
S	O
chimera	O
with	O
the	O
cytoplasmic	O
and	O
transmembrane	O
domains	O
of	O
mouse	O
hepatitis	O
virus	O
,	O
displayed	O
wild	O
-	O
type	O
-	O
like	O
activity	O
in	O
both	O
assays	O
.	O

The	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
is	O
the	O
major	O
organ	O
system	O
affected	O
,	O
although	O
the	O
renal	O
,	O
gastrointestinal	O
(	O
GI	O
),	O
endocrine	B-CHED
,	O
and	O
cardiovascular	O
(	O
CV	O
)	O
systems	O
also	O
may	O
be	O
involved	O
.	O

Thus	O
,	O
in	O
contrast	O
to	O
various	O
viruses	O
including	O
HIV	O
(	O
human	O
immunodeficiency	O
virus	O
)	O
examined	O
in	O
parallel	O
,	O
the	O
functions	O
of	O
the	O
SARS	O
-	O
CoV	O
Spike	O
glycoprotein	B-CHED
exhibit	O
a	O
significant	O
and	O
surprising	O
independence	O
of	O
redox	O
state	O
,	O
which	O
may	O
contribute	O
to	O
the	O
wide	O
host	O
range	O
of	O
the	O
virus	O
.	O

Coinfections	O
and	O
sequential	O
infections	O
by	O
HCMV	O
and	O
respiratory	O
viruses	O
were	O
significantly	O
more	O
frequent	O
in	O
patients	O
with	O
acute	O
rejection	O
and	O
steroid	B-CHED
treatment	O
.	O

Molecular	O
approaches	O
can	O
serve	O
to	O
boost	O
expression	O
levels	O
and	O
target	O
the	O
expressed	O
protein	B-CHED
for	O
appropriate	O
post	O
-	O
translational	O
modification	O
.	O

Many	O
antigens	B-CHED
have	O
been	O
expressed	O
in	O
plants	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
inhibits	O
the	O
activity	O
of	O
cyclin	O
-	O
cyclin	O
-	O
dependent	O
kinase	O
complex	O
and	O
blocks	O
S	O
phase	O
progression	O
in	O
mammalian	O
cells	O
.	O

The	O
N	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
bears	O
signature	O
motifs	O
for	O
binding	O
to	O
cyclin	O
and	O
phosphorylation	O
by	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
CDK	O
)	O
and	O
has	O
recently	O
been	O
reported	O
by	O
us	O
to	O
get	O
phosphorylated	O
by	O
the	O
cyclin	O
-	O
CDK	O
complex	O
(	O
Surjit	O
,	O
M	O
.,	O
Kumar	O
,	O
R	O
.,	O
Mishra	O
,	O
R	O
.	O
N	O
.,	O
Reddy	O
,	O
M	O
.	O
K	O
.,	O
Chow	O
,	O
V	O
.	O
T	O
.,	O
and	O
Lal	O
,	O
S	O
.	O
K	O
.	O
(	O
2005	O
)	O
J	O
.	O
Virol	O
.	O
79	O
,	O
11476	O
-	O
11486	O
).	O

TITLE	O
:	O
Antiviral	B-CHED
applications	O
of	O
RNAi	O
for	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Until	O
the	O
appearance	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
caused	O
by	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
early	O
2003	O
,	O
coronavirus	O
infection	O
was	O
not	O
considered	O
to	O
be	O
serious	O
enough	O
to	O
be	O
controlled	O
by	O
either	O
vaccination	O
or	O
specific	O
antiviral	B-CHED
therapy	O
.	O

TITLE	O
:	O
Fibrinogen	O
-	O
like	O
protein	B-CHED
2	O
fibroleukin	O
expression	O
and	O
its	O
correlation	O
with	O
disease	O
progression	O
in	O
murine	O
hepatitis	O
virus	O
type	O
3	O
-	O
induced	O
fulminant	O
hepatitis	O
and	O
in	O
patients	O
with	O
severe	O
viral	O
hepatitis	O
B	O
.	O
ABSTRACT	O
:	O
To	O
evaluate	O
the	O
expression	O
of	O
fibrinogen	O
-	O
like	O
protein	B-CHED
2	O
(	O
fgl2	O
)	O
and	O
its	O
correlation	O
with	O
disease	O
progression	O
in	O
both	O
mice	O
and	O
patients	O
with	O
severe	O
viral	O
hepatitis	O
.	O

PCA	B-CHED
significantly	O
increased	O
in	O
PBMC	O
in	O
patients	O
with	O
severe	O
AOC	O
hepatitis	O
B	O
.	O
The	O
molecular	O
and	O
cellular	O
results	O
reported	O
here	O
in	O
both	O
mice	O
and	O
patients	O
with	O
severe	O
viral	O
hepatitis	O
suggest	O
that	O
virus	O
-	O
induced	O
hfgl2	O
prothrombinase	O
/	O
fibroleukin	O
expression	O
and	O
the	O
coagulation	O
activity	O
associated	O
with	O
the	O
encoded	O
fgl2	O
protein	B-CHED
play	O
a	O
pivotal	O
role	O
in	O
initiating	O
severe	O
hepatitis	O
.	O

Patients	O
were	O
subjected	O
to	O
a	O
protocol	O
including	O
(	O
i	O
)	O
withdrawal	O
of	O
most	O
immunosuppressants	O
,	O
(	O
ii	O
)	O
early	O
use	O
of	O
immunoenhancers	O
and	O
continuous	O
renal	O
replacement	O
therapy	O
(	O
CRRT	O
),	O
(	O
iii	O
)	O
reasonable	O
administration	O
of	O
antibiotic	B-CHED
regimen	O
,	O
(	O
iv	O
)	O
prompt	O
mechanical	O
ventilating	O
strategy	O
,	O
and	O
(	O
v	O
)	O
adequate	O
nutrition	O
.	O

TITLE	O
:	O
Characterization	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
membrane	O
protein	B-CHED
.	O

Further	O
analyses	O
revealed	O
that	O
M	O
contained	O
a	O
single	O
N	O
-	O
glycosylation	O
site	O
at	O
asparagine	B-CHED
4	O
.	O

ABSTRACT	O
:	O
New	O
pathogens	O
and	O
antimicrobial	B-CHED
-	O
resistant	O
forms	O
of	O
older	O
pathogens	O
continue	O
to	O
emerge	O
,	O
some	O
with	O
the	O
potential	O
for	O
rapid	O
,	O
global	O
spread	O
and	O
high	O
morbidity	O
and	O
mortality	O
.	O

ABSTRACT	O
:	O
Current	O
methods	O
for	O
interpreting	O
oligonucleotide	B-CHED
-	O
based	O
SNP	O
-	O
detection	O
microarrays	O
,	O
SNP	O
chips	O
,	O
are	O
based	O
on	O
statistics	O
and	O
require	O
extensive	O
parameter	O
tuning	O
as	O
well	O
as	O
extremely	O
high	O
-	O
resolution	O
images	O
of	O
the	O
chip	O
being	O
processed	O
.	O

This	O
fragment	O
encompassed	O
all	O
of	O
the	O
genes	O
encoding	O
the	O
structural	O
proteins	B-CHED
of	O
the	O
virus	O
.	O

Sequence	O
analysis	O
found	O
that	O
ten	O
type	O
II	O
CCVs	O
fragments	O
of	O
M	O
gene	O
shared	O
a	O
high	O
similarity	O
with	O
reference	O
strain	O
CCV	O
1	O
-	O
71	O
(	O
96	O
.	O
5	O
-	O
99	O
.	O
5	O
%),	O
and	O
four	O
type	O
I	O
CCVs	O
shared	O
a	O
high	O
similarity	O
(	O
96	O
.	O
7	O
%-	O
98	O
.	O
1	O
%)	O
with	O
a	O
reported	O
FCV	B-CHED
-	O
like	O
CCV	O
strain	O
.	O

The	O
newly	O
synthesized	O
1	B-CHED
,	I-CHED
2	I-CHED
,	I-CHED
3	I-CHED
-	I-CHED
triazole	I-CHED
analogue	O
(	O
17c	O
)	O
exhibited	O
potent	O
antiviral	B-CHED
activity	O
(	O
EC	O
(	O
50	O
)	O
0	O
.	O
4	O
microM	O
)	O
against	O
vaccinia	O
virus	O
and	O
moderate	O
activities	O
(	O
EC	O
(	O
50	O
)	O
39	O
microM	O
)	O
against	O
cowpox	O
virus	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARSCoV	O
)	O
(	O
EC	O
(	O
50	O
)	O
47	O
microM	O
).	O

ABSTRACT	O
:	O
Animal	O
-	O
derived	O
,	O
protein	B-CHED
-	O
containing	O
surfactants	B-CHED
seem	O
to	O
be	O
superior	O
to	O
protein	B-CHED
-	O
free	O
surfactants	B-CHED
.	O

0	O
.	O
1	O
mL	O
/	O
cm	O
H2O	B-CHED
per	O
kg	O
vs	O
0	O
.	O
3	O
+/-	O

0	O
.	O
1	O
mL	O
/	O
cm	O
H2O	B-CHED
per	O
kg	O
).	O

The	O
demonstration	O
of	O
successful	O
postexposure	O
MAb	O
201	O
therapy	O
in	O
an	O
animal	O
model	O
that	O
demonstrates	O
viral	O
replication	O
and	O
associated	O
pulmonary	O
pathological	O
findings	O
suggests	O
that	O
MAb	O
201	O
may	O
be	O
useful	O
in	O
the	O
arsenal	O
of	O
tools	O
to	O
combat	B-CHED
SARS	O
.	O

Our	O
method	O
relies	O
on	O
the	O
efficiency	O
of	O
site	O
-	O
specific	O
solution	O
-	O
phase	O
coupling	O
of	O
biotinylated	O
synthetic	O
peptides	B-CHED
to	O
NeutrAvidin	O
(	O
NA	O
)	O
and	O
localized	O
microdispensing	O
of	O
peptide	B-CHED
-	O
NA	O
-	O
complexes	O
onto	O
activated	O
glass	O
surfaces	O
.	O

By	O
using	O
spacer	O
molecules	O
of	O
different	O
type	O
and	O
length	O
for	O
NA	O
-	O
mediated	O
peptide	B-CHED
presentation	O
,	O
we	O
show	O
that	O
the	O
incorporation	O
of	O
a	O
minimum	O
spacer	O
length	O
is	O
imperative	O
for	O
antibody	O
binding	O
,	O
whereas	O
the	O
peptide	B-CHED
immobilization	O
direction	O
has	O
only	O
secondary	O
importance	O
for	O
antibody	O
affinity	O
and	O
binding	O
.	O

ABSTRACT	O
:	O
Serum	O
samples	O
collected	O
from	O
178	O
shot	O
wild	O
boars	O
(	O
Sus	O
scrofa	O
)	O
were	O
tested	O
for	O
the	O
presence	O
of	O
antibodies	O
against	O
classical	O
swine	O
fever	O
virus	O
,	O
Aujeszky	O
'	O
s	O
disease	O
virus	O
(	O
ADV	O
),	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
,	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
),	O
transmissible	O
gastroenteritis	O
virus	O
,	O
swine	O
influenza	O
virus	O
,	O
porcine	O
parvovirus	O
(	O
PPV	B-CHED
),	O
swine	O
vesicular	O
disease	O
virus	O
,	O
Actinobacillus	O
pleuropneumoniae	O
(	O
APP	B-CHED
),	O
Mycoplasma	O
hyopneumoniae	O
,	O
Salmonella	O
spp	O
.,	O
Brucella	O
spp	O
.	O

To	O
analyse	O
the	O
antigenicity	O
of	O
the	O
SARS	O
-	O
CoV	O
genome	O
and	O
identify	O
potential	O
antigenic	O
epitopes	O
in	O
the	O
structural	O
proteins	B-CHED
.	O

Epitopes	O
at	O
the	O
N	O
-	O
terminus	O
of	O
the	O
membrane	O
protein	B-CHED
and	O
the	O
C	O
-	O
terminus	O
of	O
nucleocapsid	O
protein	B-CHED
elicited	O
strong	O
antibody	O
responses	O
.	O

Antibodies	O
were	O
also	O
detected	O
for	O
some	O
putative	O
proteins	B-CHED
,	O
noticeably	O
the	O
C	O
-	O
termini	O
of	O
SARS3a	O
and	O
SARS6	O
.	O

He	O
was	O
transferred	O
from	O
another	O
hospital	O
to	O
the	O
department	O
of	O
intensive	O
care	O
medicine	B-CHED
for	O
further	O
diagnosis	O
and	O
treatment	O
.	O

The	O
conserved	O
glycosylation	O
of	O
the	O
coronavirus	O
M	O
proteins	B-CHED
and	O
the	O
resemblance	O
of	O
the	O
3a	O
protein	B-CHED
to	O
them	O
led	O
us	O
to	O
investigate	O
the	O
glycosylation	O
of	O
these	O
two	O
SARS	O
-	O
CoV	O
membrane	O
proteins	B-CHED
.	O

While	O
the	O
M	O
protein	B-CHED
acquired	O
cotranslationally	O
oligosaccharides	B-CHED
that	O
could	O
be	O
removed	O
by	O
PNGaseF	O
,	O
the	O
3a	O
protein	B-CHED
acquired	O
its	O
modifications	O
posttranslationally	O
,	O
and	O
they	O
were	O
not	O
sensitive	O
to	O
the	O
N	O
-	O
glycosidase	O
enzyme	O
.	O

By	O
using	O
an	O
antiserum	O
raised	O
against	O
the	O
pp1a	O
/	O
pp1ab	O
residues	O
526	O
-	O
713	O
,	O
the	O
upstream	O
processing	O
product	O
,	O
nsp2	O
,	O
was	O
identified	O
as	O
an	O
85	O
kDa	O
protein	B-CHED
in	O
TGEV	O
-	O
infected	O
cells	O
.	O

Furthermore	O
,	O
PL1	O
(	O
pro	B-CHED
)	O
was	O
confirmed	O
to	O
be	O
flanked	O
at	O
its	O
C	O
terminus	O
by	O
a	O
domain	O
(	O
called	O
X	O
)	O
that	O
mediates	O
ADP	B-CHED
-	O
ribose	B-CHED
1	O
''-	O
phosphatase	O
activity	O
.	O

These	O
preliminary	O
data	O
suggest	O
that	O
a	O
severe	O
reduction	O
in	O
compliance	O
in	O
the	O
early	O
phase	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
is	O
associated	O
with	O
both	O
collagen	O
deposition	O
and	O
surfactant	B-CHED
degradation	O
.	O

Cellular	O
mRNA	B-CHED
transcription	O
,	O
which	O
was	O
reported	O
to	O
be	O
up	O
-	O
regulated	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Caco	O
-	O
2	O
cells	O
,	O
was	O
not	O
up	O
-	O
regulated	O
in	O
virus	O
-	O
infected	O
Vero	O
E6	O
cells	O
,	O
partially	O
as	O
a	O
result	O
of	O
apoptosis	O
.	O

These	O
results	O
suggested	O
that	O
inhibition	O
of	O
cell	O
proliferation	O
is	O
regulated	O
by	O
both	O
the	O
phosphatidylinositol	B-CHED
3	O
'-	O
kinase	O
/	O
Akt	O
signaling	O
pathway	O
and	O
by	O
apoptosis	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

TITLE	O
:	O
Environmental	O
factors	O
on	O
the	O
SARS	O
epidemic	O
:	O
air	B-CHED
temperature	O
,	O
passage	O
of	O
time	O
and	O
multiplicative	O
effect	O
of	O
hospital	O
infection	O
.	O

In	O
contrast	O
to	O
primary	O
effectors	O
,	O
reactivated	O
memory	O
cells	O
persisted	O
in	O
the	O
CNS	B-CHED
at	O
higher	O
frequencies	O
and	O
retained	O
ex	O
vivo	O
cytolytic	O
activity	O
.	O

ABSTRACT	O
:	O
The	O
recombinant	O
nucleocapsid	O
(	O
rN	O
)	O
protein	B-CHED
of	O
the	O
coronavirus	O
(	O
CoV	O
)	O
responsible	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
was	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
extracted	O
from	O
cell	O
lysates	O
containing	O
6M	O
urea	B-CHED
,	O
then	O
purified	O
by	O
Ni	O
(	O
2	O
+)-	O
affinity	O
chromatography	O
.	O

To	O
identify	O
the	O
B	O
-	O
cell	O
immunodominant	O
epitopes	O
of	O
the	O
rN	O
protein	B-CHED
in	O
the	O
mouse	O
and	O
monkey	O
,	O
the	O
reactivities	O
of	O
antisera	O
raised	O
against	O
purified	O
rN	O
proteins	B-CHED
formulated	O
in	O
ISA	O
-	O
51	O
/	O
CpG	O
were	O
tested	O
with	O
a	O
panel	O
of	O
overlapping	O
synthetic	O
peptides	B-CHED
covering	O
the	O
entire	O
N	O
protein	B-CHED
sequence	O
.	O

To	O
identify	O
functional	O
CTL	O
epitopes	O
of	O
the	O
N	O
protein	B-CHED
,	O
BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
peptides	B-CHED
containing	O
the	O
H	O
-	O
2K	O
(	O
d	O
)	O
CTL	O
motif	O
emulsified	O
in	O
adjuvant	B-CHED
ISA	O
-	O
51	O
/	O
CpG	O
.	O
Using	O
an	O
IFN	O
-	O
gamma	O
secretion	O
cell	O
assay	O
and	O
analysis	O
by	O
flow	O
cytometry	O
,	O
peptides	B-CHED
containing	O
residues	O
81	O
-	O
95	O
were	O
found	O
to	O
be	O
capable	O
of	O
stimulating	O
both	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
cell	O
proliferation	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Side	O
effects	O
of	O
interferon	O
-	O
ribavirin	B-CHED
combination	O
therapy	O
limit	O
the	O
sustained	O
viral	O
response	O
achievable	O
in	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
patients	O
.	O

128	O
IU	O
/	O
L	O
(	O
ribavirin	B-CHED
);	O
848	O
+/-	O

An	O
increased	O
concentration	O
of	O
NO	O
in	O
exhaled	O
air	B-CHED
has	O
been	O
reported	O
in	O
airway	O
diseases	O
,	O
characterized	O
by	O
airway	O
inflammation	O
,	O
such	O
as	O
bronchial	O
asthma	O
,	O
where	O
its	O
concentration	O
is	O
related	O
to	O
bronchial	O
hyperresponsiveness	O
and	O
sputum	O
eosinophilia	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
ecto	O
-	O
domain	O
of	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	B-CHED
vaccine	O
,	O
with	O
or	O
without	O
adjuvant	B-CHED
,	O
is	O
immunogenic	O
and	O
induces	O
high	O
titers	O
of	O
virus	O
neutralizing	O
antibodies	O
to	O
levels	O
similar	O
to	O
those	O
achieved	O
with	O
the	O
full	O
S	O
glycoprotein	B-CHED
vaccine	O
.	O

According	O
to	O
the	O
analysis	O
of	O
461	O
cases	O
divided	O
by	O
stages	O
and	O
different	O
ponderance	O
,	O
within	O
7	O
days	O
after	O
illness	O
,	O
in	O
the	O
ITCWM	O
group	O
,	O
the	O
glucocorticoid	B-CHED
'	O
s	O
average	O
dosage	O
decreased	O
.	O

Despite	O
the	O
availability	O
of	O
antimicrobial	B-CHED
agents	O
,	O
pneumonia	O
constitutes	O
the	O
sixth	O
most	O
common	O
cause	O
of	O
death	O
and	O
the	O
number	O
one	O
cause	O
of	O
death	O
from	O
infection	O
.	O

Furthermore	O
,	O
the	O
efficiencies	O
of	O
frameshifting	O
mediated	O
by	O
the	O
hepta	O
-	O
and	O
octo	O
-	O
uridine	B-CHED
stretches	O
were	O
not	O
affected	O
by	O
mutations	O
introduced	O
into	O
a	O
downstream	O
stem	O
-	O
loop	O
structure	O
that	O
totally	O
abolish	O
the	O
frameshift	O
event	O
mediated	O
by	O
the	O
original	O
slippery	O
sequence	O
of	O
ORF	O
1a	O
and	O
1b	O
.	O

Taken	O
together	O
,	O
this	O
study	O
identifies	O
the	O
hepta	O
-	O
and	O
octo	O
-	O
uridine	B-CHED
stretches	O
that	O
function	O
as	O
sole	O
elements	O
for	O
efficient	O
+	O
1	O
and	O
-	O
1	O
ribosomal	O
frameshift	O
events	O
.	O

Moreover	O
,	O
SARS	O
-	O
CoV	O
induced	O
THP	B-CHED
-	O
1	O
cells	O
to	O
express	O
CCL2	B-CHED
/	O
MCP	B-CHED
-	O
1	O
,	O
CXCL8	O
/	O
IL	O
-	O
8	O
,	O
CCL3	B-CHED
/	O
MIP	O
-	O
1alpha	O
,	O
CXCL10	O
/	O
IP	O
-	O
10	O
,	O
CCL4	B-CHED
/	O
MIP	O
-	O
1beta	O
,	O
and	O
CCL5	O
/	O
RANTES	O
,	O
which	O
attracted	O
neutrophils	O
,	O
monocytes	O
,	O
and	O
activated	O
T	O
cells	O
in	O
a	O
chemotaxis	O
assay	O
.	O

TITLE	O
:	O
Biochemical	O
and	O
functional	O
characterization	O
of	O
the	O
membrane	O
association	O
and	O
membrane	O
permeabilizing	O
activity	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
envelope	O
protein	B-CHED
.	O

In	O
this	O
work	O
we	O
present	O
the	O
NMR	O
structure	O
of	O
the	O
HR2	O
domain	O
(	O
residues	O
1141	O
-	O
1193	O
)	O
from	O
SARS	O
-	O
CoV	O
(	O
termed	O
S2	O
-	O
HR2	O
)	O
in	O
the	O
presence	O
of	O
the	O
co	O
-	O
solvent	B-CHED
trifluoroethanol	B-CHED
.	O

Alanine	B-CHED
scanning	O
mutagenesis	O
analysis	O
was	O
performed	O
to	O
identify	O
determinants	O
on	O
ACE2	O
critical	O
for	O
SARS	O
-	O
CoV	O
infection	O
.	O

22	O
-	O
44	O
and	O
351	O
-	O
357	O
)	O
artificially	O
linked	O
together	O
by	O
glycine	B-CHED
,	O
exhibited	O
a	O
potent	O
antiviral	B-CHED
activity	O
with	O
IC50	O
of	O
about	O
0	O
.	O
1	O
microM	O
.	O
This	O
novel	O
peptide	B-CHED
is	O
a	O
promising	O
candidate	O
as	O
a	O
therapeutic	O
agent	O
against	O
this	O
deadly	O
emerging	O
pathogen	O
.	O

Aimed	O
at	O
generating	O
analogues	O
by	O
metabolic	O
engineering	O
,	O
the	O
valinomycin	B-CHED
biosynthetic	O
gene	O
cluster	O
has	O
been	O
cloned	O
from	O
Streptomyces	O
tsusimaensis	O
ATCC	O
15141	O
.	O

Sequence	O
analysis	O
of	O
the	O
NRPS	O
system	O
reveals	O
four	O
distinctive	O
modules	O
,	O
two	O
of	O
which	O
contain	O
unusual	O
domain	O
organizations	O
that	O
are	O
presumably	O
involved	O
in	O
the	O
generation	O
of	O
biosynthetic	O
precursors	O
D	O
-	O
alpha	B-CHED
-	I-CHED
hydroxyisovaleric	I-CHED
acid	I-CHED
and	O
L	B-CHED
-	I-CHED
lactic	I-CHED
acid	I-CHED
.	O

In	O
the	O
absence	O
of	O
an	O
effective	O
vaccine	O
,	O
antiviral	B-CHED
agents	I-CHED
could	O
provide	O
an	O
important	O
response	O
measure	O
.	O

To	O
determine	O
whether	O
proteolytic	O
cleavage	O
of	O
the	O
S	O
glycoprotein	B-CHED
might	O
be	O
important	O
for	O
the	O
newly	O
emerged	O
SARS	O
-	O
CoV	O
,	O
we	O
introduced	O
a	O
furin	O
recognition	O
site	O
at	O
single	O
basic	O
residues	O
within	O
the	O
putative	O
S1	O
-	O
S2	O
junctional	O
region	O
.	O

Because	O
of	O
its	O
critical	O
role	O
in	O
viral	O
entry	O
,	O
the	O
S	O
protein	B-CHED
is	O
an	O
important	O
target	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
CoV	O
therapeutics	O
and	O
prophylactics	O
.	O

The	O
mechanisms	O
that	O
contribute	O
to	O
disturbed	O
alveolar	O
fibrin	O
turnover	O
are	O
localized	O
tissue	O
factor	O
-	O
mediated	O
thrombin	O
generation	O
and	O
depression	O
of	O
bronchoalveolar	O
urokinase	O
plasminogen	O
activator	O
-	O
mediated	O
fibrinolysis	O
,	O
caused	O
by	O
the	O
increase	O
of	O
plasminogen	O
activator	O
inhibitors	B-CHED
.	O

Theoretical	O
considerations	O
suggest	O
that	O
this	O
anticoagulant	B-CHED
therapy	O
will	O
benefit	O
patients	O
with	O
primary	O
lung	O
pathology	O
including	O
VILI	O
,	O
but	O
clinical	O
studies	O
are	O
needed	O
to	O
examine	O
this	O
hypothesis	O
before	O
such	O
therapy	O
is	O
to	O
be	O
advocated	O
as	O
a	O
standard	O
of	O
care	O
in	O
critically	O
ill	O
patients	O
.	O

Moreover	O
,	O
the	O
reported	O
results	O
indicated	O
that	O
the	O
use	O
of	O
one	O
single	O
protein	B-CHED
as	O
a	O
detection	O
antigen	B-CHED
of	O
SARS	O
-	O
CoV	O
infection	O
may	O
lead	O
to	O
false	O
-	O
positive	O
diagnosis	O
.	O

These	O
may	O
be	O
rectified	O
by	O
using	O
more	O
than	O
one	O
protein	B-CHED
for	O
the	O
serodiagnosis	O
of	O
SARS	O
-	O
CoV	O
.	O

Hydrocortisone	B-CHED
and	O
other	O
glucorticoid	O
agents	O
have	O
a	O
powerful	O
modulating	O
effect	O
on	O
inflammation	O
and	O
balance	B-CHED
between	O
pro	B-CHED
-	O
and	O
anti	O
-	O
inflammatory	O
factors	O
.	O

Modest	O
sequence	O
conservation	O
within	O
gene	O
1	O
has	O
enabled	O
the	O
design	O
of	O
oligonucleotide	B-CHED
primers	O
for	O
use	O
in	O
diagnostic	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reactions	O
,	O
which	O
will	O
be	O
useful	O
for	O
the	O
detection	O
of	O
new	O
coronaviruses	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
diagnostics	O
using	O
a	O
coronavirus	O
protein	B-CHED
microarray	O
.	O

ABSTRACT	O
:	O
To	O
monitor	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
infection	O
,	O
a	O
coronavirus	O
protein	B-CHED
microarray	O
that	O
harbors	O
proteins	B-CHED
from	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
five	O
additional	O
coronaviruses	O
was	O
constructed	O
.	O

We	O
further	O
show	O
that	O
IBV	O
was	O
not	O
inactivated	O
,	O
and	O
fusion	O
was	O
unaffected	O
,	O
by	O
prior	O
exposure	O
to	O
pH	O
5	O
.	O
0	O
buffer	B-CHED
.	O

The	O
patient	O
did	O
not	O
respond	O
to	O
antibiotic	B-CHED
and	O
antifungal	B-CHED
therapy	O
.	O

Patients	O
>	O
or	O
=	O
18	O
years	O
old	O
who	O
either	O
had	O
not	O
received	O
corticosteroid	B-CHED
or	O
had	O
taken	O
corticosteroids	B-CHED
within	O
14	O
days	O
from	O
symptom	O
onset	O
were	O
included	O
.	O

Patients	O
receiving	O
corticosteroids	B-CHED
beyond	O
15	O
days	O
or	O
other	O
investigational	O
treatment	O
within	O
21	O
days	O
from	O
symptom	O
onset	O
were	O
excluded	O
.	O

Crude	O
death	O
rate	O
was	O
lower	O
among	O
1188	O
steroid	B-CHED
-	O
treated	O
patients	O
compared	O
to	O
99	O
patients	O
in	O
Group	O
No	O
Steroid	B-CHED
(	O
17	O
.	O
0	O
%	O
vs	O
.	O
28	O
.	O
3	O
%).	O

Patients	O
on	O
hydrocortisone	B-CHED
(	O
Group	O
HC	O
)	O
had	O
the	O
highest	O
positive	O
culture	O
rates	O
.	O

ABSTRACT	O
:	O
In	O
contrast	O
to	O
indocyanine	B-CHED
green	I-CHED
(	O
ICG	B-CHED
)	O
blood	O
clearance	O
,	O
the	O
plasma	O
disappearance	O
rate	O
(	O
PDR	O
)	O
of	O
ICG	B-CHED
does	O
not	O
require	O
absolute	O
ICG	B-CHED
blood	O
concentrations	O
and	O
today	O
can	O
be	O
assessed	O
transcutaneously	O
.	O

The	O
SARS	O
-	O
CoV	O
S	O
and	O
M	O
protein	B-CHED
-	O
targeted	O
Fab	O
or	O
IgG	O
antibodies	O
showed	O
significant	O
neutralizing	O
activities	O
in	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
inhibition	O
neutralization	O
test	O
,	O
these	O
antibodies	O
were	O
able	O
to	O
completely	O
neutralize	O
the	O
SARS	O
virus	O
and	O
protect	O
the	O
Vero	O
cells	O
from	O
CPE	O
after	O
virus	O
infection	O
.	O

ABSTRACT	O
:	O
To	O
prepare	O
and	O
characterize	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
against	O
the	O
recombinant	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
of	O
3	O
human	O
coronaviruses	O
SARS	O
-	O
CoV	O
,	O
229E	O
and	O
OC43	O
and	O
study	O
the	O
antigenic	O
relationship	O
between	O
the	O
3	O
N	O
proteins	B-CHED
.	O

RESULTS	O
:	O
The	O
mAbs	O
against	O
the	O
recombinant	O
N	O
proteins	B-CHED
of	O
SARS	O
-	O
CoV	O
,	O
229E	O
and	O
OC43	O
were	O
obtained	O
,	O
which	O
reacted	O
specifically	O
with	O
the	O
corresponding	O
viral	O
N	O
protein	B-CHED
as	O
shown	O
by	O
indirect	O
ELISA	O
,	O
Western	O
blotting	O
and	O
indirect	O
immunofluorescence	O
assay	O
.	O

APTT	O
,	O
PC	O
,	O
AT	O
-	O
III	O
,	O
PAI	O
,	O
APC	O
-	O
R	O
,	O
and	O
PLG	B-CHED
were	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
a	O
highly	O
efficacious	O
method	O
for	O
preparation	O
of	O
soluble	O
SARS	O
S	O
-	O
protein	B-CHED
using	O
adenovirus	O
vector	O
to	O
meet	O
the	O
requirement	O
for	O
S	O
-	O
protein	B-CHED
investigation	O
.	O

The	O
human	O
adenovirus	O
vector	O
was	O
used	O
to	O
express	O
the	O
soluble	O
S	O
-	O
protein	B-CHED
(	O
corresponding	O
to	O
1	O
approximately	O
1190	O
amino	B-CHED
acids	I-CHED
)	O
fused	O
with	O
Myc	O
/	O
His	O
tag	O
using	O
codon	O
-	O
optimized	O
gene	O
construct	O
in	O
HEK239	O
cells	O
.	O

Moreover	O
,	O
in	O
vivo	O
signalling	O
pathway	O
assay	O
indicated	O
that	O
3CLpro	O
increased	O
the	O
activation	O
of	O
the	O
nuclear	O
factor	O
-	O
kappa	O
B	O
-	O
dependent	O
reporter	O
,	O
but	O
inhibited	O
activator	O
protein	B-CHED
-	O
1	O
-	O
dependent	O
transcription	O
.	O

Additional	O
comparative	O
genomic	O
studies	O
,	O
including	O
sequence	O
similarity	O
and	O
protein	B-CHED
secondary	O
structure	O
analyses	O
,	O
suggested	O
that	O
SARS	O
-	O
CoV	O
may	O
bear	O
a	O
closer	O
relationship	O
with	O
group	O
2	O
than	O
with	O
the	O
other	O
coronavirus	O
groups	O
.	O

Testing	O
of	O
nasopharyngeal	O
aspirates	O
(	O
NPA	B-CHED
)	O
from	O
children	O
,	O
throat	O
swabs	O
,	O
and	O
nasal	O
swabs	O
from	O
adults	O
indicated	O
ImmunoCard	O
STAT	O
!	O

ABSTRACT	O
:	O
To	O
test	O
the	O
hypothesis	O
that	O
the	O
interaction	O
between	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
and	O
glucocorticoid	B-CHED
receptor	O
alpha	O
(	O
GRalpha	O
)	O
is	O
a	O
key	O
pathogenetic	O
mechanism	O
regulating	O
the	O
progression	O
of	O
systemic	O
and	O
pulmonary	O
inflammation	O
in	O
sepsis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
we	O
used	O
an	O
ex	O
vivo	O
model	O
of	O
systemic	O
inflammation	O
.	O

We	O
similarly	O
hypothesized	O
that	O
a	O
ventilatory	O
strategy	O
based	O
on	O
PEEP	B-CHED
above	O
the	O
lower	O
inflection	O
point	O
of	O
the	O
pressure	O
volume	O
curve	O
of	O
the	O
respiratory	O
system	O
(	O
Pflex	O
)	O
set	O
on	O
day	O
1	O
with	O
a	O
low	O
tidal	O
volume	O
would	O
result	O
in	O
improved	O
outcome	O
in	O
patients	O
with	O
severe	O
and	O
persistent	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

A	O
mechanical	O
ventilation	O
strategy	O
with	O
a	O
PEEP	B-CHED
level	O
set	O
on	O
day	O
1	O
above	O
Pflex	O
and	O
a	O
low	O
tidal	O
volume	O
compared	O
with	O
a	O
strategy	O
with	O
a	O
higher	O
tidal	O
volume	O
and	O
relatively	O
low	O
PEEP	B-CHED
has	O
a	O
beneficial	O
impact	O
on	O
outcome	O
in	O
patients	O
with	O
severe	O
and	O
persistent	O
ARDS	O
.	O

The	O
destruction	O
of	O
pancreatic	O
parenchyma	O
induces	O
a	O
systemic	O
activation	O
of	O
coagulation	O
,	O
kinin	O
,	O
complement	O
and	O
fibrinolytic	O
cascades	O
with	O
liberation	O
of	O
cytokines	O
and	O
reactive	O
oxygen	B-CHED
metabolites	B-CHED
which	O
,	O
if	O
severe	O
and	O
overwhelming	O
,	O
can	O
lead	O
to	O
shock	O
,	O
acute	O
renal	O
failure	O
and	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

In	O
selected	O
circumstances	O
,	O
endoscopic	O
retrograde	O
cholangiopancreatography	O
(	O
ERCP	O
),	O
antibiotics	B-CHED
and	O
surgical	O
drainage	O
are	O
used	O
.	O

Successful	O
lung	O
-	O
protective	O
ventilation	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
and	O
renal	O
failure	O
may	O
require	O
modification	O
of	O
hemodialysis	O
in	O
order	O
to	O
combat	B-CHED
severe	O
acidemia	O
.	O

Recently	O
,	O
we	O
identified	O
cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)-	O
derived	O
prostaglandin	B-CHED
E	O
(	O
2	O
)	O
(	O
PGE	B-CHED
(	O
2	O
))	O
and	O
lipoxin	B-CHED
A	O
(	O
4	O
)	O
(	O
LXA	O
(	O
4	O
))	O
as	O
pivotal	O
mediators	O
in	O
vivo	O
for	O
resolution	O
of	O
acid	O
-	O
initiated	O
acute	O
lung	O
injury	O
.	O

Upper	O
limit	O
estimates	O
of	O
ADE	B-CHED
rate	O
were	O
derived	O
from	O
review	O
of	O
published	O
clinical	O
trials	O
reporting	O
gemcitabine	B-CHED
-	O
associated	O
lung	O
injury	O
rates	O
of	O
10	O
%	O
or	O
higher	O
.	O

Eleven	O
Phase	O
II	O
or	O
Phase	O
III	O
clinical	O
trials	O
with	O
317	O
patients	O
identified	O
gemcitabine	B-CHED
-	O
associated	O
lung	O
injury	O
rates	O
of	O
greater	O
than	O
10	O
%,	O
with	O
the	O
highest	O
rates	O
(	O
22	O
%	O
and	O
42	O
%)	O
being	O
observed	O
in	O
Phase	O
III	O
clinical	O
trials	O
where	O
Hodgkin	O
disease	O
patients	O
were	O
treated	O
with	O
a	O
regimen	O
that	O
included	O
gemcitabine	B-CHED
and	O
bleomycin	B-CHED
.	O

In	O
the	O
course	O
of	O
these	O
studies	O
,	O
it	O
has	O
been	O
observed	O
that	O
regardless	O
of	O
the	O
gene	O
insert	O
(	O
expressing	O
the	O
vaccine	O
immunogen	B-CHED
or	O
cytokine	O
adjuvant	B-CHED
)	O
and	O
regardless	O
of	O
the	O
promoter	O
used	O
to	O
drive	O
expression	O
of	O
the	O
gene	O
insert	O
in	O
the	O
plasmid	O
backbone	O
,	O
the	O
plasmid	O
vaccines	O
do	O
not	O
biodistribute	O
widely	O
and	O
remain	O
essentially	O
in	O
the	O
site	O
of	O
injection	O
,	O
in	O
the	O
muscle	O
and	O
overlying	O
subcutis	O
.	O

This	O
chapter	O
will	O
highlight	O
recent	O
discoveries	O
that	O
have	O
provided	O
insight	O
into	O
the	O
diverse	O
biologic	O
roles	O
of	O
chemokines	O
and	O
their	O
receptors	O
in	O
coordinating	O
immune	O
responses	O
following	O
viral	O
infection	O
of	O
the	O
CNS	B-CHED
.	O

Oral	O
and	O
nasal	O
inoculations	O
of	O
recombinant	O
L	O
.	O
casei	O
into	O
mice	O
resulted	O
in	O
high	O
levels	O
of	O
serum	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
and	O
mucosal	O
IgA	O
,	O
as	O
demonstrated	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
using	O
S	O
protein	B-CHED
peptides	B-CHED
.	O

Analysis	O
of	O
various	O
cell	O
cycle	O
-	O
regulatory	O
proteins	B-CHED
and	O
cellular	O
morphology	O
indicated	O
that	O
there	O
was	O
a	O
down	O
-	O
regulation	O
of	O
cyclins	O
D1	O
and	O
D2	O
(	O
G1	O
regulatory	O
cyclins	O
)	O
and	O
that	O
a	O
proportion	O
of	O
virus	O
-	O
infected	O
cells	O
underwent	O
aberrant	O
cytokinesis	O
,	O
in	O
which	O
the	O
cells	O
underwent	O
nuclear	O
,	O
but	O
not	O
cytoplasmic	O
,	O
division	O
.	O

TITLE	O
:	O
Structure	O
,	O
function	O
and	O
evolution	O
of	O
the	O
hemagglutinin	O
-	O
esterase	O
proteins	B-CHED
of	O
corona	B-CHED
-	O
and	O
toroviruses	O
.	O

The	O
nucleotide	B-CHED
sequences	O
of	O
the	O
7a7b	O
amplification	O
products	O
were	O
determined	O
and	O
analyzed	O
.	O

Although	O
the	O
7b	O
gene	O
was	O
also	O
found	O
to	O
contain	O
mutations	O
,	O
these	O
were	O
primarily	O
point	O
mutations	O
resulting	O
in	O
minor	O
amino	B-CHED
acid	I-CHED
changes	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
interaction	O
of	O
a	O
SARS	O
-	O
CoV	O
7a	O
and	O
small	O
glutamine	B-CHED
-	O
rich	O
tetratricopeptide	O
repeat	O
-	O
containing	O
protein	B-CHED
(	O
SGT	O
).	O

Recent	O
studies	O
indicate	O
that	O
the	O
RAS	B-CHED
also	O
plays	O
a	O
critical	O
role	O
in	O
acute	O
lung	O
diseases	O
,	O
especially	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Thus	O
,	O
the	O
RAS	B-CHED
appears	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Replication	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
requires	O
proteolytic	O
processing	O
of	O
the	O
replicase	O
polyprotein	O
by	O
two	O
viral	O
cysteine	B-CHED
proteases	O
,	O
a	O
chymotrypsin	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
and	O
a	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
).	O

To	O
gain	O
insight	O
into	O
the	O
active	O
-	O
site	O
recognition	O
of	O
the	O
C	O
-	O
terminal	O
tail	O
of	O
ubiquitin	O
and	O
the	O
related	O
LXGG	O
motif	O
,	O
we	O
propose	O
a	O
model	O
of	O
PLpro	O
in	O
complex	O
with	O
ubiquitin	O
-	O
aldehyde	B-CHED
that	O
reveals	O
well	O
defined	O
sites	O
within	O
the	O
catalytic	O
cleft	O
that	O
help	O
to	O
account	O
for	O
strict	O
substrate	O
-	O
recognition	O
motifs	O
.	O

Currently	O
,	O
in	O
spite	O
of	O
encouraging	O
results	O
in	O
preclinical	O
studies	O
,	O
only	O
a	O
few	O
antisense	O
oligonucleotides	B-CHED
and	O
ribozymes	O
have	O
turned	O
out	O
to	O
be	O
efficient	O
antiviral	B-CHED
compounds	O
in	O
clinical	O
trials	O
.	O

The	O
deduced	O
sequence	O
of	O
66	O
amino	B-CHED
acids	I-CHED
had	O
66	O
to	O
74	O
%	O
amino	B-CHED
acid	I-CHED
identity	O
with	O
the	O
corresponding	O
sequence	O
of	O
coronaviruses	O
in	O
groups	O
1	O
,	O
2	O
and	O
3	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
,	O
or	O
SCV	O
),	O
which	O
caused	O
a	O
world	O
-	O
wide	O
epidemic	O
in	O
2002	O
and	O
2003	O
,	O
binds	O
to	O
a	O
receptor	O
,	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
through	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
its	O
envelope	O
(	O
spike	O
,	O
S	O
)	O
glycoprotein	B-CHED
.	O

The	O
antibody	O
epitope	B-CHED
is	O
dominated	O
by	O
a	O
10	O
-	O
residue	O
-	O
long	O
protruding	O
beta6	O
-	O
beta7	O
loop	O
with	O
two	O
putative	O
ACE2	O
-	O
binding	O
hotspot	O
residues	O
(	O
Ile	B-CHED
-	O
489	O
and	O
Tyr	B-CHED
-	O
491	O
).	O

TITLE	O
:	O
[	O
Microenvironment	O
of	O
positive	O
pressure	O
powered	O
air	B-CHED
purifying	O
medical	O
protective	O
equipment	O
].	O

Here	O
we	O
present	O
a	O
rapid	O
and	O
high	O
-	O
throughput	O
screening	O
method	O
to	O
study	O
the	O
substrate	O
specificity	O
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
).	O

Sialic	B-CHED
acid	I-CHED
-	O
dependent	O
infection	O
was	O
also	O
observed	O
with	O
strain	O
M41	O
of	O
IBV	O
,	O
which	O
infects	O
primary	O
chicken	O
kidney	O
cells	O
but	O
not	O
cells	O
from	O
other	O
species	O
.	O

Here	O
,	O
it	O
is	O
discussed	O
that	O
binding	O
to	O
sialic	B-CHED
acid	I-CHED
may	O
be	O
used	O
by	O
IBV	O
for	O
primary	O
attachment	O
to	O
the	O
cell	O
surface	O
;	O
tighter	O
binding	O
and	O
subsequent	O
fusion	O
between	O
the	O
viral	O
and	O
the	O
cellular	O
membrane	O
may	O
require	O
interaction	O
with	O
a	O
second	O
receptor	O
.	O

In	O
contrast	O
,	O
the	O
relative	O
conservation	O
of	O
the	O
M	O
and	O
E	O
proteins	B-CHED
of	O
BCoV	O
including	O
Korean	O
WD	O
strains	O
and	O
the	O
other	O
coronaviruses	O
suggested	O
that	O
structural	O
constraints	O
on	O
these	O
proteins	B-CHED
are	O
rigid	O
,	O
resulting	O
in	O
more	O
limited	O
evolution	O
of	O
these	O
proteins	B-CHED
.	O

TITLE	O
:	O
Continuous	O
nebulized	O
albuterol	B-CHED
attenuates	O
acute	O
lung	O
injury	O
in	O
an	O
ovine	O
model	O
of	O
combined	O
burn	O
and	O
smoke	O
inhalation	O
.	O

The	O
wet	O
-	O
to	O
-	O
dry	O
lung	O
weight	O
ratio	O
and	O
bronchial	O
obstruction	O
scores	O
were	O
lower	O
for	O
sheep	O
receiving	O
albuterol	B-CHED
.	O

TITLE	O
:	O
Nucleic	O
-	O
acid	O
-	O
based	O
antiviral	B-CHED
agents	I-CHED
against	O
positive	O
single	O
-	O
stranded	O
RNA	O
viruses	O
.	O

In	O
this	O
review	O
,	O
iwe	O
provide	O
an	O
overview	O
of	O
the	O
antiviral	B-CHED
antisense	O
field	O
,	O
highlighting	O
specific	O
studies	O
of	O
interest	O
over	O
the	O
past	O
several	O
years	O
,	O
using	O
our	O
experience	O
with	O
coxsackievirus	O
B3	O
as	O
a	O
reference	O
point	O
.	O

The	O
success	O
of	O
anti	O
-	O
HIV	O
-	O
1	O
therapy	O
using	O
specific	O
and	O
potent	O
protease	B-CHED
inhibitors	I-CHED
suggests	O
that	O
viral	O
proteases	O
can	O
be	O
the	O
valid	O
molecular	O
targets	O
for	O
the	O
development	O
of	O
antiviral	B-CHED
drugs	I-CHED
against	O
other	O
viruses	O
.	O

This	O
work	O
reviews	O
features	O
of	O
viral	O
proteases	O
with	O
respective	O
to	O
the	O
development	O
of	O
effective	O
antiviral	B-CHED
therapy	O
.	O

The	O
above	O
helicases	O
and	O
all	O
related	O
viral	O
proteins	B-CHED
are	O
classified	O
here	O
based	O
on	O
their	O
evolutionary	O
and	O
functional	O
similarities	O
,	O
and	O
the	O
key	O
mechanistic	O
features	O
of	O
each	O
group	O
are	O
noted	O
.	O

Thus	O
,	O
alpha	O
,	O
beta	O
-	O
unsaturated	O
peptidomimetics	B-CHED
,	O
anilides	O
,	O
metal	B-CHED
-	O
conjugated	O
compounds	O
,	O
boronic	B-CHED
acids	I-CHED
,	O
quinolinecarboxylate	O
derivatives	O
,	O
thiophenecarboxylates	O
,	O
phthalhydrazide	O
-	O
substituted	O
ketoglutamine	O
analogues	O
,	O
isatin	B-CHED
and	O
natural	B-CHED
products	I-CHED
have	O
been	O
identified	O
as	O
potent	O
inhibitors	B-CHED
of	O
the	O
SARS	O
-	O
CoV	O
main	O
protease	O
.	O

A	O
number	O
of	O
conserved	O
negatively	O
charged	O
amino	B-CHED
acids	I-CHED
are	O
located	O
within	O
domain	O
III	O
in	O
the	O
carboxy	B-CHED
end	O
of	O
all	O
coronavirus	O
N	O
proteins	B-CHED
.	O

Aspartic	B-CHED
acid	I-CHED
residues	O
440	O
and	O
441	O
were	O
identified	O
as	O
functionally	O
important	O
.	O

When	O
either	O
amino	B-CHED
acid	I-CHED
was	O
replaced	O
by	O
a	O
positively	O
charged	O
residue	O
or	O
both	O
were	O
changed	O
to	O
alanine	B-CHED
,	O
viruses	O
were	O
recovered	O
that	O
contained	O
second	O
-	O
site	O
changes	O
within	O
N	O
,	O
but	O
not	O
in	O
the	O
M	O
or	O
envelope	O
protein	B-CHED
.	O

A	O
few	O
viruses	O
were	O
recovered	O
that	O
retained	O
the	O
D441	O
-	O
to	O
-	O
arginine	B-CHED
change	O
and	O
no	O
compensatory	O
changes	O
.	O

The	O
observed	O
effects	O
were	O
dose	O
-	O
dependent	O
(	O
IC50	O
values	O
of	O
2	O
-	O
4	O
microM	O
)	O
and	O
not	O
a	O
result	O
of	O
peptide	B-CHED
-	O
mediated	O
cell	O
cytotoxicity	O
.	O

ABSTRACT	O
:	O
Because	O
of	O
the	O
conflicting	O
data	O
concerning	O
the	O
SARS	O
-	O
CoV	O
inhibitory	O
efficacy	O
of	O
ribavirin	B-CHED
,	O
an	O
inosine	B-CHED
monophosphate	I-CHED
(	O
IMP	B-CHED
)	O
dehydrogenase	O
inhibitor	B-CHED
,	O
studies	O
were	O
done	O
to	O
evaluate	O
the	O
efficacy	O
of	O
ribavirin	B-CHED
and	O
other	O
IMP	B-CHED
dehydrogenase	O
inhibitors	B-CHED
(	O
5	O
-	O
ethynyl	B-CHED
-	O
1	O
-	O
beta	O
-	O
D	O
-	O
ribofuranosylimidazole	O
-	O
4	O
-	O
carboxamide	B-CHED
(	O
EICAR	O
),	O
mizoribine	O
,	O
and	O
mycophenolic	B-CHED
acid	I-CHED
)	O
in	O
preventing	O
viral	O
replication	O
in	O
the	O
lungs	O
of	O
BALB	O
/	O
c	O
mice	O
,	O
a	O
replication	O
model	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
infections	O
(	O
Subbarao	O
,	O
K	O
.,	O
McAuliffe	O
,	O
J	O
.,	O
Vogel	O
,	O
L	O
.,	O
Fahle	O
,	O
G	O
.,	O
Fischer	O
,	O
S	O
.,	O
Tatti	O
,	O
K	O
.,	O
Packard	O
,	O
M	O
.,	O
Shieh	O
,	O
W	O
.	O
J	O
.,	O
Zaki	O
,	O
S	O
.,	O
Murphy	O
,	O
B	O
.,	O
2004	O
.	O

ABSTRACT	O
:	O
A	O
new	O
human	O
coronavirus	O
,	O
HCoV	O
-	O
NL63	O
,	O
was	O
identified	O
recently	O
from	O
two	O
Dutch	O
children	O
with	O
acute	O
respiratory	O
infection	O
(	O
ARI	B-CHED
)	O
by	O
two	O
scientists	O
in	O
the	O
Netherlands	O
in	O
2004	O
.	O

To	O
investigate	O
if	O
this	O
newly	O
discovered	O
virus	O
is	O
associated	O
with	O
acute	O
respiratory	O
infections	O
in	O
pediatric	O
patients	O
in	O
Beijing	O
,	O
tests	O
were	O
developed	O
to	O
detect	O
HCoV	O
-	O
NL63	O
gene	O
fragments	O
from	O
throat	O
swab	O
and	O
nasopharyngeal	O
aspirates	O
collected	O
from	O
children	O
in	O
outpatient	O
and	O
inpatient	O
departments	O
with	O
ARI	B-CHED
in	O
Beijing	O
from	O
Dec	B-CHED
.	O
2003	O
to	O
Mar	O
.	O
2004	O
.	O

Amplicon	O
of	O
PCR	O
from	O
1a	O
gene	O
of	O
HCoV	O
-	O
NL63	O
was	O
sequenced	O
and	O
the	O
sequences	O
were	O
compared	O
with	O
those	O
in	O
GenBank	O
nucleotide	B-CHED
sequence	O
database	O
.	O

Immunohistochemical	O
stains	O
showed	O
a	O
strong	O
positivity	O
of	O
X4	O
protein	B-CHED
in	O
denudation	O
cells	O
,	O
vascular	O
endothelial	O
cells	O
and	O
also	O
erythrocytes	O
and	O
neutrophils	O
in	O
the	O
alveoli	O
of	O
the	O
lung	O
tissues	O
from	O
the	O
4	O
cases	O
.	O

METHODS	O
:	O
S2	O
gene	O
fragment	O
was	O
amplified	O
from	O
SARS	O
-	O
CoV	O
GD322	O
genome	O
with	O
RT	O
-	O
PCR	O
and	O
ligated	O
to	O
pGEM	B-CHED
-	O
T	O
vector	O
for	O
sequence	O
analysis	O
after	O
transformation	O
of	O
the	O
plasmid	O
into	O
E	O
.	O
coli	O
DH5a	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
dimerization	O
domain	O
reveals	O
evolutionary	O
linkage	O
between	O
corona	B-CHED
-	O
and	O
arteriviridae	O
.	O

We	O
have	O
previously	O
shown	O
that	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
forms	O
a	O
dimer	O
in	O
solution	O
through	O
its	O
C	O
-	O
terminal	O
domain	O
.	O

These	O
matured	O
MoDCs	O
displayed	O
an	O
enhanced	O
ability	O
to	O
present	O
antigen	B-CHED
to	O
and	O
thus	O
stimulate	O
T	O
cells	O
.	O

Here	O
we	O
combined	O
screening	O
of	O
phage	O
display	O
random	O
peptide	B-CHED
libraries	O
with	O
a	O
unique	O
computer	O
algorithm	O
""""	O
Mapitope	O
""""	O
to	O
identify	O
the	O
discontinuous	O
epitope	B-CHED
of	O
80R	O
,	O
a	O
potent	O
neutralizing	O
human	O
anti	O
-	O
SARS	O
monoclonal	O
antibody	O
against	O
the	O
spike	O
protein	B-CHED
.	O

Here	O
,	O
a	O
class	O
of	O
stable	O
benzotriazole	B-CHED
esters	B-CHED
was	O
reported	O
as	O
mechanism	O
-	O
based	O
inactivators	O
of	O
3CL	O
(	O
pro	B-CHED
),	O
and	O
the	O
most	O
potent	O
inactivator	O
exhibited	O
a	O
k	O
(	O
inact	O
)	O
of	O
0	O
.	O
0011	O
s	O
(-	O
1	O
)	O
and	O
a	O
K	O
(	O
i	O
)	O
of	O
7	O
.	O
5	O
nM	O
.	O
Mechanistic	O
investigation	O
with	O
kinetic	O
and	O
mass	O
spectrometry	O
analyses	O
indicates	O
that	O
the	O
active	O
site	O
Cys145	O
is	O
acylated	O
,	O
and	O
that	O
no	O
irreversible	O
inactivation	O
was	O
observed	O
with	O
the	O
use	O
of	O
the	O
C145A	O
mutant	O
.	O

Moreover	O
,	O
this	O
new	O
class	O
of	O
bioorganometallic	O
compounds	O
exert	O
antiviral	B-CHED
effects	O
with	O
some	O
selectivity	O
toward	O
SARS	O
-	O
CoV	O
infection	O
.	O

However	O
,	O
glucocorticoid	B-CHED
therapy	O
induced	O
hyperglycemia	O
with	O
an	O
increase	O
in	O
plasma	O
osmolality	O
,	O
complicated	O
with	O
hypoalbuminemia	O
,	O
and	O
gastrointestinal	O
bleeding	O
.	O

It	O
is	O
sometimes	O
difficult	O
to	O
diagnose	O
congestive	O
heart	O
failure	O
or	O
amiodarone	B-CHED
-	O
induced	O
pulmonary	O
infiltrates	O
in	O
patients	O
with	O
severe	O
left	O
ventricular	O
dysfunction	O
.	O

The	O
chimeric	O
particle	O
system	O
will	O
enable	O
structural	O
and	O
functional	O
studies	O
of	O
the	O
HCV	O
glycoproteins	B-CHED
.	O

TITLE	O
:	O
Inflammation	O
inhibitors	B-CHED
were	O
remarkably	O
up	O
-	O
regulated	O
in	O
plasma	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
patients	O
at	O
progressive	O
phase	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
2	O
-	O
D	O
DIGE	O
and	O
MS	O
to	O
analyze	O
the	O
protein	B-CHED
profiles	O
of	O
plasma	O
from	O
SARS	O
patients	O
,	O
in	O
the	O
search	O
for	O
proteomic	O
alterations	O
associated	O
with	O
the	O
disease	O
progression	O
,	O
which	O
could	O
provide	O
some	O
clues	O
to	O
the	O
pathogenesis	O
.	O

Most	O
of	O
the	O
proteins	B-CHED
showed	O
significant	O
changes	O
(	O
up	O
-	O
or	O
down	O
-	O
regulated	O
)	O
in	O
the	O
progressive	O
phase	O
of	O
disease	O
,	O
and	O
there	O
was	O
a	O
trend	O
back	O
to	O
normal	O
level	O
during	O
the	O
convalescent	O
phase	O
.	O

TITLE	O
:	O
Cross	O
-	O
neutralization	O
of	O
human	O
and	O
palm	O
civet	O
severe	O
acute	O
respiratory	O
syndrome	O
coronaviruses	O
by	O
antibodies	O
targeting	O
the	O
receptor	O
-	O
binding	O
domain	O
of	O
spike	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
considered	O
as	O
a	O
protective	O
Ag	O
for	O
vaccine	O
design	O
.	O

A	O
retrospective	O
review	O
of	O
work	O
logs	O
and	O
patient	O
assignments	O
,	O
detailed	O
review	O
of	O
medical	O
records	O
of	O
patients	O
with	O
SARS	O
,	O
and	O
comprehensive	O
telephone	O
-	O
based	O
interviews	O
of	O
HCWs	O
who	O
met	B-CHED
the	O
case	O
definition	O
for	O
SARS	O
after	O
implementation	O
of	O
infection	O
control	O
precautions	O
.	O

Of	O
the	O
remaining	O
15	O
,	O
only	O
9	O
(	O
60	O
%)	O
reported	O
that	O
they	O
had	O
received	O
formal	B-CHED
infection	O
control	O
training	O
.	O

Several	O
glycopeptide	B-CHED
derivatives	O
modified	O
with	O
hydrophobic	O
substituents	O
showed	O
selective	O
antiviral	B-CHED
activity	O
.	O

One	O
Fab	O
clone	O
,	O
AS3	B-CHED
-	O
3	O
,	O
reacted	O
with	O
the	O
spike	O
protein	B-CHED
in	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

ORF3	O
encodes	O
a	O
predicted	O
154	O
-	O
amino	O
-	O
acid	O
protein	B-CHED
that	O
lacks	O
similarity	O
to	O
any	O
known	O
protein	B-CHED
,	O
and	O
is	O
designated	O
3b	O
in	O
this	O
article	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
envelope	O
(	O
E	O
)	O
protein	B-CHED
is	O
a	O
small	O
integral	O
membrane	O
protein	B-CHED
with	O
multi	O
-	O
functions	O
in	O
virion	O
assembly	O
,	O
morphogenesis	O
and	O
virus	O
-	O
host	O
interaction	O
.	O

In	O
this	O
report	O
,	O
we	O
study	O
the	O
membrane	O
topology	O
of	O
the	O
SARS	O
-	O
CoV	O
E	O
protein	B-CHED
by	O
immunofluorescent	O
staining	O
of	O
cells	O
differentially	O
permeabilized	O
with	O
detergents	B-CHED
and	O
proteinase	O
K	O
protection	O
assay	O
.	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
secondary	O
to	O
inhalation	O
of	O
chlorine	B-CHED
gas	O
in	O
sheep	O
.	O

RESULTS	O
:	O
In	O
Phase	O
1	O
,	O
lung	O
function	O
was	O
well	O
maintained	O
in	O
Group	O
1	O
;	O
Cl2	B-CHED
caused	O
immediate	O
and	O
sustained	O
acute	O
lung	O
injury	O
(	O
PaO2	O
-	O
to	O
-	O
FiO2	O
ratio	O
,	O
PFR	O
<	O
3	O
.	O
0	O
)	O
in	O
Group	O
2	O
and	O
ARDS	O
(	O
PFR	O
<	O
2	O
.	O
0	O
)	O
in	O
Groups	O
3	O
and	O
4	O
.	O

From	O
this	O
it	O
can	O
be	O
seen	O
how	O
the	O
pseudoknot	O
interacts	O
with	O
the	O
ribosome	O
to	O
block	O
the	O
mRNA	B-CHED
entrance	O
channel	O
,	O
compromising	O
the	O
translocation	O
process	O
and	O
leading	O
to	O
a	O
spring	O
-	O
like	O
deformation	O
of	O
the	O
P	O
-	O
site	O
transfer	B-CHED
RNA	I-CHED
.	O

ABSTRACT	O
:	O
A	O
method	O
for	O
the	O
parallel	O
solid	O
-	O
phase	O
synthesis	O
of	O
peptide	B-CHED
aldehydes	B-CHED
has	O
been	O
developed	O
.	O

Several	O
potent	O
inhibitors	B-CHED
were	O
found	O
with	O
IC	O
(	O
50	O
)	O
values	O
in	O
the	O
low	O
micromolar	O
range	O
.	O

In	O
the	O
latter	O
model	O
,	O
which	O
has	O
now	O
gained	O
considerable	O
support	O
,	O
subgenomic	O
mRNA	B-CHED
synthesis	O
takes	O
place	O
from	O
a	O
complementary	O
set	O
of	O
subgenome	O
-	O
size	O
minus	O
-	O
strand	O
RNAs	O
,	O
produced	O
by	O
discontinuous	O
minus	O
-	O
strand	O
synthesis	O
.	O

They	O
have	O
demonstrated	O
that	O
,	O
unlike	O
a	O
typical	O
viral	O
outbreak	O
that	O
is	O
spread	O
through	O
person	O
-	O
to	O
-	O
person	O
contact	O
,	O
the	O
SARS	O
virus	O
in	O
this	O
case	O
was	O
spread	O
primarily	O
through	O
the	O
air	B-CHED
.	O

ABSTRACT	O
:	O
In	O
this	O
contribution	O
,	O
the	O
classification	O
of	O
protein	B-CHED
binding	O
sites	O
using	O
the	O
physicochemical	O
properties	O
exposed	O
to	O
their	O
pockets	O
is	O
presented	O
.	O

We	O
give	O
examples	O
of	O
the	O
Cavbase	O
similarity	O
analysis	O
detecting	O
pronounced	O
similarities	O
in	O
the	O
binding	O
sites	O
of	O
proteins	B-CHED
unrelated	O
in	O
sequence	O
.	O

A	O
similarity	O
search	O
using	O
SARS	O
M	O
(	O
pro	B-CHED
)	O
protease	O
subpockets	O
as	O
queries	O
retrieved	O
ligands	O
and	O
ligand	B-CHED
fragments	O
accommodated	O
in	O
a	O
physicochemical	O
environment	O
similar	O
to	O
that	O
of	O
the	O
query	O
.	O

This	O
allowed	O
the	O
characterization	O
of	O
the	O
protease	O
recognition	O
pockets	O
and	O
the	O
identification	O
of	O
molecular	O
building	O
blocks	O
that	O
can	O
be	O
incorporated	O
into	O
novel	O
antiviral	B-CHED
compounds	O
.	O

TITLE	O
:	O
Template	O
-	O
based	O
coiled	O
-	O
coil	O
antigens	B-CHED
elicit	O
neutralizing	O
antibodies	O
to	O
the	O
SARS	O
-	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
Spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
of	O
coronaviruses	O
(	O
CoV	O
)	O
mediates	O
viral	O
entry	O
into	O
host	O
cells	O
.	O

Eighteen	O
surface	O
residues	O
from	O
two	O
regions	O
of	O
HRN	B-CHED
and	O
HRC	O
were	O
incorporated	O
into	O
the	O
template	O
and	O
used	O
to	O
generate	O
four	O
anti	O
-	O
sera	O
,	O
HRN1	O
,	O
HRN2	O
,	O
HRC1	O
,	O
and	O
HRC2	O
.	O

Indeed	O
,	O
in	O
a	O
recent	O
study	O
we	O
reported	O
that	O
the	O
alpha	O
-	O
helical	O
putative	O
transmembrane	O
domain	O
of	O
E	O
protein	B-CHED
(	O
ETM	O
)	O
forms	O
several	O
SDS	B-CHED
-	O
resistant	O
TM	O
interactions	O
:	O
a	O
dimer	O
,	O
a	O
trimer	O
,	O
and	O
two	O
pentameric	O
forms	O
.	O

Herein	O
,	O
we	O
have	O
studied	O
multiple	O
isotopically	O
labeled	O
ETM	O
peptides	B-CHED
reconstituted	O
in	O
model	O
lipid	B-CHED
bilayers	O
,	O
using	O
the	O
orientational	O
parameters	O
derived	O
from	O
infrared	O
dichroic	O
data	O
.	O

We	O
have	O
independently	O
confirmed	O
that	O
the	O
full	O
polypeptide	B-CHED
of	O
E	O
protein	B-CHED
can	O
also	O
aggregate	O
as	O
pentamers	O
after	O
expression	O
in	O
Escherichia	O
coli	O
.	O

The	O
model	O
we	O
report	O
for	O
this	O
pentameric	O
alpha	O
-	O
helical	O
bundle	O
may	O
explain	O
some	O
of	O
the	O
permabilizing	O
properties	O
of	O
protein	B-CHED
E	O
,	O
and	O
should	O
be	O
the	O
basis	O
of	O
mutagenesis	O
efforts	O
in	O
future	O
functional	O
studies	O
.	O

The	O
results	O
may	O
contribute	O
to	O
development	O
of	O
antiviral	B-CHED
therapeutics	O
for	O
IBV	O
and	O
studying	O
the	O
determinants	O
for	O
viral	O
and	O
cell	O
interaction	O
.	O

Furthermore	O
,	O
it	O
has	O
been	O
shown	O
that	O
a	O
bradykinin	B-CHED
2	O
receptor	O
(	O
B2R	O
)	O
antagonist	B-CHED
attenuates	O
the	O
inflammatory	O
changes	O
in	O
the	O
same	O
animal	O
model	O
.	O

Lymphopenia	O
(	O
p	O
=	O
0	O
.	O
03	O
),	O
extent	O
of	O
radiographic	O
opacification	O
at	O
acute	O
illness	O
(	O
p	O
=	O
0	O
.	O
047	O
),	O
and	O
duration	O
of	O
use	O
of	O
ribavirin	B-CHED
(	O
p	O
=	O
0	O
.	O
03	O
)	O
were	O
significant	O
risk	O
factors	O
in	O
predicting	O
whether	O
abnormal	O
CT	O
features	O
persisted	O
12	O
months	O
after	O
diagnosis	O
.	O

The	O
sialic	B-CHED
acid	I-CHED
binding	O
activity	O
may	O
allow	O
TGEV	O
to	O
overcome	O
the	O
mucus	O
barrier	O
in	O
the	O
gut	O
and	O
to	O
get	O
access	O
to	O
the	O
intestinal	O
epithelium	O
for	O
initiation	O
of	O
infection	O
.	O

Group	O
D	O
mAb	O
(	O
S25	O
)	O
was	O
directed	O
against	O
a	O
unique	O
epitope	B-CHED
by	O
its	O
competitive	O
binding	O
.	O

These	O
findings	O
suggested	O
that	O
emodin	B-CHED
may	O
be	O
considered	O
as	O
a	O
potential	O
lead	O
therapeutic	O
agent	O
in	O
the	O
treatment	O
of	O
SARS	O
.	O

In	O
parallel	O
,	O
another	O
recombinant	O
pHS	O
was	O
generated	O
by	O
introducing	O
a	O
fragment	O
designated	O
S1	O
encoding	O
the	O
major	O
antigen	B-CHED
sites	O
of	O
S	O
gene	O
from	O
TGEV	O
strain	O
TH	O
-	O
98	O
into	O
a	O
prokaryotic	O
expression	O
vector	O
pP	O
(	O
RO	O
)	O
EX	O
HTc	O
.	O

TITLE	O
:	O
Antigenic	O
and	O
immunogenic	O
characterization	O
of	O
recombinant	O
baculovirus	O
-	O
expressed	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	B-CHED
:	O
implication	O
for	O
vaccine	O
design	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
mediates	O
the	O
receptor	O
interaction	O
and	O
immune	O
recognition	O
and	O
is	O
considered	O
a	O
major	O
target	O
for	O
vaccine	O
design	O
.	O

These	O
data	O
suggest	O
that	O
the	O
recombinant	O
baculovirus	O
-	O
expressed	O
S	O
protein	B-CHED
vaccines	O
possess	O
excellent	O
immunogenicity	O
,	O
thereby	O
inducing	O
highly	O
potent	O
neutralizing	O
responses	O
against	O
human	O
and	O
animal	O
SARS	O
-	O
CoV	O
variants	O
.	O

Among	O
the	O
anti	O
-	O
S1	O
MAbs	O
,	O
17	O
MAbs	O
targeted	O
the	O
N	O
-	O
terminal	O
region	O
(	O
amino	B-CHED
acids	I-CHED
[	O
aa	O
]	O
12	O
to	O
327	O
),	O
9	O
MAbs	O
recognized	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
;	O
aa	O
318	O
to	O
510	O
),	O
and	O
6	O
MAbs	O
reacted	O
with	O
the	O
C	O
-	O
terminal	O
region	O
of	O
S1	O
domain	O
that	O
contains	O
the	O
major	O
immunodominant	O
site	O
(	O
aa	O
528	O
to	O
635	O
).	O

However	O
,	O
acidification	O
is	O
likely	O
not	O
a	O
direct	O
trigger	O
for	O
MHV	O
-	O
2	O
spike	O
-	O
mediated	O
membrane	O
fusion	O
,	O
as	O
low	O
-	O
pH	O
treatment	O
is	O
unable	O
to	O
overcome	O
ammonium	B-CHED
chloride	I-CHED
inhibition	O
,	O
and	O
it	O
also	O
cannot	O
induce	O
cell	O
-	O
cell	O
fusion	O
between	O
MHV	O
-	O
2	O
-	O
infected	O
cells	O
.	O

TITLE	O
:	O
Delineation	O
and	O
modelling	O
of	O
a	O
nucleolar	O
retention	O
signal	O
in	O
the	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
.	O

A	O
titanium	B-CHED
containing	O
polyoxotungstate	O
,	O
PM	O
-	O
523	O
exhibited	O
potent	O
anti	O
-	O
influenza	O
virus	O
(	O
FluV	O
)	O
A	O
and	O
anti	O
-	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
activities	O
in	O
vitro	O
.	O

Its	O
prevalence	O
in	O
this	O
cohort	O
is	O
comparable	O
to	O
those	O
reported	O
in	O
the	O
literature	O
for	O
SARS	O
patients	O
with	O
high	O
-	O
dose	O
corticosteroid	B-CHED
therapy	O
.	O

The	O
Day	O
>	O
51	O
increase	O
in	O
serum	O
OC	O
and	O
BALP	O
coincided	O
with	O
the	O
timing	O
of	O
corticosteroid	B-CHED
withdrawal	O
.	O

These	O
two	O
genes	O
encode	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RDRP	O
)	O
and	O
envelope	O
E	O
protein	B-CHED
.	O

Conventional	O
tests	O
including	O
cultures	O
of	O
blood	O
,	O
sputum	O
,	O
urine	O
antigen	B-CHED
detection	O
of	O
Streptococcus	O
pneumoniae	O
and	O
Legionella	O
pneumophila	O
,	O
and	O
paired	O
serologies	O
were	O
routinely	O
performed	O
.	O

TITLE	O
:	O
Isatin	B-CHED
compounds	O
as	O
noncovalent	O
SARS	O
coronavirus	O
3C	O
-	O
like	O
protease	B-CHED
inhibitors	I-CHED
.	O

Out	O
of	O
the	O
59	O
,	O
363	O
compounds	O
docked	O
,	O
93	O
were	O
selected	O
for	O
the	O
inhibition	O
assay	O
,	O
and	O
21	O
showed	O
inhibition	O
against	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
(	O
IC	O
(	O
50	O
)	O
<	O
or	O
=	O
30	O
microM	O
),	O
with	O
three	O
of	O
them	O
having	O
common	O
substructures	O
.	O

4	O
-	O
Amino	O
and	O
4	O
-	O
methoxy	B-CHED
pyrimidine	B-CHED
derivatives	O
were	O
also	O
made	O
.	O

Compounds	O
in	O
which	O
the	O
base	O
moiety	O
was	O
substituted	O
by	O
5	O
-	O
chloro	B-CHED
-	O
(	O
25	O
),	O
5	O
-(	O
2	O
-	O
bromovinyl	O
)-	O
(	O
32	O
),	O
or	O
5	O
-	O
bromo	B-CHED
-	O
6	O
-	O
methyl	B-CHED
-	O
(	O
37	O
)	O
groups	O
possess	O
significant	O
activity	O
against	O
duck	O
-	O
HBV	O
,	O
wild	O
-	O
type	O
human	O
HBV	O
(	O
2	O
.	O
2	O
.	O
15	O
cells	O
),	O
and	O
lamivudine	B-CHED
-	O
resistant	O
HBV	O
containing	O
single	O
and	O
double	O
mutations	O
.	O

The	O
anti	O
-	O
HBV	O
activity	O
exhibited	O
by	O
compounds	O
25	O
,	O
32	O
,	O
and	O
37	O
was	O
superior	O
for	O
human	O
HBV	O
and	O
comparable	O
for	O
DHBV	O
to	O
that	O
of	O
the	O
corresponding	O
purine	B-CHED
nucleoside	I-CHED
,	O
ganciclovir	B-CHED
.	O

Interferon	O
responses	O
are	O
not	O
triggered	O
during	O
infection	O
,	O
although	O
the	O
L	O
cells	O
can	O
be	O
readily	O
stimulated	O
to	O
produce	O
interferon	O
by	O
dsRNA	B-CHED
,	O
a	O
known	O
potent	O
inducer	O
of	O
interferon	O
.	O

TITLE	O
:	O
Surveillance	O
for	O
febrile	O
respiratory	O
infections	O
during	O
Cobra	O
Gold	B-CHED
2003	O
.	O

TITLE	O
:	O
DNA	O
hybridization	O
sensor	O
based	O
on	O
aurothiomalate	B-CHED
electroactive	O
label	B-CHED
on	O
glassy	O
carbon	B-CHED
electrodes	O
.	O

In	O
order	O
to	O
label	B-CHED
this	O
single	O
strand	O
,	O
a	O
mixture	B-CHED
of	O
sodium	B-CHED
aurothiomalate	I-CHED
and	O
the	O
strand	O
is	O
prepared	O
.	O

It	O
contains	O
two	O
heptad	O
repeat	O
regions	O
,	O
denoted	O
HRN	B-CHED
and	O
HRC	O
.	O

Among	O
the	O
401	O
SARS	O
patients	O
studied	O
,	O
147	O
of	O
249	O
noncritical	O
patients	O
(	O
59	O
.	O
0	O
%)	O
received	O
corticosteroids	B-CHED
(	O
mean	O
daily	O
dose	O
,	O
105	O
.	O
3	O
+/-	O

Analysis	O
of	O
these	O
401	O
confirmed	O
cases	O
did	O
not	O
show	O
any	O
benefits	O
of	O
corticosteroid	B-CHED
on	O
the	O
death	O
rate	O
and	O
hospitalization	O
days	O
.	O

After	O
adjustment	O
for	O
possible	O
confounders	O
,	O
treatment	O
with	O
corticosteroid	B-CHED
was	O
shown	O
contributing	O
to	O
lower	O
overall	O
mortality	O
,	O
instant	O
mortality	O
,	O
and	O
shorter	O
hospitalization	O
stay	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

CONCLUSIONS	O
:	O
This	O
Guangzhou	O
retrospective	O
study	O
revealed	O
that	O
proper	O
use	O
of	O
corticosteroid	B-CHED
in	O
confirmed	O
critical	O
SARS	O
resulted	O
in	O
lowered	O
mortality	O
and	O
shorter	O
hospitalization	O
stay	O
,	O
and	O
was	O
not	O
associated	O
with	O
significant	O
secondary	O
lower	O
respiratory	O
infection	O
and	O
other	O
complications	O
.	O

Although	O
he	O
was	O
given	O
antibiotics	B-CHED
,	O
lung	O
infiltrates	O
increased	O
and	O
his	O
symptoms	O
worsened	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
memory	O
T	O
-	O
cell	O
responses	O
against	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
were	O
persistent	O
for	O
more	O
than	O
1	O
year	O
after	O
SARS	O
-	O
CoV	O
infection	O
by	O
detecting	O
the	O
production	O
of	O
IFN	O
-	O
gamma	O
using	O
ELISA	O
and	O
ELISpot	O
assays	O
.	O

The	O
ARDS	O
dog	O
model	O
was	O
replicated	O
by	O
intratracheal	O
instillation	O
of	O
hydrochloric	B-CHED
acid	I-CHED
,	O
and	O
mechanical	O
ventilation	O
was	O
carried	O
out	O
according	O
to	O
the	O
following	O
ventilatory	O
protocols	O
.	O

ABSTRACT	O
:	O
A	O
38	O
-	O
year	O
-	O
old	O
Japanese	O
man	B-CHED
was	O
referred	O
to	O
our	O
hospital	O
in	O
June	O
2003	O
for	O
treatment	O
of	O
acute	O
respiratory	O
failure	O
with	O
severe	O
eosinophilia	O
.	O

A	O
case	O
report	O
is	O
presented	O
of	O
a	O
patient	O
who	O
aspirated	O
the	O
PEG	B-CHED
solution	O
and	O
ultimately	O
died	O
because	O
of	O
respiratory	O
failure	O
.	O

The	O
3	O
viruses	O
(	O
PEDV	O
,	O
TGEV	O
,	O
and	O
porcine	O
GAR	B-CHED
)	O
are	O
major	O
agents	O
in	O
viral	O
enteric	O
diseases	O
of	O
piglets	O
.	O

A	O
mixture	B-CHED
of	O
3	O
pairs	O
of	O
published	O
primers	O
was	O
used	O
for	O
amplification	O
of	O
viral	O
nucleic	B-CHED
acids	I-CHED
,	O
yielding	O
3	O
different	O
amplicons	O
with	O
sizes	O
of	O
859	O
bp	O
,	O
651	O
bp	O
,	O
and	O
309	O
bp	O
for	O
TGEV	O
,	O
PEDV	O
,	O
and	O
porcine	O
GAR	B-CHED
,	O
respectively	O
.	O

Conversely	O
,	O
the	O
M	O
protein	B-CHED
expressed	O
in	O
mammalian	O
cells	O
did	O
not	O
induce	O
apoptosis	O
.	O

TITLE	O
:	O
Conformational	O
states	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	B-CHED
ectodomain	O
.	O

Protease	O
cleavage	O
of	O
the	O
trimer	O
occurs	O
at	O
the	O
S1	O
-	O
S2	O
boundary	O
;	O
an	O
ensuing	O
S1	O
dissociation	O
leads	O
to	O
a	O
major	O
rearrangement	O
of	O
the	O
trimeric	O
S2	O
and	O
to	O
formation	O
of	O
rosettes	O
likely	O
to	O
represent	O
clusters	B-CHED
of	O
elongated	O
,	O
postfusion	O
trimers	O
of	O
S2	O
associated	O
through	O
their	O
fusion	O
peptides	B-CHED
.	O

TITLE	O
:	O
Hexamethylene	B-CHED
amiloride	B-CHED
blocks	O
E	O
protein	B-CHED
ion	O
channels	O
and	O
inhibits	O
coronavirus	O
replication	O
.	O

ABSTRACT	O
:	O
All	O
coronaviruses	O
encode	O
a	O
small	O
hydrophobic	O
envelope	O
(	O
E	O
)	O
protein	B-CHED
,	O
which	O
mediates	O
viral	O
assembly	O
and	O
morphogenesis	O
by	O
an	O
unknown	O
mechanism	O
.	O

It	O
appears	O
,	O
therefore	O
,	O
that	O
coronavirus	O
E	O
proteins	B-CHED
in	O
general	O
,	O
belong	O
to	O
the	O
virus	O
ion	O
channels	O
family	O
.	O

Taken	O
together	O
,	O
the	O
data	O
provide	O
evidence	O
of	O
a	O
link	O
between	O
inhibition	O
of	O
E	O
protein	B-CHED
ion	O
channel	O
activity	O
and	O
the	O
antiviral	B-CHED
activity	O
of	O
HMA	O
.	O

CONCLUSIONS	O
:	O
The	O
MDD	B-CHED
system	O
can	O
distinguish	O
the	O
13	O
respiratory	O
viruses	O
,	O
which	O
helps	O
diagnosis	O
of	O
respiratory	O
viral	O
infection	O
.	O

TITLE	O
:	O
Association	O
of	O
SARS	O
susceptibility	O
with	O
single	O
nucleic	B-CHED
acid	I-CHED
polymorphisms	O
of	O
OAS1	O
and	O
MxA	O
genes	O
:	O
a	O
case	O
-	O
control	O
study	O
.	O

Ambroxol	O
plays	O
a	O
role	O
in	O
facilitating	O
synthesis	O
and	O
secretion	O
of	O
pulmonary	O
surfactant	B-CHED
protein	B-CHED
A	O
and	O
relieves	O
the	O
lung	O
tissue	O
injury	O
induced	O
by	O
paraquat	B-CHED
poisoning	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
class	O
of	O
non	O
-	O
nucleoside	B-CHED
HCV	O
NS5B	O
polymerase	O
inhibitors	B-CHED
has	O
been	O
identified	O
from	O
screening	O
.	O

The	O
K	O
(	O
d	O
)	O
for	O
tRNA	B-CHED
is	O
2	O
.	O
1	O
+/-	O
0	O
.	O
2	O
microM	O
.	O

On	O
univariate	O
analysis	O
,	O
male	O
gender	O
,	O
advanced	O
age	O
,	O
presence	O
of	O
comorbidities	O
,	O
neutrophilia	O
,	O
lymphopaenia	O
,	O
hyponatraemia	O
,	O
hypoalbuminaemia	O
,	O
transaminitis	O
and	O
elevated	O
LDH	O
or	O
C	O
-	O
reactive	O
protein	B-CHED
were	O
found	O
to	O
be	O
significant	O
predictors	O
.	O

At	O
the	O
same	O
time	O
,	O
however	O
,	O
countries	O
are	O
increasingly	O
seeking	O
to	O
collaborate	O
internationally	O
in	O
infectious	O
disease	O
surveillance	O
and	O
response	O
,	O
as	O
shown	O
in	O
the	O
current	O
situation	O
of	O
avian	O
influenza	O
(	O
H5N1	O
),	O
and	O
in	O
the	O
formal	B-CHED
agreement	O
leading	O
to	O
the	O
revised	O
International	O
Health	O
Regulations	O
(	O
IHR	O
),	O
suggesting	O
that	O
a	O
new	O
world	O
order	O
prevails	O
over	O
issues	O
that	O
once	O
had	O
been	O
considered	O
the	O
sole	O
domain	O
of	O
a	O
sovereign	O
nation	O
.	O

Indeed	O
,	O
HCWs	O
had	O
lost	B-CHED
their	O
lives	O
to	O
SARS	O
.	O

Retention	O
was	O
72	O
to	O
73	O
percent	O
of	O
baseline	O
fibrinogen	O
and	O
Factor	O
(	O
F	O
)	O
VIII	O
activity	O
and	O
78	O
to	O
98	O
percent	O
for	O
FII	O
,	O
FV	O
,	O
FVII	O
,	O
F	O
IX	O
,	O
FX	O
,	O
FXI	O
,	O
FXIII	O
,	O
protein	B-CHED
C	O
,	O
protein	B-CHED
S	O
,	O
antithrombin	O
,	O
and	O
alpha2	O
-	O
antiplasmin	O
.	O

The	O
more	O
recent	O
design	O
of	O
wide	O
-	O
spectrum	O
inhibitors	B-CHED
targeting	O
the	O
coronavirus	O
main	O
proteases	O
may	O
lead	O
to	O
the	O
discovery	O
of	O
new	O
antivirals	B-CHED
against	O
multiple	O
coronavirus	O
induced	O
diseases	O
.	O

Coexpression	O
of	O
7a	O
protein	B-CHED
with	O
SCoV	O
S	O
,	O
M	O
,	O
N	O
,	O
and	O
E	O
proteins	B-CHED
resulted	O
in	O
production	O
of	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
carrying	O
7a	O
protein	B-CHED
,	O
while	O
7a	O
protein	B-CHED
was	O
not	O
released	O
from	O
cells	O
expressing	O
7a	O
protein	B-CHED
alone	O
.	O

Although	O
the	O
virus	O
spreading	O
has	O
been	O
contained	O
,	O
due	O
preparedness	O
and	O
planning	O
,	O
including	O
the	O
successful	O
development	O
of	O
antiviral	B-CHED
drugs	I-CHED
against	O
SARS	O
-	O
CoV	O
,	O
is	O
necessary	O
for	O
possible	O
reappearance	O
of	O
SARS	O
.	O

Binding	O
of	O
viral	O
peptides	B-CHED
was	O
affected	O
by	O
the	O
naturally	O
occurring	O
polymorphisms	O
at	O
residues	O
190	O
and	O
192	O
,	O
which	O
are	O
located	O
at	O
second	O
extracellular	O
loop	O
-	O
transmembrane	O
helix	O
5	O
interface	O
.	O

Substitution	O
of	O
R190	O
with	O
W190	O
enhanced	O
the	O
affinity	O
for	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
peptide	B-CHED
6	O
fold	O
but	O
reduced	O
the	O
affinity	O
for	O
N	O
-	O
formyl	B-CHED
-	O
Nle	B-CHED
-	O
Leu	B-CHED
-	O
Phe	B-CHED
by	O
2	O
.	O
5	O
fold	O
.	O

It	O
also	O
blocked	O
beta	O
arrestin	O
translocation	O
and	O
receptor	O
downregulation	O
induced	O
by	O
formyl	B-CHED
-	O
Nle	B-CHED
-	O
Leu	B-CHED
-	O
Phe	B-CHED
.	O

ABSTRACT	O
:	O
To	O
achieve	O
the	O
greatest	O
output	O
from	O
their	O
limited	O
genomes	O
,	O
viruses	O
frequently	O
make	O
use	O
of	O
alternative	O
open	O
reading	O
frames	O
,	O
in	O
which	O
translation	O
is	O
initiated	O
from	O
a	O
start	O
codon	O
within	O
an	O
existing	O
gene	O
and	O
,	O
being	O
out	O
of	O
frame	O
,	O
gives	O
rise	O
to	O
a	O
distinct	O
protein	B-CHED
product	O
.	O

These	O
alternative	O
protein	B-CHED
products	O
are	O
,	O
as	O
yet	O
,	O
poorly	O
characterized	O
structurally	O
.	O

TITLE	O
:	O
Human	O
memory	O
T	O
cell	O
responses	O
to	O
SARS	O
-	O
CoV	O
E	O
protein	B-CHED
.	O

The	O
results	O
of	O
T	O
-	O
cell	O
responses	O
to	O
9	O
individual	O
peptides	B-CHED
indicated	O
that	O
the	O
E	O
protein	B-CHED
contained	O
at	O
least	O
two	O
major	O
T	O
cell	O
epitopes	O
(	O
E2	O
amino	B-CHED
acid	I-CHED
[	O
aa	O
]	O
9	O
-	O
26	O
and	O
E5	O
-	O
6	O
:	O
aa	O
33	O
-	O
57	O
)	O
which	O
were	O
important	O
in	O
eliciting	O
cellular	O
immune	O
response	O
to	O
SARS	O
-	O
CoV	O
E	O
protein	B-CHED
in	O
humans	O
.	O

RNAi	O
.	O
jp	O
/)	O
is	O
a	O
web	O
-	O
based	O
online	O
software	O
system	O
that	O
provides	O
efficient	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
design	O
for	O
antiviral	B-CHED
RNA	O
interference	O
(	O
RNAi	O
).	O

Taurocholic	B-CHED
acid	I-CHED
injection	O
induced	O
a	O
severe	O
pancreatic	O
injury	O
that	O
started	O
as	O
early	O
as	O
2h	O
after	O
the	O
injection	O
and	O
persisted	O
without	O
recovery	O
over	O
the	O
18	O
-	O
h	O
study	O
period	O
.	O

ABSTRACT	O
:	O
Pneumocystis	O
pneumonia	O
(	O
PCP	B-CHED
)	O
is	O
a	O
severe	O
infection	O
of	O
the	O
immunocompromised	O
host	O
,	O
resulting	O
in	O
diffuse	O
alveolar	O
damage	O
and	O
life	O
-	O
threatening	O
respiratory	O
failure	O
.	O

The	O
minimum	O
surface	O
tension	O
of	O
LA	O
was	O
impaired	O
(	O
p	O
<	O
.	O
001	O
)	O
in	O
V	O
-	O
PCP	B-CHED
more	O
than	O
in	O
SB	O
-	O
PCP	B-CHED
and	O
was	O
strongly	O
correlated	O
with	O
the	O
reduction	O
in	O
palmitic	B-CHED
acid	I-CHED
levels	O
in	O
PC	O
LA	O
(	O
r	O
=	O
-.	O
81	O
).	O

ABSTRACT	O
:	O
Enteral	O
diets	O
enriched	O
with	O
eicosapentaenoic	B-CHED
acid	I-CHED
(	O
EPA	B-CHED
),	O
gamma	B-CHED
-	I-CHED
linolenic	I-CHED
acid	I-CHED
(	O
GLA	B-CHED
),	O
and	O
antioxidants	B-CHED
have	O
previously	O
been	O
shown	O
to	O
improve	O
outcomes	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Patients	O
were	O
randomized	O
to	O
be	O
continuously	O
tube	O
-	O
fed	O
with	O
either	O
a	O
diet	O
enriched	O
with	O
EPA	B-CHED
,	O
GLA	B-CHED
,	O
and	O
elevated	O
antioxidants	B-CHED
or	O
an	O
isonitrogenous	O
and	O
isocaloric	O
control	O
diet	O
,	O
delivered	O
at	O
a	O
constant	O
rate	O
to	O
achieve	O
a	O
minimum	O
of	O
75	O
%	O
of	O
basal	O
energy	O
expenditure	O
x	O
1	O
.	O
3	O
during	O
a	O
minimum	O
of	O
4	O
days	O
.	O

This	O
result	O
suggests	O
a	O
mechanism	O
of	O
inactivation	O
of	O
3C	O
peptidases	O
by	O
methyl	B-CHED
ketone	I-CHED
inhibitors	B-CHED
that	O
is	O
distinct	O
from	O
that	O
occurring	O
in	O
the	O
structurally	O
related	O
serine	B-CHED
proteinases	O
or	O
in	O
the	O
papain	O
-	O
like	O
cysteine	B-CHED
peptidases	O
.	O

SARS	O
-	O
Cov	O
and	O
SARS	O
-	O
like	O
-	O
CoV	O
were	O
detected	O
in	O
these	O
specimens	O
using	O
diagnostic	O
kit	O
for	O
novel	O
coronavirus	O
N	O
protein	B-CHED
(	O
ELISA	O
),	O
SARS	O
-	O
CoV	O
Virus	O
RNA	O
detection	O
kit	O
,	O
fluorescence	O
PCR	O
,	O
Genchip	O
,	O
RT	O
-	O
PCR	O
and	O
cell	O
isolation	O
culture	O
methods	O
.	O

ABSTRACT	O
:	O
Serum	O
samples	O
from	O
18	O
pumas	O
(	O
Puma	O
concolor	O
),	O
one	O
ocelot	O
(	O
Leopardus	O
pardalis	O
),	O
and	O
two	O
little	O
spotted	O
cats	O
(	O
Leopardus	O
tigrinus	O
)	O
collected	O
from	O
free	O
-	O
ranging	O
animals	O
in	O
Brazil	O
between	O
1998	O
and	O
2004	O
were	O
tested	O
by	O
indirect	O
immunofluorescence	O
(	O
IFA	O
)	O
for	O
antibodies	O
to	O
feline	O
herpesvirus	O
1	O
(	O
FHV	O
1	O
),	O
calicivirus	O
(	O
FCV	B-CHED
),	O
coronavirus	O
(	O
FCoV	O
),	O
parvo	O
-	O
virus	O
(	O
FPV	O
),	O
Ehrlichia	O
canis	O
,	O
Anaplasma	O
pha	O
-	O
gocytophilum	O
,	O
and	O
Bartonella	O
henselae	O
.	O

TITLE	O
:	O
Dodecamer	O
structure	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nonstructural	O
protein	B-CHED
nsp10	O
.	O

The	O
MHV	O
-	O
A59	O
nsp15	O
monomer	O
structure	O
has	O
a	O
novel	O
protein	B-CHED
fold	O
.	O

The	O
high	O
sequence	O
conservation	O
of	O
nsp15	O
in	O
coronaviruses	O
,	O
including	O
that	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
suggests	O
that	O
this	O
protein	B-CHED
may	O
provide	O
a	O
new	O
target	O
for	O
the	O
design	O
of	O
antiviral	B-CHED
therapeutics	O
.	O

TITLE	O
:	O
The	O
human	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
8b	O
protein	B-CHED
is	O
distinct	O
from	O
its	O
counterpart	O
in	O
animal	O
SARS	O
-	O
CoV	O
and	O
down	O
-	O
regulates	O
the	O
expression	O
of	O
the	O
envelope	O
protein	B-CHED
in	O
infected	O
cells	O
.	O

Interestingly	O
,	O
the	O
SARS	O
-	O
CoV	O
isolated	O
from	O
animals	O
contains	O
an	O
extra	O
29	O
-	O
nucleotide	B-CHED
in	O
this	O
region	O
such	O
that	O
these	O
proteins	B-CHED
are	O
fused	O
to	O
become	O
a	O
single	O
protein	B-CHED
,	O
8ab	O
.	O

Here	O
,	O
we	O
compared	O
the	O
cellular	O
properties	O
of	O
the	O
8a	O
,	O
8b	O
and	O
8ab	O
proteins	B-CHED
by	O
examining	O
their	O
cellular	O
localizations	O
and	O
their	O
abilities	O
to	O
interact	O
with	O
other	O
SARS	O
-	O
CoV	O
proteins	B-CHED
.	O

TITLE	O
:	O
Synthesis	O
,	O
crystal	O
structure	O
,	O
structure	O
-	O
activity	O
relationships	O
,	O
and	O
antiviral	B-CHED
activity	O
of	O
a	O
potent	O
SARS	O
coronavirus	O
3CL	O
protease	B-CHED
inhibitor	I-CHED
.	O

ABSTRACT	O
:	O
A	O
potent	O
SARS	O
coronavirus	O
(	O
CoV	O
)	O
3CL	O
protease	B-CHED
inhibitor	I-CHED
(	O
TG	O
-	O
0205221	O
,	O
Ki	O
=	O
53	O
nM	O
)	O
has	O
been	O
developed	O
.	O

A	O
novel	O
HLA	O
-	O
A	O
*	O
0201	O
-	O
restricted	O
decameric	O
epitope	B-CHED
P15	O
(	O
S411	O
-	O
420	O
,	O
KLPDDFMGCV	O
)	O
derived	O
from	O
the	O
S	O
protein	B-CHED
was	O
identified	O
and	O
found	O
to	O
localize	O
within	O
the	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
receptor	O
-	O
binding	O
region	O
of	O
the	O
S1	O
domain	O
.	O

A	O
phylogenetic	O
analysis	O
of	O
the	O
M	O
gene	O
sequences	O
revealed	O
not	O
only	O
clearly	O
segregating	O
canine	O
coronavirus	O
(	O
ccov	O
)	O
in	O
the	O
dogs	O
,	O
typical	O
ccov	O
sequences	O
and	O
the	O
recently	O
described	O
fcov	O
-	O
like	O
ccov	O
,	O
but	O
also	O
at	O
least	O
two	O
genetic	O
clusters	B-CHED
of	O
fcov	O
in	O
the	O
cats	O
,	O
one	O
species	O
-	O
specific	O
,	O
the	O
other	O
more	O
closely	O
related	O
to	O
fcov	O
-	O
like	O
ccov	O
.	O

The	O
hypothesis	O
was	O
originally	O
proposed	O
based	O
on	O
biochemical	O
activities	O
of	O
the	O
aminoquinolines	B-CHED
(	O
e	O
.	O
g	O
.,	O
pamaquine	O
(	O
plasmoquine	O
(	O
TM	O
)),	O
primaquine	B-CHED
and	O
chloroquine	B-CHED
),	O
but	O
recent	O
publications	O
demonstrated	O
that	O
some	O
of	O
these	O
drugs	O
definitely	O
adversely	O
affect	O
HIV	O
and	O
other	O
viruses	O
and	O
logically	O
would	O
cause	O
them	O
to	O
evolve	O
resistance	O
.	O

A	O
short	O
corticotropin	B-CHED
test	O
was	O
performed	O
in	O
each	O
patient	O
to	O
assess	O
the	O
adrenal	O
function	O
.	O

We	O
further	O
found	O
that	O
over	O
-	O
expression	O
of	O
Egr	O
-	O
1	O
suppressed	O
the	O
expression	O
of	O
BNip3	O
,	O
a	O
pro	B-CHED
-	O
apoptotic	O
member	O
of	O
the	O
Bcl	O
-	O
2	O
family	O
.	O

All	O
six	O
patients	O
were	O
transferred	O
to	O
the	O
care	O
of	O
the	O
authors	O
at	O
an	O
intensive	O
care	O
unit	O
at	O
a	O
public	O
hospital	O
,	O
where	O
they	O
received	O
intensive	O
cardiopulmonary	O
support	O
(	O
including	O
dialysis	O
),	O
high	O
-	O
dose	O
methylprednisolone	B-CHED
,	O
and	O
an	O
anti	O
-	O
interleukin	O
-	O
2	O
receptor	O
antagonist	B-CHED
antibody	O
.	O

With	O
this	O
clinical	O
success	O
,	O
administration	O
of	O
drotecogin	O
alfa	O
(	O
recombinant	O
activated	O
protein	B-CHED
C	O
),	O
the	O
importance	O
of	O
coagulation	O
in	O
the	O
pathogenesis	O
of	O
human	O
sepsis	O
is	O
becoming	O
clearer	O
.	O

The	O
results	O
of	O
clinical	O
trials	O
have	O
been	O
variable	O
,	O
however	O
,	O
in	O
part	O
due	O
to	O
the	O
various	O
surfactant	B-CHED
preparations	O
used	O
,	O
the	O
different	O
delivery	O
and	O
dosing	O
methods	O
employed	O
,	O
and	O
the	O
types	O
of	O
patients	O
targeted	O
for	O
this	O
therapy	O
.	O

Furthermore	O
,	O
nsp1	O
expression	O
promoted	O
degradation	O
of	O
expressed	O
RNA	O
transcripts	O
and	O
host	O
endogenous	O
mRNAs	O
,	O
leading	O
to	O
a	O
strong	O
host	O
protein	B-CHED
synthesis	O
inhibition	O
.	O

These	O
data	O
suggested	O
that	O
,	O
in	O
infected	O
cells	O
,	O
nsp1	O
promotes	O
host	O
mRNA	B-CHED
degradation	O
and	O
thereby	O
suppresses	O
host	O
gene	O
expression	O
,	O
including	O
proteins	B-CHED
involved	O
in	O
host	O
innate	O
immune	O
functions	O
.	O

SCoV	O
nsp1	O
-	O
mediated	O
promotion	O
of	O
host	O
mRNA	B-CHED
degradation	O
may	O
play	O
an	O
important	O
role	O
in	O
SCoV	O
pathogenesis	O
.	O

TITLE	O
:	O
Structural	O
and	O
functional	O
basis	O
for	O
ADP	B-CHED
-	O
ribose	B-CHED
and	O
poly	O
(	O
ADP	B-CHED
-	O
ribose	B-CHED
)	O
binding	O
by	O
viral	O
macro	O
domains	O
.	O

In	O
addition	O
,	O
a	O
small	O
number	O
of	O
animal	O
RNA	O
viruses	O
,	O
such	O
as	O
corona	B-CHED
-	O
and	O
toroviruses	O
,	O
alphaviruses	O
,	O
and	O
hepatitis	O
E	O
virus	O
,	O
encode	O
macro	O
domains	O
for	O
which	O
,	O
however	O
,	O
structural	O
and	O
functional	O
information	O
is	O
extremely	O
limited	O
.	O

ABSTRACT	O
:	O
We	O
have	O
recently	O
demonstrated	O
that	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
receptor	O
angiotensin	B-CHED
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
also	O
mediates	O
cellular	O
entry	O
of	O
the	O
newly	O
discovered	O
human	O
coronavirus	O
(	O
hCoV	O
)	O
NL63	O
.	O

Alternatively	O
,	O
dimerisation	O
of	O
the	O
nucleocapsid	O
protein	B-CHED
may	O
result	O
in	O
juxtaposition	O
of	O
the	O
amino	B-CHED
acid	I-CHED
sequences	O
316	O
-	O
325	O
and	O
361	O
-	O
367	O
on	O
one	O
nucleoprotein	O
molecule	O
to	O
amino	B-CHED
acid	I-CHED
286	O
-	O
295	O
on	O
the	O
second	O
peptide	B-CHED
.	O

In	O
this	O
study	O
,	O
the	O
complete	O
genome	O
of	O
Cal99	O
was	O
sequenced	O
,	O
and	O
the	O
structural	O
protein	B-CHED
genes	O
were	O
compared	O
with	O
those	O
of	O
commonly	O
used	O
IBV	O
vaccines	O
as	O
well	O
as	O
those	O
of	O
isolates	O
from	O
naturally	O
occurring	O
outbreaks	O
in	O
different	O
parts	O
of	O
the	O
world	O
,	O
to	O
elucidate	O
potential	O
sources	O
of	O
genetic	O
material	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
explores	O
the	O
balance	B-CHED
between	O
common	O
good	O
and	O
individual	O
liberty	O
in	O
the	O
context	O
of	O
public	O
health	O
regulation	O
.	O

A	O
substantial	O
amount	O
of	O
S	O
protein	B-CHED
accumulates	O
in	O
the	O
ER	O
.	O

TITLE	O
:	O
Preparation	O
and	O
characterization	O
of	O
a	O
novel	O
monoclonal	O
antibody	O
specific	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
nucleocapsid	O
(	O
SARS	O
-	O
CoV	O
N	O
)	O
protein	B-CHED
has	O
been	O
found	O
to	O
be	O
important	O
to	O
the	O
processes	O
related	O
to	O
viral	O
pathogenesis	O
,	O
such	O
as	O
virus	O
replication	O
,	O
interference	O
of	O
the	O
cell	O
process	O
and	O
modulation	O
of	O
host	O
immune	O
response	O
;	O
detection	O
of	O
the	O
antigen	B-CHED
has	O
been	O
used	O
for	O
the	O
early	O
diagnosis	O
of	O
infection	O
.	O

Finally	O
,	O
old	O
and	O
new	O
promising	O
agents	O
are	O
in	O
the	O
pipeline	O
of	O
pharmaceutical	B-CHED
companies	O
to	O
treat	O
emerging	O
viral	O
infections	O
.	O

To	O
investigate	O
the	O
subcellular	O
localization	O
of	O
S1	O
during	O
transient	O
expression	O
in	O
tobacco	O
leaves	O
,	O
a	O
translational	O
fusion	O
consisting	O
of	O
S1	O
and	O
the	O
green	O
fluorescent	O
protein	B-CHED
(	O
GFP	O
)	O
was	O
generated	O
.	O

The	O
complete	O
S	O
protein	B-CHED
(	O
1	O
,	O
167	O
amino	B-CHED
acids	I-CHED
)	O
was	O
compared	O
with	O
published	O
S	O
protein	B-CHED
sequences	O
of	O
other	O
avian	O
and	O
mammalian	O
coronaviruses	O
.	O

TITLE	O
:	O
Phage	O
-	O
displayed	O
peptides	B-CHED
having	O
antigenic	O
similarities	O
with	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
neutralizing	O
epitopes	O
.	O

Sequence	O
analysis	O
suggested	O
that	O
these	O
peptides	B-CHED
are	O
similar	O
with	O
(	O
1368	O
)	O
GPRLQPY	O
(	O
1374	O
)	O
found	O
at	O
the	O
carboxy	B-CHED
-	O
terminal	O
of	O
the	O
S	O
protein	B-CHED
.	O

This	O
new	O
finding	O
suggests	O
that	O
the	O
newly	O
discovered	O
peptide	B-CHED
motifs	O
mimic	O
a	O
neutralizing	O
epitope	B-CHED
PEDV	O
.	O

While	O
the	O
parental	O
MHV	O
-	O
A59	O
is	O
fully	O
dependent	O
on	O
murine	O
CEACAM1a	O
for	O
its	O
entry	O
,	O
viruses	O
carrying	O
the	O
variant	O
mutations	O
in	O
the	O
amino	O
-	O
terminal	O
part	O
of	O
their	O
S	O
protein	B-CHED
had	O
become	O
dependent	O
on	O
both	O
CEACAM1a	O
and	O
heparan	B-CHED
sulfate	I-CHED
.	O

The	O
observations	O
suggest	O
that	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
the	O
S	O
protein	B-CHED
,	O
including	O
the	O
receptor	O
-	O
binding	O
domain	O
,	O
and	O
a	O
region	O
in	O
the	O
central	O
part	O
of	O
the	O
S	O
protein	B-CHED
containing	O
HR1	O
and	O
FP	O
,	O
i	O
.	O
e	O
.,	O
regions	O
far	O
apart	O
in	O
the	O
linear	O
sequence	O
,	O
communicate	O
and	O
may	O
even	O
interact	O
physically	O
in	O
the	O
higher	O
-	O
order	O
structure	O
of	O
the	O
spike	O
.	O

We	O
herein	O
report	O
a	O
33	O
-	O
year	O
-	O
old	O
man	B-CHED
who	O
presented	O
with	O
chronic	O
pulmonary	O
complications	O
after	O
a	O
recovery	O
from	O
TEN	O
.	O

A	O
jet	O
plume	O
of	O
air	B-CHED
leaked	O
through	O
the	O
mask	O
exhaust	O
holes	O
to	O
a	O
radial	O
distance	O
of	O
0	O
.	O
25	O
m	O
from	O
the	O
mask	O
during	O
the	O
application	O
of	O
IPAP	O
at	O
10	O
cm	O
H2O	B-CHED
with	O
some	O
leakage	O
from	O
the	O
nasal	O
bridge	O
.	O

An	O
analysis	O
of	O
captured	O
digital	O
images	O
showed	O
that	O
the	O
exhaled	O
air	B-CHED
at	O
the	O
peak	O
of	O
simulated	O
exhalation	O
reached	O
a	O
distance	O
of	O
approximately	O
0	O
.	O
40	O
m	O
.	O

Respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
(	O
46	O
.	O
5	O
%)	O
was	O
the	O
most	O
common	O
virus	O
identified	O
in	O
MEF	B-CHED
samples	O
,	O
followed	O
by	O
human	O
rhinovirus	O
(	O
HRV	O
)	O
(	O
25	O
.	O
6	O
%),	O
human	O
coronavirus	O
(	O
HCV	O
)	O
(	O
11	O
.	O
6	O
%),	O
influenza	O
(	O
IV	O
)	O
type	O
A	O
(	O
9	O
.	O
3	O
%),	O
adenovirus	O
type	O
sub	O
type	O
A	O
(	O
AV	O
)	O
(	O
4	O
%),	O
and	O
parainfluenza	O
(	O
PIV	O
)	O
type	O
-	O
3	O
(	O
2	O
%)	O
by	O
RT	O
-	O
PCR	O
.	O

In	O
response	O
to	O
the	O
WHO	O
request	O
we	O
conducted	O
a	O
systematic	O
review	O
of	O
the	O
published	O
literature	O
on	O
ribavirin	B-CHED
,	O
corticosteroids	B-CHED
,	O
lopinavir	O
and	O
ritonavir	B-CHED
(	O
LPV	O
/	O
r	O
),	O
type	O
I	O
interferon	O
(	O
IFN	O
),	O
intravenous	O
immunoglobulin	O
(	O
IVIG	O
),	O
and	O
SARS	O
convalescent	O
plasma	O
from	O
both	O
in	O
vitro	O
studies	O
and	O
in	O
SARS	O
patients	O
.	O

In	O
total	O
,	O
54	O
SARS	O
treatment	O
studies	O
,	O
15	O
in	O
vitro	O
studies	O
,	O
and	O
three	O
acute	O
respiratory	O
distress	O
syndrome	O
studies	O
met	B-CHED
our	O
inclusion	O
criteria	O
.	O

TITLE	O
:	O
Replication	O
of	O
murine	O
hepatitis	O
virus	O
is	O
regulated	O
by	O
papain	O
-	O
like	O
proteinase	O
1	O
processing	O
of	O
nonstructural	O
proteins	B-CHED
1	O
,	O
2	O
,	O
and	O
3	O
.	O

An	O
additional	O
two	O
gnotobiotic	O
calves	O
were	O
inoculated	O
with	O
HECV	O
-	O
4408	O
and	O
euthanized	O
at	O
PID	B-CHED
5	O
.	O

Moderate	O
villous	O
atrophy	O
was	O
observed	O
in	O
the	O
small	O
intestines	O
,	O
and	O
viral	O
antigen	B-CHED
was	O
detected	O
in	O
villous	O
enterocytes	O
of	O
the	O
small	O
and	O
large	O
intestines	O
by	O
immunohistochemistry	O
.	O

In	O
contrast	O
,	O
mutation	O
of	O
amino	B-CHED
acid	I-CHED
Gln	B-CHED
-	O
74	O
to	O
an	O
alanine	B-CHED
,	O
which	O
does	O
not	O
affect	O
the	O
binding	O
activity	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
,	O
showed	O
minimal	O
,	O
if	O
any	O
,	O
detrimental	O
effect	O
on	O
the	O
infectivity	O
of	O
IBV	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
B	O
-	O
cell	O
antigenic	O
epitope	B-CHED
at	O
the	O
N	O
-	O
terminus	O
of	O
SARS	O
-	O
CoV	O
M	O
protein	B-CHED
and	O
characterization	O
of	O
monoclonal	O
antibody	O
against	O
the	O
protein	B-CHED
.	O

The	O
encoded	O
protein	B-CHED
shared	O
96	O
.	O
4	O
%	O
amino	B-CHED
acid	I-CHED
identities	O
compared	O
with	O
CV777	O
,	O
96	O
.	O
1	O
%	O
with	O
Brl	O
/	O
87	O
,	O
98	O
%	O
with	O
JS2004	O
,	O
96	O
.	O
90	O
%	O
with	O
chinju99	O
,	O
respectively	O
.	O

In	O
contrast	O
,	O
another	O
RNA	O
-	O
binding	O
protein	B-CHED
,	O
PTB	O
,	O
did	O
not	O
show	O
these	O
activities	O
.	O

Univariate	O
analysis	O
yielded	O
significant	O
differences	O
in	O
parity	O
(	O
P	O
=	O
0	O
.	O
034	O
),	O
maternal	O
platelet	O
counts	O
(	O
P	O
=	O
0	O
.	O
02	O
),	O
and	O
maternal	O
serum	O
potassium	B-CHED
levels	O
(	O
P	O
=	O
0	O
.	O
016	O
)	O
among	O
the	O
groups	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
was	O
introduced	O
to	O
the	O
United	O
States	O
through	O
air	B-CHED
travel	O
.	O

Serology	O
was	O
negative	O
for	O
all	O
127	O
participants	O
,	O
including	O
three	O
of	O
four	O
who	O
met	B-CHED
the	O
clinical	O
case	O
criteria	O
for	O
SARS	O
,	O
and	O
the	O
fourth	O
had	O
a	O
mild	O
illness	O
that	O
lasted	O
only	O
5	O
days	O
.	O

ELISA	O
and	O
Western	O
blot	O
demonstrated	O
that	O
the	O
S1	O
could	O
react	O
with	O
the	O
convalescent	O
sera	O
of	O
people	O
infected	O
by	O
SARS	O
-	O
CoV	O
.	O
Furthermore	O
,	O
ligand	B-CHED
blot	O
assay	O
showed	O
that	O
the	O
recombinant	O
S1	O
could	O
react	O
with	O
ACE2	O
,	O
the	O
receptor	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
molecular	O
mass	O
of	O
expressed	O
S1	O
was	O
about	O
70	O
kDa	O
,	O
which	O
was	O
higher	O
than	O
that	O
of	O
the	O
30	O
kDa	O
expected	O
.	O

PNGase	O
F	O
deglycosylation	O
resulted	O
in	O
a	O
protein	B-CHED
band	O
of	O
30	O
kDa	O
.	O

No	O
distinct	O
calcitonin	B-CHED
-	O
positive	O
cells	O
were	O
detectable	O
in	O
the	O
SARS	O
thyroids	O
.	O

Mapping	O
studies	O
localized	O
the	O
critical	O
N	O
sequences	O
for	O
this	O
interaction	O
to	O
amino	B-CHED
acids	I-CHED
170	O
-	O
210	O
,	O
which	O
includes	O
the	O
SR	O
-	O
rich	O
motif	O
.	O

In	O
this	O
article	O
,	O
we	O
introduce	O
its	O
ventilation	O
design	O
and	O
evaluate	O
the	O
airflow	O
performance	O
in	O
relation	O
to	O
different	O
combinations	O
of	O
medical	O
lamp	O
configurations	O
and	O
modes	O
of	O
launching	O
infectious	O
particles	O
into	O
the	O
room	O
air	B-CHED
.	O

ABSTRACT	O
:	O
Coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
envelops	O
the	O
genomic	O
RNA	O
to	O
form	O
long	O
helical	O
nucleocapsid	O
during	O
virion	O
assembly	O
.	O

ABSTRACT	O
:	O
To	O
extend	O
the	O
potential	O
of	O
antibodies	O
and	O
their	O
derivatives	O
to	O
provide	O
passive	O
protection	O
against	O
enteric	O
infections	O
when	O
supplied	O
orally	O
in	O
crude	O
plant	O
extracts	O
,	O
we	O
have	O
expressed	O
both	O
a	O
small	O
immune	O
protein	B-CHED
(	O
SIP	O
)	O
and	O
a	O
full	O
-	O
length	O
antibody	O
in	O
plants	O
using	O
two	O
different	O
plant	O
virus	O
vectors	O
based	O
on	O
potato	O
virus	O
X	O
(	O
PVX	O
)	O
and	O
cowpea	O
mosaic	O
virus	O
(	O
CPMV	O
).	O

The	O
alphaSIP	O
molecule	O
consisted	O
of	O
a	O
single	O
chain	O
antibody	O
(	O
scFv	O
)	O
specific	O
for	O
the	O
porcine	O
coronavirus	O
,	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
linked	O
to	O
the	O
alpha	O
-	O
CH3	B-CHED
domain	O
from	O
human	O
IgA	O
.	O
To	O
express	O
the	O
full	O
-	O
length	O
IgA	O
,	O
the	O
individual	O
light	O
and	O
heavy	O
chains	O
from	O
the	O
TGEV	O
-	O
specific	O
mAb	O
6A	O
.	O
C3	O
were	O
inserted	O
into	O
separate	O
PVX	O
constructs	O
and	O
plants	O
were	O
co	O
-	O
infected	O
with	O
both	O
constructs	O
.	O

Infection	O
with	O
antibiotic	B-CHED
-	O
resistant	O
pathogens	O
such	O
as	O
MRSA	O
and	O
VRE	O
is	O
controllable	O
to	O
a	O
low	O
level	O
by	O
active	O
detection	O
and	O
isolation	O
of	O
colonized	O
and	O
infected	O
patients	O
.	O

However	O
,	O
the	O
process	O
of	O
adaptive	O
evolution	O
of	O
S	O
protein	B-CHED
and	O
the	O
exact	O
positively	O
selected	O
sites	O
associated	O
with	O
this	O
process	O
remain	O
unknown	O
.	O

CONCLUSIONS	O
:	O
The	O
variation	O
of	O
positive	O
selective	O
pressures	O
and	O
positively	O
selected	O
sites	O
are	O
likely	O
to	O
contribute	O
to	O
the	O
adaptive	O
evolution	O
of	O
S	O
protein	B-CHED
from	O
animals	O
to	O
humans	O
.	O

ABSTRACT	O
:	O
Armored	O
RNA	O
has	O
been	O
increasingly	O
used	O
as	O
both	O
an	O
external	O
and	O
internal	O
positive	O
control	O
in	O
nucleic	B-CHED
acid	I-CHED
-	O
based	O
assays	O
for	O
RNA	O
virus	O
.	O

Alanine	B-CHED
was	O
also	O
present	O
in	O
this	O
protein	B-CHED
in	O
PRCV	O
-	O
ISU	O
-	O
1	O
.	O

Sequence	O
comparisons	O
at	O
both	O
genomic	O
and	O
protein	B-CHED
levels	O
indicated	O
that	O
PRCV	O
-	O
ISU	O
-	O
1	O
had	O
a	O
closer	O
relationship	O
with	O
TGEV	O
Miller	O
strains	O
than	O
Purdue	O
strains	O
.	O

Therefore	O
application	O
of	O
PIC	O
antagonists	B-CHED
may	O
reduce	O
the	O
severity	O
and	O
mortality	O
of	O
SARS	O
.	O

ALI	O
was	O
initiated	O
by	O
intratracheal	O
HCl	B-CHED
instillation	O
and	O
characterized	O
by	O
severe	O
,	O
PMN	O
-	O
dependent	O
decrease	O
in	O
arterial	O
partial	O
pressure	O
of	O
O	O
(	O
2	O
)	O
(>	O
70	O
%)	O
in	O
nonuremic	O
mice	O
.	O

The	O
display	O
sequence	O
analysis	O
demonstrated	O
that	O
among	O
the	O
twenty	O
phage	O
clones	O
,	O
eight	O
clones	O
displayed	O
the	O
same	O
seven	O
-	O
peptide	B-CHED
TPEQQFT	O
.	O

This	O
study	O
may	O
provide	O
information	O
for	O
further	O
structural	O
and	O
functional	O
analysis	O
of	O
spike	O
protein	B-CHED
and	O
development	O
vaccine	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
The	O
results	O
presented	O
here	O
demonstrate	O
that	O
the	O
MHV	O
and	O
SARS	O
-	O
CoV	O
nsp2	O
proteins	B-CHED
are	O
not	O
required	O
for	O
the	O
production	O
of	O
infectious	O
virus	O
,	O
for	O
polyprotein	O
expression	O
or	O
processing	O
,	O
or	O
for	O
viral	O
replication	O
complex	O
formation	O
in	O
cell	O
culture	O
.	O

The	O
nsp2	O
protein	B-CHED
domain	O
resides	O
in	O
a	O
region	O
of	O
the	O
coronavirus	O
replicase	O
that	O
is	O
relatively	O
nonconserved	O
across	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
We	O
have	O
investigated	O
novel	O
vaccines	O
strategies	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
CoV	O
infection	O
using	O
cDNA	O
constructs	O
encoding	O
the	O
structural	O
antigens	B-CHED
;	O
spike	O
(	O
S	O
),	O
membrane	O
(	O
M	O
),	O
envelope	O
(	O
E	O
),	O
or	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
,	O
derived	O
from	O
SARS	O
CoV	O
(	O
strain	O
HKU39849	O
,	O
TW1	O
,	O
or	O
FFM	O
-	O
1	O
).	O

On	O
the	O
other	O
hand	O
,	O
we	O
have	O
developed	O
SARS	O
DNA	O
vaccines	O
that	O
induce	O
human	O
neutralizing	O
antibodies	O
and	O
human	O
monoclonal	O
antibodies	O
against	O
SARS	O
CoV	O
.	O
Transgenic	O
mice	O
expressing	O
SARS	O
-	O
CoV	O
receptor	O
(	O
angiotensin	B-CHED
converting	O
enzyme	O
2	O
)	O
are	O
also	O
under	O
development	O
.	O

Specific	O
immobilization	O
of	O
GBP	O
-	O
EGFP	O
fusion	O
protein	B-CHED
and	O
its	O
interaction	O
with	O
the	O
antibody	O
in	O
the	O
microchannels	O
could	O
be	O
demonstrated	O
.	O

Our	O
results	O
identified	O
the	O
region	O
location	O
between	O
amino	B-CHED
acid	I-CHED
(	O
aa	O
)	O
residues	O
324	O
to	O
386	O
of	O
the	O
S	O
protein	B-CHED
.	O

Infected	O
A	O
/	O
J	O
mice	O
had	O
significantly	O
higher	O
cytokine	O
levels	O
,	O
particularly	O
macrophage	O
chemoattractant	O
protein	B-CHED
1	O
(	O
MCP	B-CHED
-	O
1	O
/	O
CCL	B-CHED
-	O
2	O
),	O
gamma	O
interferon	O
,	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
partial	O
S1	O
gene	O
sequences	O
showed	O
that	O
five	O
field	O
viruses	O
clustered	O
together	O
with	O
793	O
/	O
B	O
-	O
type	O
strains	O
,	O
having	O
91	O
.	O
3	O
-	O
98	O
.	O
5	O
%	O
nucleotide	B-CHED
identity	O
within	O
the	O
group	O
,	O
and	O
one	O
isolate	O
had	O
very	O
close	O
sequence	O
relationship	O
(	O
94	O
.	O
6	O
%	O
identity	O
)	O
with	O
624	O
/	O
I	O
strain	O
.	O

Overall	O
,	O
the	O
results	O
support	O
a	O
role	O
for	O
nitric	B-CHED
oxide	I-CHED
in	O
controlling	O
MHV	O
-	O
3	O
infection	O
.	O

In	O
particular	O
,	O
in	O
CD8	O
+	O
cells	O
cultured	O
in	O
the	O
presence	O
of	O
the	O
PEC	O
culture	O
supernatant	O
,	O
the	O
expression	O
levels	O
of	O
TNFR1	O
and	O
TNFR2	O
mRNA	B-CHED
were	O
increased	O
,	O
indicating	O
that	O
CD8	O
+	O
cells	O
are	O
more	O
susceptible	O
to	O
apoptosis	O
induction	O
by	O
TNF	O
-	O
alpha	O
than	O
other	O
lymphocyte	O
subsets	O
,	O
particularly	O
B	O
cells	O
(	O
CD21	O
+	O
cells	O
).	O

TITLE	O
:	O
Antibodies	O
against	O
trimeric	O
S	O
glycoprotein	B-CHED
protect	O
hamsters	O
against	O
SARS	O
-	O
CoV	O
challenge	O
despite	O
their	O
capacity	O
to	O
mediate	O
FcgammaRII	O
-	O
dependent	O
entry	O
into	O
B	O
cells	O
in	O
vitro	O
.	O

TITLE	O
:	O
Characterisation	O
of	O
the	O
RNA	O
binding	O
properties	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
nucleocapsid	O
protein	B-CHED
amino	O
-	O
terminal	O
region	O
.	O

The	O
interaction	O
of	O
N	O
protein	B-CHED
with	O
viral	O
RNA	O
was	O
investigated	O
using	O
circular	O
dichroism	O
and	O
surface	O
plasmon	O
resonance	O
.	O

On	O
day	O
5	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
PaO	B-CHED
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
in	O
both	O
groups	O
.	O

The	O
genomes	O
are	O
27	O
,	O
538	O
and	O
27	O
,	O
550	O
nucleotides	B-CHED
long	O
,	O
respectively	O
,	O
and	O
share	O
the	O
same	O
genome	O
organization	O
.	O

Unlike	O
patient	O
sera	O
,	O
however	O
,	O
the	O
mouse	O
antisera	O
were	O
unable	O
to	O
inhibit	O
the	O
infectivity	O
of	O
S	O
protein	B-CHED
-	O
expressing	O
(	O
SARS	O
-	O
CoV	O
-	O
S	O
)	O
pseudovirus	O
.	O

Phylogenetic	O
analyses	O
performed	O
on	O
both	O
replicase	O
gene	O
and	O
nucleocapsid	O
protein	B-CHED
could	O
not	O
add	B-CHED
support	O
to	O
a	O
close	O
relationship	O
between	O
avian	O
and	O
SARS	O
coronaviruses	O
,	O
but	O
all	O
the	O
novel	O
avian	O
coronaviruses	O
were	O
found	O
to	O
harbour	O
s2m	O
.	O

Optimal	O
PEEP	B-CHED
were	O
maintained	O
after	O
RM	O
to	O
stabilize	O
lung	O
volume	O
.	O

The	O
circulating	O
toxins	B-CHED
deriving	O
from	O
the	O
bacterial	O
wall	O
can	O
activate	O
the	O
septic	O
cascade	O
that	O
induces	O
many	O
systemic	O
reactions	O
involving	O
the	O
activation	O
of	O
the	O
cellular	O
immunity	O
,	O
complement	O
and	O
coagulation	O
system	O
.	O

The	O
coding	O
region	O
of	O
the	O
S	O
gene	O
of	O
attenuated	O
PEDV	O
DR13	O
had	O
20	O
nucleotide	B-CHED
changes	O
that	O
appeared	O
to	O
be	O
significant	O
determinants	O
of	O
function	O
in	O
that	O
they	O
produced	O
changes	O
in	O
its	O
predicted	O
amino	B-CHED
acid	I-CHED
sequence	O
.	O

The	O
attenuated	O
PEDV	O
DR13	O
S	O
protein	B-CHED
contains	O
28	O
Asn	B-CHED
-	O
Xaa	O
-	O
Ser	B-CHED
/	O
Thr	B-CHED
sequons	O
,	O
21	O
asparagines	O
that	O
are	O
predicted	O
to	O
be	O
N	O
-	O
glycosylated	O
and	O
a	O
stretch	O
of	O
highly	O
hydrophobic	O
residues	O
at	O
positions	O
1	O
,	O
327	O
-	O
1	O
,	O
347	O
,	O
which	O
is	O
predicted	O
to	O
form	O
an	O
alpha	O
-	O
helix	O
and	O
to	O
function	O
as	O
a	O
membrane	O
anchor	O
.	O

By	O
day	O
3	O
of	O
hospitalization	O
,	O
age	O
(	O
p	O
<	O
0	O
.	O
0001	O
),	O
change	O
in	O
ANC	O
(	O
p	O
=	O
0	O
.	O
0003	O
),	O
and	O
change	O
in	O
bilirubin	B-CHED
(	O
p	O
=	O
0	O
.	O
0065	O
)	O
were	O
discriminating	O
variables	O
.	O

Recombinant	O
N	O
protein	B-CHED
was	O
extracted	O
from	O
infected	O
cells	O
,	O
analysed	O
by	O
SDS	B-CHED
-	O
PAGE	O
and	O
Western	O
blot	O
,	O
and	O
purified	O
by	O
Ni2	O
+	O
affinity	O
procedure	O
.	O

This	O
model	O
of	O
lethal	O
infection	O
with	O
SARS	O
-	O
CoV	O
should	O
be	O
useful	O
for	O
studies	O
of	O
pathogenesis	O
and	O
for	O
the	O
development	O
of	O
antiviral	B-CHED
therapies	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
replication	O
is	O
facilitated	O
by	O
a	O
number	O
of	O
highly	O
conserved	O
viral	O
proteins	B-CHED
.	O

Here	O
we	O
show	O
that	O
inhibition	O
of	O
the	O
Raf	O
/	O
MEK	B-CHED
/	O
ERK	O
signaling	O
pathway	O
by	O
the	O
MEK	B-CHED
inhibitor	B-CHED
UO126	O
significantly	O
impaired	O
MHV	O
progeny	O
production	O
(	O
a	O
reduction	O
of	O
95	O
to	O
99	O
%	O
in	O
virus	O
titer	O
),	O
which	O
correlated	O
with	O
the	O
phosphorylation	O
status	O
of	O
ERK1	O
/	O
2	O
.	O

During	O
ICU	O
stay	O
,	O
AKI	O
patients	O
had	O
markers	O
of	O
more	O
severe	O
disease	O
:	O
increased	O
occurrence	O
of	O
severe	O
sepsis	O
or	O
septic	O
shock	O
,	O
higher	O
number	O
of	O
antibiotics	B-CHED
,	O
and	O
longer	O
use	O
of	O
vasoactive	O
drugs	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
ligustrazine	O
,	O
extracted	O
from	O
Ligusticum	O
wallichii	O
a	O
traditional	O
Chinese	O
medicine	B-CHED
,	O
on	O
lung	O
injury	O
in	O
a	O
rat	O
model	O
of	O
acute	O
necrotizing	O
pancreatitis	O
(	O
ANP	O
).	O

ABSTRACT	O
:	O
This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
Hochu	O
-	O
ekki	O
-	O
to	O
(	O
TJ	O
-	O
41	O
),	O
a	O
Japanese	O
herbal	O
medicine	B-CHED
,	O
on	O
the	O
development	O
of	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)-	O
induced	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
in	O
mice	O
.	O

ALI	O
was	O
induced	O
in	O
female	O
BALB	O
/	O
c	O
mice	O
by	O
the	O
intranasal	O
administration	O
of	O
0	O
.	O
1	O
mg	O
/	O
kg	O
LPS	B-CHED
.	O

The	O
preadministration	O
of	O
TJ	O
-	O
41	O
significantly	O
inhibited	O
increases	O
in	O
the	O
serum	O
level	O
of	O
keratinocyte	O
chemoattractant	O
(	O
KC	O
),	O
which	O
is	O
a	O
murine	O
chemotaxin	O
for	O
neutrophils	O
that	O
corresponds	O
to	O
human	O
interleukin	O
-	O
8	O
,	O
with	O
respect	O
to	O
its	O
concentration	O
at	O
24	O
h	O
after	O
LPS	B-CHED
challenge	O
.	O

CONCLUSIONS	O
:	O
It	O
was	O
found	O
that	O
complications	O
such	O
as	O
DIC	B-CHED
,	O
diastolic	O
dysfunction	O
,	O
abdominal	O
compartment	O
syndrome	O
,	O
ARDS	O
and	O
hepatic	O
dysfunction	O
were	O
more	O
frequent	O
in	O
severe	O
established	O
shock	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
continuous	O
high	O
volume	O
hemofiltration	O
(	O
HVHF	O
)	O
on	O
respiration	O
,	O
hemodynamics	O
,	O
and	O
oxygen	B-CHED
metabolism	O
in	O
severe	O
sepsis	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

DO	O
(	O
2	O
),	O
VO	O
(	O
2	O
)	O
and	O
O	O
(	O
2	O
)	O
ER	O
were	O
stabilized	O
at	O
72	O
hours	O
with	O
amelioration	O
of	O
partial	O
pressure	O
of	O
oxygen	B-CHED
in	O
artery	O
(	O
PaO	B-CHED
(	O
2	O
)),	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
and	O
peak	O
airway	O
pressure	O
(	O
Ppeak	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

CONCLUSIONS	O
:	O
Continuous	O
HVHF	O
shows	O
significant	O
beneficial	O
effects	O
on	O
pulmonary	O
function	O
of	O
severe	O
sepsis	O
patients	O
with	O
ARDS	O
as	O
a	O
result	O
of	O
removal	O
of	O
cytokines	O
,	O
decrease	O
of	O
TFC	O
and	O
amelioration	O
of	O
disturbance	O
in	O
respiration	O
,	O
hemodynamics	O
and	O
oxygen	B-CHED
metabolism	O
.	O

Ten	O
lions	O
(	O
71	O
%)	O
had	O
antibodies	O
against	O
FIV	O
,	O
11	O
(	O
79	O
%)	O
had	O
antibodies	O
against	O
CDV	B-CHED
,	O
11	O
(	O
79	O
%)	O
had	O
antibodies	O
against	O
FCV	B-CHED
,	O
nine	O
(	O
64	O
%)	O
had	O
antibodies	O
against	O
FHV1	O
,	O
and	O
five	O
(	O
36	O
%)	O
had	O
antibodies	O
against	O
FPV	O
.	O

Two	O
of	O
the	O
11	O
CDV	B-CHED
-	O
seropositive	O
lions	O
were	O
subadults	O
,	O
indicating	O
recent	O
exposure	O
of	O
this	O
population	O
to	O
CDV	B-CHED
or	O
a	O
CDV	B-CHED
-	O
like	O
virus	O
.	O

Through	O
SPR	O
technology	O
-	O
based	O
assay	O
,	O
52	O
from	O
these	O
256	O
compounds	O
were	O
discovered	O
to	O
show	O
binding	O
to	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
).	O

Using	O
mouse	O
-	O
feline	O
APN	O
chimeras	O
,	O
we	O
identified	O
three	O
small	O
,	O
discontinuous	O
regions	O
,	O
amino	B-CHED
acids	I-CHED
(	O
aa	O
)	O
288	O
to	O
290	O
,	O
aa	O
732	O
to	O
746	O
(	O
called	O
R1	O
),	O
and	O
aa	O
764	O
to	O
788	O
(	O
called	O
R2	O
)	O
in	O
fAPN	O
that	O
determined	O
the	O
host	O
ranges	O
of	O
these	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
The	O
3	O
'	O
cis	O
-	O
acting	O
element	O
for	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
RNA	O
synthesis	O
resides	O
entirely	O
within	O
the	O
301	O
-	O
nucleotide	B-CHED
3	O
'	O
untranslated	O
region	O
(	O
3	O
'	O
UTR	O
)	O
of	O
the	O
viral	O
genome	O
and	O
consists	O
of	O
three	O
regions	O
.	O

Tests	O
on	O
physical	O
properties	O
showed	O
that	O
N95	O
respirators	O
had	O
significantly	O
lower	O
air	B-CHED
permeability	O
and	O
water	B-CHED
vapor	O
permeability	O
than	O
surgical	O
masks	O
.	O

Here	O
we	O
describe	O
a	O
method	O
for	O
the	O
reductive	O
methylation	O
of	O
lysine	B-CHED
residues	O
which	O
is	O
simple	O
,	O
inexpensive	O
,	O
and	O
efficient	O
,	O
and	O
report	O
on	O
its	O
application	O
to	O
ten	O
proteins	B-CHED
.	O

One	O
follow	O
-	O
up	O
study	O
of	O
long	O
-	O
term	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
survivors	O
using	O
the	O
Structural	O
Clinical	O
Interview	O
for	O
the	O
DSM	B-CHED
-	O
IV	O
(	O
SCID	O
)	O
has	O
shown	O
that	O
43	O
.	O
5	O
%	O
of	O
these	O
patients	O
met	B-CHED
the	O
criteria	O
for	O
a	O
full	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
),	O
8	O
.	O
9	O
%	O
of	O
these	O
patients	O
for	O
a	O
subthreshold	O
or	O
partial	O
PTSD	O
(	O
sub	O
-	O
PTSD	O
)	O
at	O
hospital	O
discharge	O
,	O
and	O
23	O
.	O
9	O
%	O
of	O
them	O
still	O
suffered	O
from	O
full	O
PTSD	O
,	O
17	O
.	O
8	O
%	O
of	O
them	O
from	O
sub	O
-	O
PTSD	O
.	O

Afterwards	O
,	O
influenza	O
A	O
H3N2	B-CHED
was	O
detected	O
from	O
bronchial	O
extracts	O
.	O

It	O
has	O
now	O
been	O
determined	O
that	O
SARS	O
-	O
CoV	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
3b	O
,	O
ORF	O
6	O
,	O
and	O
N	O
proteins	B-CHED
antagonize	O
interferon	O
,	O
a	O
key	O
component	O
of	O
the	O
innate	O
immune	O
response	O
.	O

Furthermore	O
,	O
protein	B-CHED
6	O
coimmunoprecipitated	O
with	O
viral	O
RNAs	O
and	O
colocalized	O
on	O
cytoplasmic	O
vesicles	O
with	O
replicating	O
viral	O
RNAs	O
.	O

TITLE	O
:	O
Naturally	O
occurring	O
anti	O
-	O
Escherichia	O
coli	O
protein	B-CHED
antibodies	O
in	O
the	O
sera	O
of	O
healthy	O
humans	O
cause	O
analytical	O
interference	O
in	O
a	O
recombinant	O
nucleocapsid	O
protein	B-CHED
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
serodiagnosis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Standard	O
histological	O
staining	O
hematoxylin	B-CHED
and	O
eosin	O
was	O
performed	O
and	O
blindly	O
scored	O
by	O
a	O
pathologist	O
for	O
evidence	O
of	O
lung	O
injury	O
(	O
pulmonary	O
edema	O
,	O
accumulations	O
of	O
neutrophils	O
and	O
mononuclear	O
cells	O
,	O
thickness	O
of	O
alveolar	O
-	O
capillary	O
membrane	O
,	O
perivascular	O
infiltrate	O
,	O
and	O
hemorrhage	O
).	O

Caerulein	B-CHED
-	O
treated	O
STAT6	O
and	O
STAT4	O
mice	O
had	O
markedly	O
increased	O
MPO	O
activity	O
as	O
compared	O
with	O
their	O
saline	O
controls	O
during	O
the	O
first	O
6	O
h	O
.	O
Both	O
caerulein	B-CHED
-	O
treated	O
STAT4	O
-	O
and	O
STAT6	O
-	O
deficient	O
mice	O
had	O
significantly	O
increased	O
MPO	O
activity	O
in	O
comparison	O
with	O
wild	O
-	O
type	O
mice	O
with	O
pancreatitis	O
at	O
6	O
h	O
.	O
We	O
found	O
the	O
maximal	O
lung	O
injury	O
after	O
caerulein	B-CHED
-	O
induced	O
pancreatitis	O
occurred	O
at	O
different	O
time	O
-	O
points	O
in	O
STAT4	O
and	O
STAT6	O
-	O
deficient	O
mice	O
.	O

The	O
first	O
ORF	O
is	O
translated	O
from	O
the	O
full	O
-	O
length	O
genomic	O
mRNA	B-CHED
while	O
the	O
remaining	O
ORFs	O
are	O
translated	O
from	O
eight	O
subgeomic	O
RNAs	O
(	O
sgRNAs	O
).	O

In	O
conclusion	O
,	O
the	O
ProTide	B-CHED
approach	O
is	O
highly	O
successful	O
when	O
applied	O
to	O
L	O
-	O
Cd4A	O
with	O
potency	O
improvements	O
in	O
vitro	O
as	O
high	O
as	O
9000	O
-	O
fold	O
against	O
HIV	O
.	O

In	O
multivariate	O
analysis	O
,	O
the	O
presence	O
of	O
peripheral	O
edema	O
before	O
pleurodesis	O
(	O
p	O
=	O
0	O
.	O
005	O
),	O
any	O
preoperative	O
requirement	O
for	O
supplemental	O
oxygen	B-CHED
(	O
p	O
=	O
0	O
.	O
032	O
),	O
and	O
chemotherapy	O
within	O
14	O
days	O
before	O
pleurodesis	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
were	O
identified	O
as	O
predictors	O
of	O
ALI	O
or	O
severe	O
postoperative	O
hypoxemia	O
.	O

It	O
is	O
characterized	O
by	O
a	O
transient	O
deficiency	O
of	O
alveolar	O
surfactant	B-CHED
during	O
the	O
first	O
week	O
of	O
life	O
.	O

Lectins	O
of	O
algal	O
origin	O
whose	O
antiviral	B-CHED
properties	O
make	O
them	O
candidate	O
agents	O
for	O
prevention	O
of	O
viral	O
transmission	O
through	O
topical	O
applications	O
include	O
cyanovirin	O
-	O
N	O
,	O
Microcystis	O
viridis	O
lectin	O
,	O
scytovirin	O
,	O
and	O
griffithsin	O
.	O

RESULTS	O
:	O
Interferon	O
-	O
gamma	O
inducible	O
protein	B-CHED
10	O
(	O
IP	O
-	O
10	O
)	O
was	O
markedly	O
elevated	O
in	O
the	O
blood	O
during	O
the	O
early	O
stage	O
of	O
SARS	O
[(	O
7	O
,	O
600	O
+/-	O
2	O
,	O
400	O
)	O
ng	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
01	O
],	O
and	O
remained	O
at	O
a	O
high	O
level	O
in	O
the	O
progressive	O
stage	O
[(	O
8	O
,	O
100	O
+/-	O

The	O
cytoplasmic	O
portion	O
of	O
the	O
S	O
glycoprotein	B-CHED
contains	O
four	O
cysteine	B-CHED
-	O
rich	O
amino	B-CHED
acid	I-CHED
clusters	B-CHED
.	O

ABSTRACT	O
:	O
We	O
generated	O
a	O
recombinant	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
pseudotype	O
(	O
VSV	O
Delta	O
G	O
*	O
SG	O
)	O
by	O
replacing	O
the	O
envelope	O
G	O
gene	O
with	O
the	O
GFP	O
gene	O
and	O
complementing	O
with	O
spike	O
glycoprotein	B-CHED
(	O
S	O
)	O
of	O
SARS	O
-	O
CoV	O
in	O
trans	O
.	O

The	O
eosinophils	O
may	O
be	O
associated	O
with	O
permanent	O
mucosal	O
damage	O
,	O
as	O
seen	O
in	O
the	O
present	O
case	O
,	O
by	O
releasing	O
mediators	O
that	O
have	O
a	O
pro	B-CHED
-	O
fibrogenetic	O
role	O
.	O

We	O
report	O
our	O
experience	O
of	O
managing	O
five	O
patients	O
with	O
paraquat	B-CHED
poisoning	O
using	O
immunosuppressive	O
therapy	O
.	O

All	O
patients	O
had	O
hepatic	O
failure	O
with	O
median	O
peak	O
bilirubin	B-CHED
being	O
22	O
.	O
1	O
+/-	O

Four	O
of	O
the	O
five	O
patients	O
had	O
renal	O
failure	O
(	O
median	O
peak	O
creatinine	B-CHED
3	O
.	O
8	O
+/-	O

is	O
one	O
of	O
eight	O
Bioinformatics	O
Resource	O
Centers	O
(	O
BRCs	O
)	O
funded	O
by	O
the	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infection	O
Diseases	O
(	O
NIAID	O
)	O
to	O
create	O
a	O
data	O
and	O
analysis	O
resource	O
for	O
selected	O
NIAID	O
priority	O
pathogens	O
,	O
specifically	O
proteobacteria	O
of	O
the	O
genera	O
Brucella	O
,	O
Rickettsia	O
and	O
Coxiella	O
,	O
and	O
corona	B-CHED
-,	O
calici	O
-	O
and	O
lyssaviruses	O
and	O
viruses	O
associated	O
with	O
hepatitis	O
A	O
and	O
E	O
.	O
The	O
goal	O
of	O
the	O
project	O
is	O
to	O
provide	O
a	O
comprehensive	O
bioinformatics	O
resource	O
for	O
these	O
pathogens	O
,	O
including	O
consistently	O
annotated	O
genome	O
,	O
proteome	O
and	O
metabolic	O
pathway	O
data	O
to	O
facilitate	O
research	O
into	O
counter	B-CHED
-	O
measures	O
,	O
including	O
drugs	O
,	O
vaccines	O
and	O
diagnostics	O
.	O

The	O
dimeric	O
enzyme	O
dissociated	O
at	O
guanidinium	B-CHED
chloride	I-CHED
concentration	O
of	O
<	O
0	O
.	O
4	O
M	O
,	O
at	O
which	O
the	O
enzymatic	O
activity	O
loss	O
showed	O
close	O
correlation	O
with	O
the	O
subunit	O
dissociation	O
.	O

As	O
all	O
these	O
pathologies	O
may	O
have	O
high	O
social	O
and	O
economic	O
costs	O
and	O
appropriate	O
therapy	O
is	O
not	O
always	O
available	O
,	O
the	O
specialist	O
in	O
Occupational	O
Medicine	B-CHED
plays	O
a	O
pre	O
-	O
eminent	O
role	O
in	O
early	O
diagnosis	O
and	O
prevention	O
of	O
respiratory	O
diseases	O
linked	O
to	O
indoor	O
air	B-CHED
pollution	O
in	O
the	O
workplace	O
.	O

ABSTRACT	O
:	O
Nucleoside	B-CHED
analogs	O
that	O
have	O
6	O
-	O
chloropurine	O
as	O
a	O
nucleobase	B-CHED
were	O
synthesized	O
and	O
evaluated	O
to	O
develop	O
novel	O
anti	O
-	O
SARS	O
-	O
CoV	O
agents	O
.	O

The	O
study	O
aimed	O
to	O
describe	O
the	O
experience	O
and	O
behaviour	O
of	O
family	O
physicians	O
and	O
the	O
use	O
of	O
personal	O
protection	O
equipment	O
(	O
PPE	B-CHED
)	O
in	O
their	O
encounters	O
with	O
SARS	O
patients	O
.	O

Mutation	O
of	O
any	O
of	O
these	O
serine	B-CHED
residues	O
to	O
alanine	B-CHED
had	O
a	O
debilitating	O
effect	O
on	O
the	O
catalytic	O
activity	O
of	O
3CLpro	O
.	O

The	O
second	O
serum	O
samples	O
from	O
these	O
14	O
flocks	O
were	O
further	O
examined	O
against	O
a	O
panel	O
of	O
five	O
IBV	O
antigens	B-CHED
(	O
Ark	O
,	O
Conn	O
,	O
DE	O
-	O
072	O
,	O
JMK	O
,	O
and	O
Mass	O
)	O
by	O
HI	O
test	O
to	O
determine	O
the	O
serotype	O
(	O
s	O
)	O
of	O
IBV	O
they	O
have	O
been	O
exposed	O
to	O
.	O

In	O
SARS	O
treatment	O
there	O
are	O
applied	O
antiviral	B-CHED
drugs	I-CHED
and	O
glicocorticosteroids	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
with	O
diluted	O
porcine	O
surfactant	B-CHED
in	O
mechanically	O
ventilated	O
term	O
infants	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
due	O
to	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	B-CHED
).	O

Eight	O
consecutive	O
mechanically	O
ventilated	O
term	O
infants	O
with	O
severe	O
ARDS	O
due	O
to	O
MAS	B-CHED
underwent	O
BAL	B-CHED
with	O
15	O
mL	O
/	O
kg	O
of	O
diluted	O
(	O
5	O
.	O
3mg	O
phospholipid	B-CHED
/	O
mL	O
)	O
surfactant	B-CHED
saline	O
suspension	O
(	O
porcine	O
surfactant	B-CHED
[	O
Curosurf	O
]).	O

Compared	O
with	O
pre	O
-	O
BAL	B-CHED
values	O
,	O
significant	O
improvements	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
mean	O
values	O
for	O
partial	O
pressure	O
of	O
oxygen	B-CHED
in	O
arterial	O
blood	O
,	O
partial	O
pressure	O
of	O
carbon	B-CHED
dioxide	I-CHED
in	O
arterial	O
blood	O
,	O
pH	O
,	O
arterial	O
/	O
alveolar	O
O2	O
ratio	O
and	O
oxygenation	O
index	O
were	O
documented	O
at	O
3	O
and	O
6	O
hours	O
after	O
BAL	B-CHED
.	O

In	O
all	O
patients	O
,	O
tracheal	O
fluids	O
that	O
had	O
been	O
meconium	O
-	O
stained	O
prior	O
to	O
BAL	B-CHED
were	O
clear	O
of	O
meconium	O
after	O
BAL	B-CHED
.	O

Four	O
severe	O
laboratory	O
-	O
confirmed	O
SARS	O
patients	O
received	O
routine	O
western	O
-	O
medicine	B-CHED
treatment	O
plus	O
different	O
supplementary	O
treatment	O
:	O
CM	O
A	O
,	O
CM	O
B	O
and	O
CM	O
C	O
(	O
placebo	O
control	O
).	O

TITLE	O
:	O
[	O
Experimental	O
study	O
of	O
glucocorticoid	B-CHED
in	O
the	O
treatment	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
induced	O
by	O
E	O
.	O
coli	O
].	O

In	O
the	O
latter	O
two	O
groups	O
methylprednisolone	B-CHED
20	O
mg	O
was	O
intravenously	O
,	O
given	O
every	O
12	O
hours	O
(	O
4	O
mg	O
(-	O
1	O
)	O
xkg	O
(-	O
1	O
)	O
xd	O
(-	O
1	O
)).	O

But	O
the	O
treatment	O
has	O
no	O
influence	O
on	O
pulmonary	O
surfactant	B-CHED
(	O
PS	O
),	O
surface	O
tension	O
and	O
lung	O
pathology	O
of	O
ARDS	O
in	O
piglets	O
challenged	O
with	O
intraperitoneal	O
E	O
.	O
coli	O
.	O

In	O
support	O
of	O
this	O
,	O
we	O
found	O
that	O
the	O
dibasic	O
motif	O
on	O
the	O
SARS	O
S	O
protein	B-CHED
was	O
required	O
for	O
its	O
localization	O
to	O
the	O
ERGIC	O
/	O
Golgi	O
region	O
when	O
coexpressed	O
with	O
SARS	O
membrane	O
(	O
M	O
)	O
protein	B-CHED
.	O

TITLE	O
:	O
Essential	O
role	O
for	O
collectrin	O
in	O
renal	O
amino	B-CHED
acid	I-CHED
transport	O
.	O

ABSTRACT	O
:	O
Angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
a	O
regulator	O
of	O
the	O
renin	O
angiotensin	B-CHED
system	O
involved	O
in	O
acute	O
lung	O
failure	O
,	O
cardiovascular	O
functions	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
infections	O
in	O
mammals	O
.	O

Expression	O
of	O
collectrin	O
in	O
Xenopus	O
oocytes	O
and	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
(	O
MDCK	O
)	O
cells	O
enhances	O
amino	B-CHED
acid	I-CHED
transport	O
by	O
the	O
transporter	O
B	O
(	O
0	O
)	O
AT1	O
.	O

TITLE	O
:	O
Quaternary	O
structure	O
,	O
substrate	O
selectivity	O
and	O
inhibitor	B-CHED
design	O
for	O
SARS	O
3C	O
-	O
like	O
proteinase	O
.	O

The	O
protein	B-CHED
exists	O
as	O
a	O
dimer	O
/	O
monomer	O
mixture	B-CHED
in	O
solution	O
and	O
the	O
dimer	O
was	O
confirmed	O
to	O
be	O
the	O
active	O
species	O
for	O
the	O
enzyme	O
reaction	O
.	O

As	O
the	O
enzyme	O
can	O
cut	O
eleven	O
different	O
sites	O
on	O
the	O
viral	O
polyprotein	O
,	O
the	O
substrate	O
specificity	O
has	O
been	O
studied	O
by	O
synthesized	O
peptides	B-CHED
corresponding	O
or	O
similar	O
to	O
the	O
cleavage	O
sites	O
on	O
the	O
polyprotein	O
.	O

This	O
review	O
summarizes	O
the	O
recent	O
advances	O
in	O
biological	O
and	O
structural	O
studies	O
,	O
together	O
with	O
development	O
of	O
inhibitors	B-CHED
targeting	O
CoV	O
M	O
(	O
pro	B-CHED
)	O
s	O
.	O

Here	O
,	O
this	O
system	O
was	O
compared	O
with	O
an	O
autotransporter	O
protein	B-CHED
surface	O
display	O
system	O
.	O

Nelfinavir	O
,	O
beta	O
-	O
D	O
-	O
N4	O
-	O
hydroxycytidine	O
,	O
calpain	O
inhibitor	B-CHED
VI	O
,	O
3	O
-	O
deazaneplanocin	O
A	O
and	O
Alferon	O
(	O
human	O
leukocyte	O
IFN	O
-	O
alpha	O
-	O
n3	O
)	O
did	O
not	O
significantly	O
reduce	O
lung	O
virus	O
titres	O
in	O
mice	O
.	O

Anti	B-CHED
-	I-CHED
inflammatory	I-CHED
agents	I-CHED
,	O
chloroquine	B-CHED
,	O
amodiaquin	O
and	O
pentoxifylline	O
,	O
were	O
also	O
inactive	O
in	O
vivo	O
,	O
suggesting	O
that	O
although	O
they	O
may	O
be	O
useful	O
in	O
ameliorating	O
the	O
hyperinflammatory	O
response	O
induced	O
by	O
the	O
virus	O
infection	O
,	O
they	O
will	O
not	O
significantly	O
reduce	O
the	O
replication	O
of	O
the	O
virus	O
,	O
the	O
inducer	O
of	O
inflammatory	O
response	O
.	O

TITLE	O
:	O
Antiviral	B-CHED
activity	O
of	O
nucleoside	B-CHED
analogues	I-CHED
against	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
coV	O
).	O

Treatment	O
with	O
sivelestat	O
sodium	B-CHED
hydrate	I-CHED
also	O
decreased	O
serum	O
neutrophil	O
elastase	O
activity	O
.	O

TITLE	O
:	O
Coupling	O
molecular	O
beacons	O
to	O
barcoded	O
metal	B-CHED
nanowires	O
for	O
multiplexed	O
,	O
sealed	O
chamber	O
DNA	O
bioassays	O
.	O

ABSTRACT	O
:	O
We	O
have	O
combined	O
molecular	O
beacon	O
(	O
MB	O
)	O
probes	O
with	O
barcoded	O
metal	B-CHED
nanowires	O
to	O
enable	O
no	O
-	O
wash	O
,	O
sealed	O
chamber	O
,	O
multiplexed	O
detection	O
of	O
nucleic	B-CHED
acids	I-CHED
.	O

We	O
used	O
a	O
well	O
-	O
established	O
recombinant	O
vaccinia	O
virus	O
(	O
VV	O
)-	O
based	O
expression	O
system	O
that	O
lacks	O
the	O
viral	O
IFN	O
antagonist	B-CHED
E3L	O
to	O
screen	O
viral	O
genes	O
for	O
their	O
ability	O
to	O
rescue	O
the	O
IFN	O
sensitivity	O
of	O
the	O
mutant	O
.	O

Group	O
2	O
and	O
3	O
E	O
proteins	B-CHED
were	O
readily	O
exchangeable	O
for	O
that	O
of	O
MHV	O
.	O

These	O
findings	O
suggest	O
that	O
E	O
protein	B-CHED
facilitates	O
viral	O
assembly	O
in	O
a	O
manner	O
that	O
does	O
not	O
require	O
E	O
protein	B-CHED
to	O
make	O
sequence	O
-	O
specific	O
contacts	O
with	O
M	O
protein	B-CHED
.	O

The	O
entire	O
ectodomain	O
of	O
S	O
protein	B-CHED
was	O
fused	O
between	O
the	O
gp64	O
signal	O
peptide	B-CHED
and	O
the	O
VSV	O
-	O
G	O
membrane	O
anchor	O
and	O
successfully	O
displayed	O
on	O
the	O
baculovirus	O
surface	O
.	O

These	O
results	O
confirmed	O
a	O
successful	O
surface	O
display	O
of	O
S	O
protein	B-CHED
on	O
baculoviruse	O
,	O
and	O
suggested	O
a	O
potential	O
role	O
of	O
S	O
-	O
displayed	O
baculoviruses	O
as	O
a	O
novel	O
live	O
virus	O
-	O
based	O
vaccine	O
candidate	O
for	O
SARS	O
-	O
CoV	O
.	O

Our	O
results	O
show	O
that	O
additional	O
residues	O
at	O
the	O
N	O
terminus	O
,	O
but	O
not	O
at	O
the	O
C	O
terminus	O
,	O
of	O
M	O
(	O
pro	B-CHED
)	O
are	O
detrimental	O
to	O
enzyme	O
activity	O
.	O

Chi	B-CHED
-	O
square	O
test	O
and	O
multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
were	O
performed	O
.	O

RESULTS	O
:	O
All	O
Dutch	O
isolates	O
were	O
identical	O
in	O
the	O
ORF4a	O
/	O
b	O
region	O
at	O
amino	B-CHED
acid	I-CHED
level	O
.	O

Cholesterol	B-CHED
depletion	O
by	O
pretreatment	O
of	O
Vero	O
E6	O
cells	O
with	O
methyl	B-CHED
-	O
beta	B-CHED
-	I-CHED
cyclodextrin	I-CHED
(	O
MbetaCD	O
)	O
inhibited	O
the	O
production	O
of	O
SARS	O
-	O
CoV	O
particles	O
released	O
from	O
the	O
infected	O
cells	O
.	O

In	O
contrast	O
,	O
cholesterol	B-CHED
depletion	O
at	O
the	O
post	O
-	O
entry	O
stage	O
(	O
3h	O
post	O
-	O
infection	O
)	O
caused	O
only	O
a	O
limited	O
effect	O
on	O
virus	O
particle	O
release	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
coronavirus	O
main	O
peptidase	O
(	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	B-CHED
))	O
plays	O
an	O
essential	O
role	O
in	O
the	O
life	O
-	O
cycle	O
of	O
the	O
virus	O
and	O
is	O
a	O
primary	O
target	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
agents	O
.	O

The	O
structural	O
data	O
further	O
suggest	O
that	O
the	O
binding	O
of	O
APE	O
to	O
M	O
(	O
pro	B-CHED
)	O
follows	O
an	O
induced	O
-	O
fit	O
model	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
retrospective	O
study	O
in	O
the	O
medical	O
intensive	O
care	O
unit	O
of	O
the	O
Casablanca	O
Ibn	B-CHED
-	O
Rochd	O
University	O
hospital	O
.	O

All	O
patients	O
received	O
quinine	B-CHED
therapy	O
with	O
loading	O
dose	O
and	O
symptomatic	O
treatment	O
.	O

Although	O
AV	O
-	O
ECLA	O
is	O
highly	O
effective	O
in	O
eliminating	O
CO2	B-CHED
,	O
if	O
combined	O
with	O
apnoeic	O
oxygenation	O
,	O
normocapnia	O
was	O
not	O
achievable	O
.	O

Structural	O
information	O
indicated	O
that	O
both	O
of	O
these	O
amino	B-CHED
acids	I-CHED
are	O
available	O
for	O
interaction	O
with	O
protein	B-CHED
complexes	O
involved	O
in	O
this	O
process	O
.	O

ABSTRACT	O
:	O
To	O
study	O
changes	O
in	O
oxygen	B-CHED
metabolism	O
and	O
evaluate	O
metabolic	O
status	O
in	O
tissue	O
and	O
cell	O
after	O
severe	O
trauma	O
,	O
and	O
to	O
investigate	O
value	O
of	O
monitoring	O
oxygen	B-CHED
metabolism	O
in	O
the	O
course	O
of	O
development	O
of	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
)	O
in	O
trauma	O
between	O
patients	O
.	O

Oxygen	B-CHED
deficiency	O
metabolic	O
variables	O
tended	O
to	O
deteriorate	O
in	O
the	O
non	O
survival	O
group	O
.	O

The	O
optimum	O
diagnostic	O
procedure	O
is	O
examination	O
of	O
thick	O
and	O
thin	O
blood	O
films	O
by	O
an	O
expert	O
to	O
detect	O
and	O
speciate	O
the	O
malarial	O
parasites	O
;	O
P	O
.	O
falciparum	O
malaria	O
can	O
be	O
diagnosed	O
almost	O
as	O
accurately	O
using	O
rapid	O
diagnostic	O
tests	O
(	O
RDTs	O
)	O
which	O
detect	O
plasmodial	O
antigens	B-CHED
or	O
enzymes	O
,	O
although	O
RDTs	O
for	O
other	O
Plasmodium	O
species	O
are	O
not	O
as	O
reliable	O
.	O

Intravenous	O
artesunate	B-CHED
is	O
unlicensed	O
in	O
the	O
EU	O
.	O

Assistance	O
in	O
obtaining	O
artesunate	B-CHED
may	O
be	O
sought	O
from	O
specialist	O
tropical	O
medicine	B-CHED
centres	O
,	O
on	O
consultation	O
,	O
for	O
named	O
patients	O
.	O

Sequence	O
analysis	O
of	O
the	O
S	O
-	O
gene	O
fragment	O
amplified	O
by	O
RT	O
-	O
PCR	O
(	O
595bp	O
)	O
showed	O
similarity	O
to	O
group	O
II	O
coronaviruses	O
,	O
with	O
the	O
highest	O
nucleotide	B-CHED
identity	O
(	O
98	O
%)	O
to	O
the	O
only	O
CRCoV	O
strain	O
currently	O
available	O
in	O
the	O
GenBank	O
database	O
(	O
strain	O
T101	O
).	O

Specifically	O
,	O
chronic	O
alcohol	O
ingestion	O
decreases	O
the	O
levels	O
of	O
the	O
antioxidant	B-CHED
glutathione	B-CHED
within	O
the	O
alveolar	O
space	O
by	O
as	O
much	O
as	O
80	O
-	O
90	O
%,	O
and	O
,	O
as	O
a	O
consequence	O
,	O
impairs	O
alveolar	O
epithelial	O
surfactant	B-CHED
production	O
and	O
barrier	O
integrity	O
,	O
decreases	O
alveolar	O
macrophage	O
function	O
,	O
and	O
renders	O
the	O
lung	O
susceptible	O
to	O
oxidant	B-CHED
-	O
mediated	O
injury	O
.	O

We	O
conclude	O
that	O
:	O
(	O
1	O
)	O
it	O
is	O
important	O
to	O
determine	O
whether	O
the	O
unrecorded	O
positive	O
status	O
of	O
a	O
symptom	O
means	O
that	O
the	O
status	O
is	O
negative	O
or	O
that	O
the	O
status	O
is	O
unknown	O
;	O
(	O
2	O
)	O
inclusion	O
of	O
misdiagnosis	O
error	O
rates	O
produces	O
more	O
realistic	O
results	O
;	O
(	O
3	O
)	O
the	O
naive	O
Bayes	O
classifier	O
,	O
which	O
assumes	O
all	O
symptoms	O
behave	O
independently	O
,	O
is	O
slightly	O
outperformed	O
by	O
CADDY	B-CHED
,	O
which	O
includes	O
available	O
multi	O
-	O
symptom	O
information	O
on	O
correlations	O
;	O
as	O
more	O
information	O
regarding	O
symptom	O
correlations	O
becomes	O
available	O
,	O
the	O
advantage	O
of	O
CADDY	B-CHED
over	O
the	O
naive	O
Bayes	O
classifier	O
should	O
increase	O
;	O
(	O
4	O
)	O
overlooking	O
low	O
-	O
probability	O
,	O
high	O
-	O
consequence	O
events	O
is	O
less	O
likely	O
if	O
the	O
standard	O
output	O
summary	O
is	O
augmented	O
with	O
a	O
list	O
of	O
rare	O
syndromes	O
that	O
are	O
consistent	O
with	O
observed	O
symptoms	O
,	O
and	O
(	O
5	O
)	O
accumulating	O
patient	O
-	O
level	O
probabilities	O
across	O
a	O
larger	O
population	O
can	O
aid	O
in	O
biosurveillance	O
for	O
disease	O
outbreaks	O
.	O

One	O
of	O
them	O
,	O
a	O
54	O
-	O
year	O
-	O
old	O
woman	O
,	O
had	O
difficulty	O
breathing	O
and	O
lost	B-CHED
consciousness	O
.	O

TITLE	O
:	O
Role	O
of	O
the	O
coronavirus	O
E	O
viroporin	O
protein	B-CHED
transmembrane	O
domain	O
in	O
virus	O
assembly	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
envelope	O
(	O
E	O
)	O
proteins	B-CHED
are	O
small	O
(	O
approximately	O
75	O
-	O
to	O
110	O
-	O
amino	O
-	O
acid	O
)	O
membrane	O
proteins	B-CHED
that	O
have	O
a	O
short	O
hydrophilic	O
amino	O
terminus	O
,	O
a	O
relatively	O
long	O
hydrophobic	O
membrane	O
domain	O
,	O
and	O
a	O
long	O
hydrophilic	O
carboxy	B-CHED
-	O
terminal	O
domain	O
.	O

The	O
protein	B-CHED
is	O
a	O
minor	O
virion	O
structural	O
component	O
that	O
plays	O
an	O
important	O
,	O
not	O
fully	O
understood	O
role	O
in	O
virus	O
production	O
.	O

Currently	O
,	O
facility	O
engineers	O
and	O
designers	O
of	O
heating	O
,	O
ventilation	O
,	O
and	O
air	B-CHED
-	O
conditioning	O
(	O
HVAC	O
)	O
systems	O
have	O
few	O
analytical	O
tools	O
to	O
estimate	O
a	O
room	O
'	O
s	O
leakage	O
area	O
and	O
establish	O
an	O
appropriate	O
flow	O
differential	O
(	O
DeltaQ	O
)	O
in	O
hospitals	O
,	O
shelters	O
,	O
and	O
other	O
facilities	O
where	O
communicable	O
diseases	O
are	O
present	O
.	O

Thus	O
,	O
reducing	O
the	O
length	O
of	O
C	O
-	O
terminal	O
extension	O
of	O
signal	O
peptide	B-CHED
by	O
signal	O
peptidase	O
cleavage	O
could	O
facilitate	O
further	O
cleavage	O
by	O
SPP	O
.	O

Angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
is	O
the	O
functional	O
receptor	O
for	O
SARS	O
-	O
CoV	O
;	O
DC	O
-	O
SIGN	O
and	O
CD209L	O
(	O
L	O
-	O
SIGN	O
)	O
can	O
enhance	O
viral	O
entry	O
.	O

The	O
program	O
accepts	O
GenBank	O
,	O
EMBL	O
and	O
FASTA	O
files	O
as	O
an	O
input	O
,	O
and	O
it	O
displays	O
multiple	O
DNA	O
nucleotide	B-CHED
composition	O
graphs	O
(	O
skews	O
and	O
walks	O
)	O
in	O
a	O
single	O
window	O
to	O
allow	O
direct	O
comparisons	O
between	O
the	O
sequences	O
.	O

Our	O
study	O
reveals	O
a	O
strong	O
need	O
for	O
a	O
multidisciplinary	O
study	O
in	O
investigating	O
disease	O
outbreaks	O
,	O
and	O
the	O
impact	O
of	O
indoor	O
air	B-CHED
environments	O
on	O
the	O
spread	O
of	O
airborne	O
infectious	O
diseases	O
.	O

TITLE	O
:	O
Inhibitor	B-CHED
design	O
for	O
SARS	O
coronavirus	O
main	O
protease	O
based	O
on	O
""""	O
distorted	O
key	O
theory	O
"""."	O

Flexible	O
molecular	O
alignments	O
of	O
the	O
11	O
cleavable	O
peptides	B-CHED
have	O
provided	O
useful	O
insights	O
into	O
the	O
chemical	O
properties	O
of	O
their	O
amino	B-CHED
acid	I-CHED
residues	O
close	O
to	O
the	O
cleavage	O
site	O
.	O

TITLE	O
:	O
Spike	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
stimulates	O
cyclooxygenase	O
-	O
2	O
expression	O
via	O
both	O
calcium	B-CHED
-	O
dependent	O
and	O
calcium	B-CHED
-	O
independent	O
protein	B-CHED
kinase	O
C	O
pathways	O
.	O

However	O
,	O
these	O
antigens	B-CHED
are	O
often	O
poorly	O
immunogenic	O
,	O
and	O
thus	O
require	O
the	O
use	O
of	O
adjuvants	B-CHED
to	O
induce	O
adequate	O
immunity	O
.	O

In	O
the	O
event	O
of	O
a	O
bird	O
-	O
to	O
-	O
human	O
or	O
human	O
-	O
to	O
-	O
human	O
outbreak	O
in	O
Hong	O
Kong	O
,	O
many	O
anticipated	O
high	O
fatality	O
rates	O
(	O
70	O
.	O
5	O
%	O
and	O
74	O
.	O
4	O
%,	O
respectively	O
),	O
permanent	O
physical	O
damage	O
(	O
52	O
.	O
0	O
%	O
and	O
54	O
.	O
9	O
%,	O
respectively	O
),	O
inadequate	O
vaccines	O
(	O
50	O
.	O
0	O
%	O
and	O
64	O
.	O
4	O
%,	O
respectively	O
),	O
insufficient	O
medicine	B-CHED
supplies	O
(	O
43	O
.	O
7	O
%	O
and	O
54	O
.	O
5	O
%,	O
respectively	O
),	O
inadequate	O
hospital	O
infection	O
control	O
(	O
35	O
.	O
1	O
%	O
and	O
43	O
.	O
3	O
%,	O
respectively	O
),	O
high	O
susceptibility	O
of	O
family	O
members	O
contracting	O
H5N1	O
(	O
13	O
.	O
9	O
%	O
and	O
24	O
.	O
3	O
%,	O
respectively	O
),	O
and	O
impact	O
on	O
oneself	O
/	O
family	O
worse	O
than	O
those	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
21	O
.	O
2	O
and	O
25	O
.	O
0	O
%,	O
respectively	O
).	O

The	O
expression	O
of	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
18	O
mRNA	B-CHED
were	O
decreased	O
significantly	O
in	O
the	O
SAP	O
-	O
ICE	O
-	O
I	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
,	O
vs	O
SAP	O
-	O
S	O
),	O
whereas	O
Caspase	O
-	O
1	O
mRNA	B-CHED
expression	O
had	O
no	O
significant	O
difference	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

In	O
contrast	O
to	O
human	O
influenza	O
A	O
H1NI	O
viruses	O
,	O
the	O
H5N1	O
viruses	O
hyper	O
-	O
induce	O
cytokines	O
(	O
tumour	O
necrosis	O
factor	O
[	O
TNF	O
]	O
alpha	O
,	O
interferon	O
beta	O
)	O
and	O
chemokines	O
(	O
IP10	O
,	O
MIP1alpha	O
,	O
MCP	B-CHED
)	O
in	O
in	O
vitro	O
cultures	O
of	O
primary	O
human	O
macrophages	O
.	O

The	O
predicted	O
B	O
cell	O
epitope	B-CHED
peptide	B-CHED
of	O
SARS	O
coronavirus	O
S2	O
spike	O
protein	B-CHED
can	O
induce	O
the	O
antigenicity	O
of	O
S2	O
protein	B-CHED
,	O
which	O
provides	O
some	O
fundamental	O
data	O
for	O
developing	O
engineering	O
vaccine	O
against	O
SARS	O
coronavirus	O
infection	O
.	O

TITLE	O
:	O
Early	O
cytokine	O
mRNA	B-CHED
expression	O
profiles	O
predict	O
Morbillivirus	O
disease	O
outcome	O
in	O
ferrets	O
.	O

The	O
nucleotide	B-CHED
and	O
amino	B-CHED
acid	I-CHED
sequence	O
of	O
the	O
S1	O
gene	O
had	O
a	O
similar	O
degree	O
of	O
identity	O
(	O
88	O
.	O
98	O
-	O
99	O
.	O
28	O
%)	O
among	O
the	O
four	O
Chinese	O
IBV	O
isolates	O
.	O

The	O
identity	O
of	O
the	O
S1	O
protein	B-CHED
gene	O
between	O
the	O
four	O
Chinese	O
IBV	O
isolates	O
and	O
14	O
strains	O
of	O
other	O
IBVs	O
varied	O
from	O
70	O
.	O
06	O
to	O
81	O
.	O
59	O
%.	O

Existing	O
in	O
non	O
-	O
identified	O
animal	O
reservoirs	O
,	O
SARS	O
-	O
CoV	O
continues	O
to	O
represent	O
a	O
threat	O
to	O
humans	O
because	O
there	O
is	O
no	O
effective	O
specific	O
antiviral	B-CHED
therapy	O
for	O
coronavirus	O
infections	O
.	O

Starting	O
from	O
the	O
observation	O
that	O
cyclopentenone	O
cyclooxygenase	O
(	O
COX	O
)	O
metabolites	B-CHED
are	O
active	O
against	O
several	O
RNA	O
viruses	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
the	O
COX	B-CHED
inhibitor	I-CHED
indomethacin	B-CHED
on	O
coronavirus	O
replication	O
.	O

In	O
this	O
study	O
,	O
the	O
pro	B-CHED
-	O
apoptotic	O
role	O
of	O
the	O
SARS	O
-	O
CoV	O
Membrane	O
(	O
M	O
)	O
structural	O
protein	B-CHED
is	O
described	O
.	O

The	O
epsilonSIP	O
molecule	O
consisted	O
of	O
a	O
single	O
-	O
chain	O
antibody	O
(	O
scFv	O
)	O
specific	O
for	O
the	O
porcine	O
coronavirus	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
linked	O
to	O
the	O
epsilon	O
-	O
CH4	B-CHED
domain	O
from	O
human	O
immunoglobulin	O
E	O
(	O
IgE	O
).	O

In	O
some	O
constructs	O
,	O
the	O
sequence	O
encoding	O
the	O
epsilonSIP	O
molecule	O
was	O
flanked	O
by	O
the	O
leader	O
peptide	B-CHED
from	O
the	O
original	O
murine	O
antibody	O
at	O
its	O
N	O
-	O
terminus	O
and	O
an	O
endoplasmic	O
reticulum	O
retention	O
signal	O
(	O
HDEL	O
)	O
at	O
its	O
C	O
-	O
terminus	O
to	O
allow	O
the	O
expressed	O
protein	B-CHED
to	O
be	O
directed	O
to	O
,	O
and	O
retained	O
within	O
,	O
the	O
endoplasmic	O
reticulum	O
.	O

ABSTRACT	O
:	O
To	O
survey	O
the	O
dynamic	O
changing	O
and	O
persistence	O
of	O
the	O
special	O
antibodies	O
,	O
including	O
total	O
IgM	O
,	O
IgG	O
,	O
nucleocapsid	O
protein	B-CHED
and	O
spike	O
protein	B-CHED
antibodies	O
,	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
patients	O
with	O
SARS	O
.	O

ABSTRACT	O
:	O
Many	O
viruses	O
encode	O
antagonists	B-CHED
to	O
prevent	O
interferon	O
(	O
IFN	O
)	O
induction	O
.	O

TITLE	O
:	O
Platelet	O
aggregation	O
and	O
aspirin	B-CHED
non	O
-	O
responsiveness	O
increase	O
when	O
an	O
acute	O
coronary	O
syndrome	O
is	O
complicated	O
by	O
an	O
infection	O
.	O

The	O
CRP	O
levels	O
were	O
independently	O
associated	O
with	O
platelet	O
aggregation	O
and	O
aspirin	B-CHED
non	O
-	O
responsiveness	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
respectively	O
).	O

Eggs	O
with	O
watery	O
whites	O
which	O
were	O
laid	O
by	O
infected	O
hens	O
could	O
be	O
attributed	O
to	O
cytopathological	O
changes	O
in	O
the	O
granular	O
epithelial	O
cells	O
and	O
tubular	O
gland	O
epithelial	O
cells	O
of	O
the	O
magnum	O
resulting	O
in	O
reduced	O
synthesis	O
of	O
albumen	O
proteins	B-CHED
.	O

Captive	O
maned	O
wolves	O
are	O
susceptible	O
to	O
,	O
and	O
die	O
from	O
,	O
common	O
infectious	O
diseases	O
of	O
domestic	O
dogs	O
(	O
Canis	O
familiaris	O
)	O
including	O
canine	O
distemper	O
virus	O
(	O
CDV	B-CHED
),	O
canine	O
parvovirus	O
(	O
CPV	O
),	O
rabies	O
virus	O
,	O
and	O
canine	O
adenovirus	O
(	O
CAV	O
).	O

In	O
August	O
2002	O
,	O
Alfacell	O
received	O
a	O
US	O
patent	O
(	O
No	O
.	O
6	O
423	O
515	O
B1	O
)	O
entitled	O
'	O
Methods	O
of	O
Making	O
Nucleic	B-CHED
Acids	I-CHED
Encoding	O
Ribonucleases	O
'.	O

TITLE	O
:	O
SARS	O
molecular	O
epidemiology	O
:	O
a	O
Chinese	O
fairy	O
tale	O
of	O
controlling	O
an	O
emerging	O
zoonotic	O
disease	O
in	O
the	O
genomics	O
era	B-CHED
.	O

ABSTRACT	O
:	O
Myelin	O
transcription	O
factor	O
1	O
(	O
Myt1	O
)	O
is	O
a	O
zinc	B-CHED
-	O
finger	O
DNA	O
binding	O
protein	B-CHED
that	O
influences	O
developing	O
oligodendrocyte	O
progenitor	O
(	O
OP	O
)	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
myelin	O
gene	O
transcription	O
in	O
vitro	O
.	O

Cells	O
with	O
nuclear	O
Myt1	O
immunoreactivity	O
were	O
mainly	O
OP	O
cells	O
,	O
identified	O
by	O
co	O
-	O
localization	O
with	O
platelet	O
-	O
derived	O
growth	O
factor	O
alpha	O
receptor	O
,	O
with	O
additional	O
phenotypes	O
being	O
either	O
oligodendrocytes	O
or	O
neural	O
stem	O
cells	O
,	O
identified	O
by	O
CC1	O
antigen	B-CHED
and	O
Musashi1	O
,	O
respectively	O
.	O

Patient	O
purified	O
IgG	O
recognized	O
a	O
band	O
of	O
approximately	O
110	O
kDa	O
on	O
protein	B-CHED
extracts	O
of	O
mouse	O
cerebellum	O
,	O
cortex	O
and	O
brainstem	O
and	O
immunolabelled	O
cultured	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	B-CHED
)	O
cells	O
,	O
transfected	O
with	O
human	O
GABA	B-CHED
(	O
B	O
)	O
R1	O
and	O
rat	O
GABA	B-CHED
(	O
B	O
)	O
R2	O
receptors	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
accessory	O
protein	B-CHED
6	O
is	O
a	O
virion	O
-	O
associated	O
protein	B-CHED
and	O
is	O
released	O
from	O
6	O
protein	B-CHED
-	O
expressing	O
cells	O
.	O

Further	O
studies	O
were	O
carried	O
out	O
with	O
various	O
arginine	B-CHED
-	O
rich	O
peptides	B-CHED
conjugated	O
to	O
the	O
5TERM	O
PMO	O
sequence	O
in	O
order	O
to	O
evaluate	O
efficacy	O
and	O
toxicity	O
and	O
thereby	O
select	O
candidates	O
for	O
in	O
vivo	O
testing	O
.	O

Pregnant	O
women	O
should	O
be	O
treated	O
aggressively	O
with	O
supportive	O
care	O
and	O
antiviral	B-CHED
medications	O
,	O
as	O
the	O
significant	O
risk	O
of	O
maternal	O
mortality	O
outweighs	O
the	O
potential	O
fetal	O
risks	O
.	O

Long	O
-	O
term	O
exposure	O
of	O
HIV	O
to	O
CBAs	O
in	O
cell	O
culture	O
results	O
in	O
the	O
progressive	O
deletion	O
of	O
N	B-CHED
-	I-CHED
glycans	I-CHED
of	O
HIV	O
gpl20	O
in	O
an	O
attempt	O
of	O
the	O
virus	O
to	O
escape	O
drug	O
pressure	O
.	O

In	O
addition	O
,	O
the	O
sequence	O
of	O
the	O
3	O
'-	O
proximal	O
third	O
of	O
the	O
liver	O
derived	O
genomic	O
RNA	O
(	O
FCoV	O
C1Li	O
),	O
which	O
encompasses	O
the	O
structural	O
and	O
accessory	O
protein	B-CHED
genes	O
of	O
the	O
virus	O
,	O
was	O
also	O
determined	O
.	O

Primers	O
were	O
used	O
to	O
amplify	O
the	O
conserved	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
genome	O
,	O
and	O
the	O
nucleocapsid	O
protein	B-CHED
gene	O
of	O
TCoV	O
.	O
Histopathological	O
and	O
direct	O
immunohistochemical	O
examinations	O
were	O
performed	O
to	O
detect	O
TCoV	O
antigen	B-CHED
in	O
infected	O
intestine	O
and	O
bursa	O
slides	O
.	O

After	O
attenuation	O
,	O
two	O
to	O
six	O
amino	B-CHED
acid	I-CHED
substitutions	O
were	O
found	O
in	O
the	O
spike	O
1	O
subunit	O
,	O
and	O
two	O
or	O
three	O
amino	B-CHED
acid	I-CHED
substitutions	O
were	O
found	O
in	O
the	O
spike	O
2	O
subunit	O
.	O

ABSTRACT	O
:	O
Naloxone	B-CHED
is	O
a	O
non	O
-	O
selective	O
,	O
short	O
-	O
acting	O
opioid	B-CHED
receptor	I-CHED
antagonist	I-CHED
that	O
has	O
a	O
long	O
clinical	O
history	O
of	O
successful	O
use	O
and	O
is	O
presently	O
considered	O
a	O
safe	O
drug	O
over	O
a	O
wide	O
dose	O
range	O
(	O
up	O
to	O
10	O
mg	O
).	O

In	O
opioid	O
-	O
dependent	O
patients	O
,	O
naloxone	B-CHED
is	O
used	O
in	O
the	O
treatment	O
of	O
opioid	O
-	O
overdose	O
-	O
induced	O
respiratory	O
depression	O
,	O
in	O
(	O
ultra	O
)	O
rapid	O
detoxification	O
and	O
in	O
combination	O
with	O
buprenorphine	B-CHED
for	O
maintenance	O
therapy	O
(	O
to	O
prevent	O
intravenous	O
abuse	O
).	O

Recombinant	O
N	O
protein	B-CHED
ELISA	O
(	O
rnELISA	O
)	O
demonstrated	O
98	O
.	O
7	O
%	O
specificities	O
among	O
(	O
80	O
)	O
PEDV	O
-	O
free	O
individuals	O
,	O
and	O
98	O
%	O
sensitivity	O
ranging	O
among	O
(	O
103	O
)	O
clinical	O
samples	O
with	O
PEDV	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicated	O
that	O
nucleocapsid	O
protein	B-CHED
may	O
be	O
a	O
useful	O
antigen	B-CHED
for	O
the	O
sera	O
-	O
diagnosis	O
of	O
PEDV	O
and	O
it	O
was	O
also	O
suggested	O
that	O
the	O
ELISA	O
is	O
a	O
highly	O
sensitive	O
and	O
specific	O
test	O
for	O
detecting	O
antibodies	O
to	O
PEDV	O
.	O

ABSTRACT	O
:	O
The	O
sequential	O
determination	O
of	O
crystal	O
structures	O
of	O
the	O
SARS	O
coronavirus	O
spike	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
complex	O
with	O
its	O
cellular	O
receptor	O
or	O
neutralizing	O
antibody	O
opened	O
a	O
door	O
for	O
the	O
design	O
and	O
development	O
of	O
antiviral	B-CHED
competitive	O
inhibitors	B-CHED
.	O

Sixteen	O
ventilated	O
trauma	O
patients	O
with	O
severe	O
refractory	O
hypoxemia	O
(	O
PaO	B-CHED
(	O
2	O
)/	O
FIO	O
(	O
2	O
)<	O
150	O
mmHg	O
)	O
and	O
lung	O
contusions	O
.	O

Residues	O
248	O
-	O
280	O
form	O
a	O
positively	O
charged	O
groove	O
similar	O
to	O
that	O
found	O
in	O
the	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
nucleocapsid	O
protein	B-CHED
.	O

Packing	O
of	O
the	O
octamers	O
in	O
the	O
crystal	O
forms	O
two	O
parallel	O
,	O
basic	O
helical	O
grooves	O
,	O
which	O
may	O
be	O
oligonucleotide	B-CHED
attachment	O
sites	O
,	O
and	O
suggests	O
a	O
mechanism	O
for	O
helical	O
RNA	O
packaging	O
in	O
the	O
virus	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
65	O
-	O
year	O
-	O
old	O
man	B-CHED
who	O
had	O
repeated	O
lung	O
injuries	O
after	O
reduced	O
-	O
intensity	O
allogeneic	O
stem	O
cell	O
transplantation	O
(	O
RIST	O
)	O
for	O
renal	O
cell	O
carcinoma	O
.	O

Thirty	O
years	O
later	O
,	O
cortisone	B-CHED
was	O
discovered	O
and	O
rapidly	O
proven	O
to	O
have	O
numerous	O
and	O
diversified	O
physiological	O
functions	O
in	O
the	O
host	O
response	O
to	O
stress	O
.	O

Recently	O
,	O
a	O
link	O
between	O
septic	O
shock	O
and	O
adrenal	O
insufficiency	O
,	O
or	O
systemic	O
inflammation	O
-	O
induced	O
glucocorticoid	B-CHED
receptor	O
resistance	O
has	O
been	O
established	O
.	O

The	O
C	O
-	O
terminal	O
ORF1a	O
protein	B-CHED
nsp10	O
colocalizes	O
with	O
viral	O
replication	O
complexes	O
,	O
but	O
its	O
role	O
in	O
transcription	O
/	O
replication	O
is	O
not	O
well	O
defined	O
.	O

We	O
found	O
that	O
HCoV	O
-	O
NL63	O
replicase	O
products	O
can	O
be	O
detected	O
at	O
24	O
h	O
postinfection	O
and	O
that	O
these	O
proteins	B-CHED
accumulate	O
in	O
perinuclear	O
sites	O
,	O
consistent	O
with	O
membrane	O
-	O
associated	O
replication	O
complexes	O
.	O

Priming	O
with	O
the	O
helper	O
peptides	B-CHED
(	O
e	O
.	O
g	O
.,	O
NP111	O
and	O
NP351	O
)	O
significantly	O
accelerated	O
the	O
immune	O
response	O
induced	O
by	O
recombinant	O
NP	O
,	O
as	O
determined	O
by	O
the	O
production	O
of	O
NP	O
-	O
specific	O
antibodies	O
.	O

When	O
fused	O
with	O
a	O
conserved	O
neutralizing	O
epitope	B-CHED
(	O
SP1143	O
-	O
1157	O
)	O
from	O
the	O
spike	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
,	O
NP111	O
and	O
NP351	O
assisted	O
in	O
the	O
production	O
of	O
high	O
-	O
titer	O
neutralizing	O
antibodies	O
in	O
vivo	O
.	O

Finally	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
common	O
assay	O
components	O
including	O
DTT	O
,	O
NaCl	B-CHED
,	O
EDTA	B-CHED
and	O
DMSO	B-CHED
on	O
enzymatic	O
activity	O
,	O
and	O
we	O
recommend	O
standardized	O
assay	O
conditions	O
and	O
constructs	O
for	O
routine	O
SARS	O
-	O
CoV	O
3CLpro	O
assays	O
to	O
facilitate	O
direct	O
comparisons	O
between	O
SARS	O
-	O
CoV	O
3CLpro	O
inhibitors	B-CHED
under	O
development	O
worldwide	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
replicase	O
proteins	B-CHED
in	O
pathogenesis	O
.	O

The	O
SARS	O
epidemic	O
also	O
brought	O
new	O
attention	O
to	O
the	O
proteins	B-CHED
translated	O
from	O
ORF1a	O
and	O
ORF1b	O
of	O
the	O
input	O
genome	O
RNA	O
,	O
also	O
known	O
as	O
the	O
replicase	O
/	O
transcriptase	O
gene	O
.	O

Thus	O
,	O
the	O
evolution	O
of	O
the	O
ORF1ab	O
proteins	B-CHED
may	O
be	O
determined	O
as	O
much	O
by	O
issues	O
of	O
host	O
range	O
and	O
virulence	O
as	O
they	O
are	O
by	O
specific	O
requirements	O
for	O
intracellular	O
replication	O
.	O

Furthermore	O
,	O
the	O
catalytic	O
nucleophile	B-CHED
Lys	B-CHED
289	O
points	O
in	O
a	O
diametrically	O
opposite	O
direction	O
,	O
a	O
consequence	O
of	O
an	O
outward	O
displacement	O
of	O
the	O
supporting	O
loop	O
(	O
residues	O
276	O
to	O
295	O
).	O

The	O
purified	O
S	O
-	O
protein	B-CHED
bound	O
to	O
Vero	O
but	O
not	O
293T	O
cells	O
and	O
was	O
itself	O
recognized	O
by	O
lung	O
surfactant	B-CHED
protein	B-CHED
D	O
(	O
SP	O
-	O
D	O
),	O
a	O
collectin	O
found	O
in	O
the	O
lung	O
alveoli	O
.	O

Cell	O
cycle	O
analysis	O
demonstrated	O
that	O
3a	O
expression	O
was	O
associated	O
with	O
blockage	O
of	O
cell	O
cycle	O
progression	O
at	O
G1	O
phase	O
in	O
HEK	O
293	O
,	O
COS	B-CHED
-	O
7	O
,	O
and	O
Vero	O
cells	O
24	O
-	O
60	O
h	O
after	O
transfection	O
.	O

Mutation	O
analysis	O
of	O
3a	O
revealed	O
that	O
C	O
-	O
terminal	O
region	O
(	O
176	O
aa	O
approximately	O
274	O
aa	O
),	O
including	O
a	O
potential	O
calcium	B-CHED
ATPase	O
motif	O
,	O
was	O
essential	O
for	O
induction	O
of	O
cell	O
cycle	O
arrest	O
.	O

Parenteral	O
ivermectin	B-CHED
is	O
found	O
to	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
disseminated	O
strongyloidiasis	O
.	O

Ground	O
-	O
glass	O
hepatocellular	O
inclusions	O
(	O
positive	O
with	O
periodic	B-CHED
acid	I-CHED
-	O
Schiff	O
stain	O
for	O
glycogen	B-CHED
)	O
were	O
reported	O
in	O
three	O
separate	O
series	O
of	O
patients	O
who	O
were	O
hepatitis	O
B	O
virus	O
-	O
negative	O
,	O
often	O
transplant	O
recipients	O
,	O
immunosuppressed	O
and	O
on	O
multiple	O
medications	O
.	O

TITLE	O
:	O
Manipulation	O
of	O
the	O
infectious	O
bronchitis	O
coronavirus	O
genome	O
for	O
vaccine	O
development	O
and	O
analysis	O
of	O
the	O
accessory	O
proteins	B-CHED
.	O

This	O
result	O
was	O
reinforced	O
when	O
FRAP	O
and	O
FLIP	O
analysis	O
indicated	O
that	O
N	O
protein	B-CHED
was	O
more	O
mobile	O
within	O
the	O
nucleoplasm	O
and	O
nucleolus	O
in	O
the	O
G2	O
/	O
M	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

The	O
plant	O
lectins	O
possessed	O
marked	O
antiviral	B-CHED
properties	O
against	O
both	O
coronaviruses	O
with	O
EC	O
(	O
50	O
)	O
values	O
in	O
the	O
lower	O
microgram	O
/	O
ml	O
range	O
(	O
middle	O
nanomolar	O
range	O
),	O
being	O
non	O
-	O
toxic	O
(	O
CC	O
(	O
50	O
))	O
at	O
50	O
-	O
100	O
microg	O
/	O
ml	O
.	O

Coimmunoprecipitation	O
experiments	O
showed	O
that	O
7a	O
interacts	O
with	O
Bcl	O
-	O
XL	O
and	O
other	O
prosurvival	O
proteins	B-CHED
(	O
Bcl	O
-	O
2	O
,	O
Bcl	O
-	O
w	O
,	O
Mcl	O
-	O
1	O
,	O
and	O
A1	O
)	O
but	O
not	O
with	O
the	O
proapoptotic	O
proteins	B-CHED
(	O
Bax	O
,	O
Bak	O
,	O
Bad	O
,	O
and	O
Bid	O
).	O

Sequence	O
analysis	O
of	O
the	O
complete	O
genomes	O
revealed	O
differences	O
at	O
123	O
and	O
149	O
nucleotides	B-CHED
(	O
nt	O
)	O
throughout	O
the	O
entire	O
genome	O
between	O
the	O
respiratory	O
and	O
enteric	O
strains	O
for	O
samples	O
AH65	O
and	O
AH187	O
,	O
respectively	O
,	O
indicating	O
the	O
presence	O
of	O
intra	O
-	O
host	O
BCoV	O
quasispecies	O
.	O

TITLE	O
:	O
Sequence	O
analysis	O
of	O
the	O
partial	O
spike	O
glycoprotein	B-CHED
gene	O
of	O
porcine	O
epidemic	O
diarrhea	O
viruses	O
isolated	O
in	O
Korea	O
.	O

In	O
addition	O
,	O
the	O
G1	O
Korean	O
PEDV	O
isolates	O
didn	O
'	O
t	O
had	O
several	O
specific	O
nucleotides	B-CHED
and	O
amino	B-CHED
acids	I-CHED
which	O
were	O
found	O
in	O
the	O
G2	O
and	O
G3	O
Korean	O
PEDV	O
isolates	O
,	O
and	O
especially	O
the	O
G1	O
-	O
1	O
Korean	O
PEDV	O
isolates	O
had	O
specific	O
nucleotides	B-CHED
and	O
amino	B-CHED
acids	I-CHED
which	O
were	O
not	O
found	O
in	O
the	O
G1	O
-	O
2	O
,	O
G1	O
-	O
3	O
,	O
G2	O
,	O
and	O
G3	O
Korean	O
PEDV	O
isolates	O
.	O

The	O
expressed	O
S1	O
protein	B-CHED
was	O
successfully	O
detected	O
with	O
indirect	O
immunofluorescent	O
assay	O
.	O

ABSTRACT	O
:	O
Post	O
-	O
emetic	O
spontaneous	O
rupture	O
of	O
the	O
esophagus	O
(	O
Boerhaave	O
'	O
s	O
syndrome	O
)	O
is	O
still	O
a	O
life	O
-	O
threatening	O
condition	O
,	O
despite	O
recent	O
advances	O
in	O
thoracic	O
surgery	O
and	O
critical	O
care	O
medicine	B-CHED
.	O

ABSTRACT	O
:	O
Open	O
reading	O
frame	O
9b	O
(	O
ORF	O
9b	O
)	O
encodes	O
a	O
98	O
amino	B-CHED
acid	I-CHED
group	O
-	O
specific	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
).	O

RACE	O
RT	O
-	O
PCR	O
amplification	O
of	O
the	O
Vbeta	O
chains	O
of	O
five	O
of	O
ten	O
the	O
cross	O
-	O
reactive	O
TCC	B-CHED
confirmed	O
clonality	O
and	O
sequencing	O
identified	O
the	O
CDR3	O
region	O
associated	O
with	O
cross	O
-	O
reactivity	O
.	O

RESULTS	O
:	O
The	O
ELSO	O
registry	O
currently	O
includes	O
31	O
,	O
340	O
ECMO	O
cases	O
,	O
of	O
which	O
151	O
were	O
post	O
-	O
LTx	O
patients	O
with	O
primary	O
graft	O
dysfunction	O
(	O
PGD	B-CHED
).	O

The	O
SARS	O
-	O
CoV	O
receptor	O
,	O
human	O
angiotensin	B-CHED
1	O
converting	O
enzyme	O
2	O
(	O
hACE2	O
),	O
was	O
detected	O
exclusively	O
on	O
the	O
apical	O
surface	O
of	O
cells	O
in	O
polarized	O
Calu	O
-	O
3	O
cells	O
and	O
human	O
airway	O
epithelial	O
cultures	O
(	O
HAE	O
),	O
indicating	O
that	O
hACE2	O
was	O
accessible	O
by	O
SARS	O
-	O
CoV	O
after	O
lumenal	O
airway	O
delivery	O
.	O

To	O
assess	O
infectivity	O
in	O
ciliated	O
airway	O
cultures	O
derived	O
from	O
susceptible	O
animal	O
species	O
we	O
generated	O
a	O
recombinant	O
SARS	O
-	O
CoV	O
by	O
deletion	O
of	O
open	O
reading	O
frame	O
7a	O
/	O
7b	O
(	O
ORF	O
7a	O
/	O
7b	O
)	O
and	O
insertion	O
of	O
the	O
green	O
fluorescent	O
protein	B-CHED
(	O
GFP	B-CHED
)	O
resulting	O
in	O
SARS	O
-	O
CoV	O
GFP	B-CHED
.	O

Most	O
of	O
the	O
ORFs	O
were	O
highly	O
conserved	O
;	O
however	O
,	O
the	O
predicted	O
spike	O
protein	B-CHED
(	O
S	O
)	O
has	O
9	O
and	O
12	O
amino	B-CHED
acid	I-CHED
differences	O
from	O
BCoV	O
LUN	O
and	O
ENT	O
,	O
respectively	O
,	O
and	O
shows	O
a	O
higher	O
relative	O
number	O
of	O
changes	O
than	O
the	O
other	O
proteins	B-CHED
.	O

While	O
MHV	O
strain	O
A59	O
appeared	O
to	O
induce	O
IFN	O
-	O
beta	O
gene	O
transcription	O
and	O
low	O
levels	O
of	O
nuclear	O
translocation	O
of	O
the	O
IFN	O
-	O
beta	O
transcription	O
factor	O
interferon	O
regulatory	O
factor	O
3	O
(	O
IRF	O
-	O
3	O
),	O
MHV	O
did	O
not	O
induce	O
IFN	O
-	O
beta	O
protein	B-CHED
production	O
during	O
the	O
course	O
of	O
infection	O
in	O
L2	O
mouse	O
fibroblast	O
cells	O
.	O

One	O
hundred	O
news	O
media	O
reports	O
(	O
print	O
,	O
radio	B-CHED
,	O
television	O
,	O
and	O
Internet	O
)	O
were	O
analyzed	O
in	O
terms	O
of	O
message	O
repetition	O
,	O
context	O
,	O
source	O
,	O
and	O
grammar	O
.	O

First	O
,	O
potential	O
compounds	O
were	O
extracted	O
from	O
protein	B-CHED
-	O
ligand	B-CHED
complexes	O
selected	O
from	O
Protein	B-CHED
Data	O
Bank	O
database	O
based	O
on	O
structural	O
similarity	O
to	O
the	O
target	O
protein	B-CHED
.	O

In	O
the	O
seven	O
unvaccinated	O
groups	O
,	O
CDV	B-CHED
titers	O
were	O
low	O
and	O
occurred	O
in	O
20	O
-	O
100	O
%	O
of	O
the	O
animals	O
;	O
antibody	O
titers	O
against	O
CPV	O
were	O
found	O
in	O
seven	O
of	O
eight	O
areas	O
.	O

The	O
viral	O
genome	O
and	O
its	O
expression	O
within	O
the	O
host	O
cell	O
undergoes	O
extensive	O
translational	O
and	O
enzymatic	O
processing	O
to	O
form	O
the	O
4	O
structural	O
,	O
8	O
accessory	O
and	O
16	O
nonstructural	O
proteins	B-CHED
.	O

Recent	O
studies	O
regarding	O
SARS	O
and	O
SARS	O
-	O
CoV	O
have	O
clarified	O
that	O
activation	O
of	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinases	O
(	O
MAPKs	O
)	O
plays	O
important	O
roles	O
in	O
upregulation	O
of	O
cytokine	O
expression	O
and	O
apoptosis	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

TITLE	O
:	O
A	O
fluorogenic	O
peptide	B-CHED
containing	O
the	O
processing	O
site	O
of	O
human	O
SARS	O
corona	B-CHED
virus	O
S	O
-	O
protein	B-CHED
:	O
kinetic	O
evaluation	O
and	O
NMR	O
structure	O
elucidation	O
.	O

(	O
1	O
)	O
H	O
NMR	O
spectra	O
from	O
2D	O
COSY	O
and	O
ROESY	O
experiments	O
under	O
physiological	O
buffer	B-CHED
and	O
pH	O
conditions	O
indicated	O
that	O
this	O
peptide	B-CHED
possesses	O
a	O
structure	O
with	O
a	O
turn	O
at	O
its	O
C	O
-	O
terminal	O
segment	O
,	O
close	O
to	O
the	O
cleavage	O
site	O
.	O

After	O
treatment	O
with	O
prednisone	B-CHED
,	O
oral	O
cyclophosphamide	B-CHED
and	O
plasmapheresis	O
,	O
chest	O
X	O
-	O
ray	O
and	O
hemoptysis	O
improved	O
,	O
but	O
renal	O
failure	O
persisted	O
.	O

ABSTRACT	O
:	O
The	O
truncated	O
fragment	O
M	O
'	O
gene	O
,	O
encoding	O
the	O
exterior	O
of	O
the	O
viral	O
envelope	O
protein	B-CHED
of	O
PEDV	O
,	O
was	O
subcloned	O
into	O
prokaryotic	O
expression	O
vector	O
pGEX	O
-	O
6p	O
-	O
1	O
.	O

TITLE	O
:	O
Comparison	O
of	O
immunoglobulin	O
G	O
responses	O
to	O
the	O
spike	O
and	O
nucleocapsid	O
proteins	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
in	O
patients	O
with	O
SARS	O
.	O

During	O
laparoscopic	O
laparotomy	O
,	O
abundant	O
pus	B-CHED
was	O
found	O
in	O
the	O
peritoneal	O
cavity	O
.	O

Lithium	B-CHED
chloride	I-CHED
(	O
LiCl	B-CHED
)	O
is	O
a	O
potent	O
inhibitor	B-CHED
of	O
the	O
DNA	O
virus	O
herpes	O
simplex	O
virus	O
but	O
not	O
RNA	O
viruses	O
.	O

Other	O
therapies	O
such	O
as	O
steroids	B-CHED
may	O
have	O
a	O
place	O
in	O
MD	O
treatment	O
but	O
more	O
definitive	O
studies	O
are	O
necessary	O
.	O

In	O
order	O
to	O
further	O
characterize	O
the	O
functional	O
properties	O
of	O
this	O
protein	B-CHED
,	O
we	O
initiated	O
studies	O
to	O
check	O
its	O
RNA	O
binding	O
activity	O
.	O

Spontaneous	O
pneumomediastinum	O
usually	O
only	O
requires	O
rest	B-CHED
,	O
analgesia	O
and	O
management	O
of	O
the	O
underlying	O
condition	O
.	O

This	O
downregulation	O
,	O
which	O
is	O
reminiscent	O
of	O
a	O
cellular	O
stress	O
response	O
,	O
was	O
dependent	O
on	O
viral	O
replication	O
and	O
caused	O
by	O
mRNA	B-CHED
decay	O
.	O

However	O
,	O
MHV	O
replication	O
per	O
se	O
does	O
not	O
appear	O
to	O
benefit	O
from	O
the	O
inhibition	O
of	O
host	O
protein	B-CHED
synthesis	O
,	O
at	O
least	O
in	O
vitro	O
,	O
since	O
viral	O
replication	O
was	O
not	O
negatively	O
affected	O
but	O
rather	O
enhanced	O
in	O
cells	O
with	O
impaired	O
translational	O
shutoff	O
.	O

Mutational	O
analyses	O
revealed	O
that	O
two	O
regions	O
of	O
N	O
protein	B-CHED
were	O
essential	O
for	O
its	O
function	O
in	O
the	O
activation	O
of	O
IL	O
-	O
6	O
.	O

Our	O
findings	O
show	O
that	O
the	O
spike	O
DNA	O
vaccine	O
has	O
good	O
immunogenicity	O
and	O
can	O
induce	O
specific	O
humoral	O
and	O
cellular	O
immunities	O
in	O
BALB	O
/	O
c	O
mice	O
,	O
while	O
IL	O
-	O
2	O
plays	O
an	O
immunoadjuvant	B-CHED
role	O
and	O
enhances	O
the	O
humoral	O
and	O
cellular	O
immune	O
responses	O
.	O

At	O
admission	O
,	O
temperature	O
,	O
heart	O
rate	O
,	O
blood	O
pressure	O
,	O
Glasgow	O
Coma	O
Scale	O
score	O
,	O
base	O
deficit	O
,	O
hemoglobin	B-CHED
,	O
platelets	O
,	O
prothrombin	O
time	O
/	O
International	O
Normalized	O
Ratio	O
,	O
and	O
Injury	O
Severity	O
Score	O
were	O
similar	O
in	O
both	O
groups	O
as	O
were	O
administered	O
units	O
of	O
fresh	O
frozen	O
plasma	O
,	O
fresh	O
whole	O
blood	O
,	O
cryoprecipitate	O
(	O
cryo	O
),	O
and	O
crystalloid	O
.	O

However	O
,	O
the	O
antigenic	O
properties	O
of	O
this	O
N	O
protein	B-CHED
are	O
largely	O
unknown	O
.	O

During	O
the	O
SARS	O
outbreak	O
in	O
2003	O
,	O
we	O
used	O
the	O
10	O
-	O
item	O
Perceived	O
Stress	O
Scale	O
(	O
PSS	B-CHED
-	O
10	O
)	O
to	O
assess	O
SARS	O
survivors	O
treated	O
in	O
2	O
major	O
hospitals	O
(	O
non	O
-	O
health	O
care	O
workers	O
,	O
n	O
=	O
49	O
;	O
health	O
care	O
workers	O
,	O
n	O
=	O
30	O
).	O

METHODS	O
:	O
During	O
the	O
SARS	O
outbreak	O
in	O
2003	O
,	O
we	O
used	O
the	O
10	O
-	O
item	O
Perceived	O
Stress	O
Scale	O
(	O
PSS	B-CHED
-	O
10	O
)	O
to	O
assess	O
SARS	O
survivors	O
treated	O
in	O
2	O
major	O
hospitals	O
(	O
non	O
-	O
health	O
care	O
workers	O
,	O
n	O
=	O
49	O
;	O
health	O
care	O
workers	O
,	O
n	O
=	O
30	O
).	O

By	O
2004	O
,	O
however	O
,	O
stress	O
levels	O
in	O
the	O
high	O
-	O
risk	O
group	O
were	O
not	O
only	O
higher	O
(	O
PSS	B-CHED
-	O
10	O
score	O
=	O
18	O
.	O
6	O
)	O
but	O
also	O
significantly	O
higher	O
than	O
scores	O
among	O
low	O
-	O
risk	O
health	O
care	O
worker	O
control	O
subjects	O
(	O
PSS	B-CHED
-	O
10	O
score	O
=	O
14	O
.	O
8	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

RESULTS	O
:	O
In	O
2003	O
,	O
high	O
-	O
risk	O
health	O
care	O
workers	O
had	O
elevated	O
stress	O
levels	O
(	O
PSS	B-CHED
-	O
10	O
score	O
=	O
17	O
.	O
0	O
)	O
that	O
were	O
not	O
significantly	O
different	O
from	O
levels	O
in	O
low	O
-	O
risk	O
health	O
care	O
worker	O
control	O
subjects	O
(	O
PSS	B-CHED
-	O
10	O
score	O
=	O
15	O
.	O
9	O
).	O

The	O
usual	O
causative	O
pathogen	O
,	O
namely	O
Fusobacterium	O
necrophorum	O
,	O
shows	O
a	O
varying	O
sensitivity	O
to	O
macrolides	B-CHED
.	O

For	O
instance	O
,	O
ACE	O
has	O
been	O
shown	O
to	O
work	O
not	O
only	O
by	O
generating	O
angiotensin	B-CHED
-	O
II	O
but	O
also	O
by	O
interacting	O
with	O
receptors	O
outside	O
the	O
renin	O
-	O
angiotensin	B-CHED
system	O
.	O

Therefore	O
,	O
the	O
whole	O
dynamics	O
of	O
the	O
RAS	B-CHED
has	O
to	O
be	O
re	O
-	O
evaluated	O
in	O
light	O
of	O
this	O
new	O
information	O
.	O

The	O
highly	O
immunogenic	O
D2	O
peptide	B-CHED
contains	O
both	O
neutralizing	O
and	O
Th	O
cell	O
epitopes	O
.	O

TITLE	O
:	O
Analysis	O
of	O
intraviral	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
of	O
the	O
SARS	O
coronavirus	O
ORFeome	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
genome	O
is	O
predicted	O
to	O
encode	O
14	O
functional	O
open	O
reading	O
frames	O
,	O
leading	O
to	O
the	O
expression	O
of	O
up	O
to	O
30	O
structural	O
and	O
non	O
-	O
structural	O
protein	B-CHED
products	O
.	O

Nsp2	O
,	O
nsp8	O
and	O
ORF9b	O
showed	O
a	O
wide	O
range	O
of	O
interactions	O
with	O
other	O
viral	O
proteins	B-CHED
.	O

We	O
show	O
that	O
also	O
accessory	O
protein	B-CHED
ORF9b	O
does	O
not	O
play	O
a	O
pivotal	O
role	O
for	O
viral	O
replication	O
,	O
as	O
it	O
can	O
be	O
deleted	O
from	O
the	O
virus	O
displaying	O
normal	O
plaque	O
sizes	O
and	O
growth	O
characteristics	O
in	O
Vero	O
cells	O
.	O

ALI	O
was	O
induced	O
by	O
oleic	B-CHED
acid	I-CHED
in	O
rabbits	O
.	O

In	O
addition	O
,	O
based	O
on	O
structural	O
comparison	O
to	O
the	O
avian	O
coronavirus	O
N	O
protein	B-CHED
,	O
a	O
nuclear	O
export	O
signal	O
was	O
identified	O
in	O
the	O
C	O
-	O
terminal	O
region	O
of	O
the	O
protein	B-CHED
.	O

These	O
results	O
suggest	O
that	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
SARS	O
,	O
especially	O
in	O
inflammation	O
and	O
high	O
fever	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
required	O
dose	O
and	O
anticoagulatory	O
effect	O
of	O
argatroban	B-CHED
(	O
Mitsubishi	O
,	O
Pharma	O
Deutschland	O
GmbH	O
,	O
Dsseldorf	O
,	O
Germany	O
),	O
a	O
direct	O
thrombin	B-CHED
inhibitor	I-CHED
approved	O
for	O
anticoagulation	O
in	O
patients	O
with	O
heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
(	O
HIT	O
)	O
undergoing	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

These	O
studies	O
suggest	O
that	O
the	O
3	O
'-	O
terminal	O
nucleotides	B-CHED
of	O
the	O
EAV	O
genome	O
play	O
a	O
critical	O
role	O
in	O
viral	O
RNA	O
synthesis	O
.	O

The	O
application	O
of	O
functional	O
genomics	O
approaches	O
to	O
the	O
discovery	O
of	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
-	O
2	O
(	O
ACE2	O
)	O
as	O
a	O
counterbalance	O
to	O
the	O
well	O
known	O
hypertensive	O
target	O
ACE	O
will	O
be	O
highlighted	O
and	O
their	O
differential	O
cellular	O
targeting	O
and	O
enzymology	O
addressed	O
.	O

Soluble	O
N18	O
antibody	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
HB2151	O
,	O
purified	O
by	O
Ni	O
-	O
NTA	B-CHED
affinity	O
chromatography	O
and	O
verified	O
by	O
SDS	B-CHED
-	O
PAGE	O
and	O
Western	O
blot	O
.	O

Using	O
immunohistochemistry	O
to	O
examine	O
both	O
banked	O
human	O
lung	O
specimens	O
from	O
patients	O
with	O
ALI	O
and	O
lungs	O
from	O
mice	O
with	O
LPS	B-CHED
-	O
induced	O
pneumonitis	O
,	O
we	O
found	O
that	O
pulmonary	O
SDF	O
-	O
1	O
expression	O
increases	O
during	O
ALI	O
.	O

Then	O
the	O
plasmid	O
pR	O
-	O
alpha	O
-	O
S1	O
was	O
introduced	O
into	O
mycobacterium	O
bovis	O
BCG	B-CHED
by	O
electroporation	O
to	O
construct	O
a	O
recombinate	O
strain	O
rBCG	O
-	O
Sl	O
.	O

The	O
recombinant	O
glycoprotein	B-CHED
S	O
was	O
detected	O
by	O
SDS	B-CHED
-	O
PAGE	O
and	O
Western	O
blot	O
after	O
induced	O
by	O
1ng	O
/	O
mL	O
nisin	O
.	O

In	O
order	O
to	O
detect	O
the	O
location	O
of	O
expressed	O
protein	B-CHED
,	O
the	O
yellow	O
and	O
green	O
fluorescence	O
of	O
the	O
recombinant	O
strain	O
pNZ8112	O
-	O
Sa	O
/	O
NZ9000	O
was	O
detected	O
by	O
the	O
IFA	O
experiments	O
,	O
which	O
indicated	O
that	O
the	O
expressed	O
recombinant	O
protein	B-CHED
was	O
secreted	O
and	O
located	O
on	O
the	O
surface	O
of	O
the	O
bacterium	O
cell	O
.	O

ABSTRACT	O
:	O
The	O
membrane	O
fusion	O
process	O
mediated	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
S	O
protein	B-CHED
and	O
its	O
cellular	O
receptor	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
had	O
been	O
reconstituted	O
using	O
two	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	B-CHED
)	O
cell	O
lines	O
that	O
constitutively	O
express	O
these	O
recombinant	O
proteins	B-CHED
separately	O
.	O

Both	O
genes	O
were	O
transiently	O
expressed	O
in	O
either	O
of	O
the	O
CHO	B-CHED
cell	O
lines	O
,	O
followed	O
by	O
fusion	O
treatment	O
.	O

Computed	O
tomography	O
scans	O
revealed	O
ground	O
-	O
glass	O
opacity	O
and	O
surrounding	O
ring	O
-	O
shaped	O
air	B-CHED
-	O
space	O
consolidation	O
,	O
the	O
""""	O
reversed	O
halo	O
sign	O
"""."	O

The	O
COX	O
inhibitors	B-CHED
reduced	O
MHV	O
infection	O
at	O
a	O
post	O
-	O
binding	O
step	O
,	O
but	O
early	O
in	O
the	O
replication	O
cycle	O
.	O

Both	O
viral	O
RNA	O
and	O
viral	O
protein	B-CHED
synthesis	O
were	O
affected	O
with	O
subsequent	O
loss	O
of	O
progeny	O
virus	O
production	O
.	O

ABSTRACT	O
:	O
Adrenomedullin	O
(	O
AM	O
),	O
an	O
endogenous	O
peptide	B-CHED
,	O
has	O
been	O
shown	O
to	O
have	O
a	O
variety	O
of	O
protective	O
effects	O
on	O
the	O
cardiovascular	O
system	O
.	O

The	O
animals	O
were	O
intratracheally	O
injected	O
with	O
either	O
LPS	B-CHED
(	O
1	O
mg	O
/	O
kg	O
)	O
or	O
saline	O
.	O

Biochemical	O
determinations	O
indicated	O
hypoxia	O
,	O
hyperglycaemia	O
,	O
increased	O
nitrite	B-CHED
/	O
nitrate	B-CHED
,	O
methyl	B-CHED
guanidine	B-CHED
and	O
other	O
factors	O
.	O

So	O
far	O
antivirals	B-CHED
are	O
hardly	O
available	O
to	O
combat	B-CHED
infections	O
with	O
viruses	O
of	O
this	O
order	O
.	O

Both	O
groups	O
were	O
matched	O
for	O
spirometry	O
,	O
BMI	O
,	O
and	O
AHI	O
,	O
but	O
oxygen	B-CHED
desaturation	O
was	O
worse	O
in	O
the	O
OSA	O
-	O
plus	O
-	O
OHS	O
group	O
.	O

CPAP	O
significantly	O
improved	O
rapid	O
eye	O
movement	O
(	O
REM	O
)	O
duration	O
(	O
p	O
<	O
0	O
.	O
005	O
),	O
AHI	O
(	O
p	O
<	O
0	O
.	O
005	O
),	O
arousal	O
indexes	O
(	O
p	O
<	O
0	O
.	O
005	O
),	O
and	O
percentage	O
of	O
total	O
sleep	O
time	O
(	O
TST	O
)	O
with	O
oxygen	B-CHED
saturation	O
(	O
SpO2	O
)	O
<	O
90	O
%	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
in	O
both	O
groups	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
expression	O
of	O
the	O
2	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
receptors	O
,	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
and	O
CD209L	O
in	O
different	O
human	O
organ	O
/	O
tissue	O
derived	O
microvascular	O
endothelial	O
cells	O
.	O

We	O
describe	O
an	O
autoselection	O
system	O
for	O
recombinant	O
protein	B-CHED
expression	O
in	O
Saccharomyces	O
cerevisiae	O
which	O
increases	O
yields	O
5	O
-	O
10	O
-	O
fold	O
compared	O
to	O
conditional	O
selection	O
for	O
expression	O
plasmids	O
.	O

Such	O
plasmids	O
are	O
stably	O
maintained	O
,	O
even	O
in	O
rich	O
medium	O
,	O
so	O
optimising	O
biomass	O
production	O
and	O
yields	O
of	O
recombinant	O
protein	B-CHED
.	O

However	O
,	O
for	O
other	O
pathogens	O
which	O
are	O
not	O
exposed	O
to	O
such	O
environmental	O
stress	O
,	O
activation	O
of	O
fusogenicity	O
can	O
result	O
from	O
precise	O
thiol	B-CHED
/	O
disulfide	B-CHED
rearrangements	O
mediated	O
by	O
either	O
an	O
endogenous	O
redox	O
autocatalytic	O
isomerase	O
or	O
a	O
cell	O
-	O
associated	O
oxidoreductase	O
.	O

Comparison	O
of	O
the	O
nucleotide	B-CHED
sequences	O
of	O
the	O
PCR	O
products	O
with	O
those	O
of	O
the	O
published	O
N	O
,	O
M	O
,	O
and	O
S	O
genes	O
(	O
476	O
to	O
497	O
,	O
672	O
,	O
and	O
687	O
to	O
690	O
nucleotides	B-CHED
,	O
respectively	O
)	O
of	O
toroviruses	O
showed	O
high	O
sequence	O
identities	O
(	O
up	O
to	O
99	O
.	O
4	O
%,	O
98	O
.	O
7	O
%,	O
and	O
94	O
.	O
9	O
%	O
for	O
the	O
N	O
,	O
M	O
,	O
and	O
S	O
genes	O
,	O
respectively	O
)	O
between	O
the	O
isolate	O
and	O
BToVs	O
.	O

ABSTRACT	O
:	O
Acute	O
hypercytokinaemia	O
represents	O
an	O
imbalance	O
of	O
pro	B-CHED
-	O
inflammatory	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
,	O
and	O
is	O
believed	O
to	O
be	O
responsible	O
for	O
the	O
development	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
multiple	O
organ	O
failure	O
in	O
severe	O
cases	O
of	O
avian	O
(	O
H5N1	O
)	O
influenza	O
.	O

Steroids	B-CHED
have	O
been	O
used	O
for	O
many	O
decades	O
in	O
a	O
wide	O
variety	O
of	O
inflammatory	O
conditions	O
in	O
which	O
hypercytokinaemia	O
plays	O
a	O
role	O
,	O
such	O
as	O
sepsis	O
and	O
viral	O
infections	O
,	O
including	O
severe	O
acquired	O
respiratory	O
syndromes	O
and	O
avian	O
influenza	O
.	O

Here	O
,	O
we	O
evaluate	O
various	O
vaccination	O
regimens	O
using	O
combinations	O
of	O
DNA	O
-	O
S	O
,	O
MVA	B-CHED
-	O
S	O
,	O
and	O
adenovirus	O
type	O
5	O
(	O
Ad5	O
-	O
S	O
)	O
vaccines	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
generated	O
anti	O
-	O
KC	O
(	O
KC	O
=	O
chemokine	O
(	O
CXC	O
motif	O
)	O
ligand	B-CHED
1	O
(	O
CXCL1	O
))	O
autoantibody	O
:	O
KC	O
immune	O
complexes	O
(	O
KC	O
-	O
functional	O
IL	O
-	O
8	O
)	O
in	O
lungs	O
of	O
mice	O
to	O
develop	O
a	O
mouse	O
model	O
of	O
autoimmune	O
complex	O
-	O
induced	O
lung	O
inflammation	O
.	O

Two	O
adverse	O
outcomes	O
were	O
examined	O
:	O
hospital	O
mortality	O
and	O
the	O
development	O
of	O
oxygenation	O
failure	O
based	O
on	O
the	O
estimated	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
of	O
<	O
200	O
mm	O
Hg	O
.	O

The	O
presenting	O
ALT	B-CHED
and	O
CPK	O
level	O
and	O
the	O
day	O
7	O
and	O
day	O
10	O
platelet	O
counts	O
were	O
predictive	O
of	O
oxygenation	O
failure	O
while	O
the	O
day	O
7	O
LDH	O
was	O
predictive	O
of	O
death	O
.	O

CONCLUSIONS	O
:	O
This	O
large	O
-	O
scale	O
analysis	O
identified	O
important	O
discriminatory	O
parameters	O
related	O
to	O
the	O
patients	O
'	O
demographic	O
profile	O
(	O
age	O
and	O
gender	O
),	O
severity	O
of	O
illness	O
(	O
pulse	O
rate	O
and	O
neutrophil	O
count	O
),	O
and	O
multisystem	O
derangement	O
(	O
platelet	O
count	O
,	O
CPK	O
,	O
ALT	B-CHED
and	O
LDH	O
),	O
all	O
of	O
which	O
prognosticated	O
adverse	O
outcomes	O
during	O
the	O
SARS	O
episode	O
.	O

ABSTRACT	O
:	O
Glucocorticoids	B-CHED
have	O
been	O
shown	O
to	O
improve	O
survival	O
when	O
used	O
in	O
patients	O
with	O
septic	O
shock	O
.	O

injection	O
of	O
10	O
mug	O
/	O
kg	O
leptin	O
(	O
leptin	O
group	O
)	O
or	O
2	O
mL	O
saline	O
(	O
AP	O
group	O
)	O
after	O
cerulein	B-CHED
injections	O
.	O

Recent	O
studies	O
revealed	O
that	O
M	O
protein	B-CHED
could	O
interact	O
with	O
N	O
protein	B-CHED
in	O
the	O
Golgi	O
complex	O
.	O

The	O
plasmid	O
,	O
pEGFP	O
-	O
M	O
,	O
encoding	O
SCoV	O
M	O
protein	B-CHED
as	O
a	O
fusion	O
protein	B-CHED
with	O
EGFP	O
,	O
was	O
used	O
for	O
silencing	O
and	O
for	O
reporter	O
gene	O
detection	O
in	O
HEK	O
293T	O
cells	O
transfected	O
with	O
siRNA	O
constructs	O
.	O

Retention	O
of	O
import	O
factors	O
at	O
the	O
ER	O
/	O
Golgi	O
membrane	O
leads	O
to	O
a	O
loss	O
of	O
STAT1	O
transport	O
into	O
the	O
nucleus	B-CHED
in	O
response	O
to	O
interferon	O
signaling	O
,	O
thus	O
blocking	O
the	O
expression	O
of	O
STAT1	O
-	O
activated	O
genes	O
that	O
establish	O
an	O
antiviral	B-CHED
state	O
.	O

The	O
timing	O
and	O
dosage	O
regimens	O
of	O
steroid	B-CHED
in	O
the	O
treatment	O
of	O
SARS	O
are	O
controversial	O
.	O

Dysfunction	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
with	O
decreased	O
glucocorticoid	B-CHED
activity	O
is	O
being	O
increasingly	O
recognized	O
in	O
critically	O
ill	O
patients	O
,	O
particularly	O
those	O
with	O
sepsis	O
.	O

Critical	O
illness	O
-	O
related	O
corticosteroid	B-CHED
insufficiency	O
leads	O
to	O
an	O
exaggerated	O
proinflammatory	O
response	O
with	O
increased	O
tissue	O
injury	O
and	O
organ	O
dysfunction	O
.	O

Finally	O
,	O
we	O
report	O
the	O
successful	O
rational	O
improvement	O
of	O
this	O
scaffold	O
with	O
second	O
generation	O
inhibitors	B-CHED
.	O

Inhibitors	B-CHED
of	O
the	O
ubiquitous	O
chaperone	O
,	O
heat	O
shock	O
protein	B-CHED
90	O
(	O
Hsp90	O
),	O
block	O
the	O
activity	O
of	O
certain	O
proinflammatory	O
mediators	O
in	O
vitro	O
.	O

TITLE	O
:	O
Expression	O
of	O
CXC	O
chemokine	O
ligand	B-CHED
10	O
from	O
the	O
mouse	O
hepatitis	O
virus	O
genome	O
results	O
in	O
protection	O
from	O
viral	O
-	O
induced	O
neurological	O
and	O
liver	O
disease	O
.	O

The	O
presence	O
of	O
sialic	B-CHED
acid	I-CHED
on	O
HeLa	O
cells	O
contributed	O
to	O
efficient	O
virus	O
replication	O
,	O
while	O
human	O
aminopeptidase	O
N	O
was	O
not	O
involved	O
in	O
the	O
infection	O
.	O

Fusion	O
is	O
mediated	O
by	O
the	O
viral	O
S	O
protein	B-CHED
.	O

The	O
results	O
imply	O
that	O
endocytosis	O
plays	O
a	O
major	O
role	O
in	O
MHV	O
-	O
A59	O
infection	O
and	O
the	O
acidic	O
pH	O
of	O
the	O
endosomal	O
compartment	O
triggers	O
a	O
conformational	O
change	O
of	O
the	O
S	O
protein	B-CHED
mediating	O
fusion	O
.	O

One	O
notable	O
exception	O
is	O
ACE2	O
residue	O
354	O
,	O
at	O
the	O
boundary	O
of	O
the	O
SARS	O
-	O
CoV	O
binding	O
site	O
,	O
whose	O
alteration	O
markedly	O
inhibited	O
utilization	O
by	O
the	O
HCoV	O
-	O
NL63	O
but	O
not	O
SARS	O
-	O
CoV	O
S	O
proteins	B-CHED
.	O

ABSTRACT	O
:	O
Coronaviruses	O
express	O
open	O
reading	O
frame	O
1a	O
(	O
ORF1a	O
)	O
and	O
ORF1b	O
polyproteins	O
from	O
which	O
16	O
nonstructural	O
proteins	B-CHED
(	O
nsp	O
)	O
are	O
derived	O
.	O

The	O
mutant	O
virus	O
was	O
not	O
viable	O
,	O
suggesting	O
that	O
the	O
uncleaved	O
protein	B-CHED
may	O
be	O
essential	O
for	O
replication	O
or	O
proteolytic	O
processing	O
.	O

Here	O
,	O
we	O
discuss	O
our	O
recent	O
findings	O
regarding	O
(	O
R	O
-	O
Ahx	B-CHED
-	O
R	O
)(	O
4	O
)	O
AhxB	O
(	O
Ahx	B-CHED
is	O
6	B-CHED
-	I-CHED
aminohexanoic	I-CHED
acid	I-CHED
and	O
B	O
is	O
beta	B-CHED
-	I-CHED
alanine	I-CHED
)	O
CPP	O
-	O
PMO	O
conjugates	O
in	O
DMD	O
(	O
Duchenne	O
muscular	O
dystrophy	O
)	O
and	O
murine	O
coronavirus	O
research	O
.	O

An	O
(	O
R	O
-	O
Ahx	B-CHED
-	O
R	O
)(	O
4	O
)	O
AhxB	O
-	O
PMO	O
conjugate	O
was	O
the	O
most	O
effective	O
compound	O
in	O
inducing	O
the	O
correction	O
of	O
mutant	O
dystrophin	O
transcripts	O
in	O
myoblasts	O
derived	O
from	O
a	O
canine	O
model	O
of	O
DMD	O
.	O

ABSTRACT	O
:	O
The	O
immune	O
effect	O
of	O
two	O
recombinant	O
protein	B-CHED
fragments	O
of	O
spike	O
protein	B-CHED
in	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
)	O
was	O
investigated	O
in	O
Balb	O
/	O
c	O
mice	O
.	O

To	O
understand	O
the	O
functions	O
of	O
these	O
proteins	B-CHED
,	O
we	O
cloned	O
cDNA	O
fragments	O
covering	O
these	O
ORFs	O
into	O
expression	O
plasmids	O
,	O
and	O
expressed	O
the	O
constructs	O
in	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
systems	O
.	O

The	O
fusion	O
protein	B-CHED
was	O
determined	O
to	O
assemble	O
into	O
pentamers	O
,	O
as	O
was	O
evidenced	O
by	O
its	O
ability	O
to	O
bind	O
to	O
GM1	B-CHED
gangliosides	B-CHED
,	O
and	O
evidenced	O
an	O
average	O
level	O
of	O
expression	O
in	O
a	O
transgenic	O
rice	O
endosperm	O
.	O

ABSTRACT	O
:	O
Feline	O
angiotensin	B-CHED
converting	O
enzyme	O
2	O
(	O
fACE2	O
)	O
gene	O
was	O
amplified	O
from	O
domestic	O
cat	O
lung	O
with	O
RT	O
-	O
PCR	O
,	O
cloned	O
and	O
sequenced	O
.	O

The	O
protein	B-CHED
signatures	O
,	O
or	O
biomarkers	O
,	O
can	O
be	O
used	O
to	O
diagnose	O
infection	O
,	O
predict	O
disease	O
states	O
and	O
to	O
inform	O
on	O
disease	O
processes	O
.	O

However	O
,	O
only	O
few	O
data	O
are	O
available	O
regarding	O
the	O
time	O
-	O
course	O
and	O
duration	O
of	O
surfactant	B-CHED
changes	O
in	O
ARDS	O
patients	O
,	O
although	O
this	O
information	O
may	O
largely	O
influence	O
the	O
optimum	O
design	O
of	O
clinical	O
trials	O
addressing	O
surfactant	B-CHED
replacement	O
therapy	O
.	O

At	O
T0	O
,	O
a	O
severe	O
and	O
highly	O
significant	O
reduction	O
in	O
SP	O
-	O
A	O
,	O
SP	O
-	O
B	O
and	O
SP	O
-	O
C	O
,	O
the	O
LA	O
fraction	O
,	O
PC	O
and	O
phosphatidylglycerol	B-CHED
(	O
PG	O
)	O
percentages	O
,	O
and	O
dipalmitoylation	O
of	O
PC	O
(	O
DPPC	B-CHED
)	O
was	O
encountered	O
.	O

Over	O
time	O
,	O
significant	O
improvements	O
were	O
encountered	O
especially	O
in	O
view	O
of	O
LA	O
content	O
,	O
DPPC	B-CHED
,	O
PG	O
and	O
SP	O
-	O
A	O
,	O
but	O
minimum	O
surface	O
tension	O
of	O
LA	O
was	O
not	O
fully	O
restored	O
(	O
15	O
mN	O
/	O
m	O
at	O
T2	O
).	O

Outcome	O
analysis	O
revealed	O
that	O
non	O
-	O
survivors	O
had	O
even	O
more	O
unfavourable	O
surfactant	B-CHED
properties	O
as	O
compared	O
to	O
survivors	O
.	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
(	O
HCoV	O
)	O
are	O
recognized	O
respiratory	O
pathogens	O
that	O
may	O
be	O
involved	O
in	O
other	O
pathologies	O
such	O
as	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
diseases	O
.	O

BCoV	O
strains	O
with	O
99	O
-	O
100	O
%	O
nucleotide	B-CHED
identity	O
in	O
the	O
S	O
gene	O
were	O
isolated	O
from	O
nasal	O
,	O
ocular	O
and	O
rectal	O
swabs	O
,	O
thus	O
proving	O
the	O
absence	O
of	O
separate	O
clusters	B-CHED
of	O
virus	O
on	O
the	O
basis	O
of	O
tissue	O
tropism	O
.	O

Protein	B-CHED
6	O
consists	O
of	O
an	O
N	O
-	O
terminal	O
hydrophobic	O
peptide	B-CHED
and	O
a	O
C	O
-	O
terminal	O
region	O
containing	O
intracellular	O
protein	B-CHED
sorting	O
motifs	O
.	O

Expression	O
of	O
the	O
viral	O
spike	O
protein	B-CHED
significantly	O
induced	O
ER	O
stress	O
and	O
Cxcl2	O
mRNA	B-CHED
upregulation	O
,	O
while	O
expression	O
of	O
the	O
other	O
structural	O
genes	O
did	O
not	O
.	O

However	O
,	O
at	O
that	O
point	O
in	O
infection	O
,	O
translation	O
of	O
host	O
mRNA	B-CHED
is	O
already	O
severely	O
reduced	O
in	O
infected	O
cells	O
,	O
preventing	O
the	O
synthesis	O
of	O
CXCL2	O
and	O
ER	O
stress	O
proteins	B-CHED
despite	O
their	O
increased	O
mRNA	B-CHED
concentrations	O
.	O

The	O
severe	O
course	O
of	O
disease	O
in	O
CDS	B-CHED
may	O
be	O
related	O
to	O
a	O
higher	O
incidence	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

The	O
SARS	O
-	O
CoV	O
genome	O
encodes	O
28	O
proteins	B-CHED
in	O
three	O
distinct	O
classes	O
,	O
many	O
of	O
them	O
with	O
unknown	O
function	O
and	O
sharing	O
low	O
similarity	O
to	O
other	O
proteins	B-CHED
.	O

VLPs	O
also	O
conferred	O
protective	O
immunity	O
against	O
the	O
infection	O
of	O
Spike	O
protein	B-CHED
pseudotyped	O
murine	O
leukaemia	O
virus	O
.	O

There	O
have	O
been	O
only	O
few	O
scattered	O
reports	O
in	O
the	O
literature	O
on	O
the	O
association	O
of	O
HELLP	O
syndrome	O
and	O
APS	B-CHED
,	O
which	O
was	O
successfully	O
managed	O
with	O
the	O
combination	O
of	O
various	O
immunosuppressive	O
and	O
immunomodulatory	O
treatment	O
modalities	O
.	O

Although	O
preliminary	O
evidence	O
suggests	O
a	O
role	O
for	O
steroids	B-CHED
in	O
early	O
ARDS	O
and	O
SCAP	O
,	O
there	O
are	O
not	O
enough	O
data	O
to	O
suggest	O
routine	O
administration	O
of	O
steroids	B-CHED
in	O
these	O
conditions	O
.	O

Therefore	O
,	O
they	O
are	O
attractive	O
therapeutic	O
targets	O
for	O
the	O
development	O
of	O
novel	O
antiviral	B-CHED
therapies	O
.	O

The	O
sensitivity	O
of	O
coronaviruses	O
towards	O
CBA	B-CHED
was	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
processing	O
of	O
the	O
N	O
-	O
linked	O
carbohydrates	B-CHED
.	O

All	O
together	O
,	O
these	O
results	O
show	O
that	O
CBA	B-CHED
exhibit	O
promising	O
capabilities	O
to	O
inhibit	O
coronavirus	O
infections	O
.	O

Further	O
investigation	O
showed	O
M	O
protein	B-CHED
suppressed	O
Cox	O
-	O
2	O
expression	O
using	O
a	O
luciferase	O
reporter	O
gene	O
assay	O
,	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
analysis	O
.	O

Analysis	O
of	O
the	O
sequence	O
identified	O
11	O
open	O
reading	O
frames	O
which	O
encode	O
two	O
replicase	O
polyproteins	O
,	O
five	O
structural	O
proteins	B-CHED
(	O
hemagglutinin	O
esterase	O
,	O
spike	O
,	O
envelope	O
,	O
membrane	O
,	O
and	O
nucleocapsid	O
)	O
and	O
four	O
accessory	O
proteins	B-CHED
(	O
NS2	O
,	O
p4	O
.	O
7	O
,	O
p12	O
.	O
7	O
,	O
and	O
I	O
).	O

The	O
two	O
replicase	O
polyproteins	O
are	O
predicted	O
to	O
be	O
proteolytically	O
processed	O
by	O
three	O
virus	O
-	O
encoded	O
proteases	O
into	O
16	O
non	O
-	O
structural	O
proteins	B-CHED
(	O
nsp1	O
-	O
16	O
).	O

TITLE	O
:	O
The	O
efficacy	O
of	O
Chinese	O
medicine	B-CHED
for	O
SARS	O
:	O
a	O
review	O
of	O
Chinese	O
publications	O
after	O
the	O
crisis	O
.	O

Subsequently	O
,	O
a	O
pool	O
of	O
17	O
-	O
19	O
mers	O
overlapped	O
SARS	O
CoV	O
S	O
peptides	B-CHED
,	O
which	O
served	O
as	O
immunogens	O
,	O
were	O
scanned	O
to	O
identify	O
the	O
specific	O
epitopes	O
for	O
T	O
cells	O
.	O

ABSTRACT	O
:	O
We	O
used	O
swine	O
testicle	O
(	O
ST	O
)	O
cells	O
infected	O
with	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
and	O
an	O
indirect	O
immunofluorescent	O
assay	O
with	O
antibodies	O
against	O
TGEV	O
spike	O
and	O
nucleocapsid	O
proteins	B-CHED
to	O
screen	O
small	O
-	O
molecule	O
compounds	O
that	O
inhibit	O
TGEV	O
replication	O
.	O

ABSTRACT	O
:	O
The	O
coadministration	O
of	O
protease	B-CHED
inhibitors	I-CHED
with	O
anticancer	O
drugs	O
in	O
the	O
management	O
of	O
human	O
immunodeficiency	O
virus	O
-	O
related	O
malignancies	O
can	O
cause	O
potential	O
drug	O
-	O
drug	O
interactions	O
.	O

Continuing	O
research	O
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
regulation	O
of	O
cell	O
death	O
during	O
viral	O
infection	O
and	O
the	O
identification	O
of	O
novel	O
antiviral	B-CHED
targets	O
.	O

They	O
include	O
asparagine	B-CHED
residues	O
at	O
amino	B-CHED
acid	I-CHED
positions	O
109	O
,	O
118	O
,	O
119	O
,	O
158	O
,	O
227	O
,	O
589	O
,	O
and	O
699	O
,	O
which	O
are	O
distinct	O
from	O
residues	O
of	O
the	O
ACE2	O
-	O
binding	O
domain	O
(	O
amino	B-CHED
acids	I-CHED
318	O
to	O
510	O
).	O

Europeans	O
were	O
less	O
likely	O
to	O
use	O
a	O
benzodiazepine	B-CHED
alone	O
(	O
25	O
%	O
vs	O
.	O
39	O
%,	O
p	O
<	O
.	O
001	O
)	O
but	O
more	O
likely	O
to	O
use	O
an	O
opioid	O
alone	O
(	O
37	O
%	O
vs	O
.	O
26	O
%,	O
p	O
<	O
.	O
009	O
).	O

The	O
peak	O
occurrence	O
of	O
cases	O
and	O
deaths	O
coincided	O
with	O
the	O
replacement	O
of	O
the	O
influenza	O
A	O
(	O
H3N2	B-CHED
)	O
Panama	O
strain	O
,	O
which	O
had	O
been	O
circulating	O
in	O
Colombia	O
since	O
1999	O
,	O
by	O
three	O
new	O
influenza	O
A	O
(	O
H3N2	B-CHED
)	O
strains	O
(	O
Korea	O
,	O
Fujian	O
,	O
and	O
Wyoming	O
).	O

Before	O
admission	O
,	O
corticosteroids	B-CHED
were	O
not	O
instituted	O
in	O
84	O
%	O
of	O
the	O
cases	O
.	O

Sequence	O
analysis	O
of	O
the	O
PEDV	O
N	O
gene	O
revealed	O
that	O
Korean	O
field	O
PEDV	O
isolates	O
had	O
93	O
.	O
6	O
%	O
and	O
89	O
.	O
6	O
%	O
identity	O
with	O
the	O
vaccine	O
virus	O
at	O
nucleotide	B-CHED
and	O
amino	B-CHED
acid	I-CHED
sequence	O
levels	O
,	O
respectively	O
,	O
suggesting	O
progressive	O
point	O
mutations	O
of	O
the	O
PEDV	O
genome	O
in	O
the	O
field	O
.	O

The	O
combination	O
of	O
the	O
surgical	O
approach	O
,	O
pre	O
-	O
existing	O
pulmonary	O
disorders	O
,	O
poor	O
nutritional	O
status	O
and	O
the	O
release	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
may	O
be	O
contributing	O
factors	O
.	O

N	B-CHED
-	I-CHED
acetylcysteine	I-CHED
((	O
NAC	O
)	O
has	O
been	O
shown	O
to	O
have	O
oxygen	B-CHED
scavenging	O
abilities	O
.	O

It	O
has	O
been	O
suggested	O
that	O
E	O
protein	B-CHED
can	O
form	O
a	O
membrane	O
destabilizing	O
transmembrane	O
(	O
TM	O
)	O
hairpin	O
,	O
or	O
homooligomerize	O
to	O
form	O
a	O
regular	O
TM	O
alpha	O
-	O
helical	O
bundle	O
.	O

TITLE	O
:	O
Impaired	O
plasmacytoid	O
dendritic	O
cell	O
innate	O
immune	O
responses	O
in	O
patients	O
with	O
herpes	O
virus	O
-	O
associated	O
acute	O
retinal	B-CHED
necrosis	O
.	O

ABSTRACT	O
:	O
Plasmacytoid	O
dendritic	O
cells	O
(	O
PDC	B-CHED
),	O
the	O
main	O
producers	O
of	O
type	O
I	O
IFNs	O
in	O
the	O
blood	O
,	O
are	O
important	O
for	O
the	O
recognition	O
and	O
control	O
of	O
viral	O
and	O
bacterial	O
infections	O
.	O

Fluorescently	O
tagged	O
MSCs	O
were	O
detected	O
in	O
the	O
lung	O
tissues	O
by	O
confocal	O
microscopy	O
and	O
flow	O
cytometry	O
in	O
both	O
nave	O
and	O
LPS	B-CHED
-	O
injured	O
animals	O
up	O
to	O
3	O
d	O
.	O
Treatment	O
with	O
MSCs	O
alone	O
significantly	O
reduced	O
LPS	B-CHED
-	O
induced	O
acute	O
pulmonary	O
inflammation	O
in	O
mice	O
,	O
while	O
administration	O
of	O
pANGPT1	O
-	O
transfected	O
MSCs	O
resulted	O
in	O
a	O
further	O
improvement	O
in	O
both	O
alveolar	O
inflammation	O
and	O
permeability	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
prevalence	O
and	O
genetic	O
diversity	O
of	O
CD	O
BCoVs	O
based	O
on	O
the	O
deduced	O
amino	B-CHED
acid	I-CHED
(	O
aa	O
)	O
sequences	O
of	O
the	O
spike	O
(	O
S	O
)	O
and	O
haemagglutinin	O
/	O
esterase	O
(	O
HE	O
)	O
proteins	B-CHED
in	O
South	O
Korea	O
.	O

Virus	O
-	O
induced	O
chemokine	O
expression	O
was	O
reduced	O
by	O
the	O
IL	O
-	O
1	O
receptor	O
antagonist	B-CHED
,	O
suggesting	O
that	O
IL	O
-	O
1	O
produced	O
by	O
infected	O
cells	O
induces	O
uninfected	O
cells	O
to	O
express	O
chemokines	O
.	O

A	O
coronavirus	O
(	O
CoV	O
)	O
nonstructural	O
protein	B-CHED
,	O
nsp14	O
,	O
contains	O
conserved	O
active	O
-	O
site	O
motifs	O
of	O
cellular	O
exonucleases	O
,	O
including	O
DNA	O
proofreading	O
enzymes	O
,	O
and	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
(	O
SARS	O
-	O
CoV	O
)	O
nsp14	O
has	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	O
(	O
ExoN	O
)	O
activity	O
in	O
vitro	O
.	O

This	O
study	O
developed	O
and	O
evaluated	O
five	O
groups	O
of	O
multiplex	O
nested	O
PCR	O
assays	O
that	O
could	O
simultaneously	O
detect	O
21	O
different	O
respiratory	O
pathogens	O
:	O
influenza	O
A	O
virus	O
(	O
H1N1	O
,	O
H3N2	B-CHED
,	O
and	O
H5N1	O
);	O
influenza	O
B	O
virus	O
;	O
parainfluenza	O
virus	O
types	O
1	O
,	O
2	O
,	O
3	O
,	O
4a	O
,	O
and	O
4b	O
;	O
respiratory	O
syncytial	O
virus	O
A	O
and	O
B	O
;	O
human	O
rhinoviruses	O
;	O
human	O
enteroviruses	O
;	O
human	O
coronaviruses	O
OC43	O
and	O
229E	O
;	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
;	O
human	O
metapneumoviruses	O
;	O
Mycoplasma	O
pneumoniae	O
;	O
Chlamydophila	O
pneumoniae	O
;	O
Legionella	O
pneumophila	O
;	O
and	O
adenoviruses	O
(	O
A	O
to	O
F	O
).	O

The	O
primary	O
target	O
cells	O
are	O
pneumocytes	O
and	O
enterocytes	O
,	O
both	O
cell	O
types	O
abundantly	O
expressing	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
which	O
is	O
the	O
main	O
SARS	O
-	O
CoV	O
receptor	O
.	O

ABSTRACT	O
:	O
The	O
size	O
and	O
diversity	O
of	O
ribosome	O
display	O
libraries	O
depends	O
upon	O
stability	O
of	O
the	O
complex	O
formed	O
between	O
the	O
ribosome	O
,	O
mRNA	B-CHED
and	O
translated	O
protein	B-CHED
.	O

During	O
in	O
vitro	O
translation	O
in	O
rabbit	O
reticulocyte	O
lysate	O
,	O
we	O
observed	O
that	O
incorporation	O
of	O
the	O
pseudoknot	O
into	O
the	O
mRNA	B-CHED
resulted	O
in	O
production	O
of	O
a	O
translational	O
intermediate	O
that	O
corresponded	O
to	O
the	O
expected	O
size	O
for	O
ribosomal	O
arrest	O
at	O
the	O
pseudoknot	O
.	O

Clinicopathological	O
abnormalities	O
included	O
nonregenerative	O
anaemia	O
,	O
hypoalbuminaemia	O
,	O
increased	O
globulin	O
concentration	O
,	O
and	O
mildly	O
elevated	O
aspartate	B-CHED
aminotransferase	O
and	O
alkaline	O
phosphatase	O
activities	O
.	O

These	O
observations	O
imply	O
nsp4	O
to	O
assemble	O
in	O
the	O
membrane	O
as	O
a	O
tetraspanning	O
transmembrane	O
protein	B-CHED
with	O
a	O
Nendo	O
/	O
Cendo	O
topology	O
.	O

Both	O
viruses	O
also	O
downregulated	O
IFN	O
-	O
and	O
pro	B-CHED
-	O
inflammatory	O
cytokine	O
-	O
associated	O
pathways	O
.	O

Although	O
airway	O
cells	O
secrete	O
TNF	O
-	O
alpha	O
in	O
response	O
to	O
ricin	O
,	O
blocking	O
TNF	O
-	O
alpha	O
did	O
not	O
prevent	O
ricin	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O
Decreased	O
levels	O
of	O
IkappaB	O
-	O
alpha	O
in	O
airway	O
cells	O
exposed	O
to	O
ricin	O
suggest	O
that	O
translational	O
suppression	O
may	O
be	O
responsible	O
for	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O
Inhibition	O
of	O
p38	O
MAPK	O
by	O
a	O
chemical	O
inhibitor	B-CHED
or	O
NF	O
-	O
kappaB	O
by	O
short	O
interfering	O
RNA	O
resulted	O
in	O
a	O
marked	O
reduction	O
in	O
the	O
expression	O
of	O
proinflammatory	O
genes	O
,	O
demonstrating	O
the	O
importance	O
of	O
these	O
two	O
pathways	O
in	O
ricin	O
intoxication	O
.	O

TITLE	O
:	O
RNA	O
interference	O
and	O
antiviral	B-CHED
therapy	O
.	O

ABSTRACT	O
:	O
Using	O
the	O
complete	O
genome	O
sequences	O
of	O
19	O
coronavirus	O
genomes	O
,	O
we	O
analyzed	O
the	O
codon	O
usage	O
bias	O
,	O
dinucleotide	B-CHED
relative	O
abundance	O
and	O
cytosine	B-CHED
deamination	O
in	O
coronavirus	O
genomes	O
.	O

Cytosine	B-CHED
deamination	O
and	O
selection	O
of	O
CpG	O
suppressed	O
clones	O
by	O
the	O
immune	O
system	O
are	O
the	O
two	O
major	O
independent	O
biochemical	O
and	O
biological	O
selective	O
forces	O
that	O
shape	O
codon	O
usage	O
bias	O
in	O
coronavirus	O
genomes	O
.	O

Further	O
,	O
this	O
protein	B-CHED
has	O
also	O
been	O
proposed	O
to	O
be	O
an	O
efficient	O
diagnostic	O
tool	O
and	O
a	O
candidate	O
vaccine	O
against	O
the	O
SARS	O
-	O
CoV	O
.	O
Hence	O
,	O
towards	O
the	O
end	O
of	O
this	O
article	O
,	O
we	O
will	O
discuss	O
some	O
recent	O
progress	O
regarding	O
the	O
possible	O
clinically	O
relevant	O
use	O
of	O
the	O
N	O
-	O
protein	B-CHED
.	O

The	O
secondary	O
structure	O
and	O
the	O
characteristics	O
of	O
sample	O
BJ8081	O
N	O
and	O
E	O
proteins	B-CHED
were	O
predicted	O
by	O
bioinformatics	O
.	O

TITLE	O
:	O
[	O
Expression	O
of	O
recombinant	O
spike	O
protein	B-CHED
of	O
SARS	O
-	O
coronavirus	O
in	O
vaccinia	O
virus	O
and	O
analysis	O
of	O
its	O
immunogenicity	O
].	O

There	O
were	O
deletions	O
or	O
insertions	O
in	O
the	O
M	O
gene	O
of	O
Chinese	O
isolates	O
at	O
amino	B-CHED
acid	I-CHED
position	O
2	O
to	O
6	O
,	O
leading	O
to	O
the	O
loss	O
or	O
gain	O
of	O
a	O
glycosylation	O
site	O
.	O

The	O
N	O
-	O
protein	B-CHED
fragments	O
comprising	O
aa	O
360	O
to	O
412	O
and	O
aa	O
1	O
to	O
213	O
reacted	O
specifically	O
with	O
SARS	O
convalescent	O
-	O
phase	O
sera	O
but	O
not	O
with	O
negative	O
human	O
sera	O
in	O
ELISA	O
;	O
the	O
fragment	O
comprising	O
aa	O
1	O
to	O
213	O
cross	O
-	O
reacted	O
with	O
antisera	O
to	O
animal	O
CoVs	O
,	O
whereas	O
the	O
fragment	O
comprising	O
aa	O
360	O
to	O
412	O
did	O
not	O
cross	O
-	O
react	O
and	O
could	O
be	O
a	O
potential	O
candidate	O
for	O
SARS	O
diagnosis	O
.	O

TITLE	O
:	O
[	O
Severe	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
after	O
treatment	O
with	O
minocycline	B-CHED
].	O

These	O
data	O
demonstrate	O
a	O
critical	O
direct	O
antiviral	B-CHED
role	O
of	O
IFN	O
-	O
I	O
in	O
controlling	O
virus	O
dissemination	O
within	O
the	O
CNS	B-CHED
,	O
even	O
in	O
the	O
presence	O
of	O
potent	O
cellular	O
immune	O
responses	O
.	O

TITLE	O
:	O
Molecular	O
docking	O
identifies	O
the	O
binding	O
of	O
3	O
-	O
chloropyridine	B-CHED
moieties	O
specifically	O
to	O
the	O
S1	O
pocket	O
of	O
SARS	O
-	O
CoV	O
Mpro	O
.	O

The	O
coding	O
region	O
of	O
the	O
ORF3	O
gene	O
of	O
attenuated	O
-	O
type	O
PEDVs	O
including	O
attenuated	O
DR13	O
,	O
KPED	O
-	O
9	O
,	O
and	O
P	O
-	O
5V	O
had	O
51	O
nucleotide	B-CHED
deletions	O
that	O
were	O
not	O
found	O
in	O
the	O
ORF3	O
genes	O
of	O
wild	O
-	O
type	O
PEDVs	O
including	O
CV777	O
,	O
Br1	O
/	O
87	O
,	O
LZC	O
,	O
parent	O
DR13	O
,	O
and	O
12	O
field	O
samples	O
.	O

As	O
the	O
infection	O
progresses	O
,	O
macrophages	O
in	O
the	O
CNS	B-CHED
down	O
-	O
regulate	O
expression	O
of	O
Ly	O
-	O
6C	O
and	O
CD62L	O
,	O
consistent	O
with	O
maturation	O
,	O
and	O
a	O
higher	O
frequency	O
express	O
CD11c	O
,	O
a	O
marker	O
for	O
dendritic	O
cells	O
(	O
DCs	O
).	O

An	O
exploratory	O
analysis	O
of	O
the	O
effect	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
on	O
mortality	O
showed	O
a	O
relative	O
risk	O
of	O
2	O
.	O
60	O
in	O
the	O
HC	O
group	O
(	O
p	O
=	O
.	O
0004	O
),	O
while	O
in	O
the	O
nonhomozygote	O
carriers	O
(	O
NHC	B-CHED
)	O
group	O
the	O
relative	O
risk	O
was	O
3	O
.	O
34	O
(	O
p	O
=	O
.	O
0001	O
).	O

First	O
,	O
modulation	O
of	O
immunity	O
benefitted	O
MODS	O
/	O
severe	O
sepsis	O
;	O
second	O
,	O
early	O
anticoagulant	B-CHED
therapy	O
was	O
essential	O
to	O
MODS	O
/	O
severe	O
sepsis	O
,	O
because	O
disseminated	O
intravascular	O
coagulopathy	O
occurred	O
in	O
44	O
.	O
1	O
%	O
of	O
MODS	O
;	O
third	O
,	O
Chinese	O
herb	O
medicines	O
could	O
promote	O
and	O
protect	O
gastrointestinal	O
function	O
in	O
MODS	O
/	O
severe	O
sepsis	O
;	O
fourth	O
,	O
institution	O
of	O
mechanical	O
ventilation	O
with	O
low	O
tidal	O
volume	O
(	O
VT	O
)	O
was	O
effective	O
and	O
safe	O
in	O
ARDS	O
.	O

By	O
using	O
various	O
biochemical	O
,	O
biophysical	O
and	O
genetic	O
techniques	O
,	O
interaction	O
of	O
the	O
3a	O
protein	B-CHED
with	O
caveolin	O
-	O
1	O
is	O
demonstrated	O
.	O

Therapies	O
included	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
,	O
heliox	O
and	O
surfactant	B-CHED
.	O

Studies	O
have	O
shown	O
potential	O
for	O
benefit	O
of	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
in	O
newborns	O
with	O
hypoxemic	O
respiratory	O
failure	O
and	O
pulmonary	O
hypertension	O
,	O
surfactant	B-CHED
in	O
respiratory	O
distress	O
syndrome	O
in	O
preterm	O
neonates	O
and	O
heliox	O
in	O
severe	O
upper	O
airway	O
obstruction	O
.	O

It	O
was	O
previously	O
found	O
that	O
cockerels	O
vaccinated	O
with	O
live	O
attenuated	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
AIBV	O
)	O
have	O
decreased	O
serum	O
testosterone	B-CHED
concentrations	O
,	O
epididymal	O
stones	O
and	O
reduced	O
fertility	O
.	O

In	O
conclusion	O
,	O
pre	O
-	O
pubertal	O
vaccination	O
against	O
AIBV	O
and	O
subsequent	O
epididymal	O
stone	O
formation	O
had	O
a	O
limited	O
effect	O
on	O
sperm	O
concentration	O
,	O
sperm	O
quality	O
and	O
plasma	O
testosterone	B-CHED
concentrations	O
.	O

Diagnosis	O
is	O
based	O
on	O
a	O
finding	O
of	O
elevated	O
serum	O
levels	O
of	O
components	O
that	O
are	O
normally	O
found	O
within	O
the	O
muscle	O
cell	O
,	O
chiefly	O
muscle	O
enzymes	O
and	O
myoglobin	B-CHED
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
bismuth	B-CHED
complexes	O
were	O
synthesized	O
and	O
characterized	O
,	O
and	O
most	O
of	O
them	O
exhibited	O
inhibition	O
against	O
the	O
SARS	O
coronavirus	O
helicase	O
ATPase	O
and	O
duplex	O
-	O
unwinding	O
activities	O
at	O
micromolar	O
concentrations	O
.	O

Diagn	O
.,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
U	O
.	O
S	O
.	O
A	O
.]	O
and	O
add	B-CHED
strength	O
to	O
a	O
working	O
hypothesis	O
that	O
C	O
.	O
difficile	O
infection	O
and	O
the	O
accompanying	O
intoxication	O
can	O
manifest	O
as	O
diarrhea	O
in	O
calves	O
.	O

TITLE	O
:	O
Continuous	O
negative	O
extrathoracic	O
pressure	O
combined	O
with	O
high	O
-	O
frequency	O
oscillation	O
improves	O
oxygenation	O
with	O
less	O
impact	O
on	O
blood	O
pressure	O
than	O
high	O
-	O
frequency	O
oscillation	O
alone	O
in	O
a	O
rabbit	O
model	O
of	O
surfactant	B-CHED
depletion	O
.	O

In	O
alveolar	O
epithelial	O
cells	O
exposed	O
to	O
severe	O
hypoxia	O
,	O
we	O
have	O
reported	O
that	O
increased	O
production	O
of	O
mitochondrial	O
reactive	B-CHED
oxygen	I-CHED
species	I-CHED
leads	O
to	O
Na	O
,	O
K	O
-	O
ATPase	O
endocytosis	O
and	O
degradation	O
.	O

ABSTRACT	O
:	O
SARS	O
-	O
CoV	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	B-CHED
))	O
is	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
drug	O
discovery	O
,	O
and	O
its	O
dimerization	O
has	O
been	O
extensively	O
proved	O
to	O
be	O
indispensable	O
for	O
enzymatic	O
activity	O
.	O

TITLE	O
:	O
Structural	O
basis	O
of	O
mercury	B-CHED
-	O
and	O
zinc	B-CHED
-	O
conjugated	O
complexes	O
as	O
SARS	O
-	O
CoV	O
3C	O
-	O
like	O
protease	B-CHED
inhibitors	I-CHED
.	O

This	O
was	O
accompanied	O
or	O
immediately	O
followed	O
by	O
a	O
potent	O
Th1	O
adaptive	O
immunity	O
as	O
evidenced	O
by	O
the	O
activation	O
of	O
T	O
-	O
cell	O
signaling	B-CHED
molecules	I-CHED
,	O
surface	O
markers	O
,	O
and	O
effector	B-CHED
molecules	O
.	O

The	O
key	O
molecular	O
signatures	O
identified	O
may	O
provide	O
new	O
opportunities	O
for	O
improved	O
prophylactic	O
and	O
therapeutic	O
strategies	O
to	O
combat	B-CHED
mucosal	O
infections	O
.	O

The	O
epitopes	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
were	O
analyzed	O
by	O
epitope	B-CHED
prediction	O
software	O
.	O

The	O
S1	O
glycoprotein	B-CHED
genes	O
of	O
these	O
IBV	O
isolates	O
were	O
amplified	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RTPCR	O
)	O
and	O
analyzed	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
envelope	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
,	O
a	O
Class	O
I	O
viral	O
fusion	O
protein	B-CHED
,	O
is	O
responsible	O
for	O
the	O
fusion	O
between	O
the	O
membranes	O
of	O
the	O
virus	O
and	O
the	O
target	O
cell	O
.	O

In	O
order	O
to	O
gain	O
new	O
insight	O
into	O
the	O
protein	B-CHED
membrane	O
alteration	O
leading	O
to	O
the	O
viral	O
fusion	O
mechanism	O
,	O
a	O
peptide	B-CHED
pertaining	O
to	O
the	O
putative	O
pre	O
-	O
transmembrane	O
domain	O
(	O
PTM	O
)	O
of	O
the	O
S	O
glycoprotein	B-CHED
has	O
been	O
studied	O
by	O
infrared	O
and	O
fluorescence	O
spectroscopies	O
regarding	O
its	O
structure	O
,	O
its	O
ability	O
to	O
induce	O
membrane	O
leakage	O
,	O
aggregation	O
,	O
and	O
fusion	O
,	O
as	O
well	O
as	O
its	O
affinity	O
toward	O
specific	O
phospholipids	B-CHED
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
protein	B-CHED
7a	O
binds	O
directly	O
and	O
specifically	O
to	O
human	O
lymphocyte	O
function	O
-	O
associated	O
antigen	B-CHED
1	O
(	O
LFA	O
-	O
1	O
)	O
on	O
the	O
cell	O
surface	O
of	O
Jurkat	O
cells	O
.	O

Coinfected	O
pigs	O
showed	O
a	O
greater	O
and	O
more	O
sustained	O
transcription	O
of	O
proinflammatory	O
cytokines	O
,	O
especially	O
IL	O
-	O
6	O
and	O
MCP	B-CHED
-	O
1	O
,	O
than	O
pigs	O
infected	O
with	O
either	O
PRCV	O
or	O
B	O
.	O
bronchiseptica	O
alone	O
.	O

TITLE	O
:	O
Specific	O
and	O
efficient	O
cleavage	O
of	O
fusion	O
proteins	B-CHED
by	O
recombinant	O
plum	O
pox	O
virus	O
NIa	O
protease	O
.	O

Recombinant	O
PPV	B-CHED
NIa	O
protease	O
reached	O
its	O
maximal	O
proteolytic	O
activity	O
at	O
approximately	O
30	O
degrees	O
C	O
.	O
Salt	B-CHED
concentration	O
and	O
only	O
one	O
of	O
the	O
tested	O
protease	B-CHED
inhibitors	I-CHED
had	O
minor	O
influences	O
on	O
the	O
proteolytic	O
activity	O
of	O
PPV	B-CHED
NIa	O
protease	O
.	O

ABSTRACT	O
:	O
A	O
55	O
-	O
year	O
-	O
old	O
woman	O
with	O
vitiligo	O
,	O
hypothyroidism	O
,	O
interstitial	O
lung	O
disease	O
and	O
diabetes	O
mellitus	O
developed	O
severe	O
insulin	B-CHED
resistance	O
during	O
a	O
hospital	O
admission	O
for	O
respiratory	O
failure	O
.	O

Her	O
interstitial	O
lung	O
disease	O
had	O
been	O
treated	O
with	O
glucocorticoids	B-CHED
,	O
but	O
after	O
their	O
withdrawal	O
her	O
insulin	B-CHED
requirements	O
had	O
increased	O
dramatically	O
.	O

On	O
d	O
10	O
,	O
20	O
,	O
30	O
,	O
40	O
,	O
and	O
50	O
after	O
the	O
first	O
vaccination	O
,	O
the	O
proliferation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
in	O
response	O
to	O
concanavalin	O
A	O
stimulation	O
as	O
well	O
as	O
the	O
proportions	O
of	O
CD3	O
(+),	O
CD4	O
(+),	O
and	O
CD8	O
(+)	O
peripheral	O
blood	O
mononuclear	O
cells	O
were	O
determined	O
by	O
the	O
3	B-CHED
-(	I-CHED
4	I-CHED
,	I-CHED
5	I-CHED
-	I-CHED
dimethylthiazol	I-CHED
-	I-CHED
2	I-CHED
-	I-CHED
yl	I-CHED
)-	I-CHED
2	I-CHED
,	I-CHED
5	I-CHED
-	I-CHED
diphenyltetrazolium	I-CHED
bromide	I-CHED
method	O
and	O
flow	O
cytometry	O
,	O
respectively	O
.	O

TITLE	O
:	O
Amino	B-CHED
acid	I-CHED
substitutions	O
in	O
the	O
S2	O
subunit	O
of	O
mouse	O
hepatitis	O
virus	O
variant	O
V51	O
encode	O
determinants	O
of	O
host	O
range	O
expansion	O
.	O

When	O
we	O
tested	O
20	O
SARS	O
-	O
negative	O
NPA	B-CHED
samples	O
,	O
the	O
CLEIA	O
was	O
shown	O
to	O
have	O
high	O
specificity	O
(	O
100	O
%).	O

ABSTRACT	O
:	O
General	O
theories	O
on	O
the	O
inactivation	O
of	O
viruses	O
in	O
the	O
presence	O
of	O
a	O
concentrated	O
protein	B-CHED
,	O
such	O
as	O
the	O
allantoic	O
fluid	O
of	O
chicken	O
eggs	O
,	O
are	O
not	O
useful	O
.	O

In	O
addition	O
,	O
patients	O
in	O
the	O
ICU	O
are	O
often	O
treated	O
with	O
stress	O
hormones	B-CHED
like	O
epinephrine	B-CHED
,	O
norepinephrine	B-CHED
,	O
or	O
cortisol	B-CHED
.	O

This	O
can	O
possibly	O
be	O
explained	O
by	O
a	O
cortisol	B-CHED
-	O
induced	O
temporary	O
impairment	O
in	O
traumatic	O
memory	O
retrieval	O
that	O
has	O
previously	O
been	O
demonstrated	O
in	O
both	O
rats	O
and	O
humans	O
.	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
induces	O
a	O
biphasic	O
disease	O
in	O
BALB	O
/	O
c	O
mice	O
that	O
consists	O
of	O
an	O
acute	O
retinitis	O
followed	O
by	O
progression	O
to	O
a	O
chronic	O
retinal	B-CHED
degeneration	O
with	O
autoimmune	O
reactivity	O
.	O

Retinal	B-CHED
degeneration	O
resistant	O
CD	O
-	O
1	O
mice	O
do	O
not	O
develop	O
the	O
late	O
phase	O
.	O

After	O
intravenous	O
inoculation	O
,	O
infectious	O
virus	O
was	O
isolated	O
from	O
rectal	O
swabs	O
,	O
and	O
virus	O
antigen	B-CHED
was	O
detected	O
in	O
intestinal	O
cells	O
on	O
day	O
14	O
p	O
.	O
i	O
.	O

The	O
Naranjo	O
adverse	O
drug	O
reaction	O
probability	O
scale	O
score	O
indicated	O
that	O
the	O
association	O
between	O
azacitidine	B-CHED
and	O
hyperthermia	O
was	O
probable	O
.	O

However	O
,	O
the	O
novel	O
IBV	O
genotype	O
lacked	O
either	O
all	O
or	O
most	O
of	O
the	O
genes	O
coding	O
for	O
nonstructural	O
proteins	B-CHED
at	O
the	O
3	O
'	O
end	O
of	O
the	O
genome	O
and	O
had	O
a	O
unique	O
open	O
reading	O
frame	O
,	O
X1	O
.	O

This	O
study	O
has	O
demonstrated	O
for	O
the	O
first	O
time	O
the	O
existence	O
of	O
a	O
naturally	O
occurring	O
IBV	O
genotype	O
devoid	O
of	O
some	O
of	O
the	O
genes	O
coding	O
for	O
nonstructural	O
proteins	B-CHED
and	O
has	O
also	O
indicated	O
that	O
all	O
of	O
the	O
accessory	O
genes	O
are	O
dispensable	O
for	O
the	O
growth	O
of	O
IBV	O
and	O
that	O
such	O
viruses	O
are	O
able	O
to	O
cause	O
clinical	O
disease	O
and	O
economic	O
loss	O
.	O

ABSTRACT	O
:	O
Acute	O
organophosphate	B-CHED
insecticide	I-CHED
poisoning	O
can	O
manifest	O
3	O
different	O
phases	O
of	O
toxic	O
effects	O
,	O
namely	O
,	O
acute	O
cholinergic	O
crisis	O
,	O
intermediate	O
syndrome	O
(	O
IMS	O
),	O
and	O
delayed	O
neuropathy	O
.	O

This	O
work	O
makes	O
it	O
possible	O
to	O
study	O
the	O
structure	O
and	O
potential	O
functions	O
of	O
proteins	B-CHED
encoding	O
by	O
these	O
two	O
genes	O
.	O

ABSTRACT	O
:	O
Angiotensin	B-CHED
-	O
converting	O
enzyme	O
-	O
2	O
(	O
ACE2	O
)	O
is	O
a	O
regulatory	O
protein	B-CHED
of	O
the	O
renin	O
-	O
angiotensin	B-CHED
system	O
(	O
RAS	B-CHED
)	O
and	O
a	O
receptor	O
for	O
the	O
causative	O
agent	O
of	O
severe	O
-	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
the	O
SARS	O
-	O
coronavirus	O
.	O

The	O
virus	O
replication	O
kinetics	O
,	O
histopathological	O
changes	O
and	O
mRNA	B-CHED
expression	O
levels	O
of	O
proinflammatory	O
cytokines	O
in	O
the	O
brain	O
did	O
not	O
differ	O
between	O
TNFalpha	O
-	O
deficient	O
and	O
control	O
C57BL	O
/	O
6	O
mice	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
aerosolized	O
anticoagulants	B-CHED
will	O
reduce	O
the	O
degree	O
of	O
airway	O
obstruction	O
and	O
improve	O
pulmonary	O
function	O
in	O
sheep	O
with	O
severe	O
combined	O
burn	O
and	O
smoke	O
inhalation	O
injury	O
by	O
preventing	O
the	O
formation	O
of	O
airway	O
fibrin	O
clots	O
.	O

To	O
identify	O
the	O
most	O
important	O
antigenic	O
region	O
of	O
S1	O
,	O
the	O
truncated	O
S1	O
-	O
GST	O
fusion	O
proteins	B-CHED
were	O
examined	O
for	O
their	O
ability	O
to	O
react	O
with	O
immune	O
serum	O
against	O
PEDV	O
and	O
to	O
elicit	O
the	O
formation	O
of	O
neutralization	O
antibodies	O
in	O
immunized	O
animals	O
.	O

ABSTRACT	O
:	O
Peptides	B-CHED
based	O
on	O
heptad	O
repeat	O
(	O
HR	O
)	O
domains	O
of	O
class	O
I	O
viral	O
fusion	O
proteins	B-CHED
are	O
considered	O
promising	O
antiviral	B-CHED
drugs	I-CHED
targeting	O
virus	O
cell	O
entry	O
.	O

Transferred	O
CD8	O
T	O
cell	O
-	O
enriched	O
splenocytes	O
reconstitute	O
demyelination	O
,	O
and	O
this	O
ability	O
is	O
dependent	O
on	O
donor	B-CHED
IFN	O
-	O
gamma	O
.	O

Rodenticides	B-CHED
include	O
thallium	B-CHED
,	O
superwarfarins	O
,	O
barium	B-CHED
carbonate	B-CHED
and	O
phosphides	O
(	O
aluminium	B-CHED
and	O
zinc	B-CHED
phosphide	B-CHED
).	O

A	O
monomeric	O
form	O
of	O
IBV	O
M	O
(	O
pro	B-CHED
)	O
was	O
identified	O
for	O
the	O
first	O
time	O
in	O
CoV	O
M	O
(	O
pro	B-CHED
)	O
structures	O
.	O

Furthermore	O
,	O
all	O
S	O
proteins	B-CHED
analyzed	O
were	O
posttranslationally	O
cleaved	O
into	O
the	O
subunits	O
S1	O
and	O
S2	O
.	O

In	O
coexpression	O
experiments	O
,	O
the	O
S	O
protein	B-CHED
was	O
found	O
to	O
colocalize	O
with	O
a	O
Golgi	O
marker	O
.	O

Blocking	O
studies	O
on	O
human	O
lung	O
fibroblasts	O
indicate	O
that	O
IL	O
-	O
1beta	O
is	O
the	O
major	O
cyclooxygenase	O
-	O
2	O
mRNA	B-CHED
and	O
PGE2	B-CHED
-	O
inducing	O
factor	O
in	O
pulmonary	O
edema	O
fluid	O
and	O
accounts	O
for	O
the	O
differential	O
PGE2	B-CHED
induction	O
noted	O
in	O
samples	O
from	O
ALI	O
patients	O
.	O

In	O
an	O
inhibition	O
assay	O
of	O
carbon	B-CHED
particle	O
phagocytosis	O
as	O
a	O
representation	O
of	O
natural	O
phagocytosis	O
,	O
neutrophils	O
binding	O
with	O
TAG3	O
or	O
TAG4	O
were	O
inhibited	O
from	O
carbon	B-CHED
particle	O
-	O
phagocytosis	O
by	O
42	O
.	O
5	O
%	O
and	O
53	O
.	O
2	O
%	O
(%	O
inhibition	O
),	O
respectively	O
,	O
but	O
in	O
an	O
inhibition	O
assay	O
using	O
TAG3	O
MoAb	O
,	O
HNA	O
-	O
2a	O
strongly	O
positive	O
neutrophils	O
were	O
more	O
weakly	O
inhibited	O
than	O
HNA	O
-	O
2a	O
weak	O
-	O
positive	O
neutrophils	O
,	O
39	O
.	O
2	O
%	O
and	O
54	O
.	O
0	O
%	O
(%	O
inhibition	O
),	O
respectively	O
.	O

These	O
results	O
also	O
suggested	O
that	O
natural	O
phagocytosis	O
would	O
be	O
inhibited	O
when	O
antibodies	O
combined	O
with	O
every	O
antigen	B-CHED
on	O
the	O
cell	O
membrane	O
.	O

Minimum	O
surface	O
tensions	O
for	O
LS	O
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
and	O
CLSE	O
(	O
1	O
mg	O
/	O
ml	O
)	O
were	O
raised	O
from	O
<	O
1	O
mN	O
/	O
m	O
to	O
15	O
.	O
7	O
+/-	O
1	O
.	O
2	O
and	O
18	O
.	O
7	O
+/-	O
1	O
.	O
3	O
mN	O
/	O
m	O
after	O
5	O
min	O
of	O
bubble	O
pulsation	O
in	O
the	O
presence	O
of	O
total	O
TB	O
lipids	B-CHED
(	O
0	O
.	O
15	O
mg	O
/	O
ml	O
).	O

In	O
transfected	O
Vero	O
E6	O
and	O
A549	O
cells	O
,	O
SARS	O
-	O
CoV	O
N	O
was	O
localized	O
both	O
in	O
the	O
cytoplasm	O
and	O
nucleus	B-CHED
,	O
whereas	O
in	O
Caco	O
-	O
2	O
and	O
N2a	O
cells	O
,	O
nearly	O
no	O
nuclear	O
localization	O
was	O
observed	O
.	O

RESULTS	O
:	O
Key	O
recommendations	O
,	O
listed	O
by	O
category	O
,	O
include	O
early	O
goal	O
-	O
directed	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
hrs	O
after	O
recognition	O
(	O
1C	O
);	O
blood	O
cultures	O
before	O
antibiotic	B-CHED
therapy	O
(	O
1C	O
);	O
imaging	O
studies	O
performed	O
promptly	O
to	O
confirm	O
potential	O
source	O
of	O
infection	O
(	O
1C	O
);	O
administration	O
of	O
broad	O
-	O
spectrum	O
antibiotic	B-CHED
therapy	O
within	O
1	O
hr	O
of	O
diagnosis	O
of	O
septic	O
shock	O
(	O
1B	O
)	O
and	O
severe	O
sepsis	O
without	O
septic	O
shock	O
(	O
1D	O
);	O
reassessment	O
of	O
antibiotic	B-CHED
therapy	O
with	O
microbiology	O
and	O
clinical	O
data	O
to	O
narrow	O
coverage	O
,	O
when	O
appropriate	O
(	O
1C	O
);	O
a	O
usual	O
7	O
-	O
10	O
days	O
of	O
antibiotic	B-CHED
therapy	O
guided	O
by	O
clinical	O
response	O
(	O
1D	O
);	O
source	O
control	O
with	O
attention	O
to	O
the	O
balance	B-CHED
of	O
risks	O
and	O
benefits	O
of	O
the	O
chosen	O
method	O
(	O
1C	O
);	O
administration	O
of	O
either	O
crystalloid	O
or	O
colloid	O
fluid	O
resuscitation	O
(	O
1B	O
);	O
fluid	O
challenge	O
to	O
restore	O
mean	O
circulating	O
filling	O
pressure	O
(	O
1C	O
);	O
reduction	O
in	O
rate	O
of	O
fluid	O
administration	O
with	O
rising	O
filing	O
pressures	O
and	O
no	O
improvement	O
in	O
tissue	O
perfusion	O
(	O
1D	O
);	O
vasopressor	O
preference	O
for	O
norepinephrine	B-CHED
or	O
dopamine	B-CHED
to	O
maintain	O
an	O
initial	O
target	O
of	O
mean	O
arterial	O
pressure	O
>	O
or	O
=	O
65	O
mm	O
Hg	O
(	O
1C	O
);	O
dobutamine	B-CHED
inotropic	O
therapy	O
when	O
cardiac	O
output	O
remains	O
low	O
despite	O
fluid	O
resuscitation	O
and	O
combined	O
inotropic	O
/	O
vasopressor	O
therapy	O
(	O
1C	O
);	O
stress	O
-	O
dose	O
steroid	B-CHED
therapy	O
given	O
only	O
in	O
septic	O
shock	O
after	O
blood	O
pressure	O
is	O
identified	O
to	O
be	O
poorly	O
responsive	O
to	O
fluid	O
and	O
vasopressor	O
therapy	O
(	O
2C	O
);	O
recombinant	O
activated	O
protein	B-CHED
C	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
clinical	O
assessment	O
of	O
high	O
risk	O
for	O
death	O
(	O
2B	O
except	O
2C	O
for	O
postoperative	O
patients	O
).	O

The	O
sensitivity	O
and	O
specificity	O
of	O
N	O
and	O
N199	O
proteins	B-CHED
in	O
human	O
sera	O
diagnosis	O
were	O
approximate	O
(	O
P	O
=	O
0	O
.	O
743	O
),	O
which	O
was	O
higher	O
than	O
whole	O
viral	O
protein	B-CHED
but	O
the	O
difference	O
was	O
not	O
significant	O
(	O
P	O
=	O
0	O
.	O
234	O
).	O

RESULTS	O
:	O
All	O
112	O
infants	O
who	O
had	O
an	O
ARI	B-CHED
had	O
cough	O
,	O
and	O
39	O
(	O
35	O
%)	O
had	O
wheeze	O
.	O

Significant	O
improvements	O
in	O
peak	O
pressure	O
,	O
PEEP	B-CHED
,	O
FiO2	O
,	O
P	O
:	O
F	O
ratio	O
,	O
Pco2	O
,	O
Po2	O
,	O
and	O
ETco2	O
were	O
noted	O
.	O

TITLE	O
:	O
Chimeric	O
coronavirus	O
-	O
like	O
particles	O
carrying	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SCoV	O
)	O
S	O
protein	B-CHED
protect	O
mice	O
against	O
challenge	O
with	O
SCoV	O
.	O
ABSTRACT	O
:	O
We	O
tested	O
the	O
efficacy	O
of	O
coronavirus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
for	O
protecting	O
mice	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SCoV	O
)	O
infection	O
.	O

In	O
this	O
study	O
,	O
we	O
aim	O
to	O
search	O
for	O
and	O
compare	O
immunodominant	O
regions	O
of	O
the	O
spike	O
(	O
S	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	B-CHED
which	O
are	O
recognized	O
by	O
sera	O
from	O
different	O
animal	O
species	O
,	O
including	O
mouse	O
,	O
rat	O
,	O
rabbit	O
,	O
civet	O
,	O
pig	O
and	O
horse	O
.	O

Twelve	O
overlapping	O
recombinant	O
protein	B-CHED
fragments	O
were	O
produced	O
in	O
Escherichia	O
coli	O
,	O
six	O
each	O
for	O
the	O
S	O
and	O
N	O
proteins	B-CHED
,	O
which	O
covered	O
the	O
entire	O
coding	O
region	O
of	O
the	O
two	O
proteins	B-CHED
.	O

Purified	O
recombinant	O
antigens	B-CHED
were	O
immobilized	O
on	O
nitrocellulose	B-CHED
membranes	O
and	O
applied	O
in	O
a	O
line	O
immunoassay	O
,	O
which	O
allows	O
rapid	O
detection	O
of	O
antibodies	O
to	O
5	O
different	O
HCoVs	O
in	O
a	O
single	O
experiment	O
.	O

Here	O
we	O
report	O
nuclear	O
magnetic	O
resonance	O
and	O
molecular	O
modelling	O
studies	O
on	O
the	O
9	O
-	O
O	O
-	O
acetyl	B-CHED
esterase	O
showing	O
that	O
the	O
alpha	O
-	O
configured	O
Neu5	O
,	O
9Ac	O
(	O
2	O
)	O
is	O
strictly	O
preferred	O
by	O
the	O
INF	O
-	O
C	O
and	O
BCoV	O
esterases	O
.	O

Feline	O
infectious	O
peritonitis	O
was	O
confirmed	O
by	O
histology	O
or	O
immunostaining	O
of	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
antigen	B-CHED
in	O
effusion	O
or	O
tissue	O
macrophages	O
or	O
both	O
.	O

Amoxapine	B-CHED
was	O
stopped	O
,	O
resulting	O
in	O
complete	O
resolution	O
of	O
the	O
pulmonary	O
infiltrates	O
.	O

The	O
aromatic	B-CHED
amino	I-CHED
acids	I-CHED
in	O
the	O
JMD	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	B-CHED
play	O
critical	O
roles	O
in	O
receptor	O
-	O
dependent	O
virus	O
-	O
cell	O
and	O
cell	O
-	O
cell	O
fusion	O
.	O

Both	O
genosensors	O
rely	O
on	O
the	O
hybridization	O
of	O
the	O
oligonucleotide	B-CHED
target	O
with	O
its	O
complementary	O
probe	O
,	O
which	O
is	O
immobilized	O
on	O
positively	O
charged	O
polylysine	B-CHED
modified	O
screen	O
-	O
printed	O
carbon	B-CHED
electrodes	O
(	O
SPCEs	O
),	O
through	O
electrostatic	O
interactions	O
.	O

In	O
the	O
other	O
design	O
,	O
the	O
target	O
is	O
labeled	O
using	O
an	O
Au	O
(	O
I	O
)	O
complex	O
,	O
sodium	B-CHED
aurothiomalate	I-CHED
,	O
and	O
the	O
duplex	O
formation	O
is	O
detected	O
by	O
measuring	O
,	O
for	O
first	O
time	O
,	O
the	O
current	O
generated	O
by	O
the	O
hydrogen	B-CHED
evolution	O
catalyzed	O
by	O
the	O
gold	B-CHED
label	B-CHED
.	O

The	O
membrane	O
(	O
M	O
)	O
protein	B-CHED
genes	O
of	O
six	O
PEDV	O
isolates	O
were	O
amplified	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
then	O
cloned	O
,	O
sequenced	O
,	O
and	O
compared	O
with	O
each	O
other	O
as	O
well	O
as	O
those	O
ten	O
PEDV	O
reference	O
strains	O
.	O

Endocytic	O
entry	O
of	O
SARS	O
-	O
CoV	O
may	O
expand	O
the	O
cellular	O
range	O
of	O
SARS	O
-	O
CoV	O
infection	O
,	O
and	O
our	O
findings	O
here	O
contribute	O
to	O
the	O
understanding	O
of	O
SARS	O
-	O
CoV	O
pathogenesis	O
,	O
providing	O
new	O
information	O
for	O
anti	B-CHED
-	I-CHED
viral	I-CHED
drug	I-CHED
research	O
.	O

Clinical	O
manifestation	O
,	O
direct	O
laryngoscope	O
,	O
CT	O
,	O
X	O
-	O
ray	O
barium	B-CHED
meal	O
examination	O
results	O
and	O
the	O
treatment	O
process	O
were	O
recorded	O
.	O

Except	O
for	O
3	O
in	O
47	O
cases	O
whose	O
parents	O
refused	O
treatment	O
,	O
dyspnea	O
in	O
other	O
44	O
cases	O
were	O
relieved	O
with	O
inhaling	O
oxygen	B-CHED
and	O
drug	O
treatment	O
,	O
37	O
case	O
received	O
tracheal	O
intubation	O
and	O
sputum	O
suction	O
,	O
19	O
cases	O
received	O
direct	O
laryngoscope	O
or	O
self	O
-	O
retaining	O
laryngoscope	O
operation	O
.	O

Except	O
for	O
3	O
in	O
47	O
cases	O
whose	O
parents	O
refused	O
treatment	O
,	O
dyspnea	O
in	O
other	O
44	O
cases	O
were	O
relieved	O
with	O
inhaling	O
oxygen	B-CHED
and	O
drug	O
treatment	O
,	O
37	O
case	O
received	O
tracheal	O
intubation	O
and	O
sputum	O
suction	O
,	O
19	O
cases	O
received	O
direct	O
laryngoscope	O
or	O
self	O
-	O
retaining	O
laryngoscope	O
operation	O
.	O

The	O
kinetic	O
mechanism	O
for	O
3CLpro	O
-	O
mediated	O
ester	B-CHED
hydrolysis	O
,	O
including	O
the	O
individual	O
rate	O
constants	O
,	O
is	O
consistent	O
with	O
a	O
simple	O
double	O
displacement	O
mechanism	O
.	O

When	O
homologous	O
peptidic	O
amide	B-CHED
and	O
ester	B-CHED
substrates	O
were	O
compared	O
,	O
a	O
series	O
of	O
interesting	O
observations	O
emerged	O
.	O

Proton	B-CHED
inventory	O
(	O
PI	O
)	O
studies	O
on	O
amide	B-CHED
peptide	B-CHED
hydrolysis	O
were	O
consistent	O
with	O
two	O
proton	B-CHED
-	O
transfer	O
reactions	O
in	O
the	O
transition	O
state	O
while	O
the	O
ester	B-CHED
data	O
was	O
consistent	O
with	O
a	O
single	O
proton	B-CHED
-	O
transfer	O
reaction	O
.	O

Presented	O
here	O
is	O
a	O
review	O
of	O
recently	O
reported	O
agents	O
present	O
in	O
pomegranate	O
juice	O
(	O
polyphenols	B-CHED
,	O
beta	B-CHED
-	I-CHED
sitosterol	I-CHED
,	O
sugars	O
and	O
ellagic	B-CHED
acid	I-CHED
)	O
and	O
fulvic	O
acid	O
,	O
described	O
here	O
as	O
the	O
envelope	O
virus	O
neutralising	O
compounds	O
(	O
EVNCs	O
)	O
and	O
complex	O
molecules	O
like	O
lectins	O
and	O
mucins	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	B-CHED
of	O
SARS	O
-	O
associated	O
coronavirus	O
inhibits	O
B23	O
phosphorylation	O
.	O

In	O
this	O
study	O
,	O
the	O
N	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
was	O
found	O
to	O
associate	O
with	O
B23	O
,	O
a	O
phosphoprotein	O
in	O
nucleolus	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Mean	O
amino	B-CHED
acid	I-CHED
identity	O
amongst	O
these	O
Brazilian	O
strains	O
was	O
94	O
.	O
07	O
%;	O
amongst	O
these	O
and	O
serotypes	O
D274	O
,	O
4	O
/	O
91	O
,	O
and	O
Massachusetts	O
,	O
mean	O
amino	B-CHED
acid	I-CHED
identity	O
was	O
77	O
.	O
17	O
%,	O
69	O
.	O
94	O
%,	O
and	O
68	O
.	O
93	O
%,	O
respectively	O
.	O

ABSTRACT	O
:	O
Highly	O
pathogenic	O
avian	O
influenza	O
A	O
(	O
HPAI	O
)	O
subtype	O
H5N1	O
has	O
caused	O
family	O
case	O
clusters	B-CHED
,	O
mostly	O
in	O
Southeast	O
Asia	O
,	O
that	O
could	O
be	O
due	O
to	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

Using	O
the	O
combination	O
of	O
yeast	O
two	O
-	O
hybrid	O
screening	O
and	O
GST	O
pull	O
-	O
down	O
assays	O
,	O
we	O
have	O
now	O
analyzed	O
all	O
potential	O
interactions	O
between	O
SARS	O
-	O
Coronavirus	O
nonstructural	O
proteins	B-CHED
,	O
which	O
may	O
contribute	O
to	O
the	O
structure	O
and	O
/	O
or	O
function	O
of	O
the	O
viral	O
replication	O
/	O
transcription	O
complex	O
.	O

We	O
demonstrate	O
the	O
existence	O
of	O
a	O
complex	O
network	O
of	O
interactions	O
involving	O
all	O
16	O
nonstructural	O
proteins	B-CHED
.	O

They	O
are	O
nucleic	B-CHED
acid	I-CHED
-	O
binding	O
proteins	B-CHED
whose	O
main	O
recognized	O
function	O
is	O
to	O
package	O
viral	O
genomes	O
into	O
protective	O
structures	O
called	O
nucleocapsids	O
.	O

Purification	O
of	O
the	O
desired	O
bispecific	O
immunoprobe	O
with	O
high	O
specific	O
activity	O
from	O
a	O
mixture	B-CHED
of	O
bispecific	O
and	O
monospecific	O
monoclonal	O
antibodies	O
requires	O
special	O
strategies	O
.	O

We	O
describe	O
a	O
hypophosphatemia	O
-	O
related	O
ARDS	O
case	O
report	O
of	O
a	O
50	O
-	O
year	O
-	O
old	O
woman	O
with	O
ACTH	B-CHED
dependent	O
Cushing	O
'	O
s	O
syndrome	O
secondary	O
to	O
ectopic	O
CRH	B-CHED
production	O
.	O

The	O
hypothesis	O
may	O
be	O
confirmed	O
by	O
:	O
(	O
1	O
)	O
demonstrating	O
an	O
improvement	O
in	O
physiologic	O
parameters	O
,	O
intracranial	O
pressure	O
,	O
and	O
brain	O
oxygenation	O
with	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
use	O
in	O
severely	O
head	O
injured	O
patients	O
,	O
and	O
(	O
2	O
)	O
demonstrating	O
a	O
decrease	O
in	O
biochemical	O
serum	O
markers	O
in	O
such	O
patients	O
;	O
specifically	O
,	O
glial	O
fibrillary	O
acidic	O
protein	B-CHED
,	O
inflammatory	O
cytokines	O
,	O
and	O
biomarkers	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
,	O
and	O
(	O
3	O
)	O
documentation	O
of	O
outcomes	O
.	O

We	O
postulated	O
that	O
additional	O
factors	O
should	O
regulate	O
transcription	O
of	O
sg	O
mRNA	B-CHED
N	O
.	O
In	O
this	O
report	O
,	O
we	O
have	O
described	O
a	O
novel	O
transcription	O
regulation	O
mechanism	O
operating	O
in	O
CoV	O
by	O
which	O
a	O
9	O
-	O
nucleotide	B-CHED
(	O
nt	O
)	O
sequence	O
located	O
449	O
nt	O
upstream	O
of	O
the	O
N	O
gene	O
TRS	O
core	O
sequence	O
(	O
CS	O
-	O
N	O
)	O
interacts	O
with	O
a	O
complementary	O
sequence	O
just	O
upstream	O
of	O
CS	O
-	O
N	O
,	O
specifically	O
increasing	O
the	O
accumulation	O
of	O
sg	O
mRNA	B-CHED
N	O
.	O
Alteration	O
of	O
this	O
complementarity	O
in	O
mutant	O
replicon	O
genomes	O
showed	O
a	O
correlation	O
between	O
the	O
predicted	O
stability	O
of	O
the	O
base	O
pairing	O
between	O
9	O
-	O
nt	O
sequences	O
and	O
the	O
accumulation	O
of	O
sg	O
mRNA	B-CHED
N	O
.	O
This	O
interaction	O
is	O
exclusively	O
conserved	O
in	O
group	O
1a	O
CoVs	O
,	O
the	O
only	O
CoV	O
subgroup	O
in	O
which	O
the	O
N	O
gene	O
is	O
not	O
the	O
most	O
3	O
'	O
gene	O
in	O
the	O
viral	O
genome	O
.	O

Apart	O
from	O
the	O
respiratory	O
depressant	O
effect	O
of	O
opioids	O
,	O
crack	O
cocaine	B-CHED
is	O
the	O
most	O
common	O
cause	O
of	O
respiratory	O
complications	O
,	O
mainly	O
linked	O
with	O
its	O
mode	O
of	O
use	O
,	O
with	O
airway	O
burns	O
,	O
pneumothorax	O
,	O
pneumomediastinum	O
,	O
and	O
lung	O
syndromes	O
being	O
well	O
-	O
recognised	O
sequelae	O
.	O

(	O
3	O
)	O
Length	O
of	O
stay	O
in	O
hospital	O
of	O
patients	O
steroid	B-CHED
usage	O
in	O
medium	O
dosage	O
seemed	O
to	O
be	O
0	O
.	O
619	O
time	O
less	O
risky	O
than	O
in	O
patients	O
without	O
steroid	B-CHED
usage	O
(	O
chi	B-CHED
(	O
2	O
)=	O
7	O
.	O
262	O
,	O
P	O
=	O
0	O
.	O
007	O
),	O
and	O
that	O
in	O
patients	O
with	O
immunomodulator	B-CHED
(	O
including	O
gamma	O
globulin	O
,	O
thymic	O
peptide	B-CHED
and	O
interferon	O
)	O
was	O
0	O
.	O
671	O
time	O
less	O
risky	O
than	O
in	O
patients	O
without	O
immunomodulator	B-CHED
(	O
chi	B-CHED
(	O
2	O
)=	O
10	O
.	O
252	O
,	O
P	O
=	O
0	O
.	O
001	O
).	O

Prompt	O
antidote	B-CHED
treatment	O
and	O
aggressive	O
supportive	O
emergency	O
and	O
intensive	O
care	O
unit	O
therapy	O
contribute	O
to	O
improved	O
survival	O
after	O
acute	O
organophosphate	O
poisoning	O
.	O

But	O
relapses	O
are	O
frequent	O
after	O
stopping	O
corticosteroid	B-CHED
treatment	O
,	O
as	O
well	O
as	O
the	O
occurrence	O
of	O
severe	O
asthma	O
.	O

Among	O
uncircumcised	O
men	O
,	O
HPV	O
prevalence	O
in	O
the	O
foreskin	O
(	O
44	O
%)	O
was	O
comparable	O
to	O
that	O
in	O
the	O
glans	O
/	O
corona	B-CHED
,	O
and	O
type	O
-	O
specific	O
positivity	O
was	O
observed	O
between	O
the	O
2	O
sites	O
(	O
kappa	O
=	O
0	O
.	O
52	O
).	O

ABSTRACT	O
:	O
The	O
effectiveness	O
and	O
potential	O
immunosuppressive	O
effects	O
of	O
anti	O
-	O
inflammatory	O
glucocorticoids	B-CHED
in	O
the	O
lungs	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
are	O
undefined	O
.	O

Of	O
these	O
,	O
15	O
(	O
13	O
.	O
7	O
%)	O
developed	O
ARI	B-CHED
in	O
the	O
immediate	O
postoperative	O
period	O
.	O

All	O
of	O
the	O
children	O
that	O
developed	O
ARI	B-CHED
presented	O
quadriplegia	O
.	O

To	O
determine	O
if	O
chemokine	O
expression	O
corresponds	O
with	O
the	O
cellular	O
infiltrate	O
,	O
chemokine	O
protein	B-CHED
and	O
RNA	O
levels	O
from	O
the	O
brains	O
of	O
infected	O
mice	O
were	O
quantified	O
.	O

Thus	O
,	O
chemokine	O
patterns	O
correspond	O
with	O
the	O
cellular	O
infiltrate	O
,	O
and	O
the	O
spike	O
protein	B-CHED
influences	O
levels	O
of	O
macrophage	O
,	O
but	O
not	O
T	O
-	O
cell	O
,	O
chemokines	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
critical	O
homeostasis	O
regulator	O
GADD34	O
,	O
which	O
recruits	O
protein	B-CHED
phosphatase	O
1	O
to	O
dephosphorylate	O
eIF2alpha	O
during	O
the	O
recovery	O
phase	O
of	O
the	O
UPR	O
,	O
is	O
not	O
expressed	O
during	O
MHV	O
infection	O
.	O

Here	O
we	O
report	O
that	O
the	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	B-CHED
)	O
C	O
-	O
terminal	O
domain	O
alone	O
(	O
residues	O
187	O
to	O
306	O
;	O
M	O
(	O
pro	B-CHED
)-	O
C	O
)	O
is	O
produced	O
in	O
Escherichia	O
coli	O
in	O
both	O
monomeric	O
and	O
dimeric	O
forms	O
,	O
and	O
no	O
exchange	O
could	O
be	O
observed	O
between	O
them	O
at	O
room	O
temperature	O
.	O

However	O
,	O
no	O
C	O
-	O
terminal	O
domain	O
-	O
mediated	O
dimerization	O
form	O
can	O
be	O
detected	O
for	O
wild	O
-	O
type	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	B-CHED
).	O

Notably	O
,	O
SARS	O
-	O
CoV	O
-	O
mt	O
infection	O
,	O
but	O
not	O
SARS	O
-	O
CoV	O
-	O
WT	O
infection	O
,	O
induced	O
high	O
levels	O
of	O
beta	O
interferon	O
(	O
IFN	O
)	O
mRNA	B-CHED
accumulation	O
and	O
high	O
titers	O
of	O
type	O
I	O
IFN	O
production	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
suggest	O
that	O
H2S	B-CHED
exerts	O
protective	O
effects	O
in	O
acute	O
lung	O
injury	O
,	O
at	O
least	O
in	O
part	O
through	O
the	O
activation	O
of	O
anti	O
-	O
inflammatory	O
and	O
antioxidant	B-CHED
pathways	O
.	O

All	O
patients	O
presented	O
antibodies	O
to	O
lipopolysaccharides	B-CHED
and	O
alpha	O
-	O
hemolysin	O
,	O
but	O
the	O
level	O
did	O
not	O
correlate	O
with	O
P	O
(	O
a	O
)	O
O	O
(	O
2	O
)/	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
).	O

It	O
is	O
now	O
well	O
established	O
that	O
the	O
causative	O
agent	O
,	O
a	O
newly	O
identified	O
coronavirus	O
termed	O
SARS	O
-	O
CoV	O
,	O
employs	O
multiple	O
passive	O
and	O
active	O
mechanisms	O
to	O
avoid	O
induction	O
of	O
the	O
antiviral	B-CHED
type	O
I	O
interferons	O
in	O
tissue	O
cells	O
.	O

ABSTRACT	O
:	O
Cytotoxic	O
T	O
lymphocyte	O
escape	O
occurs	O
in	O
many	O
human	O
infections	O
,	O
as	O
well	O
as	O
mice	O
infected	O
with	O
the	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
,	O
which	O
exhibit	O
CTL	O
escape	O
variants	O
with	O
mutations	O
in	O
a	O
single	O
epitope	B-CHED
from	O
the	O
spike	O
glycoprotein	B-CHED
(	O
S510	O
).	O

To	O
define	O
more	O
precisely	O
the	O
basis	O
for	O
this	O
preferential	O
selection	O
,	O
we	O
combine	O
x	O
-	O
ray	O
crystallographic	O
studies	O
of	O
the	O
MHC	O
class	O
I	O
(	O
D	O
(	O
b	O
))/	O
S510	O
complexes	O
with	O
viral	O
reverse	O
genetics	O
to	O
identify	O
a	O
prominent	O
TCR	O
contact	O
residue	O
(	O
tryptophan	B-CHED
at	O
position	O
4	O
)	O
prone	O
to	O
escape	O
mutations	O
.	O

This	O
study	O
documents	O
PHE	B-CHED
-	O
CoV	O
infection	O
in	O
South	O
America	O
.	O

Three	O
different	O
amino	B-CHED
acids	I-CHED
were	O
explored	O
in	O
the	O
P1	O
-	O
position	O
and	O
in	O
the	O
P2	O
-	O
P4	O
positions	O
varying	O
amino	B-CHED
acids	I-CHED
and	O
long	O
alkyl	O
chain	O
were	O
incorporated	O
.	O

All	O
inhibitors	B-CHED
were	O
evaluated	O
in	O
an	O
in	O
vitro	O
assay	O
using	O
purified	O
enzyme	O
and	O
fluorogenic	O
substrate	O
peptide	B-CHED
.	O

ABSTRACT	O
:	O
During	O
acute	O
viral	O
hepatitis	O
,	O
the	O
intrahepatic	O
tolerance	O
sustained	O
by	O
immunosuppressive	O
cytokines	O
such	O
as	O
interleukin	O
(	O
IL	O
)-	O
4	O
,	O
IL	O
-	O
10	O
,	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)-	O
beta	O
and	O
prostaglandin	B-CHED
E2	I-CHED
(	O
PGE2	B-CHED
),	O
produced	O
by	O
Kupffer	O
cells	O
(	O
KC	O
),	O
liver	O
sinusoidal	O
endothelial	O
cells	O
(	O
LSEC	O
),	O
natural	O
killer	O
(	O
NK	O
)	O
T	O
cells	O
and	O
natural	O
regulatory	O
T	O
cells	O
may	O
be	O
disturbed	O
.	O

These	O
results	O
indicate	O
that	O
viral	O
permissivity	O
of	O
KC	O
and	O
LSEC	O
is	O
involved	O
in	O
the	O
decrease	O
of	O
IL	O
-	O
10	O
and	O
PGE2	B-CHED
,	O
while	O
KC	O
may	O
play	O
an	O
additional	O
role	O
in	O
the	O
apoptosis	O
of	O
NK	O
and	O
NK	O
T	O
cells	O
during	O
acute	O
viral	O
hepatitis	O
.	O

SARS	O
-	O
3CL	O
(	O
pro	B-CHED
)	O
is	O
a	O
viral	O
cysteine	B-CHED
protease	O
critical	O
to	O
the	O
pathogen	O
'	O
s	O
life	O
cycle	O
and	O
hence	O
a	O
therapeutic	O
target	O
of	O
importance	O
.	O

Biological	O
evaluation	O
of	O
a	O
screened	O
selection	O
of	O
compounds	O
was	O
carried	O
out	O
to	O
identify	O
novel	O
inhibitors	B-CHED
of	O
the	O
viral	O
protease	O
.	O

Like	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
NL63	O
also	O
employs	O
the	O
human	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
hACE2	O
)	O
receptor	O
for	O
cellular	O
entry	O
.	O

To	O
identify	O
residues	O
in	O
the	O
spike	O
protein	B-CHED
of	O
NL63	O
that	O
are	O
important	O
for	O
hACE2	O
binding	O
,	O
this	O
study	O
first	O
generated	O
a	O
series	O
of	O
S1	O
-	O
truncated	O
variants	O
,	O
examined	O
their	O
associations	O
with	O
the	O
hACE2	O
receptor	O
and	O
subsequently	O
mapped	O
a	O
minimal	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
that	O
consisted	O
of	O
141	O
residues	O
(	O
aa	O
476	O
-	O
616	O
)	O
towards	O
the	O
C	O
terminus	O
of	O
the	O
S1	O
domain	O
.	O

ABSTRACT	O
:	O
Live	O
attenuated	O
recombinant	O
measles	O
viruses	O
(	O
rMV	O
)	O
expressing	O
a	O
codon	O
-	O
optimised	O
spike	O
glycoprotein	B-CHED
(	O
S	O
)	O
or	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
generated	O
(	O
rMV	O
-	O
S	O
and	O
rMV	O
-	O
N	O
).	O

In	O
contrast	O
,	O
with	O
an	O
intranasal	O
(	O
IN	O
)	O
immunization	O
protocol	O
,	O
inactivated	O
SARS	O
-	O
CoV	O
alone	O
failed	O
to	O
induce	O
any	O
detectable	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgA	O
antibodies	O
in	O
sera	O
,	O
saliva	O
,	O
lung	O
,	O
and	O
intestine	O
,	O
except	O
for	O
a	O
small	O
quantity	O
of	O
IgA	O
antibodies	O
in	O
fecal	O
extracts	O
and	O
the	O
genital	O
tract	O
,	O
along	O
with	O
IgG	O
antibodies	O
in	O
sera	O
,	O
but	O
when	O
given	O
with	O
adjuvant	B-CHED
CpG	O
ODN	O
2006	O
,	O
inactivated	O
SARS	O
-	O
CoV	O
induced	O
significant	O
amounts	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgG	O
antibodies	O
in	O
sera	O
,	O
and	O
a	O
detectable	O
amount	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgA	O
antibodies	O
in	O
sera	O
and	O
all	O
tested	O
mucosal	O
secretions	O
and	O
tissues	O
(	O
i	O
.	O
e	O
.,	O
saliva	O
,	O
the	O
genital	O
tract	O
,	O
fecal	O
extract	O
,	O
lung	O
,	O
and	O
intestine	O
).	O

Prior	O
work	O
has	O
shown	O
disordered	O
inflammation	O
and	O
coagulation	O
in	O
ALI	O
,	O
with	O
strong	O
correlations	O
between	O
biomarker	B-CHED
abnormalities	O
and	O
worse	O
clinical	O
outcomes	O
.	O

The	O
mRNA	B-CHED
of	O
human	O
beta	O
actin	O
gene	O
could	O
be	O
amplified	O
efficiently	O
in	O
all	O
the	O
tissue	O
samples	O
.	O

The	O
mRNA	B-CHED
of	O
human	O
ACE2	O
was	O
expressed	O
efficiently	O
in	O
the	O
normal	O
lung	O
tissue	O
,	O
but	O
not	O
in	O
the	O
cartilage	O
and	O
cancellous	O
bone	O
under	O
the	O
weight	O
-	O
bearing	O
area	O
of	O
the	O
femoral	O
head	O
.	O

The	O
mRNA	B-CHED
of	O
human	O
ACE2	O
was	O
expressed	O
efficiently	O
in	O
the	O
normal	O
lung	O
tissue	O
,	O
but	O
not	O
in	O
the	O
cartilage	O
and	O
cancellous	O
bone	O
under	O
the	O
weight	O
-	O
bearing	O
area	O
of	O
the	O
femoral	O
head	O
.	O

Sequencing	O
analysis	O
of	O
the	O
viral	O
structural	O
proteins	B-CHED
revealed	O
four	O
and	O
one	O
amino	B-CHED
acid	I-CHED
substitutions	O
in	O
the	O
S	O
and	O
membrane	O
(	O
M	O
)	O
proteins	B-CHED
,	O
respectively	O
.	O

Proteins	B-CHED
packaged	O
during	O
virus	O
assembly	O
may	O
subsequently	O
form	O
the	O
first	O
line	O
of	O
attack	O
and	O
host	O
manipulation	O
upon	O
infection	O
.	O

Surprisingly	O
,	O
the	O
hub	O
with	O
the	O
most	O
potential	O
connections	O
was	O
not	O
the	O
viral	O
M	O
protein	B-CHED
but	O
the	O
nonstructural	O
protein	B-CHED
3	O
(	O
nsp3	O
),	O
which	O
is	O
one	O
of	O
the	O
novel	O
virion	O
components	O
identified	O
by	O
mass	O
spectrometry	O
.	O

Based	O
on	O
new	O
experimental	O
data	O
and	O
a	O
bioinformatics	O
analysis	O
across	O
the	O
Coronaviridae	O
,	O
we	O
propose	O
a	O
higher	O
-	O
resolution	O
functional	O
domain	O
architecture	O
for	O
nsp3	O
that	O
determines	O
the	O
interaction	O
capacity	O
of	O
this	O
protein	B-CHED
.	O

Using	O
recombinant	O
protein	B-CHED
domains	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
we	O
identified	O
two	O
additional	O
RNA	O
-	O
binding	O
domains	O
of	O
nsp3	O
.	O

TITLE	O
:	O
Persistent	O
replication	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
in	O
human	O
tubular	O
kidney	O
cells	O
selects	O
for	O
adaptive	O
mutations	O
in	O
the	O
membrane	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Many	O
retroviruses	O
use	O
-	O
1	O
ribosomal	O
frameshifting	O
as	O
part	O
of	O
the	O
mechanism	O
in	O
translational	O
control	O
of	O
viral	O
protein	B-CHED
synthesis	O
.	O

Here	O
we	O
investigate	O
the	O
free	O
energy	O
landscape	O
for	O
a	O
minimal	O
-	O
1	O
programmed	O
ribosomal	O
frameshifting	O
machinery	O
,	O
including	O
the	O
codon	O
-	O
anticodon	O
base	O
pairs	O
at	O
the	O
slippery	O
site	O
,	O
the	O
downstream	O
messenger	B-CHED
RNA	I-CHED
structure	O
and	O
the	O
spacer	O
between	O
the	O
slippery	O
site	O
and	O
the	O
downstream	O
structure	O
.	O

ABSTRACT	O
:	O
Apple	O
latent	O
spherical	O
virus	O
(	O
ALSV	O
)	O
expressing	O
green	O
,	O
cyan	O
,	O
and	O
yellow	O
fluorescent	O
proteins	B-CHED
(	O
GFP	O
,	O
CFP	O
,	O
and	O
YFP	O
)	O
was	O
constructed	O
and	O
used	O
to	O
analyze	O
the	O
local	O
and	O
systemic	O
movement	O
of	O
the	O
virus	O
in	O
infected	O
plants	O
.	O

Oleic	B-CHED
acid	I-CHED
resulted	O
in	O
sepsis	O
-	O
like	O
responses	O
including	O
ALI	O
,	O
inflammatory	O
reaction	O
,	O
and	O
increased	O
neutrophil	O
-	O
derived	O
factors	O
.	O

Epitope	B-CHED
mapping	O
analysis	O
indicated	O
that	O
monoclonal	O
antibody	O
SN5	O
-	O
25	O
recognized	O
the	O
amino	B-CHED
acid	I-CHED
sequence	O
Q	O
(	O
245	O
)	O
TVTKK	O
(	O
250	O
)	O
On	O
SARS	O
-	O
NP	O
.	O

Serological	O
cross	O
-	O
reactivity	O
between	O
SARS	O
-	O
CoV	O
and	O
human	O
CoV	O
-	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
was	O
investigated	O
by	O
peptide	B-CHED
spot	O
assay	O
.	O

Four	O
antisense	O
peptides	B-CHED
were	O
designed	O
based	O
on	O
the	O
degeneracy	O
of	O
genetic	O
codes	O
.	O

The	O
results	O
indicate	O
this	O
preferred	O
polypeptide	B-CHED
can	O
be	O
used	O
as	O
a	O
lead	O
compound	O
of	O
potent	O
inhibitor	B-CHED
of	O
SARS	O
-	O
CoV	O
.	O
The	O
mechanism	O
study	O
suggests	O
the	O
specific	O
recognition	O
between	O
the	O
DP	O
and	O
the	O
target	O
peptide	B-CHED
was	O
due	O
to	O
sequence	O
-	O
dependent	O
and	O
multi	O
-	O
modal	O
affinity	O
interaction	O
.	O

Overall	O
,	O
these	O
observations	O
suggest	O
that	O
isogenic	O
demyelinating	O
and	O
nondemyelinating	O
strains	O
of	O
MHV	O
,	O
differing	O
in	O
the	O
spike	O
protein	B-CHED
expressed	O
,	O
infect	O
neurons	O
and	O
glial	O
cells	O
in	O
different	O
proportions	O
and	O
that	O
differential	O
tropism	O
to	O
a	O
particular	O
CNS	B-CHED
cell	O
type	O
may	O
play	O
a	O
significant	O
role	O
in	O
mediating	O
the	O
onset	O
and	O
mechanisms	O
of	O
demyelination	O
.	O

The	O
SARS	O
-	O
CoV	O
M	O
protein	B-CHED
is	O
predicted	O
as	O
a	O
triple	O
-	O
spanning	O
membrane	O
protein	B-CHED
lack	O
of	O
a	O
conventional	O
signal	O
peptide	B-CHED
.	O

TITLE	O
:	O
Identification	O
of	O
two	O
novel	O
B	O
cell	O
epitopes	O
on	O
porcine	O
epidemic	O
diarrhea	O
virus	O
spike	O
protein	B-CHED
.	O

These	O
mini	O
-	O
GST	O
fusion	O
proteins	B-CHED
were	O
scanned	O
by	O
ELISA	O
and	O
Western	O
blotting	O
with	O
the	O
six	O
McAbs	O
,	O
and	O
the	O
result	O
showed	O
that	O
S1D5	O
(	O
residues	O
744	O
-	O
759	O
)	O
and	O
S1D6	O
(	O
residues	O
756	O
-	O
771	O
)	O
are	O
two	O
linear	O
epitopes	O
of	O
the	O
PEDV	O
S	O
protein	B-CHED
.	O

A	O
Chinese	O
multiherb	O
remedy	O
used	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
SARS	O
has	O
robust	O
inhibitory	O
effect	O
on	O
complement	O
system	O
through	O
the	O
CP	O
and	O
AP	O
,	O
and	O
its	O
anticomplementary	O
activity	O
could	O
be	O
attributed	O
to	O
the	O
flavonoids	B-CHED
present	O
in	O
some	O
ingredient	O
herbs	O
.	O

Luteolin	B-CHED
could	O
be	O
a	O
potential	O
anticomplementary	O
agent	O
.	O

Nine	O
flavonoids	B-CHED
(	O
2	O
,	O
3	O
,	O
6	O
,	O
8	O
,	O
10	O
-	O
13	O
,	O
15	O
)	O
were	O
found	O
to	O
show	O
inhibitory	O
effects	O
towards	O
the	O
CP	O
and	O
AP	O
of	O
complement	O
system	O
,	O
luteolin	B-CHED
(	O
10	O
)	O
was	O
the	O
most	O
potent	O
with	O
the	O
CH50	O
and	O
AP50	O
values	O
of	O
0	O
.	O
19	O
and	O
0	O
.	O
17	O
mM	O
.	O
The	O
bioactive	O
flavonoids	B-CHED
were	O
mainly	O
derived	O
from	O
Herba	O
Houttuyniae	O
,	O
Flos	O
Chrysanthemi	O
Indici	O
and	O
Herba	O
Artemisiae	O
Scopariae	O
.	O

Here	O
,	O
however	O
,	O
we	O
show	O
that	O
some	O
group	O
1	O
coronavirus	O
spike	O
proteins	B-CHED
carry	O
a	O
furin	O
enzyme	O
recognition	O
motif	O
and	O
can	O
actually	O
be	O
cleaved	O
,	O
as	O
demonstrated	O
for	O
a	O
feline	O
coronavirus	O
.	O

Vascular	O
lesions	O
,	O
e	O
.	O
g	O
.	O
degeneration	O
of	O
endothelial	O
cells	O
,	O
perivascular	O
and	O
intramural	O
oedema	O
,	O
fibrinoid	O
necrosis	O
,	O
vasculitis	O
,	O
perivasculitis	O
,	O
and	O
vascular	O
thrombi	O
were	O
observed	O
in	O
all	O
cases	O
,	O
associated	O
with	O
the	O
presence	O
of	O
PCV2	O
antigen	B-CHED
.	O

The	O
viral	O
antigen	B-CHED
was	O
present	O
in	O
the	O
intravascular	O
mononuclear	O
cells	O
,	O
endothelial	O
cells	O
,	O
myocytes	O
and	O
infiltrating	O
inflammatory	O
cells	O
in	O
lymph	O
and	O
blood	O
vessels	O
.	O

Three	O
of	O
the	O
compounds	O
,	O
which	O
also	O
had	O
furan	B-CHED
rings	O
,	O
inhibited	O
the	O
cleavage	O
activity	O
of	O
HAV	O
3C	O
(	O
pro	B-CHED
)	O
with	O
K	O
(	O
ic	O
)	O
s	O
of	O
120	O
-	O
240nM	O
.	O
HPLC	O
-	O
based	O
assays	O
revealed	O
that	O
the	O
inhibitors	B-CHED
were	O
slowly	O
hydrolyzed	O
by	O
both	O
HAV	O
3C	O
(	O
pro	B-CHED
)	O
and	O
SARS	O
3CL	O
(	O
pro	B-CHED
),	O
confirming	O
the	O
identity	O
of	O
the	O
expected	O
products	O
.	O

TITLE	O
:	O
Coronavirus	O
nonstructural	O
protein	B-CHED
16	O
is	O
a	O
cap	O
-	O
0	O
binding	O
enzyme	O
possessing	O
(	O
nucleoside	B-CHED
-	O
2	O
'	O
O	O
)-	O
methyltransferase	O
activity	O
.	O

Procalcitonin	O
(	O
PCT	O
)	O
has	O
been	O
evaluated	O
for	O
its	O
utility	O
in	O
determining	O
the	O
aetiology	O
of	O
community	O
-	O
acquired	O
pneumonia	O
(	O
CAP	O
),	O
choice	O
of	O
antibiotics	B-CHED
and	O
prediction	O
of	O
outcome	O
.	O

HCl	B-CHED
(	O
IC	O
(	O
50	O
)=	O
195	O
+/-	O
71	O
.	O
2	O
microM	O
).	O

Therefore	O
,	O
treating	O
SARS	O
infections	O
with	O
compounds	O
like	O
promazine	B-CHED
is	O
not	O
warranted	O
.	O

SARS	O
-	O
CoV	O
pseudotyped	O
with	O
mutated	O
S	O
protein	B-CHED
was	O
used	O
to	O
measure	O
viral	O
infectivity	O
.	O

Western	O
blot	O
showed	O
that	O
both	O
anti	O
-	O
CCoV	O
mAbs	O
only	O
reacted	O
with	O
a	O
protein	B-CHED
of	O
50	O
kD	O
,	O
a	O
weight	O
consistent	O
with	O
the	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
viral	O
nucleocapsid	O
.	O

Immunohistochemically	O
,	O
all	O
cases	O
were	O
positive	O
for	O
coronavirus	O
antigen	B-CHED
using	O
monoclonal	O
antibody	O
FIPV3	O
-	O
70	O
.	O

In	O
8	O
of	O
the	O
trials	O
(	O
n	O
=	O
633	O
),	O
the	O
ratio	O
of	O
partial	O
pressure	O
of	O
oxygen	B-CHED
to	O
inspired	O
fraction	O
of	O
oxygen	B-CHED
on	O
day	O
1	O
was	O
34	O
%	O
higher	O
among	O
patients	O
in	O
the	O
prone	O
position	O
than	O
among	O
those	O
who	O
remained	O
supine	O
(	O
p	O
<	O
0	O
.	O
001	O
);	O
these	O
results	O
were	O
similar	O
in	O
4	O
trials	O
on	O
day	O
2	O
and	O
in	O
5	O
trials	O
on	O
day	O
3	O
.	O

When	O
evaluating	O
epidemiologically	O
high	O
-	O
risk	O
patients	O
with	O
community	O
-	O
acquired	O
pneumonia	O
and	O
no	O
immediate	O
alternative	O
diagnosis	O
,	O
a	O
low	O
absolute	O
neutrophil	O
count	O
on	O
presentation	O
,	O
along	O
with	O
poor	O
responses	O
after	O
72	O
h	O
of	O
antibiotic	B-CHED
treatment	O
,	O
may	O
raise	O
the	O
index	O
of	O
suspicion	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

All	O
surviving	O
patient	O
responded	O
well	O
to	O
antibiotic	B-CHED
therapy	O
,	O
and	O
the	O
average	O
duration	O
to	O
defervescence	O
after	O
treatment	O
was	O
1	O
.	O
8	O
days	O
.	O

Blood	O
gas	O
and	O
hemodynamic	O
data	O
were	O
recorded	O
over	O
4	O
h	O
.	O
After	O
sacrifice	O
,	O
protein	B-CHED
analysis	O
from	O
lung	O
lavage	O
and	O
histologic	O
evaluation	O
were	O
performed	O
.	O

Ultrastructural	O
analysis	O
of	O
globoid	O
-	O
shaped	O
tangles	O
in	O
the	O
brainstem	O
revealed	O
the	O
presence	O
of	O
straight	O
and	O
paired	O
helicoidal	O
filaments	O
compatible	O
with	O
a	O
PSP	B-CHED
.	O

TITLE	O
:	O
Search	O
for	O
potential	O
target	O
site	O
of	O
nucleocapsid	O
gene	O
for	O
the	O
design	O
of	O
an	O
epitope	B-CHED
-	O
based	O
SARS	O
DNA	O
vaccine	O
.	O

Results	O
showed	O
that	O
N1	O
and	O
N3	O
fragments	O
of	O
N	O
protein	B-CHED
expressed	O
by	O
E	O
.	O
coli	O
were	O
able	O
to	O
react	O
with	O
sera	O
of	O
SARS	O
patients	O
but	O
N2	O
could	O
not	O
.	O

TITLE	O
:	O
Ethyl	B-CHED
pyruvate	B-CHED
.	O

Ethyl	B-CHED
pyruvate	B-CHED
has	O
been	O
shown	O
to	O
improve	O
cardiac	O
function	O
after	O
coronary	O
ischemia	O
and	O
reperfusion	O
.	O

We	O
classified	O
patients	O
as	O
having	O
confirmed	O
cases	O
of	O
Nipah	O
virus	O
infection	O
if	O
they	O
had	O
antibodies	O
reactive	O
with	O
Nipah	O
virus	O
antigen	B-CHED
.	O

It	O
was	O
demonstrated	O
that	O
the	O
N	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
induces	O
aggregation	O
of	O
EF1alpha	O
,	O
inhibiting	O
protein	B-CHED
translation	O
and	O
cytokinesis	O
by	O
blocking	O
F	O
-	O
actin	O
bundling	O
.	O

Proliferation	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
and	O
other	O
human	O
cell	O
lines	O
was	O
significantly	O
inhibited	O
by	O
the	O
infection	O
of	O
recombinant	O
retrovirus	O
expressing	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
.	O

In	O
this	O
study	O
,	O
protein	B-CHED
6	O
was	O
expressed	O
from	O
plasmid	O
DNAs	O
and	O
accumulated	O
in	O
cells	O
prior	O
to	O
infection	O
by	O
wild	O
-	O
type	O
MHV	O
.	O

Output	O
of	O
MHV	O
progeny	O
was	O
significantly	O
increased	O
by	O
preexisting	O
protein	B-CHED
6	O
.	O

Protein	B-CHED
6	O
with	O
C	O
-	O
terminal	O
deletion	O
mutations	O
no	O
longer	O
interfered	O
with	O
nuclear	O
import	O
processes	O
but	O
still	O
retained	O
much	O
of	O
the	O
capacity	O
to	O
augment	O
MHV	O
infections	O
.	O

Angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
the	O
cellular	O
receptor	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

The	O
RTC	O
appeared	O
to	O
be	O
protected	O
by	O
membranes	O
,	O
as	O
newly	O
synthesized	O
viral	O
RNA	O
and	O
several	O
replicase	O
/	O
transcriptase	O
subunits	O
were	O
protease	O
-	O
and	O
nuclease	O
-	O
resistant	O
and	O
became	O
susceptible	O
to	O
degradation	O
only	O
upon	O
addition	O
of	O
a	O
non	O
-	O
ionic	O
detergent	B-CHED
.	O

We	O
investigated	O
serum	O
LD	O
isoenzymes	O
and	O
blood	O
lymphocyte	O
subsets	O
of	O
SARS	O
patients	O
,	O
and	O
found	O
LD1	O
activity	O
as	O
the	O
best	O
biochemical	O
prognostic	O
indicator	B-CHED
for	O
death	O
,	O
while	O
CD3	O
+,	O
CD4	O
+,	O
CD8	O
+	O
and	O
natural	O
killer	O
cell	O
counts	O
were	O
promising	O
predictors	O
for	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admission	O
.	O

The	O
TCoV	O
genome	O
is	O
organized	O
as	O
follows	O
:	O
5	O
'	O
UTR	O
--	O
replicase	O
(	O
ORFs	O
1a	O
,	O
1b	O
)--	O
spike	O
(	O
S	O
)	O
protein	B-CHED
--	O
ORF3	O
(	O
ORFs	O
3a	O
,	O
3b	O
)--	O
small	O
envelop	O
(	O
E	O
or	O
3c	O
)	O
protein	B-CHED
--	O
membrane	O
(	O
M	O
)	O
protein	B-CHED
--	O
ORF5	O
(	O
ORFs	O
X	O
,	O
5a	O
,	O
5b	O
)--	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
--	O
3	O
'	O
UTR	O
--	O
poly	O
(	O
A	O
).	O

The	O
results	O
of	O
this	O
study	O
provided	O
scientific	O
data	O
to	O
support	O
the	O
efficient	O
and	O
safe	O
use	O
of	O
HC	O
to	O
combat	B-CHED
SARS	O
.	O

In	O
contrast	O
to	O
sepsis	O
-	O
induced	O
ALI	O
,	O
BAL	B-CHED
fluid	O
cell	O
counts	O
remained	O
constant	O
with	O
no	O
infiltration	O
of	O
neutrophils	O
.	O

ABSTRACT	O
:	O
Quetiapine	B-CHED
is	O
an	O
atypical	B-CHED
antipsychotic	I-CHED
with	O
good	O
tolerability	O
,	O
but	O
has	O
recently	O
been	O
associated	O
with	O
respiratory	O
dysfunction	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
report	O
on	O
moderate	O
to	O
severe	O
respiratory	O
dysfunction	O
after	O
normal	O
oral	O
doses	O
of	O
quetiapine	B-CHED
in	O
two	O
obese	O
patients	O
with	O
sleep	O
apnea	O
syndrome	O
(	O
SAS	O
).	O

TITLE	O
:	O
The	O
fetal	O
brain	O
in	O
bovine	O
viral	O
diarrhea	O
virus	O
-	O
infected	O
calves	O
:	O
lesions	O
,	O
distribution	O
,	O
and	O
cellular	O
heterogeneity	O
of	O
viral	O
antigen	B-CHED
at	O
190	O
days	O
gestation	O
.	O

The	O
distribution	O
of	O
viral	O
antigen	B-CHED
was	O
examined	O
by	O
immunohistochemical	O
labeling	O
using	O
the	O
15C5	O
anti	O
-	O
BVDV	O
monoclonal	O
antibody	O
.	O

TITLE	O
:	O
Structural	O
and	O
dynamic	O
characterization	O
of	O
the	O
interaction	O
of	O
the	O
putative	O
fusion	O
peptide	B-CHED
of	O
the	O
S2	O
SARS	O
-	O
CoV	O
virus	O
protein	B-CHED
with	O
lipid	B-CHED
membranes	O
.	O

From	O
fluorescence	O
and	O
infrared	O
spectroscopies	O
,	O
the	O
peptide	B-CHED
ability	O
to	O
induce	O
membrane	O
leakage	O
,	O
aggregation	O
and	O
fusion	O
,	O
as	O
well	O
as	O
its	O
affinity	O
toward	O
specific	O
phospholipids	B-CHED
,	O
was	O
assessed	O
.	O

ABSTRACT	O
:	O
With	O
more	O
and	O
more	O
complete	O
genome	O
sequences	O
having	O
been	O
released	O
,	O
phylogenetic	O
analysis	O
is	O
entering	O
a	O
new	O
era	B-CHED
--	O
that	O
of	O
phylogenomics	O
.	O

In	O
the	O
proposed	O
model	O
of	O
respiratory	O
failure	O
,	O
SARS	O
-	O
CoV	O
down	O
-	O
regulates	O
its	O
receptor	O
,	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
but	O
the	O
mechanism	O
involved	O
is	O
unknown	O
.	O

Intriguingly	O
,	O
viral	O
infection	O
,	O
judged	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
of	O
SARS	O
-	O
CoV	O
mRNA	B-CHED
expression	O
,	O
was	O
significantly	O
attenuated	O
by	O
deletion	O
of	O
the	O
cytoplasmic	O
tail	O
of	O
ACE2	O
or	O
knock	O
-	O
down	O
of	O
TACE	O
expression	O
by	O
siRNA	O
.	O

We	O
previously	O
showed	O
that	O
the	O
brain	O
was	O
a	O
major	O
target	O
organ	O
for	O
infection	O
in	O
mice	O
that	O
are	O
transgenic	O
for	O
the	O
SARS	O
-	O
CoV	O
receptor	O
(	O
human	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
).	O

We	O
designed	O
a	O
recombinant	O
HCoV	O
-	O
229E	O
and	O
a	O
recombinant	O
HCoV	O
-	O
NL63	O
nucleocapsid	O
protein	B-CHED
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
performed	O
a	O
seroepidemiology	O
survey	O
on	O
longitudinal	O
and	O
cross	O
-	O
sectional	O
serum	O
samples	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
consensus	O
statements	O
for	O
the	O
diagnosis	O
and	O
management	O
of	O
corticosteroid	B-CHED
insufficiency	O
in	O
critically	O
ill	O
adult	O
patients	O
.	O

Prior	O
studies	O
using	O
single	O
indicator	B-CHED
thermodilution	O
have	O
reported	O
that	O
21	O
%	O
to	O
35	O
%	O
of	O
patients	O
with	O
clinical	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
have	O
normal	O
EVLW	O
(<	O
10	O
mL	O
/	O
kg	O
).	O

Analysis	O
of	O
the	O
data	O
sets	O
used	O
and	O
the	O
results	O
of	O
this	O
comparison	O
show	O
that	O
conclusions	O
about	O
the	O
relative	O
performance	O
of	O
different	O
B	O
-	O
cell	O
epitope	B-CHED
prediction	O
methods	O
drawn	O
on	O
the	O
basis	O
of	O
experiments	O
using	O
data	O
sets	O
of	O
unique	O
B	O
-	O
cell	O
epitopes	O
are	O
likely	O
to	O
yield	O
overly	O
optimistic	O
estimates	O
of	O
performance	O
of	O
evaluated	O
methods	O
.	O

In	O
the	O
H5N1	O
/	O
PR8	O
-	O
5B19	O
virus	O
,	O
the	O
HA	O
cleavage	O
site	O
was	O
modified	O
to	O
resemble	O
that	O
of	O
low	O
-	O
pathogenic	O
avian	O
strains	O
and	O
a	O
portion	O
of	O
the	O
NA	O
stalk	O
region	O
was	O
replaced	O
by	O
the	O
immunodominant	O
5B19	O
epitope	B-CHED
of	O
the	O
S2	O
glycoprotein	B-CHED
of	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

HRV	O
infections	O
result	O
in	O
undue	O
antibiotic	B-CHED
prescriptions	O
,	O
sizable	O
healthcare	O
-	O
related	O
expenditure	O
and	O
exacerbation	O
of	O
expiratory	O
wheezing	O
associated	O
with	O
hospital	O
admission	O
.	O

RESULTS	O
:	O
HRV	O
infections	O
result	O
in	O
undue	O
antibiotic	B-CHED
prescriptions	O
,	O
sizable	O
healthcare	O
-	O
related	O
expenditure	O
and	O
exacerbation	O
of	O
expiratory	O
wheezing	O
associated	O
with	O
hospital	O
admission	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
feasibility	O
,	O
safety	O
,	O
and	O
efficacy	O
on	O
PaO	B-CHED
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
ratio	O
of	O
prone	O
positioning	O
(	O
PP	O
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
after	O
cardiac	O
surgery	O
.	O

After	O
supine	O
repositioning	O
(	O
SR	O
),	O
PaO	B-CHED
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
declined	O
to	O
146	O
(	O
range	O
,	O
72	O
-	O
320	O
;	O
not	O
significant	O
).	O

TITLE	O
:	O
Mouse	O
hepatitis	O
virus	O
infection	O
of	O
the	O
CNS	B-CHED
:	O
a	O
model	O
for	O
defense	O
,	O
disease	O
,	O
and	O
repair	O
.	O

ABSTRACT	O
:	O
Viral	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
results	O
in	O
varied	O
outcomes	O
ranging	O
from	O
encephalitis	O
,	O
paralytic	O
poliomyelitis	O
or	O
other	O
serious	O
consequences	O
.	O

The	O
light	O
microscopic	O
evaluation	O
showed	O
that	O
pulmonary	O
architecture	O
was	O
preserved	O
,	O
and	O
infiltration	O
of	O
neutrophil	O
and	O
edema	O
decreased	O
in	O
sepsis	O
+	O
leflunomide	B-CHED
group	O
.	O

Since	O
the	O
antibodies	O
for	O
Tsutsugamushi	O
were	O
elevated	O
we	O
arrived	O
at	O
the	O
diagnosis	O
of	O
Tsutsugamushi	O
disease	O
with	O
DIC	B-CHED
and	O
ARDS	O
.	O

The	O
administration	O
of	O
tetracycline	B-CHED
was	O
sufficient	O
to	O
significantly	O
improve	O
his	O
condition	O
.	O

A	O
DNA	O
prime	O
-	O
protein	B-CHED
boost	O
strategy	O
greatly	O
enhanced	O
the	O
antibody	O
generation	O
and	O
the	O
immune	O
sera	O
not	O
only	O
reacted	O
with	O
the	O
lysates	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
cells	O
but	O
also	O
neutralized	O
the	O
cytopathic	O
effect	O
of	O
SARS	O
by	O
75	O
%	O
at	O
1	O
:	O
160	O
dilution	O
.	O

The	O
novel	O
immunogenic	O
S	O
protein	B-CHED
peptide	B-CHED
revealed	O
in	O
this	O
study	O
provides	O
new	O
target	O
for	O
SARS	O
vaccine	O
design	O
;	O
and	O
our	O
work	O
indicated	O
multi	O
-	O
epitope	B-CHED
DNA	O
vaccine	O
as	O
an	O
effective	O
means	O
for	O
eliciting	O
polyvalent	O
humoral	O
immune	O
response	O
against	O
SARS	O
-	O
CoV	O
.	O

A	O
phylogenetic	O
tree	O
based	O
on	O
nucleotide	B-CHED
sequences	O
of	O
HVR	O
I	O
of	O
all	O
the	O
IBV	O
showed	O
that	O
they	O
were	O
classified	O
into	O
5	O
distinct	O
Clusters	B-CHED
.	O

TITLE	O
:	O
Use	O
of	O
albumin	O
quotient	O
and	O
IgG	O
index	O
to	O
differentiate	O
blood	O
-	O
vs	O
brain	O
-	O
derived	O
proteins	B-CHED
in	O
the	O
cerebrospinal	O
fluid	O
of	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
.	O

4	O
%	O
of	O
the	O
cardiac	O
output	O
,	O
permitted	O
an	O
oxygen	B-CHED
transfer	O
and	O
carbon	B-CHED
dioxide	I-CHED
removal	O
of	O
298	O
.	O
4	O
+/-	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
high	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
combined	O
with	O
exogenous	O
pulmonary	O
surfactant	B-CHED
(	O
PS	O
)	O
on	O
apoptosis	O
of	O
lung	O
tissue	O
in	O
rabbit	O
suffering	O
from	O
steam	O
inhalation	O
injury	O
.	O

Caspase	O
-	O
3	O
and	O
p73	O
mRNA	B-CHED
expression	O
in	O
lung	O
tissue	O
in	O
groups	O
with	O
exogenous	O
PS	O
group	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
the	O
corresponding	O
group	O
without	O
exogenous	O
PS	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

Whereas	O
the	O
structural	O
design	O
of	O
the	O
RDE	O
-	O
acetylesterase	O
domain	O
remained	O
unaltered	O
,	O
the	O
HE	O
receptor	O
-	O
binding	O
domain	O
underwent	O
remodeling	O
to	O
such	O
extent	O
that	O
the	O
ligand	B-CHED
is	O
now	O
bound	O
in	O
opposite	O
orientation	O
.	O

ARF1	O
,	O
the	O
cellular	O
effector	B-CHED
of	O
GBF1	O
,	O
also	O
appeared	O
to	O
be	O
involved	O
in	O
MHV	O
replication	O
,	O
as	O
siRNAs	O
targeting	O
this	O
small	O
GTPase	O
inhibited	O
MHV	O
infection	O
significantly	O
.	O

The	O
mixing	O
performance	O
of	O
the	O
active	O
micromixer	O
was	O
evaluated	O
in	O
aqueous	O
-	O
aqueous	O
systems	O
including	O
dyes	B-CHED
for	O
visual	O
observation	O
.	O

In	O
this	O
study	O
,	O
we	O
expressed	O
a	O
fusion	O
protein	B-CHED
containing	O
the	O
human	O
codon	O
-	O
optimized	O
RBD	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
linked	O
to	O
the	O
Fc	O
portion	O
of	O
human	O
IgG1	O
(	O
named	O
RBD	O
-	O
Fc	O
)	O
in	O
HEK293	O
cells	O
.	O

We	O
demonstrated	O
that	O
the	O
RBD	O
spike	O
protein	B-CHED
alone	O
could	O
be	O
internalized	O
into	O
SARS	O
-	O
CoV	O
susceptible	O
cells	O
together	O
with	O
ACE2	O
.	O

The	O
results	O
further	O
the	O
understanding	O
of	O
the	O
important	O
role	O
of	O
the	O
N	O
finger	O
for	O
catalysis	O
as	O
well	O
as	O
the	O
design	O
of	O
benzotriazole	B-CHED
inhibitors	B-CHED
with	O
improved	O
specificity	O
.	O

Albumin	O
-	O
INF	O
-	O
alpha	O
and	O
albumin	O
-	O
INF	O
-	O
beta	O
are	O
novel	O
recombinant	O
proteins	B-CHED
consisting	O
of	O
IFN	O
-	O
alpha	O
or	O
IFN	O
-	O
beta	O
genetically	O
fused	O
to	O
human	O
albumin	O
.	O

The	O
in	O
vitro	O
antiviral	B-CHED
activity	O
of	O
albumin	O
-	O
IFN	O
-	O
alpha	O
was	O
evaluated	O
against	O
representative	O
bioterrorism	O
viral	O
agents	O
and	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
virus	O
.	O

The	O
CoV	O
main	O
protease	O
(	O
M	O
(	O
pro	B-CHED
)),	O
which	O
is	O
a	O
key	O
enzyme	O
in	O
viral	O
replication	O
via	O
the	O
proteolytic	O
processing	O
of	O
the	O
replicase	O
polyproteins	O
,	O
has	O
been	O
recognized	O
as	O
an	O
attractive	O
target	O
for	O
rational	O
drug	O
design	O
.	O

The	O
number	O
of	O
days	O
on	O
the	O
ventilator	O
,	O
peak	O
inspiratory	O
pressure	O
rates	O
,	O
arterial	O
oxygen	B-CHED
tension	O
(	O
PaO2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
(	O
FiO2	O
)	O
ratio	O
and	O
incidence	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
were	O
recorded	O
for	O
those	O
patients	O
.	O

TITLE	O
:	O
Peptides	B-CHED
from	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
as	O
tags	O
for	O
protein	B-CHED
expression	O
and	O
purification	O
.	O

To	O
test	O
the	O
efficacy	O
of	O
activated	O
protein	B-CHED
C	O
(	O
APC	O
)	O
as	O
a	O
therapy	O
for	O
patients	O
with	O
ALI	O
.	O

Reports	O
using	O
historical	O
matched	O
controls	O
have	O
suggested	O
that	O
treatment	O
with	O
interferon	O
alfacon	O
-	O
1	O
(	O
a	O
synthetic	O
interferon	O
)	O
combined	O
with	O
steroid	B-CHED
,	O
protease	B-CHED
inhibitors	I-CHED
together	O
with	O
ribavirin	B-CHED
,	O
or	O
convalescent	O
plasma	O
containing	O
neutralizing	O
antibody	O
,	O
could	O
be	O
useful	O
.	O

During	O
the	O
reaction	O
pathway	O
,	O
an	O
intermediate	O
is	O
formed	O
by	O
hydrogen	B-CHED
and	O
water	B-CHED
molecule	O
migration	O
from	O
a	O
histidine	B-CHED
residue	I-CHED
and	O
solvent	B-CHED
,	O
respectively	O
.	O

The	O
patient	O
was	O
improved	O
from	O
cholinergic	O
crisis	O
by	O
administration	O
of	O
antidotes	B-CHED
.	O

Baseline	O
and	O
follow	O
-	O
up	O
censuses	O
with	O
prospective	O
monitoring	O
of	O
pregnant	O
women	O
and	O
newborns	O
from	O
September	O
2001	O
to	O
August	O
2002	O
were	O
conducted	O
in	O
83	O
randomly	O
selected	O
clusters	B-CHED
of	O
300	O
households	O
each	O
.	O

Urbani	O
grew	O
with	O
similar	O
kinetics	O
in	O
both	O
the	O
DBT	B-CHED
-	O
cACE2	O
and	O
the	O
DBT	B-CHED
-	O
hACE2	O
cells	O
,	O
while	O
icSZ16	O
-	O
S	O
only	O
grew	O
in	O
DBT	B-CHED
-	O
cACE2	O
cells	O
.	O

To	O
prevent	O
the	O
potential	O
serious	O
consequences	O
of	O
pandemic	O
influenza	O
,	O
timely	O
implementation	O
of	O
pharmaceutical	B-CHED
and	O
non	O
-	O
pharmaceutical	B-CHED
interventions	O
locally	O
within	O
the	O
outbreak	O
area	O
is	O
the	O
key	O
to	O
minimizing	O
global	O
spread	O
.	O

ABSTRACT	O
:	O
The	O
pathology	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
in	O
cats	O
and	O
ferrets	O
is	O
poorly	O
described	O
,	O
and	O
the	O
distribution	O
of	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
a	O
receptor	O
for	O
SARS	O
-	O
CoV	O
,	O
in	O
the	O
respiratory	O
tracts	O
of	O
these	O
species	O
is	O
unknown	O
.	O

All	O
infected	O
cats	O
and	O
ferrets	O
had	O
diffuse	O
alveolar	O
damage	O
associated	O
with	O
SARS	O
-	O
CoV	O
antigen	B-CHED
expression	O
.	O

So	O
,	O
this	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
effects	O
of	O
combined	O
treatment	O
with	O
cyclophosphamide	B-CHED
and	O
glucocorticoids	B-CHED
in	O
patients	O
with	O
paraquat	B-CHED
poisoning	O
.	O

CONCLUSIONS	O
:	O
Pulse	O
therapy	O
with	O
cyclophosphamide	B-CHED
and	O
methylprednisolone	B-CHED
may	O
be	O
effective	O
in	O
preventing	O
respiratory	O
failure	O
and	O
reducing	O
mortality	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
paraquat	B-CHED
poisoning	O
.	O

In	O
severe	O
sepsis	O
,	O
only	O
recombinant	O
human	O
activated	O
protein	B-CHED
C	O
administration	O
has	O
demonstrated	O
a	O
mortality	O
reduction	O
,	O
together	O
with	O
faster	O
improvement	O
in	O
respiratory	O
dysfunction	O
and	O
shorter	O
duration	O
of	O
mechanical	O
ventilation	O
.	O

Phylogenetic	O
characterization	O
of	O
HCoV	O
-	O
NL63	O
circulating	O
in	O
Italy	O
indicates	O
that	O
this	O
virus	O
circulates	O
as	O
a	O
mixture	B-CHED
of	O
variant	O
strains	O
,	O
as	O
observed	O
in	O
other	O
countries	O
.	O

TITLE	O
:	O
A	O
single	O
amino	B-CHED
acid	I-CHED
substitution	O
in	O
the	O
S1	O
and	O
S2	O
Spike	O
protein	B-CHED
domains	O
determines	O
the	O
neutralization	O
escape	O
phenotype	O
of	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
In	O
response	O
to	O
SARS	O
-	O
CoV	O
infection	O
,	O
neutralizing	O
antibodies	O
are	O
generated	O
against	O
the	O
Spike	O
(	O
S	O
)	O
protein	B-CHED
.	O

The	O
S2	O
domain	O
of	O
protein	B-CHED
S	O
has	O
been	O
suggested	O
to	O
have	O
two	O
fusion	O
peptides	B-CHED
,	O
one	O
located	O
at	O
its	O
N	O
-	O
terminus	O
,	O
downstream	O
of	O
the	O
furin	O
cleavage	O
,	O
and	O
another	O
,	O
more	O
internal	O
,	O
located	O
immediately	O
upstream	O
of	O
the	O
HR1	O
.	O

As	O
part	O
of	O
such	O
efforts	O
,	O
a	O
simple	O
,	O
easy	O
to	O
use	O
immunoswab	O
method	O
was	O
developed	O
by	O
generating	O
a	O
panel	O
of	O
monoclonal	O
antibodies	O
(	O
MAbs	O
),	O
Bispecific	O
MAbs	O
and	O
chicken	O
polyclonal	O
IgY	O
antibody	O
against	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
(	O
NP	O
).	O

Confirming	O
these	O
findings	O
,	O
Western	O
blot	O
studies	O
have	O
shown	O
lower	O
renal	O
expression	O
of	O
the	O
sodium	O
/	O
hydrogen	B-CHED
exchanger	O
isoform	O
3	O
and	O
of	O
aquaporin	O
2	O
,	O
together	O
with	O
higher	O
renal	O
expression	O
of	O
the	O
Na	O
-	O
K	O
-	O
2Cl	O
cotransporter	O
NKCC2	O
,	O
in	O
infected	O
animals	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
is	O
phosphorylated	O
primarily	O
within	O
the	O
RS	O
-	O
rich	O
region	O
in	O
cells	O
and	O
by	O
SR	O
protein	B-CHED
kinase	O
1	O
in	O
vitro	O
.	O

We	O
further	O
found	O
that	O
RS	O
motif	O
phosphorylation	O
did	O
not	O
significantly	O
affect	O
RNA	O
binding	O
of	O
the	O
nucleocapsid	O
protein	B-CHED
but	O
impaired	O
its	O
multimerization	O
ability	O
.	O

Collectively	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
Golgi	O
complex	O
retention	O
signal	O
of	O
the	O
ORF7b	O
protein	B-CHED
resides	O
solely	O
within	O
the	O
TMD	O
.	O

Virus	O
infection	O
and	O
some	O
individual	O
viral	O
proteins	B-CHED
,	O
including	O
the	O
3a	O
protein	B-CHED
,	O
induce	O
apoptosis	O
.	O

However	O
,	O
the	O
cellular	O
targets	O
leading	O
to	O
3a	O
protein	B-CHED
-	O
mediated	O
apoptosis	O
have	O
not	O
been	O
fully	O
characterized	O
.	O

ABSTRACT	O
:	O
Nondepolarizing	O
neuromuscular	O
blocking	O
agents	O
(	O
NNMBAs	O
)	O
are	O
commonly	O
used	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
),	O
mainly	O
to	O
facilitate	O
mechanical	O
ventilation	O
in	O
critically	O
ill	O
patients	O
who	O
are	O
not	O
responding	O
to	O
sedatives	B-CHED
and	O
analgesics	O
alone	O
.	O

Patients	O
with	O
APS	B-CHED
may	O
exhibit	O
a	O
broad	O
spectrum	O
of	O
pulmonary	O
diseases	O
.	O

Despite	O
advances	O
in	O
antimicrobial	B-CHED
therapy	O
and	O
supportive	O
measures	O
,	O
this	O
rate	O
has	O
not	O
changed	O
in	O
recent	O
years	O
,	O
suggesting	O
that	O
other	O
factors	O
are	O
also	O
responsible	O
for	O
the	O
poor	O
outcome	O
.	O

We	O
performed	O
a	O
pooled	O
analysis	O
of	O
all	O
five	O
multicenter	O
studies	O
in	O
which	O
patients	O
with	O
ARDS	O
due	O
to	O
various	O
predisposing	O
events	O
were	O
treated	O
with	O
rSP	O
-	O
C	O
surfactant	B-CHED
.	O

In	O
this	O
study	O
,	O
the	O
antioxidant	B-CHED
effects	O
of	O
conventional	O
N	B-CHED
-	I-CHED
acetylcysteine	I-CHED
(	O
NAC	B-CHED
)	O
and	O
liposomally	O
entrapped	O
N	B-CHED
-	I-CHED
acetylcysteine	I-CHED
(	O
L	O
-	O
NAC	B-CHED
)	O
were	O
evaluated	O
in	O
experimental	O
animals	O
challenged	O
with	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
).	O

Our	O
results	O
suggested	O
that	O
the	O
delivery	O
of	O
NAC	O
as	O
a	O
liposomal	O
formulation	O
improved	O
its	O
prophylactic	O
effectiveness	O
against	O
LPS	B-CHED
-	O
induced	O
lung	O
injuries	O
.	O

The	O
development	O
of	O
very	O
high	O
levels	O
of	O
cortisol	B-CHED
has	O
been	O
associated	O
with	O
severe	O
illness	O
and	O
a	O
raised	O
risk	O
of	O
death	O
.	O

ABSTRACT	O
:	O
Altered	O
protease	O
activity	O
is	O
considered	O
important	O
for	O
tumour	O
invasion	O
and	O
metastasis	O
,	O
processes	O
in	O
which	O
the	O
cysteine	B-CHED
proteases	O
cathepsin	O
B	O
and	O
L	O
are	O
involved	O
.	O

ABSTRACT	O
:	O
The	O
sialylation	O
pattern	O
of	O
serum	O
alpha1	O
-	O
acid	O
glycoprotein	B-CHED
(	O
AGP	O
)	O
in	O
non	O
-	O
symptomatic	O
cats	O
infected	O
by	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
and	O
its	O
possible	O
relationship	O
with	O
the	O
amount	O
of	O
FCoVs	O
shed	O
in	O
faeces	O
were	O
investigated	O
.	O

Variations	O
of	O
AGP	O
sialylation	O
were	O
recorded	O
only	O
in	O
cats	O
from	O
group	O
C	O
,	O
on	O
which	O
viral	O
shedding	O
peaked	O
before	O
the	O
occurrence	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
in	O
the	O
cattery	O
,	O
and	O
decreased	O
1	O
month	O
later	O
,	O
when	O
serum	O
AGP	O
had	O
an	O
increase	O
of	O
alpha	O
(	O
2	O
,	O
3	O
)-	O
linked	O
sialic	B-CHED
acid	I-CHED
.	O

Using	O
a	O
peptide	B-CHED
library	O
derived	O
from	O
N	O
,	O
we	O
found	O
that	O
amino	B-CHED
acids	I-CHED
101	O
-	O
115	O
constituted	O
a	O
novel	O
binding	O
site	O
for	O
M	O
.	O
We	O
examined	O
the	O
ability	O
of	O
N	O
mutants	O
to	O
interact	O
with	O
M	O
and	O
form	O
pseudoparticles	O
,	O
and	O
our	O
observations	O
indicated	O
that	O
M	O
bound	O
to	O
NDelta	O
(	O
101	O
-	O
115	O
),	O
N1	O
-	O
150	O
,	O
N151	O
-	O
300	O
,	O
and	O
N301	O
-	O
422	O
,	O
but	O
not	O
to	O
N1	O
-	O
150Delta	O
(	O
101	O
-	O
115	O
).	O

These	O
results	O
indicated	O
that	O
the	O
minimum	O
portion	O
of	O
N	O
required	O
for	O
the	O
interaction	O
with	O
M	O
and	O
pseudoparticle	O
formation	O
consists	O
of	O
amino	B-CHED
acids	I-CHED
301	O
-	O
422	O
.	O

TITLE	O
:	O
Baculovirus	O
up	O
-	O
regulates	O
antiviral	B-CHED
systems	O
and	O
induces	O
protection	O
against	O
infectious	O
bronchitis	O
virus	O
challenge	O
in	O
neonatal	O
chicken	O
.	O

Furthermore	O
,	O
it	O
was	O
identified	O
that	O
budded	O
virus	O
(	O
BV	O
)	O
can	O
induce	O
antiviral	B-CHED
effects	O
in	O
HD	O
11	O
cells	O
contrary	O
to	O
occlusion	O
-	O
derived	O
virus	O
(	O
ODV	O
).	O

Haplotype	O
H125	O
in	O
CSA	B-CHED
and	O
H97	O
in	O
CSB	O
as	O
well	O
as	O
SNPs	O
in	O
high	O
linkage	O
disequilibrium	O
with	O
these	O
two	O
haplotypes	O
were	O
significantly	O
associated	O
with	O
a	O
13	O
%	O
to	O
15	O
%	O
reduction	O
in	O
the	O
mean	O
number	O
of	O
chromatid	O
breaks	O
per	O
cell	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
cellular	O
localisation	O
and	O
function	O
of	O
the	O
SARS	O
-	O
CoV	O
accessory	O
proteins	B-CHED
was	O
determined	O
.	O

The	O
adenovirus	O
-	O
mediated	O
overexpression	O
of	O
SARS	O
-	O
CoV	O
N	O
-	O
terminal	O
domain	O
(	O
S1	O
)	O
and	O
other	O
structural	O
proteins	B-CHED
,	O
including	O
E	O
,	O
M	O
and	O
N	O
protein	B-CHED
,	O
do	O
not	O
induce	O
apoptosis	O
.	O

We	O
have	O
generated	O
monoclonal	O
antibodies	O
against	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
X1	O
/	O
3a	O
protein	B-CHED
(	O
3a	O
),	O
which	O
are	O
suitable	O
for	O
western	O
blotting	O
,	O
immunocytochemistry	O
,	O
and	O
immunohistochemistry	O
.	O

When	O
used	O
with	O
a	O
single	O
-	O
chain	O
-	O
trimer	O
system	O
,	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
epitope	B-CHED
(	O
N220	O
-	O
N228	O
LALLLLDRL	O
)	O
can	O
stimulate	O
a	O
cytotoxic	O
T	O
-	O
cell	O
response	O
against	O
N	O
-	O
protein	B-CHED
expressing	O
cells	O
in	O
the	O
HLA	O
-	O
A2	O
.	O
1K	O
(	O
b	O
)	O
transgenic	O
mouse	O
model	O
.	O

We	O
have	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
the	O
helicase	O
of	O
a	O
ribonucleic	B-CHED
acid	I-CHED
virus	O
,	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
is	O
a	O
valid	O
target	O
for	O
drug	O
development	O
.	O

Rapid	O
improvement	O
of	O
PaO2	O
/	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
from	O
172	O
mmHg	O
(	O
NIV	O
)	O
to	O
310	O
mmHg	O
with	O
HFO	O
.	O

Addition	O
of	O
exogenous	O
cholesterol	B-CHED
resulted	O
in	O
a	O
restoration	O
of	O
the	O
infectivity	O
confirming	O
our	O
conclusion	O
that	O
efficient	O
TGEV	O
infection	O
requires	O
cholesterol	B-CHED
in	O
both	O
the	O
viral	O
and	O
the	O
cellular	O
membranes	O
.	O

Interestingly	O
,	O
when	O
a	O
fluorescent	O
protein	B-CHED
tag	O
is	O
added	O
to	O
the	O
C	O
-	O
terminal	O
end	O
of	O
N	O
or	O
S	O
protein	B-CHED
,	O
but	O
not	O
M	O
protein	B-CHED
,	O
the	O
chimeric	O
viral	O
proteins	B-CHED
can	O
be	O
assembled	O
within	O
VLPs	O
and	O
allow	O
visualization	O
of	O
VLP	O
production	O
and	O
trafficking	O
in	O
living	O
cells	O
by	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
imaging	O
technologies	O
.	O

Both	O
the	O
whole	O
killed	O
SARS	O
-	O
CoV	O
vaccine	O
(	O
with	O
and	O
without	O
alum	O
)	O
and	O
adenovirus	O
-	O
based	O
vectors	O
encoding	O
the	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
)	O
protein	B-CHED
induced	O
neutralizing	O
antibody	O
responses	O
and	O
reduced	O
viral	O
replication	O
and	O
shedding	O
in	O
the	O
upper	O
respiratory	O
tract	O
and	O
progression	O
of	O
virus	O
to	O
the	O
lower	O
respiratory	O
tract	O
.	O

In	O
this	O
study	O
,	O
the	O
pathway	O
of	O
internalization	O
is	O
characterized	O
by	O
evaluating	O
the	O
effect	O
of	O
chemical	O
inhibitors	B-CHED
and	O
/	O
or	O
expression	O
of	O
dominant	O
-	O
negative	O
(	O
DN	O
)	O
proteins	B-CHED
on	O
the	O
percentage	O
of	O
internalized	O
virions	O
per	O
cell	O
and	O
infection	O
.	O

TITLE	O
:	O
Steroid	B-CHED
-	O
induced	O
osteonecrosis	O
:	O
the	O
number	O
of	O
lesions	O
is	O
related	O
to	O
the	O
dosage	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
the	O
relationship	O
between	O
the	O
dosage	O
of	O
steroids	B-CHED
and	O
the	O
number	O
and	O
distribution	O
of	O
osteonecrotic	O
lesions	O
in	O
patients	O
treated	O
with	O
steroids	B-CHED
during	O
the	O
SARS	O
epidemic	O
in	O
Beijing	O
,	O
China	O
in	O
2003	O
.	O

Healthy	O
IFA	O
-	O
seronegative	O
cats	O
were	O
seronegative	O
for	O
antibodies	O
against	O
the	O
7b	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
encodes	O
15	O
nonstructural	O
proteins	B-CHED
(	O
nsps	O
)	O
which	O
play	O
crucial	O
roles	O
in	O
RNA	O
transcription	O
and	O
genome	O
replication	O
.	O

The	O
chimeric	O
proteins	B-CHED
were	O
N	O
protein	B-CHED
and	O
ORF57	O
protein	B-CHED
which	O
had	O
their	O
own	O
NoLS	O
replaced	O
with	O
those	O
from	O
ORF57	O
and	O
Rev	O
proteins	B-CHED
,	O
respectively	O
.	O

RT	O
-	O
PCR	O
technique	O
was	O
utilized	O
to	O
amplify	O
the	O
M	O
gene	O
sequence	O
encoding	O
membrane	O
protein	B-CHED
of	O
IBV	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
structural	O
proteins	B-CHED
(	O
S	O
,	O
E	O
,	O
M	O
,	O
and	O
NC	O
)	O
localize	O
in	O
different	O
subcellular	O
positions	O
when	O
expressed	O
individually	O
.	O

The	O
cytoplasmic	O
C	O
-	O
terminus	O
domain	O
of	O
SARS	O
-	O
CoV	O
M	O
protein	B-CHED
was	O
responsible	O
for	O
binding	O
to	O
NC	O
protein	B-CHED
.	O

Inhibitor	B-CHED
10	O
with	O
a	O
5	O
-	O
chloropyridinyl	O
ester	B-CHED
at	O
position	O
4	O
of	O
the	O
indole	B-CHED
ring	O
is	O
the	O
most	O
potent	O
inhibitor	B-CHED
with	O
a	O
SARS	O
-	O
CoV	O
3CLpro	O
IC	O
(	O
50	O
)	O
value	O
of	O
30	O
nM	O
and	O
an	O
antiviral	B-CHED
EC	O
(	O
50	O
)	O
value	O
of	O
6	O
.	O
9	O
microM	O
.	O
Molecular	O
docking	O
studies	O
have	O
provided	O
possible	O
binding	O
modes	O
of	O
these	O
inhibitors	B-CHED
.	O

Additional	O
sporadic	O
NS	O
substitutions	O
in	O
clone	O
Rh11	O
-	O
7	O
reduced	O
the	O
level	O
of	O
rh	O
-	O
ACE2	O
protein	B-CHED
expression	O
and	O
did	O
not	O
support	O
viral	O
entry	O
effectively	O
.	O

TITLE	O
:	O
A	O
prime	O
-	O
boost	O
vaccination	O
protocol	O
optimizes	O
immune	O
responses	O
against	O
the	O
nucleocapsid	O
protein	B-CHED
of	O
the	O
SARS	O
coronavirus	O
.	O

Careful	O
attention	O
must	O
be	O
paid	O
to	O
haemodynamic	O
stabilisation	O
and	O
optimising	O
fluid	O
balance	B-CHED
.	O

Currently	O
,	O
specific	O
treatment	O
choices	O
for	O
malaria	O
include	O
parenteral	O
artemisinins	O
or	O
intravenous	O
quinine	B-CHED
along	O
with	O
doxycycline	B-CHED
.	O

Appropriate	O
broad	O
spectrum	O
antibiotic	B-CHED
therapy	O
must	O
be	O
started	O
when	O
there	O
is	O
a	O
clinical	O
suspicion	O
after	O
procuring	O
the	O
microbiological	O
specimens	O
.	O

Early	O
diagnosis	O
,	O
institution	O
of	O
specific	O
antimalarial	B-CHED
treatment	O
and	O
assisted	O
ventilation	O
can	O
be	O
life	O
-	O
saving	O
.	O

By	O
contrast	O
,	O
salt	B-CHED
and	O
water	B-CHED
retention	O
can	O
be	O
severe	O
and	O
complicated	O
with	O
hypertension	O
,	O
congestive	O
heart	O
failure	O
or	O
pulmonary	O
edema	O
.	O

Once	O
the	O
vicious	O
circle	O
of	O
right	O
heart	O
failure	O
is	O
reached	O
an	O
optimal	O
balance	B-CHED
has	O
to	O
be	O
found	O
between	O
preload	O
and	O
afterload	O
.	O

Depletion	O
of	O
cholesterol	B-CHED
from	O
the	O
ACE2	O
-	O
expressing	O
cells	O
reduced	O
the	O
binding	O
of	O
S	O
-	O
expressing	O
cells	O
by	O
50	O
%	O
whereas	O
the	O
binding	O
of	O
soluble	O
S	O
protein	B-CHED
was	O
not	O
affected	O
.	O

The	O
heavily	O
glycosylated	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
binds	O
to	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
which	O
serves	O
as	O
a	O
cellular	O
receptor	O
.	O

TITLE	O
:	O
Hepatitis	O
C	O
is	O
a	O
predictor	O
of	O
acute	O
liver	O
injury	O
among	O
hospitalizations	O
for	O
acetaminophen	B-CHED
overdose	O
in	O
the	O
United	O
States	O
:	O
a	O
nationwide	O
analysis	O
.	O

Efficiency	O
of	O
bovine	O
antibody	O
production	O
could	O
be	O
enhanced	O
using	O
cholera	O
toxin	O
subunit	O
b	O
,	O
and	O
milk	O
production	O
could	O
be	O
rapidly	O
accelerated	O
using	O
recombinant	O
bovine	O
somatotropin	O
hormone	B-CHED
.	O

MYLK	O
encodes	O
protein	B-CHED
isoforms	O
involved	O
in	O
multiple	O
components	O
of	O
the	O
inflammatory	O
response	O
,	O
including	O
apoptosis	O
,	O
vascular	O
permeability	O
,	O
and	O
leukocyte	O
diapedesis	O
.	O

Single	O
nucleotide	B-CHED
polymorphisms	O
were	O
individually	O
assessed	O
at	O
the	O
genotype	O
level	O
,	O
and	O
multiple	O
logistic	O
regression	O
models	O
were	O
used	O
to	O
adjust	O
for	O
baseline	O
variables	O
.	O

Ninety	O
-	O
one	O
of	O
the	O
273	O
subjects	O
(	O
33	O
%)	O
met	B-CHED
criteria	O
for	O
acute	O
lung	O
injury	O
within	O
5	O
days	O
of	O
traumatic	O
insult	O
.	O

Multivariate	O
analyses	O
demonstrated	O
the	O
association	O
of	O
each	O
MYLK	O
single	O
nucleotide	B-CHED
polymorphism	O
with	O
acute	O
lung	O
injury	O
to	O
be	O
independent	O
of	O
age	O
,	O
injury	O
severity	O
score	O
,	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
III	O
,	O
and	O
the	O
mechanism	O
of	O
trauma	O
.	O

RESULTS	O
:	O
Ninety	O
-	O
one	O
of	O
the	O
273	O
subjects	O
(	O
33	O
%)	O
met	B-CHED
criteria	O
for	O
acute	O
lung	O
injury	O
within	O
5	O
days	O
of	O
traumatic	O
insult	O
.	O

The	O
proportion	O
of	O
hospitals	O
that	O
reported	O
having	O
new	O
nosocomial	O
vancomycin	B-CHED
-	O
resistant	O
Enterococcus	O
(	O
VRE	O
)	O
cases	O
was	O
greater	O
in	O
2005	O
than	O
in	O
1999	O
(	O
chi	B-CHED
(	O
2	O
)	O
=	O
10	O
.	O
5	O
,	O
P	O
=	O
.	O
001	O
).	O

ABSTRACT	O
:	O
To	O
determine	O
whether	O
the	O
variable	O
nucleotide	B-CHED
tandem	O
repeat	O
polymorphism	O
in	O
intron	O
2	O
of	O
the	O
interleukin	O
-	O
1	O
receptor	O
antagonist	B-CHED
gene	O
is	O
associated	O
with	O
lung	O
injury	O
in	O
children	O
with	O
community	O
-	O
acquired	O
pneumonia	O
.	O

How	O
these	O
structures	O
are	O
assembled	O
is	O
still	O
largely	O
unknown	O
,	O
but	O
it	O
is	O
likely	O
that	O
the	O
membrane	O
-	O
spanning	O
members	O
of	O
these	O
nonstructural	O
proteins	B-CHED
(	O
nsps	O
)	O
are	O
responsible	O
for	O
the	O
induction	O
of	O
the	O
double	O
-	O
membrane	O
vesicles	O
and	O
for	O
anchoring	O
the	O
replication	O
complexes	O
to	O
these	O
membranes	O
.	O

Subsequently	O
,	O
we	O
verified	O
that	O
in	O
nsp4	O
,	O
all	O
four	O
hydrophobic	O
domains	O
span	O
the	O
lipid	B-CHED
bilayer	O
.	O

These	O
contents	O
include	O
myoglobin	B-CHED
,	O
creatine	B-CHED
phosphokinase	O
,	O
potassium	B-CHED
,	O
aldolase	O
,	O
lactate	B-CHED
dehydrogenase	O
and	O
glutamic	O
-	O
oxaloacetic	O
transaminase	O
.	O

The	O
peak	O
of	O
creatine	B-CHED
phosphokinase	O
(	O
186	O
.	O
080	O
U	O
/	O
L	O
;	O
normal	O
range	O
0	O
-	O
177	O
)	O
was	O
recorded	O
at	O
12	O
hours	O
of	O
admission	O
.	O

The	O
peak	O
of	O
potassium	B-CHED
level	O
before	O
dialysis	O
was	O
6	O
.	O
8	O
mmol	O
/	O
L	O
.	O
Emergency	O
fasciotomy	O
of	O
the	O
anterior	O
and	O
posterior	O
compartment	O
syndrome	O
was	O
performed	O
by	O
a	O
team	O
of	O
physicians	O
after	O
clinical	O
examination	O
.	O

The	O
patient	O
was	O
hypovolemic	O
and	O
IV	O
rehydratation	O
with	O
crystalloids	O
,	O
sodium	B-CHED
bicarbonate	I-CHED
and	O
mannitol	B-CHED
started	O
immediately	O
upon	O
admission	O
.	O

The	O
results	O
indicated	O
for	O
the	O
first	O
time	O
that	O
the	O
tetrapeptide	B-CHED
sequence	O
is	O
enough	O
for	O
inhibitory	O
activities	O
of	O
peptide	B-CHED
-	O
aldehyde	B-CHED
derivatives	O
.	O

ABSTRACT	O
:	O
OBJECTIVES	O
:	O
5	B-CHED
-	I-CHED
Fluorouracil	I-CHED
(	O
5	B-CHED
-	I-CHED
FU	I-CHED
)	O
is	O
an	O
integral	O
part	O
of	O
treatment	O
of	O
GI	O
malignancies	O
.	O

TITLE	O
:	O
Mechanistic	O
analysis	O
of	O
macrophage	O
response	O
to	O
IRAK	O
-	O
1	O
gene	O
knockdown	O
by	O
a	O
smart	O
polymer	B-CHED
-	O
antisense	O
oligonucleotide	B-CHED
therapeutic	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
report	O
the	O
impact	O
on	O
gene	O
expression	O
induced	O
by	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)	O
stimulation	O
of	O
THP	B-CHED
-	O
1	O
cells	O
treated	O
with	O
an	O
antisense	O
oligonucleotide	B-CHED
(	O
ASODN	O
)	O
against	O
the	O
IRAK	O
-	O
1	O
gene	O
using	O
cDNA	O
microarrays	O
and	O
quantitative	O
RT	O
-	O
PCR	O
.	O

The	O
therapeutic	O
ASODN	O
was	O
delivered	O
using	O
a	O
pH	O
-	O
sensitive	O
,	O
membrane	O
-	O
interactive	O
polymer	B-CHED
that	O
destabilizes	O
the	O
endosomal	O
membrane	O
to	O
enhance	O
access	O
cytoplasmic	O
delivery	O
in	O
targeted	O
cells	O
.	O

TITLE	O
:	O
Antiviral	B-CHED
therapy	O
for	O
respiratory	O
tract	O
infections	O
.	O

Dyspnea	O
increased	O
significantly	O
after	O
challenge	O
in	O
all	O
three	O
groups	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
p	O
=	O
0	O
.	O
04	O
,	O
and	O
p	O
=	O
0	O
.	O
002	O
,	O
respectively	O
),	O
and	O
blood	O
oxygen	B-CHED
saturation	O
dropped	O
post	O
-	O
challenge	O
in	O
the	O
Dead	O
Worm	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
the	O
20	O
ng	O
/	O
mL	O
Ag	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
groups	O
.	O

X	O
-	O
domain	O
(	O
also	O
called	O
macro	O
domain	O
)	O
proteins	B-CHED
possess	O
poly	O
-	O
ADP	B-CHED
-	O
ribose	B-CHED
binding	O
and	O
/	O
or	O
ADP	B-CHED
-	O
ribose	B-CHED
-	O
1	O
''-	O
phosphatase	O
(	O
ADRP	O
)	O
activity	O
.	O

A	O
certain	O
number	O
of	O
viruses	O
are	O
able	O
to	O
incorporate	O
their	O
nucleic	B-CHED
acid	I-CHED
into	O
the	O
genome	O
of	O
the	O
host	O
-	O
cell	O
,	O
leading	O
to	O
rearrangement	O
of	O
the	O
cell	O
genes	O
and	O
formation	O
of	O
malignant	O
tumors	O
.	O

Twelve	O
healthy	O
pigs	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
according	O
to	O
the	O
body	O
posture	O
during	O
mechanical	O
ventilation	O
after	O
oleic	B-CHED
acid	I-CHED
-	O
induced	O
lung	O
injury	O
:	O
supine	O
position	O
group	O
and	O
prone	O
position	O
group	O
.	O

Mass	O
spectroscopy	O
(	O
MALDI	O
,	O
SELDI	O
,	O
and	O
LC	O
/	O
MS	O
)	O
confirmed	O
that	O
the	O
bands	O
are	O
proteolytic	O
products	O
of	O
N	O
-	O
protein	B-CHED
and	O
the	O
cleavage	O
sites	O
are	O
four	O
SR	O
motifs	O
in	O
the	O
serine	B-CHED
-	O
arginine	B-CHED
-	O
rich	O
region	O
-	O
sites	O
not	O
suggestive	O
of	O
any	O
known	O
protease	O
.	O

These	O
proteins	B-CHED
are	O
quickly	O
internalized	O
upon	O
binding	O
of	O
antibodies	O
.	O

Here	O
,	O
the	O
internalization	O
and	O
subsequent	O
trafficking	O
of	O
the	O
antigen	B-CHED
-	O
antibody	O
complexes	O
were	O
characterized	O
using	O
biochemical	O
,	O
cell	O
biological	O
and	O
genetic	O
approaches	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
viral	O
antigen	B-CHED
-	O
antibody	O
complexes	O
were	O
not	O
internalized	O
through	O
any	O
of	O
the	O
previously	O
described	O
pathways	O
.	O

TITLE	O
:	O
Interaction	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
and	O
NL63	O
coronavirus	O
spike	O
proteins	B-CHED
with	O
angiotensin	B-CHED
converting	O
enzyme	O
-	O
2	O
.	O

Here	O
we	O
show	O
that	O
the	O
bacterially	O
expressed	O
human	O
PP11	O
displays	O
RNA	O
binding	O
capability	O
and	O
cleaves	O
single	O
stranded	O
RNA	O
in	O
a	O
Mn	O
(	O
2	O
+)-	O
dependent	O
manner	O
at	O
uridylates	O
,	O
to	O
produce	O
molecules	O
with	O
2	O
',	O
3	O
'-	O
cyclic	O
phosphate	B-CHED
ends	O
.	O

Epitope	B-CHED
enhancement	O
can	O
elicit	O
more	O
potent	O
T	O
cell	O
responses	O
and	O
can	O
subsequently	O
lead	O
to	O
a	O
stronger	O
memory	O
pool	O
;	O
however	O
,	O
the	O
molecular	O
basis	O
of	O
such	O
enhancement	O
is	O
unclear	O
.	O

We	O
used	O
the	O
consensus	O
peptide	B-CHED
-	O
binding	O
motif	O
for	O
the	O
Major	O
Histocompatibility	O
Complex	O
molecule	O
H	O
-	O
2K	O
(	O
b	O
)	O
to	O
design	O
a	O
heteroclitic	O
version	O
of	O
the	O
mouse	O
hepatitis	O
virus	O
-	O
specific	O
subdominant	O
S598	O
determinant	O
.	O

ABSTRACT	O
:	O
The	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
N	O
-	O
aryl	O
-	O
O	O
-(	O
2	O
-	O
phthalimidoethyl	O
)	O
thiocarbamates	O
(	O
C	O
-	O
TCs	O
)	O
and	O
their	O
imide	B-CHED
ring	O
-	O
opened	O
congeners	O
(	O
O	O
-	O
TCs	O
)	O
as	O
non	O
-	O
nucleoside	B-CHED
HIV	B-CHED
-	I-CHED
1	I-CHED
reverse	I-CHED
transcriptase	I-CHED
inhibitors	I-CHED
were	O
further	O
investigated	O
.	O

ABSTRACT	O
:	O
In	O
the	O
present	O
study	O
,	O
LNA	B-CHED
-	O
probe	O
based	O
real	O
-	O
time	O
PCR	O
was	O
designed	O
for	O
the	O
detection	O
and	O
absolute	O
quantification	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
from	O
the	O
oviduct	O
of	O
unvaccinated	O
and	O
vaccinated	O
hens	O
after	O
IBV	O
challenge	O
.	O

TITLE	O
:	O
Detection	O
of	O
antibodies	O
against	O
SARS	O
-	O
Coronavirus	O
using	O
recombinant	O
truncated	O
nucleocapsid	O
proteins	B-CHED
by	O
ELISA	O
.	O

In	O
ELISA	O
using	O
N1	O
or	O
N3	O
as	O
the	O
antigens	B-CHED
,	O
positive	O
results	O
were	O
observed	O
in	O
10	O
of	O
10	O
(	O
100	O
%)	O
SARS	O
-	O
CoV	O
-	O
positive	O
human	O
sera	O
.	O

They	O
still	O
formed	O
soluble	O
aggregates	O
even	O
when	O
the	O
GroEL	O
was	O
removed	O
by	O
urea	B-CHED
.	O

The	O
proteins	B-CHED
expressed	O
in	O
P	O
.	O
pastoris	O
were	O
relatively	O
soluble	O
.	O

Recombinant	O
N	O
protein	B-CHED
was	O
purified	O
and	O
used	O
as	O
an	O
antigen	B-CHED
to	O
develop	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
the	O
serological	O
detection	O
of	O
TCoV	O
that	O
was	O
then	O
validated	O
using	O
experimentally	O
derived	O
turkey	O
serum	O
.	O

CONCLUSIONS	O
:	O
The	O
emergency	O
preparedness	O
training	O
program	O
met	B-CHED
its	O
aims	O
and	O
objectives	O
satisfactorily	O
,	O
and	O
improved	O
the	O
emergency	O
capability	O
of	O
public	O
health	O
leaders	O
.	O

CRCoV	O
was	O
shown	O
to	O
reduce	O
the	O
mRNA	B-CHED
levels	O
of	O
the	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
6	O
and	O
the	O
chemokine	O
IL	O
-	O
8	O
during	O
the	O
72	O
h	O
post	O
-	O
inoculation	O
.	O

MDO2	O
also	O
hydrolyzed	O
ADP	B-CHED
-	O
ribose	B-CHED
-	O
1	O
''	O
phosphate	B-CHED
,	O
resembling	O
Poa1p	O
in	O
all	O
these	O
properties	O
.	O

Moreover	O
,	O
combination	O
of	O
an	O
HR	O
-	O
1	O
peptide	B-CHED
,	O
N46	O
,	O
and	O
its	O
mutated	O
version	O
,	O
N46eg	O
,	O
shows	O
synergistic	O
inhibition	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
1	O
.	O
39	O
+/-	O
0	O
.	O
05	O
microM	O
and	O
combination	O
index	O
of	O
0	O
.	O
75	O
+/-	O
0	O
.	O
15	O
,	O
suggesting	O
a	O
common	O
strategy	O
to	O
achieve	O
promising	O
inhibition	O
by	O
HR1	O
peptide	B-CHED
for	O
other	O
class	O
I	O
envelope	O
viruses	O
.	O

TITLE	O
:	O
Conserved	O
amino	B-CHED
acids	I-CHED
W423	O
and	O
N424	O
in	O
receptor	O
-	O
binding	O
domain	O
of	O
SARS	O
-	O
CoV	O
are	O
potential	O
targets	O
for	O
therapeutic	O
monoclonal	O
antibody	O
.	O

ABSTRACT	O
:	O
The	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
on	O
spike	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
the	O
main	O
region	O
interacting	O
with	O
the	O
viral	O
receptor	O
-	O
ACE2	O
and	O
is	O
a	O
useful	O
target	O
for	O
induction	O
of	O
neutralizing	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

Importantly	O
,	O
W423	O
and	O
N424	O
residues	O
are	O
essential	O
for	O
mAb	O
recognition	O
and	O
are	O
highly	O
conserved	O
among	O
107	O
different	O
strains	O
of	O
SARS	O
,	O
indicating	O
that	O
the	O
residues	O
are	O
the	O
most	O
critical	O
in	O
the	O
epitope	B-CHED
which	O
is	O
a	O
novel	O
potential	O
target	O
for	O
therapeutic	O
mAbs	O
.	O

Transduced	O
cells	O
that	O
bind	O
soluble	O
HCoV	O
-	O
HKU1	O
S	O
(	O
1	O
-	O
600	O
)	O
glycoprotein	B-CHED
with	O
C	O
-	O
terminal	O
FLAG	O
were	O
sorted	O
.	O

ABSTRACT	O
:	O
Phylogenetic	O
analyses	O
have	O
provided	O
strong	O
evidence	O
that	O
amino	B-CHED
acid	I-CHED
changes	O
in	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
animal	O
and	O
human	O
SARS	O
coronaviruses	O
(	O
SARS	O
-	O
CoVs	O
)	O
during	O
and	O
between	O
two	O
zoonotic	O
transfers	O
(	O
2002	O
/	O
03	O
and	O
2003	O
/	O
04	O
)	O
are	O
the	O
result	O
of	O
positive	O
selection	O
.	O

As	O
,	O
Mn	O
,	O
Zn	O
existed	O
in	O
the	O
Fe	O
-	O
Mn	O
oxide	B-CHED
fraction	O
,	O
Pb	O
was	O
present	O
in	O
the	O
Fe	O
-	O
Mn	O
oxide	B-CHED
and	O
residual	O
fractions	O
,	O
and	O
Cu	O
was	O
present	O
in	O
the	O
organic	O
matter	O
fraction	O
.	O

Q7R	O
could	O
be	O
considered	O
as	O
a	O
lead	O
compound	O
for	O
development	O
of	O
anti	O
-	O
PEDV	O
drugs	O
to	O
may	O
be	O
used	O
to	O
during	O
the	O
early	O
stage	O
of	O
PEDV	O
replication	O
and	O
the	O
structure	O
-	O
activity	O
data	O
of	O
Q7R	O
may	O
usefully	O
guideline	O
to	O
design	O
other	O
related	O
antiviral	B-CHED
agents	I-CHED
.	O

While	O
pulmonary	O
Mphi	O
are	O
situated	O
at	O
the	O
luminal	B-CHED
epithelial	O
surface	O
,	O
DC	O
reside	O
abundantly	O
underneath	O
the	O
epithelium	O
.	O

Taken	O
together	O
,	O
our	O
results	O
provide	O
insights	O
into	O
the	O
molecular	O
and	O
cellular	O
bases	B-CHED
of	O
the	O
host	O
antiviral	B-CHED
innate	O
immunity	O
within	O
the	O
lungs	O
that	O
eventually	O
lead	O
to	O
an	O
exacerbated	O
inflammatory	O
cascades	O
and	O
severe	O
tissue	O
damage	O
in	O
SARS	O
patients	O
.	O

Oxygen	B-CHED
transfer	O
capacity	O
averaged	O
41	O
.	O
7	O
+/-	O
20	O
.	O
8	O
mL	O
x	O
min	O
(-	O
1	O
),	O
carbon	B-CHED
dioxide	I-CHED
removal	O
was	O
148	O
.	O
0	O
+/-	O
63	O
.	O
4	O
mL	O
x	O
min	O
(-	O
1	O
).	O

The	O
utility	O
of	O
plaque	O
assays	O
with	O
agrose	O
overlay	O
was	O
demonstrated	O
for	O
purifying	O
virus	O
,	O
thereby	O
increasing	O
viral	O
infectivity	O
by	O
1	O
log	O
10	O
PFU	B-CHED
/	O
mL	O
.	O
CONCLUSIONS	O
:	O
CaCo	O
-	O
2	O
cells	O
support	O
hCoV	O
-	O
NL63	O
better	O
than	O
LLC	O
-	O
MK2	O
cells	O
and	O
enable	O
cytopathogenic	O
plaque	O
assays	O
.	O

Other	O
mechanisms	O
may	O
,	O
either	O
in	O
the	O
absence	O
of	O
or	O
in	O
combination	O
with	O
ADE	B-CHED
,	O
be	O
involved	O
.	O

No	O
divalent	O
metal	B-CHED
ion	O
was	O
required	O
for	O
in	O
vitro	O
enzymatic	O
activity	O
of	O
the	O
TCoV	O
nsp15	O
.	O

The	O
vertical	O
expandable	O
prosthetic	O
titanium	B-CHED
rib	B-CHED
(	O
VEPTR	O
)	O
reconstructs	O
the	O
chest	O
wall	O
to	O
address	O
the	O
thoracic	O
insufficiency	O
seen	O
in	O
this	O
patient	O
population	O
.	O

42	O
respectively	O
,	O
and	O
the	O
matching	O
rate	O
of	O
protein	B-CHED
points	O
was	O
ranged	O
from	O
85	O
%	O
to	O
95	O
%;	O
eighteen	O
differentially	O
expressed	O
proteins	B-CHED
were	O
discovered	O
including	O
transthyretin	O
,	O
serpin	O
peptidase	B-CHED
inhibitor	I-CHED
,	O
alpha	O
-	O
1	O
-	O
antitrypsin	O
precursor	O
,	O
serum	O
amyloid	O
P	O
components	O
,	O
etc	O
.	O

There	O
were	O
differentially	O
expressed	O
serum	O
proteins	B-CHED
in	O
three	O
groups	O
.	O

The	O
length	O
of	O
complete	O
genome	O
was	O
28590	O
nucletides	O
,	O
and	O
was	O
composed	O
of	O
7	O
ORFs	O
,	O
which	O
was	O
flanked	O
by	O
untranslated	O
regions	O
(	O
UTRs	O
)	O
with	O
315	O
bases	B-CHED
at	O
the	O
5	O
'-	O
end	O
and	O
277	O
bases	B-CHED
at	O
the	O
3	O
'-	O
end	O
.	O

TITLE	O
:	O
Development	O
of	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
-	O
based	O
test	O
with	O
a	O
cocktail	O
of	O
nucleocapsid	O
and	O
spike	O
proteins	B-CHED
for	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
-	O
specific	O
antibody	O
.	O

Medical	O
records	O
and	O
autopsy	O
reports	O
were	O
reviewed	O
to	O
describe	O
the	O
clinical	O
presentation	O
,	O
hospital	O
course	O
,	O
and	O
pathology	O
observed	O
in	O
persons	O
hospitalized	O
or	O
deceased	O
as	O
a	O
result	O
of	O
chlorine	B-CHED
gas	O
exposure	O
.	O

Many	O
surviving	O
victims	O
developed	O
significant	O
pulmonary	O
signs	O
and	O
severe	O
airway	O
inflammation	O
;	O
41	O
(	O
58	O
%)	O
hospitalized	O
persons	O
met	B-CHED
PO2	O
/	O
FiO2	O
criteria	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
or	O
acute	O
lung	O
injury	O
.	O

Hypoxia	O
on	O
room	O
air	B-CHED
and	O
PO2	O
/	O
FiO2	O
ratio	O
predicted	O
severity	O
of	O
outcome	O
as	O
assessed	O
by	O
the	O
duration	O
of	O
hospitalization	O
and	O
the	O
need	O
for	O
intensive	O
care	O
support	O
.	O

At	O
this	O
time	O
,	O
interest	O
in	O
developing	O
inhibitors	B-CHED
is	O
limited	O
to	O
viruses	O
that	O
cause	O
chronic	O
disease	O
,	O
viruses	O
that	O
have	O
the	O
potential	O
to	O
cause	O
large	O
-	O
scale	O
epidemics	O
,	O
or	O
viruses	O
that	O
are	O
sufficiently	O
ubiquitous	O
that	O
treating	O
an	O
acute	O
infection	O
would	O
be	O
beneficial	O
even	O
if	O
the	O
infection	O
was	O
ultimately	O
self	O
-	O
limiting	O
.	O

TITLE	O
:	O
Multiple	O
nucleic	B-CHED
acid	I-CHED
binding	O
sites	O
and	O
intrinsic	O
disorder	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
:	O
implications	O
for	O
ribonucleocapsid	O
protein	B-CHED
packaging	O
.	O

We	O
have	O
shown	O
previously	O
that	O
the	O
N	O
protein	B-CHED
contains	O
two	O
structural	O
domains	O
--	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
;	O
residues	O
45	O
to	O
181	O
)	O
and	O
the	O
C	O
-	O
terminal	O
dimerization	O
domain	O
(	O
CTD	O
;	O
residues	O
248	O
to	O
365	O
)--	O
flanked	O
by	O
long	O
stretches	O
of	O
disordered	O
regions	O
accounting	O
for	O
almost	O
half	O
of	O
the	O
entire	O
sequence	O
.	O

In	O
a	O
further	O
search	O
for	O
clues	O
to	O
the	O
function	O
,	O
we	O
found	O
that	O
SUD	O
-	O
M	O
(	O
527	O
-	O
651	O
)	O
has	O
the	O
closest	O
three	O
-	O
dimensional	O
structure	O
homology	O
with	O
another	O
domain	O
of	O
nsp3	O
,	O
the	O
ADP	B-CHED
-	O
ribose	B-CHED
-	O
1	O
"""-"	O
phosphatase	O
nsp3b	O
,	O
although	O
the	O
two	O
proteins	B-CHED
share	O
only	O
5	O
%	O
sequence	O
identity	O
in	O
the	O
homologous	O
sequence	O
regions	O
.	O

These	O
studies	O
are	O
revealing	O
a	O
rich	O
set	O
of	O
novel	O
viral	O
proteins	B-CHED
that	O
engage	O
,	O
modify	O
,	O
and	O
/	O
or	O
disrupt	O
host	O
cell	O
signaling	O
and	O
nuclear	O
import	O
machinery	O
for	O
the	O
benefit	O
of	O
virus	O
replication	O
.	O

ABSTRACT	O
:	O
A	O
remarkably	O
conserved	O
43	O
-	O
nucleotide	B-CHED
-	O
long	O
motif	O
present	O
at	O
the	O
3	O
'-	O
end	O
of	O
the	O
genomes	O
of	O
several	O
members	O
of	O
the	O
polyadenylated	O
RNA	O
virus	O
families	O
Astroviridae	O
,	O
Coronaviridae	O
,	O
and	O
Picornaviridae	O
can	O
be	O
used	O
for	O
the	O
detection	O
and	O
sequence	O
characterization	O
of	O
the	O
viruses	O
harboring	O
it	O
.	O

Thus	O
,	O
VSV	O
pseudotyped	O
with	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
is	O
useful	O
for	O
developing	O
a	O
rapid	O
detection	O
system	O
for	O
neutralizing	O
antibody	O
specific	O
for	O
SARS	O
-	O
CoV	O
infection	O
as	O
well	O
as	O
studying	O
the	O
S	O
-	O
mediated	O
cell	O
entry	O
of	O
SARS	O
-	O
CoV	O
.	O

We	O
have	O
shown	O
that	O
the	O
sialic	B-CHED
acid	I-CHED
binding	O
activity	O
mediates	O
the	O
binding	O
of	O
TGEV	O
to	O
a	O
mucin	O
-	O
like	O
glycoprotein	B-CHED
present	O
in	O
porcine	O
brush	O
border	O
membranes	O
.	O

In	O
addition	O
,	O
several	O
S	O
protein	B-CHED
-	O
specific	O
antibodies	O
are	O
shown	O
to	O
have	O
in	O
vitro	O
neutralization	O
activity	O
.	O

ABSTRACT	O
:	O
In	O
general	O
,	O
a	O
whole	O
virion	O
serves	O
as	O
a	O
simple	O
vaccine	O
antigen	B-CHED
and	O
often	O
essential	O
material	O
for	O
the	O
analysis	O
of	O
immune	O
responses	O
against	O
virus	O
infection	O
.	O

This	O
study	O
investigated	O
the	O
effects	O
of	O
glutamine	B-CHED
(	O
Gln	B-CHED
)	O
on	O
neutrophil	O
recruitment	O
in	O
a	O
model	O
of	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)-	O
induced	O
ALI	O
.	O

Mice	O
were	O
killed	O
at	O
0	O
,	O
6	O
,	O
12	O
,	O
and	O
24	O
h	O
after	O
LPS	B-CHED
administration	O
(	O
n	O
=	O
10	O
/	O
group	O
).	O

CXC	O
chemokines	O
as	O
well	O
as	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
were	O
significantly	O
elevated	O
and	O
reached	O
peaks	O
at	O
6	O
h	O
in	O
the	O
Gln	B-CHED
group	O
,	O
which	O
was	O
earlier	O
than	O
in	O
the	O
control	O
group	O
.	O

These	O
results	O
were	O
consistent	O
with	O
the	O
histopathological	O
findings	O
that	O
Gln	B-CHED
supplementation	O
causes	O
more	O
severe	O
interstitial	O
inflammation	O
and	O
fibrosis	O
in	O
a	O
model	O
of	O
ALI	O
induced	O
by	O
LPS	B-CHED
.	O

Delivery	O
of	O
nebulized	O
bronchodilators	O
,	O
heparin	B-CHED
and	O
n	O
-	O
acetyl	B-CHED
cysteine	B-CHED
,	O
normally	O
mainstays	O
of	O
smoke	O
inhalation	O
therapy	O
,	O
was	O
impossible	O
during	O
HFOV	O
.	O

ABSTRACT	O
:	O
Protein	B-CHED
-	O
protein	B-CHED
interactions	O
play	O
a	O
central	O
role	O
in	O
biological	O
processes	O
and	O
thus	O
are	O
an	O
appealing	O
target	O
for	O
innovative	O
drug	O
design	O
a	O
nd	O
development	O
.	O

ABSTRACT	O
:	O
In	O
this	O
paper	O
,	O
we	O
propose	O
two	O
metrics	O
to	O
compare	O
DNA	O
and	O
protein	B-CHED
sequences	O
based	O
on	O
a	O
Poisson	O
model	O
of	O
word	O
occurrences	O
.	O

TITLE	O
:	O
The	O
novel	O
CD4	O
+	O
CD25	O
+	O
regulatory	O
T	O
cell	O
effector	B-CHED
molecule	O
fibrinogen	O
-	O
like	O
protein	B-CHED
2	O
contributes	O
to	O
the	O
outcome	O
of	O
murine	O
fulminant	O
viral	O
hepatitis	O
.	O

The	O
breakdown	O
of	O
viruses	O
was	O
as	O
follows	O
:	O
14	O
.	O
5	O
%	O
were	O
RV	O
,	O
9	O
.	O
4	O
%	O
were	O
RSV	O
,	O
7	O
.	O
4	O
%	O
were	O
hMPV	O
,	O
7	O
.	O
2	O
%	O
were	O
PIV	O
,	O
and	O
2	O
.	O
9	O
%	O
were	O
HBoV	O
.	O
The	O
new	O
method	O
will	O
contribute	O
to	O
advances	O
in	O
the	O
accuracy	O
of	O
diagnosis	O
and	O
should	O
also	O
result	O
in	O
the	O
appropriate	O
use	O
of	O
antimicrobials	B-CHED
.	O

In	O
order	O
to	O
validate	O
this	O
approach	O
,	O
we	O
infused	O
two	O
AAV	O
(	O
AAV1	O
-	O
GFP	O
and	O
AAV2	O
-	O
hAADC	O
)	O
into	O
three	O
different	O
regions	O
of	O
non	O
-	O
human	O
primate	O
brain	O
(	O
corona	B-CHED
radiata	O
,	O
putamen	O
,	O
and	O
thalamus	O
).	O

ABSTRACT	O
:	O
We	O
present	O
three	O
cases	O
of	O
rare	O
side	O
effects	O
which	O
appeared	O
to	O
be	O
attributable	O
to	O
antibacterial	B-CHED
drug	I-CHED
treatment	O
.	O

A	O
82	O
-	O
year	O
-	O
old	O
female	O
patient	O
used	O
moxifloxacin	B-CHED
(	O
400	O
mg	O
/	O
d	O
)	O
for	O
febrile	O
bronchopulmonary	O
infection	O
for	O
one	O
week	O
.	O

Using	O
high	O
resolution	O
PAGE	O
analysis	O
,	O
this	O
protein	B-CHED
could	O
be	O
separated	O
into	O
phosphorylated	O
and	O
unphosphorylated	O
isoforms	O
.	O

GSK	O
-	O
3	O
-	O
specific	O
inhibitor	B-CHED
treatment	O
dephosphorylated	O
the	O
N	O
protein	B-CHED
,	O
and	O
this	O
could	O
be	O
recovered	O
by	O
the	O
constitutively	O
active	O
GSK	O
-	O
3	O
kinase	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
triggers	O
apoptosis	O
via	O
protein	B-CHED
kinase	O
R	O
but	O
is	O
resistant	O
to	O
its	O
antiviral	B-CHED
activity	O
.	O

However	O
,	O
virus	O
replication	O
was	O
not	O
impaired	O
by	O
these	O
events	O
,	O
suggesting	O
that	O
SARS	O
-	O
CoV	O
possesses	O
a	O
mechanism	O
to	O
overcome	O
the	O
inhibitory	O
effects	O
of	O
phosphorylated	O
eIF2alpha	O
on	O
viral	O
mRNA	B-CHED
translation	O
.	O

Moreover	O
,	O
knockdown	O
of	O
PU	O
.	O
1	O
through	O
the	O
use	O
of	O
small	O
interfering	O
RNA	O
led	O
to	O
a	O
decrease	O
in	O
LSECtin	O
mRNA	B-CHED
levels	O
in	O
THP	B-CHED
-	O
1	O
and	O
monocyte	O
-	O
derived	O
dendritic	O
cells	O
,	O
thus	O
confirming	O
the	O
involvement	O
of	O
PU	O
.	O
1	O
in	O
the	O
myeloid	O
expression	O
of	O
the	O
lectin	O
.	O

We	O
hypothesized	O
that	O
two	O
of	O
the	O
hydrophilic	O
structural	O
coronoviral	O
proteins	B-CHED
(	O
S	O
and	O
E	O
)	O
would	O
regulate	O
alveolar	O
fluid	O
clearance	O
by	O
decreasing	O
the	O
cell	O
surface	O
expression	O
and	O
activity	O
of	O
amiloride	B-CHED
-	O
sensitive	O
epithelial	O
sodium	O
(	O
Na	O
(+))	O
channels	O
(	O
ENaC	O
),	O
the	O
rate	O
-	O
limiting	O
protein	B-CHED
in	O
transepithelial	O
Na	O
(+)	O
vectorial	O
transport	O
across	O
distal	O
lung	O
epithelial	O
cells	O
.	O

Consistent	O
with	O
the	O
whole	O
cell	O
data	O
,	O
expression	O
of	O
S	O
and	O
E	O
proteins	B-CHED
decreased	O
ENaC	O
single	O
-	O
channel	O
activity	O
in	O
oocytes	O
,	O
and	O
these	O
effects	O
were	O
partially	O
abrogated	O
by	O
PKCalpha	O
/	O
beta1	O
inhibitors	B-CHED
.	O

Finally	O
,	O
transfection	O
of	O
human	O
airway	O
epithelial	O
(	O
H441	O
)	O
cells	O
with	O
SARS	O
E	O
protein	B-CHED
decreased	O
whole	O
cell	O
amiloride	B-CHED
-	O
sensitive	O
currents	O
.	O

Antibody	O
dependent	O
enhancement	O
(	O
ADE	B-CHED
)	O
of	O
macrophage	O
infection	O
occurs	O
in	O
the	O
presence	O
of	O
antibodies	O
to	O
FIPV	O
S	O
protein	B-CHED
,	O
and	O
a	O
close	O
relationship	O
between	O
ADE	B-CHED
and	O
neutralizing	O
epitopes	O
has	O
been	O
reported	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
the	O
same	O
or	O
different	O
serotype	O
of	O
FIPV	O
induces	O
ADE	B-CHED
in	O
cats	O
.	O

These	O
results	O
support	O
the	O
notion	O
that	O
clinical	O
disease	O
in	O
coronavirus	O
-	O
induced	O
acute	O
encephalitis	O
results	O
from	O
a	O
balance	B-CHED
between	O
factors	O
critical	O
for	O
virus	O
clearance	O
,	O
such	O
as	O
virus	O
-	O
specific	O
effector	B-CHED
T	O
cells	O
and	O
anti	O
-	O
inflammatory	O
elements	O
,	O
such	O
as	O
Tregs	O
.	O

ABSTRACT	O
:	O
The	O
effects	O
of	O
the	O
combination	O
of	O
a	O
'	O
lowest	O
'	O
lung	O
ventilation	O
with	O
extracorporeal	O
elimination	O
of	O
carbon	B-CHED
dioxide	I-CHED
by	O
interventional	O
lung	O
assist	O
are	O
described	O
in	O
a	O
patient	O
presenting	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
fulminant	O
pneumonia	O
.	O

In	O
picornavirus	O
,	O
a	O
chymotrypsin	O
-	O
like	O
protease	O
(	O
3C	O
(	O
pro	B-CHED
))	O
is	O
required	O
for	O
viral	O
replication	O
by	O
processing	O
the	O
polyproteins	O
,	O
and	O
thus	O
it	O
is	O
regarded	O
as	O
an	O
antiviral	B-CHED
drug	I-CHED
target	O
.	O

A	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	B-CHED
))	O
also	O
exists	O
in	O
human	O
coronaviruses	O
(	O
CoV	O
)	O
such	O
as	O
229E	O
and	O
the	O
one	O
causing	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

As	O
shown	O
in	O
the	O
present	O
study	O
,	O
some	O
of	O
these	O
compounds	O
were	O
also	O
found	O
to	O
be	O
active	O
against	O
3C	O
(	O
pro	B-CHED
)	O
of	O
CV	O
strain	O
B3	O
(	O
CVB3	O
).	O

Biophysical	O
analyses	O
with	O
circular	O
dichroism	O
,	O
transmission	O
electron	O
microscopy	O
and	O
dynamic	O
light	O
scattering	O
confirmed	O
the	O
computational	O
design	O
showing	O
alpha	O
-	O
helcial	O
nanoparticles	B-CHED
with	O
sizes	O
of	O
about	O
25	O
nm	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
devotes	O
a	O
significant	O
portion	O
of	O
its	O
genome	O
to	O
producing	O
nonstructural	O
proteins	B-CHED
required	O
for	O
viral	O
replication	O
.	O

TITLE	O
:	O
The	O
identification	O
of	O
a	O
calmodulin	O
-	O
binding	O
domain	O
within	O
the	O
cytoplasmic	O
tail	O
of	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
-	O
2	O
.	O

ABSTRACT	O
:	O
Angiotensin	B-CHED
-	O
converting	O
enzyme	O
(	O
ACE	O
)-	O
2	O
is	O
a	O
homolog	O
of	O
the	O
well	O
-	O
characterized	O
plasma	O
membrane	O
-	O
bound	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
.	O

TITLE	O
:	O
Attenuation	O
of	O
pulmonary	O
inflammation	O
after	O
exposure	O
to	O
blast	O
overpressure	O
by	O
N	B-CHED
-	I-CHED
acetylcysteine	I-CHED
amide	B-CHED
.	O

The	O
relatively	O
higher	O
inhibition	O
of	O
chemokine	O
mRNAs	O
compared	O
with	O
reduction	O
in	O
MPO	O
activity	O
and	O
CD11b	O
is	O
in	O
accordance	O
with	O
an	O
antioxidant	B-CHED
effect	O
of	O
NACA	O
on	O
reactive	B-CHED
oxygen	I-CHED
species	I-CHED
(	O
ROS	B-CHED
)	O
accumulation	O
,	O
rather	O
than	O
by	O
an	O
effect	O
on	O
neutrophil	O
sequestration	O
.	O

This	O
novel	O
phenotype	O
suggests	O
a	O
strategy	O
to	O
investigate	O
the	O
function	O
of	O
the	O
MHV	O
-	O
A59	O
ns2	O
protein	B-CHED
involving	O
the	O
search	O
for	O
organ	O
-	O
specific	O
proteins	B-CHED
or	O
RNAs	O
that	O
react	O
differentially	O
to	O
wild	O
-	O
type	O
and	O
mutant	O
ns2	O
proteins	B-CHED
.	O

In	O
this	O
study	O
,	O
healthy	O
pregnant	O
heifers	O
were	O
vaccinated	O
at	O
approximately	O
3	O
months	O
of	O
gestation	O
with	O
either	O
a	O
polyvalent	O
oil	O
-	O
adjuvanted	O
vaccine	O
containing	O
inactivated	O
coronavirus	O
,	O
rotavirus	O
,	O
E	O
.	O
coli	O
K99	O
subunit	O
antigen	B-CHED
,	O
and	O
Clostridium	O
perfringens	O
b	O
and	O
e	O
toxoid	O
or	O
normal	O
saline	O
as	O
a	O
placebo	O
.	O

The	O
incidence	O
of	O
complications	O
and	O
the	O
effects	O
on	O
tidal	O
volumes	O
and	O
inspiratory	O
plateau	O
pressures	O
were	O
primary	O
outcome	O
parameters	O
,	O
while	O
oxygenation	O
improvement	O
and	O
carbon	B-CHED
dioxide	I-CHED
removal	O
capabilities	O
were	O
secondary	O
study	O
parameters	O
.	O

Initiation	O
of	O
iLA	O
resulted	O
in	O
a	O
marked	O
removal	O
in	O
arterial	O
carbon	B-CHED
dioxide	I-CHED
allowing	O
a	O
rapid	O
reduction	O
in	O
tidal	O
volume	O
(<	O
or	O
=	O
6	O
ml	O
/	O
kg	O
)	O
and	O
inspiratory	O
plateau	O
pressure	O
.	O

RESULTS	O
:	O
Initiation	O
of	O
iLA	O
resulted	O
in	O
a	O
marked	O
removal	O
in	O
arterial	O
carbon	B-CHED
dioxide	I-CHED
allowing	O
a	O
rapid	O
reduction	O
in	O
tidal	O
volume	O
(<	O
or	O
=	O
6	O
ml	O
/	O
kg	O
)	O
and	O
inspiratory	O
plateau	O
pressure	O
.	O

The	O
turkey	O
/	O
UK	O
/	O
412	O
/	O
00	O
also	O
resembled	O
IBV	O
,	O
but	O
not	O
mammalian	O
coronaviruses	O
,	O
in	O
having	O
three	O
open	O
reading	O
frames	O
in	O
the	O
gene	O
encoding	O
E	O
protein	B-CHED
(	O
gene	O
3	O
).	O

The	O
increase	O
in	O
IL	O
-	O
8	O
stimulated	O
by	O
a	O
concentration	O
of	O
5	O
.	O
6nM	O
of	O
S	O
was	O
comparable	O
to	O
concentrations	O
seen	O
for	O
S	O
protein	B-CHED
binding	O
to	O
ACE2	O
or	O
to	O
neutralizing	O
monoclonal	O
antibody	O
suggesting	O
a	O
physiological	O
relevance	O
.	O

TITLE	O
:	O
Respiratory	O
disease	O
in	O
calves	O
:	O
microbiological	O
investigations	O
on	O
trans	O
-	O
tracheally	O
aspirated	O
bronchoalveolar	O
fluid	O
and	O
acute	O
phase	O
protein	B-CHED
response	O
.	O

The	O
detection	O
rates	O
were	O
as	O
follows	O
:	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
was	O
the	O
most	O
commonly	O
detected	O
in	O
52	O
.	O
7	O
%	O
(	O
87	O
/	O
165	O
),	O
human	O
metapneumovirus	O
(	O
hMPV	O
)	O
in	O
15	O
.	O
8	O
%,	O
human	O
corona	B-CHED
virus	O
(	O
hCoV	O
)	O
in	O
5	O
.	O
5	O
%,	O
adenovirus	O
in	O
9	O
.	O
7	O
%,	O
human	O
bocavirus	O
(	O
hBoV	O
)	O
in	O
5	O
.	O
5	O
%,	O
parainfluenza	O
virus	O
(	O
PIV	O
)	O
in	O
3	O
.	O
6	O
%,	O
rhinovirus	O
(	O
RV	O
)	O
in	O
4	O
.	O
2	O
%,	O
and	O
the	O
influenza	O
virus	O
in	O
3	O
%	O
of	O
the	O
patients	O
with	O
ALRIs	O
.	O

Moreover	O
,	O
these	O
results	O
underline	O
that	O
embryonic	O
tissues	O
in	O
addition	O
to	O
CAM	O
could	O
be	O
also	O
used	O
as	O
possible	O
source	O
to	O
generate	O
IBV	O
antigens	B-CHED
for	O
diagnostic	O
purposes	O
.	O

The	O
three	O
major	O
diagnostic	O
methods	O
available	O
for	O
SARS	O
includes	O
viral	O
RNA	O
detection	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
virus	O
induced	O
antibodies	O
by	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
or	O
by	O
enzyme	O
linked	O
immunosorbant	O
assay	O
(	O
ELISA	O
)	O
of	O
nucleocapsid	O
protein	B-CHED
(	O
NP	O
).	O

The	O
spike	O
glycoprotein	B-CHED
of	O
SARS	O
-	O
CoV	O
is	O
the	O
major	O
inducer	O
of	O
neutralizing	O
antibodies	O
.	O

S1	O
and	O
RBD	O
proteins	B-CHED
initialized	O
significantly	O
lower	O
levels	O
of	O
nAb	O
production	O
.	O

Our	O
results	O
demonstrate	O
that	O
SQ	O
protein	B-CHED
may	O
be	O
an	O
effective	O
vaccine	O
candidate	O
and	O
a	O
convenient	O
and	O
safe	O
diagnostic	O
antigen	B-CHED
for	O
SARS	O
-	O
CoV	O
.	O

Here	O
we	O
investigated	O
immunocompromised	O
adults	O
with	O
suspected	O
Pneumocystis	O
jirovecii	O
pneumonia	O
(	O
PCP	B-CHED
)	O
for	O
new	O
respiratory	O
viruses	O
.	O

Preliminary	O
data	O
suggest	O
that	O
patients	O
with	O
vasodilatory	O
shock	O
after	O
cardiac	O
surgery	O
and	O
patients	O
with	O
liver	O
cirrhosis	O
and	O
sepsis	O
can	O
benefit	O
from	O
corticosteroids	B-CHED
.	O

Critical	O
illness	O
-	O
related	O
corticosteroid	B-CHED
insufficiency	O
can	O
also	O
occur	O
in	O
patients	O
with	O
trauma	O
,	O
traumatic	O
brain	O
injury	O
,	O
acute	O
pancreatitis	O
and	O
burn	O
injuries	O
,	O
but	O
data	O
from	O
clinical	O
trials	O
on	O
these	O
target	O
groups	O
are	O
insufficient	O
at	O
present	O
.	O

When	O
we	O
fixed	O
fever	O
prevalence	O
at	O
1	O
%	O
in	O
all	O
studies	O
to	O
allow	O
comparisons	O
,	O
the	O
derived	O
PPV	B-CHED
varied	O
from	O
3	O
.	O
5	O
%	O
to	O
65	O
.	O
4	O
%	O
and	O
NPV	O
was	O
>	O
or	O
=	O
99	O
%.	O

ABSTRACT	O
:	O
Recently	O
,	O
several	O
potently	O
neutralizing	O
fully	O
human	O
monoclonal	O
antibodies	O
(	O
hmAbs	O
)	O
targeting	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
CoV	O
)	O
S	O
glycoprotein	B-CHED
,	O
and	O
the	O
G	O
glycoprotein	B-CHED
of	O
the	O
paramyxoviruses	O
Hendra	O
virus	O
(	O
HeV	O
)	O
and	O
Nipah	O
virus	O
(	O
NiV	O
)	O
have	O
been	O
discovered	O
[	O
corrected	O
].	O

Comparison	O
of	O
the	O
genome	O
sequences	O
of	O
the	O
virulent	O
and	O
attenuated	O
Ark	O
DPI	O
viruses	O
reveals	O
that	O
these	O
viruses	O
are	O
similar	O
and	O
differ	O
only	O
by	O
21	O
nucleotides	B-CHED
,	O
resulting	O
in	O
17	O
amino	B-CHED
acids	I-CHED
changes	O
.	O

By	O
comparing	O
the	O
deduced	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
virulent	O
and	O
attenuated	O
viruses	O
,	O
we	O
identified	O
sequence	O
changes	O
responsible	O
for	O
the	O
adaptation	O
and	O
attenuation	O
of	O
the	O
IBV	O
-	O
Ark	O
DPI	O
strain	O
.	O

TITLE	O
:	O
Successful	O
use	O
of	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
to	O
decrease	O
intracranial	O
pressure	O
in	O
a	O
patient	O
with	O
severe	O
traumatic	O
brain	O
injury	O
complicated	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
role	O
for	O
an	O
anti	O
-	O
inflammatory	O
mechanism	O
?	O

ABSTRACT	O
:	O
Use	O
of	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
in	O
humans	O
with	O
traumatic	O
brain	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
has	O
twice	O
previously	O
been	O
reported	O
to	O
be	O
beneficial	O
.	O

Positively	O
interacting	O
proteins	B-CHED
were	O
further	O
tested	O
using	O
a	O
mammalian	O
cell	O
hybrid	O
system	O
and	O
co	O
-	O
immunoprecipitation	O
in	O
the	O
human	O
A549	O
cell	O
line	O
,	O
which	O
has	O
been	O
shown	O
to	O
support	O
SARS	O
coronavirus	O
replication	O
.	O

Since	O
Ddx5	O
is	O
a	O
multifunctional	O
protein	B-CHED
that	O
plays	O
important	O
roles	O
in	O
transcriptional	O
regulation	O
,	O
its	O
interaction	O
with	O
SARS	O
coronavirus	O
helicase	O
provides	O
interesting	O
clues	O
for	O
studying	O
virus	O
-	O
host	O
cell	O
interactions	O
in	O
SARS	O
-	O
CoV	O
infections	O
.	O

This	O
aggressive	O
-	O
albeit	O
controversial	O
-	O
concept	O
allows	O
for	O
an	O
adequate	O
infection	O
control	O
by	O
adjunctive	O
antibiotics	B-CHED
and	O
reduces	O
the	O
imminent	O
risk	O
of	O
a	O
secondary	O
loss	O
of	O
fixation	O
due	O
to	O
compromises	O
in	O
initial	O
fixation	O
techniques	O
.	O

TITLE	O
:	O
Survival	O
of	O
surrogate	O
coronaviruses	O
in	O
water	B-CHED
.	O

To	O
assess	O
potential	O
risks	O
from	O
this	O
pathway	O
,	O
there	O
is	O
a	O
need	O
for	O
surrogates	O
for	O
SARS	O
coronavirus	O
to	O
provide	O
representative	O
data	O
on	O
viral	O
survival	O
in	O
contaminated	O
water	B-CHED
.	O

All	O
participants	O
completed	O
the	O
Chinese	O
Health	O
Questionnaire	O
(	O
CHQ	B-CHED
),	O
Eysenck	O
Personality	O
Questionnaire	O
,	O
and	O
Parental	O
Bonding	O
Instrument	O
at	O
the	O
first	O
stage	O
and	O
the	O
CHQ	B-CHED
again	O
a	O
year	O
later	O
.	O

In	O
this	O
experiment	O
,	O
we	O
studied	O
the	O
effect	O
of	O
dexamethasone	B-CHED
on	O
nitric	B-CHED
oxide	I-CHED
synthases	O
and	O
whether	O
dexamethasone	B-CHED
could	O
attenuate	O
endotoxin	O
-	O
induced	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

The	O
modulation	O
of	O
UPR	O
by	O
S	O
protein	B-CHED
involves	O
activation	O
of	O
PERK	B-CHED
protein	B-CHED
kinase	O
.	O

Viral	O
infectivity	O
is	O
associated	O
with	O
the	O
cleavage	O
of	O
S	O
protein	B-CHED
by	O
the	O
cellular	O
protease	O
factor	O
Xa	O
.	O

Two	O
new	O
aspects	O
of	O
the	O
interaction	O
between	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
and	O
the	O
cell	O
have	O
been	O
defined	O
.	O

We	O
analyzed	O
the	O
modified	O
APACHE	O
-	O
II	O
score	O
,	O
the	O
sepsis	O
-	O
related	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
score	O
,	O
mean	O
blood	O
pressure	O
(	O
mBP	O
),	O
catecholamine	B-CHED
index	O
(	O
CAI	O
),	O
P	O
/	O
F	O
ratio	O
,	O
and	O
28	O
days	O
mortality	O
before	O
and	O
after	O
PMX	O
-	O
DHP	O
treatment	O
.	O

TITLE	O
:	O
Differential	O
stepwise	O
evolution	O
of	O
SARS	O
coronavirus	O
functional	O
proteins	B-CHED
in	O
different	O
host	O
species	O
.	O

Similar	O
to	O
previous	O
studies	O
,	O
the	O
spike	O
protein	B-CHED
underwent	O
strong	O
positive	O
selection	O
in	O
the	O
early	O
and	O
middle	O
phases	O
,	O
and	O
became	O
stabilized	O
in	O
the	O
late	O
phase	O
.	O

No	O
positive	O
selection	O
was	O
found	O
in	O
any	O
proteins	B-CHED
of	O
bat	O
SARS	O
-	O
like	O
-	O
CoV	O
.	O
Furthermore	O
,	O
specific	O
amino	B-CHED
acid	I-CHED
sites	O
that	O
may	O
be	O
the	O
targets	O
of	O
positive	O
selection	O
in	O
each	O
group	O
are	O
identified	O
.	O

No	O
positive	O
selection	O
was	O
found	O
in	O
any	O
proteins	B-CHED
of	O
bat	O
SARS	O
-	O
like	O
-	O
CoV	O
.	O
Furthermore	O
,	O
specific	O
amino	B-CHED
acid	I-CHED
sites	O
that	O
may	O
be	O
the	O
targets	O
of	O
positive	O
selection	O
in	O
each	O
group	O
are	O
identified	O
.	O

CONCLUSIONS	O
:	O
This	O
extensive	O
evolutionary	O
analysis	O
revealed	O
the	O
stepwise	O
evolution	O
of	O
different	O
functional	O
proteins	B-CHED
of	O
SARS	O
-	O
CoVs	O
at	O
different	O
epidemic	O
stages	O
and	O
different	O
hosts	O
.	O

In	O
the	O
case	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
,	O
truncation	O
of	O
the	O
cytoplasmic	O
tail	O
resulted	O
in	O
increased	O
infectivity	O
.	O

Our	O
results	O
indicate	O
that	O
related	O
glycoproteins	B-CHED
may	O
show	O
substantial	O
differences	O
in	O
their	O
ability	O
to	O
mediate	O
pseudotype	O
infection	O
.	O

ABSTRACT	O
:	O
nsp1	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
a	O
group	O
2b	O
CoV	O
,	O
suppresses	O
host	O
gene	O
expression	O
by	O
promoting	O
host	O
mRNA	B-CHED
degradation	O
and	O
translation	O
inhibition	O
.	O

The	O
patients	O
showed	O
a	O
statistically	O
significant	O
improvement	O
in	O
Pao	B-CHED
(	O
2	O
)/	O
Fio	O
(	O
2	O
)	O
(	O
92	O
+/-	O
12	O
vs	O
227	O
+/-	O

3	O
vs	O
37	O
+/-	O
6	O
,	O
P	O
<	O
.	O
0001	O
)	O
with	O
extended	O
PPV	B-CHED
.	O

Today	O
,	O
the	O
multidisciplinary	O
treatment	O
of	O
severe	O
sepsis	O
includes	O
haemodynamic	O
,	O
respiratory	O
,	O
endocrine	B-CHED
,	O
immune	O
,	O
and	O
coagulation	O
aspects	O
besides	O
the	O
control	O
of	O
the	O
underlying	O
infection	O
.	O

AAV1	O
-	O
hrGFP	O
infusions	O
resulted	O
in	O
approximately	O
550	O
,	O
700	O
,	O
and	O
73	O
mm	O
(	O
3	O
)	O
coverage	O
after	O
infusion	O
into	O
corona	B-CHED
radiata	O
,	O
striatum	O
,	O
and	O
basal	O
forebrain	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
To	O
construct	O
the	O
expression	O
plasmid	O
of	O
S2	O
extracellular	O
domain	O
(	O
S2ED	O
)	O
of	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
Cov	O
)	O
spike	O
protein	B-CHED
(	O
S	O
protein	B-CHED
)	O
and	O
enhanced	O
green	O
fluorescent	O
protein	B-CHED
(	O
EGFP	O
)	O
to	O
obtain	O
the	O
fusion	O
protein	B-CHED
expressed	O
in	O
prokaryotic	O
cells	O
.	O

After	O
purification	O
by	O
Ni	O
-	O
NTA	B-CHED
agarose	B-CHED
beads	O
,	O
the	O
soluble	O
fractions	O
of	O
the	O
fusion	O
protein	B-CHED
were	O
collected	O
and	O
identified	O
by	O
SDS	B-CHED
-	O
PAGE	O
and	O
Western	O
blotting	O
.	O

The	O
patient	O
was	O
diagnosed	O
with	O
Lemierre	O
'	O
s	O
syndrome	O
,	O
and	O
an	O
alternative	O
treatment	O
regimen	O
with	O
prolonged	O
administration	O
of	O
ampicillin	B-CHED
,	O
clindamycin	B-CHED
,	O
and	O
metronidazole	B-CHED
resulted	O
in	O
improvement	O
of	O
the	O
patient	O
'	O
s	O
respiratory	O
function	O
and	O
general	O
condition	O
.	O

Various	O
pre	O
-	O
and	O
postnatal	O
factors	O
,	O
-	O
such	O
as	O
exposure	O
to	O
chorioamnionitis	O
,	O
pneumonia	O
,	O
fluid	O
lung	O
,	O
sepsis	O
and	O
asphyxia	O
-	O
can	O
induce	O
an	O
injurious	O
inflammatory	O
response	O
in	O
the	O
lung	O
which	O
may	O
subsequently	O
affect	O
surfactant	B-CHED
function	O
,	O
synthesis	O
and	O
alveolar	O
stability	O
.	O

Surfactant	B-CHED
inactivation	O
and	O
dysfunction	O
is	O
also	O
a	O
hallmark	O
in	O
newborns	O
with	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	B-CHED
),	O
for	O
which	O
a	O
beneficial	O
effect	O
of	O
exogenous	O
surfactant	B-CHED
replacement	O
.	O

The	O
other	O
Argentinean	O
isolates	O
formed	O
three	O
separate	O
clusters	B-CHED
(	O
A	O
,	O
B	O
and	O
C	O
),	O
distant	O
from	O
the	O
vaccine	O
serotypes	O
,	O
with	O
no	O
correlation	O
between	O
the	O
generated	O
clusters	B-CHED
and	O
a	O
geographic	O
pattern	O
.	O

In	O
addition	O
,	O
the	O
utilization	O
of	O
HVR1	O
/	O
2	O
and	O
HVR1	O
sequences	O
resulted	O
in	O
trees	O
with	O
similar	O
topology	O
but	O
the	O
phylogenetic	O
relationships	O
using	O
HVR1	O
/	O
2	O
nucleotide	B-CHED
sequences	O
were	O
better	O
supported	O
by	O
higher	O
bootstrap	O
values	O
.	O

ABSTRACT	O
:	O
Clinical	O
use	O
of	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
(	O
BMMSCs	O
)	O
holds	O
great	O
promise	O
for	O
regenerative	O
medicine	B-CHED
in	O
intractable	O
lung	O
diseases	O
,	O
such	O
as	O
lung	O
fibrosis	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

A	O
total	O
of	O
39	O
SARS	O
patients	O
who	O
had	O
no	O
previous	O
diabetes	O
and	O
received	O
no	O
steroid	B-CHED
treatment	O
were	O
compared	O
to	O
39	O
matched	O
healthy	O
siblings	O
during	O
a	O
3	O
-	O
year	O
follow	O
-	O
up	O
period	O
.	O

Thirty	O
C3H	O
/	O
Hej	O
mice	O
received	O
10	O
Pfu	B-CHED
MHV	O
-	O
3	O
intraperitoneally	O
,	O
the	O
CD4	O
-	O
CD8	O
-	O
T	O
cells	O
were	O
isolated	O
using	O
magnetic	O
bead	O
sorting	O
on	O
0	O
,	O
4	O
,	O
15	O
,	O
30	O
,	O
40	O
days	O
post	O
MHV	O
-	O
3	O
infection	O
.	O

The	O
extent	O
of	O
the	O
sustained	O
injury	O
and	O
the	O
subsequent	O
cellular	O
innate	O
immune	O
response	O
is	O
reflected	O
by	O
changes	O
in	O
a	O
functional	O
PMN	O
phenotype	O
of	O
fMLP	B-CHED
-	O
induced	O
active	O
FcgammaRII	O
in	O
the	O
peripheral	O
blood	O
.	O

Most	O
neonates	O
receiving	O
ECMO	O
suffer	O
from	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	B-CHED
),	O
congenital	O
diaphragmatic	O
hernia	O
(	O
CDH	B-CHED
),	O
sepsis	O
or	O
persistent	O
pulmonary	O
hypertension	O
(	O
PPH	O
).	O

Compared	O
with	O
the	O
Dutch	O
population	O
height	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
weight	O
for	O
height	O
were	O
lower	O
in	O
the	O
CDH	B-CHED
group	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Likewise	O
,	O
treatment	O
with	O
2	O
.	O
5	O
-	O
10	O
mM	O
EtP	B-CHED
(	O
but	O
not	O
NaP	O
)	O
reduced	O
ICAM	O
-	O
1	O
and	O
VCAM	O
-	O
1	O
expression	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

TITLE	O
:	O
APOBEC3G	O
cytidine	B-CHED
deaminase	O
association	O
with	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
The	O
paper	O
provides	O
the	O
results	O
of	O
intracardiac	O
circulation	O
ultrasound	O
study	O
in	O
37	O
preterm	O
neonatal	O
infants	O
,	O
including	O
24	O
patients	O
with	O
severe	O
respiratory	O
distress	O
syndrome	O
(	O
RDS	O
),	O
receiving	O
the	O
exogenous	O
surfactant	B-CHED
Curosurf	O
in	O
the	O
complex	O
therapy	O
of	O
the	O
disease	O
.	O

Six	O
trials	O
with	O
a	O
total	O
of	O
2	O
,	O
484	O
patients	O
from	O
102	O
intensive	O
care	O
units	O
and	O
9	O
countries	O
met	B-CHED
the	O
eligibility	O
criteria	O
.	O

There	O
was	O
no	O
evidence	O
of	O
a	O
significant	O
increase	O
in	O
baro	O
-	O
trauma	O
in	O
patients	O
receiving	O
high	O
PEEP	B-CHED
,	O
with	O
a	O
pooled	O
risk	O
of	O
0	O
.	O
95	O
(	O
95	O
%	O
CI	O
0	O
.	O
62	O
-	O
1	O
.	O
45	O
,	O
P	O
=	O
0	O
.	O
81	O
).	O

High	O
PEEP	B-CHED
strategy	O
may	O
have	O
a	O
clinically	O
relevant	O
independent	O
mortality	O
benefit	O
.	O

Recently	O
,	O
a	O
30	O
-	O
nucleotide	B-CHED
(	O
nt	O
)	O
cis	O
-	O
replication	O
stem	O
-	O
loop	O
VI	O
(	O
SLVI	O
)	O
has	O
been	O
mapped	O
at	O
nt	O
101	O
to	O
130	O
within	O
a	O
288	O
-	O
nt	O
5	O
'-	O
terminal	O
segment	O
of	O
the	O
738	O
-	O
nt	O
nsp1	O
cistron	O
in	O
a	O
BCoV	O
defective	O
interfering	O
(	O
DI	O
)	O
RNA	O
.	O

Here	O
,	O
we	O
(	O
i	O
)	O
establish	O
by	O
mutation	O
analysis	O
that	O
the	O
72	O
-	O
nt	O
intracistronic	O
SLV	O
immediately	O
upstream	O
of	O
SLVI	O
is	O
also	O
a	O
DI	O
RNA	O
cis	O
-	O
replication	O
signal	O
,	O
(	O
ii	O
)	O
show	O
by	O
gel	O
shift	O
and	O
UV	O
-	O
cross	O
-	O
linking	O
analyses	O
that	O
cellular	O
proteins	B-CHED
of	O
approximately	O
60	O
and	O
100	O
kDa	O
,	O
but	O
not	O
viral	O
proteins	B-CHED
,	O
bind	O
SLV	O
and	O
SLVI	O
,	O
(	O
SLV	O
-	O
VI	O
)	O
and	O
(	O
iii	O
)	O
demonstrate	O
by	O
gel	O
shift	O
analysis	O
that	O
nsp1	O
purified	O
from	O
Escherichia	O
coli	O
does	O
not	O
bind	O
SLV	O
-	O
VI	O
but	O
does	O
bind	O
three	O
5	O
'	O
untranslated	O
region	O
(	O
UTR	O
)-	O
and	O
one	O
3	O
'	O
UTR	O
-	O
located	O
cis	O
-	O
replication	O
SLs	B-CHED
.	O

ALRT	O
missions	O
comprised	O
0	O
.	O
6	O
%	O
of	O
all	O
critical	O
patient	O
movements	O
out	O
of	O
the	O
combat	B-CHED
theater	O
and	O
1	O
%	O
of	O
ventilator	O
transports	O
.	O

TITLE	O
:	O
Thiopurine	B-CHED
analogue	O
inhibitors	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
papain	O
-	O
like	O
protease	O
,	O
a	O
deubiquitinating	O
and	O
deISGylating	O
enzyme	O
.	O

The	O
best	O
docking	O
score	O
and	O
binding	O
energy	O
for	O
6MP	O
and	O
6TG	O
is	O
against	O
ubiquitin	O
-	O
specific	O
protease	O
(	O
USP	O
)	O
14	O
,	O
suggesting	O
that	O
6MP	O
and	O
6TG	O
are	O
potential	O
inhibitors	B-CHED
of	O
USP14	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
M	O
protein	B-CHED
inhibits	O
type	O
I	O
interferon	O
production	O
by	O
impeding	O
the	O
formation	O
of	O
TRAF3	O
.	O
TANK	O
.	O
TBK1	O
/	O
IKKepsilon	O
complex	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
SARS	O
coronavirus	O
M	O
protein	B-CHED
inhibits	O
gene	O
transcription	O
of	O
type	O
I	O
interferons	O
.	O

Consequently	O
,	O
the	O
expression	O
of	O
M	O
protein	B-CHED
prevents	O
the	O
formation	O
of	O
TRAF3	O
.	O
TANK	O
.	O
TBK1	O
/	O
IKKepsilon	O
complex	O
and	O
thereby	O
inhibits	O
TBK1	O
/	O
IKKepsilon	O
-	O
dependent	O
activation	O
of	O
IRF3	O
/	O
IRF7	O
transcription	O
factors	O
.	O

These	O
data	O
are	O
the	O
first	O
to	O
demonstrate	O
glia	O
cell	O
type	O
-	O
dependent	O
B7	O
-	O
H1	O
regulation	O
in	O
vivo	O
,	O
resulting	O
in	O
adverse	O
effects	O
on	O
antiviral	B-CHED
CD8	O
T	O
cell	O
function	O
.	O

Tumour	O
compression	O
on	O
the	O
airways	O
or	O
the	O
great	O
vessels	O
may	O
create	O
a	O
critical	O
respiratory	O
and	O
/	O
or	O
haemodynamic	O
situation	O
,	O
and	O
therefore	O
the	O
standard	O
of	O
intraoperative	O
management	O
includes	O
induction	O
of	O
anaesthesia	O
in	O
the	O
operating	O
theatre	O
on	O
an	O
adjustable	O
surgical	O
table	O
,	O
the	O
use	O
of	O
short	O
-	O
acting	O
anaesthetics	B-CHED
,	O
avoidance	O
of	O
muscle	B-CHED
relaxants	I-CHED
and	O
maintenance	O
of	O
spontaneous	O
respiration	O
.	O

ABSTRACT	O
:	O
Protein	B-CHED
sequences	O
are	O
treated	O
as	O
stochastic	O
processes	O
on	O
the	O
basis	O
of	O
a	O
reduced	O
amino	B-CHED
acid	I-CHED
alphabet	O
of	O
10	O
types	O
of	O
amino	B-CHED
acids	I-CHED
.	O

ABSTRACT	O
:	O
Eight	O
accessory	O
proteins	B-CHED
have	O
been	O
identified	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

ORF9b	O
as	O
one	O
of	O
these	O
accessory	O
proteins	B-CHED
is	O
located	O
in	O
subgenomic	O
mRNA9	O
and	O
encodes	O
a	O
98	O
amino	B-CHED
acid	I-CHED
protein	B-CHED
.	O

This	O
finding	O
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
properties	O
of	O
the	O
SARS	O
-	O
CoV	O
9b	O
protein	B-CHED
.	O

To	O
understand	O
the	O
biodistribution	O
of	O
CPMV	O
in	O
the	O
CNS	B-CHED
,	O
we	O
examined	O
CPMV	O
uptake	O
during	O
infection	O
of	O
mice	O
with	O
neurotropic	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

Surfactant	B-CHED
inactivation	O
--	O
and	O
dysfunction	O
--	O
is	O
also	O
a	O
hallmark	O
in	O
newborns	O
with	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	B-CHED
),	O
pneumonia	O
and	O
other	O
disorders	O
affecting	O
the	O
pulmonary	O
function	O
.	O

A	O
functional	O
screen	O
identifies	O
the	O
hepatitis	O
C	O
virus	O
NS3	O
/	O
4A	O
and	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nonstructural	O
protein	B-CHED
(	O
NSP15	O
)	O
as	O
inhibitors	B-CHED
of	O
MAVS	O
-	O
induced	O
apoptosis	O
,	O
possibly	O
as	O
a	O
method	O
of	O
immune	O
evasion	O
.	O

This	O
study	O
describes	O
a	O
novel	O
role	O
for	O
MAVS	O
in	O
controlling	O
viral	O
infections	O
through	O
the	O
induction	O
of	O
apoptosis	O
,	O
and	O
identifies	O
viral	O
proteins	B-CHED
which	O
inhibit	O
this	O
host	O
response	O
.	O

One	O
case	O
-	O
control	O
study	O
has	O
reported	O
an	O
association	O
between	O
susceptibility	O
to	O
SARS	O
and	O
mannan	B-CHED
-	O
binding	O
lectin	O
(	O
MBL	O
)	O
in	O
China	O
.	O

Tag	O
single	O
nucleotide	B-CHED
polymorphisms	O
(	O
tagSNPs	O
)	O
were	O
chosen	O
using	O
pairwise	O
tagging	O
algorithms	O
.	O

The	O
split	O
probe	O
strategy	O
allowed	O
detection	O
of	O
down	O
to	O
10	O
viral	O
nucleic	B-CHED
acid	I-CHED
equivalents	O
of	O
CoV	O
from	O
all	O
known	O
CoV	O
groups	O
.	O

Among	O
these	O
nsps	O
,	O
nsp9	O
has	O
been	O
shown	O
to	O
possess	O
single	B-CHED
-	I-CHED
stranded	I-CHED
DNA	I-CHED
/	O
RNA	O
-	O
binding	O
properties	O
.	O

TITLE	O
:	O
Ectodomain	O
shedding	O
of	O
angiotensin	B-CHED
converting	O
enzyme	O
2	O
in	O
human	O
airway	O
epithelia	O
.	O

In	O
the	O
case	O
of	O
the	O
S2	O
domain	O
of	O
protein	B-CHED
S	O
,	O
it	O
has	O
been	O
found	O
a	O
highly	O
hydrophobic	O
and	O
interfacial	O
domain	O
flanked	O
by	O
the	O
heptad	O
repeat	O
1	O
and	O
2	O
regions	O
;	O
significantly	O
,	O
different	O
peptides	B-CHED
pertaining	O
to	O
this	O
domain	O
have	O
shown	O
a	O
significant	O
leakage	O
effect	O
and	O
an	O
important	O
plaque	O
formation	O
inhibition	O
,	O
which	O
,	O
similarly	O
to	O
HIV	O
-	O
1	O
gp41	O
,	O
support	O
the	O
role	O
of	O
this	O
region	O
in	O
the	O
fusion	O
process	O
.	O

To	O
address	O
this	O
,	O
a	O
portion	O
of	O
the	O
S1	O
region	O
of	O
the	O
spike	O
glycoprotein	B-CHED
of	O
TCoV	O
carrying	O
relevant	O
B	O
cell	O
epitopes	O
(	O
amino	B-CHED
acid	I-CHED
positions	O
54	O
-	O
395	O
)	O
was	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

TITLE	O
:	O
Identification	O
of	O
in	O
vivo	O
-	O
interacting	O
domains	O
of	O
the	O
murine	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
.	O

Infection	O
of	O
aged	O
,	O
but	O
not	O
young	O
,	O
mice	O
with	O
recombinant	O
viruses	O
bearing	O
spike	O
glycoproteins	B-CHED
derived	O
from	O
early	O
human	O
or	O
palm	O
civet	O
isolates	O
resulted	O
in	O
death	O
accompanied	O
by	O
pathological	O
changes	O
associated	O
with	O
ARDS	O
.	O

The	O
chimeric	O
DNA	O
-	O
RNA	O
hammerhead	O
ribozyme	O
targeting	O
SARS	O
-	O
CoV	O
significantly	O
inhibited	O
multiplication	O
of	O
MHV	O
in	O
DBT	B-CHED
cells	O
by	O
about	O
60	O
%.	O

We	O
found	O
that	O
RBD193	O
-	O
CHO	B-CHED
reacted	O
strongly	O
with	O
a	O
panel	O
of	O
six	O
monoclonal	O
antibodies	O
recognizing	O
various	O
conformational	O
and	O
linear	O
epitopes	O
in	O
RBD	O
,	O
suggesting	O
that	O
this	O
recombinant	O
protein	B-CHED
maintains	O
intact	O
conformation	O
and	O
good	O
antigenicity	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
does	O
not	O
modulate	O
transcription	O
of	O
the	O
human	O
FGL2	O
gene	O
.	O

ABSTRACT	O
:	O
Among	O
the	O
structural	O
and	O
nonstructural	O
proteins	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
plays	O
pivotal	O
roles	O
in	O
the	O
biology	O
and	O
pathogenesis	O
of	O
viral	O
infection	O
.	O

N	O
protein	B-CHED
is	O
thought	O
to	O
dysregulate	O
cell	O
signalling	O
and	O
the	O
transcription	O
of	O
cellular	O
genes	O
,	O
including	O
FGL2	O
,	O
which	O
encodes	O
a	O
prothrombinase	O
implicated	O
in	O
vascular	O
thrombosis	O
,	O
fibrin	O
deposition	O
and	O
pneumocyte	O
necrosis	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
did	O
not	O
support	O
the	O
model	O
in	O
which	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
specifically	O
modulates	O
transcription	O
of	O
the	O
FGL2	O
gene	O
to	O
cause	O
fibrosis	O
and	O
vascular	O
thrombosis	O
.	O

We	O
also	O
sought	O
to	O
determine	O
whether	O
they	O
could	O
interfere	O
with	O
the	O
clathrin	O
-	O
dependent	O
endocytosis	O
pathway	O
using	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
as	O
an	O
indicator	B-CHED
.	O

Leaf	O
extracts	O
had	O
better	O
virucidal	O
activity	O
than	O
roots	O
,	O
and	O
ethyl	B-CHED
acetate	I-CHED
extracts	O
exhibited	O
the	O
highest	O
efficacy	O
among	O
extracts	O
tested	O
.	O

179	O
.	O
0	O
mg	O
/	O
L	O
)	O
cats	O
were	O
detectable	O
,	O
suggesting	O
that	O
the	O
simple	O
infection	O
by	O
FCoVs	O
does	O
not	O
influence	O
TSA	B-CHED
levels	O
.	O

Compared	O
with	O
seropositive	O
controls	O
,	O
the	O
concentration	O
of	O
TSA	B-CHED
was	O
higher	O
in	O
cats	O
with	O
FIP	O
(	O
556	O
.	O
7	O
+/-	O

As	O
there	O
is	O
no	O
evidence	O
for	O
Nsp3	O
entering	O
the	O
nucleus	B-CHED
of	O
the	O
host	O
cell	O
,	O
the	O
SARS	O
-	O
CoV	O
genomic	O
RNA	O
or	O
host	O
-	O
cell	O
mRNA	B-CHED
containing	O
long	O
G	O
-	O
stretches	O
may	O
be	O
targets	O
of	O
SUD	O
.	O

Mutation	O
of	O
the	O
most	O
N	B-CHED
-	I-CHED
terminal	I-CHED
residue	I-CHED
(	O
S798	O
)	O
had	O
little	O
or	O
no	O
effect	O
on	O
membrane	O
fusion	O
.	O

This	O
open	O
-	O
label	B-CHED
,	O
single	O
-	O
dose	O
,	O
randomized	O
-	O
sequence	O
,	O
2	O
-	O
period	O
crossover	O
study	O
was	O
conducted	O
in	O
healthy	O
native	O
Chinese	O
male	O
volunteers	O
.	O

Autopsy	O
heart	O
samples	O
from	O
patients	O
who	O
succumbed	O
to	O
the	O
SARS	O
crisis	O
in	O
Toronto	O
(	O
Canada	O
)	O
were	O
used	O
to	O
investigate	O
the	O
impact	O
of	O
SARS	O
on	O
myocardial	O
structure	O
,	O
inflammation	O
and	O
ACE2	O
protein	B-CHED
expression	O
.	O

TITLE	O
:	O
Comparative	O
analysis	O
of	O
the	O
effect	O
of	O
glycyrrhizin	B-CHED
diammonium	O
and	O
lithium	B-CHED
chloride	I-CHED
on	O
infectious	O
bronchitis	O
virus	O
infection	O
in	O
vitro	O
.	O

Our	O
results	O
showed	O
that	O
GD	O
had	O
a	O
direct	O
antiviral	B-CHED
activity	O
,	O
leading	O
to	O
complete	O
inhibition	O
of	O
cell	O
infection	O
.	O

The	O
integrin	O
-	O
binding	O
motif	O
Arg	B-CHED
-	O
Gly	B-CHED
-	O
Asp	B-CHED
(	O
RGD	O
)	O
was	O
incorporated	O
into	O
the	O
pcDNA	O
3	O
.	O
1	O
mammalian	O
expression	O
vector	O
expressing	O
the	O
codon	O
-	O
optimized	O
extracellular	O
domain	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	B-CHED
,	O
and	O
tested	O
by	O
immunizing	O
C57BL	O
/	O
6	O
mice	O
.	O

Significant	O
cell	O
-	O
mediated	O
immune	O
responses	O
were	O
characterized	O
by	O
cytotoxic	O
T	O
-	O
lymphocyte	O
(	O
51	O
)	O
Cr	O
release	O
assay	O
and	O
interferon	O
-	O
gamma	O
secretion	O
ELISPOT	O
assay	O
against	O
RMA	O
-	O
S	O
target	O
cells	O
presenting	O
predicted	O
MHC	O
class	O
I	O
H2	O
-	O
Kb	O
epitopes	O
,	O
including	O
those	O
spanning	O
residues	O
884	O
-	O
891	O
and	O
1116	O
-	O
1123	O
within	O
the	O
S2	O
subunit	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
.	O

The	O
deceased	O
case	O
of	O
SJS	O
had	O
been	O
treated	O
with	O
corticosteroid	B-CHED
alone	O
and	O
died	O
for	O
acute	O
respiratory	O
disorder	O
after	O
24	O
days	O
from	O
the	O
onset	O
of	O
the	O
eruption	O
.	O

Four	O
deceased	O
cases	O
of	O
TEN	O
were	O
treated	O
with	O
corticosteroids	B-CHED
with	O
or	O
without	O
IVIG	O
,	O
and	O
2	O
of	O
them	O
merged	O
sepsis	O
.	O

RESULTS	O
:	O
Corticosteroid	B-CHED
was	O
administered	O
systemically	O
in	O
all	O
cases	O
except	O
one	O
case	O
of	O
TEN	O
which	O
developed	O
methicillin	B-CHED
resistant	O
staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
pneumoniae	O
before	O
the	O
onset	O
of	O
the	O
eruption	O
.	O

Four	O
deceased	O
cases	O
of	O
TEN	O
were	O
treated	O
with	O
corticosteroids	B-CHED
with	O
or	O
without	O
IVIG	O
,	O
and	O
2	O
of	O
them	O
merged	O
sepsis	O
.	O

TITLE	O
:	O
Sivelestat	O
(	O
selective	O
neutrophil	B-CHED
elastase	I-CHED
inhibitor	I-CHED
)	O
improves	O
the	O
mortality	O
rate	O
of	O
sepsis	O
associated	O
with	O
both	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
disseminated	O
intravascular	O
coagulation	O
patients	O
.	O

The	O
DIC	B-CHED
score	O
of	O
sivelestat	O
group	O
improved	O
on	O
day	O
3	O
in	O
comparison	O
to	O
day	O
1	O
,	O
and	O
those	O
of	O
control	O
group	O
remained	O
unchanged	O
until	O
day	O
4	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
whether	O
the	O
surface	O
-	O
linked	O
liposomal	O
peptide	B-CHED
was	O
applicable	O
to	O
a	O
vaccine	O
based	O
on	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

stimulation	O
with	O
cerulein	B-CHED
.	O

Addition	O
of	O
doxycycline	B-CHED
significantly	O
reduced	O
TNF	O
-	O
alpha	O
-	O
induced	O
PMN	O
transmigration	O
across	O
Matrigel	O
membrane	O
(	O
12	O
.	O
6	O
+/-	O
2	O
.	O
6	O
vs	O
.	O
20	O
.	O
1	O
+/-	O

The	O
use	O
of	O
ELISA	O
technology	O
provided	O
an	O
efficient	O
and	O
effective	O
mean	O
of	O
evaluating	O
the	O
presence	O
of	O
coronavirus	O
PED	O
antigen	B-CHED
in	O
field	O
samples	O
and	O
indicates	O
that	O
this	O
procedure	O
is	O
a	O
very	O
useful	O
tool	O
in	O
epidemiological	O
studies	O
.	O

Sub	O
-	O
muM	O
inhibitors	B-CHED
of	O
HCV	O
emerge	O
.	O

We	O
demonstrate	O
that	O
chloroquine	B-CHED
,	O
a	O
widely	O
used	O
drug	O
with	O
well	O
-	O
known	O
antimalarial	B-CHED
effects	O
,	O
inhibits	O
HCoV	O
-	O
OC43	O
replication	O
in	O
HRT	O
-	O
18	O
cells	O
,	O
with	O
a	O
50	O
%	O
effective	O
concentration	O
(+/-	O

The	O
highest	O
survival	O
rate	O
(	O
98	O
.	O
6	O
%)	O
of	O
the	O
pups	O
was	O
found	O
when	O
mother	O
mice	O
were	O
treated	O
daily	O
with	O
a	O
concentration	O
of	O
15	O
mg	O
of	O
chloroquine	B-CHED
per	O
kg	O
of	O
body	O
weight	O
.	O

Our	O
results	O
show	O
that	O
chloroquine	B-CHED
can	O
be	O
highly	O
effective	O
against	O
HCoV	O
-	O
OC43	O
infection	O
in	O
newborn	O
mice	O
and	O
may	O
be	O
considered	O
as	O
a	O
future	O
drug	O
against	O
HCoVs	O
.	O

Poisoned	O
patients	O
may	O
present	O
with	O
cholinergic	O
syndrome	O
,	O
and	O
judicious	O
use	O
of	O
atropine	B-CHED
seems	O
justified	O
.	O

Nitric	B-CHED
oxide	I-CHED
(	O
NO	O
)	O
is	O
generated	O
by	O
both	O
inducible	O
and	O
constitutive	O
isoforms	O
of	O
nitric	B-CHED
oxide	I-CHED
synthase	O
(	O
NOS	O
).	O

During	O
steroid	B-CHED
treatment	O
,	O
a	O
gradual	O
vanishing	O
of	O
the	O
pathologic	O
laughter	O
and	O
improvement	O
of	O
the	O
motor	O
and	O
speech	O
functions	O
occurred	O
.	O

Based	O
on	O
sequence	O
analysis	O
of	O
the	O
3	O
'-	O
7kb	O
region	O
,	O
the	O
CK	O
/	O
CH	O
/	O
LHLJ	O
/	O
04V	O
virus	O
population	O
contained	O
subpopulations	O
with	O
a	O
mixture	B-CHED
of	O
genetic	O
mutants	O
.	O

During	O
vaccination	O
of	O
rN	O
protein	B-CHED
,	O
the	O
expression	O
of	O
IFN	O
-	O
gamma	O
and	O
IL	O
-	O
10	O
was	O
evidently	O
up	O
-	O
regulated	O
in	O
splenocytes	O
at	O
different	O
time	O
points	O
,	O
while	O
the	O
expression	O
of	O
IL	O
-	O
2	O
and	O
IL	O
-	O
4	O
was	O
not	O
.	O

Up	O
to	O
now	O
,	O
this	O
is	O
the	O
first	O
study	O
that	O
plant	O
-	O
expressed	O
recombinant	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
can	O
induce	O
strong	O
humoral	O
and	O
cellular	O
responses	O
in	O
mice	O
.	O

Based	O
on	O
expert	O
opinion	O
,	O
the	O
following	O
are	O
recommended	O
:	O
1	O
)	O
avoid	O
tidal	O
volumes	O
>	O
or	O
=	O
10	O
mL	O
/	O
kg	O
body	O
weight	O
;	O
2	O
)	O
keep	O
plateau	O
pressure	O
<	O
or	O
=	O
30	O
cm	O
H2O	B-CHED
,	O
arterial	O
pH	O
at	O
7	O
.	O
30	O
to	O
7	O
.	O
45	O
,	O
and	O
Pao2	O
60	O
to	O
80	O
torr	O
(	O
8	O
to	O
10	O
.	O
7	O
kPa	O
)	O
(	O
Spo2	O
>	O
or	O
=	O
90	O
%);	O
3	O
)	O
provide	O
sedation	O
,	O
analgesia	O
,	O
and	O
stress	O
ulcer	O
prophylaxis	O
;	O
and	O
4	O
)	O
use	O
a	O
10	O
g	O
/	O
dL	O
hemoglobin	B-CHED
threshold	O
for	O
packed	O
red	O
blood	O
cell	O
transfusion	O
in	O
unstable	O
patients	O
(	O
shock	O
or	O
profound	O
hypoxia	O
).	O

TITLE	O
:	O
2	O
-	O
Arylbenzimidazoles	O
as	O
antiviral	B-CHED
and	O
antiproliferative	O
agents	O
--	O
Part	O
2	O
.	O

In	O
particular	O
,	O
compounds	O
26	O
and	O
28	O
showed	O
a	O
similar	O
potency	O
of	O
6	B-CHED
-	I-CHED
MP	I-CHED
and	O
etoposide	B-CHED
.	O

ABSTRACT	O
:	O
The	O
glycosylated	O
membrane	O
protein	B-CHED
M	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
the	O
main	O
structural	O
component	O
of	O
the	O
virion	O
and	O
mediates	O
assembly	O
and	O
budding	O
of	O
viral	O
particles	O
.	O

We	O
discuss	O
inactivated	O
vaccines	O
,	O
virally	O
and	O
bacterially	O
vectored	O
vaccines	O
,	O
recombinant	O
protein	B-CHED
and	O
DNA	O
vaccines	O
,	O
as	O
well	O
as	O
the	O
use	O
of	O
attenuated	O
vaccines	O
.	O

ABSTRACT	O
:	O
Various	O
approaches	O
have	O
been	O
developed	O
to	O
improve	O
the	O
efficacy	O
of	O
DNA	O
vaccination	O
,	O
such	O
as	O
the	O
use	O
of	O
plasmids	O
expressing	O
cytokines	O
as	O
molecular	O
adjuvants	B-CHED
.	O

ABSTRACT	O
:	O
3	O
-	O
Chlorobenzofuran	O
-	O
2	O
-	O
carbaldehyde	B-CHED
was	O
condensed	O
with	O
substituted	O
acetophenone	B-CHED
by	O
using	O
the	O
Claisen	O
-	O
Schmidt	O
condensation	O
to	O
obtain	O
3	O
-(	O
3	O
-	O
chlorobenzofuran	O
-	O
2	O
-	O
yl	O
)-	O
1	O
-(	O
substituted	O
phenyl	B-CHED
)-	O
2	O
-	O
propen	O
-	O
1	O
-	O
one	O
(	O
2a	O
-	O
m	O
)	O
which	O
upon	O
further	O
treatment	O
with	O
hydrazine	B-CHED
hydrate	I-CHED
gave	O
2	O
-[	O
3	O
-(	O
substituted	O
phenyl	B-CHED
)-	O
4	O
,	O
5	O
-	O
dihydro	O
-	O
1H	O
-	O
5	O
-	O
pyrazolyl	O
)	O
benzofuran	B-CHED
-	O
3	O
-	O
yl	O
chloride	B-CHED
derivatives	O
(	O
3a	O
-	O
m	O
).	O

The	O
limit	O
of	O
detection	O
for	O
Y	O
.	O
pestis	O
,	O
B	O
.	O
anthracis	O
spores	O
,	O
SEB	O
,	O
ricin	O
,	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
in	O
milk	O
powder	O
was	O
20	O
cfu	O
,	O
111	O
cfu	O
,	O
110pg	O
,	O
5	O
.	O
4	O
ng	O
and	O
2	O
ng	O
per	O
test	O
respectively	O
.	O

The	O
manifestations	O
of	O
delirium	O
tremens	O
persisted	O
with	O
titration	O
of	O
a	O
lorazepam	B-CHED
infusion	O
in	O
excess	O
of	O
40	O
mg	O
/	O
hour	O
.	O

Subsequent	O
scheduled	O
phenobarbital	B-CHED
administration	O
allowed	O
for	O
a	O
successful	O
and	O
orderly	O
weaning	O
of	O
the	O
continuous	O
benzodiazepine	B-CHED
infusion	O
and	O
adjunctive	O
agents	O
used	O
in	O
AWS	O
management	O
.	O

However	O
,	O
there	O
is	O
a	O
paucity	O
of	O
data	O
on	O
patients	O
'	O
and	O
nurses	O
'	O
abilities	O
and	O
perspectives	O
on	O
MDI	B-CHED
with	O
spacer	O
for	O
the	O
treatment	O
of	O
acute	O
airway	O
obstruction	O
during	O
such	O
an	O
outbreak	O
.	O

Fifty	O
-	O
eight	O
percent	O
of	O
the	O
patients	O
thought	O
MDI	B-CHED
with	O
spacer	O
was	O
easier	O
to	O
use	O
than	O
nebulizer	O
,	O
and	O
34	O
%	O
thought	O
MDI	B-CHED
was	O
as	O
easy	O
to	O
use	O
as	O
nebulizer	O
.	O

RESULTS	O
:	O
Forty	O
-	O
six	O
patients	O
(	O
92	O
%)	O
were	O
able	O
to	O
use	O
MDI	B-CHED
with	O
spacer	O
effectively	O
.	O

AFM	O
and	O
SPR	O
imaging	O
analyses	O
demonstrated	O
that	O
anti	O
-	O
SCVme	O
specifically	O
bound	O
to	O
the	O
fusion	O
protein	B-CHED
immobilized	O
onto	O
the	O
gold	B-CHED
-	O
micropatterned	O
chip	O
,	O
implying	O
that	O
appropriate	O
orientation	O
of	O
bound	O
fusion	O
protein	B-CHED
by	O
GBP	O
resulted	O
in	O
optimal	O
exposure	O
of	O
the	O
SCVme	O
domain	O
to	O
the	O
assay	O
solution	O
,	O
resulting	O
in	O
efficient	O
capture	O
of	O
anti	O
-	O
SCVme	O
antibody	O
.	O

The	O
prevalence	O
of	O
FCoV	O
II	O
antibodies	O
in	O
the	O
sampled	O
population	O
based	O
on	O
the	O
gold	B-CHED
standard	O
was	O
62	O
%	O
(	O
95	O
%	O
CI	O
0	O
.	O
44	O
-	O
0	O
.	O
77	O
)	O
among	O
multi	O
-	O
cat	O
environments	O
,	O
and	O
4	O
%	O
(	O
95	O
%	O
CI	O
0	O
.	O
01	O
-	O
0	O
.	O
11	O
)	O
among	O
single	O
cat	O
households	O
.	O

All	O
patients	O
had	O
fever	O
,	O
cough	O
,	O
dyspnea	O
or	O
respiratory	O
distress	O
,	O
increased	O
serum	O
lactate	B-CHED
dehydrogenase	O
levels	O
,	O
and	O
bilateral	O
patchy	O
pneumonia	O
.	O

Within	O
7	O
days	O
after	O
contact	O
with	O
the	O
initial	O
case	O
patients	O
,	O
a	O
mild	O
or	O
moderate	O
influenza	O
-	O
like	O
illness	O
developed	O
in	O
22	O
health	O
care	O
workers	O
;	O
they	O
were	O
treated	O
with	O
oseltamivir	B-CHED
,	O
and	O
none	O
were	O
hospitalized	O
.	O

Expression	O
of	O
S	O
protein	B-CHED
derived	O
from	O
Vero	O
-	O
and	O
CK	O
-	O
adapted	O
strains	O
showed	O
efficient	O
induction	O
of	O
membrane	O
fusion	O
.	O

This	O
study	O
demonstrates	O
that	O
acquisition	O
of	O
the	O
cell	O
-	O
cell	O
fusion	O
activity	O
in	O
S	O
protein	B-CHED
determines	O
the	O
selection	O
and	O
/	O
or	O
adaptation	O
of	O
a	O
coronavirus	O
from	O
chicken	O
embryo	O
to	O
cultured	O
cells	O
of	O
human	O
and	O
animal	O
origins	O
.	O

TITLE	O
:	O
Host	O
cell	O
proteins	B-CHED
interacting	O
with	O
the	O
3	O
'	O
end	O
of	O
TGEV	O
coronavirus	O
genome	O
influence	O
virus	O
replication	O
.	O

Ten	O
proteins	B-CHED
were	O
preferentially	O
pulled	O
down	O
with	O
either	O
the	O
5	O
'	O
or	O
3	O
'	O
ends	O
of	O
the	O
genome	O
and	O
identified	O
by	O
proteomic	O
analysis	O
.	O

The	O
potential	O
function	O
of	O
the	O
3	O
'	O
end	O
-	O
interacting	O
proteins	B-CHED
in	O
virus	O
replication	O
was	O
studied	O
by	O
analyzing	O
the	O
effect	O
of	O
their	O
silencing	O
using	O
a	O
TGEV	O
-	O
derived	O
replicon	O
and	O
the	O
infectious	O
virus	O
.	O

Mutations	O
,	O
insertions	O
,	O
deletions	O
and	O
recombination	O
of	O
the	O
S1	O
protein	B-CHED
gene	O
contribute	O
to	O
the	O
genetic	O
diversity	O
of	O
IBV	O
in	O
China	O
.	O

CONCLUSIONS	O
:	O
Mutations	O
,	O
insertions	O
,	O
deletions	O
and	O
recombination	O
of	O
the	O
S1	O
protein	B-CHED
gene	O
contribute	O
to	O
the	O
genetic	O
diversity	O
of	O
IBV	O
in	O
China	O
.	O

However	O
,	O
recent	O
studies	O
have	O
shown	O
etomidate	B-CHED
to	O
decrease	O
circulating	O
cortisol	B-CHED
concentrations	O
,	O
potentially	O
influencing	O
inflammation	O
.	O

Post	O
hoc	O
,	O
patients	O
were	O
grouped	O
according	O
to	O
whether	O
they	O
did	O
or	O
did	O
not	O
receive	O
etomidate	B-CHED
for	O
prehospital	O
airway	O
management	O
.	O

RESULTS	O
:	O
Over	O
a	O
2	O
-	O
year	O
period	O
,	O
94	O
study	O
patients	O
underwent	O
RSI	O
,	O
of	O
which	O
35	O
received	O
etomidate	B-CHED
(	O
37	O
%).	O

CONCLUSIONS	O
:	O
Single	O
-	O
dose	O
etomidate	B-CHED
for	O
RSI	O
in	O
severely	O
injured	O
trauma	O
patients	O
is	O
associated	O
with	O
increased	O
ARDS	O
and	O
multiple	O
organ	O
dysfunction	O
syndrome	O
,	O
in	O
part	O
,	O
because	O
of	O
an	O
effect	O
of	O
etomidate	B-CHED
on	O
the	O
inflammatory	O
response	O
.	O

ABSTRACT	O
:	O
Assuming	O
that	O
no	O
human	O
had	O
any	O
previously	O
acquired	O
immunoprotection	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
during	O
the	O
2003	O
SARS	O
outbreak	O
,	O
the	O
biological	O
bases	B-CHED
for	O
possible	O
difference	O
in	O
individual	O
susceptibility	O
are	O
intriguing	O
.	O

Average	O
prescribed	O
Synbiotic	O
dose	O
was	O
10	O
(	O
10	O
)	O
colony	O
-	O
forming	O
units	O
or	O
more	O
of	O
lactic	B-CHED
acid	I-CHED
bacteria	O
per	O
day	O
for	O
the	O
duration	O
of	O
treatment	O
(	O
median	O
33	O
days	O
).	O

Copolymers	B-CHED
were	O
tested	O
for	O
functional	O
efficacy	O
by	O
measuring	O
both	O
albumin	O
permeability	O
(	O
P	O
(	O
DA	O
))	O
and	O
hydraulic	O
conductivity	O
(	O
L	O
(	O
p	O
))	O
across	O
cultured	O
endothelial	O
monolayers	O
.	O

There	O
are	O
six	O
amino	B-CHED
acid	I-CHED
changes	O
in	O
rdACE2	O
compared	O
with	O
huACE2	O
,	O
and	O
four	O
changes	O
compared	O
with	O
pcACE2	O
,	O
within	O
the	O
18	O
residues	O
of	O
ACE2	O
known	O
to	O
make	O
direct	O
contact	O
with	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
.	O

The	O
full	O
genome	O
of	O
the	O
IBADAN	O
reference	O
strain	O
(	O
NGA	O
/	O
A116E7	O
/	O
2006	O
)	O
had	O
a	O
genetic	O
distance	O
of	O
9	O
.	O
7	O
-	O
16	O
.	O
4	O
%	O
at	O
the	O
nucleotide	B-CHED
level	O
with	O
all	O
available	O
fully	O
sequenced	O
strains	O
.	O

A	O
comparison	O
of	O
S1	O
sequences	O
identified	O
several	O
amino	B-CHED
acids	I-CHED
that	O
may	O
play	O
a	O
role	O
in	O
IBV	O
antigenicity	O
.	O

An	O
approximately	O
70	O
kDa	O
fragment	O
of	O
the	O
N	O
-	O
terminal	O
globular	O
domain	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
(	O
SN	O
protein	B-CHED
)	O
from	O
the	O
coronavirus	O
TGEV	O
was	O
used	O
as	O
the	O
transmissible	O
gastroenteritis	O
virus	O
antigen	B-CHED
model	O
.	O

However	O
,	O
in	O
this	O
regard	O
not	O
much	O
work	O
has	O
been	O
done	O
in	O
avian	O
medicine	B-CHED
.	O

Here	O
we	O
expand	O
this	O
range	O
of	O
the	O
spectral	O
density	O
to	O
low	O
fields	O
through	O
field	O
cycling	O
using	O
the	O
nucleocapsid	O
protein	B-CHED
of	O
the	O
SARS	O
coronavirus	O
as	O
a	O
model	O
system	O
.	O

At	O
present	O
long	O
-	O
term	O
oxygen	B-CHED
therapy	O
(	O
LTOT	O
)	O
is	O
the	O
logical	O
treatment	O
of	O
PH	O
since	O
alveolar	O
hypoxia	O
is	O
considered	O
to	O
be	O
the	O
major	O
determinant	O
of	O
the	O
elevation	O
of	O
PAP	B-CHED
and	O
PVR	O
.	O

Upon	O
the	O
basis	O
of	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
inhibitor	B-CHED
24	O
-	O
bound	O
to	O
SARS	O
-	O
CoV	O
PLpro	O
,	O
a	O
drug	O
design	O
template	O
was	O
created	O
.	O

The	O
gene	O
that	O
encodes	O
a	O
double	O
-	O
mutant	O
IBV	O
nsp2	O
N	O
-	O
terminal	O
domain	O
(	O
residues	O
9	O
-	O
393	O
of	O
the	O
polyprotein	O
,	O
with	O
mutations	O
Q132L	O
and	O
L270F	O
)	O
was	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
the	O
protein	B-CHED
was	O
subjected	O
to	O
crystallization	O
trials	O
.	O

Therefore	O
,	O
the	O
LSPCF	O
fiber	O
-	O
optic	O
biosensor	O
shows	O
an	O
ability	O
to	O
detect	O
very	O
low	O
concentration	O
(	O
approximately	O
1	O
pg	O
/	O
mL	O
)	O
of	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
in	O
serum	O
.	O

Both	O
cases	O
had	O
a	O
history	O
of	O
COPD	O
and	O
had	O
received	O
systemic	O
steroid	B-CHED
treatment	O
before	O
or	O
during	O
admission	O
.	O

Case	O
2	O
received	O
albendazole	B-CHED
and	O
antibiotic	B-CHED
treatment	O
for	O
over	O
2	O
weeks	O
,	O
but	O
developed	O
refractory	O
aseptic	O
meningitis	O
and	O
died	O
of	O
septic	O
shock	O
.	O

In	O
a	O
model	O
of	O
LPS	B-CHED
-	O
induced	O
ALI	O
,	O
VASP	O
(-/-)	O
mice	O
demonstrated	O
increased	O
pulmonary	O
damage	O
compared	O
with	O
wild	O
-	O
type	O
animals	O
.	O

The	O
binding	O
affinities	O
of	O
the	O
truncated	O
N	O
proteins	B-CHED
and	O
RNA	O
follow	O
the	O
order	O
:	O
residues	O
1	O
-	O
173	O
-	O
residues	O
233	O
-	O
300	O
>	O
residues	O
174	O
-	O
232	O
.	O

CONCLUSIONS	O
:	O
Common	O
household	O
disinfectants	B-CHED
and	O
antiseptics	O
were	O
effective	O
at	O
inactivating	O
MHV	O
,	O
a	O
possible	O
surrogate	O
for	O
SARS	O
-	O
CoV	O
,	O
from	O
surfaces	O
when	O
used	O
as	O
directed	O
.	O

ABSTRACT	O
:	O
Multiple	O
sclerosis	O
(	O
MS	O
)	O
is	O
an	O
inflammatory	O
demyelinating	O
disease	O
of	O
the	O
CNS	B-CHED
.	O

In	O
the	O
current	O
studies	O
,	O
neurotropic	O
strains	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
that	O
induce	O
meningitis	O
,	O
encephalitis	O
,	O
and	O
demyelination	O
in	O
the	O
CNS	B-CHED
,	O
an	O
animal	O
model	O
of	O
MS	O
,	O
were	O
used	O
to	O
evaluate	O
mechanisms	O
of	O
axonal	O
injury	O
.	O

These	O
results	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
neuroprotective	O
strategies	O
for	O
CNS	B-CHED
demyelinating	O
disease	O
,	O
and	O
our	O
model	O
identifies	O
the	O
spike	O
protein	B-CHED
as	O
a	O
therapeutic	O
target	O
to	O
prevent	O
axonal	O
transport	O
of	O
neurotropic	O
viruses	O
.	O

Methicillin	B-CHED
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
rates	O
increased	O
from	O
1999	O
to	O
2005	O
(	O
F	O
=	O
9	O
.	O
4	O
,	O
P	O
=	O
0	O
.	O
003	O
).	O

The	O
proportion	O
of	O
hospitals	O
that	O
reported	O
having	O
new	O
nosocomial	O
Vancomycin	B-CHED
-	O
resistant	O
Enterococcus	O
(	O
VRE	O
)	O
cases	O
was	O
greater	O
in	O
2005	O
than	O
in	O
1999	O
(	O
X	O
=	O
10	O
.	O
5	O
,	O
P	O
=	O
0	O
.	O
001	O
).	O

Upon	O
receptor	O
binding	O
,	O
the	O
spike	O
(	O
S	O
)	O
proteins	B-CHED
of	O
both	O
viruses	O
are	O
activated	O
for	O
membrane	O
fusion	O
by	O
proteases	O
,	O
such	O
as	O
trypsin	O
,	O
present	O
in	O
the	O
environment	O
,	O
facilitating	O
virus	O
entry	O
from	O
the	O
cell	O
surface	O
.	O

The	O
exposure	O
of	O
receptor	O
-	O
bound	O
S	O
protein	B-CHED
to	O
trypsin	O
or	O
cathepsin	O
L	O
(	O
CPL	O
)	O
induces	O
the	O
formation	O
of	O
six	O
-	O
helix	O
bundles	O
(	O
6HB	O
),	O
the	O
final	O
conformation	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
the	O
efficacy	O
of	O
rhesus	O
theta	O
-	O
defensin	O
1	O
(	O
RTD	O
-	O
1	O
),	O
a	O
novel	O
cyclic	O
antimicrobial	B-CHED
peptide	B-CHED
,	O
as	O
a	O
prophylactic	O
antiviral	B-CHED
in	O
a	O
mouse	O
model	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
lung	O
disease	O
.	O

We	O
performed	O
a	O
prospective	O
,	O
multicenter	O
,	O
observational	O
study	O
to	O
investigate	O
the	O
time	O
-	O
course	O
of	O
lipopolysaccharide	B-CHED
binding	O
protein	B-CHED
(	O
LBP	B-CHED
)	O
serum	O
levels	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
examined	O
whether	O
serial	O
serum	O
levels	O
of	O
LBP	B-CHED
could	O
be	O
used	O
as	O
a	O
marker	O
of	O
outcome	O
.	O

While	O
comparing	O
the	O
interactions	O
that	O
humans	O
and	O
bats	O
establish	O
with	O
Lyssavirus	O
,	O
scientists	O
try	O
to	O
understand	O
the	O
molecular	O
basis	O
ofpathogenicity	O
in	O
man	B-CHED
,	O
a	O
indispensable	O
prerequisite	O
to	O
identify	O
antiviral	B-CHED
targets	O
in	O
a	O
perspective	O
of	O
therapy	O
.	O

At	O
higher	O
applied	O
voltages	O
,	O
more	O
virus	O
particles	O
were	O
captured	O
from	O
air	B-CHED
with	O
maximum	O
log	O
reductions	O
of	O
6	O
.	O
8	O
and	O
6	O
.	O
3	O
for	O
the	O
plaque	O
assay	O
and	O
4	O
.	O
2	O
and	O
3	O
.	O
5	O
for	O
the	O
qPCR	O
assay	O
at	O
-	O
10	O
kV	O
for	O
T3	O
and	O
MS2	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
A	O
new	O
commercially	O
available	O
antigen	B-CHED
-	O
capture	O
,	O
blocking	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
antigen	B-CHED
-	O
capture	O
b	O
-	O
ELISA	O
),	O
based	O
on	O
baculovirus	O
truncated	O
-	O
S	O
recombinant	O
protein	B-CHED
of	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
and	O
3	O
specific	O
monoclonal	O
antibodies	O
,	O
was	O
developed	O
and	O
evaluated	O
by	O
examining	O
a	O
panel	O
of	O
453	O
positive	O
Porcine	O
respiratory	O
coronavirus	O
(	O
PRCoV	O
),	O
31	O
positive	O
TGEV	O
,	O
and	O
126	O
negative	O
field	O
sera	O
by	O
using	O
another	O
commercially	O
available	O
differential	O
coronavirus	O
b	O
-	O
ELISA	O
as	O
the	O
reference	O
technique	O
to	O
differentiate	O
TGEV	O
-	O
from	O
PRCoV	O
-	O
induced	O
antibodies	O
.	O

The	O
recombinant	O
S	O
protein	B-CHED
-	O
based	O
ELISA	O
appeared	O
to	O
be	O
100	O
%	O
sensitive	O
for	O
TGEV	O
and	O
PRCoV	O
detection	O
and	O
highly	O
specific	O
for	O
TGEV	O
and	O
PRCoV	O
detection	O
(	O
100	O
%	O
and	O
92	O
.	O
06	O
%,	O
respectively	O
),	O
when	O
qualitative	O
results	O
(	O
positive	O
or	O
negative	O
)	O
were	O
compared	O
with	O
those	O
of	O
the	O
reference	O
technique	O
.	O

The	O
AIV	O
matrix	O
protein	B-CHED
(	O
M	O
),	O
and	O
HA	O
and	O
NA	O
genes	O
,	O
IBV	O
nucleoprotein	O
(	O
NP	O
)	O
gene	O
,	O
NDV	O
NP	O
gene	O
,	O
and	O
IBDV	O
A	O
fragment	O
gene	O
were	O
cloned	O
into	O
plasmids	O
.	O

ABSTRACT	O
:	O
A	O
rapid	O
antiviral	B-CHED
immune	O
response	O
may	O
be	O
related	O
to	O
viral	O
interaction	O
with	O
the	O
host	O
cell	O
leading	O
to	O
activation	O
of	O
macrophages	O
via	O
pattern	O
recognition	O
receptors	O
(	O
PPRs	O
)	O
or	O
specific	O
viral	O
receptors	O
.	O

Depending	O
on	O
mouse	O
strain	O
,	O
the	O
viral	O
fixation	O
to	O
heparan	B-CHED
sulfate	I-CHED
/	O
TLR2	O
stimulated	O
differently	O
the	O
p38	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinase	O
(	O
MAPK	O
)	O
and	O
nuclear	O
factor	O
(	O
NF	O
)-	O
kappaB	O
in	O
the	O
induction	O
of	O
IL	O
-	O
6	O
and	O
TNF	O
-	O
alpha	O
.	O

TITLE	O
:	O
A	O
synergistic	O
interferon	O
-	O
gamma	O
production	O
is	O
induced	O
by	O
mouse	O
hepatitis	O
virus	O
in	O
interleukin	O
-	O
12	O
(	O
IL	O
-	O
12	O
)/	O
IL	O
-	O
18	O
-	O
activated	O
natural	O
killer	O
cells	O
and	O
modulated	O
by	O
carcinoembryonic	O
antigen	B-CHED
-	O
related	O
cell	O
adhesion	O
molecules	O
(	O
CEACAM	O
)	O
1a	O
receptor	O
.	O

TITLE	O
:	O
Efficient	O
induction	O
of	O
cytotoxic	O
T	O
lymphocytes	O
specific	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
by	O
immunization	O
with	O
surface	O
-	O
linked	O
liposomal	O
peptides	B-CHED
derived	O
from	O
a	O
non	O
-	O
structural	O
polyprotein	O
1a	O
.	O

Six	O
liposomal	O
peptides	B-CHED
effectively	O
induced	O
IFN	O
-	O
gamma	O
-	O
producing	O
CD8	O
(+)	O
T	O
cells	O
and	O
seven	O
liposomal	O
peptides	B-CHED
including	O
the	O
six	O
peptides	B-CHED
primed	O
CTLs	O
showing	O
in	O
vivo	O
killing	O
activities	O
.	O

Further	O
,	O
CTLs	O
induced	O
by	O
the	O
seven	O
liposomal	O
peptides	B-CHED
lysed	O
an	O
HLA	O
-	O
A	O
*	O
0201	O
positive	O
cell	O
line	O
expressing	O
naturally	O
processed	O
,	O
pp1a	O
-	O
derived	O
peptides	B-CHED
.	O

Of	O
note	O
,	O
one	O
of	O
the	O
liposomal	O
peptides	B-CHED
induced	O
high	O
numbers	O
of	O
long	O
-	O
lasting	O
memory	O
CTLs	O
.	O

Diarrheic	O
samples	O
(	O
n	O
=	O
191	O
)	O
were	O
assayed	O
for	O
rotavirus	O
group	O
A	O
,	O
bovine	O
coronavirus	O
(	O
BCoV	O
),	O
Cryptosporidium	O
,	O
and	O
Escherichia	O
coli	O
F5	O
by	O
antigen	B-CHED
ELISA	O
.	O

Glycogen	B-CHED
content	O
(	O
mg	O
/	O
g	O
tissue	O
)	O
from	O
different	O
tissues	O
was	O
measured	O
using	O
the	O
anthrone	B-CHED
reagent	B-CHED
.	O

general	O
ward	O
:	O
110	O
patients	O
with	O
oxygen	B-CHED
saturation	O
<	O
96	O
%	O
and	O
/	O
or	O
risk	O
factors	O
(	O
65	O
.	O
5	O
%	O
had	O
asthma	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
obesity	O
,	O
pregnancy	O
or	O
other	O
)	O
were	O
admitted	O
(	O
5	O
times	O
more	O
than	O
in	O
1999	O
-	O
2006	O
).	O

ABSTRACT	O
:	O
A	O
56	O
-	O
year	O
-	O
old	O
previously	O
healthy	O
man	B-CHED
was	O
admitted	O
to	O
our	O
hospital	O
with	O
a	O
severe	O
chest	O
pain	O
that	O
started	O
shortly	O
after	O
being	O
stung	O
by	O
a	O
honeybee	O
.	O

The	O
enhanced	O
protection	O
appears	O
to	O
be	O
dependent	O
upon	O
the	O
prior	O
development	O
of	O
inducible	O
bronchus	O
-	O
associated	O
lymphoid	O
tissue	O
(	O
iBALT	O
)	O
in	O
the	O
lung	O
in	O
response	O
to	O
the	O
PCN	B-CHED
treatment	O
and	O
to	O
be	O
mediated	O
through	O
CD4	O
+	O
T	O
cell	O
and	O
B	O
cell	O
dependent	O
mechanisms	O
.	O

Furthermore	O
,	O
GADD34	O
,	O
a	O
component	O
of	O
the	O
protein	B-CHED
phosphatase	O
1	O
(	O
PP1	O
)	O
complex	O
,	O
which	O
dephosphorylates	O
eIF	O
-	O
2alpha	O
,	O
was	O
significantly	O
induced	O
in	O
IBV	O
-	O
infected	O
cells	O
.	O

Inhibition	O
of	O
the	O
PP1	O
activity	O
by	O
okadaic	B-CHED
acid	I-CHED
and	O
overexpression	O
of	O
GADD34	O
,	O
eIF	O
-	O
2alpha	O
,	O
and	O
PKR	O
,	O
as	O
well	O
as	O
their	O
mutant	O
constructs	O
in	O
virus	O
-	O
infected	O
cells	O
,	O
showed	O
that	O
these	O
viral	O
regulatory	O
strategies	O
played	O
a	O
synergistic	O
role	O
in	O
facilitating	O
coronavirus	O
replication	O
.	O

TITLE	O
:	O
Bid	O
cleavage	O
,	O
cytochrome	B-CHED
c	I-CHED
release	O
and	O
caspase	O
activation	O
in	O
canine	O
coronavirus	O
-	O
induced	O
apoptosis	O
.	O

TITLE	O
:	O
Coronavirus	O
N	O
protein	B-CHED
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
specifically	O
binds	O
the	O
transcriptional	O
regulatory	O
sequence	O
(	O
TRS	O
)	O
and	O
melts	O
TRS	O
-	O
cTRS	O
RNA	O
duplexes	O
.	O

ABSTRACT	O
:	O
All	O
coronaviruses	O
(	O
CoVs	O
),	O
including	O
the	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
encode	O
a	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
that	O
harbors	O
two	O
independent	O
RNA	O
binding	O
domains	O
of	O
known	O
structure	O
,	O
but	O
poorly	O
characterized	O
RNA	O
binding	O
properties	O
.	O

Compared	O
to	O
those	O
of	O
the	O
rFPV	O
-	O
IBVS1	O
and	O
the	O
attenuated	O
live	O
IB	O
vaccine	O
groups	O
,	O
chickens	O
in	O
the	O
rFPV	O
-	O
IBVS1	O
-	O
ChIFNgamma	O
group	O
eliminated	O
virus	O
more	O
quickly	O
and	O
decreased	O
the	O
presence	O
of	O
viral	O
antigen	B-CHED
more	O
significantly	O
in	O
renal	O
tissue	O
.	O

Both	O
virus	O
-	O
specific	O
CD4	O
and	O
CD8	O
T	O
cells	O
are	O
functional	O
,	O
as	O
assessed	O
by	O
cytokine	O
expression	O
and	O
degranulation	O
after	O
peptide	B-CHED
exposure	O
.	O

Viral	O
sequences	O
from	O
healthy	O
cats	O
were	O
distinct	O
from	O
sick	O
cats	O
on	O
the	O
basis	O
of	O
genetic	O
distances	O
observed	O
in	O
the	O
membrane	O
and	O
nonstructural	O
protein	B-CHED
7b	O
genes	O
.	O

In	O
addition	O
,	O
5	O
membrane	O
protein	B-CHED
amino	B-CHED
acid	I-CHED
residues	O
with	O
functional	O
potential	O
differentiated	O
healthy	O
cats	O
from	O
cats	O
with	O
FIP	O
.	O

A	O
/	O
H5N1	O
nucleic	B-CHED
acid	I-CHED
was	O
detected	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
in	O
a	O
nasopharyngeal	O
aspirate	O
.	O

After	O
comprehensive	O
management	O
with	O
antiviral	B-CHED
agents	I-CHED
,	O
antibiotics	B-CHED
,	O
convalescent	O
serum	O
and	O
invasive	O
ventilation	O
,	O
her	O
clinical	O
condition	O
improved	O
and	O
turned	O
to	O
stable	O
.	O

ABSTRACT	O
:	O
Nitric	B-CHED
oxide	I-CHED
is	O
an	O
important	O
molecule	O
playing	O
a	O
key	O
role	O
in	O
a	O
broad	O
range	O
of	O
biological	O
process	O
such	O
as	O
neurotransmission	O
,	O
vasodilatation	O
and	O
immune	O
responses	O
.	O

Secondly	O
,	O
NO	O
or	O
its	O
derivatives	O
cause	O
a	O
reduction	O
in	O
viral	O
RNA	O
production	O
in	O
the	O
early	O
steps	O
of	O
viral	O
replication	O
,	O
and	O
this	O
could	O
possibly	O
be	O
due	O
to	O
an	O
effect	O
on	O
one	O
or	O
both	O
of	O
the	O
cysteine	B-CHED
proteases	O
encoded	O
in	O
Orf1a	O
of	O
SARS	O
-	O
CoV	O
.	O

The	O
autoAb	O
recognized	O
conformational	O
as	O
well	O
as	O
linear	O
antigenic	O
determinants	O
in	O
the	O
enzyme	O
,	O
and	O
the	O
autoimmune	O
response	O
was	O
not	O
entirely	O
restricted	O
to	O
molecular	O
mimicry	O
and	O
/	O
or	O
epitope	B-CHED
spreading	O
.	O

The	O
C	O
-	O
terminal	O
portion	O
of	O
the	O
enzyme	O
(	O
sequence	O
390	O
-	O
419	O
)	O
presented	O
only	O
one	O
major	O
epitope	B-CHED
,	O
located	O
between	O
residues	O
390	O
and	O
409	O
.	O

Death	O
of	O
probable	O
SARS	O
cases	O
was	O
only	O
significantly	O
associated	O
with	O
high	O
age	O
and	O
use	O
of	O
a	O
respiratory	O
machine	O
(	O
mainly	O
for	O
the	O
most	O
severe	O
cases	O
),	O
whereas	O
e	O
.	O
g	O
.	O
co	O
-	O
morbidity	O
and	O
steroid	B-CHED
treatment	O
showed	O
no	O
impact	O
in	O
multivariate	O
analysis	O
.	O

Comparison	O
of	O
the	O
deduced	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
the	O
spike	O
protein	B-CHED
in	O
the	O
CRCoV	O
and	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
strains	O
revealed	O
twenty	O
sequence	O
variations	O
.	O

The	O
dynamic	O
properties	O
of	O
the	O
different	O
states	O
,	O
which	O
are	O
stabilized	O
under	O
different	O
experimental	O
conditions	O
,	O
extend	O
the	O
current	O
model	O
of	O
viral	O
membrane	O
fusion	O
and	O
give	O
insight	O
into	O
the	O
design	O
of	O
structure	O
-	O
based	O
antagonists	B-CHED
of	O
SARS	O
-	O
CoV	O
in	O
particular	O
,	O
as	O
well	O
as	O
other	O
enveloped	O
viruses	O
such	O
as	O
HIV	O
.	O

All	O
patients	O
were	O
severely	O
hypoxemic	O
(	O
mean	O
[	O
SD	O
]	O
ratio	O
of	O
Pao	B-CHED
(	O
2	O
)	O
to	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
[	O
Fio	O
(	O
2	O
)]	O
of	O
147	O
[	O
128	O
]	O
mm	O
Hg	O
)	O
at	O
ICU	O
admission	O
.	O

By	O
using	O
""""	O
rest	B-CHED
""""	O
ventilator	O
settings	O
and	O
venovenous	O
ECLS	O
,	O
the	O
patient	O
remained	O
stable	O
for	O
a	O
total	O
of	O
6	O
.	O
5	O
days	O
(	O
160	O
hours	O
)	O
when	O
he	O
was	O
successfully	O
transitioned	O
to	O
a	O
conventional	O
ventilator	O
and	O
decannulated	O
.	O

The	O
patient	O
was	O
discharged	O
home	O
on	O
hospital	O
day	O
50	O
on	O
room	O
air	B-CHED
.	O

ABSTRACT	O
:	O
The	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
structure	O
of	O
a	O
globular	O
domain	O
of	O
residues	O
1071	O
to	O
1178	O
within	O
the	O
previously	O
annotated	O
nucleic	B-CHED
acid	I-CHED
-	O
binding	O
region	O
(	O
NAB	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nonstructural	O
protein	B-CHED
3	O
(	O
nsp3	O
)	O
has	O
been	O
determined	O
,	O
and	O
N	O
-	O
and	O
C	O
-	O
terminally	O
adjoining	O
polypeptide	B-CHED
segments	O
of	O
37	O
and	O
25	O
residues	O
,	O
respectively	O
,	O
have	O
been	O
shown	O
to	O
form	O
flexibly	O
extended	O
linkers	O
to	O
the	O
preceding	O
globular	O
domain	O
and	O
to	O
the	O
following	O
,	O
as	O
yet	O
uncharacterized	O
domain	O
.	O

This	O
binding	O
site	O
is	O
similar	O
to	O
the	O
ssRNA	O
-	O
binding	O
site	O
of	O
the	O
sterile	O
alpha	O
motif	O
domain	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
Vts1p	O
protein	B-CHED
,	O
although	O
the	O
two	O
proteins	B-CHED
do	O
not	O
share	O
a	O
common	O
globular	O
fold	O
.	O

Overall	O
,	O
detection	O
of	O
a	O
viral	O
etiological	O
agent	O
was	O
achieved	O
in	O
90	O
.	O
8	O
%	O
of	O
outbreaks	O
using	O
a	O
combination	O
of	O
DFA	B-CHED
,	O
NATs	O
,	O
and	O
RVP	O
.	O

The	O
other	O
available	O
treatment	O
[	O
such	O
as	O
cytotoxic	O
agents	O
,	O
steroids	B-CHED
]	O
may	O
lead	O
to	O
life	O
-	O
threatening	O
complications	O
and	O
may	O
be	O
difficult	O
to	O
manage	O
in	O
the	O
long	O
term	O
.	O

ABSTRACT	O
:	O
A	O
rare	O
side	O
effect	O
of	O
antipsychotic	O
medication	O
is	O
neuroleptic	B-CHED
malignant	O
syndrome	O
,	O
mainly	O
characterized	O
by	O
hyperthermia	O
,	O
altered	O
mental	O
state	O
,	O
haemodynamic	O
dysregulation	O
,	O
elevated	O
serum	O
creatine	B-CHED
kinase	O
and	O
rigor	O
.	O

The	O
prevalence	O
of	O
neuroleptic	B-CHED
malignant	O
syndrome	O
is	O
between	O
0	O
.	O
02	O
%	O
and	O
2	O
.	O
44	O
%	O
for	O
patients	O
taking	O
neuroleptics	B-CHED
and	O
it	O
is	O
not	O
necessary	O
to	O
fulfil	O
all	O
cardinal	O
features	O
characterizing	O
the	O
syndrome	O
to	O
be	O
diagnosed	O
with	O
neuroleptic	B-CHED
malignant	O
syndrome	O
.	O

CONCLUSIONS	O
:	O
Numerous	O
case	O
reports	O
have	O
been	O
published	O
about	O
patients	O
who	O
developed	O
neuroleptic	B-CHED
malignant	O
syndrome	O
due	O
to	O
Olanzapin	O
(	O
Zyprexa	B-CHED
(	O
R	O
))	O
medication	O
.	O

An	O
alternative	O
heavy	O
immunosuppressive	O
therapy	O
was	O
administered	O
combining	O
cyclophosphamide	B-CHED
10	O
mg	O
/	O
kg	O
/	O
day	O
for	O
10	O
days	O
with	O
methylprednisolone	B-CHED
40	O
mg	O
/	O
kg	O
/	O
day	O
for	O
5	O
days	O
,	O
which	O
was	O
then	O
tapered	O
down	O
over	O
3	O
weeks	O
.	O

Current	O
concepts	O
of	O
MAS	B-CHED
pathophysiology	O
.	O

Finally	O
,	O
risk	O
factors	O
for	O
MAS	B-CHED
development	O
to	O
identify	O
those	O
newborns	O
that	O
develop	O
MAS	B-CHED
and	O
those	O
who	O
do	O
not	O
are	O
discussed	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nsp1	O
protein	B-CHED
suppresses	O
host	O
gene	O
expression	O
,	O
including	O
type	O
I	O
interferon	O
production	O
,	O
by	O
promoting	O
host	O
mRNA	B-CHED
degradation	O
and	O
inhibiting	O
host	O
translation	O
,	O
in	O
infected	O
cells	O
.	O

Furthermore	O
,	O
the	O
nsp1	O
-	O
40S	O
ribosome	O
complex	O
induced	O
the	O
modification	O
of	O
the	O
5	O
'	O
region	O
of	O
capped	O
mRNA	B-CHED
template	O
and	O
rendered	O
the	O
template	B-CHED
RNA	I-CHED
translationally	O
incompetent	O
.	O

As	O
this	O
mutant	O
virus	O
is	O
more	O
neurovirulent	O
in	O
mice	O
,	O
our	O
results	O
also	O
suggest	O
that	O
two	O
mutations	O
in	O
the	O
S	O
glycoprotein	B-CHED
could	O
eventually	O
modulate	O
viral	O
neuropathogenesis	O
.	O

Acute	O
respiratory	O
distress	O
syndrome	O
was	O
induced	O
by	O
lipopolysaccharide	B-CHED
infusion	O
.	O

Furthermore	O
,	O
angiotensin	B-CHED
II	I-CHED
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
levels	O
,	O
both	O
of	O
which	O
were	O
substantially	O
increased	O
,	O
returned	O
to	O
basal	O
values	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
novel	O
linear	O
B	O
-	O
cell	O
epitope	B-CHED
in	O
the	O
M	O
protein	B-CHED
of	O
avian	O
infectious	O
bronchitis	O
coronaviruses	O
.	O

ELISA	O
and	O
western	O
blotting	O
also	O
showed	O
that	O
this	O
epitope	B-CHED
could	O
be	O
recognized	O
by	O
IBV	O
-	O
positive	O
serum	O
from	O
chicken	O
.	O

TITLE	O
:	O
A	O
new	O
mouse	O
-	O
adapted	O
strain	O
of	O
SARS	O
-	O
CoV	O
as	O
a	O
lethal	O
model	O
for	O
evaluating	O
antiviral	B-CHED
agents	I-CHED
in	O
vitro	O
and	O
in	O
vivo	O
.	O

It	O
had	O
nine	O
mutations	O
affecting	O
10	O
amino	B-CHED
acid	I-CHED
residues	O
.	O

In	O
vitro	O
efficacy	O
against	O
v2163	O
was	O
shown	O
with	O
known	O
inhibitors	B-CHED
of	O
SARS	O
-	O
CoV	O
replication	O
.	O

Alanine	B-CHED
scanning	O
mutagenesis	O
was	O
performed	O
to	O
assess	O
the	O
roles	O
of	O
individual	O
residues	O
within	O
this	O
region	O
of	O
S	O
,	O
which	O
was	O
previously	O
uncharacterized	O
.	O

Genomics	O
tools	O
such	O
as	O
high	O
-	O
throughput	O
sequencing	O
,	O
mRNA	B-CHED
expression	O
profiling	O
,	O
and	O
microarray	O
-	O
based	O
analysis	O
of	O
single	O
nucleotide	B-CHED
polymorphisms	O
are	O
providing	O
unprecedented	O
ways	O
to	O
analyze	O
the	O
diversity	O
of	O
the	O
genomes	O
of	O
emerging	O
pathogens	O
as	O
well	O
as	O
the	O
molecular	O
basis	O
of	O
the	O
host	O
response	O
to	O
them	O
.	O

While	O
mAb	O
341C	O
binds	O
to	O
a	O
mostly	O
linear	O
epitope	B-CHED
composed	O
of	O
residues	O
(	O
507	O
)	O
PAT	O
(	O
509	O
)	O
and	O
V	O
(	O
349	O
),	O
mAb	O
240C	O
binds	O
to	O
an	O
epitope	B-CHED
that	O
partially	O
overlaps	O
the	O
former	O
by	O
at	O
least	O
two	O
residues	O
(	O
P	O
(	O
507	O
)	O
and	O
A	O
(	O
508	O
)).	O

The	O
epitope	B-CHED
corresponding	O
to	O
mAb	O
540C	O
is	O
a	O
conformational	O
one	O
,	O
involving	O
residues	O
L	O
(	O
504	O
)	O
and	O
N	O
(	O
505	O
).	O

However	O
,	O
thus	O
far	O
full	O
-	O
length	O
nsp12	O
has	O
proven	O
refractory	O
to	O
expression	O
in	O
bacterial	O
systems	O
,	O
which	O
has	O
hindered	O
both	O
the	O
biochemical	O
characterization	O
of	O
coronavirus	O
RNA	O
synthesis	O
and	O
RdRp	O
-	O
targeted	O
antiviral	B-CHED
drug	I-CHED
design	O
.	O

TITLE	O
:	O
Evaluating	O
protein	B-CHED
similarity	O
from	O
coarse	O
structures	O
.	O

To	O
verify	O
the	O
proposed	O
method	O
,	O
numerical	O
experiments	O
are	O
conducted	O
in	O
four	O
different	O
protein	B-CHED
data	O
sets	O
.	O

The	O
majority	O
of	O
patients	O
had	O
proteinuria	O
(	O
98	O
%),	O
with	O
25	O
%	O
having	O
proteinuria	O
in	O
the	O
nephrotic	O
range	O
(	O
proteinuria	O
/	O
urinary	O
creatinine	B-CHED
>	O
3	O
g	O
/	O
g	O
).	O

We	O
have	O
developed	O
a	O
pulmonary	O
formulation	O
of	O
tissue	O
plasminogen	O
activator	O
(	O
pf	O
-	O
tPA	B-CHED
)	O
that	O
withstands	O
nebulization	O
and	O
reaches	O
the	O
lower	O
airways	O
.	O

Antibiotic	B-CHED
therapy	O
does	O
not	O
significantly	O
benefit	O
most	O
patients	O
with	O
AOM	O
,	O
but	O
long	O
-	O
term	O
prophylactic	O
antibiotic	B-CHED
therapy	O
can	O
reduce	O
the	O
risk	O
of	O
otitis	O
media	O
recurrence	O
among	O
children	O
at	O
high	O
risk	O
.	O

ABSTRACT	O
:	O
Viruses	O
employ	O
different	O
strategies	O
to	O
circumvent	O
the	O
antiviral	B-CHED
actions	O
of	O
the	O
innate	O
immune	O
response	O
.	O

In	O
addition	O
,	O
these	O
patients	O
may	O
have	O
sepsis	O
-	O
induced	O
hyperglycemia	O
,	O
defective	O
arginine	B-CHED
-	O
vasopressin	B-CHED
secretion	O
,	O
adrenal	O
insufficiency	O
,	O
or	O
compartmental	O
syndrome	O
.	O

Finally	O
,	O
overexpression	O
of	O
ADP	B-CHED
-	O
ribosylation	O
factor	O
1	O
(	O
Arf1	O
),	O
a	O
small	O
GTPase	O
essential	O
for	O
the	O
maintenance	O
of	O
the	O
Golgi	O
apparatus	O
,	O
restored	O
Golgi	O
morphology	O
during	O
infection	O
.	O

Other	O
medical	O
concerns	O
include	O
recurrent	O
oral	O
staphylococcal	O
infections	O
,	O
otitis	O
media	O
,	O
ocular	O
herpes	O
simplex	O
virus	O
keratitis	O
,	O
asthma	O
,	O
steroid	B-CHED
-	O
induced	O
gastritis	O
,	O
steroid	B-CHED
-	O
induced	O
cataracts	O
,	O
recurrent	O
upper	O
respiratory	O
infections	O
,	O
and	O
acute	O
pharyngitis	O
.	O

Treatment	O
of	O
JHMV	O
-	O
infected	O
mice	O
with	O
anti	O
-	O
CXCR2	O
blocking	O
antibody	O
reduced	O
PMN	O
trafficking	O
into	O
the	O
CNS	B-CHED
by	O
>	O
95	O
%,	O
dampened	O
MMP	B-CHED
-	O
9	O
activity	O
,	O
and	O
abrogated	O
blood	O
-	O
brain	O
-	O
barrier	O
(	O
BBB	B-CHED
)	O
breakdown	O
.	O

Pooling	O
across	O
all	O
trials	O
,	O
corticosteroids	B-CHED
did	O
not	O
significantly	O
reduce	O
hospital	O
mortality	O
(	O
relative	O
risk	O
,	O
0	O
.	O
84	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
66	O
-	O
1	O
.	O
06	O
).	O

Interestingly	O
,	O
there	O
are	O
two	O
serotypes	O
,	O
type	O
I	O
and	O
type	O
II	O
FCoVs	O
,	O
that	O
can	O
cause	O
both	O
persistent	O
infection	O
and	O
FIP	O
,	O
even	O
though	O
their	O
main	O
determinant	O
of	O
host	O
cell	O
tropism	O
,	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
,	O
is	O
of	O
different	O
phylogeny	O
and	O
displays	O
limited	O
sequence	O
identity	O
.	O

A	O
specific	O
one	O
-	O
step	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RRT	O
-	O
PCR	O
)	O
assay	O
for	O
detection	O
and	O
quantitation	O
of	O
TCoV	O
in	O
the	O
turkey	O
tissues	O
was	O
developed	O
using	O
a	O
dual	O
-	O
labeled	O
fluorescent	B-CHED
probe	I-CHED
.	O

The	O
fluorogenic	O
probe	O
labeled	O
with	O
a	O
reporter	O
dye	B-CHED
(	O
FAM	O
,	O
6	O
-	O
carboxytetramethylrhodamin	O
)	O
and	O
a	O
quencher	O
dye	B-CHED
(	O
AbsoluteQuencher	O
)	O
was	O
designed	O
to	O
bind	O
to	O
a	O
186	O
base	O
-	O
pair	O
fragment	O
flanked	O
by	O
the	O
two	O
PCR	O
primers	O
targeting	O
the	O
3	O
'	O
end	O
of	O
spike	O
gene	O
of	O
TCoV	O
.	O
The	O
assay	O
was	O
performed	O
on	O
different	O
avian	O
viruses	O
and	O
bacteria	O
to	O
determine	O
the	O
specificity	O
as	O
well	O
as	O
serial	O
dilutions	O
of	O
TCoV	O
for	O
the	O
sensitivity	O
.	O

Mutation	O
of	O
R667	O
or	O
R797	O
did	O
not	O
affect	O
the	O
expression	O
of	O
S	O
-	O
protein	B-CHED
but	O
resulted	O
in	O
a	O
differential	O
efficacy	O
of	O
pseudotyping	O
into	O
SARS	O
-	O
CoVpp	O
.	O

A	O
recent	O
meta	O
-	O
analysis	O
provides	O
support	O
for	O
prolonged	O
corticosteroid	B-CHED
treatment	O
in	O
ALI	O
-	O
ARDS	O
.	O

TITLE	O
:	O
Caring	O
for	O
HIV	O
-	O
infected	O
patients	O
in	O
the	O
ICU	O
in	O
the	O
highly	O
active	O
antiretroviral	O
therapy	O
era	B-CHED
.	O

Due	O
to	O
their	O
antimicrobial	B-CHED
properties	O
and	O
immunostimulatory	O
activity	O
,	O
beta	O
-	O
defensins	O
are	O
potential	O
tools	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
respiratory	O
disease	O
.	O

Furthermore	O
CBD103	O
was	O
demonstrated	O
to	O
have	O
antimicrobial	B-CHED
activity	O
against	O
the	O
respiratory	O
pathogen	O
Bordetella	O
bronchiseptica	O
.	O

Rapid	O
influenza	O
antigen	B-CHED
testing	O
was	O
negative	O
.	O

Compared	O
with	O
the	O
Salt	B-CHED
Lake	O
County	O
population	O
,	O
patients	O
with	O
novel	O
A	O
(	O
H1N1	O
)	O
were	O
more	O
likely	O
to	O
be	O
obese	O
(	O
22	O
%	O
vs	O
74	O
%;	O
P	O
<	O
.	O
001	O
),	O
medically	O
uninsured	O
(	O
14	O
%	O
vs	O
45	O
%;	O
P	O
<	O
.	O
001	O
),	O
and	O
Hispanic	O
(	O
13	O
%	O
vs	O
23	O
%;	O
P	O
<	O
.	O
01	O
)	O
or	O
Pacific	O
Islander	O
(	O
1	O
%	O
vs	O
26	O
%;	O
P	O
<	O
.	O
001	O
).	O

An	O
increasing	O
body	O
of	O
evidence	O
suggests	O
that	O
kidney	O
and	O
lung	O
interact	O
(	O
crosstalk	O
)	O
during	O
severe	O
insults	O
,	O
such	O
as	O
shock	O
,	O
trauma	O
,	O
and	O
sepsis	O
,	O
due	O
to	O
a	O
loss	O
of	O
the	O
normal	O
balance	B-CHED
of	O
immune	O
,	O
inflammatory	O
and	O
soluble	O
mediators	O
.	O

Extracorporeal	O
CO2	B-CHED
removal	O
and	O
renal	O
replacement	O
associated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
might	O
be	O
interesting	O
options	O
for	O
a	O
future	O
approach	O
to	O
pulmonary	O
/	O
renal	O
syndrome	O
.	O

While	O
a	O
substantial	O
IFN	O
-	O
alpha	O
response	O
was	O
also	O
elicited	O
from	O
the	O
porcine	O
pDCs	O
by	O
pseudorabies	O
virus	O
(	O
PrV	O
),	O
swine	O
influenza	O
virus	O
(	O
SIV	O
),	O
and	O
TLR7	O
and	O
9	O
agonists	B-CHED
,	O
there	O
was	O
an	O
agent	O
-	O
dependent	O
induction	O
of	O
varying	O
amounts	O
of	O
IL	O
-	O
2	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
12	O
,	O
IFN	O
-	O
gamma	O
,	O
and	O
TNF	O
-	O
alpha	O
.	O

TITLE	O
:	O
Evidence	O
lost	B-CHED
to	O
treatment	O
of	O
critically	O
-	O
ill	O
patients	O
?	O

Treatment	O
includes	O
the	O
use	O
of	O
non	O
-	O
steroid	B-CHED
antirheumatic	B-CHED
drugs	I-CHED
and	O
corticosteroids	B-CHED
.	O

Here	O
we	O
show	O
that	O
CD8	O
(+)	O
T	O
cell	O
-	O
stimulating	O
activity	O
can	O
be	O
effectively	O
augmented	O
by	O
combining	O
DNA	O
vaccination	O
with	O
protein	B-CHED
transfer	O
.	O

C57BL	O
/	O
6	O
mice	O
were	O
injected	O
intramuscularly	O
with	O
an	O
anti	O
-	O
SARS	O
-	O
CoV	O
DNA	O
vaccine	O
admixed	O
with	O
a	O
lipid	B-CHED
-	O
derived	O
conjugate	O
of	O
4	O
-	O
1BBL	O
,	O
a	O
potential	O
CD8	O
(+)	O
T	O
-	O
cell	O
co	O
-	O
stimulator	O
.	O

TITLE	O
:	O
[	O
Exogenous	O
pulmonary	O
surfactant	B-CHED
replacement	O
combined	O
with	O
recruitment	O
maneuver	O
in	O
prevention	O
of	O
alveolar	O
derecruitment	O
in	O
rabbits	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
].	O

Compared	O
with	O
the	O
baseline	O
and	O
with	O
the	O
control	O
group	O
,	O
PIP	B-CHED
and	O
Cst	O
in	O
the	O
3	O
intervention	O
groups	O
improved	O
significantly	O
(	O
F	O
=	O
74	O
.	O
911	O
,	O
15	O
.	O
863	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
volume	O
of	O
blood	O
being	O
lost	B-CHED
can	O
be	O
reduced	O
by	O
direct	O
methods	O
where	O
possible	O
(	O
i	O
.	O
e	O
.,	O
hemostasis	O
at	O
the	O
point	O
of	O
bleeding	O
),	O
or	O
by	O
improving	O
the	O
coagulation	O
profile	O
of	O
the	O
patient	O
,	O
thereby	O
improving	O
the	O
extrinsic	O
coagulation	O
.	O

Interestingly	O
,	O
N	O
protein	B-CHED
and	O
its	O
deletion	O
mutants	O
with	O
RNA	O
chaperone	O
activity	O
enhanced	O
template	O
switching	O
in	O
a	O
retrovirus	O
-	O
derived	O
heterologous	O
system	O
,	O
reinforcing	O
the	O
concept	O
that	O
TGEV	O
N	O
protein	B-CHED
is	O
an	O
RNA	O
chaperone	O
that	O
could	O
be	O
involved	O
in	O
template	O
switching	O
.	O

In	O
heparin	B-CHED
group	O
,	O
the	O
28	O
-	O
day	O
mortality	O
was	O
statistically	O
reduced	O
(	O
15	O
.	O
4	O
%	O
vs	O
32	O
.	O
4	O
%,	O
P	O
=	O
0	O
.	O
03	O
).	O

The	O
immunized	O
mice	O
released	O
IFN	O
-	O
gamma	O
and	O
lysed	O
target	O
cells	O
upon	O
stimulation	O
with	O
Sp8	O
peptide	B-CHED
-	O
pulsed	O
autologous	O
dendritic	O
cells	O
in	O
comparison	O
to	O
other	O
candidates	O
.	O

The	O
adjusted	O
excess	O
case	O
fatality	O
ratios	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
receiving	O
the	O
combined	O
therapy	O
of	O
ribavirin	B-CHED
and	O
corticosteroids	B-CHED
within	O
2	O
days	O
of	O
admission	O
,	O
compared	O
with	O
those	O
receiving	O
neither	O
treatment	O
within	O
2	O
days	O
of	O
admission	O
,	O
were	O
3	O
.	O
8	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-	O
1	O
.	O
5	O
to	O
9	O
.	O
2	O
)	O
in	O
Hong	O
Kong	O
and	O
2	O
.	O
1	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-	O
44	O
.	O
3	O
to	O
48	O
.	O
5	O
)	O
in	O
Toronto	O
.	O

The	O
results	O
suggest	O
that	O
FCV	B-CHED
was	O
associated	O
with	O
FGS	O
in	O
some	O
of	O
the	O
cats	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
regulatory	O
network	O
to	O
explore	O
and	O
model	O
the	O
regulatory	O
relationships	O
of	O
protein	B-CHED
biomarkers	O
and	O
classify	O
different	O
disease	O
groups	O
.	O

We	O
believe	O
our	O
method	O
is	O
promising	O
in	O
mining	O
knowledge	O
of	O
protein	B-CHED
regulations	O
and	O
be	O
powerful	O
for	O
disease	O
classification	O
.	O

Both	O
crystal	O
forms	O
contained	O
large	O
solvent	B-CHED
channels	O
and	O
had	O
a	O
solvent	B-CHED
content	O
of	O
higher	O
than	O
70	O
%.	O

For	O
the	O
in	O
vivo	O
study	O
,	O
18	O
Beagle	O
puppies	O
of	O
7	O
weeks	O
of	O
age	O
were	O
divided	O
into	O
three	O
groups	O
;	O
the	O
control	O
group	O
was	O
fed	O
only	O
on	O
a	O
regular	O
diet	O
and	O
the	O
two	O
treatment	O
groups	O
were	O
fed	O
on	O
a	O
diet	O
supplemented	O
with	O
either	O
1	O
x	O
10	O
(	O
9	O
)	O
colony	O
forming	O
units	O
(	O
CFU	O
)/	O
day	O
of	O
L	O
.	O
casei	O
or	O
L	O
.	O
casei	O
expressing	O
cGM	O
-	O
CSF	O
protein	B-CHED
for	O
7	O
weeks	O
.	O

Body	O
weight	O
was	O
measured	O
,	O
and	O
fecal	O
and	O
blood	O
samples	O
were	O
collected	O
from	O
the	O
dogs	O
during	O
the	O
experiment	O
for	O
the	O
measurement	O
of	O
hematology	O
,	O
fecal	O
immunoglobulin	O
(	O
Ig	O
)	O
A	O
and	O
IgG	O
,	O
circulating	O
IgA	O
and	O
IgG	O
,	O
and	O
canine	O
corona	B-CHED
virus	O
(	O
CCV	O
)-	O
specific	O
IgG	O
.	O
There	O
were	O
no	O
differences	O
in	O
body	O
weights	O
among	O
the	O
groups	O
,	O
but	O
monocyte	O
counts	O
in	O
hematology	O
and	O
serum	O
IgA	O
were	O
higher	O
in	O
the	O
group	O
receiving	O
L	O
.	O
casei	O
expressing	O
cGMCSF	O
than	O
in	O
the	O
other	O
two	O
groups	O
.	O

The	O
multifunctional	O
nucleocapsid	O
protein	B-CHED
is	O
complexed	O
with	O
the	O
genomic	O
RNA	O
,	O
interacts	O
with	O
the	O
viral	O
membrane	O
protein	B-CHED
during	O
virion	O
assembly	O
,	O
and	O
plays	O
an	O
import	O
role	O
in	O
enhancing	O
the	O
efficiency	O
of	O
transcription	O
.	O

RESULTS	O
:	O
Rats	O
with	O
LC	O
,	O
CASP	O
,	O
LC	O
+	O
CASP	O
all	O
had	O
severe	O
lung	O
injury	O
compared	O
with	O
uninjured	O
controls	O
based	O
on	O
decreased	O
arterial	O
oxygenation	O
or	O
increased	O
BAL	B-CHED
albumin	O
at	O
5	O
or	O
24	O
hours	O
postinsult	O
.	O

Anti	O
-	O
annexin	O
A2	O
antibodies	O
bound	O
to	O
purified	O
S2	O
proteins	B-CHED
,	O
and	O
anti	O
-	O
S2	O
bound	O
to	O
immunoprecipitated	O
annexin	O
A2	O
from	O
A549	O
cell	O
lysate	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

ARDS	O
was	O
present	O
in	O
6	O
patients	O
(	O
17	O
.	O
6	O
%)	O
with	O
DPA	B-CHED
and	O
24	O
patients	O
(	O
30	O
.	O
8	O
%)	O
with	O
diversion	O
(	O
p	O
=	O
0	O
.	O
149	O
).	O

We	O
did	O
not	O
find	O
significant	O
differences	O
in	O
morbidity	O
or	O
mortality	O
when	O
we	O
compared	O
DPA	B-CHED
versus	O
diversion	O
surgical	O
treatment	O
.	O

TITLE	O
:	O
Picornaviral	O
3C	O
protease	B-CHED
inhibitors	I-CHED
and	O
the	O
dual	O
3C	O
protease	O
/	O
coronaviral	O
3C	O
-	O
like	O
protease	B-CHED
inhibitors	I-CHED
.	O

This	O
study	O
also	O
confirms	O
that	O
barbiturate	B-CHED
use	O
is	O
an	O
important	O
risk	O
factor	O
of	O
EOVAP	O
whereas	O
Methicillin	B-CHED
-	O
susceptible	O
S	O
.	O
aureus	O
was	O
found	O
to	O
be	O
the	O
main	O
pathogen	O
involved	O
in	O
EOVAP	O
.	O

Recently	O
,	O
it	O
was	O
reported	O
that	O
vitamin	B-CHED
K	I-CHED
,	O
especially	O
vitamins	B-CHED
K1	O
and	O
K2	O
,	O
exerts	O
a	O
variety	O
of	O
biological	O
effects	O
,	O
and	O
these	O
compounds	O
are	O
expected	O
to	O
be	O
candidates	O
for	O
therapeutic	O
agents	O
against	O
various	O
diseases	O
.	O

TITLE	O
:	O
Broad	O
-	O
spectrum	O
in	O
vitro	O
activity	O
and	O
in	O
vivo	O
efficacy	O
of	O
the	O
antiviral	B-CHED
protein	B-CHED
griffithsin	O
against	O
emerging	O
viruses	O
of	O
the	O
family	O
Coronaviridae	O
.	O

Our	O
results	O
provide	O
insights	O
into	O
the	O
potential	O
utility	O
of	O
air	B-CHED
travel	O
restrictions	O
on	O
controlling	O
influenza	O
pandemics	O
in	O
the	O
winter	O
of	O
2009	O
/	O
2010	O
.	O

ABSTRACT	O
:	O
Multiple	O
sclerosis	O
(	O
MS	O
)	O
is	O
a	O
progressive	O
inflammatory	O
and	O
/	O
or	O
demyelinating	O
disease	O
of	O
the	O
human	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
).	O

Overall	O
,	O
our	O
study	O
supports	O
the	O
development	O
of	O
therapeutic	O
strategies	O
based	O
on	O
nitroxides	B-CHED
to	O
manage	O
neuroinflammatory	O
diseases	O
,	O
including	O
MS	O
.	O

Of	O
these	O
,	O
49	O
met	B-CHED
inclusion	O
criteria	O
and	O
were	O
thus	O
eligible	O
to	O
participate	O
in	O
the	O
study	O
.	O

TITLE	O
:	O
Are	O
corticosteroids	B-CHED
useful	O
in	O
late	O
-	O
stage	O
acute	O
respiratory	O
distress	O
syndrome	O
?	O

However	O
the	O
mucosal	O
antigen	B-CHED
-	O
specific	O
immune	O
response	O
is	O
weak	O
because	O
most	O
protein	B-CHED
antigens	B-CHED
can	O
evoke	O
only	O
a	O
weak	O
immune	O
response	O
when	O
they	O
are	O
applied	O
mucosally	O
.	O

Unfortunately	O
,	O
the	O
development	O
of	O
safe	O
and	O
effective	O
mucosal	O
adjuvant	B-CHED
has	O
proved	O
to	O
be	O
challenging	O
.	O

However	O
,	O
48	O
h	O
after	O
infection	O
with	O
cl	O
-	O
2	O
,	O
viral	O
antigen	B-CHED
-	O
positive	O
cells	O
in	O
the	O
grey	O
matter	O
with	O
the	O
shape	O
of	O
neurons	O
,	O
which	O
do	O
not	O
express	O
MHVR	O
,	O
were	O
detected	O
,	O
while	O
srr7	O
infection	O
was	O
observed	O
primarily	O
in	O
the	O
white	O
matter	O
.	O

Syncytial	O
giant	O
cells	O
(	O
SGCs	O
)	O
expressing	O
viral	O
and	O
CD11b	O
antigens	B-CHED
were	O
also	O
detected	O
among	O
these	O
inflammatory	O
cells	O
.	O

These	O
antigen	B-CHED
-	O
positive	O
cells	O
appeared	O
in	O
the	O
subarachnoidal	O
space	O
prior	O
to	O
viral	O
antigen	B-CHED
spread	O
into	O
the	O
brain	O
parenchyma	O
,	O
indicating	O
that	O
viral	O
encephalitis	O
starts	O
with	O
the	O
infection	O
of	O
infiltrating	O
monocytes	O
which	O
express	O
MHVR	O
.	O

Treatment	O
with	O
antibiotics	B-CHED
and	O
various	O
modes	O
of	O
mechanical	O
ventilation	O
in	O
the	O
intensive	O
care	O
unit	O
were	O
successful	O
.	O

ABSTRACT	O
:	O
The	O
combination	O
of	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
and	O
extracorporeal	O
carbon	B-CHED
dioxide	I-CHED
removal	O
with	O
the	O
interventional	O
lung	O
assist	O
(	O
iLA	O
)	O
in	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
represents	O
a	O
novel	O
treatment	O
option	O
.	O

Biopsy	O
-	O
proven	O
acute	O
rejection	O
(>	O
or	O
=	O
grade	O
2	O
)	O
or	O
decline	O
in	O
forced	O
expiratory	O
volume	O
in	O
1	O
sec	B-CHED
>	O
or	O
=	O
20	O
%	O
occurred	O
in	O
16	O
of	O
48	O
(	O
33	O
.	O
3	O
%)	O
patients	O
within	O
3	O
months	O
of	O
RVI	O
when	O
compared	O
with	O
3	O
of	O
45	O
(	O
6	O
.	O
7	O
%)	O
RVI	O
-	O
negative	O
patients	O
within	O
a	O
comparable	O
time	O
frame	O
(	O
P	O
=	O
0	O
.	O
001	O
).	O

Community	O
-	O
acquired	O
RVIs	O
are	O
frequently	O
detected	O
in	O
BAL	B-CHED
samples	O
from	O
lung	O
transplant	O
patients	O
.	O

ABSTRACT	O
:	O
The	O
hypokalemic	O
paralysis	O
is	O
a	O
disease	O
characterized	O
by	O
the	O
development	O
of	O
acute	O
muscular	O
weakness	O
,	O
associated	O
to	O
low	O
levels	O
of	O
blood	O
potassium	B-CHED
(<	O
3	O
.	O
5	O
meq	O
/	O
L	O
).	O

Comparative	O
sequence	O
analysis	O
of	O
the	O
distal	O
one	O
-	O
third	O
of	O
the	O
genomes	O
of	O
one	O
FRSCV	O
and	O
one	O
FRECV	O
strain	O
showed	O
that	O
these	O
two	O
ferret	O
coronaviruses	O
share	O
>	O
96	O
%	O
nucleotide	B-CHED
sequence	O
identities	O
in	O
the	O
membrane	O
(	O
M	O
),	O
nucleocapsid	O
(	O
N	O
)	O
and	O
non	O
-	O
structural	O
protein	B-CHED
genes	O
(	O
partial	O
polymerase	O
,	O
open	O
reading	O
frames	O
[	O
ORFs	O
]	O
3	O
and	O
7b	O
).	O

No	O
associations	O
were	O
observed	O
between	O
the	O
myosin	O
light	O
chain	O
kinase	O
gene	O
single	O
nucleotide	B-CHED
polymorphisms	O
genotyped	O
in	O
children	O
with	O
community	O
-	O
acquired	O
pneumonia	O
and	O
increased	O
severity	O
of	O
lung	O
injury	O
.	O

Specifically	O
,	O
we	O
found	O
a	O
temporal	O
and	O
spatial	O
activation	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
kappaB	O
,	O
activator	O
protein	B-CHED
(	O
AP	O
)-	O
1	O
,	O
and	O
interferon	O
regulatory	O
factor	O
(	O
IRF	O
)-	O
3	O
/	O
7	O
in	O
infected	O
2B4	O
cells	O
at	O
12	O
-,	O
24	O
-,	O
and	O
48	O
-	O
hrs	O
post	O
infection	O
(	O
p	O
.	O
i	O
.),	O
resulting	O
in	O
the	O
activation	O
of	O
many	O
antiviral	B-CHED
genes	O
,	O
including	O
interferon	O
(	O
IFN	O
)-	O
beta	O
,	O
-	O
lambdas	O
,	O
inflammatory	O
mediators	O
,	O
and	O
many	O
IFN	O
-	O
stimulated	O
genes	O
(	O
ISGs	O
).	O

Pathohistological	O
analysis	O
of	O
the	O
samples	O
retrieved	O
by	O
bronchoscopy	O
pointed	O
to	O
a	O
pneumonia	O
,	O
and	O
diagnosis	O
of	O
LD	O
was	O
confirmed	O
by	O
positive	O
urine	O
test	O
for	O
LP	O
antigen	B-CHED
.	O

Treatment	O
with	O
antibiotics	B-CHED
(	O
erythromycin	B-CHED
,	O
rifampicin	B-CHED
,	O
azithromycin	B-CHED
)	O
combined	O
with	O
ARDS	O
treatment	O
led	O
to	O
a	O
clinical	O
recovery	O
of	O
the	O
patient	O
together	O
with	O
complete	O
resolution	O
of	O
inflammatory	O
lesions	O
seen	O
on	O
chest	O
radiography	O
.	O

All	O
patients	O
exhibited	O
severe	O
cardiopulmonary	O
failure	O
with	O
a	O
mean	O
oxygenation	O
ratio	O
(	O
partial	O
pressure	O
of	O
oxygen	B-CHED
to	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
ratio	O
)	O
of	O
74	O
+/-	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
examine	O
the	O
potential	O
antiviral	B-CHED
activity	O
of	O
lactic	B-CHED
acid	I-CHED
bacteria	O
(	O
LAB	O
)	O
using	O
animal	O
and	O
human	O
intestinal	O
and	O
macrophage	O
cell	O
line	O
models	O
of	O
non	O
tumor	O
origin	O
.	O

Expression	O
of	O
p6	O
,	O
or	O
of	O
its	O
N	O
-	O
terminal	O
41	O
-	O
amino	O
-	O
acid	O
region	O
,	O
in	O
the	O
absence	O
of	O
other	O
viral	O
proteins	B-CHED
,	O
induced	O
the	O
formation	O
of	O
membranous	O
structures	O
,	O
some	O
of	O
which	O
were	O
similar	O
to	O
double	O
membrane	O
vesicles	O
involved	O
in	O
virus	O
replication	O
.	O

Here	O
,	O
we	O
show	O
that	O
immunization	O
with	O
rSARS	O
-	O
CoV	O
-	O
DeltaE	O
or	O
SARS	O
-	O
CoV	O
-	O
Delta	O
[	O
E	O
,	O
6	O
-	O
9b	O
]	O
(	O
deleted	O
in	O
accessory	O
proteins	B-CHED
(	O
6	O
,	O
7a	O
,	O
7b	O
,	O
8a	O
,	O
8b	O
,	O
9b	O
)	O
in	O
addition	O
to	O
E	O
)	O
nearly	O
completely	O
protected	O
BALB	O
/	O
c	O
mice	O
from	O
fatal	O
respiratory	O
disease	O
caused	O
by	O
mouse	O
-	O
adapted	O
SARS	O
-	O
CoV	O
and	O
partly	O
protected	O
hACE2	O
Tg	O
mice	O
from	O
lethal	O
disease	O
.	O

TITLE	O
:	O
Efficacy	O
and	O
safety	O
of	O
quinine	B-CHED
-	O
artesunate	B-CHED
in	O
an	O
HIV	O
-	O
positive	O
patient	O
with	O
severe	O
falciparum	O
malaria	O
.	O

Until	O
recently	O
,	O
intravenous	O
quinine	B-CHED
was	O
the	O
standard	O
treatment	O
;	O
however	O
,	O
artemisin	O
derivatives	O
are	O
now	O
regarded	O
as	O
the	O
first	O
-	O
line	O
treatment	O
for	O
multidrug	O
-	O
resistant	O
falciparum	O
malaria	O
.	O

Artesunate	B-CHED
was	O
imported	O
from	O
the	O
foreign	O
market	O
,	O
and	O
written	O
consent	O
for	O
its	O
administration	O
was	O
obtained	O
in	O
advance	O
.	O

TITLE	O
:	O
Identification	O
of	O
N	O
-	O
linked	O
carbohydrates	B-CHED
from	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
spike	O
glycoprotein	B-CHED
.	O

Interestingly	O
,	O
the	O
tree	O
topology	O
based	O
on	O
the	O
nucleotide	B-CHED
sequences	O
representing	O
the	O
S1	O
domain	O
or	O
the	O
S1	O
N	O
-	O
terminal	O
region	O
most	O
nearly	O
resembled	O
the	O
full	O
S	O
gene	O
-	O
based	O
phylogenetic	O
tree	O
.	O

Furthermore	O
,	O
the	O
recent	O
explosion	O
of	O
research	O
into	O
the	O
ACE2	O
homolog	O
,	O
collectrin	O
,	O
has	O
revealed	O
a	O
new	O
physiological	O
function	O
of	O
ACE2	O
as	O
an	O
amino	B-CHED
acid	I-CHED
transporter	O
,	O
which	O
explains	O
the	O
pathogenic	O
role	O
of	O
gene	O
mutations	O
in	O
Hartnup	O
disorder	O
.	O

TITLE	O
:	O
Automated	O
detection	O
of	O
conformational	O
epitopes	O
using	O
phage	O
display	O
Peptide	B-CHED
sequences	O
.	O

The	O
algorithm	O
uses	O
peptide	B-CHED
sequences	O
from	O
phage	O
display	O
experiments	O
as	O
input	O
,	O
and	O
ranks	O
all	O
surface	O
exposed	O
patches	O
according	O
to	O
the	O
frequency	O
distribution	O
of	O
similar	O
residues	O
in	O
the	O
peptides	B-CHED
and	O
in	O
the	O
patch	O
.	O

RESULTS	O
:	O
We	O
present	O
a	O
fully	O
automated	O
search	O
method	O
,	O
EpiSearch	O
that	O
predicts	O
the	O
possible	O
location	O
of	O
conformational	O
epitopes	O
on	O
the	O
surface	O
of	O
an	O
antigen	B-CHED
.	O

Ap4A	O
-	O
hydrolase	O
is	O
responsible	O
for	O
metabolizing	O
the	O
""""	O
allarmone	O
""""	O
nucleotide	B-CHED
Ap4A	O
and	O
therefore	O
likely	O
involved	O
in	O
regulation	O
of	O
cell	O
proliferation	O
,	O
DNA	O
replication	O
,	O
RNA	O
processing	O
,	O
apoptosis	O
and	O
DNA	O
repair	O
.	O

Infants	O
who	O
received	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
had	O
diminished	O
fT	O
(	O
4	O
)	O
levels	O
compared	O
to	O
infants	O
who	O
did	O
not	O
receive	O
this	O
therapy	O
.	O

In	O
our	O
study	O
sample	O
,	O
there	O
was	O
an	O
association	O
between	O
severity	O
of	O
illness	O
and	O
fT	O
(	O
4	O
)	O
levels	O
at	O
birth	O
,	O
and	O
infants	O
requiring	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
showed	O
decreased	O
fT	O
(	O
4	O
)	O
over	O
the	O
study	O
time	O
.	O

The	O
lung	O
samples	O
of	O
a	O
20	O
-	O
year	O
-	O
old	O
man	B-CHED
who	O
had	O
suffered	O
a	O
serious	O
motorbike	O
accident	O
were	O
obtained	O
for	O
histological	O
examination	O
.	O

ABSTRACT	O
:	O
Neutralizing	O
antibody	O
responses	O
to	O
the	O
surface	O
glycoproteins	B-CHED
of	O
enveloped	O
viruses	O
play	O
an	O
important	O
role	O
in	O
immunity	O
.	O

Three	O
of	O
the	O
chimeric	O
mAbs	O
retain	O
their	O
binding	O
specificity	O
while	O
one	O
conformational	O
mAb	O
,	O
F26G19	O
,	O
lost	B-CHED
its	O
ability	O
to	O
bind	O
the	O
S	O
protein	B-CHED
despite	O
high	O
level	O
expression	O
.	O

For	O
instance	O
,	O
insulin	B-CHED
inhibits	O
NF	O
-	O
kappaB	O
--	O
dependent	O
synthesis	O
of	O
pro	B-CHED
-	O
inflammatory	O
factors	O
and	O
attenuates	O
production	O
of	O
ROS	B-CHED
.	O

We	O
propose	O
that	O
administering	O
inhalable	O
insulin	B-CHED
to	O
hyperglycemic	O
ALI	O
/	O
ARDS	O
patients	O
could	O
directly	O
reduce	O
alveolar	O
inflammation	O
while	O
reducing	O
circulating	O
glucose	B-CHED
levels	O
.	O

All	O
were	O
managed	O
with	O
a	O
lung	O
protective	O
ventilator	O
strategy	O
(	O
average	O
number	O
of	O
days	O
on	O
the	O
ventilator	O
:	O
16	O
),	O
and	O
4	O
patients	O
also	O
required	O
additional	O
rescue	O
therapies	O
for	O
refractory	O
hypoxemia	O
,	O
including	O
very	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
inhaled	O
epoprostenol	B-CHED
,	O
recruitment	O
maneuvers	O
,	O
and	O
prone	O
positioning	O
.	O

TITLE	O
:	O
Nanoparticle	B-CHED
detection	O
of	O
respiratory	O
infection	O
.	O

Although	O
immunoreactivity	O
for	O
surfactant	B-CHED
protein	B-CHED
SP	O
-	O
A	O
and	O
ABCA3	O
was	O
diminished	O
,	O
that	O
for	O
SP	O
-	O
B	O
and	O
proSP	O
-	O
C	O
was	O
robust	O
,	O
although	O
irregularly	O
distributed	O
,	O
corresponding	O
to	O
the	O
distribution	O
of	O
type	O
II	O
pneumocytes	O
.	O

Our	O
analysis	O
indicated	O
that	O
this	O
kind	O
of	O
effects	O
mostly	O
comes	O
from	O
the	O
information	O
palindrome	O
structure	O
itself	O
or	O
from	O
the	O
synonymous	O
codon	O
usage	O
,	O
but	O
not	O
from	O
the	O
translation	O
information	O
from	O
codons	O
to	O
amino	B-CHED
acids	I-CHED
.	O

The	O
report	O
prepared	O
by	O
the	O
study	O
group	O
was	O
discussed	O
by	O
members	O
of	O
Working	O
Groups	O
who	O
met	B-CHED
three	O
times	O
in	O
Italy	O
.	O

The	O
nucleocapsid	O
protein	B-CHED
as	O
well	O
as	O
the	O
nsp1	O
and	O
nsp3	O
proteins	B-CHED
of	O
MHV	O
has	O
been	O
reported	O
to	O
have	O
IFN	O
antagonist	B-CHED
activity	O
.	O

However	O
,	O
in	O
primary	O
cell	O
types	O
such	O
as	O
plasmacytoid	O
dendritic	O
cells	O
(	O
pDC	B-CHED
)	O
and	O
macrophages	O
,	O
IFN	O
is	O
induced	O
by	O
MHV	O
infection	O
and	O
an	O
antiviral	B-CHED
state	O
is	O
established	O
.	O

Currently	O
,	O
we	O
are	O
investigating	O
immune	O
and	O
endocrine	B-CHED
interactions	O
in	O
the	O
chicken	O
,	O
in	O
particular	O
the	O
cells	O
and	O
molecules	O
that	O
are	O
known	O
to	O
be	O
involved	O
in	O
such	O
interactions	O
in	O
mammals	O
.	O

ABSTRACT	O
:	O
Poliovirus	O
2B	O
protein	B-CHED
is	O
a	O
well	O
-	O
known	O
viroporin	O
implicated	O
in	O
plasma	O
membrane	O
permeabilization	O
to	O
ions	B-CHED
and	O
low	O
-	O
molecular	O
-	O
weight	O
compounds	O
during	O
infection	O
.	O

Here	O
,	O
we	O
present	O
a	O
thermal	O
targeting	O
strategy	O
--	O
dynamic	O
affinity	O
modulation	O
(	O
DAM	O
)--	O
using	O
elastin	O
-	O
like	O
polypeptide	B-CHED
diblock	B-CHED
copolymers	I-CHED
(	O
ELP	O
(	O
BC	O
)	O
s	O
)	O
that	O
self	O
-	O
assemble	O
from	O
a	O
low	O
-	O
affinity	O
to	O
high	O
-	O
avidity	O
state	O
by	O
a	O
tunable	O
thermal	O
""""	O
switch	O
""","	O
thereby	O
restricting	O
activity	O
to	O
the	O
desired	O
site	O
of	O
action	O
.	O

No	O
differences	O
were	O
found	O
in	O
Clara	O
cell	O
secretory	O
protein	B-CHED
and	O
in	O
serum	O
cytokines	O
levels	O
.	O

Our	O
aim	O
was	O
to	O
develop	O
a	O
reproducible	O
invasively	O
-	O
monitored	O
porcine	O
model	O
of	O
acetaminophen	B-CHED
-	O
induced	O
ALF	O
.	O

Vasodilators	O
such	O
as	O
sodium	B-CHED
nitroprusside	I-CHED
or	O
nitroglycerin	B-CHED
were	O
capable	O
of	O
reducing	O
the	O
CC	O
-	O
induced	O
pulmonary	O
pathology	O
and	O
hemodynamic	O
alterations	O
.	O

CD209	O
facilitates	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
spike	O
protein	B-CHED
-	O
bearing	O
pseudotype	O
driven	O
infection	O
of	O
permissive	O
cells	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Since	O
DNA	O
sequencing	O
techniques	O
first	O
became	O
available	O
almost	O
30	O
years	O
ago	O
,	O
the	O
amount	O
of	O
nucleic	B-CHED
acid	I-CHED
sequence	O
data	O
has	O
increased	O
enormously	O
.	O

Fifty	O
-	O
three	O
patients	O
were	O
complicated	O
with	O
pneumonia	O
(	O
70	O
.	O
67	O
%)	O
and	O
41	O
patients	O
with	O
pre	O
-	O
existing	O
medical	O
conditions	O
(	O
54	O
.	O
67	O
%),	O
65	O
patients	O
with	O
fever	O
(	O
86	O
.	O
67	O
%),	O
63	O
patients	O
with	O
cough	O
and	O
sputum	O
(	O
84	O
.	O
00	O
%),	O
61	O
patients	O
with	O
dyspnea	O
(	O
81	O
.	O
33	O
%),	O
1	O
patients	O
with	O
meningitis	O
as	O
the	O
main	O
manifestation	O
,	O
2	O
patients	O
with	O
acute	O
pulmonary	O
edema	O
and	O
left	O
heart	O
failure	O
,	O
28	O
patients	O
with	O
leucopenia	O
(	O
37	O
.	O
33	O
%),	O
28	O
patients	O
with	O
myocardial	O
enzyme	O
abnormalities	O
(	O
37	O
.	O
33	O
%),	O
23	O
patients	O
with	O
blood	O
glucose	B-CHED
abnormalities	O
(	O
30	O
.	O
67	O
%),	O
8	O
patients	O
with	O
coagulopathy	O
(	O
10	O
.	O
67	O
%),	O
4	O
patients	O
with	O
lipid	B-CHED
abnormalities	O
(	O
5	O
.	O
33	O
%),	O
51	O
patients	O
with	O
increased	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
68	O
.	O
00	O
%).	O

Forty	O
-	O
eight	O
patients	O
received	O
oseltamivir	B-CHED
,	O
27	O
patients	O
received	O
anti	O
-	O
virus	O
""""	O
Jun	O
Ke	O
Ao	O
Wei	O
""""	O
capsules	O
.	O

The	O
spike	O
protein	B-CHED
,	O
responsible	O
for	O
viral	O
entry	O
,	O
is	O
a	O
major	O
determinant	O
of	O
tropism	O
and	O
virulence	O
.	O

TITLE	O
:	O
Computational	O
approaches	O
for	O
the	O
discovery	O
of	O
cysteine	B-CHED
protease	I-CHED
inhibitors	I-CHED
against	O
malaria	O
and	O
SARS	O
.	O

The	O
article	O
describes	O
rational	O
approaches	O
for	O
the	O
design	O
of	O
inhibitors	B-CHED
and	O
focuses	O
on	O
a	O
variety	O
of	O
structure	O
as	O
well	O
as	O
ligand	B-CHED
-	O
based	O
modeling	O
strategies	O
adopted	O
for	O
the	O
discovery	O
of	O
the	O
inhibitors	B-CHED
.	O

TITLE	O
:	O
Mutation	O
of	O
Glu	B-CHED
-	O
166	O
blocks	O
the	O
substrate	O
-	O
induced	O
dimerization	O
of	O
SARS	O
coronavirus	O
main	O
protease	O
.	O

TITLE	O
:	O
A	O
novel	O
B	O
-	O
cell	O
epitope	B-CHED
of	O
avian	O
infectious	O
bronchitis	O
virus	O
N	O
protein	B-CHED
.	O

These	O
peptides	B-CHED
and	O
five	O
heterogeneous	O
IBV	O
strains	O
were	O
used	O
to	O
identify	O
the	O
epitope	B-CHED
recognized	O
by	O
2D2	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
Western	O
blotting	O
analysis	O
.	O

The	O
identified	O
epitope	B-CHED
might	O
be	O
useful	O
for	O
clinical	O
applications	O
and	O
as	O
a	O
tool	O
for	O
further	O
study	O
of	O
the	O
structure	O
and	O
function	O
of	O
the	O
IBV	O
N	O
protein	B-CHED
.	O

The	O
results	O
showed	O
that	O
this	O
recombinant	O
protein	B-CHED
was	O
correctly	O
folded	O
,	O
being	O
able	O
to	O
maintain	O
intact	O
conformation	O
and	O
authentic	O
antigenicity	O
.	O

TITLE	O
:	O
Identification	O
of	O
SARS	O
-	O
COV	O
spike	O
protein	B-CHED
-	O
derived	O
and	O
HLA	O
-	O
A2	O
-	O
restricted	O
human	O
CTL	O
epitopes	O
by	O
using	O
a	O
new	O
muramyl	B-CHED
dipeptidederivative	O
adjuvant	B-CHED
.	O

Forty	O
-	O
three	O
candidate	O
peptides	B-CHED
having	O
HLA	O
-	O
A2	O
-	O
binding	O
motifs	O
were	O
selected	O
in	O
silico	O
and	O
HLA	O
-	O
A2	O
/	O
Db	O
chimeric	O
MHC	O
class	O
I	O
-	O
transgenic	O
mice	O
were	O
immunized	O
with	O
these	O
peptides	B-CHED
and	O
a	O
new	O
derivative	O
of	O
muramyl	B-CHED
dipeptide	I-CHED
that	O
can	O
induce	O
upregulation	O
of	O
HLA	O
-	O
DR	O
,	O
CD80	O
,	O
CD86	O
,	O
and	O
CD40	O
in	O
human	O
CD14	O
+	O
antigen	B-CHED
presenting	O
cells	O
,	O
was	O
administered	O
as	O
an	O
adjuvant	B-CHED
.	O

Similar	O
ventilation	O
strategies	O
in	O
mL	O
/	O
kg	O
PBW	O
and	O
PEEP	B-CHED
were	O
used	O
among	O
patients	O
regardless	O
of	O
P	O
/	O
F	O
ratio	O
.	O

In	O
contrast	O
to	O
a	O
well	O
documented	O
role	O
in	O
innate	O
immunity	O
,	O
we	O
propose	O
that	O
STAT1	O
also	O
protects	O
mice	O
via	O
its	O
role	O
as	O
an	O
antagonist	B-CHED
of	O
unrestrained	O
cell	O
proliferation	O
.	O

TITLE	O
:	O
[	O
Characterization	O
of	O
human	O
coronavirus	O
229E	O
infection	O
among	O
patients	O
with	O
respiratory	O
symptom	O
in	O
Beijing	O
,	O
Oct	O
-	O
Dec	B-CHED
,	O
2007	O
].	O

Logistic	O
regression	O
indicated	O
that	O
compared	O
with	O
the	O
persons	O
with	O
the	O
thoughts	O
of	O
nothing	O
serious	O
of	O
SARS	O
,	O
without	O
any	O
dread	O
of	O
SARS	O
,	O
and	O
knowing	O
nothing	O
about	O
prevention	O
of	O
SARS	O
,	O
the	O
perceived	O
stress	O
was	O
significantly	O
related	O
with	O
perceiving	O
of	O
the	O
thread	O
to	O
certain	O
extent	O
(	O
beta	O
=	O
0	O
.	O
41	O
,	O
Wald	O
chi	B-CHED
(	O
2	O
)	O
=	O
4	O
.	O
84	O
,	O
P	O
=	O
0	O
.	O
03	O
),	O
worrying	O
little	O
about	O
the	O
epidemic	O
(	O
beta	O
=	O
0	O
.	O
50	O
,	O
Wald	O
chi	B-CHED
(	O
2	O
)	O
=	O
6	O
.	O
69	O
,	O
P	O
=	O
0	O
.	O
01	O
),	O
worrying	O
about	O
it	O
to	O
certain	O
extent	O
(	O
beta	O
=	O
1	O
.	O
39	O
,	O
Wald	O
chi	B-CHED
(	O
2	O
)	O
=	O
48	O
.	O
59	O
,	O
P	O
=	O
0	O
.	O
00	O
)	O
and	O
scared	O
so	O
much	O
(	O
beta	O
=	O
1	O
.	O
77	O
,	O
Wald	O
chi	B-CHED
(	O
2	O
)	O
=	O
53	O
.	O
59	O
,	O
P	O
=	O
0	O
.	O
00	O
),	O
and	O
knowing	O
little	O
about	O
the	O
prevention	O
(	O
beta	O
=	O
0	O
.	O
74	O
,	O
Wald	O
chi	B-CHED
(	O
2	O
)	O
=	O
4	O
.	O
48	O
,	O
P	O
=	O
0	O
.	O
03	O
),	O
knowing	O
something	O
about	O
prevention	O
(	O
beta	O
=	O
-	O
0	O
.	O
98	O
,	O
Wald	O
chi	B-CHED
(	O
2	O
)	O
=	O
8	O
.	O
29	O
,	O
P	O
=	O
0	O
.	O
00	O
)	O
and	O
knowing	O
the	O
prevention	O
very	O
well	O
(	O
beta	O
=	O
-	O
1	O
.	O
18	O
,	O
Wald	O
chi	B-CHED
(	O
2	O
)	O
=	O
10	O
.	O
66	O
,	O
P	O
=	O
0	O
.	O
00	O
).	O

While	O
conventional	O
vaccines	O
work	O
well	O
against	O
homologous	O
types	O
,	O
new	O
strategies	O
are	O
needed	O
to	O
counter	B-CHED
this	O
instability	O
.	O

Early	O
treatment	O
with	O
an	O
effective	O
antiviral	B-CHED
agent	I-CHED
before	O
day	O
10	O
may	O
decrease	O
the	O
peak	O
viral	O
load	O
,	O
and	O
thus	O
ameliorate	O
the	O
clinical	O
symptoms	O
and	O
mortality	O
,	O
and	O
reduce	O
viral	O
shedding	O
and	O
the	O
risk	O
of	O
transmission	O

There	O
is	O
a	O
long	O
history	O
of	O
investigations	O
concluding	O
that	O
,	O
if	O
used	O
properly	O
,	O
UVGI	O
can	O
be	O
safe	O
and	O
highly	O
effective	O
in	O
disinfecting	O
the	O
air	B-CHED
,	O
thereby	O
preventing	O
transmission	O
of	O
a	O
variety	O
of	O
airborne	O
infections	O
.	O

CpG	O
had	O
an	O
adjuvant	B-CHED
effect	O
on	O
IgA	O
production	O
in	O
genital	O
tract	O
washes	O
when	O
administered	O
intranasally	O
but	O
only	O
affected	O
IgA	O
production	O
in	O
faeces	O
samples	O
when	O
administered	O
intraperitoneally	O
.	O

TITLE	O
:	O
Nitric	B-CHED
oxide	I-CHED
is	O
elicited	O
and	O
inhibits	O
viral	O
replication	O
in	O
pigs	O
infected	O
with	O
porcine	O
respiratory	O
coronavirus	O
but	O
not	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
.	O

We	O
examined	O
NO	O
levels	O
by	O
Greiss	O
assay	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
of	O
pigs	O
infected	O
with	O
either	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
or	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
a	O
member	O
of	O
Nidovirales	O
,	O
like	O
CoV	O
.	O
The	O
antiviral	B-CHED
effects	O
of	O
NO	O
on	O
these	O
two	O
viruses	O
were	O
tested	O
in	O
an	O
in	O
vitro	O
system	O
using	O
a	O
NO	O
donor	B-CHED
,	O
S	O
-	O
nitroso	B-CHED
-	O
N	B-CHED
-	I-CHED
acetylpenicillamine	I-CHED
(	O
SNAP	O
).	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
if	O
lipoteichoic	B-CHED
acid	I-CHED
(	O
LTA	O
),	O
produced	O
by	O
Staphylococcus	O
aureus	O
,	O
exacerbates	O
respiratory	O
disease	O
in	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)-	O
infected	O
pigs	O
,	O
as	O
has	O
previously	O
been	O
shown	O
with	O
lipopolysaccharide	B-CHED
.	O

B6	O
mice	O
that	O
are	O
homozygous	O
for	O
1a	O
are	O
highly	O
susceptible	O
to	O
MHV	O
-	O
A59	O
infection	O
,	O
with	O
a	O
50	O
%	O
lethal	O
dose	O
(	O
LD	O
(	O
50	O
))	O
of	O
10	O
(	O
2	O
.	O
5	O
)	O
PFU	B-CHED
,	O
while	O
chimeric	O
cB61ba	O
mice	O
and	O
SJL	O
mice	O
homozygous	O
for	O
1ba	O
and	O
1b	O
,	O
respectively	O
,	O
survived	O
following	O
inoculation	O
with	O
10	O
(	O
5	O
)	O
PFU	B-CHED
.	O

The	O
coronavirus	O
main	O
protease	O
,	O
3CL	O
(	O
pro	B-CHED
),	O
is	O
a	O
key	O
target	O
for	O
broad	O
-	O
spectrum	O
antiviral	B-CHED
development	O
because	O
of	O
its	O
critical	O
role	O
in	O
viral	O
maturation	O
and	O
high	O
degree	O
of	O
structural	O
conservation	O
among	O
coronaviruses	O
.	O

When	O
the	O
measurement	O
was	O
repeated	O
29	O
h	O
after	O
therapy	O
was	O
discontinued	O
,	O
V	O
(	O
D	O
)/	O
V	O
(	O
T	O
)	O
had	O
increased	O
modestly	O
,	O
to	O
0	O
.	O
34	O
,	O
whereas	O
alveolar	O
V	O
(	O
D	O
)	O
had	O
increased	O
to	O
71	O
mL	O
,	O
or	O
43	O
%	O
of	O
the	O
pre	O
-	O
activated	O
-	O
protein	B-CHED
-	O
C	O
baseline	O
measurement	O
.	O

Alveolar	O
V	O
(	O
T	O
)	O
rose	O
from	O
260	O
mL	O
to	O
369	O
mL	O
and	O
decreased	O
slightly	O
after	O
termination	O
of	O
activated	O
protein	B-CHED
C	O
(	O
336	O
mL	O
).	O

This	O
suggests	O
that	O
activated	O
protein	B-CHED
C	O
may	O
have	O
reduced	O
microvascular	O
obstruction	O
.	O

However	O
,	O
knockdown	O
of	O
RIG	O
-	O
I	O
only	O
partially	O
blocked	O
NF	O
-	O
kappaB	O
activity	O
induced	O
by	O
MHV	O
infection	O
and	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
by	O
a	O
decoy	O
peptide	B-CHED
inhibitor	B-CHED
had	O
little	O
effect	O
on	O
IFN	O
-	O
alpha	O
/	O
beta	O
production	O
.	O

One	O
patient	O
who	O
suffered	O
from	O
hypoxic	O
brain	O
injury	O
due	O
to	O
cardiac	O
arrest	O
at	O
home	O
secondary	O
to	O
H1N1	O
pneumonia	O
became	O
a	O
kidney	O
and	O
liver	O
donor	B-CHED
.	O

The	O
usefulness	O
of	O
procalcitonin	O
and	O
C	O
-	O
reactive	O
protein	B-CHED
as	O
indicators	O
of	O
the	O
presence	O
or	O
absence	O
of	O
viral	O
infection	O
in	O
this	O
setting	O
also	O
needs	O
to	O
be	O
evaluated	O
.	O

During	O
AECOPD	O
,	O
procalcitonin	O
and	O
C	O
-	O
reactive	O
protein	B-CHED
levels	O
did	O
not	O
differ	O
significantly	O
between	O
patients	O
with	O
or	O
without	O
a	O
proven	O
viral	O
infection	O
.	O

Our	O
results	O
demonstrated	O
that	O
a	O
P1	O
-	O
Asn	B-CHED
substitution	O
at	O
the	O
nsp4	O
-	O
5	O
/	O
Q2779	O
,	O
nsp5	O
-	O
6	O
/	O
Q3086	O
,	O
nsp7	O
-	O
8	O
/	O
Q3462	O
,	O
nsp8	O
-	O
9	O
/	O
Q3672	O
,	O
and	O
nsp9	O
-	O
10	O
/	O
Q3783	O
sites	O
,	O
a	O
P1	O
-	O
Glu	B-CHED
substitution	O
at	O
the	O
nsp8	O
-	O
9	O
/	O
Q3672	O
site	O
,	O
and	O
a	O
P1	O
-	O
His	O
substitution	O
at	O
the	O
nsp15	O
-	O
16	O
/	O
Q6327	O
site	O
were	O
tolerated	O
and	O
allowed	O
recovery	O
of	O
infectious	O
mutant	O
viruses	O
,	O
albeit	O
with	O
variable	O
degrees	O
of	O
growth	O
defects	O
.	O

In	O
contrast	O
,	O
a	O
P1	O
-	O
Asn	B-CHED
substitution	O
at	O
the	O
nsp6	O
-	O
7	O
/	O
Q3379	O
,	O
nsp12	O
-	O
13	O
/	O
Q4868	O
,	O
nsp13	O
-	O
14	O
/	O
Q5468	O
,	O
and	O
nsp14	O
-	O
15	O
/	O
Q5989	O
sites	O
,	O
as	O
well	O
as	O
a	O
P1	O
-	O
Pro	B-CHED
substitution	O
at	O
the	O
nsp15	O
-	O
16	O
/	O
Q6327	O
site	O
,	O
abolished	O
3CLpro	O
-	O
mediated	O
cleavage	O
at	O
the	O
corresponding	O
position	O
and	O
blocked	O
the	O
recovery	O
of	O
infectious	O
viruses	O
.	O

All	O
three	O
patients	O
had	O
dramatic	O
reduction	O
in	O
pediatric	O
logistic	O
organ	O
dysfunction	O
scores	O
,	O
oxygen	B-CHED
requirements	O
,	O
and	O
vasopressor	O
requirements	O
after	O
two	O
exchanges	O
.	O

A	O
urinary	O
antigen	B-CHED
test	O
is	O
now	O
available	O
to	O
aid	O
in	O
diagnosis	O
,	O
but	O
it	O
is	O
not	O
specific	O
and	O
is	O
positive	O
in	O
patients	O
who	O
have	O
histoplasmosis	O
as	O
well	O
as	O
blastomycosis	O
.	O

Our	O
previous	O
work	O
demonstrated	O
that	O
genetic	O
inactivation	O
of	O
the	O
coronavirus	O
exoribonuclease	O
(	O
ExoN	O
)	O
in	O
nonstructural	O
protein	B-CHED
14	O
(	O
nsp14	O
)	O
of	O
murine	O
hepatitis	O
virus	O
results	O
in	O
a	O
15	O
-	O
fold	O
decrease	O
in	O
replication	O
fidelity	O
.	O

They	O
were	O
inoculated	O
intratracheally	O
with	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
followed	O
by	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)	O
24h	O
later	O
.	O

TNF	O
-	O
alpha	O
was	O
completely	O
neutralized	O
in	O
3	O
of	O
the	O
4	O
animals	O
euthanized	O
at	O
4	O
HPI	O
and	O
significantly	O
lower	O
than	O
in	O
the	O
PRCV	O
-	O
LPS	B-CHED
group	O
at	O
all	O
times	O
.	O

Anti	O
-	O
neutrophil	O
cytoplasmic	O
antibody	O
(	O
ANCA	B-CHED
)	O
associated	O
vasculitis	O
""""	O
and	O
glomerular	O
basement	O
membrane	O
"("""	O
Goodpasture	O
'	O
s	O
""")"	O
disease	O
are	O
the	O
commonest	O
causes	O
but	O
other	O
pathologies	O
including	O
systemic	O
lupus	O
erythematosus	O
and	O
the	O
anti	O
-	O
phospholipid	B-CHED
syndrome	O
are	O
also	O
implicated	O
.	O

The	O
nucleocapsid	O
protein	B-CHED
(	O
NP	O
)	O
of	O
SARS	O
-	O
CoV	O
may	O
be	O
critical	O
for	O
pathogenicity	O
.	O

TITLE	O
:	O
Viral	O
proteins	B-CHED
function	O
as	O
ion	O
channels	O
.	O

This	O
review	O
summarizes	O
the	O
recent	O
advances	O
in	O
viral	O
encoded	O
ion	O
channel	O
proteins	B-CHED
(	O
or	O
viroporins	O
),	O
including	O
PBCV	O
-	O
1	O
KcV	O
,	O
influenza	O
M2	O
,	O
HIV	O
-	O
1	O
Vpu	O
,	O
HCV	O
p7	O
,	O
picornavirus	O
2B	O
,	O
and	O
coronavirus	O
E	O
and	O
3a	O
.	O

Seventy	O
-	O
one	O
consecutive	O
ACS	O
episodes	O
in	O
67	O
patients	O
were	O
randomly	O
allocated	O
to	O
oxygen	B-CHED
(	O
n	O
=	O
36	O
)	O
or	O
NIV	O
(	O
n	O
=	O
35	O
)	O
for	O
3	O
days	O
in	O
a	O
medical	O
step	O
-	O
down	O
unit	O
.	O

NIV	O
promptly	O
lowered	O
the	O
respiratory	O
rate	O
,	O
raised	O
PaO2	O
,	O
and	O
decreased	O
alveolar	O
-	O
arterial	O
oxygen	B-CHED
gradient	O
((	O
A	O
-	O
a	O
)	O
O2	O
),	O
which	O
remained	O
unchanged	O
with	O
oxygen	B-CHED
alone	O
.	O

On	O
day	O
3	O
,	O
the	O
groups	O
did	O
not	O
differ	O
regarding	O
the	O
proportion	O
of	O
episodes	O
with	O
normal	O
PaO2	O
(	O
35	O
%	O
with	O
NIV	O
and	O
25	O
%	O
with	O
oxygen	B-CHED
;	O
P	O
=	O
0	O
.	O
5	O
)	O
or	O
A	O
-	O
a	O
).	O

ABSTRACT	O
:	O
Recently	O
,	O
a	O
coronavirus	O
strain	O
(	O
179	O
/	O
07	O
-	O
11	O
)	O
was	O
isolated	O
from	O
water	B-CHED
buffalo	O
(	O
Bubalus	O
bubalis	O
)	O
and	O
the	O
virus	O
which	O
displayed	O
a	O
strict	O
genetic	O
and	O
biological	O
relatedness	O
with	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
was	O
referred	O
to	O
as	O
bubaline	O
coronavirus	O
(	O
BuCoV	O
).	O

TITLE	O
:	O
Upregulation	O
of	O
the	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-CHED
2	O
via	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
-	O
ACE2	O
signaling	O
pathway	O
.	O

MHV	O
infection	O
was	O
affected	O
not	O
only	O
by	O
inhibition	O
of	O
the	O
proteasome	O
but	O
also	O
by	O
interfering	O
with	O
protein	B-CHED
ubiquitination	O
.	O

ABSTRACT	O
:	O
Nitric	B-CHED
oxide	I-CHED
(	O
NO	O
)	O
plays	O
an	O
important	O
role	O
in	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
in	O
ventilator	O
-	O
induced	O
lung	O
injury	O
(	O
VILI	O
).	O

ABSTRACT	O
:	O
The	O
aim	O
of	O
this	O
paper	O
was	O
the	O
evaluation	O
of	O
clinical	O
characteristics	O
,	O
demographics	O
and	O
therapeutic	O
response	O
for	O
oseltamivir	B-CHED
,	O
among	O
patients	O
with	O
swine	O
flu	O
confirmed	O
,	O
hospitalized	O
in	O
the	O
Hospital	O
For	O
Infectious	O
Diseases	O
in	O
Warsaw	O
,	O
Poland	O
.	O

Oseltamivir	B-CHED
safety	O
and	O
tolerability	O
were	O
verified	O
in	O
patients	O
with	O
new	O
variant	O
infection	O
A	O
/	O
H1N1	O
.	O

Here	O
,	O
we	O
show	O
that	O
DBA	B-CHED
/	O
2	O
mice	O
infected	O
with	O
P	O
.	O
berghei	O
ANKA	O
constitute	O
a	O
new	O
model	O
for	O
malaria	O
-	O
associated	O
ALI	O
.	O

In	O
addition	O
,	O
either	O
splenectomization	O
or	O
administration	O
of	O
the	O
anti	O
-	O
inflammatory	O
molecule	O
carbon	B-CHED
monoxide	I-CHED
led	O
to	O
a	O
significant	O
reduction	O
in	O
the	O
levels	O
of	O
sera	O
VEGF	O
and	O
to	O
protection	O
from	O
ALI	O
.	O

The	O
crystals	O
diffracted	O
to	O
2	O
.	O
20	O
A	O
resolution	O
and	O
belonged	O
to	O
space	O
group	O
P422	O
,	O
with	O
unit	O
-	O
cell	O
parameters	O
a	O
=	O
66	O
.	O
6	O
,	O
c	O
=	O
50	O
.	O
8	O
A	O
.	O
Assuming	O
the	O
presence	O
of	O
two	O
molecules	O
in	O
the	O
asymmetric	O
unit	O
,	O
the	O
solvent	B-CHED
content	O
is	O
43	O
.	O
0	O
%	O
(	O
V	O
(	O
M	O
)	O
=	O
2	O
.	O
16	O
A	O
(	O
3	O
)	O
Da	O
(-	O
1	O
)).	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
coronavirus	O
gene	O
product	O
that	O
can	O
protect	O
that	O
same	O
virus	O
from	O
the	O
antiviral	B-CHED
state	O
induced	O
by	O
IFN	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	O
-	O
like	O
novel	O
protease	B-CHED
inhibitors	I-CHED
:	O
design	O
,	O
synthesis	O
,	O
protein	B-CHED
-	O
ligand	B-CHED
X	O
-	O
ray	O
structure	O
and	O
biological	O
evaluation	O
.	O

Because	O
of	O
the	O
complexity	O
of	O
the	O
IBV	O
life	O
cycle	O
and	O
the	O
small	O
number	O
of	O
viral	O
structural	O
proteins	B-CHED
,	O
important	O
virus	O
-	O
host	O
relationships	O
likely	O
remain	O
to	O
be	O
discovered	O
.	O

CoV	O
-	O
induced	O
DMVs	O
,	O
however	O
,	O
lack	O
conventional	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
or	O
Golgi	O
protein	B-CHED
markers	O
,	O
leaving	O
their	O
membrane	O
origins	O
in	O
question	O
.	O

This	O
review	O
provides	O
an	O
update	O
of	O
the	O
epidemiology	O
,	O
pathophysiology	O
,	O
clinical	O
presentation	O
,	O
treatment	O
and	O
outcome	O
of	O
amiodarone	B-CHED
pulmonary	O
effects	O
and	O
toxicity	O
.	O

Amiodarone	B-CHED
-	O
related	O
adverse	O
pulmonary	O
effects	O
may	O
develop	O
as	O
early	O
as	O
from	O
the	O
first	O
few	O
days	O
of	O
treatment	O
to	O
several	O
years	O
later	O
.	O

TITLE	O
:	O
T	O
cell	O
epitope	B-CHED
specificity	O
and	O
pathogenesis	O
of	O
mouse	O
hepatitis	O
virus	O
-	O
1	O
-	O
induced	O
disease	O
in	O
susceptible	O
and	O
resistant	O
hosts	O
.	O

For	O
coronaviruses	O
,	O
it	O
was	O
long	O
speculated	O
that	O
replication	O
of	O
the	O
giant	O
RNA	O
genome	O
and	O
transcription	O
of	O
multiple	O
subgenomic	O
mRNA	B-CHED
species	O
by	O
a	O
unique	O
discontinuous	O
transcription	O
mechanism	O
may	O
require	O
host	O
cofactors	B-CHED
.	O

The	O
higher	O
rate	O
of	O
hepatitis	O
B	O
e	O
antigen	B-CHED
(	O
HBeAg	O
)	O
seroconversion	O
during	O
telbivudine	B-CHED
treatment	O
than	O
other	O
potent	O
anti	B-CHED
-	I-CHED
HBV	I-CHED
agents	I-CHED
suggests	O
a	O
potential	O
immunomodulatory	O
effect	O
.	O

Furthermore	O
,	O
telbivudine	B-CHED
treatment	O
enhanced	O
the	O
ability	O
of	O
T	O
cells	O
to	O
undergo	O
proliferation	O
and	O
secrete	O
cytokines	O
but	O
did	O
not	O
affect	O
cytotoxicity	O
of	O
infected	O
hepatocytes	O
.	O

Special	O
attention	O
has	O
been	O
provided	O
to	O
the	O
use	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
as	O
vector	O
for	O
the	O
expression	O
of	O
PRRSV	O
antigens	B-CHED
.	O

TITLE	O
:	O
Crystallization	O
and	O
preliminary	O
X	O
-	O
ray	O
diffraction	O
analysis	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
human	O
coronavirus	O
OC43	O
nucleocapsid	O
protein	B-CHED
.	O

TITLE	O
:	O
Combat	B-CHED
-	O
associated	O
drowning	O
.	O

The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
describe	O
the	O
clinical	O
course	O
and	O
outcome	O
of	O
drowning	O
cases	O
related	O
to	O
current	O
US	O
military	O
combat	B-CHED
operations	O
.	O

This	O
retrospective	O
case	O
series	O
spans	O
December	O
2002	O
to	O
January	O
2009	O
of	O
survivors	O
transferred	O
to	O
an	O
echelon	O
IV	O
military	O
trauma	O
center	O
in	O
Europe	O
serving	O
as	O
the	O
primary	O
evacuation	O
hub	O
for	O
ongoing	O
combat	B-CHED
operations	O
.	O

As	O
such	O
,	O
understanding	O
mechanisms	O
associated	O
with	O
promoting	O
repair	O
within	O
the	O
CNS	B-CHED
in	O
the	O
context	O
of	O
a	O
persistent	O
viral	O
infection	O
is	O
critical	O
given	O
the	O
possible	O
viral	O
etiology	O
of	O
MS	O
.	O

The	O
presence	O
of	O
respiratory	O
virus	O
was	O
associated	O
with	O
increased	O
levels	O
of	O
interferon	O
gamma	O
-	O
inducible	O
protein	B-CHED
10	O
(	O
IP	O
-	O
10	O
)	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
eotaxin	O
-	O
1	O
(	O
p	O
=	O
0	O
.	O
017	O
)	O
in	O
BAL	B-CHED
.	O

IP	O
-	O
10	O
may	O
be	O
a	O
useful	O
biomarker	B-CHED
for	O
respiratory	O
viral	O
infection	O
.	O

Virus	O
samples	O
were	O
purified	O
and	O
dialyzed	O
in	O
phosphate	B-CHED
buffered	O
saline	O
(	O
8	O
to	O
9	O
log	O
PFU	B-CHED
/	O
mL	O
)	O
and	O
then	O
further	O
diluted	O
in	O
deionized	O
water	B-CHED
for	O
SERS	O
measurement	O
.	O

In	O
the	O
second	O
example	O
,	O
the	O
interaction	O
of	O
epoxide	B-CHED
inhibitors	B-CHED
with	O
the	O
main	O
protease	O
of	O
the	O
SARS	O
coronavirus	O
was	O
investigated	O
.	O

TITLE	O
:	O
Surfactant	B-CHED
protein	B-CHED
D	O
deficiency	O
increases	O
lung	O
injury	O
during	O
endotoxemia	O
.	O

Although	O
surfactant	B-CHED
protein	B-CHED
(	O
SP	B-CHED
)-	O
D	O
plays	O
a	O
critical	O
role	O
in	O
pulmonary	O
innate	O
immunity	O
and	O
several	O
clinical	O
studies	O
suggest	O
that	O
this	O
protein	B-CHED
may	O
be	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
ARDS	O
,	O
little	O
is	O
known	O
regarding	O
the	O
function	O
of	O
SP	B-CHED
-	O
D	O
in	O
ARDS	O
.	O

Moreover	O
,	O
recombinant	O
virus	O
harboring	O
the	O
S	O
glycoprotein	B-CHED
mutations	O
retained	O
its	O
neurotropism	O
,	O
productively	O
infecting	O
neurons	O
.	O

The	O
proteins	B-CHED
showed	O
discrepant	O
binding	O
activity	O
to	O
either	O
pAPN	O
antibody	O
or	O
TGE	O
virions	O
.	O

The	O
lost	B-CHED
to	O
follow	O
up	O
rate	O
was	O
24	O
%	O
for	O
the	O
SARS	O
group	O
compared	O
with	O
7	O
%	O
for	O
non	O
-	O
SARS	O
.	O

TITLE	O
:	O
Endocrine	B-CHED
cells	O
of	O
the	O
adenohypophysis	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Most	O
cases	O
appeared	O
to	O
be	O
primary	O
viral	O
pneumonia	O
,	O
but	O
only	O
one	O
case	O
was	O
positive	O
for	O
a	O
urinary	O
pneumococcal	O
antigen	B-CHED
.	O

All	O
24	O
patients	O
received	O
oseltamivir	B-CHED
after	O
admission	O
.	O

7	O
.	O
3	O
cm	O
H2O	B-CHED
.	O

The	O
lesion	O
in	O
the	O
BCoV	O
N	O
substitution	O
mutant	O
could	O
be	O
compensated	O
for	O
by	O
reverting	O
mutations	O
in	O
the	O
central	O
,	O
serine	B-CHED
-	O
and	O
arginine	B-CHED
-	O
rich	O
(	O
SR	O
)	O
domain	O
of	O
the	O
N	O
protein	B-CHED
.	O

A	O
similarly	O
defective	O
MHV	O
N	O
mutant	O
bearing	O
an	O
insertion	O
of	O
the	O
SR	O
region	O
from	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
N	O
protein	B-CHED
was	O
rescued	O
by	O
the	O
same	O
two	O
classes	O
of	O
reverting	O
mutations	O
.	O

During	O
a	O
vascular	O
occlusion	O
test	O
,	O
the	O
microcirculation	O
was	O
moderately	O
to	O
severely	O
compromised	O
with	O
a	O
NIRS	O
ascending	O
slope	O
of	O
2	O
.	O
39	O
%	O
sec	B-CHED
(-	O
1	O
)	O

(	O
1	O
.	O
75	O
-	O
2	O
.	O
67	O
%	O
sec	B-CHED
(-	O
1	O
)),	O
66	O
%	O
(	O
60	O
-	O
86	O
%)	O
of	O
perfused	O
small	O
vessels	O
in	O
the	O
sublingual	O
microcirculation	O
,	O
and	O
a	O
microvascular	O
flow	O
index	O
of	O
1	O
.	O
9	O
(	O
1	O
.	O
3	O
-	O
2	O
.	O
6	O
).	O

TEM	B-CHED
examinations	O
of	O
mixed	O
infections	O
with	O
Chlamydia	O
abortus	O
and	O
Chlamydia	O
pecorum	O
revealed	O
aberrant	O
chlamydial	O
inclusions	O
containing	O
reticulate	O
-	O
like	O
,	O
pleomorphic	O
ABs	O
,	O
which	O
were	O
up	O
to	O
2	O
microm	O
in	O
diameter	O
.	O

TITLE	O
:	O
SARS	O
spike	O
protein	B-CHED
induces	O
phenotypic	O
conversion	O
of	O
human	O
B	O
cells	O
to	O
macrophage	O
-	O
like	O
cells	O
.	O

MHV	O
-	O
Brts31	O
has	O
near	O
-	O
normal	O
levels	O
of	O
RNA	O
synthesis	O
at	O
the	O
permissive	O
temperature	O
of	O
33	O
degrees	O
C	O
but	O
is	O
unable	O
to	O
synthesize	O
viral	O
RNA	O
when	O
the	O
infection	O
is	O
initiated	O
and	O
maintained	O
at	O
the	O
nonpermissive	O
temperature	O
of	O
39	O
.	O
5	O
degrees	O
C	O
.	O
Sequence	O
analysis	O
of	O
MHV	O
-	O
Brts31	O
RNA	O
indicated	O
that	O
a	O
single	O
G	O
-	O
to	O
-	O
A	O
transition	O
at	O
codon	O
1307	O
in	O
open	O
reading	O
frame	O
1a	O
,	O
which	O
results	O
in	O
a	O
replacement	O
of	O
methionine	B-CHED
-	O
475	O
with	O
isoleucine	B-CHED
in	O
nonstructural	O
protein	B-CHED
3	O
(	O
nsp3	O
),	O
was	O
responsible	O
for	O
the	O
ts	O
phenotype	O
.	O

Its	O
tertiary	O
structure	O
is	O
compared	O
with	O
that	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
PL2	O
(	O
pro	B-CHED
),	O
a	O
downstream	O
paralog	O
that	O
is	O
conserved	O
in	O
the	O
nsp3	O
'	O
s	O
of	O
all	O
coronaviruses	O
.	O

The	O
purified	O
recombinant	O
TGEV	O
PL1	O
(	O
pro	B-CHED
)	O
was	O
shown	O
to	O
cleave	O
a	O
peptide	B-CHED
mimicking	O
the	O
cognate	O
nsp2	O
|	O
nsp3	O
cleavage	O
site	O
.	O

Like	O
its	O
PL2	O
(	O
pro	B-CHED
)	O
paralogs	O
from	O
several	O
coronaviruses	O
,	O
TGEV	O
PL1	O
(	O
pro	B-CHED
)	O
was	O
also	O
found	O
to	O
have	O
deubiquitinating	O
activity	O
in	O
an	O
in	O
vitro	O
cleavage	O
assay	O
,	O
implicating	O
it	O
in	O
counteracting	O
ubiquitin	O
-	O
regulated	O
host	O
cell	O
pathways	O
,	O
likely	O
including	O
innate	O
immune	O
responses	O
.	O

In	O
combination	O
with	O
the	O
prior	O
characterization	O
of	O
PL2	O
(	O
pro	B-CHED
)	O
from	O
other	O
alphacoronaviruses	O
,	O
e	O
.	O
g	O
.,	O
human	O
coronaviruses	O
229E	O
and	O
NL63	O
,	O
our	O
results	O
unequivocally	O
establish	O
that	O
these	O
viruses	O
employ	O
two	O
PL	O
(	O
pro	B-CHED
)	O
s	O
with	O
overlapping	O
specificities	O
toward	O
both	O
viral	O
and	O
cellular	O
substrates	O
.	O

After	O
6	O
months	O
of	O
nCPAP	O
therapy	O
,	O
serum	O
concentrations	O
of	O
DNA	O
,	O
IL	O
-	O
6	O
,	O
and	O
MDA	B-CHED
were	O
significantly	O
decreased	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

One	O
workshop	O
focused	O
on	O
potential	O
new	O
classes	O
of	O
antibiotics	B-CHED
,	O
while	O
the	O
other	O
explored	O
the	O
possibility	O
of	O
treating	O
infectious	O
diseases	O
by	O
modulating	O
the	O
immune	O
system	O
.	O

A	O
new	O
type	O
of	O
medicine	B-CHED
has	O
appeared	O
,	O
in	O
the	O
form	O
of	O
on	O
-	O
board	O
medical	O
assistance	O
.	O

Herein	O
we	O
report	O
the	O
synthesis	O
,	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
),	O
and	O
pharmacokinetic	O
properties	O
of	O
this	O
new	O
class	O
of	O
thiourea	B-CHED
compounds	O
that	O
showed	O
potent	O
inhibitory	O
activities	O
against	O
HCV	O
in	O
the	O
cell	O
-	O
based	O
subgenomic	O
HCV	O
replicon	O
assay	O
.	O

A	O
CoV	O
grouping	O
criterion	O
was	O
developed	O
by	O
comparing	O
amino	B-CHED
acid	I-CHED
identities	O
across	O
an	O
816	O
-	O
bp	O
fragment	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerases	O
(	O
RdRp	O
)	O
of	O
all	O
accepted	O
mammalian	O
CoV	O
species	O
(	O
RdRp	O
-	O
based	O
grouping	O
units	O
[	O
RGU	O
]).	O

ABSTRACT	O
:	O
Several	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
within	O
the	O
SARS	O
-	O
CoV	O
proteome	O
have	O
been	O
identified	O
,	O
one	O
of	O
them	O
being	O
between	O
non	O
-	O
structural	O
proteins	B-CHED
nsp10	O
and	O
nsp16	O
.	O

Thus	O
,	O
the	O
nsp10	O
-	O
nsp16	O
interface	O
may	O
represent	O
an	O
attractive	O
target	O
for	O
antivirals	B-CHED
against	O
human	O
and	O
animal	O
pathogenic	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
ORF8a	O
protein	B-CHED
is	O
39	O
residues	O
long	O
and	O
contains	O
a	O
single	O
transmembrane	O
domain	O
.	O

Computational	O
modeling	O
studies	O
including	O
multi	O
nanosecond	O
molecular	O
dynamics	O
simulations	O
in	O
a	O
hydrated	O
POPC	O
lipid	B-CHED
bilayer	O
are	O
done	O
with	O
a	O
22	O
amino	B-CHED
acid	I-CHED
transmembrane	O
helix	O
to	O
predict	O
a	O
putative	O
homooligomeric	O
helical	O
bundle	O
model	O
.	O

TITLE	O
:	O
CD8	O
+	O
T	O
cell	O
response	O
in	O
HLA	O
-	O
A	O
*	O
0201	O
transgenic	O
mice	O
is	O
elicited	O
by	O
epitopes	O
from	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
.	O

Most	O
of	O
the	O
HLA	O
-	O
A	O
*	O
0201	O
restricted	O
peptide	B-CHED
-	O
specific	O
CD8	O
(+)	O
T	O
cells	O
represented	O
a	O
memory	O
subset	O
with	O
CD45RB	O
(	O
high	O
)	O
and	O
CD62L	O
(	O
low	O
).	O

Acanthopanacis	O
cortex	O
and	O
Torilis	O
fructus	O
might	O
exert	O
their	O
antiviral	B-CHED
activities	O
in	O
MHV	O
-	O
A59	O
-	O
infected	O
cells	O
by	O
inducing	O
cyclooxygenase	O
-	O
2	O
expression	O
via	O
the	O
activation	O
of	O
extracellular	O
signal	O
-	O
related	O
kinase	O
(	O
ERK	O
)	O
and	O
p38	O
or	O
ERK	O
alone	O
,	O
respectively	O
.	O

After	O
varying	O
periods	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
with	O
appropriate	O
antibiotic	B-CHED
and	O
ancillary	O
care	O
,	O
all	O
four	O
patients	O
were	O
discharged	O
home	O
.	O

TITLE	O
:	O
Association	O
between	O
mannose	B-CHED
-	O
binding	O
lectin	O
gene	O
polymorphism	O
and	O
pediatric	O
cytomegalovirus	O
infection	O
.	O

TITLE	O
:	O
Acute	O
pathophysiological	O
effects	O
of	O
intratracheal	O
instillation	O
of	O
budesonide	B-CHED
and	O
exogenous	O
surfactant	B-CHED
in	O
a	O
neonatal	O
surfactant	B-CHED
-	O
depleted	O
piglet	O
model	O
.	O

Total	O
protein	B-CHED
was	O
assessed	O
in	O
1	O
-	O
to	O
8	O
-	O
day	O
-	O
old	O
calves	O
.	O

The	O
viral	O
spike	O
(	O
S	O
)	O
protein	B-CHED
mediates	O
the	O
interaction	O
between	O
TGEV	O
and	O
its	O
susceptible	O
cells	O
.	O

Lysine	B-CHED
(	O
K	O
)	O
and	O
arginine	B-CHED
(	O
R	O
)	O
substitutions	O
were	O
replaced	O
in	O
recovered	O
viruses	O
by	O
neutrally	O
charged	O
glutamine	B-CHED
(	O
Q	O
)	O
and	O
leucine	B-CHED
(	O
L	O
),	O
respectively	O
,	O
after	O
only	O
one	O
passage	O
.	O

E121Q	O
and	O
E121L	O
M	O
proteins	B-CHED
were	O
capable	O
of	O
forming	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
when	O
coexpressed	O
with	O
E	O
,	O
whereas	O
E121R	O
and	O
E121K	O
proteins	B-CHED
were	O
not	O
.	O

the	O
internal	O
control	O
,	O
ND5	O
mRNA	B-CHED
,	O
was	O
detected	O
successfully	O
in	O
all	O
reactions	O
.	O

TITLE	O
:	O
Synthesis	O
,	O
antiviral	B-CHED
activity	O
and	O
cytotoxicity	O
evaluation	O
of	O
Schiff	B-CHED
bases	I-CHED
of	O
some	O
2	O
-	O
phenyl	B-CHED
quinazoline	B-CHED
-	O
4	O
(	O
3	O
)	O
H	O
-	O
ones	O
.	O

Compound	O
2a	O
showed	O
better	O
antiviral	B-CHED
activity	O
against	O
the	O
entire	O
tested	O
virus	O
.	O

ABSTRACT	O
:	O
Increased	O
levels	O
of	O
atrial	O
natriuretic	O
peptide	B-CHED
(	O
ANP	O
)	O
in	O
the	O
models	O
of	O
sepsis	O
,	O
pulmonary	O
edema	O
,	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
suggest	O
its	O
potential	O
role	O
in	O
the	O
modulation	O
of	O
acute	O
lung	O
injury	O
.	O

ANP	O
treatment	O
stimulated	O
Rac	O
-	O
dependent	O
PAK1	O
phosphorylation	O
,	O
attenuated	O
endothelial	O
permeability	O
caused	O
by	O
LPS	B-CHED
,	O
TNF	O
-	O
	O
,	O
and	O
IL	O
-	O
6	O
,	O
decreased	O
LPS	B-CHED
-	O
induced	O
cell	O
and	O
protein	B-CHED
accumulation	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
and	O
suppressed	O
Evans	O
blue	O
extravasation	O
in	O
the	O
murine	O
model	O
of	O
acute	O
lung	O
injury	O
.	O

In	O
rescue	O
experiments	O
,	O
ANP	O
injection	O
significantly	O
reduced	O
lung	O
injury	O
in	O
Nppa	O
(-/-)	O
mice	O
caused	O
by	O
LPS	B-CHED
.	O

The	O
available	O
data	O
derive	O
from	O
case	O
reports	O
and	O
case	O
series	O
and	O
thus	O
the	O
deduction	O
of	O
conclusions	O
regarding	O
the	O
effect	O
,	O
if	O
any	O
,	O
of	O
antiviral	B-CHED
treatment	O
is	O
debatable	O
.	O

CONCLUSIONS	O
:	O
The	O
available	O
data	O
derive	O
from	O
case	O
reports	O
and	O
case	O
series	O
and	O
thus	O
the	O
deduction	O
of	O
conclusions	O
regarding	O
the	O
effect	O
,	O
if	O
any	O
,	O
of	O
antiviral	B-CHED
treatment	O
is	O
debatable	O
.	O

Recruitment	O
of	O
the	O
N	O
protein	B-CHED
to	O
the	O
RTCs	O
requires	O
the	O
C	O
-	O
terminal	O
N2b	O
domain	O
,	O
which	O
interacts	O
with	O
other	O
N	O
proteins	B-CHED
in	O
an	O
RNA	O
-	O
independent	O
manner	O
.	O

Given	O
the	O
low	O
levels	O
of	O
neuronal	O
expression	O
of	O
ceacam1a	O
,	O
primary	O
neurons	O
from	O
wild	O
-	O
type	O
and	O
ceacam1a	O
knockout	O
mice	O
were	O
inoculated	O
with	O
MHV	O
to	O
determine	O
the	O
extent	O
to	O
which	O
CEACAM1a	O
-	O
independent	O
infection	O
might	O
contribute	O
to	O
CNS	B-CHED
infection	O
.	O

ABSTRACT	O
:	O
A	O
conserved	O
nucleic	B-CHED
acid	I-CHED
fragment	O
of	O
the	O
nucleocapsid	O
gene	O
of	O
Swine	O
Transmissible	O
Gastroenteritis	O
Coronavirus	O
(	O
TGEV	O
)	O
was	O
chosen	O
as	O
the	O
target	O
,	O
six	O
special	O
primers	O
were	O
designed	O
successfully	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
genome	O
encodes	O
eight	O
accessory	O
proteins	B-CHED
.	O

Growth	B-CHED
hormone	I-CHED
releasing	O
peptide	B-CHED
-	O
2	O
(	O
GHRP	O
-	O
2	O
),	O
a	O
ghrelin	O
agonist	B-CHED
,	O
has	O
been	O
shown	O
to	O
exert	O
beneficial	O
effects	O
on	O
various	O
inflammatory	O
diseases	O
.	O

In	O
contrast	O
,	O
these	O
lung	O
injury	O
indexes	O
were	O
attenuated	O
in	O
rats	O
that	O
received	O
a	O
subcutaneous	O
injection	O
of	O
GHRP	O
-	O
2	O
(	O
100	O
microg	O
/	O
kg	O
)	O
0	O
.	O
5	O
h	O
prior	O
to	O
LPS	B-CHED
administration	O
.	O

The	O
similarity	O
between	O
the	O
clinical	O
features	O
of	O
the	O
case	O
we	O
present	O
and	O
those	O
reported	O
in	O
connection	O
to	O
abrupt	O
withdrawal	O
of	O
intrathecal	O
baclofen	B-CHED
is	O
emphasized	O
.	O

ABSTRACT	O
:	O
As	O
protein	B-CHED
folding	O
is	O
an	O
imperfect	O
process	O
,	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
contains	O
folding	O
as	O
well	O
as	O
ER	O
-	O
associated	O
degradation	O
(	O
ERAD	O
)	O
machineries	O
.	O

In	O
addition	O
,	O
antiviral	B-CHED
activity	O
was	O
determined	O
by	O
inhibition	O
studies	O
on	O
the	O
infection	O
cycle	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
measured	O
as	O
minimum	O
concentration	O
of	O
cherry	O
extracts	O
that	O
inhibited	O
50	O
%	O
of	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
on	O
PEDV	O
.	O

Our	O
data	O
indicate	O
that	O
Korean	O
native	O
cherry	O
cultivars	O
could	O
be	O
beneficial	O
supplements	O
of	O
dietary	O
antioxidants	B-CHED
and	O
natural	O
antiviral	B-CHED
agents	I-CHED
.	O

ABSTRACT	O
:	O
After	O
renovation	O
of	O
the	O
adult	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
with	O
installation	O
of	O
ten	O
single	O
rooms	O
,	O
an	O
enhanced	O
infection	O
control	O
program	O
was	O
conducted	O
to	O
control	O
the	O
spread	O
of	O
methicillin	B-CHED
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
in	O
our	O
hospital	O
.	O

The	O
usage	O
density	O
of	O
broad	O
-	O
spectrum	O
antibiotics	B-CHED
and	O
fluoroquinolones	O
increased	O
from	O
phase	O
1	O
to	O
3	O
.	O

TITLE	O
:	O
Trimethoprim	B-CHED
/	I-CHED
Sulfamethoxazole	I-CHED
pharmacokinetics	O
in	O
two	O
patients	O
undergoing	O
continuous	O
venovenous	O
hemodiafiltration	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
extent	O
of	O
elimination	O
of	O
trimethoprim	B-CHED
(	O
TMP	B-CHED
)	O
and	O
sulfamethoxazole	B-CHED
(	O
SMX	B-CHED
)	O
via	O
continuous	O
venovenous	O
hemodiafiltration	O
(	O
CVVHDF	O
)	O
in	O
2	O
critically	O
ill	O
patients	O
with	O
renal	O
failure	O
.	O

A	O
77	O
-	O
year	O
-	O
old	O
man	B-CHED
was	O
admitted	O
for	O
aortic	O
root	O
replacement	O
and	O
developed	O
septic	O
shock	O
and	O
nosocomial	O
pneumonia	O
due	O
to	O
Stenotrophomonas	O
maltophilia	O
.	O

Factors	O
contributing	O
to	O
the	O
continual	O
emergence	O
include	O
mutations	O
,	O
insertions	O
and	O
deletions	O
in	O
the	O
S1	O
protein	B-CHED
genes	O
;	O
recombination	O
between	O
local	O
IBV	O
strains	O
circulating	O
in	O
chicken	O
flocks	O
in	O
China	O
;	O
and	O
recombination	O
between	O
local	O
strains	O
and	O
vaccine	O
strains	O
.	O

Postinjury	O
treatments	O
with	O
tiotropium	O
bromide	B-CHED
were	O
as	O
effective	O
as	O
pretreatment	O
in	O
preventing	O
pulmonary	O
insufficiency	O
,	O
although	O
a	O
trend	O
toward	O
decreased	O
obstruction	O
was	O
present	O
only	O
in	O
all	O
post	O
-	O
treatment	O
conditions	O
.	O

A	O
minority	O
of	O
studies	O
met	B-CHED
the	O
predefined	O
methodologic	O
quality	O
criteria	O
.	O

TITLE	O
:	O
Protective	O
immune	O
responses	O
induced	O
by	O
in	O
ovo	O
immunization	O
with	O
recombinant	O
adenoviruses	O
expressing	O
spike	O
(	O
S1	O
)	O
glycoprotein	B-CHED
of	O
infectious	O
bronchitis	O
virus	O
fused	O
/	O
co	O
-	O
administered	O
with	O
granulocyte	O
-	O
macrophage	O
colony	O
stimulating	O
factor	O
.	O

The	O
3	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
and	O
partial	O
S1	O
gene	O
nucleotide	B-CHED
sequences	O
for	O
the	O
17	O
IB	O
virus	O
strains	O
were	O
determined	O
and	O
their	O
identity	O
with	O
those	O
of	O
the	O
relative	O
reference	O
strains	O
compared	O
to	O
confirm	O
the	O
classifications	O
generated	O
using	O
the	O
HRM	O
curve	O
analysis	O
.	O

Within	O
the	O
purpose	O
of	O
developing	O
new	O
antiseptics	O
molecules	O
,	O
the	O
antiseptic	O
virucidal	O
activity	O
of	O
two	O
calix	B-CHED
[	I-CHED
4	I-CHED
]	I-CHED
arene	I-CHED
derivatives	O
,	O
the	O
tetra	B-CHED
-	O
para	B-CHED
-	O
sulfonato	B-CHED
-	O
calix	B-CHED
[	I-CHED
4	I-CHED
]	I-CHED
arene	I-CHED
(	O
C	O
[	O
4	O
]	O
S	O
)	O
and	O
the	O
1	O
,	O
3	O
-	O
bis	O
(	O
bithiazolyl	O
)-	O
tetra	B-CHED
-	O
para	B-CHED
-	O
sulfonato	B-CHED
-	O
calix	B-CHED
[	I-CHED
4	I-CHED
]	I-CHED
arene	I-CHED
(	O
C	O
[	O
4	O
]	O
S	O
-	O
BTZ	O
)	O
were	O
evaluated	O
toward	O
the	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
229E	O
).	O

TITLE	O
:	O
The	O
SARS	O
coronavirus	O
E	O
protein	B-CHED
interacts	O
with	O
PALS1	O
and	O
alters	O
tight	O
junction	O
formation	O
and	O
epithelial	O
morphogenesis	O
.	O

Here	O
we	O
report	O
that	O
the	O
carboxy	B-CHED
-	O
terminal	O
domain	O
of	O
the	O
SARS	O
-	O
CoV	O
E	O
small	O
envelope	O
protein	B-CHED
(	O
E	O
)	O
binds	O
to	O
human	O
PALS1	O
.	O

These	O
emerging	O
sublineages	O
display	O
varying	O
levels	O
of	O
drug	O
resistance	O
and	O
in	O
some	O
cases	O
an	O
increased	O
preference	O
for	O
binding	O
to	O
human	O
2	O
,	O
6	O
-	O
linked	O
sialic	B-CHED
acid	I-CHED
cellular	O
receptors	O
.	O

The	O
purified	O
recombinant	O
M	O
protein	B-CHED
was	O
used	O
to	O
immunize	O
rabbits	O
to	O
generate	O
a	O
polyclonal	O
antibody	O
.	O

Immune	O
condition	O
may	O
be	O
restored	O
by	O
hypertonic	O
saline	O
resuscitation	O
that	O
inhibits	O
pro	B-CHED
-	O
inflammatory	O
effects	O
of	O
cytokine	O
.	O

(	O
1	O
)	O
Wild	O
HS	O
:	O
resuscitation	O
with	O
hypertonic	O
saline	O
(	O
4	O
mL	O
/	O
Kg	O
of	O
7	O
.	O
5	O
%	O
NaCl	B-CHED
)	O
and	O
the	O
shed	O
blood	O
(	O
SB	O
);	O
(	O
2	O
)	O
wild	O
2LR	O
:	O
resuscitation	O
with	O
lactated	O
Ringer	O
'	O
s	O
solution	O
and	O
the	O
SB	O
;	O
(	O
3	O
)	O
iNOS	O
knockout	O
HS	O
:	O
similarly	O
resuscitated	O
as	O
wild	O
HS	O
;	O
(	O
4	O
)	O
iNOS	O
knockout	O
2LR	O
:	O
similarly	O
resuscitated	O
as	O
wild	O
2LR	O
.	O

Plasma	O
levels	O
of	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
TNF	O
-	O
	O
,	O
MCP	B-CHED
-	O
1	O
,	O
and	O
IL	O
-	O
10	O
increased	O
at	O
2	O
h	O
.	O
Both	O
in	O
wild	O
type	O
and	O
iNOS	O
knockout	O
mice	O
,	O
hypertonic	O
saline	O
resuscitation	O
decreased	O
plasma	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
	O
,	O
and	O
MCP	B-CHED
-	O
1	O
levels	O
at	O
2	O
h	O
;	O
CD4	O
(+)	O
T	O
cells	O
in	O
spleen	O
and	O
thymus	O
decreased	O
at	O
24	O
,	O
48	O
,	O
and	O
72	O
h	O
,	O
and	O
Foxp3	O
(+)	O
Tregs	O
in	O
spleen	O
at	O
48	O
h	O
increased	O
,	O
however	O
,	O
hypertonic	O
saline	O
resuscitation	O
did	O
not	O
affect	O
the	O
Foxp3	O
(+).	O

ABSTRACT	O
:	O
In	O
the	O
present	O
study	O
,	O
anti	O
-	O
IBV	O
(	O
infectious	O
bronchitis	O
virus	O
)	O
activity	O
of	O
1	B-CHED
,	I-CHED
8	I-CHED
-	I-CHED
cineole	I-CHED
was	O
studied	O
by	O
MTT	B-CHED
assay	O
,	O
as	O
well	O
as	O
docking	O
and	O
molecular	O
dynamic	O
(	O
MD	O
)	O
simulations	O
.	O

Droplet	O
counts	O
in	O
mean	O
diameter	O
size	O
ranges	O
from	O
0	O
.	O
3	O
to	O
>	O
10	O
m	O
were	O
measured	O
with	O
an	O
counter	B-CHED
placed	O
adjacent	O
to	O
the	O
face	O
and	O
at	O
a	O
1	O
-	O
m	O
distance	O
from	O
the	O
subject	O
/	O
patient	O
,	O
at	O
the	O
height	O
of	O
the	O
nose	O
/	O
mouth	O
of	O
an	O
average	O
health	O
-	O
care	O
worker	O
.	O

TITLE	O
:	O
Evolved	O
variants	O
of	O
the	O
membrane	O
protein	B-CHED
can	O
partially	O
replace	O
the	O
envelope	O
protein	B-CHED
in	O
murine	O
coronavirus	O
assembly	O
.	O

Further	O
,	O
the	O
lysosome	O
-	O
tropic	O
reagents	B-CHED
failed	O
to	O
inhibit	O
,	O
whereas	O
the	O
heptad	O
repeat	O
peptide	B-CHED
efficiently	O
inhibited	O
viral	O
entry	O
into	O
cells	O
,	O
suggesting	O
that	O
TMPRSS2	O
affects	O
the	O
S	O
protein	B-CHED
at	O
the	O
cell	O
surface	O
and	O
induces	O
virus	O
-	O
plasma	O
membrane	O
fusion	O
.	O

On	O
the	O
other	O
hand	O
,	O
production	O
of	O
virus	O
in	O
TMPRSS2	O
-	O
expressing	O
cells	O
did	O
not	O
result	O
in	O
S	O
-	O
protein	B-CHED
cleavage	O
or	O
increased	O
infectivity	O
of	O
the	O
resulting	O
virus	O
.	O

More	O
potent	O
activity	O
appeared	O
to	O
be	O
associated	O
with	O
the	O
presence	O
of	O
an	O
apigenin	B-CHED
moiety	O
at	O
position	O
C	O
-	O
3	O
'	O
of	O
flavones	B-CHED
,	O
as	O
biflavone	O
had	O
an	O
effect	O
on	O
3CL	O
(	O
pro	B-CHED
)	O
inhibitory	O
activity	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	B-CHED
))	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
is	O
required	O
for	O
autoprocessing	O
of	O
the	O
polyprotein	O
,	O
and	O
is	O
a	O
potential	O
target	O
for	O
treating	O
coronaviral	O
infection	O
.	O

In	O
this	O
review	O
we	O
summarize	O
the	O
aerosol	O
model	O
of	O
rabbitpox	O
,	O
discuss	O
the	O
development	O
efforts	O
that	O
have	O
thus	O
far	O
used	O
this	O
model	O
for	O
antiviral	B-CHED
testing	O
,	O
and	O
comment	O
on	O
the	O
prospects	O
for	O
its	O
use	O
in	O
future	O
evaluations	O
requiring	O
a	O
poxviral	O
model	O
with	O
a	O
focus	O
on	O
respiratory	O
infection	O
.	O

A	O
set	O
of	O
double	O
-	O
stable	O
eukaryotic	O
cell	O
lines	O
(	O
BHK	O
-	O
Tet	O
-	O
SARS	O
-	O
N	O
)	O
with	O
inducible	O
control	O
of	O
the	O
SARS	O
-	O
CoV	O
neucleocapsid	O
gene	O
expression	O
was	O
identified	O
by	O
using	O
SDS	B-CHED
-	O
PAGE	O
and	O
Western	O
-	O
blot	O
analysis	O
.	O

TITLE	O
:	O
Cxcl16	O
interact	O
with	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
in	O
and	O
out	O
cell	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
N	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
could	O
inhibit	O
IFN	O
-	O
beta	O
(	O
IFN	O
-	O
	O
)	O
induced	O
by	O
poly	O
(	O
I	O
:	O
C	O
)	O
or	O
Sendai	O
virus	O
.	O

TITLE	O
:	O
Importance	O
of	O
controlling	O
nanotube	B-CHED
density	O
for	O
highly	O
sensitive	O
and	O
reliable	O
biosensors	O
functional	O
in	O
physiological	O
conditions	O
.	O

While	O
nanotubes	O
have	O
been	O
employed	O
in	O
the	O
fabrication	O
of	O
multiple	O
sensors	O
,	O
little	O
attention	O
has	O
previously	O
been	O
paid	O
to	O
how	O
the	O
nanotube	B-CHED
density	O
affects	O
the	O
biosensor	O
performance	O
.	O

This	O
work	O
allowed	O
dissection	O
of	O
several	O
molecular	O
signatures	O
present	O
during	O
SARS	O
-	O
CoV	O
which	O
are	O
part	O
of	O
a	O
robust	O
IFN	O
antiviral	B-CHED
response	O
.	O

However	O
,	O
the	O
specificities	O
of	O
ISG20	O
'	O
s	O
antiviral	B-CHED
action	O
remain	O
poorly	O
defined	O
.	O

Determination	O
of	O
virus	O
-	O
induced	O
cytopathogenic	O
effects	O
and	O
virus	O
titres	O
revealed	O
that	O
EPs	O
	O
7630	O
at	O
concentrations	O
up	O
to	O
100	O
g	O
/	O
ml	O
interfered	O
with	O
replication	O
of	O
seasonal	O
influenza	O
A	O
virus	O
strains	O
(	O
H1N1	O
,	O
H3N2	B-CHED
),	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
coronavirus	O
,	O
parainfluenza	O
virus	O
,	O
and	O
coxsackie	O
virus	O
but	O
did	O
not	O
affect	O
replication	O
of	O
highly	O
pathogenic	O
avian	O
influenza	O
A	O
virus	O
(	O
H5N1	O
),	O
adenovirus	O
,	O
or	O
rhinovirus	O
.	O

RESULTS	O
:	O
Kidney	O
screening	O
with	O
IHC	O
showed	O
sensitivity	O
,	O
specificity	O
,	O
PPV	B-CHED
and	O
NPV	O
of	O
95	O
.	O
45	O
%,	O
73	O
.	O
68	O
%,	O
80	O
.	O
77	O
%	O
and	O
93	O
.	O
33	O
%,	O
respectively	O
.	O

Unlike	O
the	O
nsp1	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
a	O
betacoronavirus	O
,	O
the	O
TGEV	O
nsp1	O
protein	B-CHED
was	O
unable	O
to	O
bind	O
40S	O
ribosomal	O
subunits	O
or	O
promote	O
host	O
mRNA	B-CHED
degradation	O
.	O

ABSTRACT	O
:	O
The	O
immune	O
responses	O
in	O
patients	O
with	O
novel	O
A	O
(	O
H1N1	O
)	O
virus	O
infection	O
(	O
nvA	B-CHED
(	O
H1N1	O
))	O
are	O
incompletely	O
characterized	O
.	O

ABSTRACT	O
:	O
By	O
revisiting	O
the	O
air	B-CHED
distribution	O
and	O
bioaerosol	O
dispersion	O
in	O
Ward	O
8A	O
where	O
the	O
largest	O
nosocomial	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
outbreak	O
occurred	O
in	O
Hong	O
Kong	O
in	O
2003	O
,	O
we	O
found	O
an	O
interesting	O
phenomenon	O
.	O

ACE2	O
immunoprecipitation	O
captured	O
transmembrane	O
protease	O
/	O
serine	B-CHED
subfamily	O
member	O
2	O
(	O
TMPRSS2	O
),	O
a	O
known	O
human	O
airway	O
and	O
alveolar	O
protease	O
.	O

PTX3	O
expression	O
is	O
increased	O
in	O
animals	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
in	O
patients	O
with	O
sepsis	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
is	O
considered	O
to	O
be	O
a	O
potential	O
biomarker	B-CHED
for	O
these	O
diseases	O
.	O

LPS	B-CHED
instillation	O
induced	O
ALI	O
in	O
both	O
PTX3	O
-	O
KO	O
and	O
WT	O
mice	O
.	O

RESULTS	O
:	O
LPS	B-CHED
instillation	O
induced	O
ALI	O
in	O
both	O
PTX3	O
-	O
KO	O
and	O
WT	O
mice	O
.	O

PTX3	O
deficiency	O
also	O
enhanced	O
LPS	B-CHED
-	O
induced	O
tissue	O
factor	O
expression	O
/	O
activation	O
in	O
the	O
lung	O
and	O
increased	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
and	O
monocyte	O
chemoattractant	O
protein	B-CHED
-	O
1	O
levels	O
in	O
the	O
plasma	O
.	O

The	O
observation	O
that	O
JHM	O
.	O
SD	O
infects	O
more	O
cells	O
and	O
expresses	O
more	O
antigen	B-CHED
,	O
but	O
produces	O
less	O
infectious	O
virus	O
per	O
cell	O
than	O
A59	O
,	O
implies	O
that	O
efficient	O
replication	O
is	O
not	O
always	O
a	O
correlate	O
of	O
high	O
neurovirulence	O
.	O

Differences	O
in	O
the	O
S	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	B-CHED
between	O
A59	O
and	O
JHM	O
.	O
SD	O
contribute	O
to	O
JHM	O
.	O
SD	O
neuropathogenicity	O
.	O

TITLE	O
:	O
Zn	O
(	O
2	O
+)	O
inhibits	O
coronavirus	O
and	O
arterivirus	O
RNA	O
polymerase	O
activity	O
in	O
vitro	O
and	O
zinc	B-CHED
ionophores	B-CHED
block	O
the	O
replication	O
of	O
these	O
viruses	O
in	O
cell	O
culture	O
.	O

Poxvirus	O
and	O
coronavirus	O
mutants	O
that	O
lacked	O
2	O
'-	O
O	O
MTase	O
activity	O
similarly	O
showed	O
enhanced	O
sensitivity	O
to	O
the	O
antiviral	B-CHED
actions	O
of	O
IFN	O
and	O
,	O
specifically	O
,	O
IFIT	O
proteins	B-CHED
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
2	O
'-	O
O	O
methylation	O
of	O
the	O
5	O
'	O
cap	O
of	O
viral	O
RNA	O
functions	O
to	O
subvert	O
innate	O
host	O
antiviral	B-CHED
responses	O
through	O
escape	O
of	O
IFIT	O
-	O
mediated	O
suppression	O
,	O
and	O
suggest	O
an	O
evolutionary	O
explanation	O
for	O
2	O
'-	O
O	O
methylation	O
of	O
cellular	O
mRNA	B-CHED
:	O
to	O
distinguish	O
self	O
from	O
non	O
-	O
self	O
RNA	O
.	O

In	O
this	O
study	O
,	O
the	O
increase	O
of	O
SARS	O
-	O
CoV	O
3CLpro	O
peptidase	O
activity	O
in	O
presence	O
of	O
kosmotropic	O
salts	B-CHED
and	O
crowding	O
agents	O
is	O
described	O
.	O

The	O
activation	O
followed	O
the	O
Hofmeister	O
series	O
of	O
anions	B-CHED
,	O
with	O
two	O
orders	O
of	O
magnitude	O
enhancement	O
in	O
the	O
presence	O
of	O
NaSO	O
,	O
whereas	O
the	O
crowding	O
agents	O
polyethylene	B-CHED
glycol	I-CHED
and	O
bovine	O
serum	O
albumin	O
increased	O
the	O
hydrolytic	O
rate	O
up	O
to	O
3	O
times	O
.	O

Here	O
we	O
report	O
the	O
application	O
of	O
AUC	O
to	O
protein	B-CHED
size	O
-	O
and	O
-	O
shape	O
distribution	O
analysis	O
and	O
structure	O
-	O
and	O
-	O
function	O
analysis	O
in	O
the	O
presence	O
of	O
ligands	O
or	O
lipids	B-CHED
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
impact	O
of	O
inflammation	O
,	O
water	B-CHED
metabolism	O
and	O
immune	O
function	O
on	O
the	O
establishment	O
of	O
a	O
mouse	O
model	O
of	O
damp	B-CHED
-	O
heat	O
syndrome	O
with	O
MHV	O
-	O
A59	O
infection	O
.	O

Cox	O
regression	O
analysis	O
adjusted	O
for	O
severity	O
and	O
potential	O
confounding	O
factors	O
identified	O
that	O
early	O
use	O
of	O
corticosteroids	B-CHED
was	O
not	O
significantly	O
associated	O
with	O
mortality	O
[	O
hazard	O
ratio	O
(	O
HR	O
)	O
1	O
.	O
3	O
,	O
95	O
%	O
CI	O
0	O
.	O
7	O
-	O
2	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
4	O
]	O
but	O
was	O
still	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
HAP	O
(	O
OR	O
2	O
.	O
2	O
,	O
95	O
%	O
CI	O
1	O
.	O
0	O
-	O
4	O
.	O
8	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Neutral	O
endopeptidase	O
(	O
NEP	O
),	O
an	O
enzyme	O
that	O
cleaves	O
inflammatory	O
bioactive	O
peptides	B-CHED
,	O
may	O
play	O
a	O
protective	O
role	O
in	O
the	O
pathogenesis	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

In	O
this	O
experimental	O
and	O
clinical	O
study	O
of	O
ALI	O
/	O
ARDS	O
,	O
the	O
activity	O
of	O
NEP	O
was	O
significantly	O
decreased	O
in	O
plasma	O
and	O
increased	O
in	O
the	O
alveolar	O
air	B-CHED
space	O
.	O

Immuno	O
-	O
histochemical	O
and	O
Western	O
immunoblot	O
studies	O
in	O
mice	O
confirmed	O
a	O
)	O
the	O
presence	O
of	O
NEP	O
in	O
the	O
alveolar	O
wall	O
,	O
a	O
critical	O
target	O
in	O
ALI	O
/	O
ARDS	O
,	O
and	O
b	O
)	O
a	O
decrease	O
in	O
its	O
expression	O
in	O
HCl	B-CHED
-	O
and	O
LPS	B-CHED
-	O
induced	O
ALI	O
.	O

Consider	O
aminophylline	B-CHED
(	O
5	O
mg	O
/	O
kgBW	O
).	O

Advanced	O
life	O
support	O
:	O
adrenaline	B-CHED
(	O
epinephrine	B-CHED
)	O
10	O
g	O
/	O
kgBW	O
i	O
.	O
v	O
.	O
or	O
i	O
.	O
o	O
.	O

The	O
structural	O
modifications	O
induced	O
by	O
tryptophan	B-CHED
oxidation	O
were	O
severe	O
,	O
with	O
a	O
reduction	O
in	O
helical	O
extent	O
from	O
approximately	O
three	O
helical	O
turns	O
to	O
,	O
at	O
most	O
,	O
one	O
turn	O
,	O
and	O
were	O
observed	O
in	O
a	O
variety	O
of	O
solvent	B-CHED
environments	O
,	O
including	O
sodium	B-CHED
dodecyl	I-CHED
sulfate	I-CHED
(	O
SDS	B-CHED
)	O
micelles	O
,	O
dodecyl	B-CHED
phosphocholine	B-CHED
(	O
DPC	B-CHED
)	O
micelles	O
,	O
and	O
a	O
40	O
%	O
hexafluoro	B-CHED
-	I-CHED
2	I-CHED
-	I-CHED
propanol	I-CHED
(	O
HFIP	B-CHED
)	O
aqueous	O
solution	O
.	O

Interestingly	O
,	O
the	O
character	O
of	O
the	O
disruptions	O
to	O
peptide	B-CHED
-	O
lipid	B-CHED
interactions	O
caused	O
by	O
tryptophan	B-CHED
oxidation	O
was	O
highly	O
dependent	O
on	O
the	O
charge	O
of	O
the	O
lipid	B-CHED
headgroup	O
.	O

After	O
plasmapheresis	O
and	O
corticosteroid	B-CHED
treatment	O
,	O
her	O
clinical	O
course	O
improved	O
with	O
successful	O
extubation	O
.	O

Based	O
on	O
the	O
inter	O
-	O
nucleotide	B-CHED
distance	O
sequence	O
,	O
we	O
propose	O
the	O
conditional	O
multinomial	O
distribution	O
profile	O
for	O
the	O
complete	O
genomic	O
sequence	O
.	O

Determination	O
of	O
vanadium	B-CHED
concentration	O
in	O
blood	O
was	O
carried	O
out	O
by	O
means	O
of	O
mass	O
spectrometer	O
(	O
ICP	O
-	O
MS	O
)	O
using	O
rhodium	B-CHED
((	O
103	O
)	O
Rh	O
)	O
as	O
the	O
internal	O
standard	O
.	O

TITLE	O
:	O
A	O
structural	O
analysis	O
of	O
M	O
protein	B-CHED
in	O
coronavirus	O
assembly	O
and	O
morphology	O
.	O

ABSTRACT	O
:	O
The	O
M	O
protein	B-CHED
of	O
coronavirus	O
plays	O
a	O
central	O
role	O
in	O
virus	O
assembly	O
,	O
turning	O
cellular	O
membranes	O
into	O
workshops	O
where	O
virus	O
and	O
host	O
factors	O
come	O
together	O
to	O
make	O
new	O
virus	O
particles	O
.	O

ABSTRACT	O
:	O
In	O
a	O
previous	O
study	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
was	O
cultured	O
in	O
the	O
presence	O
of	O
bananin	O
,	O
an	O
effective	O
adamantane	B-CHED
-	O
related	O
molecule	O
with	O
antiviral	B-CHED
activity	O
.	O

The	O
sensitivity	O
of	O
this	O
method	O
for	O
BCoV	O
and	O
group	O
A	O
BRV	O
was	O
10	O
PFU	B-CHED
/	O
100	O
l	O
and	O
1	O
PFU	B-CHED
/	O
100	O
l	O
,	O
respectively	O
.	O

The	O
biological	O
activity	O
of	O
CTB	O
-	O
COE	O
fusion	O
protein	B-CHED
to	O
its	O
receptor	O
,	O
G	O
(	O
M1	O
)-	O
ganglioside	B-CHED
,	O
in	O
transgenic	O
plants	O
was	O
confirmed	O
via	O
G	O
(	O
M1	O
)-	O
ELISA	O
with	O
anti	O
-	O
cholera	O
toxin	O
and	O
anti	O
-	O
COE	O
antibody	O
.	O

Immunochemical	O
staining	O
with	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
against	O
N	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
was	O
used	O
to	O
determine	O
the	O
stomach	O
and	O
enteric	O
tissues	O
among	O
5	O
SARS	O
patients	O
with	O
their	O
nucleocapsid	O
antibody	O
titer	O
ascended	O
obviously	O
after	O
1	O
(	O
st	O
)-	O
7	O
(	O
th	O
)	O
year	O
.	O

However	O
,	O
systemic	O
corticosteroid	B-CHED
was	O
not	O
associated	O
with	O
improving	O
28	O
-	O
day	O
and	O
3	O
-	O
month	O
survival	O
rates	O
.	O

Based	O
on	O
this	O
finding	O
,	O
a	O
liposome	O
vaccine	O
that	O
is	O
capable	O
of	O
inducing	O
CTL	O
response	O
against	O
internal	O
antigens	B-CHED
of	O
influenza	O
viruses	O
and	O
removing	O
virus	O
-	O
infected	O
cells	O
in	O
the	O
host	O
has	O
been	O
developed	O
.	O

Compared	O
to	O
the	O
90	O
children	O
admitted	O
during	O
the	O
2008	O
-	O
09	O
season	O
,	O
children	O
admitted	O
with	O
2009	O
H1N1	O
influenza	O
were	O
significantly	O
older	O
,	O
had	O
a	O
shorter	O
length	O
of	O
hospitalization	O
,	O
more	O
use	O
of	O
antivirals	B-CHED
,	O
and	O
a	O
higher	O
incidence	O
of	O
ARDS	O
.	O

Overall	O
,	O
our	O
study	O
shows	O
that	O
the	O
SILAC	O
approach	O
is	O
a	O
suitable	O
tool	O
to	O
study	O
host	O
-	O
pathogen	O
interactions	O
and	O
to	O
identify	O
host	O
proteins	B-CHED
involved	O
in	O
virus	O
replication	O
.	O

This	O
inactivity	O
is	O
likely	O
due	O
to	O
virus	O
-	O
mediated	O
interference	O
since	O
the	O
typical	O
IFN	O
-	O
	O
response	O
by	O
either	O
purified	O
or	O
nonsorted	O
porcine	O
pDC	B-CHED
to	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
or	O
the	O
Toll	O
-	O
like	O
receptor	O
9	O
agonist	B-CHED
,	O
oligodeoxynucleotide	O
(	O
ODN	O
)	O
D19	O
,	O
was	O
markedly	O
reduced	O
in	O
the	O
presence	O
of	O
PRRSV	O
.	O

Last	O
,	O
the	O
expression	O
kinetics	O
of	O
the	O
APRIL	O
and	O
BAFF	O
receptors	O
coincided	O
with	O
CNS	B-CHED
accumulation	O
of	O
ASC	O
.	O

TITLE	O
:	O
Partial	O
deletion	O
in	O
the	O
spike	O
endodomain	O
of	O
mouse	O
hepatitis	O
virus	O
decreases	O
the	O
cytopathic	O
effect	O
but	O
maintains	O
foreign	O
protein	B-CHED
expression	O
in	O
infected	O
cells	O
.	O

Fluorescein	B-CHED
-	O
KCl	B-CHED
solution	O
was	O
sprayed	O
onto	O
the	O
faces	O
of	O
participants	O
wearing	O
the	O
facemasks	O
and	O
performing	O
intermittent	O
exercises	O
on	O
a	O
treadmill	O
in	O
a	O
climatic	O
chamber	O
.	O

The	O
main	O
protease	O
(	O
M	O
(	O
pro	B-CHED
))	O
of	O
SARS	O
-	O
CoV	O
is	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
SARS	O
drug	O
development	O
as	O
it	O
is	O
essential	O
for	O
the	O
polyprotein	O
processing	O
.	O

Thus	O
,	O
during	O
the	O
initial	O
period	O
of	O
SARS	O
-	O
CoV	O
infection	O
,	O
this	O
novel	O
active	O
form	O
AOM	O
(	O
pro	B-CHED
)	O
should	O
play	O
a	O
major	O
role	O
in	O
cleaving	O
polyproteins	O
as	O
the	O
protein	B-CHED
level	O
is	O
extremely	O
low	O
.	O

We	O
also	O
discovered	O
that	O
amino	B-CHED
acid	I-CHED
mutation	O
in	O
the	O
neutralizing	O
epitope	B-CHED
reduced	O
viral	O
replication	O
in	O
monocytes	O
/	O
macrophages	O
.	O

The	O
analysis	O
of	O
the	O
pattern	O
of	O
nucleotide	B-CHED
substitutions	O
disclosed	O
""""	O
hot	O
spots	O
""""	O
sites	O
which	O
may	O
represent	O
immunological	O
domains	O
.	O

Eight	O
peptides	B-CHED
containing	O
Th1	O
epitopes	O
were	O
identified	O
in	O
N	O
protein	B-CHED
,	O
and	O
3	O
peptides	B-CHED
derived	O
from	O
residues	O
81	O
to	O
100	O
and	O
137	O
to	O
164	O
showed	O
strong	O
inductivity	O
of	O
fIFN	O
-	O
	O
production	O
in	O
PBMCs	O
isolated	O
from	O
type	O
I	O
FIPV	O
-	O
and	O
type	O
II	O
FIPV	O
-	O
infected	O
non	O
-	O
FIP	O
cats	O
.	O

The	O
Th1	O
and	O
linear	O
immunodominant	O
antibody	O
-	O
binding	O
epitopes	O
were	O
located	O
at	O
different	O
positions	O
in	O
both	O
the	O
S2	O
domain	O
and	O
N	O
protein	B-CHED
.	O

Highly	O
significant	O
decreases	O
in	O
haematocrit	O
and	O
albumin	O
levels	O
and	O
an	O
increase	O
in	O
total	O
bilirubin	B-CHED
level	O
were	O
noted	O
in	O
both	O
effusive	O
and	O
non	O
-	O
effusive	O
FIP	O
,	O
at	O
first	O
presentation	O
and	O
before	O
death	O
.	O

However	O
,	O
a	O
defined	O
biological	B-CHED
role	I-CHED
for	O
2	O
'-	O
O	O
-	O
methylation	O
of	O
mRNA	B-CHED
remains	O
elusive	O
.	O

TITLE	O
:	O
Characterization	O
and	O
utility	O
of	O
monoclonal	O
antibodies	O
against	O
spike	O
protein	B-CHED
of	O
transmissible	O
gastroenteritis	O
virus	O
.	O

These	O
mAbs	O
were	O
capable	O
of	O
reacting	O
with	O
the	O
TGEV	O
S1	O
protein	B-CHED
analysed	O
by	O
ELISA	O
and	O
Western	O
blot	O
.	O

TITLE	O
:	O
LTB4	B-CHED
increases	O
nasal	O
neutrophil	O
activity	O
and	O
conditions	O
neutrophils	O
to	O
exert	O
antiviral	B-CHED
effects	O
.	O

We	O
suggest	O
that	O
the	O
condition	O
induced	O
by	O
LTB4	B-CHED
reflects	O
an	O
enhanced	O
state	O
of	O
innate	O
defense	O
.	O

The	O
herd	O
status	O
regarding	O
the	O
calves	O
'	O
passive	O
transfer	O
(	O
total	O
protein	B-CHED
),	O
levels	O
of	O
	O
-	O
tocopherol	B-CHED
,	O
	O
-	O
carotene	B-CHED
and	O
retinol	B-CHED
,	O
and	O
excretion	O
of	O
faecal	O
pathogens	O
(	O
Cryptosporidium	O
spp	O
.,	O
Escherichia	O
coli	O
F5	O
,	O
rota	O
and	O
corona	B-CHED
virus	O
)	O
was	O
evaluated	O
based	O
on	O
targeted	O
sampling	O
of	O
high	O
risk	O
calf	O
groups	O
;	O
in	O
each	O
herd	O
,	O
blood	O
and	O
faecal	O
samples	O
were	O
collected	O
from	O
calves	O
1	O
-	O
7	O
and	O
1	O
-	O
14	O
days	O
old	O
,	O
respectively	O
.	O

Oseltamivir	B-CHED
was	O
used	O
in	O
80	O
(	O
96	O
%)	O
patients	O
.	O

TITLE	O
:	O
Beneficial	O
effects	O
of	O
concomitant	O
neuronal	O
and	O
inducible	O
nitric	B-CHED
oxide	I-CHED
synthase	O
inhibition	O
in	O
ovine	O
burn	O
and	O
inhalation	O
injury	O
.	O

Results	O
from	O
the	O
in	O
silico	O
study	O
indicated	O
that	O
<	O
1	O
%	O
errors	O
in	O
virus	O
identification	O
could	O
be	O
achieved	O
when	O
nucleotide	B-CHED
-	O
based	O
search	O
programs	O
(	O
BLASTn	O
or	O
tBLASTx	O
),	O
viral	O
genome	O
only	O
databases	O
and	O
sequence	O
reads	O
>	O
200	O
nt	O
were	O
considered	O
.	O

ABSTRACT	O
:	O
To	O
express	O
the	O
nuclear	O
capsid	O
protein	B-CHED
(	O
N	O
protein	B-CHED
)	O
and	O
the	O
spike	O
protein	B-CHED
(	O
S	O
protein	B-CHED
)	O
of	O
HCoV	O
-	O
HKU1	O
,	O
and	O
to	O
develop	O
the	O
corresponding	O
serum	O
assay	O
for	O
antibody	O
detection	O
.	O

RESULTS	O
:	O
Expression	O
of	O
S	O
and	O
N	O
protein	B-CHED
were	O
confirmed	O
;	O
100	O
normal	O
adult	O
serum	O
were	O
analyzed	O
using	O
the	O
established	O
serological	O
detection	O
assay	O
,	O
in	O
which	O
HCoV	O
-	O
HKU1	O
S	O
antibody	O
positive	O
rate	O
was	O
47	O
%,	O
N	O
antibody	O
positive	O
rate	O
was	O
48	O
%,	O
Both	O
S	O
and	O
N	O
antibodies	O
positive	O
were	O
21	O
%,	O
Both	O
S	O
and	O
N	O
antibodies	O
negative	O
were	O
22	O
%.	O

In	O
LPS	B-CHED
-	O
treated	O
rats	O
,	O
we	O
observed	O
increased	O
levels	O
of	O
oxidative	O
products	O
,	O
decreased	O
levels	O
of	O
antioxidants	B-CHED
in	O
lung	O
tissues	O
and	O
increased	O
levels	O
of	O
serum	O
marker	O
enzymes	O
,	O
suggesting	O
multiple	O
organ	O
injury	O
.	O

Genotyping	O
was	O
performed	O
on	O
seven	O
linkage	O
disequilibrium	O
-	O
tag	O
single	O
nucleotide	B-CHED
polymorphisms	O
in	O
the	O
surfactant	B-CHED
protein	B-CHED
B	O
gene	O
.	O

In	O
the	O
years	O
to	O
come	O
,	O
control	O
of	O
antimicrobial	B-CHED
drug	I-CHED
resistance	O
and	O
nosocomial	O
infections	O
will	O
continue	O
to	O
pose	O
challenges	O
in	O
the	O
light	O
of	O
an	O
increasing	O
number	O
of	O
senior	O
citizens	O
and	O
individuals	O
with	O
chronic	O
diseases	O
.	O

We	O
discuss	O
the	O
role	O
of	O
computational	O
chemistry	O
in	O
the	O
development	O
of	O
small	O
molecules	O
as	O
agents	O
against	O
HIV	O
integrase	O
,	O
HIV	O
-	O
1	O
protease	O
,	O
HIV	O
-	O
1	O
reverse	O
transcriptase	O
,	O
the	O
influenza	O
virus	O
M2	O
channel	O
protein	B-CHED
,	O
influenza	O
virus	O
neuraminidase	O
,	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	O
and	O
spike	O
protein	B-CHED
,	O
thymidine	B-CHED
kinases	O
of	O
herpes	O
viruses	O
,	O
hepatitis	O
c	O
virus	O
proteins	B-CHED
and	O
other	O
flaviviruses	O
as	O
well	O
as	O
human	O
rhinovirus	O
coat	O
protein	B-CHED
and	O
proteases	O
,	O
and	O
other	O
picornaviridae	O
.	O

ABSTRACT	O
:	O
The	O
leader	O
proteinase	O
(	O
L	O
(	O
pro	B-CHED
))	O
of	O
foot	O
-	O
and	O
-	O
mouth	O
disease	O
virus	O
(	O
FMDV	O
)	O
is	O
a	O
papain	O
-	O
like	O
proteinase	O
that	O
plays	O
an	O
important	O
role	O
in	O
FMDV	O
pathogenesis	O
.	O

Here	O
we	O
demonstrate	O
that	O
FMDV	O
Lb	O
(	O
pro	B-CHED
),	O
a	O
shorter	O
form	O
of	O
L	O
(	O
pro	B-CHED
),	O
has	O
deubiquitinating	O
activity	O
.	O

There	O
were	O
also	O
statistically	O
significant	O
differences	O
between	O
survivors	O
and	O
nonsurvivors	O
in	O
success	O
of	O
noninvasive	O
ventilation	O
,	O
time	O
to	O
confirmation	O
of	O
the	O
H1N1	O
virus	O
after	O
ICU	O
admission	O
,	O
creatinine	B-CHED
,	O
lactate	B-CHED
dehydrogenase	O
,	O
pH	O
,	O
P	O
(	O
aCO	O
(	O
2	O
)),	O
and	O
P	O
(	O
aO	O
(	O
2	O
))/	O
F	O
(	O
IO	O
(	O
2	O
)).	O

There	O
were	O
also	O
statistically	O
significant	O
differences	O
between	O
survivors	O
and	O
nonsurvivors	O
in	O
success	O
of	O
noninvasive	O
ventilation	O
,	O
time	O
to	O
confirmation	O
of	O
the	O
H1N1	O
virus	O
after	O
ICU	O
admission	O
,	O
creatinine	B-CHED
,	O
lactate	B-CHED
dehydrogenase	O
,	O
pH	O
,	O
P	O
(	O
aCO	O
(	O
2	O
)),	O
and	O
P	O
(	O
aO	O
(	O
2	O
))/	O
F	O
(	O
IO	O
(	O
2	O
)).	O

ABSTRACT	O
:	O
Sixteen	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
field	O
isolates	O
obtained	O
from	O
vaccinated	O
commercial	O
broiler	O
chickens	O
showing	O
clinical	O
respiratory	O
disease	O
were	O
characterized	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
and	O
sequence	O
analysis	O
of	O
the	O
hypervariable	O
region	O
of	O
the	O
S1	O
spike	O
glycoprotein	B-CHED
gene	O
.	O

All	O
the	O
isolates	O
showed	O
85	O
%	O
amino	B-CHED
acid	I-CHED
identity	O
with	O
recently	O
described	O
Australian	O
isolates	O
,	O
particularly	O
N1	O
-	O
62	O
.	O

In	O
the	O
remaining	O
five	O
experiments	O
,	O
the	O
oxygenation	O
increased	O
significantly	O
(	O
arterial	O
oxygen	B-CHED
saturation	O
[	O
SaO2	O
]	O
from	O
79	O
	O
5	O
%	O
before	O
HEXMO	O
to	O
92	O
%	O
	O
11	O
%	O
after	O
4	O
hours	O
)	O
facilitated	O
by	O
a	O
mean	O
oxygen	B-CHED
transfer	O
of	O
66	O
	O
29	O
ml	O
/	O
dl	O
through	O
the	O
oxygenator	O
.	O

Earlier	O
research	O
determined	O
metabolic	O
oxidative	O
stress	O
in	O
hosts	O
deficient	O
in	O
antioxidant	B-CHED
selenium	B-CHED
(	O
Se	B-CHED
)	O
(<	O
1	O
Mol	O
Se	B-CHED
/	O
L	O
of	O
blood	O
)	O
induces	O
both	O
impaired	O
human	O
host	O
immunocompetence	O
and	O
rapidly	O
mutated	O
benign	O
variants	O
of	O
RNA	O
viruses	O
to	O
virulence	O
.	O

In	O
contrast	O
,	O
other	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
,	O
including	O
osteopontin	O
and	O
CCL3	B-CHED
,	O
were	O
upregulated	O
in	O
the	O
lungs	O
of	O
African	O
green	O
monkeys	O
to	O
a	O
significantly	O
greater	O
extent	O
than	O
in	O
macaques	O
.	O

Sequence	O
analysis	O
showed	O
most	O
of	O
the	O
revertants	O
had	O
the	O
same	O
single	O
amino	B-CHED
acid	I-CHED
mutation	O
at	O
Nsp16	O
position	O
43	O
.	O

Patients	O
who	O
had	O
prehospital	O
use	O
of	O
both	O
statins	O
and	O
aspirin	B-CHED
had	O
the	O
lowest	O
rates	O
of	O
severe	O
sepsis	O
,	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
mortality	O
.	O

This	O
effect	O
may	O
be	O
potentiated	O
by	O
prehospital	O
aspirin	B-CHED
use	O
.	O

Antiphospholipid	O
syndrome	O
(	O
APS	B-CHED
),	O
manifesting	O
as	O
vascular	O
thromboembolic	O
events	O
and	O
morbidities	O
of	O
pregnancy	O
in	O
the	O
presence	O
of	O
antiphospholipid	O
antibodies	O
(	O
aPL	O
),	O
has	O
been	O
described	O
in	O
patients	O
with	O
SLE	O
.	O

Though	O
emergency	O
transcatheter	O
arterial	O
embolization	O
(	O
TAE	O
)	O
of	O
the	O
left	O
fourth	O
ICA	B-CHED
was	O
successfully	O
accomplished	O
by	O
the	O
radiologist	O
.	O

The	O
repeated	O
computed	O
tomography	O
angiogram	O
of	O
chest	O
demonstrated	O
remission	O
of	O
ruptured	O
ICA	B-CHED
.	O

Both	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	B-CHED
)	O
and	O
CAPS	O
share	O
similar	O
characteristics	O
encompassing	O
thrombotic	O
microangiopathy	O
,	O
bleeding	O
,	O
thromboembolism	O
,	O
and	O
multiple	O
organ	O
dysfunction	O
.	O

All	O
virus	O
-	O
infected	O
mice	O
receiving	O
UDA	B-CHED
treatments	O
were	O
also	O
significantly	O
protected	O
against	O
weight	O
loss	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

UDA	B-CHED
also	O
effectively	O
reduced	O
lung	O
pathology	O
scores	O
.	O

UDA	B-CHED
specifically	O
inhibited	O
the	O
replication	O
of	O
live	O
SARS	O
-	O
CoV	O
or	O
SARS	O
-	O
CoV	O
pseudotyped	O
virus	O
when	O
added	O
just	O
before	O
,	O
but	O
not	O
after	O
,	O
adsorption	O
.	O

These	O
data	O
suggested	O
that	O
UDA	B-CHED
likely	O
inhibits	O
SARS	O
-	O
CoV	O
infection	O
by	O
targeting	O
early	O
stages	O
of	O
the	O
replication	O
cycle	O
,	O
namely	O
,	O
adsorption	O
or	O
penetration	O
.	O

In	O
addition	O
,	O
the	O
coexpression	O
of	O
nsp4	O
with	O
nsp3	O
affected	O
the	O
subcellular	O
localization	O
of	O
the	O
two	O
proteins	B-CHED
.	O

Mechanism	O
of	O
action	O
studies	O
showed	O
that	O
these	O
derivatives	O
do	O
not	O
intercalate	O
into	O
DNA	O
and	O
do	O
not	O
chelate	O
the	O
divalent	O
cofactor	B-CHED
Mg	O
(	O
2	O
+)	O
.	O

NIV	O
should	O
not	O
be	O
considered	O
as	O
an	O
alternative	O
to	O
ETI	B-CHED
in	O
severe	O
communicable	O
airborne	O
infections	O
likely	O
to	O
progress	O
to	O
ARDS	O
.	O

NIV	O
is	O
being	O
used	O
increasingly	O
as	O
an	O
alternative	O
to	O
ETI	B-CHED
in	O
end	O
-	O
stage	O
symptomatic	O
patients	O
,	O
especially	O
to	O
relieve	O
dyspnoea	O
.	O

All	O
7	O
patients	O
were	O
treated	O
with	O
oral	O
oseltamivir	B-CHED
,	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
,	O
and	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
prior	O
to	O
ECMO	O
.	O

The	O
onset	O
is	O
usually	O
triggered	O
by	O
infections	O
of	O
the	O
upper	O
respiratory	O
tract	O
or	O
by	O
preceding	O
medication	O
,	O
among	O
which	O
nonsteroidal	O
anti	B-CHED
-	I-CHED
inflammatory	I-CHED
agents	I-CHED
,	O
antibiotics	B-CHED
,	O
and	O
anticonvulsants	B-CHED
are	O
the	O
most	O
common	O
triggers	O
.	O

Treatment	O
includes	O
early	O
admission	O
to	O
a	O
burn	O
unit	O
,	O
where	O
treatment	O
with	O
precise	O
fluid	O
,	O
electrolyte	O
,	O
protein	B-CHED
,	O
and	O
energy	O
supplementation	O
,	O
moderate	O
mechanical	O
ventilation	O
,	O
and	O
expert	O
wound	O
care	O
can	O
be	O
provided	O
.	O

Of	O
these	O
patients	O
,	O
57	O
(	O
26	O
%)	O
were	O
positioned	O
prone	O
because	O
of	O
a	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
below	O
100	O
mmHg	O
after	O
24	O
-	O
48	O
h	O
of	O
mechanical	O
ventilation	O
.	O

Tidal	O
volume	O
was	O
7	O
	O
2	O
mL	O
/	O
kg	O
,	O
PEEP	B-CHED
5	O
.	O
6	O
	O
1	O
.	O
2	O
cmH	B-CHED
(	O
2	O
)	O
O	O
,	O
and	O
plateau	O
pressure	O
27	O
	O
3	O
cmH	B-CHED
(	O
2	O
)	O
O	O
.	O
Prone	O
sessions	O
lasted	O
18	O
h	O
/	O
day	O
and	O
3	O
.	O
4	O
	O
1	O
.	O
1	O
sessions	O
were	O
required	O
to	O
obtain	O
an	O
FiO	O
(	O
2	O
)	O
below	O
60	O
%.	O

In	O
patients	O
with	O
a	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
below	O
60	O
mmHg	O
,	O
the	O
60	O
-	O
day	O
mortality	O
was	O
28	O
%.	O

We	O
demonstrate	O
the	O
clinical	O
feasibility	O
of	O
routine	O
PP	O
in	O
patients	O
with	O
a	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
below	O
100	O
mmHg	O
after	O
24	O
-	O
48	O
h	O
and	O
suggest	O
that	O
,	O
when	O
combined	O
with	O
a	O
low	O
stretch	O
ventilation	O
strategy	O
,	O
it	O
is	O
protective	O
with	O
a	O
high	O
survival	O
rate	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
RNA	O
-	O
RNA	O
and	O
RNA	O
-	O
protein	B-CHED
interactions	O
that	O
represent	O
modest	O
examples	O
of	O
complex	O
quaternary	O
RNA	O
-	O
protein	B-CHED
structures	O
required	O
for	O
the	O
fine	O
-	O
tuning	O
of	O
virus	O
replication	O
.	O

The	O
highly	O
conserved	O
pentaloop	O
of	O
SL2	O
is	O
stacked	O
on	O
5	O
-	O
bp	O
stem	O
and	O
adopts	O
a	O
canonical	O
CUYG	O
tetraloop	O
fold	O
with	O
the	O
3	O
'	O
nucleotide	B-CHED
(	O
U51	O
)	O
flipped	O
out	O
of	O
the	O
stack	O
.	O

17	O
differentially	O
expressed	O
proteins	B-CHED
from	O
tracheal	O
tissues	O
and	O
19	O
differentially	O
expressed	O
proteins	B-CHED
from	O
kidney	O
tissues	O
were	O
identified	O
.	O

TITLE	O
:	O
A	O
Canadian	O
Critical	O
Care	O
Trials	O
Group	O
project	O
in	O
collaboration	O
with	O
the	O
international	O
forum	O
for	O
acute	O
care	O
trialists	O
-	O
Collaborative	O
H1N1	O
Adjuvant	B-CHED
Treatment	O
pilot	O
trial	O
(	O
CHAT	O
):	O
study	O
protocol	O
and	O
design	O
of	O
a	O
randomized	O
controlled	O
trial	O
.	O

While	O
supportive	O
care	O
and	O
neuraminidase	B-CHED
inhibitors	I-CHED
are	O
the	O
main	O
treatment	O
for	O
influenza	O
,	O
data	O
from	O
observational	O
and	O
interventional	O
studies	O
suggest	O
that	O
the	O
course	O
of	O
influenza	O
can	O
be	O
favorably	O
influenced	O
by	O
agents	O
not	O
classically	O
considered	O
as	O
influenza	O
treatments	O
.	O

The	O
patients	O
in	O
the	O
control	O
group	O
(	O
38	O
cases	O
)	O
received	O
standard	O
treatment	O
and	O
Chinese	O
herbal	O
decoction	O
for	O
purgation	O
;	O
those	O
in	O
the	O
treatment	O
group	O
(	O
43	O
cases	O
)	O
received	O
additional	O
1	O
mg	O
/(	O
kg	O
	O
d	O
)	O
dexamethasone	B-CHED
(	O
Dx	O
)	O
treatment	O
for	O
three	O
days	O
based	O
on	O
the	O
above	O
treatment	O
.	O

Colloidal	B-CHED
gold	I-CHED
-	O
labeled	O
rabbit	O
anti	O
-	O
pig	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
was	O
used	O
as	O
the	O
detection	O
reagent	B-CHED
,	O
and	O
the	O
PHEV	O
recombinant	O
antigens	B-CHED
and	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
were	O
coated	O
on	O
the	O
prototype	O
strip	O
and	O
the	O
control	O
lines	O
,	O
respectively	O
.	O

Treatment	O
is	O
mainly	O
supportive	O
combining	O
oxygen	B-CHED
supplementation	O
adequate	O
hydration	O
analgesia	O
and	O
sedation	O
.	O

Furthermore	O
,	O
NL63	O
-	O
CoV	O
RBD	O
inhibits	O
hACE2	O
-	O
dependent	O
transduction	O
by	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
,	O
a	O
successful	O
application	O
of	O
the	O
hot	O
spot	O
theory	O
that	O
has	O
the	O
potential	O
to	O
become	O
a	O
new	O
antiviral	B-CHED
strategy	O
against	O
SARS	O
-	O
CoV	O
infections	O
.	O

The	O
Dutch	O
GHOR	O
,	O
American	O
CDC	O
and	O
WHO	O
,	O
and	O
British	O
HPA	B-CHED
case	O
definitions	O
were	O
evaluated	O
.	O

The	O
air	B-CHED
sacs	O
are	O
lined	O
by	O
different	O
types	O
of	O
epithelia	O
and	O
are	O
relatively	O
isolated	O
from	O
the	O
environment	O
,	O
so	O
they	O
represent	O
a	O
unique	O
tissue	O
in	O
which	O
to	O
study	O
virus	O
-	O
induced	O
lesions	O
.	O

Early	O
implementation	O
of	O
extra	O
-	O
corporeal	O
membrane	O
oxygenation	O
support	O
in	O
conjunction	O
with	O
a	O
specific	O
anti	O
-	O
influenza	O
viral	O
medication	O
(	O
Oseltamivir	B-CHED
)	O
led	O
to	O
the	O
patient	O
'	O
s	O
complete	O
recovery	O
from	O
cardiogenic	O
shock	O
in	O
2	O
weeks	O
.	O

Therefore	O
,	O
plasma	O
exchange	O
was	O
discontinued	O
and	O
corticosteroid	B-CHED
was	O
tapered	O
as	O
quickly	O
as	O
possible	O
.	O

Both	O
inhibitors	B-CHED
prevented	O
the	O
usual	O
exponential	O
increase	O
in	O
viral	O
RNA	O
synthesis	O
,	O
with	O
immunofluorescence	O
and	O
electron	O
microscopy	O
indicating	O
that	O
RVN	O
development	O
came	O
to	O
a	O
standstill	O
.	O

The	O
MFI	O
was	O
evaluated	O
for	O
its	O
diagnostic	O
power	O
,	O
with	O
panels	O
of	O
mouse	O
sera	O
classified	O
as	O
positive	O
or	O
negative	O
for	O
anti	O
-	O
MHV	O
antibodies	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
MHV	O
virion	O
antigen	B-CHED
and	O
indirect	O
fluorescent	O
antibody	O
assay	O
.	O

Based	O
on	O
the	O
assessment	O
by	O
MFI	O
using	O
the	O
S2	O
and	O
N	O
antigens	B-CHED
,	O
only	O
3	O
serum	O
samples	O
showed	O
double	O
-	O
negative	O
results	O
,	O
indicating	O
a	O
false	O
-	O
negative	O
rate	O
of	O
1	O
.	O
3	O
%.	O

Similarly	O
,	O
the	O
S2	O
and	O
N	O
antigen	B-CHED
-	O
based	O
MFI	O
was	O
98	O
%	O
sensitive	O
and	O
100	O
%	O
specific	O
in	O
detecting	O
anticoronavirus	O
antibodies	O
in	O
rat	O
sera	O
.	O

There	O
was	O
a	O
mean	O
delay	O
of	O
5	O
.	O
7	O
	O
3	O
.	O
1	O
days	O
in	O
initiation	O
of	O
antivirals	B-CHED
.	O

The	O
various	O
prediction	O
algorithms	O
are	O
being	O
used	O
to	O
capture	O
the	O
MHC	O
peptide	B-CHED
binding	O
preference	O
,	O
allowing	O
the	O
rapid	O
scan	O
of	O
entire	O
pathogen	O
proteomes	O
for	O
peptide	B-CHED
likely	O
to	O
bind	O
MHC	O
,	O
saving	O
the	O
cost	O
,	O
effort	O
,	O
and	O
time	O
.	O

This	O
method	O
uses	O
a	O
natural	O
representation	O
of	O
genomic	O
data	O
by	O
binary	O
indicator	B-CHED
sequences	O
of	O
each	O
nucleotide	B-CHED
(	O
adenine	B-CHED
(	O
A	O
),	O
cytosine	B-CHED
(	O
C	O
),	O
guanine	B-CHED
(	O
G	O
),	O
and	O
thymine	B-CHED
(	O
T	O
)).	O

One	O
hundred	O
and	O
fourteen	O
children	O
aged	O
6	O
-	O
14	O
years	O
with	O
chronic	O
stable	O
asthma	O
and	O
on	O
regular	O
inhaled	O
steroid	B-CHED
were	O
monitored	O
for	O
respiratory	O
symptoms	O
over	O
a	O
full	O
calendar	O
year	O
from	O
recruitment	O
.	O

Plausible	O
explanations	O
for	O
much	O
lower	O
virus	O
detection	O
rate	O
than	O
previously	O
reported	O
include	O
improved	O
personal	O
hygiene	O
and	O
precautionary	O
measures	O
taken	O
during	O
respiratory	O
tract	O
infections	O
in	O
the	O
immediate	O
post	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
period	O
together	O
with	O
a	O
significant	O
contribution	O
of	O
other	O
adverse	O
factors	O
like	O
environmental	O
air	B-CHED
pollution	O
.	O

For	O
this	O
to	O
occur	O
,	O
the	O
viral	O
envelope	O
proteins	B-CHED
must	O
be	O
efficiently	O
targeted	O
to	O
the	O
Golgi	O
region	O
of	O
the	O
secretory	O
pathway	O
.	O

We	O
show	O
that	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
SARS	O
-	O
CoV	O
E	O
protein	B-CHED
is	O
sufficient	O
to	O
redirect	O
a	O
plasma	O
membrane	O
protein	B-CHED
to	O
the	O
Golgi	O
region	O
.	O

This	O
motif	O
is	O
conserved	O
in	O
E	O
proteins	B-CHED
of	O
beta	O
and	O
gamma	O
coronaviruses	O
(	O
formerly	O
referred	O
to	O
as	O
group	O
2	O
and	O
3	O
coronaviruses	O
),	O
where	O
it	O
also	O
functions	O
as	O
a	O
Golgi	O
complex	O
-	O
targeting	O
signal	O
.	O

Infection	O
by	O
other	O
viruses	O
employing	O
similar	O
viral	O
entry	O
mechanisms	O
(	O
such	O
as	O
HIV	O
-	O
1	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
)	O
can	O
be	O
inhibited	O
with	O
synthetic	O
peptides	B-CHED
corresponding	O
to	O
the	O
native	O
CHR	O
sequence	O
"("""	O
C	O
-	O
peptides	B-CHED
""")."	O

We	O
found	O
that	O
this	O
peptide	B-CHED
specifically	O
inhibited	O
viral	O
entry	O
mediated	O
by	O
filovirus	O
GP	O
proteins	B-CHED
and	O
infection	O
by	O
authentic	O
filoviruses	O
.	O

Mechanistic	O
studies	O
suggested	O
that	O
the	O
peptide	B-CHED
acts	O
by	O
blocking	O
a	O
membrane	O
fusion	O
intermediate	O
.	O

TITLE	O
:	O
Phylogenetic	O
analysis	O
of	O
protein	B-CHED
sequences	O
based	O
on	O
distribution	O
of	O
length	O
about	O
common	O
sub	O
-	O
string	O
.	O

TITLE	O
:	O
[	O
Expression	O
of	O
green	O
fluorescent	O
protein	B-CHED
using	O
an	O
infectious	O
cDNA	O
clone	O
of	O
infectious	O
bronchitis	O
virus	O
].	O

Inactivated	O
SARS	O
-	O
CoV	O
has	O
been	O
explored	O
as	O
a	O
vaccine	O
against	O
SARS	O
-	O
CoV	O
.	O
However	O
,	O
safe	O
and	O
potent	O
adjuvants	B-CHED
,	O
especially	O
with	O
more	O
efficient	O
and	O
economical	O
needle	O
-	O
free	O
vaccination	O
are	O
always	O
needed	O
more	O
urgently	O
in	O
a	O
pandemic	O
.	O

Fifty	O
-	O
three	O
compounds	O
from	O
35	O
main	O
groups	O
were	O
tested	O
in	O
an	O
in	O
vitro	O
assay	O
for	O
inhibition	O
of	O
3CL	O
(	O
pro	B-CHED
)	O
expressed	O
by	O
Escherichia	O
coli	O
.	O

Seven	O
of	O
the	O
53	O
compounds	O
were	O
selected	O
;	O
their	O
IC	O
(	O
50	O
)	O
ranged	O
from	O
38	O
.	O
57	O
	O
2	O
.	O
41	O
to	O
101	O
.	O
38	O
	O
3	O
.	O
27	O
M	O
.	O
Two	O
strong	O
3CL	O
(	O
pro	B-CHED
)	O
inhibitors	B-CHED
were	O
further	O
identified	O
as	O
competitive	O
inhibitors	B-CHED
of	O
3CL	O
(	O
pro	B-CHED
)	O
with	O
K	O
(	O
i	O
)	O
values	O
of	O
9	O
.	O
11	O
	O
1	O
.	O
6	O
and	O
9	O
.	O
93	O
	O
0	O
.	O
44	O
M	O
.	O
Hydrophobic	O
and	O
hydrogen	B-CHED
bond	O
interactions	O
of	O
compound	O
with	O
amino	B-CHED
acid	I-CHED
residues	O
in	O
the	O
active	O
site	O
of	O
3CL	O
(	O
pro	B-CHED
)	O
were	O
also	O
identified	O
.	O

Our	O
study	O
provides	O
no	O
evidence	O
of	O
a	O
beneficial	O
effect	O
of	O
corticosteroids	B-CHED
in	O
patients	O
with	O
ARDS	O
secondary	O
to	O
influenza	O
pneumonia	O
,	O
but	O
suggests	O
that	O
very	O
early	O
corticosteroid	B-CHED
therapy	O
may	O
be	O
harmful	O
.	O

Increasing	O
quartiles	O
of	O
plasma	O
cotinine	B-CHED
were	O
associated	O
with	O
the	O
development	O
of	O
ALI	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
for	O
developing	O
ALI	O
in	O
highest	O
cotinine	B-CHED
quartile	O
,	O
3	O
.	O
25	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
22	O
-	O
8	O
.	O
68	O
;	O
P	O
=	O
0	O
.	O
017	O
for	O
trend	O
across	O
quartiles	O
).	O

Strains	O
from	O
the	O
QX	O
genotype	O
that	O
shared	O
one	O
specific	O
amino	B-CHED
acid	I-CHED
substitution	O
also	O
form	O
a	O
separate	O
genetic	O
cluster	O
.	O

CONCLUSIONS	O
:	O
Patients	O
with	O
clinically	O
stable	O
asthma	O
and	O
healthy	O
controls	O
have	O
similar	O
detection	O
rates	O
of	O
respiratory	O
viruses	O
in	O
samples	O
from	O
nasopharynx	O
,	O
sputum	O
and	O
exhaled	O
air	B-CHED
.	O

Rapid	O
identification	O
of	O
Panton	O
-	O
Valentine	O
leukocidin	O
in	O
methicillin	B-CHED
-	O
sensitive	O
S	O
.	O
aureus	O
isolates	O
causing	O
severe	O
infections	O
is	O
necessary	O
so	O
as	O
not	O
to	O
miss	O
their	O
potentially	O
devastating	O
consequences	O
.	O

ABSTRACT	O
:	O
Immunoglobulin	O
in	O
cerebral	O
spinal	O
fluid	O
and	O
antibody	O
secreting	O
cells	O
(	O
ASC	O
)	O
within	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
parenchyma	O
are	O
common	O
hallmarks	O
of	O
microbial	O
infections	O
and	O
autoimmune	O
disorders	O
.	O

Compared	O
to	O
the	O
published	O
representative	O
strains	O
,	O
nucleotides	B-CHED
and	O
amino	B-CHED
acids	I-CHED
sequence	O
analysis	O
indicated	O
that	O
the	O
S1	O
genes	O
of	O
these	O
strains	O
and	O
the	O
reference	O
strains	O
displayed	O
homologies	O
ranging	O
from	O
75	O
.	O
1	O
%	O
to	O
99	O
.	O
8	O
%	O
and	O
from	O
73	O
.	O
1	O
%	O
to	O
99	O
.	O
8	O
%	O
respectively	O
.	O

S1	O
protein	B-CHED
of	O
the	O
major	O
pandemic	O
strains	O
contained	O
540	O
or	O
542	O
amino	B-CHED
acids	I-CHED
with	O
the	O
cleavage	O
site	O
of	O
HRRRR	O
or	O
RRFRR	O
.	O

His	O
-	O
tagged	O
RdRp	O
was	O
expressed	O
in	O
baculovirus	O
,	O
purified	O
and	O
used	O
as	O
immunogen	B-CHED
to	O
produce	O
mAbs	O
.	O

Coronavirus	O
was	O
the	O
most	O
sensitive	O
virus	O
,	O
with	O
decimal	O
reduction	O
(	O
D	O
)	O
values	O
of	O
1	O
.	O
2	O
and	O
0	O
.	O
63	O
h	O
after	O
addition	O
of	O
0	O
.	O
5	O
%	O
(	O
wt	O
/	O
wt	O
)	O
ammonia	B-CHED
at	O
14	O
and	O
25	O
	O
C	O
,	O
respectively	O
.	O

Examples	O
include	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
or	O
influenza	O
A	O
virus	O
H3N2	B-CHED
.	O

A	O
total	O
of	O
67	O
(	O
68	O
.	O
4	O
%)	O
patients	O
received	O
oseltamivir	B-CHED
,	O
89	O
(	O
90	O
.	O
1	O
%)	O
was	O
applied	O
to	O
antibiotics	B-CHED
and	O
64	O
(	O
65	O
.	O
3	O
%)	O
were	O
treated	O
with	O
a	O
combined	O
therapy	O
.	O

Antiviral	B-CHED
therapy	O
was	O
applied	O
to	O
43	O
(	O
43	O
.	O
3	O
%)	O
patients	O
in	O
the	O
first	O
48	O
hours	O
from	O
the	O
onset	O
of	O
the	O
disease	O
,	O
of	O
whom	O
only	O
one	O
(	O
3	O
.	O
4	O
)	O
developed	O
ARDS	O
.	O

Patients	O
with	O
H1N1	O
associated	O
with	O
ARDS	O
may	O
be	O
given	O
a	O
trial	O
of	O
IV	O
IgG	O
.	O
More	O
case	O
reports	O
and	O
trials	O
are	O
required	O
to	O
ascertain	O
the	O
efficacy	O
of	O
IV	O
IgG	O
and	O
the	O
best	O
dosage	O
and	O
timing	O
of	O
starting	O
IV	O
IgG	O
in	O
relation	O
to	O
antiviral	B-CHED
therapy	O
.	O

These	O
domains	O
possess	O
ADP	B-CHED
-	O
ribose	B-CHED
-	O
1	O
-	O
phosphatase	O
(	O
ADRP	O
)	O
activity	O
and	O
/	O
or	O
bind	O
poly	O
(	O
ADP	B-CHED
-	O
ribose	B-CHED
),	O
poly	O
(	O
A	O
)	O
or	O
poly	O
(	O
G	O
).	O

ABSTRACT	O
:	O
This	O
study	O
explored	O
the	O
feasibility	O
of	O
Lactobacillus	O
pentosus	O
as	O
a	O
live	O
vehicle	O
to	O
deliver	O
and	O
express	O
antigen	B-CHED
.	O

First	O
of	O
all	O
,	O
L	O
.	O
pentosus	O
transformed	O
by	O
electroporation	O
with	O
the	O
plasmids	O
pg611	O
-	O
6D	O
(	O
anchored	O
)	O
and	O
pg612	O
-	O
6D	O
(	O
secretory	O
)	O
based	O
on	O
the	O
xylose	B-CHED
operon	O
generated	O
the	O
recombinant	O
strains	O
rLppg611	O
-	O
6D	O
and	O
rLppg612	O
-	O
6D	O
,	O
respectively	O
,	O
expressing	O
the	O
D	O
antigenic	O
site	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
for	O
intragastric	O
administration	O
in	O
mice	O
.	O

The	O
main	O
protease	O
(	O
M	O
(	O
pro	B-CHED
))	O
of	O
SARS	O
-	O
CoV	O
is	O
essential	O
for	O
the	O
viral	O
life	O
cycle	O
,	O
and	O
is	O
considered	O
to	O
be	O
an	O
attractive	O
target	O
of	O
anti	O
-	O
SARS	O
drug	O
development	O
.	O

Although	O
HFOV	O
has	O
failed	O
to	O
show	O
a	O
mortality	O
benefit	O
in	O
ARDS	O
patients	O
,	O
the	O
unique	O
lung	O
recruitment	O
by	O
HFOV	O
can	O
be	O
a	O
useful	O
therapeutic	O
option	O
for	O
severe	O
ARDS	O
patients	O
in	O
combination	O
with	O
sufficient	O
lung	O
rest	B-CHED
produced	O
by	O
ECMO	O
.	O

LocaPep	O
is	O
a	O
computer	O
program	O
developed	O
to	O
localize	O
epitopes	O
using	O
a	O
new	O
clusters	B-CHED
algorithm	O
that	O
focuses	O
on	O
protein	B-CHED
surface	O
properties	O
.	O

TITLE	O
:	O
In	O
silico	O
investigations	O
of	O
possible	O
routes	O
of	O
assembly	O
of	O
ORF	O
3a	O
from	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
ORF	O
3a	O
of	O
human	O
severe	O
acute	O
respiratory	O
syndrome	O
corona	B-CHED
virus	O
(	O
SARS	O
-	O
CoV	O
)	O
has	O
been	O
identified	O
as	O
a	O
274	O
amino	B-CHED
acid	I-CHED
membrane	O
protein	B-CHED
.	O

When	O
expressed	O
in	O
Xenopus	O
oocytes	O
the	O
protein	B-CHED
forms	O
channels	O
.	O

Molecular	O
dynamics	O
simulations	O
for	O
20	O
ns	O
are	O
performed	O
as	O
a	O
short	O
equilibration	O
to	O
assess	O
the	O
bundle	O
stability	O
in	O
a	O
lipid	B-CHED
environment	O
.	O

Filters	O
are	O
installed	O
in	O
the	O
heating	O
,	O
ventilation	O
,	O
and	O
air	B-CHED
-	O
conditioning	O
(	O
HVAC	O
)	O
systems	O
of	O
buildings	O
to	O
protect	O
ventilation	O
equipment	O
and	O
maintain	O
healthy	O
indoor	O
air	B-CHED
quality	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
accessory	O
protein	B-CHED
3b	O
induces	O
AP	O
-	O
1	O
transcriptional	O
activity	O
through	O
activation	O
of	O
JNK	O
and	O
ERK	O
pathways	O
.	O

ABSTRACT	O
:	O
ADAM17	O
,	O
also	O
known	O
as	O
tumor	O
necrosis	O
factor	O
	O
-	O
converting	O
enzyme	O
,	O
is	O
involved	O
in	O
the	O
ectodomain	O
shedding	O
of	O
many	O
integral	O
membrane	O
proteins	B-CHED
.	O

These	O
data	O
indicate	O
that	O
MHV	O
spreads	O
by	O
retrograde	O
axonal	O
transport	O
to	O
the	O
eye	O
and	O
that	O
targeting	O
spike	O
protein	B-CHED
interactions	O
with	O
axonal	O
transport	O
machinery	O
is	O
a	O
potential	O
therapeutic	O
strategy	O
for	O
central	O
nervous	O
system	O
viral	O
infections	O
and	O
associated	O
diseases	O
.	O

ABSTRACT	O
:	O
Nuclear	O
factor	O
-	O
B	O
(	O
NF	O
-	O
B	O
)	O
is	O
required	O
for	O
transcription	O
of	O
many	O
pro	B-CHED
-	O
inflammatory	O
genes	O
and	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

TITLE	O
:	O
Action	O
mechanisms	O
of	O
lithium	B-CHED
chloride	I-CHED
on	O
cell	O
infection	O
by	O
transmissible	O
gastroenteritis	O
coronavirus	O
.	O

Lithium	B-CHED
chloride	I-CHED
(	O
LiCl	B-CHED
)	O
has	O
been	O
found	O
to	O
be	O
effective	O
against	O
several	O
DNA	O
viruses	O
,	O
such	O
as	O
Herpes	O
simplex	O
virus	O
and	O
vaccinia	O
virus	O
.	O

Our	O
data	O
indicate	O
that	O
LiCl	B-CHED
inhibits	O
TGEV	O
infection	O
by	O
exerting	O
an	O
anti	O
-	O
apoptotic	O
effect	O
.	O

Animals	O
were	O
randomized	O
into	O
two	O
groups	O
:	O
in	O
the	O
first	O
PEEP	B-CHED
was	O
titrated	O
according	O
to	O
Xrs	O
(	O
FOT	O
group	O
),	O
in	O
the	O
control	O
group	O
PEEP	B-CHED
was	O
set	O
according	O
to	O
the	O
ARDSNet	O
protocol	O
(	O
ARDSNet	O
group	O
).	O

RESULTS	O
:	O
The	O
PEEP	B-CHED
levels	O
set	O
in	O
the	O
FOT	O
group	O
were	O
significantly	O
higher	O
compared	O
to	O
those	O
set	O
in	O
the	O
ARDSNet	O
group	O
during	O
the	O
whole	O
trial	O
.	O

RESULTS	O
:	O
5H10	O
,	O
which	O
recognized	O
the	O
same	O
epitope	B-CHED
that	O
is	O
also	O
a	O
cleavage	O
site	O
critical	O
for	O
the	O
entry	O
of	O
SARS	O
-	O
CoV	O
into	O
host	O
cells	O
,	O
inhibited	O
propagation	O
of	O
the	O
virus	O
and	O
pathological	O
changes	O
found	O
in	O
Rhesus	O
macaques	O
infected	O
with	O
the	O
virus	O
through	O
the	O
nasal	O
route	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
survive	O
and	O
propagate	O
,	O
RNA	O
viruses	O
must	O
achieve	O
a	O
balance	B-CHED
between	O
the	O
capacity	O
for	O
adaptation	O
to	O
new	O
environmental	O
conditions	O
or	O
host	O
cells	O
with	O
the	O
need	O
to	O
maintain	O
an	O
intact	O
and	O
replication	O
competent	O
genome	O
.	O

Elucidation	O
of	O
the	O
mechanisms	O
of	O
nsp14	O
-	O
mediated	O
proofreading	O
will	O
have	O
major	O
implications	O
for	O
our	O
understanding	O
of	O
the	O
evolution	O
of	O
RNA	O
viruses	O
,	O
and	O
also	O
will	O
provide	O
a	O
robust	O
model	O
to	O
investigate	O
the	O
balance	B-CHED
between	O
fidelity	O
,	O
diversity	O
and	O
pathogenesis	O
.	O

The	O
discovery	O
of	O
a	O
protein	B-CHED
distinct	O
from	O
a	O
viral	O
RdRp	O
that	O
regulates	O
replication	O
fidelity	O
also	O
raises	O
the	O
possibility	O
that	O
RNA	O
genome	O
replication	O
fidelity	O
may	O
be	O
adaptable	O
to	O
differing	O
replication	O
environments	O
and	O
selective	O
pressures	O
,	O
rather	O
than	O
being	O
a	O
fixed	O
determinant	O
.	O

fDC	B-CHED
-	O
SIGN	O
was	O
not	O
involved	O
in	O
FIPV	O
II	O
binding	O
but	O
infection	O
was	O
reduced	O
with	O
64	O
%	O
when	O
fDC	B-CHED
-	O
SIGN	O
was	O
blocked	O
.	O

In	O
-	O
situ	O
hybridization	O
for	O
Pneumocystis	O
spp	O
.,	O
Ziehl	O
-	O
Neelsen	O
staining	O
and	O
immunohistochemistry	O
for	O
distemper	O
,	O
coronavirus	O
and	O
influenza	O
antigen	B-CHED
were	O
negative	O
in	O
all	O
cases	O
.	O

ABSTRACT	O
:	O
We	O
have	O
shown	O
that	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
A59	O
develop	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	B-CHED
hydrolase	O
(	O
FAH	O
).	O

Among	O
the	O
other	O
42	O
patients	O
,	O
5	O
(	O
11	O
.	O
9	O
%)	O
seroconverted	O
from	O
HBcAb	O
-	O
negative	O
to	O
HBcAb	O
-	O
positive	O
,	O
whereas	O
one	O
HBcAb	O
-	O
positive	O
recipient	O
became	O
hepatitis	O
B	O
virus	O
surface	O
antigen	B-CHED
-	O
positive	O
with	O
clinical	O
signs	O
of	O
active	O
hepatitis	O
6	O
years	O
after	O
transplantation	O
.	O

Therefore	O
,	O
the	O
development	O
of	O
novel	O
antiviral	B-CHED
agents	I-CHED
is	O
needed	O
to	O
close	O
the	O
vaccination	O
gap	O
and	O
silence	O
outbreaks	O
.	O

In	O
this	O
investigation	O
,	O
we	O
further	O
tested	O
mucroporin	O
and	O
the	O
optimized	O
mucroporin	O
-	O
M1	O
for	O
their	O
antiviral	B-CHED
activity	O
.	O

This	O
case	O
illustrates	O
the	O
importance	O
of	O
considering	O
exogenous	O
surfactant	B-CHED
therapy	O
early	O
in	O
the	O
course	O
of	O
acute	O
respiratory	O
failure	O
secondary	O
to	O
hydrocarbon	B-CHED
aspiration	O
.	O

Dexamethasone	B-CHED
was	O
used	O
to	O
prevent	O
further	O
hemolysis	O
in	O
both	O
foals	O
,	O
and	O
to	O
treat	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
1	O
of	O
the	O
foals	O
.	O

Inhaled	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	O
10	O
ppm	O
)	O
was	O
administered	O
to	O
the	O
patient	O
as	O
a	O
rescue	O
treatment	O
,	O
resulting	O
in	O
a	O
gradual	O
but	O
dramatic	O
improvement	O
in	O
pulmonary	O
oxygenation	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
9b	O
protein	B-CHED
diffuses	O
into	O
nucleus	B-CHED
,	O
undergoes	O
active	O
Crm1	O
mediated	O
nucleocytoplasmic	O
export	O
and	O
triggers	O
apoptosis	O
when	O
retained	O
in	O
the	O
nucleus	B-CHED
.	O

We	O
found	O
that	O
an	O
export	O
signal	O
deficient	O
SARS	O
-	O
CoV	O
9b	O
protein	B-CHED
induces	O
apoptosis	O
in	O
transiently	O
transfected	O
cells	O
and	O
showed	O
elevated	O
caspase	O
-	O
3	O
activity	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
characterized	O
lesions	O
in	O
the	O
respiratory	O
tract	O
and	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
of	O
ferrets	O
(	O
n	O
=	O
8	O
)	O
inoculated	O
intranasally	O
with	O
influenza	O
virus	O
A	O
/	O
Indonesia	O
/	O
5	O
/	O
2005	O
(	O
H5N1	O
).	O

ABSTRACT	O
:	O
(	O
See	O
the	O
editorial	O
commentary	O
by	O
Corona	B-CHED
and	O
Flores	O
,	O
on	O
pages	O
177	O
-	O
8	O
.)	O

This	O
study	O
was	O
a	O
prospective	O
,	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blinded	O
,	O
controlled	O
trial	O
designed	O
to	O
investigate	O
whether	O
EPA	B-CHED
/	O
GLA	B-CHED
could	O
have	O
an	O
effective	O
role	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
early	O
sepsis	O
(	O
systemic	O
inflammatory	O
response	O
syndrome	O
with	O
confirmed	O
or	O
presumed	O
infection	O
and	O
without	O
any	O
organ	O
dysfunction	O
)	O
by	O
reducing	O
the	O
progression	O
of	O
the	O
disease	O
to	O
severe	O
sepsis	O
(	O
sepsis	O
associated	O
with	O
at	O
least	O
one	O
organ	O
failure	O
)	O
or	O
septic	O
shock	O
(	O
sepsis	O
associated	O
with	O
hypotension	O
despite	O
adequate	O
fluid	O
resuscitation	O
).	O

TITLE	O
:	O
Synthesis	O
of	O
enantiomerically	O
pure	O
D	O
-	O
and	O
L	O
-	O
bicyclo	O
[	O
3	O
.	O
1	O
.	O
0	O
]	O
hexenyl	O
carbanucleosides	O
and	O
their	O
antiviral	B-CHED
evaluation	O
.	O

D	O
-	O
Counterpart	O
nucleosides	B-CHED
were	O
also	O
prepared	O
according	O
to	O
the	O
same	O
synthetic	O
method	O
.	O

Despite	O
its	O
galectin	O
fold	O
,	O
MHV	O
NTD	O
does	O
not	O
bind	O
sugars	O
,	O
but	O
instead	O
binds	O
mCEACAM1a	O
through	O
exclusive	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
.	O

Median	O
length	O
of	O
hospitalization	O
was	O
shorter	O
for	O
hemoglobin	B-CHED
SC	O
episodes	O
when	O
compared	O
to	O
hemoglobin	B-CHED
SS	O
episodes	O
(	O
3	O
.	O
0	O
vs	O
.	O
5	O
.	O
0	O
days	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

A	O
germicide	O
can	O
be	O
considered	O
to	O
have	O
an	O
efficient	O
ATS	O
-	O
D	O
antiviral	B-CHED
activity	O
if	O
it	O
induces	O
a	O
>	O
3	O
or	O
>	O
4	O
log	O
(	O
10	O
)	O
reduction	O
(	O
American	O
and	O
European	O
regulatory	O
agency	O
requirements	O
,	O
respectively	O
)	O
in	O
viral	O
titers	O
in	O
a	O
defined	O
contact	O
time	O
.	O

While	O
avian	O
infectious	O
bronchitis	O
coronavirus	O
(	O
IBV	O
)	O
infection	O
and	O
avian	O
influenza	O
A	O
virus	O
(	O
IAV	O
)	O
infection	O
both	O
depend	O
on	O
2	O
,	O
3	O
-	O
linked	O
sialic	B-CHED
acids	I-CHED
,	O
the	O
host	O
tropism	O
of	O
IBV	O
is	O
restricted	O
compared	O
to	O
that	O
of	O
IAV	O
.	O

A	O
'	O
low	O
-	O
grade	O
'	O
inflammatory	O
stimulus	O
in	O
utero	O
may	O
'	O
prime	O
'	O
the	O
fetal	O
lung	O
for	O
accelerated	O
maturation	O
of	O
the	O
surfactant	B-CHED
system	O
,	O
especially	O
in	O
conjunction	O
with	O
prenatal	O
steroids	B-CHED
,	O
and	O
may	O
protect	O
the	O
preterm	O
infant	O
from	O
developing	O
moderate	O
to	O
severe	O
RDS	O
.	O

Depending	O
on	O
the	O
severity	O
of	O
inflammatory	O
injury	O
to	O
the	O
alveolar	O
-	O
capillary	O
unit	O
,	O
however	O
,	O
serum	O
proteins	B-CHED
will	O
leak	O
into	O
the	O
airways	O
and	O
induce	O
surfactant	B-CHED
inactivation	O
.	O

Adverse	O
event	O
reports	O
identified	O
three	O
health	O
care	O
workers	O
who	O
developed	O
nevirapine	B-CHED
-	O
associated	O
Stevens	O
-	O
Johnson	O
syndrome	O
following	O
occupational	O
exposure	O
to	O
HIV	O
-	O
infected	O
blood	O
or	O
blood	O
products	O
;	O
four	O
persons	O
with	O
localized	O
hypersensitivity	O
and	O
fatal	O
cardiac	O
events	O
associated	O
with	O
rapamycin	B-CHED
-	O
or	O
paclitaxel	B-CHED
-	O
coated	O
coronary	O
artery	O
stent	O
placements	O
;	O
and	O
six	O
persons	O
with	O
breast	O
cancer	O
who	O
developed	O
severe	O
or	O
fatal	O
anaphylaxis	O
after	O
receiving	O
adjuvant	B-CHED
chemotherapy	O
with	O
Cremophor	O
-	O
EL	O
containing	O
paclitaxel	B-CHED
.	O

Furthermore	O
,	O
the	O
truncated	O
rS	O
-	O
AD	O
peptide	B-CHED
was	O
able	O
to	O
bind	O
to	O
the	O
surface	O
of	O
cells	O
from	O
swine	O
testes	O
in	O
a	O
competitive	O
manner	O
and	O
completely	O
inhibit	O
viral	O
infection	O
.	O

ABSTRACT	O
:	O
A	O
2	O
-	O
year	O
-	O
old	O
black	O
girl	O
was	O
diagnosed	O
with	O
Sweet	O
syndrome	O
and	O
cutis	O
laxa	O
,	O
and	O
she	O
was	O
given	O
corticosteroid	B-CHED
therapy	O
.	O

We	O
observed	O
suspected	O
TMV	O
virions	O
in	O
HeLa	O
cells	O
by	O
TEM	B-CHED
(	O
transmission	O
electron	O
microscopy	O
).	O

Three	O
large	O
multicenter	O
randomized	O
controlled	O
trials	O
did	O
not	O
demonstrate	O
a	O
significant	O
effect	O
on	O
patient	O
outcome	O
of	O
higher	O
or	O
lower	O
PEEP	B-CHED
at	O
a	O
fixed	O
low	O
tidal	O
volume	O
.	O

WNv	O
antigen	B-CHED
was	O
detected	O
in	O
brain	O
,	O
spleen	O
,	O
heart	O
,	O
kidney	O
,	O
liver	O
,	O
gonads	O
,	O
intestine	O
,	O
lung	O
,	O
and	O
pancreas	O
.	O

TITLE	O
:	O
The	O
NS1	O
glycoprotein	B-CHED
can	O
generate	O
dramatic	O
antibody	O
-	O
enhanced	O
dengue	O
viral	O
replication	O
in	O
normal	O
out	O
-	O
bred	O
mice	O
resulting	O
in	O
lethal	O
multi	O
-	O
organ	O
disease	O
.	O

We	O
describe	O
a	O
rather	O
rare	O
but	O
fatal	O
side	O
effect	O
of	O
lithium	B-CHED
:	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
a	O
46	O
-	O
year	O
-	O
old	O
female	O
on	O
lithium	B-CHED
for	O
the	O
treatment	O
of	O
bipolar	O
disease	O
.	O

The	O
patients	O
were	O
treated	O
with	O
saline	O
hydration	O
(	O
50	O
%)	O
or	O
hemodialysis	O
(	O
50	O
%),	O
indicating	O
that	O
hemodialysis	O
may	O
be	O
a	O
permissive	O
factor	O
in	O
lithium	B-CHED
-	O
associated	O
ARDS	O
development	O
rather	O
than	O
a	O
required	O
component	O
.	O

Rous	O
sarcoma	O
virus	O
(	O
RSV	O
)	O
offers	O
a	O
unique	O
model	O
system	O
for	O
dissecting	O
these	O
early	O
steps	O
because	O
the	O
RSV	O
Gag	O
protein	B-CHED
undergoes	O
transient	O
nuclear	O
trafficking	O
prior	O
to	O
plasma	O
membrane	O
transport	O
.	O

Although	O
her	O
respiratory	O
symptoms	O
responded	O
well	O
to	O
antibiotic	B-CHED
treatment	O
,	O
her	O
renal	O
function	O
worsened	O
,	O
with	O
severe	O
proteinuria	O
and	O
edema	O
.	O

After	O
initiation	O
of	O
steroid	B-CHED
therapy	O
,	O
her	O
renal	O
function	O
improved	O
.	O

All	O
the	O
patients	O
received	O
neuraminidase	B-CHED
inhibitors	I-CHED
(	O
oseltaminir	O
),	O
while	O
60	O
patients	O
(	O
96	O
.	O
7	O
%)	O
were	O
treated	O
with	O
antibiotics	B-CHED
,	O
and	O
39	O
(	O
62	O
.	O
9	O
%)	O
with	O
corticosteroids	B-CHED
.	O

Furthermore	O
,	O
the	O
generation	O
,	O
distribution	O
and	O
phenotype	O
of	O
long	O
-	O
lasting	O
peptide	B-CHED
-	O
specific	O
memory	O
CD8	O
(+)	O
T	O
cells	O
were	O
assessed	O
by	O
ELISA	O
,	O
ELISPOT	O
and	O
flow	O
cytometry	O
.	O

TITLE	O
:	O
IFN	O
-	O
	O
-	O
and	O
IL	O
-	O
10	O
-	O
expressing	O
virus	O
epitope	B-CHED
-	O
specific	O
Foxp3	O
(+)	O
T	O
reg	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
during	O
encephalomyelitis	O
.	O

Identification	O
of	O
T	O
reg	O
cell	O
target	O
epitopes	O
by	O
cytokine	O
production	O
is	O
also	O
applicable	O
in	O
autoimmune	O
disease	O
because	O
myelin	O
oligodendrocyte	O
glycoprotein	B-CHED
-	O
specific	O
Foxp3	O
(+)	O
T	O
reg	O
cells	O
express	O
IL	O
-	O
10	O
and	O
IL	O
-	O
17	O
at	O
the	O
peak	O
of	O
disease	O
in	O
mice	O
with	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
24	O
-	O
year	O
gravida	O
4	O
para	B-CHED
2	O
with	O
singleton	O
pregnancy	O
admitted	O
to	O
obstetrical	O
unit	O
for	O
fever	O
up	O
to	O
38	O
	O
C	O
during	O
the	O
20th	O
week	O
of	O
a	O
so	O
far	O
uncomplicated	O
pregnancy	O
.	O

She	O
was	O
treated	O
for	O
influenza	O
,	O
which	O
was	O
isolated	O
repeatedly	O
from	O
oropharynx	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
fluids	O
,	O
and	O
later	O
empirically	O
for	O
lupus	O
pneumonitis	O
,	O
but	O
died	O
6	O
months	O
after	O
transplant	O
.	O

PD	O
-	O
1	O
-	O
deficient	O
mice	O
exhibited	O
significantly	O
higher	O
expression	O
of	O
the	O
effector	B-CHED
molecule	O
which	O
initiates	O
fibrinogen	O
deposition	O
,	O
fibrinogen	O
-	O
like	O
protein	B-CHED
2	O
(	O
FGL2	O
),	O
than	O
did	O
their	O
wild	O
-	O
type	O
(	O
WT	O
)	O
littermates	O
.	O

Fluorescence	O
double	O
-	O
staining	O
revealed	O
that	O
FGL2	O
and	O
PD	O
-	O
1	O
were	O
not	O
co	O
-	O
expressed	O
on	O
the	O
same	O
cells	O
,	O
while	O
quantitative	O
RT	O
-	O
PCR	O
demonstrated	O
that	O
higher	O
levels	O
of	O
IFN	O
-	O
	O
and	O
TNF	O
-	O
	O
mRNA	B-CHED
transcription	O
occurred	O
in	O
PD	O
-	O
1	O
-	O
deficient	O
mice	O
in	O
response	O
to	O
MHV	O
-	O
3	O
infection	O
.	O

In	O
addition	O
,	O
mutation	O
of	O
MHV	O
nonstructural	O
protein	B-CHED
2	O
(	O
ns2	O
)	O
abrogates	O
the	O
ability	O
of	O
the	O
virus	O
to	O
replicate	O
in	O
the	O
liver	O
and	O
induce	O
hepatitis	O
but	O
does	O
not	O
affect	O
replication	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
).	O

These	O
data	O
imply	O
that	O
the	O
ability	O
of	O
MHV	O
to	O
replicate	O
in	O
macrophages	O
is	O
a	O
prerequisite	O
for	O
replication	O
in	O
the	O
liver	O
and	O
induction	O
of	O
hepatitis	O
but	O
not	O
for	O
replication	O
or	O
disease	O
in	O
the	O
CNS	B-CHED
,	O
underscoring	O
the	O
importance	O
of	O
IFN	O
signaling	O
in	O
macrophages	O
in	O
vivo	O
for	O
protection	O
of	O
the	O
host	O
from	O
hepatitis	O
.	O

TITLE	O
:	O
Cyclosporin	B-CHED
A	I-CHED
inhibits	O
the	O
replication	O
of	O
diverse	O
coronaviruses	O
.	O

siRNA	O
-	O
mediated	O
knockdown	O
of	O
the	O
expression	O
of	O
the	O
prominent	O
CsA	B-CHED
targets	O
cyclophilin	O
A	O
and	O
B	O
did	O
not	O
affect	O
SARS	O
-	O
CoV	O
replication	O
,	O
suggesting	O
either	O
that	O
these	O
specific	O
cyclophilin	O
family	O
members	O
are	O
dispensable	O
or	O
that	O
the	O
reduced	O
expression	O
levels	O
suffice	O
to	O
support	O
replication	O
.	O

TITLE	O
:	O
Local	O
renin	O
-	O
angiotensin	B-CHED
II	I-CHED
systems	O
,	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
and	O
its	O
homologue	O
ACE2	O
:	O
their	O
potential	O
role	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
obstructive	O
pulmonary	O
diseases	O
,	O
pulmonary	O
hypertension	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Moreover	O
,	O
drugs	O
that	O
inhibit	O
the	O
synthesis	O
of	O
AngII	O
(	O
ACE	O
inhibitors	B-CHED
)	O
or	O
that	O
antagonize	O
its	O
actions	O
on	O
its	O
receptors	O
(	O
Angiotensin	B-CHED
II	I-CHED
receptor	O
blockers	O
-	O
ARBs	O
)	O
have	O
been	O
shown	O
to	O
provide	O
beneficial	O
effects	O
.	O

TITLE	O
:	O
[	O
Expression	O
and	O
purification	O
of	O
different	O
segments	O
from	O
HCoV	O
-	O
NL63	O
nucleocapsid	O
protein	B-CHED
and	O
their	O
application	O
in	O
detection	O
of	O
antibodies	O
].	O

TITLE	O
:	O
[	O
Characterization	O
and	O
development	O
of	O
recombinant	O
vaccinia	O
viruses	O
expressing	O
different	O
segments	O
of	O
spike	O
protein	B-CHED
derived	O
from	O
human	O
coronavirus	O
NL	O
-	O
63	O
].	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
of	O
HCoV	O
-	O
NL63	O
is	O
a	O
major	O
target	O
in	O
the	O
development	O
of	O
diagnostic	O
assays	O
and	O
vaccines	O
,	O
but	O
its	O
antigenic	O
and	O
immunogenic	O
properties	O
remain	O
unclear	O
.	O

Four	O
fragments	O
coding	O
spike	O
proteins	B-CHED
(	O
S1	O
,	O
S2	O
,	O
RL	O
and	O
RS	O
)	O
from	O
HCoV	O
-	O
NL63	O
were	O
amplified	O
and	O
cloned	O
into	O
the	O
expression	O
vector	O
derived	O
from	O
vaccinia	O
virus	O
(	O
Tiantan	O
strain	O
),	O
and	O
recombinant	O
vaccinia	O
viruses	O
expressing	O
four	O
segments	O
of	O
spike	O
proteins	B-CHED
were	O
generated	O
(	O
vJSC1175	O
-	O
S1	O
;	O
vJSC1175	O
-	O
S2	O
;	O
vJSC1175	O
-	O
RL	O
;	O
vJSC1175	O
-	O
RS	O
),	O
respectively	O
.	O

TITLE	O
:	O
Anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
antibodies	O
trigger	O
infection	O
of	O
human	O
immune	O
cells	O
via	O
a	O
pH	O
-	O
and	O
cysteine	B-CHED
protease	O
-	O
independent	O
FcR	O
pathway	O
.	O

These	O
observations	O
prompted	O
us	O
to	O
investigate	O
the	O
mechanisms	O
underlying	O
antibody	O
-	O
dependent	O
enhancement	O
(	O
ADE	B-CHED
)	O
of	O
SARS	O
-	O
CoV	O
infection	O
in	O
vitro	O
.	O

Here	O
,	O
we	O
developed	O
a	O
real	O
-	O
time	O
monitoring	O
system	O
for	O
airborne	O
influenza	O
H3N2	B-CHED
viruses	O
by	O
integrating	O
electronically	O
addressable	O
silicon	B-CHED
nanowire	B-CHED
(	O
SiNW	O
)	O
sensor	O
devices	O
,	O
microfluidics	O
and	O
bioaerosol	O
-	O
to	O
-	O
hydrosol	O
air	B-CHED
sampling	O
techniques	O
.	O

When	O
airborne	O
influenza	O
H3N2	B-CHED
virus	O
samples	O
were	O
collected	O
and	O
delivered	O
to	O
antibody	O
-	O
modified	O
SiNW	O
devices	O
,	O
discrete	O
nanowire	B-CHED
conductance	O
changes	O
were	O
observed	O
within	O
seconds	O
.	O

One	O
molecule	O
is	O
assumed	O
to	O
be	O
present	O
per	O
asymmetric	O
unit	O
,	O
which	O
gives	O
a	O
Matthews	O
coefficient	O
of	O
2	O
.	O
89	O
3	O
Da	O
(-	O
1	O
)	O
and	O
a	O
solvent	B-CHED
content	O
of	O
56	O
.	O
2	O
%.	O

A	O
screen	O
of	O
individual	O
IBV	O
non	O
-	O
structural	O
proteins	B-CHED
(	O
nsps	O
)	O
showed	O
that	O
autophagy	O
was	O
activated	O
by	O
IBV	O
nsp6	O
.	O

The	O
vesicles	O
recruited	O
double	O
FYVE	O
-	O
domain	O
containing	O
protein	B-CHED
(	O
DFCP	O
)	O
indicating	O
localised	O
concentration	O
of	O
phosphatidylinositol	B-CHED
3	O
phosphate	B-CHED
,	O
and	O
therefore	O
shared	O
many	O
features	O
with	O
omegasomes	O
formed	O
from	O
the	O
ER	O
in	O
response	O
to	O
starvation	O
.	O

Furthermore	O
,	O
myeloid	O
cell	O
depletion	O
implicated	O
MMP9	O
in	O
facilitating	O
leukocyte	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
infiltration	O
via	O
loss	O
of	O
BBB	B-CHED
integrity	O
.	O

In	O
this	O
study	O
,	O
an	O
assay	O
for	O
one	O
of	O
the	O
human	O
coronaviruses	O
,	O
OC43	O
,	O
was	O
developed	O
using	O
a	O
truncated	O
recombinant	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
antigen	B-CHED
in	O
an	O
enzyme	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
evaluated	O
using	O
serum	O
collected	O
from	O
HCoV	O
-	O
OC43	O
-	O
infected	O
patients	O
,	O
healthy	O
adults	O
,	O
and	O
patients	O
with	O
other	O
respiratory	O
virus	O
infections	O
.	O

ABSTRACT	O
:	O
The	O
XendoU	O
family	O
of	O
enzymes	O
includes	O
several	O
proteins	B-CHED
displaying	O
high	O
sequence	O
homology	O
.	O

To	O
develop	O
an	O
antigen	B-CHED
that	O
is	O
more	O
specific	O
,	O
more	O
sensitive	O
,	O
and	O
easier	O
to	O
prepare	O
for	O
serological	O
diagnosis	O
,	O
the	O
antigenic	O
sites	O
in	O
the	O
MHV	O
-	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
were	O
screened	O
in	O
this	O
study	O
.	O

Since	O
there	O
is	O
no	O
effective	O
treatment	O
against	O
SARS	O
,	O
these	O
transduced	O
T	O
cells	O
specific	O
for	O
an	O
immunodominant	O
SARS	O
epitope	B-CHED
may	O
provide	O
a	O
new	O
avenue	O
for	O
treatment	O
during	O
a	O
SARS	O
outbreak	O
.	O

With	O
several	O
prognostic	O
indicators	O
(	O
including	O
status	O
myoclonus	O
)	O
having	O
been	O
validated	O
in	O
the	O
pre	O
-	O
hypothermia	O
era	B-CHED
,	O
their	O
current	O
relevance	O
is	O
debatable	O
.	O

There	O
is	O
very	O
little	O
evidence	O
on	O
the	O
value	O
of	O
administering	O
estrogen	B-CHED
in	O
cases	O
of	O
seawater	O
drowning	O
which	O
can	O
induce	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ALI	O
/	O
ARDS	O
).	O

Here	O
,	O
we	O
describe	O
a	O
rapid	O
and	O
safe	O
cell	O
-	O
based	O
high	O
-	O
throughput	O
screening	O
system	O
,	O
dual	O
envelope	O
pseudovirion	O
(	O
DEP	B-CHED
)	O
assay	O
,	O
for	O
specifically	O
screening	O
inhibitors	B-CHED
of	O
viral	O
entry	O
.	O

The	O
assay	O
system	O
employs	O
a	O
novel	O
dual	O
envelope	O
strategy	O
,	O
using	O
lentiviral	O
pseudovirions	O
as	O
targets	O
whose	O
entry	O
is	O
driven	O
by	O
the	O
SARS	O
-	O
CoV	O
Spike	O
glycoprotein	B-CHED
.	O

In	O
conclusion	O
,	O
in	O
patients	O
with	O
ALI	O
/	O
ARDS	O
related	O
to	O
AML	O
FAB	O
-	O
M5	O
,	O
adding	O
dexamethasone	B-CHED
to	O
conventional	O
chemotherapy	O
seemed	O
effective	O
and	O
safe	O
.	O

MK	O
-	O
p10	O
S	O
protein	B-CHED
had	O
four	O
mutations	O
relative	O
to	O
the	O
original	O
virus	O
S	O
,	O
and	O
one	O
of	O
these	O
(	O
H	O
	O
R	O
at	O
position	O
1381	O
,	O
H1381R	O
)	O
in	O
the	O
cytoplasmic	O
tail	O
(	O
CT	O
)	O
was	O
suggested	O
to	O
be	O
responsible	O
for	O
the	O
increased	O
fusion	O
activity	O
.	O

TITLE	O
:	O
Report	O
of	O
the	O
'	O
mechanisms	O
of	O
lung	O
injury	O
and	O
immunomodulator	B-CHED
interventions	O
in	O
influenza	O
'	O
workshop	O
,	O
21	O
March	O
2010	O
,	O
Ventura	O
,	O
California	O
,	O
USA	O
.	O

Aldehyde	B-CHED
inhibitors	B-CHED
can	O
bind	O
reversibly	O
to	O
the	O
active	O
-	O
site	O
sulfhydryl	O
of	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	B-CHED
).	O

We	O
also	O
determined	O
a	O
crystal	O
structure	O
of	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	B-CHED
)	O
in	O
complex	O
with	O
aldehyde	B-CHED
Cm	O
-	O
FF	O
-	O
H	O
,	O
which	O
has	O
its	O
P1	O
-	O
phenylalanine	B-CHED
residue	I-CHED
bound	O
to	O
the	O
relatively	O
hydrophilic	O
S1	O
pocket	O
of	O
the	O
enzyme	O
and	O
yet	O
exhibits	O
a	O
high	O
inhibitory	O
activity	O
against	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	B-CHED
),	O
with	O
K	O
(	O
i	O
)=	O
2	O
.	O
24	O
	O
0	O
.	O
58	O
M	O
.	O
These	O
results	O
show	O
that	O
the	O
stringent	O
substrate	O
specificity	O
of	O
the	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	B-CHED
)	O
with	O
respect	O
to	O
the	O
P1	O
and	O
P2	O
positions	O
can	O
be	O
overruled	O
by	O
the	O
highly	O
electrophilic	O
character	O
of	O
the	O
aldehyde	B-CHED
warhead	O
,	O
thereby	O
constituting	O
a	O
deviation	O
from	O
the	O
dogma	O
that	O
peptidic	O
inhibitors	B-CHED
need	O
to	O
correspond	O
to	O
the	O
observed	O
cleavage	O
specificity	O
of	O
the	O
target	O
protease	O
.	O

Prenatal	O
administration	O
of	O
glucocorticoids	B-CHED
and	O
postnatal	O
surfactant	B-CHED
therapy	O
remains	O
an	O
established	O
principle	O
in	O
perinatal	O
care	O
for	O
very	O
preterm	O
neonates	O
.	O

Because	O
SHEDD	O
-	O
fA	O
is	O
an	O
intensive	O
and	O
high	O
-	O
efficiency	O
modality	O
,	O
removal	O
of	O
useful	O
drugs	O
or	O
nutrients	B-CHED
may	O
be	O
observed	O
.	O

Indeed	O
,	O
following	O
mitogenic	O
stimulation	O
,	O
T	O
cells	O
lacking	O
casp8	O
or	O
its	O
adaptor	O
protein	B-CHED
FADD	O
(	O
Fas	O
-	O
associated	O
death	O
domain	O
protein	B-CHED
)	O
develop	O
a	O
hyperautophagic	O
morphology	O
,	O
and	O
die	O
a	O
programmed	O
necrosis	O
-	O
like	O
death	O
process	O
termed	O
necroptosis	O
.	O

A	O
61	O
-	O
year	O
-	O
old	O
female	O
on	O
multiple	O
medications	O
,	O
including	O
several	O
antipsychotics	B-CHED
,	O
rapidly	O
deteriorated	O
,	O
with	O
fever	O
,	O
lead	O
-	O
pipe	O
rigidity	O
,	O
and	O
decreased	O
level	O
of	O
consciousness	O
.	O

TITLE	O
:	O
Thioacetamide	B-CHED
-	O
induced	O
fulminant	O
hepatic	O
failure	O
induces	O
cerebral	O
mitochondrial	O
dysfunction	O
by	O
altering	O
the	O
electron	O
transport	O
chain	O
complexes	O
.	O

Further	O
the	O
activity	O
of	O
pyruvate	B-CHED
dehydrogenase	O
at	O
18	O
and	O
24	O
h	O
after	O
the	O
induction	O
of	O
FHF	O
was	O
inhibited	O
by	O
29	O
and	O
43	O
%,	O
respectively	O
.	O

We	O
enrolled	O
125	O
(	O
first	O
period	O
,	O
n	O
=	O
54	O
)	O
patients	O
with	O
arterial	O
oxygen	B-CHED
tension	O
(	O
P	O
(	O
a	O
,	O
O	O
(	O
2	O
)))/	O
inspiratory	O
oxygen	B-CHED
fraction	O
(	O
F	O
(	O
I	O
,	O
O	O
(	O
2	O
)))	O
of	O
<	O
150	O
mmHg	O
for	O
>	O
12	O
consecutive	O
hours	O
at	O
an	O
end	O
-	O
expiratory	O
pressure	O
of	O
	O
8	O
cmH	B-CHED
(	O
2	O
)	O
O	O
.	O
Patients	O
were	O
randomly	O
assigned	O
to	O
an	O
HFO	O
-	O
TGI	O
group	O
(	O
receiving	O
HFO	O
-	O
TGI	O
sessions	O
with	O
RMs	O
,	O
interspersed	O
with	O
lung	O
-	O
protective	O
CMV	O
;	O
n	O
=	O
61	O
)	O
or	O
CMV	O
group	O
(	O
receiving	O
lung	O
-	O
protective	O
CMV	O
and	O
RMs	O
;	O
n	O
=	O
64	O
).	O

Mutations	O
in	O
MTU1	O
are	O
associated	O
with	O
acute	O
infantile	O
liver	O
failure	O
,	O
and	O
this	O
has	O
been	O
ascribed	O
to	O
a	O
transient	O
lack	O
of	O
cysteine	B-CHED
,	O
the	O
sulfur	B-CHED
donor	B-CHED
for	O
the	O
thiouridylation	O
reaction	O
,	O
resulting	O
in	O
a	O
mitochondrial	O
translation	O
defect	O
during	O
early	O
development	O
.	O

A	O
mutation	O
in	O
tRNA	B-CHED
(	O
Lys	B-CHED
)	O
that	O
causes	O
myoclonic	O
epilepsy	O
with	O
ragged	O
-	O
red	O
fibers	O
(	O
MERRF	O
)	O
is	O
also	O
reported	O
to	O
prevent	O
modification	O
of	O
the	O
wobble	O
U	O
.	O
Here	O
we	O
show	O
that	O
mitochondrial	O
translation	O
is	O
unaffected	O
in	O
fibroblasts	O
from	O
an	O
MTU1	O
patient	O
,	O
in	O
which	O
MTU1	O
is	O
undetectable	O
by	O
immunoblotting	O
,	O
despite	O
the	O
severe	O
reduction	O
in	O
the	O
2	O
-	O
thiolation	O
of	O
mitochondrial	O
tRNA	B-CHED
(	O
Lys	B-CHED
),	O
tRNA	B-CHED
(	O
Glu	B-CHED
)	O
and	O
tRNA	B-CHED
(	O
Gln	B-CHED
).	O

There	O
was	O
also	O
an	O
average	O
reduction	O
of	O
37	O
%	O
in	O
air	B-CHED
exchange	O
volume	O
with	O
the	O
use	O
of	O
N95	O
respirators	O
.	O

We	O
found	O
several	O
proteins	B-CHED
that	O
could	O
interact	O
with	O
the	O
nucleocapsid	O
protein	B-CHED
of	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

These	O
health	O
effects	O
are	O
also	O
of	O
concern	O
for	O
postnatal	O
exposure	O
to	O
ambient	O
and	O
indoor	O
air	B-CHED
pollution	O
.	O

PAC	O
patients	O
received	O
inotropic	O
drugs	O
more	O
frequently	O
(	O
57	O
.	O
8	O
%	O
vs	O
50	O
.	O
0	O
%;	O
P	O
<	O
0	O
.	O
001	O
),	O
had	O
a	O
larger	O
positive	O
IV	O
fluid	O
balance	B-CHED
after	O
surgery	O
(	O
3220	O
mL	O
vs	O
3022	O
mL	O
;	O
P	O
=	O
0	O
.	O
003	O
),	O
and	O
experienced	O
longer	O
time	O
to	O
tracheal	O
extubation	O
(	O
15	O
.	O
40	O
hours	O
[	O
11	O
.	O
28	O
/	O
20	O
.	O
80	O
]	O
versus	O
13	O
.	O
18	O
hours	O
[	O
9	O
.	O
58	O
/	O
19	O
.	O
33	O
],	O
median	O
plus	O
Q1	O
/	O
Q3	O
interquartile	O
range	O
;	O
P	O
<	O
0	O
.	O
0001	O
).	O

TITLE	O
:	O
Coronavirus	O
infection	O
induces	O
DNA	O
replication	O
stress	O
partly	O
through	O
interaction	O
of	O
its	O
nonstructural	O
protein	B-CHED
13	O
with	O
the	O
p125	O
subunit	O
of	O
DNA	O
polymerase	O
	O
.	O

Here	O
,	O
we	O
identified	O
ANXA2	O
as	O
a	O
RNA	O
binding	O
protein	B-CHED
(	O
RBP	O
)	O
that	O
binds	O
IBV	O
(	O
Infectious	O
Bronchitis	O
Virus	O
)	O
pseudoknot	O
RNA	O
.	O

Using	O
an	O
adjuvanted	O
and	O
an	O
unadjuvanted	O
double	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
(	O
DIV	O
)	O
vaccine	O
,	O
we	O
demonstrate	O
an	O
eosinophilic	O
immunopathology	O
in	O
aged	O
mice	O
comparable	O
to	O
that	O
seen	O
in	O
mice	O
immunized	O
with	O
the	O
SARS	O
nucleocapsid	O
protein	B-CHED
,	O
and	O
poor	O
protection	O
against	O
a	O
nonlethal	O
heterologous	O
challenge	O
.	O

22	O
cases	O
of	O
GBS	O
were	O
reported	O
in	O
the	O
pediatric	O
department	O
of	O
Ibn	B-CHED
El	O
Jazzar	O
'	O
s	O
hospital	O
of	O
Kairouan	O
from	O
January	O
1990	O
to	O
September	O
2009	O
.	O

The	O
evolution	O
was	O
favourable	O
in	O
10	O
cases	O
with	O
total	O
recovery	O
three	O
cases	O
of	O
drop	O
foot	O
gait	O
were	O
observed	O
,	O
seven	O
patients	O
were	O
lost	B-CHED
to	O
follow	O
up	O
and	O
two	O
patients	O
are	O
dead	O
.	O

ABSTRACT	O
:	O
Houttuynia	O
cordata	O
Thunb	O
.	O
is	O
a	O
medicinal	O
plant	O
widely	O
used	O
in	O
folk	O
medicine	B-CHED
in	O
several	O
Asian	O
countries	O
.	O

It	O
has	O
been	O
reported	O
that	O
a	O
water	B-CHED
extract	O
of	O
H	O
.	O
cordata	O
exhibits	O
activity	O
against	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
and	O
the	O
virus	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
although	O
the	O
mechanisms	O
are	O
not	O
fully	O
understood	O
yet	O
.	O

Inhibition	O
of	O
glutamate	B-CHED
excitotoxicity	O
using	O
a	O
2	O
-	O
amino	O
-	O
3	O
-(	O
5	O
-	O
methyl	B-CHED
-	O
3	O
-	O
oxo	B-CHED
-	O
1	O
,	O
2	O
-	O
oxazol	O
-	O
4	O
-	O
yl	O
)	O
propranoic	O
acid	O
(	O
AMPA	B-CHED
)	O
receptor	O
antagonist	B-CHED
(	O
GYKI	O
-	O
52466	O
)	O
improved	O
clinical	O
scores	O
related	O
to	O
the	O
paralysis	O
and	O
motor	O
disabilities	O
in	O
S	O
mutant	O
virus	O
-	O
infected	O
mice	O
,	O
as	O
well	O
as	O
protected	O
the	O
CNS	B-CHED
from	O
neuronal	O
dysfunctions	O
,	O
as	O
illustrated	O
by	O
restoration	O
of	O
the	O
phosphorylation	O
state	O
of	O
neurofilaments	O
.	O

TITLE	O
:	O
Identifying	O
public	O
health	O
competencies	O
relevant	O
to	O
family	O
medicine	B-CHED
.	O

The	O
effect	O
of	O
circumcision	O
was	O
stronger	O
at	O
the	O
glans	O
/	O
corona	B-CHED
(	O
OR	O
,	O
0	O
.	O
47	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
37	O
-	O
0	O
.	O
60	O
)	O
and	O
urethra	O
(	O
OR	O
,	O
0	O
.	O
35	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
12	O
-	O
1	O
.	O
05	O
)	O
compared	O
with	O
sites	O
more	O
distal	O
to	O
the	O
foreskin	O
.	O

The	O
average	O
PC	O
volume	O
percentage	O
was	O
21	O
.	O
86	O
%	O
	O
13	O
.	O
90	O
%	O
(	O
range	O
,	O
5	O
.	O
6	O
%	O
to	O
61	O
.	O
0	O
%),	O
which	O
was	O
inconsistently	O
correlated	O
with	O
the	O
admission	O
partial	O
pressure	O
of	O
oxygen	B-CHED
/	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
ratio	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
083	O
).	O

Patients	O
with	O
a	O
PC	O
volume	O
percentage	O
exceeding	O
the	O
best	O
cutoff	O
of	O
21	O
.	O
5	O
%	O
were	O
defined	O
as	O
the	O
severe	O
PC	B-CHED
group	I-CHED
.	O

The	O
partial	O
pressure	O
of	O
oxygen	B-CHED
/	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
ratio	O
,	O
the	O
needed	O
maximal	O
positive	O
end	O
-	O
expiratory	O
pressure	O
level	O
,	O
and	O
ARDS	O
incidence	O
between	O
the	O
severe	O
group	O
and	O
the	O
general	O
group	O
was	O
significantly	O
different	O
(	O
p	O
<.	O
05	O
).	O

CONCLUSIONS	O
:	O
The	O
presence	O
of	O
gross	O
vulva	O
oedema	O
in	O
pre	O
-	O
eclampsia	O
may	O
be	O
an	O
indicator	B-CHED
of	O
severity	O
of	O
disease	O
and	O
or	O
deteriorating	O
fetomaternal	O
condition	O
.	O

This	O
ICAR	O
was	O
a	O
fitting	O
testament	O
to	O
the	O
'	O
father	O
of	O
antiviral	B-CHED
chemotherapy	O
',	O
Bill	O
Prusoff	O
,	O
who	O
died	O
aged	O
90	O
in	O
April	O
2011	O
.	O

In	O
this	O
trial	O
,	O
the	O
cytokine	O
levels	O
of	O
IL6	O
,	O
IL8	O
and	O
IL10	O
were	O
measured	O
and	O
compared	O
in	O
30	O
patients	O
who	O
had	O
undergone	O
an	O
extended	O
radical	B-CHED
thoracoabdominal	O
esophagectomy	O
for	O
esophageal	O
cancer	O
,	O
via	O
anterolateral	O
thoracotomy	O
(	O
n	O
=	O
17	O
)	O
or	O
posterolateral	O
thoracotomy	O
(	O
n	O
=	O
13	O
).	O

Collectively	O
,	O
our	O
results	O
show	O
that	O
HAT	B-CHED
cleaves	O
and	O
activates	O
SARS	O
-	O
S	O
and	O
might	O
support	O
viral	O
spread	O
in	O
patients	O
.	O

The	O
most	O
common	O
method	O
for	O
diagnosing	O
HCoV	O
-	O
HKU1	O
infection	O
is	O
RT	O
-	O
PCR	O
or	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
using	O
RNA	O
extracted	O
from	O
respiratory	O
tract	O
samples	O
such	O
as	O
nasopharyngeal	O
aspirates	O
(	O
NPA	B-CHED
).	O

Here	O
we	O
review	O
recent	O
data	O
indicating	O
that	O
coronaviruses	O
probably	O
co	O
-	O
opt	O
membranous	O
carriers	O
derived	O
from	O
the	O
endoplasmic	O
reticulum	O
,	O
which	O
contain	O
proteins	B-CHED
that	O
regulate	O
disposal	O
of	O
misfolded	O
polypeptides	B-CHED
,	O
for	O
their	O
replication	O
.	O

Areas	O
that	O
have	O
the	O
highest	O
occurrence	O
of	O
recombination	O
are	O
located	O
in	O
regions	O
of	O
the	O
genome	O
that	O
code	O
for	O
nonstructural	O
proteins	B-CHED
2	O
,	O
3	O
and	O
16	O
,	O
and	O
the	O
structural	O
spike	O
glycoprotein	B-CHED
.	O

Surfactant	B-CHED
has	O
been	O
used	O
to	O
improve	O
pulmonary	O
gas	O
exchange	O
for	O
severe	O
respiratory	O
distress	O
in	O
other	O
pediatric	O
populations	O
but	O
has	O
not	O
been	O
studied	O
in	O
pediatric	O
burn	O
-	O
injured	O
patients	O
.	O

Here	O
,	O
the	O
authors	O
report	O
a	O
case	O
series	O
of	O
seven	O
severely	O
burned	O
pediatric	O
patients	O
who	O
received	O
surfactant	B-CHED
for	O
acute	O
respiratory	O
distress	O
and	O
severe	O
hypoxemia	O
.	O

Plasma	O
angiotensin	B-CHED
-	O
II	O
levels	O
were	O
associated	O
with	O
genotype	O
in	O
the	O
ARDS	O
group	O
,	O
but	O
not	O
controls	O
,	O
being	O
higher	O
in	O
D	O
allele	O
carriers	O
(	O
p	O
=	O
0	O
.	O
016	O
).	O

ACE	O
I	O
/	O
D	O
polymorphism	O
modified	O
angiotensin	B-CHED
-	O
II	O
levels	O
in	O
pediatric	O
ARDS	O
,	O
but	O
its	O
pathogenic	O
role	O
is	O
not	O
well	O
understood	O
and	O
needs	O
to	O
be	O
addressed	O
in	O
future	O
studies	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
monoclonal	O
antibodies	O
developed	O
using	O
a	O
prokaryotic	O
expressed	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Mannose	B-CHED
-	O
binding	O
lectin	O
(	O
MBL	O
),	O
a	O
C	O
-	O
type	O
collectin	O
with	O
structural	O
similarities	O
to	O
C1q	O
,	O
is	O
an	O
innate	O
pattern	O
-	O
recognition	O
molecule	O
that	O
is	O
sequestered	O
to	O
sites	O
of	O
inflammation	O
and	O
infections	O
.	O

Total	O
lung	O
compliance	O
was	O
21	O
mL	O
cm	O
H2O	B-CHED
-	O
1	O
,	O
and	O
SAP	O
/	O
DAP	B-CHED
was	O
63	O
/	O
39	O
mm	O
Hg	O
).	O

Further	O
treatment	O
was	O
complicated	O
by	O
septic	O
shock	O
due	O
to	O
Pseudomonas	O
aeruginosa	O
infection	O
of	O
the	O
vagina	O
,	O
treated	O
with	O
piperacillin	B-CHED
/	O
tazobactam	O
.	O

Compared	O
to	O
H120	O
vaccine	O
strain	O
,	O
point	O
mutation	O
,	O
short	O
insertion	O
,	O
and	O
deletion	O
occurred	O
at	O
many	O
positions	O
in	O
the	O
S1	O
protein	B-CHED
of	O
the	O
seven	O
strains	O
.	O

The	O
first	O
is	O
primer	O
-	O
dependent	O
and	O
associated	O
with	O
the	O
106	O
-	O
kDa	O
non	O
-	O
structural	O
protein	B-CHED
12	O
(	O
nsp12	O
),	O
whereas	O
the	O
second	O
is	O
catalysed	O
by	O
the	O
22	O
-	O
kDa	O
nsp8	O
.	O

Neuromuscular	O
blocking	O
agents	O
(	O
NMBAs	O
)	O
are	O
used	O
to	O
facilitate	O
mechanical	O
ventilation	O
in	O
patients	O
with	O
ARDS	O
and	O
have	O
been	O
shown	O
to	O
improve	O
arterial	O
partial	O
pressure	O
of	O
oxygen	B-CHED
.	O

Conversely	O
,	O
inhibition	O
of	O
cyclophilins	O
by	O
cyclosporine	B-CHED
A	O
(	O
CspA	O
)	O
blocked	O
the	O
replication	O
of	O
CoVs	O
of	O
all	O
genera	O
,	O
including	O
SARS	O
-	O
CoV	O
,	O
human	O
CoV	O
-	O
229E	O
and	O
-	O
NL	O
-	O
63	O
,	O
feline	O
CoV	O
,	O
as	O
well	O
as	O
avian	O
infectious	O
bronchitis	O
virus	O
.	O

The	O
therapeutic	O
effects	O
of	O
EC	O
-	O
SOD	O
and	O
copper	B-CHED
-	O
zinc	B-CHED
SOD	O
(	O
CuZn	O
-	O
SOD	O
)	O
via	O
an	O
aerosol	O
delivery	O
system	O
for	O
lung	O
injury	O
and	O
systemic	O
oxidative	O
stress	O
at	O
24	O
,	O
48	O
,	O
72	O
and	O
96	O
h	O
of	O
hyperoxia	O
were	O
measured	O
by	O
bronchoalveolar	O
lavage	O
,	O
wet	O
/	O
dry	O
ratio	O
,	O
lung	O
histology	O
,	O
and	O
8	O
-	O
oxo	B-CHED
-	O
2	B-CHED
'-	I-CHED
deoxyguanosine	I-CHED
(	O
8	B-CHED
-	I-CHED
oxo	I-CHED
-	I-CHED
dG	I-CHED
)	O
in	O
lung	O
and	O
liver	O
tissues	O
.	O

TITLE	O
:	O
Quinoline	B-CHED
tricyclic	O
derivatives	O
.	O

Quinoline	B-CHED
derivatives	O
were	O
also	O
tested	O
against	O
representatives	O
of	O
other	O
RNA	O
virus	O
families	O
containing	O
single	O
-	O
stranded	O
,	O
either	O
positive	O
-	O
sense	O
(	O
ssRNA	O
(+))	O
or	O
negative	O
-	O
sense	O
(	O
RNA	O
(-)),	O
and	O
double	O
-	O
stranded	O
genomes	O
(	O
dsRNA	B-CHED
),	O
as	O
well	O
as	O
against	O
representatives	O
of	O
two	O
DNA	O
virus	O
families	O
.	O

Using	O
cerebrospinal	O
fluid	O
from	O
patients	O
with	O
multiple	O
sclerosis	O
,	O
spinal	O
cord	O
from	O
experimental	O
autoimmune	O
encephalomyelitis	O
and	O
coronavirus	O
-	O
induced	O
encephalitis	O
,	O
we	O
demonstrate	O
that	O
central	O
nervous	O
system	O
-	O
infiltrating	O
CD8	O
(+)	O
T	O
lymphocytes	O
are	O
mostly	O
of	O
the	O
effector	B-CHED
memory	O
phenotype	O
(	O
CD62L	O
(-)	O
CCR7	O
(-)	O
granzymeB	O
(	O
hi	O
)).	O

We	O
also	O
demonstrate	O
that	O
in	O
vivo	O
neutralization	O
of	O
very	O
late	O
antigen	B-CHED
-	O
4	O
restricts	O
central	O
nervous	O
system	O
infiltration	O
of	O
CD8	O
(+)	O
T	O
lymphocytes	O
in	O
active	O
immunization	O
and	O
adoptive	O
transfer	O
experimental	O
autoimmune	O
encephalomyelitis	O
,	O
and	O
in	O
coronavirus	O
-	O
induced	O
encephalitis	O
.	O

TITLE	O
:	O
Thiazolides	O
as	O
novel	O
antiviral	B-CHED
agents	I-CHED
.	O

The	O
information	O
in	O
this	O
review	O
,	O
which	O
summarises	O
current	O
knowledge	O
of	O
infectious	O
diseases	O
affecting	O
the	O
CNS	B-CHED
,	O
is	O
collated	O
from	O
publications	O
on	O
the	O
infectious	O
diseases	O
comprising	O
previous	O
research	O
papers	O
,	O
review	O
articles	O
,	O
case	O
series	O
,	O
case	O
reports	O
and	O
textbooks	O
,	O
supplemented	O
by	O
the	O
clinical	O
experience	O
of	O
the	O
authors	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
is	O
a	O
severe	O
form	O
of	O
respiratory	O
failure	O
characterized	O
by	O
acute	O
onset	O
of	O
significant	O
hypoxaemia	O
(	O
PaO2	O
:	O
FiO2	O
<	O
200mmHg	O
)	O
with	O
diffuse	O
bilateral	O
pulmonary	O
air	B-CHED
-	O
space	O
shadowing	O
on	O
chest	O
X	O
-	O
ray	O
,	O
without	O
clinical	O
signs	O
of	O
heart	O
failure	O
(	O
Bernard	O
et	O
al	O
,	O
1994	O
).	O

ABSTRACT	O
:	O
We	O
previously	O
reported	O
widespread	O
differential	O
expression	O
of	O
long	O
non	O
-	O
protein	B-CHED
-	O
coding	O
RNAs	O
(	O
ncRNAs	O
)	O
in	O
response	O
to	O
virus	O
infection	O
.	O

Our	O
results	O
demonstrated	O
that	O
mitochondrial	O
SIRT3	O
and	O
SIRT4	O
protein	B-CHED
expression	O
increased	O
from	O
12	O
and	O
24	O
h	O
post	O
infection	O
(	O
p	O
.	O
i	O
.)	O
onwards	O
,	O
respectively	O
,	O
whereas	O
the	O
nuclear	O
SIRT1	O
expression	O
increased	O
during	O
the	O
first	O
12	O
h	O
p	O
.	O
i	O
.	O

TITLE	O
:	O
Combined	O
recombinant	O
human	O
activated	O
protein	B-CHED
C	O
and	O
ceftazidime	B-CHED
prevent	O
the	O
onset	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
severe	O
sepsis	O
.	O

Combined	O
rhAPC	O
and	O
ceftazidime	B-CHED
significantly	O
improved	O
cardiopulmonary	O
function	O
,	O
reduced	O
pulmonary	O
and	O
cardiac	O
tissue	O
injury	O
,	O
and	O
prevented	O
the	O
onset	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
ovine	O
severe	O
sepsis	O
without	O
obvious	O
adverse	O
effects	O
.	O

Surfactant	B-CHED
protein	B-CHED
A	O
(	O
SP	O
-	O
A	O
)	O
and	O
SP	O
-	O
D	O
are	O
part	O
of	O
the	O
innate	O
immune	O
system	O
in	O
the	O
distal	O
lung	O
.	O

In	O
contrast	O
,	O
there	O
was	O
a	O
modest	O
reduction	O
in	O
infection	O
in	O
AMs	O
by	O
SP	O
-	O
A	O
,	O
but	O
not	O
by	O
SP	O
-	O
D	O
.	O
In	O
summary	O
,	O
AMs	O
are	O
an	O
important	O
target	O
for	O
HCoV	O
-	O
229E	O
,	O
and	O
they	O
can	O
mount	O
a	O
pro	B-CHED
-	O
inflammatory	O
innate	O
immune	O
response	O
to	O
infection	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
survival	O
time	O
of	O
cats	O
treated	O
with	O
PPF	B-CHED
(	O
8	O
days	O
,	O
95	O
%	O
CI	O
5	O
.	O
4	O
-	O
10	O
.	O
6	O
)	O
versus	O
placebo	O
(	O
7	O
.	O
5	O
days	O
,	O
95	O
%	O
CI	O
4	O
.	O
4	O
-	O
9	O
.	O
6	O
).	O

TITLE	O
:	O
Acute	O
phase	O
proteins	B-CHED
as	O
a	O
tool	O
for	O
differential	O
diagnosis	O
of	O
wasting	O
diseases	O
in	O
growing	O
pigs	O
.	O

Diminished	O
rDC	O
migration	O
associated	O
with	O
virus	O
-	O
specific	O
defects	O
in	O
T	O
cell	O
responses	O
and	O
was	O
not	O
a	O
result	O
of	O
cell	O
-	O
intrinsic	O
defect	O
,	O
rather	O
it	O
reflected	O
the	O
observed	O
age	O
-	O
dependent	O
increases	O
in	O
PGD	B-CHED
(	O
2	O
)	O
expression	O
.	O

Decision	O
support	O
systems	O
(	O
DSS	O
)	O
may	O
support	O
clinicians	O
in	O
finding	O
the	O
correct	O
balance	B-CHED
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
a	O
computerized	O
model	O
-	O
based	O
DSS	O
for	O
its	O
advice	O
on	O
inspired	O
oxygen	B-CHED
fraction	O
,	O
tidal	O
volume	O
and	O
respiratory	O
frequency	O
.	O

Compared	O
to	O
the	O
baseline	O
ventilator	O
settings	O
set	O
as	O
part	O
of	O
routine	O
clinical	O
care	O
,	O
the	O
system	O
suggested	O
lower	O
tidal	O
volumes	O
and	O
inspired	O
oxygen	B-CHED
fraction	O
,	O
but	O
higher	O
frequency	O
,	O
with	O
all	O
suggestions	O
and	O
the	O
model	O
simulated	O
outcome	O
comparing	O
well	O
with	O
the	O
respiratory	O
goals	O
of	O
the	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Network	O
from	O
2000	O
.	O

ABSTRACT	O
:	O
A	O
combined	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
method	O
was	O
developed	O
for	O
the	O
detection	O
and	O
differentiation	O
of	O
wild	O
-	O
type	O
and	O
vaccine	O
strains	O
of	O
the	O
canine	O
distemper	O
virus	O
(	O
CDV	B-CHED
).	O

The	O
combined	O
RT	O
-	O
PCR	O
method	O
detected	O
effectively	O
and	O
differentiated	O
the	O
CDV	B-CHED
wild	O
-	O
type	O
and	O
vaccine	O
strains	O
by	O
two	O
separate	O
RT	O
-	O
PCRs	O
.	O

This	O
paper	O
emphasizes	O
the	O
need	O
to	O
suspect	O
influenza	O
B	O
virus	O
infection	O
in	O
critically	O
ill	O
immunocompromised	O
patients	O
with	O
progressive	O
deterioration	O
of	O
cardiopulmonary	O
function	O
despite	O
treatment	O
with	O
antibiotics	B-CHED
.	O

Plasma	O
levels	O
of	O
two	O
markers	O
of	O
oxidative	O
stress	O
[	O
thiobarbituric	B-CHED
acid	I-CHED
reactive	O
substances	O
(	O
TBARS	O
)	O
and	O
reduced	O
ascorbic	B-CHED
acid	I-CHED
(	O
RAA	O
)]	O
and	O
both	O
HSP27	O
and	O
HSP70	O
were	O
measured	O
.	O

The	O
compound	O
1	O
,	O
evaluated	O
in	O
HepG	O
2	O
.	O
2	O
.	O
15	O
cells	O
expressing	O
permanently	O
HBV	O
,	O
significantly	O
reduced	O
the	O
levels	O
of	O
HBV	O
antigens	B-CHED
and	O
HBV	O
DNA	O
in	O
a	O
dose	O
-	O
dependent	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

TITLE	O
:	O
High	O
-	O
level	O
mucosal	O
and	O
systemic	O
immune	O
responses	O
induced	O
by	O
oral	O
administration	O
with	O
Lactobacillus	O
-	O
expressed	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
S1	O
region	O
combined	O
with	O
Lactobacillus	O
-	O
expressed	O
N	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
evaluate	O
the	O
immunogenicity	O
,	O
safety	O
,	O
and	O
tolerability	O
of	O
the	O
MF	O
-	O
59	O
adjuvanted	O
seasonal	O
influenza	O
vaccine	O
in	O
children	O
and	O
adolescents	O
with	O
juvenile	O
idiopathic	O
arthritis	O
(	O
JIA	O
)	O
treated	O
with	O
different	O
anti	B-CHED
-	I-CHED
rheumatic	I-CHED
drugs	I-CHED
,	O
60	O
pediatric	O
patients	O
with	O
JIA	O
(	O
30	O
treated	O
with	O
disease	O
-	O
modifying	O
anti	B-CHED
-	I-CHED
rheumatic	I-CHED
drugs	I-CHED
[	O
DMARDs	O
]	O
and	O
30	O
with	O
etanercept	O
)	O
were	O
compared	O
with	O
30	O
healthy	O
controls	O
of	O
similar	O
gender	O
and	O
age	O
.	O

In	O
this	O
study	O
,	O
two	O
siRNA	O
expression	O
plasmids	O
(	O
shN1	O
and	O
shN2	O
)	O
were	O
generated	O
to	O
target	O
two	O
different	O
coding	O
regions	O
of	O
the	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
)	O
of	O
PHEV	O
.	O

Appropriate	O
nutrition	O
could	O
limit	O
protein	B-CHED
catabolism	O
.	O

Nutritional	O
support	O
limits	O
but	O
does	O
not	O
stop	O
the	O
loss	O
of	O
total	O
body	O
protein	B-CHED
mass	O
occurring	O
in	O
acute	O
severe	O
illness	O
.	O

Glutamine	B-CHED
and	O
possibly	O
leucine	B-CHED
may	O
improve	O
clinical	O
outcome	O
,	O
but	O
it	O
is	O
unclear	O
whether	O
these	O
benefits	O
occur	O
through	O
an	O
impact	O
on	O
total	O
body	O
protein	B-CHED
mass	O
and	O
its	O
turnover	O
,	O
or	O
through	O
other	O
mechanisms	O
.	O

VIRsiRNAdb	O
would	O
prove	O
useful	O
for	O
researchers	O
in	O
picking	O
up	O
the	O
best	O
viral	O
siRNA	O
for	O
antiviral	B-CHED
therapeutics	O
development	O
and	O
also	O
for	O
developing	O
better	O
viral	O
siRNA	O
design	O
tools	O
.	O

ABSTRACT	O
:	O
The	O
cessation	O
of	O
sedation	O
in	O
brain	O
-	O
injured	O
patients	O
may	O
result	O
in	O
severe	O
agitation	O
and	O
/	O
or	O
acute	O
withdrawal	O
syndrome	O
related	O
to	O
the	O
prolonged	O
administration	O
of	O
large	O
doses	O
of	O
benzodiazepines	B-CHED
and	O
/	O
or	O
opioids	O
.	O

On	O
cessation	O
of	O
opioid	O
infusion	O
and	O
clorazepate	B-CHED
,	O
clinical	O
data	O
were	O
collected	O
for	O
48	O
hours	O
:	O
heart	O
rate	O
,	O
systolic	O
blood	O
pressure	O
,	O
respiratory	O
rate	O
,	O
agitation	O
,	O
and	O
pupil	O
diameter	O
.	O

RESULTS	O
:	O
Of	O
40	O
patients	O
,	O
there	O
were	O
10	O
who	O
did	O
not	O
require	O
buprenorphine	B-CHED
.	O

The	O
pathophysiology	O
of	O
MAS	B-CHED
is	O
multifactorial	O
and	O
includes	O
acute	O
airway	O
obstruction	O
,	O
surfactant	B-CHED
dysfunction	O
or	O
inactivation	O
,	O
chemical	O
pneumonitis	O
with	O
release	O
of	O
vasoconstrictive	O
and	O
inflammatory	O
mediators	O
,	O
and	O
persistent	O
pulmonary	O
hypertension	O
of	O
newborn	O
(	O
PPHN	O
).	O

Approaches	O
to	O
the	O
prevention	O
of	O
MAS	B-CHED
have	O
changed	O
over	O
time	O
with	O
collaboration	O
between	O
obstetricians	O
and	O
pediatricians	O
forming	O
the	O
foundations	O
for	O
care	O
.	O

The	O
SARS	O
-	O
CoV	O
papain	O
-	O
like	O
protease	O
(	O
PLP	O
)	O
is	O
an	O
attractive	O
target	O
for	O
pharmaceutical	B-CHED
development	O
because	O
it	O
is	O
essential	O
for	O
virus	O
replication	O
and	O
is	O
conserved	O
among	O
human	O
coronaviruses	O
.	O

In	O
addition	O
,	O
our	O
findings	O
indicate	O
that	O
the	O
HE	O
protein	B-CHED
of	O
BToV	O
may	O
not	O
be	O
necessary	O
for	O
viral	O
replication	O
.	O

Itraconazole	B-CHED
is	O
the	O
drug	O
of	O
choice	O
for	O
most	O
forms	O
of	O
the	O
disease	O
;	O
amphotericin	B-CHED
B	I-CHED
is	O
reserved	O
for	O
the	O
more	O
severe	O
forms	O
.	O

TITLE	O
:	O
Performance	O
of	O
different	O
mono	O
-	O
and	O
multiplex	O
nucleic	B-CHED
acid	I-CHED
amplification	O
tests	O
on	O
a	O
multipathogen	O
external	O
quality	O
assessment	O
panel	O
.	O

Clinical	O
signs	O
,	O
gross	O
and	O
microscopic	O
findings	O
were	O
evaluated	O
,	O
viral	O
nucleic	B-CHED
acid	I-CHED
detection	O
was	O
assessed	O
by	O
in	O
situ	O
hybridization	O
(	O
ISH	O
)	O
in	O
several	O
tissues	O
and	O
viral	O
RNA	O
was	O
detected	O
by	O
RT	O
-	O
PCR	O
in	O
trachea	O
,	O
kidney	O
and	O
nasal	O
and	O
cloacal	O
swabs	O
.	O

The	O
escape	O
of	O
viral	O
mRNAs	O
from	O
nsp1	O
-	O
induced	O
RNA	O
cleavage	O
may	O
be	O
an	O
important	O
strategy	O
by	O
which	O
the	O
virus	O
circumvents	O
the	O
action	O
of	O
nsp1	O
leading	O
to	O
the	O
efficient	O
accumulation	O
of	O
viral	O
mRNAs	O
and	O
viral	O
proteins	B-CHED
during	O
infection	O
.	O

CONCLUSIONS	O
:	O
RSV	O
was	O
the	O
main	O
pathogen	O
of	O
ARI	B-CHED
,	O
and	O
the	O
new	O
-	O
found	O
virus	O
MPV	O
was	O
also	O
another	O
crucial	O
pathogen	O
.	O

New	O
cluster	O
2	O
IBV	O
strains	O
showed	O
low	O
amino	B-CHED
acid	I-CHED
homology	O
(<	O
58	O
.	O
7	O
%)	O
compared	O
with	O
previous	O
isolates	O
.	O

ABSTRACT	O
:	O
This	O
article	O
reviews	O
case	O
series	O
and	O
trials	O
that	O
evaluated	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
respiratory	O
failure	O
and	O
describes	O
patient	O
and	O
circuit	O
management	O
in	O
the	O
modern	O
era	B-CHED
of	O
ECMO	O
support	O
.	O

The	O
replicase	O
proteins	B-CHED
of	O
arteriviruses	O
are	O
associated	O
with	O
double	O
-	O
membrane	O
vesicles	O
(	O
DMVs	O
),	O
which	O
were	O
previously	O
proposed	O
to	O
derive	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
).	O

CONCLUSIONS	O
:	O
Ergothioneine	B-CHED
should	O
be	O
considered	O
for	O
additional	O
testing	O
as	O
a	O
potential	O
therapy	O
for	O
treating	O
and	O
preventing	O
ARDS	O
.	O

Monovalent	O
antisera	O
against	O
three	O
vaccine	O
strains	O
and	O
seven	O
field	O
isolates	O
of	O
different	O
genotypes	O
were	O
prepared	O
by	O
immunizing	O
rabbits	O
with	O
mineral	B-CHED
oil	O
adjuvant	B-CHED
preparations	O
containing	O
viruses	O
propagated	O
in	O
chicken	O
embryos	O
.	O

ABSTRACT	O
:	O
Among	O
different	O
coronavirus	O
genera	O
,	O
the	O
receptor	O
-	O
binding	O
S1	O
subunits	O
of	O
their	O
spike	O
proteins	B-CHED
differ	O
in	O
primary	O
,	O
secondary	O
,	O
and	O
tertiary	O
structures	O
.	O

Of	O
567	O
patients	O
included	O
,	O
36	O
%	O
were	O
HPS	B-CHED
-	O
confirmed	O
.	O

During	O
all	O
steps	O
,	O
we	O
calculated	O
the	O
size	O
of	O
the	O
non	O
-	O
aerated	O
(-	O
100	O
to	O
+	O
100	O
HU	O
)	O
compartment	O
and	O
the	O
recruitability	O
of	O
the	O
lungs	O
(	O
the	O
percent	O
mass	O
of	O
collapsed	O
tissue	O
re	O
-	O
aerated	O
from	O
baseline	O
to	O
maximum	O
PEEP	B-CHED
).	O

ABSTRACT	O
:	O
Human	O
serum	O
albumin	O
(	O
HSA	O
),	O
the	O
most	O
abundant	O
protein	B-CHED
in	O
plasma	O
,	O
is	O
a	O
monomeric	O
multi	O
-	O
domain	O
macromolecule	B-CHED
,	O
representing	O
the	O
main	O
determinant	O
of	O
plasma	O
oncotic	O
pressure	O
and	O
the	O
main	O
modulator	O
of	O
fluid	O
distribution	O
between	O
body	O
compartments	O
.	O

HSA	O
displays	O
an	O
extraordinary	O
ligand	B-CHED
binding	O
capacity	O
,	O
providing	O
a	O
depot	O
and	O
carrier	O
for	O
many	O
endogenous	O
and	O
exogenous	O
compounds	O
.	O

TITLE	O
:	O
Two	O
palmitylated	O
cysteine	B-CHED
residues	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
(	O
S	O
)	O
protein	B-CHED
are	O
critical	O
for	O
S	O
incorporation	O
into	O
virus	O
-	O
like	O
particles	O
,	O
but	O
not	O
for	O
M	O
-	O
S	O
co	O
-	O
localization	O
.	O

Here	O
,	O
we	O
propose	O
a	O
structure	O
model	O
of	O
the	O
ORF3	O
protein	B-CHED
consisting	O
of	O
four	O
TM	O
domains	O
and	O
forming	O
a	O
tetrameric	O
assembly	O
.	O

In	O
patients	O
with	O
influenza	O
A	O
/	O
H1N1	O
pneumonia	O
,	O
empirical	O
antibiotic	B-CHED
therapy	O
should	O
be	O
provided	O
due	O
to	O
the	O
possibility	O
of	O
bacterial	O
coinfection	O
.	O

A	O
beta	B-CHED
-	I-CHED
lactam	I-CHED
plus	O
a	O
macrolide	B-CHED
should	O
be	O
administered	O
as	O
soon	O
as	O
possible	O
.	O

The	O
renin	O
-	O
angiotensin	B-CHED
system	O
(	O
RAS	B-CHED
)	O
through	O
Angiotensin	B-CHED
-	O
converting	O
enzyme	O
(	O
ACE	O
)-	O
generated	O
Angiotensin	B-CHED
II	I-CHED
contributes	O
to	O
lung	O
injury	O
.	O

The	O
gene	O
responsible	O
for	O
the	O
synthesis	O
of	O
this	O
sialic	B-CHED
acid	I-CHED
was	O
also	O
found	O
to	O
be	O
upregulated	O
.	O

Sputum	O
culture	O
revealed	O
the	O
presence	O
of	O
MRSA	O
,	O
and	O
HSV	O
was	O
isolated	O
in	O
broncho	O
-	O
alveoler	O
lavage	O
(	O
BAL	B-CHED
)	O
fluid	O
.	O

Consistent	O
with	O
this	O
observation	O
,	O
pharmacological	O
inhibitors	B-CHED
of	O
PI4KB	O
blocked	O
entry	O
of	O
SARS	O
pseudovirions	O
.	O

ABSTRACT	O
:	O
Experimental	O
pharmacotherapies	O
for	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
have	O
not	O
met	B-CHED
with	O
success	O
in	O
the	O
clinical	O
realm	O
.	O

The	O
peptide	B-CHED
also	O
inhibits	O
proliferation	O
of	O
coronavirus	O
NL63	O
.	O

Peptide	B-CHED
(	O
438	O
)	O
YKYRYL	O
(	O
443	O
)	O
is	O
part	O
of	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
.	O
Peptide	B-CHED
libraries	O
were	O
screened	O
by	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
to	O
identify	O
RBD	O
binding	O
epitopes	O
.	O

Based	O
on	O
this	O
information	O
the	O
peptide	B-CHED
can	O
be	O
used	O
as	O
lead	O
structure	O
to	O
design	O
potential	O
entry	O
inhibitors	B-CHED
against	O
SARS	O
-	O
CoV	O
and	O
related	O
viruses	O
.	O

TITLE	O
:	O
Alcohol	O
worsens	O
acute	O
lung	O
injury	O
by	O
inhibiting	O
alveolar	O
sodium	O
transport	O
through	O
the	O
adenosine	B-CHED
A1	O
receptor	O
.	O

We	O
hypothesized	O
that	O
alcohol	O
might	O
worsen	O
lung	O
injury	O
by	O
increasing	O
lung	O
adenosine	B-CHED
levels	O
,	O
resulting	O
in	O
impaired	O
active	O
Na	O
(+)	O
transport	O
in	O
the	O
lung	O
.	O

ABSTRACT	O
:	O
To	O
recognize	O
the	O
etiological	O
agent	O
responsible	O
for	O
severe	O
acute	O
respiratory	O
failure	O
(	O
ARF	O
)	O
in	O
patients	O
in	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
is	O
important	O
to	O
determine	O
their	O
treatment	O
and	O
prognosis	O
,	O
and	O
to	O
avoid	O
the	O
excessive	O
use	O
of	O
antibiotics	B-CHED
.	O

The	O
human	O
-	O
optimized	O
RBD	O
contains	O
all	O
of	O
the	O
hACE2	O
-	O
adapted	O
residues	O
(	O
Phe	B-CHED
-	O
442	O
,	O
Phe	B-CHED
-	O
472	O
,	O
Asn	B-CHED
-	O
479	O
,	O
Asp	B-CHED
-	O
480	O
,	O
and	O
Thr	B-CHED
-	O
487	O
)	O
and	O
possesses	O
exceptionally	O
high	O
affinity	O
for	O
hACE2	O
but	O
relative	O
low	O
affinity	O
for	O
cACE2	O
.	O

A	O
natural	O
flavonoid	B-CHED
quercetin	B-CHED
has	O
a	O
3	O
,	O
5	O
-	O
dihydroxychromone	O
pharmacophore	O
which	O
is	O
in	O
bioisosteric	O
relationship	O
with	O
the	O
1	O
,	O
3	O
-	O
diketoacid	O
moiety	O
of	O
the	O
ADK	O
.	O

Thus	O
,	O
it	O
was	O
of	O
our	O
interest	O
to	O
test	O
the	O
antiviral	B-CHED
activity	O
of	O
the	O
quercetin	B-CHED
derivatives	O
with	O
an	O
arylmethyl	O
group	O
attached	O
.	O

Hypothermia	O
and	O
other	O
metabolic	O
abnormalities	O
are	O
now	O
better	O
explained	O
thanks	O
to	O
actual	O
knowledge	O
about	O
endogenous	O
H2S	B-CHED
function	O
.	O

Here	O
,	O
we	O
compared	O
the	O
effects	O
of	O
three	O
reducing	B-CHED
agents	I-CHED
-	O
dithiothreitol	B-CHED
(	O
DTT	O
),	O
	O
-	O
mercaptoethanol	B-CHED
(	O
	O
-	O
MCE	O
),	O
and	O
tris	B-CHED
(	I-CHED
2	I-CHED
-	I-CHED
carboxyethyl	I-CHED
)	I-CHED
phosphine	I-CHED
(	O
TCEP	B-CHED
)-	O
as	O
well	O
as	O
GSH	B-CHED
against	O
three	O
drug	O
target	O
proteins	B-CHED
.	O

Approximately	O
100	O
,	O
000	O
compounds	O
were	O
computationally	O
screened	O
for	O
each	O
target	O
protein	B-CHED
,	O
and	O
experimental	O
testing	O
of	O
high	O
-	O
scoring	O
compounds	O
(~	O
560	O
compounds	O
)	O
with	O
the	O
four	O
reducing	B-CHED
agents	I-CHED
surprisingly	O
produced	O
many	O
nonoverlapping	O
hits	O
.	O

More	O
importantly	O
,	O
we	O
found	O
that	O
various	O
reducing	B-CHED
agents	I-CHED
altered	O
inhibitor	B-CHED
potency	O
(	O
IC	O
(	O
50	O
))	O
from	O
approximately	O
10	O
M	O
with	O
one	O
reducing	B-CHED
agent	I-CHED
to	O
complete	O
loss	O
(	O
IC	O
(	O
50	O
)>	O
200	O
M	O
)	O
of	O
inhibitory	O
activity	O
with	O
another	O
reducing	B-CHED
agent	I-CHED
.	O

Therefore	O
,	O
the	O
choice	O
of	O
reducing	B-CHED
agent	I-CHED
in	O
an	O
HTS	O
is	O
critical	O
because	O
this	O
may	O
lead	O
to	O
the	O
pursuit	O
of	O
falsely	O
identified	O
active	O
compounds	O
or	O
failure	O
to	O
identify	O
the	O
true	O
active	O
compounds	O
.	O

The	O
better	O
stability	O
of	O
SARS	O
coronavirus	O
at	O
low	O
temperature	O
and	O
low	O
humidity	O
environment	O
may	O
facilitate	O
its	O
transmission	O
in	O
community	O
in	O
subtropical	O
area	O
(	O
such	O
as	O
Hong	O
Kong	O
)	O
during	O
the	O
spring	O
and	O
in	O
air	B-CHED
-	O
conditioned	O
environments	O
.	O

Plasmacytoid	O
dendritic	O
cells	O
(	O
pDCs	O
)	O
are	O
innate	O
immune	O
cells	O
that	O
produce	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
I	O
)	O
and	O
other	O
cytokines	O
in	O
response	O
to	O
virus	O
-	O
derived	O
nucleic	B-CHED
acids	I-CHED
.	O

The	O
setting	O
of	O
ventilator	O
support	O
were	O
significantly	O
decreased	O
,	O
and	O
arterial	O
oxygen	B-CHED
saturation	O
[	O
SaO	O
(	O
2	O
)],	O
arterial	O
blood	O
carbon	B-CHED
dioxide	I-CHED
partial	O
pressure	O
[	O
PaCO	O
(	O
2	O
)]	O
and	O
blood	O
pH	O
value	O
were	O
improved	O
significantly	O
after	O
the	O
V	O
-	O
V	O
mode	O
ECMO	O
.	O

Upon	O
addition	O
of	O
Nsp7	O
,	O
the	O
RNA	O
polymerase	O
activity	O
is	O
further	O
enhanced	O
so	O
that	O
RNA	O
up	O
to	O
template	O
length	O
(	O
67	O
nucleotides	B-CHED
)	O
can	O
be	O
synthesized	O
.	O

Settings	O
of	O
mechanical	O
ventilation	O
(	O
prior	O
to	O
ECMO	O
vs	O
2	O
hours	O
post	O
-	O
ECMO	O
)	O
were	O
:	O
peak	O
airway	O
pressure	O
(	O
31	O
	O
7	O
)	O
vs	O
(	O
25	O
	O
6	O
)	O
cm	O
H2O	B-CHED
,	O
respiratory	O
rate	O
(	O
15	O
	O
4	O
)	O
vs	O
(	O
22	O
	O
6	O
)	O
breaths	O
/	O
min	O
,	O
FiO2	O
0	O
.	O
8	O
-	O
1	O
.	O
0	O
vs	O
0	O
.	O
35	O
-	O
0	O
.	O
50	O
,	O
PEEP	B-CHED
(	O
16	O
	O
5	O
)	O
vs	O
(	O
12	O
	O
4	O
)	O
cm	O
H2O	B-CHED
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
quantitative	O
detection	O
system	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
targeting	O
the	O
nucleocapsid	O
protein	B-CHED
(	O
NP	O
),	O
to	O
determine	O
the	O
presence	O
and	O
degree	O
of	O
infection	O
in	O
suspected	O
individuals	O
.	O

The	O
sensitivity	O
of	O
the	O
developed	O
heterosandwich	O
ELISA	O
can	O
detect	O
the	O
viral	O
antigen	B-CHED
at	O
18	O
.	O
5	O
pg	O
/	O
mL	O
of	O
recombinant	O
NP	O
.	O

Six	O
Chinese	O
mini	O
-	O
piglets	O
were	O
used	O
to	O
establish	O
ALI	O
models	O
by	O
oleic	B-CHED
acid	I-CHED
.	O

In	O
addition	O
,	O
TGEV	O
infection	O
down	O
-	O
regulated	O
Bcl	O
-	O
2	O
,	O
up	O
-	O
regulated	O
Bax	O
expression	O
,	O
promoted	O
translocation	O
of	O
Bax	O
to	O
mitochondria	O
,	O
activated	O
mitochondria	O
-	O
mediated	O
apoptotic	O
pathway	O
,	O
which	O
in	O
turn	O
caused	O
the	O
release	O
of	O
cytochrome	B-CHED
c	I-CHED
and	O
the	O
activation	O
of	O
caspase	O
-	O
9	O
.	O

These	O
findings	O
demonstrate	O
that	O
long	O
-	O
distance	O
communication	O
pathways	O
between	O
multiple	O
residues	O
and	O
domains	O
of	O
nsp5	O
play	O
a	O
significant	O
role	O
in	O
nsp5	O
activity	O
and	O
viral	O
replication	O
,	O
suggesting	O
possible	O
novel	O
targets	O
for	O
non	O
-	O
active	O
site	O
inhibitors	B-CHED
of	O
nsp5	O
.	O

This	O
study	O
describes	O
two	O
families	O
of	O
peptides	B-CHED
,	O
hapivirins	O
and	O
diprovirins	O
,	O
whose	O
design	O
was	O
inspired	O
by	O
retrocyclins	O
.	O

These	O
new	O
peptides	B-CHED
were	O
active	O
against	O
H3N2	B-CHED
and	O
H1N1	O
strains	O
of	O
IAV	O
.	O

The	O
IC	O
(	O
50	O
)	O
of	O
six	O
flavonoid	B-CHED
compounds	O
were	O
47	O
-	O
381	O
M	O
.	O
Quercetin	B-CHED
,	O
epigallocatechin	O
gallate	B-CHED
and	O
gallocatechin	B-CHED
gallate	B-CHED
(	O
GCG	O
)	O
displayed	O
good	O
inhibition	O
toward	O
3CL	O
(	O
pro	B-CHED
)	O
with	O
IC	O
(	O
50	O
)	O
values	O
of	O
73	O
,	O
73	O
and	O
47	O
M	O
,	O
respectively	O
.	O

Currently	O
,	O
the	O
use	O
of	O
corticosteroid	B-CHED
therapy	O
for	O
severe	O
pandemic	O
influenza	O
A	O
(	O
H1N1	O
)	O
pneumonia	O
is	O
controversial	O
,	O
but	O
even	O
the	O
late	O
administration	O
of	O
corticosteroid	B-CHED
therapy	O
may	O
be	O
effective	O
.	O

Seven	O
critically	O
ill	O
patients	O
on	O
venovenous	O
ECMO	O
for	O
severe	O
pandemic	O
(	O
H1N1	O
)	O
influenza	O
associated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
were	O
treated	O
with	O
various	O
doses	O
of	O
oseltamivir	B-CHED
(	O
75	O
or	O
150	O
mg	O
twice	O
daily	O
).	O

Based	O
on	O
these	O
results	O
,	O
we	O
recommend	O
that	O
oseltamivir	B-CHED
dosage	O
should	O
be	O
decreased	O
and	O
plasma	O
levels	O
of	O
OC	O
be	O
monitored	O
in	O
patients	O
receiving	O
CVVHDF	O
because	O
of	O
acute	O
kidney	O
injury	O
.	O

Such	O
protein	B-CHED
-	O
protein	B-CHED
interaction	O
networks	O
and	O
their	O
analysis	O
represent	O
a	O
powerful	O
resource	O
from	O
a	O
therapeutic	O
perspective	O
.	O

Ten	O
adult	O
patients	O
with	O
severe	O
ARDS	O
secondary	O
to	O
H1N1	O
infection	O
(	O
Pao	B-CHED
(	O
2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
,	O
69	O
mm	O
Hg	O
[	O
56	O
-	O
84	O
];	O
Murray	O
score	O
,	O
3	O
.	O
5	O
[	O
3	O
.	O
5	O
-	O
3	O
.	O
8	O
])	O
were	O
included	O
,	O
and	O
60	O
%	O
survived	O
to	O
hospital	O
discharge	O
.	O

Antibody	O
against	O
RbCoV	O
was	O
detected	O
in	O
20	O
(	O
67	O
%)	O
of	O
30	O
rabbit	O
sera	O
tested	O
by	O
an	O
N	O
-	O
protein	B-CHED
-	O
based	O
Western	O
blot	O
assay	O
,	O
whereas	O
neutralizing	O
antibody	O
was	O
detected	O
in	O
1	O
of	O
these	O
20	O
rabbits	O
.	O

Deoxynivalenol	O
affected	O
the	O
blood	O
biochemistry	O
,	O
whereas	O
plasma	O
total	O
protein	B-CHED
and	O
uric	B-CHED
acid	I-CHED
concentrations	O
in	O
birds	O
fed	O
contaminated	O
grains	O
were	O
decreased	O
compared	O
with	O
those	O
of	O
the	O
controls	O
.	O

The	O
one	O
-	O
step	O
multiplex	O
RT	O
-	O
PCR	O
with	O
newly	O
designed	O
primers	O
to	O
detect	O
GAR	B-CHED
had	O
higher	O
sensitivity	O
than	O
a	O
single	O
RT	O
-	O
PCR	O
with	O
conventional	O
primers	O
,	O
with	O
no	O
false	O
-	O
positive	O
reactions	O
observed	O
for	O
ten	O
other	O
kinds	O
of	O
bovine	O
RNA	O
viruses	O
To	O
assess	O
its	O
field	O
applicability	O
,	O
59	O
of	O
60	O
fecal	O
samples	O
containing	O
one	O
of	O
these	O
five	O
viruses	O
from	O
all	O
25	O
epidemic	O
diarrhea	O
outbreaks	O
in	O
adult	O
cattle	O
were	O
positive	O
in	O
the	O
one	O
-	O
step	O
multiplex	O
RT	O
-	O
PCR	O
assay	O
.	O

It	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
TAZ	O
gene	O
coding	O
for	O
the	O
tafazzin	O
,	O
a	O
protein	B-CHED
involved	O
in	O
the	O
remodeling	O
of	O
cardiolipin	B-CHED
.	O

Loss	O
of	O
cardiolipin	B-CHED
in	O
the	O
inner	O
mitochondrial	O
membrane	O
results	O
in	O
respiratory	O
chain	O
dysfunction	O
.	O

TITLE	O
:	O
Biflavonoids	B-CHED
of	O
Dacrydium	O
balansae	O
with	O
potent	O
inhibitory	O
activity	O
on	O
dengue	O
2	O
NS5	O
polymerase	O
.	O

Four	O
biflavonoids	B-CHED
(	O
1	O
-	O
4	O
),	O
three	O
sterols	B-CHED
(	O
5	O
-	O
7	O
),	O
and	O
two	O
stilbene	B-CHED
derivatives	O
(	O
8	O
-	O
9	O
)	O
were	O
identified	O
and	O
evaluated	O
for	O
their	O
antiviral	B-CHED
potential	O
on	O
the	O
DV	O
-	O
NS5	O
RdRp	O
.	O

Biflavonoids	B-CHED
appeared	O
to	O
be	O
potent	O
inhibitors	B-CHED
of	O
DV	O
-	O
NS5	O
RdRp	O
with	O
IC	O
(	O
50	O
)	O
s	O
between	O
0	O
.	O
26	O
and	O
3	O
.	O
12	O
M	O
.	O
Inhibitory	O
activity	O
evaluations	O
against	O
the	O
RNA	O
polymerase	O
from	O
other	O
Flaviviridae	O
viruses	O
allowed	O
us	O
to	O
conclude	O
that	O
these	O
compounds	O
are	O
specific	O
inhibitors	B-CHED
of	O
the	O
DV	O
RNA	O
polymerase	O
.	O

Current	O
literature	O
in	O
the	O
PubMed	O
database	O
and	O
other	O
sources	O
was	O
reviewed	O
in	O
order	O
to	O
evaluate	O
the	O
current	O
treatment	O
recommendations	O
,	O
efficacy	O
of	O
this	O
treatment	O
,	O
and	O
finally	O
the	O
risk	O
of	O
complications	O
after	O
off	O
-	O
label	B-CHED
use	O
of	O
rFVIIa	O
in	O
respect	O
to	O
DAH	O
.	O

The	O
effects	O
of	O
DOX	O
on	O
ALI	O
were	O
determined	O
by	O
measuring	O
inflammation	O
,	O
capillary	O
leakage	O
,	O
and	O
MMP	B-CHED
activities	O
.	O

Although	O
without	O
statistical	O
significance	O
,	O
the	O
nonsurvivors	O
tended	O
to	O
have	O
lower	O
white	O
blood	O
cell	O
counts	O
,	O
higher	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
),	O
and	O
longer	O
pre	O
-	O
ECMO	O
intubation	O
time	O
.	O

TITLE	O
:	O
Replication	O
of	O
murine	O
coronavirus	O
requires	O
multiple	O
cysteines	O
in	O
the	O
endodomain	O
of	O
spike	O
protein	B-CHED
.	O

Common	O
genes	O
and	O
pathways	O
were	O
found	O
through	O
a	O
rigorous	O
,	O
iterative	O
analysis	O
pipeline	O
where	O
relevant	O
host	O
mRNA	B-CHED
expression	O
datasets	O
were	O
identified	O
,	O
analyzed	O
for	O
quality	O
and	O
gene	O
differential	O
expression	O
,	O
then	O
mapped	O
to	O
pathways	O
for	O
enrichment	O
analysis	O
.	O

We	O
suggest	O
five	O
new	O
therapeutic	O
indications	O
for	O
existing	O
small	O
molecules	O
or	O
biological	O
agents	O
targeting	O
proteins	B-CHED
encoded	O
by	O
the	O
genes	O
F3	O
,	O
IL1B	O
,	O
TNF	O
,	O
CASP1	O
and	O
MMP9	O
.	O

A	O
novel	O
potassium	B-CHED
channel	O
gene	O
KCTD9	O
was	O
highly	O
expressed	O
in	O
hepatic	O
NK	O
cells	O
and	O
T	O
cells	O
of	O
fulminant	O
hepatitis	O
mice	O
induced	O
by	O
MHV	O
-	O
3	O
.	O

In	O
the	O
absence	O
of	O
accurate	O
pneumonia	O
diagnostics	O
,	O
patients	O
hospitalized	O
with	O
suspected	O
influenza	O
and	O
lung	O
infiltrates	O
on	O
chest	O
radiography	O
should	O
receive	O
early	O
and	O
aggressive	O
treatment	O
with	O
antibiotics	B-CHED
and	O
influenza	O
antiviral	B-CHED
agents	I-CHED
.	O

Their	O
lethality	O
for	O
man	B-CHED
has	O
fostered	O
extensive	O
research	O
both	O
on	O
the	O
cellular	O
receptors	O
they	O
use	O
and	O
their	O
entry	O
pathways	O
.	O

A	O
prospective	O
observational	O
case	O
series	O
of	O
consenting	O
symptomatic	O
patients	O
with	O
acute	O
OP	O
poisoning	O
were	O
assessed	O
with	O
daily	O
physical	O
examinations	O
and	O
repetitive	O
nerve	O
stimulation	O
(	O
RNS	B-CHED
)	O
studies	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
quantify	O
CNS	B-CHED
and	O
muscarinic	O
dysfunction	O
to	O
assist	O
in	O
the	O
development	O
of	O
better	O
treatments	O
for	O
the	O
severe	O
and	O
early	O
OP	O
poisoning	O
.	O

TITLE	O
:	O
Proteomics	O
analysis	O
of	O
differentially	O
expressed	O
proteins	B-CHED
in	O
chicken	O
trachea	O
and	O
kidney	O
after	O
infection	O
with	O
the	O
highly	O
virulent	O
and	O
attenuated	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
in	O
vivo	O
.	O

Fifty	O
-	O
eight	O
differentially	O
expressed	O
proteins	B-CHED
were	O
identified	O
.	O

RESULTS	O
:	O
Fifty	O
-	O
eight	O
differentially	O
expressed	O
proteins	B-CHED
were	O
identified	O
.	O

All	O
broilers	O
in	O
the	O
dexamethasone	B-CHED
group	O
died	O
.	O

Anti	B-CHED
-	I-CHED
inflammatory	I-CHED
drugs	I-CHED
cannot	O
be	O
considered	O
as	O
an	O
alternative	O
for	O
antibiotic	B-CHED
treatment	O
.	O

This	O
syndrome	O
is	O
characterized	O
by	O
noncardiogenic	O
pulmonary	O
edema	O
,	O
diffuse	O
pulmonary	O
infiltrates	O
,	O
and	O
hypoxemia	O
refractory	O
to	O
oxygen	B-CHED
delivery	O
.	O

(	O
2	O
)	O
Heme	B-CHED
up	O
-	O
regulates	O
HO	O
-	O
1	O
and	O
CXCL10	O
production	O
through	O
STAT3	O
pathway	O
,	O
and	O
regulates	O
CXCL10	O
at	O
the	O
transcriptional	O
level	O
in	O
vitro	O
.	O

Simultaneous	O
treatment	O
of	O
the	O
cells	O
with	O
camostat	O
and	O
EST	O
[(	O
23	O
,	O
25	O
)	O
trans	O
-	O
epoxysuccinyl	O
-	O
L	O
-	O
leucylamindo	O
-	O
3	O
-	O
methylbutane	O
ethyl	B-CHED
ester	B-CHED
],	O
a	O
cathepsin	O
inhibitor	B-CHED
,	O
efficiently	O
prevented	O
both	O
cell	O
entry	O
and	O
the	O
multistep	O
growth	O
of	O
SARS	O
-	O
CoV	O
in	O
human	O
Calu	O
-	O
3	O
airway	O
epithelial	O
cells	O
.	O

Besides	O
the	O
use	O
of	O
low	O
tidal	O
volumes	O
,	O
the	O
most	O
beneficial	O
setting	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
has	O
been	O
in	O
the	O
focus	O
of	O
researchers	O
.	O

TITLE	O
:	O
Calreticulin	O
as	O
a	O
hydrophilic	O
chimeric	O
molecular	O
adjuvant	B-CHED
enhances	O
IgG	O
responses	O
to	O
the	O
spike	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

TITLE	O
:	O
Anti	O
-	O
HIV	O
-	O
1	O
activity	O
of	O
a	O
new	O
scorpion	O
venom	O
peptide	B-CHED
derivative	O
Kn2	O
-	O
7	O
.	O

In	O
the	O
absence	O
of	O
an	O
effective	O
vaccine	O
for	O
HIV	O
,	O
development	O
of	O
new	O
anti	B-CHED
-	I-CHED
HIV	I-CHED
agents	I-CHED
is	O
urgently	O
needed	O
.	O

In	O
conclusion	O
,	O
CsA	B-CHED
inhibited	O
FIPV	O
replication	O
in	O
vitro	O
and	O
further	O
studies	O
are	O
needed	O
to	O
verify	O
the	O
practical	O
value	O
of	O
CsA	B-CHED
as	O
an	O
anti	O
-	O
FIPV	O
treatment	O
in	O
vivo	O
.	O

Here	O
,	O
we	O
show	O
that	O
both	O
HAT	B-CHED
and	O
TMPRSS2	O
are	O
coexpressed	O
with	O
2	O
,	O
6	O
-	O
linked	O
sialic	B-CHED
acids	I-CHED
,	O
the	O
major	O
receptor	O
determinant	O
of	O
human	O
influenza	O
viruses	O
,	O
throughout	O
the	O
human	O
respiratory	O
tract	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
E	O
protein	B-CHED
is	O
a	O
small	O
membrane	O
protein	B-CHED
with	O
a	O
single	O
predicted	O
hydrophobic	O
domain	O
(	O
HD	O
),	O
and	O
has	O
a	O
poorly	O
defined	O
role	O
in	O
infection	O
.	O

TITLE	O
:	O
Identification	O
of	O
myricetin	B-CHED
and	O
scutellarein	B-CHED
as	O
novel	O
chemical	O
inhibitors	B-CHED
of	O
the	O
SARS	O
coronavirus	O
helicase	O
,	O
nsP13	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
myricetin	B-CHED
and	O
scutellarein	B-CHED
did	O
not	O
exhibit	O
cytotoxicity	O
against	O
normal	O
breast	O
epithelial	O
MCF10A	O
cells	O
.	O

ABSTRACT	O
:	O
Inoculation	O
of	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
JHMV	O
)	O
into	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
of	O
susceptible	O
strains	O
of	O
mice	O
results	O
in	O
wide	O
-	O
spread	O
replication	O
within	O
glial	O
cells	O
accompanied	O
by	O
infiltration	O
of	O
virus	O
-	O
specific	O
T	O
lymphocytes	O
that	O
control	O
virus	O
through	O
cytokine	O
secretion	O
and	O
cytolytic	O
activity	O
.	O

TITLE	O
:	O
Is	O
high	O
PEEP	B-CHED
ventilation	O
strategy	O
safe	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
after	O
severe	O
traumatic	O
brain	O
injury	O
?	O

The	O
goal	O
of	O
this	O
review	O
is	O
to	O
highlight	O
the	O
properties	O
and	O
functions	O
of	O
the	O
E	O
protein	B-CHED
,	O
and	O
speculate	O
on	O
how	O
they	O
may	O
be	O
related	O
.	O

The	O
coronavirus	O
spike	O
protein	B-CHED
and	O
acquisition	O
of	O
fusion	O
competence	O
.	O

Factor	O
VIII	O
(	O
FVIII	O
)	O
levels	O
were	O
very	O
low	O
and	O
evidence	O
of	O
FVIII	O
inhibitor	B-CHED
was	O
found	O
.	O

The	O
patient	O
was	O
treated	O
with	O
volume	O
expansion	O
therapy	O
,	O
high	O
levels	O
of	O
oxygen	B-CHED
,	O
multiple	O
transfusions	O
,	O
methylprednisolone	B-CHED
,	O
desmopressine	B-CHED
and	O
rituximab	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
series	O
of	O
3	O
-	O
hydroxyquinolin	O
-	O
2	O
(	O
1H	O
)-	O
ones	O
as	O
selective	O
inhibitors	B-CHED
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	O
associated	O
RNase	O
H	O
activity	O
.	O

Esters	B-CHED
and	O
amide	B-CHED
groups	O
were	O
introduced	O
at	O
position	O
4	O
of	O
the	O
basis	O
scaffold	O
and	O
some	O
modulations	O
of	O
the	O
benzenic	O
moiety	O
were	O
performed	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
partial	O
penton	O
nucleotide	B-CHED
confirmed	O
a	O
close	O
relationship	O
with	O
stains	O
circulating	O
in	O
the	O
Beijing	O
region	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
established	O
rOv	O
-	O
ASP	B-CHED
-	O
1	O
'	O
s	O
adjuvanticity	O
in	O
mice	O
during	O
the	O
course	O
of	O
two	O
sequential	O
vaccinations	O
using	O
two	O
vaccine	O
model	O
systems	O
:	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
and	O
a	O
commercial	O
influenza	O
virus	O
hemagglutinin	O
(	O
HA	O
)	O
vaccine	O
comprised	O
of	O
three	O
virus	O
strains	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
biochemical	O
and	O
biological	O
properties	O
of	O
nonstructural	O
protein	B-CHED
(	O
nsp	O
)	O
15	O
among	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
in	O
virus	O
-	O
infected	O
and	O
ectopically	O
expressed	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	B-CHED
,	O
containing	O
two	O
subunits	O
,	O
S1	O
and	O
S2	O
,	O
is	O
the	O
major	O
immunity	O
-	O
eliciting	O
antigen	B-CHED
of	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
a	O
highly	O
contagious	O
disease	O
of	O
chickens	O
.	O

Here	O
we	O
identify	O
the	O
complex	O
comprising	O
the	O
type	O
-	O
I	O
transmembrane	O
protein	B-CHED
SEL1L	O
and	O
the	O
cytosolic	O
protein	B-CHED
LC3	O
-	O
I	O
as	O
an	O
ERAD	O
tuning	O
receptor	O
regulating	O
the	O
COPII	O
-	O
independent	O
,	O
vesicle	O
-	O
mediated	O
removal	O
of	O
the	O
lumenal	O
ERAD	O
regulators	O
EDEM1	O
and	O
OS	O
-	O
9	O
from	O
the	O
ER	O
.	O

TITLE	O
:	O
RNA	O
3	O
'-	O
end	O
mismatch	O
excision	O
by	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nonstructural	O
protein	B-CHED
nsp10	O
/	O
nsp14	O
exoribonuclease	O
complex	O
.	O

BTLA	O
-	O
deficient	O
(	O
BTLA	O
-/-)	O
mice	O
and	O
their	O
wild	O
-	O
type	O
littermates	O
were	O
infected	O
with	O
murine	O
hepatitis	O
virus	O
strain	O
-	O
3	O
(	O
MHV	O
-	O
3	O
),	O
and	O
the	O
levels	O
of	O
tissue	O
damage	O
,	O
cell	O
apoptosis	O
,	O
serum	O
liver	O
enzymes	O
,	O
fibrinogen	O
-	O
like	O
protein	B-CHED
2	O
(	O
FGL2	O
)	O
and	O
cytokine	O
production	O
were	O
measured	O
and	O
compared	O
.	O

The	O
development	O
of	O
a	O
severe	O
and	O
acute	O
methemoglobinemia	O
following	O
the	O
administration	O
of	O
MCP	B-CHED
is	O
described	O
in	O
this	O
case	O
report	O
.	O

While	O
prolonged	O
corticosteroid	B-CHED
use	O
is	O
a	O
known	O
risk	O
factor	O
for	O
development	O
of	O
invasive	O
fungal	O
disease	O
,	O
the	O
authors	O
postulate	O
that	O
by	O
causing	O
immunologic	O
defects	O
and	O
FLAARDS	O
,	O
the	O
2009	O
-	O
pandemic	O
H1N1	O
virus	O
may	O
represent	O
an	O
additional	O
independent	O
risk	O
for	O
the	O
development	O
of	O
C	O
neoformans	O
meningitis	O
in	O
a	O
previously	O
healthy	O
individual	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
65	O
-	O
year	O
-	O
old	O
female	O
with	O
relapsed	O
ovarian	O
cancer	O
who	O
developed	O
a	O
severe	O
hypersensitivity	O
reaction	O
during	O
the	O
second	O
cycle	O
of	O
carboplatin	B-CHED
treatment	O
.	O

Alveolar	O
fluid	O
clearance	O
,	O
lung	O
water	B-CHED
,	O
and	O
lung	O
mechanics	O
were	O
measured	O
at	O
2	O
and	O
6	O
days	O
after	O
inoculation	O
in	O
live	O
,	O
ventilated	O
mice	O
by	O
BSA	O
instillation	O
,	O
magnetic	O
resonance	O
imaging	O
,	O
and	O
forced	O
-	O
oscillation	O
techniques	O
,	O
respectively	O
.	O

Nebulized	O
A77	O
-	O
1726	O
also	O
reversed	O
influenza	O
-	O
induced	O
increases	O
in	O
lung	O
water	B-CHED
content	O
and	O
volume	O
,	O
improved	O
pulmonary	O
mechanics	O
,	O
reduced	O
bronchoalveolar	O
lavage	O
fluid	O
ATP	B-CHED
and	O
neutrophil	O
content	O
,	O
and	O
increased	O
IL	O
-	O
6	O
concentrations	O
.	O

Two	O
molecules	O
were	O
found	O
in	O
the	O
asymmetric	O
unit	O
;	O
the	O
Matthews	O
coefficient	O
was	O
3	O
.	O
9	O
	O
(	O
3	O
)	O
Da	O
(-	O
1	O
),	O
corresponding	O
to	O
a	O
solvent	B-CHED
content	O
of	O
68	O
.	O
2	O
%.	O

Treatment	O
during	O
the	O
1960s	O
consisted	O
primarily	O
of	O
physiologic	O
saline	O
(	O
balanced	O
electrolyte	O
solution	O
[	O
BES	B-CHED
])	O
and	O
whole	O
blood	O
supported	O
with	O
sodium	B-CHED
bicarbonate	I-CHED
for	O
acidosis	O
.	O

The	O
decade	O
of	O
1970s	O
saw	O
the	O
implementation	O
of	O
component	O
therapy	O
by	O
the	O
American	O
Blood	O
Banking	O
Association	O
so	O
that	O
HS	O
was	O
treated	O
with	O
BES	B-CHED
and	O
packed	O
red	O
blood	O
cells	O
(	O
RBC	O
).	O

We	O
defined	O
influenza	O
as	O
unsuspected	O
if	O
testing	O
was	O
not	O
requested	O
and	O
the	O
patient	O
was	O
not	O
receiving	O
empirical	O
antiviral	B-CHED
therapy	O
after	O
sample	O
collection	O
.	O

However	O
,	O
the	O
quantitative	O
and	O
qualitative	O
measures	O
of	O
protein	B-CHED
intrinsic	O
disorder	O
in	O
species	O
with	O
known	O
genomes	O
are	O
still	O
not	O
available	O
.	O

TITLE	O
:	O
Spike	O
protein	B-CHED
fusion	O
peptide	B-CHED
and	O
feline	O
coronavirus	O
virulence	O
.	O

Culturing	O
the	O
virus	O
at	O
the	O
suboptimal	O
temperature	O
of	O
37	O
	O
C	O
resulted	O
in	O
low	O
replication	O
of	O
the	O
virus	O
and	O
the	O
effect	O
on	O
ACE2	O
expression	O
was	O
lost	B-CHED
.	O

Synthetic	O
macromolecules	B-CHED
have	O
changed	O
the	O
world	O
and	O
currently	O
play	O
a	O
major	O
role	O
in	O
all	O
aspects	O
of	O
daily	O
life	O
.	O

DNA	O
as	O
a	O
polymer	B-CHED
block	O
provides	O
several	O
advantages	O
over	O
other	O
biopolymers	B-CHED
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
replication	O
inhibitor	B-CHED
that	O
interferes	O
with	O
the	O
nucleic	B-CHED
acid	I-CHED
unwinding	O
of	O
the	O
viral	O
helicase	O
.	O

Hence	O
,	O
it	O
is	O
possible	O
that	O
SSYA10	O
-	O
001	O
inhibits	O
unwinding	O
by	O
nsp13	O
by	O
affecting	O
conformational	O
changes	O
during	O
the	O
course	O
of	O
the	O
reaction	O
or	O
translocation	O
on	O
the	O
nucleic	B-CHED
acid	I-CHED
.	O

SSYA10	O
-	O
001	O
will	O
be	O
a	O
valuable	O
tool	O
for	O
studying	O
the	O
specific	O
role	O
of	O
nsp13	O
in	O
the	O
SARS	O
-	O
CoV	O
life	O
cycle	O
,	O
which	O
could	O
be	O
a	O
model	O
for	O
other	O
nidoviruses	O
and	O
also	O
a	O
candidate	O
for	O
further	O
development	O
as	O
a	O
SARS	O
antiviral	B-CHED
target	O
.	O

The	O
mean	O
dose	O
of	O
polidocanol	B-CHED
used	O
for	O
balloon	O
-	O
occluded	O
retrograde	O
transvenous	O
obliteration	O
(	O
3	O
.	O
9	O
	O
1	O
.	O
5	O
mL	O
)	O
was	O
significantly	O
smaller	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
than	O
the	O
dose	O
of	O
contrast	O
medium	O
used	O
for	O
venography	O
(	O
16	O
.	O
4	O
	O
7	O
.	O
9	O
mL	O
).	O

He	O
recovered	O
after	O
clarithromycin	B-CHED
therapy	O
and	O
intensive	O
supportive	O
care	O
.	O

ABSTRACT	O
:	O
To	O
increase	O
immune	O
responses	O
of	O
plant	O
-	O
based	O
vaccines	O
in	O
intestine	O
mucosal	O
immune	O
systems	O
,	O
a	O
synthetic	O
neutralizing	O
epitope	B-CHED
(	O
sCOE	O
)	O
gene	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
was	O
fused	O
with	O
M	O
cell	O
-	O
targeting	O
ligand	B-CHED
(	O
Co1	O
)	O
and	O
introduced	O
into	O
a	O
plant	O
expression	O
vector	O
under	O
the	O
control	O
of	O
rice	O
amylase	O
3D	O
promoter	O
.	O

These	O
results	O
indicated	O
that	O
oral	O
immunization	O
of	O
plant	O
-	O
produced	O
COE	O
-	O
Co1	O
fusion	O
protein	B-CHED
could	O
elicit	O
efficient	O
systemic	O
and	O
mucosal	O
immune	O
responses	O
against	O
the	O
COE	O
antigen	B-CHED
.	O

Key	O
message	O
Neutralizing	O
epitope	B-CHED
from	O
porcine	O
epidemic	O
diarrhea	O
virus	O
-	O
M	O
cell	O
targeting	O
ligand	B-CHED
fusion	O
protein	B-CHED
was	O
produced	O
in	O
transgenic	O
rice	O
calli	O
and	O
elicited	O
systemic	O
and	O
mucosal	O
immune	O
responses	O
by	O
oral	O
administration	O
in	O
mice	O
.	O

Before	O
ECMO	O
,	O
patients	O
had	O
severe	O
respiratory	O
failure	O
despite	O
advanced	O
mechanical	O
ventilatory	O
support	O
with	O
a	O
mean	O
partial	O
pressure	O
of	O
arterial	O
oxygen	B-CHED
/	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
of	O
52	O
.	O
9	O
	O
5	O
.	O
1	O
(	O
45	O
.	O
0	O
-	O
63	O
.	O
8	O
)	O
mm	O
Hg	O
,	O
positive	O
end	O
-	O
expiratory	O
pressure	O
of	O
17	O
.	O
2	O
	O
4	O
.	O
2	O
cmH	B-CHED
(	O
2	O
)	O
O	O
,	O
and	O
a	O
Murray	O
Lung	O
Score	O
of	O
3	O
.	O
6	O
(	O
3	O
.	O
25	O
-	O
3	O
.	O
75	O
).	O

Two	O
hundred	O
and	O
three	O
patients	O
with	O
high	O
altitude	O
pulmonary	O
edema	O
(	O
HAPE	O
)	O
or	O
high	O
altitude	O
cerebral	O
edema	O
(	O
HACE	O
)	O
met	B-CHED
inclusion	O
criteria	O
were	O
included	O
,	O
and	O
were	O
randomly	O
divided	O
into	O
Bundle	O
treatment	O
group	O
(	O
n	O
=	O
125	O
)	O
and	O
conventional	O
treatment	O
control	O
group	O
(	O
n	O
=	O
78	O
).	O

Adoptive	O
transfer	O
of	O
TCR	O
(+)	O
DN	O
T	O
cells	O
led	O
to	O
dramatically	O
decreased	O
survival	O
in	O
MHV	O
-	O
3	O
-	O
infected	O
mice	O
,	O
accompanied	O
by	O
deteriorated	O
histopathology	O
and	O
elevated	O
ALT	B-CHED
and	O
AST	O
levels	O
.	O

ABSTRACT	O
:	O
Porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
is	O
not	O
only	O
a	O
poor	O
inducer	O
of	O
type	O
I	O
interferon	O
but	O
also	O
inhibits	O
the	O
efficient	O
induction	O
of	O
type	O
I	O
interferon	O
by	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
and	O
synthetic	O
dsRNA	B-CHED
molecules	O
,	O
Poly	O
I	O
:	O
C	O
.	O
However	O
,	O
the	O
mechanistic	O
basis	O
by	O
which	O
PRRSV	O
interferes	O
with	O
the	O
induction	O
of	O
type	O
I	O
interferon	O
in	O
its	O
natural	O
host	O
cells	O
remains	O
less	O
well	O
defined	O
.	O

Both	O
classes	O
inhibit	O
the	O
RT	O
-	O
associated	O
polymerase	O
activity	O
:	O
the	O
NRTIs	O
compete	O
with	O
the	O
natural	O
dNTP	B-CHED
substrate	O
and	O
act	O
as	O
chain	O
terminators	O
,	O
while	O
the	O
NNRTIs	O
bind	O
to	O
an	O
allosteric	O
pocket	O
and	O
inhibit	O
polymerization	O
noncompetitively	O
.	O

Using	O
a	O
consensus	O
process	O
,	O
a	O
panel	O
of	O
experts	O
convened	O
in	O
2011	O
(	O
an	O
initiative	O
of	O
the	O
European	O
Society	O
of	O
Intensive	O
Care	O
Medicine	B-CHED
endorsed	O
by	O
the	O
American	O
Thoracic	O
Society	O
and	O
the	O
Society	O
of	O
Critical	O
Care	O
Medicine	B-CHED
)	O
developed	O
the	O
Berlin	O
Definition	O
,	O
focusing	O
on	O
feasibility	O
,	O
reliability	O
,	O
validity	O
,	O
and	O
objective	O
evaluation	O
of	O
its	O
performance	O
.	O

CBP	O
adjuvant	B-CHED
treatment	O
for	O
ALI	O
/	O
ARDS	O
could	O
reduce	O
pulmonary	O
edema	O
,	O
improve	O
PaO2	O
/	O
FiO2	O
and	O
Cdyn	O
,	O
and	O
improve	O
mechanical	O
ventilation	O
parameters	O
.	O

CONCLUSIONS	O
:	O
CBP	O
adjuvant	B-CHED
treatment	O
for	O
ALI	O
/	O
ARDS	O
could	O
reduce	O
pulmonary	O
edema	O
,	O
improve	O
PaO2	O
/	O
FiO2	O
and	O
Cdyn	O
,	O
and	O
improve	O
mechanical	O
ventilation	O
parameters	O
.	O

This	O
study	O
focused	O
on	O
exploring	O
the	O
clinical	O
efficacy	O
of	O
exogenous	O
pulmonary	O
surfactant	B-CHED
in	O
treating	O
infant	O
patients	O
with	O
acute	O
lung	O
injury	O
after	O
cardiac	O
surgery	O
with	O
the	O
use	O
of	O
extracorporeal	O
circulation	O
.	O

Ten	O
infant	O
patients	O
in	O
the	O
treatment	O
group	O
were	O
given	O
pulmonary	O
surfactant	B-CHED
by	O
tracheal	O
instillation	O
during	O
mechanical	O
ventilating	O
postoperatively	O
.	O

Therapeutic	O
interventions	O
include	O
inotropic	O
support	O
(	O
21	O
%),	O
methylprednisolone	B-CHED
therapy	O
(	O
33	O
%),	O
and	O
antimicrobial	B-CHED
therapy	O
(	O
88	O
%).	O

This	O
review	O
discusses	O
coronavirus	O
entry	O
mechanisms	O
focusing	O
on	O
the	O
different	O
triggers	O
used	O
by	O
coronaviruses	O
to	O
initiate	O
the	O
conformational	O
change	O
of	O
the	O
S	O
protein	B-CHED
:	O
receptor	O
binding	O
,	O
low	O
pH	O
exposure	O
and	O
proteolytic	O
activation	O
.	O

The	O
results	O
of	O
the	O
study	O
suggest	O
that	O
zinc	B-CHED
salts	B-CHED
do	O
not	O
interfere	O
with	O
TGEV	O
-	O
cell	O
binding	O
but	O
that	O
they	O
mediate	O
antiviral	B-CHED
effects	O
through	O
inhibition	O
of	O
viral	O
penetration	O
or	O
egress	O
or	O
the	O
intracellular	O
phase	O
of	O
the	O
viral	O
life	O
-	O
cycle	O
.	O

Herein	O
we	O
have	O
used	O
a	O
novel	O
fusion	O
protein	B-CHED
consisting	O
of	O
a	O
modified	O
	O
-	O
barrel	O
to	O
purify	O
both	O
wild	O
type	O
and	O
cysteine	B-CHED
-	O
less	O
mutants	O
of	O
two	O
representatives	O
of	O
coronavirus	O
E	O
proteins	B-CHED
:	O
the	O
shortest	O
(	O
76	O
residues	O
),	O
from	O
SARS	O
-	O
CoV	O
E	O
,	O
and	O
one	O
of	O
the	O
longest	O
(	O
109	O
residues	O
),	O
from	O
the	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
E	O
).	O

The	O
fusion	O
construct	O
was	O
subsequently	O
cleaved	O
with	O
cyanogen	B-CHED
bromide	B-CHED
and	O
all	O
polypeptides	B-CHED
were	O
obtained	O
with	O
high	O
purity	O
.	O

On	O
the	O
treatment	O
topic	O
,	O
accumulating	O
evidence	O
suggesting	O
worse	O
outcomes	O
argues	O
against	O
the	O
use	O
of	O
corticosteroids	B-CHED
,	O
but	O
some	O
noninvasive	O
ventilating	O
modalities	O
require	O
further	O
assessment	O
.	O

Protein	B-CHED
6	O
immunoprecipitation	O
from	O
extracts	O
of	O
SARS	O
-	O
CoV	O
infected	O
cells	O
and	O
mass	O
spectrometry	O
analysis	O
revealed	O
an	O
interaction	O
of	O
viral	O
proteins	B-CHED
6	O
and	O
9b	O
in	O
biologically	O
relevant	O
conditions	O
.	O

Flow	O
cytometry	O
(	O
using	O
an	O
anti	O
-	O
feline	O
AGP	O
antibody	O
),	O
serum	O
protein	B-CHED
electrophoresis	O
,	O
routine	O
haematology	O
and	O
measurement	O
of	O
the	O
serum	O
AGP	O
concentration	O
were	O
performed	O
using	O
blood	O
samples	O
from	O
32	O
healthy	O
cats	O
(	O
19	O
FCoV	O
-	O
seropositive	O
),	O
13	O
cats	O
with	O
FIP	O
and	O
12	O
with	O
other	O
diseases	O
(	O
6	O
FCoV	O
-	O
seropositive	O
).	O

TITLE	O
:	O
Coronavirus	O
E	O
protein	B-CHED
forms	O
ion	O
channels	O
with	O
functionally	O
and	O
structurally	O
-	O
involved	O
membrane	O
lipids	B-CHED
.	O

The	O
ion	O
conductance	O
was	O
also	O
controlled	O
by	O
the	O
lipid	B-CHED
composition	O
of	O
the	O
membrane	O
.	O

The	O
prevalence	O
of	O
ROP	O
in	O
this	O
study	O
was	O
19	O
.	O
2	O
%;	O
low	O
gestational	O
age	O
,	O
sepsis	O
,	O
oxygen	B-CHED
therapy	O
,	O
and	O
frequent	O
blood	O
transfusions	O
were	O
significant	O
risk	O
factors	O
for	O
ROP	O
.	O

Gestational	O
age	O
,	O
sepsis	O
,	O
oxygen	B-CHED
therapy	O
,	O
and	O
frequency	O
of	O
blood	O
transfusions	O
remained	O
significant	O
variables	O
after	O
logistic	O
regression	O
analysis	O
.	O

CONCLUSIONS	O
:	O
The	O
prevalence	O
of	O
ROP	O
in	O
this	O
study	O
was	O
19	O
.	O
2	O
%;	O
low	O
gestational	O
age	O
,	O
sepsis	O
,	O
oxygen	B-CHED
therapy	O
,	O
and	O
frequent	O
blood	O
transfusions	O
were	O
significant	O
risk	O
factors	O
for	O
ROP	O
.	O

ABSTRACT	O
:	O
Paediatric	O
infectious	O
diseases	O
have	O
been	O
reported	O
since	O
Hippocrates	O
,	O
and	O
were	O
always	O
closely	O
linked	O
with	O
the	O
evolution	O
of	O
medicine	B-CHED
.	O

Impaired	O
gas	O
exchange	O
in	O
influenza	O
-	O
infected	O
mice	O
was	O
accompanied	O
by	O
progressive	O
hemoglobin	B-CHED
desaturation	O
,	O
hypercapnia	O
,	O
uncompensated	O
respiratory	O
acidosis	O
,	O
hyperkalemia	O
,	O
and	O
polycythemia	O
.	O

TITLE	O
:	O
Structural	O
bases	B-CHED
of	O
coronavirus	O
attachment	O
to	O
host	O
aminopeptidase	O
N	O
and	O
its	O
inhibition	O
by	O
neutralizing	O
antibodies	O
.	O

The	O
data	O
provide	O
detailed	O
information	O
on	O
the	O
architecture	O
of	O
the	O
dimeric	O
pAPN	O
ectodomain	O
and	O
its	O
interaction	O
with	O
the	O
CoV	O
S	O
.	O
We	O
show	O
that	O
a	O
protruding	O
receptor	O
-	O
binding	O
edge	O
in	O
the	O
S	O
determines	O
virus	O
-	O
binding	O
specificity	O
for	O
recessed	O
glycan	B-CHED
-	O
containing	O
surfaces	O
in	O
the	O
membrane	O
-	O
distal	O
region	O
of	O
the	O
pAPN	O
ectodomain	O
.	O

Influenza	O
virus	O
infection	O
is	O
treated	O
worldwide	O
mainly	O
by	O
neuraminidase	B-CHED
inhibitors	I-CHED
(	O
NAIs	O
).	O

Combination	O
therapy	O
of	O
laninamivir	O
octanoate	B-CHED
with	O
artificial	O
surfactant	B-CHED
reduces	O
lethality	O
in	O
mice	O
infected	O
with	O
influenza	O
virus	O
,	O
and	O
eventually	O
suppresses	O
DAD	O
formation	O
and	O
preserves	O
lung	O
function	O
.	O

TITLE	O
:	O
Tanshinones	O
as	O
selective	O
and	O
slow	O
-	O
binding	O
inhibitors	B-CHED
for	O
SARS	O
-	O
CoV	O
cysteine	B-CHED
proteases	O
.	O

A	O
literature	O
search	O
for	O
studies	O
involving	O
the	O
seven	O
isolated	O
tanshinone	O
hits	O
showed	O
that	O
at	O
present	O
,	O
none	O
have	O
been	O
identified	O
as	O
coronaviral	O
protease	B-CHED
inhibitors	I-CHED
.	O

We	O
have	O
identified	O
that	O
all	O
of	O
the	O
isolated	O
tanshinones	O
are	O
good	O
inhibitors	B-CHED
of	O
both	O
cysteine	B-CHED
proteases	O
.	O

There	O
was	O
a	O
close	O
correlation	O
between	O
hepatic	O
or	O
serum	O
IL	O
-	O
17	O
concentration	O
and	O
the	O
severity	O
of	O
liver	O
injury	O
defined	O
by	O
ALT	B-CHED
level	O
,	O
respectively	O
.	O

Possible	O
implications	O
concerning	O
the	O
mechanism	O
of	O
function	O
of	O
the	O
viral	O
proteins	B-CHED
are	O
discussed	O
.	O

Enhanced	O
ERAD	O
activity	O
may	O
interfere	O
with	O
protein	B-CHED
biogenesis	O
by	O
inappropriately	O
targeting	O
not	O
-	O
yet	O
-	O
native	O
protein	B-CHED
folding	O
intermediates	O
for	O
disposal	O
.	O

ABSTRACT	O
:	O
Clara	O
cell	O
protein	B-CHED
16	O
(	O
CC16	O
)	O
has	O
recently	O
gained	O
acceptance	O
as	O
a	O
blood	O
biomarker	B-CHED
for	O
detecting	O
direct	O
and	O
indirect	O
lung	O
injury	O
.	O

Calnexin	O
bound	O
to	O
most	O
truncated	O
mutants	O
of	O
S	O
protein	B-CHED
,	O
and	O
S	O
protein	B-CHED
bound	O
to	O
all	O
mutants	O
of	O
calnexin	O
.	O

In	O
S	O
-	O
pseudovirus	O
,	O
the	O
incorporation	O
of	O
S	O
protein	B-CHED
into	O
viral	O
particles	O
was	O
obviously	O
inhibited	O
.	O

Coronaviruses	O
have	O
several	O
to	O
more	O
than	O
10	O
different	O
species	O
of	O
subgenomic	O
mRNA	B-CHED
and	O
generally	O
only	O
the	O
OFR	O
located	O
in	O
the	O
5	O
'	O
end	O
of	O
each	O
mRNA	B-CHED
is	O
translated	O
.	O

Those	O
proteins	B-CHED
assemble	O
to	O
the	O
vesicles	O
located	O
from	O
ER	O
to	O
Golgi	O
(	O
ER	O
Golgi	O
intermediate	O
compartment	O
)	O
and	O
virions	O
bud	O
into	O
the	O
vesicles	O
.	O

An	O
immunochromatographic	O
strip	O
was	O
developed	O
for	O
the	O
detection	O
of	O
PHE	B-CHED
-	O
CoV	O
.	O
The	O
colloidal	B-CHED
gold	I-CHED
-	O
labeled	O
MAb	O
4D4	O
was	O
used	O
as	O
the	O
detection	O
reagent	B-CHED
,	O
and	O
the	O
MAb	O
1E2	O
and	O
goat	O
anti	O
-	O
mouse	O
IgG	O
coated	O
the	O
strip	O
'	O
s	O
test	O
and	O
control	O
lines	O
,	O
respectively	O
.	O

Based	O
on	O
its	O
high	O
specificity	O
,	O
sensitivity	O
,	O
and	O
stability	O
,	O
the	O
immunochromatographic	O
strip	O
would	O
be	O
suitable	O
for	O
on	O
-	O
site	O
detection	O
of	O
PHE	B-CHED
-	O
CoV	O
for	O
surveillance	O
and	O
epidemiological	O
purposes	O
.	O

TITLE	O
:	O
Moutan	O
cortex	O
radicis	O
improves	O
lipopolysaccharide	B-CHED
-	O
induced	O
acute	O
lung	O
injury	O
in	O
rats	O
through	O
anti	O
-	O
inflammation	O
.	O

Furthermore	O
,	O
leukocyte	O
infiltration	O
and	O
protein	B-CHED
exudation	O
in	O
the	O
alveolar	O
space	O
were	O
less	O
severe	O
in	O
the	O
MCR	O
-	O
LPS	B-CHED
group	O
than	O
in	O
the	O
LPS	B-CHED
group	O
.	O

A	O
minimum	O
level	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
and	O
mutually	O
exclusive	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
thresholds	O
were	O
chosen	O
for	O
the	O
different	O
levels	O
of	O
ARDS	O
severity	O
(	O
mild	O
,	O
moderate	O
,	O
severe	O
)	O
to	O
better	O
categorize	O
patients	O
with	O
different	O
outcomes	O
and	O
potential	O
responses	O
to	O
therapy	O
.	O

TITLE	O
:	O
Foldon	O
unfolding	O
mediates	O
the	O
interconversion	O
between	O
M	O
(	O
pro	B-CHED
)-	O
C	O
monomer	O
and	O
3D	O
domain	O
-	O
swapped	O
dimer	O
.	O

RESULTS	O
:	O
The	O
levels	O
of	O
creatine	B-CHED
kinase	O
(	O
CK	O
),	O
creatine	B-CHED
kinase	O
-	O
MB	O
(	O
CK	O
-	O
MB	O
)	O
and	O
cardiac	O
troponin	O
I	O
(	O
cTnI	O
)	O
in	O
milder	O
,	O
moderate	O
and	O
severe	O
poisoning	O
groups	O
were	O
significantly	O
elevated	O
compared	O
by	O
the	O
healthy	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Proteomic	O
analysis	O
,	O
Western	O
blot	O
,	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O
assays	O
indicated	O
PLpro	O
upregulating	O
TGF	O
-	O
1	O
-	O
associated	O
genes	O
:	O
HSP27	O
,	O
protein	B-CHED
disulfide	I-CHED
isomerase	O
A3	O
precursor	O
,	O
glial	O
fibrillary	O
acidic	O
protein	B-CHED
,	O
vimentin	O
,	O
retinal	B-CHED
dehydrogenase	O
2	O
,	O
and	O
glutathione	B-CHED
transferase	O
omega	O
-	O
1	O
.	O

Accordingly	O
,	O
a	O
global	O
movement	O
of	O
'	O
One	O
-	O
Health	O
/	O
One	O
-	O
Medicine	B-CHED
'	O
has	O
been	O
launched	O
to	O
foster	O
collaborative	O
efforts	O
amongst	O
animal	O
and	O
human	O
health	O
officials	O
and	O
researchers	O
to	O
address	O
these	O
problems	O
.	O

However	O
,	O
traditional	O
viral	O
detection	O
methods	O
rely	O
on	O
prior	O
sequence	O
or	O
antigen	B-CHED
knowledge	O
.	O

Moreover	O
,	O
Y367	O
,	O
S370	O
,	O
and	O
L374	O
are	O
anchors	O
in	O
the	O
epitope	B-CHED
,	O
while	O
C366	O
,	O
G368	O
,	O
V369	O
,	O
A371	O
,	O
T372	O
,	O
and	O
K373	O
may	O
directly	O
interact	O
with	O
TCR	O
on	O
the	O
surface	O
of	O
CD8	O
-	O
T	O
cells	O
.	O

Upper	O
respiratory	O
tract	O
infection	O
preceded	O
HSP	B-CHED
in	O
over	O
half	O
of	O
the	O
patients	O
and	O
antistreptolyzin	O
O	O
(	O
ASO	B-CHED
)	O
titer	O
was	O
positive	O
in	O
11	O
of	O
the	O
24	O
(	O
46	O
%)	O
children	O
tested	O
at	O
presentation	O
.	O

Daily	O
fluid	O
output	O
of	O
patients	O
showed	O
a	O
tendency	O
of	O
increase	O
in	O
both	O
groups	O
from	O
PBD	B-CHED
3	O
to	O
10	O
.	O

We	O
have	O
used	O
the	O
JHMV	O
-	O
induced	O
demyelination	O
model	O
to	O
evaluate	O
the	O
antigenicity	O
of	O
transplanted	O
allogeneic	O
NPCs	O
within	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
of	O
mice	O
with	O
established	O
immune	O
-	O
mediated	O
demyelination	O
.	O

ABSTRACT	O
:	O
Pulmonary	O
surfactant	B-CHED
(	O
PS	O
)	O
administration	O
has	O
been	O
attempted	O
for	O
the	O
treatment	O
of	O
adults	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

Animals	O
treated	O
with	O
air	B-CHED
-	O
PS	O
for	O
20	O
minutes	O
had	O
significantly	O
improved	O
lung	O
function	O
,	O
reduced	O
pulmonary	O
edema	O
,	O
decreased	O
concentration	O
of	O
total	O
protein	B-CHED
and	O
proinflammatory	O
cytokines	O
in	O
BALF	O
,	O
ameliorated	O
lung	O
injury	O
,	O
and	O
improved	O
animal	O
survival	O
.	O

In	O
the	O
O2	O
-	O
PS	O
-	O
Dex	O
group	O
,	O
lung	O
edema	O
,	O
total	O
protein	B-CHED
,	O
and	O
inflammatory	O
cytokines	O
in	O
BALF	O
were	O
significantly	O
reduced	O
in	O
comparison	O
with	O
the	O
O2	O
-	O
PS	O
group	O
.	O

In	O
fact	O
,	O
stress	O
in	O
children	O
has	O
been	O
reported	O
to	O
increase	O
corticosteroid	B-CHED
levels	O
.	O

The	O
6x	O
His	O
-	O
tagged	O
N	O
protein	B-CHED
was	O
used	O
as	O
antigen	B-CHED
for	O
ELISA	O
assay	O
and	O
evaluated	O
for	O
the	O
serum	O
samples	O
from	O
patients	O
with	O
SARS	O
positive	O
and	O
the	O
plasma	O
samples	O
from	O
the	O
HIV	O
-	O
1	O
positive	O
and	O
negative	O
IDUs	O
.	O

the	O
specificity	O
of	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
-	O
based	O
IgG	O
ELISA	O
assay	O
for	O
the	O
detection	O
of	O
the	O
SARS	O
-	O
CoV	O
N	O
specific	O
IgG	O
in	O
plasma	O
samples	O
from	O
IDUs	O
with	O
HIV	O
-	O
1	O
positive	O
is	O
,	O
therefore	O
,	O
questionable	O
.	O

All	O
urinary	O
samples	O
were	O
negative	O
for	O
FCV	B-CHED
and	O
FCoV	O
.	O
One	O
(	O
1	O
%)	O
of	O
the	O
FLUTD	O
cats	O
was	O
found	O
to	O
be	O
positive	O
for	O
FHV	O
-	O
1	O
.	O

The	O
leucine	B-CHED
-	O
rich	O
repeat	O
regions	O
in	O
Massachusetts	O
strains	O
consisted	O
of	O
stretches	O
of	O
63	O
to	O
69	O
amino	B-CHED
acids	I-CHED
,	O
while	O
in	O
the	O
QX	O
-	O
like	O
strains	O
they	O
contained	O
59	O
amino	B-CHED
acids	I-CHED
in	O
length	O
.	O

immunization	O
induced	O
antigen	B-CHED
-	O
specific	O
CD8	O
+	O
T	O
cell	O
responses	O
in	O
the	O
lungs	O
that	O
are	O
superior	O
to	O
those	O
induced	O
by	O
intramuscular	O
immunization	O
.	O

The	O
homogeneity	O
of	O
coronavirus	O
NL63	O
with	O
those	O
published	O
in	O
the	O
GenBank	O
at	O
nucleotide	B-CHED
levels	O
was	O
97	O
%-	O
100	O
%.	O

Treatment	O
with	O
inhaled	O
epoprostenol	B-CHED
improved	O
gas	O
exchange	O
in	O
severely	O
hypoxemic	O
surgical	O
patients	O
.	O

In	O
penehyclidine	O
hydrochloride	B-CHED
sequential	O
to	O
atropine	B-CHED
group	O
,	O
except	O
for	O
1	O
case	O
of	O
cancer	O
of	O
gastric	O
cardia	O
with	O
poisoning	O
after	O
operation	O
showing	O
intermediate	O
syndrome	O
of	O
poisoning	O
,	O
the	O
remaining	O
patients	O
did	O
not	O
have	O
any	O
complication	O
,	O
and	O
the	O
incidence	O
of	O
complications	O
was	O
1	O
.	O
67	O
.	O
No	O
death	O
occurred	O
in	O
all	O
the	O
patients	O
,	O
and	O
the	O
cure	O
rate	O
was	O
100	O
.	O
00	O
.	O
Time	O
of	O
recovery	O
from	O
ChE	O
activity	O
to	O
70	O
	O
was	O

Vaccination	O
of	O
specific	O
-	O
pathogen	O
-	O
free	O
chickens	O
with	O
the	O
F	O
-	O
strain	O
MG	O
vaccine	O
completely	O
protected	O
them	O
against	O
the	O
effects	O
of	O
MG	O
intratracheal	O
infectious	O
challenge	O
,	O
as	O
evidenced	O
by	O
a	O
lack	O
of	O
significant	O
difference	O
in	O
air	B-CHED
sac	O
and	O
tracheal	O
lesion	O
scores	O
and	O
tracheal	O
mucosal	O
thickness	O
with	O
those	O
of	O
unchallenged	O
media	O
control	O
chickens	O
.	O

One	O
hybridoma	O
cell	O
line	O
secreting	O
anti	O
-	O
M	O
protein	B-CHED
monoclonal	O
antibody	O
(	O
McAb	O
)	O
was	O
generated	O
and	O
designated	O
4D4	O
.	O

The	O
motif	O
195WAFYVR200	O
was	O
the	O
minimal	O
requirement	O
for	O
reactivity	O
,	O
as	O
demonstrated	O
by	O
removing	O
amino	B-CHED
acids	I-CHED
individually	O
from	O
both	O
ends	O
of	O
the	O
motif	O
193TGWAFYVR200	O
.	O

The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
state	O
of	O
the	O
evidence	O
concerning	O
the	O
willingness	O
of	O
HCP	B-CHED
to	O
work	O
during	O
an	O
influenza	O
public	O
health	O
emergency	O
,	O
to	O
identify	O
the	O
gaps	O
for	O
future	O
investigation	O
,	O
and	O
to	O
facilitate	O
evidence	O
-	O
based	O
influenza	O
public	O
health	O
emergency	O
planning	O
.	O

Factors	O
associated	O
with	O
a	O
willingness	O
to	O
work	O
during	O
an	O
influenza	O
public	O
health	O
emergency	O
include	O
:	O
being	O
male	O
,	O
being	O
a	O
doctor	O
or	O
nurse	O
,	O
working	O
in	O
a	O
clinical	O
or	O
emergency	O
department	O
,	O
working	O
full	O
-	O
time	O
,	O
prior	O
influenza	O
education	O
and	O
training	O
,	O
prior	O
experience	O
working	O
during	O
an	O
influenza	O
emergency	O
,	O
the	O
perception	O
of	O
value	O
in	O
response	O
,	O
the	O
belief	O
in	O
duty	O
,	O
the	O
availability	O
of	O
personal	O
protective	O
equipment	O
(	O
PPE	B-CHED
),	O
and	O
confidence	O
in	O
one	O
'	O
s	O
employer	O
.	O

Interventions	O
that	O
resulted	O
in	O
the	O
greatest	O
increase	O
in	O
the	O
HCP	B-CHED
'	O
s	O
willingness	O
to	O
work	O
were	O
preferential	O
access	O
to	O
Tamiflu	B-CHED
for	O
the	O
HCP	B-CHED
and	O
his	O
/	O
her	O
family	O
,	O
and	O
the	O
provision	O
of	O
a	O
vaccine	O
for	O
the	O
individual	O
and	O
his	O
/	O
her	O
family	O
.	O

Three	O
pharmacologic	O
treatment	O
strategies	O
are	O
reviewed	O
in	O
detail	O
:	O
corticosteroids	B-CHED
,	O
fluid	O
management	O
,	O
and	O
neuromuscular	O
blocking	O
agents	O
.	O

Further	O
,	O
in	O
accordance	O
with	O
Executive	O
Order	O
13546	O
,	O
""""	O
Optimizing	O
the	O
Security	O
of	O
Biological	O
Select	O
Agents	O
and	O
Toxins	B-CHED
in	O
the	O
United	O
States	O
","""	O
HHS	O
/	O
CDC	O
has	O
designated	O
those	O
select	O
agents	O
and	O
toxins	B-CHED
that	O
present	O
the	O
greatest	O
risk	O
of	O
deliberate	O
misuse	O
with	O
the	O
most	O
significant	O
potential	O
for	O
mass	O
casualties	O
or	O
devastating	O
effects	O
to	O
the	O
economy	O
,	O
critical	O
infrastructure	O
;	O
or	O
public	O
confidence	O
as	O
""""	O
Tier	O
1	O
""""	O
agents	O
;	O
established	O
new	O
security	O
requirements	O
for	O
entities	O
possessing	O
Tier	O
1	O
agents	O
,	O
including	O
the	O
requirement	O
to	O
conduct	O
pre	O
-	O
access	O
assessments	O
and	O
on	O
-	O
going	O
monitoring	O
of	O
personnel	O
with	O
access	O
to	O
Tier	O
1	O
agents	O
and	O
toxins	B-CHED
;	O
and	O
made	O
revisions	O
to	O
the	O
regulations	O
to	O
clarify	O
regulatory	O
language	O
concerning	O
security	O
,	O
training	O
,	O
biosafety	O
,	O
and	O
incident	O
response	O
.	O

High	O
prevalence	O
of	O
viral	O
agents	O
and	O
parasites	O
such	O
as	O
CDV	B-CHED
,	O
CPV	O
,	O
and	O
Ancylostomidae	O
indicates	O
that	O
this	O
population	O
faces	O
considerable	O
risk	O
of	O
outbreaks	O
and	O
chronic	O
debilitating	O
parasites	O
.	O

APN	O
is	O
a	O
cell	O
surface	O
-	O
anchored	O
and	O
seahorse	O
-	O
shaped	O
zinc	B-CHED
-	O
aminopeptidase	O
that	O
forms	O
head	O
-	O
to	O
-	O
head	O
dimers	O
.	O

As	O
a	O
bridge	O
to	O
recovery	O
after	O
LTx	O
-	O
used	O
as	O
lung	O
support	O
for	O
patients	O
with	O
PGD	B-CHED
or	O
severe	O
hypoxemia	O
.	O

TITLE	O
:	O
Air	B-CHED
cleaning	O
technologies	O
:	O
an	O
evidence	O
-	O
based	O
analysis	O
.	O

However	O
,	O
general	O
wear	O
and	O
tear	O
over	O
time	O
may	O
compromise	O
the	O
HVAC	O
system	O
'	O
s	O
effectiveness	O
to	O
maintain	O
adequate	O
indoor	O
air	B-CHED
quality	O
.	O

There	O
are	O
many	O
types	O
of	O
in	O
-	O
room	O
air	B-CHED
cleaners	O
.	O

The	O
ion	O
generator	O
uses	O
an	O
alternating	O
plasma	O
discharge	O
to	O
split	O
water	B-CHED
molecules	O
into	O
positively	O
and	O
negatively	O
charged	O
ions	B-CHED
.	O

TITLE	O
:	O
Isolation	O
of	O
a	O
novel	O
coronavirus	O
from	O
a	O
man	B-CHED
with	O
pneumonia	O
in	O
Saudi	O
Arabia	O
.	O

We	O
recently	O
determined	O
the	O
crystal	O
structure	O
of	O
MHV	O
NTD	O
complexed	O
with	O
its	O
protein	B-CHED
receptor	O
murine	O
carcinoembryonic	O
antigen	B-CHED
-	O
related	O
cell	O
adhesion	O
molecule	O
1	O
(	O
CEACAM1	O
),	O
which	O
surprisingly	O
revealed	O
a	O
human	O
galectin	O
(	O
galactose	B-CHED
-	O
binding	O
lectin	O
)	O
fold	O
in	O
MHV	O
NTD	O
.	O

Perspective	O
of	O
dual	O
inhibitors	B-CHED
.	O

DAMPs	O
can	O
function	O
as	O
either	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
agonists	B-CHED
or	O
antagonists	B-CHED
,	O
and	O
can	O
modulate	O
both	O
TLR	O
and	O
nod	O
-	O
like	O
receptor	O
(	O
NLR	O
)	O
signalling	O
cascades	O
.	O

ABSTRACT	O
:	O
In	O
patients	O
with	O
the	O
most	O
severe	O
forms	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
refractory	O
to	O
conventional	O
mechanical	O
ventilation	O
and	O
adjunctive	O
or	O
rescue	O
therapies	O
like	O
kinetic	O
therapy	O
,	O
inhaled	O
vasodilators	O
or	O
extracorporeal	O
CO2	B-CHED
-	O
elimination	O
(	O
extracorporeal	O
lung	O
assist	O
),	O
the	O
use	O
of	O
the	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
can	O
secure	O
gas	O
exchange	O
.	O

TITLE	O
:	O
Understanding	O
Viral	O
Transmission	O
Behavior	O
via	O
Protein	B-CHED
Intrinsic	O
Disorder	O
Prediction	O
:	O
Coronaviruses	O
.	O

Sequence	O
and	O
phylogenetic	O
analyses	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
spike	O
protein	B-CHED
gene	O
showed	O
that	O
pantropic	O
CCoV	O
strains	O
are	O
closely	O
related	O
to	O
each	O
other	O
,	O
with	O
the	O
exception	O
of	O
two	O
divergent	O
French	O
viruses	O
that	O
clustered	O
with	O
enteric	O
strains	O
.	O

In	O
October	O
2011	O
,	O
Xigris	O
(	O
drotrecogin	O
alfa	O
,	O
a	O
recombinant	O
activated	O
protein	B-CHED
C	O
)	O
was	O
withdrawn	O
from	O
the	O
market	O
following	O
the	O
failure	O
of	O
its	O
worldwide	O
trial	O
that	O
had	O
attempted	O
to	O
demonstrate	O
improved	O
outcome	O
.	O

We	O
found	O
that	O
polyclonal	O
antibodies	O
derived	O
from	O
transmissible	O
gastroenteritis	O
coronavirus	O
HR2	O
and	O
upstream	O
region	O
were	O
cross	O
-	O
reactive	O
with	O
the	O
S	O
proteins	B-CHED
of	O
the	O
same	O
serogroup	O
in	O
western	O
blotting	O
.	O

Sixteen	O
naturally	O
infected	O
FIV	O
/	O
FeLV	O
cats	O
were	O
followed	O
during	O
rFeIFN	O
therapy	O
in	O
order	O
to	O
monitor	O
clinical	O
signs	O
and	O
to	O
correlate	O
with	O
excretion	O
of	O
concomitant	O
viruses	O
(	O
FCV	B-CHED
,	O
FHV	O
-	O
1	O
,	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
and	O
parvovirus	O
(	O
FPV	O
)).	O

The	O
13	O
FCV	B-CHED
positive	O
cats	O
and	O
the	O
FPV	O
positive	O
cat	O
were	O
negative	O
on	O
D65	O
.	O

TITLE	O
:	O
Formic	B-CHED
acid	I-CHED
poisoning	O
in	O
a	O
tertiary	O
care	O
center	O
in	O
South	O
India	O
:	O
A	O
2	O
-	O
year	O
retrospective	O
analysis	O
of	O
clinical	O
profile	O
and	O
predictors	O
of	O
mortality	O
.	O

TITLE	O
:	O
Expected	O
and	O
observed	O
mortality	O
in	O
critically	O
ill	O
patients	O
receiving	O
initial	O
antibiotic	B-CHED
therapy	O
.	O

TITLE	O
:	O
Biogenesis	O
of	O
the	O
vaccinia	O
virus	O
membrane	O
:	O
genetic	O
and	O
ultrastructural	O
analysis	O
of	O
the	O
contributions	O
of	O
the	O
A14	O
and	O
A17	O
proteins	B-CHED
.	O

When	O
the	O
proteins	B-CHED
are	O
induced	O
at	O
12	O
h	O
postinfection	O
(	O
hpi	O
),	O
crescents	O
appear	O
at	O
the	O
periphery	O
of	O
the	O
electron	O
-	O
dense	O
virosomes	O
,	O
with	O
the	O
accumulated	O
vesicles	O
likely	O
contributing	O
to	O
their	O
formation	O
.	O

In	O
vivo	O
,	O
the	O
biological	O
competency	O
of	O
A17	O
was	O
reduced	O
by	O
mutations	O
that	O
prevented	O
its	O
serine	B-CHED
-	O
threonine	B-CHED
phosphorylation	O
and	O
restored	O
by	O
phosphomimetic	O
substitutions	O
.	O

ABSTRACT	O
:	O
Nonstructural	O
protein	B-CHED
(	O
nsp	O
)	O
3	O
is	O
the	O
largest	O
of	O
16	O
nsps	O
translated	O
from	O
the	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
genome	O
.	O

The	O
N	O
-	O
terminal	O
most	O
domain	O
of	O
nsp3	O
,	O
nsp3a	O
,	O
has	O
been	O
identified	O
by	O
reverse	O
genetics	O
as	O
a	O
likely	O
binding	O
partner	O
of	O
MHV	O
nucleocapsid	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Patients	O
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
after	O
infection	O
with	O
severe	O
respiratory	O
viruses	O
(	O
e	O
.	O
g	O
.,	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
,	O
H5N1	O
avian	O
influenza	O
virus	O
),	O
exhibited	O
unusually	O
high	O
levels	O
of	O
CXCL10	O
,	O
which	O
belongs	O
to	O
the	O
non	O
-	O
ELR	O
(	O
glutamic	O
-	O
leucine	B-CHED
-	O
arginine	B-CHED
)	O
CXC	O
chemokine	O
superfamily	O
.	O

TITLE	O
:	O
Construction	O
of	O
recombinant	O
lactobacilli	O
expressing	O
the	O
core	O
neutralizing	O
epitope	B-CHED
(	O
COE	B-CHED
)	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
and	O
a	O
fusion	O
protein	B-CHED
consisting	O
of	O
COE	B-CHED
and	O
Escherichia	O
coli	O
heat	O
-	O
labile	O
enterotoxin	O
B	O
,	O
and	O
comparison	O
of	O
the	O
immune	O
responses	O
by	O
orogastric	O
immunization	O
.	O

ABSTRACT	O
:	O
The	O
core	O
neutralizing	O
epitope	B-CHED
(	O
COE	O
)	O
region	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
the	O
subunit	O
vaccine	O
against	O
PEDV	O
infection	O
.	O

Ochroconis	O
gallopavum	O
is	O
a	O
neurotropic	O
dematiaceous	O
mold	B-CHED
responsible	O
for	O
life	O
-	O
threatening	O
respiratory	O
and	O
central	O
nervous	O
system	O
infections	O
in	O
domestic	O
poultry	O
and	O
in	O
immunologically	O
compromised	O
humans	O
.	O

A	O
69	O
-	O
year	O
-	O
old	O
white	O
man	B-CHED
with	O
a	O
history	O
of	O
bilateral	O
lung	O
transplantation	O
6	O
years	O
ago	O
presented	O
with	O
acute	O
onset	O
of	O
severe	O
respiratory	O
distress	O
.	O

Additional	O
intravenous	O
therapy	O
with	O
tobramycin	B-CHED
and	O
imipenem	B-CHED
was	O
started	O
upon	O
detection	O
of	O
Enterobacter	O
clocae	O
and	O
Enterococci	O
in	O
the	O
sputum	O
.	O

By	O
multivariate	O
analysis	O
,	O
increasing	O
values	O
of	O
age	O
,	O
lactate	B-CHED
,	O
and	O
plateau	O
pressure	O
under	O
ECMO	O
were	O
associated	O
with	O
death	O
.	O

ABSTRACT	O
:	O
The	O
need	O
for	O
the	O
timely	O
collection	O
of	O
diagnostic	O
biosamples	O
during	O
symptomatic	O
episodes	O
represents	O
a	O
major	O
obstacle	O
to	O
large	O
-	O
scale	O
studies	O
on	O
acute	O
respiratory	O
infection	O
(	O
ARI	B-CHED
)	O
epidemiology	O
.	O

The	O
patient	O
had	O
normal	O
values	O
of	O
arterial	O
pressure	O
(	O
130	O
/	O
80	O
mmHg	O
)	O
and	O
heart	O
rate	O
(	O
64	O
/	O
min	O
(-	O
1	O
));	O
roentgenographic	O
lungs	O
examination	O
and	O
computerized	O
tomography	O
(	O
CT	O
)	O
brain	O
examination	O
did	O
not	O
reveal	O
pathological	O
changes	O
in	O
lung	O
and	O
brain	O
parenchyma	O
;	O
toxicological	O
analyses	O
confirmed	O
the	O
presence	O
of	O
heroin	B-CHED
in	O
patient	O
'	O
s	O
organism	O
.	O

ABSTRACT	O
:	O
A	O
55	O
-	O
year	O
-	O
old	O
man	B-CHED
was	O
transferred	O
to	O
our	O
hospital	O
with	O
spontaneous	O
esophageal	O
rupture	O
.	O

The	O
genome	O
contains	O
30	O
,	O
119	O
nucleotides	B-CHED
and	O
contains	O
at	O
least	O
10	O
predicted	O
open	O
reading	O
frames	O
,	O
9	O
of	O
which	O
are	O
predicted	O
to	O
be	O
expressed	O
from	O
a	O
nested	O
set	O
of	O
seven	O
subgenomic	O
mRNAs	O
.	O

Exogenous	O
surfactant	B-CHED
replacement	O
in	O
animal	O
models	O
of	O
ARDS	O
and	O
neonatal	O
respiratory	O
distress	O
syndrome	O
shows	O
consistent	O
improvements	O
in	O
gas	O
exchange	O
and	O
survival	O
.	O

Crucially	O
,	O
the	O
mechanism	O
of	O
lung	O
injury	O
in	O
neonates	O
is	O
different	O
from	O
that	O
in	O
ARDS	O
:	O
surfactant	B-CHED
inhibition	O
by	O
plasma	O
constituents	O
is	O
a	O
typical	O
feature	O
of	O
ARDS	O
,	O
whereas	O
the	O
primary	O
pathology	O
in	O
neonates	O
is	O
the	O
deficiency	O
of	O
surfactant	B-CHED
material	O
due	O
to	O
reduced	O
synthesis	O
.	O

IBV	O
antigens	B-CHED
were	O
detected	O
by	O
immunohistochemical	O
analysis	O
in	O
the	O
trachea	O
,	O
lung	O
,	O
kidney	O
,	O
and	O
bursa	O
,	O
consistent	O
with	O
histopathologic	O
observations	O
,	O
virus	O
isolation	O
,	O
and	O
reverse	O
transcription	O
PCR	O
detection	O
.	O

Based	O
on	O
the	O
protein	B-CHED
disorder	O
prediction	O
system	O
,	O
a	O
comprehensive	O
series	O
of	O
HCoV	O
-	O
229E	O
N	O
protein	B-CHED
mutants	O
with	O
truncated	O
CTD	O
was	O
generated	O
and	O
systematically	O
investigated	O
by	O
biophysical	O
and	O
biochemical	O
analyses	O
to	O
clarify	O
the	O
role	O
of	O
the	O
C	O
-	O
terminal	O
tail	O
of	O
the	O
HCoV	O
-	O
229E	O
N	O
protein	B-CHED
in	O
oligomerization	O
.	O

Only	O
a	O
subset	O
of	O
cytokines	O
(	O
IFN	O
-	O
	O
,	O
CXCL8	O
,	O
CCL2	B-CHED
,	O
CCL4	B-CHED
,	O
CCL5	O
,	O
and	O
CCL20	O
)	O
correlated	O
with	O
self	O
-	O
reported	O
respiratory	O
tract	O
symptoms	O
.	O

Therefore	O
,	O
ck	O
/	O
CH	O
/	O
LZJ	O
/	O
111113	O
originated	O
from	O
the	O
recombination	O
events	O
between	O
ck	O
/	O
CH	O
/	O
LDL	B-CHED
/	O
091022	O
-	O
and	O
4	O
/	O
91	O
-	O
like	O
strains	O
at	O
three	O
switch	O
sites	O
located	O
upstream	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
gene	O
,	O
and	O
the	O
3	O
'	O
ends	O
of	O
S1	O
and	O
nuceocapsid	O
(	O
N	O
)	O
genes	O
,	O
respectively	O
.	O

We	O
performed	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
using	O
as	O
bait	O
the	O
carboxy	B-CHED
-	O
terminal	O
endodomain	O
of	O
S	O
,	O
which	O
faces	O
the	O
cytosol	O
during	O
and	O
after	O
opening	O
of	O
the	O
fusion	O
pore	O
at	O
early	O
stages	O
of	O
the	O
virus	O
life	O
cycle	O
.	O

Here	O
we	O
show	O
that	O
the	O
ezrin	O
membrane	O
-	O
actin	O
linker	O
interacts	O
with	O
S	O
endodomain	O
through	O
the	O
F1	O
lobe	O
of	O
its	O
FERM	O
domain	O
and	O
that	O
both	O
the	O
eight	O
carboxy	B-CHED
-	O
terminal	O
amino	O
-	O
acids	O
and	O
a	O
membrane	O
-	O
proximal	O
cysteine	B-CHED
cluster	O
of	O
S	O
endodomain	O
are	O
important	O
for	O
this	O
interaction	O
in	O
vitro	O
.	O

Furthermore	O
,	O
deletion	O
of	O
the	O
eight	O
carboxy	B-CHED
-	O
terminal	O
amino	B-CHED
acids	I-CHED
of	O
S	O
enhanced	O
S	O
-	O
pseudotyped	O
particles	O
infection	O
.	O

The	O
scope	O
of	O
this	O
article	O
is	O
to	O
review	O
screening	O
strategies	O
and	O
recent	O
advances	O
in	O
this	O
area	O
,	O
with	O
a	O
particular	O
emphasis	O
on	O
antivirals	B-CHED
targeting	O
the	O
step	O
of	O
viral	O
entry	O
for	O
emerging	O
lipid	B-CHED
-	O
enveloped	O
viruses	O
such	O
as	O
Ebola	O
virus	O
and	O
SARS	O
-	O
coronavirus	O
.	O

Indeed	O
,	O
several	O
studies	O
have	O
described	O
the	O
ability	O
of	O
HCoVs	O
(	O
i	O
.	O
e	O
.	O
HCoV	O
229E	O
,	O
HCoV	O
OC43	O
(	O
also	O
known	O
as	O
betacoronavirus	O
1	O
),	O
NL63	O
,	O
HKU1	O
or	O
SARS	O
-	O
CoV	O
)	O
to	O
survive	O
in	O
different	O
environmental	O
conditions	O
(	O
e	O
.	O
g	O
.	O
temperature	O
and	O
humidity	O
),	O
on	O
different	O
supports	O
found	O
in	O
hospital	O
settings	O
such	O
as	O
aluminum	B-CHED
,	O
sterile	O
sponges	O
or	O
latex	O
surgical	O
gloves	O
or	O
in	O
biological	O
fluids	O
.	O

Finally	O
,	O
taking	O
into	O
account	O
the	O
persisting	O
lack	O
of	O
specific	O
antiviral	B-CHED
treatments	O
(	O
there	O
is	O
,	O
in	O
fact	O
,	O
no	O
specific	O
treatment	O
available	O
to	O
fight	O
coronaviruses	O
infections	O
),	O
the	O
Coronaviridae	O
specificities	O
(	O
i	O
.	O
e	O
.	O
pathogenicity	O
,	O
potential	O
environmental	O
resistance	O
)	O
make	O
them	O
a	O
challenging	O
model	O
for	O
the	O
development	O
of	O
efficient	O
means	O
of	O
prevention	O
,	O
as	O
an	O
adapted	O
antisepsis	O
-	O
disinfection	O
,	O
to	O
prevent	O
the	O
environmental	O
spread	O
of	O
such	O
infective	O
agents	O
.	O

This	O
review	O
will	O
summarize	O
current	O
knowledge	O
on	O
the	O
capacity	O
of	O
human	O
coronaviruses	O
to	O
survive	O
in	O
the	O
environment	O
and	O
the	O
efficacy	O
of	O
well	O
-	O
known	O
antiseptic	O
-	O
disinfectants	B-CHED
against	O
them	O
,	O
with	O
particular	O
focus	O
on	O
the	O
development	O
of	O
new	O
methodologies	O
to	O
evaluate	O
the	O
activity	O
of	O
new	O
antiseptic	O
-	O
disinfectants	B-CHED
on	O
viruses	O
.	O

Here	O
we	O
review	O
current	O
knowledge	O
of	O
coronavirus	O
induced	O
membrane	O
rearrangements	O
and	O
the	O
involvement	O
of	O
autophagy	O
or	O
autophagy	O
protein	B-CHED
microtubule	O
associated	O
protein	B-CHED
1B	O
light	O
chain	O
3	O
(	O
LC3	O
)	O
in	O
coronavirus	O
replication	O
.	O

The	O
IC	O
(	O
50	O
)	O
values	O
of	O
the	O
inhibitors	B-CHED
were	O
in	O
the	O
range	O
of	O
4	O
.	O
6	O
-	O
49	O
M	O
,	O
demonstrating	O
that	O
the	O
nitrile	B-CHED
warhead	O
can	O
effectively	O
inactivate	O
the	O
3CL	O
(	O
pro	B-CHED
)	O
autocleavage	O
process	O
.	O

We	O
have	O
further	O
showed	O
that	O
the	O
peptidomimetic	B-CHED
inhibitor	B-CHED
,	O
Cbz	B-CHED
-	O
AVLQ	O
-	O
CN	O
,	O
has	O
broad	O
-	O
spectrum	O
inhibition	O
against	O
3CL	O
(	O
pro	B-CHED
)	O
from	O
human	O
coronavirus	O
strains	O
229E	O
,	O
NL63	O
,	O
OC43	O
,	O
HKU1	O
,	O
and	O
infectious	O
bronchitis	O
virus	O
,	O
with	O
IC	O
(	O
50	O
)	O
values	O
ranging	O
from	O
1	O
.	O
3	O
to	O
3	O
.	O
7	O
M	O
,	O
but	O
no	O
detectable	O
inhibition	O
against	O
caspase	O
-	O
3	O
.	O

TITLE	O
:	O
[	O
Acute	O
onset	O
pulmonary	O
toxicity	O
associated	O
to	O
amiodarone	B-CHED
].	O

ABSTRACT	O
:	O
Amiodarone	B-CHED
is	O
a	O
potent	O
anti	O
-	O
arrhythmic	O
drug	O
with	O
a	O
well	O
-	O
known	O
potential	O
chronic	O
pulmonary	O
toxicity	O
.	O

We	O
found	O
a	O
relationship	O
between	O
arterial	O
oxygen	B-CHED
saturation	O
(	O
SaO	O
(	O
2	O
))	O
and	O
its	O
relevant	O
parameters	O
.	O

CXCR2	O
is	O
a	O
chemokine	O
receptor	O
that	O
upon	O
binding	O
to	O
specific	O
ligands	O
promotes	O
host	O
defense	O
through	O
recruitment	O
of	O
myeloid	O
cells	O
to	O
the	O
CNS	B-CHED
as	O
well	O
as	O
protecting	O
oligodendroglia	O
from	O
cytokine	O
-	O
mediated	O
death	O
in	O
response	O
to	O
MHV	O
infection	O
.	O

We	O
also	O
demonstrated	O
that	O
noncanonical	O
TRS	O
-	O
Bs	O
may	O
provide	O
a	O
mechanism	O
by	O
which	O
coronaviruses	O
can	O
control	O
protein	B-CHED
expression	O
levels	O
by	O
reducing	O
sgmRNA	O
synthesis	O
.	O

Glyceraldehyde	B-CHED
-	I-CHED
3	I-CHED
-	I-CHED
phosphate	I-CHED
dehydrogenase	O
and	O
Ubiquitin	O
were	O
chosen	O
for	O
normalization	O
in	O
this	O
experimental	O
set	O
.	O

TITLE	O
:	O
Discovery	O
,	O
synthesis	O
,	O
and	O
structure	O
-	O
based	O
optimization	O
of	O
a	O
series	O
of	O
N	O
-(	O
tert	B-CHED
-	I-CHED
butyl	I-CHED
)-	O
2	O
-(	O
N	O
-	O
arylamido	O
)-	O
2	O
-(	O
pyridin	B-CHED
-	I-CHED
3	I-CHED
-	I-CHED
yl	I-CHED
)	O
acetamides	B-CHED
(	O
ML188	O
)	O
as	O
potent	O
noncovalent	O
small	O
molecule	O
inhibitors	B-CHED
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
3CL	O
protease	O
.	O

ABSTRACT	O
:	O
A	O
high	O
-	O
throughput	O
screen	O
of	O
the	O
NIH	O
molecular	O
libraries	O
sample	O
collection	O
and	O
subsequent	O
optimization	O
of	O
a	O
lead	O
dipeptide	B-CHED
-	O
like	O
series	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
main	O
protease	O
(	O
3CLpro	O
)	O
inhibitors	B-CHED
led	O
to	O
the	O
identification	O
of	O
probe	O
compound	O
ML188	O
(	O
16	O
-(	O
R	O
),	O
(	O
R	O
)-	O
N	O
-(	O
4	O
-(	O
tert	B-CHED
-	I-CHED
butyl	I-CHED
)	O
phenyl	B-CHED
)-	O
N	O
-(	O
2	O
-(	O
tert	O
-	O
butylamino	O
)-	O
2	O
-	O
oxo	B-CHED
-	O
1	O
-(	O
pyridin	B-CHED
-	I-CHED
3	I-CHED
-	I-CHED
yl	I-CHED
)	O
ethyl	B-CHED
)	O
furan	B-CHED
-	O
2	O
-	O
carboxamide	B-CHED
,	O
Pubchem	O
CID	O
:	O
46897844	O
).	O

Unlike	O
the	O
majority	O
of	O
reported	O
coronavirus	O
3CLpro	O
inhibitors	B-CHED
that	O
act	O
via	O
covalent	O
modification	O
of	O
the	O
enzyme	O
,	O
16	O
-(	O
R	O
)	O
is	O
a	O
noncovalent	O
SARS	O
-	O
CoV	O
3CLpro	O
inhibitor	B-CHED
with	O
moderate	O
MW	O
and	O
good	O
enzyme	O
and	O
antiviral	B-CHED
inhibitory	O
activity	O
.	O

Here	O
we	O
investigated	O
whether	O
it	O
might	O
utilize	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
SARS	O
-	O
CoV	O
receptor	O
.	O

Coronaviruses	O
have	O
a	O
reservoir	O
in	O
bats	O
and	O
because	O
this	O
novel	O
virus	O
is	O
related	O
to	O
SARS	O
-	O
CoV	O
,	O
we	O
investigated	O
whether	O
it	O
might	O
replicate	O
in	O
bat	O
cells	O
and	O
use	O
the	O
same	O
receptor	O
(	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
[	O
ACE2	O
]).	O

TITLE	O
:	O
Antiviral	B-CHED
agents	I-CHED
derived	O
from	O
novel	O
1	O
-	O
adamantyl	O
singlet	O
nitrenes	O
.	O

One	O
N	O
-	O
phenacyl	O
amantadine	B-CHED
derivative	O
was	O
investigated	O
for	O
inhibiting	O
the	O
in	O
vitro	O
replication	O
of	O
respiratory	O
viruses	O
(	O
influenza	O
A	O
viruses	O
,	O
influenza	O
B	O
virus	O
,	O
human	O
parainfluenza	O
virus	O
type	O
3	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
).	O

Two	O
ketone	B-CHED
-	O
stabilized	O
1	O
-	O
adamantyl	O
singlet	O
nitrenes	O
were	O
discovered	O
serendipitously	O
.	O

The	O
ACoV	O
was	O
genetically	O
most	O
similar	O
to	O
the	O
common	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
229E	O
with	O
92	O
.	O
2	O
%	O
nucleotide	B-CHED
identity	O
over	O
the	O
entire	O
genome	O
.	O

The	O
most	O
significant	O
laboratory	O
changes	O
were	O
decreases	O
in	O
the	O
hemoglobin	B-CHED
,	O
hematocrit	O
and	O
platelet	O
levels	O
,	O
with	O
increased	O
levels	O
of	O
transaminases	O
and	O
bilirubin	B-CHED
.	O

We	O
found	O
that	O
the	O
MW	O
is	O
derived	O
primarily	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
contains	O
markers	O
of	O
rough	O
ER	O
as	O
well	O
as	O
markers	O
of	O
early	O
and	O
late	O
endosomes	O
,	O
COP	O
vesicles	O
,	O
mitochondria	O
and	O
lipid	B-CHED
droplets	O
(	O
LDs	O
).	O

DMVs	O
are	O
induced	O
primarily	O
by	O
NS5A	O
whereas	O
NS4B	O
induces	O
single	O
membrane	O
vesicles	O
arguing	O
that	O
MW	O
formation	O
requires	O
the	O
concerted	O
action	O
of	O
several	O
HCV	O
replicase	O
proteins	B-CHED
.	O

During	O
viral	O
encephalomyelitis	O
,	O
the	O
absence	O
of	O
CD4	O
T	O
cells	O
decreases	O
CD8	O
T	O
cell	O
activity	O
and	O
impedes	O
viral	O
control	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
).	O

ABSTRACT	O
:	O
The	O
full	O
or	O
partial	O
unfolding	O
of	O
proteins	B-CHED
is	O
widely	O
believed	O
to	O
play	O
an	O
essential	O
role	O
in	O
three	O
-	O
dimensional	O
domain	O
swapping	O
.	O

IFN	O
-	O
	O
and	O
IFN	O
-	O
	O
mRNA	B-CHED
and	O
proteins	B-CHED
were	O
not	O
rapidly	O
induced	O
whereas	O
IFN	O
-	O
	O
production	O
in	O
lung	O
,	O
measured	O
by	O
Elispot	O
assay	O
,	O
increased	O
over	O
time	O
at	O
2	O
and	O
4	O
dpi	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
here	O
the	O
design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
molecules	O
toward	O
the	O
development	O
of	O
novel	O
peptidomimetic	B-CHED
inhibitors	B-CHED
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
).	O

Safety	O
was	O
evaluated	O
as	O
the	O
occurrence	O
of	O
hypotension	O
and	O
low	O
pulse	O
oxymeter	O
oxygen	B-CHED
saturation	O
during	O
the	O
maneuver	O
and	O
development	O
of	O
airleaks	O
after	O
.	O

The	O
further	O
plaque	O
and	O
CPE	O
inhibition	O
assay	O
in	O
vitro	O
showed	O
that	O
KIOM	O
198	O
has	O
much	O
stronger	O
antiviral	B-CHED
activity	O
than	O
KIOM	O
124	O
.	O

TITLE	O
:	O
Oxygen	B-CHED
therapy	O
in	O
critical	O
illness	O
:	O
precise	O
control	O
of	O
arterial	O
oxygenation	O
and	O
permissive	O
hypoxemia	O
.	O

Whilst	O
the	O
harms	O
of	O
tissue	O
hypoxia	O
are	O
well	O
recognized	O
,	O
the	O
possibility	O
of	O
harm	O
from	O
excess	O
oxygen	B-CHED
administration	O
,	O
or	O
other	O
interventions	O
targeted	O
at	O
mitigating	O
hypoxemia	O
,	O
may	O
be	O
inadequately	O
appreciated	O
.	O

Both	O
strategies	O
will	O
require	O
accurate	O
monitoring	O
of	O
oxygen	B-CHED
administration	O
and	O
arterial	O
oxygenation	O
.	O

At	O
the	O
high	O
-	O
intensity	O
corona	B-CHED
conditions	O
,	O
nearly	O
complete	O
protection	O
from	O
viral	O
and	O
bacterial	O
respiratory	O
infection	O
was	O
afforded	O
to	O
the	O
murine	O
models	O
for	O
all	O
biological	O
agents	O
tested	O
.	O

ABSTRACT	O
:	O
Bovine	O
coronaviruses	O
(	O
BCoVs	O
)	O
isolated	O
in	O
Japan	O
consist	O
of	O
four	O
genetic	O
groups	O
,	O
as	O
determined	O
by	O
phylogenetic	O
analysis	O
using	O
the	O
polymorphic	O
region	O
(	O
aa	O
456	O
-	O
592	O
)	O
of	O
the	O
S	O
glycoprotein	B-CHED
gene	O
.	O

This	O
amino	B-CHED
acid	I-CHED
constitutes	O
a	O
neutralization	O
epitope	B-CHED
of	O
BCoV	O
,	O
which	O
is	O
distinct	O
from	O
aa	O
528	O
of	O
the	O
Quebec	O
strain	O
.	O

CCL2	B-CHED
has	O
been	O
implicated	O
in	O
both	O
proinflammatory	O
and	O
anti	O
-	O
inflammatory	O
responses	O
and	O
has	O
been	O
suggested	O
as	O
a	O
target	O
for	O
therapy	O
in	O
some	O
inflammatory	O
disorders	O
.	O

Collectively	O
,	O
these	O
results	O
show	O
that	O
persistent	O
CCL2	B-CHED
overexpression	O
establishes	O
and	O
sustains	O
an	O
immunological	O
milieu	O
that	O
is	O
both	O
inflammatory	O
and	O
immunosuppressive	O
and	O
predisposes	O
mice	O
to	O
a	O
defective	O
immune	O
response	O
to	O
a	O
minimally	O
lethal	O
virus	O
.	O

Since	O
the	O
1980s	O
the	O
measurement	O
of	O
arterial	O
oxygen	B-CHED
saturation	O
by	O
pulse	O
oximetry	O
has	O
also	O
been	O
increasingly	O
used	O
as	O
an	O
adjunct	O
to	O
(	O
but	O
not	O
a	O
replacement	O
for	O
)	O
P	O
(	O
aO	O
(	O
2	O
)).	O

High	O
concentrations	O
of	O
inspired	O
oxygen	B-CHED
may	O
play	O
a	O
role	O
in	O
such	O
injury	O
,	O
but	O
aggressive	O
measures	O
to	O
reduce	O
them	O
in	O
order	O
to	O
avoid	O
oxygen	B-CHED
toxicity	O
-	O
which	O
dominated	O
ventilator	O
management	O
in	O
previous	O
decades	O
-	O
have	O
been	O
tempered	O
in	O
the	O
present	O
era	B-CHED
of	O
lung	O
-	O
protective	O
ventilation	O
.	O

ABSTRACT	O
:	O
The	O
non	O
	O
structural	O
protein	B-CHED
13	O
(	O
nsp13	O
)	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
SARS	O
	O
CoV	O
)	O
is	O
a	O
helicase	O
that	O
separates	O
double	O
	O
stranded	O
RNA	O
or	O
DNA	O
with	O
a	O
5	O
'	O
3	O
'	O
polarity	O
,	O
using	O
the	O
energy	O
of	O
nucleotide	B-CHED
hydrolysis	O
.	O

ABSTRACT	O
:	O
Messenger	B-CHED
RNA	I-CHED
encoded	O
signals	O
that	O
are	O
involved	O
in	O
programmed	O
-	O
1	O
ribosomal	O
frameshifting	O
(-	O
1	O
PRF	O
)	O
are	O
typically	O
two	O
-	O
stemmed	O
hairpin	O
(	O
H	O
)-	O
type	O
pseudoknots	O
(	O
pks	O
).	O

Complementation	O
experiments	O
,	O
using	O
BHK	O
-	O
21	O
cells	O
expressing	O
wild	O
-	O
type	O
HE	O
,	O
either	O
transiently	O
or	O
in	O
a	O
stable	O
ectopic	O
expression	O
,	O
demonstrate	O
that	O
this	O
protein	B-CHED
plays	O
a	O
very	O
significant	O
role	O
in	O
the	O
production	O
of	O
infectious	O
recombinant	O
coronaviral	O
particles	O
that	O
can	O
subsequently	O
more	O
efficiently	O
infect	O
susceptible	O
epithelial	O
and	O
neuronal	O
cells	O
.	O

From	O
the	O
ethanolic	O
extract	O
of	O
E	O
.	O
neriifolia	O
leaves	O
,	O
23	O
compounds	O
were	O
isolated	O
,	O
including	O
22	O
triterpenoids	B-CHED
and	O
one	O
flavonoid	B-CHED
glycoside	B-CHED
.	O

Blood	O
glyphosate	B-CHED
concentrations	O
had	O
a	O
mean	O
value	O
of	O
61	O
mg	O
/	O
L	O
(	O
range	O
0	O
.	O
6	O
-	O
150	O
mg	O
/	O
L	O
)	O
and	O
4146	O
mg	O
/	O
L	O
(	O
range	O
690	O
-	O
7480	O
mg	O
/	O
L	O
)	O
respectively	O
in	O
mild	O
-	O
moderate	O
intoxication	O
and	O
fatal	O
cases	O
.	O

ABSTRACT	O
:	O
Microbial	O
infections	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
are	O
often	O
associated	O
with	O
local	O
accumulation	O
of	O
antibody	O
(	O
Ab	O
)-	O
secreting	O
cells	O
(	O
ASC	O
).	O

By	O
providing	O
a	O
source	O
of	O
Ab	O
at	O
the	O
site	O
of	O
infection	O
,	O
CNS	B-CHED
-	O
localized	O
ASC	O
play	O
a	O
critical	O
role	O
in	O
acute	O
viral	O
control	O
and	O
in	O
preventing	O
viral	O
recrudescence	O
.	O

Moreover	O
,	O
the	O
few	O
ASC	O
recruited	O
to	O
the	O
CNS	B-CHED
in	O
CXCL10	O
(-/-)	O
mice	O
were	O
confined	O
to	O
the	O
vasculature	O
,	O
distinct	O
from	O
the	O
parenchymal	O
localization	O
in	O
wild	O
-	O
type	O
and	O
CXCL9	O
(-/-)	O
mice	O
.	O

They	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	O
low	O
V	O
(	O
T	O
)	O
ventilation	O
(	O
3	O
ml	O
/	O
kg	O
)	O
combined	O
with	O
extracorporeal	O
CO2	B-CHED
elimination	O
,	O
or	O
to	O
a	O
ARDSNet	O
strategy	O
(	O
6	O
ml	O
/	O
kg	O
)	O
without	O
the	O
extracorporeal	O
device	O
.	O

Secondary	O
outcome	O
parameters	O
were	O
respiratory	O
mechanics	O
,	O
gas	O
exchange	O
,	O
analgesic	B-CHED
/	O
sedation	O
use	O
,	O
complications	O
and	O
hospital	O
mortality	O
.	O

Independent	O
predictors	O
for	O
refeeding	O
syndrome	O
were	O
starvation	O
and	O
baseline	O
low	O
-	O
serum	O
magnesium	B-CHED
concentration	O
.	O

Likewise	O
,	O
TAK1	O
,	O
another	O
client	O
protein	B-CHED
of	O
Hsp90	O
and	O
signaling	O
component	O
of	O
the	O
IL	O
-	O
1	O
pathway	O
,	O
is	O
also	O
detergent	B-CHED
insoluble	O
after	O
heat	O
shock	O
.	O

Remarkably	O
,	O
IL	O
-	O
1	O
-	O
dependent	O
p38	O
activation	O
24	O
h	O
after	O
heat	O
shock	O
did	O
not	O
result	O
in	O
an	O
inhibition	O
of	O
ENaC	O
mRNA	B-CHED
expression	O
and	O
channel	O
function	O
.	O

Low	O
NOS	O
substrate	O
levels	O
have	O
been	O
shown	O
in	O
other	O
disease	O
states	O
to	O
lead	O
to	O
NOS	O
uncoupling	O
and	O
oxidative	O
injury	O
suggesting	O
a	O
potential	O
mechanism	O
for	O
the	O
association	O
between	O
low	O
citrulline	B-CHED
and	O
ARDS	O
.	O

ABSTRACT	O
:	O
Angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
a	O
negative	O
regulator	O
of	O
the	O
renin	O
-	O
angiotensin	B-CHED
system	O
,	O
and	O
functions	O
as	O
the	O
key	O
SARS	O
coronavirus	O
receptor	O
and	O
stabilizer	O
of	O
neutral	O
amino	B-CHED
acid	I-CHED
transporters	O
.	O

In	O
addition	O
,	O
ACE2	O
is	O
structurally	O
a	O
chimeric	O
protein	B-CHED
that	O
has	O
emerged	O
from	O
the	O
duplication	O
of	O
2	O
genes	O
:	O
homology	O
with	O
ACE	O
at	O
the	O
carboxypeptidase	O
domain	O
and	O
homology	O
with	O
Collectrin	O
in	O
the	O
transmembrane	O
C	O
-	O
terminal	O
domain	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
E	O
protein	B-CHED
causes	O
endoplasmic	O
reticulum	O
stress	O
and	O
up	O
-	O
regulates	O
interleukin	O
-	O
8	O
expression	O
.	O

However	O
,	O
the	O
subcellular	O
localization	O
and	O
other	O
functions	O
of	O
PEDV	O
E	O
protein	B-CHED
still	O
require	O
more	O
research	O
.	O

The	O
PEDV	O
E	O
protein	B-CHED
has	O
no	O
effect	O
on	O
the	O
intestinal	O
epithelial	O
cells	O
(	O
IEC	O
)	O
growth	O
,	O
cell	O
cycle	O
and	O
cyclin	O
A	O
expression	O
.	O

The	O
data	O
suggest	O
that	O
either	O
the	O
RNA	O
sequence	O
or	O
the	O
ratio	O
of	O
viral	O
proteins	B-CHED
resulting	O
from	O
different	O
levels	O
of	O
frameshifting	O
affects	O
viral	O
replication	O
.	O

CGS	O
-	O
21680	O
prevented	O
the	O
oxygen	B-CHED
-	O
induced	O
augmentation	O
of	O
lung	O
injury	O
after	O
LPS	B-CHED
only	O
in	O
WT	O
mice	O
.	O

Thereafter	O
,	O
a	O
dynamic	O
CT	O
(	O
4	O
images	O
/	O
sec	B-CHED
for	O
8	O
sec	B-CHED
)	O
was	O
taken	O
at	O
each	O
Vt	O
at	O
a	O
fixed	O
transverse	O
region	O
between	O
the	O
middle	O
and	O
lower	O
third	O
of	O
the	O
lungs	O
.	O

Recombination	O
analysis	O
showed	O
that	O
Sczy3	O
is	O
a	O
chimeric	O
strain	O
derived	O
from	O
LX4	O
(	O
major	O
parental	O
sequence	O
)	O
and	O
H120	O
(	O
minor	O
parental	O
sequence	O
)	O
suggesting	O
that	O
recombination	O
occurred	O
in	O
a	O
region	O
containing	O
the	O
3	O
'	O
terminal	O
5a	O
sequence	O
(	O
83	O
nt	O
),	O
the	O
5	O
'	O
terminal	O
5b	O
sequence	O
(	O
222	O
nt	O
),	O
and	O
the	O
5	O
'	O
terminal	O
nucleocapsid	O
protein	B-CHED
gene	O
sequence	O
(	O
132	O
nt	O
).	O

Recommendations	O
specific	O
to	O
pediatric	O
severe	O
sepsis	O
include	O
:	O
therapy	O
with	O
face	O
mask	O
oxygen	B-CHED
,	O
high	O
flow	O
nasal	O
cannula	O
oxygen	B-CHED
,	O
or	O
nasopharyngeal	O
continuous	O
PEEP	B-CHED
in	O
the	O
presence	O
of	O
respiratory	O
distress	O
and	O
hypoxemia	O
(	O
2C	O
),	O
use	O
of	O
physical	O
examination	O
therapeutic	O
endpoints	O
such	O
as	O
capillary	O
refill	O
(	O
2C	O
);	O
for	O
septic	O
shock	O
associated	O
with	O
hypovolemia	O
,	O
the	O
use	O
of	O
crystalloids	O
or	O
albumin	O
to	O
deliver	O
a	O
bolus	O
of	O
20	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
or	O
albumin	O
equivalent	O
)	O
over	O
5	O
-	O
10	O
min	O
(	O
2C	O
);	O
more	O
common	O
use	O
of	O
inotropes	O
and	O
vasodilators	O
for	O
low	O
cardiac	O
output	O
septic	O
shock	O
associated	O
with	O
elevated	O
systemic	O
vascular	O
resistance	O
(	O
2C	O
);	O
and	O
use	O
of	O
hydrocortisone	B-CHED
only	O
in	O
children	O
with	O
suspected	O
or	O
proven	O
""""	O
absolute	O
"""'"	O
adrenal	O
insufficiency	O
(	O
2C	O
).	O

RESULTS	O
:	O
Key	O
recommendations	O
and	O
suggestions	O
,	O
listed	O
by	O
category	O
,	O
include	O
:	O
early	O
quantitative	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
h	O
after	O
recognition	O
(	O
1C	O
);	O
blood	O
cultures	O
before	O
antibiotic	B-CHED
therapy	O
(	O
1C	O
);	O
imaging	O
studies	O
performed	O
promptly	O
to	O
confirm	O
a	O
potential	O
source	O
of	O
infection	O
(	O
UG	O
);	O
administration	O
of	O
broad	O
-	O
spectrum	O
antimicrobials	B-CHED
therapy	O
within	O
1	O
h	O
of	O
the	O
recognition	O
of	O
septic	O
shock	O
(	O
1B	O
)	O
and	O
severe	O
sepsis	O
without	O
septic	O
shock	O
(	O
1C	O
)	O
as	O
the	O
goal	O
of	O
therapy	O
;	O
reassessment	O
of	O
antimicrobial	B-CHED
therapy	O
daily	O
for	O
de	O
-	O
escalation	O
,	O
when	O
appropriate	O
(	O
1B	O
);	O
infection	O
source	O
control	O
with	O
attention	O
to	O
the	O
balance	B-CHED
of	O
risks	O
and	O
benefits	O
of	O
the	O
chosen	O
method	O
within	O
12	O
h	O
of	O
diagnosis	O
(	O
1C	O
);	O
initial	O
fluid	O
resuscitation	O
with	O
crystalloid	O
(	O
1B	O
)	O
and	O
consideration	O
of	O
the	O
addition	O
of	O
albumin	O
in	O
patients	O
who	O
continue	O
to	O
require	O
substantial	O
amounts	O
of	O
crystalloid	O
to	O
maintain	O
adequate	O
mean	O
arterial	O
pressure	O
(	O
2C	O
)	O
and	O
the	O
avoidance	O
of	O
hetastarch	O
formulations	O
(	O
1B	O
);	O
initial	O
fluid	O
challenge	O
in	O
patients	O
with	O
sepsis	O
-	O
induced	O
tissue	O
hypoperfusion	O
and	O
suspicion	O
of	O
hypovolemia	O
to	O
achieve	O
a	O
minimum	O
of	O
30	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
more	O
rapid	O
administration	O
and	O
greater	O
amounts	O
of	O
fluid	O
may	O
be	O
needed	O
in	O
some	O
patients	O
(	O
1C	O
);	O
fluid	O
challenge	O
technique	O
continued	O
as	O
long	O
as	O
hemodynamic	O
improvement	O
is	O
based	O
on	O
either	O
dynamic	O
or	O
static	O
variables	O
(	O
UG	O
);	O
norepinephrine	B-CHED
as	O
the	O
first	O
-	O
choice	O
vasopressor	O
to	O
maintain	O
mean	O
arterial	O
pressure	O
	O
65	O
mmHg	O
(	O
1B	O
);	O
epinephrine	B-CHED
when	O
an	O
additional	O
agent	O
is	O
needed	O
to	O
maintain	O
adequate	O
blood	O
pressure	O
(	O
2B	O
);	O
vasopressin	B-CHED
(	O
0	O
.	O
03	O
U	O
/	O
min	O
)	O
can	O
be	O
added	O
to	O
norepinephrine	B-CHED
to	O
either	O
raise	O
mean	O
arterial	O
pressure	O
to	O
target	O
or	O
to	O
decrease	O
norepinephrine	B-CHED
dose	O
but	O
should	O
not	O
be	O
used	O
as	O
the	O
initial	O
vasopressor	O
(	O
UG	O
);	O
dopamine	B-CHED
is	O
not	O
recommended	O
except	O
in	O
highly	O
selected	O
circumstances	O
(	O
2C	O
);	O
dobutamine	B-CHED
infusion	O
administered	O
or	O
added	O
to	O
vasopressor	O
in	O
the	O
presence	O
of	O
(	O
a	O
)	O
myocardial	O
dysfunction	O
as	O
suggested	O
by	O
elevated	O
cardiac	O
filling	O
pressures	O
and	O
low	O
cardiac	O
output	O
,	O
or	O
(	O
b	O
)	O
ongoing	O
signs	O
of	O
hypoperfusion	O
despite	O
achieving	O
adequate	O
intravascular	O
volume	O
and	O
adequate	O
mean	O
arterial	O
pressure	O
(	O
1C	O
);	O
avoiding	O
use	O
of	O
intravenous	O
hydrocortisone	B-CHED
in	O
adult	O
septic	O
shock	O
patients	O
if	O
adequate	O
fluid	O
resuscitation	O
and	O
vasopressor	O
therapy	O
are	O
able	O
to	O
restore	O
hemodynamic	O
stability	O
(	O
2C	O
);	O
hemoglobin	B-CHED
target	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
in	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
ischemic	O
coronary	O
artery	O
disease	O
,	O
or	O
acute	O
hemorrhage	O
(	O
1B	O
);	O
low	O
tidal	O
volume	O
(	O
1A	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
(	O
1B	O
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
in	O
ARDS	O
(	O
1B	O
);	O
higher	O
rather	O
than	O
lower	O
level	O
of	O
PEEP	B-CHED
for	O
patients	O
with	O
sepsis	O
-	O
induced	O
moderate	O
or	O
severe	O
ARDS	O
(	O
2C	O
);	O
recruitment	O
maneuvers	O
in	O
sepsis	O
patients	O
with	O
severe	O
refractory	O
hypoxemia	O
due	O
to	O
ARDS	O
(	O
2C	O
);	O
prone	O
positioning	O
in	O
sepsis	O
-	O
induced	O
ARDS	O
patients	O
with	O
a	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
of	O
	O
100	O
mm	O
Hg	O
in	O
facilities	O
that	O
have	O
experience	O
with	O
such	O
practices	O
(	O
2C	O
);	O
head	O
-	O
of	O
-	O
bed	O
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ARDS	O
who	O
do	O
not	O
have	O
evidence	O
of	O
tissue	O
hypoperfusion	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	O
(	O
1A	O
);	O
minimizing	O
use	O
of	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
targeting	O
specific	O
titration	O
endpoints	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
if	O
possible	O
in	O
the	O
septic	O
patient	O
without	O
ARDS	O
(	O
1C	O
);	O
a	O
short	O
course	O
of	O
neuromuscular	O
blocker	O
(	O
no	O
longer	O
than	O
48	O
h	O
)	O
for	O
patients	O
with	O
early	O
ARDS	O
and	O
a	O
PaO	B-CHED
(	O
2	O
)/	O
FI	O
O	O
(	O
2	O
)	O
<	O
150	O
mm	O
Hg	O
(	O
2C	O
);	O
a	O
protocolized	O
approach	O
to	O
blood	O
glucose	B-CHED
management	O
commencing	O
insulin	B-CHED
dosing	O
when	O
two	O
consecutive	O
blood	O
glucose	B-CHED
levels	O
are	O
>	O
180	O
mg	O
/	O
dL	O
,	O
targeting	O
an	O
upper	O
blood	O
glucose	B-CHED
	O
180	O
mg	O
/	O
dL	O
(	O
1A	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
venous	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	O
vein	O
thrombosis	O
(	O
1B	O
);	O
use	O
of	O
stress	O
ulcer	O
prophylaxis	O
to	O
prevent	O
upper	O
gastrointestinal	O
bleeding	O
in	O
patients	O
with	O
bleeding	O
risk	O
factors	O
(	O
1B	O
);	O
oral	O
or	O
enteral	O
(	O
if	O
necessary	O
)	O
feedings	O
,	O
as	O
tolerated	O
,	O
rather	O
than	O
either	O
complete	O
fasting	O
or	O
provision	O
of	O
only	O
intravenous	O
glucose	B-CHED
within	O
the	O
first	O
48	O
h	O
after	O
a	O
diagnosis	O
of	O
severe	O
sepsis	O
/	O
septic	O
shock	O
(	O
2C	O
);	O
and	O
addressing	O
goals	O
of	O
care	O
,	O
including	O
treatment	O
plans	O
and	O
end	O
-	O
of	O
-	O
life	O
planning	O
(	O
as	O
appropriate	O
)	O
(	O
1B	O
),	O
as	O
early	O
as	O
feasible	O
,	O
but	O
within	O
72	O
h	O
of	O
intensive	O
care	O
unit	O
admission	O
(	O
2C	O
).	O

A	O
	O
-	O
CoV	O
with	O
96	O
.	O
5	O
%	O
amino	B-CHED
acid	I-CHED
identity	O
to	O
the	O
	O
-	O
CoV	O
associated	O
with	O
human	O
disease	O
in	O
the	O
Middle	O
East	O
was	O
found	O
in	O
a	O
Nyctinomops	O
laticaudatus	O
bat	O
,	O
suggesting	O
that	O
efforts	O
to	O
identify	O
the	O
viral	O
reservoir	O
should	O
include	O
surveillance	O
of	O
the	O
bat	O
families	O
Molossidae	O
/	O
Vespertilionidae	O
,	O
or	O
the	O
closely	O
related	O
Nycteridae	O
/	O
Emballonuridae	O
.	O

We	O
genotyped	O
the	O
insertion	O
/	O
deletion	O
polymorphism	O
of	O
the	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
gene	O
(	O
polymerase	O
chain	O
reaction	O
)	O
and	O
the	O
following	O
single	O
-	O
nucleotide	B-CHED
polymorphisms	O
(	O
TaqMan	O
SNP	O
genotyping	O
assay	O
):	O
tumor	O
necrosis	O
factor	O
	O
-	O
376	O
G	O
/	O
A	O
,	O
-	O
308	O
G	O
/	O
A	O
,	O
and	O
-	O
238	O
G	O
/	O
A	O
;	O
interleukin	O
8	O
-	O
251	O
T	O
/	O
A	O
;	O
pre	O
-	O
B	O
cell	O
colony	O
-	O
enhancing	O
factor	O
-	O
1001	O
G	O
/	O
T	O
;	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
+	O
405	O
C	O
/	O
G	O
and	O
+	O
936	O
C	O
/	O
T	O
.	O
Polymorphisms	O
were	O
selected	O
based	O
on	O
reports	O
on	O
their	O
association	O
with	O
ARDS	O
.	O

Influenza	O
antiviral	B-CHED
agents	I-CHED
should	O
be	O
started	O
early	O
in	O
hospitalized	O
patients	O
with	O
suspected	O
influenza	O
,	O
including	O
those	O
with	O
asthma	O
.	O

A	O
recent	O
meta	O
-	O
analysis	O
of	O
pooled	O
controlled	O
small	O
trials	O
(	O
n	O
=	O
970	O
)	O
of	O
patients	O
admitted	O
with	O
CAP	O
found	O
improved	O
short	O
-	O
term	O
mortality	O
in	O
the	O
subgroup	O
with	O
severe	O
CAP	O
and	O
/	O
or	O
receiving	O
>	O
5	O
days	O
of	O
glucocorticoid	B-CHED
treatment	O
.	O

The	O
sequences	O
of	O
nucleocapsid	O
(	O
N	O
)	O
genes	O
of	O
32	O
representative	O
field	O
strains	O
were	O
determined	O
,	O
and	O
the	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
of	O
these	O
N	O
genes	O
were	O
1326	O
nucleotides	B-CHED
long	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
explore	O
the	O
use	O
of	O
corticosteroids	B-CHED
in	O
intensive	O
care	O
,	O
their	O
impact	O
on	O
patient	O
outcome	O
and	O
to	O
provide	O
practical	O
guidance	O
for	O
the	O
use	O
of	O
corticosteroids	B-CHED
in	O
the	O
ICU	O
.	O

But	O
use	O
of	O
corticosteroids	B-CHED
carries	O
the	O
risk	O
of	O
severe	O
adverse	O
effects	O
,	O
partly	O
because	O
of	O
their	O
anti	O
-	O
infammatory	O
effects	O
.	O

Recently	O
,	O
clinical	O
research	O
has	O
focused	O
on	O
critical	O
illness	O
-	O
related	O
corticosteroid	B-CHED
insufficiency	O
and	O
several	O
trials	O
investigated	O
the	O
role	O
of	O
corticosteroids	B-CHED
therapy	O
in	O
septic	O
and	O
critically	O
ill	O
patients	O
with	O
severe	O
systemic	O
inflammation	O
such	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
severe	O
community	O
-	O
acquired	O
pneumonia	O
and	O
meningitis	O
.	O

For	O
the	O
calculations	O
,	O
137	O
groups	O
of	O
chickens	O
were	O
subdivided	O
into	O
10	O
clusters	B-CHED
based	O
on	O
age	O
(	O
young	O
or	O
adult	O
),	O
vaccination	O
(	O
none	O
,	O
homologous	O
or	O
heterologous	O
),	O
challenge	O
(	O
IBV	O
or	O
mock	O
infected	O
)	O
and	O
location	O
of	O
vaccination	O
(	O
isolator	O
at	O
GD	O
or	O
in	O
the	O
field	O
).	O

The	O
results	O
were	O
used	O
to	O
estimate	O
the	O
required	O
number	O
of	O
chickens	O
per	O
group	O
for	O
the	O
different	O
clusters	B-CHED
using	O
2	O
,	O
5	O
or	O
10	O
TOCs	O
per	O
chicken	O
to	O
be	O
able	O
to	O
detect	O
effect	O
sizes	O
of	O
6	O
.	O
25	O
%,	O
12	O
.	O
5	O
%,	O
25	O
%	O
and	O
50	O
%	O
between	O
groups	O
of	O
chickens	O
with	O
95	O
%	O
confidence	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
80	O
%	O
power	O
.	O

This	O
meta	O
-	O
analysis	O
provided	O
data	O
that	O
allow	O
research	O
workers	O
to	O
estimate	O
the	O
number	O
of	O
chickens	O
that	O
should	O
be	O
included	O
in	O
each	O
group	O
in	O
order	O
to	O
obtain	O
reliable	O
results	O
based	O
on	O
particular	O
combinations	O
of	O
infectious	O
bronchitis	O
vaccination	O
and	O
challenge	O
strains	O
as	O
defined	O
by	O
the	O
presented	O
clusters	B-CHED
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
are	O
characterized	O
by	O
a	O
disruption	O
of	O
the	O
endothelium	O
and	O
alveolar	O
epithelial	O
barriers	O
involving	O
increased	O
microvascular	O
permeability	O
,	O
thus	O
resulting	O
in	O
the	O
set	O
of	O
protein	B-CHED
-	O
rich	O
pulmonary	O
edema	O
.	O

Plasma	O
kallistatin	O
,	O
kallikrein	O
,	O
and	O
other	O
biomarkers	O
of	O
inflammation	O
(	O
tumor	O
necrosis	O
factor	O
-	O
	O
(	O
TNF	O
-	O
	O
),	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
)),	O
and	O
anti	O
-	O
coagulation	O
(	O
protein	B-CHED
C	O
,	O
anti	O
-	O
thrombin	O
III	O
)	O
were	O
measured	O
on	O
days	O
1	O
and	O
4	O
of	O
ICU	O
admission	O
.	O

Most	O
of	O
the	O
title	O
compounds	O
displayed	O
excellent	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
at	O
submicromolar	O
concentrations	O
ranging	O
from	O
34	O
nM	O
to	O
5	O
.	O
08	O
M	O
.	O
The	O
most	O
promising	O
compound	O
8g	O
inhibited	O
HIV	O
-	O
1	O
IIIB	O
in	O
MT	O
-	O
4	O
cells	O
at	O
a	O
low	O
EC50	O
value	O
(	O
0	O
.	O
034	O
M	O
),	O
which	O
was	O
lower	O
than	O
the	O
reference	O
drug	O
nevirapine	B-CHED
and	O
delavirdine	B-CHED
.	O

Other	O
therapies	O
,	O
including	O
corticosteroids	B-CHED
,	O
have	O
not	O
demonstrated	O
benefit	O
.	O

BAL	B-CHED
neutrophilia	O
in	O
BOS	O
and	O
RAS	B-CHED
were	O
elevated	O
at	O
days	O
360	O
,	O
540	O
,	O
and	O
720	O
versus	O
control	O
.	O

BOS	O
,	O
but	O
especially	O
RAS	B-CHED
patients	O
,	O
experienced	O
more	O
frequent	O
episodes	O
of	O
increased	O
BAL	B-CHED
eosinophilia	O
(	O
2	O
%;	O
P	O
<	O
0	O
.	O
0001	O
).	O

Acute	O
rejection	O
,	O
lymphocytic	O
bronchiolitis	O
,	O
colonization	O
with	O
pseudomonas	O
,	O
infection	O
,	O
and	O
BAL	B-CHED
eosinophilia	O
and	O
neutrophilia	O
are	O
risk	O
factors	O
for	O
the	O
later	O
development	O
not	O
only	O
of	O
RAS	B-CHED
but	O
also	O
of	O
BOS	O
.	O

ABSTRACT	O
:	O
In	O
recent	O
years	O
,	O
pharmaceutical	B-CHED
chemists	O
have	O
synthesized	O
large	O
numbers	O
of	O
andrographolide	B-CHED
derivatives	O
,	O
which	O
bear	O
important	O
biological	O
activities	O
such	O
as	O
anti	O
-	O
inflammatory	O
,	O
antibacterial	O
,	O
antivirus	O
,	O
antitumor	O
,	O
antidiabetic	B-CHED
,	O
and	O
antifeedant	B-CHED
.	O

Trials	O
had	O
to	O
report	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
mortality	O
;	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
respiratory	O
support	O
,	O
oxygen	B-CHED
therapy	O
,	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
,	O
or	O
stay	O
in	O
hospital	O
;	O
infection	O
;	O
long	O
-	O
term	O
cognitive	O
impairment	O
,	O
neurodevelopmental	O
progress	O
,	O
or	O
other	O
long	O
-	O
term	O
morbidities	O
.	O

The	O
stimulation	O
by	O
N	O
-	O
terminal	O
pro	B-CHED
-	O
sequence	O
removal	O
is	O
due	O
to	O
the	O
cis	O
(	O
intra	O
-	O
dimer	O
and	O
inter	O
-	O
protomer	O
)	O
effect	O
of	O
formation	O
of	O
the	O
new	O
N	O
-	O
terminus	O
,	O
whereas	O
that	O
by	O
C	O
-	O
terminal	O
cleavage	O
is	O
due	O
to	O
removal	O
of	O
its	O
trans	O
(	O
inter	O
-	O
dimer	O
)	O
inhibitory	O
effect	O
.	O

Directed	O
protease	O
expression	O
and	O
inhibition	O
analyses	O
revealed	O
that	O
TMPRSS2	O
and	O
endosomal	O
cathepsins	O
activate	O
EMC	O
-	O
S	O
for	O
virus	O
-	O
cell	O
fusion	O
and	O
constitute	O
potential	O
targets	O
for	O
antiviral	B-CHED
intervention	O
.	O

Phylogenetic	O
analysis	O
of	O
S1	O
subunit	O
glycoprotein	B-CHED
genes	O
revealed	O
that	O
field	O
isolates	O
from	O
2009	O
-	O
2011	O
mostly	O
belonged	O
to	O
the	O
LX4	O
type	O
,	O
while	O
those	O
from	O
1985	O
-	O
2008	O
belonged	O
to	O
the	O
HN08	O
type	O
,	O
and	O
a	O
few	O
others	O
belonged	O
to	O
the	O
4	O
/	O
91	O
type	O
,	O
the	O
TW	O
type	O
and	O
the	O
Mass	O
type	O
.	O

The	O
immunocompromised	O
state	O
and	O
the	O
delicate	O
glucocorticoid	B-CHED
balance	B-CHED
in	O
subjects	O
with	O
severe	O
Cushing	O
'	O
s	O
syndrome	O
necessitate	O
a	O
specific	O
diagnostic	O
and	O
therapeutic	O
approach	O
.	O

Three	O
hundred	O
six	O
patients	O
with	O
severe	O
acute	O
pancreatitis	O
were	O
divided	O
randomly	O
into	O
5	O
groups	O
:	O
basic	O
treatment	O
,	O
somatostatin	B-CHED
,	O
somatostatin	B-CHED
+	O
ulinastatin	O
,	O
somatostatin	B-CHED
+	O
S	O
miltiorrhiza	O
and	O
somatostatin	B-CHED
+	O
ulinastatin	O
+	O
S	O
miltiorrhiza	O
.	O

The	O
indications	O
included	O
acute	O
fulminant	O
myocarditis	O
(	O
AFM	O
)	O
(	O
n	O
=	O
6	O
),	O
congenital	O
diaphragmatic	O
hernia	O
(	O
CDH	B-CHED
)	O
(	O
n	O
=	O
3	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
(	O
n	O
=	O
6	O
),	O
enterovirus	O
71	O
(	O
n	O
=	O
3	O
),	O
viral	O
sepsis	O
(	O
n	O
=	O
2	O
),	O
refractory	O
ventricular	O
fibrillation	O
due	O
to	O
long	O
QT	O
syndrome	O
(	O
n	O
=	O
1	O
),	O
and	O
pulmonary	O
edema	O
with	O
brain	O
herniation	O
(	O
n	O
=	O
1	O
).	O

The	O
other	O
10	O
critical	O
residues	O
were	O
distributed	O
throughout	O
the	O
N7	O
-	O
MTase	O
domain	O
but	O
localized	O
mainly	O
in	O
the	O
S	B-CHED
-	I-CHED
adenosyl	I-CHED
-	I-CHED
l	I-CHED
-	I-CHED
methionine	I-CHED
(	O
SAM	B-CHED
)-	O
binding	O
pocket	O
and	O
key	O
structural	O
elements	O
of	O
the	O
MTase	O
fold	O
of	O
nsp14	O
.	O

ABSTRACT	O
:	O
The	O
effects	O
of	O
excess	O
alcohol	O
consumption	O
(	O
alcohol	O
misuse	O
)	O
on	O
outcomes	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
have	O
been	O
inconsistent	O
,	O
and	O
there	O
are	O
no	O
studies	O
examining	O
this	O
association	O
in	O
the	O
era	B-CHED
of	O
low	O
tidal	O
volume	O
ventilation	O
and	O
a	O
fluid	O
conservative	O
strategy	O
.	O

In	O
this	O
proof	O
-	O
of	O
-	O
concept	O
study	O
,	O
we	O
introduced	O
a	O
3	O
-	O
amino	O
-	O
4	O
-	O
piperazinylphenyl	O
functionality	O
to	O
the	O
chromone	B-CHED
scaffold	O
and	O
evaluated	O
the	O
antiviral	B-CHED
activities	O
of	O
the	O
resulting	O
chromone	B-CHED
derivatives	O
.	O

Taken	O
together	O
,	O
this	O
result	O
indicates	O
the	O
possible	O
pharmacophoric	O
role	O
of	O
the	O
2	O
-	O
pyridinylpiperazine	O
functionality	O
attached	O
to	O
the	O
chromone	B-CHED
scaffold	O
,	O
which	O
warrants	O
further	O
in	O
-	O
depth	O
structure	O
-	O
activity	O
relationship	O
study	O
.	O

Polymyxin	B-CHED
B	I-CHED
-	O
immobilized	O
fiber	O
column	O
direct	O
hemoperfusion	O
(	O
PMX	O
-	O
DHP	O
)	O
is	O
a	O
medical	O
device	O
that	O
reduces	O
blood	O
endotoxin	O
levels	O
in	O
sepsis	O
.	O

Use	O
of	O
combination	O
of	O
bronchodilators	O
and	O
inhaled	O
corticosteroids	B-CHED
was	O
more	O
frequent	O
in	O
younger	O
patients	O
with	O
more	O
severe	O
airways	O
obstruction	O
and	O
lower	O
CCI	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
white	O
matter	O
integrity	O
of	O
the	O
corona	B-CHED
radiata	O
,	O
cingulate	O
gyri	O
,	O
and	O
corpus	O
callosum	O
in	O
patients	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
infection	O
through	O
diffusion	O
tensor	O
imaging	O
(	O
DTI	O
).	O

Further	O
studies	O
show	O
that	O
PEDV	O
N	O
protein	B-CHED
induces	O
ER	O
stress	O
and	O
activates	O
NF	O
-	O
B	O
,	O
which	O
is	O
responsible	O
for	O
the	O
up	O
-	O
regulation	O
of	O
IL	O
-	O
8	O
and	O
Bcl	O
-	O
2	O
expression	O
.	O

Feline	O
coronavirus	O
antigen	B-CHED
was	O
detected	O
in	O
both	O
the	O
heart	O
and	O
intestinal	O
tissue	O
by	O
immunohistochemistry	O
.	O

TITLE	O
:	O
Immunogenicity	O
and	O
protection	O
efficacy	O
of	O
monomeric	O
and	O
trimeric	O
recombinant	O
SARS	O
coronavirus	O
spike	O
protein	B-CHED
subunit	O
vaccine	O
candidates	O
.	O

TITLE	O
:	O
Complete	O
protection	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
-	O
mediated	O
lethal	O
respiratory	O
disease	O
in	O
aged	O
mice	O
by	O
immunization	O
with	O
a	O
mouse	O
-	O
adapted	O
virus	O
lacking	O
E	O
protein	B-CHED
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
the	O
increased	O
circulating	O
concentrations	O
of	O
soluble	O
fibrinogen	O
found	O
during	O
the	O
acute	O
-	O
phase	O
response	O
can	O
act	O
as	O
a	O
natural	O
antagonist	B-CHED
of	O
leukocyte	O
recruitment	O
,	O
and	O
therefore	O
might	O
contribute	O
to	O
the	O
resolution	O
of	O
inflammation	O
.	O

Ornithobacterium	O
rhinotracheale	O
(	O
ORT	O
)	O
was	O
isolated	O
from	O
respiratory	O
tract	O
tissues	O
,	O
and	O
16S	B-CHED
rRNA	B-CHED
gene	O
sequencing	O
on	O
three	O
isolates	O
revealed	O
two	O
distinct	O
genotypes	O
,	O
one	O
previously	O
associated	O
with	O
some	O
electrophoretic	O
type	O
(	O
ET	O
)	O
1	O
strains	O
and	O
the	O
other	O
a	O
novel	O
genotype	O
that	O
clustered	O
among	O
sequences	O
previously	O
associated	O
with	O
ET	O
3	O
,	O
ET	O
4	O
,	O
ET	O
5	O
and	O
ET	O
6	O
isolates	O
.	O

Bioinformatics	O
analysis	O
demonstrated	O
a	O
significant	O
B	O
-	O
cell	O
epitope	B-CHED
overlapping	O
the	O
heptad	O
repeat	O
-	O
2	O
region	O
of	O
Spike	O
protein	B-CHED
.	O

The	O
chest	O
radiograph	O
showed	O
that	O
interstitial	O
disease	O
predominates	O
at	O
the	O
lung	O
bases	B-CHED
in	O
all	O
cases	O
with	O
a	O
large	O
aspect	O
of	O
the	O
pulmonary	O
arteries	O
in	O
two	O
cases	O
.	O

CONCLUSIONS	O
:	O
Plasminogen	O
activator	O
inhibitor	B-CHED
-	O
1	O
is	O
sensitive	O
blood	O
symbol	O
for	O
screening	O
high	O
-	O
risk	O
susceptible	O
population	O
;	O
4G	O
/	O
4G	O
PAI	O
-	O
1	O
genotype	O
may	O
be	O
an	O
etiological	O
factor	O
in	O
osteonecrosis	O
.	O

Those	O
who	O
had	O
BHR	O
and	O
abnormal	O
PEF	B-CHED
variability	O
remained	O
unchanged	O
.	O

ABSTRACT	O
:	O
We	O
present	O
a	O
serological	O
assay	O
for	O
the	O
specific	O
detection	O
of	O
IgM	O
and	O
IgG	O
antibodies	O
against	O
the	O
emerging	O
human	O
coronavirus	O
hCoV	O
-	O
EMC	O
and	O
the	O
SARS	O
-	O
CoV	O
based	O
on	O
protein	B-CHED
microarray	O
technology	O
.	O

ABSTRACT	O
:	O
The	O
identification	O
of	O
a	O
novel	O
	O
coronavirus	O
,	O
nCoV	O
,	O
as	O
the	O
causative	O
agent	O
of	O
severe	O
respiratory	O
illness	O
in	O
humans	O
originating	O
in	O
Saudi	O
Arabia	O
,	O
Qatar	O
and	O
Jordan	O
has	O
raised	O
concerns	O
about	O
the	O
possibility	O
of	O
a	O
coronavirus	O
pandemic	O
similar	O
to	O
that	O
of	O
SARS	O
-	O
CoV	O
.	O
As	O
a	O
definitive	O
treatment	O
regimen	O
has	O
never	O
been	O
thoroughly	O
evaluated	O
for	O
coronavirus	O
infections	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
rapidly	O
identify	O
potential	O
therapeutics	O
to	O
address	O
future	O
cases	O
of	O
nCoV	O
.	O
To	O
determine	O
an	O
intervention	O
strategy	O
,	O
the	O
effect	O
of	O
interferon	O
-	O
2b	O
and	O
ribavirin	B-CHED
on	O
nCoV	O
isolate	O
hCoV	O
-	O
EMC	O
/	O
2012	O
replication	O
in	O
Vero	O
and	O
LLC	O
-	O
MK2	O
cells	O
was	O
evaluated	O
.	O

Compared	O
to	O
the	O
NS	B-CHED
group	I-CHED
,	O
patients	O
in	O
the	O
SH	O
and	O
SHG	O
groups	O
accessed	O
the	O
endpoint	O
more	O
quickly	O
(	O
3	O
.	O
9	O
	O
0	O
.	O
23	O
d	O
and	O
4	O
.	O
1	O
	O
0	O
.	O
21	O
d	O
vs	O
5	O
.	O
8	O
	O
0	O
.	O
25	O
d	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
with	O
less	O
fluid	O
volume	O
(	O
67	O
.	O
26	O
	O
28	O
.	O
53	O
mL	O
/	O
kg	O
/	O
d	O
,	O
61	O
.	O
79	O
	O
27	O
.	O
61	O
mL	O
/	O
kg	O
per	O
day	O
vs	O
85	O
.	O
23	O
	O
21	O
.	O
27	O
mL	O
/	O
kg	O
per	O
day	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
VL	O
and	O
VH	O
amplicons	O
were	O
combined	O
using	O
SOE	O
-	O
PCR	O
by	O
a	O
12	O
amino	B-CHED
acid	I-CHED
flexible	O
linker	O
(	O
SSGGGGSGGGGS	O
),	O
which	O
produced	O
the	O
scFv	O
gene	O
(	O
named	O
scFv	O
/	O
6E6	O
).	O

Moreover	O
,	O
the	O
recombinant	O
scFv	O
/	O
6E6	O
protein	B-CHED
was	O
purified	O
from	O
the	O
inclusion	O
body	O
form	O
by	O
the	O
gel	O
-	O
cutting	O
measure	O
followed	O
by	O
electroelution	O
and	O
dialysis	O
.	O

TITLE	O
:	O
Corticosteroid	B-CHED
use	O
in	O
the	O
intensive	O
care	O
unit	O
:	O
a	O
survey	O
of	O
intensivists	O
.	O

Respondents	O
reported	O
rarely	O
prescribing	O
corticosteroids	B-CHED
for	O
ALI	O
,	O
but	O
accepted	O
them	O
for	O
bronchospasm	O
,	O
suspected	O
adrenal	O
insufficiency	O
due	O
to	O
previous	O
corticosteroid	B-CHED
use	O
,	O
and	O
vasopressor	O
-	O
refractory	O
septic	O
shock	O
.	O

These	O
competing	O
indications	O
will	O
complicate	O
the	O
design	O
and	O
interpretation	O
of	O
any	O
future	O
large	O
-	O
scale	O
trial	O
of	O
corticosteroids	B-CHED
in	O
critical	O
illness	O
.	O

High	O
mobility	O
group	O
box	O
1	O
(	O
HMGB1	O
),	O
which	O
was	O
identified	O
originally	O
as	O
a	O
DNA	O
binding	O
protein	B-CHED
,	O
has	O
been	O
proposed	O
as	O
a	O
mediator	O
of	O
acute	O
lung	O
injury	O
.	O

MERS	O
-	O
CoV	O
infection	O
did	O
not	O
prevent	O
the	O
IFN	O
-	O
induced	O
nuclear	O
translocation	O
of	O
phosphorylated	O
STAT1	O
,	O
in	O
contrast	O
to	O
infection	O
with	O
SARS	O
-	O
CoV	O
where	O
this	O
block	O
inhibits	O
the	O
expression	O
of	O
antiviral	B-CHED
genes	O
.	O

Based	O
on	O
the	O
208	O
base	O
pair	O
(	O
bp	O
)	O
sequence	O
of	O
novel	O
HCoV	O
reported	O
by	O
HPA	B-CHED
of	O
UK	O
,	O
we	O
designed	O
and	O
obtained	O
several	O
pairs	O
of	O
primer	O
(	O
F	O
-	O
1	O
,	O
R	O
-	O
1	O
;	O
F	O
-	O
2	O
,	O
R	O
-	O
2	O
)	O
and	O
Taqman	O
probes	O
(	O
TZ1	O
,	O
TZ2	O
)	O
for	O
detection	O
of	O
novel	O
HCoV	O
.	O
Two	O
of	O
probes	O
were	O
modified	O
with	O
LNA	B-CHED
(	O
LNA	B-CHED
-	O
TZ1	O
,	O
LNA	B-CHED
-	O
TZ2	O
).	O

Of	O
these	O
,	O
7	O
risk	O
factors	O
were	O
significantly	O
associated	O
with	O
severe	O
ALRI	O
in	O
a	O
consistent	O
manner	O
across	O
studies	O
,	O
with	O
the	O
following	O
meta	O
-	O
analysis	O
estimates	O
of	O
odds	O
ratios	O
(	O
with	O
95	O
%	O
confidence	O
intervals	O
):	O
low	O
birth	O
weight	O
3	O
.	O
18	O
(	O
1	O
.	O
02	O
-	O
9	O
.	O
90	O
),	O
lack	O
of	O
exclusive	O
breastfeeding	O
2	O
.	O
34	O
(	O
1	O
.	O
42	O
-	O
3	O
.	O
88	O
),	O
crowding	O
-	O
more	O
than	O
7	O
persons	O
per	O
household	O
1	O
.	O
96	O
(	O
1	O
.	O
53	O
-	O
2	O
.	O
52	O
),	O
exposure	O
to	O
indoor	O
air	B-CHED
pollution	O
1	O
.	O
57	O
(	O
1	O
.	O
06	O
-	O
2	O
.	O
31	O
),	O
incomplete	O
immunization	O
1	O
.	O
83	O
(	O
1	O
.	O
32	O
-	O
2	O
.	O
52	O
),	O
undernutrition	O
-	O
weight	O
-	O
for	O
-	O
age	O
less	O
than	O
2	O
standard	O
deviations	O
4	O
.	O
47	O
(	O
2	O
.	O
10	O
-	O
9	O
.	O
49	O
),	O
and	O
HIV	O
infection	O
4	O
.	O
15	O
(	O
2	O
.	O
57	O
-	O
9	O
.	O
74	O
).	O

ABSTRACT	O
:	O
The	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
characterized	O
by	O
severe	O
impairment	O
of	O
gas	O
exchange	O
and	O
remains	O
a	O
challenge	O
for	O
modern	O
intensive	O
care	O
medicine	B-CHED
.	O

ABSTRACT	O
:	O
The	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
main	O
protease	O
(	O
M	O
(	O
pro	B-CHED
))	O
cleaves	O
two	O
virion	O
polyproteins	O
(	O
pp1a	O
and	O
pp1ab	O
);	O
this	O
essential	O
process	O
represents	O
an	O
attractive	O
target	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
drugs	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
a	O
C	B-CHED
-	I-CHED
terminal	I-CHED
residue	I-CHED
,	O
Arg298	O
,	O
interacts	O
with	O
Ser123	O
of	O
the	O
other	O
monomer	O
in	O
the	O
dimer	O
,	O
and	O
mutation	O
of	O
Arg298	O
results	O
in	O
a	O
monomeric	O
structure	O
with	O
a	O
collapsed	O
substrate	O
-	O
binding	O
pocket	O
.	O

The	O
potential	O
interactome	O
of	O
the	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
N	O
protein	B-CHED
was	O
mapped	O
using	O
stable	O
isotope	O
labeling	O
with	O
amino	B-CHED
acids	I-CHED
in	O
cell	O
culture	O
(	O
SILAC	O
)	O
coupled	O
to	O
a	O
green	O
fluorescent	O
protein	B-CHED
-	O
nanotrap	O
pulldown	O
methodology	O
and	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
.	O

Furthermore	O
,	O
dieckol	B-CHED
(	O
8	O
)	O
exhibited	O
a	O
high	O
association	O
rate	O
in	O
the	O
SPR	O
sensorgram	O
and	O
formed	O
extremely	O
strong	O
hydrogen	B-CHED
bonds	O
to	O
the	O
catalytic	O
dyad	O
(	O
Cys145	O
and	O
His41	O
)	O
of	O
the	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
).	O

Recently	O
,	O
chloroquine	B-CHED
has	O
been	O
reported	O
to	O
antiviral	B-CHED
effect	O
.	O

It	O
was	O
demonstrated	O
that	O
chloroquine	B-CHED
has	O
inhibitory	O
effect	O
against	O
the	O
replication	O
of	O
FIPV	O
and	O
anti	O
-	O
inflammatory	O
effect	O
in	O
vitro	O
.	O

TITLE	O
:	O
Identification	O
of	O
residues	O
of	O
SARS	O
-	O
CoV	O
nsp1	O
that	O
differentially	O
affect	O
inhibition	O
of	O
gene	O
expression	O
and	O
antiviral	B-CHED
signaling	O
.	O

RESULTS	O
:	O
In	O
comparisons	O
with	O
the	O
control	O
subjects	O
(	O
n	O
=	O
18	O
)	O
and	O
convalescent	O
SARS	O
patients	O
without	O
PTSD	O
(	O
n	O
=	O
26	O
),	O
the	O
SARS	O
-	O
related	O
PTSD	O
group	O
(	O
n	O
=	O
18	O
)	O
had	O
significantly	O
lower	O
N	O
-	O
acetylaspartate	O
/	O
creatine	B-CHED
(	O
NAA	B-CHED
/	O
Cr	O
)	O
in	O
4	O
regions	O
of	O
interest	O
while	O
the	O
NAA	B-CHED
/	O
Cr	O
of	O
the	O
convalescent	O
SARS	O
patients	O
was	O
significantly	O
lower	O
than	O
controls	O
in	O
3	O
regions	O
of	O
interest	O
(	O
ACG	O
,	O
PCG	O
and	O
LAPWM	O
).	O

The	O
peptides	B-CHED
identified	O
in	O
this	O
study	O
are	O
useful	O
reagents	B-CHED
for	O
detection	O
of	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
DNA	O
sequencing	O
showed	O
that	O
two	O
phage	O
displayed	O
peptides	B-CHED
HHKTWHPPVMHL	O
(	O
phage	O
-	O
H	O
)	O
and	O
SQWHPRSASYPM	O
(	O
phage	O
-	O
S	O
)	O
that	O
were	O
specific	O
ligands	O
to	O
the	O
S1	O
protein	B-CHED
.	O

TITLE	O
:	O
A	O
combination	O
of	O
epitope	B-CHED
prediction	O
and	O
molecular	O
docking	O
allows	O
for	O
good	O
identification	O
of	O
MHC	O
class	O
I	O
restricted	O
T	O
-	O
cell	O
epitopes	O
.	O

Knockdown	O
of	O
PERK	B-CHED
by	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
suppressed	O
the	O
activation	O
of	O
GADD153	O
and	O
the	O
IBV	O
-	O
induced	O
apoptosis	O
.	O

Biochemistry	O
revealed	O
markedly	O
elevated	O
creatinine	B-CHED
kinase	O
and	O
aspartate	B-CHED
aminotransferase	O
which	O
indicated	O
a	O
myopathy	O
.	O

Mouse	O
hepatitis	O
virus	O
genomes	O
containing	O
three	O
or	O
four	O
nucleotide	B-CHED
mutations	O
that	O
destabilize	O
either	O
S3	O
or	O
S4	O
were	O
viable	O
,	O
whereas	O
genomes	O
carrying	O
these	O
mutations	O
in	O
both	O
S3	O
and	O
S4	O
were	O
not	O
viable	O
.	O

Patients	O
with	O
diethyl	O
-	O
OPs	O
required	O
intubation	O
significantly	O
earlier	O
and	O
showed	O
lower	O
and	O
more	O
sustained	O
inhibited	O
activity	O
of	O
the	O
plasma	O
-	O
cholinesterase	O
on	O
admission	O
compared	O
with	O
patients	O
ingesting	O
dimethyl	B-CHED
-	O
OPs	O
.	O

He	O
has	O
developed	O
well	O
upon	O
treatment	O
with	O
B12	B-CHED
,	O
carnitine	B-CHED
,	O
and	O
hypoproteic	O
diet	O
.	O

Furthermore	O
,	O
it	O
suggests	O
that	O
an	O
early	O
treatment	O
with	O
vitamins	B-CHED
might	O
be	O
beneficial	O
for	O
patients	O
presenting	O
with	O
neonatal	O
-	O
onset	O
hyperammonemia	O
regardless	O
of	O
the	O
suspected	O
disease	O
and	O
before	O
receiving	O
the	O
biochemical	O
diagnosis	O
.	O

We	O
set	O
out	O
to	O
measure	O
changes	O
in	O
HDL	B-CHED
in	O
sepsis	O
-	O
mediated	O
ARDS	O
patients	O
,	O
and	O
to	O
study	O
the	O
potential	O
of	O
L	O
-	O
4F	O
to	O
prevent	O
sepsis	O
-	O
mediated	O
ARDS	O
in	O
a	O
rodent	O
model	O
of	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)-	O
mediated	O
acute	O
lung	O
injury	O
,	O
and	O
a	O
combination	O
of	O
primary	O
human	O
leukocytes	O
and	O
human	O
ARDS	O
serum	O
.	O

L	O
-	O
4F	O
inhibits	O
the	O
activation	O
of	O
isolated	O
human	O
leukocytes	O
and	O
neutrophils	O
by	O
ARDS	O
serum	O
and	O
LPS	B-CHED
in	O
vitro	O
.	O

The	O
main	O
protective	O
mechanisms	O
of	O
L	O
-	O
4F	O
are	O
due	O
to	O
direct	O
inhibition	O
of	O
endotoxin	O
activity	O
and	O
preservation	O
of	O
HDL	B-CHED
anti	O
-	O
oxidant	B-CHED
activity	O
.	O

Compared	O
with	O
quinine	B-CHED
,	O
intravenous	O
artemisinin	B-CHED
compounds	O
(	O
artesunate	B-CHED
,	O
arteether	O
,	O
artemether	B-CHED
)	O
are	O
well	O
tolerated	O
by	O
patients	O
and	O
have	O
fewer	O
side	O
effects	O
.	O

CART	O
after	O
paracentesis	O
reduces	O
protein	B-CHED
loss	O
in	O
ascites	O
by	O
reinfusion	O
of	O
autologous	O
protein	B-CHED
instead	O
of	O
exogenous	O
albumin	O
preparations	O
.	O

VV	O
-	O
ECMO	O
is	O
used	O
for	O
patients	O
with	O
severe	O
ARDS	O
to	O
secure	O
adequate	O
oxygenation	O
of	O
the	O
organs	O
while	O
protecting	O
the	O
lungs	O
from	O
harmful	O
ventilation	O
pressures	O
or	O
prolonged	O
inspiratory	O
fraction	O
of	O
oxygen	B-CHED
.	O

Typical	O
examples	O
include	O
poisoning	O
due	O
to	O
calcium	B-CHED
channel	O
antagonists	B-CHED
,	O
beta	O
-	O
blockers	O
,	O
tricyclic	B-CHED
antidepressants	I-CHED
,	O
chloroquine	B-CHED
and	O
colchicine	B-CHED
.	O

The	O
replication	O
of	O
wild	O
-	O
type	O
MHV	O
strain	O
A59	O
(	O
A59	O
)	O
and	O
a	O
mutant	O
with	O
an	O
inactive	O
phosphodiesterase	O
(	O
ns2	O
-	O
H126R	O
)	O
was	O
assessed	O
in	O
primary	O
hepatocytes	O
and	O
primary	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
cell	O
types	O
-	O
neurons	O
,	O
astrocytes	O
,	O
and	O
oligodendrocytes	O
.	O

Activation	O
of	O
RNase	O
L	O
correlated	O
with	O
the	O
induction	O
of	O
type	O
I	O
interferon	O
and	O
the	O
consequent	O
high	O
levels	O
of	O
OAS	O
mRNA	B-CHED
induced	O
in	O
these	O
cell	O
types	O
.	O

This	O
review	O
describes	O
the	O
suppressive	O
effects	O
of	O
CsA	B-CHED
on	O
coronavirus	O
replication	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
membrane	O
(	O
M	O
)	O
proteins	B-CHED
are	O
capable	O
of	O
self	O
-	O
assembly	O
and	O
release	O
in	O
the	O
form	O
of	O
membrane	O
-	O
enveloped	O
vesicles	O
,	O
and	O
of	O
forming	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
when	O
coexpressed	O
with	O
SARS	O
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
.	O

Combined	O
,	O
these	O
results	O
indicate	O
the	O
involvement	O
of	O
specific	O
M	O
amino	B-CHED
acids	I-CHED
during	O
SARS	O
-	O
CoV	O
virus	O
assembly	O
,	O
and	O
suggest	O
that	O
aromatic	O
residue	O
retention	O
at	O
specific	O
positions	O
is	O
critical	O
for	O
M	O
function	O
in	O
terms	O
of	O
directing	O
virus	O
assembly	O
.	O

He	O
cofounded	O
Inimex	O
Pharmaceuticals	B-CHED
,	O
Inc	O
.	O
(	O
BC	O
,	O
Canada	O
),	O
and	O
is	O
Director	O
of	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Accelerated	O
Vaccine	O
Initiative	O
.	O

TITLE	O
:	O
Common	O
topics	O
in	O
adolescent	O
critical	O
care	O
medicine	B-CHED
.	O

ABSTRACT	O
:	O
Apolipoprotein	B-CHED
D	O
(	O
ApoD	O
)	O
gene	O
expression	O
is	O
increased	O
in	O
several	O
neurological	O
disorders	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
and	O
multiple	O
sclerosis	O
.	O

The	O
N	O
protein	B-CHED
consists	O
of	O
two	O
structural	O
domains	O
interspersed	O
between	O
intrinsically	O
disordered	O
regions	O
and	O
dimerizes	O
through	O
the	O
C	O
-	O
terminal	O
structural	O
domain	O
(	O
CTD	O
).	O

Haematology	O
and	O
serum	O
biochemistry	O
revealed	O
severe	O
panleukopenia	O
,	O
thrombocytopenia	O
,	O
markedly	O
elevated	O
alanine	B-CHED
aminotransferase	O
(	O
ALT	B-CHED
)	O
and	O
five	O
-	O
fold	O
increased	O
pre	O
-	O
prandial	O
bile	B-CHED
acids	I-CHED
.	O

ABSTRACT	O
:	O
The	O
design	O
,	O
synthesis	O
,	O
and	O
in	O
vitro	O
evaluation	O
of	O
the	O
first	O
macrocyclic	O
inhibitor	B-CHED
of	O
3C	O
and	O
3C	O
-	O
like	O
proteases	O
of	O
picornavirus	O
,	O
norovirus	O
,	O
and	O
coronavirus	O
are	O
reported	O
.	O

Several	O
factors	O
contribute	O
to	O
the	O
inflammatory	O
process	O
,	O
including	O
hypoxia	O
(	O
inadequate	O
oxygen	B-CHED
),	O
hyperoxia	O
(	O
higher	O
than	O
normal	O
partial	O
pressure	O
of	O
oxygen	B-CHED
),	O
inflammatory	O
mediators	O
(	O
such	O
as	O
cytokines	O
),	O
infections	O
(	O
viral	O
and	O
bacterial	O
),	O
and	O
environmental	O
conditions	O
(	O
such	O
as	O
cigarette	O
smoke	O
or	O
noxious	O
gases	O
).	O

The	O
most	O
commonly	O
used	O
immunosuppressive	O
drug	O
is	O
methotrexate	B-CHED
at	O
a	O
dose	O
of	O
up	O
to	O
25	O
mg	O
/	O
week	O
.	O

TITLE	O
:	O
In	O
vitro	O
antiviral	B-CHED
activity	O
of	O
phlorotannins	B-CHED
isolated	O
from	O
Ecklonia	O
cava	O
against	O
porcine	O
epidemic	O
diarrhea	O
coronavirus	O
infection	O
and	O
hemagglutination	O
.	O

We	O
confirmed	O
the	O
chylomicronemia	O
syndrome	O
with	O
a	O
triglyceride	B-CHED
assay	O
.	O

RESULTS	O
:	O
After	O
3	O
sessions	O
of	O
plasmapheresis	O
,	O
his	O
triglyceride	B-CHED
levels	O
were	O
significantly	O
reduced	O
,	O
his	O
oxygenation	O
improved	O
,	O
and	O
his	O
acute	O
kidney	O
injury	O
resolved	O
.	O

TITLE	O
:	O
[	O
Prokaryotic	O
expression	O
and	O
characterization	O
of	O
two	O
recombinant	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
proteins	B-CHED
of	O
human	O
coronavirus	O
NL63	O
(	O
HcoV	O
-	O
NL63	O
)].	O

In	O
this	O
study	O
,	O
we	O
prepared	O
2	O
purified	O
recombinant	O
HCoV	O
-	O
NL63	O
RBD	O
proteins	B-CHED
using	O
in	O
E	O
.	O
coli	O
system	O
and	O
identified	O
the	O
proteins	B-CHED
by	O
Western	O
blotting	O
.	O

8mM	O
IPTG	B-CHED
induction	O
for	O
4h	O
.	O

RL	O
or	O
RS	O
protein	B-CHED
with	O
95	O
%	O
purity	O
was	O
obtained	O
and	O
reacted	O
positively	O
with	O
anti	O
-	O
sera	O
from	O
mice	O
immunized	O
with	O
the	O
recombinant	O
vaccinia	O
virus	O
(	O
Tiantan	O
strain	O
)	O
in	O
which	O
HCoV	O
-	O
NL63	O
RL	O
or	O
RS	O
protein	B-CHED
was	O
expressed	O
.	O

The	O
percentage	O
of	O
apoptotic	O
cells	O
increased	O
with	O
the	O
incubation	O
time	O
and	O
reached	O
a	O
maximum	O
at	O
96h	O
post	O
-	O
infection	O
,	O
as	O
determined	O
using	O
flow	O
cytometry	O
and	O
fluorescence	O
microscopy	O
of	O
cells	O
that	O
were	O
stained	O
with	O
annexin	O
V	O
-	O
FITC	B-CHED
and	O
propidium	B-CHED
iodide	I-CHED
(	O
PI	O
).	O

Salmonella	O
was	O
also	O
cultured	O
from	O
overnight	O
selenite	B-CHED
enrichment	O
broth	O
.	O

TITLE	O
:	O
Inhibitory	O
effect	O
of	O
resveratrol	B-CHED
against	O
duck	O
enteritis	O
virus	O
in	O
vitro	O
.	O

In	O
the	O
indirect	O
immunofluorescence	O
assay	O
,	O
proteins	B-CHED
expression	O
in	O
DEV	O
infected	O
duck	O
embryo	O
fibroblasts	O
(	O
DEFs	O
)	O
within	O
24	O
h	O
post	O
-	O
infection	O
(	O
p	O
.	O
i	O
.)	O
was	O
also	O
effectively	O
suppressed	O
by	O
resveratrol	B-CHED
.	O

In	O
summary	O
,	O
the	O
resveratrol	B-CHED
has	O
a	O
good	O
activity	O
against	O
DEV	O
infection	O
in	O
vitro	O
,	O
which	O
could	O
be	O
attributed	O
to	O
that	O
fact	O
that	O
several	O
essential	O
immediate	O
early	O
viral	O
proteins	B-CHED
for	O
virus	O
replication	O
were	O
impacted	O
by	O
resveratrol	B-CHED
.	O

Acute	O
renal	O
failure	O
,	O
cerebral	O
malaria	O
,	O
high	O
bilirubin	B-CHED
,	O
anaemia	O
,	O
metabolic	O
acidosis	O
and	O
death	O
were	O
also	O
found	O
in	O
vivax	O
malaria	O
but	O
less	O
frequently	O
than	O
in	O
falciparum	O
and	O
mixed	O
malaria	O
.	O

Studies	O
have	O
also	O
reported	O
a	O
high	O
prevalence	O
of	O
vitamin	B-CHED
D	I-CHED
deficiency	O
in	O
the	O
critically	O
ill	O
and	O
an	O
association	O
with	O
adverse	O
outcomes	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
an	O
emerging	O
virus	O
involved	O
in	O
cases	O
and	O
case	O
clusters	B-CHED
of	O
severe	O
acute	O
respiratory	O
infection	O
in	O
the	O
Arabian	O
Peninsula	O
,	O
Tunisia	O
,	O
Morocco	O
,	O
France	O
,	O
Italy	O
,	O
Germany	O
,	O
and	O
the	O
UK	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
the	O
recently	O
emerged	O
human	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
mediates	O
infection	O
by	O
binding	O
to	O
the	O
cellular	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
).	O

TITLE	O
:	O
Solution	O
NMR	O
analyses	O
of	O
the	O
C	O
-	O
type	O
carbohydrate	B-CHED
recognition	O
domain	O
of	O
DC	O
-	O
SIGNR	O
protein	B-CHED
reveal	O
different	O
binding	O
modes	O
for	O
HIV	O
-	O
derived	O
oligosaccharides	B-CHED
and	O
smaller	O
glycan	B-CHED
fragments	O
.	O

(	O
15	O
)	O
N	O
relaxation	O
measurements	O
provided	O
the	O
first	O
information	O
on	O
the	O
dynamics	O
of	O
the	O
carbohydrate	B-CHED
recognition	O
domain	O
,	O
demonstrating	O
that	O
it	O
is	O
a	O
highly	O
flexible	O
domain	O
that	O
undergoes	O
ligand	B-CHED
-	O
induced	O
conformational	O
and	O
dynamic	O
changes	O
that	O
may	O
explain	O
the	O
ability	O
of	O
DC	O
-	O
SIGNR	O
to	O
accommodate	O
a	O
range	O
of	O
glycans	B-CHED
on	O
viral	O
surfaces	O
.	O

All	O
patients	O
were	O
seen	O
by	O
doctors	O
,	O
no	O
one	O
had	O
received	O
antiviral	B-CHED
therapy	O
,	O
4	O
/	O
5	O
were	O
treated	O
with	O
antibiotics	B-CHED
before	O
they	O
were	O
hospitalized	O
.	O

They	O
received	O
oseltamivir	B-CHED
treatment	O
on	O
the	O
4th	O
to	O
9th	O
day	O
.	O

CONCLUSIONS	O
:	O
Delayed	O
diagnosis	O
and	O
antiviral	B-CHED
treatment	O
initiation	O
has	O
a	O
significant	O
impact	O
on	O
mortality	O
in	O
A	O
(	O
H1N1	O
)	O
influenza	O
.	O

Both	O
cholesterol	B-CHED
-	O
and	O
cholesterol	B-CHED
-	O
PEG3	O
-	O
tagged	O
peptides	B-CHED
were	O
able	O
to	O
protect	O
chicken	O
embryos	O
from	O
infection	O
with	O
different	O
serotypes	O
of	O
NDV	O
and	O
IBV	O
when	O
administered	O
12	O
h	O
prior	O
to	O
virus	O
inoculation	O
.	O

As	O
an	O
example	O
of	O
the	O
latter	O
,	O
a	O
research	O
program	O
was	O
reported	O
that	O
identified	O
compounds	O
with	O
activity	O
against	O
HIV	O
-	O
1	O
and	O
-	O
2	O
,	O
herpes	O
virus	O
,	O
influenza	O
virus	O
and	O
Coxsackie	O
virus	O
(	O
Dejmek	O
,	O
M	O
.	O
et	O
al	O
.,	O
Abst	O
35	O
),	O
while	O
studies	O
with	O
Griffithsin	O
,	O
a	O
red	O
algae	O
-	O
derived	O
protein	B-CHED
with	O
potent	O
,	O
broad	O
antiviral	B-CHED
activity	O
against	O
hepatitis	O
C	O
virus	O
,	O
coronavirus	O
and	O
Japanese	O
encephalitis	O
virus	O
,	O
among	O
others	O
,	O
showed	O
it	O
also	O
inhibited	O
HIV	O
,	O
although	O
only	O
when	O
the	O
tight	O
dimer	O
structure	O
is	O
respected	O
(	O
Xue	O
,	O
J	O
.	O
et	O
al	O
.,	O
Abst	O
104	O
).	O

This	O
case	O
highlights	O
the	O
importance	O
of	O
prompt	O
therapy	O
with	O
early	O
ECMO	O
support	O
in	O
combination	O
with	O
ribavirin	B-CHED
,	O
IVIG	O
and	O
steroids	B-CHED
in	O
patients	O
affected	O
by	O
severe	O
HPIV	O
-	O
3	O
pneumonia	O
and	O
THI	O
.	O

Combination	O
therapy	O
with	O
levofloxacin	B-CHED
and	O
rifampin	B-CHED
was	O
started	O
on	O
admission	O
.	O

In	O
medicine	B-CHED
,	O
a	O
definition	O
or	O
syndrome	O
representing	O
""""	O
a	O
constellation	O
of	O
symptomatology	O
seen	O
in	O
association	O
""""	O
should	O
stand	O
the	O
trial	O
of	O
time	O
after	O
it	O
is	O
coined	O
.	O

In	O
the	O
last	O
20	O
years	O
,	O
many	O
natural	O
substances	O
have	O
shown	O
antiviral	B-CHED
activity	O
against	O
HIV	O
-	O
1	O
,	O
but	O
only	O
a	O
few	O
against	O
the	O
RNase	O
H	O
function	O
.	O

Active	O
extracts	O
were	O
fractionated	O
up	O
to	O
obtain	O
the	O
main	O
components	O
that	O
have	O
been	O
isolated	O
,	O
tested	O
,	O
and	O
identified	O
to	O
be	O
betulinic	B-CHED
acid	I-CHED
,	O
shikimic	B-CHED
acid	I-CHED
,	O
chlorogenic	B-CHED
acid	I-CHED
,	O
quercetin	B-CHED
,	O
5	B-CHED
,	I-CHED
7	I-CHED
,	I-CHED
3	I-CHED
',	I-CHED
5	I-CHED
'-	I-CHED
tetrahydroxyflavanone	I-CHED
,	O
and	O
5	B-CHED
,	I-CHED
7	I-CHED
,	I-CHED
3	I-CHED
',	I-CHED
5	I-CHED
'-	I-CHED
tetrahydroxyflavanone	I-CHED
7	O
-	O
O	O
-	O
glucoside	B-CHED
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
receptor	O
-	O
binding	O
domain	O
in	O
the	O
S	O
protein	B-CHED
of	O
the	O
novel	O
human	O
coronavirus	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
as	O
an	O
essential	O
target	O
for	O
vaccine	O
development	O
.	O

The	O
main	O
factor	O
associated	O
with	O
non	O
-	O
severe	O
presentation	O
was	O
an	O
early	O
(<	O
48	O
h	O
)	O
implementation	O
of	O
oseltamivir	B-CHED
treatment	O
(	O
P	O
=	O
0	O
.	O
038	O
).	O

Although	O
the	O
study	O
failed	O
to	O
achieve	O
its	O
main	O
objective	O
,	O
due	O
mainly	O
to	O
the	O
difficulty	O
of	O
carrying	O
a	O
study	O
of	O
this	O
nature	O
in	O
the	O
midst	O
of	O
a	O
pandemic	O
,	O
it	O
allowed	O
the	O
description	O
of	O
a	O
panel	O
of	O
unusual	O
and	O
complicated	O
forms	O
and	O
confirmed	O
the	O
added	O
value	O
of	O
early	O
oseltamivir	B-CHED
treatment	O
in	O
limiting	O
severity	O
in	O
hospitalized	O
children	O
and	O
adults	O
.	O

Obstetric	O
sepsis	O
requires	O
early	O
broad	O
-	O
spectrum	O
antibiotic	B-CHED
therapy	O
and	O
may	O
necessitate	O
surgical	O
intervention	O
.	O

ABSTRACT	O
:	O
The	O
membrane	O
(	O
M	O
)	O
protein	B-CHED
is	O
one	O
of	O
the	O
major	O
structural	O
proteins	B-CHED
of	O
coronavirus	O
particles	O
.	O

Plaque	O
-	O
reduction	O
assays	O
revealed	O
that	O
pepTGEV	O
-	O
M7	O
was	O
able	O
to	O
prevent	O
TGEV	O
infection	O
in	O
vitro	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
following	O
pretreatment	O
of	O
the	O
virus	O
with	O
the	O
peptide	B-CHED
.	O

Here	O
we	O
delineate	O
the	O
molecular	O
basis	O
of	O
this	O
specific	O
interaction	O
by	O
presenting	O
the	O
first	O
crystal	O
structures	O
of	O
both	O
the	O
free	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
and	O
its	O
complex	O
with	O
CD26	O
.	O

To	O
deliver	O
viral	O
antigens	B-CHED
to	O
the	O
mucosal	O
immune	O
system	O
of	O
chickens	O
safely	O
and	O
effectively	O
,	O
we	O
constructed	O
a	O
Lactococcus	O
lactis	O
strain	O
carrying	O
IBV	O
multi	O
-	O
epitope	B-CHED
gene	O
EpiC	O
fused	O
with	O
the	O
gene	O
of	O
the	O
cell	O
-	O
wall	O
anchoring	O
domain	O
of	O
Staphylococcus	O
aureus	O
protein	B-CHED
A	O
.	O
SDS	B-CHED
-	O
PAGE	O
and	O
Western	O
blot	O
results	O
indicated	O
that	O
the	O
fused	O
peptide	B-CHED
was	O
located	O
partially	O
on	O
the	O
cell	O
surface	O
.	O

Both	O
H7N9	O
viruses	O
replicated	O
to	O
higher	O
titre	O
in	O
human	O
airway	O
epithelial	O
cells	O
and	O
in	O
the	O
respiratory	O
tract	O
of	O
ferrets	O
compared	O
to	O
a	O
seasonal	O
H3N2	B-CHED
virus	O
.	O

Severity	O
categories	O
of	O
ARDS	O
described	O
by	O
the	O
Berlin	O
definition	O
have	O
good	O
predictive	O
validity	O
and	O
may	O
be	O
associated	O
with	O
increased	O
extravascular	O
lung	O
water	B-CHED
and	O
pulmonary	O
vascular	O
permeability	O
.	O

No	O
survivors	O
were	O
dependent	O
on	O
oxygen	B-CHED
.	O

No	O
survivors	O
were	O
dependent	O
on	O
oxygen	B-CHED
.	O

The	O
identified	O
proteins	B-CHED
were	O
involved	O
in	O
the	O
regulation	O
of	O
essential	O
processes	O
such	O
as	O
cellular	O
structure	O
and	O
integrity	O
,	O
RNA	O
processing	O
,	O
protein	B-CHED
biosynthesis	O
and	O
modification	O
,	O
vesicle	O
transport	O
,	O
signal	O
transduction	O
,	O
and	O
the	O
mitochondrial	O
pathway	O
.	O

The	O
present	O
study	O
provides	O
protein	B-CHED
-	O
related	O
information	O
that	O
should	O
be	O
useful	O
for	O
understanding	O
the	O
host	O
cell	O
response	O
to	O
TGEV	O
infection	O
and	O
the	O
underlying	O
mechanism	O
of	O
TGEV	O
replication	O
and	O
pathogenicity	O
.	O

Five	O
hours	O
after	O
LPS	B-CHED
,	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
and	O
plasma	O
were	O
obtained	O
.	O

TEE	O
depicted	O
ACP	B-CHED
in	O
45	O
/	O
200	O
patients	O
[	O
22	O
.	O
5	O
%;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
16	O
.	O
9	O
-	O
28	O
.	O
9	O
%],	O
PFO	B-CHED
in	O
31	O
patients	O
(	O
15	O
.	O
5	O
%;	O
95	O
%	O
CI	O
10	O
.	O
8	O
-	O
21	O
.	O
3	O
%),	O
and	O
both	O
ACP	B-CHED
and	O
PFO	B-CHED
in	O
9	O
patients	O
(	O
4	O
.	O
5	O
%;	O
95	O
%	O
CI	O
2	O
.	O
1	O
-	O
8	O
.	O
4	O
%).	O

PaCO	O
>	O
60	O
mmHg	O
was	O
strongly	O
associated	O
with	O
ACP	B-CHED
[	O
odds	O
ratio	O
(	O
OR	O
)	O
3	O
.	O
70	O
;	O
95	O
%	O
CI	O
1	O
.	O
32	O
-	O
10	O
.	O
38	O
;	O
p	O
=	O
0	O
.	O
01	O
].	O

Lung	O
CD34	O
,	O
KDR	O
,	O
and	O
lung	O
stromal	O
cell	O
-	O
derived	O
factor	O
-	O
1	O
messenger	B-CHED
RNA	I-CHED
expression	O
were	O
higher	O
in	O
the	O
acute	O
lung	O
injury	O
group	O
than	O
in	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
group	O
.	O

Furthermore	O
,	O
the	O
expression	O
of	O
CD34	O
,	O
KDR	O
,	O
and	O
CD133	O
messenger	B-CHED
RNA	I-CHED
in	O
lung	O
tissue	O
was	O
correlated	O
with	O
stromal	O
cell	O
-	O
derived	O
factor	O
-	O
1	O
in	O
the	O
lung	O
.	O

These	O
viruses	O
include	O
important	O
human	O
and	O
animal	O
pathogens	O
,	O
such	O
as	O
influenza	O
,	O
parainfluenza	O
,	O
mumps	O
,	O
corona	B-CHED
,	O
noro	O
,	O
rota	O
,	O
and	O
DNA	O
tumor	O
viruses	O
.	O

Older	O
age	O
,	O
severe	O
deficits	O
at	O
onset	O
,	O
injured	O
cranial	O
nerves	O
,	O
requiring	O
MV	O
,	O
and	O
axonal	O
lesion	O
patterns	O
in	O
the	O
NCS	B-CHED
were	O
demonstrated	O
as	O
poor	O
prognostic	O
factors	O
.	O

These	O
new	O
tools	O
have	O
the	O
potential	O
to	O
significantly	O
reduce	O
the	O
time	O
needed	O
to	O
design	O
string	O
-	O
of	O
-	O
epitope	B-CHED
vaccines	O
for	O
previously	O
unknown	O
pathogens	O
.	O

The	O
RVA	O
PDE	O
forms	O
the	O
carboxy	B-CHED
-	O
terminal	O
domain	O
of	O
the	O
minor	O
core	O
protein	B-CHED
VP3	O
(	O
VP3	O
-	O
CTD	O
)	O
and	O
shares	O
sequence	O
and	O
predicted	O
structural	O
homology	O
with	O
ns2	O
,	O
including	O
two	O
catalytic	O
HxT	O
/	O
S	O
motifs	O
.	O

ABSTRACT	O
:	O
Gemcitabine	B-CHED
is	O
widely	O
accepted	O
as	O
the	O
standard	O
treatment	O
for	O
pancreatic	O
cancer	O
,	O
but	O
it	O
can	O
cause	O
unpredictable	O
side	O
effects	O
.	O

Two	O
family	O
clusters	B-CHED
have	O
been	O
identified	O
,	O
1	O
in	O
Riyadh	O
and	O
1	O
in	O
Manchester	O
,	O
England	O
.	O

Surveillance	O
has	O
been	O
extended	O
to	O
include	O
clusters	B-CHED
of	O
cases	O
or	O
health	O
-	O
care	O
workers	O
with	O
severe	O
,	O
undiagnosed	O
respiratory	O
illness	O
regardless	O
of	O
travel	O
history	O
.	O

Binding	O
of	O
the	O
IBV	O
spike	O
protein	B-CHED
to	O
host	O
cells	O
was	O
in	O
all	O
experiments	O
sialic	B-CHED
acid	I-CHED
dependent	O
,	O
whereas	O
the	O
soluble	O
TGEV	O
spike	O
showed	O
binding	O
to	O
APN	O
but	O
had	O
no	O
detectable	O
sialic	B-CHED
acid	I-CHED
binding	O
activity	O
.	O

When	O
tested	O
with	O
a	O
50	O
-	O
ml	O
reservoir	O
,	O
a	O
high	O
fractional	O
oxygen	B-CHED
concentration	O
was	O
achieved	O
:	O
mean	O
(	O
SD	O
)	O
0	O
.	O
83	O
(	O
0	O
.	O
11	O
)	O
at	O
a	O
flow	O
of	O
15	O
l	O
.	O
min	O
(-	O
1	O
)	O
oxygen	B-CHED
.	O

These	O
results	O
suggested	O
that	O
hepatic	O
CD69	O
+	O
NK	O
cells	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	O
of	O
FHF	O
by	O
enhancing	O
degranulation	O
and	O
cytotoxic	O
ability	O
of	O
NK	O
cells	O
and	O
increasing	O
the	O
production	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
this	O
locus	O
,	O
which	O
contains	O
the	O
gene	O
for	O
accessory	O
protein	B-CHED
3a	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
encodes	O
a	O
protein	B-CHED
that	O
forms	O
ion	O
channels	O
and	O
regulates	O
virus	O
release	O
.	O

Our	O
findings	O
revealed	O
that	O
the	O
ORF4a	O
proteins	B-CHED
were	O
expressed	O
in	O
infected	O
cells	O
and	O
localized	O
at	O
the	O
endoplasmic	O
reticulum	O
/	O
Golgi	O
intermediate	O
compartment	O
(	O
ERGIC	O
).	O

The	O
ORF4a	O
proteins	B-CHED
formed	O
homo	O
-	O
oligomers	O
through	O
disulfide	B-CHED
bridges	O
and	O
possessed	O
ion	O
channel	O
activity	O
in	O
both	O
Xenopus	O
oocytes	O
and	O
yeast	O
.	O

The	O
present	O
study	O
investigated	O
the	O
chemical	O
stability	O
of	O
an	O
oral	O
ribavirin	B-CHED
suspension	O
(	O
200	O
mg	O
/	O
5mL	O
)	O
prepared	O
extemporaneously	O
from	O
oral	O
capsules	O
using	O
a	O
sugar	O
-	O
free	O
suspension	O
formula	O
.	O

After	O
demonstrating	O
that	O
these	O
cells	O
were	O
functional	O
and	O
responded	O
to	O
epitope	B-CHED
M133	O
,	O
these	O
TCR	O
chains	O
were	O
used	O
to	O
generate	O
an	O
epitope	B-CHED
M133	O
-	O
specific	O
TCR	O
Tg	O
mouse	O
.	O

TITLE	O
:	O
Inhaled	O
epoprostenol	B-CHED
to	O
support	O
the	O
severely	O
hypoxemic	O
patient	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Research	O
comparing	O
the	O
2	O
inhaled	O
vasodilators	O
suggests	O
that	O
epoprostenol	B-CHED
is	O
equally	O
efficacious	O
,	O
easier	O
to	O
administer	O
,	O
less	O
costly	O
,	O
and	O
has	O
fewer	O
adverse	O
effects	O
.	O

ABSTRACT	O
:	O
Respiratory	O
infections	O
stemming	O
from	O
influenza	O
viruses	O
and	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
corona	B-CHED
virus	O
(	O
SARS	O
-	O
CoV	O
)	O
represent	O
a	O
serious	O
public	O
health	O
threat	O
as	O
emerging	O
pandemics	O
.	O

TITLE	O
:	O
Altered	O
pro	B-CHED
-	O
inflammatory	O
cytokine	O
mRNA	B-CHED
levels	O
in	O
chickens	O
infected	O
with	O
infectious	O
bronchitis	O
virus	O
.	O

In	O
addition	O
,	O
the	O
mRNA	B-CHED
levels	O
of	O
the	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
1	O
,	O
and	O
lipopolysaccharide	B-CHED
-	O
induced	O
tumor	O
necrosis	O
factor	O
-	O
	O
factor	O
and	O
the	O
serum	O
levels	O
of	O
1	O
-	O
acid	O
glycoprotein	B-CHED
,	O
which	O
is	O
a	O
major	O
acute	O
phase	O
protein	B-CHED
,	O
were	O
measured	O
.	O

In	O
addition	O
,	O
ACE2	O
has	O
functions	O
independent	O
of	O
the	O
RAS	B-CHED
:	O
ACE2	O
is	O
the	O
receptor	O
for	O
the	O
SARS	O
coronavirus	O
and	O
ACE2	O
is	O
essential	O
for	O
expression	O
of	O
neutral	O
amino	B-CHED
acid	I-CHED
transporters	O
in	O
the	O
gut	O
.	O

An	O
essential	O
packaging	O
signal	O
component	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
has	O
been	O
further	O
delimited	O
to	O
the	O
first	O
598	O
nucleotides	B-CHED
(	O
nt	O
)	O
from	O
the	O
5	O
'	O
end	O
of	O
its	O
RNA	O
genome	O
,	O
by	O
using	O
recombinant	O
viruses	O
transcribing	O
subgenomic	O
mRNA	B-CHED
that	O
included	O
potential	O
packaging	O
signals	O
.	O

Furthermore	O
,	O
these	O
studies	O
identify	O
ExoN	O
as	O
the	O
first	O
viral	O
protein	B-CHED
distinct	O
from	O
the	O
RdRp	O
that	O
determines	O
the	O
sensitivity	O
of	O
RNA	O
viruses	O
to	O
mutagens	B-CHED
.	O

To	O
accomplish	O
this	O
,	O
it	O
is	O
necessary	O
to	O
evaluate	O
neutralizing	O
antibodies	O
and	O
screen	O
for	O
MERS	O
-	O
CoV	O
entry	O
inhibitors	B-CHED
.	O

Furthermore	O
,	O
one	O
small	O
molecule	O
HIV	B-CHED
entry	I-CHED
inhibitor	I-CHED
targeting	O
gp41	O
(	O
ADS	O
-	O
J1	O
)	O
and	O
the	O
3	O
-	O
hydroxyphthalic	O
anhydride	O
-	O
modified	O
human	O
serum	O
albumin	O
(	O
HP	O
-	O
HSA	O
)	O
could	O
significantly	O
inhibit	O
MERS	O
-	O
CoV	O
pseudovirus	O
infection	O
.	O

Furthermore	O
,	O
one	O
small	O
molecule	O
HIV	B-CHED
entry	I-CHED
inhibitor	I-CHED
targeting	O
gp41	O
(	O
ADS	O
-	O
J1	O
)	O
and	O
the	O
3	O
-	O
hydroxyphthalic	O
anhydride	O
-	O
modified	O
human	O
serum	O
albumin	O
(	O
HP	O
-	O
HSA	O
)	O
could	O
significantly	O
inhibit	O
MERS	O
-	O
CoV	O
pseudovirus	O
infection	O
.	O

The	O
initial	O
PaO2	O
/	O
FiO2	O
index	O
was	O
64	O
(	O
51	O
-	O
67	O
)	O
mmHg	O
and	O
the	O
arterial	O
carbon	B-CHED
dioxide	I-CHED
tension	O
was	O
60	O
(	O
50	O
-	O
71	O
)	O
mmHg	O
.	O

TITLE	O
:	O
Risperidone	B-CHED
-	O
induced	O
acute	O
eosinophilic	O
pneumonia	O
.	O

AEP	O
has	O
rarely	O
been	O
associated	O
with	O
first	O
-	O
generation	O
antipsychotics	B-CHED
and	O
never	O
been	O
reported	O
after	O
use	O
of	O
second	O
-	O
generation	O
antipsychotics	B-CHED
,	O
such	O
as	O
risperidone	B-CHED
.	O

Pathophysiological	O
mechanisms	O
implicated	O
in	O
the	O
development	O
of	O
AEP	O
in	O
our	O
patient	O
seem	O
to	O
be	O
associated	O
with	O
eotaxin	O
and	O
serotonin	B-CHED
eosinophilic	O
-	O
specific	O
chemoattracting	O
action	O
,	O
through	O
the	O
serotoninergic	O
action	O
of	O
risperidone	B-CHED
.	O

CONCLUSIONS	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
a	O
clinical	O
adverse	O
reaction	O
of	O
AEP	O
from	O
an	O
atypical	B-CHED
antipsychotic	I-CHED
agent	I-CHED
(	O
risperidone	B-CHED
).	O

A	O
docking	O
study	O
involving	O
binding	O
between	O
the	O
dipeptidic	O
lead	O
compound	O
4	O
and	O
3CLpro	O
suggested	O
the	O
modification	O
of	O
a	O
structurally	O
flexible	O
P3	O
N	O
-(	O
3	O
-	O
methoxyphenyl	O
)	O
glycine	B-CHED
with	O
various	O
rigid	O
P3	O
moieties	O
in	O
4	O
.	O

Further	O
optimization	O
showed	O
that	O
a	O
methoxy	B-CHED
substitution	O
at	O
the	O
4	O
-	O
position	O
on	O
the	O
indole	B-CHED
unit	O
was	O
highly	O
favorable	O
for	O
enhancing	O
the	O
inhibitory	O
potency	O
.	O

ABSTRACT	O
:	O
This	O
article	O
introduces	O
a	O
series	O
of	O
invited	O
papers	O
in	O
Antiviral	B-CHED
Research	O
marking	O
the	O
10th	O
anniversary	O
of	O
the	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
caused	O
by	O
a	O
novel	O
coronavirus	O
that	O
emerged	O
in	O
southern	O
China	O
in	O
late	O
2002	O
.	O

The	O
combination	O
of	O
interferon	O
-	O
2b	O
and	O
ribavirin	B-CHED
was	O
effective	O
in	O
reducing	O
MERS	O
-	O
CoV	O
replication	O
in	O
vitro	O
;	O
therefore	O
,	O
we	O
initiated	O
this	O
treatment	O
8	O
h	O
after	O
inoculation	O
of	O
rhesus	O
macaques	O
.	O

ABSTRACT	O
:	O
Poly	O
-	O
	O
-	O
glutamic	B-CHED
acid	I-CHED
(	O
	O
-	O
PGA	B-CHED
)	O
is	O
an	O
anionic	O
polypeptide	B-CHED
secreted	O
by	O
Bacillus	O
sp	O
.	O
that	O
has	O
been	O
shown	O
to	O
activate	O
immune	O
cells	O
through	O
interactions	O
with	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
).	O

Here	O
,	O
we	O
demonstrate	O
that	O
	O
-	O
PGA	B-CHED
induces	O
type	O
I	O
IFN	O
signaling	O
pathway	O
via	O
the	O
TLR4	O
signaling	O
pathway	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
characteristic	O
of	O
changes	O
in	O
extravascular	O
lung	O
water	B-CHED
index	O
(	O
EVLWI	O
)	O
of	O
H7N9	O
avian	O
influenza	O
patients	O
who	O
complicated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
to	O
approach	O
the	O
relevance	O
between	O
EVLWI	O
and	O
severity	O
,	O
pulmonary	O
oxygenation	O
in	O
patients	O
with	O
lung	O
injury	O
.	O

This	O
virus	O
constitutes	O
a	O
vaccine	O
candidate	O
that	O
may	O
represent	O
a	O
balance	B-CHED
between	O
safety	O
and	O
efficacy	O
for	O
the	O
induction	O
of	O
mucosal	O
immunity	O
,	O
which	O
is	O
needed	O
to	O
prevent	O
MERS	O
-	O
CoV	O
infection	O
.	O

Stimulation	O
of	O
PMNs	O
by	O
LPS	B-CHED
led	O
to	O
increased	O
expression	O
of	O
aquaporin	O
-	O
1	O
in	O
vitro	O
,	O
which	O
could	O
be	O
abrogated	O
by	O
the	O
NF	O
-	O
B	O
inhibitor	B-CHED
EF	O
-	O
24	O
.	O

TITLE	O
:	O
Beta	O
-	O
Agonist	B-CHED
Lung	O
injury	O
TrIal	O
-	O
2	O
(	O
BALTI	O
-	O
2	O
):	O
a	O
multicentre	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
and	O
economic	O
evaluation	O
of	O
intravenous	O
infusion	O
of	O
salbutamol	B-CHED
versus	O
placebo	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

A	O
total	O
of	O
326	O
patients	O
were	O
randomised	O
;	O
162	O
were	O
allocated	O
to	O
salbutamol	B-CHED
and	O
164	O
to	O
placebo	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
43	O
-	O
year	O
-	O
old	O
man	B-CHED
,	O
scheduled	O
for	O
OLT	O
due	O
to	O
alcoholic	O
cirrhosis	O
with	O
hemosiderosis	O
.	O

In	O
addition	O
,	O
LIMK1	O
or	O
SSH	O
-	O
1L	O
depletion	O
inhibited	O
RelA	O
/	O
p65	O
phosphorylation	O
at	O
Ser	B-CHED
(	O
536	O
),	O
a	O
critical	O
event	O
conferring	O
transcriptional	O
competency	O
to	O
the	O
bound	O
NF	O
-	O
B	O
.	O
However	O
,	O
unlike	O
SSH	O
-	O
1L	O
,	O
LIMK1	O
knockdown	O
also	O
impairs	O
the	O
release	O
of	O
RelA	O
/	O
p65	O
by	O
blocking	O
IKK	O
-	O
dependent	O
phosphorylation	O
/	O
degradation	O
of	O
IB	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
protein	B-CHED
is	O
the	O
major	O
viral	O
attachment	O
protein	B-CHED
of	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
ultimately	O
determines	O
viral	O
tropism	O
.	O

Recombinant	O
rMERS	O
-	O
CoV	O
,	O
rMERS	O
-	O
CoV	O
	O
ORF5	O
,	O
and	O
MERS	O
-	O
CoV	O
-	O
RFP	B-CHED
replicated	O
to	O
high	O
titers	O
,	O
whereas	O
MERS	O
-	O
ORF3	O
-	O
5	O
showed	O
1	O
-	O
1	O
.	O
5	O
logs	O
reduced	O
titer	O
compared	O
with	O
rMERS	O
-	O
CoV	O
.	O
Northern	O
blot	O
analyses	O
confirmed	O
the	O
associated	O
molecular	O
changes	O
in	O
the	O
recombinant	O
viruses	O
,	O
and	O
sequence	O
analysis	O
demonstrated	O
that	O
RFP	B-CHED
was	O
expressed	O
from	O
the	O
appropriate	O
consensus	O
sequence	O
AACGAA	O
.	O

The	O
following	O
characteristics	O
(	O
or	O
predictors	O
)	O
were	O
compared	O
between	O
the	O
groups	O
:	O
age	O
,	O
sex	O
,	O
calculated	O
amount	O
of	O
glufosinate	B-CHED
(	O
volume	O
of	O
ingested	O
poison	B-CHED
(	O
glufosinate	B-CHED
-	O
containing	O
herbicide	B-CHED
)	O
	O
glufosinate	B-CHED
concentration	O
of	O
the	O
product	O
),	O
time	O
duration	O
from	O
poison	B-CHED
ingestion	O
to	O
arrival	O
at	O
our	O
hospital	O
,	O
use	O
of	O
gastric	O
lavage	O
,	O
use	O
of	O
whole	O
bowel	O
irrigation	O
,	O
Glasgow	O
Coma	O
Scale	O
,	O
laboratory	O
parameters	O
,	O
PaO	O
/	O
FiO	O
ratio	O
(	O
P	O
/	O
F	O
ratio	O
),	O
shock	O
index	O
,	O
and	O
presence	O
or	O
absence	O
of	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
on	O
arrival	O
.	O

Severe	O
effects	O
following	O
acute	O
glufosinate	B-CHED
poisoning	O
were	O
associated	O
with	O
two	O
positive	O
SIRS	O
criteria	O
.	O

In	O
parallel	O
,	O
the	O
L2	O
-	O
MHV3	O
infection	O
in	O
mice	O
induced	O
fulminant	O
hepatitis	O
associated	O
with	O
up	O
-	O
regulated	O
IL	O
-	O
33	O
expression	O
as	O
well	O
as	O
pro	B-CHED
-	O
inflammatory	O
cytokine	O
microenvironment	O
in	O
liver	O
.	O

A	O
low	O
vitamin	B-CHED
A	I-CHED
diet	O
compromised	O
the	O
serum	O
IgG1	O
responses	O
against	O
inactivated	O
BCoV	O
vaccine	O
,	O
which	O
suggested	O
suppressed	O
T	O
-	O
helper	O
2	O
-	O
associated	O
antibody	O
(	O
IgG1	O
)	O
responses	O
.	O

RESULTS	O
:	O
The	O
low	O
vitamin	B-CHED
A	I-CHED
diet	O
reduced	O
serum	O
retinol	B-CHED
concentrations	O
between	O
days	O
112	O
and	O
140	O
.	O

TITLE	O
:	O
Structure	O
of	O
the	O
fusion	O
core	O
and	O
inhibition	O
of	O
fusion	O
by	O
a	O
heptad	O
repeat	O
peptide	B-CHED
derived	O
from	O
the	O
S	O
protein	B-CHED
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

The	O
HR	O
sequences	O
were	O
variably	O
truncated	O
and	O
then	O
connected	O
with	O
a	O
flexible	O
amino	B-CHED
acid	I-CHED
linker	O
.	O

HA1	O
region	O
characterization	O
showed	O
an	O
overall	O
protein	B-CHED
identity	O
of	O
98	O
.	O
5	O
-	O
99	O
.	O
4	O
%.	O

Blood	O
was	O
analyzed	O
for	O
glucose	B-CHED
and	O
insulin	B-CHED
levels	O
.	O

Calves	O
received	O
a	O
daily	O
dose	O
of	O
either	O
a	O
placebo	O
composed	O
of	O
80	O
mg	O
of	O
zinc	B-CHED
-	O
free	O
powder	O
,	O
381	O
.	O
54	O
mg	O
of	O
zinc	B-CHED
methionine	B-CHED
(	O
Met	B-CHED
)	O
(	O
equivalent	O
to	O
80	O
mg	O
of	O
zinc	B-CHED
),	O
or	O
99	O
.	O
69	O
mg	O
of	O
zinc	B-CHED
oxide	I-CHED
(	O
ZO	O
)	O
(	O
equivalent	O
to	O
80	O
mg	O
of	O
zinc	B-CHED
)	O
in	O
2L	O
of	O
a	O
zinc	B-CHED
-	O
free	O
oral	O
rehydration	O
solution	O
(	O
ORS	O
).	O

Exit	O
liver	O
zinc	B-CHED
concentrations	O
for	O
the	O
calves	O
in	O
the	O
placebo	O
,	O
zinc	B-CHED
Met	B-CHED
,	O
and	O
ZO	O
treatment	O
groups	O
were	O
728	O
.	O
9	O
(	O
SEM	O
=	O
182	O
.	O
9	O
),	O
1141	O
.	O
0	O
(	O
SEM	O
=	O
423	O
.	O
8	O
),	O
and	O
636	O
.	O
8	O
(	O
SEM	O
=	O
81	O
.	O
5	O
)	O
mg	O
/	O
kg	O
dry	O
weight	O
,	O
respectively	O
.	O

To	O
study	O
both	O
early	O
and	O
late	O
cytokine	O
responses	O
associated	O
with	O
MERS	O
-	O
CoV	O
infection	O
,	O
we	O
measured	O
the	O
mRNA	B-CHED
levels	O
of	O
eight	O
cytokine	O
genes	O
[	O
TNF	O
-	O
	O
,	O
IL	O
-	O
1	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IFN	O
-	O
	O
,	O
monocyte	O
chemotactic	O
protein	B-CHED
-	O
1	O
,	O
transforming	O
growth	O
factor	O
-	O
	O
and	O
IFN	O
-	O
	O
-	O
induced	O
protein	B-CHED
(	O
IP	O
)-	O
10	O
]	O
in	O
cell	O
lysates	O
of	O
polarized	O
airway	O
epithelial	O
Calu	O
-	O
3	O
cells	O
infected	O
with	O
MERS	O
-	O
CoV	O
or	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
up	O
to	O
30	O
h	O
post	O
-	O
infection	O
.	O

The	O
activation	O
of	O
IL	O
-	O
8	O
and	O
attenuated	O
IFN	O
-	O
	O
response	O
by	O
MERS	O
-	O
CoV	O
were	O
also	O
confirmed	O
by	O
protein	B-CHED
measurements	O
in	O
the	O
culture	O
supernatant	O
when	O
compared	O
with	O
SARS	O
-	O
CoV	O
and	O
Sendai	O
virus	O
.	O

Mice	O
that	O
were	O
infected	O
with	O
800	O
plaque	O
forming	O
unit	O
(	O
PFU	B-CHED
)	O
of	O
CA	O
/	O
07	O
virus	O
rapidly	O
lost	B-CHED
weight	O
,	O
which	O
was	O
concurrent	O
with	O
detection	O
of	O
high	O
pulmonary	O
concentrations	O
of	O
MCP	B-CHED
-	O
1	O
,	O
MIG	O
,	O
IP	O
-	O
10	O
and	O
TIMP	O
-	O
1	O
.	O

In	O
contrast	O
,	O
when	O
mice	O
were	O
infected	O
with	O
800	O
PFU	B-CHED
of	O
NL	O
/	O
602	O
virus	O
,	O
minimal	O
weight	O
loss	O
was	O
observed	O
,	O
and	O
concentrations	O
of	O
cytokines	O
in	O
the	O
lung	O
were	O
significantly	O
lower	O
.	O

This	O
study	O
evaluates	O
the	O
feasibility	O
of	O
intrapleural	O
steroid	B-CHED
instillation	O
(	O
IPSI	O
)	O
in	O
patients	O
with	O
ARDS	O
and	O
MODS	O
unresponsive	O
to	O
conventional	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

The	O
codon	O
adaptation	O
index	O
(	O
CAI	O
)	O
showed	O
a	O
lower	O
adaptation	O
of	O
S	O
to	O
G	O
.	O
gallus	O
compared	O
to	O
NSP2	O
,	O
PL	O
(	O
pro	B-CHED
)	O
and	O
N	O
.	O
The	O
effective	O
number	O
of	O
codons	O
(	O
Nc	O
)	O
and	O
GC3	O
%	O
revealed	O
that	O
natural	O
selection	O
and	O
genetic	O
drift	O
are	O
the	O
evolutionary	O
forces	O
driving	O
the	O
codon	O
usage	O
evolution	O
of	O
both	O
A	O
.	O
coronavirus	O
and	O
G	O
.	O
gallus	O
regardless	O
of	O
the	O
gene	O
being	O
considered	O
.	O

Virus	O
CU	O
evolves	O
independently	O
for	O
each	O
gene	O
in	O
a	O
manner	O
predicted	O
by	O
the	O
protein	B-CHED
function	O
,	O
with	O
a	O
balance	B-CHED
between	O
natural	O
selection	O
and	O
mutation	O
pressure	O
,	O
giving	O
further	O
molecular	O
basis	O
for	O
the	O
viruses	O
'	O
ability	O
to	O
exploit	O
the	O
host	O
'	O
s	O
cellular	O
environment	O
in	O
a	O
concerted	O
virus	O
-	O
host	O
molecular	O
evolution	O
.	O

TGEV	O
infection	O
promoted	O
p21	O
accumulation	O
,	O
down	O
-	O
regulated	O
cell	O
cycle	O
-	O
regulatory	O
proteins	B-CHED
cyclins	O
B1	O
,	O
cdc2	O
,	O
cdk2	O
and	O
PCNA	O
.	O

The	O
serum	O
concentrations	O
achievable	O
at	O
therapeutic	O
doses	O
of	O
mycophenolic	B-CHED
acid	I-CHED
and	O
interferon	O
-	O
1b	O
were	O
60	O
-	O
300	O
and	O
3	O
-	O
4	O
times	O
higher	O
than	O
the	O
concentrations	O
at	O
which	O
in	O
-	O
vitro	O
anti	O
-	O
MERS	O
-	O
CoV	O
activities	O
were	O
demonstrated	O
,	O
whereas	O
that	O
of	O
ribavirin	B-CHED
was	O
	O
2	O
times	O
lower	O
.	O

Interferon	O
-	O
1b	O
with	O
mycophenolic	B-CHED
acid	I-CHED
should	O
be	O
considered	O
in	O
treatment	O
trials	O
of	O
MERS	O
.	O

ABSTRACT	O
:	O
A	O
35	O
-	O
years	O
-	O
old	O
right	O
-	O
handed	O
man	B-CHED
admitted	O
to	O
our	O
hospital	O
with	O
a	O
worsening	O
of	O
dysarthria	O
,	O
left	O
facial	O
palsy	O
and	O
left	O
hemiparesis	O
for	O
2	O
days	O
.	O

Magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
showed	O
acute	O
ischemic	O
infarction	O
spreading	O
from	O
the	O
right	O
corona	B-CHED
radiate	O
to	O
the	O
right	O
internal	O
capsule	O
without	O
contrast	O
enhancement	O
.	O

Although	O
argatroban	B-CHED
and	O
edaravone	B-CHED
were	O
administered	O
,	O
his	O
neurological	O
deficits	O
were	O
worsened	O
to	O
be	O
difficult	O
to	O
walk	O
independently	O
.	O

This	O
review	O
is	O
aimed	O
at	O
the	O
clinical	O
neurologist	O
in	O
that	O
it	O
offers	O
insights	O
into	O
potential	O
adverse	O
events	O
of	O
each	O
of	O
the	O
approved	O
MS	O
therapeutics	O
:	O
interferon	O
beta	O
,	O
glatiramer	O
acetate	B-CHED
,	O
mitoxantrone	B-CHED
,	O
natalizumab	O
,	O
fingolimod	B-CHED
and	O
teriflunomide	B-CHED
,	O
as	O
well	O
as	O
recently	O
approved	O
therapeutics	O
such	O
as	O
dimethyl	B-CHED
fumarate	B-CHED
and	O
alemtuzumab	O
.	O

While	O
a	O
multitude	O
of	O
studies	O
have	O
examined	O
nucleocapsid	O
function	O
,	O
none	O
have	O
described	O
the	O
effects	O
of	O
OC43	O
nucleocapsid	O
on	O
the	O
transcription	O
factor	O
NF	O
-	O
B	O
.	O
We	O
report	O
that	O
the	O
nucleocapsid	O
protein	B-CHED
of	O
OC43	O
causes	O
potentiation	O
of	O
NF	O
-	O
B	O
activation	O
.	O

Patients	O
under	O
invasive	O
or	O
noninvasive	O
mechanical	O
ventilation	O
,	O
with	O
PaO2	O
/	O
FiO2	O
<	O
300	O
mmHg	O
regardless	O
of	O
the	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
level	O
,	O
and	O
acute	O
onset	O
of	O
new	O
or	O
increased	O
bilateral	O
infiltrates	O
or	O
opacities	O
on	O
chest	O
X	O
-	O
ray	O
were	O
screened	O
from	O
ICU	O
admission	O
up	O
to	O
discharge	O
.	O

The	O
activity	O
of	O
host	O
cell	O
proteases	O
,	O
which	O
cleave	O
and	O
activate	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
,	O
is	O
essential	O
for	O
viral	O
infectivity	O
and	O
constitutes	O
a	O
target	O
for	O
intervention	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
and	O
bioevaluation	O
of	O
viral	O
3C	O
and	O
3C	O
-	O
like	O
protease	B-CHED
inhibitors	I-CHED
.	O

Anti	O
-	O
malarial	O
therapy	O
consisted	O
in	O
intravenous	O
quinine	B-CHED
(	O
in	O
two	O
patients	O
)	O
and	O
intravenous	O
quinidine	B-CHED
(	O
in	O
one	O
patient	O
),	O
plus	O
clindamycin	B-CHED
or	O
doxycycline	B-CHED
.	O

To	O
overcome	O
the	O
innate	O
antiviral	B-CHED
response	O
,	O
RNA	O
viruses	O
encode	O
suppressors	O
of	O
IFN	O
-	O
	O
/	O
	O
induction	O
,	O
which	O
block	O
RLRs	O
recognition	O
of	O
dsRNA	B-CHED
by	O
means	O
of	O
different	O
mechanisms	O
that	O
can	O
be	O
categorized	O
into	O
:	O
(	O
i	O
)	O
dsRNA	B-CHED
binding	O
and	O
/	O
or	O
shielding	O
"("""	O
hide	O
"""),"	O
(	O
ii	O
)	O
dsRNA	B-CHED
termini	O
processing	O
"("""	O
mask	O
""")"	O
and	O
(	O
iii	O
)	O
direct	O
interaction	O
with	O
components	O
of	O
the	O
RLRs	O
pathway	O
"("""	O
hit	O
""")."	O

Additional	O
87	O
NPA	B-CHED
specimens	O
were	O
collected	O
from	O
healthy	O
children	O
for	O
routine	O
examination	O
on	O
the	O
physical	O
examination	O
center	O
,	O
and	O
the	O
clinical	O
data	O
were	O
collected	O
.	O

There	O
were	O
209	O
samples	O
(	O
59	O
.	O
9	O
%)	O
of	O
the	O
349	O
NPA	B-CHED
specimens	O
were	O
positive	O
for	O
viruses	O
,	O
which	O
included	O
117	O
cases	O
positive	O
for	O
human	O
rhinovirus	O
(	O
HRV	O
),	O
60	O
for	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
20	O
for	O
influenza	O
virus	O
A	O
(	O
Inf	O
A	O
),	O
10	O
for	O
adenovirus	O
(	O
ADV	O
),	O
6	O
for	O
parainfluenza	O
virus	O
type	O
3	O
(	O
PIV	O
-	O
3	O
),	O
6	O
for	O
human	O
Boca	O
virus	O
(	O
HBoV	O
),	O
5	O
for	O
influenza	O
virus	O
C	O
(	O
Inf	O
C	O
),	O
4	O
for	O
parainfluenza	O
virus	O
type	O
4	O
(	O
PIV	O
-	O
4	O
),	O
4	O
for	O
human	O
coronavirus	O
-	O
HKU1	O
/	O
OC43	O
,	O
3	O
for	O
influenza	O
virus	O
B	O
(	O
Inf	O
B	O
),	O
3	O
for	O
WU	O
Polyomavirus	O
(	O
WUPyV	O
),	O
2	O
parainfluenza	O
virus	O
type	O
1	O
(	O
PIV	O
-	O
1	O
),	O
2	O
human	O
metapneumovirus	O
(	O
HMPV	O
)	O
and	O
1	O
human	O
coronavirus	O
-	O
NL63	O
/	O
229E	O
.	O

Our	O
objective	O
was	O
to	O
determine	O
whether	O
nitric	B-CHED
oxide	I-CHED
reduces	O
hospital	O
mortality	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
PaO2	O
/	O
FIO2	O
	O
100	O
mm	O
Hg	O
)	O
but	O
not	O
in	O
patients	O
with	O
mild	O
-	O
moderate	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
100	O
<	O
PaO2	O
/	O
FIO2	O
	O
300	O
mm	O
Hg	O
)	O
at	O
the	O
time	O
of	O
randomization	O
.	O

Data	O
were	O
collected	O
from	O
Medline	O
,	O
Embase	O
,	O
and	O
Cochrane	O
CENTRAL	O
electronic	O
databases	O
(	O
inception	O
to	O
May	O
2013	O
);	O
proceedings	O
from	O
five	O
conferences	O
(	O
to	O
May	O
2013	O
);	O
and	O
trial	O
registries	O
(	O
http	O
://	O
www	O
.	O
clinicaltrials	O
.	O
gov	O
and	O
http	O
://	O
www	O
.	O
controlled	O
-	O
trials	O
.	O
com	B-CHED
).	O

ABSTRACT	O
:	O
In	O
neonatal	O
rodents	O
,	O
a	O
loss	O
of	O
brain	O
stem	O
serotonin	B-CHED
[	O
5	B-CHED
-	I-CHED
hydroxytryptamine	I-CHED
(	O
5	B-CHED
-	I-CHED
HT	I-CHED
)]	O
in	O
utero	O
or	O
at	O
birth	O
compromises	O
anoxia	O
-	O
induced	O
gasping	O
and	O
the	O
recovery	O
of	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
breathing	O
with	O
reoxygenation	O
(	O
i	O
.	O
e	O
.,	O
autoresuscitation	O
).	O

How	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
is	O
influenced	O
after	O
an	O
acute	O
loss	O
of	O
brain	O
stem	O
5	B-CHED
-	I-CHED
HT	I-CHED
content	O
is	O
unknown	O
.	O

Pups	O
were	O
exposed	O
to	O
a	O
maximum	O
of	O
15	O
anoxic	O
episodes	O
,	O
separated	O
by	O
5	O
min	O
of	O
room	O
air	B-CHED
to	O
allow	O
autoresuscitation	O
.	O

TITLE	O
:	O
Calcium	B-CHED
signaling	O
-	O
related	O
proteins	B-CHED
are	O
associated	O
with	O
broncho	O
-	O
pulmonary	O
dysplasia	O
progression	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
highlight	O
protein	B-CHED
changes	O
in	O
the	O
broncho	O
-	O
alveolar	O
lavage	O
fluid	O
(	O
BALF	O
),	O
thus	O
providing	O
an	O
appropriate	O
picture	O
on	O
what	O
is	O
happening	O
in	O
the	O
locus	O
of	O
injury	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
suggests	O
a	O
subset	O
of	O
proteins	B-CHED
to	O
be	O
investigated	O
to	O
better	O
treat	O
BPD	O
babies	O
and	O
facilitate	O
the	O
definition	O
of	O
potential	O
drug	O
targets	O
for	O
novel	O
therapies	O
.	O

A	O
key	O
aspect	O
in	O
biomarker	B-CHED
discovery	O
is	O
uncovering	O
molecules	O
that	O
appear	O
early	O
during	O
disease	O
initiation	O
,	O
when	O
the	O
natural	O
history	O
of	O
the	O
disease	O
can	O
be	O
modified	O
.	O

Among	O
trauma	O
and	O
surgical	O
patients	O
,	O
large	O
volume	O
crystalloid	O
resuscitation	O
and	O
markers	O
of	O
shock	O
/	O
hypotension	O
and	O
metabolic	O
derangement	O
/	O
organ	O
failure	O
were	O
risk	O
factors	O
for	O
IAH	O
and	O
ACS	O
while	O
increased	O
disease	O
severity	O
scores	O
and	O
elevated	O
creatinine	B-CHED
were	O
risk	O
factors	O
for	O
ACS	O
in	O
severe	O
acute	O
pancreatitis	O
patients	O
.	O

TITLE	O
:	O
Activity	O
of	O
and	O
effect	O
of	O
subcutaneous	O
treatment	O
with	O
the	O
broad	O
-	O
spectrum	O
antiviral	B-CHED
lectin	O
griffithsin	O
in	O
two	O
laboratory	O
rodent	O
models	O
.	O

Zippered	O
ER	O
lacked	O
luminal	B-CHED
space	O
,	O
suggesting	O
zippering	O
of	O
ER	O
cisternae	O
,	O
while	O
spherules	O
appeared	O
as	O
uniform	O
invaginations	O
of	O
zippered	O
ER	O
.	O

Diverse	O
SARS	O
-	O
like	O
coronaviruses	O
(	O
SL	O
-	O
CoVs	O
)	O
have	O
now	O
been	O
reported	O
from	O
bats	O
in	O
China	O
,	O
Europe	O
and	O
Africa	O
,	O
but	O
none	O
is	O
considered	O
a	O
direct	O
progenitor	O
of	O
SARS	O
-	O
CoV	O
because	O
of	O
their	O
phylogenetic	O
disparity	O
from	O
this	O
virus	O
and	O
the	O
inability	O
of	O
their	O
spike	O
proteins	B-CHED
to	O
use	O
the	O
SARS	O
-	O
CoV	O
cellular	O
receptor	O
molecule	O
,	O
the	O
human	O
angiotensin	B-CHED
converting	O
enzyme	O
II	O
(	O
ACE2	O
).	O

ABSTRACT	O
:	O
An	O
AUG	O
-	O
initiated	O
upstream	O
open	O
reading	O
frame	O
(	O
uORF	O
)	O
encoding	O
a	O
potential	O
polypeptide	B-CHED
of	O
3	O
to	O
13	O
amino	B-CHED
acids	I-CHED
(	O
aa	O
)	O
is	O
found	O
within	O
the	O
5	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
>	O
75	O
%	O
of	O
coronavirus	O
genomes	O
based	O
on	O
38	O
reference	O
strains	O
.	O

As	O
a	O
strongly	O
dissociated	O
anion	B-CHED
(	O
pK	O
'=	O
3	O
.	O
7	O
)	O
directly	O
changing	O
the	O
strong	O
ion	O
difference	O
,	O
lactate	B-CHED
causes	O
a	O
reduction	O
in	O
the	O
dependent	O
anion	B-CHED
[	O
HCO3	O
-]	O
and	O
a	O
rise	O
in	O
[	O
H	O
+],	O
resulting	O
in	O
""""	O
metabolic	O
""""	O
acidosis	O
in	O
the	O
CSF	O
.	O

These	O
data	O
indicated	O
that	O
activation	O
of	O
the	O
NF	O
-	O
B	O
signaling	O
pathway	O
represents	O
a	O
major	O
contribution	O
to	O
the	O
inflammation	O
induced	O
after	O
SARS	O
-	O
CoV	O
infection	O
and	O
that	O
NF	O
-	O
B	O
inhibitors	B-CHED
are	O
promising	O
antivirals	B-CHED
in	O
infections	O
caused	O
by	O
SARS	O
-	O
CoV	O
and	O
potentially	O
other	O
pathogenic	O
human	O
coronaviruses	O
.	O

Increased	O
clinical	O
disease	O
in	O
Ifit2	O
(-/-)	O
mice	O
coincided	O
with	O
higher	O
viral	O
loads	O
and	O
enhanced	O
viral	O
spread	O
throughout	O
the	O
CNS	B-CHED
parenchyma	O
.	O

Collectively	O
,	O
the	O
data	O
implicate	O
Ifit2	O
as	O
a	O
positive	O
regulator	O
of	O
IFN	O
-	O
	O
/	O
	O
expression	O
,	O
rather	O
than	O
direct	O
antiviral	B-CHED
mediator	O
,	O
during	O
MHV	O
-	O
induced	O
encephalitis	O
.	O

Anti	O
-	O
CD25	O
treatment	O
did	O
not	O
affect	O
CNS	B-CHED
recruitment	O
of	O
inflammatory	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
CNS	B-CHED
inflammation	O
,	O
progression	O
of	O
viral	O
control	O
and	O
viral	O
persistence	O
are	O
relatively	O
independent	O
of	O
CD25	O
(+)	O
CD4	O
(+)	O
Treg	O
.	O

In	O
addition	O
,	O
TGEV	O
infection	O
lowered	O
mitochondrial	O
transmembrane	O
potential	O
in	O
PK	O
-	O
15	O
cell	O
line	O
,	O
which	O
could	O
be	O
inhibited	O
by	O
ROS	B-CHED
scavengers	O
,	O
pyrrolidinedithiocarbamic	O
(	O
PDTC	O
)	O
and	O
N	B-CHED
-	I-CHED
acetyl	I-CHED
-	I-CHED
l	I-CHED
-	I-CHED
cysteine	I-CHED
(	O
NAC	O
).	O

Furthermore	O
,	O
a	O
single	O
amino	B-CHED
acid	I-CHED
change	O
in	O
the	O
viral	O
S	O
protein	B-CHED
modulated	O
virus	O
-	O
induced	O
neuropathology	O
in	O
mice	O
from	O
an	O
encephalitis	O
to	O
a	O
neuropathology	O
characterized	O
by	O
flaccid	O
paralysis	O
,	O
which	O
involves	O
glutamate	B-CHED
excitotoxicity	O
.	O

All	O
of	O
these	O
effects	O
were	O
associated	O
with	O
strong	O
expression	O
of	O
PARP	B-CHED
and	O
NF	O
-	O
B	O
.	O
Treatment	O
with	O
3	O
-	O
AB	O
prevented	O
the	O
LPS	B-CHED
-	O
induced	O
metabolic	O
acidosis	O
and	O
hypotension	O
,	O
reduced	O
the	O
plasma	O
levels	O
of	O
lactate	B-CHED
,	O
creatinine	B-CHED
and	O
potassium	B-CHED
,	O
reduced	O
the	O
cytokine	O
mRNA	B-CHED
expressions	O
,	O
reduced	O
the	O
expression	O
of	O
PARP	B-CHED
and	O
NF	O
-	O
B	O
,	O
improved	O
pulmonary	O
edema	O
and	O
oxygenation	O
and	O
preserved	O
renal	O
function	O
.	O

In	O
this	O
issue	O
,	O
Klaus	O
et	O
al	O
.	O
(	O
2013	O
)	O
identify	O
the	O
cargo	O
receptor	O
endoplasmic	O
reticulum	O
(	O
ER	O
)-	O
Golgi	O
intermediate	O
compartment	O
53	O
kDa	O
protein	B-CHED
(	O
ERGIC	O
-	O
53	O
)	O
as	O
a	O
binding	O
partner	O
for	O
viral	O
GPs	O
and	O
a	O
crucial	O
cellular	O
factor	O
required	O
for	O
infectious	O
virus	O
production	O
.	O

We	O
identified	O
human	O
proteins	B-CHED
that	O
interact	O
with	O
the	O
glycoproteins	B-CHED
(	O
GPs	B-CHED
)	O
of	O
a	O
prototypic	O
arenavirus	O
and	O
hantavirus	O
and	O
show	O
that	O
the	O
lectin	O
endoplasmic	O
reticulum	O
(	O
ER	O
)-	O
Golgi	O
intermediate	O
compartment	O
53	O
kDa	O
protein	B-CHED
(	O
ERGIC	O
-	O
53	O
),	O
a	O
cargo	O
receptor	O
required	O
for	O
glycoprotein	B-CHED
trafficking	O
within	O
the	O
early	O
exocytic	O
pathway	O
,	O
associates	O
with	O
arenavirus	O
,	O
hantavirus	O
,	O
coronavirus	O
,	O
orthomyxovirus	O
,	O
and	O
filovirus	O
GPs	B-CHED
.	O

We	O
examined	O
PCP	B-CHED
preparedness	O
and	O
response	O
to	O
the	O
2009	O
influenza	O
pandemic	O
in	O
Japan	O
,	O
and	O
explored	O
the	O
role	O
of	O
a	O
pandemic	O
preparedness	O
plan	O
during	O
the	O
pandemic	O
.	O

RESULTS	O
:	O
Serologic	O
and	O
neutralization	O
responses	O
against	O
the	O
spike	O
glycoprotein	B-CHED
were	O
primarily	O
strain	O
specific	O
,	O
with	O
a	O
very	O
low	O
level	O
of	O
cross	O
-	O
reactivity	O
within	O
or	O
across	O
subgroups	O
.	O

The	O
only	O
pathogen	O
identified	O
by	O
PCR	O
on	O
BAL	B-CHED
and	O
serology	O
was	O
Mycoplasma	O
pneumoniae	O
.	O

TITLE	O
:	O
Cell	O
-	O
based	O
antiviral	B-CHED
screening	O
against	O
coronaviruses	O
:	O
developing	O
virus	O
-	O
specific	O
and	O
broad	O
-	O
spectrum	O
inhibitors	B-CHED
.	O

ABSTRACT	O
:	O
To	O
combat	B-CHED
the	O
public	O
health	O
threat	O
from	O
emerging	O
coronaviruses	O
(	O
CoV	O
),	O
the	O
development	O
of	O
antiviral	B-CHED
therapies	O
with	O
either	O
virus	O
-	O
specific	O
or	O
pan	B-CHED
-	O
coronaviral	O
activities	O
is	O
necessary	O
.	O

The	O
recent	O
emergence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
necessitates	O
adapting	O
methods	O
that	O
have	O
been	O
used	O
to	O
identify	O
antivirals	B-CHED
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
developing	O
new	O
approaches	O
to	O
more	O
efficiently	O
screen	O
antiviral	B-CHED
drugs	I-CHED
.	O

Acid	O
-	O
induced	O
lung	O
injury	O
in	O
WT	O
mice	O
was	O
characterized	O
by	O
decreased	O
lung	O
compliance	O
and	O
increased	O
protein	B-CHED
and	O
cytokine	O
concentration	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
evaluate	O
the	O
extended	O
temporal	O
relationship	O
between	O
neutrophil	O
chemotactic	O
factor	O
expression	O
and	O
influx	O
of	O
neutrophils	O
into	O
the	O
lung	O
after	O
intratracheal	O
administration	O
of	O
either	O
LPS	B-CHED
or	O
bleomycin	B-CHED
.	O

Consequently	O
,	O
new	O
aptamer	O
-	O
based	O
therapeutics	O
have	O
the	O
potential	O
to	O
lead	O
a	O
revolution	O
in	O
the	O
development	O
of	O
anti	B-CHED
-	I-CHED
infective	I-CHED
drugs	I-CHED
.	O

Several	O
clinical	O
trials	O
have	O
compared	O
high	O
PEEP	B-CHED
levels	O
versus	O
conventional	O
PEEP	B-CHED
.	O

Unfortunately	O
,	O
all	O
of	O
them	O
have	O
small	O
sample	O
sizes	O
and	O
have	O
used	O
different	O
means	O
to	O
determine	O
optimum	O
PEEP	B-CHED
.	O

Based	O
on	O
the	O
analysis	O
of	O
the	O
partial	O
S	O
glycoprotein	B-CHED
genes	O
,	O
the	O
Thai	O
PEDV	O
isolates	O
were	O
clustered	O
into	O
2	O
groups	O
related	O
to	O
Korean	O
and	O
Chinese	O
field	O
isolates	O
.	O

Clarithromycin	B-CHED
(	O
1	O
g	O
)	O
was	O
administered	O
intravenously	O
once	O
daily	O
for	O
4	O
days	O
consecutively	O
in	O
302	O
patients	O
;	O
another	O
298	O
patients	O
were	O
treated	O
with	O
placebo	O
.	O

The	O
groups	O
were	O
well	O
matched	O
for	O
demographics	O
,	O
disease	O
severity	O
,	O
microbiology	O
and	O
appropriateness	O
of	O
the	O
administered	O
antimicrobials	B-CHED
.	O

This	O
series	O
of	O
review	O
articles	O
will	O
discuss	O
the	O
pathophysiology	O
of	O
sepsis	O
;	O
comorbidities	O
,	O
such	O
as	O
multiorgan	O
dysfunction	O
syndrome	O
(	O
MODS	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
endocrine	B-CHED
issues	O
;	O
and	O
finally	O
,	O
management	O
of	O
sepsis	O
and	O
septic	O
shock	O
.	O

TITLE	O
:	O
Molecular	O
characterization	O
of	O
major	O
structural	O
protein	B-CHED
genes	O
of	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
isolates	O
in	O
southern	O
china	O
.	O

Positive	O
selections	O
were	O
detected	O
in	O
not	O
only	O
S1	O
but	O
also	O
M	O
and	O
N	O
gene	O
proteins	B-CHED
.	O

The	O
serum	O
MMP	B-CHED
-	O
9	O
was	O
positively	O
correlated	O
with	O
the	O
APACHE	O
II	O
score	O
on	O
the	O
1st	O
day	O
(	O
r	O
=	O
0	O
.	O
430	O
,	O
P	O
=	O
0	O
.	O
01	O
).	O

The	O
peptide	B-CHED
(	O
FP5	O
)	O
exhibiting	O
the	O
most	O
effective	O
antiviral	B-CHED
effect	O
was	O
further	O
combined	O
with	O
a	O
known	O
anti	B-CHED
-	I-CHED
viral	I-CHED
agent	I-CHED
,	O
human	O
interferon	O
-	O
	O
(	O
IFN	O
-	O
	O
),	O
and	O
a	O
significant	O
synergistic	O
antiviral	B-CHED
effect	O
was	O
observed	O
.	O

TITLE	O
:	O
Mapping	O
of	O
the	O
receptor	O
-	O
binding	O
domain	O
and	O
amino	B-CHED
acids	I-CHED
critical	O
for	O
attachment	O
in	O
the	O
spike	O
protein	B-CHED
of	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

Critical	O
amino	B-CHED
acids	I-CHED
for	O
attachment	O
of	O
M41	O
spike	O
are	O
present	O
within	O
the	O
N	O
-	O
terminal	O
residues	O
19	O
-	O
69	O
,	O
which	O
overlap	O
with	O
a	O
hypervariable	O
region	O
in	O
the	O
S1	O
gene	O
.	O

TITLE	O
:	O
Synthesis	O
,	O
modification	O
and	O
docking	O
studies	O
of	O
5	O
-	O
sulfonyl	B-CHED
isatin	B-CHED
derivatives	O
as	O
SARS	O
-	O
CoV	O
3C	O
-	O
like	O
protease	B-CHED
inhibitors	I-CHED
.	O

3CL	O
(	O
pro	B-CHED
)	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
viral	O
replication	O
cycle	O
and	O
is	O
a	O
potential	O
target	O
for	O
SARS	O
inhibitor	B-CHED
development	O
.	O

Individual	O
structural	O
and	O
accessory	O
protein	B-CHED
-	O
coding	O
plasmids	O
with	O
an	O
N	O
-	O
terminal	O
HA	O
tag	O
were	O
constructed	O
and	O
transiently	O
transfected	O
into	O
cells	O
,	O
and	O
their	O
native	O
expression	O
and	O
subcellular	O
localization	O
were	O
assessed	O
using	O
Wes	O
tern	O
blotting	O
and	O
indirect	O
immunofluorescence	O
.	O

The	O
campaign	O
identified	O
a	O
reversible	O
small	O
molecule	O
inhibitor	B-CHED
exhibiting	O
mixed	O
-	O
type	O
inhibition	O
with	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
11	O
.	O
1	O
M	O
.	O
Together	O
,	O
these	O
results	O
validate	O
our	O
protocols	O
as	O
suitable	O
approaches	O
to	O
screen	O
virtual	O
and	O
chemical	O
libraries	O
,	O
and	O
the	O
newly	O
identified	O
compound	O
reported	O
in	O
our	O
study	O
represents	O
a	O
promising	O
structural	O
scaffold	O
to	O
pursue	O
for	O
further	O
SARS	O
-	O
CoV	O
3CLpro	O
inhibitor	B-CHED
development	O
.	O

A	O
genome	O
-	O
wide	O
association	O
study	O
using	O
43	O
,	O
211	O
single	O
nucleotide	B-CHED
polymorphism	O
markers	O
was	O
performed	O
to	O
identify	O
the	O
major	O
loci	O
affecting	O
the	O
immune	O
response	O
against	O
IBV	O
.	O

This	O
study	O
detected	O
20	O
significant	O
(	O
P	O
<	O
1	O
.	O
16	O
	O
10	O
(-	O
6	O
))	O
effect	O
single	O
nucleotide	B-CHED
polymorphisms	O
for	O
the	O
antibody	O
level	O
against	O
IBV	O
.	O

ABSTRACT	O
:	O
Diagnostic	O
ability	O
of	O
alveolar	O
-	O
arterial	O
oxygen	B-CHED
gradient	O
(	O
A	O
-	O
aDO2	O
and	O
respiratory	O
index	O
(	O
RI	O
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
was	O
underestimated	O
before	O
recent	O
time	O
.	O

TITLE	O
:	O
BacMam	O
virus	O
-	O
based	O
surface	O
display	O
of	O
the	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
S1	O
glycoprotein	B-CHED
confers	O
strong	O
protection	O
against	O
virulent	O
IBV	O
challenge	O
in	O
chickens	O
.	O

Although	O
six	O
sheep	O
sera	O
reacted	O
with	O
MERS	O
-	O
CoV	O
antigen	B-CHED
,	O
neutralising	O
antibodies	O
were	O
not	O
detected	O
.	O

Neither	O
baseline	O
PEEP	B-CHED
nor	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
correlated	O
with	O
outcome	O
.	O

The	O
differential	O
demyelination	O
properties	O
of	O
RSA59	O
and	O
RSMHV2	O
may	O
be	O
a	O
function	O
of	O
spike	O
protein	B-CHED
-	O
mediated	O
neuronal	O
transport	O
.	O

The	O
high	O
percentage	O
of	O
novel	O
protein	B-CHED
folds	O
identified	O
among	O
SARS	O
-	O
CoV	O
proteins	B-CHED
is	O
discussed	O
.	O

The	O
nucleotide	B-CHED
sequence	O
of	O
an	O
ORF1a	O
fragment	O
(	O
940	O
nucleotides	B-CHED
)	O
and	O
a	O
4	O
	O
2	O
kb	O
concatenated	O
fragment	O
were	O
very	O
similar	O
to	O
the	O
MERS	O
-	O
CoV	O
from	O
two	O
human	O
cases	O
on	O
the	O
same	O
farm	O
and	O
a	O
MERS	O
-	O
CoV	O
isolate	O
from	O
Hafr	O
-	O
Al	O
-	O
Batin	O
.	O

The	O
purified	O
recombinant	O
proteins	B-CHED
of	O
these	O
constructs	O
were	O
compared	O
for	O
their	O
antigenicity	O
,	O
functionality	O
and	O
immunogenicity	O
in	O
mice	O
using	O
alum	O
as	O
the	O
adjuvant	B-CHED
.	O

We	O
previously	O
reported	O
that	O
SARS	O
-	O
CoV	O
PLpro	O
acts	O
as	O
both	O
deubiquitinase	O
(	O
DUB	O
)	O
and	O
IFN	O
antagonist	B-CHED
,	O
but	O
the	O
function	O
of	O
the	O
MERS	O
-	O
CoV	O
PLpro	O
was	O
poorly	O
understood	O
.	O

These	O
findings	O
indicate	O
that	O
MERS	O
-	O
CoV	O
PLpro	O
acts	O
as	O
a	O
viral	O
DUB	O
and	O
suppresses	O
production	O
of	O
IFN	O
-	O
	O
by	O
an	O
interfering	O
IRF3	O
-	O
mediated	O
signalling	O
pathway	O
,	O
in	O
addition	O
to	O
recognizing	O
and	O
processing	O
the	O
CS	O
at	O
the	O
N	O
terminus	O
of	O
replicase	O
polyprotein	O
to	O
release	O
the	O
non	O
-	O
structural	O
proteins	B-CHED
.	O

Despite	O
great	O
progress	O
in	O
the	O
management	O
of	O
ARDS	O
with	O
novel	O
agents	O
and	O
sophisticated	O
techniques	O
,	O
including	O
antimicrobial	B-CHED
drugs	I-CHED
,	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
prostaglandins	B-CHED
,	O
nitric	B-CHED
oxide	I-CHED
,	O
prostacyclin	B-CHED
,	O
exogenous	O
surfactant	B-CHED
administration	O
and	O
activated	O
protein	B-CHED
C	O
,	O
supportive	O
treatment	O
based	O
mostly	O
on	O
advanced	O
mechanical	O
ventilation	O
in	O
the	O
intensive	O
care	O
units	O
seems	O
to	O
be	O
the	O
most	O
important	O
for	O
the	O
prognosis	O
.	O

The	O
role	O
of	O
the	O
HE	O
protein	B-CHED
during	O
the	O
torovirus	O
infection	O
cycle	O
remains	O
unknown	O
,	O
although	O
it	O
is	O
believed	O
to	O
be	O
important	O
in	O
the	O
natural	O
infection	O
process	O
.	O

In	O
a	O
previous	O
study	O
,	O
PToV	O
virus	O
strains	O
with	O
HE	O
proteins	B-CHED
from	O
the	O
two	O
lineages	O
were	O
found	O
coexisting	O
in	O
a	O
pig	O
herd	O
,	O
and	O
they	O
were	O
even	O
obtained	O
from	O
the	O
same	O
animal	O
at	O
two	O
consecutive	O
sampling	O
time	O
points	O
.	O

There	O
are	O
limited	O
data	O
on	O
the	O
efficacy	O
of	O
early	O
fluid	O
resuscitation	O
with	O
third	O
-	O
generation	O
hydroxyethyl	O
starch	B-CHED
(	O
HES	O
130	O
)	O
in	O
burn	O
injury	O
.	O

TITLE	O
:	O
Early	O
hypercytokinemia	O
is	O
associated	O
with	O
interferon	O
-	O
induced	O
transmembrane	O
protein	B-CHED
-	O
3	O
dysfunction	O
and	O
predictive	O
of	O
fatal	O
H7N9	O
infection	O
.	O

The	O
HNE	B-CHED
inhibitory	O
activity	O
of	O
ursolic	B-CHED
acid	I-CHED
was	O
further	O
verified	O
using	O
a	O
mouse	O
model	O
of	O
acute	O
smoke	O
-	O
induced	O
lung	O
inflammation	O
.	O

The	O
activities	O
of	O
ERK	O
,	O
JNK	O
,	O
and	O
p38MAPK	O
were	O
induced	O
by	O
LPS	B-CHED
stimulation	O
on	O
murine	O
macrophage	O
cell	O
line	O
,	O
but	O
only	O
p38MAPK	O
signaling	O
was	O
dramatically	O
suppressed	O
by	O
pretreatment	O
with	O
the	O
FJU	O
-	O
C4	O
compound	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

We	O
demonstrate	O
the	O
causative	O
role	O
of	O
H1N1	O
in	O
refractory	O
ARDS	O
of	O
a	O
previously	O
healthy	O
15	O
-	O
year	O
-	O
old	O
man	B-CHED
who	O
presented	O
to	O
the	O
intensive	O
care	O
unit	O
with	O
a	O
hypoxic	O
and	O
persistent	O
cardiogenic	O
shock	O
refractory	O
to	O
conventional	O
management	O
as	O
the	O
leading	O
symptom	O
of	O
influenza	O
A	O
.	O
Because	O
of	O
compromised	O
cardiopulmonary	O
function	O
,	O
venovenous	O
ECMO	O
was	O
applied	O
24	O
h	O
after	O
admission	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
deduced	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
seven	O
full	O
-	O
length	O
genomes	O
of	O
Colorado	O
HKU1	O
viruses	O
and	O
the	O
spike	O
glycoproteins	B-CHED
from	O
four	O
additional	O
HKU1	O
viruses	O
from	O
Colorado	O
and	O
three	O
from	O
Brazil	O
demonstrated	O
remarkable	O
conservation	O
of	O
these	O
sequences	O
with	O
genotypes	O
circulating	O
in	O
Hong	O
Kong	O
and	O
France	O
.	O

Within	O
genotype	O
A	O
,	O
all	O
but	O
one	O
of	O
the	O
Colorado	O
HKU1	O
sequences	O
formed	O
a	O
unique	O
subclade	O
defined	O
by	O
three	O
amino	B-CHED
acid	I-CHED
substitutions	O
(	O
W197F	O
,	O
F613Y	O
and	O
S752F	O
)	O
in	O
the	O
spike	O
glycoprotein	B-CHED
and	O
exhibited	O
a	O
unique	O
signature	O
in	O
the	O
acidic	O
tandem	O
repeat	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
nsp3	O
subdomain	O
.	O

High	O
levels	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
IL	O
-	O
1	O
,-	O
6	O
,-	O
8	O
,-	O
12	O
,	O
tumour	O
necrosis	O
factor	O
alpha	O
and	O
interferon	O
gamma	O
were	O
found	O
in	O
all	O
injured	O
patients	O
compared	O
to	O
healthy	O
controls	O
.	O

Secretion	O
of	O
large	O
amounts	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
and	O
decreased	O
level	O
of	O
anti	O
-	O
inflammatory	O
cytokines	O
during	O
the	O
acute	O
phase	O
of	O
trauma	O
may	O
lead	O
to	O
the	O
development	O
of	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
in	O
unstable	O
polytraumatized	O
patients	O
.	O

It	O
is	O
not	O
understood	O
whether	O
HCoV	O
-	O
HKU1	O
S	O
protein	B-CHED
has	O
similar	O
activity	O
.	O

In	O
this	O
study	O
we	O
compared	O
S	O
proteins	B-CHED
of	O
SARS	O
-	O
CoV	O
and	O
HCoV	O
-	O
HKU1	O
for	O
their	O
ability	O
to	O
activate	O
the	O
UPR	O
.	O

Transmembrane	O
serine	B-CHED
protease	O
TMPRSS2	O
catalyzed	O
the	O
cleavage	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
,	O
but	O
not	O
the	O
counterpart	O
in	O
HCoV	O
-	O
HKU1	O
.	O

Using	O
phospholipid	B-CHED
-	O
coated	O
oxygen	B-CHED
microbubbles	O
(	O
OMBs	O
),	O
we	O
demonstrate	O
100	O
%	O
survival	O
for	O
rats	O
experiencing	O
acute	O
lung	O
trauma	O
to	O
at	O
least	O
2	O
h	O
.	O
In	O
contrast	O
,	O
all	O
untreated	O
rats	O
and	O
rats	O
treated	O
with	O
peritoneal	O
oxygenated	O
saline	O
died	O
within	O
30	O
min	O
.	O

For	O
rats	O
treated	O
with	O
OMBs	O
,	O
hemoglobin	B-CHED
saturation	O
and	O
heart	O
rate	O
were	O
at	O
normal	O
levels	O
over	O
the	O
2	O
-	O
h	O
timeframe	O
.	O

Accordingly	O
,	O
the	O
DKO	O
mice	O
exhibited	O
an	O
80	O
%	O
mortality	O
rate	O
following	O
a	O
sublethal	O
dose	O
of	O
LPS	B-CHED
challenge	O
.	O

CoV	O
accessory	O
proteins	B-CHED
,	O
for	O
example	O
those	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
(	O
SARS	O
-	O
CoV	O
),	O
have	O
been	O
shown	O
to	O
block	O
innate	O
antiviral	B-CHED
signalling	O
pathways	O
.	O

We	O
therefore	O
hypothesized	O
that	O
MERS	O
-	O
CoV	O
and	O
the	O
phylogenetically	O
related	O
BtCoV	O
-	O
HKU4	O
and	O
BtCoV	O
-	O
HKU5	O
may	O
encode	O
proteins	B-CHED
with	O
similar	O
capabilities	O
.	O

We	O
also	O
analysed	O
the	O
subcellular	O
localization	O
of	O
p4b	O
from	O
MERS	O
-	O
CoV	O
,	O
BtCoV	O
-	O
HKU4	O
and	O
BtCoV	O
-	O
HKU5	O
and	O
demonstrated	O
that	O
all	O
are	O
localized	O
to	O
the	O
nucleus	B-CHED
.	O

TITLE	O
:	O
Successful	O
treatment	O
of	O
cardiogenic	O
shock	O
with	O
an	O
intraaortic	O
balloon	O
pump	O
following	O
aluminium	B-CHED
phosphide	I-CHED
poisoning	O
.	O

AUC	O
for	O
APS	B-CHED
was	O
0	O
.	O
726	O
(	O
0	O
.	O
647	O
-	O
0	O
.	O
805	O
),	O
P	O
=	O
0	O
.	O
000	O
.	O

ABSTRACT	O
:	O
Ion	O
channels	O
are	O
specialized	O
proteins	B-CHED
that	O
enable	O
the	O
movement	O
of	O
charges	O
through	O
otherwise	O
impermeable	O
lipidic	O
membranes	O
.	O

TITLE	O
:	O
Blocking	O
of	O
exchange	O
proteins	B-CHED
directly	O
activated	O
by	O
cAMP	B-CHED
leads	O
to	O
reduced	O
replication	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

In	O
this	O
study	O
,	O
we	O
revealed	O
a	O
novel	O
positive	O
function	O
of	O
an	O
exchange	O
protein	B-CHED
directly	O
activated	O
by	O
cyclic	B-CHED
AMP	I-CHED
1	O
(	O
cAMP	B-CHED
-	O
1	O
;	O
Epac	O
-	O
1	O
)	O
on	O
MERS	O
-	O
CoV	O
replication	O
.	O

Specifically	O
,	O
we	O
have	O
shown	O
that	O
Epac	O
-	O
specific	O
inhibitor	B-CHED
treatment	O
or	O
silencing	O
Epac	O
-	O
1	O
gene	O
expression	O
rendered	O
cells	O
resistant	O
to	O
viral	O
infection	O
.	O

We	O
believe	O
Epac	O
-	O
1	O
inhibitors	B-CHED
deserve	O
further	O
study	O
as	O
potential	O
therapeutic	O
agents	O
for	O
MERS	O
-	O
CoV	O
infection	O
.	O

Using	O
a	O
standard	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
neutralization	O
test	O
,	O
serial	O
sera	O
from	O
three	O
sheep	O
and	O
three	O
horses	O
were	O
all	O
negative	O
while	O
sera	O
from	O
9	O
of	O
11	O
dromedary	O
camels	O
from	O
Dubai	O
were	O
positive	O
for	O
antibodies	O
supported	O
by	O
similar	O
results	O
in	O
a	O
MERS	O
-	O
CoV	O
recombinant	O
partial	O
spike	O
protein	B-CHED
antibody	O
ELISA	O
.	O

The	O
most	O
effective	O
one	O
was	O
the	O
glycoside	B-CHED
juglanin	O
(	O
carrying	O
an	O
arabinose	B-CHED
residue	O
)	O
with	O
an	O
IC50	O
value	O
of	O
2	O
.	O
3	O
M	O
for	O
inhibition	O
of	O
the	O
3a	O
-	O
mediated	O
current	O
.	O

Heroin	B-CHED
addiction	O
is	O
common	O
,	O
with	O
an	O
estimated	O
3	O
.	O
7	O
million	O
Americans	O
reporting	O
to	O
have	O
used	O
it	O
at	O
some	O
point	O
in	O
their	O
lives	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
influence	O
of	O
the	O
variation	O
of	O
the	O
original	O
skeletons	O
of	O
natural	O
phenanthroindo	O
/	O
quinolizidine	B-CHED
alkaloids	I-CHED
on	O
antiviral	B-CHED
activities	O
,	O
two	O
types	O
of	O
structurally	O
totally	O
novel	O
analogues	O
7a	O
,	O
7b	O
,	O
16a	O
,	O
and	O
16b	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
against	O
tobacco	O
mosaic	O
virus	O
(	O
TMV	O
)	O
for	O
the	O
first	O
time	O
.	O

Bioassay	O
results	O
indicated	O
that	O
all	O
four	O
of	O
the	O
newly	O
designed	O
analogues	O
showed	O
good	O
to	O
excellent	O
antiviral	B-CHED
activities	O
,	O
among	O
which	O
analogue	O
16a	O
dispalyed	O
comparable	O
activity	O
with	O
that	O
of	O
ningnanmycin	O
,	O
perhaps	O
one	O
of	O
the	O
most	O
successful	O
commercial	O
antiviral	B-CHED
agents	I-CHED
,	O
thus	O
emerging	O
as	O
a	O
potential	O
inhibitor	B-CHED
of	O
plant	O
virus	O
and	O
serving	O
as	O
a	O
new	O
lead	O
for	O
further	O
optimization	O
.	O

Further	O
structure	O
-	O
activity	O
relationships	O
are	O
also	O
discussed	O
,	O
demonstrating	O
for	O
the	O
first	O
time	O
that	O
the	O
same	O
changes	O
of	O
the	O
original	O
skeletons	O
of	O
phenanthroindolizidine	O
and	O
phenanthroquinolizidine	O
exihibted	O
totally	O
different	O
antiviral	B-CHED
activities	O
results	O
,	O
providing	O
some	O
original	O
and	O
useful	O
information	O
about	O
the	O
preferential	O
conformation	O
for	O
maintaining	O
high	O
activities	O
.	O

This	O
case	O
series	O
report	O
showed	O
that	O
lung	O
injury	O
and	O
respiratory	O
failure	O
can	O
occur	O
as	O
a	O
result	O
of	O
inhaling	O
humidifier	O
disinfectants	B-CHED
.	O

Between	O
December	O
2012	O
and	O
August	O
2013	O
,	O
114	O
patients	O
were	O
tested	O
for	O
suspected	O
MERS	O
-	O
CoV	O
;	O
of	O
these	O
,	O
11	O
ICU	O
patients	O
(	O
10	O
%)	O
met	B-CHED
the	O
definition	O
of	O
confirmed	O
or	O
probable	O
cases	O
.	O

ABSTRACT	O
:	O
The	O
5	O
'	O
end	O
of	O
eukaryotic	O
mRNA	B-CHED
contains	O
the	O
type	O
-	O
1	O
(	O
m7GpppNm	O
)	O
or	O
type	O
-	O
2	O
(	O
m7GpppNmNm	O
)	O
cap	O
structure	O
.	O

For	O
antiviral	B-CHED
development	O
,	O
a	O
structural	O
feature	O
unique	O
to	O
the	O
flavivirus	O
methyltransferase	O
was	O
successfully	O
used	O
to	O
design	O
selective	O
inhibitors	B-CHED
that	O
block	O
viral	O
methyltransferase	O
without	O
affecting	O
host	O
methyltransferases	O
.	O

TITLE	O
:	O
Therapeutic	O
effect	O
of	O
intravenous	O
infusion	O
of	O
perfluorocarbon	O
emulsion	O
on	O
LPS	B-CHED
-	O
induced	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

This	O
could	O
be	O
achieved	O
with	O
clear	O
guidelines	O
on	O
the	O
Assessment	O
Intervention	O
Reassessment	O
(	O
AIR	B-CHED
)	O
cyclewith	O
validated	O
measures	O
adapted	O
to	O
neonates	O
.	O

We	O
screened	O
a	O
library	O
of	O
5	O
,	O
000	O
small	O
molecules	O
and	O
discovered	O
a	O
small	O
molecule	O
that	O
can	O
inhibit	O
the	O
cathepsin	O
L	O
cleavage	O
of	O
all	O
viral	O
peptides	B-CHED
with	O
minimal	O
inhibition	O
of	O
cleavage	O
of	O
a	O
host	O
protein	B-CHED
-	O
derived	O
peptide	B-CHED
(	O
pro	B-CHED
-	O
neuropeptide	O
Y	O
).	O

In	O
addition	O
,	O
the	O
Hendra	O
and	O
Nipah	O
virus	O
fusion	O
glycoproteins	B-CHED
were	O
not	O
cleaved	O
in	O
the	O
presence	O
of	O
the	O
small	O
molecule	O
in	O
a	O
cell	O
-	O
based	O
cleavage	O
assay	O
.	O

As	O
expected	O
,	O
the	O
interaction	O
of	O
N	O
protein	B-CHED
with	O
M	O
protein	B-CHED
was	O
not	O
affected	O
in	O
either	O
of	O
the	O
chimeric	O
viruses	O
.	O

This	O
work	O
describes	O
the	O
interactions	O
of	O
the	O
two	O
RNA	O
-	O
binding	O
domains	O
of	O
the	O
nucleocapsid	O
protein	B-CHED
of	O
a	O
model	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
.	O

The	O
viral	O
papain	O
-	O
like	O
proteases	O
(	O
PLPs	O
)	O
are	O
critical	O
for	O
processing	O
the	O
amino	O
-	O
terminal	O
end	O
of	O
the	O
replicase	O
and	O
are	O
attractive	O
targets	O
for	O
antiviral	B-CHED
therapies	O
.	O

In	O
these	O
groups	O
100	O
%	O
of	O
the	O
PBFIPV	O
-	O
DF	O
-	O
2	O
-	O
R3i	O
immunised	O
animals	O
developed	O
antibody	O
-	O
dependent	O
enhancement	O
(	O
ADE	B-CHED
).	O

Recombinant	O
FCoV	O
nucleocapsid	O
protein	B-CHED
(	O
rNP	O
)	O
was	O
used	O
as	O
a	O
conjugate	O
or	O
test	O
line	O
in	O
all	O
3	O
ICA	B-CHED
kits	O
(	O
CJIgG	O
/	O
TNP	B-CHED
,	O
CJNP	O
/	O
TNP	B-CHED
,	O
and	O
CJNP	O
/	O
TPA	B-CHED
).	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
rivastigmine	B-CHED
poisoning	O
resulting	O
in	O
a	O
full	O
cholinergic	O
syndrome	O
with	O
nicotinic	O
,	O
muscarinic	O
,	O
and	O
central	O
effects	O
requiring	O
supportive	O
or	O
intensive	O
care	O
in	O
a	O
pediatric	O
patient	O
.	O

The	O
importance	O
of	O
the	O
C	O
-	O
terminal	O
hydrophobic	O
residues	O
led	O
us	O
to	O
identify	O
a	O
42	O
-	O
residue	O
substructure	O
on	O
the	O
central	O
core	O
that	O
is	O
structurally	O
conserved	O
in	O
all	O
existing	O
CoV	O
S2	O
fusion	O
proteins	B-CHED
(	O
root	O
mean	O
squared	O
deviation	O
=	O
0	O
.	O
4	O
	O
).	O

It	O
is	O
a	O
traditional	O
Chinese	O
herbal	O
medicine	B-CHED
.	O

Triterpenoid	B-CHED
is	O
one	O
of	O
the	O
mainly	O
active	O
components	O
of	O
licorice	O
.	O

In	O
recent	O
years	O
,	O
the	O
broad	O
-	O
spectrum	O
antiviral	B-CHED
activity	O
of	O
many	O
triterpenoids	B-CHED
in	O
licorice	O
was	O
confirmed	O
,	O
and	O
these	O
findings	O
have	O
become	O
a	O
hot	O
spot	O
of	O
antiviral	B-CHED
immunity	O
.	O

MERS	O
-	O
CoV	O
4a	O
protein	B-CHED
interacted	O
with	O
PACT	O
in	O
an	O
RNA	O
-	O
dependent	O
manner	O
but	O
not	O
with	O
RIG	O
-	O
I	O
or	O
MDA5	O
.	O

It	O
will	O
therefore	O
be	O
critical	O
to	O
clarify	O
how	O
MERS	O
-	O
CoV	O
cripples	O
the	O
host	O
proteins	B-CHED
that	O
sense	O
viruses	O
and	O
to	O
compare	O
MERS	O
-	O
CoV	O
with	O
its	O
ancestral	O
viruses	O
in	O
bats	O
in	O
the	O
counteraction	O
of	O
virus	O
sensing	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
relationship	O
between	O
extravascular	O
lung	O
water	B-CHED
index	O
(	O
EVLWI	O
),	O
pulmonary	O
vascular	O
permeability	O
index	O
(	O
PVPI	O
)	O
and	O
the	O
severity	O
categories	O
defined	O
by	O
the	O
Berlin	O
definition	O
,	O
and	O
investigate	O
the	O
prognostic	O
value	O
of	O
EVLWI	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Silver	B-CHED
nanomaterials	O
(	O
Ag	O
NMs	O
)	O
have	O
attracted	O
great	O
interests	O
in	O
recent	O
years	O
due	O
to	O
their	O
excellent	O
anti	O
-	O
microorganism	O
properties	O
.	O

Moreover	O
,	O
further	O
results	O
showed	O
that	O
Ag	O
NPs	O
and	O
silver	B-CHED
nanowires	O
decreased	O
the	O
number	O
of	O
apoptotic	O
cells	O
induced	O
by	O
TGEV	O
through	O
regulating	O
p38	O
/	O
mitochondria	O
-	O
caspase	O
-	O
3	O
signaling	O
pathway	O
.	O

Our	O
data	O
indicate	O
that	O
Ag	O
NMs	O
are	O
effective	O
in	O
prevention	O
of	O
TGEV	O
-	O
mediated	O
cell	O
infection	O
as	O
a	O
virucidal	O
agent	O
or	O
as	O
an	O
inhibitor	B-CHED
of	O
viral	O
entry	O
and	O
the	O
present	O
findings	O
may	O
provide	O
new	O
insights	O
into	O
antiviral	B-CHED
therapy	O
of	O
coronaviruses	O
.	O

In	O
this	O
study	O
,	O
a	O
simple	O
,	O
quick	O
,	O
and	O
safe	O
cell	O
adhesion	O
inhibition	O
assay	O
was	O
developed	O
to	O
determine	O
the	O
potential	O
cellular	O
binding	O
site	O
on	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
.	O

The	O
MTase	O
inhibitors	B-CHED
previously	O
identified	O
by	O
in	O
vitro	O
biochemical	O
assays	O
were	O
tested	O
,	O
and	O
some	O
,	O
such	O
as	O
sinefungin	O
,	O
effectively	O
suppressed	O
N7	O
-	O
MTase	O
in	O
the	O
yeast	O
system	O
.	O

The	O
Ub	O
core	O
makes	O
mostly	O
hydrophilic	O
interactions	O
with	O
PLpro	O
,	O
while	O
the	O
Leu	B-CHED
-	O
Arg	B-CHED
-	O
Gly	B-CHED
-	I-CHED
Gly	I-CHED
C	O
-	O
terminus	O
of	O
Ub	O
is	O
located	O
in	O
the	O
catalytic	O
cleft	O
of	O
PLpro	O
,	O
mimicking	O
the	O
P4	O
-	O
P1	O
residues	O
and	O
providing	O
the	O
first	O
atomic	O
insights	O
into	O
its	O
catalysis	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
TGEV	O
N	O
protein	B-CHED
might	O
play	O
an	O
important	O
role	O
in	O
TGEV	O
infection	O
-	O
induced	O
p53	O
activation	O
and	O
cell	O
cycle	O
arrest	O
at	O
the	O
S	O
and	O
G2	O
/	O
M	O
phases	O
and	O
apoptosis	O
occurrence	O
.	O

Proteolytic	O
processing	O
of	O
coronavirus	O
spike	O
(	O
S	O
)	O
fusion	O
proteins	B-CHED
during	O
virus	O
entry	O
has	O
been	O
suggested	O
but	O
not	O
yet	O
formally	O
demonstrated	O
,	O
while	O
the	O
nature	O
and	O
functionality	O
of	O
the	O
resulting	O
subunit	O
is	O
still	O
unclear	O
.	O

TITLE	O
:	O
""""	O
Don	O
'	O
t	O
forget	O
the	O
migrants	O
""":"	O
exploring	O
preparedness	O
and	O
response	O
strategies	O
to	O
combat	B-CHED
the	O
potential	O
spread	O
of	O
MERS	O
-	O
CoV	O
virus	O
through	O
migrant	O
workers	O
in	O
Sri	O
Lanka	O
.	O

The	O
aims	O
of	O
the	O
current	O
study	O
were	O
to	O
identify	O
Mycoplasma	O
suis	O
antigens	B-CHED
and	O
develop	O
a	O
multiplex	O
microbead	O
immunoassay	O
(	O
MIA	O
).	O

Based	O
on	O
bioinformatics	O
,	O
putative	O
antigens	B-CHED
were	O
identified	O
within	O
positive	O
inserts	O
;	O
gene	O
fragments	O
were	O
expressed	O
and	O
purified	O
as	O
polyhistidine	O
fusion	O
proteins	B-CHED
,	O
and	O
immunoreactivity	O
was	O
confirmed	O
by	O
Western	O
blot	O
.	O

TITLE	O
:	O
Intranasal	O
vaccination	O
with	O
recombinant	O
receptor	O
-	O
binding	O
domain	O
of	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
induces	O
much	O
stronger	O
local	O
mucosal	O
immune	O
responses	O
than	O
subcutaneous	O
immunization	O
:	O
Implication	O
for	O
designing	O
novel	O
mucosal	O
MERS	O
vaccines	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
the	O
identification	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
as	O
an	O
antiviral	B-CHED
target	O
.	O

TITLE	O
:	O
The	O
discovery	O
of	O
asunaprevir	O
(	O
BMS	O
-	O
650032	O
),	O
an	O
orally	O
efficacious	O
NS3	O
protease	B-CHED
inhibitor	I-CHED
for	O
the	O
treatment	O
of	O
hepatitis	O
C	O
virus	O
infection	O
.	O

We	O
have	O
shown	O
before	O
that	O
CsA	B-CHED
and	O
FK506	B-CHED
inhibit	O
coronavirus	O
replication	O
(	O
Carbajo	O
-	O
Lozoya	O
,	O
J	O
.,	O
Mller	O
,	O
M	O
.	O
A	O
.,	O
Kallies	O
,	O
S	O
.,	O
Thiel	O
,	O
V	O
.,	O
Drosten	O
,	O
C	O
.,	O
von	O
Brunn	O
,	O
A	O
.	O
Replication	O
of	O
human	O
coronaviruses	O
SARS	O
-	O
CoV	O
,	O
HCoV	O
-	O
NL63	O
and	O
HCoV	O
-	O
229E	O
is	O
inhibited	O
by	O
the	O
drug	O
FK506	B-CHED
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
illness	O
(	O
ARI	B-CHED
)	O
accounts	O
for	O
a	O
large	O
proportion	O
of	O
all	O
visits	O
to	O
pediatric	O
health	O
facilities	O
.	O

Quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
analyses	O
allow	O
sensitive	O
detection	O
of	O
viral	O
nucleic	B-CHED
acids	I-CHED
,	O
but	O
it	O
is	O
not	O
clear	O
to	O
what	O
extent	O
specific	O
viruses	O
contribute	O
to	O
disease	O
because	O
many	O
viruses	O
have	O
been	O
detected	O
in	O
asymptomatic	O
children	O
.	O

Finally	O
,	O
the	O
less	O
lipophilic	O
bis	O
(	O
amide	B-CHED
)	O
3e	O
and	O
methoxypyridine	O
5c	O
exhibit	O
significantly	O
improved	O
metabolic	O
stability	O
and	O
are	O
viable	O
candidates	O
for	O
advancing	O
to	O
in	O
vivo	O
studies	O
.	O

We	O
present	O
the	O
first	O
and	O
an	O
unusual	O
case	O
of	O
East	O
African	O
trypanosomiasis	O
imported	O
to	O
Poland	O
by	O
a	O
patient	O
returning	O
from	O
a	O
tourist	O
trip	O
to	O
Uganda	O
and	O
Rwanda	O
,	O
which	O
was	O
successfully	O
treated	O
with	O
pentamidine	B-CHED
.	O

A	O
61	O
-	O
year	O
-	O
old	O
Polish	O
man	B-CHED
was	O
admitted	O
to	O
the	O
Department	O
because	O
of	O
high	O
-	O
grade	O
fever	O
and	O
multi	O
-	O
organ	O
dysfunction	O
after	O
a	O
tourist	O
trip	O
to	O
East	O
Africa	O
.	O

Viruses	O
detected	O
,	O
based	O
on	O
frequency	O
were	O
Rhinovirus	O
,	O
Adenovirus	O
,	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
and	O
corona	B-CHED
virus	O
.	O

The	O
survival	O
ratio	O
showed	O
statistically	O
significant	O
differences	O
in	O
mild	O
and	O
moderate	O
ARDS	O
-	O
patients	O
treated	O
with	O
the	O
neutrophil	B-CHED
elastase	I-CHED
inhibitor	I-CHED
.	O

The	O
survival	O
ratio	O
showed	O
statistically	O
significant	O
differences	O
in	O
mild	O
and	O
moderate	O
ARDS	O
-	O
patients	O
treated	O
with	O
the	O
neutrophil	B-CHED
elastase	I-CHED
inhibitor	I-CHED
.	O

Within	O
a	O
few	O
days	O
,	O
the	O
same	O
virus	O
was	O
detected	O
in	O
a	O
Qatari	O
patient	O
receiving	O
intensive	O
care	O
in	O
a	O
London	O
hospital	O
,	O
a	O
situation	O
reminiscent	O
of	O
the	O
role	O
air	B-CHED
travel	O
played	O
in	O
the	O
spread	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
2002	O
.	O

In	O
this	O
study	O
,	O
a	O
one	O
-	O
step	O
,	O
reverse	O
transcription	O
loop	O
-	O
mediated	O
isothermal	O
amplification	O
(	O
RT	O
-	O
LAMP	O
)	O
assay	O
was	O
developed	O
that	O
targets	O
a	O
region	O
in	O
the	O
FHMNV	O
spike	O
protein	B-CHED
gene	O
.	O

The	O
assay	O
was	O
optimized	O
,	O
and	O
the	O
best	O
results	O
were	O
obtained	O
at	O
8	O
mM	O
of	O
Mg	O
(	O
2	O
+)	O
with	O
an	O
incubation	O
time	O
of	O
40	O
min	O
at	O
63	O
	O
C	O
in	O
the	O
presence	O
of	O
calcein	B-CHED
.	O

ABSTRACT	O
:	O
Proteolytic	O
cleavage	O
of	O
the	O
hemagglutinin	O
(	O
HA	O
)	O
protein	B-CHED
is	O
essential	O
for	O
influenza	O
A	O
virus	O
(	O
IAV	O
)	O
to	O
acquire	O
infectivity	O
.	O

At	O
the	O
beginning	O
,	O
the	O
diagnosis	O
of	O
NMLS	O
secondary	O
to	O
dopamine	B-CHED
decrease	O
was	O
difficult	O
to	O
make	O
,	O
because	O
her	O
initial	O
blood	O
examination	O
revealed	O
that	O
her	O
serum	O
CK	O
levels	O
were	O
mildly	O
elevated	O
and	O
decreased	O
to	O
normal	O
range	O
rapidly	O
.	O

Lacking	O
understanding	O
of	O
FH	O
pathogenesis	O
has	O
in	O
essence	B-CHED
hindered	O
efficient	O
clinical	O
treatment	O
.	O

Therefore	O
,	O
radical	B-CHED
scavengers	O
are	O
promising	O
compounds	O
for	O
the	O
treatment	O
of	O
neuronal	O
dysfunction	O
in	O
RS	O
and	O
deserve	O
further	O
detailed	O
evaluation	O
.	O

To	O
this	O
aim	O
,	O
we	O
generated	O
live	O
attenuated	O
recombinant	O
measles	O
vaccine	O
(	O
MV	O
)	O
candidates	O
expressing	O
either	O
the	O
membrane	O
-	O
anchored	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
or	O
its	O
secreted	O
soluble	O
ectodomain	O
(	O
Ssol	O
).	O

In	O
mice	O
susceptible	O
to	O
measles	O
virus	O
,	O
recombinant	O
MV	O
expressing	O
the	O
anchored	O
full	O
-	O
length	O
S	O
induced	O
the	O
highest	O
titers	O
of	O
neutralizing	O
antibodies	O
and	O
fully	O
protected	O
immunized	O
animals	O
from	O
intranasal	O
infectious	O
challenge	O
with	O
SARS	O
-	O
CoV	O
.	O
As	O
compared	O
to	O
immunization	O
with	O
adjuvanted	O
recombinant	O
Ssol	O
protein	B-CHED
,	O
recombinant	O
MV	O
induced	O
stronger	O
and	O
Th1	O
-	O
biased	O
responses	O
,	O
a	O
hallmark	O
of	O
live	O
attenuated	O
viruses	O
and	O
a	O
highly	O
desirable	O
feature	O
for	O
an	O
antiviral	B-CHED
vaccine	O
.	O

Although	O
glucose	B-CHED
transporter	O
-	O
4	O
mRNA	B-CHED
was	O
decreased	O
by	O
cachexia	O
,	O
LoFS	O
increased	O
muscle	O
glucose	B-CHED
transporter	O
-	O
4	O
mRNA	B-CHED
in	O
both	O
BL	O
-	O
6	O
and	O
Min	O
mice	O
.	O

However	O
,	O
in	O
Min	O
mice	O
,	O
LoFS	O
was	O
not	O
able	O
to	O
induce	O
muscle	O
proliferator	O
-	O
activated	O
receptor	O
-	O
	O
coactivator	O
-	O
1	O
targets	O
nuclear	O
respiratory	O
factor	O
-	O
1	O
and	O
mitochondrial	O
transcription	O
factor	O
A	O
mRNA	B-CHED
.	O

We	O
estimated	O
R0	O
for	O
the	O
three	O
clusters	B-CHED
to	O
be	O
:	O
0	O
.	O
19	O
in	O
Shanghai	O
(	O
0	O
.	O
01	O
-	O
0	O
.	O
49	O
),	O
0	O
.	O
29	O
in	O
Jiangsu	O
(	O
0	O
.	O
03	O
-	O
0	O
.	O
73	O
);	O
and	O
0	O
.	O
03	O
in	O
Zhejiang	O
(	O
0	O
.	O
00	O
-	O
0	O
.	O
22	O
).	O

In	O
both	O
,	O
MS	O
and	O
coronavirus	O
-	O
induced	O
encephalomyelitis	O
,	O
this	O
was	O
associated	O
with	O
massive	O
microglial	O
and	O
macrophage	O
activation	O
,	O
accompanied	O
by	O
the	O
expression	O
of	O
the	O
NADPH	B-CHED
oxidase	O
subunit	O
p22phox	O
but	O
only	O
sparse	O
expression	O
of	O
inducible	O
nitric	B-CHED
oxide	I-CHED
synthase	O
(	O
iNOS	O
).	O

Previous	O
studies	O
of	O
coronavirus	O
replication	O
complex	O
organization	O
and	O
protein	B-CHED
interactions	O
have	O
utilized	O
protein	B-CHED
overexpression	O
studies	O
and	O
immunofluorescence	O
of	O
fixed	O
cells	O
.	O

We	O
demonstrate	O
that	O
the	O
fusion	O
of	O
green	O
fluorescent	O
protein	B-CHED
and	O
firefly	O
luciferase	O
with	O
either	O
nonstructural	O
protein	B-CHED
2	O
or	O
3	O
is	O
tolerated	O
and	O
that	O
these	O
reporter	O
-	O
replicase	O
fusions	O
can	O
be	O
used	O
to	O
quantitate	O
replication	O
complex	O
formation	O
and	O
virus	O
replication	O
.	O

Fueling	O
the	O
explosive	B-CHED
growth	O
is	O
a	O
combination	O
of	O
technological	O
improvements	O
and	O
accumulating	O
,	O
although	O
controversial	O
,	O
evidence	O
.	O

The	O
role	O
of	O
ECMO	O
used	O
primarily	O
for	O
extracorporeal	O
carbon	B-CHED
dioxide	I-CHED
removal	O
(	O
ECCO2R	O
)	O
in	O
the	O
support	O
of	O
patients	O
with	O
hypercapnic	O
respiratory	O
failure	O
and	O
less	O
severe	O
forms	O
of	O
ARDS	O
is	O
also	O
evolving	O
.	O

Finally	O
,	O
the	O
activity	O
of	O
this	O
nuclear	O
export	O
signal	O
(	O
NES	O
)	O
was	O
inhibited	O
by	O
the	O
antibiotic	B-CHED
Lepomycin	O
B	O
,	O
suggesting	O
that	O
N	O
is	O
exported	O
by	O
a	O
chromosome	O
region	O
maintenance	O
1	O
-	O
related	O
export	O
pathway	O
.	O

ABSTRACT	O
:	O
Double	O
-	O
stranded	O
RNA	O
-	O
dependent	O
protein	B-CHED
kinase	O
(	O
PKR	O
)	O
regulates	O
antiviral	B-CHED
activity	O
,	O
immune	O
responses	O
,	O
apoptosis	O
and	O
neurotoxicity	O
.	O

Gliatropic	O
coronavirus	O
infection	O
induced	O
PKR	O
activation	O
in	O
infected	O
as	O
well	O
uninfected	O
cells	O
within	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
).	O

In	O
a	O
recent	O
study	O
,	O
high	O
matrix	O
metalloproteinases	O
(	O
MMP	B-CHED
-	O
8	O
)	O
levels	O
in	O
tracheal	O
aspirates	O
of	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
patients	O
were	O
associated	O
with	O
worse	O
outcome	O
.	O

In	O
patients	O
with	O
sepsis	O
,	O
an	O
imbalance	O
between	O
MMPs	O
and	O
their	O
tissue	O
inhibitors	B-CHED
(	O
TIMPs	O
)	O
has	O
been	O
associated	O
with	O
impaired	O
survival	O
.	O

HPV	O
was	O
virucidal	O
(>	O
4	O
-	O
log	O
reduction	O
)	O
against	O
FCV	B-CHED
,	O
adenovirus	O
,	O
TGEV	O
and	O
AIV	O
at	O
the	O
lowest	O
vaporized	O
volume	O
tested	O
(	O
25	O
mL	O
).	O

Therefore	O
,	O
we	O
performed	O
time	O
course	O
experiments	O
in	O
which	O
Vero	O
cells	O
were	O
C	O
.	O
pecorum	O
/	O
PEDV	O
infected	O
in	O
the	O
presence	O
of	O
cycloheximide	B-CHED
(	O
CHX	O
),	O
which	O
inhibits	O
viral	O
but	O
not	O
chlamydial	O
protein	B-CHED
synthesis	O
.	O

The	O
reovirus	O
outer	O
capsid	O
protein	B-CHED
1	O
is	O
recognized	O
as	O
the	O
primary	O
determinant	O
of	O
reovirus	O
-	O
induced	O
apoptosis	O
.	O

Similarly	O
,	O
improvements	O
in	O
carbon	B-CHED
dioxide	I-CHED
(	O
CO2	B-CHED
)	O
clearance	O
,	O
pulmonary	O
vascular	O
pressures	O
and	O
inflammation	O
were	O
observed	O
and	O
confirmed	O
by	O
histology	O
and	O
by	O
the	O
decrease	O
in	O
lung	O
edema	O
.	O

ABSTRACT	O
:	O
This	O
research	O
was	O
conducted	O
to	O
investigate	O
the	O
effect	O
of	O
supplementation	O
of	O
zinc	B-CHED
(	O
Zn	O
)	O
and	O
ascorbic	B-CHED
acid	I-CHED
(	O
AA	O
)	O
in	O
heat	O
-	O
stressed	O
broilers	O
.	O

We	O
next	O
determined	O
whether	O
2	B-CHED
-	I-CHED
Deoxy	I-CHED
-	I-CHED
d	I-CHED
-	I-CHED
glucose	I-CHED
(	O
2	O
-	O
DG	O
),	O
an	O
ER	O
stress	O
inducer	O
,	O
possessed	O
antiviral	B-CHED
activity	O
against	O
PEDV	O
infection	O
.	O

All	O
these	O
results	O
support	O
the	O
therapeutic	O
potential	O
of	O
using	O
2	O
-	O
DG	O
or	O
glucose	B-CHED
/	O
mannose	B-CHED
analogs	O
to	O
induce	O
the	O
UPR	O
to	O
block	O
virus	O
replication	O
.	O

The	O
genome	O
of	O
the	O
ck	O
/	O
CH	O
/	O
IBTZ	O
/	O
2012	O
strain	O
is	O
27	O
,	O
691	O
nucleotides	B-CHED
in	O
length	O
and	O
includes	O
more	O
than	O
10	O
open	O
reading	O
frames	O
.	O

The	O
cleavage	O
site	O
within	O
the	O
spike	O
protein	B-CHED
(	O
S	O
)	O
of	O
ck	O
/	O
CH	O
/	O
IBTZ	O
/	O
2012	O
is	O
HRRKR	O
,	O
which	O
is	O
different	O
from	O
the	O
majority	O
of	O
the	O
IBVs	O
in	O
China	O
for	O
their	O
cleavage	O
sits	O
are	O
HRRRR	O
.	O

A	O
negative	O
correlation	O
between	O
antiviral	B-CHED
cytokines	O
and	O
IL	O
-	O
10	O
,	O
IL	O
-	O
17	O
,	O
IL	O
-	O
37	O
,	O
FOXP3	O
,	O
and	O
RORC2	O
was	O
observed	O
only	O
in	O
the	O
presence	O
of	O
viruses	O
,	O
and	O
interestingly	O
,	O
IL	O
-	O
13	O
strongly	O
correlated	O
with	O
antiviral	B-CHED
cytokines	O
.	O

A	O
negative	O
correlation	O
between	O
antiviral	B-CHED
cytokines	O
and	O
IL	O
-	O
10	O
,	O
IL	O
-	O
17	O
,	O
IL	O
-	O
37	O
,	O
FOXP3	O
,	O
and	O
RORC2	O
was	O
observed	O
only	O
in	O
the	O
presence	O
of	O
viruses	O
,	O
and	O
interestingly	O
,	O
IL	O
-	O
13	O
strongly	O
correlated	O
with	O
antiviral	B-CHED
cytokines	O
.	O

TITLE	O
:	O
Community	O
case	O
clusters	B-CHED
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
in	O
Hafr	O
Al	O
-	O
Batin	O
,	O
Kingdom	O
of	O
Saudi	O
Arabia	O
:	O
a	O
descriptive	O
genomic	O
study	O
.	O

ABSTRACT	O
:	O
Poxviruses	O
are	O
important	O
pathogens	O
of	O
man	B-CHED
and	O
numerous	O
domestic	O
and	O
wild	O
animal	O
species	O
.	O

Based	O
on	O
the	O
theory	O
of	O
traditional	O
Chinese	O
medicine	B-CHED
,	O
mix	O
-	O
using	O
herbs	O
provide	O
a	O
synergistic	O
benefit	O
on	O
preventing	O
and	O
healing	O
respiratory	O
tract	O
infections	O
.	O

Our	O
results	O
showed	O
that	O
indirubin	O
derivatives	O
have	O
a	O
potential	O
to	O
be	O
used	O
as	O
an	O
adjunct	O
to	O
antiviral	B-CHED
therapy	O
for	O
the	O
treatment	O
of	O
severe	O
human	O
H5N1	O
disease	O
.	O

Six	O
,	O
165	O
and	O
293	O
articles	O
were	O
found	O
when	O
PubMed	O
(	O
a	O
service	O
of	O
the	O
U	O
.	O
S	O
.	O
National	O
Library	O
of	O
Medicine	B-CHED
)	O
was	O
searched	O
for	O
the	O
terms	O
'	O
mycoplasma	O
'	O
and	O
'	O
ICU	O
',	O
'	O
mycoplasma	O
'	O
and	O
'	O
mortality	O
',	O
and	O
'	O
mycoplasma	O
'	O
and	O
'	O
severe	O
'.	O

Macrolide	B-CHED
resistance	O
genotypes	O
have	O
been	O
detected	O
.	O

We	O
determined	O
that	O
the	O
initial	O
appropriate	O
antibiotics	B-CHED
use	O
was	O
an	O
independent	O
clinical	O
factor	O
and	O
day	O
1	O
high	O
-	O
mobility	O
group	O
protein	B-CHED
B1	O
(	O
HMGB1	O
)	O
concentration	O
was	O
an	O
independent	O
biomarker	B-CHED
for	O
ICU	O
mortality	O
.	O

With	O
antimicrobial	B-CHED
therapy	O
and	O
other	O
supportive	O
treatment	O
,	O
clinical	O
symptoms	O
and	O
oxygenation	O
of	O
the	O
patient	O
improved	O
gradually	O
.	O

Neutrophil	O
elastase	O
,	O
nuclear	O
factor	O
-	O
B	O
(	O
NF	O
-	O
B	O
),	O
and	O
NF	O
-	O
B	O
repressing	O
factor	O
(	O
NRF	O
)	O
have	O
previously	O
been	O
shown	O
to	O
participate	O
in	O
the	O
regulation	O
of	O
macrophage	O
inflammatory	O
protein	B-CHED
-	O
2	O
(	O
MIP	O
-	O
2	O
)	O
during	O
airway	O
inflammation	O
.	O

Lung	O
and	O
blood	O
bacterial	O
burden	O
was	O
not	O
affected	O
by	O
MV	O
pneumonia	O
and	O
MV	O
increased	O
lung	O
AM	O
expression	O
,	O
whereas	O
receptor	O
activity	O
modifying	O
protein	B-CHED
(	O
RAMP	O
)	O
1	O
-	O
3	O
expression	O
was	O
increased	O
in	O
pneumonia	O
and	O
reduced	O
by	O
MV	O
.	O

Vaccination	O
strategies	O
for	O
coronaviruses	O
have	O
involved	O
live	O
attenuated	O
virus	O
,	O
recombinant	O
viruses	O
,	O
non	O
-	O
replicative	O
virus	O
-	O
like	O
particles	O
expressing	O
coronavirus	O
proteins	B-CHED
or	O
DNA	O
plasmids	O
expressing	O
coronavirus	O
genes	O
.	O

Pearson	O
chi	B-CHED
-	O
square	O
test	O
).	O

Pearson	O
chi	B-CHED
-	O
square	O
test	O
).	O

The	O
data	O
suggest	O
that	O
the	O
YXX	O
motif	O
of	O
the	O
SARS	O
-	O
CoV	O
3a	O
protein	B-CHED
is	O
necessary	O
for	O
Golgi	O
to	O
plasma	O
membrane	O
transport	O
,	O
in	O
the	O
absence	O
of	O
which	O
the	O
protein	B-CHED
is	O
targeted	O
to	O
lysosomal	O
degradation	O
compartment	O
via	O
lipid	B-CHED
droplets	O
.	O

Changing	O
all	O
three	O
E	O
cysteine	B-CHED
residues	O
to	O
alanines	O
did	O
not	O
exert	O
negative	O
effects	O
on	O
E	O
release	O
,	O
E	O
association	O
with	O
N	O
,	O
or	O
E	O
enhancement	O
of	O
VLP	O
production	O
,	O
suggesting	O
that	O
E	O
palmitoylation	O
modification	O
or	O
disulfide	B-CHED
bond	O
formation	O
is	O
not	O
required	O
for	O
SARS	O
-	O
CoV	O
virus	O
assembly	O
.	O

TITLE	O
:	O
Bioinformatics	O
insight	O
into	O
the	O
spike	O
glycoprotein	B-CHED
gene	O
of	O
field	O
porcine	O
epidemic	O
diarrhea	O
strains	O
during	O
2011	O
-	O
2013	O
in	O
Guangdong	O
,	O
China	O
.	O

Here	O
,	O
we	O
used	O
a	O
well	O
-	O
characterized	O
nonimmune	O
human	O
Ab	O
-	O
phage	O
library	O
and	O
a	O
panning	O
strategy	O
with	O
proteoliposomes	O
and	O
cells	O
to	O
identify	O
seven	O
human	O
nAbs	O
against	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
Spike	O
protein	B-CHED
.	O

These	O
nAbs	O
bind	O
to	O
three	O
different	O
epitopes	O
in	O
the	O
RBD	O
and	O
human	O
dipeptidyl	O
peptidase	O
4	O
(	O
hDPP4	O
)	O
interface	O
with	O
subnanomolar	O
/	O
nanomolar	O
binding	O
affinities	O
and	O
block	O
the	O
binding	O
of	O
MERS	O
-	O
CoV	O
Spike	O
protein	B-CHED
with	O
its	O
hDPP4	O
receptor	O
.	O

Moreover	O
,	O
in	O
the	O
absence	O
of	O
a	O
licensed	O
vaccine	O
or	O
antiviral	B-CHED
for	O
MERS	O
,	O
this	O
panel	O
of	O
nAbs	O
offers	O
the	O
possibility	O
of	O
developing	O
human	O
mAb	O
-	O
based	O
immunotherapy	O
,	O
especially	O
for	O
health	O
-	O
care	O
workers	O
.	O

Knocking	O
down	O
E	O
protein	B-CHED
IC	O
activity	O
did	O
not	O
significantly	O
affect	O
virus	O
growth	O
in	O
infected	O
mice	O
but	O
decreased	O
edema	O
accumulation	O
,	O
the	O
major	O
determinant	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
leading	O
to	O
death	O
.	O

The	O
highest	O
-	O
affinity	O
MAb	O
,	O
m336	O
,	O
neutralized	O
both	O
pseudotyped	O
and	O
live	O
MERS	O
-	O
CoV	O
with	O
exceptional	O
potency	O
,	O
50	O
%	O
neutralization	O
at	O
0	O
.	O
005	O
and	O
0	O
.	O
07	O
g	O
/	O
ml	O
,	O
respectively	O
,	O
likely	O
by	O
competing	O
with	O
DPP4	O
for	O
binding	O
to	O
the	O
S	O
glycoprotein	B-CHED
.	O

Based	O
on	O
these	O
results	O
and	O
previous	O
data	O
,	O
in	O
silico	O
docking	O
analysis	O
showed	O
a	O
putative	O
RDS1643	O
binding	O
region	O
that	O
reaches	O
into	O
the	O
PFV	B-CHED
RNase	O
H	O
active	O
site	O
.	O

TITLE	O
:	O
Proteolytic	O
activation	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
coronavirus	O
spike	O
fusion	O
protein	B-CHED
by	O
trypsin	O
in	O
cell	O
culture	O
.	O

However	O
,	O
independent	O
of	O
preexisting	O
cerebral	O
autoregulation	O
may	O
not	O
further	O
be	O
impaired	O
when	O
a	O
high	O
PEEP	B-CHED
was	O
chosen	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
prognostic	O
significance	O
of	O
early	O
lactate	B-CHED
clearance	O
rate	O
for	O
severe	O
acute	O
respiratory	O
failure	O
patients	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

(	O
3	O
)	O
Kaplan	O
-	O
Meier	O
survival	O
analysis	O
showed	O
that	O
90	O
d	O
survival	O
rate	O
of	O
the	O
high	O
lactate	B-CHED
clearance	O
rate	O
group	O
and	O
the	O
low	O
lactate	B-CHED
clearance	O
rate	O
group	O
were	O
78	O
.	O
3	O
%	O
and	O
30	O
%,	O
with	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
(	O
	O
=	O
10	O
.	O
103	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

(	O
4	O
)	O
Multivariate	O
logistic	O
regression	O
analysis	O
showed	O
that	O
0	O
h	O
blood	O
lactate	B-CHED
(	O
OR	O
=	O
1	O
.	O
318	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
159	O
	O
6	O
.	O
882	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
6	O
h	O
lactate	B-CHED
clearance	O
rate	O
(	O
OR	O
=	O
6	O
.	O
921	O
,	O
95	O
%	O
CI	O
:	O
4	O
.	O
469	O
	O
15	O
.	O
036	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
APACHEII	O
score	O
(	O
OR	O
=	O
4	O
.	O
417	O
,	O
95	O
%	O
CI	O
:	O
3	O
.	O
058	O
	O
10	O
.	O
356	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
independent	O
risk	O
factors	O
associated	O
with	O
mortality	O
of	O
patients	O
on	O
ECMO	O
.	O

TITLE	O
:	O
The	O
correlation	O
between	O
prolonged	O
corrected	O
QT	O
interval	O
with	O
the	O
frequency	O
of	O
respiratory	O
arrest	O
,	O
endotracheal	O
intubation	O
,	O
and	O
mortality	O
in	O
acute	O
methadone	B-CHED
overdose	O
.	O

Participants	O
were	O
152	O
patients	O
aged	O
15	O
-	O
65	O
with	O
negative	O
urinary	O
dipstick	O
test	O
for	O
cyclic	O
antidepressants	B-CHED
,	O
no	O
history	O
of	O
other	O
QTc	O
-	O
prolonging	O
conditions	O
and	O
co	O
-	O
ingestions	O
,	O
no	O
severe	O
comorbidities	O
affecting	O
the	O
outcomes	O
,	O
and	O
positive	O
urinary	O
dipstick	O
results	O
for	O
methadone	B-CHED
.	O

The	O
patient	O
was	O
managed	O
by	O
intravenous	O
quinine	B-CHED
and	O
norepinephrine	B-CHED
infusion	O
due	O
to	O
refractory	O
shock	O
.	O

The	O
patient	O
ultimately	O
recovered	O
,	O
but	O
quadriamputation	O
was	O
necessary	O
to	O
treat	O
symmetrical	O
peripheral	O
gangrene	O
(	O
SPG	B-CHED
).	O

Pathological	O
findings	O
and	O
biomolecular	O
diagnostic	O
test	O
results	O
were	O
compatible	O
with	O
an	O
initial	O
FPV	O
infection	O
that	O
,	O
in	O
consequence	O
of	O
the	O
lymphoid	O
depletion	O
,	O
has	O
fostered	O
coinfection	O
or	O
reactivation	O
of	O
chronic	O
-	O
latent	O
infections	O
with	O
FeHV	O
-	O
1	O
,	O
FCV	B-CHED
,	O
and	O
FCoV	O
.	O
In	O
the	O
reported	O
case	O
,	O
the	O
simultaneous	O
presence	O
of	O
different	O
viruses	O
exacerbated	O
the	O
clinical	O
status	O
of	O
the	O
host	O
,	O
resulting	O
in	O
multiple	O
organ	O
damage	O
and	O
leading	O
it	O
to	O
its	O
death	O
.	O

Nucleotide	B-CHED
sequence	O
analysis	O
based	O
on	O
individual	O
virus	O
genes	O
indicated	O
a	O
close	O
relationship	O
between	O
the	O
S	O
gene	O
of	O
SHQP	O
/	O
YM	O
/	O
2013	O
and	O
those	O
of	O
the	O
four	O
Korean	O
field	O
strains	O
from	O
2008	O
-	O
2009	O
.	O

Combination	O
therapy	O
with	O
interferon	O
-	O
2b	O
and	O
ribavirin	B-CHED
has	O
been	O
used	O
successfully	O
as	O
primary	O
treatment	O
and	O
prophylaxis	O
in	O
SARS	O
.	O

Preliminary	O
SARs	O
showed	O
that	O
the	O
substituted	O
groups	O
with	O
hydrogen	B-CHED
donor	I-CHED
at	O
13a	O
position	O
were	O
found	O
to	O
be	O
favorable	O
for	O
keeping	O
high	O
antiviral	B-CHED
activity	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
SSYA10	O
-	O
001	O
as	O
a	O
replication	O
inhibitor	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
mouse	O
hepatitis	O
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronaviruses	O
.	O

In	O
addition	O
,	O
the	O
data	O
revealed	O
that	O
highly	O
virulent	O
HPAI	O
virus	O
and	O
MERS	O
-	O
CoV	O
induce	O
repressive	O
histone	B-CHED
modifications	O
,	O
which	O
downregulate	O
expression	O
of	O
ISG	O
subsets	O
.	O

TITLE	O
:	O
The	O
3	O
'-	O
terminal	O
55	O
nucleotides	B-CHED
of	O
bovine	O
coronavirus	O
defective	O
interfering	O
RNA	O
harbor	O
cis	O
-	O
acting	O
elements	O
required	O
for	O
both	O
negative	O
-	O
and	O
positive	O
-	O
strand	O
RNA	O
synthesis	O
.	O

We	O
then	O
tested	O
the	O
association	O
of	O
subphenotypes	O
with	O
clinical	O
outcomes	O
in	O
both	O
cohorts	O
and	O
with	O
the	O
response	O
to	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
in	O
the	O
ALVEOLI	O
cohort	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
PEDV	O
infection	O
inhibits	O
the	O
synthesis	O
of	O
type	O
I	O
interferon	O
(	O
IFN	O
),	O
and	O
viral	O
papain	O
-	O
like	O
protease	O
2	O
has	O
been	O
identified	O
as	O
an	O
IFN	O
antagonist	B-CHED
.	O

However	O
,	O
sialic	B-CHED
acid	I-CHED
binding	O
was	O
not	O
a	O
prerequisite	O
for	O
the	O
initiation	O
of	O
infection	O
and	O
virus	O
-	O
receptor	O
engagement	O
was	O
even	O
more	O
efficient	O
after	O
desialylation	O
of	O
cells	O
,	O
indicating	O
that	O
FECV	O
requires	O
sialidases	O
for	O
efficient	O
enterocyte	O
infections	O
.	O

Meta	O
-	O
analyses	O
have	O
suggested	O
better	O
survival	O
in	O
patients	O
with	O
an	O
arterial	O
oxygen	B-CHED
tension	O
(	O
PaO2	O
)/	O
inspiratory	O
oxygen	B-CHED
fraction	O
(	O
FIO2	O
)	O
ratio	O
<	O
100	O
mmHg	O
.	O

The	O
initial	O
patient	O
presentation	O
was	O
of	O
uncomplicated	O
P	O
.	O
vivax	O
(	O
0	O
.	O
5	O
%	O
parasitaemia	O
)	O
in	O
a	O
term	O
,	O
multigravida	O
woman	O
who	O
responded	O
rapidly	O
to	O
oral	O
artesunate	B-CHED
and	O
mefloquine	B-CHED
treatment	O
,	O
clearing	O
her	O
blood	O
stage	O
parasites	O
within	O
48	O
hours	O
.	O

TITLE	O
:	O
Severe	O
flucloxacillin	B-CHED
-	O
induced	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(	O
AGEP	O
),	O
with	O
toxic	O
epidermal	O
necrolysis	O
(	O
TEN	O
)-	O
like	O
features	O
:	O
does	O
overlap	O
between	O
AGEP	O
and	O
TEN	O
exist	O
?	O

We	O
present	O
a	O
severe	O
case	O
of	O
AGEP	O
,	O
caused	O
by	O
flucloxacillin	B-CHED
,	O
clinically	O
presenting	O
with	O
TEN	O
-	O
like	O
features	O
and	O
pronounced	O
systemic	O
symptoms	O
with	O
haemodynamic	O
and	O
respiratory	O
instability	O
.	O

Furthermore	O
,	O
in	O
contrast	O
to	O
its	O
protective	O
role	O
in	O
limiting	O
CNS	B-CHED
autoimmunity	O
and	O
preventing	O
immunopathology	O
,	O
these	O
data	O
define	O
a	O
detrimental	O
role	O
of	O
IL	O
-	O
27	O
in	O
promoting	O
demyelination	O
by	O
delaying	O
viral	O
control	O
.	O

Circular	O
dichroism	O
and	O
Tyr	B-CHED
/	O
Trp	B-CHED
fluorescence	O
analyses	O
indicated	O
that	O
the	O
secondary	O
and	O
tertiary	O
structure	O
of	O
MERS	O
-	O
CoV	O
PLpro	O
is	O
well	O
organized	O
and	O
folded	O
.	O

Overall	O
,	O
MERS	O
-	O
CoV	O
PLpro	O
bound	O
by	O
an	O
endogenous	O
metal	B-CHED
ion	O
shows	O
a	O
folded	O
structure	O
and	O
potent	O
proteolytic	O
and	O
deubiquitination	O
activity	O
.	O

RESULTS	O
:	O
Circular	O
dichroism	O
and	O
Tyr	B-CHED
/	O
Trp	B-CHED
fluorescence	O
analyses	O
indicated	O
that	O
the	O
secondary	O
and	O
tertiary	O
structure	O
of	O
MERS	O
-	O
CoV	O
PLpro	O
is	O
well	O
organized	O
and	O
folded	O
.	O

TITLE	O
:	O
DV	O
-	O
curve	O
representation	O
of	O
protein	B-CHED
sequences	O
and	O
its	O
application	O
.	O

ABSTRACT	O
:	O
Two	O
patients	O
,	O
returning	O
to	O
the	O
Netherlands	O
from	O
pilgrimage	O
in	O
Medina	B-CHED
and	O
Mecca	O
,	O
Kingdom	O
of	O
Saudi	O
Arabia	O
,	O
were	O
diagnosed	O
with	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
in	O
May	O
2014	O
.	O

Replacing	O
proline	O
939	O
with	O
the	O
corresponding	O
HCoV	O
-	O
OC43	O
residue	O
,	O
leucine	B-CHED
,	O
decreased	O
the	O
ability	O
MHV	O
to	O
induce	O
cell	O
-	O
cell	O
fusion	O
,	O
providing	O
experimental	O
support	O
for	O
an	O
earlier	O
proposal	O
that	O
residues	O
929	O
-	O
944	O
make	O
up	O
the	O
fusion	O
peptide	B-CHED
of	O
the	O
MHV	O
S	O
protein	B-CHED
.	O

Patients	O
with	O
ARDS	O
who	O
respond	O
to	O
increased	O
PEEP	B-CHED
by	O
improved	O
oxygenation	O
have	O
a	O
lower	O
risk	O
of	O
death	O
.	O

Severe	O
lung	O
disease	O
in	O
newborn	O
infants	O
and	O
older	O
patients	O
is	O
caused	O
by	O
mutations	O
in	O
genes	O
regulating	O
alveolar	O
epithelial	O
cells	O
and	O
surfactant	B-CHED
homeostasis	O
.	O

Meta	O
-	O
analysis	O
of	O
older	O
trials	O
of	O
prostaglandin	B-CHED
E1	I-CHED
also	O
showed	O
no	O
effect	O
.	O

PCP	B-CHED
is	O
responsible	O
for	O
pneumonia	O
in	O
56	O
.	O
6	O
%	O
HIV	O
-	O
positive	O
patients	O
in	O
Croatia	O
,	O
primarily	O
those	O
who	O
do	O
not	O
know	O
that	O
they	O
are	O
HIV	O
infected	O
.	O

Coexisting	O
consolidated	O
pneumonia	O
with	O
sonographic	O
air	B-CHED
bronchograms	O
was	O
noted	O
in	O
one	O
patient	O
who	O
did	O
not	O
survive	O
.	O

TITLE	O
:	O
Surfactant	B-CHED
protein	B-CHED
A	O
genetic	O
variants	O
associate	O
with	O
severe	O
respiratory	O
insufficiency	O
in	O
pandemic	O
influenza	O
A	O
virus	O
infection	O
.	O

The	O
patient	O
was	O
a	O
38	O
-	O
year	O
-	O
old	O
man	B-CHED
.	O

Oseltamivir	B-CHED
,	O
anti	B-CHED
-	I-CHED
infective	I-CHED
drugs	I-CHED
,	O
methylprednisolone	B-CHED
,	O
albumin	O
,	O
and	O
intravenous	O
immunoglobulin	O
were	O
administered	O
.	O

Antiviral	B-CHED
therapy	O
in	O
the	O
early	O
stage	O
and	O
sufficient	O
supportive	O
management	O
are	O
key	O
to	O
the	O
treatment	O
of	O
infections	O
with	O
this	O
virus	O
,	O
and	O
proper	O
doses	O
of	O
methylprednisolone	B-CHED
and	O
intravenous	O
immunoglobulin	O
are	O
recommended	O
.	O

One	O
of	O
the	O
epimers	O
,	O
4	O
-[(	O
1S	O
,	O
3R	O
,	O
4R	O
,	O
7R	O
)-	O
7	O
-	O
hydroxy	B-CHED
-	O
1	O
-(	O
hydroxymethyl	B-CHED
)-	O
2	O
,	O
5	O
-	O
dioxabicyclo	O
[	O
2	O
.	O
2	O
.	O
1	O
]	O
heptan	B-CHED
-	O
3	O
-	O
yl	O
]-	O
3	O
-	O
oxo	B-CHED
-	O
3	O
,	O
4	O
-	O
dihydropyrazine	O
-	O
2	O
-	O
carboxamide	B-CHED
8a	O
,	O
with	O
high	O
antiviral	B-CHED
activities	O
(	O
IC50	O
=	O
7	O
.	O
41	O
,	O
5	O
.	O
63	O
m	O
for	O
H3N2	B-CHED
and	O
H1N1	O
,	O
respectively	O
)	O
and	O
remarkable	O
low	O
cytotoxicity	O
(	O
TC50	O
>	O
200	O
m	O
),	O
has	O
great	O
potential	O
for	O
further	O
development	O
as	O
a	O
novel	O
anti	O
-	O
influenza	O
A	O
agent	O
.	O

Phylogenetic	O
analysis	O
and	O
deduced	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
the	O
S	O
gene	O
showed	O
amino	B-CHED
acid	I-CHED
variations	O
in	O
each	O
genotype	O
.	O

Sputum	O
samples	O
were	O
collected	O
from	O
all	O
pilgrims	O
admitted	O
to	O
15	O
healthcare	O
facilities	O
in	O
the	O
cities	O
of	O
Makkah	O
and	O
Medina	B-CHED
,	O
Saudi	O
Arabia	O
,	O
who	O
were	O
diagnosed	O
with	O
severe	O
CAP	O
on	O
admission	O
,	O
presenting	O
with	O
bilateral	O
pneumonia	O
.	O

The	O
upregulated	O
genes	O
were	O
mainly	O
involved	O
in	O
immune	O
system	O
processes	O
,	O
antigen	B-CHED
processing	O
and	O
presentation	O
,	O
the	O
Jak	O
-	O
STAT	O
signalling	O
pathway	O
,	O
the	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
signalling	O
pathway	O
,	O
Toll	O
-	O
like	O
receptor	O
signalling	O
and	O
apoptosis	O
-	O
related	O
proteases	O
.	O

A	O
computed	O
tomography	O
angiography	O
(	O
CTA	B-CHED
)	O
was	O
negative	O
for	O
pulmonary	O
embolism	O
and	O
showed	O
bilateral	O
infiltrates	O
.	O

A	O
tidal	O
volume	O
of	O
6	O
ml	O
/	O
kg	O
or	O
less	O
was	O
targeted	O
by	O
76	O
%	O
of	O
respondents	O
,	O
and	O
58	O
%	O
targeted	O
a	O
positive	O
end	O
-	O
expiratory	O
pressure	O
of	O
6	O
-	O
10	O
cm	O
H2O	B-CHED
while	O
ventilating	O
patients	O
on	O
VV	O
-	O
ECMO	O
.	O

The	O
role	O
of	O
bacterial	O
infections	O
in	O
acute	O
exacerbations	O
of	O
asthma	O
will	O
also	O
be	O
reviewed	O
as	O
well	O
as	O
the	O
benefit	O
of	O
empiric	O
antibiotics	B-CHED
and	O
the	O
role	O
of	O
macrolides	B-CHED
in	O
both	O
acute	O
and	O
chronic	O
asthma	O
.	O

ABSTRACT	O
:	O
Data	O
on	O
the	O
efficacy	O
of	O
Peg	B-CHED
-	O
interferon	O
/	O
ribavirin	B-CHED
therapy	O
for	O
chronic	O
hepatitis	O
C	O
are	O
mostly	O
derived	O
from	O
treatment	O
of	O
selected	O
patients	O
enrolled	O
in	O
clinical	O
trials	O
.	O

Independent	O
observational	O
multicentre	O
study	O
including	O
consecutive	O
patients	O
receiving	O
Peg	B-CHED
-	O
interferon	O
/	O
ribavirin	B-CHED
in	O
the	O
18	O
months	O
before	O
(	O
retrospective	O
phase	O
)	O
and	O
after	O
(	O
prospective	O
phase	O
)	O
the	O
start	O
of	O
the	O
study	O
.	O

Activation	O
of	O
the	O
three	O
branches	O
of	O
UPR	O
modulates	O
a	O
wide	O
variety	O
of	O
signaling	O
pathways	O
,	O
such	O
as	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
(	O
MAP	O
)	O
kinase	O
activation	O
,	O
autophagy	O
,	O
apoptosis	O
,	O
and	O
innate	O
immune	O
response	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
prevalence	O
,	O
epidemiology	O
and	O
genetic	O
diversity	O
of	O
human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
among	O
adult	O
patients	O
with	O
acute	O
respiratory	O
infections	O
(	O
ARI	B-CHED
)	O
in	O
Beijing	O
,	O
five	O
hundred	O
and	O
fifty	O
-	O
nine	O
nasopharyngeal	O
swab	O
samples	O
were	O
collected	O
from	O
adult	O
patients	O
with	O
ARI	B-CHED
in	O
Beijing	O
.	O

IBV	O
NSP6	O
also	O
limited	O
autophagosome	O
and	O
omegasome	O
expansion	O
in	O
response	O
to	O
starvation	O
and	O
Torin1	O
and	O
could	O
therefore	O
limit	O
the	O
size	O
of	O
autophagosomes	O
induced	O
following	O
inhibition	O
of	O
MTOR	O
signaling	O
,	O
as	O
well	O
as	O
those	O
induced	O
independently	O
by	O
the	O
NSP6	O
protein	B-CHED
itself	O
.	O

The	O
overall	O
structure	O
of	O
the	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	B-CHED
)	O
is	O
similar	O
to	O
that	O
of	O
the	O
corresponding	O
SARS	O
-	O
CoV	O
enzyme	O
,	O
but	O
the	O
architecture	O
of	O
the	O
oxyanion	O
hole	O
and	O
of	O
the	O
S3	O
as	O
well	O
as	O
the	O
S5	O
specificity	O
sites	O
differ	O
from	O
the	O
latter	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
the	O
antiviral	B-CHED
activity	O
against	O
HIV	O
-	O
infected	O
cells	O
of	O
different	O
types	O
of	O
chelating	O
ligands	O
and	O
of	O
their	O
metal	B-CHED
complexes	O
.	O

However	O
,	O
docetaxel	B-CHED
-	O
associated	O
adverse	O
events	O
(	O
AEs	O
)	O
such	O
as	O
febrile	O
neutropenia	O
(	O
FN	O
)	O
can	O
impair	O
quality	O
of	O
life	O
and	O
may	O
become	O
life	O
-	O
threatening	O
.	O

Non	O
-	O
hematological	O
AEs	O
as	O
well	O
as	O
substantial	O
hematological	O
AEs	O
were	O
recognized	O
in	O
the	O
Japanese	O
population	O
treated	O
with	O
docetaxel	B-CHED
chemotherapy	O
against	O
CRPC	O
.	O

Pre	O
-	O
and	O
post	O
-	O
treatment	O
lymphopenia	O
and	O
pre	O
-	O
treatment	O
serum	O
albumin	O
should	O
be	O
considered	O
in	O
order	O
to	O
minimize	O
the	O
risk	O
of	O
FN	O
when	O
selecting	O
patients	O
with	O
prostate	O
cancer	O
for	O
docetaxel	B-CHED
therapy	O
,	O
and	O
when	O
considering	O
dose	O
modifications	O
,	O
and	O
the	O
prophylactic	O
use	O
of	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
.	O

Analysis	O
of	O
the	O
S1	O
gene	O
sequences	O
amplified	O
from	O
the	O
62	O
isolated	O
strains	O
together	O
with	O
40	O
reference	O
strains	O
published	O
in	O
Genbank	O
showed	O
nucleotide	B-CHED
homologies	O
ranging	O
from	O
63	O
.	O
5	O
to	O
99	O
.	O
9	O
%	O
and	O
amino	B-CHED
acid	I-CHED
homologies	O
ranging	O
from	O
57	O
.	O
9	O
to	O
100	O
%.	O

The	O
patient	O
owned	O
a	O
rabbit	O
and	O
,	O
before	O
the	O
onset	O
of	O
the	O
disease	O
,	O
repaired	O
some	O
rubber	B-CHED
pipes	B-CHED
damaged	O
by	O
rodents	O
.	O

Treatment	O
with	O
ceftriaxone	B-CHED
was	O
initiated	O
in	O
combination	O
with	O
volume	O
restitution	O
.	O

On	O
re	O
-	O
evaluation	O
of	O
history	O
,	O
we	O
found	O
that	O
he	O
was	O
a	O
goldsmith	O
by	O
occupation	O
,	O
smelting	O
silver	B-CHED
and	O
gold	B-CHED
for	O
the	O
past	O
8	O
-	O
10	O
years	O
.	O

The	O
purified	O
recombinant	O
S1	O
protein	B-CHED
was	O
found	O
to	O
mediate	O
highly	O
potent	O
antibody	O
responses	O
in	O
immunized	O
rabbits	O
.	O

We	O
then	O
tested	O
the	O
ability	O
of	O
vaccination	O
with	O
the	O
recombinant	O
S1	O
protein	B-CHED
to	O
protect	O
piglets	O
against	O
PEDV	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
antiviral	B-CHED
activity	O
of	O
new	O
phenylimidazopyridines	O
and	O
N	O
-	O
benzylidenequinolinamines	O
derived	O
by	O
molecular	O
simplification	O
of	O
phenylimidazo	O
[	O
4	O
,	O
5	O
-	O
g	O
]	O
quinolines	B-CHED
.	O

Similarly	O
,	O
the	O
imidazo	O
[	O
4	O
,	O
5	O
-	O
c	O
]	O
pyridines	B-CHED
and	O
N	O
-	O
benzylidenequinolinamines	O
derivatives	O
resulted	O
active	O
against	O
Bovine	O
Viral	O
Diarrhoea	O
virus	O
(	O
BVDV	O
),	O
at	O
concentrations	O
ranging	O
from	O
1	O
.	O
2	O
to	O
28	O
M	O
.	O
Above	O
all	O
compounds	O
1	O
,	O
3a	O
and	O
3f	O
showed	O
an	O
EC50	O
of	O
the	O
same	O
order	O
of	O
magnitude	O
of	O
the	O
reference	O
drug	O
,	O
the	O
2	O
'-	O
C	O
-	O
methyl	B-CHED
-	O
guanosine	B-CHED
.	O

In	O
this	O
study	O
,	O
29	O
pooled	O
samples	O
from	O
commercial	O
Danish	O
blue	O
mussels	O
were	O
tested	O
for	O
porcine	O
pathogens	O
and	O
indicator	B-CHED
bacteria	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
).	O

Based	O
on	O
the	O
detection	O
of	O
PCV2	O
in	O
clean	O
areas	O
with	O
low	O
prevalence	O
of	O
the	O
normally	O
applied	O
fecal	O
indicator	B-CHED
E	O
.	O
coli	O
,	O
testing	O
for	O
PCV2	O
may	O
be	O
a	O
more	O
sensitive	O
and	O
robust	O
specific	O
porcine	O
waste	O
indicator	B-CHED
in	O
shellfish	O
harvesting	O
areas	O
.	O

TITLE	O
:	O
Substitution	O
at	O
aspartic	B-CHED
acid	I-CHED
1128	O
in	O
the	O
SARS	O
coronavirus	O
spike	O
glycoprotein	B-CHED
mediates	O
escape	O
from	O
a	O
S2	O
domain	O
-	O
targeting	O
neutralizing	O
monoclonal	O
antibody	O
.	O

The	O
SARS	O
-	O
CoV	O
surface	O
Spike	O
(	O
S	O
)	O
protein	B-CHED
is	O
a	O
major	O
antigenic	B-CHED
determinant	I-CHED
in	O
eliciting	O
neutralizing	O
antibody	O
production	O
during	O
SARS	O
-	O
CoV	O
infection	O
.	O

In	O
our	O
previous	O
work	O
,	O
we	O
showed	O
that	O
a	O
panel	O
of	O
murine	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
that	O
target	O
the	O
S2	O
subunit	O
of	O
the	O
S	O
protein	B-CHED
are	O
capable	O
of	O
neutralizing	O
SARS	O
-	O
CoV	O
infection	O
in	O
vitro	O
(	O
Lip	O
KM	O
et	O
al	O
,	O
J	O
Virol	O
.	O

MAb	O
1A9	O
is	O
a	O
broadly	O
neutralizing	O
mAb	O
that	O
prevents	O
viral	O
entry	O
mediated	O
by	O
the	O
S	O
proteins	B-CHED
of	O
human	O
and	O
civet	O
SARS	O
-	O
CoVs	O
as	O
well	O
as	O
bat	O
SL	O
-	O
CoVs	O
.	O

Enzyme	O
activity	O
is	O
reconstituted	O
when	O
a	O
small	O
intravirion	O
peptide	B-CHED
(	O
	O
-	O
peptide	B-CHED
)	O
is	O
complementing	O
the	O
inactive	O
mutant	O
form	O
M15	O
of	O
	O
-	O
galactosidase	O
.	O

MVA	B-CHED
can	O
encode	O
one	O
or	O
more	O
foreign	O
antigens	B-CHED
and	O
thus	O
functions	O
as	O
a	O
multivalent	O
vaccine	O
.	O

Here	O
we	O
studied	O
another	O
mutant	O
with	O
S284	O
-	O
T285	O
-	O
I286	O
replaced	O
by	O
Ala	B-CHED
(	O
STI	O
/	O
A	O
)	O
with	O
a	O
3	O
.	O
6	O
-	O
fold	O
activity	O
increase	O
and	O
slightly	O
enhanced	O
dimerization	O
.	O

Groups	O
:	O
G1	O
-	O
conservative	O
approach	O
(	O
without	O
treatment	O
),	O
G2	O
-	O
pharmacologic	O
(	O
indomethacin	B-CHED
or	O
ibuprofen	B-CHED
),	O
G3	O
-	O
surgical	O
ligation	O
(	O
independent	O
of	O
previous	O
treatment	O
).	O

Apgar	O
score	O
<	O
4	O
,	O
male	O
gender	O
,	O
Score	O
for	O
Neonatal	O
Acute	O
Physiology	O
Perinatal	O
Extension	O
(	O
SNAPPE	O
II	O
),	O
respiratory	O
distress	O
syndrome	O
(	O
RDS	O
),	O
late	O
sepsis	O
(	O
LS	O
),	O
mechanical	O
ventilation	O
(	O
MV	O
),	O
surfactant	B-CHED
(<	O
2	O
h	O
of	O
life	O
),	O
and	O
time	O
of	O
MV	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
suggested	O
that	O
higher	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
should	O
be	O
used	O
only	O
in	O
patients	O
with	O
higher	O
lung	O
recruitability	O
.	O

To	O
overcome	O
the	O
compressive	O
forces	O
and	O
to	O
lift	O
up	O
the	O
thoracic	O
cage	O
,	O
a	O
similar	O
PEEP	B-CHED
level	O
is	O
required	O
in	O
higher	O
and	O
lower	O
recruiters	O
(	O
16	O
.	O
8	O
	O
4	O
vs	O
.	O
16	O
.	O
6	O
	O
5	O
.	O
6	O
,	O
P	O
=	O
1	O
).	O

Diagnostic	O
viral	O
reverse	O
transcriptase	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
of	O
nose	O
and	O
throat	O
swabs	O
(	O
NTS	O
)	O
is	O
useful	O
for	O
patient	O
care	O
by	O
informing	O
antiviral	B-CHED
use	O
and	O
appropriate	O
isolation	O
.	O

Intravenous	O
immunization	O
with	O
peptide	B-CHED
-	O
loaded	O
dendritic	O
cells	O
(	O
DCs	O
)	O
followed	O
by	O
intranasal	O
boosting	O
with	O
recombinant	O
vaccinia	O
virus	O
(	O
rVV	O
)	O
encoding	O
S436	O
or	O
S525	O
resulted	O
in	O
accumulation	O
of	O
virus	O
-	O
specific	O
memory	O
CD8	O
T	O
cells	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BAL	B-CHED
),	O
lungs	O
,	O
and	O
spleen	O
.	O

ABSTRACT	O
:	O
Animal	O
studies	O
using	O
oleic	B-CHED
acid	I-CHED
(	O
OA	O
)	O
model	O
to	O
produce	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
have	O
been	O
inconsistent	O
.	O

TITLE	O
:	O
Simultaneous	O
Concentration	O
of	O
Bovine	O
Viruses	O
and	O
Agricultural	O
Zoonotic	O
Bacteria	O
from	O
Water	B-CHED
Using	O
Sodocalcic	O
Glass	O
Wool	O
Filters	O
.	O

The	O
recovery	O
efficiencies	O
were	O
determined	O
for	O
bovine	O
viral	O
diarrhea	O
virus	O
types	O
1	O
and	O
2	O
,	O
bovine	O
rotavirus	O
group	O
A	O
,	O
bovine	O
coronavirus	O
,	O
poliovirus	O
Sabin	O
III	O
,	O
toxigenic	O
Escherichia	O
coli	O
,	O
and	O
Campylobacter	O
jejuni	O
seeded	O
into	O
water	B-CHED
with	O
three	O
different	O
turbidity	O
levels	O
(	O
0	O
.	O
5	O
,	O
215	O
,	O
and	O
447	O
NTU	O
).	O

These	O
experiments	O
imply	O
that	O
the	O
nsp10	O
surface	O
that	O
interacts	O
with	O
nsp14	O
and	O
nsp16	O
and	O
possibly	O
other	O
subunits	O
of	O
the	O
viral	O
replication	O
complex	O
may	O
be	O
a	O
target	O
for	O
the	O
development	O
of	O
antiviral	B-CHED
compounds	O
against	O
pathogenic	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Antibody	O
titers	O
after	O
vaccination	O
against	O
Infectious	O
Bronchitis	O
Virus	O
(	O
IBV	O
),	O
Newcastle	O
Disease	O
Virus	O
(	O
NDV	O
)	O
and	O
after	O
natural	O
infection	O
with	O
Campylobacter	O
were	O
analyzed	O
in	O
five	O
trials	O
with	O
Lohmann	O
Silver	B-CHED
laying	O
hens	O
kept	O
in	O
two	O
different	O
housing	O
systems	O
.	O

TITLE	O
:	O
Clathrin	O
-	O
and	O
serine	B-CHED
proteases	O
-	O
dependent	O
uptake	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
into	O
Vero	O
cells	O
.	O

RNase	O
H	O
is	O
a	O
promising	O
drug	O
target	O
for	O
which	O
no	O
inhibitor	B-CHED
is	O
available	O
for	O
therapy	O
.	O

Most	O
of	O
the	O
ester	B-CHED
derivatives	O
showed	O
selectivity	O
for	O
HIV	O
-	O
1	O
RNase	O
H	O
versus	O
IN	O
,	O
while	O
acids	O
inhibited	O
both	O
functions	O
.	O

Biochemical	O
analysis	O
verified	O
double	O
-	O
mutant	O
3CLpro	O
enzyme	O
as	O
impaired	O
for	O
protease	O
activity	O
and	O
exhibiting	O
reduced	O
sensitivity	O
to	O
the	O
inhibitor	B-CHED
and	O
revealed	O
a	O
delayed	O
kinetics	O
of	O
inhibitor	B-CHED
hydrolysis	O
and	O
activity	O
restoration	O
.	O

Furthermore	O
,	O
the	O
inhibitor	B-CHED
-	O
resistant	O
virus	O
was	O
shown	O
to	O
be	O
highly	O
attenuated	O
in	O
mice	O
.	O

Our	O
study	O
provides	O
the	O
first	O
insight	O
into	O
the	O
pathogenicity	O
and	O
mechanism	O
of	O
3CLpro	O
inhibitor	B-CHED
-	O
resistant	O
CoV	O
mutants	O
,	O
revealing	O
a	O
low	O
genetic	O
barrier	O
but	O
high	O
fitness	O
cost	O
of	O
resistance	O
.	O

Overall	O
,	O
our	O
study	O
provides	O
the	O
first	O
analysis	O
of	O
the	O
low	O
barrier	O
but	O
high	O
cost	O
of	O
resistance	O
to	O
a	O
CoV	O
3CLpro	O
inhibitor	B-CHED
,	O
which	O
will	O
facilitate	O
the	O
further	O
development	O
of	O
protease	B-CHED
inhibitors	I-CHED
as	O
anti	O
-	O
coronavirus	O
therapeutics	O
.	O

Importance	O
:	O
Evaluating	O
viral	O
protease	B-CHED
inhibitors	I-CHED
in	O
a	O
small	O
-	O
animal	O
model	O
is	O
a	O
critical	O
step	O
in	O
the	O
path	O
toward	O
antiviral	B-CHED
drug	I-CHED
development	O
.	O

We	O
used	O
this	O
system	O
to	O
demonstrate	O
the	O
in	O
vivo	O
efficacy	O
of	O
an	O
inhibitor	B-CHED
of	O
the	O
papain	O
-	O
like	O
protease	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

It	O
is	O
synergistic	O
with	O
neuraminidase	B-CHED
inhibitors	I-CHED
,	O
and	O
combination	O
therapy	O
with	O
oseltamivir	B-CHED
is	O
being	O
studied	O
in	O
humans	O
as	O
part	O
of	O
ongoing	O
Phase	O
3	O
clinical	O
development	O
.	O

Fraction	O
of	O
inspired	O
oxygen	B-CHED
(	O
Fio	O
(	O
2	O
))	O
and	O
PEEP	B-CHED
are	O
typically	O
titrated	O
to	O
maintain	O
arterial	O
oxygen	B-CHED
saturation	O
(	O
Spo	O
(	O
2	O
))	O
of	O
88	O
to	O
95	O
%	O
(	O
Pao	B-CHED
(	O
2	O
)	O
55	O
-	O
80	O
mm	O
Hg	O
).	O

This	O
motif	O
is	O
palmitoylated	O
in	O
the	O
Betacoronaviruses	O
MHV	O
and	O
SARS	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
demonstrate	O
by	O
metabolic	O
labeling	O
with	O
[(	O
3	O
)	O
H	O
]-	O
palmitic	B-CHED
acid	I-CHED
that	O
the	O
S	O
protein	B-CHED
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
),	O
an	O
Alphacoronavirus	O
,	O
is	O
palmitoylated	O
as	O
well	O
.	O

Determinants	O
of	O
hospital	O
mortality	O
and	O
response	O
to	O
corticosteroid	B-CHED
therapy	O
were	O
identified	O
by	O
logistic	O
regression	O
.	O

In	O
mechanically	O
ventilated	O
patients	O
,	O
overdistension	O
induced	O
by	O
high	O
PEEP	B-CHED
settings	O
was	O
associated	O
with	O
CT	O
fibrosis	O
and	O
hospital	O
mortality	O
.	O

These	O
studies	O
clearly	O
indicate	O
a	O
significant	O
change	O
in	O
the	O
conformation	O
of	O
the	O
Cyto3a	O
protein	B-CHED
after	O
binding	O
with	O
calcium	B-CHED
.	O

TITLE	O
:	O
The	O
PDZ	O
-	O
binding	O
motif	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
envelope	O
protein	B-CHED
is	O
a	O
determinant	O
of	O
viral	O
pathogenesis	O
.	O

Antiviral	B-CHED
strategies	O
aiming	O
to	O
prevent	O
viral	O
activation	O
might	O
thus	O
need	O
to	O
encompass	O
inhibitors	B-CHED
targeting	O
MSPL	O
and	O
DESC1	O
.	O

This	O
in	O
turn	O
will	O
facilitate	O
the	O
development	O
of	O
antiviral	B-CHED
strategies	O
for	O
use	O
in	O
humans	O
and	O
other	O
species	O
.	O

A	O
significant	O
proportion	O
of	O
these	O
peptides	B-CHED
are	O
oxidatively	O
modified	O
,	O
most	O
commonly	O
through	O
covalent	O
linkage	O
with	O
the	O
antioxidant	B-CHED
glutathione	B-CHED
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
alterations	O
in	O
the	O
cellular	O
redox	O
state	O
induced	O
by	O
viral	O
infection	O
are	O
communicated	O
to	O
the	O
immune	O
system	O
through	O
the	O
presentation	O
of	O
S	O
-	O
glutathionylated	O
viral	O
peptides	B-CHED
,	O
resulting	O
in	O
altered	O
T	O
cell	O
recognition	O
.	O

TITLE	O
:	O
FTY720	B-CHED
(	O
fingolimod	B-CHED
)	O
modulates	O
the	O
severity	O
of	O
viral	O
-	O
induced	O
encephalomyelitis	O
and	O
demyelination	O
.	O

We	O
hypothesized	O
that	O
FTY720	B-CHED
treatment	O
would	O
affect	O
lymphocyte	O
migration	O
to	O
the	O
CNS	B-CHED
and	O
influence	O
disease	O
severity	O
in	O
a	O
mouse	O
model	O
of	O
viral	O
-	O
induced	O
neurologic	O
disease	O
.	O

These	O
results	O
correlated	O
with	O
impaired	O
ability	O
to	O
control	O
viral	O
replication	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
within	O
the	O
CNS	B-CHED
at	O
days	O
7	O
and	O
14	O
post	O
-	O
infection	O
,	O
which	O
was	O
associated	O
with	O
diminished	O
accumulation	O
of	O
virus	O
-	O
specific	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
into	O
the	O
CNS	B-CHED
.	O

Reduced	O
neuroinflammation	O
in	O
FTY720	B-CHED
-	O
treated	O
mice	O
correlated	O
with	O
increased	O
retention	O
of	O
T	O
lymphocytes	O
within	O
draining	O
cervical	O
lymph	O
nodes	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Treatment	O
with	O
FTY720	B-CHED
did	O
not	O
affect	O
virus	O
-	O
specific	O
T	O
cell	O
proliferation	O
,	O
expression	O
of	O
IFN	O
-	O
	O
,	O
TNF	O
-	O
	O
or	O
cytolytic	O
activity	O
.	O

ABSTRACT	O
:	O
The	O
unfolded	O
-	O
protein	B-CHED
response	O
(	O
UPR	O
)	O
is	O
a	O
signal	O
transduction	O
cascade	O
triggered	O
by	O
perturbation	O
of	O
the	O
homeostasis	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
).	O

Probable	O
cases	O
of	O
secondary	O
transmission	O
occurred	O
in	O
6	O
of	O
26	O
clusters	B-CHED
(	O
23	O
%).	O

We	O
report	O
the	O
case	O
of	O
a	O
61	O
-	O
year	O
-	O
old	O
man	B-CHED
with	O
past	O
medical	O
history	O
of	O
chronic	O
respiratory	O
failure	O
with	O
emphysema	O
,	O
and	O
a	O
known	O
multiple	O
myeloma	O
(	O
Durie	O
and	O
Salmon	O
stage	O
III	O
B	O
and	O
t	O
(	O
4	O
;	O
14	O
)	O
translocation	O
).	O

The	O
purified	O
recombinant	O
N	O
protein	B-CHED
based	O
single	O
serum	O
dilution	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
developed	O
for	O
IBV	O
to	O
measure	O
specific	O
antibody	O
in	O
the	O
sera	O
of	O
chickens	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygen	B-CHED
(	O
ECMO	O
)	O
has	O
been	O
used	O
for	O
many	O
years	O
in	O
patients	O
with	O
life	O
-	O
threatening	O
hypoxaemia	O
and	O
/	O
or	O
hypercarbia	O
.	O

In	O
contrast	O
,	O
binding	O
of	O
HCoV	O
-	O
NL63	O
to	O
heparan	B-CHED
sulfates	I-CHED
was	O
required	O
for	O
viral	O
attachment	O
and	O
infection	O
of	O
target	O
cells	O
,	O
showing	O
that	O
these	O
molecules	O
serve	O
as	O
attachment	O
receptors	O
for	O
HCoV	O
-	O
NL63	O
.	O

Conducted	O
research	O
showed	O
that	O
heparan	B-CHED
sulfate	I-CHED
proteoglycans	B-CHED
function	O
as	O
adhesion	O
molecules	O
,	O
increasing	O
the	O
virus	O
density	O
on	O
cell	O
surface	O
and	O
possibly	O
facilitating	O
the	O
interaction	O
between	O
HCoV	O
-	O
NL63	O
and	O
its	O
receptor	O
.	O

The	O
substantial	O
rise	O
in	O
the	O
global	O
numbers	O
of	O
patients	O
with	O
respiratory	O
tract	O
infections	O
caused	O
by	O
pan	B-CHED
-	O
antibiotic	B-CHED
-	O
resistant	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	O
,	O
multidrug	O
-	O
resistant	O
Mycobacterium	O
tuberculosis	O
,	O
and	O
multiazole	O
-	O
resistant	O
fungi	O
has	O
focused	O
attention	O
on	O
investments	O
into	O
development	O
of	O
new	O
drugs	O
and	O
treatment	O
regimens	O
.	O

To	O
compare	O
the	O
full	O
-	O
length	O
genome	O
sequences	O
of	O
the	O
Chinese	O
IBV	O
strain	O
CK	O
/	O
CH	O
/	O
LDL	B-CHED
/	O
97I	O
and	O
its	O
embryo	O
-	O
passaged	O
,	O
attenuated	O
level	O
to	O
identify	O
sequence	O
substitutions	O
responsible	O
for	O
the	O
attenuation	O
and	O
define	O
markers	O
of	O
attenuation	O
.	O

Among	O
the	O
9	O
nsps	O
in	O
the	O
ORF1	O
region	O
,	O
nsp3	O
contained	O
the	O
most	O
nucleotide	B-CHED
substitutions	O
.	O

Our	O
simulations	O
,	O
comprising	O
the	O
free	O
enzyme	O
as	O
well	O
as	O
substrate	O
-	O
enzyme	O
and	O
inhibitor	B-CHED
-	O
enzyme	O
complexes	O
,	O
lead	O
us	O
to	O
predict	O
that	O
zwitterion	B-CHED
formation	O
is	O
fostered	O
by	O
substrate	O
binding	O
but	O
not	O
inhibitor	B-CHED
binding	O
.	O

These	O
findings	O
suggest	O
ways	O
to	O
achieve	O
improved	O
inhibitors	B-CHED
.	O

We	O
observed	O
that	O
complement	O
activation	O
,	O
coagulation	O
and	O
pro	B-CHED
-	O
inflammatory	O
cytokine	O
production	O
were	O
upregulated	O
in	O
the	O
HBV	O
(+)	O
patients	O
with	O
FH	O
.	O

In	O
addition	O
to	O
diffuse	O
alveolar	O
damage	O
,	O
sub	O
-	O
pleural	O
and	O
intrapulmonary	O
air	B-CHED
cysts	O
might	O
occur	O
in	O
influenza	O
-	O
related	O
ARDS	O
and	O
may	O
lead	O
to	O
spontaneous	O
pneumothorax	O
.	O

The	O
results	O
also	O
indicate	O
that	O
the	O
indole	B-CHED
-	O
based	O
	O
-	O
amino	B-CHED
acids	I-CHED
as	O
efficient	O
NNRTIs	O
displayed	O
comparable	O
anti	O
-	O
HIV	O
-	O
1	O
activities	O
to	O
the	O
reference	O
drug	O
NVP	B-CHED
.	O

A	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
the	O
MERS	O
-	O
CoV	O
envelope	O
-	O
embedded	O
spike	O
protein	B-CHED
specifically	O
engages	O
human	O
CD26	O
(	O
hCD26	O
)	O
to	O
initiate	O
viral	O
entry	O
.	O

The	O
outcome	O
measurements	O
included	O
mortality	O
rate	O
,	O
cure	O
rate	O
,	O
resolution	O
of	O
pulmonary	O
infiltrate	O
,	O
use	O
of	O
corticosteroid	B-CHED
,	O
and	O
time	O
to	O
defervescence	O
.	O

Compared	O
with	O
patients	O
receiving	O
WM	O
treatment	O
alone	O
,	O
patients	O
receiving	O
integrative	O
treatment	O
were	O
more	O
likely	O
to	O
have	O
complete	O
or	O
partial	O
resolution	O
of	O
pulmonary	O
infiltrate	O
(	O
RD	O
=	O
0	O
.	O
18	O
,	O
95	O
%	O
CI	O
;	O
0	O
.	O
07	O
to	O
0	O
.	O
30	O
),	O
lower	O
average	O
daily	O
dosage	O
(	O
mg	O
)	O
of	O
corticosteroid	B-CHED
(	O
WMD	O
=-	O
60	O
.	O
27	O
,	O
95	O
%	O
CI	O
;	O
-	O
70	O
.	O
58	O
to	O
-	O
49	O
.	O
96	O
),	O
higher	O
CD4	O
+	O
counts	O
(	O
cells	O
/	O
uL	O
)	O
(	O
WMD	O
=	O
167	O
.	O
96	O
,	O
95	O
%	O
CI	O
;	O
109	O
.	O
68	O
to	O
226	O
.	O
24	O
),	O
and	O
shorter	O
time	O
to	O
defervescence	O
(	O
days	O
)	O
(	O
WMD	O
=	O
-	O
1	O
.	O
06	O
,	O
95	O
%	O
CI	O
;-	O
1	O
.	O
60	O
to	O
-	O
0	O
.	O
53	O
).	O

The	O
level	O
of	O
serum	O
IL	O
-	O
8	O
was	O
positively	O
correlated	O
with	O
white	O
blood	O
cell	O
count	O
and	O
ISS	O
score	O
,	O
and	O
inversely	O
correlated	O
with	O
oxygen	B-CHED
index	O
.	O

The	O
isolation	O
of	O
PEDV	O
in	O
cell	O
culture	O
is	O
the	O
first	O
step	O
toward	O
the	O
development	O
of	O
an	O
attenuated	O
vaccine	O
,	O
to	O
study	O
the	O
biology	O
of	O
PEDV	O
and	O
to	O
develop	O
in	O
vitro	O
PEDV	O
immunoassays	O
,	O
inactivation	O
assays	O
and	O
screen	O
for	O
PEDV	O
antivirals	B-CHED
.	O

Representative	O
strains	O
of	O
these	O
three	O
genetic	O
groups	O
were	O
passaged	O
serially	O
and	O
grew	O
to	O
titers	O
of	O
	O
5	O
-	O
6log10	O
plaque	O
forming	O
units	O
/	O
mL	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
the	O
isolation	O
in	O
cell	O
culture	O
of	O
an	O
S	O
INDEL	O
PEDV	O
strain	O
and	O
a	O
PEDV	O
strain	O
with	O
a	O
large	O
(	O
197aa	O
)	O
deletion	O
in	O
the	O
S	O
protein	B-CHED
.	O

RESULTS	O
:	O
Health	O
concerns	O
and	O
social	O
experiences	O
motivated	O
the	O
participants	O
to	O
practise	O
tai	O
chi	B-CHED
in	O
post	O
-	O
SARS	O
Hong	O
Kong	O
.	O

CONCLUSIONS	O
:	O
The	O
participants	O
practised	O
tai	O
chi	B-CHED
not	O
only	O
because	O
they	O
sought	O
to	O
improve	O
their	O
health	O
but	O
also	O
because	O
it	O
provided	O
a	O
crucial	O
social	O
function	O
and	O
meaning	O
to	O
them	O
.	O

We	O
have	O
further	O
hypothesized	O
that	O
the	O
immunogenicity	O
of	O
highly	O
conserved	O
epitopes	O
on	O
the	O
HIV	O
-	O
1	O
envelope	O
glycoproteins	B-CHED
(	O
Envs	O
)	O
may	O
be	O
reduced	O
or	O
eliminated	O
by	O
their	O
very	O
weak	O
or	O
absent	O
interactions	O
with	O
germline	O
antibodies	O
and	O
immune	O
responses	O
leading	O
to	O
the	O
elicitation	O
of	O
bnAbs	O
may	O
not	O
be	O
initiated	O
and	O
/	O
or	O
sustained	O
.	O

RESULTS	O
:	O
Significant	O
improvement	O
was	O
observed	O
in	O
HR	O
,	O
MAP	O
,	O
PaO2	O
/	O
FiO2	O
,	O
total	O
bilirubin	B-CHED
(	O
TBIL	O
)	O
and	O
alanine	B-CHED
aminotransferase	O
(	O
ALT	B-CHED
)	O
levels	O
after	O
treatment	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
large	O
panel	O
of	O
human	O
nAbs	O
against	O
an	O
epitope	B-CHED
that	O
overlaps	O
the	O
interface	O
between	O
the	O
RBD	O
and	O
its	O
receptor	O
,	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
to	O
assess	O
their	O
cross	O
-	O
neutralization	O
activities	O
against	O
a	O
panel	O
of	O
human	O
and	O
zoonotic	O
SARS	O
-	O
CoVs	O
and	O
neutralization	O
escape	O
mutants	O
.	O

However	O
,	O
RBD	O
-	O
directed	O
nAbs	O
may	O
be	O
useful	O
for	O
providing	O
broad	O
neutralization	O
and	O
prevention	O
of	O
escape	O
variants	O
when	O
combined	O
with	O
other	O
nAbs	O
that	O
target	O
a	O
second	O
conserved	O
epitope	B-CHED
with	O
less	O
plasticity	O
and	O
more	O
structural	O
constraint	O
.	O

Sequence	O
comparison	O
revealed	O
that	O
the	O
22	O
Korean	O
CCV	O
strains	O
had	O
an	O
87	O
.	O
2	O
to	O
100	O
%	O
nucleotide	B-CHED
homology	O
.	O

A	O
defined	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
can	O
potentially	O
serve	O
as	O
a	O
subunit	O
vaccine	O
candidate	O
against	O
MERS	O
-	O
CoV	O
infections	O
.	O

Thus	O
,	O
depending	O
on	O
the	O
specific	O
virus	O
and	O
the	O
tissue	O
(	O
s	O
)	O
involved	O
,	O
the	O
activity	O
of	O
both	O
of	O
these	O
arginine	B-CHED
-	O
hydrolyzing	O
enzymes	O
can	O
either	O
exacerbate	O
or	O
limit	O
the	O
severity	O
of	O
virus	O
-	O
induced	O
disease	O
.	O

This	O
research	O
provides	O
in	O
vivo	O
data	O
supporting	O
the	O
ability	O
of	O
a	O
liquid	O
antimicrobial	B-CHED
product	O
to	O
reduce	O
this	O
risk	O
.	O

Sal	B-CHED
CURB	O
	O
(	O
Kemin	O
Industries	O
,	O
Des	B-CHED
Moines	O
,	O
IA	O
,	O
USA	O
)	O
is	O
a	O
FDA	O
-	O
approved	O
liquid	O
antimicrobial	B-CHED
used	O
to	O
control	O
Salmonella	O
contamination	O
in	O
poultry	O
and	O
swine	O
diets	O
.	O

To	O
test	O
its	O
effect	O
against	O
PEDV	O
,	O
Sal	B-CHED
CURB	O
-	O
treated	O
feed	O
was	O
spiked	O
with	O
a	O
stock	O
isolate	O
of	O
PEDV	O
(	O
Ct	O
=	O
25	O
.	O
22	O
),	O
which	O
PEDV	O
-	O
nave	O
piglets	O
were	O
allowed	O
to	O
ingest	O
via	O
natural	O
feeding	O
behavior	O
(	O
ad	O
libitum	O
)	O
for	O
a	O
14	O
-	O
day	O
period	O
.	O

In	O
addition	O
,	O
the	O
Sal	B-CHED
CURB	O
-	O
treated	O
feed	O
samples	O
had	O
higher	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
mean	O
PEDV	O
Ct	O
values	O
than	O
samples	O
from	O
the	O
positive	O
control	O
group	O
.	O

We	O
previously	O
reported	O
tripartite	O
motif	O
protein	B-CHED
56	O
(	O
TRIM56	O
)	O
as	O
a	O
host	O
restriction	O
factor	O
of	O
bovine	O
viral	O
diarrhea	O
virus	O
,	O
a	O
ruminant	O
pathogen	O
.	O

Employing	O
a	O
retroviral	O
vector	O
system	O
for	O
analysis	O
of	O
coronavirus	O
entry	O
,	O
we	O
investigated	O
the	O
susceptibility	O
of	O
human	O
-	O
adapted	O
and	O
emerging	O
coronaviruses	O
to	O
inhibition	O
by	O
IFITM	O
proteins	B-CHED
.	O

The	O
differential	O
IFITM	O
-	O
sensitivity	O
of	O
coronaviruses	O
observed	O
in	O
293T	O
cells	O
afforded	O
the	O
opportunity	O
to	O
investigate	O
whether	O
efficiency	O
of	O
entry	O
inhibition	O
by	O
IFITMs	O
and	O
endosomal	O
cholesterol	B-CHED
accumulation	O
correlate	O
.	O

Collectively	O
,	O
these	O
results	O
show	O
that	O
the	O
emerging	O
MERS	O
-	O
CoV	O
is	O
a	O
target	O
of	O
the	O
antiviral	B-CHED
activity	O
of	O
IFITM	O
proteins	B-CHED
and	O
demonstrate	O
that	O
mechanisms	O
other	O
than	O
accumulation	O
of	O
endosomal	O
cholesterol	B-CHED
can	O
contribute	O
to	O
viral	O
entry	O
inhibition	O
by	O
IFITMs	O
.	O

TITLE	O
:	O
Diagnostic	O
value	O
of	O
surfactant	B-CHED
protein	B-CHED
-	O
a	O
in	O
severe	O
acute	O
pancreatitis	O
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Ca2	O
+	O
influx	O
and	O
ATP	B-CHED
release	O
mediated	O
by	O
mechanical	O
stretch	O
in	O
human	O
lung	O
fibroblasts	O
.	O

In	O
this	O
study	O
,	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
Spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
of	O
MERS	O
-	O
CoV	O
was	O
analyzed	O
through	O
Computational	O
Immunology	O
approach	O
to	O
identify	O
the	O
antigenic	O
determinants	O
(	O
epitopes	O
).	O

A	O
9	O
-	O
mer	O
epitope	B-CHED
CYSSLILDY	O
displayed	O
interactions	O
with	O
the	O
maximum	O
number	O
of	O
MHC	O
class	O
-	O
I	O
molecules	O
and	O
projected	O
the	O
highest	O
peak	O
in	O
the	O
B	O
-	O
cell	O
antigenicity	O
plot	O
which	O
concludes	O
that	O
it	O
could	O
be	O
a	O
better	O
choice	O
for	O
designing	O
an	O
epitope	B-CHED
based	O
peptide	B-CHED
vaccine	O
against	O
MERSCoV	O
considering	O
that	O
it	O
must	O
undergo	O
further	O
in	O
vitro	O
and	O
in	O
vivo	O
experiments	O
.	O

TITLE	O
:	O
Insulin	B-CHED
upregulates	O
the	O
expression	O
of	O
epithelial	O
sodium	O
channel	O
in	O
vitro	O
and	O
in	O
a	O
mouse	O
model	O
of	O
acute	O
lung	O
injury	O
:	O
role	O
of	O
mTORC2	O
/	O
SGK1	O
pathway	O
.	O

Finally	O
,	O
we	O
testified	O
the	O
role	O
of	O
mTORC2	O
in	O
vivo	O
by	O
demonstrating	O
that	O
PP242	O
prevented	O
insulin	B-CHED
-	O
stimulated	O
SGK1	O
activation	O
and	O
ENaC	O
increase	O
during	O
ALI	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
C	O
-	O
terminus	O
of	O
M	O
-	O
protein	B-CHED
interacts	O
with	O
the	O
PH	O
(	O
pleckstrin	O
homology	O
)	O
domain	O
of	O
PDK1	O
.	O

The	O
complete	O
genome	O
of	O
CK	O
/	O
CH	O
/	O
SD09	O
/	O
005	O
consisted	O
of	O
27691	O
nucleotides	B-CHED
(	O
nt	O
),	O
excluding	O
the	O
5	O
'	O
cap	O
and	O
3	O
'	O
poly	O
A	O
tail	O
.	O

After	O
LPS	B-CHED
-	O
injection	O
,	O
the	O
lungs	O
were	O
harvested	O
to	O
assess	O
leukocyte	O
infiltration	O
,	O
cytokine	O
and	O
chemokine	O
production	O
,	O
ERK	O
-	O
MAPK	O
activation	O
and	O
immunopathology	O
.	O

RESULTS	O
:	O
LPS	B-CHED
-	O
induced	O
acute	O
lung	O
inflammation	O
was	O
significantly	O
exacerbated	O
in	O
Spred	O
-	O
2	O
(-/-)	O
mice	O
compared	O
with	O
WT	O
mice	O
,	O
as	O
indicated	O
by	O
the	O
numbers	O
of	O
infiltrating	O
leukocytes	O
,	O
levels	O
of	O
alveolar	O
TNF	O
-	O
	O
,	O
CXCL2	O
and	O
CCL2	B-CHED
in	O
a	O
later	O
phase	O
,	O
and	O
lung	O
pathology	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
is	O
associated	O
with	O
high	O
mortality	O
and	O
has	O
no	O
approved	O
antiviral	B-CHED
therapy	O
.	O

In	O
patients	O
with	O
severe	O
MERS	O
-	O
CoV	O
infection	O
,	O
ribavirin	B-CHED
and	O
interferon	O
alfa	O
-	O
2a	O
therapy	O
is	O
associated	O
with	O
significantly	O
improved	O
survival	O
at	O
14	O
days	O
,	O
but	O
not	O
at	O
28	O
days	O
.	O

Nevertheless	O
,	O
for	O
almost	O
three	O
decades	O
now	O
,	O
data	O
reported	O
in	O
the	O
scientific	O
literature	O
has	O
also	O
demonstrated	O
that	O
,	O
like	O
it	O
was	O
described	O
for	O
other	O
human	O
viruses	O
,	O
coronaviruses	O
have	O
neuroinvasive	O
capacities	O
since	O
they	O
can	O
spread	O
from	O
the	O
respiratory	O
tract	O
to	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
).	O

We	O
estimated	O
the	O
mean	O
serial	O
intervals	O
for	O
influenza	O
A	O
(	O
H3N2	B-CHED
)	O
(	O
2	O
.	O
2	O
days	O
),	O
pandemic	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
(	O
2	O
.	O
8	O
days	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
7	O
.	O
5	O
days	O
),	O
measles	O
(	O
11	O
.	O
7	O
days	O
),	O
varicella	O
(	O
14	O
.	O
0	O
days	O
),	O
smallpox	O
(	O
17	O
.	O
7	O
days	O
),	O
mumps	O
(	O
18	O
.	O
0	O
days	O
),	O
rubella	O
(	O
18	O
.	O
3	O
days	O
),	O
and	O
pertussis	O
(	O
22	O
.	O
8	O
days	O
).	O

Until	O
now	O
there	O
is	O
no	O
recorded	O
clinically	O
effective	O
antiviral	B-CHED
chemotherapeutic	O
agent	O
for	O
treatment	O
of	O
diseases	O
caused	O
by	O
PEDV	O
.	O

Overall	O
,	O
this	O
research	O
revealed	O
that	O
polysaccharide	B-CHED
could	O
inhibit	O
PEDV	O
infection	O
,	O
and	O
that	O
polysaccharide	B-CHED
may	O
be	O
involved	O
in	O
PEDV	O
-	O
Vero	O
cell	O
interactions	O
,	O
as	O
the	O
virus	O
attachment	O
and	O
entry	O
to	O
the	O
Vero	O
cells	O
was	O
hindered	O
by	O
the	O
polysaccharide	B-CHED
.	O

Therefore	O
,	O
polysaccharide	B-CHED
possessing	O
effective	O
inhibitory	O
effect	O
on	O
viral	O
attachment	O
and	O
entry	O
steps	O
of	O
PEDV	O
life	O
cycle	O
is	O
a	O
good	O
candidate	O
for	O
development	O
of	O
antivirals	B-CHED
.	O

In	O
response	O
to	O
the	O
ER	O
stress	O
,	O
signaling	O
pathways	O
of	O
the	O
unfolded	O
protein	B-CHED
response	O
(	O
UPR	O
)	O
are	O
activated	O
.	O

TITLE	O
:	O
Efficacy	O
of	O
an	O
extravascular	O
lung	O
water	B-CHED
-	O
driven	O
negative	O
fluid	O
balance	B-CHED
protocol	O
.	O

We	O
analyzed	O
the	O
impact	O
of	O
this	O
negative	O
fluid	O
balance	B-CHED
strategy	O
upon	O
pulmonary	O
,	O
hemodynamic	O
,	O
and	O
renal	O
function	O
.	O

Our	O
data	O
demonstrate	O
a	O
deficit	O
in	O
the	O
nerve	O
-	O
evoked	O
cholinergic	O
component	O
of	O
contraction	O
that	O
is	O
not	O
due	O
to	O
the	O
ability	O
of	O
the	O
smooth	O
muscle	O
to	O
respond	O
to	O
acetylcholine	B-CHED
.	O

RESULTS	O
:	O
The	O
maximum	O
effect	O
of	O
EFS	B-CHED
was	O
not	O
significantly	O
different	O
between	O
CIE	O
and	O
control	O
bladders	O
.	O

Treatment	O
consisted	O
of	O
immediate	O
administration	O
of	O
intravenous	O
acyclovir	B-CHED
and	O
a	O
lung	O
-	O
protective	O
ventilation	O
strategy	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
membrane	O
-	O
associated	O
papain	O
-	O
like	O
protease	O
PLP2	O
(	O
PLP2	O
-	O
TM	O
)	O
of	O
coronaviruses	O
acts	O
as	O
a	O
novel	O
autophagy	O
-	O
inducing	O
protein	B-CHED
.	O

These	O
results	O
suggested	O
that	O
coronavirus	O
papain	O
-	O
like	O
protease	O
induces	O
incomplete	O
autophagy	O
by	O
interacting	O
with	O
Beclin1	O
,	O
which	O
in	O
turn	O
modulates	O
coronavirus	O
replication	O
and	O
antiviral	B-CHED
innate	O
immunity	O
.	O

In	O
addition	O
to	O
this	O
replicative	O
function	O
,	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	B-CHED
)	O
was	O
recently	O
shown	O
to	O
be	O
a	O
deubiquitinating	O
enzyme	O
(	O
DUB	O
)	O
and	O
to	O
possess	O
deISGylating	O
activity	O
,	O
as	O
previously	O
reported	O
for	O
other	O
coronaviral	O
PL	O
(	O
pro	B-CHED
)	O
domains	O
,	O
including	O
that	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Guided	O
by	O
this	O
structure	O
,	O
mutations	O
were	O
introduced	O
into	O
PL	O
(	O
pro	B-CHED
)	O
to	O
specifically	O
disrupt	O
Ub	O
binding	O
without	O
affecting	O
viral	O
polyprotein	O
cleavage	O
,	O
as	O
determined	O
using	O
an	O
in	O
trans	O
nsp3	O
	O
4	O
cleavage	O
assay	O
.	O

Having	O
developed	O
a	O
strategy	O
to	O
selectively	O
disable	O
PL	O
(	O
pro	B-CHED
)	O
DUB	O
activity	O
,	O
we	O
were	O
able	O
to	O
specifically	O
examine	O
the	O
effects	O
of	O
this	O
activity	O
on	O
the	O
innate	O
immune	O
response	O
.	O

ABSTRACT	O
:	O
In	O
May	O
2014	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
,	O
with	O
closely	O
related	O
viral	O
genomes	O
,	O
was	O
diagnosed	O
in	O
two	O
Dutch	O
residents	O
,	O
returning	O
from	O
a	O
pilgrimage	O
to	O
Medina	B-CHED
and	O
Mecca	O
,	O
Kingdom	O
of	O
Saudi	O
Arabia	O
(	O
KSA	O
).	O

RBC	O
transfusion	O
sensitized	O
mice	O
to	O
LPS	B-CHED
-	O
induced	O
lung	O
inflammation	O
through	O
release	O
of	O
the	O
danger	O
signal	O
HMGB1	O
.	O

The	O
swift	O
resolution	O
over	O
10	O
h	O
of	O
a	O
severe	O
acute	O
hypoxemic	O
respiratory	O
failure	O
(	O
P	O
/	O
F	O
=	O
57	O
)	O
caused	O
by	O
aspiration	O
following	O
heroin	B-CHED
overdose	O
,	O
using	O
non	O
-	O
invasive	O
ventilation	O
(	O
NIV	O
)-	O
high	O
PEEP	B-CHED
(	O
15	O
-	O
20	O
cm	O
H2O	B-CHED
)-	O
low	O
pressure	O
support	O
(	O
8	O
cm	O
H20	O
)	O
is	O
reported	O
.	O

High	O
eosinophilia	O
is	O
connected	O
with	O
production	O
of	O
cytotoxic	O
eosinophilic	O
proteins	B-CHED
which	O
can	O
cause	O
eosinophilic	O
vasculitis	O
or	O
eosinophilic	O
myocarditis	O
.	O

Because	O
most	O
of	O
the	O
viral	O
envelope	O
glycoproteins	B-CHED
contain	O
N	O
-	O
linked	O
glycans	B-CHED
,	O
inhibition	O
of	O
ER	O
glucosidases	O
with	O
derivatives	O
of	O
1	O
-	O
deoxynojirimycin	O
,	O
i	O
.	O
e	O
.,	O
iminosugars	O
,	O
efficiently	O
disrupts	O
the	O
morphogenesis	O
of	O
a	O
broad	O
spectrum	O
of	O
enveloped	O
viruses	O
.	O

Indeed	O
,	O
we	O
demonstrate	O
here	O
that	O
iminosugar	O
treatment	O
altered	O
the	O
N	O
-	O
linked	O
glycan	B-CHED
structure	O
of	O
angiotensin	B-CHED
I	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
which	O
did	O
not	O
affect	O
its	O
expression	O
on	O
the	O
cell	O
surface	O
or	O
its	O
binding	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
glycoprotein	B-CHED
.	O

TITLE	O
:	O
Determination	O
of	O
'	O
recruited	O
volume	O
'	O
following	O
a	O
PEEP	B-CHED
step	O
is	O
not	O
a	O
measure	O
of	O
lung	O
recruitability	O
.	O

TITLE	O
:	O
Nebulized	O
perflubron	B-CHED
and	O
carbon	B-CHED
dioxide	I-CHED
rapidly	O
dilate	O
constricted	O
airways	O
in	O
an	O
ovine	O
model	O
of	O
allergic	O
asthma	O
.	O

The	O
carbon	B-CHED
dioxide	I-CHED
,	O
which	O
is	O
highly	O
soluble	O
in	O
perflubron	B-CHED
,	O
was	O
used	O
to	O
relax	O
airway	O
smooth	O
muscle	O
.	O

These	O
differentially	O
expressed	O
proteins	B-CHED
were	O
involved	O
in	O
the	O
cell	O
cycle	O
,	O
cellular	O
growth	O
and	O
proliferation	O
,	O
the	O
innate	O
immune	O
response	O
,	O
etc	O
.	O

In	O
this	O
model	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
MV	O
with	O
VT	O
	O
3	O
ml	O
/	O
kg	O
and	O
extracorporeal	O
carbon	B-CHED
dioxide	I-CHED
removal	O
without	O
SB	O
slightly	O
reduced	O
lung	O
histologic	O
damage	O
,	O
but	O
not	O
inflammation	O
,	O
as	O
compared	O
to	O
MV	O
with	O
VT	O
=	O
4	O
to	O
6	O
ml	O
/	O
kg	O
.	O

Of	O
607	O
subjects	O
admitted	O
,	O
560	O
required	O
ventilatory	O
or	O
oxygen	B-CHED
support	O
,	O
among	O
whom	O
180	O
received	O
noninvasive	O
ventilatory	O
support	O
.	O

TITLE	O
:	O
Multiple	O
bilateral	O
branch	O
retinal	B-CHED
artery	O
occlusions	O
in	O
a	O
patient	O
with	O
sickle	O
cell	O
disease	O
with	O
vancomycin	B-CHED
red	O
man	B-CHED
syndrome	O
.	O

The	O
potential	O
for	O
complications	O
from	O
vancomycin	B-CHED
infusion	O
during	O
acute	O
sickle	O
crisis	O
should	O
be	O
considered	O
,	O
although	O
further	O
study	O
is	O
warranted	O
.	O

CONCLUSIONS	O
:	O
Retinal	B-CHED
artery	O
occlusion	O
is	O
a	O
rare	O
but	O
potentially	O
devastating	O
complication	O
of	O
sickle	O
cell	O
disease	O
.	O

In	O
contrast	O
,	O
MERS	O
-	O
CoV	O
,	O
which	O
contains	O
a	O
minimal	O
furin	O
cleavage	O
site	O
just	O
upstream	O
of	O
the	O
fusion	O
peptide	B-CHED
,	O
was	O
negatively	O
affected	O
by	O
inhibition	O
of	O
furin	O
,	O
but	O
not	O
of	O
lysosomal	O
proteases	O
.	O

TITLE	O
:	O
Altered	O
molecular	O
specificity	O
of	O
surfactant	B-CHED
phosphatidycholine	O
synthesis	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Role	O
of	O
the	O
lipid	B-CHED
rafts	O
in	O
the	O
life	O
cycle	O
of	O
canine	O
coronavirus	O
.	O

The	O
extraction	O
of	O
cholesterol	B-CHED
leads	O
to	O
disorganization	O
of	O
lipid	B-CHED
microdomains	O
and	O
to	O
dissociation	O
of	O
proteins	B-CHED
bound	O
to	O
lipid	B-CHED
rafts	O
.	O

Cholesterol	B-CHED
depletion	O
from	O
the	O
cell	O
membrane	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
reduction	O
,	O
but	O
not	O
abolishment	O
,	O
of	O
virus	O
infectivity	O
,	O
and	O
at	O
a	O
concentration	O
of	O
15	O
mM	O
,	O
the	O
reduction	O
in	O
the	O
infection	O
rate	O
was	O
about	O
68	O
%.	O

MCD	O
treatment	O
was	O
used	O
to	O
verify	O
if	O
cholesterol	B-CHED
in	O
the	O
envelope	O
was	O
required	O
for	O
CCoV	O
infection	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
SP3	O
peptide	B-CHED
,	O
corresponding	O
to	O
amino	B-CHED
-	I-CHED
acid	I-CHED
residues	I-CHED
736	O
-	O
761	O
of	O
the	O
S	O
protein	B-CHED
,	O
elicited	O
robust	O
neutralizing	O
activities	O
by	O
blocking	O
viral	O
entry	O
at	O
the	O
postbinding	O
and	O
membrane	O
fusion	O
steps	O
.	O

We	O
analyzed	O
the	O
upper	O
respiratory	O
tract	O
bacterial	O
content	O
of	O
57	O
healthy	O
asymptomatic	O
people	O
(	O
17	O
health	O
-	O
care	O
workers	O
and	O
40	O
community	O
people	O
)	O
and	O
59	O
patients	O
acutely	O
infected	O
with	O
influenza	O
,	O
parainfluenza	O
,	O
rhino	O
,	O
respiratory	O
syncytial	O
,	O
corona	B-CHED
,	O
adeno	O
,	O
or	O
metapneumo	O
viruses	O
using	O
culture	O
-	O
independent	O
pyrosequencing	O
.	O

Among	O
recombinant	O
spike	O
S1	O
,	O
S2	O
,	O
S3	O
,	O
and	O
nucleocapsid	O
N	O
protein	B-CHED
of	O
PEDV	O
,	O
S3	O
protein	B-CHED
presented	O
the	O
highest	O
antibody	O
level	O
in	O
the	O
K	O
/	O
K	O
group	O
.	O

Knockdown	O
of	O
ATF3	O
in	O
resident	O
cells	O
resulted	O
in	O
decreased	O
junctional	O
protein	B-CHED
expression	O
and	O
increased	O
paracellular	O
leak	O
.	O

Some	O
studies	O
have	O
indicated	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
protein	B-CHED
of	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
is	O
a	O
good	O
candidate	O
antigen	B-CHED
for	O
a	O
MERS	O
-	O
CoV	O
subunit	O
vaccine	O
.	O

We	O
also	O
examined	O
the	O
protein	B-CHED
products	O
of	O
these	O
genomic	O
sequences	O
for	O
their	O
structural	O
flexibility	O
and	O
found	O
that	O
it	O
is	O
not	O
necessary	O
for	O
a	O
newly	O
acquired	O
,	O
overlapping	O
protein	B-CHED
product	O
to	O
be	O
intrinsically	O
disordered	O
,	O
in	O
contrast	O
to	O
earlier	O
suggestions	O
.	O

Individual	O
patient	O
data	O
were	O
analyzed	O
from	O
two	O
randomized	O
double	O
blind	O
placebo	O
controlled	O
trials	O
assessing	O
the	O
therapeutic	O
effectiveness	O
of	O
carrageenan	B-CHED
nasal	O
spray	O
in	O
acute	O
common	O
cold	O
.	O

Administration	O
of	O
carrageenan	B-CHED
nasal	O
spray	O
in	O
children	O
as	O
well	O
as	O
in	O
adults	O
suffering	O
from	O
virus	O
-	O
confirmed	O
common	O
cold	O
reduced	O
duration	O
of	O
disease	O
,	O
increased	O
viral	O
clearance	O
and	O
reduced	O
relapses	O
of	O
symptoms	O
.	O

In	O
receiver	O
operating	O
characteristics	O
analysis	O
,	O
serum	O
interferon	O
-	O
	O
-	O
induced	O
protein	B-CHED
10	O
yielded	O
an	O
area	O
under	O
curve	O
of	O
0	O
.	O
67	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
53	O
-	O
0	O
.	O
77	O
;	O
P	O
=	O
.	O
018	O
).	O

This	O
is	O
in	O
part	O
due	O
to	O
increased	O
production	O
of	O
reactive	B-CHED
oxygen	I-CHED
species	I-CHED
.	O

ELPeso	O
was	O
calculated	O
from	O
esophageal	O
pressure	O
measurement	O
at	O
each	O
PEEP	B-CHED
.	O

Colonic	O
tissues	O
from	O
all	O
4	O
animals	O
were	O
positive	O
by	O
fluorescent	O
antibody	O
testing	O
and	O
/	O
or	O
immunohistochemical	O
staining	O
for	O
BoCV	O
antigen	B-CHED
.	O

Before	O
combining	O
lung	O
recruitment	O
maneuver	O
,	O
24	O
h	O
after	O
combining	O
lung	O
recruitment	O
maneuver	O
,	O
and	O
at	O
the	O
end	O
of	O
combining	O
lung	O
recruitment	O
maneuver	O
,	O
variables	O
of	O
blood	O
gas	O
analysis	O
(	O
pH	O
,	O
PaO2	O
,	O
and	O
PaCO2	O
)	O
were	O
obtained	O
by	O
blood	O
gas	O
analyzer	O
,	O
and	O
the	O
OI	O
values	O
were	O
calculated	O
;	O
hemodynamic	O
parameters	O
including	O
heart	O
rate	O
,	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
),	O
central	O
venous	O
pressure	O
(	O
CVP	O
)	O
of	O
all	O
patients	O
and	O
the	O
cardiac	O
output	O
(	O
CO	O
),	O
extravascular	O
lung	O
water	B-CHED
index	O
(	O
EVLWI	O
)	O
of	O
4	O
patients	O
who	O
received	O
pulse	O
contour	O
cardiac	O
output	O
(	O
PiCCO	O
)	O
monitoring	O
were	O
monitored	O
.	O

The	O
scores	O
for	O
protein	B-CHED
were	O
significantly	O
higher	O
in	O
cases	O
with	O
longer	O
survival	O
after	O
burn	O
(	O
p	O
<	O
0	O
.	O
03	O
).	O

Coronaviruses	O
have	O
evolved	O
multiple	O
strategies	O
for	O
proteolytic	O
activation	O
of	O
spike	O
,	O
and	O
a	O
large	O
number	O
of	O
host	O
proteases	O
have	O
been	O
shown	O
to	O
proteolytically	O
process	O
the	O
spike	O
protein	B-CHED
.	O

The	O
S	O
is	O
a	O
multifunctional	O
glycoprotein	B-CHED
that	O
mediates	O
both	O
attachment	O
of	O
CoV	O
particles	O
to	O
cell	O
surface	O
receptor	O
molecules	O
as	O
well	O
as	O
membrane	O
penetration	O
by	O
fusion	O
.	O

Systemic	O
corticosteroids	B-CHED
should	O
not	O
be	O
systematic	O
.	O

The	O
catalytic	O
Cys	B-CHED
of	O
PLP1	O
is	O
unusual	O
in	O
being	O
adjacent	O
to	O
an	O
Ala	B-CHED
instead	O
of	O
a	O
Typ	O
.	O

The	O
patient	O
met	B-CHED
the	O
criteria	O
for	O
ARDS	O
with	O
a	O
PaO2	O
/	O
FiO2	O
ratio	O
of	O
94mmHg	O
.	O

Treatment	O
also	O
included	O
transfusion	O
of	O
two	O
red	O
-	O
cell	O
pack	O
on	O
day	O
1	O
and	O
2	O
after	O
admission	O
in	O
order	O
to	O
maintain	O
hemoglobin	B-CHED
level	O
above	O
8g	O
/	O
dL	O
,	O
and	O
a	O
daily	O
folic	B-CHED
acid	I-CHED
supplementation	O
.	O

The	O
pattern	O
of	O
SHAPE	O
reactivity	O
of	O
in	O
virio	O
genomic	O
RNA	O
,	O
ex	O
virio	O
genomic	O
RNA	O
,	O
and	O
in	O
vitro	O
synthesized	O
RNA	O
was	O
similar	O
,	O
suggesting	O
that	O
binding	O
of	O
N	O
protein	B-CHED
or	O
other	O
proteins	B-CHED
to	O
virion	O
RNA	O
fails	O
to	O
protect	O
the	O
RNA	O
from	O
reaction	O
with	O
lipid	B-CHED
permeable	O
SHAPE	O
reagent	B-CHED
.	O

In	O
contrast	O
,	O
LRNV	O
harbored	O
by	O
Rattus	O
norvegicus	O
formed	O
a	O
distinct	O
lineage	O
within	O
the	O
genus	O
Alphacoronavirus	O
in	O
the	O
3CL	O
(	O
pro	B-CHED
),	O
RdRp	O
,	O
and	O
Hel	O
gene	O
trees	O
,	O
but	O
formed	O
a	O
more	O
divergent	O
lineage	O
in	O
the	O
N	O
and	O
S	O
gene	O
trees	O
,	O
indicative	O
of	O
a	O
recombinant	O
origin	O
.	O

These	O
results	O
suggest	O
that	O
these	O
direct	O
acting	O
antiviral	B-CHED
compounds	O
,	O
or	O
their	O
derivatives	O
,	O
warrant	O
further	O
investigation	O
for	O
clinical	O
use	O
in	O
cats	O
with	O
FIP	O
.	O

ABSTRACT	O
:	O
Respiratory	O
tract	O
infections	O
(	O
RTIs	O
)	O
are	O
common	O
during	O
the	O
Hajj	O
season	O
and	O
are	O
caused	O
by	O
a	O
variety	O
of	O
organisms	O
,	O
which	O
can	O
be	O
transmitted	O
via	O
the	O
air	B-CHED
or	O
contaminated	O
surfaces	O
.	O

The	O
protocol	O
consisted	O
of	O
2	O
points	O
of	O
action	O
:	O
preventive	O
vaccination	O
of	O
dams	O
against	O
E	O
.	O
coli	O
,	O
rota	O
-	O
and	O
coronavirus	O
,	O
and	O
preventive	O
administration	O
of	O
halofuginone	O
lactate	B-CHED
to	O
newborn	O
calves	O
.	O

After	O
a	O
1	O
-	O
week	O
dosage	O
of	O
chemotherapeutic	O
drugs	O
(	O
pegaspargase	O
and	O
mitoxantrone	B-CHED
),	O
he	O
suffered	O
SAP	O
combined	O
with	O
ARDS	O
.	O

In	O
these	O
experiments	O
we	O
utilize	O
transfections	O
,	O
chromatin	O
immunoprecipitation	O
,	O
Electro	O
-	O
mobility	O
Shift	O
Assays	O
(	O
EMSA	O
)	O
and	O
protein	B-CHED
localization	O
to	O
identify	O
where	O
IRF3	O
and	O
IRF3	O
(	O
5D	O
)	O
are	O
inhibited	O
by	O
PLpro	O
.	O

To	O
find	O
out	O
whether	O
the	O
S	O
protein	B-CHED
interacts	O
with	O
cellular	O
proteins	B-CHED
via	O
this	O
sorting	O
signal	O
,	O
a	O
pulldown	O
assay	O
with	O
GST	O
fusion	O
proteins	B-CHED
was	O
performed	O
.	O

Immunofluorescence	O
assays	O
confirmed	O
a	O
co	O
-	O
localization	O
between	O
the	O
TGEV	O
S	O
protein	B-CHED
and	O
filamin	O
A	O
.	O
Further	O
experiments	O
have	O
to	O
be	O
performed	O
to	O
prove	O
a	O
significant	O
impact	O
of	O
filamin	O
A	O
on	O
TGEV	O
infection	O
.	O

TITLE	O
:	O
Crystallization	O
and	O
preliminary	O
crystallographic	O
study	O
of	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
main	O
protease	O
in	O
complex	O
with	O
an	O
inhibitor	B-CHED
.	O

TITLE	O
:	O
Expression	O
,	O
crystallization	O
and	O
preliminary	O
crystallographic	O
study	O
of	O
the	O
functional	O
mutant	O
(	O
N60K	O
)	O
of	O
nonstructural	O
protein	B-CHED
9	O
from	O
Human	O
coronavirus	O
HKU1	O
.	O

Compared	O
with	O
pressure	O
support	O
,	O
neurally	O
adjusted	O
ventilatory	O
assist	O
has	O
been	O
shown	O
to	O
improve	O
patient	O
-	O
ventilator	O
interaction	O
and	O
synchrony	O
in	O
patients	O
with	O
the	O
most	O
challenging	O
respiratory	O
system	O
mechanics	O
,	O
such	O
as	O
very	O
low	O
compliance	O
consequent	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
high	O
resistance	O
and	O
air	B-CHED
trapping	O
due	O
to	O
chronic	O
airflow	O
obstruction	O
;	O
enhance	O
redistribution	O
of	O
the	O
ventilation	O
in	O
the	O
dependent	O
lung	O
regions	O
;	O
avert	O
the	O
risk	O
of	O
patient	O
-	O
ventilator	O
asynchrony	O
due	O
to	O
sedation	O
;	O
avoid	O
central	O
apneas	O
;	O
limit	O
the	O
risk	O
of	O
high	O
(	O
injurious	O
)	O
tidal	O
volumes	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
of	O
varied	O
severity	O
;	O
and	O
improve	O
patient	O
-	O
ventilator	O
interaction	O
and	O
synchrony	O
during	O
noninvasive	O
ventilation	O
,	O
irrespective	O
of	O
the	O
interface	O
utilized	O
.	O

This	O
explains	O
their	O
participation	O
in	O
virtually	O
every	O
metabolic	O
process	O
that	O
involves	O
nucleic	B-CHED
acids	I-CHED
,	O
including	O
DNA	O
replication	O
,	O
recombination	O
and	O
repair	O
,	O
transcription	O
,	O
translation	O
,	O
as	O
well	O
as	O
RNA	O
processing	O
.	O

EMS	O
patients	O
had	O
a	O
shorter	O
time	O
to	O
receiving	O
antibiotics	B-CHED
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
central	O
line	O
placement	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
than	O
did	O
walk	O
-	O
in	O
patients	O
.	O

Here	O
,	O
we	O
provide	O
evidence	O
that	O
PLP2	O
,	O
a	O
catalytic	O
domain	O
of	O
the	O
nonstructural	O
protein	B-CHED
3	O
of	O
human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
),	O
deubiquitinates	O
and	O
stabilizes	O
the	O
cellular	O
oncoprotein	O
MDM2	O
and	O
induces	O
the	O
proteasomal	O
degradation	O
of	O
p53	O
.	O

Patients	O
underwent	O
a	O
three	O
-	O
step	O
ventilator	O
protocol	O
(	O
at	O
clinical	O
,	O
5	O
cm	O
H2O	B-CHED
,	O
or	O
15	O
cm	O
H2O	B-CHED
positive	O
end	O
-	O
expiratory	O
pressure	O
).	O

The	O
Berlin	O
definition	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
assessed	O
at	O
5	O
cm	O
H2O	B-CHED
allows	O
a	O
better	O
evaluation	O
of	O
lung	O
recruitability	O
and	O
edema	O
than	O
at	O
higher	O
positive	O
end	O
-	O
expiratory	O
pressure	O
clinically	O
set	O
.	O

To	O
address	O
these	O
issues	O
,	O
we	O
compared	O
in	O
a	O
murine	O
model	O
a	O
range	O
of	O
recombinant	O
spike	O
protein	B-CHED
or	O
inactivated	O
whole	O
-	O
virus	O
vaccine	O
candidates	O
alone	O
or	O
adjuvanted	O
with	O
either	O
alum	O
,	O
CpG	O
,	O
or	O
Advax	O
,	O
a	O
new	O
delta	O
inulin	B-CHED
-	O
based	O
polysaccharide	B-CHED
adjuvant	B-CHED
.	O

Whereas	O
unadjuvanted	O
or	O
alum	O
-	O
formulated	O
vaccines	O
were	O
associated	O
with	O
significantly	O
increased	O
lung	O
eosinophilic	O
immunopathology	O
on	O
day	O
6	O
postchallenge	O
,	O
this	O
was	O
not	O
seen	O
in	O
mice	O
immunized	O
with	O
vaccines	O
formulated	O
with	O
delta	O
inulin	B-CHED
adjuvant	B-CHED
.	O

Protection	O
against	O
eosinophilic	O
immunopathology	O
by	O
vaccines	O
containing	O
delta	O
inulin	B-CHED
adjuvants	B-CHED
correlated	O
better	O
with	O
enhanced	O
T	O
-	O
cell	O
gamma	O
interferon	O
(	O
IFN	O
-	O
	O
)	O
recall	O
responses	O
rather	O
than	O
reduced	O
interleukin	O
-	O
4	O
(	O
IL	O
-	O
4	O
)	O
responses	O
,	O
suggesting	O
that	O
immunopathology	O
predominantly	O
reflects	O
an	O
inadequate	O
vaccine	O
-	O
induced	O
Th1	O
response	O
.	O

N	O
protein	B-CHED
possibly	O
interacts	O
with	O
host	O
factors	O
to	O
modulate	O
cellular	O
functions	O
.	O

TITLE	O
:	O
Cytokine	O
systems	O
approach	O
demonstrates	O
differences	O
in	O
innate	O
and	O
pro	B-CHED
-	O
inflammatory	O
host	O
responses	O
between	O
genetically	O
distinct	O
MERS	O
-	O
CoV	O
isolates	O
.	O

They	O
had	O
higher	O
blood	O
MxA	O
protein	B-CHED
levels	O
(	O
median	O
[	O
interquartile	O
range	O
])	O
than	O
asymptomatic	O
virus	O
-	O
negative	O
children	O
(	O
695	O
[	O
345	O
-	O
1370	O
]	O
g	O
/	O
L	O
vs	O
.	O
110	O
[	O
55	O
-	O
170	O
]	O
g	O
/	O
L	O
;	O
p	O
<	O
0	O
.	O
001	O
).	O

Asymptomatic	O
virus	O
-	O
negative	O
children	O
vaccinated	O
with	O
a	O
live	O
virus	O
vaccine	O
had	O
elevated	O
MxA	O
protein	B-CHED
levels	O
(	O
240	O
[	O
120	O
-	O
540	O
]	O
g	O
/	O
L	O
),	O
but	O
significantly	O
lower	O
than	O
children	O
with	O
an	O
acute	O
respiratory	O
infection	O
,	O
who	O
had	O
not	O
received	O
vaccinations	O
(	O
740	O
[	O
350	O
-	O
1425	O
]	O
g	O
/	O
L	O
;	O
p	O
<	O
0	O
.	O
001	O
).	O

NLRP3	O
(-/-)	O
mice	O
exhibited	O
diminished	O
expression	O
and	O
activation	O
of	O
Stat3	O
,	O
which	O
regulates	O
MMP	B-CHED
-	O
9	O
and	O
Bcl	O
-	O
2	O
,	O
in	O
addition	O
to	O
increased	O
numbers	O
of	O
apoptotic	O
alveolar	O
epithelial	O
cells	O
.	O

This	O
unexpected	O
similarity	O
suggests	O
an	O
unexplored	O
vulnerability	O
,	O
trafficking	O
to	O
NPC1	O
(+)	O
LE	O
/	O
Lys	B-CHED
,	O
as	O
a	O
therapeutic	O
target	O
for	O
SARS	O
and	O
EBOV	O
.	O

Other	O
rats	O
,	O
including	O
Norway	O
rats	O
from	O
Hong	O
Kong	O
,	O
possessed	O
antibodies	O
only	O
against	O
N	O
protein	B-CHED
and	O
not	O
against	O
the	O
spike	O
polypeptide	B-CHED
,	O
suggesting	O
infection	O
by	O
CoVs	O
different	O
from	O
ChRCoV	O
HKU24	O
.	O

TITLE	O
:	O
The	O
SARS	O
-	O
coronavirus	O
papain	O
-	O
like	O
protease	O
:	O
structure	O
,	O
function	O
and	O
inhibition	O
by	O
designed	O
antiviral	B-CHED
compounds	O
.	O

This	O
review	O
provides	O
an	O
up	O
-	O
to	O
-	O
date	O
discussion	O
on	O
the	O
SARS	O
-	O
CoV	O
papain	O
-	O
like	O
protease	O
including	O
a	O
brief	O
overview	O
of	O
the	O
SARS	O
-	O
CoV	O
genome	O
and	O
replication	O
followed	O
by	O
a	O
more	O
in	O
-	O
depth	O
discussion	O
on	O
the	O
structure	O
and	O
catalytic	O
mechanism	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
,	O
the	O
multiple	O
cellular	O
functions	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
,	O
the	O
inhibition	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
by	O
small	O
molecule	O
inhibitors	B-CHED
,	O
and	O
the	O
prospect	O
of	O
inhibiting	O
papain	O
-	O
like	O
protease	O
from	O
other	O
coronaviruses	O
.	O

Fifteen	O
patients	O
received	O
antiviral	B-CHED
treatment	O
;	O
four	O
(	O
27	O
%)	O
began	O
treatment	O
within	O
48	O
hours	O
of	O
symptom	O
onset	O
.	O

During	O
the	O
influenza	O
season	O
,	O
pregnant	O
women	O
with	O
suspected	O
influenza	O
should	O
receive	O
prompt	O
empiric	O
antiviral	B-CHED
therapy	O
,	O
regardless	O
of	O
rapid	O
influenza	O
diagnostic	O
test	O
results	O
or	O
vaccination	O
status	O
.	O

Thus	O
,	O
we	O
suggested	O
that	O
LiCl	B-CHED
inhibited	O
PRRSV	O
infection	O
by	O
up	O
-	O
regulating	O
the	O
level	O
of	O
antiviral	B-CHED
cytokine	O
TNF	O
-	O
	O
at	O
an	O
early	O
infection	O
stage	O
.	O

These	O
compounds	O
were	O
evaluated	O
for	O
their	O
antiviral	B-CHED
activity	O
against	O
PEDV	O
replication	O
,	O
and	O
the	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
were	O
discussed	O
.	O

They	O
were	O
found	O
to	O
inhibit	O
PEDV	O
genes	O
encoding	O
GP6	O
nucleocapsid	O
,	O
GP2	O
spike	O
,	O
and	O
GP5	O
membrane	O
protein	B-CHED
synthesis	O
based	O
on	O
RT	O
-	O
PCR	O
data	O
.	O

Since	O
indoleamine	B-CHED
-	O
2	O
,	O
3	O
-	O
dioxygenase	O
(	O
IDO	B-CHED
)	O
is	O
the	O
key	O
and	O
rate	O
-	O
limiting	O
enzyme	O
of	O
tryptophan	B-CHED
catabolism	O
,	O
the	O
aim	O
of	O
this	O
work	O
was	O
to	O
explore	O
whether	O
specific	O
inhibition	O
of	O
IDO	B-CHED
by	O
Levo	O
-	O
1	O
-	O
methyl	B-CHED
tryptophan	B-CHED
(	O
MT	O
)	O
could	O
affect	O
MHV	O
actions	O
.	O

Furthermore	O
,	O
the	O
hepatotropism	O
of	O
MHV	O
-	O
JHM	O
depends	O
not	O
on	O
the	O
spike	O
protein	B-CHED
and	O
viral	O
entry	O
but	O
rather	O
on	O
a	O
combination	O
of	O
the	O
structural	O
protein	B-CHED
M	O
and	O
nonstructural	O
replicase	O
-	O
associated	O
proteins	B-CHED
nsp1	O
and	O
nsp13	O
,	O
which	O
are	O
conserved	O
among	O
betacoronaviruses	O
.	O

Small	O
and	O
economical	O
animal	O
models	O
are	O
required	O
for	O
the	O
controlled	O
and	O
extensive	O
studies	O
needed	O
for	O
elucidating	O
pathogenesis	O
and	O
development	O
of	O
vaccines	O
and	O
antivirals	B-CHED
against	O
MERS	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
egg	O
-	O
laying	O
phase	O
and	O
estrogen	B-CHED
affect	O
the	O
induction	O
of	O
cytotoxic	O
cells	O
in	O
response	O
to	O
avian	O
infectious	O
bronchitis	O
(	O
IB	O
)	O
virus	O
at	O
early	O
stage	O
of	O
infection	O
in	O
the	O
oviduct	O
.	O

Attenuated	O
IB	O
virus	O
(	O
aIBV	O
group	O
)	O
or	O
its	O
vehicle	O
(	O
control	O
group	O
)	O
was	O
introduced	O
to	O
the	O
oviductal	O
magnum	O
lumen	O
of	O
White	O
Leghorn	O
hens	O
in	O
the	O
laying	O
and	O
molting	O
phase	O
,	O
as	O
well	O
as	O
molting	O
hens	O
injected	O
with	O
estradiol	B-CHED
benzoate	B-CHED
(	O
M	O
-	O
EB	O
hens	O
)	O
or	O
corn	O
oil	O
(	O
M	O
-	O
oil	O
hens	O
).	O

The	O
Cell	O
'	O
s	O
First	O
Line	O
of	O
Antiviral	B-CHED
Defense	O
.	O

CNS	B-CHED
involvement	O
should	O
be	O
considered	O
in	O
patients	O
with	O
MERS	O
-	O
CoV	O
and	O
progressive	O
neurological	O
disease	O
,	O
and	O
further	O
elucidation	O
of	O
the	O
pathophysiology	O
of	O
this	O
virus	O
is	O
needed	O
.	O

In	O
this	O
study	O
,	O
LC	O
-	O
MS	O
/	O
MS	O
coupled	O
to	O
iTRAQ	O
labeling	O
was	O
used	O
to	O
quantitatively	O
identify	O
differentially	O
expressed	O
cellular	O
proteins	B-CHED
in	O
PEDV	O
-	O
infected	O
Vero	O
cells	O
.	O

These	O
differentially	O
expressed	O
proteins	B-CHED
were	O
involved	O
in	O
apoptosis	O
,	O
signal	O
transduction	O
,	O
and	O
stress	O
responses	O
.	O

Here	O
,	O
we	O
show	O
that	O
IBV	O
PLpro	O
can	O
degrade	O
Lys	B-CHED
(	O
48	O
)-	O
and	O
Lys	B-CHED
(	O
63	O
)-	O
linked	O
polyubiquitin	O
chains	O
to	O
monoubiquitin	O
but	O
not	O
linear	O
polyubiquitin	O
.	O

Most	O
of	O
them	O
exhibited	O
significantly	O
higher	O
anti	O
-	O
TMV	O
activity	O
than	O
commercial	O
plant	O
virucides	O
ribavirin	B-CHED
,	O
harmine	B-CHED
,	O
and	O
lead	O
compound	O
.	O

ABSTRACT	O
:	O
Advances	O
in	O
physiology	O
and	O
biochemistry	O
have	O
provided	O
fundamental	O
insights	O
into	O
the	O
role	O
of	O
pulmonary	O
surfactant	B-CHED
in	O
the	O
pathogenesis	O
and	O
treatment	O
of	O
preterm	O
infants	O
with	O
respiratory	O
distress	O
syndrome	O
.	O

HIV	O
-	O
1	O
integrase	O
(	O
IN	O
)	O
and	O
reverse	O
transcriptase	O
-	O
associated	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
are	O
both	O
selective	O
targets	O
for	O
HIV	O
-	O
1	O
chemotherapy	O
,	O
and	O
the	O
identification	O
of	O
dual	O
IN	O
/	O
RNase	O
H	O
inhibitors	B-CHED
is	O
an	O
attractive	O
strategy	O
for	O
new	O
drug	O
development	O
.	O

Of	O
the	O
7	O
,	O
803	O
nasal	O
swabs	O
tested	O
in	O
the	O
epidemiological	O
survey	O
,	O
MERS	O
-	O
CoV	O
nucleic	B-CHED
acid	I-CHED
was	O
detected	O
by	O
real	O
-	O
time	O
PCR	O
in	O
a	O
total	O
of	O
126	O
(	O
1	O
.	O
6	O
%)	O
camels	O
.	O

Consistently	O
,	O
nanomolar	O
concentrations	O
of	O
the	O
cardiotonic	O
steroids	B-CHED
ouabain	B-CHED
and	O
bufalin	B-CHED
,	O
which	O
are	O
known	O
not	O
to	O
affect	O
the	O
transport	O
function	O
of	O
Na	O
(+),	O
K	O
(+)-	O
ATPase	O
,	O
inhibited	O
infection	O
of	O
cells	O
with	O
MHV	O
,	O
FIPV	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
CoV	O
,	O
and	O
VSV	O
,	O
but	O
not	O
IAV	O
,	O
when	O
the	O
compounds	O
were	O
present	O
during	O
virus	O
inoculation	O
.	O

Among	O
them	O
,	O
twelve	O
representative	O
compounds	O
were	O
further	O
quantified	O
as	O
chemical	O
markers	O
in	O
quantitative	O
analysis	O
,	O
including	O
salidroside	O
,	O
chlorogenic	B-CHED
acid	I-CHED
,	O
forsythoside	O
E	O
,	O
cryptochlorogenic	O
acid	O
,	O
amygdalin	B-CHED
,	O
sweroside	O
,	O
hyperin	O
,	O
rutin	B-CHED
,	O
forsythoside	O
A	O
,	O
phillyrin	O
,	O
rhein	O
,	O
and	O
glycyrrhizic	B-CHED
acid	I-CHED
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
nucleotide	B-CHED
composition	O
of	O
the	O
RNA	O
genome	O
of	O
the	O
six	O
human	O
coronaviruses	O
.	O

The	O
nucleotide	B-CHED
biases	O
are	O
more	O
pronounced	O
in	O
the	O
unpaired	O
regions	O
of	O
the	O
structured	O
RNA	O
genome	O
,	O
which	O
may	O
suggest	O
a	O
certain	O
biological	B-CHED
function	I-CHED
for	O
these	O
distinctive	O
sequence	O
signatures	O
.	O

As	O
reported	O
previously	O
,	O
LiCl	B-CHED
efficiently	O
impairs	O
the	O
replication	O
of	O
a	O
variety	O
of	O
viruses	O
,	O
including	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
and	O
pseudorabies	O
herpesvirus	O
.	O

None	O
of	O
the	O
gp3	O
proteins	B-CHED
modulate	O
the	O
viral	O
replication	O
cycle	O
of	O
heterologous	O
genotype	O
II	O
CCoV	O
in	O
canine	O
cell	O
line	O
,	O
leading	O
to	O
the	O
conclusion	O
that	O
the	O
gp3	O
proteins	B-CHED
are	O
probably	O
advantageous	O
only	O
for	O
CCoV	O
-	O
I	O
and	O
atypical	O
FCoV	O
strains	O
.	O

Employing	O
a	O
pathogenic	O
animal	O
model	O
of	O
SARS	O
-	O
CoV	O
infection	O
,	O
we	O
demonstrated	O
that	O
viral	O
spread	O
and	O
pathogenesis	O
of	O
SARS	O
-	O
CoV	O
is	O
driven	O
by	O
serine	B-CHED
rather	O
than	O
cysteine	B-CHED
proteases	O
and	O
can	O
be	O
effectively	O
prevented	O
by	O
camostat	O
.	O

We	O
found	O
amino	B-CHED
acid	I-CHED
differences	O
located	O
at	O
44	O
positions	O
across	O
an	O
alignment	O
of	O
the	O
six	O
virus	O
translatomes	O
and	O
,	O
at	O
21	O
of	O
these	O
positions	O
,	O
the	O
differences	O
fully	O
or	O
partially	O
discriminated	O
between	O
the	O
genomes	O
derived	O
from	O
the	O
faecal	O
samples	O
and	O
the	O
genomes	O
derived	O
from	O
the	O
tissue	O
lesion	O
samples	O
.	O

The	O
piglets	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
:	O
small	O
VT	O
group	O
(	O
VT	O
=	O
6	O
ml	O
/	O
kg	O
,	O
n	O
=	O
6	O
),	O
middle	O
VT	O
group	O
(	O
VT	O
=	O
10	O
ml	O
/	O
kg	O
,	O
n	O
=	O
6	O
),	O
and	O
large	O
VT	O
group	O
(	O
VT	O
=	O
15	O
ml	O
/	O
kg	O
,	O
n	O
=	O
6	O
),	O
with	O
the	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
set	O
as	O
10	O
cmH2O	O
.	O

While	O
the	O
study	O
group	O
showed	O
a	O
significant	O
increase	O
in	O
EPA	B-CHED
and	O
GLA	B-CHED
concentrations	O
at	O
day	O
4	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
and	O
day	O
8	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
the	O
Omega	O
-	O
3	O
Index	O
(	O
O	O
-	O
3I	O
)	O
failed	O
to	O
reach	O
those	O
suggested	O
as	O
being	O
optimal	O
to	O
obtain	O
clinical	O
efficacy	O
.	O

Innovative	O
strategies	O
using	O
optimized	O
dosing	O
of	O
antimicrobials	B-CHED
,	O
maximizing	O
the	O
pharmacokinetic	O
and	O
pharmacodynamic	O
properties	O
of	O
drugs	O
in	O
critically	O
ill	O
patients	O
,	O
and	O
newer	O
routes	O
of	O
drug	O
delivery	O
are	O
being	O
explored	O
to	O
combat	B-CHED
drug	O
-	O
resistant	O
pathogens	O
.	O

The	O
S	O
genes	O
of	O
those	O
isolates	O
were	O
9	O
nucleotides	B-CHED
longer	O
in	O
length	O
than	O
JS120103	O
and	O
the	O
other	O
reference	O
strains	O
in	O
genogroup	O
1	O
,	O
with	O
15	O
bp	O
insertion	O
and	O
6	O
bp	O
deletion	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
use	O
of	O
a	O
single	O
dose	O
of	O
methylene	B-CHED
blue	I-CHED
in	O
a	O
patient	O
with	O
burn	O
-	O
induced	O
vasoplegia	O
refractory	O
to	O
fluids	O
,	O
vasopressors	O
,	O
and	O
steroids	B-CHED
.	O

Despite	O
the	O
eventual	O
outcome	O
,	O
this	O
is	O
the	O
longest	O
reported	O
survival	O
following	O
methylene	B-CHED
blue	I-CHED
administration	O
for	O
vasoplegia	O
secondary	O
to	O
burn	O
injury	O
.	O

Furthermore	O
,	O
the	O
in	O
vivo	O
efficacy	O
of	O
3CLpro	O
inhibitors	B-CHED
was	O
evaluated	O
using	O
a	O
mouse	O
model	O
of	O
coronavirus	O
infection	O
.	O

Intraperitoneal	O
administration	O
of	O
two	O
3CLpro	O
inhibitors	B-CHED
in	O
mice	O
infected	O
with	O
murine	O
hepatitis	O
virus	O
A59	O
,	O
a	O
hepatotropic	O
coronavirus	O
,	O
resulted	O
in	O
significant	O
reductions	O
in	O
virus	O
titers	O
and	O
pathological	O
lesions	O
in	O
the	O
liver	O
compared	O
to	O
the	O
findings	O
for	O
the	O
controls	O
.	O

However	O
,	O
no	O
studies	O
have	O
previously	O
reported	O
a	O
structural	O
platform	O
for	O
the	O
design	O
of	O
antiviral	B-CHED
drugs	I-CHED
with	O
activities	O
against	O
these	O
viruses	O
or	O
on	O
the	O
efficacy	O
of	O
3CLpro	O
inhibitors	B-CHED
against	O
coronavirus	O
infection	O
in	O
experimental	O
animals	O
.	O

One	O
hour	O
after	O
adjustment	O
of	O
PEEP	B-CHED
and	O
inspiratory	O
driving	O
pressure	O
guided	O
by	O
transpulmonary	O
pressure	O
,	O
PaCO2	O
decreased	O
to	O
64	O
.	O
5	O
	O
16	O
.	O
89	O
mmHg	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	B-CHED
of	O
human	O
coronavirus	O
NL63	O
.	O

The	O
genome	O
of	O
coronaviruses	O
encodes	O
a	O
hydrophobic	O
transmembrane	O
protein	B-CHED
,	O
the	O
envelope	O
(	O
E	O
)	O
protein	B-CHED
.	O

Viral	O
proteins	B-CHED
with	O
ion	O
channel	O
activity	O
are	O
collectively	O
termed	O
""""	O
viroporins	O
"""."	O

TITLE	O
:	O
Arbekacin	B-CHED
treatment	O
of	O
a	O
patient	O
infected	O
with	O
a	O
Pseudomonas	O
putida	O
producing	O
a	O
metallo	O
-	O
beta	O
-	O
lactamase	O
.	O

Colistin	B-CHED
is	O
traditionally	O
the	O
drug	O
of	O
last	O
resort	O
to	O
treat	O
infections	O
with	O
multidrug	O
-	O
resistant	O
Pseudomonas	O
.	O

ABSTRACT	O
:	O
Here	O
,	O
we	O
measured	O
presepsins	O
(	O
PSPs	O
)	O
in	O
four	O
patients	O
with	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
or	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
and	O
discuss	O
the	O
relationship	O
between	O
PSP	B-CHED
and	O
kidney	O
dysfunction	O
.	O

By	O
then	O
,	O
PSP	B-CHED
had	O
risen	O
to	O
3	O
,	O
977	O
,	O
along	O
with	O
elevation	O
of	O
other	O
conventional	O
biomarkers	O
.	O

ABSTRACT	O
:	O
The	O
ability	O
to	O
identify	O
the	O
functional	O
correlates	O
of	O
structural	O
and	O
sequence	O
variation	O
in	O
proteins	B-CHED
is	O
a	O
critical	O
capability	O
.	O

TITLE	O
:	O
Analysis	O
of	O
cathepsin	O
and	O
furin	O
proteolytic	O
enzymes	O
involved	O
in	O
viral	O
fusion	O
protein	B-CHED
activation	O
in	O
cells	O
of	O
the	O
bat	O
reservoir	O
host	O
.	O

In	O
particular	O
,	O
sialic	B-CHED
acid	I-CHED
-	O
mediated	O
tissue	O
binding	O
of	O
spike	O
proteins	B-CHED
can	O
be	O
analyzed	O
by	O
pretreating	O
tissues	O
with	O
various	O
neuraminidases	O
or	O
by	O
blocking	O
the	O
binding	O
of	O
the	O
viral	O
proteins	B-CHED
with	O
specific	O
lectins	O
.	O

After	O
the	O
identification	O
of	O
specific	O
cellular	O
factors	O
interacting	O
with	O
the	O
target	O
viral	O
protein	B-CHED
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
screening	O
system	O
,	O
co	O
-	O
immunoprecipitation	O
and	O
confocal	O
microscopy	O
analyses	O
are	O
often	O
used	O
to	O
verify	O
the	O
virus	O
-	O
host	O
protein	B-CHED
interactions	O
in	O
cells	O
.	O

TITLE	O
:	O
A	O
field	O
-	O
proven	O
yeast	O
two	O
-	O
hybrid	O
protocol	O
used	O
to	O
identify	O
coronavirus	O
-	O
host	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
.	O

These	O
sites	O
harbor	O
the	O
CoV	O
replication	O
-	O
transcription	O
complexes	O
(	O
RTCs	O
):	O
multi	O
-	O
protein	B-CHED
complexes	O
consisting	O
of	O
16	O
nonstructural	O
proteins	B-CHED
(	O
nsps	O
),	O
the	O
CoV	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
)	O
and	O
presumably	O
host	O
proteins	B-CHED
.	O

MAb	O
2D1	O
reacted	O
with	O
S	O
protein	B-CHED
of	O
PEDV	O
specifically	O
.	O

The	O
monoclonal	O
antibody	O
2D1	O
may	O
provide	O
a	O
useful	O
tool	O
as	O
a	O
specific	O
diagnostic	O
reagent	B-CHED
for	O
detecting	O
S	O
protein	B-CHED
of	O
the	O
Chinese	O
variant	O
of	O
PEDV	O
and	O
for	O
further	O
investigation	O
into	O
the	O
virus	O
'	O
pathogenic	O
mechanism	O
.	O

TITLE	O
:	O
Development	O
and	O
characterization	O
of	O
neutralizing	O
monoclonal	O
antibodies	O
against	O
the	O
S1	O
subunit	O
protein	B-CHED
of	O
QX	O
-	O
like	O
avian	O
infectious	O
bronchitis	O
virus	O
strain	O
Sczy3	O
.	O

Eleven	O
anti	O
-	O
IBV	O
MAbs	O
were	O
generated	O
,	O
and	O
two	O
MAbs	O
1C8	O
and	O
2C10	O
were	O
positive	O
in	O
indirect	O
ELISA	O
against	O
both	O
His	O
-	O
S1	O
protein	B-CHED
and	O
the	O
purified	O
whole	O
viral	O
antigen	B-CHED
.	O

The	O
anti	O
-	O
S1	O
MAbs	O
produced	O
in	O
the	O
present	O
work	O
may	O
be	O
valuable	O
in	O
developing	O
an	O
antigen	B-CHED
-	O
capture	O
ELISA	O
test	O
for	O
antigen	B-CHED
detection	O
or	O
a	O
competitive	O
ELISA	O
test	O
for	O
antibody	O
detection	O
or	O
therapeutic	O
medicine	B-CHED
for	O
IB	O
in	O
poultry	O
.	O

Only	O
a	O
few	O
molecules	O
of	O
the	O
envelope	O
(	O
E	O
)	O
protein	B-CHED
are	O
assembled	O
into	O
virions	O
.	O

TITLE	O
:	O
Inhaled	O
nitric	B-CHED
oxide	I-CHED
to	O
improve	O
oxygenation	O
for	O
safe	O
critical	O
care	O
transport	O
of	O
adults	O
with	O
severe	O
hypoxemia	O
.	O

A	O
50	O
-	O
year	O
-	O
old	O
man	B-CHED
presented	O
a	O
septic	O
shock	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
bilateral	O
infiltrates	O
mainly	O
in	O
the	O
upper	O
lobes	O
on	O
chest	O
radiography	O
.	O

Detailed	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
studies	O
on	O
the	O
aglycone	O
of	O
compound	O
3	O
indicated	O
that	O
both	O
the	O
type	O
of	O
pentacyclic	O
triterpene	B-CHED
and	O
the	O
subtle	O
modification	O
of	O
ursolic	B-CHED
acid	I-CHED
as	O
an	O
aglycon	O
had	O
key	O
influences	O
on	O
the	O
antiviral	B-CHED
activity	O
.	O

In	O
particular	O
,	O
the	O
nature	O
of	O
the	O
aromatic	O
group	O
in	O
the	O
position	O
4	O
of	O
the	O
thiazole	B-CHED
ring	O
plays	O
a	O
key	O
role	O
in	O
the	O
modulation	O
of	O
the	O
activity	O
towards	O
the	O
two	O
RT	O
-	O
associated	O
functions	O
.	O

In	O
this	O
report	O
,	O
we	O
identified	O
several	O
potential	O
cellular	O
nsp16	O
-	O
interacting	O
proteins	B-CHED
from	O
a	O
human	O
thymus	O
cDNA	O
library	O
by	O
yeast	O
two	O
-	O
hybrid	O
screening	O
.	O

As	O
in	O
the	O
case	O
of	O
SARS	O
-	O
CoV	O
,	O
MERS	O
virus	O
lacking	O
E	O
protein	B-CHED
represents	O
a	O
potential	O
vaccine	O
.	O

Real	O
-	O
time	O
RT	O
-	O
PCR	O
of	O
CSF	O
showed	O
a	O
specificity	O
of	O
100	O
%	O
in	O
diagnosing	O
FIP	O
,	O
a	O
sensitivity	O
of	O
42	O
.	O
1	O
%,	O
a	O
PPV	B-CHED
of	O
100	O
%	O
and	O
an	O
NPV	O
of	O
57	O
.	O
7	O
%.	O

CONCLUSIONS	O
:	O
Veno	O
-	O
venous	O
CO2	B-CHED
removal	O
therapy	O
enabled	O
protective	O
ventilation	O
while	O
maintaining	O
normocarbia	O
during	O
ARDS	O
.	O

TITLE	O
:	O
Isolation	O
,	O
synthesis	O
and	O
anti	O
-	O
hepatitis	O
B	O
virus	O
evaluation	O
of	O
p	B-CHED
-	I-CHED
hydroxyacetophenone	I-CHED
derivatives	O
from	O
Artemisia	O
capillaris	O
.	O

We	O
purified	O
6	O
lignans	B-CHED
from	O
Schisandra	O
chinensis	O
fruits	O
and	O
assayed	O
their	O
effects	O
on	O
HIV	O
-	O
1	O
RT	O
and	O
viral	O
replication	O
.	O

Genetically	O
,	O
the	O
S	O
and	O
N	O
genes	O
of	O
the	O
PDCoV	O
isolates	O
were	O
relatively	O
stable	O
during	O
the	O
first	O
20	O
passages	O
in	O
cell	O
culture	O
,	O
with	O
only	O
5	O
nucleotide	B-CHED
changes	O
,	O
each	O
corresponding	O
to	O
an	O
amino	B-CHED
acid	I-CHED
change	O
.	O

[	O
18F	O
]	O
fluoro	B-CHED
-	O
2	B-CHED
-	I-CHED
deoxy	I-CHED
-	I-CHED
D	I-CHED
-	I-CHED
glucose	I-CHED
uptake	O
rate	O
was	O
computed	O
for	O
the	O
total	O
lung	O
,	O
four	O
horizontal	O
regions	O
from	O
top	O
to	O
bottom	O
(	O
nondependent	O
to	O
dependent	O
regions	O
)	O
and	O
for	O
voxels	O
grouped	O
by	O
similar	O
density	O
using	O
standard	O
Hounsfield	O
units	O
classification	O
.	O

The	O
objective	O
of	O
this	O
report	O
was	O
to	O
compare	O
the	O
prevalence	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
associated	O
mortality	O
between	O
military	O
service	O
members	O
with	O
burns	O
sustained	O
during	O
or	O
in	O
support	O
of	O
combat	B-CHED
operations	O
and	O
civilian	O
burn	O
patients	O
treated	O
at	O
a	O
single	O
burn	O
center	O
.	O

In	O
this	O
study	O
,	O
the	O
therapeutic	O
index	O
of	O
recombinant	O
human	O
interferon	O
alpha	O
2b	O
anti	O
-	O
HPIV	O
was	O
1476	O
.	O
63	O
,	O
the	O
therapeutic	O
index	O
of	O
recombinant	O
human	O
interferon	O
alpha	O
2b	O
anti	O
-	O
RSV	O
was	O
141	O
.	O
37	O
,	O
the	O
therapeutic	O
index	O
of	O
recombinant	O
human	O
interferon	O
alpha	O
2b	O
anti	O
-	O
coronavirus	O
was	O
more	O
than	O
2820	O
.	O
76	O
,	O
and	O
the	O
antiviral	B-CHED
effect	O
of	O
recombinant	O
human	O
interferon	O
alpha	O
2b	O
was	O
better	O
than	O
ribavirin	B-CHED
(	O
RBV	B-CHED
).	O

Auxiliary	O
partial	O
orthotopic	O
living	O
donor	B-CHED
liver	O
transplantion	O
(	O
APOLDLT	O
)	O
was	O
performed	O
.	O

The	O
APOLDLT	O
is	O
a	O
life	O
-	O
saving	O
modality	O
for	O
rescuing	O
patients	O
with	O
high	O
-	O
risk	O
acute	O
liver	O
failure	O
following	O
HBV	O
infection	O
without	O
available	O
donor	B-CHED
and	O
hence	O
is	O
recommended	O
under	O
standardized	O
antiviral	B-CHED
therapy	O
coverage	O
as	O
stated	O
above	O
.	O

In	O
contrast	O
,	O
it	O
is	O
found	O
that	O
incorporating	O
highly	O
PEGylated	O
polymers	B-CHED
allows	O
the	O
production	O
of	O
compacted	O
(	O
43	O
nm	O
)	O
and	O
colloidally	O
stable	O
DNA	O
NP	O
that	O
avoid	O
adhesive	O
trapping	O
within	O
the	O
brain	O
parenchyma	O
.	O

TITLE	O
:	O
Acute	O
phosphine	B-CHED
poisoning	O
on	O
board	O
a	O
bulk	O
carrier	O
:	O
analysis	O
of	O
factors	O
leading	O
to	O
a	O
fatal	O
case	O
.	O

To	O
analyse	O
circumstances	O
resulting	O
in	O
toxic	O
exposure	O
to	O
phosphine	B-CHED
in	O
the	O
sea	O
transport	O
sector	O
.	O

The	O
following	O
day	O
,	O
the	O
captain	O
issued	O
a	O
rescue	O
call	O
from	O
the	O
same	O
vessel	O
for	O
a	O
41	O
-	O
year	O
-	O
old	O
man	B-CHED
also	O
with	O
abdominal	O
pain	O
,	O
vomiting	O
and	O
dizziness	O
.	O

High	O
-	O
dose	O
systemic	O
corticosteroids	B-CHED
were	O
associated	O
with	O
worse	O
outcomes	O
in	O
patients	O
with	O
A	O
(	O
H1N1	O
)	O
pdm09	O
or	O
A	O
(	O
H5N1	O
).	O

There	O
is	O
no	O
specific	O
antiviral	B-CHED
treatment	O
or	O
vaccine	O
available	O
.	O

ABSTRACT	O
:	O
Although	O
widespread	O
vaccination	O
against	O
canine	O
distemper	O
virus	O
(	O
CDV	B-CHED
)	O
has	O
been	O
conducted	O
for	O
many	O
decades	O
,	O
several	O
canine	O
distemper	O
outbreaks	O
in	O
vaccinated	O
animals	O
have	O
been	O
reported	O
frequently	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
elucidate	O
the	O
anti	O
-	O
inflammatory	O
mechanism	O
of	O
eucalyptol	B-CHED
in	O
relation	O
to	O
tissue	O
remodelling	O
in	O
acute	O
lung	O
inflammation	O
.	O

TITLE	O
:	O
Targeting	O
N	B-CHED
-	I-CHED
glycan	I-CHED
cryptic	O
sugar	O
moieties	O
for	O
broad	O
-	O
spectrum	O
virus	O
neutralization	O
:	O
progress	O
in	O
identifying	O
conserved	O
molecular	O
targets	O
in	O
viruses	O
of	O
distinct	O
phylogenetic	O
origins	O
.	O

In	O
addition	O
,	O
the	O
benefit	O
could	O
be	O
counteracted	O
by	O
an	O
increased	O
risk	O
of	O
acute	O
air	B-CHED
leak	O
.	O

Specifically	O
,	O
use	O
of	O
these	O
building	O
blocks	O
to	O
investigate	O
protein	B-CHED
folding	O
and	O
misfolding	O
has	O
been	O
of	O
particular	O
value	O
since	O
it	O
can	O
provide	O
tremendous	O
insights	O
into	O
peptide	B-CHED
aggregation	O
related	O
to	O
a	O
variety	O
of	O
protein	B-CHED
misfolding	O
diseases	O
,	O
or	O
amyloid	O
diseases	O
(	O
e	O
.	O
g	O
.,	O
Alzheimer	O
'	O
s	O
disease	O
,	O
Parkinson	O
'	O
s	O
disease	O
,	O
type	O
-	O
II	O
diabetes	O
).	O

Early	O
diagnosis	O
and	O
management	O
with	O
oxygenation	O
,	O
antibiotics	B-CHED
and	O
immunosuppresents	O
can	O
prevent	O
complications	O
and	O
mortality	O
.	O

RVs	O
were	O
found	O
in	O
262	O
patients	O
(	O
27	O
.	O
5	O
%):	O
influenza	O
virus	O
A	O
(	O
IFV	O
A	O
,	O
9	O
.	O
9	O
%)	O
comprised	O
of	O
pandemic	O
H1N1	O
(	O
6	O
.	O
7	O
%)	O
and	O
seasonal	O
H3N2	B-CHED
(	O
3	O
.	O
5	O
%),	O
human	O
rhinovirus	O
(	O
4	O
.	O
3	O
%),	O
adenovirus	O
(	O
4	O
.	O
2	O
%),	O
human	O
metapneumovirus	O
(	O
1	O
.	O
8	O
%),	O
parainfluenza	O
virus	O
1	O
,	O
3	O
and	O
2	O
(	O
1	O
.	O
7	O
%,	O
1	O
.	O
5	O
%	O
and	O
1	O
.	O
2	O
%).	O

Using	O
small	O
interfering	O
RNAs	O
to	O
screen	O
different	O
mRNA	B-CHED
components	O
of	O
the	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
or	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
signalling	O
pathways	O
,	O
we	O
demonstrated	O
that	O
TLR2	O
,	O
TLR3	O
and	O
TLR9	O
contribute	O
to	O
NF	O
-	O
B	O
activation	O
in	O
response	O
to	O
PEDV	O
infection	O
,	O
but	O
not	O
RIG	O
-	O
I	O
.	O
By	O
screening	O
PEDV	O
structural	O
proteins	B-CHED
for	O
their	O
ability	O
to	O
induce	O
NF	O
-	O
B	O
activities	O
,	O
we	O
found	O
that	O
PEDV	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
)	O
could	O
activate	O
NF	O
-	O
B	O
and	O
that	O
the	O
central	O
region	O
of	O
N	O
was	O
essential	O
for	O
NF	O
-	O
B	O
activation	O
.	O

However	O
,	O
diagnostic	O
tools	O
other	O
than	O
polymerase	O
chain	O
reaction	O
for	O
PDCoV	O
detection	O
were	O
lacking	O
and	O
Koch	O
'	O
s	O
postulates	O
had	O
not	O
been	O
fulfilled	O
to	O
confirm	O
the	O
pathogenic	O
potential	O
of	O
PDCoV	O
.	O
In	O
the	O
present	O
study	O
,	O
PDCoV	O
peptide	B-CHED
-	O
specific	O
rabbit	O
antisera	O
were	O
developed	O
and	O
used	O
in	O
immunofluorescence	O
and	O
immunohistochemistry	O
assays	O
to	O
assist	O
PDCoV	O
diagnostics	O
.	O

In	O
the	O
course	O
of	O
infectious	O
cycles	O
many	O
nuclear	O
-	O
cytoplasmic	O
shuttling	O
proteins	B-CHED
of	O
mostly	O
nuclear	O
distribution	O
are	O
detained	O
in	O
the	O
cytoplasm	O
by	O
viruses	O
and	O
re	O
-	O
purposed	O
for	O
their	O
own	O
gain	O
.	O

Both	O
the	O
high	O
-	O
CCL2	B-CHED
-	O
producing	O
GG	O
genotype	O
and	O
the	O
low	O
-	O
MBL	O
-	O
producing	O
B	O
allele	O
were	O
consistently	O
associated	O
with	O
increased	O
risks	O
of	O
SARS	O
-	O
CoV	O
infection	O
in	O
all	O
4	O
case	O
-	O
control	O
populations	O
(	O
joint	O
P	O
=	O
1	O
.	O
6	O
	O
10	O
(-	O
4	O
)	O
and	O
4	O
.	O
9	O
	O
10	O
(-	O
8	O
),	O
for	O
CCL2	B-CHED
and	O
MBL	O
respectively	O
),	O
with	O
no	O
interaction	O
between	O
polymorphisms	O
could	O
be	O
detected	O
.	O

The	O
CCL2	B-CHED
G	O
-	O
2518A	O
and	O
MBL	O
codon	O
54	O
variant	O
have	O
a	O
significantly	O
cumulative	O
effect	O
on	O
increased	O
risk	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Resistance	O
to	O
rocuronium	B-CHED
and	O
cisatracurium	O
in	O
a	O
patient	O
with	O
a	O
spinal	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

It	O
was	O
identified	O
to	O
be	O
approximately	O
32	O
kDa	O
as	O
a	O
His	O
-	O
tagged	O
fusion	O
protein	B-CHED
and	O
can	O
bind	O
IBV	O
positive	O
serum	O
by	O
western	O
blot	O
analysis	O
.	O

However	O
,	O
FOB	O
-	O
BAL	B-CHED
carries	O
a	O
risk	O
of	O
significant	O
hypoxaemia	O
and	O
subsequent	O
tracheal	O
intubation	O
during	O
and	O
after	O
the	O
procedure	O
.	O

Conclusion	O
FOB	O
-	O
BAL	B-CHED
using	O
LMA	O
and	O
CPAP	O
appears	O
to	O
be	O
safe	O
and	O
effective	O
in	O
patients	O
who	O
develop	O
severe	O
acute	O
hypoxaemia	O
.	O

Implications	O
of	O
these	O
findings	O
extend	O
to	O
the	O
use	O
of	O
virus	O
entry	O
antagonists	B-CHED
,	O
such	O
as	O
protease	B-CHED
inhibitors	I-CHED
,	O
which	O
might	O
be	O
most	O
effective	O
when	O
localized	O
to	O
these	O
microdomains	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
biological	O
evaluation	O
and	O
molecular	O
docking	O
studies	O
of	O
phenylpropanoid	B-CHED
derivatives	O
as	O
potent	O
anti	B-CHED
-	I-CHED
hepatitis	I-CHED
B	I-CHED
virus	I-CHED
agents	I-CHED
.	O

TITLE	O
:	O
Inhibition	O
of	O
HMGCoA	O
reductase	O
by	O
simvastatin	B-CHED
protects	O
mice	O
from	O
injurious	O
mechanical	O
ventilation	O
.	O

We	O
explored	O
the	O
utility	O
of	O
simvastatin	B-CHED
in	O
a	O
mouse	O
model	O
of	O
severe	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

Three	O
doses	O
of	O
simvastatin	B-CHED
(	O
20	O
mg	O
/	O
kg	O
)	O
or	O
saline	O
were	O
injected	O
intraperitoneally	O
on	O
days	O
-	O
2	O
,	O
-	O
1	O
and	O
0	O
of	O
the	O
experiment	O
.	O

Thus	O
,	O
the	O
efficient	O
incorporation	O
of	O
viral	O
envelope	O
proteins	B-CHED
into	O
CoV	O
virions	O
depends	O
on	O
protein	B-CHED
trafficking	O
and	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
near	O
the	O
ERGIC	O
.	O

This	O
decreased	O
-	O
fidelity	O
phenotype	O
was	O
confirmed	O
using	O
two	O
additional	O
nucleoside	B-CHED
analogs	O
,	O
5	B-CHED
-	I-CHED
azacytidine	I-CHED
and	O
ribavirin	B-CHED
.	O

It	O
is	O
important	O
to	O
improve	O
diagnostic	O
criteria	O
for	O
a	O
precise	O
definition	O
of	O
ARDS	O
and	O
transfer	O
it	O
in	O
practice	O
of	O
emergency	O
and	O
family	O
medicine	B-CHED
,	O
microbiology	O
,	O
intensive	O
care	O
units	O
,	O
hospital	O
departments	O
of	O
infectious	O
and	O
respiratory	O
diseases	O
.	O

The	O
clinical	O
feature	O
like	O
dyspnoea	O
,	O
cough	O
,	O
low	O
blood	O
pressure	O
(	O
MAP	O
<	O
65	O
mmHg	O
),	O
IVC	O
collapsibility	O
(	O
by	O
ultrasound	O
)	O
and	O
laboratory	O
parameters	O
like	O
decreased	O
Hemoglobin	B-CHED
,	O
Hematocrit	O
,	O
Serum	O
albumin	O
,	O
and	O
increased	O
serum	O
creatinine	B-CHED
,	O
serum	O
total	O
bilirubin	B-CHED
,	O
SGOT	O
,	O
SGPT	O
,	O
LDH	O
,	O
CPK	O
,	O
and	O
serum	O
lactate	B-CHED
were	O
statistically	O
significant	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
in	O
scrub	O
typhus	O
patients	O
group	O
with	O
ARDS	O
.	O

While	O
assays	O
detecting	O
nucleic	B-CHED
acids	I-CHED
were	O
implemented	O
quickly	O
,	O
assays	O
to	O
detect	O
anti	O
-	O
PDCoV	O
antibodies	O
have	O
not	O
been	O
available	O
.	O

We	O
have	O
devised	O
a	O
study	O
of	O
two	O
known	O
and	O
standardized	O
animal	O
models	O
(	O
hemorrhagic	O
shock	O
[	O
HS	O
]	O
and	O
oleic	B-CHED
acid	I-CHED
[	O
OA	O
])	O
to	O
more	O
closely	O
reproduce	O
the	O
pathophysiology	O
of	O
posttraumatic	O
acute	O
lung	O
injury	O
.	O

Patients	O
with	O
ACP	B-CHED
exhibited	O
a	O
restricted	O
left	O
ventricle	O
(	O
LV	O
)	O
secondary	O
to	O
RV	O
dilatation	O
and	O
had	O
concomitant	O
RV	O
dysfunction	O
,	O
irrespective	O
of	O
associated	O
PFO	B-CHED
,	O
but	O
preserved	O
LV	O
systolic	O
function	O
.	O

This	O
study	O
examined	O
the	O
co	O
-	O
detections	O
,	O
the	O
distribution	O
of	O
viruses	O
,	O
symptoms	O
,	O
and	O
illness	O
burden	O
associated	O
with	O
ARI	B-CHED
between	O
December	O
2012	O
and	O
March	O
2013	O
.	O

Phylogenetic	O
analysis	O
revealed	O
that	O
the	O
Malagasy	O
strains	O
belong	O
to	O
the	O
genus	O
Betacoronavirus	O
but	O
form	O
three	O
distinct	O
clusters	B-CHED
,	O
which	O
seem	O
to	O
represent	O
previously	O
undescribed	O
genetic	O
lineages	O
.	O

TITLE	O
:	O
Anti	O
-	O
inflammatory	O
effects	O
of	O
novel	O
curcumin	B-CHED
analogs	O
in	O
experimental	O
acute	O
lung	O
injury	O
.	O

The	O
active	O
compounds	O
,	O
a17	O
,	O
a18	O
,	O
c9	O
and	O
c26	O
,	O
exhibited	O
their	O
anti	O
-	O
inflammatory	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
exhibited	O
greater	O
stability	O
than	O
curcumin	B-CHED
in	O
vitro	O
.	O

In	O
vivo	O
,	O
LPS	B-CHED
significantly	O
increased	O
protein	B-CHED
concentration	O
and	O
number	O
of	O
inflammatory	O
cells	O
in	O
BALF	O
,	O
pulmonary	O
edema	O
,	O
pathological	O
changes	O
of	O
lung	O
tissue	O
,	O
inflammatory	O
cytokines	O
in	O
serum	O
and	O
BALF	O
,	O
macrophage	O
infiltration	O
,	O
inflammatory	O
gene	O
expression	O
,	O
and	O
MAPKs	O
phosphorylation	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
uses	O
cell	O
-	O
surface	O
heparan	B-CHED
sulfate	I-CHED
as	O
an	O
attachment	O
factor	O
.	O

These	O
2	O
peptides	B-CHED
specifically	O
inhibited	O
type	O
I	O
and	O
type	O
II	O
FIPV	O
,	O
but	O
did	O
FHV	O
or	O
FCV	B-CHED
infection	O
.	O

The	O
results	O
show	O
limited	O
knowledge	O
of	O
PPE	B-CHED
requirements	O
(	O
20	O
%-	O
30	O
%)	O
for	O
various	O
chemical	O
warfare	O
agents	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
of	O
the	O
tested	O
cohort	O
indicate	O
that	O
current	O
knowledge	O
regarding	O
PPE	B-CHED
for	O
chemical	O
warfare	O
agents	O
remains	O
very	O
limited	O
.	O

ABSTRACT	O
:	O
Vitamin	B-CHED
D	I-CHED
deficiency	O
has	O
been	O
implicated	O
as	O
a	O
pathogenic	O
factor	O
in	O
sepsis	O
and	O
intensive	O
therapy	O
unit	O
mortality	O
but	O
has	O
not	O
been	O
assessed	O
as	O
a	O
risk	O
factor	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

The	O
high	O
similarity	O
of	O
the	O
S	O
protein	B-CHED
among	O
the	O
Taiwan	O
and	O
the	O
globally	O
emerged	O
non	O
-	O
S	O
INDEL	O
PEDV	O
strains	O
suggests	O
that	O
the	O
Taiwan	O
new	O
variants	O
may	O
share	O
similar	O
pathogenesis	O
and	O
immunogenicity	O
as	O
the	O
global	O
outbreak	O
variants	O
.	O

There	O
are	O
very	O
few	O
cases	O
in	O
the	O
literature	O
that	O
described	O
leukoencephalopathy	O
following	O
benzodiazepines	B-CHED
,	O
especially	O
with	O
an	O
acute	O
and	O
progressive	O
course	O
.	O

CONCLUSIONS	O
:	O
Toxic	O
leukoencephalopathy	O
can	O
occur	O
acutely	O
following	O
an	O
overdose	O
of	O
benzodiazepine	B-CHED
and	O
respiratory	O
failure	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
the	O
crucial	O
domain	O
of	O
the	O
S1	O
subunit	O
of	O
the	O
S	O
protein	B-CHED
that	O
interacts	O
with	O
NCAM	O
.	O

TITLE	O
:	O
Human	O
Coronavirus	O
HKU1	O
Spike	O
Protein	B-CHED
Uses	O
O	B-CHED
-	I-CHED
Acetylated	I-CHED
Sialic	I-CHED
Acid	I-CHED
as	O
an	O
Attachment	O
Receptor	O
Determinant	O
and	O
Employs	O
Hemagglutinin	O
-	O
Esterase	O
Protein	B-CHED
as	O
a	O
Receptor	O
-	O
Destroying	O
Enzyme	O
.	O

However	O
,	O
unlike	O
other	O
group	O
2a	O
CoVs	O
,	O
e	O
.	O
g	O
.,	O
hCoV	O
-	O
OC43	O
,	O
for	O
which	O
9	O
-	O
O	B-CHED
-	I-CHED
acetylated	I-CHED
sialic	I-CHED
acid	I-CHED
(	O
9	O
-	O
O	O
-	O
Ac	O
-	O
Sia	O
)	O
serves	O
as	O
a	O
receptor	O
determinant	O
,	O
HKU1	O
-	O
S1	O
bound	O
with	O
neither	O
9	O
-	O
O	O
-	O
Ac	O
-	O
Sia	O
-	O
containing	O
glycoprotein	B-CHED
(	O
s	O
)	O
nor	O
rat	O
and	O
mouse	O
erythrocytes	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
,	O
similarly	O
to	O
other	O
members	O
of	O
the	O
group	O
2a	O
CoVs	O
,	O
sialic	B-CHED
acid	I-CHED
moieties	O
on	O
glycoproteins	B-CHED
are	O
critical	O
receptor	O
determinants	O
for	O
the	O
hCoV	O
-	O
HKU1	O
infection	O
.	O

Interestingly	O
,	O
the	O
virus	O
seems	O
to	O
employ	O
a	O
type	O
of	O
sialic	B-CHED
acid	I-CHED
different	O
from	O
those	O
employed	O
by	O
other	O
group	O
2a	O
CoVs	O
.	O

These	O
findings	O
further	O
confirm	O
that	O
the	O
3CL	O
(	O
pro	B-CHED
)	O
of	O
coronaviruses	O
can	O
be	O
inhibited	O
by	O
broad	O
spectrum	O
lead	B-CHED
compounds	I-CHED
.	O

RESULTS	O
:	O
A	O
high	O
quality	O
homology	O
model	O
of	O
the	O
OC43	O
3CL	O
(	O
pro	B-CHED
)	O
was	O
successfully	O
generated	O
in	O
an	O
active	O
conformation	O
.	O

The	O
stability	O
of	O
the	O
ligand	B-CHED
was	O
subsequently	O
confirmed	O
by	O
molecular	O
dynamics	O
.	O

CONCLUSIONS	O
:	O
The	O
lead	O
compound	O
16R	O
may	O
represent	O
a	O
broad	O
-	O
spectrum	O
inhibitor	B-CHED
of	O
the	O
3CL	O
(	O
pro	B-CHED
)	O
of	O
OC43	O
and	O
potentially	O
other	O
coronaviruses	O
.	O

Therefore	O
,	O
the	O
first	O
objective	O
of	O
this	O
prospective	O
longitudinal	O
cohort	O
study	O
was	O
to	O
determine	O
associations	O
between	O
serum	O
protein	B-CHED
fractions	O
as	O
determined	O
by	O
routine	O
electrophoresis	O
(	O
total	O
protein	B-CHED
,	O
albumin	O
,	O
alpha	O
-	O
1	O
and	O
-	O
2	O
globulins	O
,	O
beta	O
-	O
globulins	O
and	O
Ig	O
'	O
s	O
)	O
at	O
arrival	O
and	O
BRD	O
and	O
NCD	O
in	O
the	O
first	O
3	O
weeks	O
of	O
the	O
production	O
cycle	O
.	O

As	O
found	O
in	O
other	O
coronaviruses	O
,	O
the	O
majority	O
of	O
the	O
positive	O
-	O
stranded	O
RNA	O
MERS	O
-	O
CoV	O
genome	O
is	O
translated	O
into	O
two	O
polyproteins	O
,	O
one	O
created	O
by	O
a	O
ribosomal	O
frameshift	O
,	O
that	O
are	O
cleaved	O
at	O
three	O
sites	O
by	O
a	O
papain	O
-	O
like	O
protease	O
and	O
at	O
11	O
sites	O
by	O
a	O
3C	O
-	O
like	O
protease	O
(	O
3	O
CL	O
(	O
pro	B-CHED
)).	O

Under	O
PCV	B-CHED
mode	O
,	O
compared	O
with	O
the	O
initial	O
level	O
of	O
tidal	O
volume	O
(	O
V	O
T	O
),	O
ARF	O
patients	O
showed	O
30	O
.	O
0	O
%	O
and	O
27	O
.	O
8	O
%	O
decrease	O
at	O
1	O
min	O
and	O
10	O
min	O
,	O
respectively	O
.	O

Under	O
VCV	O
mode	O
,	O
compared	O
with	O
the	O
initial	O
level	O
,	O
38	O
.	O
6	O
%	O
and	O
37	O
.	O
5	O
%	O
increase	O
in	O
peak	O
airway	O
pressure	O
(	O
PAP	B-CHED
)	O
were	O
found	O
at	O
1	O
min	O
and	O
10	O
min	O
,	O
respectively	O
.	O

TITLE	O
:	O
Review	O
of	O
Non	O
-	O
Bacterial	O
Infections	O
in	O
Respiratory	O
Medicine	B-CHED
:	O
Viral	O
Pneumonia	O
.	O

Ribavirin	B-CHED
has	O
been	O
used	O
in	O
children	O
with	O
syncytial	O
respiratory	O
virus	O
,	O
and	O
in	O
immunosuppressed	O
subjects	O
.	O

Apart	O
from	O
these	O
drugs	O
,	O
no	O
antiviral	B-CHED
has	O
been	O
shown	O
to	O
be	O
effective	O
.	O

The	O
use	O
of	O
fluid	O
resuscitation	O
is	O
an	O
important	O
treatment	O
for	O
sepsis	O
,	O
but	O
positive	O
fluid	O
balance	B-CHED
may	O
induce	O
pulmonary	O
injury	O
.	O

As	O
an	O
alternative	O
,	O
fluid	O
resuscitation	O
with	O
hypertonic	O
saline	O
((	O
HS	O
)	O
NaCl	B-CHED
7	O
.	O
5	O
%)	O
has	O
been	O
described	O
as	O
a	O
promising	O
therapeutical	O
agent	O
in	O
sepsis	O
-	O
induced	O
ARDS	O
by	O
the	O
diminished	O
amount	O
of	O
fluid	O
necessary	O
.	O

In	O
addition	O
,	O
hypertonic	O
saline	O
prevented	O
pulmonary	O
injury	O
by	O
decreasing	O
metalloproteinase	O
9	O
(	O
MMP	B-CHED
-	O
9	O
)	O
activity	O
in	O
tissue	O
.	O

A	O
previously	O
healthy	O
35	O
-	O
year	O
-	O
old	O
Japanese	O
man	B-CHED
who	O
developed	O
severe	O
dyspnea	O
presented	O
to	O
our	O
hospital	O
.	O

Analysis	O
of	O
the	O
200	O
to	O
300	O
regulated	O
genes	O
showed	O
that	O
genes	O
for	O
interferon	O
(	O
IFN	O
)	O
and	O
antiviral	B-CHED
pathways	O
are	O
highly	O
upregulated	O
in	O
NDV	O
-	O
infected	O
PVK	B-CHED
cells	O
,	O
including	O
genes	O
for	O
beta	O
IFN	O
,	O
RIG	O
-	O
I	O
,	O
MDA5	O
,	O
ISG15	O
,	O
and	O
IRF1	O
.	O

TITLE	O
:	O
Extracorporeal	O
Treatment	O
for	O
Salicylate	B-CHED
Poisoning	O
:	O
Systematic	O
Review	O
and	O
Recommendations	O
From	O
the	O
EXTRIP	O
Workgroup	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
supplemental	O
genistein	B-CHED
(	O
an	O
isoflavonoid	B-CHED
)	O
on	O
performance	O
,	O
lymphoid	O
organs	O
'	O
development	O
,	O
and	O
cellular	O
and	O
humoral	O
immune	O
responses	O
in	O
broiler	O
chicks	O
.	O

The	O
cutaneous	O
basophil	O
hypersensivity	O
(	O
CBH	O
)	O
test	O
was	O
measured	O
at	O
day	O
10	O
of	O
age	O
after	O
toe	O
web	O
injection	O
with	O
phytohemagglutinin	O
-	O
P	O
.	O
In	O
addition	O
,	O
sera	O
samples	O
were	O
collected	O
after	O
different	O
antigen	B-CHED
inoculations	O
to	O
investigate	O
antibody	O
responses	O
.	O

Dietary	O
inclusion	O
of	O
genistein	B-CHED
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
lymphocytes	O
and	O
subsequently	O
reduced	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
heterophil	O
to	O
lymphocyte	O
ratio	O
.	O

Mice	O
with	O
genetic	O
deficiency	O
of	O
CC	O
-	O
chemokine	O
receptor	O
(	O
CCR	O
)	O
type	O
5	O
,	O
the	O
common	O
receptor	O
of	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-CHED
(	O
CCL	B-CHED
)	O
3	O
,	O
CCL4	B-CHED
,	O
and	O
CCL5	O
,	O
displayed	O
reduced	O
lung	O
damage	O
.	O

Moreover	O
,	O
treatment	O
with	O
a	O
CCR5	B-CHED
antagonist	I-CHED
,	O
maraviroc	B-CHED
,	O
was	O
protective	O
against	O
C5a	O
-	O
ALI	O
.	O

Among	O
the	O
9	O
phages	O
selected	O
that	O
specifically	O
bound	O
to	O
rS	O
-	O
AD	O
,	O
the	O
phage	O
bearing	O
the	O
peptide	B-CHED
TLNMHLFPFHTG	O
bound	O
with	O
the	O
highest	O
affinity	O
and	O
was	O
subsequently	O
used	O
to	O
develop	O
a	O
phage	O
-	O
based	O
ELISA	O
for	O
TGEV	O
.	O

TITLE	O
:	O
Protective	O
Efficacy	O
of	O
Recombinant	O
Modified	O
Vaccinia	O
Virus	O
Ankara	O
Delivering	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Spike	O
Glycoprotein	B-CHED
.	O

In	O
all	O
cases	O
,	O
MVA	B-CHED
-	O
MERS	O
-	O
S	O
induced	O
MERS	O
-	O
CoV	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	O
and	O
virus	O
-	O
neutralizing	O
antibodies	O
.	O

TITLE	O
:	O
Development	O
and	O
Evaluation	O
of	O
Novel	O
Real	O
-	O
Time	O
Reverse	O
Transcription	O
-	O
PCR	O
Assays	O
with	O
Locked	B-CHED
Nucleic	I-CHED
Acid	I-CHED
Probes	O
Targeting	O
Leader	O
Sequences	O
of	O
Human	O
-	O
Pathogenic	O
Coronaviruses	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
findings	O
in	O
small	O
RNA	O
-	O
sequencing	O
(	O
Seq	O
)	O
data	O
analysis	O
,	O
we	O
developed	O
highly	O
sensitive	O
and	O
specific	O
real	O
-	O
time	O
reverse	O
transcription	O
(	O
RT	O
)-	O
PCR	O
assays	O
with	O
locked	B-CHED
nucleic	I-CHED
acid	I-CHED
probes	O
targeting	O
the	O
abundantly	O
expressed	O
leader	O
sequences	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
other	O
human	O
coronaviruses	O
.	O

The	O
whole	O
genome	O
sequences	O
of	O
these	O
isolates	O
are	O
28	O
,	O
035	O
nucleotides	B-CHED
in	O
length	O
and	O
have	O
characteristics	O
similar	O
to	O
those	O
of	O
other	O
PEDV	O
isolates	O
.	O

Moreover	O
,	O
after	O
carrying	O
a	O
propensity	O
score	O
-	O
matching	O
in	O
the	O
severe	O
ARDS	O
cohort	O
,	O
Kaplan	O
-	O
Meier	O
survival	O
analysis	O
confirmed	O
the	O
improved	O
28	O
-	O
day	O
survival	O
among	O
patients	O
with	O
statin	B-CHED
therapy	O
(	O
P	O
=	O
0	O
.	O
0205	O
).	O

We	O
found	O
that	O
recombinant	O
human	O
HGF	O
(	O
rhHGF	O
)	O
and	O
rhTGF	O
-	O
	O
stimulated	O
primary	O
human	O
AECs	O
to	O
secrete	O
IL	O
-	O
8	O
and	O
granulocyte	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
strongly	O
and	O
IL	O
-	O
6	O
and	O
monocyte	O
chemotactic	O
protein	B-CHED
1	O
moderately	O
.	O

Influenza	O
infection	O
stimulated	O
the	O
secretion	O
of	O
IL	O
-	O
8	O
and	O
GM	O
-	O
CSF	O
by	O
AECs	O
plated	O
on	O
rat	O
-	O
tail	O
collagen	O
through	O
EGFR	O
activation	O
likely	O
by	O
TGF	O
-	O
	O
released	O
from	O
AECs	O
and	O
through	O
c	O
-	O
Met	B-CHED
activated	O
by	O
HGF	O
secreted	O
from	O
lung	O
fibroblasts	O
.	O

HGF	O
secretion	O
by	O
fibroblasts	O
was	O
stimulated	O
by	O
AEC	O
production	O
of	O
prostaglandin	B-CHED
E2	I-CHED
during	O
influenza	O
infection	O
.	O

Using	O
positive	O
end	O
-	O
expiratory	O
pressure	O
levels	O
greater	O
than	O
15	O
cm	O
H2O	B-CHED
in	O
severe	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
under	O
the	O
condition	O
that	O
the	O
markers	O
of	O
oxygen	B-CHED
delivery	O
,	O
respiratory	O
system	O
compliance	O
,	O
and	O
hemodynamics	O
are	O
closely	O
monitored	O
as	O
positive	O
end	O
-	O
expiratory	O
pressure	O
is	O
increased	O
,	O
is	O
strongly	O
recommended	O
.	O

Taken	O
together	O
,	O
TMAs	O
provide	O
a	O
novel	O
platform	O
in	O
the	O
field	O
of	O
infectious	O
diseases	O
to	O
allow	O
identification	O
of	O
binding	O
specificities	O
of	O
viral	O
attachment	O
proteins	B-CHED
and	O
are	O
helpful	O
to	O
gain	O
insight	O
into	O
the	O
susceptibility	O
of	O
host	O
and	O
organ	O
for	O
avian	O
pathogens	O
.	O

Once	O
the	O
withdrawal	O
syndrome	O
was	O
controlled	O
,	O
the	O
clonidine	B-CHED
was	O
abruptly	O
stopped	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
the	O
spike	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
a	O
key	O
target	O
for	O
the	O
development	O
of	O
SARS	O
vaccines	O
.	O

Protein	B-CHED
kinases	O
are	O
key	O
regulators	O
in	O
signal	O
transduction	O
,	O
controlling	O
a	O
wide	O
variety	O
of	O
cellular	O
processes	O
,	O
and	O
many	O
of	O
them	O
are	O
targets	O
of	O
approved	O
drugs	O
and	O
other	O
compounds	O
.	O

The	O
identified	O
factors	O
could	O
be	O
interesting	O
targets	O
for	O
the	O
development	O
of	O
host	O
-	O
directed	O
antiviral	B-CHED
therapy	O
to	O
treat	O
infections	O
with	O
SARS	O
-	O
CoV	O
or	O
other	O
pathogenic	O
coronaviruses	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
2	O
'-	O
O	O
-	O
MTase	O
activity	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nonstructural	O
protein	B-CHED
16	O
(	O
nsp16	O
)	O
needs	O
to	O
be	O
activated	O
by	O
nsp10	O
,	O
whereas	O
nsp16	O
of	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
alone	O
possesses	O
2	O
'-	O
O	O
-	O
MTase	O
activity	O
(	O
E	O
.	O
Decroly	O
et	O
al	O
.,	O
J	O
Virol	O
82	O
:	O
8071	O
-	O
8084	O
,	O
2008	O
,	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1128	O
/	O
JVI	O
.	O
00407	O
-	O
08	O
;	O
M	O
.	O
Bouvet	O
et	O
al	O
.,	O
PLoS	O
Pathog	O
6	O
:	O
e1000863	O
,	O
2010	O
,	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1371	O
/	O
journal	O
.	O
ppat	O
.	O
1000863	O
;	O
E	O
.	O
Decroly	O
et	O
al	O
.,	O
PLoS	O
Pathog	O
7	O
:	O
e1002059	O
,	O
2011	O
,	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1371	O
/	O
journal	O
.	O
ppat	O
.	O
1002059	O
;	O
Y	O
.	O
Chen	O
et	O
al	O
.,	O
PLoS	O
Pathog	O
7	O
:	O
e1002294	O
,	O
2011	O
,	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1371	O
/	O
journal	O
.	O
ppat	O
.	O
1002294	O
)	O
.	O

This	O
work	O
makes	O
it	O
possible	O
to	O
develop	O
broad	O
-	O
spectrum	O
peptide	B-CHED
inhibitors	B-CHED
by	O
targeting	O
the	O
nsp16	O
/	O
nsp10	O
2	O
'-	O
O	O
-	O
MTase	O
of	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
The	O
3	O
'-	O
terminal	O
domain	O
of	O
the	O
most	O
conserved	O
ORF1b	O
in	O
three	O
of	O
the	O
four	O
families	O
of	O
the	O
order	O
Nidovirales	O
(	O
except	O
for	O
the	O
family	O
Arteriviridae	O
)	O
encodes	O
a	O
(	O
putative	O
)	O
2	O
'-	O
O	O
-	O
methyltransferase	O
(	O
2	O
'-	O
O	O
-	O
MTase	O
),	O
known	O
as	O
non	O
structural	O
protein	B-CHED
(	O
nsp	O
)	O
16	O
in	O
the	O
family	O
Coronaviridae	O
and	O
implicated	O
in	O
methylation	O
of	O
the	O
5	O
'	O
cap	O
structure	O
of	O
nidoviral	O
mRNAs	O
.	O

ABSTRACT	O
:	O
Trimodality	O
therapy	O
for	O
resectable	O
esophageal	O
and	O
gastroesophageal	O
junction	O
cancers	O
utilizing	O
preoperative	O
radiotherapy	O
with	O
concurrent	O
carboplatin	B-CHED
and	O
paclitaxel	B-CHED
-	O
based	O
chemotherapy	O
is	O
being	O
increasingly	O
utilized	O
secondary	O
to	O
the	O
results	O
of	O
the	O
phase	O
III	O
CROSS	O
trial	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
doubly	O
flexible	O
nucleoside	B-CHED
analogues	I-CHED
were	O
designed	O
based	O
on	O
the	O
acyclic	O
sugar	O
scaffold	O
of	O
acyclovir	B-CHED
and	O
the	O
flex	O
-	O
base	O
moiety	O
found	O
in	O
the	O
fleximers	O
.	O

Significantly	O
,	O
compound	O
2	O
displayed	O
selective	O
antiviral	B-CHED
activity	O
(	O
CC50	O
>	O
3	O
	O
EC50	O
)	O
towards	O
human	O
coronavirus	O
(	O
HCoV	O
)-	O
NL63	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
-	O
coronavirus	O
,	O
but	O
not	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
.	O

The	O
present	O
review	O
will	O
be	O
focused	O
on	O
recent	O
structural	O
and	O
protein	B-CHED
-	O
protein	B-CHED
interaction	O
information	O
involving	O
two	O
viroporins	O
found	O
in	O
enveloped	O
viruses	O
that	O
target	O
the	O
respiratory	O
tract	O
;	O
(	O
i	O
)	O
the	O
envelope	O
protein	B-CHED
in	O
coronaviruses	O
and	O
(	O
ii	O
)	O
the	O
small	O
hydrophobic	O
protein	B-CHED
in	O
paramyxoviruses	O
.	O

Analytical	O
ultracentrifugation	O
studies	O
support	O
that	O
MERS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
is	O
a	O
weakly	O
associated	O
dimer	O
(	O
Kd	O
	O
52	O
m	O
)	O
with	O
a	O
slow	O
off	O
-	O
rate	O
.	O

Recently	O
,	O
a	O
number	O
of	O
small	O
novel	O
porcine	O
DNA	O
viruses	O
have	O
emerged	O
globally	O
,	O
for	O
example	O
,	O
torque	B-CHED
teno	O
sus	O
virus	O
,	O
porcine	O
bocavirus	O
,	O
and	O
parvoviruses	O
2	O
&	O
4	O
,	O
and	O
little	O
is	O
known	O
about	O
the	O
biology	O
and	O
potential	O
pathogenicity	O
of	O
these	O
viruses	O
.	O

We	O
have	O
now	O
designed	O
a	O
peptide	B-CHED
that	O
directly	O
and	O
specifically	O
activates	O
MK2	O
,	O
causing	O
HSP27	O
phosphorylation	O
in	O
cells	O
and	O
in	O
vivo	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
human	O
MSC	O
MVs	O
on	O
lung	O
inflammation	O
,	O
protein	B-CHED
permeability	O
,	O
bacterial	O
clearance	O
,	O
and	O
survival	O
after	O
severe	O
bacterial	O
pneumonia	O
.	O

ET	O
-	O
1	O
also	O
stimulated	O
phosphorylation	O
of	O
Src	O
,	O
EGFR	O
,	O
PDGFR	O
,	O
AKT	O
,	O
p42	O
/	O
p44	O
MAPK	O
,	O
and	O
Elk	O
-	O
1	O
and	O
acetylation	O
of	O
histone	B-CHED
H4	O
on	O
HTSMCs	O
.	O

Five	O
classes	O
of	O
disinfectants	B-CHED
(	O
phenol	B-CHED
,	O
quaternary	B-CHED
ammonium	I-CHED
compound	I-CHED
,	O
sodium	O
hypochlorite	B-CHED
,	O
oxidizing	B-CHED
agent	I-CHED
,	O
and	O
quaternary	O
ammonium	B-CHED
/	O
glutaraldehyde	B-CHED
combination	O
)	O
were	O
evaluated	O
in	O
vitro	O
at	O
varying	O
concentrations	O
,	O
both	O
in	O
the	O
presence	O
and	O
absence	O
of	O
swine	O
feces	O
,	O
and	O
at	O
three	O
different	O
temperatures	O
.	O

Six	O
tagging	O
single	O
-	O
nucleotide	B-CHED
polymorphisms	O
(	O
SNPs	O
)	O
of	O
NFE2L2	O
were	O
genotyped	O
,	O
and	O
,	O
after	O
further	O
imputation	O
of	O
additional	O
34	O
SNPs	O
,	O
association	O
testing	O
with	O
ARDS	O
susceptibility	O
was	O
conducted	O
using	O
logistic	O
regression	O
analysis	O
.	O

Compared	O
with	O
GPS	O
tracer	B-CHED
tag	O
recordings	O
,	O
self	O
-	O
reported	O
contact	O
may	O
not	O
be	O
as	O
accurate	O
.	O

We	O
identified	O
a	O
novel	O
VSR	O
from	O
coronaviruses	O
,	O
a	O
group	O
of	O
medically	O
important	O
mammalian	O
viruses	O
including	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
and	O
showed	O
that	O
the	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
protein	B-CHED
)	O
of	O
coronaviruses	O
suppresses	O
RNAi	O
triggered	O
by	O
either	O
short	O
hairpin	O
RNAs	O
or	O
small	O
interfering	O
RNAs	O
in	O
mammalian	O
cells	O
.	O

IMPORTANCE	O
RNAi	O
has	O
been	O
well	O
known	O
to	O
play	O
important	O
antiviral	B-CHED
roles	O
from	O
plants	O
to	O
invertebrates	O
.	O

Mild	O
to	O
moderate	O
,	O
but	O
not	O
minimal	O
or	O
severe	O
,	O
acute	O
-	O
HCA	O
(	O
minimal	O
,	O
24	O
%;	O
mild	O
,	O
13	O
%;	O
moderate	O
,	O
19	O
%;	O
severe	O
,	O
41	O
%;	O
preterm	O
-	O
reference	O
group	O
,	O
26	O
%)	O
or	O
IAI	O
(	O
minimal	O
,	O
24	O
%;	O
mild	O
,	O
11	O
%;	O
moderate	O
,	O
17	O
%;	O
severe	O
,	O
25	O
%;	O
preterm	O
reference	O
group	O
,	O
23	O
%)	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
RDS	O
as	O
compared	O
with	O
the	O
preterm	O
reference	O
group	O
(	O
each	O
for	O
p	O
<	O
0	O
.	O
05	O
after	O
the	O
adjustment	O
of	O
gestational	O
age	O
at	O
delivery	O
,	O
antenatal	O
corticosteroid	B-CHED
use	O
,	O
newborn	O
gender	O
,	O
cesarean	O
delivery	O
and	O
preterm	O
-	O
PROM	O
as	O
a	O
cause	O
of	O
preterm	O
birth	O
).	O

Treatments	O
with	O
both	O
PDGF	O
and	O
TGF1	O
antagonists	B-CHED
may	O
result	O
in	O
a	O
better	O
anti	O
-	O
fibrotic	O
outcome	O
for	O
ALI	O
-	O
induced	O
lung	O
fibrosis	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
infection	O
(	O
ARI	B-CHED
)	O
is	O
a	O
leading	O
cause	O
of	O
morbidity	O
and	O
hospitalization	O
in	O
children	O
.	O

An	O
analysis	O
of	O
nucleotide	B-CHED
sequences	O
revealed	O
that	O
they	O
represented	O
distinctive	O
genetic	O
sequences	O
and	O
greatly	O
varied	O
in	O
complementarity	O
-	O
determining	O
region	O
three	O
of	O
the	O
heavy	O
chain	O
.	O

Likewise	O
,	O
measures	O
of	O
soluble	O
inflammatory	O
markers	O
including	O
interleukin	O
-	O
6	O
,	O
C	O
-	O
reactive	O
peptide	B-CHED
,	O
interleukin	O
-	O
8	O
,	O
and	O
soluble	O
tumor	O
necrosis	O
factor	O
receptor	O
1	O
were	O
most	O
different	O
between	O
this	O
dosing	O
arm	O
and	O
placebo	O
.	O

The	O
novel	O
p38	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinase	I-CHED
inhibitor	I-CHED
dilmapimod	O
appears	O
well	O
tolerated	O
and	O
may	O
merit	O
further	O
evaluation	O
for	O
prevention	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
other	O
organ	O
injury	O
in	O
larger	O
clinical	O
trials	O
.	O

The	O
objective	O
of	O
our	O
study	O
was	O
to	O
describe	O
lung	O
changes	O
on	O
serial	O
chest	O
radiographs	O
from	O
patients	O
infected	O
with	O
the	O
acute	O
Middle	O
East	O
respiratory	O
syndrome	O
corona	B-CHED
-	O
virus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
to	O
compare	O
the	O
chest	O
radiographic	O
findings	O
and	O
final	O
outcomes	O
with	O
those	O
of	O
health	O
care	O
workers	O
(	O
HCWs	O
)	O
infected	O
with	O
the	O
same	O
virus	O
.	O

Like	O
other	O
coronaviruses	O
,	O
PDCoV	O
commonly	O
contains	O
4	O
major	O
structural	O
proteins	B-CHED
:	O
spike	O
(	O
S	O
),	O
envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
),	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	B-CHED
.	O

We	O
used	O
a	O
standardised	O
nucleic	B-CHED
acids	I-CHED
extraction	O
protocol	O
and	O
a	O
comprehensive	O
comparative	O
approach	O
that	O
mixed	O
reference	O
to	O
well	O
established	O
real	O
-	O
time	O
PCR	O
detection	O
techniques	O
and	O
analysis	O
of	O
convergent	O
positive	O
results	O
.	O

Reovirus	O
binds	O
to	O
cell	O
surface	O
glycans	B-CHED
,	O
junctional	O
adhesion	O
molecule	O
A	O
(	O
JAM	O
-	O
A	O
),	O
and	O
the	O
Nogo	O
-	O
1	O
receptor	O
(	O
depending	O
on	O
the	O
cell	O
type	O
)	O
and	O
enters	O
cells	O
by	O
receptor	O
-	O
mediated	O
endocytosis	O
.	O

The	O
antiviral	B-CHED
properties	O
of	O
5	O
-	O
NT	O
suggest	O
that	O
serotonin	B-CHED
receptor	O
signaling	O
is	O
an	O
important	O
regulator	O
of	O
infection	O
by	O
diverse	O
virus	O
families	O
and	O
illuminate	O
a	O
potential	O
new	O
drug	O
target	O
.	O

The	O
purified	O
protein	B-CHED
was	O
analyzed	O
by	O
Western	O
blotting	O
,	O
mixed	O
with	O
oil	O
adjuvant	B-CHED
,	O
and	O
administered	O
to	O
29	O
-	O
day	O
-	O
old	O
specific	O
-	O
pathogen	O
-	O
free	O
chickens	O
.	O

Clinical	O
disease	O
was	O
severe	O
and	O
developed	O
rapidly	O
following	O
infection	O
with	O
an	O
original	O
North	O
American	O
PEDV	O
isolate	O
,	O
with	O
lesions	O
,	O
viremia	O
,	O
and	O
antigen	B-CHED
detection	O
possible	O
by	O
12	O
hpi	O
.	O

To	O
investigate	O
the	O
dynamic	O
changes	O
in	O
IBV	O
load	O
in	O
the	O
supernatant	O
of	O
primary	O
CEK	O
cells	O
,	O
we	O
developed	O
an	O
SYBR	B-CHED
Green	I-CHED
I	I-CHED
-	O
based	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
assay	O
to	O
quantify	O
nucleic	O
copy	O
numbers	O
of	O
the	O
IBV	O
-	O
Sczy3	O
strain	O
.	O

After	O
NPPV	O
treatment	O
,	O
systolic	O
pressure	O
,	O
heart	O
rate	O
,	O
respiratory	O
rate	O
,	O
and	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
decreased	O
,	O
whereas	O
oxygen	B-CHED
saturation	O
increased	O
significantly	O
in	O
the	O
NPPV	O
success	O
group	O
compared	O
with	O
the	O
failed	O
group	O
.	O

The	O
small	O
CoV	O
envelope	O
(	O
E	O
)	O
protein	B-CHED
plays	O
roles	O
in	O
assembly	O
,	O
virion	O
release	O
,	O
and	O
pathogenesis	O
.	O

The	O
E	O
protein	B-CHED
from	O
the	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
has	O
dramatic	O
effects	O
on	O
the	O
secretory	O
system	O
which	O
require	O
residues	O
in	O
the	O
HD	O
.	O

However	O
,	O
no	O
approved	O
vaccines	O
or	O
antiviral	B-CHED
therapeutics	O
exist	O
.	O

CNS	B-CHED
infection	O
by	O
neurotropic	O
coronavirus	O
with	O
replication	O
confined	O
to	O
the	O
brain	O
and	O
spinal	O
cord	O
induces	O
protective	O
IFN	O
-	O
	O
/	O
	O
via	O
Myd88	O
-	O
independent	O
activation	O
of	O
melanoma	O
differentiation	O
-	O
associated	O
gene	O
5	O
(	O
MDA5	O
).	O

AUC	O
of	O
Lac	B-CHED
was	O
0	O
.	O
793	O
,	O
the	O
cut	O
-	O
off	O
value	O
was	O
4	O
.	O
2	O
mmol	O
/	O
L	O
,	O
when	O
Lac	O
	O
4	O
.	O
2	O
mmol	O
/	O
L	O
,	O
the	O
sensitivity	O
was	O
72	O
.	O
1	O
%,	O
and	O
specificity	O
was	O
81	O
.	O
9	O
%.	O

According	O
to	O
the	O
new	O
Berlin	O
standard	O
of	O
definition	O
,	O
73	O
patients	O
with	O
moderate	O
or	O
severe	O
ARDS	O
due	O
to	O
pulmonary	O
factors	O
,	O
age	O
from	O
18	O
to	O
65	O
years	O
,	O
admitted	O
to	O
Department	O
of	O
Critical	O
Care	O
Medicine	B-CHED
of	O
Taian	O
Central	O
Hospital	O
and	O
Handan	O
Central	O
Hospital	O
were	O
enrolled	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
coronavirus	O
(	O
Co	O
-	O
V	O
)	O
contains	O
a	O
single	O
spike	O
(	O
S	O
)	O
protein	B-CHED
,	O
which	O
binds	O
to	O
a	O
receptor	O
molecule	O
,	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
;	O
also	O
known	O
as	O
CD26	O
),	O
and	O
serves	O
as	O
a	O
neutralizing	O
antigen	B-CHED
.	O

The	O
possibility	O
of	O
NPE	O
should	O
be	O
considered	O
in	O
relatively	O
young	O
patients	O
with	O
higher	O
glucose	B-CHED
and	O
lower	O
blood	O
pH	O
value	O
.	O

The	O
X	O
domain	O
was	O
proposed	O
to	O
be	O
an	O
ADP	B-CHED
-	O
ribose	B-CHED
-	O
1	O
"""-"	O
phosphatase	O
or	O
a	O
poly	O
(	O
ADP	B-CHED
-	O
ribose	B-CHED
)-	O
binding	O
protein	B-CHED
,	O
whereas	O
SUD	O
-	O
NM	O
binds	O
oligo	O
(	O
G	O
)-	O
nucleotides	B-CHED
capable	O
of	O
forming	O
G	O
-	O
quadruplexes	O
.	O

ABSTRACT	O
:	O
To	O
gain	O
entry	O
into	O
the	O
target	O
cell	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
uses	O
its	O
spike	O
(	O
S	O
)	O
protein	B-CHED
S2	O
subunit	O
to	O
fuse	O
with	O
the	O
plasma	O
or	O
endosomal	O
membrane	O
.	O

Moreover	O
,	O
HAdV	O
-	O
B14p1	O
induced	O
proinflammatory	O
chemokines	O
IP	O
-	O
10	O
and	O
I	O
-	O
Tac	B-CHED
as	O
potential	O
virulence	O
factors	O
.	O

Ulinastatin	O
plus	O
octreotide	B-CHED
can	O
significantly	O
improve	O
the	O
serum	O
and	O
clinical	O
parameters	O
and	O
reduce	O
the	O
incidence	O
of	O
complications	O
in	O
SAP	O
patients	O
.	O

However	O
,	O
with	O
early	O
diagnosis	O
and	O
antifungal	B-CHED
therapy	O
with	O
lipid	B-CHED
formulation	O
-	O
liposomal	B-CHED
amphotericin	I-CHED
B	I-CHED
and	O
surgical	O
removal	O
of	O
the	O
infected	O
area	O
,	O
the	O
outcome	O
can	O
be	O
improved	O
.	O

Stress	O
-	O
index	O
PEEP	B-CHED
was	O
the	O
level	O
at	O
which	O
the	O
airway	O
pressure	O
stress	O
index	O
was	O
1	O
,	O
and	O
open	O
-	O
lung	O
PEEP	B-CHED
was	O
the	O
level	O
at	O
which	O
it	O
was	O
required	O
to	O
keep	O
the	O
lung	O
open	O
according	O
to	O
computed	O
tomography	O
(	O
CT	O
)	O
scans	O
.	O

Mycoplasma	O
cynos	O
(	O
29	O
.	O
2	O
%),	O
B	O
.	O
bronchiseptica	O
(	O
19	O
.	O
5	O
%),	O
CAV	O
-	O
2	O
(	O
12	O
.	O
5	O
%),	O
CDV	B-CHED
(	O
7	O
.	O
4	O
%)	O
and	O
CPIV	O
(	O
3	O
.	O
2	O
%)	O
were	O
the	O
most	O
commonly	O
detected	O
pathogens	O
.	O

Brain	O
invasion	O
was	O
observed	O
only	O
in	O
MHV3	O
-	O
infected	O
mice	O
and	O
correlated	O
with	O
enhanced	O
BBB	B-CHED
permeability	O
associated	O
with	O
decreased	O
expression	O
of	O
zona	O
occludens	O
protein	B-CHED
1	O
(	O
ZO	O
-	O
1	O
),	O
VE	O
-	O
cadherin	O
,	O
and	O
occludin	O
,	O
but	O
not	O
claudin	O
-	O
5	O
,	O
in	O
the	O
brain	O
or	O
in	O
cultured	O
BMECs	O
.	O

The	O
NH	O
-	O
group	O
of	O
the	O
lactam	B-CHED
moiety	O
was	O
clearly	O
required	O
for	O
anti	O
-	O
HCV	O
activity	O
.	O

In	O
addition	O
,	O
the	O
S	O
protein	B-CHED
needs	O
to	O
be	O
cleaved	O
by	O
host	O
proteases	O
before	O
executing	O
fusion	O
,	O
making	O
these	O
proteases	O
a	O
second	O
determinant	O
of	O
coronavirus	O
interspecies	O
infection	O
.	O

Here	O
,	O
we	O
summarize	O
the	O
progress	O
made	O
in	O
the	O
past	O
decade	O
in	O
understanding	O
the	O
cross	O
-	O
species	O
transmission	O
of	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
by	O
focusing	O
on	O
the	O
features	O
of	O
the	O
S	O
protein	B-CHED
,	O
its	O
receptor	O
-	O
binding	O
characteristics	O
,	O
and	O
the	O
cleavage	O
process	O
involved	O
in	O
priming	O
.	O

How	O
CD81	O
governs	O
HCV	O
entry	O
is	O
poorly	O
characterized	O
,	O
and	O
CD81	O
protein	B-CHED
interactions	O
after	O
virus	O
binding	O
remain	O
elusive	O
.	O

ABSTRACT	O
:	O
Alogliptin	O
,	O
a	O
dipeptidyl	O
peptidase	O
-	O
4	O
(	O
DPP	B-CHED
-	O
4	O
)	O
inhibitor	B-CHED
that	O
is	O
a	O
class	O
of	O
relatively	O
new	O
oral	O
hypoglycaemic	O
drugs	O
used	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
(	O
T2DM	O
),	O
can	O
be	O
used	O
as	O
monotherapy	O
or	O
in	O
combination	O
with	O
other	O
anti	O
-	O
diabetic	O
agents	O
,	O
including	O
metformin	B-CHED
,	O
pioglitazone	B-CHED
,	O
sulfonylureas	O
and	O
insulin	B-CHED
with	O
a	O
considerable	O
therapeutic	O
effect	O
.	O

Translated	O
amino	B-CHED
acid	I-CHED
alterations	O
were	O
minimal	O
but	O
still	O
may	O
have	O
played	O
an	O
important	O
role	O
in	O
the	O
persistence	O
of	O
this	O
virus	O
despite	O
the	O
use	O
of	O
live	O
793B	O
vaccines	O
.	O

In	O
most	O
cases	O
,	O
outcomes	O
were	O
favorable	O
and	O
symptoms	O
rapidly	O
resolved	O
upon	O
discontinuation	O
of	O
minocycline	B-CHED
,	O
with	O
11	O
cases	O
employing	O
steroids	B-CHED
,	O
one	O
case	O
twelve	O
hours	O
of	O
CPAP	O
and	O
another	O
5	O
days	O
of	O
intubation	O
.	O

Amino	B-CHED
acid	I-CHED
sequence	O
comparison	O
and	O
phylogenetic	O
analysis	O
indicated	O
the	O
emergence	O
of	O
a	O
new	O
Moroccan	O
genotype	O
,	O
clustering	O
with	O
regionally	O
related	O
isolates	O
from	O
Spain	O
(	O
Spain	O
/	O
05	O
/	O
866	O
)	O
and	O
belonging	O
to	O
a	O
new	O
sub	O
-	O
genotype	O
.	O

ABSTRACT	O
:	O
The	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
nucleocapsid	O
protein	B-CHED
from	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
NP	O
-	O
NTD	O
)	O
contains	O
many	O
positively	O
charged	O
residues	O
and	O
has	O
been	O
identified	O
to	O
be	O
responsible	O
for	O
RNA	O
binding	O
during	O
ribonucleocapsid	O
formation	O
by	O
the	O
virus	O
.	O

TITLE	O
:	O
Development	O
of	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
the	O
monitoring	O
and	O
surveillance	O
of	O
antibodies	O
to	O
porcine	O
epidemic	O
diarrhea	O
virus	O
based	O
on	O
a	O
recombinant	O
membrane	O
protein	B-CHED
.	O

It	O
was	O
changed	O
to	O
a	O
low	O
flow	O
oxygen	B-CHED
inhalation	O
nasal	O
cannula	O
on	O
the	O
20th	O
day	O
,	O
and	O
oxygen	B-CHED
treatment	O
was	O
stopped	O
on	O
the	O
24th	O
day	O
.	O

At	O
the	O
same	O
time	O
symptomatic	O
treatment	O
such	O
as	O
methimazole	B-CHED
and	O
liver	O
protection	O
therapy	O
were	O
given	O
.	O

TITLE	O
:	O
Corticosteroid	B-CHED
Therapy	O
for	O
Patients	O
Hospitalized	O
With	O
Community	O
-	O
Acquired	O
Pneumonia	O
:	O
A	O
Systematic	O
Review	O
and	O
Meta	O
-	O
analysis	O
.	O

Adjunctive	O
corticosteroids	B-CHED
were	O
associated	O
with	O
possible	O
reductions	O
in	O
all	O
-	O
cause	O
mortality	O
(	O
12	O
trials	O
;	O
1974	O
patients	O
;	O
risk	O
ratio	O
[	O
RR	O
],	O
0	O
.	O
67	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
45	O
to	O
1	O
.	O
01	O
];	O
risk	O
difference	O
[	O
RD	O
],	O
2	O
.	O
8	O
%;	O
moderate	O
certainty	O
),	O
need	O
for	O
mechanical	O
ventilation	O
(	O
5	O
trials	O
;	O
1060	O
patients	O
;	O
RR	O
,	O
0	O
.	O
45	O
[	O
CI	O
,	O
0	O
.	O
26	O
to	O
0	O
.	O
79	O
];	O
RD	O
,	O
5	O
.	O
0	O
%;	O
moderate	O
certainty	O
),	O
and	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
4	O
trials	O
;	O
945	O
patients	O
;	O
RR	O
,	O
0	O
.	O
24	O
[	O
CI	O
,	O
0	O
.	O
10	O
to	O
0	O
.	O
56	O
];	O
RD	O
,	O
6	O
.	O
2	O
%;	O
moderate	O
certainty	O
).	O

Malarial	O
retinopathy	O
includes	O
retinal	B-CHED
whitening	O
,	O
vessel	O
changes	O
,	O
retinal	B-CHED
hemorrhages	O
and	O
papilledema	O
.	O

Cyclophosphamide	B-CHED
induction	O
therapy	O
was	O
effective	O
in	O
4	O
/	O
6	O
patients	O
with	O
BS	O
(	O
s	O
)	O
and	O
in	O
1	O
patient	O
with	O
SGS	O
among	O
the	O
7	O
treated	O
.	O

At	O
each	O
step	O
,	O
V	O
T	O
was	O
adjusted	O
to	O
allow	O
partial	O
pressure	O
of	O
arterial	O
carbon	B-CHED
dioxide	I-CHED
(	O
PaCO2	O
)	O
to	O
stabilize	O
between	O
57	O
and	O
63	O
mmHg	O
.	O

Although	O
two	O
SARS	O
-	O
related	O
Rhinolophus	O
sinicus	O
bat	O
CoVs	O
(	O
SARSr	O
-	O
Rs	O
-	O
BatCoVs	O
)	O
previously	O
detected	O
in	O
Chinese	O
horseshoe	O
bats	O
(	O
Rhinolophus	O
sinicus	O
)	O
in	O
Yunnan	O
,	O
RsSHC014	O
and	O
Rs3367	O
,	O
possessed	O
95	O
%	O
genome	O
identities	O
to	O
human	O
and	O
civet	O
SARSr	O
-	O
CoVs	O
,	O
their	O
ORF8	O
protein	B-CHED
exhibited	O
only	O
32	O
.	O
2	O
to	O
33	O
%	O
amino	B-CHED
acid	I-CHED
identities	O
to	O
that	O
of	O
human	O
/	O
civet	O
SARSr	O
-	O
CoVs	O
.	O

The	O
expression	O
of	O
ORF8	O
subgenomic	O
mRNA	B-CHED
suggested	O
that	O
the	O
ORF8	O
protein	B-CHED
may	O
be	O
functional	O
in	O
SARSr	O
-	O
Rf	O
-	O
BatCoVs	O
.	O

RESULTS	O
:	O
A	O
multi	O
-	O
fragment	O
antigen	B-CHED
,	O
termed	O
BE	O
,	O
which	O
was	O
composed	O
of	O
eight	O
antigenic	O
fragments	O
selected	O
from	O
the	O
three	O
major	O
proteins	B-CHED
(	O
S	O
,	O
M	O
,	O
and	O
N	O
)	O
of	O
IBV	O
,	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
viral	O
genome	O
sequence	O
has	O
high	O
similarity	O
to	O
53	O
human	O
MERS	O
-	O
CoVs	O
,	O
ranging	O
from	O
99	O
.	O
5	O
%	O
to	O
99	O
.	O
8	O
%	O
at	O
the	O
nucleotide	B-CHED
level	O
.	O

ABSTRACT	O
:	O
Light	O
fullerenes	B-CHED
attract	O
significant	O
interest	O
in	O
pharmacy	O
and	O
medicine	B-CHED
as	O
drug	O
vectors	O
and	O
antioxidants	B-CHED
and	O
to	O
block	O
AIDS	O
virus	O
enzyme	O
.	O

The	O
introduced	O
system	O
is	O
based	O
on	O
1	B-CHED
-	I-CHED
butyl	I-CHED
-	I-CHED
3	I-CHED
-	I-CHED
methylimidazolium	I-CHED
tetrafluoroborate	B-CHED
,	O
[	O
C4C1IM	O
][	O
BF4	B-CHED
]-	O
water	B-CHED
mixtures	O
.	O

Structural	O
and	O
dynamical	O
peculiarities	O
of	O
the	O
C60	B-CHED
-[	O
C4C1IM	O
][	O
BF4	B-CHED
]-	O
water	B-CHED
mixtures	O
are	O
discussed	O
.	O

Disulfide	B-CHED
cross	O
-	O
linking	O
and	O
X	O
-	O
ray	O
reflectivity	O
depth	O
profiling	O
provide	O
independent	O
support	O
of	O
the	O
results	O
.	O

Tremendous	O
and	O
successful	O
efforts	O
have	O
been	O
conducted	O
to	O
discover	O
the	O
genome	O
structure	O
,	O
epidemiology	O
,	O
clinical	O
signs	O
,	O
pathogenesis	O
,	O
diagnosis	O
and	O
antiviral	B-CHED
therapy	O
.	O

The	O
next	O
generation	O
of	O
flexible	O
nucleosides	B-CHED
shifted	O
the	O
focus	O
from	O
the	O
sugar	O
moiety	O
to	O
the	O
nucleobase	B-CHED
.	O

PEDV	O
not	O
only	O
failed	O
to	O
induce	O
IFN	O
-	O
	O
expression	O
,	O
but	O
also	O
inhibited	O
dsRNA	B-CHED
-	O
mediated	O
IFN	O
-	O
	O
production	O
in	O
IECs	O
.	O

ED	O
patients	O
with	O
opioid	O
-	O
induced	O
ventilatory	O
depression	O
requiring	O
naloxone	B-CHED
administration	O
were	O
identified	O
through	O
medical	O
toxicology	O
consultation	O
.	O

The	O
median	O
naloxone	B-CHED
dose	O
of	O
0	O
.	O
08	O
mg	O
(	O
range	O
,	O
0	O
.	O
04	O
to	O
0	O
.	O
12	O
mg	O
)	O
reversed	O
opioid	O
-	O
induced	O
ventilatory	O
and	O
CNS	B-CHED
depression	O
.	O

RESULTS	O
:	O
Fifteen	O
ED	O
patients	O
with	O
moderate	O
to	O
severe	O
opioid	O
-	O
induced	O
ventilatory	O
depression	O
(	O
median	O
RR	O
,	O
6	O
breaths	O
/	O
min	O
)	O
who	O
were	O
managed	O
using	O
low	O
-	O
dose	O
naloxone	B-CHED
strategy	O
were	O
identified	O
.	O

TITLE	O
:	O
Putative	O
phage	O
-	O
display	O
epitopes	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
S1	O
protein	B-CHED
and	O
their	O
anti	O
-	O
viral	O
activity	O
.	O

Furthermore	O
,	O
data	O
from	O
real	O
-	O
time	O
PCR	O
and	O
indirect	O
immunofluorescence	O
assays	O
were	O
consistent	O
with	O
the	O
ability	O
of	O
peptides	B-CHED
M	O
,	O
L	O
and	O
W	O
to	O
block	O
viral	O
protein	B-CHED
expression	O
and	O
thereby	O
function	O
as	O
antiviral	B-CHED
agents	I-CHED
for	O
PEDV	O
.	O

Using	O
this	O
method	O
,	O
a	O
new	O
technique	O
to	O
simultaneously	O
detect	O
6	O
kinds	O
of	O
febrile	O
respiratory	O
viruses	O
in	O
a	O
protein	B-CHED
chip	O
was	O
developed	O
.	O

TITLE	O
:	O
Balloon	O
-	O
Occluded	O
Retrograde	O
Transvenous	O
Obliteration	O
for	O
the	O
Treatment	O
of	O
Gastric	O
Varices	O
:	O
Polidocanol	B-CHED
Foam	O
Versus	O
Liquid	O
Ethanolamine	B-CHED
Oleate	B-CHED
.	O

One	O
patient	O
died	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
after	O
treatment	O
with	O
ethanolamine	B-CHED
oleate	B-CHED
.	O

This	O
review	O
focuses	O
on	O
fundamental	O
aspects	O
of	O
immune	O
responses	O
against	O
IBV	O
,	O
including	O
the	O
role	O
of	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	O
)	O
in	O
identification	O
of	O
conserved	O
viral	O
structures	O
and	O
the	O
role	O
of	O
different	O
components	O
of	O
innate	O
immunity	O
(	O
e	O
.	O
g	O
.,	O
heterophils	O
,	O
macrophages	O
,	O
dendritic	O
cells	O
,	O
acute	O
phase	O
protein	B-CHED
,	O
and	O
cytokines	O
).	O

Furthermore	O
,	O
significant	O
downregulation	O
was	O
observed	O
as	O
early	O
as	O
10	O
min	O
after	O
trauma	O
for	O
cytokines	O
and	O
complement	O
factors	O
(	O
LCR	O
-	O
1	O
,	O
C4	O
)	O
as	O
well	O
as	O
for	O
intracellular	O
signaling	B-CHED
molecules	I-CHED
(	O
inhibitory	O
protein	B-CHED
phosphatase	O
)	O
and	O
ion	O
-	O
channels	O
(	O
voltage	B-CHED
-	O
dependent	O
Ca	O
(	O
2	O
+)	O
channel	O
).	O

Furthermore	O
,	O
significant	O
downregulation	O
was	O
observed	O
as	O
early	O
as	O
10	O
min	O
after	O
trauma	O
for	O
cytokines	O
and	O
complement	O
factors	O
(	O
LCR	O
-	O
1	O
,	O
C4	O
)	O
as	O
well	O
as	O
for	O
intracellular	O
signaling	B-CHED
molecules	I-CHED
(	O
inhibitory	O
protein	B-CHED
phosphatase	O
)	O
and	O
ion	O
-	O
channels	O
(	O
voltage	B-CHED
-	O
dependent	O
Ca	O
(	O
2	O
+)	O
channel	O
).	O

Potential	O
functions	O
supported	O
by	O
NiRAN	O
may	O
include	O
nucleic	B-CHED
acid	I-CHED
ligation	O
,	O
mRNA	B-CHED
capping	O
and	O
protein	B-CHED
-	O
primed	O
RNA	O
synthesis	O
,	O
possibilities	O
that	O
remain	O
to	O
be	O
explored	O
in	O
future	O
studies	O
.	O

High	O
positive	O
end	O
-	O
expiratory	O
pressure	O
levels	O
increased	O
brain	O
tissue	O
oxygen	B-CHED
pressure	O
and	O
oxygen	B-CHED
saturation	O
,	O
without	O
increase	O
in	O
intracranial	O
pressure	O
or	O
decrease	O
in	O
cerebral	O
perfusion	O
pressure	O
.	O

In	O
addition	O
,	O
our	O
screen	O
reveals	O
an	O
unexpected	O
role	O
for	O
valosin	O
-	O
containing	O
protein	B-CHED
(	O
VCP	O
/	O
p97	O
)	O
in	O
early	O
steps	O
of	O
infection	O
.	O

Interestingly	O
,	O
consistent	O
with	O
this	O
notion	O
,	O
MERS	O
-	O
CoV	O
nsp1	O
selectively	O
targeted	O
mRNAs	O
,	O
which	O
are	O
transcribed	O
in	O
the	O
nucleus	B-CHED
and	O
transported	O
to	O
the	O
cytoplasm	O
,	O
for	O
translation	O
inhibition	O
and	O
mRNA	B-CHED
degradation	O
but	O
spared	O
exogenous	O
mRNAs	O
introduced	O
directly	O
into	O
the	O
cytoplasm	O
or	O
virus	O
-	O
like	O
mRNAs	O
that	O
originate	O
in	O
the	O
cytoplasm	O
.	O

The	O
nonstructural	O
protein	B-CHED
1	O
(	O
nsp1	O
)	O
of	O
CoVs	O
is	O
one	O
such	O
protein	B-CHED
that	O
inhibits	O
host	O
gene	O
expression	O
and	O
is	O
a	O
major	O
virulence	O
factor	O
.	O

This	O
study	O
presents	O
evidence	O
for	O
a	O
strategy	O
used	O
by	O
MERS	O
-	O
CoV	O
nsp1	O
to	O
inhibit	O
host	O
gene	O
expression	O
that	O
has	O
not	O
been	O
described	O
previously	O
for	O
any	O
viral	O
protein	B-CHED
.	O

Injured	O
lungs	O
can	O
be	O
partially	O
protected	O
by	O
optimal	O
settings	O
and	O
ventilation	O
modes	O
,	O
using	O
low	O
tidal	O
volume	O
(	O
VT	O
)	O
values	O
and	O
high	O
positive	O
-	O
end	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
).	O

Detection	O
of	O
viral	O
RNA	O
was	O
performed	O
by	O
using	O
a	O
commercial	O
real	O
-	O
time	O
PCR	O
kit	O
(	O
hCoV	O
-	O
EMC	O
Real	O
-	O
Time	O
RT	O
-	O
PCR	O
,	O
Fast	O
Track	O
Diagnostics	O
,	O
Luxembourg	O
)	O
targeting	O
the	O
MERS	O
-	O
CoV	O
E	O
protein	B-CHED
(	O
upE	O
),	O
ORF1a	O
and	O
ORF1b	O
gene	O
regions	O
.	O

TITLE	O
:	O
A	O
Multicenter	O
Retrospective	O
Review	O
of	O
Prone	O
Position	O
Ventilation	O
(	O
PPV	B-CHED
)	O
in	O
Treatment	O
of	O
Severe	O
Human	O
H7N9	O
Avian	O
Flu	O
.	O

PPV	B-CHED
provided	O
improved	O
oxygenation	O
that	O
was	O
sustained	O
after	O
returning	O
to	O
a	O
supine	O
position	O
,	O
and	O
resulted	O
in	O
decreased	O
carbon	B-CHED
dioxide	I-CHED
retention	O
.	O

Additionally	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
mean	O
values	O
for	O
arterial	O
pressure	O
(	O
MAP	O
),	O
cardiac	O
index	O
(	O
CI	O
),	O
central	O
venous	O
pressure	O
(	O
CVP	O
),	O
heart	O
rate	O
(	O
HR	O
),	O
lactic	B-CHED
acid	I-CHED
(	O
LAC	B-CHED
)	O
levels	O
or	O
the	O
doses	O
of	O
norepinephrine	B-CHED
(	O
NE	O
)	O
administered	O
when	O
compared	O
pre	O
-	O
PPV	B-CHED
,	O
post	O
-	O
PPV	B-CHED
,	O
and	O
post	O
-	O
SPV	O
.	O

Confocal	O
imaging	O
revealed	O
a	O
close	O
colocalization	O
of	O
SARS	O
-	O
CoV	O
ORF6	O
protein	B-CHED
with	O
NPIPB3	O
in	O
human	O
promonocytes	O
.	O

However	O
,	O
at	O
present	O
specific	O
preventive	O
or	O
curative	O
strategies	O
for	O
the	O
treatment	O
of	O
lung	O
failure	O
in	O
pneumonia	O
in	O
addition	O
to	O
antibiotics	B-CHED
are	O
still	O
missing	O
.	O

These	O
findings	O
strikingly	O
link	O
SARS	O
-	O
CoV	O
E	O
protein	B-CHED
IC	O
induced	O
ionic	O
disturbances	O
at	O
the	O
cell	O
level	O
to	O
immunopathological	O
consequences	O
and	O
disease	O
worsening	O
in	O
the	O
infected	O
organism	O
.	O

The	O
presence	O
of	O
more	O
than	O
one	O
virus	O
in	O
pediatric	O
patients	O
admitted	O
to	O
hospital	O
with	O
LT	O
-	O
ARI	B-CHED
is	O
very	O
frequent	O
and	O
seems	O
to	O
peak	O
at	O
12	O
-	O
24	O
months	O
of	O
age	O
.	O

Moreover	O
,	O
we	O
confirmed	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
these	O
nanoparticles	B-CHED
on	O
human	O
monocytes	O
and	O
macrophages	O
in	O
vitro	O
and	O
in	O
a	O
human	O
ex	O
vivo	O
lung	O
perfusion	O
(	O
EVLP	O
)	O
model	O
of	O
lung	O
injury	O
.	O

Here	O
,	O
we	O
engineered	O
a	O
recombinant	O
mutant	O
virus	O
lacking	O
the	O
ns12	O
.	O
9	O
protein	B-CHED
(	O
HCoV	O
-	O
OC43	O
-	O
ns12	O
.	O
9	O
)	O
to	O
characterize	O
the	O
contributions	O
of	O
ns12	O
.	O
9	O
in	O
HCoV	O
-	O
OC43	O
replication	O
.	O

The	O
ns12	O
.	O
9	O
accessory	O
protein	B-CHED
is	O
a	O
transmembrane	O
protein	B-CHED
and	O
forms	O
ion	O
channels	O
in	O
both	O
Xenopus	O
oocytes	O
and	O
yeast	O
through	O
homo	O
-	O
oligomerization	O
,	O
suggesting	O
that	O
ns12	O
.	O
9	O
is	O
a	O
newly	O
recognized	O
viroporin	O
.	O

ABSTRACT	O
:	O
ABO	O
blood	O
types	O
are	O
determined	O
by	O
antigen	B-CHED
modifications	O
on	O
glycoproteins	B-CHED
and	O
glycolipids	B-CHED
and	O
associated	O
with	O
altered	O
plasma	O
levels	O
of	O
inflammatory	O
and	O
endothelial	O
injury	O
markers	O
implicated	O
in	O
AKI	O
pathogenesis	O
.	O

AKI	O
was	O
defined	O
by	O
Acute	O
Kidney	O
Injury	O
Network	O
creatinine	B-CHED
and	O
dialysis	O
criteria	O
.	O

The	O
patient	O
recovered	O
completely	O
after	O
antimicrobial	B-CHED
treatment	O
.	O

The	O
replication	O
of	O
MVvac2	O
-	O
CoV	O
-	O
S	O
in	O
Vero	O
cells	O
turned	O
out	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
control	O
virus	O
MVvac2	O
-	O
GFP	O
(	O
encoding	O
green	O
fluorescent	O
protein	B-CHED
),	O
while	O
titers	O
of	O
MVvac2	O
-	O
CoV	O
-	O
solS	O
were	O
impaired	O
approximately	O
3	O
-	O
fold	O
.	O

The	O
genomic	O
stability	O
and	O
expression	O
of	O
the	O
inserted	O
antigens	B-CHED
were	O
confirmed	O
via	O
sequencing	O
of	O
viral	O
cDNA	O
and	O
immunoblot	O
analysis	O
.	O

The	O
integration	O
of	O
antigen	B-CHED
-	O
coding	O
genes	O
into	O
recombinant	O
MV	O
resulting	O
in	O
coexpression	O
of	O
MV	O
and	O
foreign	O
antigens	B-CHED
can	O
efficiently	O
be	O
achieved	O
.	O

TITLE	O
:	O
Assessment	O
of	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
using	O
B	O
-	O
type	O
brain	O
natriuretic	O
peptide	B-CHED
.	O

ABSTRACT	O
:	O
HIV	O
-	O
1	O
integrase	O
(	O
IN	O
)	O
active	O
site	O
inhibitors	B-CHED
are	O
the	O
latest	O
class	O
of	O
drugs	O
approved	O
for	O
HIV	O
treatment	O
.	O

Serial	O
lactate	B-CHED
monitoring	O
is	O
a	O
useful	O
tool	O
to	O
gauge	O
global	O
tissue	O
hypoxia	O
in	O
emergency	O
department	O
(	O
ED	O
)	O
patients	O
with	O
sepsis	O
.	O

We	O
hypothesized	O
that	O
patients	O
undergoing	O
serial	O
lactate	B-CHED
monitoring	O
(	O
SL	O
)	O
would	O
demonstrate	O
a	O
decreased	O
incidence	O
of	O
pulmonary	O
complications	O
.	O

Assuming	O
those	O
not	O
enrolled	O
were	O
influenza	O
negative	O
,	O
21	O
/	O
110	O
household	O
contacts	O
had	O
laboratory	O
-	O
confirmed	O
influenza	O
(	O
SAR	B-CHED
19	O
%);	O
the	O
mean	O
serial	O
interval	O
was	O
2	O
.	O
1	O
days	O
(	O
SD	O
=	O
0	O
.	O
35	O
,	O
range	O
2	O
-	O
3	O
days	O
).	O

In	O
adenovirus	O
infections	O
mean	O
C	O
-	O
reactive	O
protein	B-CHED
value	O
was	O
72	O
.	O
4	O
mg	O
/	O
L	O
and	O
white	O
blood	O
cell	O
count	O
19	O
.	O
000	O
/	O
l	O
,	O
both	O
significantly	O
higher	O
than	O
in	O
other	O
viruses	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

Given	O
the	O
previous	O
studies	O
on	O
BST	O
-	O
2	O
,	O
we	O
aimed	O
to	O
determine	O
if	O
BST	O
-	O
2	O
has	O
the	O
ability	O
to	O
restrict	O
SARS	O
-	O
CoV	O
and	O
if	O
the	O
SARS	O
-	O
CoV	O
genome	O
encodes	O
any	O
proteins	B-CHED
that	O
modulate	O
BST	O
-	O
2	O
'	O
s	O
antiviral	B-CHED
function	O
.	O

We	O
have	O
found	O
that	O
BST	O
-	O
2	O
is	O
capable	O
of	O
restricting	O
SARS	O
-	O
CoV	O
release	O
from	O
cells	O
;	O
however	O
,	O
we	O
also	O
identified	O
a	O
SARS	O
-	O
CoV	O
protein	B-CHED
that	O
inhibits	O
BST	O
-	O
2	O
function	O
.	O

EELV	O
was	O
separated	O
between	O
the	O
expected	O
increased	O
volume	O
,	O
calculated	O
as	O
the	O
product	O
of	O
the	O
respiratory	O
system	O
compliance	O
by	O
the	O
change	O
in	O
PEEP	B-CHED
,	O
and	O
the	O
additional	O
volume	O
.	O

During	O
the	O
increase	O
in	O
PEEP	B-CHED
,	O
the	O
expected	O
increased	O
volume	O
was	O
achieved	O
within	O
2	O
[	O
2	O
-	O
2	O
]	O
breaths	O
.	O

Completion	O
of	O
volume	O
changes	O
in	O
99	O
%	O
of	O
both	O
increase	O
and	O
decrease	O
in	O
PEEP	B-CHED
events	O
required	O
29	O
breaths	O
.	O

TITLE	O
:	O
A	O
humanized	O
neutralizing	O
antibody	O
against	O
MERS	O
-	O
CoV	O
targeting	O
the	O
receptor	O
-	O
binding	O
domain	O
of	O
the	O
spike	O
protein	B-CHED
.	O

Furthermore	O
,	O
oxidative	O
stress	O
,	O
probably	O
via	O
lipid	B-CHED
peroxidation	O
,	O
was	O
found	O
to	O
induce	O
PLA2G2D	O
expression	O
in	O
mice	O
and	O
in	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

We	O
show	O
that	O
IBV	O
is	O
fairly	O
resistant	O
to	O
the	O
antiviral	B-CHED
state	O
induced	O
by	O
IFN	O
and	O
identify	O
that	O
viral	O
accessory	O
protein	B-CHED
3a	O
is	O
involved	O
in	O
resistance	O
to	O
IFN	O
,	O
as	O
its	O
absence	O
renders	O
IBV	O
less	O
resistant	O
to	O
IFN	O
treatment	O
.	O

The	O
SPR	O
biosensor	O
was	O
developed	O
by	O
immobilizing	O
nine	O
respiratory	O
virus	O
-	O
specific	O
oligonucleotides	B-CHED
in	O
an	O
SPR	O
chip	O
.	O

To	O
increase	O
the	O
biosensor	O
sensitivity	O
,	O
biotin	B-CHED
was	O
used	O
to	O
label	B-CHED
the	O
PCR	O
primer	O
and	O
further	O
amplify	O
the	O
signal	O
by	O
introducing	O
streptavidin	O
after	O
hybridization	O
.	O

Since	O
most	O
of	O
the	O
patients	O
can	O
develop	O
severe	O
respiratory	O
illness	O
and	O
critical	O
care	O
management	O
is	O
needed	O
,	O
the	O
issue	O
on	O
critical	O
care	O
for	O
MERS	O
is	O
the	O
topic	O
to	O
be	O
discussed	O
in	O
critical	O
medicine	B-CHED
.	O

ABSTRACT	O
:	O
This	O
paper	O
aimed	O
to	O
identify	O
the	O
differentially	O
expressed	O
proteins	B-CHED
(	O
DEPs	O
)	O
in	O
Calu	O
-	O
3	O
cells	O
infected	O
by	O
influenza	O
A	O
virus	O
(	O
IAV	O
)	O
subtype	O
H5N1	O
.	O

This	O
have	O
enabled	O
the	O
development	O
of	O
specific	O
devices	O
for	O
the	O
extracorporeal	O
removal	O
of	O
CO2	B-CHED
.	O

Our	O
results	O
revealed	O
that	O
the	O
PEDV	O
M	O
protein	B-CHED
is	O
localized	O
throughout	O
the	O
cytoplasm	O
.	O

The	O
M	O
protein	B-CHED
altered	O
swine	O
intestinal	O
epithelial	O
cell	O
line	O
(	O
IEC	O
)	O
growth	O
and	O
induced	O
cell	O
cycle	O
arrest	O
at	O
the	O
S	O
-	O
phase	O
via	O
the	O
cyclin	O
A	O
pathway	O
.	O

Cultured	O
NPCs	O
expressed	O
transcripts	O
for	O
S1P	B-CHED
receptors	O
S1P1	O
,	O
S1P2	O
,	O
S1P3	O
,	O
S1P4	O
,	O
and	O
S1P5	O
.	O

ABSTRACT	O
:	O
In	O
2012	O
,	O
a	O
nephrologist	O
reported	O
the	O
development	O
of	O
a	O
multiorgan	O
thrombotic	O
syndromic	O
complex	O
resembling	O
thrombotic	O
thrombocytopenic	O
purpura	O
(	O
TTP	B-CHED
)	O
in	O
patients	O
who	O
were	O
abusing	O
long	O
acting	O
oxymorphone	O
hydrochloride	B-CHED
;	O
all	O
patients	O
had	O
hemolytic	O
anemia	O
and	O
thrombocytopenia	O
.	O

Multivariate	O
analysis	O
associated	O
hospital	O
mortality	O
with	O
age	O
and	O
Pao	B-CHED
CONCLUSIONS	O
:	O
The	O
overall	O
hospital	O
mortality	O
(	O
38	O
%)	O
was	O
similar	O
to	O
that	O
of	O
other	O
studies	O
and	O
according	O
to	O
the	O
presence	O
of	O
ARDS	O
(	O
Pao	B-CHED

Finally	O
,	O
using	O
a	O
receptor	O
binding	O
domain	O
protein	B-CHED
vaccine	O
and	O
a	O
MERS	O
-	O
CoV	O
fusion	O
inhibitor	B-CHED
,	O
we	O
demonstrated	O
the	O
value	O
of	O
this	O
model	O
for	O
evaluating	O
vaccines	O
and	O
antivirals	B-CHED
against	O
MERS	O
.	O

Similarly	O
,	O
significant	O
age	O
by	O
HIV	O
interactions	O
were	O
found	O
indicating	O
stronger	O
associations	O
between	O
older	O
age	O
and	O
decreased	O
FA	O
in	O
the	O
posterior	O
limbs	O
of	O
the	O
internal	O
capsules	O
,	O
cerebral	O
peduncles	O
,	O
and	O
anterior	O
corona	B-CHED
radiata	O
in	O
HIV	O
+	O
vs	O
.	O
HIV	O
-	O
participants	O
.	O

Cold	O
medicines	O
including	O
nonsteroidal	O
antiinflammatory	B-CHED
drugs	I-CHED
,	O
which	O
are	O
the	O
main	O
causative	O
drugs	O
for	O
SJS	O
/	O
TEN	O
with	O
SOCs	O
,	O
downregulate	O
the	O
production	O
of	O
prostanoids	B-CHED
,	O
including	O
PGE2	B-CHED
.	O

Although	O
the	O
functions	O
of	O
the	O
S	O
protein	B-CHED
have	O
been	O
well	O
studied	O
,	O
the	O
factors	O
shaping	O
synonymous	O
codon	O
usage	O
bias	O
and	O
nucleotide	B-CHED
composition	O
in	O
the	O
S	O
gene	O
have	O
not	O
been	O
reported	O
yet	O
.	O

TITLE	O
:	O
Assembly	O
and	O
immunogenicity	O
of	O
baculovirus	O
-	O
derived	O
infectious	O
bronchitis	O
virus	O
-	O
like	O
particles	O
carrying	O
membrane	O
,	O
envelope	O
and	O
the	O
recombinant	O
spike	O
proteins	B-CHED
.	O

ABSTRACT	O
:	O
The	O
increasing	O
emergence	O
and	O
spread	O
of	O
antimicrobial	B-CHED
resistance	O
(	O
AMR	O
)	O
is	O
a	O
serious	O
public	O
health	O
issue	O
.	O

Specifically	O
,	O
the	O
pyrido	O
[	O
2	O
,	O
3	O
-	O
g	O
]	O
quinoxalinone	O
nucleus	B-CHED
was	O
found	O
endowed	O
with	O
high	O
potency	O
against	O
several	O
pathogenic	O
RNA	O
viruses	O
as	O
etiological	O
agents	O
of	O
important	O
veterinary	O
and	O
human	O
pathologies	O
.	O

Some	O
derivatives	O
emerged	O
as	O
potential	O
leads	O
for	O
further	O
development	O
as	O
antiviral	B-CHED
agents	I-CHED
against	O
some	O
viruses	O
of	O
public	O
health	O
significance	O
,	O
such	O
as	O
RSV	O
,	O
Reo	O
,	O
BVDV	O
and	O
HCV	O
.	O

Our	O
results	O
demonstrate	O
that	O
DN	O
T	O
cells	O
contribute	O
to	O
the	O
outcome	O
of	O
MHV	O
-	O
3	O
-	O
induced	O
FVH	O
via	O
an	O
important	O
effector	B-CHED
molecule	O
mfgl2	O
.	O

The	O
antiviral	B-CHED
activity	O
of	O
(	O
R	O
,	O
R	O
)-	O
17	B-CHED
	I-CHED
HCl	I-CHED
is	O
about	O
similar	O
to	O
that	O
of	O
(	O
R	O
,	O
R	O
)-	O
17	O
.	O

Female	O
BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
the	O
purified	O
recombinant	O
truncated	O
S1	O
protein	B-CHED
,	O
and	O
three	O
monoclonal	O
antibodies	O
(	O
MAb	O
designated	O
as	O
E3	O
,	O
G8	O
,	O
and	O
G9	O
)	O
against	O
the	O
truncated	O
S1	O
protein	B-CHED
obtained	O
by	O
hydridoma	O
technique	O
.	O

Our	O
study	O
suggests	O
that	O
purified	O
truncated	O
S1	O
protein	B-CHED
and	O
the	O
three	O
developed	O
MAbs	O
could	O
be	O
useful	O
in	O
the	O
development	O
of	O
a	O
diagnostic	O
assay	O
for	O
anti	O
-	O
PEDV	O
antibodies	O
and	O
PEDV	O
antigen	B-CHED
,	O
respectively	O
.	O

RESULTS	O
:	O
Of	O
the	O
total	O
sample	O
of	O
149	O
subjects	O
with	O
ACS	O
,	O
118	O
(	O
79	O
.	O
2	O
%)	O
met	B-CHED
criteria	O
for	O
DSM	B-CHED
-	O
5	O
persistent	O
complex	O
bereavement	O
disorder	O
.	O

Treatment	O
with	O
prednisolone	B-CHED
achieved	O
good	O
clinical	O
response	O
.	O

Similarly	O
,	O
after	O
passage	O
in	O
mice	O
,	O
SARS	O
-	O
CoV	O
-	O
E	O
protein	B-CHED
8a	O
mutated	O
,	O
to	O
now	O
encode	O
a	O
PBM	O
,	O
and	O
also	O
regained	O
virulence	O
.	O

To	O
increase	O
the	O
genetic	O
stability	O
of	O
the	O
vaccine	O
candidate	O
,	O
we	O
introduced	O
small	O
attenuating	O
deletions	O
in	O
E	O
gene	O
that	O
did	O
not	O
affect	O
the	O
endogenous	O
PBM	O
,	O
preventing	O
the	O
incorporation	O
of	O
novel	O
chimeric	O
proteins	B-CHED
in	O
the	O
virus	O
genome	O
.	O

Respiratory	O
mechanics	O
,	O
blood	O
gases	O
,	O
hemodynamic	O
data	O
,	O
and	O
whole	O
-	O
lung	O
computed	O
tomography	O
scans	O
were	O
recorded	O
at	O
each	O
PEEP	B-CHED
level	O
.	O

The	O
independent	O
determinants	O
of	O
mortality	O
were	O
associated	O
with	O
ARDS	O
renal	O
recipients	O
with	O
rESKAPE	O
pneumonia	O
were	O
serum	O
creatinine	B-CHED
level	O
>	O
1	O
.	O
5	O
mg	O
/	O
dL	O
(	O
OR	O
13	O
.	O
7	O
,	O
95	O
%	O
CI	O
1	O
.	O
3	O
-	O
142	O
.	O
1	O
,	O
P	O
=	O
.	O
028	O
)	O
and	O
body	O
temperature	O
less	O
than	O
38	O
	O
C	O
(	O
OR	O
5	O
.	O
5	O
(	O
95	O
%	O
CI	O
1	O
.	O
1	O
-	O
26	O
.	O
6	O
)	O
at	O
ARDS	O
onset	O
,	O
P	O
=	O
.	O
035	O
).	O

The	O
majority	O
of	O
EPKAPE	O
isolates	O
were	O
antimicrobial	B-CHED
resistant	O
.	O

One	O
single	O
-	O
nucleotide	B-CHED
polymorphism	O
from	O
IL4	O
gene	O
was	O
significant	O
for	O
pooled	O
respiratory	O
infections	O
(	O
rs2070874	O
;	O
1	O
.	O
66	O
[	O
1	O
.	O
29	O
-	O
2	O
.	O
14	O
]).	O

ABSTRACT	O
:	O
Airflow	O
is	O
a	O
critical	O
factor	O
that	O
influences	O
air	B-CHED
quality	O
,	O
airborne	O
contaminant	O
distribution	O
,	O
and	O
disease	O
transmission	O
in	O
commercial	O
airliner	O
cabins	O
.	O

Critical	O
characteristics	O
of	O
ALI	O
are	O
alveolar	O
edema	O
,	O
infiltration	O
of	O
leukocytes	O
(	O
neutrophils	O
and	O
monocytes	O
),	O
release	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
into	O
broncho	O
-	O
alveolar	O
lavage	O
fluid	O
,	O
and	O
activation	O
of	O
integrin	O
receptors	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
43	O
-	O
year	O
-	O
old	O
man	B-CHED
who	O
ingested	O
,	O
for	O
suicidal	O
purposes	O
,	O
common	O
(	O
or	O
European	O
)	O
yew	O
leaves	O
(	O
Taxus	O
baccata	O
)	O
and	O
presented	O
severe	O
hypokalemia	O
,	O
ventricular	O
arrhythmias	O
with	O
hemodynamic	O
instability	O
accompanied	O
by	O
severe	O
multiple	O
organ	O
dysfunction	O
syndrome	O
,	O
including	O
respiratory	O
insufficiency	O
,	O
renal	O
failure	O
,	O
acid	O
-	O
base	O
imbalance	O
with	O
severe	O
hypokalemia	O
,	O
hepatic	O
dysfunction	O
and	O
coma	O
,	O
which	O
led	O
to	O
death	O
12	O
hours	O
after	O
Taxus	O
baccata	O
ingestion	O
.	O

Given	O
the	O
increasing	O
numbers	O
of	O
travelers	O
,	O
the	O
risk	O
of	O
infectious	O
disease	O
transmission	O
during	O
air	B-CHED
travel	O
is	O
a	O
significant	O
concern	O
,	O
and	O
this	O
chapter	O
focuses	O
on	O
the	O
current	O
knowledge	O
about	O
transmission	O
of	O
infectious	O
diseases	O
in	O
the	O
context	O
of	O
both	O
transmissions	O
within	O
the	O
aircraft	O
passenger	O
cabin	O
and	O
commercial	O
aircraft	O
serving	O
as	O
vehicles	O
of	O
worldwide	O
infection	O
spread	O
.	O

TITLE	O
:	O
Structure	O
-	O
based	O
virtual	O
screening	O
and	O
experimental	O
validation	O
of	O
the	O
discovery	O
of	O
inhibitors	B-CHED
targeted	O
towards	O
the	O
human	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
.	O

TITLE	O
:	O
Cleavage	O
of	O
a	O
Neuroinvasive	O
Human	O
Respiratory	O
Virus	O
Spike	O
Glycoprotein	B-CHED
by	O
Proprotein	O
Convertases	O
Modulates	O
Neurovirulence	O
and	O
Virus	O
Spread	O
within	O
the	O
Central	O
Nervous	O
System	O
.	O

ABSTRACT	O
:	O
Cystine	B-CHED
knot	O
	O
-	O
amylase	O
inhibitors	B-CHED
are	O
cysteine	B-CHED
-	O
rich	O
,	O
proline	O
-	O
rich	O
peptides	B-CHED
found	O
in	O
the	O
Amaranthaceae	O
and	O
Apocynaceae	O
plant	O
species	O
.	O

Similar	O
to	O
other	O
knottins	O
,	O
cystine	B-CHED
knot	O
	O
-	O
amylase	O
inhibitors	B-CHED
are	O
highly	O
resistant	O
to	O
degradation	O
by	O
heat	O
and	O
protease	O
treatments	O
.	O

The	O
alstotides	O
(	O
As1	O
-	O
As4	B-CHED
)	O
were	O
characterized	O
by	O
both	O
proteomic	O
and	O
genomic	O
methods	O
.	O

We	O
confirmed	O
that	O
these	O
isolates	O
emerged	O
through	O
the	O
recombination	O
of	O
LX4	O
and	O
Taiwan	O
group	O
1	O
(	O
TW1	O
)	O
viruses	O
at	O
two	O
switch	O
sites	O
,	O
one	O
was	O
in	O
the	O
Nsp	O
16	O
region	O
and	O
the	O
other	O
in	O
the	O
spike	O
protein	B-CHED
gene	O
.	O

The	O
envelope	O
spike	O
glycoprotein	B-CHED
on	O
the	O
surface	O
of	O
MERS	O
-	O
CoV	O
which	O
mediates	O
receptor	O
binding	O
,	O
membrane	O
fusion	O
and	O
viral	O
entry	O
is	O
thought	O
to	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
MERS	O
-	O
CoV	O
.	O
No	O
specific	O
and	O
effective	O
treatment	O
for	O
MERS	O
-	O
CoV	O
is	O
currently	O
recommended	O
,	O
although	O
supportive	O
treatment	O
has	O
played	O
an	O
important	O
role	O
.	O

Activation	O
and	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
recruitment	O
of	O
myelin	O
-	O
specific	O
CD4	O
T	O
cells	O
was	O
analyzed	O
by	O
flow	O
cytometry	O
during	O
encephalomyelitis	O
induced	O
by	O
a	O
glia	O
tropic	O
murine	O
coronavirus	O
.	O

Potential	O
antigen	B-CHED
-	O
presenting	O
cells	O
(	O
APC	O
)	O
ingesting	O
myelin	O
were	O
characterized	O
by	O
flow	O
cytometry	O
and	O
their	O
ability	O
to	O
activate	O
SR	O
T	O
cells	O
tested	O
by	O
co	O
-	O
culture	O
with	O
carboxyfluorescein	O
succinimidyl	O
ester	B-CHED
(	O
CFSE	O
)-	O
labeled	O
myelin	O
-	O
specific	O
CD4	O
T	O
cells	O
.	O

While	O
both	O
the	O
CNS	B-CHED
-	O
infiltrating	O
myeloid	O
population	O
and	O
microglia	O
ingested	O
myelin	O
,	O
only	O
CNS	B-CHED
-	O
infiltrating	O
APC	O
were	O
capable	O
of	O
presenting	O
endogenous	O
myelin	O
antigen	B-CHED
to	O
SR	O
T	O
cells	O
ex	O
vivo	O
.	O

Lung	O
volumes	O
were	O
measured	O
by	O
helium	B-CHED
dilution	O
and	O
inductance	O
plethysmography	O
.	O

TITLE	O
:	O
Interactions	O
among	O
SARS	O
-	O
CoV	O
accessory	O
proteins	B-CHED
revealed	O
by	O
bimolecular	O
fluorescence	O
complementation	O
assay	O
.	O

These	O
proteins	B-CHED
play	O
important	O
roles	O
in	O
various	O
biological	O
processes	O
mediated	O
by	O
interactions	O
with	O
their	O
partners	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
lesions	O
in	O
non	O
-	O
effusive	O
and	O
effusive	O
cases	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
regarding	O
aspects	O
related	O
to	O
astrocytic	O
and	O
microglial	O
reactions	O
.	O

Brain	O
and	O
cerebellum	O
were	O
evaluated	O
by	O
light	O
microscopy	O
and	O
immunohistochemistry	O
for	O
glial	O
fibrillary	O
acidic	O
protein	B-CHED
(	O
GFAP	O
)	O
and	O
vimentin	O
to	O
assess	O
astrocytic	O
morphology	O
,	O
and	O
lectin	O
histochemistry	O
for	O
Ricinus	O
communis	O
agglutinin	O
-	O
I	O
(	O
RCA	O
-	O
I	O
)	O
to	O
detect	O
microglia	O
was	O
performed	O
to	O
evaluate	O
the	O
glial	O
response	O
in	O
the	O
CNS	B-CHED
of	O
cats	O
with	O
FIP	O
.	O

RESULTS	O
:	O
An	O
important	O
astrocytic	O
response	O
in	O
many	O
areas	O
of	O
the	O
CNS	B-CHED
of	O
all	O
cats	O
,	O
including	O
the	O
periventricular	O
areas	O
of	O
lateral	O
ventricles	O
and	O
fourth	O
ventricle	O
,	O
the	O
molecular	O
layer	O
of	O
the	O
cerebellum	O
and	O
cerebral	O
cortex	O
,	O
was	O
visualized	O
.	O

Reanalysis	O
of	O
deidentified	O
data	O
from	O
the	O
phase	O
III	O
randomized	O
interleukin	O
-	O
1	O
receptor	O
antagonist	B-CHED
trial	O
in	O
severe	O
sepsis	O
.	O

ABSTRACT	O
:	O
6	O
,	O
6	O
-	O
Fused	O
ring	O
systems	O
including	O
tetrahydroisoquinolines	O
and	O
tetrahydropyrido	O
[	O
3	O
,	O
4	O
-	O
d	O
]	O
pyrimidines	B-CHED
have	O
been	O
explored	O
as	O
possible	O
replacements	O
for	O
the	O
piperazine	B-CHED
benzamide	B-CHED
portion	O
of	O
the	O
HIV	O
-	O
1	O
attachment	O
inhibitor	B-CHED
BMS	O
-	O
663068	O
.	O

ABSTRACT	O
:	O
Proton	B-CHED
transfer	O
reactions	O
are	O
of	O
crucial	O
interest	O
for	O
the	O
investigation	O
of	O
proteins	B-CHED
.	O

Compared	O
with	O
the	O
original	O
PC21A	O
,	O
piglets	O
euthanized	O
/	O
died	O
acutely	O
from	O
S	O
-	O
INDEL	O
Iowa106	O
infection	O
had	O
relatively	O
milder	O
villous	O
atrophy	O
,	O
lower	O
antigen	B-CHED
scores	O
and	O
more	O
limited	O
intestinal	O
infection	O
.	O

Of	O
the	O
patients	O
infected	O
with	O
influenza	O
A	O
,	O
viral	O
RNA	O
was	O
recovered	O
from	O
the	O
air	B-CHED
emitted	O
by	O
9	O
/	O
12	O
patients	O
using	O
the	O
low	O
-	O
volume	O
sampler	O
;	O
no	O
viral	O
RNA	O
was	O
detected	O
from	O
air	B-CHED
emitted	O
by	O
patients	O
with	O
influenza	O
B	O
(	O
n	O
=	O
3	O
).	O

Patients	O
with	O
respiratory	O
virus	O
infection	O
emit	O
virus	O
into	O
the	O
air	B-CHED
which	O
disperses	O
to	O
>	O
1	O
m	O
and	O
may	O
reach	O
the	O
breathing	O
zone	O
of	O
a	O
HCW	O
.	O

RESULTS	O
:	O
The	O
air	B-CHED
emitted	O
by	O
15	O
participants	O
with	O
laboratory	O
-	O
confirmed	O
influenza	O
virus	O
infection	O
was	O
sampled	O
.	O

Our	O
study	O
provides	O
important	O
insights	O
into	O
the	O
structural	O
requirements	O
for	O
the	O
inhibition	O
of	O
FIPV	O
-	O
3CL	O
(	O
pro	B-CHED
)	O
by	O
peptidomimetic	B-CHED
inhibitors	B-CHED
and	O
expands	O
the	O
current	O
structural	O
knowledge	O
of	O
coronaviral	O
3CL	O
(	O
pro	B-CHED
)	O
architecture	O
.	O

SYBR	B-CHED
Green	I-CHED
I	I-CHED
real	O
-	O
time	O
quantitative	O
PCR	O
was	O
adopted	O
to	O
analyze	O
the	O
proportion	O
of	O
the	O
viruses	O
with	O
30bp	O
deletion	O
in	O
P60	O
,	O
P100	O
,	O
and	O
P110	O
.	O

The	O
evolutionary	O
rate	O
of	O
the	O
PDCoV	O
genome	O
is	O
estimated	O
to	O
be	O
3	O
.	O
8	O
	O
10	O
(-	O
4	O
)	O
substitutions	O
/	O
site	O
/	O
year	O
(	O
2	O
.	O
3	O
	O
10	O
(-	O
4	O
)-	O
5	O
.	O
4	O
	O
10	O
(-	O
4	O
),	O
95	O
%	O
HPD	B-CHED
).	O

Antigenicity	O
was	O
compared	O
by	O
detection	O
of	O
polyclonal	O
antibodies	O
(	O
PAbs	O
)	O
against	O
the	O
virus	O
and	O
S	O
protein	B-CHED
using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
an	O
indirect	O
immunofluorescence	O
assay	O
(	O
IFA	O
),	O
and	O
a	O
serum	O
cross	O
-	O
neutralization	O
(	O
SN	O
)	O
assay	O
.	O

We	O
found	O
that	O
intravenous	O
LPS	B-CHED
induced	O
a	O
significant	O
increase	O
in	O
the	O
activity	O
of	O
lung	O
xanthine	B-CHED
oxidoreductase	O
(	O
XOR	O
),	O
an	O
enzyme	O
which	O
is	O
a	O
major	O
source	O
of	O
reactive	B-CHED
oxygen	I-CHED
species	I-CHED
and	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
acute	O
lung	O
injury	O
.	O

Twenty	O
-	O
one	O
peptides	B-CHED
were	O
predicted	O
to	O
be	O
potential	O
CTL	O
epitopes	O
;	O
they	O
were	O
manually	O
synthesized	O
and	O
the	O
CTL	O
responses	O
to	O
them	O
tested	O
in	O
vitro	O
.	O

Extravascular	O
lung	O
water	B-CHED
index	O
decreased	O
significantly	O
in	O
RM1	O
compared	O
with	O
that	O
in	O
RM3	O
and	O
4	O
hours	O
post	O
-	O
RRM	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

CONCLUSIONS	O
:	O
Repeated	O
recruitment	O
manoeuvres	O
during	O
lung	O
-	O
protected	O
ventilation	O
can	O
improve	O
pulmonary	O
compliance	O
and	O
oxygenation	O
and	O
significantly	O
decrease	O
extravascular	O
lung	O
water	B-CHED
in	O
ARDS	O
patients	O
.	O

We	O
herein	O
report	O
of	O
evaluating	O
a	O
recombinant	O
receptor	O
-	O
binding	O
domain	O
(	O
rRBD	O
)	O
protein	B-CHED
vaccine	O
in	O
a	O
rhesus	O
macaque	O
model	O
.	O

ABSTRACT	O
:	O
Plant	O
molecular	O
farming	O
(	O
PMF	O
),	O
defined	O
as	O
the	O
practice	O
of	O
using	O
plants	O
to	O
produce	O
human	O
therapeutic	O
proteins	B-CHED
,	O
has	O
received	O
worldwide	O
interest	O
.	O

A	O
number	O
of	O
therapeutic	O
proteins	B-CHED
have	O
been	O
produced	O
in	O
plants	O
,	O
some	O
of	O
which	O
have	O
been	O
through	O
pre	O
-	O
clinical	O
or	O
clinical	O
trials	O
and	O
are	O
close	O
to	O
commercialization	O
.	O

Biosafety	O
concerns	O
(	O
such	O
as	O
pollen	O
contamination	O
and	O
immunogenicity	O
of	O
plant	O
-	O
specific	O
glycans	B-CHED
)	O
and	O
costly	O
downstream	O
extraction	O
and	O
purification	O
requirements	O
,	O
however	O
,	O
have	O
hampered	O
PMF	O
production	O
from	O
moving	O
from	O
the	O
laboratory	O
to	O
industrial	O
application	O
.	O

Mean	O
carbon	B-CHED
dioxide	I-CHED
transfer	O
was	O
comparable	O
between	O
the	O
conventional	O
ECMO	O
and	O
ILIAS	O
(	O
211	O
.	O
36	O
	O
78	O
.	O
39	O
mL	O
/	O
min	O
vs	O
.	O
219	O
.	O
99	O
	O
76	O
.	O
72	O
mL	O
/	O
min	O
,	O
P	O
=	O
n	O
.	O
s	O
.).	O

ACP	B-CHED
was	O
found	O
in	O
164	O
of	O
the	O
752	O
patients	O
(	O
prevalence	O
of	O
22	O
%;	O
95	O
%	O
confidence	O
interval	O
19	O
-	O
25	O
%).	O

Hospital	O
mortality	O
did	O
not	O
differ	O
between	O
patients	O
with	O
or	O
without	O
ACP	B-CHED
,	O
but	O
it	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
severe	O
ACP	B-CHED
than	O
in	O
the	O
other	O
patients	O
[	O
31	O
/	O
54	O
(	O
57	O
%)	O
vs	O
.	O
291	O
/	O
698	O
(	O
42	O
%);	O
p	O
=	O
0	O
.	O
03	O
].	O

CoV	O
main	O
proteases	O
(	O
M	O
(	O
pro	B-CHED
)	O
s	O
)	O
play	O
a	O
pivotal	O
role	O
in	O
viral	O
transcription	O
and	O
replication	O
,	O
making	O
them	O
an	O
ideal	O
target	O
for	O
drug	O
development	O
.	O

Our	O
study	O
provides	O
new	O
insight	O
into	O
the	O
pharmaceutical	B-CHED
strategy	O
against	O
CoV	O
M	O
(	O
pro	B-CHED
)	O
through	O
using	O
zinc	B-CHED
as	O
an	O
adjuvant	B-CHED
therapy	O
to	O
enhance	O
the	O
efficacy	O
of	O
an	O
irreversible	O
peptidomimetic	B-CHED
inhibitor	B-CHED
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
PEDV	O
nsp5	O
gene	O
,	O
which	O
encodes	O
the	O
3C	O
-	O
like	O
protease	O
of	O
PEDV	O
,	O
is	O
another	O
IFN	O
antagonist	B-CHED
.	O

Development	O
of	O
methods	O
that	O
incorporate	O
labels	O
at	O
specific	O
atomic	O
positions	O
within	O
each	O
nucleotide	B-CHED
promises	O
to	O
expand	O
the	O
size	O
range	O
of	O
RNAs	O
that	O
can	O
be	O
studied	O
by	O
NMR	O
.	O

Fifty	O
-	O
one	O
patients	O
admitted	O
with	O
AECOPD	O
were	O
classified	O
into	O
;	O
Mild	O
exacerbation	O
:	O
Normal	O
arterial	O
blood	O
gases	O
(	O
ABG	O
)	O
treated	O
with	O
antibiotics	B-CHED
,	O
Moderate	O
:	O
Normal	O
ABG	O
treated	O
with	O
parenteral	O
corticosteroids	B-CHED
,	O
Severe	O
:	O
Type	O
1	O
respiratory	O
failure	O
,	O
Very	O
severe	O
:	O
Type	O
2	O
respiratory	O
failure	O
with	O
normal	O
pH	O
and	O
Life	O
-	O
threatening	O
:	O
Type	O
2	O
respiratory	O
failure	O
with	O
pH	O
<	O
7	O
.	O
35	O
.	O

This	O
was	O
investigated	O
by	O
exposing	O
wild	O
	O
type	O
(	O
WT	O
)	O
and	O
VDR	O
knockout	O
C57BL	O
/	O
6J	O
mice	O
to	O
LPS	B-CHED
,	O
then	O
comparing	O
the	O
healthy	O
and	O
LPS	O
	O
treated	O
mice	O
lungs	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
).	O

More	O
specifically	O
,	O
lung	O
histology	O
,	O
mRNA	B-CHED
levels	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
,	O
and	O
protein	B-CHED
expression	O
levels	O
of	O
tight	O
junction	O
proteins	B-CHED
were	O
determined	O
.	O

Using	O
a	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
biodegradable	O
polymer	B-CHED
,	O
poly	O
(	O
	O
-	O
amino	O
ester	B-CHED
),	O
colloidally	O
stable	O
sub	O
-	O
100	O
nm	O
DNA	O
nanoparticles	B-CHED
are	O
engineered	O
with	O
a	O
nonadhesive	O
polyethylene	B-CHED
glycol	I-CHED
corona	B-CHED
that	O
are	O
able	O
to	O
avoid	O
the	O
adhesive	O
and	O
steric	O
hindrances	O
imposed	O
by	O
the	O
extracellular	O
matrix	O
.	O

ABSTRACT	O
:	O
No	O
major	O
trial	O
evaluating	O
prone	O
positioning	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
has	O
incorporated	O
a	O
high	O
-	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
high	O
-	O
PEEP	B-CHED
)	O
strategy	O
despite	O
complementary	O
physiological	O
rationales	O
.	O

All	O
trials	O
employed	O
a	O
relatively	O
low	O
-	O
PEEP	B-CHED
strategy	O
.	O

TITLE	O
:	O
Variations	O
in	O
Spike	O
Glycoprotein	B-CHED
Gene	O
of	O
MERS	O
-	O
CoV	O
,	O
South	O
Korea	O
,	O
2015	O
.	O

Spike	O
glycoprotein	B-CHED
genes	O
of	O
virus	O
strains	O
from	O
South	O
Korea	O
were	O
closely	O
related	O
to	O
those	O
of	O
strains	O
from	O
Riyadh	O
,	O
Saudi	O
Arabia	O
.	O

We	O
will	O
also	O
present	O
our	O
latest	O
results	O
on	O
MERS	O
-	O
CoV	O
N	O
protein	B-CHED
and	O
its	O
potential	O
as	O
an	O
antiviral	B-CHED
drug	I-CHED
target	O
.	O

ABSTRACT	O
:	O
Glucose	B-CHED
-	O
6	O
-	O
phosphate	B-CHED
dehydrogenase	O
(	O
G6PD	O
)-	O
deficient	O
cells	O
are	O
highly	O
susceptible	O
to	O
viral	O
infection	O
.	O

Quantitative	O
real	O
-	O
time	O
PCR	O
data	O
revealed	O
the	O
inhibitory	O
effect	O
of	O
2	O
on	O
genes	O
encoding	O
essential	O
structural	O
proteins	B-CHED
(	O
GP6	O
nucleocapsid	O
,	O
GP2	O
spike	O
,	O
and	O
GP5	O
membrane	O
)	O
for	O
PEDV	O
replication	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Declining	O
C	O
-	O
reactive	O
protein	B-CHED
levels	O
correlated	O
with	O
clinical	O
improvement	O
despite	O
continued	O
positive	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
results	O
.	O

Secondary	O
annexin	O
V	O
/	O
propidium	B-CHED
iodide	I-CHED
(	O
PI	B-CHED
)	O
staining	O
revealed	O
increased	O
numbers	O
of	O
annexin	O
V	O
-	O
or	O
PI	B-CHED
-	O
positive	O
LLC	O
-	O
PK	O
and	O
ST	O
cells	O
at	O
21h	O
after	O
inoculation	O
,	O
compared	O
to	O
the	O
negative	O
controls	O
.	O

We	O
measured	O
cysteinyl	B-CHED
leukotriene	B-CHED
levels	O
in	O
urine	O
and	O
exhaled	O
breath	O
condensate	O
via	O
enzyme	O
immunoassay	O
.	O

Among	O
MCT	O
positive	O
subjects	O
,	O
those	O
on	O
hydroxyurea	B-CHED
had	O
significantly	O
less	O
severe	O
AHR	O
as	O
quantified	O
by	O
PC20	O
(	O
P	O
=	O
0	O
.	O
014	O
).	O

Among	O
MCT	O
positive	O
subjects	O
,	O
those	O
on	O
hydroxyurea	B-CHED
had	O
significantly	O
less	O
severe	O
AHR	O
as	O
quantified	O
by	O
PC20	O
(	O
P	O
=	O
0	O
.	O
014	O
).	O

We	O
characterize	O
nonspecific	O
protein	B-CHED
adsorption	O
(	O
corona	B-CHED
formation	O
)	O
to	O
membrane	O
-	O
wrapped	O
nanoparticles	B-CHED
with	O
core	O
diameters	O
of	O
approximately	O
35	O
and	O
80	O
nm	O
and	O
its	O
effect	O
on	O
the	O
GM3	B-CHED
-	O
mediated	O
targeting	O
efficacy	O
as	O
a	O
function	O
of	O
surface	O
charge	O
through	O
combined	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
.	O

The	O
stability	O
and	O
fate	O
of	O
the	O
membrane	O
wrap	O
around	O
the	O
nanoparticles	B-CHED
in	O
a	O
simulated	O
biological	O
fluid	O
and	O
after	O
uptake	O
in	O
CD169	O
-	O
expressing	O
antigen	B-CHED
-	O
presenting	O
cells	O
is	O
experimentally	O
tested	O
.	O

ABSTRACT	O
:	O
A	O
30	O
year	O
-	O
old	O
Hispanic	O
man	B-CHED
with	O
no	O
significant	O
previous	O
medical	O
history	O
presented	O
with	O
refractory	O
hypoxemia	O
after	O
flu	O
-	O
like	O
symptoms	O
.	O

In	O
this	O
report	O
,	O
we	O
examined	O
the	O
potential	O
immunomodulatory	O
effects	O
of	O
two	O
indirubin	O
derivatives	O
,	O
indirubin	O
-	O
3	O
'-(	O
2	O
,	O
3	O
-	O
dihydroxypropyl	O
)-	O
oximether	O
(	O
E804	O
)	O
and	O
indirubin	O
-	O
3	O
'-	O
oxime	B-CHED
(	O
E231	O
),	O
on	O
IAV	O
(	O
H9N2	O
)	O
infected	O
-	O
human	O
pulmonary	O
microvascular	O
endothelial	O
cells	O
(	O
HPMECs	O
).	O

Age	O
distribution	O
of	O
HCoV	O
-	O
NL63	O
infection	O
in	O
hospitalized	O
patients	O
with	O
pneumonia	O
indicated	O
that	O
the	O
group	O
aged	O
16	O
-	O
25	O
years	O
(	O
20	O
%)	O
had	O
the	O
highest	O
positive	O
rate	O
compared	O
with	O
the	O
other	O
groups	O
,	O
and	O
exhibited	O
a	O
similar	O
age	O
-	O
specific	O
pattern	O
to	O
influenza	O
A	O
/	O
H1N1	O
infection	O
,	O
but	O
not	O
influenza	O
A	O
/	O
H3N2	B-CHED
and	O
B	O
infections	O
in	O
hospitalized	O
patients	O
.	O

Systematic	O
measurements	O
with	O
the	O
THP	B-CHED
-	O
1	O
cell	O
line	O
allowed	O
for	O
the	O
establishment	O
of	O
a	O
strong	O
correlation	O
between	O
stiffening	O
and	O
the	O
severity	O
of	O
respiratory	O
status	O
(	O
mean	O
ET	O
0	O
.	O
82	O
	O
0	O
.	O
08	O
seconds	O
for	O
healthy	O
subjects	O
,	O
1	O
.	O
6	O
	O
1	O
.	O
0	O
seconds	O
for	O
ACPE	O
groups	O
,	O
10	O
.	O
5	O
	O
6	O
.	O
1	O
seconds	O
for	O
mild	O
ARDS	O
,	O
and	O
20	O
.	O
0	O
	O
8	O
.	O
1	O
seconds	O
for	O
moderate	O
to	O
severe	O
ARDS	O
;	O
p	O
<	O
0	O
.	O
05	O
).	O

A	O
sequence	O
comparison	O
of	O
the	O
partial	O
M	O
gene	O
revealed	O
nucleotide	B-CHED
homologies	O
of	O
88	O
.	O
4	O
%-	O
100	O
%	O
among	O
the	O
57	O
CCoV	O
strains	O
,	O
and	O
88	O
.	O
7	O
%-	O
96	O
.	O
2	O
%	O
identity	O
between	O
the	O
57	O
CCoV	O
strains	O
and	O
the	O
Chinese	O
reference	O
strain	O
HF3	O
.	O

PEDV	O
nsp1	O
did	O
not	O
interfere	O
the	O
IRF3	O
phosphorylation	O
and	O
nuclear	O
translocation	O
but	O
interrupted	O
the	O
enhanceosome	O
assembly	O
of	O
IRF3	O
and	O
CREB	O
-	O
binding	O
protein	B-CHED
(	O
CBP	B-CHED
)	O
by	O
degrading	O
CBP	B-CHED
.	O

Forty	O
-	O
one	O
studies	O
met	B-CHED
the	O
eligibility	O
criteria	O
.	O

Five	O
studies	O
highlighted	O
the	O
role	O
of	O
air	B-CHED
travel	O
in	O
accelerating	O
influenza	O
spread	O
to	O
new	O
areas	O
.	O

With	O
a	O
better	O
understanding	O
of	O
the	O
dynamic	O
interaction	O
between	O
host	O
and	O
coronaviruses	O
,	O
it	O
is	O
hoped	O
that	O
insights	O
on	O
the	O
pathogenesis	O
of	O
newly	O
-	O
identified	O
highly	O
pathogenic	O
human	O
coronaviruses	O
and	O
new	O
strategies	O
in	O
antiviral	B-CHED
development	O
can	O
be	O
derived	O
.	O

A	O
26	O
-	O
month	O
-	O
old	O
girl	O
received	O
a	O
human	O
leukocyte	O
antigen	B-CHED
3	O
/	O
6	O
-	O
allele	O
-	O
matched	O
transplant	O
from	O
cord	O
blood	O
.	O

TITLE	O
:	O
Extensive	O
Positive	O
Selection	O
Drives	O
the	O
Evolution	O
of	O
Nonstructural	O
Proteins	B-CHED
in	O
Lineage	O
C	O
Betacoronaviruses	O
.	O

Quantification	O
of	O
variables	O
by	O
calculating	O
the	O
area	O
under	O
the	O
ROC	O
curve	O
(	O
AUC	O
),	O
sensitivity	O
and	O
sensitivity	O
,	O
positive	O
predictive	O
value	O
(	O
PPV	B-CHED
)	O
and	O
negative	O
predictive	O
value	O
(	O
NPV	O
),	O
allowed	O
a	O
better	O
appreciation	O
of	O
these	O
prognostic	O
scores	O
.	O

The	O
in	O
vitro	O
surface	O
activity	O
and	O
inhibition	O
resistance	O
of	O
synthetic	O
S	O
-	O
MB	O
DATK	O
surfactant	B-CHED
was	O
assessed	O
in	O
the	O
presence	O
and	O
absence	O
of	O
albumin	O
,	O
lysophosphatidylcholine	B-CHED
(	O
lyso	O
-	O
PC	O
),	O
and	O
free	O
fatty	B-CHED
acids	I-CHED
(	O
palmitoleic	O
and	O
oleic	B-CHED
acid	I-CHED
).	O

S	O
-	O
MB	O
DATK	O
surfactant	B-CHED
had	O
very	O
high	O
surface	O
activity	O
in	O
all	O
assessments	O
.	O

S	O
-	O
MB	O
DATK	O
synthetic	O
surfactant	B-CHED
quickly	O
improved	O
arterial	O
oxygenation	O
and	O
lung	O
compliance	O
after	O
intratracheal	O
instillation	O
to	O
ventilated	O
rabbits	O
with	O
severe	O
surfactant	B-CHED
deficiency	O
.	O

S	O
-	O
MB	O
DATK	O
is	O
an	O
active	O
mimic	O
of	O
native	O
SP	O
-	O
B	O
.	O
Synthetic	O
surfactants	B-CHED
containing	O
S	O
-	O
MB	O
DATK	O
(	O
or	O
related	O
peptides	B-CHED
)	O
combined	O
with	O
lipids	B-CHED
appear	O
to	O
have	O
significant	O
future	O
potential	O
for	O
treating	O
clinical	O
states	O
of	O
surfactant	B-CHED
deficiency	O
or	O
dysfunction	O
,	O
such	O
as	O
neonatal	O
and	O
acute	O
respiratory	O
distress	O
syndromes	O
.	O

TITLE	O
:	O
Ribonuclease	O
H	O
/	O
DNA	O
Polymerase	O
HIV	O
-	O
1	O
Reverse	O
Transcriptase	O
Dual	O
Inhibitor	B-CHED
:	O
Mechanistic	O
Studies	O
on	O
the	O
Allosteric	O
Mode	O
of	O
Action	O
of	O
Isatin	B-CHED
-	O
Based	O
Compound	O
RMNC6	O
.	O

We	O
report	O
on	O
the	O
mechanisms	O
of	O
allosteric	O
inhibition	O
of	O
a	O
newly	O
synthesized	O
isatin	B-CHED
-	O
based	O
compound	O
designated	O
as	O
RMNC6	O
that	O
showed	O
IC50	O
values	O
of	O
1	O
.	O
4	O
and	O
9	O
.	O
8	O
M	O
on	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNase	O
H	O
and	O
polymerase	O
activities	O
,	O
respectively	O
.	O

Analysis	O
of	O
Philippine	O
strains	O
revealed	O
amino	B-CHED
acid	I-CHED
substitutions	O
in	O
the	O
SS6	O
epitope	B-CHED
region	O
(	O
LQDGQVKI	O
to	O
SQSGQVKI	O
)	O
of	O
the	O
S1	O
domain	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
dot	O
-	O
immunoblotting	O
assay	O
(	O
DIA	B-CHED
)	O
to	O
measure	O
the	O
titers	O
of	O
IBV	O
vaccines	O
that	O
originated	O
from	O
different	O
pathogenic	O
strains	O
or	O
attenuation	O
methods	O
in	O
embryonated	O
eggs	O
,	O
and	O
we	O
compared	O
this	O
assay	O
to	O
the	O
currently	O
used	O
method	O
,	O
clinical	O
sign	O
evaluation	O
.	O

TITLE	O
:	O
New	O
Potent	O
SARS	O
-	O
CoV	O
3C	O
-	O
Like	O
Protease	B-CHED
Inhibitors	I-CHED
Derived	O
from	O
Thieno	O
[	O
2	O
,	O
3	O
-	O
d	O
]-	O
pyrimidine	B-CHED
Derivatives	O
.	O

ABSTRACT	O
:	O
2	O
-	O
Amino	O
-	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
-	O
tetrahydrobenzo	O
[	O
b	O
]	O
thiophene	B-CHED
-	O
3	O
-	O
carboxamide	B-CHED
(	O
1	O
)	O
condensed	O
with	O
carbaldehydes	O
2a	O
,	O
b	O
to	O
give	O
the	O
respective	O
thienopyrimidines	O
(	O
3a	O
,	O
b	O
),	O
which	O
reacted	O
with	O
phosphoryl	B-CHED
chloride	I-CHED
and	O
hydrazine	B-CHED
hydrate	I-CHED
to	O
afford	O
the	O
respective	O
pyrimidinohydrazines	O
(	O
4a	O
,	O
b	O
).	O

Compound	O
4a	O
condensed	O
with	O
acetophenone	B-CHED
under	O
Vilsmeier	O
conditions	O
to	O
afford	O
the	O
formylated	O
pyrazolopyrimidine	B-CHED
6	O
.	O

Condensation	O
of	O
4a	O
with	O
active	O
methylenes	O
produced	O
the	O
respective	O
pyrazolopyrimidines	B-CHED
(	O
7	O
-	O
11	O
).	O

Moreover	O
,	O
4a	O
reacted	O
with	O
isatin	B-CHED
to	O
afford	O
the	O
hydrazono	O
-	O
indolin	B-CHED
-	I-CHED
2	I-CHED
-	I-CHED
one	I-CHED
14	O
.	O

Eleven	O
of	O
the	O
new	O
compounds	O
were	O
tested	O
and	O
found	O
active	O
against	O
influenza	O
A	O
neuraminidase	O
virus	O
(	O
H3N2	B-CHED
).	O

This	O
study	O
examined	O
the	O
association	O
between	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
)	O
and	O
cytokines	O
.	O

TITLE	O
:	O
[	O
Prognostic	O
value	O
of	O
extra	O
-	O
vascular	O
lung	O
water	B-CHED
index	O
and	O
pulmonary	O
vascular	O
permeability	O
index	O
in	O
patients	O
with	O
ARDS	O
].	O

Multivariate	O
Logistic	O
regression	O
analysis	O
showed	O
that	O
EVLWI	O
and	O
lactic	B-CHED
acid	I-CHED
were	O
risk	O
factors	O
for	O
ARDS	O
death	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
effect	O
of	O
mehanical	O
ventilation	O
(	O
MV	O
)	O
guided	O
by	O
transpulmonary	O
pressure	O
(	O
Ptp	B-CHED
)	O
on	O
respiratory	O
mechanics	O
and	O
gas	O
exchange	O
in	O
severe	O
acute	O
pancreatitis	O
patient	O
with	O
intraabdominal	O
hypertension	O
.	O

PEEP	B-CHED
levels	O
were	O
set	O
to	O
achieve	O
a	O
Ptp	B-CHED
of	O
0	O
to	O
10	O
cm	O
of	O
water	B-CHED
at	O
end	O
expiration	O
.	O

Recent	O
trials	O
provided	O
no	O
evidence	O
for	O
increased	O
risk	O
of	O
secondary	O
infections	O
or	O
critical	O
illness	O
neuromyopathy	O
in	O
patients	O
with	O
sepsis	O
or	O
ARDS	O
with	O
the	O
use	O
of	O
corticosteroids	B-CHED
or	O
neuromuscular	O
blockers	O
.	O

Therefore	O
,	O
a	O
further	O
understanding	O
of	O
the	O
cross	O
host	O
transmission	O
of	O
MERS	O
-	O
CoV	O
is	O
needed	O
to	O
limit	O
the	O
risks	O
this	O
virus	O
poses	O
to	O
man	B-CHED
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
clinical	O
and	O
radiographic	O
changes	O
of	O
rhesus	O
monkeys	O
following	O
infection	O
with	O
5	O
	O
10	O
(	O
6	O
)	O
PFU	B-CHED
MERS	O
-	O
CoV	O
Jordan	O
-	O
n3	O
/	O
2012	O
.	O

In	O
addition	O
,	O
the	O
production	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
and	O
the	O
activity	O
of	O
myeloperoxidase	O
in	O
pulmonary	O
tissues	O
were	O
notably	O
repressed	O
.	O

ABSTRACT	O
:	O
The	O
5	O
'-	O
cap	O
structures	O
of	O
eukaryotic	O
mRNAs	O
are	O
important	O
for	O
RNA	O
stability	O
,	O
pre	O
-	O
mRNA	B-CHED
splicing	O
,	O
mRNA	B-CHED
export	O
,	O
and	O
protein	B-CHED
translation	O
.	O

Although	O
MR	O
-	O
RT	O
harbored	O
the	O
most	O
significant	O
amino	B-CHED
acid	I-CHED
exchanges	O
T215Y	O
and	O
Q151M	O
of	O
each	O
pathway	O
,	O
it	O
exclusively	O
used	O
AZTTP	O
discrimination	O
,	O
indicating	O
that	O
the	O
two	O
mechanisms	O
are	O
mutually	O
exclusive	O
and	O
that	O
the	O
Q151M	O
pathway	O
is	O
obviously	O
preferred	O
since	O
it	O
confers	O
resistance	O
to	O
most	O
nucleoside	B-CHED
inhibitors	B-CHED
.	O

extract	O
,	O
quercetin	B-CHED
,	O
quercetrin	O
and	O
cinanserin	O
on	O
murine	O
coronavirus	O
and	O
dengue	O
virus	O
infection	O
.	O

Certain	O
flavonoids	B-CHED
exhibited	O
comparatively	O
weaker	O
antiviral	B-CHED
activity	O
,	O
notably	O
quercetin	B-CHED
which	O
could	O
inhibit	O
both	O
MHV	O
and	O
DENV	O
-	O
2	O
.	O

This	O
phenomenon	O
,	O
known	O
as	O
the	O
protein	B-CHED
corona	B-CHED
,	O
is	O
well	O
established	O
in	O
the	O
field	O
of	O
synthetic	O
nanotechnology	O
but	O
has	O
not	O
been	O
described	O
in	O
the	O
context	O
of	O
plant	O
virus	O
nanoparticles	B-CHED
(	O
VNPs	O
).	O

The	O
formed	O
corona	B-CHED
is	O
dominated	O
by	O
complement	O
proteins	B-CHED
and	O
immunoglobulins	O
,	O
the	O
binding	O
of	O
which	O
can	O
be	O
reduced	O
by	O
PEGylating	O
the	O
VNP	O
surface	O
.	O

We	O
here	O
report	O
a	O
case	O
of	O
HCoV	O
infection	O
in	O
a	O
leukemia	O
patient	O
with	O
fatal	O
ARDS	O
despite	O
successful	O
virus	O
elimination	O
by	O
pegylated	O
interferon	O
-	O
alpha	O
(	O
PEG	B-CHED
-	O
IFN	O
-	O
	O
).	O

The	O
possible	O
influence	O
of	O
the	O
emergence	O
of	O
macrolide	B-CHED
-	O
resistant	O
M	O
.	O
pneumoniae	O
on	O
extrapulmonary	O
manifestations	O
,	O
which	O
can	O
be	O
considered	O
of	O
limited	O
clinical	O
threat	O
in	O
Japan	O
where	O
the	O
resistant	O
rate	O
has	O
currently	O
decreased	O
,	O
is	O
discussed	O
on	O
the	O
basis	O
of	O
unique	O
biological	O
characteristics	O
of	O
M	O
.	O
pneumoniae	O
,	O
the	O
smallest	O
self	O
-	O
replicating	O
organism	O
.	O

However	O
,	O
it	O
remains	O
elusive	O
whether	O
or	O
not	O
a	O
pathogen	O
-	O
derived	O
protein	B-CHED
can	O
function	O
as	O
a	O
cytosolic	O
pathogen	O
-	O
associated	O
molecular	O
pattern	O
(	O
PAMP	O
).	O

All	O
patients	O
required	O
oxygen	B-CHED
therapy	O
and	O
17	O
(	O
35	O
.	O
4	O
%)	O
required	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
Meeting	O
report	O
:	O
4th	O
ISIRV	O
antiviral	B-CHED
group	O
conference	O
:	O
Novel	O
antiviral	B-CHED
therapies	O
for	O
influenza	O
and	O
other	O
respiratory	O
viruses	O
.	O

With	O
emerging	O
resistance	O
to	O
the	O
drugs	O
currently	O
licensed	O
for	O
treatment	O
and	O
prophylaxis	O
of	O
influenza	O
viruses	O
,	O
primarily	O
the	O
neuraminidase	B-CHED
inhibitor	I-CHED
oseltamivir	B-CHED
phosphate	I-CHED
(	O
Tamiflu	B-CHED
)	O
and	O
the	O
M2	O
inhibitors	B-CHED
amantadine	B-CHED
and	O
rimantadine	O
,	O
and	O
the	O
lack	O
of	O
effective	O
interventions	O
against	O
other	O
respiratory	O
viruses	O
,	O
the	O
3	O
-	O
day	O
programme	O
focused	O
on	O
the	O
discovery	O
and	O
development	O
of	O
inhibitors	B-CHED
of	O
several	O
virus	O
targets	O
and	O
key	O
host	O
cell	O
factors	O
involved	O
in	O
virus	O
replication	O
or	O
mediating	O
the	O
inflammatory	O
response	O
.	O

These	O
inhibitors	B-CHED
showed	O
protease	O
selectivity	O
and	O
no	O
cytotoxicity	O
.	O

Patients	O
treated	O
with	O
intravenous	O
quinine	B-CHED
require	O
careful	O
monitoring	O
for	O
hypoglycemia	O
.	O

Haemolysis	O
occurs	O
in	O
approximately	O
10	O
-	O
15	O
%	O
patients	O
following	O
intravenous	O
artesunate	B-CHED
treatment	O
.	O

Uncomplicated	O
falciparum	O
malaria	O
in	O
the	O
second	O
and	O
third	O
trimester	O
of	O
pregnancy	O
should	O
be	O
treated	O
with	O
artemether	B-CHED
-	O
lumefantrine	B-CHED
(	O
Grade	O
2B	O
).	O

Quinine	B-CHED
with	O
doxycycline	B-CHED
or	O
clindamycin	B-CHED
,	O
or	O
atovaquone	B-CHED
-	O
proguanil	B-CHED
at	O
appropriate	O
doses	O
for	O
weight	O
can	O
also	O
be	O
used	O
.	O

In	O
multivariable	O
analysis	O
,	O
older	O
age	O
,	O
greater	O
severity	O
scores	O
at	O
ICU	O
admission	O
,	O
and	O
hematologic	O
malignancy	O
or	O
liver	O
disease	O
were	O
independently	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
in	O
-	O
hospital	O
death	O
,	O
whereas	O
influenza	O
vaccination	O
prior	O
to	O
ICU	O
admission	O
and	O
adequate	O
antibiotic	B-CHED
administration	O
on	O
ICU	O
admission	O
were	O
associated	O
with	O
a	O
lower	O
risk	O
.	O

Based	O
on	O
2	O
prospective	O
studies	O
in	O
mostly	O
adults	O
and	O
retrospective	O
data	O
in	O
children	O
,	O
eculizumab	O
,	O
a	O
terminal	O
complement	O
inhibitor	B-CHED
,	O
is	O
approved	O
for	O
aHUS	O
treatment	O
.	O

This	O
virus	O
has	O
been	O
genotyped	O
by	O
sequence	O
analysis	O
of	O
the	O
S1	O
glycoprotein	B-CHED
gene	O
.	O

How	O
melatonin	B-CHED
directly	O
blocks	O
activation	O
of	O
the	O
NLRP3	O
inflammasome	O
in	O
ALI	O
remains	O
unclear	O
.	O

In	O
this	O
study	O
,	O
using	O
an	O
LPS	B-CHED
-	O
induced	O
ALI	O
mouse	O
model	O
,	O
we	O
found	O
intratracheal	O
(	O
i	O
.	O
t	O
.)	O
administration	O
of	O
melatonin	B-CHED
markedly	O
reduced	O
the	O
pulmonary	O
injury	O
and	O
decreased	O
the	O
infiltration	O
of	O
macrophages	O
and	O
neutrophils	O
into	O
lung	O
.	O

However	O
,	O
despite	O
some	O
previous	O
genetic	O
and	O
biochemical	O
evidence	O
that	O
mapped	O
interactions	O
with	O
N	O
to	O
the	O
carboxy	B-CHED
terminus	O
of	O
M	O
,	O
it	O
was	O
not	O
possible	O
to	O
define	O
a	O
short	O
linear	O
region	O
of	O
M	O
protein	B-CHED
sufficient	O
for	O
assembly	O
with	O
N	O
.	O
Thus	O
,	O
interactions	O
with	O
N	O
protein	B-CHED
likely	O
involve	O
multiple	O
linearly	O
discontiguous	O
regions	O
of	O
the	O
M	O
endodomain	O
.	O

Moreover	O
,	O
virions	O
of	O
the	O
M	O
chimera	O
were	O
markedly	O
deficient	O
in	O
spike	O
(	O
S	O
)	O
protein	B-CHED
incorporation	O
.	O

In	O
this	O
work	O
,	O
we	O
replaced	O
the	O
membrane	O
(	O
M	O
)	O
protein	B-CHED
of	O
the	O
model	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
with	O
its	O
counterpart	O
from	O
a	O
heterologous	O
coronavirus	O
.	O

TITLE	O
:	O
The	O
C	O
-	O
Terminal	O
Tail	O
of	O
TRIM56	O
Dictates	O
Antiviral	B-CHED
Restriction	O
of	O
Influenza	O
A	O
and	O
B	O
Viruses	O
by	O
Impeding	O
Viral	O
RNA	O
Synthesis	O
.	O

We	O
show	O
here	O
that	O
TRIM56	O
,	O
a	O
tripartite	O
-	O
motif	O
protein	B-CHED
,	O
is	O
an	O
intrinsic	O
host	O
restriction	O
factor	O
of	O
influenza	O
A	O
and	O
B	O
viruses	O
.	O

We	O
recommend	O
inpatient	O
observation	O
after	O
an	O
initial	O
infusion	O
of	O
zoledronic	B-CHED
acid	I-CHED
in	O
medically	O
complex	O
children	O
.	O

In	O
this	O
study	O
,	O
the	O
structure	O
determination	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
MERS	O
-	O
CoV	O
N	O
protein	B-CHED
via	O
X	O
-	O
ray	O
diffraction	O
measurements	O
is	O
reported	O
at	O
a	O
resolution	O
of	O
2	O
.	O
4	O
	O
.	O
Since	O
the	O
first	O
30	O
amino	B-CHED
acids	I-CHED
were	O
not	O
resolved	O
by	O
X	O
-	O
ray	O
diffraction	O
,	O
the	O
structural	O
study	O
was	O
completed	O
by	O
a	O
SAXS	O
experiment	O
to	O
propose	O
a	O
structural	O
model	O
including	O
the	O
IDR	O
.	O

Here	O
we	O
demonstrate	O
the	O
transient	O
expression	O
in	O
Nicotiana	O
benthamiana	O
of	O
two	O
important	O
antigenic	O
determinants	O
of	O
the	O
SARS	O
-	O
CoV	O
,	O
the	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
)	O
and	O
the	O
membrane	O
protein	B-CHED
(	O
M	O
)	O
using	O
a	O
virus	O
-	O
derived	O
vector	O
or	O
agro	O
-	O
infiltration	O
,	O
respectively	O
.	O

The	O
availability	O
of	O
recombinant	O
N	O
and	O
M	O
proteins	B-CHED
from	O
plants	O
opens	O
the	O
way	O
to	O
further	O
evaluation	O
of	O
their	O
potential	O
utility	O
for	O
the	O
development	O
of	O
diagnostic	O
and	O
protection	O
/	O
therapy	O
tools	O
to	O
be	O
quickly	O
manufactured	O
,	O
at	O
low	O
cost	O
and	O
with	O
minimal	O
risk	O
,	O
to	O
face	O
potential	O
new	O
highly	O
infectious	O
SARS	O
-	O
CoV	O
outbreaks	O
.	O

TITLE	O
:	O
ROS	B-CHED
-	O
activated	O
calcium	B-CHED
signaling	O
mechanisms	O
regulating	O
endothelial	O
barrier	O
function	O
.	O

Both	O
live	O
and	O
pseudoviruses	O
could	O
infected	O
Vero	O
-	O
CCL	B-CHED
-	O
81	O
(	O
monkey	O
kidney	O
),	O
Huh	O
-	O
7	O
(	O
human	O
liver	O
),	O
and	O
PK	O
-	O
15	O
(	O
pig	O
kidney	O
)	O
cells	O
efficiently	O
.	O

This	O
study	O
has	O
paved	O
the	O
avenue	O
for	O
developing	O
new	O
prophylactic	O
and	O
therapeutic	O
agents	O
with	O
broad	O
-	O
spectrum	O
antiviral	B-CHED
activities	O
.	O

The	O
guidelines	O
described	O
here	O
are	O
an	O
updated	O
version	O
that	O
includes	O
case	O
definition	O
,	O
indications	O
for	O
testing	O
,	O
specimen	O
type	O
and	O
protocols	O
for	O
specimen	O
collection	O
,	O
specimen	O
packing	O
and	O
transport	O
,	O
specimen	O
handling	O
and	O
nucleic	B-CHED
acid	I-CHED
extraction	O
,	O
molecular	O
detection	O
of	O
MERS	O
-	O
CoV	O
,	O
interpretation	O
of	O
results	O
and	O
reporting	O
,	O
and	O
laboratory	O
safety	O
.	O

The	O
spike	O
glycoprotein	B-CHED
,	O
nucleocapsid	O
and	O
1a	O
genes	O
were	O
sequenced	O
for	O
phylogenetic	O
reconstruction	O
and	O
Bayesian	O
coalescent	O
inference	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
virus	O
structure	O
,	O
the	O
replication	O
,	O
and	O
the	O
transcription	O
of	O
CoV	O
.	O
This	O
protein	B-CHED
,	O
which	O
has	O
a	O
helix	O
and	O
flexible	O
structure	O
,	O
and	O
capable	O
of	O
binding	O
on	O
to	O
the	O
viral	O
genomic	O
RNA	O
,	O
is	O
a	O
non	O
-	O
structural	O
protein	B-CHED
(	O
nsp3	O
).	O

TITLE	O
:	O
[	O
Bioinformatics	O
analysis	O
on	O
molecular	O
mechanism	O
of	O
ribavirin	B-CHED
and	O
interferon	O
-	O
	O
in	O
treating	O
MERS	O
-	O
CoV	O
].	O

The	O
correct	O
detection	O
of	O
CDV	B-CHED
had	O
been	O
achieved	O
in	O
ten	O
out	O
of	O
eleven	O
positive	O
cases	O
(	O
90	O
.	O
9	O
%)	O
upon	O
initial	O
investigation	O
,	O
but	O
the	O
presence	O
of	O
bacterial	O
pathogens	O
,	O
like	O
B	O
.	O
bronchiseptica	O
(	O
10	O
cases	O
)	O
and	O
P	O
.	O
multocida	O
(	O
17	O
cases	O
)	O
had	O
been	O
missed	O
in	O
all	O
but	O
one	O
case	O
.	O

We	O
hypothesized	O
that	O
endothelial	O
activation	O
biomarkers	O
would	O
be	O
differentially	O
expressed	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
from	O
patients	O
with	O
ARDS	O
compared	O
with	O
healthy	O
volunteers	O
,	O
and	O
that	O
biomarker	B-CHED
concentrations	O
would	O
be	O
associated	O
with	O
ARDS	O
severity	O
.	O

This	O
study	O
described	O
the	O
similarities	O
and	O
differences	O
in	O
epidemiological	O
and	O
clinical	O
characteristics	O
of	O
183	O
confirmed	O
global	O
MERS	O
cases	O
and	O
98	O
SARS	O
cases	O
in	O
Taiwan	O
associated	O
with	O
HCP	B-CHED
.	O

In	O
conclusion	O
,	O
the	O
severity	O
of	O
MERS	O
-	O
HCP	B-CHED
and	O
SARS	O
-	O
HCP	B-CHED
was	O
lower	O
than	O
that	O
of	O
MERS	O
-	O
non	O
-	O
HCP	B-CHED
and	O
SARS	O
-	O
non	O
-	O
HCP	B-CHED
due	O
to	O
younger	O
age	O
and	O
early	O
confirmation	O
in	O
HCP	B-CHED
groups	O
.	O

EGFR	O
is	O
also	O
the	O
upstream	O
activator	O
of	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathways	O
that	O
is	O
involved	O
in	O
F	O
-	O
actin	O
reorganization	O
.	O

ABSTRACT	O
:	O
To	O
design	O
an	O
alternative	O
vaccine	O
for	O
control	O
of	O
infectious	O
bronchitis	O
in	O
chickens	O
,	O
three	O
recombinant	O
duck	O
enteritis	O
viruses	O
(	O
rDEVs	O
)	O
expressing	O
the	O
N	O
,	O
S	O
,	O
or	O
S1	O
protein	B-CHED
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
were	O
constructed	O
using	O
conventional	O
homologous	O
recombination	O
methods	O
,	O
and	O
were	O
designated	O
as	O
rDEV	O
-	O
N	O
,	O
rDEV	O
-	O
S	O
,	O
and	O
rDEV	O
-	O
S1	O
,	O
respectively	O
.	O

CoV	O
genomes	O
encode	O
an	O
integral	O
viral	O
component	O
,	O
main	O
protease	O
(	O
M	O
(	O
pro	B-CHED
)),	O
which	O
is	O
essential	O
for	O
viral	O
replication	O
through	O
proteolytic	O
processing	O
of	O
RNA	O
replicase	O
machinery	O
.	O

Anti	O
-	O
glycolipid	B-CHED
reactivity	O
was	O
studied	O
in	O
patients	O
with	O
Guillain	O
-	O
Barr	O
syndrome	O
using	O
both	O
ELISA	O
and	O
combinatorial	O
microarrays	O
.	O

In	O
this	O
study	O
,	O
via	O
high	O
throughput	O
screening	O
of	O
Food	O
and	O
Drug	O
Administration	O
-	O
approved	O
drugs	O
,	O
we	O
identified	O
that	O
teicoplanin	O
,	O
a	O
glycopeptide	B-CHED
antibiotic	I-CHED
,	O
potently	O
prevents	O
the	O
entry	O
of	O
Ebola	O
envelope	O
pseudotyped	O
viruses	O
into	O
the	O
cytoplasm	O
.	O

During	O
that	O
season	O
,	O
antigenic	O
drift	O
of	O
influenza	O
virus	O
A	O
/	O
H3N2	B-CHED
/	O
occurred	O
causing	O
higher	O
rates	O
of	O
A	O
/	O
H3N2	B-CHED
/	O
infections	O
.	O

Here	O
,	O
we	O
review	O
current	O
knowledge	O
about	O
virus	O
-	O
glycan	B-CHED
interactions	O
using	O
representative	O
crystal	O
structures	O
of	O
viral	O
attachment	O
proteins	B-CHED
in	O
complex	O
with	O
glycans	B-CHED
.	O

A	O
detailed	O
understanding	O
of	O
these	O
parameters	O
is	O
important	O
for	O
the	O
prediction	O
of	O
binding	O
sites	O
where	O
structural	O
information	O
is	O
not	O
available	O
,	O
and	O
is	O
invaluable	O
for	O
the	O
development	O
of	O
antiviral	B-CHED
therapeutics	O
.	O

Donor	B-CHED
-	O
free	O
blood	O
products	O
such	O
as	O
ex	O
vivo	O
generated	O
red	O
blood	O
cells	O
offer	O
a	O
theoretical	O
way	O
to	O
avoid	O
transmission	O
-	O
transmitted	O
infection	O
risk	O
,	O
although	O
biological	O
,	O
engineering	O
,	O
and	O
manufacturing	O
challenges	O
must	O
be	O
overcome	O
before	O
this	O
approach	O
becomes	O
practical	O
.	O

We	O
found	O
that	O
MERS	O
-	O
CoV	O
shared	O
30	O
%	O
of	O
its	O
S	O
protein	B-CHED
antigenic	O
sites	O
with	O
HKU4	O
and	O
70	O
%	O
with	O
HKU5	O
bat	O
-	O
CoV	O
.	O
Whereas	O
100	O
%	O
of	O
its	O
E	O
,	O
M	O
and	O
N	O
protein	B-CHED
'	O
s	O
antigenic	O
sites	O
are	O
found	O
to	O
be	O
conserved	O
with	O
those	O
in	O
HKU4	O
and	O
HKU5	O
.	O

Thought	O
Korean	O
strains	O
of	O
PDCoV	O
isolated	O
in	O
2014	O
(	O
KNU14	O
.	O
04	O
)	O
and	O
in	O
2015	O
(	O
SL2	O
and	O
SL5	O
)	O
grouped	O
within	O
US	O
PDCoV	O
cluster	O
,	O
the	O
reconstruction	O
of	O
ancestral	O
amino	B-CHED
acid	I-CHED
changes	O
suggested	O
that	O
they	O
are	O
different	O
.	O

The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
compare	O
outcomes	O
in	O
patients	O
who	O
had	O
severe	O
hypoxemic	O
respiratory	O
failure	O
(	O
Pao2	O
/	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
<	O
100	O
)	O
who	O
received	O
early	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
as	O
an	O
adjunct	O
to	O
mechanical	O
ventilation	O
,	O
to	O
those	O
in	O
patients	O
who	O
received	O
conventional	O
mechanical	O
ventilation	O
alone	O
.	O

ABSTRACT	O
:	O
A	O
66	O
-	O
year	O
-	O
old	O
woman	O
,	O
who	O
had	O
been	O
treated	O
with	O
systemic	O
corticosteroids	B-CHED
for	O
four	O
months	O
for	O
vasculitis	O
of	O
unknown	O
etiology	O
,	O
was	O
referred	O
to	O
our	O
department	O
due	O
to	O
a	O
fever	O
,	O
dyspnea	O
and	O
patchy	O
ground	O
-	O
glass	O
opacities	O
on	O
chest	O
computed	O
tomography	O
.	O

As	O
transbronchial	O
biopsy	O
specimens	O
were	O
suggestive	O
of	O
interstitial	O
pneumonia	O
,	O
the	O
prescribed	O
dose	O
of	O
corticosteroids	B-CHED
was	O
increased	O
.	O

Metabolite	B-CHED
detection	O
and	O
quantification	O
provide	O
a	O
valuable	O
addition	O
to	O
genomics	O
and	O
proteomics	O
and	O
give	O
unique	O
insights	O
into	O
metabolic	O
changes	O
that	O
occur	O
in	O
tangent	O
to	O
alterations	O
in	O
gene	O
and	O
protein	B-CHED
activity	O
that	O
are	O
associated	O
with	O
disease	O
.	O

The	O
neutrophils	O
that	O
infiltrate	O
the	O
lungs	O
and	O
migrate	O
into	O
the	O
airways	O
express	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
such	O
as	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
	O
),	O
interleukin	O
-	O
1	O
beta	O
(	O
IL	O
-	O
1	O
),	O
and	O
contribute	O
to	O
both	O
the	O
endothelial	O
and	O
epithelial	O
integrity	O
disruption	O
of	O
the	O
barriers	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
molecular	O
docking	O
studies	O
and	O
anti	O
-	O
HBV	O
activity	O
of	O
phenylpropanoid	B-CHED
derivatives	O
.	O

Epidemiologic	O
and	O
genetic	O
sequencing	O
findings	O
suggest	O
that	O
3	O
healthcare	O
clusters	B-CHED
of	O
MERS	O
-	O
CoV	O
infection	O
occurred	O
,	O
including	O
1	O
that	O
resulted	O
in	O
20	O
infected	O
persons	O
in	O
1	O
hospital	O
.	O

Furthermore	O
,	O
pFcRn	O
-	O
transcytosed	O
viral	O
-	O
specific	O
IgG	O
reduced	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
yield	O
from	O
the	O
luminal	B-CHED
direction	O
by	O
a	O
50	O
%	O
tissue	O
culture	O
infective	O
dose	O
(	O
TCID50	O
)	O
assay	O
.	O

ABSTRACT	O
:	O
The	O
objective	O
of	O
the	O
Scandinavian	O
Society	O
of	O
Anaesthesiology	O
and	O
Intensive	O
Care	O
Medicine	B-CHED
(	O
SSAI	O
)	O
task	O
force	O
on	O
fluid	O
and	O
drug	O
therapy	O
in	O
adults	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
was	O
to	O
provide	O
clinically	O
relevant	O
,	O
evidence	O
-	O
based	O
treatment	O
recommendations	O
according	O
to	O
standards	O
for	O
trustworthy	O
guidelines	O
.	O

Two	O
other	O
novel	O
HDT	O
candidates	O
,	O
DAS181	O
and	O
resveratrol	B-CHED
show	O
antiinfluenza	O
effects	O
.	O

ABSTRACT	O
:	O
The	O
newly	O
emerging	O
human	O
pathogen	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
contains	O
a	O
macro	O
domain	O
in	O
the	O
highly	O
conserved	O
N	O
-	O
terminal	O
region	O
of	O
non	O
-	O
structural	O
protein	B-CHED
3	O
.	O

ABSTRACT	O
:	O
On	O
the	O
basis	O
of	O
structure	O
-	O
based	O
bioisosteric	O
replacement	O
and	O
molecular	O
hybridization	O
strategy	O
,	O
a	O
series	O
of	O
novel	O
dual	O
structural	O
-	O
conformation	O
inhibitors	B-CHED
targeting	O
the	O
""""	O
entrance	O
channel	O
""""	O
of	O
HIV	O
-	O
1	O
NNRTIs	O
binding	O
pocket	O
(	O
NNIBP	O
)	O
were	O
designed	O
and	O
synthesized	O
.	O

Systemic	O
corticosteroid	B-CHED
therapy	O
led	O
to	O
a	O
rapid	O
improvement	O
in	O
clinical	O
conditions	O
and	O
radiological	O
findings	O
.	O

To	O
modulate	O
carbon	B-CHED
dioxide	I-CHED
extraction	O
,	O
ECMO	O
gas	O
flow	O
(	O
GF	O
)	O
was	O
decreased	O
from	O
baseline	O
resting	O
protective	O
conditions	O
(	O
i	O
.	O
e	O
.,	O
GF100	O
%,	O
set	O
to	O
obtain	O
pressure	O
generated	O
in	O
the	O
first	O
100	O
ms	O
of	O
inspiration	O
against	O
an	O
occluded	O
airway	O
less	O
than	O
2	O
cm	O
H2O	B-CHED
,	O
respiratory	O
rate	O
less	O
than	O
or	O
equal	O
to	O
25	O
bpm	O
,	O
tidal	O
volume	O
less	O
than	O
6	O
ml	O
/	O
kg	O
,	O
and	O
peak	O
airway	O
pressure	O
less	O
than	O
25	O
cm	O
H2O	B-CHED
)	O
to	O
GF50	O
%-	O
GF25	O
%-	O
GF0	O
%	O
during	O
both	O
PSV	O
and	O
NAVA	O
(	O
random	O
order	O
for	O
ventilation	O
mode	O
).	O

RESULTS	O
:	O
At	O
higher	O
levels	O
of	O
extracorporeal	O
carbon	B-CHED
dioxide	I-CHED
extraction	O
,	O
pressure	O
generated	O
in	O
the	O
first	O
100	O
ms	O
of	O
inspiration	O
against	O
an	O
occluded	O
airway	O
decreased	O
from	O
2	O
.	O
8	O
	O
2	O
.	O
7	O
cm	O
H2O	B-CHED
(	O
PSV	O
,	O
GF0	O
%)	O
and	O
3	O
.	O
0	O
	O
2	O
.	O
1	O
cm	O
H2O	B-CHED
(	O
NAVA	O
,	O
GF0	O
%)	O
to	O
0	O
.	O
9	O
	O
0	O
.	O
5	O
cm	O
H2O	B-CHED
(	O
PSV	O
,	O
GF100	O
%)	O
and	O
1	O
.	O
0	O
	O
0	O
.	O
8	O
cm	O
H2O	B-CHED
(	O
NAVA	O
,	O
GF100	O
%;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
patients	O
'	O
inspiratory	O
muscle	O
pressure	O
passed	O
from	O
8	O
.	O
5	O
	O
6	O
.	O
3	O
and	O
6	O
.	O
5	O
	O
5	O
.	O
5	O
cm	O
H2O	B-CHED
to	O
4	O
.	O
5	O
	O
3	O
.	O
1	O
and	O
4	O
.	O
2	O
	O
3	O
.	O
7	O
cm	O
H2O	B-CHED
(	O
P	O
<	O
0	O
.	O
001	O
).	O

CoVs	O
have	O
evolved	O
several	O
mechanisms	O
to	O
counteract	O
the	O
innate	O
immune	O
response	O
at	O
different	O
levels	O
,	O
but	O
the	O
role	O
of	O
CoV	O
-	O
encoded	O
ribonucleases	O
in	O
preventing	O
activation	O
of	O
the	O
dsRNA	B-CHED
-	O
induced	O
antiviral	B-CHED
response	O
has	O
not	O
been	O
described	O
to	O
date	O
.	O

We	O
provide	O
the	O
first	O
evidence	O
that	O
conserved	O
epitope	B-CHED
(	O
s	O
)	O
on	O
the	O
respective	O
viral	O
nucleocapsid	O
proteins	B-CHED
cross	O
-	O
react	O
with	O
each	O
other	O
although	O
virus	O
neutralization	O
cross	O
-	O
reactivity	O
was	O
not	O
observed	O
.	O

Serum	O
bilirubin	B-CHED
,	O
AST	O
and	O
ALT	B-CHED
levels	O
were	O
higher	O
while	O
age	O
was	O
lower	O
in	O
both	O
overall	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
)	O
and	O
falciparum	O
malaria	O
cases	O
with	O
hepatopathy	O
than	O
without	O
hepatopathy	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
).	O

TITLE	O
:	O
Fat	O
(	O
al	O
)	O
attraction	O
:	O
Picornaviruses	O
Usurp	O
Lipid	B-CHED
Transfer	O
at	O
Membrane	O
Contact	O
Sites	O
to	O
Create	O
Replication	O
Organelles	O
.	O

Wang	O
clinical	O
respiratory	O
severity	O
score	O
was	O
found	O
,	O
by	O
using	O
multivariate	O
models	O
,	O
to	O
predict	O
nasogastric	O
tube	O
need	O
,	O
oxygen	B-CHED
desaturation	O
days	O
,	O
and	O
length	O
of	O
hospitalization	O
.	O

Like	O
many	O
coronaviruses	O
,	O
MERS	O
-	O
CoV	O
carries	O
genes	O
that	O
encode	O
multiple	O
accessory	O
proteins	B-CHED
that	O
are	O
not	O
required	O
for	O
replication	O
of	O
the	O
genome	O
but	O
are	O
likely	O
involved	O
in	O
pathogenesis	O
.	O

Here	O
we	O
report	O
that	O
MERS	O
-	O
CoV	O
,	O
a	O
lineage	O
CBetacoronavirus	O
,	O
and	O
related	O
bat	O
CoV	O
NS4b	O
accessory	O
proteins	B-CHED
have	O
phosphodiesterase	O
(	O
PDE	O
)	O
activity	O
and	O
antagonize	O
OAS	O
-	O
RNase	O
L	O
by	O
enzymatically	O
degrading	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
(	O
2	O
-	O
5A	O
),	O
activators	O
of	O
RNase	O
L	O
.	O
This	O
is	O
a	O
novel	O
function	O
for	O
NS4b	O
,	O
which	O
has	O
previously	O
been	O
reported	O
to	O
antagonize	O
IFN	O
signaling	O
.	O

Antiviral	B-CHED
treatment	O
was	O
associated	O
with	O
a	O
rapid	O
improvement	O
in	O
fever	O
,	O
ascites	O
,	O
lymphopenia	O
and	O
gross	O
signs	O
of	O
illness	O
and	O
cats	O
returned	O
to	O
normal	O
health	O
within	O
20	O
days	O
or	O
less	O
of	O
treatment	O
.	O

TITLE	O
:	O
Identification	O
of	O
the	O
Fusion	O
Peptide	B-CHED
-	O
Containing	O
Region	O
in	O
Betacoronavirus	O
Spike	O
Glycoproteins	B-CHED
.	O

The	O
synthetic	O
MERS	O
-	O
CoV	O
pFP	B-CHED
core	O
peptide	B-CHED
(	O
955IAGVGWTAGL964	O
)	O
induced	O
extensive	O
fusion	O
of	O
liposome	O
membranes	O
,	O
while	O
mutant	O
peptide	B-CHED
failed	O
to	O
induce	O
any	O
lipid	B-CHED
mixing	O
.	O

Thus	O
,	O
the	O
FPs	O
of	O
3	O
different	O
lineages	O
of	O
	O
-	O
CoVs	O
are	O
conserved	O
in	O
location	O
within	O
the	O
S	O
glycoproteins	B-CHED
and	O
in	O
their	O
functions	O
,	O
although	O
their	O
amino	B-CHED
acid	I-CHED
sequences	O
have	O
diverged	O
significantly	O
during	O
CoV	O
evolution	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
location	O
and	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
the	O
FPs	O
of	O
S	O
glycoproteins	B-CHED
of	O
3	O
	O
-	O
CoVs	O
,	O
MERS	O
-	O
CoV	O
,	O
SARS	O
-	O
CoV	O
,	O
and	O
MHV	O
,	O
and	O
demonstrated	O
that	O
they	O
were	O
essential	O
for	O
mediating	O
cell	O
-	O
cell	O
fusion	O
and	O
virus	O
entry	O
.	O

To	O
understand	O
the	O
roles	O
of	O
conserved	O
residues	O
in	O
catalysis	O
,	O
we	O
determined	O
the	O
structure	O
of	O
the	O
free	O
enzyme	O
and	O
the	O
first	O
structure	O
of	O
an	O
inhibitor	B-CHED
-	O
bound	O
alphaviral	O
protease	O
.	O

Interestingly	O
,	O
E64c	O
(	O
200	O
M	O
),	O
the	O
carboxylic	B-CHED
acid	I-CHED
form	O
of	O
the	O
E64d	O
ester	B-CHED
,	O
did	O
not	O
inhibit	O
the	O
nsP2	O
protease	O
.	O

Currently	O
,	O
not	O
much	O
is	O
known	O
about	O
HLH	O
due	O
to	O
seasonal	O
flu	O
;	O
particularly	O
,	O
IAV	O
(	O
H3N2	B-CHED
)-	O
related	O
HLH	O
cases	O
are	O
rare	O
and	O
reported	O
cases	O
showed	O
poor	O
outcomes	O
as	O
well	O
.	O

Typical	O
clinical	O
determinations	O
are	O
:	O
arterial	O
partial	O
pressure	O
of	O
oxygen	B-CHED
<	O
60	O
mmHg	O
and	O
/	O
or	O
arterial	O
oxygenation	O
<	O
88	O
%	O
and	O
/	O
or	O
the	O
ratio	O
of	O
PaO2	O
/	O
FIO2	O
<	O
100	O
.	O

A	O
negative	O
fluid	O
balance	B-CHED
is	O
associated	O
with	O
improved	O
lung	O
function	O
and	O
the	O
use	O
of	O
hemofiltration	O
might	O
be	O
indicated	O
for	O
specific	O
indications	O
.	O

RESULTS	O
:	O
The	O
donor	B-CHED
was	O
a	O
19	O
-	O
year	O
-	O
old	O
woman	O
.	O

We	O
manually	O
searched	O
reference	O
lists	O
from	O
included	O
studies	O
and	O
review	O
articles	O
;	O
searched	O
conference	O
proceedings	O
of	O
the	O
American	O
Thoracic	O
Society	O
(	O
1994	O
to	O
2015	O
),	O
Society	O
of	O
Critical	O
Care	O
Medicine	B-CHED
(	O
1994	O
to	O
2015	O
),	O
European	O
Society	O
of	O
Intensive	O
Care	O
Medicine	B-CHED
(	O
1994	O
to	O
2015	O
),	O
and	O
American	O
College	O
of	O
Chest	O
Physicians	O
(	O
1994	O
to	O
2015	O
);	O
contacted	O
clinical	O
experts	O
in	O
the	O
field	O
;	O
and	O
searched	O
for	O
unpublished	O
and	O
ongoing	O
trials	O
in	O
clinicaltrials	O
.	O
gov	O
and	O
controlled	O
-	O
trials	O
.	O
com	B-CHED
.	O

Before	O
ECLS	O
initiation	O
,	O
baseline	O
measurements	O
of	O
cardiac	O
index	O
,	O
systemic	O
vascular	O
resistance	O
,	O
mean	O
arterial	O
pressure	O
,	O
and	O
extravascular	O
lung	O
water	B-CHED
(	O
EVLW	O
)	O
were	O
performed	O
.	O

We	O
identified	O
four	O
different	O
genotypes	O
of	O
coronavirus	O
,	O
three	O
of	O
which	O
(	O
an	O
alphacoronavirus	O
and	O
two	O
betacoronaviruses	O
)	O
are	O
potentially	O
new	O
species	O
,	O
having	O
less	O
than	O
90	O
%	O
nucleotide	B-CHED
sequence	O
identity	O
with	O
the	O
most	O
closely	O
related	O
described	O
viruses	O
.	O

The	O
molecular	O
diversity	O
and	O
phylogenetic	O
relationships	O
between	O
porcine	O
epidemic	O
diarrhea	O
viruses	O
(	O
PEDV	O
)	O
prevalent	O
in	O
Gansu	O
were	O
probed	O
,	O
and	O
the	O
resultant	O
proteins	B-CHED
were	O
characterized	O
.	O

The	O
phylogeny	O
of	O
S	O
glycoprotein	B-CHED
showed	O
that	O
all	O
strains	O
were	O
clustered	O
into	O
two	O
major	O
groups	O
.	O

Weaning	O
using	O
NAVA	O
restored	O
the	O
regular	O
respiration	O
and	O
stable	O
and	O
normal	O
acid	O
-	O
base	O
balance	B-CHED
.	O

Compared	O
with	O
control	O
pigs	O
,	O
PRRS	O
infection	O
did	O
not	O
reduce	O
apparent	O
total	O
tract	O
digestibility	O
(	O
ATTD	O
)	O
of	O
nutrients	B-CHED
and	O
energy	O
.	O

However	O
,	O
Lys	B-CHED
AID	O
tended	O
to	O
be	O
reduced	O
in	O
both	O
PED	O
treatments	O
compared	O
with	O
the	O
control	O
(	O
10	O
and	O
12	O
%;	O
=	O
0	O
.	O
095	O
).	O

Interestingly	O
,	O
TER	O
was	O
increased	O
(	O
<	O
0	O
.	O
01	O
)	O
in	O
the	O
PRP	B-CHED
pigs	O
.	O

Several	O
decades	O
of	O
advances	O
in	O
acute	O
management	O
and	O
treatment	O
,	O
as	O
well	O
as	O
better	O
understanding	O
of	O
approaches	O
to	O
ventilation	O
,	O
oxygenation	O
,	O
and	O
surfactant	B-CHED
regulation	O
have	O
contributed	O
to	O
improvements	O
in	O
patient	O
recovery	O
.	O

Co	O
-	O
expression	O
of	O
the	O
third	O
EAV	O
transmembrane	O
protein	B-CHED
(	O
nsp5	O
),	O
expressed	O
as	O
part	O
of	O
a	O
self	O
-	O
cleaving	O
polypeptide	B-CHED
that	O
mimics	O
viral	O
polyprotein	O
processing	O
in	O
infected	O
cells	O
,	O
led	O
to	O
the	O
formation	O
of	O
DMVs	O
whose	O
size	O
was	O
more	O
homogenous	O
and	O
closer	O
to	O
what	O
is	O
observed	O
upon	O
EAV	O
infection	O
,	O
suggesting	O
a	O
regulatory	O
role	O
for	O
nsp5	O
in	O
modulating	O
membrane	O
curvature	O
and	O
DMV	O
formation	O
.	O

Initial	O
vital	O
signs	O
demonstrated	O
a	O
median	O
oxygen	B-CHED
saturation	O
of	O
94	O
%	O
(	O
range	O
90	O
-	O
97	O
%)	O
supported	O
with	O
a	O
FiO2	O
of	O
100	O
%	O
for	O
all	O
patients	O
with	O
a	O
median	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
of	O
16	O
(	O
range	O
14	O
-	O
20	O
).	O

TITLE	O
:	O
Development	O
of	O
a	O
SARS	O
Coronavirus	O
Vaccine	O
from	O
Recombinant	O
Spike	O
Protein	B-CHED
Plus	O
Delta	O
Inulin	B-CHED
Adjuvant	B-CHED
.	O

To	O
limit	O
the	O
deleterious	O
effects	O
of	O
mechanical	O
ventilation	O
and	O
avoid	O
excessive	O
carbon	B-CHED
dioxide	I-CHED
accumulation	O
,	O
devices	O
for	O
extracorporeal	O
CO2	B-CHED
removal	O
(	O
ECCO2R	O
),	O
have	O
been	O
developed	O
.	O

To	O
evaluate	O
which	O
type	O
or	O
component	O
of	O
full	O
-	O
body	O
PPE	B-CHED
and	O
which	O
method	O
of	O
donning	O
or	O
removing	O
(	O
doffing	O
)	O
PPE	B-CHED
have	O
the	O
least	O
risk	O
of	O
self	O
-	O
contamination	O
or	O
infection	O
for	O
HCWs	O
,	O
and	O
which	O
training	O
methods	O
most	O
increase	O
compliance	O
with	O
PPE	B-CHED
protocols	O
.	O

We	O
searched	O
MEDLINE	O
(	O
PubMed	O
up	O
to	O
8	O
January	O
2016	O
),	O
Cochrane	O
Central	O
Register	O
of	O
Trials	O
(	O
CENTRAL	O
up	O
to	O
20	O
January	O
2016	O
),	O
EMBASE	O
(	O
embase	O
.	O
com	B-CHED
up	O
to	O
8	O
January	O
2016	O
),	O
CINAHL	O
(	O
EBSCOhost	O
up	O
to	O
20	O
January	O
2016	O
),	O
and	O
OSH	O
-	O
Update	O
up	O
to	O
8	O
January	O
2016	O
.	O

Expression	O
of	O
MERS	O
-	O
CoV	O
M	O
protein	B-CHED
suppressed	O
type	O
I	O
IFN	O
expression	O
in	O
response	O
to	O
Sendai	O
virus	O
infection	O
or	O
poly	O
(	O
I	O
:	O
C	O
)	O
induction	O
.	O

This	O
suppressive	O
effect	O
was	O
found	O
to	O
be	O
specific	O
for	O
the	O
activation	O
of	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF3	O
)	O
but	O
not	O
nuclear	O
factor	O
-	O
B	O
.	O
MERS	O
-	O
CoV	O
M	O
protein	B-CHED
interacted	O
with	O
TRAF3	O
and	O
disrupted	O
TRAF3	O
-	O
TBK1	O
association	O
leading	O
to	O
reduced	O
IRF3	O
activation	O
.	O

Using	O
chimeric	O
and	O
truncation	O
mutants	O
,	O
the	O
N	O
-	O
terminal	O
transmembrane	O
domains	O
of	O
the	O
MERS	O
-	O
CoV	O
M	O
protein	B-CHED
were	O
found	O
to	O
be	O
sufficient	O
for	O
its	O
inhibitory	O
effect	O
on	O
IFN	O
expression	O
,	O
whereas	O
the	O
C	O
-	O
terminal	O
domain	O
was	O
unable	O
to	O
induce	O
this	O
suppression	O
.	O

TITLE	O
:	O
BCX4430	O
-	O
A	O
broad	O
-	O
spectrum	O
antiviral	B-CHED
adenosine	B-CHED
nucleoside	B-CHED
analog	O
under	O
development	O
for	O
the	O
treatment	O
of	O
Ebola	O
virus	O
disease	O
.	O

ABSTRACT	O
:	O
The	O
adenosine	B-CHED
nucleoside	B-CHED
analog	O
BCX4430	O
is	O
a	O
direct	O
-	O
acting	O
antiviral	B-CHED
drug	I-CHED
under	O
investigation	O
for	O
the	O
treatment	O
of	O
serious	O
and	O
life	O
-	O
threatening	O
infections	O
from	O
highly	O
pathogenic	O
viruses	O
,	O
such	O
as	O
the	O
Ebola	O
virus	O
.	O

Methods	O
Prospectively	O
,	O
CSF	O
samples	O
of	O
41	O
cats	O
were	O
investigated	O
,	O
including	O
cats	O
with	O
histopathologically	O
confirmed	O
FIP	O
and	O
neurological	O
signs	O
(	O
n	O
=	O
10	O
),	O
cats	O
with	O
confirmed	O
FIP	O
without	O
CNS	B-CHED
involvement	O
(	O
n	O
=	O
11	O
),	O
cats	O
with	O
neurological	O
signs	O
but	O
another	O
confirmed	O
CNS	B-CHED
disease	O
(	O
n	O
=	O
17	O
),	O
and	O
cats	O
without	O
neurological	O
signs	O
and	O
a	O
disease	O
other	O
than	O
FIP	O
(	O
n	O
=	O
3	O
).	O

Sensitivity	O
,	O
specificity	O
,	O
positive	O
(	O
PPV	B-CHED
)	O
and	O
negative	O
predictive	O
values	O
(	O
NPV	O
)	O
of	O
CSF	O
ICC	O
were	O
calculated	O
.	O

Conclusions	O
and	O
relevance	O
CSF	O
ICC	O
is	O
a	O
highly	O
sensitive	O
test	O
for	O
ante	O
-	O
mortem	O
diagnosis	O
of	O
FIP	O
manifesting	O
in	O
the	O
CNS	B-CHED
.	O

TITLE	O
:	O
Diminished	O
COX	O
-	O
2	O
/	O
PGE2	B-CHED
-	O
Mediated	O
Antiviral	B-CHED
Response	O
Due	O
to	O
Impaired	O
NOX	O
/	O
MAPK	O
Signaling	O
in	O
G6PD	O
-	O
Knockdown	O
Lung	O
Epithelial	O
Cells	O
.	O

ABSTRACT	O
:	O
Glucose	B-CHED
-	O
6	O
-	O
phosphate	B-CHED
dehydrogenase	O
(	O
G6PD	O
)	O
provides	O
the	O
reducing	B-CHED
agent	I-CHED
NADPH	B-CHED
to	O
meet	O
the	O
cellular	O
needs	O
for	O
reductive	O
biosynthesis	O
and	O
the	O
maintenance	O
of	O
redox	O
homeostasis	O
.	O

LCA60	O
antibody	O
was	O
generated	O
using	O
the	O
Cellclone	O
Technology	O
from	O
the	O
immortalized	O
B	O
cells	O
of	O
a	O
human	O
donor	B-CHED
recovering	O
from	O
MERS	O
.	O

Only	O
four	O
months	O
were	O
required	O
from	O
the	O
initial	O
screening	O
of	O
B	O
cells	O
to	O
the	O
development	O
of	O
a	O
stable	O
CHO	B-CHED
cell	O
line	O
suitable	O
for	O
the	O
production	O
of	O
clinical	O
grade	O
antibody	O
,	O
thereby	O
delineating	O
a	O
rapid	O
pathway	O
for	O
the	O
development	O
of	O
antiviral	B-CHED
therapies	O
against	O
emerging	O
viruses	O
.	O

Go	O
-	O
Ag	O
inhibited	O
25	O
%	O
of	O
infection	O
by	O
FCoV	O
and	O
23	O
%	O
by	O
IBDV	O
,	O
whereas	O
GO	O
only	O
inhibited	O
16	O
%	O
of	O
infection	O
by	O
FCoV	O
but	O
showed	O
no	O
antiviral	B-CHED
activity	O
against	O
the	O
infection	O
by	O
IBDV	O
.	O

It	O
was	O
previously	O
shown	O
that	O
a	O
major	O
determinant	O
of	O
PS	O
recognition	O
is	O
the	O
second	O
of	O
the	O
two	O
RNA	O
-	O
binding	O
domains	O
of	O
the	O
viral	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
.	O

TITLE	O
:	O
Coronavirus	O
Infection	O
in	O
Ferrets	O
:	O
Antigen	B-CHED
Distribution	O
and	O
Inflammatory	O
Response	O
.	O

It	O
was	O
cloned	O
and	O
sub	O
-	O
cloned	O
into	O
pGH	B-CHED
and	O
pET32a	O
(+)	O
expression	O
vector	O
.	O

The	O
recombinant	O
VP8	O
-	O
S2	O
protein	B-CHED
was	O
purified	O
by	O
Ni	O
-	O
NTA	B-CHED
chromatography	O
column	O
.	O

Here	O
,	O
we	O
present	O
the	O
crystal	O
structures	O
of	O
PEDV	O
3CL	O
(	O
pro	B-CHED
)	O
and	O
a	O
molecular	O
complex	O
between	O
an	O
inactive	O
PEDV	O
3CL	O
(	O
pro	B-CHED
)	O
variant	O
C144A	O
bound	O
to	O
a	O
peptide	B-CHED
substrate	O
.	O

The	O
dimerization	O
of	O
PEDV	O
3CL	O
(	O
pro	B-CHED
)	O
is	O
similar	O
to	O
that	O
of	O
other	O
Alphacoronavirus	O
3CL	O
(	O
pro	B-CHED
)	O
s	O
but	O
has	O
several	O
differences	O
from	O
that	O
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
from	O
the	O
genus	O
Betacoronavirus	O
.	O

Furthermore	O
,	O
the	O
non	O
-	O
conserved	O
motifs	O
in	O
the	O
pockets	O
cause	O
different	O
cleavage	O
of	O
substrate	O
between	O
PEDV	O
and	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
s	O
,	O
which	O
may	O
provide	O
new	O
insights	O
into	O
the	O
recognition	O
of	O
substrates	O
by	O
3CL	O
(	O
pro	B-CHED
)	O
s	O
in	O
various	O
coronavirus	O
genera	O
.	O

Further	O
research	O
surrounding	O
sedative	B-CHED
requirements	O
,	O
clearance	O
,	O
and	O
patient	O
response	O
during	O
ECMO	O
is	O
required	O
.	O

The	O
data	O
of	O
36	O
severe	O
ARDS	O
patients	O
admitted	O
to	O
Department	O
of	O
Critical	O
Care	O
Medicine	B-CHED
of	O
the	O
First	O
Affiliated	O
Hospital	O
of	O
Guangzhou	O
Medical	O
University	O
from	O
February	O
2013	O
to	O
January	O
2015	O
,	O
were	O
retrospectively	O
analyzed	O
.	O

(	O
2	O
)	O
Respiratory	O
mechanics	O
and	O
oxygenation	O
pre	O
-	O
PPV	B-CHED
and	O
post	O
-	O
PPV	B-CHED
:	O
compared	O
with	O
pre	O
-	O
PPV	B-CHED
,	O
oxygenation	O
index	O
(	O
PaO2	O
/	O
FiO2	O
,	O
mmHg	O
,	O
1	O
mmHg	O
=	O
0	O
.	O
133	O
kPa	O
)	O
post	O
-	O
PPV	B-CHED
was	O
significantly	O
increased	O
in	O
both	O
groups	O
[	O
ILD	O
group	O
:	O
132	O
.	O
0	O
(	O
93	O
.	O
5	O
,	O
172	O
.	O
0	O
)	O
vs	O
.	O
118	O
.	O
7	O
(	O
92	O
.	O
0	O
,	O
147	O
.	O
8	O
);	O
non	O
-	O
ILD	O
group	O
:	O
126	O
.	O
1	O
(	O
100	O
.	O
9	O
,	O
170	O
.	O
0	O
)	O
vs	O
.	O
109	O
.	O
2	O
(	O
89	O
.	O
0	O
,	O
135	O
.	O
0	O
),	O
both	O
P	O
<	O
0	O
.	O
05	O
].	O

HFNC	O
was	O
changed	O
to	O
low	O
flow	O
oxygen	B-CHED
inhalation	O
nasal	O
cannula	O
(	O
2	O
-	O
3	O
L	O
/	O
min	O
)	O
on	O
the	O
20th	O
day	O
.	O

Compared	O
with	O
the	O
early	O
group	O
,	O
the	O
6	O
-	O
hour	O
urine	O
volume	O
in	O
the	O
late	O
group	O
was	O
significantly	O
increased	O
(	O
mL	O
	O
h	O
	O
	O
	O
kg	O
	O
	O
:	O
1	O
.	O
72	O
	O
1	O
.	O
04	O
vs	O
.	O
0	O
.	O
89	O
	O
0	O
.	O
24	O
,	O
t	O
=	O
11	O
.	O
950	O
,	O
P	O
=	O
0	O
.	O
001	O
),	O
6	O
-	O
hour	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
,	O
mmHg	O
,	O
1	O
mmHg	O
=	O
0	O
.	O
133	O
kPa	O
)	O
was	O
elevated	O
(	O
64	O
.	O
24	O
	O
3	O
.	O
90	O
vs	O
.	O
56	O
.	O
21	O
	O
5	O
.	O
95	O
,	O
t	O
=	O
6	O
.	O
444	O
,	O
P	O
=	O
0	O
.	O
012	O
),	O
the	O
use	O
of	O
antibiotics	B-CHED
within	O
1	O
hour	O
was	O
increased	O
(	O
76	O
.	O
32	O
%	O
vs	O
.	O
48	O
.	O
28	O
%,	O
	O
=	O
11	O
.	O
250	O
,	O
P	O
=	O
0	O
.	O
001	O
),	O
the	O
use	O
of	O
vasocative	O
drugs	O
(	O
21	O
.	O
05	O
%	O
vs	O
.	O
89	O
.	O
66	O
%,	O
	O
=	O
61	O
.	O
942	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
and	O
hormone	B-CHED
(	O
8	O
.	O
57	O
%	O
vs	O
.	O
34	O
.	O
48	O
%,	O
	O
=	O
14	O
.	O
871	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
were	O
lowered	O
,	O
and	O
the	O
28	O
-	O
day	O
mortality	O
rate	O
was	O
lowered	O
significantly	O
[	O
34	O
.	O
21	O
%	O
(	O
26	O
/	O
76	O
)	O
vs	O
.	O
68	O
.	O
96	O
%	O
(	O
40	O
/	O
58	O
),	O
	O
=	O
15	O
.	O
897	O
,	O
P	O
=	O
0	O
.	O
000	O
].	O

In	O
the	O
late	O
group	O
,	O
it	O
was	O
shown	O
by	O
single	O
factor	O
analysis	O
that	O
the	O
age	O
,	O
the	O
case	O
history	O
of	O
chronic	O
disease	O
,	O
infection	O
sites	O
,	O
WBC	O
,	O
pH	O
value	O
,	O
Lac	B-CHED
,	O
and	O
ScvO	O
before	O
treatment	O
,	O
6	O
-	O
hour	O
urine	O
output	O
after	O
treatment	O
,	O
the	O
number	O
of	O
organ	O
with	O
failure	O
,	O
the	O
use	O
of	O
antibiotics	B-CHED
within	O
1	O
hour	O
,	O
and	O
incidence	O
of	O
AKI	O
or	O
ALI	O
/	O
ARDS	O
within	O
24	O
hours	O
were	O
risk	O
factors	O
of	O
28	O
-	O
day	O
death	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
use	O
of	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
is	O
rarely	O
indicated	O
and	O
both	O
	O

Our	O
analyses	O
show	O
:	O
1	O
)	O
28	O
potential	O
recombinant	O
sequences	O
were	O
detected	O
and	O
they	O
can	O
be	O
classified	O
into	O
seven	O
potential	O
recombinant	O
types	O
;	O
2	O
)	O
The	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
MERS	O
-	O
CoV	O
was	O
under	O
strong	O
positive	O
selection	O
when	O
MERS	O
-	O
CoV	O
transmitted	O
from	O
their	O
natural	O
host	O
to	O
human	O
;	O
3	O
)	O
Six	O
out	O
of	O
nine	O
positive	O
selection	O
sites	O
detected	O
in	O
spike	O
(	O
S	O
)	O
protein	B-CHED
are	O
located	O
in	O
its	O
receptor	O
-	O
binding	O
domain	O
which	O
is	O
in	O
direct	O
contact	O
with	O
host	O
cells	O
;	O
4	O
)	O
MERS	O
-	O
CoV	O
frequently	O
transmitted	O
back	O
and	O
forth	O
between	O
human	O
and	O
camel	O
after	O
it	O
had	O
acquired	O
the	O
human	O
-	O
camel	O
infection	O
capability	O
.	O

In	O
this	O
study	O
,	O
soluble	O
production	O
of	O
recombinant	O
spike	O
protein	B-CHED
of	O
PEDV	O
,	O
rGST	O
-	O
COE	O
and	O
rGST	O
-	O
S1D	O
,	O
were	O
achieved	O
by	O
using	O
TF	O
chaperone	O
co	O
-	O
expression	O
system	O
.	O

Because	O
it	O
represents	O
a	O
violation	O
of	O
societal	O
ideologies	O
and	O
traditional	O
Chinese	O
cultural	O
beliefs	O
,	O
the	O
meanings	O
of	O
the	O
facemask	O
that	O
had	O
developed	O
during	O
the	O
SARS	O
outbreak	O
failed	O
to	O
be	O
sustained	O
in	O
the	O
post	O
-	O
SARS	O
era	B-CHED
.	O

RESULTS	O
:	O
The	O
sociocultural	O
meanings	O
of	O
the	O
facemask	O
have	O
been	O
undergoing	O
constant	O
change	O
,	O
from	O
positive	O
to	O
negative	O
,	O
which	O
resulted	O
in	O
the	O
participants	O
displaying	O
hesitation	O
in	O
using	O
a	O
facemask	O
in	O
the	O
post	O
-	O
SARS	O
era	B-CHED
.	O

CONCLUSIONS	O
:	O
The	O
changes	O
in	O
meaning	O
not	O
only	O
influenced	O
the	O
participants	O
'	O
perceptions	O
of	O
the	O
facemask	O
but	O
also	O
influenced	O
their	O
perceptions	O
of	O
people	O
who	O
use	O
facemasks	O
,	O
which	O
ultimately	O
influenced	O
their	O
health	O
behavior	O
,	O
preventing	O
them	O
from	O
using	O
facemasks	O
in	O
the	O
post	O
-	O
SARS	O
era	B-CHED
.	O

TITLE	O
:	O
Monoclonal	O
Antibody	O
to	O
Bone	O
Marrow	O
Stromal	O
Cell	O
Antigen	B-CHED
2	O
Protein	B-CHED
of	O
Swine	O
.	O

After	O
subcloning	O
,	O
one	O
strain	O
of	O
hybridoma	O
cells	O
named	O
1B2	O
secreting	O
porcine	O
BST	O
-	O
2	O
protein	B-CHED
monoclonal	O
antibody	O
(	O
MAb	O
)	O
was	O
obtained	O
.	O

Optimal	O
management	O
remains	O
unknown	O
,	O
including	O
the	O
roles	O
of	O
adjunctive	O
corticosteroids	B-CHED
and	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O
We	O
conducted	O
a	O
retrospective	O
chart	O
review	O
of	O
patients	O
with	O
ARDS	O
caused	O
by	O
blastomycosis	O
,	O
managed	O
in	O
intensive	O
care	O
units	O
in	O
Manitoba	O
,	O
Canada	O
,	O
from	O
1992	O
to	O
2014	O
.	O

For	O
CDV	B-CHED
SN	O
titers	O
,	O
the	O
only	O
statistically	O
significant	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
difference	O
was	O
that	O
the	O
control	O
dogs	O
had	O
higher	O
SN	O
titers	O
than	O
the	O
lean	O
geriatric	O
dogs	O
.	O

These	O
results	O
suggested	O
that	O
either	O
the	O
introduction	O
of	O
a	O
disubstituted	O
amide	B-CHED
structure	O
at	O
the	O
17	O
-	O
COOH	O
of	O
OA	O
or	O
alteration	O
of	O
the	O
C	O
-	O
3	O
configuration	O
of	O
OA	O
from	O
3	O
-	O
to	O
3	O
-	O
forms	O
can	O
significantly	O
improve	O
the	O
selective	O
index	O
while	O
maintaining	O
their	O
antiviral	B-CHED
activities	O
in	O
vitro	O
.	O

Molecular	O
simulation	O
study	O
and	O
surface	O
plasmon	O
resonance	O
analysis	O
confirmed	O
that	O
compound	O
8	O
stabilized	O
HA2	O
subunit	O
of	O
hemagglutinin	O
(	O
HA	O
)	O
by	O
binding	O
with	O
amino	B-CHED
acid	I-CHED
residues	O
LYS	B-CHED
-	O
26	O
,	O
ASN	B-CHED
-	O
53	O
,	O
ASN	B-CHED
-	O
27	O
and	O
ASN	B-CHED
-	O
50	O
,	O
therefore	O
may	O
prevent	O
HA	O
from	O
conformational	O
rearranging	O
,	O
which	O
is	O
a	O
critical	O
step	O
for	O
viral	O
entry	O
.	O

and	O
of	O
viral	O
strain	O
on	O
shell	O
reflectivity	O
,	O
L	O
*	O
and	O
protoporphyrin	B-CHED
IX	I-CHED
(	O
PP	O
IX	O
)	O
in	O
eggshells	O
,	O
with	O
and	O
without	O
cuticle	O
.	O

Thirty	O
sedated	O
patients	O
with	O
ARDS	O
(	O
10	O
mild	O
,	O
14	O
moderate	O
,	O
6	O
severe	O
)	O
underwent	O
decremental	O
PEEP	B-CHED
testing	O
(	O
20	O
,	O
15	O
,	O
10	O
,	O
5	O
cm	O
H2O	B-CHED
)	O
for	O
up	O
to	O
7	O
days	O
after	O
inclusion	O
.	O

It	O
is	O
known	O
that	O
coronavirus	O
nsp14	O
acts	O
as	O
an	O
N7	O
-(	O
guanine	B-CHED
)-	O
methyltransferase	O
(	O
MTase	O
)	O
and	O
nsp16	O
as	O
a	O
2	O
'-	O
O	O
-	O
MTase	O
,	O
which	O
are	O
involved	O
in	O
the	O
modification	O
of	O
RNA	O
cap	O
structure	O
.	O

We	O
found	O
a	O
known	O
inhibitor	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
3CL	O
(	O
pro	B-CHED
),	O
(	O
R	O
)-	O
16	O
,	O
to	O
have	O
inhibitor	B-CHED
activity	O
against	O
PEDV	O
3CL	O
(	O
pro	B-CHED
),	O
despite	O
that	O
SARS	O
-	O
3CL	O
(	O
pro	B-CHED
)	O
and	O
PEDV	O
3CL	O
(	O
pro	B-CHED
)	O
share	O
only	O
45	O
.	O
4	O
%	O
sequence	O
identity	O
.	O

Protein	B-CHED
levels	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
and	O
serum	O
were	O
reduced	O
by	O
andrographolide	B-CHED
sulfonate	B-CHED
administration	O
.	O

CLA	B-CHED
and	O
CGA	O
enhanced	O
the	O
actions	O
of	O
ATG	O
and	O
exhibited	O
synergistic	O
NF	O
-	O
B	O
inactivation	O
effects	O
possibly	O
via	O
the	O
Ras	B-CHED
/	O
MAPK	O
signaling	O
pathway	O
.	O

In	O
physical	O
examination	O
his	O
body	O
temperature	O
was	O
37	O
.	O
9	O
	O
C	O
,	O
C	O
-	O
reactive	O
protein	B-CHED
level	O
was	O
high	O
,	O
and	O
the	O
other	O
systemic	O
results	O
were	O
normal	O
.	O

The	O
present	O
study	O
provided	O
a	O
novel	O
strategy	O
for	O
the	O
treatment	O
of	O
ARDS	O
by	O
specifically	O
interfering	O
with	O
cyclic	O
adenosine	B-CHED
monophosphate	I-CHED
(	O
cAMP	B-CHED
)	O
signaling	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
provided	O
a	O
novel	O
treatment	O
strategy	O
for	O
ARDS	O
by	O
modulating	O
the	O
balance	B-CHED
of	O
Treg	O
/	O
Th17	O
and	O
the	O
subsequent	O
immune	O
response	O
via	O
cAMP	B-CHED
signaling	O
,	O
which	O
requires	O
pre	O
-	O
clinical	O
and	O
clinical	O
validation	O
.	O

Additionally	O
,	O
endogenous	O
peptide	B-CHED
ligands	O
isolated	O
from	O
Ptal	B-CHED
-	O
N	O
*	O
01	O
:	O
01	O
displayed	O
a	O
relatively	O
broad	O
length	O
distribution	O
and	O
an	O
unusual	O
preference	O
for	O
a	O
C	O
-	O
terminal	O
proline	B-CHED
residue	I-CHED
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
this	O
preference	O
for	O
C	O
-	O
terminal	O
proline	O
residues	O
was	O
observed	O
in	O
Hendra	O
virus	O
-	O
derived	O
peptides	B-CHED
presented	O
by	O
Ptal	B-CHED
-	O
N	O
*	O
01	O
:	O
01	O
on	O
the	O
surface	O
of	O
infected	O
cells	O
.	O

Additionally	O
,	O
it	O
will	O
provide	O
a	O
foundation	O
to	O
understand	O
the	O
role	O
of	O
adaptive	O
immunity	O
in	O
bat	O
antiviral	B-CHED
responses	O
.	O

TITLE	O
:	O
Coronavirus	O
receptor	O
switch	O
explained	O
from	O
the	O
stereochemistry	O
of	O
protein	B-CHED
-	O
carbohydrate	B-CHED
interactions	O
and	O
a	O
single	O
mutation	O
.	O

Pulmonary	O
cellular	O
necrosis	O
was	O
labeled	O
by	O
the	O
propidium	B-CHED
Iodide	I-CHED
(	O
PI	O
)	O
staining	O
.	O

The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
is	O
a	O
DUB	O
that	O
cleaves	O
ISG15	O
,	O
a	O
two	O
-	O
domain	O
Ub	O
-	O
like	O
protein	B-CHED
,	O
and	O
Lys48	O
-	O
linked	O
polyUb	O
chains	O
,	O
releasing	O
diUb	O
(	O
Lys48	O
)	O
products	O
.	O

Inhaled	O
nitric	B-CHED
oxide	I-CHED
might	O
improve	O
outcomes	O
in	O
a	O
subset	O
of	O
patients	O
with	O
postoperative	O
pulmonary	O
hypertension	O
who	O
had	O
cardiac	O
surgery	O
;	O
however	O
,	O
it	O
has	O
not	O
been	O
shown	O
to	O
provide	O
long	O
-	O
term	O
benefit	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Use	O
of	O
aerosolised	O
antibiotics	B-CHED
for	O
ventilator	O
-	O
associated	O
pneumonia	O
and	O
ventilator	O
-	O
associated	O
tracheobronchitis	O
shows	O
promise	O
,	O
but	O
the	O
delivered	O
dose	O
can	O
be	O
highly	O
variable	O
if	O
proper	O
attention	O
is	O
not	O
paid	O
to	O
the	O
delivery	O
method	O
.	O

Pulmonary	O
vascular	O
dysfunction	O
(	O
PVD	O
)	O
and	O
acute	O
cor	O
pulmonale	O
(	O
ACP	B-CHED
)	O
are	O
common	O
during	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
their	O
prevalence	O
may	O
be	O
even	O
more	O
important	O
during	O
ARDS	O
related	O
to	O
ACS	O
(	O
ACS	O
-	O
ARDS	O
).	O

Both	O
the	O
crude	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
19	O
.	O
9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
6	O
.	O
6	O
-	O
60	O
;	O
P	O
<	O
0	O
.	O
0001	O
),	O
multivariable	O
adjustment	O
(	O
OR	O
,	O
27	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
8	O
.	O
2	O
-	O
91	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
propensity	O
-	O
matched	O
(	O
OR	O
,	O
11	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
110	O
.	O
8	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
analyses	O
found	O
a	O
significant	O
association	O
between	O
ACS	O
-	O
ARDS	O
and	O
ACP	B-CHED
.	O

ECMO	O
may	O
be	O
used	O
as	O
a	O
salvage	O
treatment	O
without	O
any	O
associated	O
hemorrhagic	O
complication	O
,	O
provided	O
anticoagulant	B-CHED
therapy	O
is	O
carefully	O
monitored	O
,	O
and	O
may	O
lead	O
to	O
complete	O
pulmonary	O
recovery	O
at	O
six	O
months	O
.	O

TITLE	O
:	O
Immune	O
evasion	O
of	O
porcine	O
enteric	O
coronaviruses	O
and	O
viral	O
modulation	O
of	O
antiviral	B-CHED
innate	O
signaling	O
.	O

Accumulating	O
evidence	O
however	O
suggests	O
that	O
IFN	O
induction	O
and	O
signaling	O
in	O
the	O
intestinal	O
epithelial	O
cells	O
differ	O
from	O
other	O
epithelial	O
cells	O
,	O
largely	O
due	O
to	O
distinct	O
features	O
of	O
the	O
gut	O
epithelial	O
mucosal	O
surface	O
and	O
commensal	O
microflora	O
,	O
and	O
it	O
appears	O
that	O
type	O
III	O
interferon	O
(	O
IFN	O
-	O
	O
)	O
plays	O
a	O
key	O
role	O
to	O
maintain	O
the	O
antiviral	B-CHED
state	O
in	O
the	O
gut	O
.	O

Furthermore	O
,	O
direct	O
pharmacological	O
inhibition	O
of	O
p38	O
MAPK	O
or	O
JNK1	O
/	O
2	O
activation	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
viral	O
RNA	O
synthesis	O
,	O
viral	O
protein	B-CHED
expression	O
,	O
and	O
progeny	O
release	O
.	O

In	O
contrast	O
to	O
ORF1ab	O
and	O
structural	O
proteins	B-CHED
,	O
the	O
putative	O
proteins	B-CHED
encoded	O
by	O
ORF3	O
,	O
ORF4a	O
,	O
ORF4b	O
,	O
ORF5	O
and	O
ORF8b	O
in	O
the	O
MERS	O
-	O
CoV	O
genome	O
do	O
not	O
share	O
homology	O
with	O
any	O
known	O
host	O
or	O
virus	O
protein	B-CHED
,	O
other	O
than	O
those	O
of	O
its	O
closely	O
related	O
lineage	O
C	O
CoVs	O
.	O

Notably	O
,	O
compared	O
to	O
classical	O
Japanese	O
strains	O
,	O
all	O
of	O
the	O
recent	O
Japanese	O
strains	O
have	O
two	O
amino	B-CHED
acid	I-CHED
substitutions	O
in	O
a	O
known	O
neutralizing	O
epitope	B-CHED
.	O

In	O
addition	O
,	O
one	O
of	O
the	O
strains	O
acquired	O
an	O
additional	O
mutation	O
in	O
another	O
neutralizing	O
epitope	B-CHED
that	O
is	O
highly	O
conserved	O
among	O
PEDVs	O
,	O
including	O
the	O
classical	O
and	O
recent	O
isolates	O
.	O

To	O
avoid	O
cross	O
-	O
reactivity	O
with	O
other	O
closely	O
related	O
swine	O
coronaviruses	O
,	O
the	O
N	O
protein	B-CHED
sequences	O
of	O
PEDV	O
were	O
analyzed	O
to	O
identify	O
sequences	O
unique	O
to	O
PEDV	O
.	O

TITLE	O
:	O
Experimental	O
and	O
numerical	O
analysis	O
of	O
B1	O
(+)	O
field	O
and	O
SAR	B-CHED
with	O
a	O
new	O
transmit	O
array	O
design	O
for	O
7T	O
breast	O
MRI	O
.	O

The	O
proposed	O
RF	O
array	O
;	O
which	O
can	O
operate	O
in	O
a	O
single	O
or	O
multi	O
transmit	O
modes	O
,	O
demonstrates	O
homogeneous	O
RF	O
field	O
excitation	O
with	O
acceptable	O
local	O
/	O
average	O
SAR	B-CHED
levels	O
for	O
breast	O
MRI	O
at	O
7T	O
.	O

RESULTS	O
:	O
The	O
school	O
leadership	O
conducted	O
ongoing	O
risk	O
assessment	O
and	O
developed	O
contingency	O
plans	O
to	O
balance	B-CHED
student	O
safety	O
and	O
continuity	O
in	O
medical	O
education	O
.	O

Pressure	O
support	O
or	O
inspiratory	O
positive	O
airway	O
pressure	O
(	O
IPAP	O
),	O
external	O
positive	O
end	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
or	O
expiratory	O
positive	O
airway	O
pressure	O
(	O
EPAP	O
)	O
levels	O
were	O
titrated	O
to	O
achieve	O
an	O
expiratory	O
tidal	O
volume	O
of	O
8	O
to	O
10	O
ml	O
/	O
kg	O
according	O
to	O
ideal	O
body	O
weight	O
,	O
SpO2	O
>	O
90	O
%	O
and	O
respiratory	O
rate	O
below	O
25	O
/	O
min	O
.	O

Further	O
,	O
we	O
demonstrate	O
that	O
HTCC	O
polymers	B-CHED
with	O
different	O
degrees	O
of	O
substitution	O
act	O
as	O
effective	O
inhibitors	B-CHED
of	O
all	O
low	O
-	O
pathogenic	O
human	O
coronaviruses	O
.	O

Many	O
viruses	O
use	O
5	O
'	O
caps	O
or	O
other	O
mechanisms	O
to	O
mimic	O
a	O
cap	O
structure	O
to	O
limit	O
detection	O
of	O
viral	O
RNAs	O
by	O
intracellular	O
innate	O
sensors	O
and	O
to	O
direct	O
efficient	O
translation	O
of	O
viral	O
proteins	B-CHED
.	O

The	O
coronavirus	O
(	O
CoV	O
)	O
nonstructural	O
protein	B-CHED
14	O
(	O
nsp14	O
)	O
is	O
a	O
multifunctional	O
protein	B-CHED
with	O
N7	O
-	O
methyltransferase	O
(	O
N7	O
-	O
MTase	O
)	O
activity	O
.	O

S25	O
-	O
229	O
IBs	O
were	O
solubilized	O
in	O
20	O
mM	O
sodium	B-CHED
acetate	I-CHED
(	O
pH	O
4	O
.	O
5	O
)	O
buffer	B-CHED
containing	O
8	O
M	O
urea	B-CHED
and	O
1	O
mM	O
dithiothreitol	B-CHED
with	O
95	O
%	O
yield	O
.	O

Solubilized	O
S25	O
-	O
229	O
IBs	O
were	O
refolded	O
by	O
10	O
-	O
fold	O
flash	B-CHED
dilution	O
and	O
purified	O
by	O
one	O
-	O
step	O
cation	B-CHED
exchange	O
chromatography	O
with	O
>	O
95	O
%	O
purity	O
and	O
20	O
%	O
yield	O
.	O

Finally	O
,	O
mouse	O
antisera	O
against	O
S25	O
-	O
229	O
showed	O
immune	O
reactivity	O
with	O
native	O
PEDV	O
S	O
protein	B-CHED
in	O
an	O
immunofluorescence	O
assay	O
.	O

ABSTRACT	O
:	O
Viral	O
replication	O
in	O
the	O
liver	O
is	O
generally	O
detected	O
by	O
cellular	O
endosomal	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
and	O
cytosolic	O
helicase	O
sensors	O
that	O
trigger	O
antiviral	B-CHED
inflammatory	O
responses	O
.	O

Resistance	O
to	O
5	B-CHED
-	I-CHED
FU	I-CHED
,	O
and	O
a	O
decreased	O
number	O
of	O
genomic	O
mutations	O
,	O
was	O
effectively	O
masked	O
by	O
nsp14	O
-	O
ExoN	O
proofreading	O
activity	O
.	O

Coronaviruses	O
from	O
the	O
genera	O
Alphacoronavirus	O
and	O
Betacoronavirus	O
,	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
establish	O
host	O
shutoff	O
via	O
their	O
nonstructural	O
protein	B-CHED
1	O
(	O
nsp1	O
).	O

On	O
Site	O
Two	O
,	O
pen	O
oral	O
fluid	O
samples	O
and	O
individual	O
pig	O
serum	O
samples	O
were	O
negative	O
for	O
both	O
PEDV	O
antibody	O
and	O
nucleic	B-CHED
acid	I-CHED
.	O

The	O
oral	O
fluid	O
IgA	O
response	O
increased	O
through	O
96	O
DPE	B-CHED
and	O
began	O
to	O
decline	O
at	O
the	O
last	O
sampling	O
on	O
111	O
DPE	B-CHED
.	O

Over	O
85	O
natural	O
dibenzylbutyrolactone	O
lignans	B-CHED
known	O
to	O
date	O
and	O
their	O
corresponding	O
plant	O
sources	O
are	O
summarized	O
herein	O
for	O
the	O
first	O
time	O
,	O
highlighting	O
a	O
taxon	O
-	O
and	O
organ	O
-	O
specific	O
accumulation	O
of	O
these	O
compounds	O
.	O

TITLE	O
:	O
Angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
prevents	O
lipopolysaccharide	B-CHED
-	O
induced	O
rat	O
acute	O
lung	O
injury	O
via	O
suppressing	O
the	O
ERK1	O
/	O
2	O
and	O
NF	O
-	O
B	O
signaling	O
pathways	O
.	O

Our	O
observation	O
suggests	O
that	O
AEC2	O
attenuates	O
LPS	B-CHED
-	O
induced	O
ARDS	O
via	O
the	O
Ang	O
-(	O
1	O
-	O
7	O
)/	O
Mas	B-CHED
pathway	O
by	O
inhibiting	O
ERK	O
/	O
NF	O
-	O
B	O
activation	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
antioxidant	B-CHED
,	O
antimicrobial	B-CHED
,	O
anti	O
-	O
HIV	O
,	O
and	O
cholinesterase	O
inhibitory	O
activities	O
of	O
aqueous	O
and	O
alcoholic	O
extracts	O
from	O
leaves	O
,	O
stems	O
,	O
and	O
flowers	O
of	O
Euphorbia	O
characias	O
.	O

The	O
ethanolic	O
leaves	O
extract	O
appeared	O
to	O
have	O
the	O
strongest	O
antibacterial	O
activity	O
against	O
Bacillus	O
cereus	O
with	O
MIC	B-CHED
value	O
of	O
312	O
.	O
5	O
g	O
/	O
mL	O
followed	O
by	O
Listeria	O
monocytogenes	O
and	O
Staphylococcus	O
aureus	O
that	O
also	O
exhibited	O
good	O
sensitivity	O
with	O
MIC	B-CHED
values	O
of	O
1250	O
g	O
/	O
mL	O
.	O
Moreover	O
,	O
all	O
the	O
extracts	O
possessed	O
anti	O
-	O
HIV	O
activity	O
.	O

This	O
study	O
suggests	O
that	O
Euphorbia	O
characias	O
extracts	O
represent	O
a	O
good	O
source	O
of	O
natural	O
bioactive	O
compounds	O
which	O
could	O
be	O
useful	O
for	O
pharmaceutical	B-CHED
application	O
as	O
well	O
as	O
in	O
food	O
system	O
for	O
the	O
prevention	O
of	O
the	O
growth	O
of	O
food	O
-	O
borne	O
bacteria	O
and	O
to	O
extend	O
the	O
shelf	O
-	O
life	O
of	O
processed	O
foods	O
.	O

TITLE	O
:	O
Response	O
to	O
Emergence	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
,	O
Abu	B-CHED
Dhabi	O
,	O
United	O
Arab	O
Emirates	O
,	O
2013	O
-	O
2014	O
.	O

TITLE	O
:	O
Outcome	O
of	O
patients	O
supported	O
by	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
aluminum	B-CHED
phosphide	I-CHED
poisoning	O
:	O
An	O
observational	O
study	O
.	O

CONCLUSIONS	O
:	O
Veno	O
-	O
arterial	O
ECMO	O
has	O
been	O
shown	O
to	O
improve	O
the	O
short	O
-	O
term	O
survival	O
of	O
patients	O
with	O
AlP	B-CHED
poisoning	O
having	O
severe	O
LV	O
myocardial	O
dysfunction	O
.	O

PEDV	O
propagation	O
in	O
vitro	O
requires	O
the	O
presence	O
of	O
trypsin	O
(-	O
like	O
)	O
proteases	O
in	O
the	O
culture	O
medium	O
,	O
which	O
capacitates	O
the	O
fusion	O
function	O
of	O
the	O
S	O
protein	B-CHED
.	O

Our	O
goal	O
was	O
to	O
assess	O
new	O
predictors	O
of	O
inadequate	O
linezolid	B-CHED
concentrations	O
often	O
observed	O
in	O
critically	O
ill	O
patients	O
.	O

Covariates	O
influencing	O
linezolid	B-CHED
pharmacokinetics	O
were	O
identified	O
by	O
multivariate	O
analysis	O
and	O
a	O
population	O
pharmacokinetic	O
model	O
.	O

Two	O
theories	O
have	O
been	O
proposed	O
:	O
reverse	O
osmotic	O
shift	O
induced	O
by	O
urea	B-CHED
removal	O
and	O
a	O
fall	O
in	O
cerebral	O
intracellular	O
pH	O
.	O
Prevention	O
is	O
the	O
key	O
to	O
the	O
management	O
of	O
DDS	B-CHED
.	O

It	O
is	O
important	O
to	O
identify	O
high	O
risk	O
patients	O
and	O
haemodialysis	O
with	O
reduced	O
dialysis	O
efficacy	O
and	O
gradual	O
urea	B-CHED
reduction	O
is	O
recommended	O
.	O

ABSTRACT	O
:	O
Aluminum	B-CHED
phosphide	I-CHED
has	O
high	O
toxicity	O
when	O
it	O
is	O
ingested	O
,	O
and	O
in	O
case	O
of	O
contact	O
with	O
moisture	O
,	O
phosphine	B-CHED
gas	O
is	O
released	O
.	O

Because	O
of	O
hypotension	O
,	O
noradrenaline	B-CHED
and	O
dopamine	B-CHED
infusions	O
were	O
started	O
.	O

Retinal	B-CHED
vasculitis	O
was	O
seen	O
in	O
13	O
.	O
7	O
%	O
(	O
36	O
/	O
262	O
),	O
and	O
the	O
risk	O
appeared	O
higher	O
in	O
females	O
.	O

TITLE	O
:	O
Comparative	O
Evaluation	O
of	O
Three	O
Homogenization	O
Methods	O
for	O
Isolating	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Nucleic	B-CHED
Acids	I-CHED
From	O
Sputum	O
Samples	O
for	O
Real	O
-	O
Time	O
Reverse	O
Transcription	O
PCR	O
.	O

Owing	O
to	O
the	O
difficulty	O
of	O
extracting	O
RNA	O
from	O
sputum	O
containing	O
mucus	O
,	O
sputum	O
homogenization	O
is	O
desirable	O
prior	O
to	O
nucleic	B-CHED
acid	I-CHED
isolation	O
.	O

The	O
results	O
showed	O
that	O
all	O
eight	O
strains	O
were	O
genetically	O
and	O
serotypically	O
different	O
from	O
the	O
strain	O
ck	O
/	O
CH	O
/	O
LDL	B-CHED
/	O
140520	O
.	O

Furthermore	O
,	O
neither	O
the	O
vaccine	O
strains	O
nor	O
the	O
attenuated	O
viruses	O
could	O
provide	O
complete	O
respiratory	O
protection	O
of	O
chickens	O
against	O
a	O
challenge	O
with	O
the	O
ck	O
/	O
CH	O
/	O
LDL	B-CHED
/	O
140520	O
strain	O
,	O
indicating	O
that	O
it	O
is	O
necessary	O
to	O
develop	O
new	O
live	O
vaccines	O
or	O
to	O
evaluate	O
the	O
use	O
of	O
established	O
vaccines	O
in	O
combination	O
to	O
control	O
naturally	O
recombinant	O
TW	O
I	O
-	O
type	O
IBV	O
strains	O
in	O
the	O
future	O
.	O

Exogenous	O
administration	O
of	O
corticosteroids	B-CHED
at	O
moderate	O
dose	O
,	O
i	O
.	O
e	O
.,	O
<	O
400	O
mg	O
of	O
hydrocortisone	B-CHED
or	O
equivalent	O
for	O
>	O
96	O
h	O
,	O
may	O
help	O
reversing	O
sepsis	O
-	O
associated	O
shock	O
and	O
organ	O
dysfunction	O
.	O

Except	O
for	O
increased	O
blood	O
glucose	B-CHED
and	O
sodium	O
levels	O
,	O
treatment	O
with	O
corticosteroids	B-CHED
was	O
rather	O
well	O
tolerated	O
in	O
the	O
context	O
of	O
clinical	O
trials	O
.	O

We	O
conclude	O
that	O
pathophysiology	O
of	O
organ	O
dysfunction	O
from	O
severe	O
sepsis	O
is	O
caused	O
by	O
pulmonary	O
VOD	O
,	O
fibrosis	O
,	O
and	O
EPA	B-CHED
-	O
facilitated	O
immunoparalysis	O
.	O

During	O
virus	O
infection	O
,	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
is	O
a	O
key	O
mediator	O
of	O
innate	O
antiviral	B-CHED
responses	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
PEDV	O
antagonizes	O
the	O
antiviral	B-CHED
effects	O
of	O
interferon	O
have	O
not	O
been	O
fully	O
characterized	O
.	O

These	O
symptoms	O
showed	O
amelioration	O
after	O
discontinuing	O
ATRA	O
and	O
initiating	O
methylprednisolone	B-CHED
.	O

On	O
day	O
48	O
,	O
he	O
suddenly	O
developed	O
severe	O
abdominal	O
pain	O
with	O
free	O
air	B-CHED
,	O
observable	O
on	O
an	O
abdominal	O
X	O
-	O
ray	O
,	O
and	O
underwent	O
emergency	O
ileocecal	O
resection	O
.	O

ABSTRACT	O
:	O
Fire	O
-	O
eater	O
'	O
s	O
pneumonia	O
is	O
an	O
exogenous	O
chemical	O
pneumonitis	O
after	O
accidental	O
aspiration	O
of	O
hydrocarbon	B-CHED
fluids	O
during	O
the	O
act	O
of	O
fire	O
-	O
eating	O
.	O

We	O
present	O
a	O
case	O
of	O
fire	O
-	O
eater	O
'	O
s	O
pneumonia	O
in	O
a	O
28	O
-	O
year	O
-	O
old	O
white	O
man	B-CHED
with	O
severe	O
pulmonary	O
complications	O
.	O

This	O
study	O
uses	O
Affymetrix	O
microarray	O
analysis	O
to	O
compare	O
differential	O
spinal	O
cord	O
mRNA	B-CHED
levels	O
between	O
mice	O
infected	O
with	O
demyelinating	O
and	O
non	O
-	O
demyelinating	O
strains	O
of	O
MHV	O
to	O
identify	O
host	O
immune	O
genes	O
expressed	O
in	O
this	O
demyelinating	O
disease	O
model	O
.	O

In	O
addition	O
,	O
novel	O
antiviral	B-CHED
drugs	I-CHED
may	O
be	O
developed	O
once	O
the	O
host	O
cell	O
pathways	O
and	O
the	O
molecular	O
mechanism	O
affecting	O
porcine	O
CoV	O
replication	O
and	O
virulence	O
are	O
known	O
.	O

Different	O
respiratory	O
system	O
pathologies	O
that	O
result	O
in	O
acute	O
respiratory	O
failure	O
(	O
such	O
as	O
increased	O
interstitial	O
fluid	O
,	O
alveolar	O
consolidation	O
,	O
pleural	O
effusion	O
)	O
cause	O
characteristic	O
ultrasonographic	O
findings	O
;	O
diaphragmatic	O
assessment	O
may	O
also	O
add	B-CHED
information	O
.	O

Mean	O
inspiratory	O
positive	O
airway	O
pressure	O
(	O
IPAP	O
)	O
was	O
14	O
cm	O
H2O	B-CHED
(	O
range	O
10	O
to	O
20	O
cm	O
H2O	B-CHED
).	O

The	O
rest	B-CHED
24	O
cases	O
were	O
all	O
improved	O
and	O
discharged	O
.	O

Spike	O
proteins	B-CHED
have	O
a	O
dual	O
function	O
during	O
entry	O
,	O
they	O
mediate	O
binding	O
to	O
the	O
host	O
cell	O
surface	O
and	O
also	O
the	O
fusion	O
of	O
the	O
viral	O
envelope	O
with	O
host	O
cell	O
membrane	O
.	O

Data	O
were	O
processed	O
with	O
Student	O
t	O
test	O
,	O
Wilcox	O
test	O
,	O
chi	B-CHED
-	O
square	O
test	O
and	O
or	O
Fisher	O
'	O
s	O
exact	O
test	O
.	O

ABSTRACT	O
:	O
BACKGROUND	O
Since	O
the	O
first	O
isolation	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
Saudi	O
Arabia	O
in	O
2012	O
,	O
sporadic	O
cases	O
,	O
clusters	B-CHED
,	O
and	O
sometimes	O
large	O
outbreaks	O
have	O
been	O
reported	O
.	O

ABSTRACT	O
:	O
The	O
structural	O
maintenance	O
of	O
chromosomes	O
(	O
SMC	O
)	O
family	O
of	O
proteins	B-CHED
supports	O
mitotic	O
proliferation	O
,	O
meiosis	O
,	O
and	O
DNA	O
repair	O
to	O
control	O
genomic	O
stability	O
.	O

Angiopoietin	O
-	O
2	O
and	O
IL	O
-	O
1	O
receptor	O
antagonist	B-CHED
concentrations	O
did	O
not	O
differ	O
between	O
groups	O
.	O

Although	O
it	O
is	O
usually	O
associated	O
with	O
elevated	O
creatine	B-CHED
phosphokinase	O
level	O
,	O
some	O
patients	O
may	O
have	O
amyopathic	O
dermatomyositis	O
(	O
ADM	O
)	O
like	O
presentation	O
with	O
predominant	O
skin	O
involvement	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
)	O
is	O
a	O
disease	O
caused	O
by	O
beta	O
corona	B-CHED
virus	O
.	O

TITLE	O
:	O
Viral	O
Macro	O
Domains	O
Reverse	O
Protein	B-CHED
ADP	B-CHED
-	O
Ribosylation	O
.	O

Using	O
two	O
murine	O
ALI	O
models	O
and	O
cells	O
culture	O
,	O
we	O
examined	O
the	O
presence	O
of	O
sCD74	O
in	O
circulation	O
and	O
alveolar	O
space	O
and	O
preliminarily	O
assessed	O
the	O
biological	B-CHED
function	I-CHED
of	O
sCD74	O
.	O

TITLE	O
:	O
Evaluating	O
the	O
efficacy	O
of	O
dexamethasone	B-CHED
in	O
the	O
treatment	O
of	O
patients	O
with	O
persistent	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O

The	O
second	O
EIA	O
uses	O
RSV	O
F	O
or	O
G	O
gene	O
-	O
expressed	O
antigen	B-CHED
in	O
HEp	B-CHED
-	O
2	O
cells	O
.	O

TITLE	O
:	O
Short	O
communication	O
:	O
antiviral	B-CHED
activity	O
of	O
porcine	O
IFN	O
-	O
3	O
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
in	O
vitro	O
.	O

All	O
ARDS	O
-	O
complicated	O
AOSD	O
cases	O
received	O
corticosteroids	B-CHED
with	O
favorable	O
outcomes	O
in	O
10	O
(	O
2	O
deceased	O
).	O

TITLE	O
:	O
Viral	O
RNA	O
in	O
Blood	O
as	O
Indicator	B-CHED
of	O
Severe	O
Outcome	O
in	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infection	O
.	O

Otherwise	O
healthy	O
152	O
patients	O
,	O
presenting	O
to	O
outpatient	O
clinics	O
with	O
ILI	O
/	O
ARI	B-CHED
,	O
were	O
included	O
.	O

RESULTS	O
:	O
During	O
the	O
study	O
period	O
,	O
138	O
patients	O
were	O
admitted	O
to	O
our	O
ICU	O
with	O
a	O
diagnosis	O
of	O
leptospirosis	O
;	O
39	O
(	O
36	O
males	O
/	O
3	O
females	O
)	O
met	B-CHED
the	O
criteria	O
for	O
ARDS	O
and	O
AKI	O
.	O

However	O
,	O
additional	O
cellular	O
binding	O
targets	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
that	O
may	O
augment	O
MERS	O
-	O
CoV	O
infection	O
have	O
not	O
been	O
further	O
explored	O
.	O

In	O
the	O
current	O
study	O
,	O
using	O
the	O
virus	O
overlay	O
protein	B-CHED
binding	O
assay	O
(	O
VOPBA	O
),	O
we	O
identified	O
carcinoembryonic	O
antigen	B-CHED
-	O
related	O
cell	O
adhesion	O
molecule	O
5	O
(	O
CEACAM5	O
)	O
as	O
a	O
novel	O
cell	O
surface	O
binding	O
target	O
of	O
MERS	O
-	O
CoV	O
.	O
CEACAM5	O
coimmunoprecipitated	O
with	O
the	O
spike	O
protein	B-CHED
of	O
MERS	O
-	O
CoV	O
in	O
both	O
overexpressed	O
and	O
endogenous	O
settings	O
.	O

The	O
identification	O
of	O
carcinoembryonic	O
antigen	B-CHED
-	O
related	O
cell	O
adhesion	O
molecule	O
5	O
(	O
CEACAM5	O
)	O
as	O
a	O
novel	O
cell	O
surface	O
binding	O
target	O
of	O
MERS	O
-	O
CoV	O
advanced	O
our	O
knowledge	O
on	O
the	O
cell	O
binding	O
biology	O
of	O
MERS	O
-	O
CoV	O
.	O
Importantly	O
,	O
CEACAM5	O
could	O
potentiate	O
the	O
entry	O
of	O
MERS	O
-	O
CoV	O
by	O
functioning	O
as	O
an	O
attachment	O
factor	O
.	O

In	O
this	O
regard	O
,	O
CEACAM5	O
could	O
serve	O
as	O
a	O
novel	O
target	O
,	O
in	O
addition	O
to	O
dipeptidyl	O
peptidase	O
-	O
4	O
(	O
DPP4	O
),	O
in	O
the	O
development	O
of	O
antiviral	B-CHED
strategies	O
for	O
MERS	O
-	O
CoV	O
.	O

CCL2	B-CHED
and	O
CCL7	O
were	O
significantly	O
elevated	O
in	O
BAL	B-CHED
fluid	O
recovered	O
from	O
LPS	B-CHED
-	O
challenged	O
volunteers	O
and	O
patients	O
with	O
ARDS	O
.	O

Furthermore	O
,	O
neutrophils	O
isolated	O
from	O
the	O
blood	O
or	O
BAL	B-CHED
fluid	O
differentially	O
regulated	O
the	O
cell	O
surface	O
expression	O
of	O
chemokine	O
(	O
C	O
-	O
X	O
-	O
C	O
motif	O
)	O
receptor	O
1	O
and	O
C	O
-	O
C	O
chemokine	O
receptor	O
type	O
2	O
during	O
ARDS	O
.	O

The	O
S1	O
protein	B-CHED
,	O
which	O
contains	O
several	O
virus	O
neutralization	O
epitopes	O
,	O
is	O
considered	O
to	O
be	O
a	O
target	O
site	O
of	O
vaccine	O
development	O
.	O

TITLE	O
:	O
Sphingomyelin	B-CHED
synthase	O
2	O
affects	O
CD14	O
	O
associated	O
induction	O
of	O
NF	O
	O
B	O
by	O
lipopolysaccharides	B-CHED
in	O
acute	O
lung	O
injury	O
in	O
mice	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
mRNA	B-CHED
and	O
protein	B-CHED
levels	O
of	O
CD14	O
were	O
significantly	O
increased	O
(	O
P	O
<	O
0	O
.	O
001	O
;	O
n	O
=	O
5	O
and	O
P	O
<	O
0	O
.	O
05	O
,	O
n	O
=	O
5	O
),	O
and	O
the	O
activity	O
of	O
SMS	O
and	O
expression	O
of	O
SMS2	O
were	O
significantly	O
upregulated	O
(	O
P	O
<	O
0	O
.	O
001	O
;	O
n	O
=	O
5	O
and	O
P	O
<	O
0	O
.	O
05	O
,	O
n	O
=	O
5	O
)	O
in	O
the	O
model	O
group	O
.	O

ABSTRACT	O
:	O
We	O
are	O
interested	O
in	O
the	O
influence	O
of	O
nucleotide	B-CHED
composition	O
on	O
the	O
fundamental	O
characteristics	O
of	O
the	O
virus	O
RNA	O
genome	O
.	O

We	O
identify	O
cellular	O
E3	O
ubiquitin	O
ligase	O
ring	O
-	O
finger	O
and	O
CHY	O
zinc	B-CHED
-	O
finger	O
domain	O
-	O
containing	O
1	O
(	O
RCHY1	O
)	O
as	O
an	O
interacting	O
partner	O
of	O
the	O
viral	O
SARS	O
-	O
unique	O
domain	O
(	O
SUD	O
)	O
and	O
papain	O
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	B-CHED
)),	O
and	O
,	O
as	O
a	O
consequence	O
,	O
the	O
involvement	O
of	O
cellular	O
p53	O
as	O
antagonist	B-CHED
of	O
coronaviral	O
replication	O
.	O

The	O
calcium	B-CHED
/	O
calmodulin	O
-	O
dependent	O
protein	B-CHED
kinase	O
II	O
delta	O
(	O
CAMK2D	O
),	O
which	O
normally	O
influences	O
RCHY1	O
stability	O
by	O
phosphorylation	O
,	O
also	O
binds	O
to	O
SUD	O
.	O

The	O
significance	O
of	O
these	O
findings	O
is	O
that	O
down	O
-	O
regulation	O
of	O
p53	O
as	O
a	O
major	O
player	O
in	O
antiviral	B-CHED
innate	O
immunity	O
provides	O
a	O
long	O
-	O
sought	O
explanation	O
for	O
delayed	O
activities	O
of	O
respective	O
genes	O
.	O

TITLE	O
:	O
Xanthine	B-CHED
Oxidase	O
-	O
Derived	O
ROS	B-CHED
Display	O
a	O
Biphasic	O
Effect	O
on	O
Endothelial	O
Cells	O
Adhesion	O
and	O
FAK	O
Phosphorylation	O
.	O

Results	O
show	O
that	O
Hx	O
-	O
XO	O
-	O
derived	O
ROS	B-CHED
induced	O
an	O
increase	O
in	O
HUVEC	O
adhesion	O
in	O
the	O
early	O
stages	O
of	O
the	O
process	O
(	O
less	O
than	O
30	O
min	O
),	O
followed	O
by	O
a	O
decrease	O
in	O
adhesion	O
in	O
the	O
later	O
stages	O
of	O
the	O
process	O
.	O

Activation	O
of	O
the	O
pro	B-CHED
-	O
inflammatory	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
B	O
(	O
NF	O
-	O
B	O
)	O
results	O
in	O
muscle	O
wasting	O
during	O
disuse	O
-	O
induced	O
skeletal	O
muscle	O
atrophy	O
(	O
ICU	O
bed	O
rest	B-CHED
)	O
and	O
septic	O
shock	O
.	O

ABSTRACT	O
:	O
To	O
date	O
,	O
there	O
have	O
been	O
several	O
systematic	O
reviews	O
with	O
meta	O
-	O
analysis	O
that	O
have	O
shown	O
no	O
reduction	O
in	O
mortality	O
with	O
the	O
use	O
of	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
(	O
iNO	O
)	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

The	O
assay	O
was	O
optimized	O
for	O
a	O
384	O
-	O
well	O
format	O
,	O
and	O
nafamostat	O
,	O
a	O
serine	B-CHED
protease	I-CHED
inhibitor	I-CHED
,	O
was	O
identified	O
as	O
a	O
potent	O
inhibitor	B-CHED
of	O
S	O
-	O
mediated	O
membrane	O
fusion	O
in	O
a	O
screening	O
of	O
about	O
1	O
,	O
000	O
drugs	O
approved	O
for	O
use	O
by	O
the	O
U	O
.	O
S	O
.	O
Food	O
and	O
Drug	O
Administration	O
.	O

Herein	O
,	O
a	O
facile	O
approach	O
to	O
formulate	O
synthetic	O
virus	O
-	O
like	O
particles	O
(	O
sVLPs	O
)	O
is	O
demonstrated	O
by	O
exploiting	O
the	O
phenomenon	O
of	O
protein	B-CHED
corona	B-CHED
formation	O
induced	O
by	O
the	O
high	O
-	O
energy	O
surfaces	O
of	O
synthetic	O
nanoparticles	B-CHED
.	O

Comparison	O
to	O
a	O
commercial	O
whole	O
inactivated	O
virus	O
vaccine	O
also	O
showed	O
evidence	O
of	O
superior	O
antiviral	B-CHED
protection	O
by	O
the	O
sVLPs	O
.	O

We	O
modelled	O
importations	O
in	O
time	O
based	O
on	O
air	B-CHED
travel	O
combined	O
with	O
incidence	O
in	O
Middle	O
East	O
.	O

Although	O
antivirals	B-CHED
were	O
available	O
,	O
prophylaxis	O
was	O
not	O
used	O
.	O

Quantitative	O
proteomics	O
is	O
a	O
powerful	O
tool	O
for	O
biomarker	B-CHED
discovery	O
in	O
cancer	O
,	O
autoimmune	O
diseases	O
,	O
and	O
ARDS	O
.	O

The	O
spike	O
glycoprotein	B-CHED
(	O
S	O
)	O
gene	O
had	O
the	O
greatest	O
similarity	O
to	O
the	O
nephropathogenic	O
BJ	O
strain	O
and	O
showed	O
an	O
8	O
amino	B-CHED
acid	I-CHED
insertion	O
(	O
YSNGNSDV	O
)	O
at	O
73	O
to	O
80	O
sites	O
and	O
3	O
amino	B-CHED
acid	I-CHED
deletion	O
at	O
sites	O
126	O
to	O
128	O
compared	O
to	O
the	O
IBV	O
vaccine	O
strains	O
.	O

Pathological	O
examinations	O
of	O
the	O
kidneys	O
revealed	O
inflammation	O
,	O
distention	O
with	O
uric	B-CHED
acid	I-CHED
deposits	O
,	O
and	O
tubular	O
degeneration	O
.	O

An	O
esophageal	O
balloon	O
catheter	O
was	O
used	O
to	O
measure	O
esophageal	O
pressures	O
(	O
Pes	O
)	O
at	O
end	O
inspiration	O
and	O
end	O
expiration	O
and	O
to	O
calculate	O
P	O
L	O
.	O
Measurements	O
were	O
taken	O
during	O
ventilation	O
with	O
CMV	O
(	O
CMVpre	O
)	O
after	O
which	O
patients	O
were	O
switched	O
to	O
HFOV	O
with	O
three	O
1	O
-	O
h	O
different	O
levels	O
of	O
mPaw	O
set	O
at	O
+	O
5	O
,	O
+	O
10	O
and	O
+	O
15	O
cm	O
H2O	B-CHED
above	O
the	O
mean	O
airway	O
pressure	O
measured	O
during	O
CMV	O
.	O

Mild	O
to	O
severe	O
atrophic	O
enteritis	O
with	O
PDCoV	O
antigen	B-CHED
staining	O
was	O
observed	O
in	O
the	O
small	O
intestine	O
of	O
affected	O
piglets	O
from	O
2	O
to	O
8	O
dpi	O
.	O

The	O
therapeutic	O
agents	O
with	O
potential	O
benefits	O
and	O
warranting	O
further	O
investigation	O
include	O
convalescent	O
plasma	O
,	O
interferon	O
-	O
	O
/	O
ribavirin	B-CHED
combination	O
therapy	O
and	O
lopinavir	O
.	O

These	O
droplets	O
or	O
droplet	O
nuclei	B-CHED
are	O
transported	O
by	O
expired	O
airflows	O
,	O
which	O
are	O
sometimes	O
affected	O
by	O
the	O
human	O
body	O
plume	O
and	O
use	O
of	O
a	O
face	O
mask	O
,	O
as	O
well	O
as	O
room	O
airflow	O
.	O

RESULTS	O
:	O
These	O
droplets	O
or	O
droplet	O
nuclei	B-CHED
are	O
transported	O
by	O
expired	O
airflows	O
,	O
which	O
are	O
sometimes	O
affected	O
by	O
the	O
human	O
body	O
plume	O
and	O
use	O
of	O
a	O
face	O
mask	O
,	O
as	O
well	O
as	O
room	O
airflow	O
.	O

Clinical	O
manifestations	O
,	O
pancreatic	O
ultrasound	O
,	O
biochemical	O
indicators	O
,	O
state	O
of	O
organ	O
damage	O
and	O
failure	O
,	O
mechanical	O
ventilation	O
,	O
severity	O
of	O
sepsis	O
,	O
mortality	O
rate	O
and	O
survival	O
were	O
compared	O
among	O
different	O
groups	O
using	O
t	O
test	O
,	O
analysis	O
of	O
variance	O
,	O
chi	B-CHED
-	O
square	O
test	O
or	O
non	O
-	O
parametric	O
test	O
.	O

The	O
risk	O
factors	O
of	O
elevated	O
amylase	O
or	O
lipase	O
were	O
age	O
,	O
convulsions	O
,	O
consciousness	O
,	O
BE	O
,	O
PCT	O
,	O
calcium	B-CHED
,	O
mechanical	O
ventilation	O
,	O
severe	O
sepsis	O
and	O
MODS	O
(	O
OR	O
=	O
1	O
.	O
155	O
,	O
1	O
.	O
491	O
,	O
2	O
.	O
237	O
,	O
0	O
.	O
949	O
,	O
0	O
.	O
604	O
,	O
1	O
.	O
008	O
,	O
0	O
.	O
660	O
,	O
1	O
.	O
907	O
,	O
0	O
.	O
836	O
,	O
P	O
all	O
<	O
0	O
.	O
05	O
).	O

RESULTS	O
:	O
(	O
1	O
)	O
Positive	O
end	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
6	O
hours	O
prior	O
to	O
VV	O
-	O
ECMO	O
support	O
in	O
the	O
survivors	O
group	O
[(	O
9	O
.	O
7	O
	O
5	O
.	O
0	O
)	O
cmH2O	O
,	O
(	O
1	O
cmH2O	O
=	O
0	O
.	O
098	O
kPa	O
)]	O
was	O
lower	O
than	O
that	O
in	O
the	O
nonsurvivors	O
group	O
[(	O
13	O
.	O
2	O
	O
5	O
.	O
4	O
)	O
cmH2O	O
,	O
t	O
=-	O
2	O
.	O
134	O
,	O
P	O
=	O
0	O
.	O
039	O
].	O

All	O
regions	O
connected	O
to	O
MERS	O
-	O
CoV	O
affected	O
countries	O
via	O
air	B-CHED
travel	O
are	O
considered	O
,	O
and	O
the	O
countries	O
at	O
highest	O
risk	O
of	O
travel	O
-	O
related	O
importations	O
of	O
MERS	O
-	O
CoV	O
were	O
identified	O
,	O
ranked	O
and	O
compared	O
with	O
actual	O
spread	O
of	O
MERS	O
cases	O
.	O

The	O
international	O
donor	B-CHED
community	O
and	O
Middle	O
Eastern	O
countries	O
should	O
make	O
available	O
resources	O
for	O
,	O
and	O
make	O
a	O
serious	O
commitment	O
to	O
,	O
taking	O
forward	O
a	O
""""	O
One	O
Health	O
""""	O
global	O
network	O
for	O
proactive	O
surveillance	O
,	O
rapid	O
detection	O
,	O
and	O
prevention	O
of	O
MERS	O
-	O
CoV	O
and	O
other	O
epidemic	O
infectious	O
diseases	O
threats	O
.	O

TITLE	O
:	O
The	O
sequence	O
of	O
the	O
full	O
spike	O
S1	O
glycoprotein	B-CHED
of	O
infectious	O
bronchitis	O
virus	O
circulating	O
in	O
Egypt	O
reveals	O
evidence	O
of	O
intra	O
-	O
genotypic	O
recombination	O
.	O

Significant	O
amino	B-CHED
acid	I-CHED
sequence	O
differences	O
between	O
the	O
two	O
subgroups	O
,	O
especially	O
in	O
the	O
epitope	B-CHED
sites	O
,	O
were	O
identified	O
.	O

To	O
determine	O
the	O
impact	O
of	O
miR	O
-	O
155	O
on	O
trafficking	O
,	O
T	O
cells	O
from	O
infected	O
WT	O
or	O
miR	O
-	O
155	O
(-/-)	O
mice	O
were	O
adoptively	O
transferred	O
into	O
RAG1	O
(-/-)	O
mice	O
,	O
and	O
T	O
cell	O
accumulation	O
into	O
the	O
CNS	B-CHED
was	O
assessed	O
using	O
flow	O
cytometry	O
.	O

TITLE	O
:	O
Multivariable	O
fractional	O
polynomial	O
interaction	O
to	O
investigate	O
continuous	O
effect	O
modifiers	O
in	O
a	O
meta	O
-	O
analysis	O
on	O
higher	O
versus	O
lower	O
PEEP	B-CHED
for	O
patients	O
with	O
ARDS	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
apply	O
the	O
MFPI	O
approach	O
to	O
investigate	O
interactions	O
between	O
four	O
continuous	O
patient	O
baseline	O
variables	O
and	O
higher	O
versus	O
lower	O
PEEP	B-CHED
on	O
clinical	O
outcomes	O
.	O

Higher	O
(	O
N	O
=	O
1136	O
)	O
versus	O
lower	O
PEEP	B-CHED
(	O
N	O
=	O
1163	O
)	O
ventilation	O
strategy	O
.	O

For	O
patients	O
with	O
a	O
respiratory	O
system	O
compliance	O
above	O
40	O
mL	O
/	O
cm	O
H2O	B-CHED
or	O
patients	O
with	O
a	O
BMI	O
above	O
35	O
kg	O
/	O
m	O
(	O
2	O
),	O
we	O
found	O
a	O
trend	O
towards	O
reduced	O
mortality	O
with	O
higher	O
PEEP	B-CHED
,	O
but	O
there	O
is	O
very	O
weak	O
statistical	O
confidence	O
in	O
these	O
findings	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
Pa	O
Twenty	O
-	O
five	O
patients	O
were	O
assigned	O
to	O
the	O
sevoflurane	B-CHED
group	O
and	O
25	O
to	O
the	O
midazolam	O
group	O
.	O

Additional	O
investigations	O
,	O
including	O
a	O
cell	O
-	O
free	O
haemoglobin	B-CHED
of	O
10	O
.	O
2	O
	O
10	O
(	O
5	O
)	O
ng	O
/	O
mL	O
and	O
an	O
undetectable	O
haptoglobin	O
,	O
confirmed	O
intravascular	O
haemolysis	O
.	O

The	O
map	O
resolves	O
the	O
extensive	O
glycan	B-CHED
shield	O
obstructing	O
the	O
protein	B-CHED
surface	O
and	O
,	O
in	O
combination	O
with	O
mass	O
spectrometry	O
,	O
provides	O
a	O
structural	O
framework	O
to	O
understand	O
the	O
accessibility	O
to	O
antibodies	O
.	O

Sequence	O
analysis	O
of	O
Nucleocapsid	O
gene	O
of	O
TioV	O
demonstrated	O
sequence	O
identity	O
of	O
99	O
.	O
87	O
%	O
and	O
99	O
.	O
99	O
%	O
nucleotide	B-CHED
and	O
amino	B-CHED
acid	I-CHED
respectively	O
with	O
of	O
TioV	O
strain	O
isolated	O
in	O
Malaysia	O
,	O
2001	O
.	O

Protein	B-CHED
histochemistry	O
showed	O
that	O
the	O
Y43H	O
change	O
allows	O
for	O
enhanced	O
binding	O
to	O
trachea	O
,	O
whereas	O
the	O
ArkDPI	O
S1	O
spike	O
with	O
H43	O
alone	O
was	O
able	O
to	O
bind	O
CAM	O
.	O

In	O
1	O
case	O
,	O
they	O
started	O
cisatracurium	O
,	O
and	O
in	O
3	O
others	O
,	O
they	O
initiated	O
inhaled	O
epoprostenol	B-CHED
.	O

Canine	O
influenza	O
virus	O
(	O
CIV	O
),	O
canine	O
parainfluenza	O
virus	O
(	O
CPIV	O
),	O
canine	O
distemper	O
virus	O
(	O
CDV	B-CHED
),	O
canine	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
),	O
canine	O
adenovirus	O
type	O
2	O
(	O
CAdV	O
-	O
2	O
)	O
and	O
canine	O
herpesvirus	O
1	O
(	O
CaHV	O
-	O
1	O
),	O
are	O
all	O
associated	O
with	O
the	O
CIRDC	O
.	O

We	O
sought	O
to	O
characterize	O
the	O
timing	O
,	O
severity	O
,	O
and	O
intensive	O
care	O
management	O
of	O
cytokine	O
release	O
syndrome	O
after	O
chimeric	O
antigen	B-CHED
receptor	O
-	O
modified	O
T	O
cell	O
therapy	O
.	O

Thirty	O
-	O
nine	O
subjects	O
with	O
relapsed	O
/	O
refractory	O
acute	O
lymphoblastic	O
leukemia	O
treated	O
with	O
chimeric	O
antigen	B-CHED
receptor	O
-	O
modified	O
T	O
cell	O
therapy	O
on	O
a	O
phase	O
I	O
/	O
IIa	O
clinical	O
trial	O
(	O
ClinicalTrials	O
.	O
gov	O
number	O
NCT01626495	O
).	O

General	O
laboratory	O
quality	O
standards	O
,	O
including	O
the	O
entire	O
laboratory	O
key	O
elements	O
was	O
improved	O
through	O
the	O
PEI	B-CHED
accreditation	O
process	O
.	O

General	O
laboratory	O
quality	O
standards	O
,	O
including	O
the	O
entire	O
laboratory	O
key	O
elements	O
was	O
improved	O
through	O
the	O
PEI	B-CHED
accreditation	O
process	O
.	O

TITLE	O
:	O
Liquid	O
extracorporeal	O
carbon	B-CHED
dioxide	I-CHED
removal	O
:	O
use	O
of	O
THAM	B-CHED
(	O
tris	B-CHED
-	O
hydroxymethyl	B-CHED
aminomethane	B-CHED
)	O
coupled	O
to	O
hemofiltration	O
to	O
control	O
hypercapnic	O
acidosis	O
in	O
a	O
porcine	O
model	O
of	O
protective	O
mechanical	O
ventilation	O
.	O

After	O
stopping	O
THAM	B-CHED
at	O
18	O
hours	O
of	O
treatment	O
a	O
profound	O
rebound	O
effect	O
was	O
observed	O
with	O
severe	O
hypercapnic	O
acidosis	O
.	O

TITLE	O
:	O
Dexmedetomidine	B-CHED
Use	O
in	O
Critically	O
Ill	O
Children	O
With	O
Acute	O
Respiratory	O
Failure	O
.	O

TITLE	O
:	O
Activated	O
GL7	O
ABSTRACT	O
:	O
Central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
inflammation	O
associated	O
with	O
viral	O
infection	O
and	O
autoimmune	O
disease	O
results	O
in	O
the	O
accumulation	O
of	O
B	O
cells	O
in	O
various	O
differentiation	O
stages	O
.	O

TITLE	O
:	O
Identification	O
and	O
subcellular	O
localization	O
of	O
porcine	O
deltacoronavirus	O
accessory	O
protein	B-CHED
NS6	O
.	O

Herein	O
,	O
we	O
identified	O
a	O
novel	O
coronavirus	O
,	O
provisionally	O
designated	O
Rousettus	O
bat	O
coronavirus	O
GCCDC1	O
(	O
Ro	O
-	O
BatCoV	O
GCCDC1	O
),	O
in	O
the	O
rectal	O
swab	O
samples	O
of	O
Rousettus	O
leschenaulti	O
bats	O
by	O
using	O
pan	B-CHED
-	O
coronavirus	O
RT	O
-	O
PCR	O
and	O
next	O
-	O
generation	O
sequencing	O
.	O

Ongoing	O
hemodynamic	O
(	O
Norepinephrine	B-CHED
and	O
Milrinone	B-CHED
infusion	O
)	O
and	O
respiratory	O
(	O
ventilator	O
)	O
support	O
in	O
the	O
ICU	O
was	O
provided	O
until	O
resolution	O
of	O
intravascular	O
fluid	O
extravasation	O
.	O

Two	O
linear	O
epitopes	O
,	O
189SVEQAVLAALKKLG202	O
and	O
246VTRFYGARSSSA257	O
,	O
located	O
in	O
the	O
LKR	O
and	O
CTD	O
of	O
TGEV	O
N	O
protein	B-CHED
,	O
respectively	O
,	O
were	O
identified	O
after	O
truncating	O
the	O
protein	B-CHED
and	O
applying	O
a	O
peptide	B-CHED
scanning	O
technique	O
.	O

In	O
HULEC	O
,	O
human	O
influenza	O
viruses	O
were	O
capable	O
of	O
binding	O
to	O
host	O
cellular	O
receptors	O
,	O
becoming	O
internalized	O
and	O
initiating	O
hemifusion	O
but	O
failing	O
to	O
uncoat	O
the	O
viral	O
nucleocapsid	O
and	O
to	O
replicate	O
in	O
host	O
nuclei	B-CHED
.	O

TITLE	O
:	O
Differential	O
Regulation	O
of	O
Self	O
-	O
reactive	O
CD4	O
ABSTRACT	O
:	O
Viral	O
infections	O
have	O
long	O
been	O
implicated	O
as	O
triggers	O
of	O
autoimmune	O
diseases	O
,	O
including	O
multiple	O
sclerosis	O
(	O
MS	O
),	O
a	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
inflammatory	O
demyelinating	O
disorder	O
.	O

Epitope	B-CHED
spreading	O
,	O
molecular	O
mimicry	O
,	O
cryptic	O
antigen	B-CHED
,	O
and	O
bystander	O
activation	O
have	O
been	O
implicated	O
as	O
mechanisms	O
responsible	O
for	O
activating	O
self	O
-	O
reactive	O
(	O
SR	O
)	O
immune	O
cells	O
,	O
ultimately	O
leading	O
to	O
organ	O
-	O
specific	O
autoimmune	O
disease	O
.	O

The	O
protein	B-CHED
complex	O
is	O
thought	O
to	O
bind	O
specific	O
cis	O
-	O
acting	O
RNA	O
elements	O
primarily	O
located	O
in	O
the	O
5	O
'-	O
and	O
3	O
'-	O
terminal	O
genome	O
regions	O
and	O
upstream	O
of	O
the	O
open	O
reading	O
frames	O
located	O
in	O
the	O
3	O
'-	O
proximal	O
one	O
-	O
third	O
of	O
the	O
genome	O
.	O

TITLE	O
:	O
Coronavirus	O
Spike	O
Protein	B-CHED
and	O
Tropism	O
Changes	O
.	O

Trimers	O
of	O
the	O
S	O
glycoproteins	B-CHED
on	O
the	O
virion	O
surface	O
accommodate	O
binding	O
to	O
a	O
cell	O
surface	O
receptor	O
and	O
fusion	O
of	O
the	O
viral	O
and	O
cellular	O
membrane	O
.	O

TITLE	O
:	O
The	O
Nonstructural	O
Proteins	B-CHED
Directing	O
Coronavirus	O
RNA	O
Synthesis	O
and	O
Processing	O
.	O

Coronavirus	O
genomes	O
(~	O
26	O
-	O
32	O
kilobases	O
)	O
are	O
the	O
largest	O
RNA	O
genomes	O
known	O
to	O
date	O
and	O
their	O
expansion	O
was	O
likely	O
enabled	O
by	O
acquiring	O
enzyme	O
functions	O
that	O
counter	B-CHED
the	O
commonly	O
high	O
error	O
frequency	O
of	O
viral	O
RNA	O
polymerases	O
.	O

Patients	O
with	O
longer	O
delay	O
between	O
onset	O
of	O
illness	O
and	O
initiation	O
of	O
oseltamivir	B-CHED
treatment	O
were	O
more	O
likely	O
to	O
develop	O
ARDS	O
.	O

Early	O
and	O
appropriate	O
antibiotics	B-CHED
remain	O
the	O
cornerstone	O
in	O
the	O
treatment	O
of	O
CAP	O
.	O

Two	O
amino	B-CHED
acid	I-CHED
substitutions	O
(	O
R642M	O
and	O
N714K	O
)	O
in	O
the	O
S	O
protein	B-CHED
of	O
HCoV	O
-	O
229E	O
clinical	O
isolates	O
altered	O
their	O
sensitivity	O
to	O
a	O
cathepsin	B-CHED
L	I-CHED
inhibitor	I-CHED
,	O
suggesting	O
that	O
these	O
amino	B-CHED
acids	I-CHED
were	O
responsible	O
for	O
cathepsin	O
L	O
use	O
.	O

The	O
1	O
-	O
microglobulin	O
-,	O
albumin	O
-,	O
and	O
IgG	O
/	O
creatinine	B-CHED
ratios	O
correlated	O
with	O
high	O
-	O
sensitivity	O
C	O
-	O
reactive	O
protein	B-CHED
48	O
h	O
after	O
admission	O
(	O
r	O
=	O
0	O
.	O
47	O
-	O
0	O
.	O
61	O
,	O
p	O
<	O
0	O
.	O
001	O
for	O
all	O
).	O

The	O
1	O
-	O
microglobulin	O
/	O
creatinine	B-CHED
ratio	O
upon	O
admission	O
predicted	O
organ	O
failure	O
[	O
adjusted	O
odds	O
ratio	O
1	O
.	O
286	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
024	O
-	O
1	O
.	O
614	O
]	O
with	O
similar	O
accuracy	O
(	O
AUROC	O
0	O
.	O
81	O
,	O
95	O
%	O
CI	O
0	O
.	O
69	O
-	O
0	O
.	O
94	O
)	O
as	O
the	O
more	O
complex	O
APACHE	O
II	O
score	O
(	O
AUROC	O
0	O
.	O
86	O
,	O
95	O
%	O
CI	O
0	O
.	O
70	O
-	O
1	O
.	O
00	O
).	O

Based	O
on	O
DNA	O
sequences	O
for	O
the	O
gene	O
encoding	O
the	O
S	O
protein	B-CHED
,	O
the	O
avian	O
coronaviruses	O
detected	O
in	O
the	O
quail	O
and	O
pheasant	O
are	O
related	O
to	O
the	O
IBV	O
793B	O
and	O
Massachusetts	O
types	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Over	O
the	O
course	O
of	O
4	O
years	O
,	O
197	O
patients	O
were	O
randomized	O
to	O
either	O
hydrocortisone	B-CHED
(	O
n	O
=	O
98	O
)	O
or	O
placebo	O
(	O
n	O
=	O
99	O
)	O
and	O
were	O
included	O
in	O
this	O
intention	O
-	O
to	O
-	O
treat	O
analysis	O
.	O

This	O
will	O
be	O
done	O
by	O
identifying	O
domains	O
that	O
are	O
conserved	O
across	O
the	O
order	O
Nidovirales	O
,	O
and	O
by	O
summarizing	O
what	O
is	O
known	O
about	O
function	O
and	O
structure	O
at	O
the	O
level	O
of	O
protein	B-CHED
domains	O
.	O

This	O
study	O
suggests	O
that	O
the	O
demonstrated	O
T	O
lymphocyte	O
activation	O
is	O
in	O
part	O
due	O
to	O
antigen	B-CHED
presentation	O
by	O
the	O
macrophages	O
as	O
well	O
as	O
cytokine	O
release	O
by	O
the	O
infected	O
macrophages	O
,	O
with	O
B2	O
haplotypes	O
showing	O
stronger	O
activation	O
.	O

Additional	O
factors	O
are	O
also	O
knowingly	O
associated	O
with	O
worse	O
outcomes	O
:	O
higher	O
values	O
of	O
ICU	O
severity	O
score	O
,	O
presence	O
of	O
severe	O
sepsis	O
,	O
and	O
lower	O
ratio	O
of	O
arterial	O
oxygen	B-CHED
tension	O
to	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
.	O

Samples	O
were	O
tested	O
for	O
antibodies	O
against	O
canine	O
distemper	O
virus	O
(	O
CDV	B-CHED
),	O
feline	O
panleukopenia	O
virus	O
,	O
enteric	O
coronavirus	O
,	O
feline	O
calicivirus	O
,	O
feline	O
herpesvirus	O
(	O
FHV	O
-	O
1	O
),	O
and	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
).	O

Only	O
hyenas	O
(	O
26	O
%,	O
5	O
/	O
19	O
)	O
were	O
positive	O
for	O
CDV	B-CHED
antibody	O
.	O

extracts	O
along	O
with	O
their	O
main	O
single	O
isolated	O
constituents	O
anthraquinone	B-CHED
derivatives	O
were	O
tested	O
on	O
both	O
HIV	O
-	O
1	O
Reverse	O
Transcriptase	O
(	O
RT	O
)-	O
associated	O
DNA	O
Polymerase	O
(	O
RDDP	O
)	O
and	O
Ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
activities	O
in	O
biochemical	O
assays	O
.	O

Sennoside	O
A	O
was	O
less	O
potent	O
when	O
tested	O
on	O
K103N	O
,	O
Y181C	O
,	O
Y188L	O
,	O
N474A	O
and	O
Q475A	O
mutated	O
RTs	O
,	O
suggesting	O
the	O
involvement	O
of	O
two	O
RT	O
binding	O
sites	O
for	O
its	O
antiviral	B-CHED
activity	O
.	O

Overexpression	O
of	O
Nur77	O
markedly	O
decreased	O
basal	O
and	O
LPS	B-CHED
-	O
induced	O
ET	O
-	O
1	O
expression	O
in	O
A549	O
cells	O
,	O
whereas	O
knockdown	O
of	O
Nur77	O
increased	O
the	O
ET	O
-	O
1	O
expression	O
.	O

TITLE	O
:	O
Isatin	B-CHED
thiazoline	O
hybrids	O
as	O
dual	O
inhibitors	B-CHED
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
3	O
-	O
3	O
-{	O
2	O
-[	O
2	O
-	O
3	O
-	O
methyl	B-CHED
-	O
4	O
-	O
phenyl	B-CHED
-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1	O
,	O
3	O
-	O
thiazol	O
-	O
2	O
-	O
ylidene	O
]	O
hydrazin	B-CHED
-	O
1	O
-	O
ylidene	O
-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1H	O
-	O
indol	B-CHED
-	I-CHED
2	I-CHED
-	I-CHED
one	I-CHED
derivatives	O
has	O
been	O
designed	O
and	O
synthesized	O
to	O
study	O
their	O
activity	O
on	O
both	O
HIV	O
-	O
1	O
(	O
Human	O
Immunodeficiency	O
Virus	O
type	O
1	O
)	O
RT	O
(	O
Reverse	O
Transcriptase	O
)	O
associated	O
functions	O
.	O

These	O
are	O
postulated	O
to	O
be	O
accumulations	O
of	O
amiodarone	B-CHED
in	O
areas	O
of	O
previous	O
inflammation	O
.	O

TITLE	O
:	O
Compliance	O
-	O
guided	O
versus	O
FiO	O
ABSTRACT	O
:	O
To	O
study	O
the	O
effect	O
of	O
setting	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
in	O
an	O
individualized	O
manner	O
(	O
based	O
on	O
highest	O
static	O
compliance	O
)	O
compared	O
to	O
setting	O
PEEP	B-CHED
according	O
to	O
FiO	O
A	O
Spanish	O
medical	O
-	O
surgical	O
ICU	O
.	O

We	O
tested	O
in	O
a	O
prospective	O
physiological	O
study	O
the	O
hypothesis	O
that	O
continuous	O
administration	O
of	O
NMB	O
agents	O
in	O
mechanically	O
ventilated	O
children	O
with	O
severe	O
acute	O
hypoxemic	O
respiratory	O
failure	O
(	O
AHRF	O
)	O
improves	O
the	O
oxygenation	O
index	O
without	O
a	O
redistribution	O
of	O
tidal	O
volume	O
V	O
Oxygenation	O
index	O
,	O
PaO	B-CHED
Twenty	O
-	O
two	O
patients	O
were	O
studied	O
(	O
N	O
=	O
18	O
met	B-CHED
the	O
criteria	O
for	O
pediatric	O
ARDS	O
).	O

To	O
establish	O
an	O
infection	O
and	O
spread	O
,	O
MERS	O
-	O
CoV	O
,	O
like	O
most	O
other	O
viruses	O
,	O
must	O
navigate	O
through	O
an	O
intricate	O
network	O
of	O
antiviral	B-CHED
host	O
responses	O
.	O

MERS	O
-	O
CoV	O
p4a	O
is	O
a	O
dsRNA	B-CHED
binding	O
protein	B-CHED
.	O

Mutation	O
of	O
the	O
dsRNA	B-CHED
binding	O
motif	O
in	O
p4a	O
disrupted	O
its	O
PKR	O
antagonistic	O
activity	O
.	O

However	O
,	O
a	O
recombinant	O
MERS	O
-	O
CoV	O
deficient	O
in	O
p4a	O
expression	O
still	O
suppressed	O
SG	O
formation	O
,	O
indicating	O
the	O
expression	O
of	O
at	O
least	O
one	O
other	O
stress	O
response	O
antagonist	B-CHED
.	O

This	O
approach	O
,	O
known	O
as	O
""""	O
dendritic	O
cell	O
targeting	O
","""	O
greatly	O
improved	O
PEDV	O
S	O
antigen	B-CHED
-	O
specific	O
T	O
cell	O
interferon	O
-	O
	O
responses	O
in	O
the	O
CD4	O

TITLE	O
:	O
Antiviral	B-CHED
Compounds	O
Against	O
Nucleocapsid	O
Protein	B-CHED
of	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
.	O

Nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
is	O
the	O
RNA	O
-	O
binding	O
protein	B-CHED
of	O
PEDV	O
,	O
which	O
plays	O
an	O
important	O
role	O
for	O
virus	O
life	O
cycle	O
.	O

SAR	B-CHED
studies	O
around	O
the	O
""""	O
Z	O
""""	O
group	O
of	O
the	O
tetracyclic	O
indole	B-CHED
scaffold	O
explored	O
fused	O
bicyclic	O
rings	O
as	O
alternates	O
to	O
the	O
phenyl	B-CHED
group	I-CHED
of	O
elbasvir	O
(	O
1	O
,	O
MK	O
-	O
8742	O
)	O
and	O
identified	O
novel	O
chromane	B-CHED
and	O
2	O
,	O
3	O
-	O
dihydrobenzofuran	O
derivatives	O
as	O
""""	O
Z	O
""""	O
group	O
replacements	O
offered	O
good	O
potency	O
across	O
all	O
genotypes	O
.	O

We	O
identified	O
a	O
shallow	O
pocket	O
adjacent	O
to	O
the	O
groove	O
in	O
the	O
NHR	O
trimer	O
and	O
added	O
a	O
short	O
artificial	O
peptide	B-CHED
consisting	O
of	O
three	O
amino	B-CHED
acids	I-CHED
(	O
IDL	O
)	O
to	O
the	O
C	O
terminus	O
of	O
a	O
fusion	O
inhibitor	B-CHED
to	O
fit	O
this	O
new	O
target	O
.	O

This	O
new	O
approach	O
of	O
identifying	O
a	O
potential	O
binding	O
pocket	O
outside	O
the	O
traditional	O
target	O
and	O
creating	O
an	O
artificial	O
tail	O
anchor	O
can	O
be	O
widely	O
applied	O
to	O
design	O
novel	O
fusion	O
inhibitors	B-CHED
against	O
other	O
class	O
I	O
enveloped	O
viruses	O
,	O
such	O
as	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

Polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
detect	O
nucleic	B-CHED
acids	I-CHED
of	O
circoviruses	O
,	O
adenoviruses	O
,	O
morbilliviruses	O
,	O
vesiviruses	O
,	O
and	O
coronaviruses	O
in	O
the	O
feces	O
from	O
twenty	O
-	O
one	O
South	O
American	O
fur	O
seals	O
(	O
Arctocephalus	O
australis	O
)	O
and	O
two	O
Subantarctic	O
fur	O
seals	O
(	O
A	O
.	O
tropicalis	O
).	O

CONCLUSIONS	O
:	O
Riboflavin	B-CHED
and	O
UV	O
light	O
effectively	O
reduced	O
the	O
titer	O
of	O
MERS	O
-	O
CoV	O
in	O
human	O
plasma	O
products	O
to	O
below	O
the	O
limit	O
of	O
detection	O
,	O
suggesting	O
that	O
the	O
treatment	O
process	O
may	O
reduce	O
the	O
risk	O
of	O
transfusion	O
transmission	O
of	O
MERS	O
-	O
CoV	O
.	O

Intense	O
research	O
efforts	O
are	O
now	O
focusing	O
on	O
defining	O
viral	O
characteristics	O
that	O
confer	O
a	O
growth	O
advantage	O
,	O
pathogenicity	O
,	O
or	O
cell	O
adaptability	O
in	O
order	O
to	O
better	O
understand	O
the	O
PEDV	O
life	O
cycle	O
and	O
identify	O
suitable	O
targets	O
for	O
antiviral	B-CHED
or	O
vaccine	O
development	O
.	O

Our	O
results	O
demonstrated	O
that	O
vaccinated	O
mice	O
were	O
fully	O
protected	O
from	O
the	O
MERS	O
-	O
CoV	O
challenge	O
,	O
as	O
indicated	O
by	O
the	O
significantly	O
lower	O
MERS	O
-	O
CoV	O
titers	O
and	O
MERS	O
-	O
CoV	O
and	O
mRNA	B-CHED
levels	O
in	O
challenged	O
mice	O
than	O
those	O
in	O
unvaccinated	O
controls	O
.	O

GILZ	O
was	O
expressed	O
in	O
about	O
	O
of	O
the	O
corticosteroid	B-CHED
-	O
treated	O
patients	O
and	O
its	O
expression	O
could	O
also	O
occur	O
independently	O
of	O
corticosteroids	B-CHED
,	O
suggesting	O
that	O
inflammatory	O
signals	O
may	O
also	O
induce	O
neutrophil	O
GILZ	O
expression	O
in	O
vivo	O
.	O

RESULTS	O
:	O
Fifteen	O
studies	O
met	B-CHED
the	O
inclusion	O
criteria	O
for	O
this	O
review	O
.	O

The	O
metabolite	B-CHED
,	O
protein	B-CHED
,	O
and	O
lipid	B-CHED
extraction	O
(	O
MPLEx	O
)	O
protocol	O
proved	O
to	O
be	O
robust	O
and	O
applicable	O
to	O
a	O
diverse	O
set	O
of	O
sample	O
types	O
,	O
including	O
cell	O
cultures	O
,	O
microbial	O
communities	O
,	O
and	O
tissues	O
.	O

To	O
illustrate	O
the	O
utility	O
of	O
this	O
protocol	O
,	O
an	O
integrative	O
multi	O
-	O
omics	O
analysis	O
was	O
performed	O
using	O
a	O
lung	O
epithelial	O
cell	O
line	O
infected	O
with	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
,	O
which	O
showed	O
the	O
impact	O
of	O
this	O
virus	O
on	O
the	O
host	O
glycolytic	O
pathway	O
and	O
also	O
suggested	O
a	O
role	O
for	O
lipids	B-CHED
during	O
infection	O
.	O

Variables	O
associated	O
with	O
mortality	O
included	O
immunosuppression	O
,	O
shock	O
at	O
time	O
of	O
admission	O
,	O
acute	O
renal	O
failure	O
,	O
occurrence	O
of	O
heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
antibodies	O
,	O
nosocomial	O
sepsis	O
and	O
duration	O
of	O
ECMO	O
.	O

Variables	O
associated	O
with	O
mortality	O
included	O
immunosuppression	O
,	O
shock	O
at	O
time	O
of	O
admission	O
,	O
acute	O
renal	O
failure	O
,	O
occurrence	O
of	O
heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
antibodies	O
,	O
nosocomial	O
sepsis	O
and	O
duration	O
of	O
ECMO	O
.	O

Neutrophils	O
infiltrated	O
the	O
LPS	B-CHED
-	O
injected	O
swim	O
bladder	O
through	O
the	O
blood	O
capillaries	O
around	O
the	O
pneumatic	O
duct	O
or	O
a	O
site	O
near	O
the	O
pronephric	O
duct	O
.	O

Microscopic	O
examinations	O
of	O
the	O
LPS	B-CHED
-	O
injected	O
swim	O
bladders	O
further	O
revealed	O
in	O
situ	O
injuries	O
,	O
including	O
epithelial	O
distortion	O
,	O
endoplasmic	O
reticulum	O
swelling	O
and	O
mitochondrial	O
injuries	O
.	O

All	O
patients	O
underwent	O
the	O
same	O
diagnostic	O
and	O
therapeutic	O
protocol	O
in	O
a	O
single	O
hospital	O
,	O
including	O
early	O
Oseltamivir	B-CHED
therapy	O
.	O

The	O
genome	O
is	O
closely	O
related	O
to	O
the	O
other	O
OC43	O
genome	O
sequences	O
available	O
,	O
ranging	O
from	O
99	O
.	O
8	O
%	O
to	O
98	O
.	O
2	O
%	O
nucleotide	B-CHED
sequence	O
identity	O
.	O

We	O
here	O
report	O
that	O
in	O
cultured	O
cells	O
low	O
-	O
micromolar	O
concentrations	O
of	O
alisporivir	O
,	O
a	O
non	O
-	O
immunosuppressive	O
cyclosporin	B-CHED
A	I-CHED
-	O
analog	O
,	O
inhibit	O
the	O
replication	O
of	O
four	O
different	O
coronaviruses	O
,	O
including	O
MERS	O
-	O
and	O
SARS	O
-	O
coronavirus	O
.	O

Nevertheless	O
,	O
our	O
data	O
provide	O
a	O
basis	O
to	O
further	O
explore	O
the	O
potential	O
of	O
Cyp	B-CHED
inhibitors	B-CHED
as	O
host	O
-	O
directed	O
,	O
broad	O
-	O
spectrum	O
inhibitors	B-CHED
of	O
coronavirus	O
replication	O
.	O

ABSTRACT	O
:	O
Eptifibatide	B-CHED
is	O
a	O
platelet	O
glycoprotein	B-CHED
IIb	O
/	O
IIIa	O
(	O
GP	O
IIb	O
/	O
IIIa	O
)	O
receptor	O
antagonist	B-CHED
that	O
inhibits	O
fibrinogen	O
binding	O
to	O
the	O
activated	O
GP	O
IIb	O
/	O
IIIa	O
site	O
and	O
prevents	O
platelet	O
-	O
platelet	O
interaction	O
and	O
clot	O
formation	O
.	O

The	O
authors	O
describe	O
a	O
patient	O
who	O
developed	O
acute	O
profound	O
thrombocytopenia	O
after	O
receiving	O
eptifibatide	B-CHED
before	O
emergent	O
coronary	O
artery	O
bypass	O
graft	O
surgery	O
.	O

A	O
67	O
-	O
year	O
-	O
old	O
man	B-CHED
with	O
a	O
normal	O
platelet	O
count	O
(	O
220	O
K	O
/	O
uL	O
)	O
developed	O
atrial	O
fibrillation	O
,	O
left	O
bundle	O
branch	O
block	O
,	O
and	O
respiratory	O
insufficiency	O
consistent	O
with	O
acute	O
coronary	O
syndrome	O
two	O
days	O
after	O
colectomy	O
.	O

He	O
received	O
eptifibatide	B-CHED
during	O
cardiac	O
catheterization	O
,	O
where	O
three	O
-	O
vessel	O
coronary	O
artery	O
disease	O
was	O
encountered	O
.	O

RESULTS	O
:	O
Ten	O
studies	O
with	O
1137	O
recovered	O
SARS	O
patients	O
met	B-CHED
the	O
inclusion	O
criteria	O
.	O

Moreover	O
,	O
inhibition	O
studies	O
showed	O
that	O
EGFR	O
modulated	O
glucose	B-CHED
uptake	O
in	O
control	O
and	O
TGEV	O
infected	O
cells	O
.	O

However	O
,	O
patients	O
from	O
the	O
ECLS	O
group	O
had	O
preoperatively	O
higher	O
lactate	B-CHED
(	O
P	O
=	O
0	O
.	O
037	O
),	O
aspartate	B-CHED
aminotransferase	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
alanine	B-CHED
aminotransferase	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
levels	O
,	O
all	O
of	O
them	O
significantly	O
decreased	O
after	O
surgery	O
(	O
P	O
=	O
0	O
.	O
004	O
,	O
P	O
=	O
0	O
.	O
017	O
,	O
and	O
P	O
=	O
0	O
.	O
001	O
,	O
respectively	O
)	O
and	O
did	O
not	O
show	O
any	O
statistical	O
differences	O
to	O
the	O
corresponding	O
values	O
from	O
the	O
control	O
group	O
(	O
P	O
=	O
0	O
.	O
597	O
,	O
P	O
=	O
0	O
.	O
491	O
,	O
and	O
P	O
=	O
0	O
.	O
339	O
,	O
respectively	O
).	O

ABSTRACT	O
:	O
The	O
use	O
of	O
porcine	O
islets	O
to	O
replace	O
insulin	B-CHED
-	O
producing	O
islet	O
	O
-	O
cells	O
,	O
destroyed	O
during	O
the	O
diabetogenic	O
disease	O
process	O
,	O
presents	O
distinct	O
challenges	O
if	O
this	O
option	O
is	O
to	O
become	O
a	O
therapeutic	O
reality	O
for	O
the	O
treatment	O
of	O
type	O
1	O
diabetes	O
.	O

Therefore	O
,	O
scientists	O
reverted	O
towards	O
the	O
investigation	O
of	O
different	O
drugs	O
that	O
can	O
more	O
specifically	O
target	O
proteins	B-CHED
.	O

The	O
corticosteroid	B-CHED
dose	O
was	O
gradually	O
tapered	O
over	O
2	O
months	O
at	O
the	O
outpatient	O
clinic	O
,	O
and	O
a	O
follow	O
-	O
up	O
CT	O
scan	O
showed	O
complete	O
resolution	O
of	O
the	O
consolidation	O
and	O
GGOs	O
.	O

RESULTS	O
:	O
Influenza	O
A	O
virus	O
accounted	O
for	O
half	O
the	O
isolated	O
viruses	O
,	O
especially	O
subtype	O
A	O
(	O
H1N1	O
)	O
pdm09	O
among	O
patients	O
aged	O
20	O
-	O
59	O
years	O
old	O
,	O
and	O
subtype	O
A	O
(	O
H3N2	B-CHED
)	O
in	O
those	O
aged	O
60	O
or	O
over	O
;	O
the	O
most	O
frequently	O
identified	O
respiratory	O
virus	O
among	O
children	O
under	O
five	O
years	O
old	O
was	O
respiratory	O
syncytial	O
virus	O
(	O
65	O
.	O
6	O
%),	O
followed	O
by	O
influenza	O
A	O
virus	O
(	O
21	O
.	O
2	O
%);	O
influenza	O
virus	O
circulated	O
in	O
all	O
seasons	O
of	O
the	O
year	O
and	O
its	O
periods	O
of	O
greatest	O
incidence	O
were	O
interspersed	O
with	O
those	O
of	O
higher	O
Respiratory	O
Syncytial	O
Virus	O
activity	O
.	O

Disseminated	O
BCG	B-CHED
infection	O
did	O
not	O
resolve	O
despite	O
administration	O
of	O
anti	O
-	O
tuberculosis	O
drugs	O
and	O
intravenous	O
immune	O
globulins	O
,	O
and	O
she	O
subsequently	O
died	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Sequence	O
analyses	O
revealed	O
that	O
3575	O
/	O
08	O
and	O
2575	O
/	O
98	O
shared	O
high	O
homology	O
in	O
their	O
structural	O
genes	O
,	O
but	O
not	O
in	O
non	O
-	O
structural	O
accessory	O
proteins	B-CHED
such	O
as	O
3a	O
,	O
3b	O
and	O
5b	O
.	O

The	O
reasons	O
for	O
the	O
sex	O
difference	O
in	O
prevalence	O
are	O
multifactorial	O
,	O
but	O
are	O
partly	O
attributable	O
to	O
protective	O
effects	O
of	O
oestrogen	B-CHED
.	O

In	O
the	O
assay	O
,	O
SYTO	O
9	O
was	O
used	O
to	O
replace	O
SYBR	B-CHED
Green	I-CHED
I	I-CHED
as	O
the	O
fluorescent	B-CHED
dye	I-CHED
,	O
and	O
GC	O
-	O
modified	O
primers	O
were	O
designed	O
to	O
improve	O
the	O
melting	O
temperature	O
(	O
Tm	O
)	O
of	O
the	O
specific	O
amplicon	O
.	O

Models	O
of	O
MERS	O
-	O
CoV	O
-	O
induced	O
severe	O
respiratory	O
disease	O
have	O
been	O
difficult	O
to	O
achieve	O
,	O
and	O
small	O
-	O
animal	O
models	O
traditionally	O
used	O
to	O
investigate	O
viral	O
pathogenesis	O
(	O
mouse	O
,	O
hamster	O
,	O
guinea	O
-	O
pig	O
and	O
ferret	O
)	O
are	O
naturally	O
resistant	O
to	O
MERS	O
-	O
CoV	O
.	O
Therefore	O
,	O
we	O
used	O
CRISPR	O
-	O
Cas9	O
gene	O
editing	O
to	O
modify	O
the	O
mouse	O
genome	O
to	O
encode	O
two	O
amino	B-CHED
acids	I-CHED
(	O
positions	O
288	O
and	O
330	O
)	O
that	O
match	O
the	O
human	O
sequence	O
in	O
the	O
dipeptidyl	O
peptidase	O
4	O
receptor	O
,	O
making	O
mice	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
infection	O
and	O
replication	O
.	O

Importantly	O
,	O
therapeutic	O
countermeasures	O
comprising	O
MERS	O
-	O
CoV	O
neutralizing	O
antibody	O
treatment	O
or	O
a	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
vaccine	O
protected	O
the	O
engineered	O
mice	O
against	O
MERS	O
-	O
CoV	O
-	O
induced	O
ARDS	O
.	O

He	O
was	O
treated	O
with	O
non	O
-	O
rebreather	O
mask	O
and	O
intravenous	O
infusion	O
of	O
naloxone	B-CHED
with	O
gradual	O
improvement	O
of	O
consciousness	O
and	O
arterial	O
blood	O
gasses	O
.	O

CONCLUSIONS	O
:	O
Heroin	B-CHED
inhalation	O
may	O
cause	O
severe	O
complications	O
,	O
such	O
as	O
non	O
-	O
cardiogenic	O
pulmonary	O
edema	O
,	O
rhabdomyolysis	O
or	O
myocardial	O
injury	O
.	O

Analysis	O
of	O
intrapatient	O
heterogeneity	O
revealed	O
a	O
relationship	O
between	O
D510G	O
and	O
I529T	O
mutations	O
in	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
viral	O
spike	O
glycoprotein	B-CHED
.	O

The	O
influence	O
of	O
the	O
increased	O
SNP	O
and	O
hydrophobic	O
properties	O
of	O
the	O
translated	O
proteins	B-CHED
on	O
the	O
vaccine	O
viruses	O
'	O
virulence	O
is	O
unknown	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
peptidyl	O
-	O
prolyl	B-CHED
cis	O
-	O
transisomerase	O
active	O
sites	O
of	O
Cyps	O
might	O
be	O
required	O
for	O
FCoV	O
replication	O
.	O

TITLE	O
:	O
Inhaled	O
nitric	B-CHED
oxide	I-CHED
and	O
the	O
risk	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
propensity	O
-	O
matched	O
cohort	O
study	O
.	O

In	O
our	O
cohort	O
,	O
Legionnaires	O
'	O
disease	O
was	O
diagnosed	O
with	O
a	O
combination	O
of	O
a	O
urinary	O
Legionella	O
antigen	B-CHED
test	O
and	O
a	O
Legionella	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
assay	O
.	O

Single	O
nucleotide	B-CHED
polymorphisms	O
,	O
amino	B-CHED
acid	I-CHED
variations	O
and	O
hydrophobicity	O
changes	O
were	O
identified	O
and	O
recorded	O
for	O
each	O
sampling	O
point	O
.	O

This	O
translated	O
into	O
64	O
amino	B-CHED
acid	I-CHED
changes	O
;	O
however	O
only	O
six	O
resulted	O
in	O
a	O
change	O
to	O
the	O
hydrophobicity	O
properties	O
.	O

Findings	O
presented	O
in	O
this	O
study	O
demonstrate	O
alteration	O
in	O
the	O
S1	O
nucleotide	B-CHED
sequence	O
following	O
co	O
-	O
administration	O
of	O
live	O
IBV	O
vaccines	O
.	O

Treatment	O
options	O
for	O
patients	O
with	O
risk	O
factors	O
for	O
Pseudomonas	O
species	O
include	O
administration	O
of	O
an	O
antipseudomonal	O
antibiotic	B-CHED
and	O
an	O
aminoglycoside	B-CHED
,	O
plus	O
azithromycin	B-CHED
or	O
a	O
fluoroquinolone	O
.	O

Seventeen	O
patients	O
with	O
genetically	O
proven	O
late	O
-	O
onset	O
Pompe	O
disease	O
(	O
50	O
	O
18	O
years	O
,	O
11	O
male	O
)	O
and	O
18	O
age	O
-	O
and	O
gender	O
-	O
matched	O
healthy	O
controls	O
(	O
44	O
	O
10	O
year	O
,	O
12	O
male	O
)	O
underwent	O
comprehensive	O
cardiovascular	O
magnetic	O
resonance	O
(	O
CMR	O
)	O
including	O
conventional	O
and	O
advanced	O
techniques	O
:	O
cine	O
and	O
feature	O
tracking	O
-	O
based	O
strain	O
imaging	O
for	O
depiction	O
of	O
(	O
even	O
subtle	O
)	O
systolic	O
LV	O
dysfunction	O
as	O
well	O
as	O
late	O
gadolinium	B-CHED
enhancement	O
(	O
LGE	O
)	O
and	O
myocardial	O
extracellular	O
volume	O
fraction	O
(	O
ECV	O
)	O
quantification	O
for	O
focal	O
and	O
diffuse	O
fibrosis	O
detection	O
.	O

TITLE	O
:	O
'	O
Between	O
Combat	B-CHED
boots	O
and	O
Birkenstocks	O
'-	O
Lessons	O
from	O
HIV	O
/	O
AIDS	O
,	O
SARS	O
,	O
H1N1	O
and	O
Ebola	O
.	O

A	O
43	O
-	O
year	O
-	O
old	O
man	B-CHED
with	O
liver	O
cirrhosis	O
due	O
to	O
hepatitis	O
C	O
virus	O
underwent	O
living	O
-	O
donor	B-CHED
liver	O
transplantation	O
.	O

Then	O
,	O
oligonucleotides	B-CHED
specific	O
for	O
PEDV	O
coated	O
on	O
AuNPs	O
were	O
eluted	O
from	O
the	O
complex	O
and	O
were	O
further	O
amplified	O
and	O
characterized	O
by	O
PCR	O
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
:	O
a	O
key	O
target	O
for	O
antivirals	B-CHED
.	O

MERS	O
-	O
CoV	O
S	O
protein	B-CHED
represents	O
a	O
key	O
target	O
for	O
developing	O
therapeutics	O
to	O
block	O
viral	O
entry	O
and	O
inhibit	O
membrane	O
fusion	O
.	O

Generally	O
,	O
human	O
neutralizing	O
mAbs	O
targeting	O
RBD	O
are	O
more	O
potent	O
than	O
those	O
targeting	O
other	O
regions	O
of	O
S	O
protein	B-CHED
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
each	O
assay	O
has	O
been	O
estimated	O
using	O
a	O
Bayesian	O
analysis	O
applied	O
to	O
the	O
ring	O
trial	O
results	O
obtained	O
with	O
the	O
different	O
assays	O
in	O
the	O
absence	O
of	O
a	O
gold	B-CHED
standard	O
.	O

As	O
the	O
subgroup	O
2	O
strains	O
have	O
not	O
been	O
isolated	O
for	O
at	O
least	O
20	O
years	O
,	O
it	O
appears	O
likely	O
that	O
an	O
unknown	O
avian	O
coronavirus	O
that	O
was	O
the	O
donor	B-CHED
of	O
the	O
S1	O
glycoprotein	B-CHED
sequence	O
of	O
N1	O
/	O
88	O
in	O
the	O
1980s	O
is	O
still	O
recombining	O
with	O
IBV	O
strains	O
in	O
the	O
field	O
.	O

Genomic	O
analysis	O
showed	O
that	O
CHN	B-CHED
-	O
HN	O
-	O
2014	O
shares	O
91	O
.	O
6	O
%-	O
99	O
.	O
4	O
%	O
nucleotide	B-CHED
identity	O
with	O
other	O
known	O
PDCoV	O
strains	O
.	O

To	O
regulate	O
this	O
activity	O
,	O
macrodomain	O
proteins	B-CHED
enzymatically	O
remove	O
covalently	O
attached	O
ADP	B-CHED
-	O
ribose	B-CHED
from	O
protein	B-CHED
targets	O
.	O

We	O
identified	O
several	O
macrodomain	O
mutations	O
that	O
greatly	O
reduced	O
nsp3	O
'	O
s	O
de	O
-	O
ADP	B-CHED
-	O
ribosylation	O
activity	O
in	O
vitro	O
Next	O
,	O
we	O
created	O
recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
strains	O
with	O
these	O
mutations	O
.	O

Here	O
,	O
we	O
found	O
that	O
the	O
macrodomain	O
is	O
an	O
important	O
virulence	O
factor	O
for	O
a	O
highly	O
pathogenic	O
human	O
CoV	O
,	O
SARS	O
-	O
CoV	O
.	O
Viruses	O
with	O
macrodomain	O
mutations	O
that	O
abrogate	O
its	O
ability	O
to	O
remove	O
ADP	B-CHED
-	O
ribose	B-CHED
from	O
protein	B-CHED
were	O
unable	O
to	O
cause	O
lethal	O
disease	O
in	O
mice	O
.	O

Two	O
linear	O
epitopes	O
,	O
243YSTEART249	O
(	O
1C3	O
)	O
and	O
243YSTEARTDNLSEQEKLLHMV262	O
(	O
4C7	O
),	O
were	O
identified	O
in	O
the	O
endodomain	O
of	O
the	O
TGEV	O
M	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
intravenous	O
injection	O
of	O
low	O
-	O
dose	O
versus	O
high	O
-	O
dose	O
gamma	O
globulin	O
combined	O
with	O
glucocorticoid	B-CHED
pulse	O
therapy	O
in	O
the	O
treatment	O
of	O
children	O
with	O
moderate	O
/	O
severe	O
acute	O
Guillain	O
-	O
Barr	O
syndrome	O
(	O
GBS	O
).	O

TITLE	O
:	O
The	O
Identification	O
and	O
Characterization	O
of	O
Two	O
Novel	O
Epitopes	O
on	O
the	O
Nucleocapsid	O
Protein	B-CHED
of	O
the	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
.	O

However	O
,	O
the	O
characterization	O
of	O
epitopes	O
on	O
the	O
PEDV	O
N	O
protein	B-CHED
remains	O
largely	O
unknown	O
.	O

Here	O
,	O
two	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
specific	O
to	O
the	O
N	O
protein	B-CHED
of	O
a	O
PEDV	O
strain	O
,	O
FJzz1	O
/	O
2011	O
,	O
were	O
generated	O
and	O
screened	O
against	O
a	O
partially	O
overlapping	O
library	O
of	O
24	O
GST	O
-	O
fusion	O
N	O
protein	B-CHED
-	O
truncated	O
constructs	O
.	O

Overall	O
,	O
this	O
compound	O
can	O
be	O
considered	O
an	O
attractive	O
lead	O
for	O
the	O
development	O
of	O
new	O
classes	O
of	O
antiviral	B-CHED
agents	I-CHED
able	O
to	O
overcome	O
the	O
problem	O
of	O
resistance	O
,	O
due	O
to	O
its	O
ability	O
to	O
exert	O
its	O
action	O
by	O
binding	O
simultaneously	O
to	O
multiple	O
viral	O
targets	O
.	O

Chemically	O
,	O
it	O
belongs	O
to	O
hydrocarbon	B-CHED
family	O
which	O
is	O
toxic	O
if	O
aspirated	O
,	O
owing	O
to	O
their	O
physical	O
properties	O
such	O
as	O
high	O
volatility	O
and	O
low	O
viscosity	O
.	O

When	O
it	O
was	O
used	O
in	O
combination	O
with	O
S1P	B-CHED
,	O
the	O
expression	O
regulation	O
result	O
of	O
related	O
genes	O
was	O
not	O
simply	O
the	O
superposition	O
of	O
each	O
other	O
,	O
but	O
more	O
significant	O
outcome	O
was	O
obtained	O
.	O

TITLE	O
:	O
Discovery	O
of	O
a	O
novel	O
accessory	O
protein	B-CHED
NS7a	O
encoded	O
by	O
porcine	O
deltacoronavirus	O
.	O

In	O
summary	O
,	O
our	O
results	O
identified	O
a	O
third	O
accessory	O
protein	B-CHED
encoded	O
by	O
PDCoV	O
,	O
which	O
will	O
enhance	O
our	O
understanding	O
of	O
PDCoV	O
.	O

Logistic	O
regression	O
analyses	O
showed	O
that	O
intraoperative	O
ACC	O
time	O
,	O
CPB	O
time	O
,	O
the	O
maximum	O
increasing	O
rate	O
of	O
lactic	B-CHED
acid	I-CHED
within	O
24	O
h	O
after	O
operation	O
,	O
serum	O
procalcitonin	O
24	O
h	O
after	O
operation	O
and	O
intraoperative	O
blood	O
loss	O
were	O
independent	O
risk	O
factors	O
for	O
postoperative	O
ARDS	O
.	O

TITLE	O
:	O
Pharmacokinetics	O
of	O
the	O
Antiviral	B-CHED
Lectin	O
Griffithsin	O
Administered	O
by	O
Different	O
Routes	O
Indicates	O
Multiple	O
Potential	O
Uses	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
,	O
PaO	O
/	O
FiO	O
<	O
100	O
on	O
PEEP	B-CHED
	O
5	O
cm	O
HO	O
)	O
is	O
treated	O
using	O
controlled	O
mechanical	O
ventilation	O
(	O
CMV	O
),	O
recently	O
combined	O
with	O
muscle	O
relaxation	O
for	O
48	O
h	O
and	O
prone	O
positioning	O
.	O

Lineage	O
A	O
Betacoronavirus	O
NS2	O
Proteins	B-CHED
and	O
the	O
Homologous	O
Torovirus	O
Berne	O
pp1a	O
Carboxy	B-CHED
-	O
Terminal	O
Domain	O
Are	O
Phosphodiesterases	O
That	O
Antagonize	O
Activation	O
of	O
RNase	O
L	O
.	O
ABSTRACT	O
:	O
Viruses	O
in	O
the	O
family	O

ABSTRACT	O
:	O
Dilmapimod	O
is	O
a	O
potent	O
p38	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinase	O
(	O
MAPK	O
)	O
inhibitor	B-CHED
and	O
was	O
investigated	O
in	O
a	O
study	O
(	O
NCT00996840	O
)	O
for	O
its	O
anti	O
-	O
inflammatory	O
effect	O
in	O
non	O
-	O
head	O
injury	O
trauma	O
patients	O
at	O
risk	O
for	O
developing	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
The	O
lipid	B-CHED
kinase	O
phosphatidylinositol	B-CHED
4	O
-	O
kinase	O
III	O
(	O
PI4KB	O
)	O
is	O
an	O
essential	O
host	O
factor	O
for	O
many	O
positive	O
-	O
sense	O
single	O
-	O
stranded	O
RNA	O
(+	O
RNA	O
)	O
viruses	O
including	O
human	O
pathogens	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
),	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
coxsackie	O
viruses	O
,	O
and	O
rhinoviruses	O
.	O

The	O
genetic	O
analyses	O
demonstrated	O
that	O
Thai	O
PDCoVs	O
have	O
97	O
.	O
0	O
-	O
97	O
.	O
8	O
and	O
92	O
.	O
2	O
-	O
94	O
.	O
0	O
%	O
similarities	O
with	O
China	O
PDCoV	O
at	O
nucleotide	B-CHED
and	O
amino	B-CHED
acid	I-CHED
levels	O
,	O
respectively	O
,	O
but	O
share	O
97	O
.	O
1	O
-	O
97	O
.	O
3	O
and	O
92	O
.	O
5	O
-	O
93	O
.	O
0	O
similarity	O
with	O
US	O
PDCoV	O
at	O
the	O
nucleotide	B-CHED
and	O
amino	B-CHED
acid	I-CHED
levels	O
,	O
respectively	O
.	O

The	O
variation	O
analyses	O
demonstrated	O
that	O
six	O
regions	O
(	O
nt	O
1317	O
-	O
1436	O
,	O
2997	O
-	O
3096	O
,	O
19	O
,	O
737	O
-	O
19	O
,	O
836	O
,	O
20	O
,	O
277	O
-	O
20	O
,	O
376	O
,	O
21	O
,	O
177	O
-	O
21	O
,	O
276	O
,	O
and	O
22	O
,	O
371	O
-	O
22	O
,	O
416	O
)	O
in	O
ORF1a	O
/	O
b	O
and	O
spike	O
genes	O
exhibit	O
high	O
sequence	O
variation	O
between	O
Thai	O
and	O
other	O
PDCoV	O
.	O
The	O
analyses	O
of	O
amino	B-CHED
acid	I-CHED
changes	O
suggested	O
that	O
they	O
could	O
potentially	O
be	O
from	O
different	O
lineages	O
.	O

So	O
far	O
,	O
the	O
most	O
commonly	O
used	O
techniques	O
to	O
ameliorate	O
gas	O
exchange	O
in	O
the	O
postextubation	O
period	O
were	O
low	O
-	O
flow	O
oxygen	B-CHED
therapy	O
and	O
non	O
-	O
invasive	O
ventilation	O
(	O
NIV	O
).	O

Total	O
RNA	O
isolated	O
from	O
allantoic	O
fluid	O
of	O
SPF	O
embryo	O
passaged	O
with	O
infected	O
chicken	O
sample	O
was	O
sequenced	O
by	O
whole	O
genome	O
shotgun	O
sequencing	O
using	O
ion	O
-	O
torrent	O
PGM	B-CHED
platform	O
.	O

The	O
sequence	O
was	O
analysed	O
for	O
the	O
presence	O
of	O
coding	O
and	O
non	O
-	O
coding	O
features	O
,	O
its	O
similarity	O
with	O
reported	O
isolates	O
and	O
epitope	B-CHED
analysis	O
of	O
capsid	O
structural	O
protein	B-CHED
.	O

Ninety	O
-	O
eight	O
percent	O
of	O
providers	O
correctly	O
identified	O
that	O
NMBAs	O
lack	O
anxiolytic	O
and	O
analgesic	B-CHED
properties	O
.	O

The	O
new	O
definition	O
of	O
ARDS	O
requires	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
to	O
assess	O
gas	O
exchange	O
and	O
has	O
better	O
predictive	O
validity	O
for	O
short	O
-	O
term	O
mortality	O
compared	O
with	O
the	O
previous	O
definition	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
prognostic	O
utility	O
of	O
oxygenation	O
with	O
PEEP	B-CHED
in	O
AE	O
-	O
IPF	O
.	O

The	O
MV	O
and	O
NIV	O
groups	O
did	O
not	O
differ	O
in	O
age	O
,	O
medical	O
history	O
,	O
etiology	O
of	O
CS	O
,	O
PaO	B-CHED
Although	O
MV	O
is	O
generally	O
recommended	O
mode	O
of	O
ventilatory	O
support	O
in	O
CS	O
,	O
a	O
fair	O
number	O
of	O
patients	O
were	O
successfully	O
treated	O
with	O
NIV	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
replicates	O
in	O
the	O
cytoplasm	O
of	O
infected	O
cells	O
,	O
but	O
its	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
localizes	O
specifically	O
to	O
the	O
nucleolus	O
.	O

In	O
this	O
study	O
,	O
we	O
confirm	O
that	O
a	O
nucleolar	O
phosphoprotein	O
nucleophosmin	O
(	O
NPM1	O
)	O
interacts	O
and	O
co	O
-	O
localizes	O
with	O
the	O
N	O
protein	B-CHED
in	O
the	O
nucleolus	O
.	O

In	O
addition	O
,	O
binding	O
of	O
N	O
protein	B-CHED
to	O
NPM1	O
protects	O
it	O
from	O
proteolytic	O
degradation	O
by	O
caspase	O
-	O
3	O
,	O
leading	O
to	O
increased	O
cell	O
survival	O
.	O

Taken	O
together	O
,	O
our	O
studies	O
demonstrate	O
a	O
specific	O
interaction	O
of	O
the	O
N	O
protein	B-CHED
with	O
the	O
host	O
cell	O
protein	B-CHED
NPM1	O
in	O
the	O
nucleolus	O
.	O

Signature	O
amino	B-CHED
acid	I-CHED
substitutions	O
and	O
a	O
glycine	B-CHED
residue	I-CHED
insertion	O
at	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
S1	O
subunit	O
of	O
the	O
spike	O
gene	O
,	O
among	O
others	O
,	O
exhibited	O
further	O
distinction	O
in	O
a	O
recombination	O
pattern	O
,	O
to	O
which	O
these	O
clusters	B-CHED
were	O
classified	O
as	O
genotypes	O
F	O
and	O
G	O
.	O
The	O
phylogeographic	O
mapping	O
of	O
the	O
global	O
spike	O
gene	O
indicated	O
that	O
the	O
genetically	O
similar	O
HCoV	O
-	O
OC43	O
genotypes	O
F	O
and	O
G	O
strains	O
were	O
potentially	O
circulating	O
in	O
China	O
,	O
Japan	O
,	O
Thailand	O
and	O
Europe	O
as	O
early	O
as	O
the	O
late	O
2000s	O
.	O

Recent	O
advances	O
include	O
promising	O
results	O
from	O
the	O
clinical	O
testing	O
of	O
recombinant	O
MVA	B-CHED
-	O
producing	O
antigens	B-CHED
of	O
highly	O
pathogenic	O
avian	O
influenza	O
virus	O
H5N1	O
or	O
Ebola	O
virus	O
.	O

Up	O
to	O
30	O
h	O
post	O
-	O
exposure	O
,	O
as	O
a	O
result	O
of	O
progressing	O
hypoxemia	O
and	O
to	O
prevent	O
carbon	B-CHED
dioxide	I-CHED
retention	O
,	O
animals	O
exhibited	O
a	O
compensatory	O
response	O
of	O
elevation	O
in	O
minute	O
volume	O
,	O
attributed	O
mainly	O
to	O
a	O
large	O
elevation	O
in	O
respiratory	O
rate	O
with	O
minimal	O
response	O
in	O
tidal	O
volume	O
.	O

Data	O
from	O
children	O
with	O
ARI	B-CHED
were	O
prospectively	O
collected	O
during	O
two	O
winter	O
seasons	O
.	O

ABSTRACT	O
:	O
Lipid	B-CHED
raft	O
is	O
an	O
important	O
element	O
for	O
the	O
cellular	O
entry	O
of	O
some	O
viruses	O
,	O
including	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

Further	O
complicating	O
the	O
situation	O
is	O
the	O
lack	O
of	O
knowledge	O
of	O
IBV	O
protein	B-CHED
and	O
host	O
cell	O
interactions	O
,	O
making	O
targeted	O
vaccine	O
intervention	O
strategies	O
near	O
impossible	O
.	O

Based	O
on	O
these	O
experimental	O
results	O
,	O
we	O
believe	O
that	O
MPLEx	O
will	O
facilitate	O
systems	O
biology	O
studies	O
of	O
infectious	O
samples	O
by	O
enabling	O
simultaneous	O
pathogen	O
inactivation	O
and	O
multi	O
-	O
omics	O
measurements	O
from	O
a	O
single	O
specimen	O
with	O
high	O
success	O
for	O
pathogens	O
with	O
exposed	O
lipid	B-CHED
membranes	O
.	O

The	O
sizes	O
of	O
deletion	O
varied	O
between	O
582	O
nt	O
(	O
194	O
aa	O
)	O
and	O
648	O
nt	O
(	O
216	O
aa	O
)	O
at	O
positions	O
28	O
-	O
714	O
(	O
10	O
-	O
238	O
)	O
on	O
the	O
S	O
gene	O
(	O
protein	B-CHED
).	O

Sandwich	O
immunoassay	O
formation	O
was	O
influenced	O
by	O
whether	O
the	O
strip	O
was	O
run	O
in	O
corona	B-CHED
forming	O
conditions	O
,	O
i	O
.	O
e	O
.,	O
in	O
human	O
serum	O
.	O

Additionally	O
,	O
the	O
serum	O
level	O
of	O
granulocyte	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
was	O
significantly	O
higher	O
in	O
CoV	O
-	O
CNS	B-CHED
infection	O
than	O
in	O
CoV	O
-	O
respiratory	O
tract	O
infection	O
.	O

Assays	O
were	O
compared	O
to	O
the	O
RealStar	O
	O
MERS	O
-	O
CoV	O
RT	O
-	O
PCR	O
(	O
Alton	O
Diagnostics	O
,	O
Hamburg	O
,	O
Germany	O
)	O
assay	O
as	O
the	O
gold	B-CHED
standard	O
.	O

ABSTRACT	O
:	O
Genetic	O
and	O
environmental	O
factors	O
,	O
i	O
.	O
e	O
.	O
infections	O
,	O
have	O
been	O
proposed	O
to	O
contribute	O
to	O
disease	O
induction	O
and	O
relapsing	O
events	O
in	O
multiple	O
sclerosis	O
(	O
MS	O
),	O
an	O
autoimmune	O
demyelinating	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
).	O

While	O
research	O
has	O
mainly	O
focused	O
on	O
virus	O
associated	O
autoimmune	O
activation	O
,	O
less	O
is	O
known	O
about	O
prevention	O
of	O
autoimmunity	O
,	O
especially	O
following	O
resolving	O
infections	O
associated	O
with	O
CNS	B-CHED
tissue	O
damage	O
.	O

Tubular	O
parenchymal	O
cells	O
,	O
lymphoid	O
and	O
plasma	O
cells	O
in	O
kidney	O
and	O
hepatocytes	O
,	O
lymphoid	O
and	O
plasma	O
cells	O
in	O
liver	O
from	O
dead	O
cats	O
were	O
also	O
positive	O
by	O
immunohistochemistry	O
for	O
the	O
viral	O
N	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Corona	B-CHED
Virus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
transmitted	O
via	O
the	O
respiratory	O
tract	O
and	O
causes	O
severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
by	O
infecting	O
lung	O
epithelial	O
cells	O
and	O
macrophages	O
.	O

The	O
effect	O
was	O
observed	O
both	O
in	O
THP	B-CHED
-	O
1	O
macrophages	O
and	O
human	O
primary	O
peripheral	O
blood	O
monocytes	O
.	O

ABSTRACT	O
:	O
Nasal	O
continuous	O
positive	O
airway	O
pressure	O
(	O
nCPAP	O
)	O
is	O
currently	O
the	O
gold	B-CHED
standard	O
for	O
respiratory	O
support	O
for	O
moderate	O
to	O
severe	O
acute	O
viral	O
bronchiolitis	O
(	O
AVB	O
).	O

No	O
patient	O
had	O
air	B-CHED
leak	O
syndrome	O
or	O
died	O
.	O

ABSTRACT	O
:	O
Emerging	O
pathogenic	O
viruses	O
such	O
as	O
Ebola	O
and	O
Middle	O
Eastern	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
can	O
cause	O
acute	O
infections	O
through	O
the	O
evasion	O
of	O
the	O
host	O
'	O
s	O
antiviral	B-CHED
immune	O
responses	O
and	O
by	O
inducing	O
the	O
upregulation	O
of	O
inflammatory	O
cytokines	O
.	O

To	O
examine	O
this	O
question	O
,	O
we	O
used	O
4	O
cell	O
types	O
:	O
human	O
immature	O
dendritic	O
cells	O
and	O
NIH3T3	O
cells	O
expressing	O
either	O
wild	O
-	O
type	O
DC	O
-	O
SIGN	O
or	O
2	O
internalization	O
-	O
deficient	O
DC	O
-	O
SIGN	O
mutants	O
,	O
in	O
which	O
either	O
the	O
3	O
cytoplasmic	O
internalization	O
motifs	O
are	O
silenced	O
by	O
alanine	B-CHED
substitutions	O
or	O
the	O
cytoplasmic	O
region	O
is	O
truncated	O
.	O

Compared	O
with	O
patients	O
who	O
avoided	O
ETI	B-CHED
,	O
those	O
who	O
failed	O
NIV	O
or	O
had	O
a	O
DNI	O
order	O
and	O
died	O
were	O
more	O
likely	O
to	O
have	O
acute	O
leukemia	O
(	O
84	O
%	O
vs	O
61	O
%;	O
P	O
=	O
.	O
02	O
)	O
and	O
at	O
baseline	O
had	O
higher	O
Paco	O
CONCLUSIONS	O
:	O
Two	O
-	O
thirds	O
of	O
patients	O
with	O
HM	O
and	O
respiratory	O
failure	O
failed	O
NIV	O
and	O
required	O
ETI	B-CHED
,	O
and	O
had	O
high	O
subsequent	O
mortality	O
.	O

TITLE	O
:	O
In	O
Situ	O
Tagged	O
nsp15	O
Reveals	O
Interactions	O
with	O
Coronavirus	O
Replication	O
/	O
Transcription	O
Complex	O
-	O
Associated	O
Proteins	B-CHED
.	O

Utilizing	O
this	O
knowledge	O
,	O
we	O
constructed	O
an	O
internal	O
hemagglutinin	O
(	O
HA	O
)	O
tag	O
that	O
replaced	O
the	O
P	O
/	O
S	O
.	O
We	O
found	O
that	O
nsp15	O
-	O
HA	O
was	O
localized	O
to	O
discrete	O
perinuclear	O
puncta	O
and	O
strongly	O
colocalized	O
with	O
nsp8	O
and	O
nsp12	O
,	O
both	O
well	O
-	O
defined	O
members	O
of	O
the	O
RTC	O
,	O
but	O
not	O
the	O
membrane	O
(	O
M	O
)	O
protein	B-CHED
,	O
involved	O
in	O
virus	O
assembly	O
.	O

Ancillary	O
supportive	O
therapeutic	O
measures	O
included	O
bronchodilators	O
,	O
antibiotics	B-CHED
,	O
steroids	B-CHED
,	O
and	O
ventilation	O
(	O
noninvasive	O
in	O
42	O
and	O
invasive	O
in	O
4	O
).	O

Antiviral	B-CHED
therapy	O
was	O
instituted	O
in	O
influenza	O
-	O
positive	O
patients	O
.	O

Suppression	O
of	O
virus	O
by	O
metalloprotease	O
inhibition	O
varied	O
among	O
tested	O
cell	O
lines	O
and	O
MHV	O
S	O
proteins	B-CHED
,	O
suggesting	O
a	O
role	O
for	O
metalloprotease	O
use	O
in	O
strain	O
-	O
dependent	O
tropism	O
.	O

We	O
conclude	O
that	O
zinc	B-CHED
metalloproteases	O
must	O
be	O
considered	O
potential	O
contributors	O
to	O
coronavirus	O
fusion	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
glycyrrhizin	B-CHED
decreased	O
the	O
mRNA	B-CHED
levels	O
of	O
proinflammatory	O
cytokines	O
.	O

Whole	O
body	O
tissue	O
accretion	O
was	O
altered	O
due	O
to	O
PED	O
,	O
with	O
fat	O
,	O
lean	O
,	O
protein	B-CHED
,	O
and	O
bone	O
mineral	B-CHED
accretion	O
reductions	O
by	O
24	O
,	O
20	O
,	O
21	O
,	O
and	O
42	O
%,	O
respectively	O
(	O
<	O
0	O
.	O
05	O
)	O
compared	O
with	O
Control	O
pigs	O
.	O

A	O
total	O
of	O
91	O
.	O
5	O
%	O
of	O
the	O
211	O
patients	O
met	B-CHED
criteria	O
for	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
using	O
the	O
Pediatric	O
Acute	O
Lung	O
Injury	O
Consensus	O
Conference	O
definition	O
:	O
61	O
.	O
1	O
%	O
were	O
severe	O
,	O
27	O
.	O
5	O
%	O
moderate	O
,	O
and	O
11	O
.	O
4	O
%	O
mild	O
.	O

To	O
obtain	O
additional	O
information	O
on	O
PPE	B-CHED
training	O
during	O
medical	O
education	O
,	O
residents	O
,	O
fellows	O
,	O
and	O
attending	O
physicians	O
completed	O
written	O
questionnaires	O
on	O
PPE	B-CHED
training	O
received	O
during	O
medical	O
school	O
and	O
on	O
knowledge	O
of	O
PPE	B-CHED
protocols	O
recommended	O
by	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
.	O

Results	O
from	O
in	O
silico	O
patients	O
with	O
mild	O
or	O
moderate	O
ARDS	O
suggest	O
that	O
the	O
detrimental	O
effects	O
of	O
RMs	O
on	O
cardiac	O
output	O
can	O
potentially	O
outweigh	O
the	O
positive	O
effects	O
of	O
alveolar	O
recruitment	O
on	O
oxygenation	O
,	O
resulting	O
in	O
overall	O
reductions	O
in	O
tissue	O
oxygen	B-CHED
delivery	O
.	O

RESULTS	O
:	O
The	O
maximal	O
recruitment	O
strategy	O
(	O
MRS	O
)	O
maneuver	O
,	O
which	O
implements	O
gradual	O
increments	O
of	O
positive	O
end	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
followed	O
by	O
PEEP	B-CHED
titration	O
,	O
produced	O
improvements	O
in	O
PF	O
ratio	O
,	O
carbon	B-CHED
dioxide	I-CHED
elimination	O
and	O
dynamic	O
strain	O
in	O
all	O
23	O
in	O
-	O
silico	O
patients	O
considered	O
.	O

Air	B-CHED
and	O
surface	O
samples	O
were	O
cultured	O
on	O
agar	O
plates	O
and	O
assessed	O
qualitatively	O
and	O
semi	O
-	O
quantitatively	O
.	O

Rapid	O
response	O
teams	O
conducted	O
repeated	O
assessments	O
of	O
IPC	B-CHED
and	O
monitored	O
implementation	O
of	O
corrective	O
measures	O
using	O
a	O
detailed	O
structured	O
checklist	O
.	O

Laboratory	O
diagnosis	O
of	O
MERS	O
-	O
CoV	O
infection	O
in	O
dromedaries	O
can	O
be	O
achieved	O
through	O
virus	O
isolation	O
using	O
Vero	O
cells	O
,	O
RNA	O
detection	O
by	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	O
-	O
PCR	O
and	O
antigen	B-CHED
detection	O
using	O
respiratory	O
specimens	O
or	O
serum	O
.	O

By	O
consecutive	O
administration	O
of	O
resveratrol	B-CHED
,	O
we	O
were	O
able	O
to	O
reduce	O
the	O
concentration	O
of	O
resveratrol	B-CHED
while	O
achieving	O
inhibitory	O
effectiveness	O
against	O
MERS	O
-	O
CoV	O
.	O
In	O
this	O
study	O
,	O
we	O
first	O
demonstrated	O
that	O
resveratrol	B-CHED
is	O
a	O
potent	O
anti	O
-	O
MERS	O
agent	O
in	O
vitro	O
.	O

A	O
44	O
years	O
-	O
old	O
female	O
with	O
H7N9	O
-	O
induced	O
ARDS	O
was	O
admitted	O
to	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
and	O
was	O
treated	O
with	O
veno	O
-	O
venous	O
ECMO	O
for	O
six	O
days	O
,	O
antiviral	B-CHED
therapy	O
,	O
prolonged	O
corticosteroid	B-CHED
infusion	O
and	O
other	O
therapies	O
.	O

The	O
aim	O
here	O
was	O
to	O
investigate	O
the	O
protective	O
role	O
of	O
epigallocatechin	O
gallate	B-CHED
(	O
EGCG	B-CHED
)	O
in	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)-	O
mediated	O
inflammatory	O
responses	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
a	O
rat	O
model	O
of	O
thermal	O
injury	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
antimicrobial	B-CHED
strategy	O
on	O
ICU	O
mortality	O
.	O

Further	O
examination	O
revealed	O
signs	O
of	O
TMA	B-CHED
,	O
and	O
the	O
patient	O
progressed	O
to	O
acute	O
renal	O
failure	O
(	O
ARF	O
).	O

Subsequent	O
treatment	O
consisted	O
of	O
elevating	O
the	O
patient	O
'	O
s	O
serum	O
homocysteine	B-CHED
level	O
and	O
starting	O
him	O
on	O
hydroxicobalamin	O
,	O
with	O
normalization	O
of	O
all	O
hematologic	O
parameters	O
although	O
the	O
microalbuminuria	O
remained	O
.	O

Community	O
-	O
ARI	B-CHED
and	O
inpatient	O
-	O
ARI	B-CHED
was	O
also	O
combined	O
with	O
mild	O
and	O
severe	O
cases	O
of	O
influenza	O
from	O
a	O
historical	O
prospective	O
study	O
as	O
mild	O
-	O
ARI	B-CHED
and	O
severe	O
-	O
ARI	B-CHED
respectively	O
to	O
evaluate	O
the	O
performance	O
of	O
clinical	O
case	O
definitions	O
.	O

Twelve	O
hours	O
following	O
ECMO	O
initiation	O
,	O
high	O
dose	O
intravenous	O
vitamin	B-CHED
C	I-CHED
was	O
begun	O
.	O

Intravenous	O
vitamin	B-CHED
C	I-CHED
as	O
a	O
treatment	O
for	O
ARDS	O
may	O
open	O
a	O
new	O
era	B-CHED
of	O
therapy	O
for	O
ARDS	O
from	O
many	O
causes	O
.	O

TITLE	O
:	O
Intravenous	O
Buprenorphine	B-CHED
:	O

ABSTRACT	O
:	O
Administration	O
of	O
naloxone	B-CHED
is	O
a	O
common	O
treatment	O
for	O
opioid	O
-	O
dependent	O
patients	O
who	O
present	O
with	O
respiratory	O
depression	O
.	O

In	O
addition	O
,	O
the	O
longer	O
half	O
-	O
life	O
of	O
buprenorphine	B-CHED
compared	O
with	O
naloxone	B-CHED
may	O
reduce	O
the	O
need	O
for	O
repetitive	O
administration	O
of	O
antidote	B-CHED
.	O

TITLE	O
:	O
Viral	O
rewiring	O
of	O
cellular	O
lipid	B-CHED
metabolism	O
to	O
create	O
membranous	O
replication	O
compartments	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
different	O
testing	O
modalities	O
available	O
for	O
the	O
ongoing	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
epidemic	O
including	O
cell	O
culture	O
,	O
nucleic	B-CHED
acid	I-CHED
amplification	O
,	O
antigen	B-CHED
detection	O
,	O
and	O
antibody	O
detection	O
assays	O
.	O

We	O
also	O
discussed	O
the	O
substrate	O
selection	O
and	O
binding	O
mode	O
of	O
PDCoV	O
nsp5	O
by	O
homologous	O
modeling	O
of	O
PDCoV	O
nsp5	O
with	O
the	O
two	O
cleaved	O
peptide	B-CHED
substrates	O
.	O

Sagittal	O
-	O
lung	O
CT	O
measurements	O
in	O
terms	O
of	O
bilateral	O
lung	O
height	O
(	O
LH	O
),	O
anterior	O
-	O
posterior	O
lung	O
diameter	O
(	O
APLD	O
),	O
diaphragm	O
height	O
(	O
DH	O
),	O
and	O
anterior	O
sterno	O
-	O
diaphragmatic	O
angle	O
(	O
ASDA	O
),	O
as	O
well	O
as	O
inter	O
-	O
pulmonary	O
septum	O
length	O
(	O
IPSL	O
)	O
on	O
axial	O
images	O
were	O
measured	O
both	O
before	O
and	O
after	O
bronchodilator	B-CHED
(	O
BD	O
)	O
administration	O
.	O

Upon	O
establishing	O
the	O
diagnosis	O
of	O
preeclampsia	O
,	O
aggressive	O
therapy	O
with	O
corticosteroids	B-CHED
,	O
antihypertensive	B-CHED
medication	O
,	O
and	O
seizure	O
prophylaxis	O
was	O
initiated	O
.	O

N	B-CHED
-	I-CHED
Acetylcysteine	I-CHED
(	O
NAC	O
)	O
has	O
been	O
shown	O
to	O
reduce	O
endotoxin	O
-	O
induced	O
intestinal	O
dysfunction	O
.	O

582	O
children	O
with	O
ARI	B-CHED
were	O
prospectively	O
followed	O
and	O
tested	O
for	O
15	O
viruses	O
.	O

Internationally	O
,	O
there	O
is	O
a	O
strong	O
trend	O
towards	O
less	O
invasive	O
surgical	O
approach	O
to	O
PTA	B-CHED
treatment	O
with	O
avoidance	O
of	O
acute	O
tonsillectomy	O
,	O
needle	O
aspiration	O
instead	O
of	O
ID	O
,	O
and	O
in	O
some	O
cases	O
even	O
antibiotic	B-CHED
treatment	O
without	O
surgical	O
drainage	O
.	O

Complications	O
secondary	O
to	O
PTA	B-CHED
may	O
be	O
avoided	O
or	O
better	O
controlled	O
with	O
improved	O
knowledge	O
concerning	O
the	O
significant	O
pathogens	O
in	O
PTA	B-CHED
.	O

Comparative	O
microbiology	O
between	O
PTA	B-CHED
patients	O
and	O
""""	O
normal	O
tonsils	O
"""."	O

TITLE	O
:	O
Polyprenyl	O
Immunostimulant	B-CHED
Treatment	O
of	O
Cats	O
with	O
Presumptive	O
Non	O
-	O
Effusive	O
Feline	O
Infectious	O
Peritonitis	O
In	O
a	O
Field	O
Study	O
.	O

The	O
survival	O
times	O
in	O
our	O
study	O
were	O
significantly	O
longer	O
in	O
cats	O
who	O
were	O
not	O
treated	O
with	O
corticosteroids	B-CHED
concurrently	O
with	O
PI	O
.	O

Most	O
confirmed	O
cases	O
so	O
far	O
were	O
part	O
of	O
MERS	O
-	O
CoV	O
clusters	B-CHED
in	O
hospital	O
settings	O
,	O
affecting	O
mainly	O
middle	O
-	O
aged	O
men	O
and	O
patients	O
with	O
a	O
chronic	O
disease	O
or	O
immuno	O
-	O
suppressed	O
status	O
.	O

The	O
PEDV	O
isolate	O
was	O
28	O
,	O
033	O
nucleotides	B-CHED
(	O
nt	O
)	O
in	O
length	O
without	O
the	O
polyadenylated	O
sequences	O
.	O

Comparative	O
analysis	O
of	O
the	O
amino	B-CHED
acids	I-CHED
encoded	O
by	O
the	O
S	O
genes	O
revealed	O
the	O
N	O
-	O
terminal	O
of	O
the	O
deduced	O
JSCZ1601	O
S	O
protein	B-CHED
had	O
a	O
novel	O
two	O
-	O
amino	O
-	O
acid	O
deletion	O
(	O
N58	O
and	O
S59	O
)	O
compared	O
with	O
all	O
identified	O
genogroups	O
.	O

Several	O
over	O
the	O
counter	B-CHED
products	O
are	O
available	O
which	O
provide	O
symptomatic	O
,	O
not	O
causal	O
relief	O
.	O

Suppression	O
of	O
autophagy	O
by	O
3	O
-	O
MA	O
increased	O
viral	O
replication	O
,	O
compared	O
with	O
the	O
mock	O
treatment	O
,	O
while	O
promoting	O
of	O
autophagy	O
by	O
rapamycin	B-CHED
reduced	O
PHEV	O
replication	O
.	O

Mechanistically	O
,	O
neuraminidase	O
inhibition	O
assay	O
and	O
hemagglutination	O
inhibition	O
assay	O
suggested	O
that	O
N30	O
did	O
not	O
directly	O
target	O
the	O
two	O
envelope	O
glycoproteins	B-CHED
required	O
for	O
viral	O
adsorption	O
or	O
release	O
.	O

We	O
identified	O
the	O
small	O
molecule	O
N30	O
,	O
as	O
an	O
inhibitor	B-CHED
of	O
IMPDH	O
,	O
might	O
be	O
a	O
potential	O
candidate	O
to	O
inhibit	O
the	O
replication	O
of	O
various	O
viruses	O
.	O

PELs	B-CHED
are	O
approximately	O
100	O
-	O
nm	O
drug	O
carriers	O
coated	O
with	O
antibodies	O
that	O
bind	O
to	O
the	O
pulmonary	O
capillary	O
endothelium	O
.	O

We	O
aim	O
to	O
use	O
such	O
preclinical	O
validation	O
to	O
move	O
PELs	B-CHED
into	O
a	O
partnership	O
with	O
industry	O
,	O
and	O
then	O
to	O
patients	O
.	O

By	O
contrast	O
,	O
PLP	O
did	O
not	O
cause	O
any	O
reduction	O
of	O
haemagglutinin	O
(	O
HA	O
)-	O
Ub	O
-	O
conjugated	B-CHED
proteins	I-CHED
.	O

HCoV	O
strains	O
were	O
identified	O
in	O
BAL	B-CHED
samples	O
using	O
strain	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
.	O

TITLE	O
:	O
Effects	O
of	O
dexamethasone	B-CHED
coadministered	O
with	O
oseltamivir	B-CHED
on	O
the	O
pharmacokinetics	O
of	O
oseltamivir	B-CHED
in	O
healthy	O
volunteers	O
.	O

ABSTRACT	O
:	O
Oseltamivir	B-CHED
is	O
widely	O
used	O
in	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
influenza	O
A	O
and	O
B	O
viral	O
infections	O
.	O

An	O
open	O
-	O
label	B-CHED
,	O
two	O
-	O
period	O
,	O
one	O
-	O
sequence	O
,	O
multiple	O
-	O
dose	O
study	O
was	O
conducted	O
in	O
19	O
healthy	O
male	O
volunteers	O
.	O

Area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
of	O
oseltamivir	B-CHED
and	O
oseltamivir	B-CHED
carboxylate	B-CHED
decreased	O
after	O
dexamethasone	B-CHED
treatment	O
for	O
6	O
days	O
.	O

The	O
geometric	O
mean	O
ratio	O
(	O
90	O
%	O
confidence	O
interval	O
)	O
of	O
the	O
metabolic	O
ratio	O
(	O
oseltamivir	B-CHED
carboxylate	B-CHED
AUC	O
Coadministration	O
of	O
dexamethasone	B-CHED
with	O
oseltamivir	B-CHED
slightly	O
decreased	O
systemic	O
exposure	O
to	O
oseltamivir	B-CHED
and	O
oseltamivir	B-CHED
carboxylate	B-CHED
in	O
healthy	O
volunteers	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
immunogenicity	O
of	O
naked	O
DNA	O
vaccines	O
expressing	O
different	O
fragments	O
of	O
MERS	O
-	O
CoV	O
S	O
protein	B-CHED
in	O
mice	O
.	O

The	O
hypothesis	O
is	O
that	O
serum	O
IP	O
-	O
10	O
concentrations	O
correlate	O
with	O
ARI	B-CHED
severity	O
and	O
detection	O
of	O
viral	O
pathogens	O
.	O

Data	O
come	O
from	O
a	O
randomized	O
controlled	O
trial	O
measuring	O
the	O
effects	O
of	O
mindfulness	O
meditation	O
or	O
exercise	O
on	O
ARI	B-CHED
(	O
Clinical	O
Trials	O
ID	O
:	O
NCT01654289	O
).	O

To	O
obtain	O
more	O
insight	O
into	O
the	O
signals	O
and	O
molecular	O
events	O
that	O
coordinate	O
global	O
host	O
responses	O
in	O
the	O
nucleus	B-CHED
of	O
coronavirus	O
-	O
infected	O
cells	O
,	O
first	O
,	O
transcriptome	O
dynamics	O
was	O
studied	O
in	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)-	O
infected	O
A549	O
and	O
HuH7	O
cells	O
,	O
respectively	O
,	O
revealing	O
a	O
core	O
signature	O
of	O
upregulated	O
genes	O
in	O
these	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
produced	O
PEDV	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
composed	O
of	O
S	O
,	O
M	O
,	O
and	O
E	O
proteins	B-CHED
with	O
a	O
baculovirus	O
expression	O
system	O
and	O
tested	O
them	O
via	O
indirect	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
and	O
Western	O
blot	O
analysis	O
.	O

CONCLUSIONS	O
:	O
Usage	O
of	O
extended	O
criteria	O
donors	O
seems	O
a	O
successful	O
strategy	O
to	O
overcome	O
shortage	O
of	O
donor	B-CHED
lungs	O
by	O
the	O
increasing	O
number	O
of	O
lung	O
transplant	O
candidates	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
nanoparticle	B-CHED
drug	O
carriers	O
that	O
interact	O
with	O
cells	O
specifically	O
in	O
the	O
mildly	O
acidic	O
tumor	O
microenvironment	O
,	O
we	O
produced	O
polymeric	O
nanoparticles	B-CHED
modified	O
with	O
amidated	O
TAT	O
peptide	B-CHED
via	O
a	O
simple	O
surface	O
modification	O
method	O
.	O

The	O
chronic	O
toxicity	O
derived	O
from	O
the	O
current	O
anti	O
-	O
retroviral	O
therapy	O
limits	O
the	O
prolonged	O
use	O
of	O
several	O
antiretroviral	O
agents	O
,	O
continuously	O
requiring	O
the	O
discovery	O
of	O
new	O
antiviral	B-CHED
agents	I-CHED
with	O
innovative	O
strategies	O
of	O
action	O
.	O

In	O
particular	O
,	O
the	O
development	O
of	O
single	O
molecules	O
targeting	O
two	O
proteins	B-CHED
(	O
dual	O
inhibitors	B-CHED
)	O
is	O
one	O
of	O
the	O
current	O
main	O
goals	O
in	O
drug	O
discovery	O
.	O

Antibody	O
neutralization	O
escape	O
mutants	O
displayed	O
single	O
amino	B-CHED
acid	I-CHED
substitutions	O
that	O
impaired	O
antibody	O
binding	O
and	O
neutralization	O
and	O
defined	O
the	O
locations	O
of	O
the	O
epitopes	O
.	O

Novel	O
CalVs	O
were	O
detected	O
in	O
Rousettus	O
aegyptiacus	O
and	O
Mops	B-CHED
condylurus	O
while	O
novel	O
Rotavirus	O
-	O
A	O
-	O
related	O
viruses	O
were	O
detected	O
in	O
Taphozous	O
bats	O
and	O
R	O
.	O
aegyptiacus	O
.	O

Further	O
sequence	O
conservation	O
analysis	O
of	O
six	O
human	O
-	O
infecting	O
coronaviruses	O
revealed	O
that	O
the	O
fusion	O
peptide	B-CHED
,	O
HR1	O
region	O
and	O
the	O
central	O
helix	O
are	O
potential	O
targets	O
for	O
eliciting	O
broadly	O
neutralizing	O
antibodies	O
.	O

Coronavirus	O
envelope	O
proteins	B-CHED
specifically	O
recognized	O
the	O
open	O
APN	O
form	O
,	O
prevented	O
ectodomain	O
progression	O
to	O
the	O
closed	O
form	O
and	O
substrate	O
hydrolysis	O
.	O

We	O
conclude	O
that	O
allosteric	O
inhibition	O
of	O
APN	O
functions	O
occurs	O
by	O
ligand	B-CHED
suppression	O
of	O
ectodomain	O
motions	O
necessary	O
for	O
catalysis	O
and	O
virus	O
cell	O
entry	O
,	O
as	O
validated	O
by	O
locking	O
APN	O
with	O
disulfides	B-CHED
.	O

TITLE	O
:	O
Multiplex	O
Paper	O
-	O
Based	O
Colorimetric	O
DNA	O
Sensor	O
Using	O
Pyrrolidinyl	O
Peptide	B-CHED
Nucleic	I-CHED
Acid	I-CHED
-	O
Induced	O
AgNPs	O
Aggregation	O
for	O
Detecting	O
MERS	O
-	O
CoV	O
,	O
MTB	O
,	O
and	O
HPV	O
Oligonucleotides	B-CHED
.	O

Factors	O
affecting	O
the	O
sensitivity	O
and	O
selectivity	O
of	O
this	O
assay	O
were	O
investigated	O
,	O
including	O
ionic	O
strength	O
,	O
AgNP	B-CHED
concentration	O
,	O
PNA	B-CHED
concentration	O
,	O
and	O
DNA	O
strand	O
mismatches	O
.	O

RESULTS	O
:	O
Two	O
hundred	O
and	O
eighty	O
-	O
eight	O
patients	O
met	B-CHED
the	O
inclusion	O
criteria	O
.	O

HVS	O
was	O
defined	O
by	O
a	O
delayed	O
return	O
of	O
the	O
end	O
-	O
tidal	O
partial	O
pressure	O
of	O
carbon	B-CHED
dioxide	I-CHED
in	O
the	O
expired	O
gas	O
to	O
baseline	O
during	O
HVPT	O
.	O

Three	O
-	O
week	O
-	O
old	O
barrows	O
were	O
inoculated	O
intragastrically	O
with	O
5	O
mL	O
of	O
PEDV	O
-	O
negative	O
feces	O
for	O
the	O
negative	O
control	O
,	O
5	O
mL	O
of	O
untreated	O
PEDV	O
-	O
positive	O
feces	O
for	O
the	O
positive	O
control	O
,	O
and	O
5	O
mL	O
or	O
10	O
mL	O
of	O
PEDV	O
-	O
positive	O
feces	O
that	O
was	O
subjected	O
to	O
treatment	O
with	O
a	O
1	O
:	O
16	O
or	O
1	O
:	O
32	O
concentrations	O
of	O
accelerated	O
hydrogen	B-CHED
peroxide	I-CHED
disinfectant	B-CHED
for	O
a	O
contact	O
time	O
of	O
30	O
min	O
at	O
20	O
	O
C	O
.	O

TITLE	O
:	O
Risk	O
and	O
Outbreak	O
Communication	O
:	O
Lessons	O
from	O
Taiwan	O
'	O
s	O
Experiences	O
in	O
the	O
Post	O
-	O
SARS	O
Era	B-CHED
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
DE	O
as	O
adjuvant	B-CHED
in	O
an	O
Ark	O
-	O
DPI	O
live	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
vaccine	O
after	O
ocular	O
or	O
spray	O
application	O
.	O

In	O
this	O
work	O
,	O
we	O
provide	O
evidence	O
that	O
MERS	O
CoV	O
3CLpro	O
and	O
PLpro	O
are	O
subject	O
to	O
different	O
genetic	O
and	O
evolutionary	O
influences	O
that	O
shape	O
the	O
protein	B-CHED
sequence	O
,	O
codon	O
usage	O
pattern	O
,	O
and	O
codon	O
usage	O
bias	O
.	O

Every	O
protein	B-CHED
had	O
one	O
common	O
cluster	O
and	O
2	O
different	O
clusters	B-CHED
.	O

Elevated	O
CCL2	B-CHED
levels	O
were	O
also	O
detected	O
in	O
confirmed	O
human	O
cases	O
of	O
H7N9	O
and	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
of	O
H7N9	O
-	O
infected	O
mice	O
.	O

Cell	O
-	O
free	O
supernatants	O
(	O
CFS	O
)	O
and	O
live	O
LAB	O
were	O
evaluated	O
for	O
antiviral	B-CHED
activities	O
by	O
co	O
-	O
incubation	O
on	O
Vero	O
cells	O
and	O
challenged	O
with	O
a	O
pandemic	O
strain	O
of	O
PEDV	O
isolated	O
from	O
pigs	O
in	O
Thailand	O
.	O

Ex	O
vivo	O
lung	O
perfusion	O
(	O
EVLP	O
)	O
is	O
gaining	O
clinical	O
acceptance	O
for	O
donor	B-CHED
lung	O
evaluation	O
and	O
rehabilitation	O
and	O
may	O
expand	O
the	O
use	O
of	O
marginal	O
organs	O
for	O
transplantation	O
.	O

Two	O
groups	O
of	O
4	O
animals	O
each	O
received	O
a	O
2	O
-	O
hour	O
infusion	O
of	O
LPS	B-CHED
through	O
the	O
external	O
jugular	O
vein	O
.	O

H1N1	O
and	O
H3N2	B-CHED
were	O
significantly	O
more	O
common	O
among	O
patients	O
with	O
chronic	O
neurologic	O
disorders	O
and	O
renal	O
failure	O
,	O
respectively	O
.	O

We	O
classified	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
based	O
on	O
an	O
oxygen	B-CHED
partial	O
pressure	O
/	O
oxygen	B-CHED
inspired	O
fraction	O
ratio	O
<	O
100	O
,	O
although	O
the	O
Berlin	O
classification	O
is	O
limited	O
in	O
considering	O
patients	O
with	O
severe	O
hypoxemia	O
managed	O
exclusively	O
with	O
noninvasive	O
ventilation	O
.	O

Treatment	O
with	O
the	O
NF	O
-	O
B	O
-	O
specific	O
inhibitor	B-CHED
BAY11	O
-	O
7082	O
significantly	O
decreased	O
TGEV	O
-	O
induced	O
proinflammatory	O
cytokine	O
production	O
,	O
but	O
did	O
not	O
affect	O
virus	O
replication	O
.	O

CONCLUSIONS	O
:	O
Aerosolized	O
tobramycin	B-CHED
was	O
an	O
effective	O
therapeutic	O
strategy	O
for	O
P	O
.	O
aeruginosa	O
VAP	O
patients	O
with	O
ARDS	O
.	O

To	O
ameliorate	O
the	O
effects	O
of	O
future	O
outbreaks	O
as	O
well	O
as	O
to	O
prepare	O
for	O
biodefense	O
,	O
a	O
process	O
for	O
the	O
production	O
of	O
a	O
recombinant	O
protein	B-CHED
vaccine	O
candidate	O
is	O
under	O
development	O
.	O

Previously	O
,	O
we	O
reported	O
the	O
5	O
L	O
scale	O
expression	O
and	O
purification	O
of	O
a	O
promising	O
recombinant	O
SARS	O
vaccine	O
candidate	O
,	O
RBD219	O
-	O
N1	O
,	O
the	O
218	O
-	O
amino	B-CHED
acid	I-CHED
residue	I-CHED
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
coronavirus	O
expressed	O
in	O
yeast	O
-	O
Pichia	O
pastoris	O
X	O
-	O
33	O
.	O

When	O
adjuvanted	O
with	O
aluminum	B-CHED
hydroxide	I-CHED
,	O
this	O
protein	B-CHED
elicited	O
high	O
neutralizing	O
antibody	O
titers	O
and	O
high	O
RBD	O
-	O
specific	O
antibody	O
titers	O
.	O

Results	O
showed	O
that	O
the	O
epitope	B-CHED
recognized	O
by	O
the	O
1B9	O
mAb	O
lies	O
in	O
the	O
spike	O
protein	B-CHED
,	O
and	O
that	O
it	O
is	O
a	O
conformational	O
epitope	B-CHED
.	O

New	O
prophylactic	O
and	O
therapeutic	O
strategies	O
to	O
combat	B-CHED
human	O
infections	O
are	O
urgently	O
needed	O
.	O

A	O
total	O
of	O
155	O
throat	O
swabs	O
were	O
collected	O
from	O
equal	O
number	O
of	O
children	O
suspected	O
to	O
have	O
SARI	O
and	O
processed	O
for	O
extraction	O
of	O
nucleic	B-CHED
acids	I-CHED
using	O
automated	O
extraction	O
system	O
.	O

TITLE	O
:	O
ROS	B-CHED
feedback	O
regulates	O
the	O
microRNA	O
-	O
19	O
-	O
targeted	O
inhibition	O
of	O
the	O
p47phox	O
-	O
mediated	O
LPS	B-CHED
-	O
induced	O
inflammatory	O
response	O
.	O

In	O
hospitalized	O
children	O
,	O
young	O
age	O
and	O
CCCs	B-CHED
,	O
but	O
not	O
HCoV	O
type	O
,	O
were	O
associated	O
with	O
increased	O
severity	O
of	O
illness	O
.	O

Immunofluorescence	O
imaging	O
of	O
nsp15	O
mutant	O
virus	O
-	O
infected	O
macrophages	O
revealed	O
significant	O
dispersal	O
of	O
dsRNA	B-CHED
early	O
during	O
infection	O
,	O
whereas	O
in	O
WT	O
virus	O
-	O
infected	O
cells	O
,	O
the	O
majority	O
of	O
the	O
dsRNA	B-CHED
was	O
associated	O
with	O
replication	O
complexes	O
.	O

We	O
present	O
two	O
cases	O
highlighting	O
the	O
diagnostic	O
and	O
clinical	O
challenges	O
of	O
BMP	B-CHED
infarction	O
.	O

A	O
57	O
-	O
year	O
-	O
old	O
man	B-CHED
rapidly	O
had	O
severe	O
vomiting	O
and	O
diarrhea	O
2	O
h	O
after	O
a	O
meal	O
.	O

Cerebral	O
angiography	O
showed	O
an	O
occluded	O
left	O
vertebral	O
artery	O
with	O
unilateral	O
left	O
-	O
sided	O
origin	O
of	O
ASA	B-CHED
.	O

CONCLUSIONS	O
:	O
Acute	O
BMP	B-CHED
infarction	O
may	O
present	O
with	O
flaccid	O
tetraplegia	O
mimicking	O
neuromuscular	O
disorders	O
.	O

Extensive	O
hemodynamics	O
,	O
oxygen	B-CHED
dynamics	O
,	O
and	O
lung	O
function	O
were	O
monitored	O
for	O
24	O
h	O
following	O
the	O
injury	O
or	O
until	O
death	O
.	O

Although	O
the	O
use	O
of	O
allopurinol	B-CHED
and	O
N	O
-	O
methyl	B-CHED
-	O
glucamine	O
antimoniate	O
is	O
off	O
-	O
label	B-CHED
in	O
cats	O
,	O
in	O
this	O
case	O
the	O
combination	O
treatment	O
was	O
followed	O
by	O
an	O
extensive	O
analytical	O
monitoring	O
,	O
supporting	O
their	O
safety	O
and	O
effectiveness	O
.	O

ICC	O
was	O
carried	O
out	O
as	O
avidin	O
-	O
biotin	B-CHED
complex	O
method	O
.	O

In	O
conclusion	O
,	O
our	O
research	O
suggests	O
that	O
IL	O
-	O
33	O
protects	O
against	O
viral	O
fulminant	O
hepatitis	O
in	O
mice	O
by	O
antagonizing	O
expression	O
of	O
the	O
pro	B-CHED
-	O
coagulant	O
protein	B-CHED
FGL2	O
.	O

CONCLUSIONS	O
:	O
Simultaneous	O
enumeration	O
of	O
antigen	B-CHED
-	O
specific	O
Bmem	O
and	O
ASC	O
using	O
the	O
Bmem	O
assay	O
optimized	O
for	O
CNS	B-CHED
-	O
derived	O
cells	O
enables	O
characterization	O
of	O
temporal	O
changes	O
during	O
microbial	O
or	O
auto	O
-	O
antigen	B-CHED
induced	O
neuroinflammation	O
.	O

Evolutionary	O
changes	O
in	O
the	O
virus	O
,	O
particularly	O
in	O
the	O
viral	O
spike	O
protein	B-CHED
which	O
mediates	O
virus	O
-	O
host	O
cell	O
contact	O
may	O
potentially	O
increase	O
transmission	O
of	O
this	O
virus	O
.	O

On	O
the	O
basis	O
of	O
differentially	O
expressed	O
proteins	B-CHED
,	O
we	O
propose	O
that	O
PEDV	O
might	O
disrupt	O
apoptosis	O
and	O
may	O
elicit	O
stronger	O
inflammatory	O
cascades	O
as	O
well	O
.	O

Rapid	O
intervention	O
necessitates	O
the	O
capacity	O
to	O
generate	O
,	O
grow	O
,	O
and	O
genetically	O
manipulate	O
infectious	O
CoVs	O
in	O
order	O
to	O
rapidly	O
evaluate	O
pathogenic	O
mechanisms	O
,	O
host	O
and	O
tissue	O
permissibility	O
,	O
and	O
candidate	O
antiviral	B-CHED
therapeutic	O
efficacy	O
.	O

CoVs	O
encode	O
the	O
largest	O
viral	O
RNA	O
genomes	O
at	O
about	O
28	O
-	O
32	O
,	O
000	O
nucleotides	B-CHED
in	O
length	O
,	O
and	O
thereby	O
complicate	O
efficient	O
engineering	O
of	O
the	O
genome	O
.	O

Modulating	O
miR	O
-	O
142	O
-	O
5p	O
activity	O
by	O
microRNA	O
mimics	O
or	O
inhibitors	B-CHED
induced	O
neurodegeneration	O
,	O
including	O
stunted	O
axon	O
elongation	O
,	O
unstable	O
dendritic	O
spine	O
formation	O
,	O
and	O
irregular	O
swelling	O
and	O
disconnection	O
in	O
neurites	O
.	O

Our	O
data	O
revealed	O
that	O
PHEV	O
adapted	O
to	O
use	O
spatiotemporal	O
control	O
of	O
host	O
microRNAs	O
to	O
invade	O
CNS	B-CHED
,	O
and	O
provided	O
new	O
insights	O
into	O
the	O
virus	O
-	O
associated	O
neurological	O
dysfunction	O
microenvironment	O
.	O

The	O
S1	O
subunit	O
of	O
the	O
viral	O
S	O
glycoprotein	B-CHED
is	O
responsible	O
for	O
virus	O
binding	O
to	O
host	O
-	O
cell	O
receptors	O
,	O
induction	O
of	O
neutralizing	O
antibody	O
and	O
hemagglutinin	O
activity	O
.	O

A	O
total	O
of	O
219	O
dogs	O
suffering	O
from	O
acute	O
gastroenteritis	O
disorders	O
and	O
67	O
controls	O
randomly	O
recruited	O
among	O
healthy	O
dogs	O
or	O
patients	O
presenting	O
without	O
enteric	O
signs	O
were	O
screened	O
by	O
a	O
panel	O
of	O
real	O
-	O
time	O
(	O
RT	O
-)	O
PCR	O
assays	O
for	O
CanineCV	O
,	O
CPV	O
,	O
CCoV	O
and	O
CDV	B-CHED
.	O

Together	O
,	O
this	O
makes	O
vDUBs	O
highly	O
attractive	O
antiviral	B-CHED
drug	I-CHED
targets	O
.	O

Phosphine	B-CHED
is	O
a	O
respiratory	O
toxin	O
that	O
inhibits	O
cytochrome	B-CHED
C	I-CHED
oxidase	O
system	O
resulting	O
in	O
renal	O
failure	O
and	O
liver	O
failure	O
.	O

A	O
35	O
year	O
old	O
Sri	O
Lankan	O
female	O
presented	O
following	O
ingestion	O
of	O
2	O
.	O
5	O
g	O
of	O
Run	O
Rat	O
,	O
which	O
is	O
a	O
branded	O
preparation	O
of	O
zinc	B-CHED
phosphide	B-CHED
,	O
resulting	O
in	O
61	O
mg	O
/	O
kg	O
poison	B-CHED
load	O
.	O

In	O
our	O
patient	O
,	O
Zinc	B-CHED
phosphide	B-CHED
poisoning	O
caused	O
severe	O
acute	O
kidney	O
injury	O
,	O
abnormal	O
liver	O
profile	O
,	O
pancreatitis	O
and	O
possible	O
myocarditis	O
.	O

The	O
AcCoV	O
-	O
JC34	O
genome	O
was	O
27	O
,	O
649	O
nucleotides	B-CHED
long	O
and	O
showed	O
a	O
structure	O
similar	O
to	O
the	O
HKU2	O
bat	O
coronavirus	O
.	O

This	O
inhibitor	B-CHED
exhibited	O
low	O
micromolar	O
antiviral	B-CHED
activity	O
against	O
various	O
influenza	O
A	O
and	O
B	O
virus	O
strains	O
,	O
including	O
the	O
highly	O
pathogenic	O
influenza	O
A	O
strains	O
H5N1	O
and	O
H7N9	O
,	O
enterovirus	O
A71	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
rhinovirus	O
A	O
,	O
SARS	O
-	O
and	O
MERS	O
-	O
coronavirus	O
.	O

ABSTRACT	O
:	O
It	O
is	O
unclear	O
whether	O
various	O
bronchodilator	B-CHED
reversibility	O
(	O
BDR	O
)	O
criteria	O
affect	O
the	O
prognosis	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
).	O

The	O
sequence	O
alignment	O
using	O
Clustal	O
W	O
shows	O
that	O
the	O
signal	O
sequence	O
present	O
at	O
the	O
cytoplasmic	O
tail	O
plays	O
an	O
important	O
role	O
in	O
spike	O
protein	B-CHED
localization	O
.	O

Although	O
the	O
pathogenesis	O
of	O
HFRS	O
and	O
HPS	B-CHED
remains	O
largely	O
unknown	O
,	O
postmortem	O
tissue	O
studies	O
have	O
identified	O
endothelial	O
cells	O
as	O
the	O
primary	O
target	O
of	O
infection	O
.	O

In	O
conclusion	O
,	O
using	O
bioinformatics	O
methods	O
,	O
we	O
analyzed	O
the	O
genome	O
sequence	O
of	O
MERS	O
-	O
CoV	O
and	O
identified	O
a	O
potential	O
B	O
-	O
cell	O
epitope	B-CHED
of	O
the	O
E	O
protein	B-CHED
,	O
which	O
might	O
significantly	O
improve	O
our	O
current	O
MERS	O
vaccine	O
development	O
strategies	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nonstructural	O
protein	B-CHED
3	O
(	O
nsp3	O
)	O
is	O
a	O
multifunctional	O
protein	B-CHED
that	O
comprises	O
multiple	O
structural	O
domains	O
.	O

Half	O
the	O
patients	O
received	O
mechanical	O
ventilation	O
within	O
1	O
(	O
1	O
-	O
2	O
)	O
day	O
following	O
ICU	O
admission	O
(	O
the	O
ratio	O
of	O
arterial	O
oxygen	B-CHED
partial	O
pressure	O
to	O
fractional	O
inspired	O
oxygen	B-CHED
(	O
PaO	B-CHED

TITLE	O
:	O
Targeting	O
endosomal	O
acidification	O
by	O
chloroquine	B-CHED
analogs	O
as	O
a	O
promising	O
strategy	O
for	O
the	O
treatment	O
of	O
emerging	O
viral	O
diseases	O
.	O

Herein	O
,	O
the	O
genomic	O
part	O
coding	O
for	O
the	O
spike	O
glycoprotein	B-CHED
ectodomain	O
was	O
replaced	O
by	O
that	O
of	O
the	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
allowing	O
for	O
the	O
selection	O
and	O
propagation	O
of	O
recombinant	O
mIBV	O
in	O
murine	O
cells	O
.	O

ARDS	O
is	O
defined	O
by	O
the	O
patient	O
'	O
s	O
oxygen	B-CHED
in	O
arterial	O
blood	O
(	O
PaO2	O
)	O
to	O
the	O
fraction	O
of	O
the	O
oxygen	B-CHED
in	O
the	O
inspired	O
air	B-CHED
(	O
FiO2	O
).	O

The	O
proportion	O
of	O
patients	O
with	O
severe	O
ARDS	O
or	O
with	O
ratios	O
of	O
the	O
partial	O
pressure	O
of	O
arterial	O
oxygen	B-CHED
(	O
PaO	B-CHED
Important	O
geo	O
-	O
economic	O
differences	O
exist	O
in	O
the	O
severity	O
,	O
clinician	O
recognition	O
,	O
and	O
management	O
of	O
ARDS	O
,	O
and	O
in	O
patients	O
'	O
outcomes	O
.	O

TITLE	O
:	O
Oral	O
administration	O
of	O
tea	B-CHED
saponins	O
to	O
relive	O
oxidative	O
stress	O
and	O
immune	O
suppression	O
in	O
chickens	O
.	O

Conversely	O
,	O
residue	O
R797	O
,	O
previously	O
reported	O
to	O
be	O
required	O
for	O
SARS	O
S	O
activation	O
by	O
trypsin	O
,	O
was	O
dispensable	O
for	O
S	O
protein	B-CHED
cleavage	O
but	O
required	O
for	O
S	O
protein	B-CHED
activation	O
by	O
TMPRSS2	O
.	O

Hence	O
,	O
here	O
we	O
tested	O
the	O
pentacyclic	O
triterpene	B-CHED
Lupeol	B-CHED
,	O
showing	O
that	O
it	O
inhibits	O
the	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNase	O
H	O
function	O
.	O

We	O
describe	O
the	O
successful	O
use	O
of	O
an	O
argatroban	B-CHED
infusion	O
in	O
this	O
setting	O
at	O
much	O
higher	O
doses	O
than	O
what	O
has	O
previously	O
been	O
reported	O
in	O
the	O
adult	O
literature	O
.	O

TITLE	O
:	O
Rapamycin	B-CHED
adjuvant	B-CHED
and	O
exacerbation	O
of	O
severe	O
influenza	O
in	O
an	O
experimental	O
mouse	O
model	O
.	O

Almost	O
all	O
participants	O
heard	O
about	O
the	O
corona	B-CHED
disease	O
and	O
causative	O
agent	O
.	O

Notably	O
,	O
epitope	B-CHED
mapping	O
by	O
peptide	B-CHED
ELISAs	O
revealed	O
that	O
nine	O
of	O
these	O
mAbs	O
recognized	O
linear	O
neutralizing	O
epitopes	O
located	O
in	O
the	O
N	O
-	O
terminus	O
of	O
the	O
S2	O
glycoprotein	B-CHED
subunit	O
(	O
amino	B-CHED
acids	I-CHED
[	O
aa	O
]	O
744	O
-	O
759	O
,	O
747	O
-	O
774	O
and	O
/	O
or	O
756	O
-	O
771	O
).	O

TITLE	O
:	O
Potent	O
Inhibition	O
of	O
HIV	O
-	O
1	O
Replication	O
in	O
Resting	O
CD4	O
T	O
Cells	O
by	O
Resveratrol	B-CHED
and	O
Pterostilbene	B-CHED
.	O

Alone	O
,	O
resveratrol	B-CHED
does	O
not	O
inhibit	O
HIV	O
-	O
1	O
infection	O
of	O
activated	O
T	O
cells	O
,	O
but	O
it	O
does	O
synergize	O
with	O
nucleoside	B-CHED
reverse	B-CHED
transcriptase	I-CHED
inhibitors	I-CHED
in	O
these	O
cells	O
to	O
inhibit	O
reverse	O
transcription	O
.	O

Bacterial	O
identification	O
can	O
be	O
challenging	O
and	O
often	O
require	O
16	O
S	O
rRNA	B-CHED
and	O
MALDI	O
-	O
TOF	O
MS	O
.	O

The	O
patient	O
was	O
treated	O
with	O
amoxicillin	B-CHED
-	O
clavulanic	B-CHED
acid	I-CHED
according	O
to	O
sensitivity	O
and	O
made	O
significant	O
recovery	O
.	O

The	O
characteristics	O
and	O
outcomes	O
of	O
patients	O
receiving	O
PEG	B-CHED
concomitantly	O
with	O
a	O
tracheostomy	O
(	O
CTPEG	O
)	O
and	O
those	O
receiving	O
delayed	O
PEG	B-CHED
(	O
DPEG	O
)	O
after	O
a	O
tracheostomy	O
were	O
compared	O
.	O

In	O
this	O
study	O
,	O
we	O
focus	O
on	O
the	O
nsp14	O
protein	B-CHED
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
virus	O
replication	O
as	O
it	O
methylates	O
the	O
RNA	O
cap	O
structure	O
at	O
the	O
N7	O
position	O
of	O
the	O
guanine	B-CHED
.	O

TITLE	O
:	O
Restoration	O
of	O
Megalin	O
-	O
Mediated	O
Clearance	O
of	O
Alveolar	O
Protein	B-CHED
as	O
a	O
Novel	O
Therapeutic	O
Approach	O
for	O
Acute	O
Lung	O
Injury	O
.	O

Plants	O
can	O
provide	O
a	O
vast	O
source	O
of	O
active	O
natural	B-CHED
products	I-CHED
for	O
the	O
discovery	O
of	O
new	O
drugs	O
.	O

This	O
study	O
was	O
conducted	O
to	O
develop	O
a	O
drug	O
delivery	O
system	O
using	O
lipid	B-CHED
-	O
core	O
nanocapsules	O
(	O
LNCs	O
)	O
to	O
improve	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
orally	O
administered	O
	O
-	O
bis	O
.	O

	O
-	O
bis	O
-	O
loaded	O
LNCs	O
(	O
	O
-	O
bis	O
-	O
LNCs	O
)	O
were	O
prepared	O
by	O
interfacial	O
deposition	O
of	O
poly	O
(	O
	O
-	O
caprolactone	B-CHED
)	O
and	O
orally	O
administered	O
in	O
a	O
mouse	O
model	O
of	O
ARDS	O
triggered	O
by	O
an	O
intranasal	O
administration	O
of	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
).	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
MBL	O
bound	O
specifically	O
to	O
the	O
spike	O
S1	O
protein	B-CHED
of	O
IBV	O
which	O
mediates	O
viral	O
attachment	O
.	O

ABSTRACT	O
:	O
Travel	O
medicine	B-CHED
defines	O
all	O
diseases	O
and	O
medical	O
situations	O
that	O
are	O
related	O
to	O
travel	O
.	O

The	O
recombination	O
occurred	O
in	O
South	O
America	O
and	O
produced	O
two	O
viral	O
variants	O
that	O
have	O
retained	O
the	O
full	O
-	O
length	O
S1	O
sequences	O
of	O
the	O
parental	O
lineages	O
but	O
are	O
extremely	O
similar	O
in	O
the	O
rest	B-CHED
of	O
their	O
genomes	O
.	O

He	O
was	O
intubated	O
(	O
day	O
12	O
)	O
because	O
of	O
progressive	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
INF	O
-	O
2a	O
and	O
ribavirin	B-CHED
treatment	O
was	O
commenced	O
.	O

Gilts	O
fed	O
the	O
low	O
lysine	B-CHED
diet	O
had	O
lower	O
average	O
daily	O
gain	O
and	O
BW	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
but	O
not	O
fat	O
depth	O
:	O
LD	O
ratio	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Corona	B-CHED
Virus	O
Alert	O
Verification	O
In	O
Mirpur	O
,	O
Azad	O
Kashmir	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
NF	O
-	O
B	O
activity	O
by	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
nonstructural	O
protein	B-CHED
1	O
for	O
innate	O
immune	O
evasion	O
.	O

Of	O
the	O
total	O
of	O
22	O
viral	O
proteins	B-CHED
,	O
nine	O
proteins	B-CHED
were	O
identified	O
as	O
NF	O
-	O
B	O
antagonists	B-CHED
,	O
and	O
nsp1	O
was	O
the	O
most	O
potent	O
suppressor	O
of	O
proinflammatory	O
cytokines	O
.	O

Nine	O
days	O
after	O
ICU	O
admission	O
,	O
steroid	B-CHED
boluses	O
were	O
started	O
and	O
allowed	O
spectacular	O
clinical	O
and	O
biological	O
improvement	O
.	O

Identifying	O
clinically	O
important	O
allergen	B-CHED
sensitivities	O
is	O
useful	O
.	O

Other	O
controller	O
approaches	O
include	O
long	O
-	O
acting	O
muscarinic	B-CHED
antagonists	I-CHED
(	O
eg	O
,	O
tiotropium	O
),	O
and	O
biological	O
agents	O
directed	O
against	O
proteins	B-CHED
involved	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
(	O
eg	O
,	O
omalizumab	O
,	O
mepolizumab	O
,	O
reslizumab	O
).	O

ABSTRACT	O
:	O
A	O
70	O
-	O
year	O
-	O
old	O
,	O
immunocompromised	O
patient	O
presented	O
to	O
the	O
emergency	O
room	O
(	O
ER	O
)	O
five	O
weeks	O
after	O
she	O
was	O
started	O
on	O
clopidogrel	B-CHED
.	O

Four	O
nucleotide	B-CHED
sequences	O
displayed	O
the	O
highest	O
identity	O
(	O
94	O
.	O
1	O
-	O
95	O
.	O
1	O
%)	O
with	O
Bat	O
-	O
CoV	O
-	O
HKU5	O
from	O
Hong	O
Kong	O
.	O

By	O
presenting	O
this	O
case	O
,	O
we	O
will	O
explore	O
and	O
discuss	O
the	O
cardiopulmonary	O
effects	O
of	O
MDMA	B-CHED
intoxication	O
that	O
can	O
lead	O
to	O
a	O
rare	O
,	O
deleterious	O
complication	O
of	O
MDMA	B-CHED
intoxication	O
other	O
than	O
previously	O
reported	O
adverse	O
outcomes	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
SP4	O
is	O
a	O
promising	O
serological	O
testing	O
protein	B-CHED
for	O
use	O
in	O
the	O
field	O
.	O

Nucleotide	B-CHED
homologies	O
ranged	O
from	O
63	O
.	O
1	O
-	O
99	O
.	O
9	O
%	O
and	O
amino	B-CHED
acid	I-CHED
homologies	O
ranging	O
from	O
60	O
.	O
2	O
-	O
100	O
%.	O

Besides	O
the	O
biological	O
interest	O
behind	O
the	O
SARS	O
coronavirus	O
non	O
-	O
structural	O
protein	B-CHED
1	O
(	O
nsp1	O
,	O
117	O
amino	B-CHED
acids	I-CHED
),	O
this	O
study	O
model	O
has	O
two	O
structural	O
features	O
that	O
motivated	O
its	O
use	O
in	O
this	O
work	O
:	O
1	O
-	O
its	O
recombinant	O
production	O
is	O
dependent	O
on	O
the	O
temperature	O
,	O
with	O
greater	O
solubility	O
when	O
expressed	O
at	O
low	O
temperatures	O
.	O

We	O
used	O
non	O
-	O
denaturing	O
purification	O
conditions	O
that	O
allowed	O
the	O
characterization	O
of	O
polypeptide	B-CHED
chains	O
of	O
different	O
lengths	O
,	O
mimicking	O
the	O
landscape	O
of	O
the	O
cotranslational	O
fold	O
of	O
a	O
	O
-	O
barrel	O
,	O
and	O
avoiding	O
the	O
major	O
technical	O
hindrances	O
of	O
working	O
with	O
the	O
nascent	O
polypeptide	B-CHED
bound	O
to	O
the	O
ribosome	O
.	O

The	O
native	O
	O
-	O
helix	O
(	O
amino	B-CHED
acids	I-CHED
24	O
-	O
37	O
)	O
was	O
identified	O
as	O
a	O
transient	O
structure	O
(~	O
20	O
-	O
30	O
%	O
propensity	O
).	O

Our	O
comprehensive	O
analyses	O
support	O
the	O
idea	O
that	O
incomplete	O
polypeptide	B-CHED
chains	O
,	O
such	O
as	O
the	O
ones	O
of	O
nascent	O
proteins	B-CHED
much	O
earlier	O
than	O
the	O
end	O
of	O
the	O
translation	O
,	O
adopt	O
an	O
abundance	O
of	O
specific	O
transient	O
folds	O
,	O
instead	O
of	O
disordered	O
conformations	O
.	O

Further	O
whole	O
genome	O
sequencing	O
identified	O
12	O
or	O
14	O
amino	B-CHED
acid	I-CHED
changes	O
in	O
the	O
cell	O
-	O
adapted	O
DEL	O
strains	O
.	O

Furthermore	O
,	O
the	O
S	O
proteins	B-CHED
of	O
virulent	O
mouse	O
-	O
adapted	O
MERS	O
-	O
CoVs	O
acquired	O
a	O
CD9	O
-	O
dependent	O
cell	O
entry	O
character	O
,	O
suggesting	O
that	O
CD9	O
is	O
a	O
selective	O
agent	O
in	O
the	O
evolution	O
of	O
CoV	O
virulence	O
.	O

Only	O
3	O
/	O
51	O
of	O
isolates	O
(	O
5	O
.	O
9	O
%)	O
were	O
resistant	O
to	O
penicillin	B-CHED
.	O

The	O
mortality	O
and	O
complication	O
rates	O
of	O
VGS	O
BSI	B-CHED
were	O
comparable	O
to	O
other	O
studies	O
,	O
and	O
no	O
specific	O
risk	O
factor	O
of	O
shock	O
presence	O
could	O
be	O
identified	O
.	O

We	O
previously	O
reported	O
that	O
type	O
I	O
FCoV	O
is	O
closely	O
associated	O
with	O
cholesterol	B-CHED
throughout	O
the	O
viral	O
life	O
cycle	O
.	O

Surprisingly	O
,	O
the	O
antiviral	B-CHED
activity	O
of	O
U18666A	O
was	O
suppressed	O
by	O
the	O
histone	B-CHED
deacetylase	I-CHED
inhibitor	I-CHED
(	O
HDACi	B-CHED
),	O
Vorinostat	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
nucleotide	B-CHED
identities	O
within	O
IS	O
-	O
1494	O
-	O
like	O
group	O
ranged	O
between	O
98	O
.	O
86	O
-	O
100	O
%,	O
while	O
each	O
of	O
the	O
QX	O
,	O
Massachusetts	O
and	O
793	O
/	O
B	O
groups	O
were	O
98	O
.	O
05	O
-	O
100	O
%,	O
98	O
.	O
20	O
-	O
100	O
%	O
and	O
93	O
.	O
29	O
-	O
100	O
%	O
respectively	O
.	O

ABSTRACT	O
:	O
Amiodarone	B-CHED
-	O
induced	O
pulmonary	O
toxicity	O
(	O
APT	O
)	O
is	O
a	O
severe	O
side	O
effect	O
that	O
can	O
lead	O
to	O
lung	O
fibrosis	O
or	O
fatal	O
respiratory	O
failure	O
.	O

The	O
patient	O
also	O
presented	O
with	O
leukocytosis	O
,	O
elevated	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
)	O
levels	O
however	O
without	O
elevated	O
procalcitonin	O
(	O
PCT	O
)	O
concentrations	O
.	O

We	O
immediately	O
started	O
glucocorticoid	B-CHED
therapy	O
with	O
prednisolone	B-CHED
50	O
mg	O
/	O
d	O
for	O
five	O
days	O
.	O

Laboratory	O
results	O
show	O
increased	O
serum	O
creatinine	B-CHED
kinase	O
and	O
AST	O
.	O

Antiviral	B-CHED
effects	O
were	O
evident	O
after	O
S	O
proteolytic	O
cleavage	O
,	O
implying	O
that	O
lipid	B-CHED
conjugates	O
affixed	O
the	O
peptides	B-CHED
at	O
sites	O
of	O
protease	O
-	O
triggered	O
fusion	O
activation	O
.	O

Unlike	O
lipid	B-CHED
-	O
free	O
peptides	B-CHED
,	O
the	O
lipopeptides	B-CHED
suppressed	O
CoV	O
S	O
protein	B-CHED
-	O
directed	O
virus	O
entry	O
taking	O
place	O
within	O
endosomes	O
.	O

These	O
findings	O
suggest	O
that	O
lipidations	O
localize	O
antiviral	B-CHED
peptides	B-CHED
to	O
protease	O
-	O
rich	O
sites	O
of	O
CoV	O
fusion	O
,	O
thereby	O
protecting	O
cells	O
from	O
diverse	O
CoVs	O
.	O

As	O
in	O
other	O
coronaviruses	O
,	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
of	O
MERS	O
-	O
CoV	O
mediates	O
receptor	O
recognition	O
and	O
membrane	O
fusion	O
and	O
is	O
the	O
primary	O
target	O
of	O
the	O
humoral	O
immune	O
response	O
during	O
infection	O
.	O

The	O
assay	O
could	O
detect	O
CDV	B-CHED
,	O
but	O
did	O
not	O
show	O
cross	O
-	O
detection	O
of	O
canine	O
parvovirus	O
-	O
2	O
(	O
CPV	O
-	O
2	O
),	O
canine	O
coronavirus	O
(	O
CCoV	O
),	O
canine	O
parainfluenza	O
virus	O
(	O
CPIV	O
),	O
pseudorabies	O
virus	O
(	O
PRV	O
)	O
or	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
),	O
demonstrating	O
high	O
specificity	O
.	O

AMD3100	O
significantly	O
reduced	O
PaO	B-CHED

Following	O
intranasal	O
infection	O
,	O
rabbits	O
developed	O
a	O
transient	O
dose	O
-	O
dependent	O
pulmonary	O
infection	O
with	O
moderately	O
high	O
levels	O
of	O
viral	O
RNA	O
,	O
viral	O
antigen	B-CHED
,	O
and	O
perivascular	O
inflammation	O
in	O
multiple	O
lung	O
lobes	O
that	O
was	O
not	O
associated	O
with	O
clinical	O
signs	O
.	O

TITLE	O
:	O
Astragalus	O
polysaccharides	B-CHED
enhance	O
the	O
immune	O
response	O
to	O
avian	O
infectious	O
bronchitis	O
virus	O
vaccination	O
in	O
chickens	O
.	O

At	O
14	O
,	O
28	O
,	O
and	O
42	O
days	O
after	O
the	O
first	O
vaccination	O
,	O
serum	O
anti	O
-	O
IBV	O
antibody	O
titers	O
;	O
peripheral	O
lymphocyte	O
proliferation	O
;	O
and	O
the	O
mRNA	B-CHED
expression	O
of	O
IL	O
-	O
1	O
,	O
IL	O
-	O
2	O
,	O
IL	O
-	O
8	O
,	O
and	O
TNF	O
-	O
	O
in	O
the	O
spleen	O
were	O
assessed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
the	O
cell	O
counting	O
kit	O
-	O
8	O
(	O
CCK	O
-	O
8	O
),	O
and	O
real	O
time	O
quantitative	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
),	O
respectively	O
.	O

To	O
compare	O
the	O
effectiveness	O
of	O
antibiotics	B-CHED
versus	O
controls	O
(	O
placebo	O
or	O
no	O
treatment	O
)	O
for	O
reducing	O
or	O
treating	O
persistent	O
respiratory	O
symptoms	O
following	O
acute	O
bronchiolitis	O
within	O
six	O
months	O
of	O
acute	O
illness	O
.	O

The	O
most	O
significant	O
metabolic	O
disruptions	O
were	O
the	O
comprehensive	O
increase	O
of	O
phosphatidylinositol	B-CHED
and	O
lysophospha	O
tidylinositol	O
levels	O
in	O
recovered	O
SARS	O
patients	O
,	O
which	O
coincided	O
with	O
the	O
effect	O
of	O
methylprednisolone	B-CHED
administration	O
investigated	O
further	O
in	O
the	O
steroid	B-CHED
treated	O
non	O
-	O
SARS	O
patients	O
with	O
severe	O
pneumonia	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
natural	O
recombinant	O
transmissible	O
gastroenteritis	O
virus	O
between	O
Purdue	O
and	O
Miller	O
clusters	B-CHED
in	O
China	O
.	O

The	O
results	O
showed	O
that	O
some	O
cells	O
were	O
able	O
to	O
survive	O
the	O
infection	O
,	O
as	O
demonstrated	O
by	O
continued	O
tdTomato	O
expression	O
after	O
virus	O
antigen	B-CHED
could	O
no	O
longer	O
be	O
detected	O
.	O

Moreover	O
,	O
alleviation	O
of	O
PEDV	O
-	O
induced	O
cell	O
death	O
in	O
IPEC	O
-	O
J2	O
cells	O
pretreated	O
with	O
rapamycin	B-CHED
demonstrates	O
a	O
protective	O
effect	O
of	O
rapamycin	B-CHED
against	O
PEDV	O
-	O
induced	O
epithelial	O
cell	O
death	O
.	O

Based	O
on	O
analysis	O
of	O
partial	O
M	O
-	O
protein	B-CHED
gene	O
,	O
the	O
KNA	O
CCoV	O
strains	O
were	O
assigned	O
to	O
CCoV	O
-	O
I	O
genotype	O
,	O
and	O
were	O
closely	O
related	O
to	O
CCoV	O
-	O
I	O
strains	O
from	O
Brazil	O
.	O

TITLE	O
:	O
[	O
Development	O
and	O
application	O
of	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
S1	O
protein	B-CHED
-	O
based	O
indirect	O
ELISA	O
for	O
porcine	O
deltacoronavirus	O
].	O

ELISA	O
results	O
showed	O
that	O
nsp1	O
significantly	O
inhibited	O
the	O
expression	O
of	O
IFN	O
-	O
	O
in	O
protein	B-CHED
level	O
.	O

Moreover	O
,	O
A15	O
retained	O
good	O
inhibition	O
potency	O
against	O
three	O
non	O
-	O
nucleoside	B-CHED
RT	O
inhibitor	B-CHED
(	O
NNRTI	O
)-	O
resistant	O
enzymes	O
,	O
confirming	O
a	O
mode	O
of	O
action	O
unrelated	O
to	O
NNRTIs	O
and	O
suggesting	O
its	O
potential	O
as	O
a	O
lead	O
compound	O
for	O
development	O
of	O
new	O
HIV	O
-	O
1	O
RT	O
dual	O
inhibitors	B-CHED
active	O
against	O
drug	O
-	O
resistant	O
viruses	O
.	O

RESULTS	O
:	O
The	O
protective	B-CHED
group	I-CHED
displayed	O
lower	O
numbers	O
of	O
Pseudomonas	O
aeruginosa	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
lung	O
tissue	O
,	O
and	O
a	O
lower	O
wet	O
-	O
to	O
-	O
dry	O
ratio	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
than	O
the	O
control	O
group	O
.	O

The	O
control	O
group	O
deteriorated	O
in	O
arterial	O
oxygen	B-CHED
tension	O
/	O
inspired	O
oxygen	B-CHED
fraction	O
,	O
whereas	O
the	O
protective	B-CHED
group	I-CHED
was	O
unchanged	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

In	O
addition	O
,	O
we	O
propose	O
the	O
feasibility	O
of	O
developing	O
effective	O
agents	O
by	O
repurposing	O
the	O
existing	O
and	O
clinically	O
approved	O
anti	O
-	O
coronavirus	O
and	O
anti	O
-	O
viral	O
peptide	B-CHED
drugs	O
.	O

The	O
emergence	O
of	O
drug	O
-	O
resistant	O
strains	O
further	O
necessitates	O
the	O
development	O
of	O
novel	O
antivirals	B-CHED
that	O
target	O
the	O
host	O
factors	O
crucial	O
for	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
An	O
increasing	O
number	O
of	O
publications	O
describe	O
the	O
potential	O
of	O
ionic	B-CHED
liquids	I-CHED
(	O
ILs	O
)	O
as	O
novel	O
antimicrobials	B-CHED
,	O
antibacterial	O
coatings	O
and	O
even	O
as	O
active	O
pharmaceutical	B-CHED
ingredients	O
.	O

Although	O
cholesterol	B-CHED
is	O
known	O
to	O
affect	O
the	O
replication	O
of	O
a	O
broad	O
range	O
of	O
viruses	O
in	O
vitro	O
,	O
its	O
significance	O
and	O
role	O
in	O
porcine	O
nidovirus	O
infection	O
remains	O
to	O
be	O
elucidated	O
.	O

Furthermore	O
,	O
pharmacological	O
sequestration	O
of	O
cellular	O
cholesterol	B-CHED
efficiently	O
blocked	O
both	O
virus	O
attachment	O
and	O
internalization	O
and	O
,	O
accordingly	O
,	O
markedly	O
affected	O
subsequent	O
post	O
-	O
entry	O
steps	O
of	O
the	O
replication	O
cycle	O
,	O
including	O
viral	O
RNA	O
and	O
protein	B-CHED
biosynthesis	O
and	O
progeny	O
virus	O
production	O
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
cell	O
membrane	O
cholesterol	B-CHED
is	O
required	O
for	O
porcine	O
nidovirus	O
entry	O
into	O
cells	O
,	O
and	O
pharmacological	O
drugs	O
that	O
hamper	O
cholesterol	B-CHED
-	O
dependent	O
virus	O
entry	O
may	O
have	O
antiviral	B-CHED
potential	O
against	O
porcine	O
nidoviruses	O
.	O

However	O
,	O
its	O
uptake	O
in	O
the	O
case	O
of	O
adult	O
respiratory	O
failure	O
has	O
been	O
slow	O
because	O
of	O
a	O
paucity	O
of	O
quality	O
evidence	O
and	O
a	O
sluggish	O
tempo	B-CHED
of	O
ECLS	O
-	O
related	O
technological	O
advances	O
.	O

These	O
differences	O
were	O
also	O
observed	O
when	O
the	O
total	O
protein	B-CHED
levels	O
in	O
both	O
groups	O
were	O
compared	O
(	O
p	O
=	O
0	O
.	O
0081	O
).	O

The	O
results	O
reveal	O
that	O
the	O
three	O
IBV	O
isolates	O
mainly	O
exhibited	O
mutations	O
in	O
the	O
hypervariable	O
regions	O
(	O
HVRs	O
)	O
of	O
the	O
S1	O
gene	O
and	O
protein	B-CHED
,	O
but	O
were	O
phylogenetically	O
and	O
serologically	O
closely	O
related	O
,	O
belonging	O
to	O
lineage	O
11	O
of	O
the	O
GI	O
genotype	O
,	O
the	O
former	O
BR	O
genotype	O
I	O
.	O
All	O
three	O
isolates	O
caused	O
persistent	O
infection	O
in	O
broiler	O
breeders	O
reared	O
in	O
the	O
field	O
,	O
despite	O
high	O
systemic	O
anti	O
-	O
IBV	O
antibody	O
titres	O
,	O
and	O
exhibited	O
tropism	O
and	O
pathogenicity	O
for	O
the	O
trachea	O
and	O
kidney	O
after	O
experimental	O
infection	O
in	O
SPF	O
chickens	O
and	O
contact	O
birds	O
.	O

TITLE	O
:	O
Efficacy	O
of	O
a	O
3C	O
-	O
like	O
protease	B-CHED
inhibitor	I-CHED
in	O
treating	O
various	O
forms	O
of	O
acquired	O
feline	O
infectious	O
peritonitis	O
.	O

The	O
continual	O
outbreaks	O
of	O
MERS	O
-	O
CoV	O
highlight	O
the	O
importance	O
of	O
developing	O
antiviral	B-CHED
therapeutics	O
.	O

Here	O
,	O
we	O
rationally	O
designed	O
a	O
novel	O
fusion	O
inhibitor	B-CHED
named	O
MERS	O
-	O
five	O
-	O
helix	O
bundle	O
(	O
MERS	O
-	O
5HB	O
)	O
derived	O
from	O
the	O
six	O
-	O
helix	O
bundle	O
(	O
MERS	O
-	O
6HB	O
)	O
which	O
was	O
formed	O
by	O
the	O
process	O
of	O
membrane	O
fusion	O
.	O

Sixteen	O
substitutions	O
resulted	O
in	O
amino	B-CHED
acid	I-CHED
coding	O
changes	O
of	O
which	O
half	O
were	O
in	O
spike	O
.	O

One	O
change	O
in	O
the	O
1b	O
gene	O
altered	O
the	O
normally	O
highly	O
conserved	O
final	O
5	O
nucleotides	B-CHED
of	O
the	O
transcription	O
regulatory	O
sequence	O
of	O
the	O
S	O
gene	O
,	O
common	O
to	O
all	O
IBV	O
QX	O
genes	O
.	O

Most	O
patients	O
received	O
NAIs	O
and	O
85	O
.	O
9	O
%	O
received	O
antibiotics	B-CHED
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
analyze	O
the	O
variations	O
of	O
non	O
-	O
enzymatic	O
antioxidants	B-CHED
in	O
plasma	O
during	O
veno	O
-	O
venous	O
ECMO	O
-	O
treatment	O
in	O
a	O
homogeneous	O
population	O
of	O
critical	O
patients	O
with	O
ARDS	O
.	O

TITLE	O
:	O
Identification	O
of	O
sialic	B-CHED
acid	I-CHED
-	O
binding	O
function	O
for	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
glycoprotein	B-CHED
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
ratio	O
of	O
partial	O
arterial	O
oxygen	B-CHED
pressure	O
to	O
the	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
between	O
the	O
two	O
groups	O
[	O
WMD	O
,	O
54	O
.	O
34	O
;	O
95	O
%	O
CI	O
:	O
(-	O
30	O
.	O
50	O
to	O
139	O
.	O
17	O
);	O
P	O
=	O
0	O
.	O
21	O
].	O

This	O
activity	O
is	O
in	O
addition	O
to	O
its	O
viral	O
polypeptide	B-CHED
cleavage	O
function	O
.	O

A	O
multispecialty	O
task	O
force	O
of	O
16	O
international	O
experts	O
in	O
critical	O
care	O
medicine	B-CHED
,	O
endocrinology	O
,	O
and	O
guideline	O
methods	O
,	O
all	O
of	O
them	O
members	O
of	O
the	O
Society	O
of	O
Critical	O
Care	O
Medicine	B-CHED
and	O
/	O
or	O
the	O
European	O
Society	O
of	O
Intensive	O
Care	O
Medicine	B-CHED
.	O

Evidence	O
-	O
based	O
recommendations	O
for	O
the	O
use	O
of	O
corticosteroids	B-CHED
in	O
critically	O
ill	O
patients	O
with	O
sepsis	O
and	O
septic	O
shock	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
major	O
trauma	O
have	O
been	O
developed	O
by	O
a	O
multispecialty	O
task	O
force	O
.	O

Early	O
recognition	O
and	O
antiviral	B-CHED
therapy	O
is	O
important	O
to	O
reduce	O
morbidity	O
and	O
mortality	O
.	O

Genomic	O
comparison	O
showed	O
that	O
these	O
two	O
viruses	O
share	O
the	O
highest	O
nucleotide	B-CHED
identities	O
(	O
99	O
.	O
10	O
%	O
and	O
98	O
.	O
79	O
%)	O
with	O
the	O
2011	O
ZMDZY	O
strain	O
,	O
but	O
only	O
96	O
.	O
65	O
%	O
and	O
96	O
.	O
50	O
%	O
nucleotide	B-CHED
identities	O
with	O
the	O
attenuated	O
CV777	O
strain	O
.	O

The	O
level	O
of	O
serum	O
zinc	B-CHED
was	O
increased	O
,	O
but	O
FVC	O
,	O
FEV1	O
,	O
and	O
TLC	O
was	O
decreased	O
significantly	O
in	O
the	O
moderate	O
and	O
severe	O
cases	O
.	O

ABSTRACT	O
:	O
Porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
(	O
PHEV	O
)	O
is	O
a	O
highly	O
neurovirulent	O
coronavirus	O
that	O
invades	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
in	O
piglets	O
.	O

Quantification	O
of	O
infected	O
cells	O
showed	O
that	O
PHEV	O
enters	O
cells	O
by	O
clathrin	O
-	O
mediated	O
endocytosis	O
(	O
CME	O
)	O
and	O
that	O
low	O
pH	O
,	O
dynamin	O
,	O
cholesterol	B-CHED
,	O
and	O
Eps15	O
are	O
indispensably	O
involved	O
in	O
this	O
process	O
.	O

Our	O
findings	O
demonstrate	O
that	O
PHEV	O
hijacks	O
the	O
CME	O
and	O
endosomal	O
system	O
of	O
the	O
host	O
to	O
enter	O
and	O
traffic	O
within	O
neural	O
cells	O
,	O
providing	O
new	O
insights	O
into	O
PHEV	O
pathogenesis	O
and	O
guidance	O
for	O
antiviral	B-CHED
drug	I-CHED
design	O
.	O

Regarding	O
the	O
deduced	O
amino	B-CHED
acid	I-CHED
sequence	O
,	O
the	O
three	O
variants	O
had	O
77	O
.	O
1	O
%-	O
85	O
.	O
2	O
%	O
similarity	O
with	O
the	O
vaccine	O
strains	O
currently	O
used	O
in	O
Egypt	O
.	O

Role	O
of	O
lnc	O
-	O
IL7R	O
as	O
potential	O
biomarker	B-CHED
in	O
ARDS	O
.	O

During	O
MHFPPV	O
set	O
with	O
RR	O
of	O
60	O
bpm	O
delivered	O
by	O
a	O
conventional	O
ventilator	O
in	O
severe	O
ARDS	O
swine	O
model	O
,	O
neither	O
the	O
inspiratory	O
pauses	O
or	O
PEEP	B-CHED
titration	O
after	O
recruitment	O
maneuver	O
allowed	O
reduction	O
of	O
VT	O
significantly	O
,	O
however	O
the	O
last	O
strategy	O
decreased	O
driving	O
pressures	O
and	O
improved	O
both	O
shunt	O
and	O
dead	O
space	O
.	O

stigmatosoma	O
,	O
collected	O
from	O
30	O
sites	O
in	O
southern	O
California	O
from	O
2009	O
-	O
2012	O
,	O
were	O
processed	O
for	O
vertebrate	O
host	O
identification	O
by	O
nucleotide	B-CHED
sequencing	O
following	O
polymerase	O
chain	O
reaction	O
to	O
amplify	O
portions	O
of	O
the	O
cytochrome	B-CHED
oxidase	O
I	O
and	O
cytochrome	B-CHED
b	I-CHED
genes	O
of	O
vertebrate	O
animals	O
.	O

TITLE	O
:	O
Lianqinjiedu	O
decoction	O
attenuates	O
LPS	B-CHED
-	O
induced	O
inflammation	O
and	O
acute	O
lung	O
injury	O
in	O
rats	O
via	O
TLR4	O
/	O
NF	O
-	O
B	O
pathway	O
.	O

These	O
mesosized	O
proteins	B-CHED
,	O
lying	O
between	O
conventional	O
proteins	B-CHED
and	O
small	O
peptides	B-CHED
,	O
are	O
easily	O
accessible	O
either	O
through	O
biosynthetic	O
precursors	O
or	O
chemical	O
synthesis	O
.	O

The	O
relative	O
haemoglobin	B-CHED
,	O
local	O
oxygen	B-CHED
consumption	O
,	O
and	O
saturation	O
values	O
in	O
the	O
microcirculation	O
were	O
observed	O
significantly	O
lower	O
during	O
shock	O
,	O
however	O
,	O
no	O
changes	O
in	O
the	O
microcirculatory	O
blood	O
flow	O
and	O
microcirculatory	O
oxygen	B-CHED
delivery	O
were	O
observed	O
.	O

The	O
median	O
arterial	O
oxygen	B-CHED
partial	O
pressure	O
to	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
ratio	O
was	O
62	O
.	O
5	O
,	O
and	O
the	O
median	O
RESP	O
score	O
was	O
6	O
.	O

Cats	O
were	O
categorised	O
as	O
with	O
FIP	O
(	O
n	O
=	O
57	O
)	O
or	O
without	O
FIP	O
(	O
n	O
=	O
45	O
)	O
based	O
on	O
gross	O
post	O
-	O
mortem	O
and	O
histopathological	O
examination	O
including	O
immunohistochemistry	O
for	O
FCoV	O
antigen	B-CHED
.	O

Glycan	B-CHED
receptor	O
-	O
binding	O
sites	O
are	O
typically	O
located	O
in	O
exposed	O
regions	O
on	O
viral	O
surfaces	O
-	O
sites	O
that	O
are	O
also	O
generally	O
prone	O
to	O
binding	O
of	O
neutralizing	O
antibodies	O
that	O
directly	O
interfere	O
with	O
virus	O
-	O
glycan	B-CHED
receptor	O
interactions	O
.	O

In	O
this	O
review	O
,	O
we	O
examine	O
the	O
locations	O
and	O
architecture	O
of	O
the	O
glycan	B-CHED
-	O
and	O
antibody	O
-	O
binding	O
sites	O
in	O
four	O
different	O
viruses	O
with	O
stalk	O
-	O
like	O
attachment	O
proteins	B-CHED
(	O
reovirus	O
,	O
influenza	O
virus	O
,	O
norovirus	O
,	O
and	O
coronavirus	O
)	O
and	O
investigate	O
the	O
mechanisms	O
by	O
which	O
antibodies	O
block	O
glycan	B-CHED
recognition	O
.	O

Those	O
viruses	O
exemplify	O
that	O
direct	O
molecular	O
mimicking	O
of	O
glycan	B-CHED
receptors	O
by	O
antibodies	O
is	O
rare	O
and	O
further	O
demonstrate	O
that	O
antibodies	O
often	O
partly	O
overlap	O
or	O
bind	O
sufficiently	O
close	O
to	O
the	O
receptor	O
-	O
binding	O
region	O
to	O
hinder	O
access	O
to	O
this	O
site	O
,	O
achieving	O
neutralization	O
partially	O
because	O
of	O
the	O
epitope	B-CHED
location	O
and	O
partly	O
due	O
to	O
their	O
sheer	O
size	O
.	O

The	O
present	O
study	O
aimed	O
to	O
develop	O
an	O
immunochromatographic	O
assay	O
(	O
ICA	B-CHED
)	O
strip	O
test	O
for	O
detecting	O
PEDV	O
in	O
faecal	O
swabs	O
.	O

DPP4	O
expression	O
was	O
measured	O
in	O
lung	O
tissue	O
of	O
lung	O
resection	O
specimens	O
of	O
never	O
-	O
smokers	O
,	O
smokers	O
without	O
airflow	O
limitation	O
,	O
COPD	O
GOLD	B-CHED
stage	O
II	O
patients	O
and	O
in	O
lung	O
explants	O
of	O
end	O
-	O
stage	O
COPD	O
patients	O
.	O

Release	O
assay	O
in	O
vitro	O
showed	O
that	O
both	O
NDV	O
and	O
IBV	O
could	O
be	O
sustainably	O
released	O
from	O
the	O
nanoparticles	B-CHED
after	O
an	O
initial	O
burst	O
release	O
.	O

This	O
study	O
indicated	O
that	O
N	O
-	O
2	O
-	O
HACC	O
-	O
CMC	O
could	O
be	O
used	O
as	O
an	O
efficient	O
adjuvant	B-CHED
and	O
delivery	O
carrier	O
for	O
further	O
development	O
of	O
mucosal	O
vaccines	O
and	O
drugs	O
and	O
could	O
have	O
an	O
immense	O
application	O
potential	O
in	O
medicine	B-CHED
.	O

Thus	O
,	O
admitted	O
patients	O
are	O
potentially	O
manageable	O
with	O
Oseltamivir	B-CHED
or	O
Zanamivir	B-CHED
therapy	O
.	O

Among	O
these	O
sites	O
,	O
8	O
sites	O
were	O
confirmed	O
in	O
the	O
S	O
protein	B-CHED
extracted	O
from	O
partially	O
purified	O
virus	O
particles	O
by	O
proteomics	O
approaches	O
.	O

The	O
impact	O
on	O
S	O
protein	B-CHED
-	O
mediated	O
cell	O
-	O
cell	O
fusion	O
,	O
viral	O
recovery	O
and	O
infectivity	O
was	O
assessed	O
,	O
leading	O
to	O
the	O
identification	O
of	O
sites	O
essential	O
for	O
the	O
functions	O
of	O
IBV	O
S	O
protein	B-CHED
.	O

Medications	O
administered	O
(	O
sedative	B-CHED
,	O
analgesic	B-CHED
,	O
paralytic	O
,	O
and	O
antipsychotic	O
),	O
sedation	O
depth	O
(	O
Sedation	O
Agitation	O
Scale	O
[	O
SAS	O
]	O
score	O
)	O
delirium	O
assessments	O
,	O
and	O
mobilization	O
were	O
recorded	O
daily	O
.	O

After	O
ECMO	O
initiation	O
,	O
96	O
%	O
patients	O
were	O
deeply	O
sedated	O
(	O
SAS	O
score	O
<	O
3	O
)	O
with	O
continuous	O
infusions	O
of	O
midazolam	O
(	O
49	O
%),	O
propofol	B-CHED
(	O
18	O
%),	O
or	O
both	O
(	O
29	O
%)	O
and	O
98	O
%	O
were	O
receiving	O
opioid	O
infusions	O
(	O
93	O
%	O
fentanyl	B-CHED
).	O

TITLE	O
:	O
ROS	B-CHED
Signaling	O
in	O
the	O
Pathogenesis	O
of	O
Acute	O
Lung	O
Injury	O
(	O
ALI	O
)	O
and	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
).	O

Further	O
research	O
to	O
generate	O
robust	O
evidence	O
and	O
repeated	O
HCP	B-CHED
trainings	O
are	O
necessary	O
to	O
ensure	O
HCP	B-CHED
and	O
patient	O
safety	O
in	O
future	O
outbreaks	O
.	O

This	O
study	O
characterized	O
the	O
ocular	O
lesions	O
of	O
FIP	O
including	O
the	O
expression	O
of	O
glial	O
fibrillary	O
acidic	O
protein	B-CHED
and	O
proliferating	O
cell	O
nuclear	O
antigen	B-CHED
by	O
Mller	O
cells	O
in	O
the	O
retina	O
in	O
cases	O
of	O
FIP	O
and	O
to	O
what	O
extent	O
macrophages	O
are	O
involved	O
in	O
ocular	O
inflammation	O
in	O
FIP	O
.	O

IBV	O
titres	O
in	O
the	O
supernatant	O
were	O
significantly	O
increased	O
when	O
CD59	O
proteins	B-CHED
were	O
overexpressed	O
in	O
cells	O
followed	O
by	O
IBV	O
infection	O
,	O
and	O
this	O
observation	O
was	O
further	O
supported	O
by	O
knockdown	O
or	O
cleavage	O
of	O
CD59	O
.	O

Furthermore	O
,	O
dendritic	O
cells	O
(	O
DCs	O
),	O
professional	O
antigen	B-CHED
-	O
presenting	O
cells	O
,	O
link	O
humoral	O
and	O
cellular	O
immune	O
responses	O
for	O
homeostasis	O
of	O
the	O
intestinal	O
immune	O
environment	O
.	O

Here	O
,	O
we	O
determined	O
the	O
cryo	O
-	O
electron	O
microscopy	O
structure	O
of	O
porcine	O
deltacoronavirus	O
(	O
PdCoV	O
)	O
spike	O
protein	B-CHED
at	O
3	O
.	O
3	O
-	O
	O
resolution	O
.	O

Many	O
different	O
vaccination	O
protocols	O
are	O
applied	O
in	O
the	O
same	O
region	O
and	O
even	O
in	O
consecutive	O
cycles	O
on	O
the	O
same	O
farm	O
in	O
order	O
to	O
find	O
the	O
perfect	O
balance	B-CHED
between	O
costs	O
and	O
benefits	O
.	O

In	O
the	O
combined	O
data	O
set	O
of	O
IBV	O
challenged	O
shell	O
gland	O
samples	O
,	O
the	O
comprehensive	O
ranking	O
showed	O
TATA	O
-	O
box	O
binding	O
protein	B-CHED
(	O
TBP	B-CHED
)	O
and	O
tyrosine	B-CHED
3	O
-	O
monooxygenase	O
/	O
tryptophan	B-CHED
5	O
-	O
monooxygenase	O
activation	O
protein	B-CHED
zeta	O
(	O
YWHAZ	O
)	O
as	O
the	O
two	O
most	O
stable	O
,	O
and	O
succinate	O
dehydrogenase	O
complex	O
flavoprotein	B-CHED
subunit	O
A	O
(	O
SDHA	O
)	O
and	O
albumin	O
(	O
ALB	O
)	O
as	O
the	O
two	O
least	O
stable	O
reference	O
genes	O
.	O

ChAd	O
vectors	O
are	O
safe	O
and	O
induce	O
antigen	B-CHED
-	O
specific	O
cellular	O
and	O
humoral	O
immunity	O
in	O
all	O
age	O
groups	O
,	O
as	O
well	O
as	O
circumventing	O
the	O
problem	O
of	O
pre	O
-	O
existing	O
immunity	O
encountered	O
with	O
human	O
Ad	O
vectors	O
.	O

LCMS	O
/	O
MS	O
coupled	O
to	O
isobaric	O
tags	O
for	O
relative	O
and	O
absolute	O
quantification	O
(	O
iTRAQ	O
)	O
is	O
used	O
to	O
profile	O
expressed	O
proteins	B-CHED
in	O
IPEC	O
-	O
J2	O
cells	O
infected	O
by	O
TGEV	O
alone	O
,	O
ETEC	O
K88	O
alone	O
,	O
and	O
by	O
both	O
agents	O
together	O
.	O

Oxalate	O
,	O
a	O
well	O
-	O
known	O
metabolite	B-CHED
of	O
vitamin	B-CHED
C	I-CHED
,	O
is	O
excreted	O
by	O
the	O
kidneys	O
and	O
can	O
exert	O
a	O
toxic	O
effect	O
on	O
epithelial	O
cells	O
and	O
causes	O
direct	O
tubular	O
damage	O
,	O
and	O
/	O
or	O
it	O
can	O
crystallize	O
within	O
the	O
tubular	O
lumen	O
.	O

CONCLUSIONS	O
:	O
Compelling	O
evidence	O
obtained	O
from	O
in	O
-	O
vitro	O
and	O
animal	O
studies	O
suggest	O
that	O
vitamin	B-CHED
C	I-CHED
,	O
a	O
circulating	O
antioxidant	B-CHED
,	O
may	O
be	O
a	O
valuable	O
adjunctive	O
therapy	O
in	O
critically	O
-	O
ill	O
patients	O
.	O

The	O
S	O
protein	B-CHED
is	O
a	O
major	O
determinant	O
of	O
the	O
zoonotic	O
potential	O
of	O
coronaviruses	O
and	O
is	O
also	O
the	O
main	O
target	O
of	O
the	O
host	O
humoral	O
immune	O
response	O
.	O

Complete	O
genomic	O
sequencing	O
and	O
analyses	O
of	O
SeACoV	O
indicated	O
that	O
the	O
extreme	O
amino	O
-	O
terminal	O
domain	O
of	O
the	O
SeACoV	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
structurally	O
similar	O
to	O
the	O
domain	O
0	O
of	O
the	O
alphacoronavirus	O
NL63	O
,	O
whereas	O
the	O
rest	B-CHED
part	O
of	O
S	O
structurally	O
resembles	O
domains	O
B	O
to	O
D	O
of	O
the	O
betacoronavirus	O
.	O

Virus	O
shedding	O
,	O
acute	O
phase	O
protein	B-CHED
responses	O
and	O
serological	O
responses	O
were	O
comparable	O
to	O
those	O
seen	O
after	O
experimental	O
challenge	O
with	O
a	O
Danish	O
PRRSV	O
-	O
2	O
reference	O
strain	O
isolated	O
in	O
1997	O
.	O

WHO	O
published	O
recommendations	O
for	O
oxygen	B-CHED
therapy	O
based	O
on	O
clinical	O
signs	O
which	O
state	O
that	O
,	O
when	O
oxygen	B-CHED
is	O
plentiful	O
,	O
it	O
should	O
be	O
given	O
to	O
children	O
with	O
central	O
cyanosis	O
,	O
inability	O
to	O
drink	O
,	O
severe	O
chest	O
indrawing	O
,	O
RR	O
>	O
70	O
breaths	O
/	O
min	O
,	O
grunting	O
with	O
every	O
breath	O
(	O
in	O
young	O
infants	O
)	O
or	O
those	O
who	O
display	O
head	O
nodding	O
.	O

Herein	O
,	O
a	O
neuraminidase	B-CHED
inhibitor	I-CHED
11b	O
absent	O
of	O
basic	O
moieties	O
was	O
discovered	O
in	O
the	O
process	O
of	O
searching	O
for	O
inhibitors	B-CHED
targeting	O
150	O
cavity	O
.	O

CoVs	O
encode	O
a	O
proofreading	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	O
within	O
nonstructural	O
protein	B-CHED
14	O
(	O
nsp14	O
-	O
ExoN	O
)	O
that	O
is	O
responsible	O
for	O
CoV	O
high	O
-	O
fidelity	O
replication	O
.	O

Therefore	O
,	O
it	O
may	O
be	O
hypothesized	O
that	O
mechanisms	O
of	O
NRDS	O
involving	O
surfactant	B-CHED
exert	O
additional	O
functions	O
to	O
promoting	O
alveolar	O
inflation	O
.	O

TITLE	O
:	O
Diversity	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronaviruses	O
in	O
109	O
dromedary	O
camels	O
based	O
on	O
full	O
-	O
genome	O
sequencing	O
,	O
Abu	B-CHED
Dhabi	O
,	O
United	O
Arab	O
Emirates	O
.	O

A	O
total	O
of	O
197	O
Japanese	O
patients	O
with	O
ARDS	O
diagnosed	O
by	O
the	O
Berlin	O
definition	O
who	O
were	O
admitted	O
to	O
the	O
Division	O
of	O
Respiratory	O
Medicine	B-CHED
from	O
October	O
2004	O
to	O
December	O
2015	O
were	O
enrolled	O
in	O
the	O
study	O
and	O
were	O
classified	O
as	O
two	O
groups	O
according	O
to	O
their	O
causes	O
:	O
a	O
drug	O
-	O
associated	O
ARDS	O
group	O
(	O
n	O
=	O
27	O
)	O
and	O
a	O
non	O
-	O
drug	O
-	O
associated	O
ARDS	O
group	O
(	O
n	O
=	O
170	O
).	O

However	O
,	O
eight	O
domains	O
of	O
Nsp3	O
exist	O
in	O
all	O
known	O
CoVs	O
:	O
the	O
ubiquitin	O
-	O
like	O
domain	O
1	O
(	O
Ubl1	O
),	O
the	O
Glu	B-CHED
-	O
rich	O
acidic	O
domain	O
(	O
also	O
called	O
""""	O
hypervariable	O
region	O
"""),"	O
a	O
macrodomain	O
(	O
also	O
named	O
""""	O
X	O
domain	O
"""),"	O
the	O
ubiquitin	O
-	O
like	O
domain	O
2	O
(	O
Ubl2	O
),	O
the	O
papain	O
-	O
like	O
protease	O
2	O
(	O
PL2	O

Secondary	O
endpoints	O
include	O
:	O
all	O
-	O
cause	O
mortality	O
at	O
28	O
,	O
90	O
,	O
180	O
and	O
360	O
days	O
;	O
organ	O
failure	O
-	O
free	O
days	O
;	O
length	O
of	O
hospital	O
stay	O
;	O
pharmacodynamic	O
assessment	O
including	O
measurement	O
of	O
myxovirus	O
resistance	O
protein	B-CHED
A	O
concentrations	O
;	O
and	O
measures	O
of	O
quality	O
of	O
life	O
,	O
respiratory	O
and	O
neurological	O
function	O
at	O
180	O
and	O
360	O
days	O
.	O

TITLE	O
:	O
Intensive	O
care	O
in	O
severe	O
malaria	O
:	O
Report	O
from	O
the	O
task	O
force	O
on	O
tropical	O
diseases	O
by	O
the	O
World	O
Federation	O
of	O
Societies	O
of	O
Intensive	O
and	O
Critical	O
Care	O
Medicine	B-CHED
.	O

The	O
drugs	O
we	O
discuss	O
belong	O
to	O
a	O
wide	O
range	O
of	O
different	O
drug	O
classes	O
,	O
such	O
as	O
cancer	O
therapeutics	O
,	O
antipsychotics	B-CHED
,	O
and	O
antimalarials	B-CHED
.	O

In	O
addition	O
,	O
samples	O
were	O
screened	O
for	O
the	O
presence	O
of	O
Streptococcus	O
pneumoniae	O
16S	B-CHED
rDNA	O
using	O
real	O
-	O
time	O
PCR	O
.	O

However	O
,	O
only	O
53	O
samples	O
had	O
a	O
concentration	O
of	O
C	O
-	O
reactive	O
protein	B-CHED
from	O
equal	O
to	O
higher	O
than	O
20	O
milligrams	O
per	O
liter	O
,	O
and	O
6	O
of	O
them	O
were	O
single	O
positive	O
for	O
Streptocuccus	O
pneumoniae	O
.	O

In	O
these	O
situations	O
,	O
establishing	O
an	O
extracorporeal	O
circuit	O
,	O
combining	O
a	O
centrifugal	O
pump	O
and	O
a	O
membrane	O
oxygenator	O
(	O
extra	O
-	O
corporeal	O
membrane	O
oxygenation	O
,	O
ECMO	O
),	O
can	O
ensure	O
total	O
pulmonary	O
assistance	O
and	O
allow	O
the	O
lungs	O
to	O
rest	B-CHED
under	O
ultraprotective	O
mechanical	O
ventilation	O
.	O

Antihistamine	B-CHED
and	O
epinephrine	B-CHED
were	O
required	O
and	O
symptom	O
resolution	O
occurred	O
.	O

The	O
APACHE	O
II	O
score	O
,	O
serum	O
levels	O
of	O
procalcitonin	O
(	O
PCT	O
)	O
and	O
brain	O
natriuretic	O
peptide	B-CHED
(	O
BNP	B-CHED
),	O
serum	O
creatinine	B-CHED
(	O
SCr	B-CHED
),	O
daily	O
tacrolimus	B-CHED
dose	O
,	O
and	O
NIV	O
support	O
condition	O
in	O
NIV	O
failure	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
NIV	O
success	O
group	O
[	O
APACHE	O
II	O
score	O
:	O
16	O
.	O
7	O
	O
5	O
.	O
7	O
vs	O
.	O
10	O
.	O
3	O
	O
2	O
.	O
1	O
,	O
PCT	O
(	O
g	O
/	O
L	O
):	O
32	O
.	O
8	O
(	O
1	O
.	O
2	O
,	O
187	O
.	O
7	O
)	O
vs	O
.	O
0	O
.	O
3	O
(	O
0	O
.	O
1	O
,	O
2	O
.	O
9	O
),	O
BNP	B-CHED
(	O
ng	O
/	O
L	O
):	O
832	O
.	O
4	O
(	O
263	O
.	O
7	O
,	O
1	O
180	O
.	O
2	O
)	O
vs	O
.	O
157	O
.	O
0	O
(	O
33	O
.	O
9	O
,	O
218	O
.	O
5	O
),	O
SCr	B-CHED
(	O
mol	O
/	O
L	O
):	O
284	O
.	O
8	O
(	O
90	O
.	O
5	O
,	O
474	O
.	O
2	O
)	O
vs	O
.	O
186	O
.	O
6	O
(	O
76	O
.	O
7	O
,	O
206	O
.	O
3	O
),	O
daily	O
tacrolimus	B-CHED
dose	O
(	O
mg	O
):	O
3	O
.	O
6	O
(	O
3	O
.	O
1	O
,	O
4	O
.	O
0	O
)	O
vs	O
.	O
2	O
.	O
6	O
(	O
2	O
.	O
0	O
,	O
3	O
.	O
5	O
),	O
inspiratory	O
positive	O
airway	O
pressure	O
(	O
IPAP	O
,	O
cmH	B-CHED

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
encode	O
a	O
mixture	B-CHED
of	O
highly	O
conserved	O
and	O
novel	O
genes	O
,	O
as	O
well	O
as	O
genetic	O
elements	O
necessary	O
for	O
infection	O
and	O
pathogenesis	O
,	O
raising	O
the	O
possibility	O
of	O
common	O
targets	O
for	O
attenuation	O
and	O
therapeutic	O
design	O
.	O

Of	O
the	O
333	O
HCP	B-CHED
who	O
participated	O
in	O
MERS	O
patient	O
care	O
,	O
35	O
HCP	B-CHED
(	O
10	O
.	O
5	O
%)	O
visited	O
the	O
MSC	O
for	O
MERS	O
-	O
like	O
symptoms	O
.	O

Although	O
a	O
considerable	O
number	O
of	O
HCP	B-CHED
experienced	O
MERS	O
-	O
related	O
symptoms	O
or	O
unprotected	O
exposure	O
during	O
MERS	O
patient	O
care	O
,	O
some	O
did	O
not	O
take	O
appropriate	O
action	O
.	O

These	O
findings	O
imply	O
that	O
for	O
infection	O
control	O
strategy	O
to	O
be	O
properly	O
performed	O
,	O
education	O
should	O
be	O
strengthened	O
so	O
that	O
HCP	B-CHED
can	O
accurately	O
recognize	O
the	O
risk	O
situation	O
and	O
properly	O
notify	O
the	O
infection	O
control	O
officer	O
.	O

To	O
investigate	O
the	O
association	O
of	O
corticosteroid	B-CHED
therapy	O
on	O
mortality	O
and	O
on	O
MERS	O
coronavirus	O
RNA	O
clearance	O
in	O
critically	O
ill	O
patients	O
with	O
MERS	O
.	O

Updates	O
were	O
also	O
given	O
on	O
the	O
use	O
of	O
the	O
currently	O
licensed	O
neuraminidase	B-CHED
inhibitors	I-CHED
.	O

Addition	O
of	O
the	O
third	O
MERS	O
-	O
CoV	O
transmembrane	O
protein	B-CHED
,	O
nsp6	O
,	O
did	O
not	O
noticeably	O
affect	O
DMV	O
formation	O
.	O

TITLE	O
:	O
Interleukin	O
-	O
36	O
and	O
IL	O
-	O
36	O
receptor	O
signaling	O
mediate	O
impaired	O
host	O
immunity	O
and	O
lung	O
injury	O
in	O
cytotoxic	O
Pseudomonas	O
aeruginosa	O
pulmonary	O
infection	O
:	O
Role	O
of	O
prostaglandin	B-CHED
E2	I-CHED
.	O

IL	O
-	O
36	O
and	O
IL	O
-	O
36	O
were	O
expressed	O
in	O
pulmonary	O
macrophages	O
(	O
PMs	B-CHED
)	O
and	O
alveolar	O
epithelial	O
cells	O
in	O
response	O
to	O
P	O
.	O
aeruginosa	O
in	O
vitro	O
.	O

We	O
therefore	O
evaluated	O
clinical	O
and	O
microbiological	O
factors	O
associated	O
with	O
the	O
presence	O
of	O
GI	O
symptoms	O
in	O
patients	O
consulting	O
a	O
general	O
practitioner	O
(	O
GP	O
)	O
for	O
ARI	B-CHED
.	O

The	O
presence	O
of	O
GI	O
symptoms	O
in	O
ARI	B-CHED
patients	O
could	O
not	O
be	O
explained	O
by	O
the	O
detection	O
of	O
respiratory	O
pathogens	O
in	O
stools	O
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
whether	O
APS	B-CHED
had	O
the	O
potential	O
to	O
inhibit	O
IBV	O
infectionby	O
utilizing	O
several	O
in	O
vitro	O
experimental	O
approaches	O
.	O

To	O
this	O
end	O
,	O
the	O
effect	O
of	O
APS	B-CHED
on	O
the	O
replication	O
of	O
IBV	O
was	O
examined	O
in	O
chicken	O
embryo	O
kidney	O
(	O
CEK	O
)	O
cells	O
.	O

Protein	B-CHED
-	O
Protein	B-CHED
Interaction	O
(	O
PPI	B-CHED
)	O
analysis	O
showed	O
that	O
DE	O
genes	O
in	O
SCDY2	O
group	O
formed	O
a	O
network	O
,	O
and	O
the	O
core	O
of	O
the	O
network	O
was	O
composed	O
by	O
cell	O
apoptosis	O
and	O
immune	O
response	O
proteins	B-CHED
.	O

However	O
,	O
most	O
current	O
inertia	O
-	O
based	O
high	O
flow	O
bioaerosol	O
samplers	O
are	O
not	O
suited	O
for	O
viral	O
aerosol	O
sampling	O
since	O
the	O
viability	O
will	O
be	O
lost	B-CHED
doing	O
the	O
sampling	O
process	O
.	O

In	O
addition	O
,	O
the	O
use	O
of	O
the	O
Co1	O
ligand	B-CHED
elicited	O
a	O
splenocyte	O
proliferative	O
response	O
more	O
effectively	O
in	O
comparison	O
with	O
the	O
COE	O
antigen	B-CHED
alone	O
and	O
supported	O
a	O
skewed	O
T	O
helper	O
2	O
type	O
of	O
immune	O
response	O
against	O
PEDV	O
.	O

RESULTS	O
:	O
BAL	B-CHED
IL	O
-	O
6	O
and	O
tumor	O
necrosis	O
factor	O
as	O
well	O
as	O
plasma	O
IL	O
-	O
6	O
were	O
significantly	O
lower	O
in	O
the	O
animals	O
administered	O
VPA	B-CHED
within	O
3	O
h	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
but	O
not	O
when	O
administered	O
later	O
(	O
4	O
,	O
6	O
,	O
9	O
h	O
).	O

Survival	O
improved	O
only	O
when	O
VPA	B-CHED
was	O
administered	O
within	O
3	O
h	O
.	O

Moreover	O
,	O
SARSr	O
-	O
CoV	O
strains	O
from	O
this	O
cave	O
were	O
more	O
closely	O
related	O
to	O
SARS	O
-	O
CoV	O
in	O
the	O
non	O
-	O
structural	O
protein	B-CHED
genes	O
ORF1a	O
and	O
1b	O
compared	O
with	O
those	O
detected	O
elsewhere	O
.	O

Cell	O
entry	O
studies	O
demonstrated	O
that	O
three	O
newly	O
identified	O
SARSr	O
-	O
CoVs	O
with	O
different	O
S	O
protein	B-CHED
sequences	O
are	O
all	O
able	O
to	O
use	O
human	O
ACE2	O
as	O
the	O
receptor	O
,	O
further	O
exhibiting	O
the	O
close	O
relationship	O
between	O
strains	O
in	O
this	O
cave	O
and	O
SARS	O
-	O
CoV	O
.	O
This	O
work	O
provides	O
new	O
insights	O
into	O
the	O
origin	O
and	O
evolution	O
of	O
SARS	O
-	O
CoV	O
and	O
highlights	O
the	O
necessity	O
of	O
preparedness	O
for	O
future	O
emergence	O
of	O
SARS	O
-	O
like	O
diseases	O
.	O

ADP	B-CHED
-	O
ribosylation	O
of	O
N	O
protein	B-CHED
was	O
also	O
observed	O
in	O
cells	O
exogenously	O
expressing	O
N	O
protein	B-CHED
by	O
transduction	O
using	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
replicon	O
particles	O
(	O
VRPs	O
).	O

Peptides	B-CHED
derived	O
from	O
the	O
HR	O
regions	O
of	O
some	O
viruses	O
have	O
also	O
been	O
shown	O
to	O
inhibit	O
viral	O
entry	O
.	O

Three	O
peptides	B-CHED
(	O
HR2M	O
,	O
HR2L	O
and	O
HR2P	O
)	O
were	O
identified	O
as	O
potential	O
competitive	O
inhibitors	B-CHED
in	O
PEDV	O
in	O
vitro	O
infection	O
assays	O
,	O
with	O
the	O
HR2P	O
peptide	B-CHED
representing	O
the	O
most	O
potent	O
inhibitor	B-CHED
.	O

Acute	O
oxygen	B-CHED
desaturation	O
was	O
observed	O
by	O
pulse	O
oximetry	O
during	O
respiratory	O
and	O
cardiac	O
suppression	O
.	O

Measured	O
with	O
the	O
patient	O
in	O
the	O
supine	O
position	O
before	O
and	O
at	O
the	O
end	O
of	O
the	O
first	O
PP	O
session	O
,	O
PaO	B-CHED

In	O
41	O
patients	O
with	O
IPS	O
,	O
we	O
evaluated	O
6	O
candidate	O
proteins	B-CHED
in	O
plasma	O
samples	O
at	O
day	O
7	O
post	O
-	O
HCT	O
and	O
at	O
onset	O
of	O
IPS	O
to	O
identify	O
potential	O
diagnostic	O
or	O
prognostic	O
biomarkers	O
for	O
IPS	O
.	O

Among	O
the	O
3	O
markers	O
,	O
ST2	O
showed	O
the	O
highest	O
PPV	B-CHED
for	O
IPS	O
occurrence	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
estradiol	B-CHED
exerts	O
a	O
protective	O
effect	O
on	O
lung	O
edema	O
and	O
cytokine	O
release	O
caused	O
by	O
intestinal	O
IR	O
in	O
male	O
rats	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
emergence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
2012	O
,	O
there	O
have	O
been	O
a	O
number	O
of	O
clusters	B-CHED
of	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

RESULTS	O
:	O
The	O
mean	O
MERS	O
-	O
CoV	O
infectious	O
titer	O
in	O
pretreatment	O
samples	O
was	O
4	O
.	O
67	O
	O
0	O
.	O
25	O
log	O
plaque	O
-	O
forming	O
units	O
(	O
pfu	B-CHED
)/	O
mL	O
,	O
which	O
was	O
reduced	O
to	O
undetectable	O
levels	O
after	O
inactivation	O
with	O
amotosalen	O
/	O
UVA	O
demonstrating	O
a	O
mean	O
log	O
reduction	O
of	O
more	O
than	O
4	O
.	O
67	O
	O
0	O
.	O
25	O
pfu	B-CHED
/	O
mL	O
.	O
Furthermore	O
,	O
inoculation	O
of	O
inactivated	O
plasma	O
on	O
Vero	O
E6	O
cells	O
did	O
not	O
result	O
in	O
any	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
even	O
after	O
7	O
days	O
of	O
incubation	O
and	O
three	O
consecutive	O
passages	O
,	O
nor	O
the	O
detection	O
of	O
MERS	O
RNA	O
compared	O
to	O
pretreatment	O
samples	O
which	O
showed	O
complete	O
CPE	O
within	O
2	O
to	O
3	O
days	O
postinoculation	O
and	O
log	O
viral	O
RNA	O
titer	O
ranging	O
from	O
9	O
.	O
48	O
to	O
10	O
.	O
22	O
copies	O
/	O
mL	O
in	O
all	O
three	O
passages	O
.	O

TITLE	O
:	O
An	O
Observational	O
Study	O
of	O
the	O
Efficacy	O
of	O
Cisatracurium	O
Compared	O
with	O
Vecuronium	B-CHED
in	O
Patients	O
with	O
or	O
at	O
Risk	O
for	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

The	O
three	O
dimensional	O
macromolecular	O
structure	O
(	O
3DMMS	O
)	O
of	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
the	O
S	O
protein	B-CHED
was	O
predicted	O
by	O
sequence	O
-	O
homology	O
method	O
using	O
the	O
protein	B-CHED
data	O
bank	O
(	O
PDB	O
).	O

An	O
81	O
-	O
year	O
-	O
old	O
previously	O
healthy	O
Korean	O
man	B-CHED
presented	O
with	O
cough	O
,	O
dyspnea	O
,	O
and	O
febrile	O
sensation	O
.	O

Evaluation	O
revealed	O
evidence	O
of	O
bilateral	O
central	O
retinal	B-CHED
artery	O
occlusion	O
and	O
bilateral	O
ischemic	O
optic	O
neuropathy	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
bilateral	O
central	O
retinal	B-CHED
artery	O
occlusion	O
with	O
both	O
anterior	O
and	O
posterior	O
ischemic	O
optic	O
neuropathy	O
,	O
presumed	O
due	O
to	O
the	O
combination	O
of	O
severe	O
systemic	O
hypotension	O
,	O
hypoxemia	O
due	O
to	O
the	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
prolonged	O
prone	O
positioning	O
.	O

Hospital	O
mortality	O
for	O
mild	O
,	O
moderate	O
and	O
severe	O
ARDS	O
was	O
17	O
.	O
0	O
,	O
27	O
.	O
9	O
and	O
50	O
.	O
0	O
%,	O
respectively	O
(	O
without	O
severe	O
ACP	B-CHED
),	O
and	O
was	O
29	O
.	O
2	O
,	O
48	O
.	O
3	O
and	O
53	O
.	O
8	O
%,	O
respectively	O
(	O
with	O
severe	O
ACP	B-CHED
).	O

The	O
presence	O
of	O
severe	O
ACP	B-CHED
appears	O
to	O
upstage	O
ARDS	O
severity	O
by	O
one	O
level	O
.	O

TITLE	O
:	O
Oxygen	B-CHED
Exposure	O
Resulting	O
in	O
Arterial	O
Oxygen	B-CHED
Tensions	O
Above	O
the	O
Protocol	O
Goal	O

Participants	O
with	O
above	O
goal	O
oxygen	B-CHED
exposure	O
were	O
more	O
likely	O
to	O
die	O
(	O
adjusted	O
interquartile	O
range	O
odds	O
ratio	O
,	O
1	O
.	O
20	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
11	O
-	O
1	O
.	O
31	O
)	O
and	O
have	O
lower	O
ventilator	O
-	O
free	O
days	O
(	O
adjusted	O
interquartile	O
range	O
mean	O
difference	O
of	O
-	O
0	O
.	O
83	O
;	O
95	O
%	O
CI	O
,	O
-	O
1	O
.	O
18	O
to	O
-	O
0	O
.	O
48	O
)	O
and	O
lower	O
hospital	O
-	O
free	O
days	O
(	O
adjusted	O
interquartile	O
range	O
mean	O
difference	O
of	O
-	O
1	O
.	O
38	O
;	O
95	O
%	O
CI	O
,	O
-	O
2	O
.	O
09	O
to	O
-	O
0	O
.	O
68	O
).	O

We	O
observed	O
a	O
dose	O
-	O
response	O
relationship	O
between	O
the	O
cumulative	O
above	O
goal	O
oxygen	B-CHED
exposure	O
and	O
worsened	O
clinical	O
outcomes	O
for	O
participants	O
with	O
mild	O
,	O
moderate	O
,	O
or	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
suggesting	O
that	O
the	O
observed	O
relationship	O
is	O
not	O
primarily	O
influenced	O
by	O
severity	O
of	O
illness	O
.	O

Surfactant	B-CHED
,	O
a	O
complex	O
mixture	B-CHED
of	O
phospholipids	B-CHED
and	O
proteins	B-CHED
,	O
is	O
secreted	O
into	O
the	O
alveolus	O
,	O
where	O
it	O
reduces	O
collapsing	O
forces	O
at	O
the	O
air	B-CHED
-	O
liquid	O
interface	O
to	O
maintain	O
lung	O
volumes	O
during	O
the	O
ventilatory	O
cycle	O
.	O

ABCA3	O
-	O
related	O
lung	O
dysfunction	O
was	O
associated	O
with	O
surfactant	B-CHED
deficiency	O
,	O
inflammation	O
,	O
and	O
alveolar	O
-	O
capillary	O
leak	O
.	O

A	O
common	O
but	O
often	O
unrecognized	O
complication	O
of	O
severe	O
hyponatremia	O
is	O
the	O
Ayus	O
-	O
Arieff	O
syndrome	O
where	O
cerebral	O
edema	O
causes	O
neurogenic	O
pulmonary	O
edema	O
via	O
centrally	O
mediated	O
increases	O
in	O
catecholamine	B-CHED
release	O
and	O
capillary	O
injury	O
.	O

TITLE	O
:	O
Structural	O
and	O
molecular	O
basis	O
of	O
mismatch	O
correction	O
and	O
ribavirin	B-CHED
excision	O
from	O
coronavirus	O
RNA	O
.	O

Moreover	O
,	O
coinfection	O
was	O
found	O
to	O
modulate	O
several	O
host	O
proteins	B-CHED
that	O
could	O
bolster	O
pathogen	O
persistence	O
.	O

Its	O
endogenous	O
character	O
makes	O
HDL	B-CHED
particularly	O
suitable	O
as	O
a	O
nanocarrier	O
platform	O
to	O
target	O
a	O
range	O
of	O
inflammatory	O
diseases	O
.	O

For	O
a	O
decade	O
and	O
a	O
half	O
,	O
our	O
laboratories	O
have	O
focused	O
on	O
HDL	B-CHED
'	O
s	O
exploitation	O
,	O
repurposing	O
,	O
and	O
reengineering	O
for	O
diagnostic	O
and	O
therapeutic	O
applications	O
,	O
generating	O
versatile	O
hybrid	O
nanomaterials	O
,	O
referred	O
to	O
as	O
nanobiologics	O
,	O
that	O
are	O
inherently	O
biocompatible	O
and	O
biodegradable	O
,	O
efficiently	O
cross	O
different	O
biological	O
barriers	O
,	O
and	O
intrinsically	O
interact	O
with	O
immune	O
cells	O
.	O

The	O
latter	O
is	O
facilitated	O
by	O
HDL	B-CHED
'	O
s	O
intrinsic	O
ability	O
to	O
interact	O
with	O
the	O
ATP	B-CHED
-	O
binding	O
cassette	O
receptor	O
A1	O
(	O
ABCA1	O
)	O
and	O
ABCG1	O
,	O
as	O
well	O
as	O
scavenger	O
receptor	O
type	O
B1	O
(	O
SR	O
-	O
BI	O
).	O

Individual	O
characteristics	O
:	O
PaO2	O
/	O
FiO2	O
=	O
110	O
	O
60	O
mmHg	O
,	O
alveolar	O
-	O
arterial	O
oxygen	B-CHED
gradient	O
(	O
A	O
-	O
aO2	O
)	O
=	O
549	O
	O
148	O
.	O
9	O
mmHg	O
,	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
=	O
8	O
.	O
7	O
	O
3	O
.	O
5	O
cmH	B-CHED

AFI	O
TAC	B-CHED
detected	O
nucleic	B-CHED
acid	I-CHED
for	O
one	O
or	O
more	O
of	O
seven	O
microbial	O
agents	O
in	O
49	O
%	O
of	O
AFI	O
blood	O
samples	O
,	O
including	O
:	O
Plasmodium	O
(	O
47	O
%),	O
Leptospira	O
(	O
3	O
%),	O
Bartonella	O
(	O
1	O
%),	O
Salmonella	O
enterica	O
(	O
1	O
%),	O
Coxiella	O
burnetii	O
(	O
1	O
%),	O
Rickettsia	O
(	O
1	O
%),	O
and	O
West	O
Nile	O
virus	O
(	O
1	O
%).	O

Specific	O
antibodies	O
secreted	O
from	O
hybridoma	O
cells	O
are	O
then	O
captured	O
by	O
the	O
antigens	B-CHED
on	O
the	O
cell	O
surface	O
.	O

Taken	O
together	O
,	O
we	O
propose	O
that	O
SARS	O
-	O
CoV	O
may	O
exploit	O
the	O
unique	O
functions	O
of	O
proteins	B-CHED
8b	O
and	O
8ab	O
as	O
novel	O
mechanisms	O
to	O
overcome	O
the	O
effect	O
of	O
IFN	O
response	O
during	O
virus	O
infection	O
.	O

In	O
the	O
MATRIX	O
(	O
Minimizing	O
Adverse	O
Haemorrhagic	O
Events	O
by	O
TRansradial	O
Access	O
Site	O
and	O
Systemic	O
Implementation	O
of	O
angioX	O
)	O
program	O
,	O
8	O
,	O
404	O
patients	O
were	O
randomized	O
to	O
TRA	O
or	O
TFA	B-CHED
.	O

Viral	O
infection	O
was	O
associated	O
with	O
mitochondrial	O
membrane	O
depolarization	O
and	O
reactive	B-CHED
oxygen	I-CHED
species	I-CHED
(	O
ROS	B-CHED
)	O
production	O
at	O
all	O
of	O
the	O
examined	O
timepoints	O
p	O
.	O
i	O
.	O

Coronavirus	O
EndoU	O
is	O
encoded	O
within	O
the	O
sequence	O
of	O
nonstructural	O
protein	B-CHED
(	O
nsp	O
)	O
15	O
,	O
which	O
was	O
initially	O
identified	O
as	O
a	O
component	O
of	O
the	O
viral	O
replication	O
complex	O
.	O

Estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
)	O
before	O
TDF	B-CHED
exposure	O
was	O
92	O
ml	O
/	O
min	O
/	O
1	O
.	O
73m	O

Hepatic	O
enzymes	O
,	O
antioxidant	B-CHED
defenses	O
and	O
lipids	B-CHED
content	O
and	O
composition	O
were	O
also	O
evaluated	O
.	O

On	O
the	O
contrary	O
,	O
in	O
P	O
.	O
chabaudi	O
AS	O
infected	O
mice	O
the	O
antioxidant	B-CHED
enzymes	O
and	O
the	O
lipid	B-CHED
content	O
and	O
composition	O
were	O
normal	O
or	O
even	O
lower	O
than	O
uninfected	O
controls	O
.	O

In	O
both	O
PCV	B-CHED
and	O
PSV	O
,	O
peak	O
transpulmonary	O
pressure	O
was	O
lower	O
,	O
whereas	O
E	O
-	O
cadherin	O
tissue	O
expression	O
,	O
which	O
is	O
related	O
to	O
epithelial	O
integrity	O
,	O
was	O
higher	O
at	O
PEEP	B-CHED
=	O
5	O
cmH2O	O
than	O
at	O
PEEP	B-CHED
=	O
2	O
cmH2O	O
.	O

During	O
PSV	O
,	O
PEEP	B-CHED
of	O
5	O
cmH2O	O
,	O
but	O
not	O
a	O
PEEP	B-CHED
of	O
2	O
cmH2O	O
,	O
reduced	O
lung	O
damage	O
and	O
inflammatory	O
markers	O
while	O
maintaining	O
epithelial	O
cell	O
integrity	O
.	O

Human	O
lung	O
epithelial	O
(	O
BEAS	O
-	O
2B	O
)	O
cells	O
were	O
incubated	O
with	O
LPS	B-CHED
in	O
the	O
presence	O
or	O
absence	O
of	O
UTI	O
.	O

The	O
FCoV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
is	O
considered	O
the	O
viral	O
regulator	O
for	O
binding	O
and	O
entry	O
to	O
the	O
cell	O
.	O

A	O
severe	O
ARDS	O
with	O
a	O
PaO	B-CHED
RESULTS	O
:	O
Out	O
of	O
1234	O
ARDS	O
patients	O
,	O
431	O
(	O
34	O
.	O
9	O
%)	O
were	O
transported	O
,	O
and	O
52	O
of	O
these	O
(	O
12	O
.	O
1	O
%)	O
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

TITLE	O
:	O
Quinoxaline	B-CHED
derivatives	O
as	O
new	O
inhibitors	B-CHED
of	O
coxsackievirus	O
B5	O
.	O

Promisingly	O
,	O
three	O
compounds	O
showed	O
a	O
very	O
potent	O
and	O
selective	O
antiviral	B-CHED
activity	O
against	O
coxsackievirus	O
B5	O
,	O
with	O
EC	O

Consistent	O
with	O
a	O
proinflammatory	O
phenotype	O
,	O
immunofluorescence	O
revealed	O
increased	O
phosphorylated	O
signal	O
transduction	O
and	O
activation	O
of	O
transcription	O
3	O
(	O
pSTAT3	O
),	O
suggesting	O
enhanced	O
Janus	O
kinase	O
(	O
JAK	O
)/	O
STAT	O
activation	O
in	O
inflammatory	O
and	O
AT2	B-CHED
cells	O
of	O
SPC	O
-	O
TK	O
/	O
SPC	O
-	O
KO	O
mice	O
.	O

Although	O
it	O
is	O
closely	O
related	O
to	O
MERS	O
-	O
CoV	O
in	O
most	O
genome	O
regions	O
,	O
its	O
spike	O
protein	B-CHED
occupies	O
a	O
phylogenetic	O
position	O
between	O
that	O
of	O
Ty	O
-	O
BatCoV	O
HKU4	O
and	O
Pi	O
-	O
BatCoV	O
HKU5	O
.	O

There	O
are	O
limited	O
data	O
on	O
how	O
to	O
balance	B-CHED
the	O
costs	O
and	O
performance	O
of	O
this	O
important	O
public	O
health	O
activity	O
.	O

In	O
sum	O
,	O
it	O
is	O
time	O
to	O
think	O
about	O
the	O
realistic	O
potential	O
of	O
Omics	O
biotechnologies	O
beyond	O
clinical	O
practice	O
and	O
precision	O
medicine	B-CHED
so	O
as	O
to	O
harness	O
the	O
opportunities	O
and	O
address	O
the	O
uncertainties	O
associated	O
not	O
only	O
with	O
GCBRs	O
but	O
also	O
with	O
other	O
emerging	O
Omics	O
applications	O
in	O
health	O
and	O
society	O
.	O

The	O
results	O
of	O
this	O
study	O
will	O
be	O
valuable	O
for	O
further	O
research	O
of	O
PDCoV	O
genetic	O
evolution	O
and	O
development	O
of	O
effective	O
diagnostic	O
reagents	B-CHED
,	O
assays	O
and	O
potential	O
vaccines	O
against	O
newly	O
emerged	O
PDCoV	O
strains	O
.	O

Galectin	O
-	O
3	O
,	O
a	O
	O
-	O
galactoside	B-CHED
-	O
binding	O
protein	B-CHED
widely	O
distributed	O
in	O
immune	O
and	O
epithelial	O
cells	O
,	O
regulates	O
various	O
immune	O
functions	O
and	O
modulates	O
microbial	O
infections	O
.	O

A	O
plateau	O
pressure	O
<	O
30	O
cmH	B-CHED

TITLE	O
:	O
MERS	O
-	O
CoV	O
4b	O
protein	B-CHED
interferes	O
with	O
the	O
NF	O
-	O
B	O
-	O
dependent	O
innate	O
immune	O
response	O
during	O
infection	O
.	O

Besides	O
pro	B-CHED
-	O
active	O
preventative	O
measures	O
intended	O
to	O
obviate	O
acquisition	O
of	O
AECOPD	O
,	O
early	O
recovery	O
from	O
severe	O
AECOPD	O
is	O
an	O
important	O
issue	O
in	O
determining	O
the	O
long	O
-	O
term	O
prognosis	O
of	O
patients	O
diagnosed	O
with	O
COPD	O
.	O

Recently	O
,	O
a	O
few	O
adjunctive	O
modalities	O
,	O
including	O
NIV	O
with	O
helmet	O
and	O
helium	B-CHED
-	O
oxygen	B-CHED
mixture	B-CHED
,	O
have	O
been	O
tried	O
in	O
cases	O
of	O
AECOPD	O
with	O
respiratory	O
failure	O
.	O

ABSTRACT	O
:	O
Recent	O
findings	O
have	O
highlighted	O
the	O
role	O
of	O
microglia	O
in	O
orchestrating	O
normal	O
development	O
and	O
refining	O
neural	O
network	O
connectivity	O
in	O
the	O
healthy	O
CNS	B-CHED
.	O

Microglia	O
are	O
not	O
only	O
vital	O
cells	O
in	O
maintaining	O
CNS	B-CHED
homeostasis	O
,	O
but	O
also	O
respond	O
to	O
injury	O
,	O
infection	O
,	O
and	O
disease	O
by	O
undergoing	O
proliferation	O
and	O
changes	O
in	O
transcription	O
and	O
morphology	O
.	O

Two	O
patients	O
received	O
ribavirin	B-CHED
and	O
IFN	O
-	O
a2b	O
in	O
addition	O
to	O
supportive	O
management	O
.	O

Nasopharyngeal	O
swabs	O
were	O
collected	O
whenever	O
an	O
elderly	O
had	O
symptoms	O
of	O
acute	O
respiratory	O
infections	O
(	O
ARI	B-CHED
).	O

The	O
molecular	O
mechanisms	O
of	O
ALI	O
and	O
ARDS	O
are	O
still	O
not	O
well	O
explored	O
,	O
but	O
available	O
reports	O
indicate	O
the	O
involvement	O
of	O
several	O
pro	B-CHED
-	O
inflammatory	O
mediators	O
including	O
cytokines	O
(	O
TNF	O
-	O
	O
,	O
IL	O
-	O
1	O
,	O
IL	O
-	O
6	O
)	O
and	O
chemokines	O
[	O
like	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
and	O
macrophage	O
inhibitory	O
factor	O
(	O
MIF	O
)],	O
as	O
well	O
as	O
macrophage	O
polarization	O
regulating	O
the	O
migration	O
and	O
pulmonary	O
infiltration	O
of	O
neutrophils	O
into	O
the	O
pulmonary	O
interstitial	O
tissue	O
,	O
causing	O
injury	O
to	O
the	O
pulmonary	O
parenchyma	O
.	O

It	O
is	O
possible	O
that	O
adverse	O
effects	O
at	O
the	O
simvastatin	B-CHED
dosage	O
used	O
outweighed	O
a	O
beneficial	O
effect	O
,	O
although	O
our	O
data	O
suggest	O
that	O
this	O
is	O
unlikely	O
.	O

High	O
-	O
dose	O
enteral	O
simvastatin	B-CHED
,	O
while	O
safe	O
and	O
with	O
minimal	O
adverse	O
effects	O
,	O
is	O
not	O
effective	O
at	O
improving	O
clinical	O
outcomes	O
in	O
patients	O
with	O
ARDS	O
.	O

The	O
effects	O
of	O
intra	O
-	O
oviductal	O
inoculation	O
with	O
attenuated	O
IBV	O
(	O
aIBV	O
)	O
on	O
the	O
expression	O
of	O
viral	O
RNA	O
recognition	O
receptors	O
and	O
innate	O
antiviral	B-CHED
factors	O
were	O
examined	O
by	O
real	O
-	O
time	O
PCR	O
and	O
immunohistochemistry	O
,	O
and	O
on	O
PGE2	B-CHED
levels	O
by	O
ELISA	O
.	O

ABSTRACT	O
:	O
Several	O
hitherto	O
unknown	O
(	O
E	O
)-	O
but	O
-	O
2	O
-	O
enyl	O
nucleoside	B-CHED
phosphonoamidate	O
analogs	O
(	O
ANPs	O
)	O
were	O
prepared	O
directed	O
with	O
nitrogen	B-CHED
reagents	B-CHED
by	O
cross	O
-	O
metathesis	O
in	O
water	B-CHED
-	O
under	O
ultrasound	O
irradiation	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
peroxygen	O
-	O
based	O
disinfectant	B-CHED
for	O
inactivation	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
at	O
low	O
temperatures	O
on	O
metal	B-CHED
surfaces	O
.	O

Compared	O
with	O
the	O
CV777	O
vaccine	O
strain	O
,	O
Eastern	O
China	O
PEDVs	O
were	O
genetically	O
distinct	O
and	O
had	O
various	O
amino	B-CHED
acid	I-CHED
differences	O
in	O
the	O
neutralizing	O
epitope	B-CHED
domain	O
of	O
the	O
S	O
protein	B-CHED
,	O
as	O
well	O
as	O
different	O
patterns	O
of	O
predicted	O
high	O
-	O
specificity	O
N	O
-	O
glycosylation	O
sites	O
.	O

Here	O
we	O
reported	O
the	O
design	O
,	O
synthesis	O
and	O
characterization	O
of	O
two	O
peptide	B-CHED
-	O
based	O
membrane	O
fusion	O
inhibitors	B-CHED
targeting	O
HCoV	O
-	O
229E	O
spike	O
protein	B-CHED
heptad	O
repeat	O
1	O
(	O
HR1	O
)	O
and	O
heptad	O
repeat	O
2	O
(	O
HR2	O
)	O
domains	O
,	O
229E	O
-	O
HR1P	O
and	O
229E	O
-	O
HR2P	O
,	O
respectively	O
.	O

Pulmonary	O
patients	O
are	O
typically	O
forced	O
to	O
maintain	O
bed	O
rest	B-CHED
,	O
or	O
at	O
least	O
spend	O
most	O
of	O
their	O
waking	O
hours	O
dealing	O
with	O
mobility	O
limitations	O
,	O
due	O
to	O
various	O
pathological	O
conditions	O
including	O
dyspnea	O
,	O
fatigue	O
,	O
and	O
poor	O
tolerance	O
of	O
movements	O
.	O

TITLE	O
:	O
Oral	O
recombinant	O
Lactobacillus	O
vaccine	O
targeting	O
the	O
intestinal	O
microfold	O
cells	O
and	O
dendritic	O
cells	O
for	O
delivering	O
the	O
core	O
neutralizing	O
epitope	B-CHED
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

In	O
this	O
study	O
,	O
an	O
oral	O
recombinant	O
Lactobacillus	O
casei	O
vaccine	O
against	O
PEDV	O
infection	O
targeting	O
the	O
intestinal	O
microfold	O
(	O
M	O
)	O
cells	O
and	O
dendritic	O
cells	O
(	O
DCs	O
)	O
for	O
delivering	O
the	O
core	O
neutralizing	O
epitope	B-CHED
(	O
COE	O
)	O
of	O
PEDV	O
spike	O
protein	B-CHED
was	O
developed	O
with	O
M	O
cell	O
-	O
targeting	O
peptide	B-CHED
(	O
Col	O
)	O
and	O
dendritic	O
cell	O
-	O
targeting	O
peptide	B-CHED
(	O
DCpep	O
).	O

Findings	O
are	O
reported	O
as	O
methylprednisolone	B-CHED
versus	O
placebo	O
.	O

Participants	O
returning	O
to	O
mechanical	O
ventilation	O
without	O
reinstitution	O
of	O
methylprednisolone	B-CHED
had	O
increased	O
risk	O
of	O
ventilator	O
dependence	O
and	O
mortality	O
.	O

Gradual	O
tapering	O
might	O
be	O
necessary	O
to	O
preserve	O
the	O
significant	O
improvements	O
achieved	O
during	O
methylprednisolone	B-CHED
administration	O
.	O

The	O
main	O
treatment	O
is	O
oxygen	B-CHED
therapy	O
at	O
high	O
concentrations	O
and	O
methylene	B-CHED
blue	I-CHED
as	O
an	O
intravenous	O
antidote	B-CHED
only	O
in	O
selected	O
cases	O
.	O

Dynamic	O
strain	O
at	O
PEEP	B-CHED
decreased	O
with	O
the	O
change	O
from	O
SP	O
to	O
PP	O
(	O
0	O
.	O
38	O
	O
0	O
.	O
14	O
to	O
0	O
.	O
33	O
	O
0	O
.	O
13	O
,	O
p	O
=	O
0	O
.	O
040	O
).	O

Lower	O
respiratory	O
tract	O
disease	O
(	O
LRTD	O
)	O
was	O
defined	O
as	O
possible	O
or	O
definite	O
infiltrate	O
seen	O
in	O
chest	O
imaging	O
,	O
need	O
for	O
oxygen	B-CHED
,	O
or	O
abnormal	O
lung	O
examination	O
in	O
conjunction	O
with	O
a	O
physician	O
diagnosis	O
of	O
LRTD	O
.	O

Penicillin	B-CHED
-	O
resistant	O
pneumococci	O
and	O
	O
-	O
lactamase	O
-	O
producing	O
H	O
.	O
influenzae	O
are	O
uncommon	O
.	O

Phylogenetic	O
analyses	O
based	O
on	O
the	O
ORF2	O
amino	B-CHED
acid	I-CHED
sequences	O
,	O
samples	O
described	O
herein	O
grouped	O
into	O
the	O
putative	O
genotype	O
'	O
a	O
'	O
closed	O
related	O
with	O
Chinese	O
samples	O
.	O

Intravenous	O
infusion	O
of	O
flurbiprofen	B-CHED
,	O
droperidol	B-CHED
,	O
and	O
morphine	B-CHED
was	O
not	O
effective	O
.	O

The	O
coding	O
region	O
for	O
the	O
surface	O
-	O
exposed	O
spike	O
protein	B-CHED
showed	O
the	O
highest	O
proportion	O
of	O
variability	O
including	O
both	O
point	O
mutations	O
and	O
small	O
deletions	O
.	O

Evasion	O
of	O
IFN	O
signaling	O
by	O
Ebola	O
viral	O
protein	B-CHED
24	O
(	O
VP24	O
)	O
is	O
a	O
critical	O
event	O
in	O
the	O
pathogenesis	O
of	O
the	O
infection	O
and	O
,	O
hence	O
,	O
VP24	O
is	O
a	O
potential	O
target	O
for	O
drug	O
development	O
.	O

Using	O
a	O
gradually	O
increasing	O
methotrexate	B-CHED
(	O
MTX	B-CHED
)	O
concentration	O
to	O
5	O
M	O
,	O
we	O
increased	O
protein	B-CHED
yield	O
by	O
a	O
factor	O
of	O
40	O
.	O

Meta	O
-	O
analyses	O
on	O
early	O
,	O
goal	O
-	O
directed	O
therapy	O
for	O
septic	O
shock	O
and	O
statin	B-CHED
therapy	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
were	O
summarized	O
.	O

These	O
viruses	O
had	O
>	O
97	O
%	O
nucleotide	B-CHED
identity	O
with	O
coronaviruses	O
detected	O
in	O
Cynopterus	O
sphinx	O
,	O
Scotophilus	O
heathii	O
and	O
S	O
.	O
kuhlii	O
bats	O
in	O
Thailand	O
.	O

The	O
most	O
divergent	O
region	O
is	O
in	O
the	O
spike	O
protein	B-CHED
,	O
which	O
only	O
shares	O
68	O
%	O
amino	B-CHED
acid	I-CHED
identity	O
with	O
BatCoV	O
HKU9	O
.	O

These	O
are	O
limited	O
,	O
however	O
,	O
by	O
the	O
need	O
to	O
elicit	O
both	O
humoral	O
and	O
cellular	O
immunity	O
,	O
as	O
well	O
as	O
the	O
efficiency	O
of	O
adjuvants	B-CHED
.	O

Nano	O
silicon	B-CHED
could	O
be	O
considered	O
for	O
use	O
as	O
an	O
antigen	B-CHED
-	O
carrier	O
and	O
adjuvant	B-CHED
for	O
veterinary	O
vaccines	O
.	O

TITLE	O
:	O
Adjunctive	O
therapy	O
with	O
azithromycin	B-CHED
for	O
moderate	O
and	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
retrospective	O
,	O
propensity	O
score	O
-	O
matching	O
analysis	O
of	O
prospectively	O
collected	O
data	O
at	O
a	O
single	O
center	O
.	O

The	O
28	O
-	O
day	O
mortality	O
rate	O
tended	O
to	O
be	O
higher	O
in	O
the	O
azithromycin	B-CHED
cohort	O
than	O
in	O
the	O
non	O
-	O
azithromycin	B-CHED
cohort	O
,	O
but	O
this	O
was	O
not	O
statistically	O
significant	O
.	O

The	O
classical	O
RSI	O
with	O
its	O
main	O
components	O
(	O
i	O
.	O
e	O
.	O
head	O
-	O
up	O
position	O
,	O
avoidance	O
of	O
positive	O
pressure	O
ventilation	O
and	O
administration	O
of	O
succinylcholine	B-CHED
)	O
was	O
published	O
nearly	O
50	O
years	O
ago	O
and	O
has	O
remained	O
almost	O
unchanged	O
.	O

The	O
CoV	O
nsp14	O
exoribonuclease	O
(	O
ExoN	O
)	O
has	O
complicated	O
development	O
of	O
antiviral	B-CHED
nucleosides	B-CHED
due	O
to	O
its	O
proofreading	O
activity	O
.	O

There	O
was	O
significantly	O
more	O
Ty	O
-	O
BatCoV	O
-	O
HKU4	O
RNA	O
-	O
positive	O
alimentary	O
samples	O
than	O
Pi	O
-	O
BatCoV	O
-	O
HKU5	O
RNA	O
-	O
positive	O
alimentary	O
samples	O
that	O
were	O
tested	O
positive	O
by	O
the	O
rapid	O
MERS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
detection	O
assay	O
(	O
P	O
<	O
0	O
.	O
001	O
by	O
Chi	B-CHED
-	O
square	O
test	O
).	O

ABSTRACT	O
:	O
The	O
ever	O
-	O
increasing	O
speed	O
and	O
scope	O
of	O
human	O
mobility	O
by	O
international	O
air	B-CHED
travel	O
has	O
led	O
to	O
a	O
global	O
transport	O
network	O
for	O
infectious	O
diseases	O
with	O
the	O
potential	O
to	O
introduce	O
pathogens	O
into	O
non	O
-	O
endemic	O
areas	O
,	O
and	O
to	O
facilitate	O
rapid	O
spread	O
of	O
novel	O
or	O
mutated	O
zoonotic	O
agents	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
glycoprotein	B-CHED
(	O
S	O
)	O
of	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
strain	O
A59	O
uses	O
murine	O
carcinoembryonic	O
antigen	B-CHED
-	O
related	O
cell	O
adhesion	O
molecule	O
1a	O
as	O
its	O
receptor	O
for	O
cell	O
entry	O
,	O
but	O
S	O
protein	B-CHED
can	O
also	O
be	O
triggered	O
in	O
the	O
absence	O
of	O
receptor	O
by	O
pH	O
8	O
.	O
0	O
alone	O
at	O
37	O
	O
C	O
.	O

Finally	O
,	O
the	O
H209A	O
mutation	O
significantly	O
increased	O
the	O
thermostability	O
of	O
S	O
protein	B-CHED
in	O
its	O
prefusion	O
conformation	O
,	O
which	O
may	O
raise	O
the	O
energy	O
barrier	O
for	O
conformational	O
change	O
of	O
S	O
protein	B-CHED
required	O
for	O
membrane	O
fusion	O
and	O
lead	O
to	O
a	O
decrease	O
in	O
virus	O
fitness	O
in	O
cell	O
culture	O
.	O

Compared	O
with	O
the	O
simple	O
ventilation	O
group	O
,	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
),	O
procalcitonin	O
(	O
PCT	O
),	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
)	O
at	O
24	O
hours	O
of	O
treatment	O
in	O
the	O
combined	O
treatment	O
group	O
were	O
significantly	O
decreased	O
[	O
WBC	O
(	O
10	O
Compared	O
with	O
lateral	O
position	O
ventilation	O
alone	O
,	O
the	O
treatment	O
of	O
combined	O
with	O
vibration	O
sputum	O
drainage	O
is	O
more	O
effective	O
for	O
improving	O
the	O
respiratory	O
function	O
of	O
patients	O
with	O
ARDS	O
,	O
reducing	O
infection	O
action	O
,	O
shortening	O
the	O
duration	O
of	O
MV	O
and	O
the	O
length	O
of	O
ICU	O
stay	O
,	O
and	O
improve	O
the	O
recovery	O
,	O
promote	O
the	O
rehabitation	O
of	O
patients	O
.	O

Our	O
results	O
showed	O
that	O
the	O
nsp7	O
protein	B-CHED
is	O
localized	O
in	O
the	O
cytoplasm	O
and	O
has	O
no	O
effect	O
on	O
intestinal	O
epithelial	O
cells	O
(	O
IECs	O
)	O
growth	O
,	O
cell	O
cycle	O
,	O
and	O
cyclin	O
A	O
expression	O
.	O

These	O
findings	O
provide	O
novel	O
information	O
about	O
the	O
function	O
of	O
the	O
poorly	O
characterized	O
TGEV	O
non	O
-	O
structural	O
protein	B-CHED
7	O
.	O

Heterogeneous	O
nuclear	O
ribonucleoprotein	O
A1	O
(	O
hnRNP	O
A1	O
)	O
is	O
a	O
cellular	O
protein	B-CHED
participating	O
in	O
the	O
splicing	O
of	O
pre	O
-	O
mRNA	B-CHED
in	O
the	O
nucleus	B-CHED
and	O
translation	O
regulation	O
in	O
the	O
cytoplasm	O
.	O

In	O
comparison	O
with	O
two	O
vaccine	O
strains	O
used	O
in	O
Japan	O
,	O
the	O
field	O
strains	O
had	O
various	O
changes	O
in	O
epitope	B-CHED
regions	O
,	O
glycosylation	O
sites	O
,	O
and	O
phosphorylation	O
sites	O
.	O

Using	O
both	O
noroviruses	O
and	O
coronaviruses	O
as	O
model	O
systems	O
,	O
we	O
demonstrate	O
the	O
utility	O
of	O
the	O
VRP	O
3526	O
platform	O
in	O
the	O
generation	O
of	O
recombinant	O
proteins	B-CHED
,	O
production	O
of	O
virus	O
-	O
like	O
particles	O
,	O
and	O

Out	O
of	O
the	O
positive	O
samples	O
,	O
23	O
showed	O
the	O
amino	B-CHED
acid	I-CHED
substitution	O
M1058L	O
in	O
the	O
spike	O
protein	B-CHED
and	O
none	O
the	O
substitution	O
S1060A	O
.	O

TITLE	O
:	O
Cigarette	O
smoke	O
exposure	O
worsens	O
acute	O
lung	O
injury	O
in	O
antibiotic	B-CHED
-	O
treated	O
bacterial	O
pneumonia	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
Contrasting	O
evidence	O
exists	O
on	O
the	O
comparative	O
efficacy	O
and	O
safety	O
of	O
bivalirudin	B-CHED
and	O
unfractionated	O
heparin	B-CHED
(	O
UFH	O
)	O
in	O
relation	O
to	O
the	O
planned	O
use	O
of	O
glycoprotein	B-CHED
IIb	O
/	O
IIIa	O
inhibitors	B-CHED
(	O
GPIs	B-CHED
).	O

Bailout	O
use	O
of	O
GPIs	B-CHED
was	O
similar	O
between	O
the	O
bivalirudin	B-CHED
and	O
UFH	O
groups	O
(	O
4	O
.	O
5	O
%	O
and	O
5	O
.	O
4	O
%)	O
(	O
p	O
=	O
0	O
.	O
11	O
).	O

Compared	O
with	O
the	O
UFH	O
and	O
UFH	B-CHED
+	I-CHED
GPI	I-CHED
groups	O
,	O
bivalirudin	B-CHED
reduced	O
bleeding	O
,	O
mainly	O
the	O
most	O
severe	O
bleeds	O
,	O
including	O
fatal	O
and	O
nonaccess	O
site	O
-	O
related	O
events	O
,	O
as	O
well	O
as	O
transfusion	O
rates	O
and	O
the	O
need	O
for	O
surgical	O
access	O
site	O
repair	O
.	O

TITLE	O
:	O
Coronavirus	O
S	O
protein	B-CHED
-	O
induced	O
fusion	O
is	O
blocked	O
prior	O
to	O
hemifusion	O
by	O
Abl	B-CHED
kinase	O
inhibitors	B-CHED
.	O

Our	O
results	O
indicate	O
that	O
membrane	O
fusion	O
(	O
both	O
virus	O
-	O
cell	O
and	O
cell	O
-	O
cell	O
)	O
is	O
blocked	O
in	O
the	O
presence	O
of	O
Abl	B-CHED
kinase	O
inhibitors	B-CHED
.	O

Studying	O
the	O
effects	O
of	O
Abl	B-CHED
kinase	O
inhibitors	B-CHED
on	O
IBV	O
will	O
be	O
useful	O
in	O
identifying	O
the	O
host	O
cell	O
pathways	O
required	O
for	O
coronavirus	O
infection	O
.	O

The	O
infant	O
was	O
treated	O
with	O
betaine	B-CHED
,	O
hydroxycobalamin	B-CHED
,	O
and	O
folic	B-CHED
acid	I-CHED
.	O

The	O
RNA	O
polymerase	O
of	O
respiratory	O
viruses	O
represents	O
an	O
attractive	O
target	O
for	O
nucleoside	B-CHED
and	O
nucleotide	B-CHED
analogs	O
acting	O
as	O
inhibitors	B-CHED
of	O
RNA	O
chain	O
synthesis	O
.	O

To	O
further	O
evaluate	O
the	O
antiviral	B-CHED
activity	O
of	O
well	O
-	O
defined	O
drugs	O
in	O
primary	O
antigen	B-CHED
presenting	O
cells	O
(	O
APCs	O
),	O
three	O
compounds	O
(	O
chloroquine	B-CHED
,	O
chlorpromazine	B-CHED
and	O
toremifine	O
),	O
each	O
with	O
broad	O
-	O
spectrum	O
antiviral	B-CHED
activity	O
in	O
immortalized	O
cell	O
lines	O
,	O
were	O
evaluated	O
in	O
MDMs	O
and	O
MDDCs	O
to	O
determine	O
their	O
antiviral	B-CHED
effect	O
on	O
MERS	O
-	O
CoV	O
infection	O
.	O

It	O
contains	O
18	O
-	O
nucleotide	B-CHED
discontinuous	O
deletions	O
of	O
the	O
open	O
reading	O
frame	O
1a	O
(	O
ORF1a	O
)	O
and	O
spike	O
regions	O
.	O

She	O
responded	O
favorably	O
to	O
10	O
days	O
of	O
azithromycin	B-CHED
and	O
atovaquone	B-CHED
and	O
21	O
days	O
of	O
oral	O
doxycycline	B-CHED
.	O

The	O
spike	O
protein	B-CHED
(	O
S1	O
subunit	O
)	O
is	O
responsible	O
for	O
the	O
molecular	O
diversity	O
of	O
the	O
virus	O
and	O
many	O
sero	O
/	O
genotypes	O
are	O
described	O
around	O
the	O
world	O
.	O

Sepsis	O
syndrome	O
is	O
developed	O
when	O
the	O
balance	B-CHED
between	O
the	O
substances	O
that	O
contribute	O
to	O
the	O
inflammation	O
and	O
anti	O
-	O
inflammatory	O
substances	O
is	O
violated	O
.	O

The	O
new	O
genome	O
shared	O
97	O
.	O
2	O
%	O
overall	O
nucleotide	B-CHED
identity	O
to	O
a	O
previous	O
Neoromicia	O
-	O
associated	O
MERS	O
-	O
related	O
virus	O
,	O
also	O
from	O
South	O
Africa	O
.	O

Therefore	O
,	O
sDPP4	O
levels	O
in	O
the	O
plasma	O
of	O
MERS	O
patients	O
are	O
significantly	O
reduced	O
below	O
the	O
threshold	O
needed	O
to	O
exert	O
an	O
antiviral	B-CHED
effect	O
against	O
MERS	O
-	O
CoV	O
infection	O
.	O

To	O
address	O
this	O
situation	O
,	O
stool	O
samples	O
from	O
325	O
dogs	O
were	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
for	O
the	O
detection	O
of	O
common	O
enteric	O
viruses	O
such	O
as	O
Canine	O
adenovirus	O
(	O
CAdV	O
),	O
Canine	O
coronavirus	O
(	O
CCoV	O
),	O
Canine	O
distemper	O
virus	O
(	O
CDV	B-CHED
),	O
Canine	O
rotavirus	O
(	O
CRV	O
)	O
and	O
Carnivorous	O
protoparvovirus	O
1	O
(	O
canine	O
parvovirus	O
2	O
;	O
CPV	O
-	O
2	O
).	O

It	O
emphasizes	O
the	O
role	O
of	O
both	O
,	O
sometimes	O
inseparable	O
,	O
diseases	O
in	O
differential	O
diagnosis	O
of	O
acute	O
symptoms	O
in	O
internal	O
medicine	B-CHED
.	O

TITLE	O
:	O
Prenylated	O
phloroglucinols	O
from	O
Hypericum	O
scruglii	O
,	O
an	O
endemic	O
species	O
of	O
Sardinia	O
(	O
Italy	O
),	O
as	O
new	O
dual	O
HIV	O
-	O
1	O
inhibitors	B-CHED
effective	O
on	O
HIV	O
-	O
1	O
replication	O
.	O

The	O
haloperidol	B-CHED
and	O
opioid	O
doses	O
were	O
associated	O
with	O
a	O
longer	O
delirium	O
duration	O
.	O

Patients	O
with	O
PTSD	O
(	O
16	O
%)	O
had	O
a	O
significantly	O
longer	O
delirium	O
duration	O
and	O
low	O
mental	O
HRQoL	O
.	O
Conclusions	O
H1N1	O
infection	O
and	O
corresponding	O
antiviral	B-CHED
medication	O
had	O
no	O
impact	O
on	O
delirium	O
.	O

Intravenous	O
artesunate	B-CHED
and	O
oral	O
doxycycline	B-CHED
were	O
started	O
and	O
he	O
made	O
a	O
full	O
recovery	O
.	O

The	O
potential	O
role	O
of	O
the	O
HCoV	O
-	O
OC43	O
structural	O
(	O
M	O
and	O
N	O
)	O
and	O
accessory	O
proteins	B-CHED
(	O
ns2a	O
and	O
ns5a	O
)	O
in	O
the	O
alteration	O
of	O
antiviral	B-CHED
gene	O
expression	O
was	O
investigated	O
in	O
this	O
study	O
.	O

All	O
cases	O
were	O
successfully	O
managed	O
with	O
liposomal	O
amphotericin	O
followed	O
by	O
azole	B-CHED
therapy	O
.	O

TITLE	O
:	O
In	O
Vitro	O
Bactericidal	O
and	O
Virucidal	O
Efficacy	O
of	O
Povidone	B-CHED
-	O
Iodine	B-CHED
Gargle	O
/	O
Mouthwash	O
Against	O
Respiratory	O
and	O
Oral	O
Tract	O
Pathogens	O
.	O

Earlier	O
,	O
we	O
reported	O
that	O
a	O
toll	O
-	O
like	O
-	O
receptor	O
7	O
(	O
TLR7	O
)	O
agonist	B-CHED
,	O
resiquimod	B-CHED
(	O
R	B-CHED
-	I-CHED
848	I-CHED
),	O
stimulated	O
the	O
systemic	O
immunity	O
when	O
adjuvanted	O
with	O
the	O
inactivated	O
Newcastle	O
disease	O
virus	O
vaccine	O
in	O
the	O
chicken	O
.	O

Here	O
,	O
we	O
report	O
the	O
effect	O
of	O
R	B-CHED
-	I-CHED
848	I-CHED
when	O
adjuvanted	O
with	O
live	O
or	O
inactivated	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
vaccines	O
with	O
special	O
emphasis	O
on	O
mucosal	O
immunity	O
.	O

Specific	O
pathogen	O
free	O
(	O
SPF	O
)	O
chicks	O
(	O
n	O
=	O
60	O
)	O
were	O
equally	O
divided	O
into	O
six	O
groups	O
at	O
two	O
weeks	O
of	O
age	O
and	O
immunized	O
with	O
either	O
inactivated	O
or	O
live	O
IBV	O
vaccine	O
adjuvanted	O
with	O
or	O
without	O
R	B-CHED
-	I-CHED
848	I-CHED
.	O

Groups	O
that	O
received	O
either	O
PBS	O
or	O
R	B-CHED
-	I-CHED
848	I-CHED
served	O
as	O
control	O
.	O

TITLE	O
:	O
Surfactant	B-CHED
Dysfunction	O
in	O
ARDS	O
and	O
Bronchiolitis	O
is	O
Repaired	O
with	O
Cyclodextrins	O
.	O

In	O
this	O
study	O
,	O
we	O
explore	O
the	O
mechanisms	O
whereby	O
surfactant	B-CHED
becomes	O
dysfunctional	O
in	O
ARDS	O
and	O
bronchiolitis	O
and	O
its	O
repair	O
with	O
a	O
cyclodextrin	B-CHED
drug	O
that	O
sequesters	O
cholesterol	B-CHED
.	O

Methyl	B-CHED
-	O
	O
-	O
cyclodextrin	B-CHED
(	O
MCD	O
)	O
restored	O
surfactant	B-CHED
function	O
to	O
normal	O
in	O
both	O
human	O
and	O
animal	O
samples	O
.	O

They	O
could	O
be	O
delivered	O
in	O
a	O
portable	O
device	O
carried	O
in	O
combat	B-CHED
and	O
used	O
following	O
exposure	O
to	O
toxic	O
gases	O
and	O
fumes	O
or	O
shock	O
secondary	O
to	O
hemorrhage	O
and	O
burns	O
.	O

After	O
removing	O
lipids	B-CHED
with	O
a	O
coefficient	O
of	O
variation	O
>	O
30	O
%,	O
differences	O
between	O
cohorts	O
were	O
identified	O
using	O
repeated	O
measures	O
analysis	O
of	O
variance	O
.	O

The	O
concentration	O
of	O
multiple	O
plasma	O
lipids	B-CHED
is	O
associated	O
with	O
mortality	O
in	O
this	O
group	O
of	O
critically	O
ill	O
patients	O
with	O
ARDS	O
.	O

Here	O
,	O
we	O
compared	O
the	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
several	O
representative	O
CoVs	O
.	O

TITLE	O
:	O
Is	O
ambient	O
air	B-CHED
pollution	O
associated	O
with	O
onset	O
of	O
sudden	O
infant	O
death	O
syndrome	O
:	O
a	O
case	O
-	O
crossover	O
study	O
in	O
the	O
UK	O
.	O

Lactate	B-CHED
levels	O
and	O
mitochondrial	O
respiratory	O
chain	O
enzyme	O
activity	O
in	O
muscle	O
,	O
liver	O
and	O
fibroblasts	O
were	O
normal	O
.	O

Plasma	O
glycine	B-CHED
was	O
elevated	O
.	O

isolates	O
,	O
respectively	O
,	O
were	O
carbapenem	B-CHED
-	O
resistant	O
,	O
which	O
was	O
not	O
associated	O
with	O
a	O
higher	O
mortality	O
risk	O
.	O

Obtained	O
results	O
confirmed	O
that	O
patients	O
with	O
chronic	O
underlying	O
illness	O
/	O
condition	O
and	O
older	O
than	O
15	O
years	O
had	O
the	O
highest	O
risk	O
for	O
serious	O
complications	O
from	O
influenza	O
and	O
highlighted	O
the	O
importance	O
of	O
start	O
of	O
antiviral	B-CHED
therapy	O
within	O
the	O
first	O
two	O
days	O
of	O
illness	O
in	O
order	O
to	O
reduce	O
the	O
risk	O
for	O
the	O
most	O
severe	O
outcomes	O
of	O
influenza	O
,	O
such	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
lethal	O
outcome	O
.	O

A	O
national	O
RV	O
surveillance	O
dataset	O
may	O
be	O
useful	O
in	O
identifying	O
RV	O
outbreaks	O
in	O
adult	O
patients	O
with	O
severe	O
ARI	B-CHED
.	O

One	O
hundred	O
seventy	O
one	O
(	O
171	O
)	O
serum	O
samples	O
were	O
collected	O
from	O
healthy	O
dromedary	O
camels	O
with	O
different	O
ages	O
and	O
genders	O
in	O
Tabuk	O
city	O
and	O
tested	O
for	O
specific	O
serum	O
IgG	O
by	O
ELISA	O
using	O
the	O
receptor	O
-	O
binding	O
S1	O
subunits	O
of	O
spike	O
proteins	B-CHED
of	O
MERS	O
-	O
CoV	O
.	O
144	O
(	O
84	O
,	O
21	O
%)	O
of	O
the	O
total	O
camel	O
sera	O
shown	O
the	O
presence	O
of	O
protein	B-CHED
-	O
specific	O
antibodies	O
against	O
MERS	O
-	O
CoV	O
.	O
These	O
results	O
may	O
provide	O
evidence	O
that	O
MERS	O
-	O
CoV	O
has	O
previously	O
infected	O
dromedary	O
camels	O
in	O
Tabuk	O
and	O
may	O
support	O
the	O
possible	O
role	O
of	O
camels	O
in	O
the	O
human	O
infection	O
.	O

ABSTRACT	O
:	O
Previous	O
data	O
suggest	O
that	O
fecal	O
S100A12	O
has	O
clinical	O
utility	O
as	O
a	O
biomarker	B-CHED
of	O
chronic	O
gastrointestinal	O
inflammation	O
(	O
idiopathic	O
inflammatory	O
bowel	O
disease	O
)	O
in	O
both	O
people	O
and	O
dogs	O
,	O
but	O
the	O
effect	O
of	O
gastrointestinal	O
pathogens	O
on	O
fecal	O
S100A12	O
concentrations	O
is	O
largely	O
unknown	O
.	O

HCoV	O
ARI	B-CHED
incidence	O
was	O
also	O
positively	O
associated	O
with	O
the	O
number	O
of	O
children	O
<	O
5	O
years	O
of	O
age	O
per	O
room	O
in	O
a	O
household	O
(	O
IRR	O
,	O
1	O
.	O
13	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
01	O
-	O
1	O
.	O
28	O
).	O

The	O
construction	O
of	O
mutations	O
in	O
the	O
fusion	O
protein	B-CHED
transmembrane	O
domains	O
(	O
TMDs	O
)	O
or	O
the	O
replacement	O
of	O
these	O
domains	O
with	O
lipid	B-CHED
anchors	O
has	O
implicated	O
the	O
TMD	O
in	O
the	O
fusion	O
process	O
.	O

TITLE	O
:	O
Effects	O
of	O
hypervariable	O
regions	O
in	O
spike	O
protein	B-CHED
on	O
pathogenicity	O
,	O
tropism	O
,	O
and	O
serotypes	O
of	O
infectious	O
bronchitis	O
virus	O
.	O

Bare	O
-	O
metal	B-CHED
stents	O
were	O
used	O
in	O
33	O
patients	O
,	O
covered	O
stents	O
in	O
26	O
,	O
and	O
both	O
types	O
in	O
6	O
.	O

Two	O
patients	O
had	O
vessel	O
spasm	O
treated	O
by	O
nitroglycerin	B-CHED
.	O

TITLE	O
:	O
Supplemental	O
flaxseed	O
modulates	O
ovarian	O
functions	O
of	O
weanling	O
gilts	O
via	O
the	O
action	O
of	O
selected	O
fatty	B-CHED
acids	I-CHED
.	O

The	O
blood	O
samples	O
for	O
the	O
levels	O
of	O
steroid	B-CHED
hormones	I-CHED
and	O
insulin	B-CHED
-	O
like	O
growth	O
factor	O
I	O
(	O
IGF	O
-	O
I	O
)	O
were	O
assessed	O
using	O
immunoassays	O
and	O
the	O
levels	O
of	O
fatty	B-CHED
acids	I-CHED
were	O
assessed	O
using	O
gas	O
chromatography	O
.	O

As	O
the	O
genesis	O
of	O
these	O
emerging	O
viruses	O
is	O
not	O
well	O
understood	O
and	O
their	O
detection	O
normally	O
occurs	O
after	O
they	O
have	O
crossed	O
over	O
and	O
adapted	O
to	O
man	B-CHED
,	O
ideally	O
,	O
strategies	O
for	O
such	O
novel	O
virus	O
detection	O
should	O
include	O
intensive	O
surveillance	O
at	O
the	O
human	O
-	O
animal	O
interface	O
,	O
particularly	O
if	O
one	O
believes	O
the	O
paradigm	O
that	O
many	O
novel	O
emerging	O
zoonotic	O
viruses	O
first	O
circulate	O
in	O
animal	O
populations	O
and	O
occasionally	O
infect	O
man	B-CHED
before	O
they	O
fully	O
adapt	O
to	O
man	B-CHED
;	O
early	O
detection	O
at	O
the	O
human	O
-	O
animal	O
interface	O
will	O
provide	O
earlier	O
warning	O
.	O

ECMO	O
is	O
a	O
complex	O
network	O
that	O
provides	O
oxygenation	O
and	O
ventilation	O
and	O
allows	O
the	O
lungs	O
to	O
rest	B-CHED
and	O
recover	O
from	O
respiratory	O
failure	O
,	O
while	O
minimizing	O
iatrogenic	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

PCs	O
and	O
plasma	O
were	O
spiked	O
with	O
high	O
titers	O
of	O
cell	O
culture	O
-	O
derived	O
EBOV	O
and	O
MERS	O
-	O
CoV	O
,	O
treated	O
with	O
various	O
light	O
doses	O
of	O
ultraviolet	O
C	O
(	O
UVC	O
;	O
THERAFLEX	O
UV	O
-	O
Platelets	O
)	O
or	O
methylene	B-CHED
blue	I-CHED
(	O
MB	B-CHED
)	O
plus	O
visible	O
light	O
(	O
MB	B-CHED
/	O
light	O
;	O
THERAFLEX	O
MB	B-CHED
-	O
Plasma	O
),	O
and	O
assessed	O
for	O
residual	O
viral	O
infectivity	O
.	O

Cross	O
-	O
correlation	O
analysis	O
was	O
conducted	O
to	O
quantify	O
the	O
temporal	O
relationship	O
between	O
antibiotic	B-CHED
use	O
and	O
respiratory	O
virus	O
activities	O
as	O
well	O
as	O
respiratory	O
infections	O
in	O
primary	O
clinics	O
.	O

Children	O
with	O
either	O
virus	O
and	O
a	O
neurologic	O
comorbidity	O
or	O
an	O
increased	O
PIM	B-CHED
3	O
probability	O
of	O
mortality	O
were	O
at	O
increased	O
risk	O
for	O
PARDS	O
.	O

Although	O
both	O
types	O
of	O
vaccine	O
could	O
induce	O
specific	O
immunoglobulin	O
G	O
against	O
MERS	O
-	O
CoV	O
,	O
neutralizing	O
antibodies	O
against	O
MERS	O
-	O
CoV	O
were	O
induced	O
only	O
by	O
heterologous	O
prime	O
-	O
boost	O
immunization	O
and	O
homologous	O
immunization	O
with	O
spike	O
protein	B-CHED
nanoparticles	B-CHED
.	O

In	O
oropharyngeal	O
and	O
nasopharyngeal	O
swab	O
specimens	O
,	O
the	O
detection	O
of	O
sub	O
-	O
genomic	O
mRNA	B-CHED
and	O
genomic	O
RNA	O
did	O
not	O
correlate	O
.	O

TITLE	O
:	O
The	O
PERK	B-CHED
Arm	O
of	O
the	O
Unfolded	O
Protein	B-CHED
Response	O
Negatively	O
Regulates	O
Transmissible	O
Gastroenteritis	O
Virus	O
Replication	O
by	O
Suppressing	O
Protein	B-CHED
Translation	O
and	O
Promoting	O
Type	O
I	O
Interferon	O
Production	O
.	O

Costs	O
of	O
severe	O
influenza	O
-	O
associated	O
ARI	B-CHED
were	O
substantial	O
.	O

The	O
median	O
cost	O
per	O
severe	O
influenza	O
-	O
associated	O
ARI	B-CHED
episode	O
was	O
$	O
232	O
among	O
healthy	O
and	O
$	O
318	O
among	O
high	O
-	O
risk	O
children	O
(	O
26	O
-	O
40	O
%	O
and	O
36	O
-	O
54	O
%	O
of	O
monthly	O
household	O
income	O
,	O
respectively	O
;	O
difference	O
in	O
medians	O
:	O
110	O
;	O
95	O
%	O
CI	O
for	O
difference	O
in	O
medians	O
:	O
-$	O
352	O
to	O
$	O
571	O
).	O

TITLE	O
:	O
Pirfenidone	O
ameliorates	O
lipopolysaccharide	B-CHED
-	O
induced	O
pulmonary	O
inflammation	O
and	O
fibrosis	O
by	O
blocking	O
NLRP3	O
inflammasome	O
activation	O
.	O

Indeed	O
,	O
cleavage	O
of	O
the	O
S1	O
/	O
S2	O
interface	O
does	O
not	O
seem	O
to	O
be	O
a	O
prerequisite	O
,	O
and	O
the	O
fusion	O
activation	O
is	O
highly	O
reliant	O
on	O
the	O
S2	O
'	O
region	O
,	O
with	O
arginine	B-CHED
residue	I-CHED
683	O
acting	O
as	O
the	O
recognition	O
site	O
.	O

The	O
binding	O
system	O
of	O
biotin	B-CHED
-	O
streptavidin	O
,	O
RCA	O
,	O
and	O
Ru	O
(	O
bpy	B-CHED
)	O

Our	O
results	O
showed	O
that	O
the	O
full	O
-	O
length	O
E	O
and	O
3a	O
proteins	B-CHED
were	O
required	O
for	O
maximal	O
SARS	O
-	O
CoV	O
replication	O
and	O
virulence	O
,	O
whereas	O
viroporin	O
8a	O
had	O
only	O
a	O
minor	O
impact	O
on	O
these	O
activities	O
.	O

ABSTRACT	O
:	O
Four	O
types	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
variants	O
with	O
a	O
large	O
deletion	O
in	O
the	O
spike	O
protein	B-CHED
were	O
detected	O
,	O
together	O
with	O
the	O
original	O
US	O
PEDV	O
,	O
from	O
pig	O
fecal	O
and	O
oral	O
fluid	O
samples	O
collected	O
during	O
2016	O
-	O
2017	O
in	O
the	O
US	O
.	O

TITLE	O
:	O
Exploration	O
of	O
(	O
hetero	O
)	O
aryl	O
Derived	O
Thienylchalcones	O
for	O
Antiviral	B-CHED
and	O
Anticancer	O
Activities	O
.	O

METHODS	O
:	O
A	O
focused	O
set	O
of	O
thienyl	B-CHED
chalcone	B-CHED
derivaties	O
II	O
-	O
VI	O
was	O
screened	O
for	O
selected	O
viruses	O
Hepatitis	O
B	O
virus	O
(	O
HBV	O
),	O
Herpes	O
simplex	O
virus	O
1	O
(	O
HSV	O
-	O
1	O
),	O
Human	O
cytomegalovirus	O
(	O
HCMV	O
),	O
Dengue	O
virus	O
2	O
(	O
DENV2	O
),	O
Influenza	O
A	O
(	O
H1N1	O
)	O
virus	O
,	O
MERS	O
coronavirus	O
,	O
Poliovirus	O
1	O
(	O
PV	O
1	O
),	O
Rift	O
Valley	O
fever	O
(	O
RVF	O
),	O
Tacaribe	O
virus	O
(	O
TCRV	O
),	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
(	O
VEE	O
)	O
and	O
Zika	O
virus	O
(	O
ZIKV	O
)	O
using	O
the	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
(	O
NIAID	O
)'	O
s	O
Division	O
of	O
Microbiology	O
and	O
Infectious	O
Diseases	O
(	O
DMID	O
)	O
antiviral	B-CHED
screening	O
program	O
.	O

RESULTS	O
:	O
All	O
thienyl	B-CHED
chalcone	B-CHED
derivatives	O
II	O
-	O
VI	O
displayed	O
moderate	O
to	O
excellent	O
antiviral	B-CHED
activity	O
towards	O
several	O
viruses	O
tested	O
.	O

The	O
drug	O
saracatinib	O
,	O
a	O
potent	O
inhibitor	B-CHED
of	O
Src	O
-	O
family	O
of	O
tyrosine	B-CHED
kinases	O
(	O
SFK	O
),	O
was	O
identified	O
as	O
an	O
inhibitor	B-CHED
of	O
MERS	O
-	O
CoV	O
replication	O
in	O
vitro	O
.	O

We	O
then	O
assayed	O
the	O
purified	O
target	O
proteins	B-CHED
through	O
immunogenicity	O
tests	O
,	O
PEDV	O
binding	O
interference	O
assays	O
,	O
circular	O
dichroism	O
(	O
CD	O
)	O
measurements	O
,	O
pAPN	O
activity	O
assay	O
and	O
structural	O
determination	O
,	O
demonstrating	O
that	O
they	O
were	O
biologically	O
functional	O
.	O

Against	O
S	O
.	O
aureus	O
,	O
0	O
.	O
5	O
%	O
sodium	O
hypochlorite	B-CHED
with	O
and	O
without	O
color	O
additive	O
met	B-CHED
Environmental	O
Protection	O
Agency	O
criteria	O
for	O
disinfection	O
success	O
.	O

Respiratory	O
tract	O
infection	O
was	O
diagnosed	O
,	O
and	O
empirical	O
antibiotics	B-CHED
were	O
started	O
.	O

The	O
intervention	O
group	O
will	O
receive	O
daily	O
staircase	O
alveolar	O
recruitment	O
manoeuvres	O
with	O
incremental	O
PEEP	B-CHED
to	O
a	O
maximum	O
of	O
40	O
cmH	B-CHED
The	O
PHARLAP	O
trial	O
will	O
determine	O
whether	O
the	O
intervention	O
strategy	O
is	O
effective	O
in	O
increasing	O
ventilator	O
-	O
free	O
days	O
in	O
patients	O
with	O
ARDS	O
.	O

But	O
results	O
also	O
showed	O
reduced	O
SOFA	O
score	O
and	O
increased	O
number	O
of	O
ventilator	O
-	O
free	O
days	O
among	O
statin	B-CHED
users	O
,	O
indicating	O
that	O
statins	O
are	O
likely	O
to	O
have	O
some	O
beneficial	O
effects	O
.	O

Statin	B-CHED
treatment	O
of	O
ALI	O
/	O
ARDS	O
patients	O
seems	O
to	O
improve	O
health	O
in	O
terms	O
of	O
organ	O
failure	O
and	O
also	O
by	O
lowering	O
the	O
need	O
for	O
ventilation	O
.	O

There	O
are	O
three	O
patterns	O
of	O
transmission	O
:	O
sporadic	O
community	O
cases	O
from	O
presumed	O
non	O
-	O
human	O
exposure	O
,	O
family	O
clusters	B-CHED
arising	O
from	O
contact	O
with	O
an	O
infected	O
family	O
index	O
case	O
,	O
and	O
healthcare	O
-	O
acquired	O
infections	O
among	O
patients	O
and	O
from	O
patients	O
to	O
healthcare	O
workers	O
.	O

This	O
goes	O
along	O
with	O
a	O
strongly	O
reduced	O
HEV	O
capsid	O
protein	B-CHED
translation	O
,	O
retention	O
of	O
viral	O
RNA	O
inside	O
the	O
cytoplasm	O
,	O
and	O
without	O
major	O
cytotoxic	O
effects	O
.	O

ABSTRACT	O
:	O
The	O
folding	O
of	O
monomeric	O
antigens	B-CHED
and	O
their	O
subsequent	O
assembly	O
into	O
higher	O
ordered	O
structures	O
are	O
crucial	O
for	O
robust	O
and	O
effective	O
production	O
of	O
nanoparticle	B-CHED
(	O
NP	O
)	O
vaccines	O
in	O
a	O
timely	O
and	O
reproducible	O
manner	O
.	O

ABSTRACT	O
:	O
Plant	O
viral	O
nanoparticles	B-CHED
(	O
VNPs	O
)	O
are	O
currently	O
being	O
developed	O
as	O
novel	O
vessels	O
for	O
delivery	O
of	O
diagnostic	O
and	O
therapeutic	O
cargos	O
to	O
sites	O
of	O
disease	O
.	O

Antigen	B-CHED
positivity	O
lasted	O
3	O
to	O
6	O
days	O
in	O
secondary	O
infections	O
and	O
13	O
days	O
in	O
primary	O
infection	O
.	O

ABSTRACT	O
:	O
Porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
(	O
PHEV	O
)	O
is	O
a	O
highly	O
neurovirulent	O
coronavirus	O
and	O
causes	O
neurological	O
dysfunction	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
),	O
but	O
the	O
neuropathological	O
mechanism	O
of	O
PHEV	O
remains	O
poorly	O
understood	O
.	O

This	O
study	O
discovered	O
that	O
the	O
extracellular	O
receptor	O
binding	O
domain	O
1	O
pertaining	O
to	O
epidermal	O
growth	O
receptor	O
(	O
EGFR	O
)	O
interact	O
with	O
TGEV	O
spike	O
protein	B-CHED
.	O

A	O
bronchoscopy	O
with	O
BAL	B-CHED
and	O
transbronchial	O
biopsies	O
did	O
not	O
show	O
acute	O
cellular	O
rejection	O
,	O
but	O
the	O
BAL	B-CHED
fluid	O
was	O
positive	O
for	O
coronavirus	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
membrane	O
-	O
associated	O
78	O
-	O
kDa	O
glucose	B-CHED
-	O
regulated	O
protein	B-CHED
(	O
GRP78	O
)	O
as	O
an	O
additional	O
binding	O
target	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
relevance	O
of	O
such	O
a	O
model	O
for	O
the	O
discovery	O
and	O
validation	O
of	O
antiviral	B-CHED
drugs	I-CHED
.	O

Fully	O
differentiated	O
3D	O
nasal	O
epithelium	O
cultures	O
were	O
inoculated	O
with	O
picornaviruses	O
,	O
a	O
coronavirus	O
and	O
influenza	O
A	O
viruses	O
in	O
the	O
absence	O
or	O
in	O
the	O
presence	O
of	O
reference	O
antiviral	B-CHED
drugs	I-CHED
.	O

Similarly	O
,	O
oseltamivir	B-CHED
reduced	O
the	O
replication	O
of	O
influenza	O
A	O
viruses	O
in	O
a	O
dose	O
dependent	O
manner	O
and	O
prevented	O
the	O
impairment	O
of	O
the	O
epithelial	O
barrier	O
function	O
and	O
cytotoxicity	O
until	O
4	O
days	O
of	O
infection	O
.	O

These	O
results	O
reveal	O
that	O
a	O
large	O
panel	O
of	O
epithelial	O
functions	O
is	O
modified	O
upon	O
viral	O
infection	O
and	O
validate	O
MucilAir	O
	O
as	O
a	O
pertinent	O
tool	O
for	O
pre	O
-	O
clinical	O
antiviral	B-CHED
drug	I-CHED
testing	O
.	O

C	B-CHED
-	I-CHED
glycosides	I-CHED
have	O
been	O
shown	O
to	O
exert	O
strong	O
anti	O
-	O
inflammatory	O
properties	O
,	O
although	O
their	O
mechanism	O
of	O
action	O
remains	O
unknown	O
.	O

ABSTRACT	O
:	O
The	O
replicase	O
gene	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
encodes	O
15	O
non	O
-	O
structural	O
proteins	B-CHED
(	O
nsps	O
).	O

In	O
the	O
current	O
study	O
,	O
gene	O
encoding	O
of	O
381aa	O
-	O
792aa	O
spike	O
protein	B-CHED
(	O
S1	O
)	O
with	O
the	O
main	O
epitope	B-CHED
relative	O
to	O
virus	O
neutralization	O
of	O
PEDV	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
and	O
inserted	O
into	O
vector	O
pET	O
-	O
30A	O
(+).	O

Meanwhile	O
,	O
recombinant	O
protein	B-CHED
expression	O
was	O
induced	O
by	O
isopropy1	O
-	O
	O
-	O
galactopyranoside	O
(	O
IPTG	B-CHED
).	O

The	O
result	O
showed	O
that	O
MAb	O
can	O
specifically	O
respond	O
to	O
S1	O
protein	B-CHED
and	O
PEDV	O
via	O
ELISA	O
,	O
Western	O
bolt	O
and	O
immunofluorescence	O
assay	O
methods	O
.	O

A	O
seroepidemiological	O
investigation	O
was	O
conducted	O
among	O
MERS	O
-	O
CoV	O
case	O
patients	O
(	O
cases	O
)	O
and	O
their	O
household	O
contacts	O
to	O
investigate	O
transmission	O
risk	O
in	O
Abu	B-CHED
Dhabi	O
,	O
United	O
Arab	O
Emirates	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
N	O
protein	B-CHED
causes	O
endoplasmic	O
reticulum	O
stress	O
,	O
up	O
-	O
regulates	O
interleukin	O
-	O
8	O
expression	O
and	O
its	O
subcellular	O
localization	O
in	O
the	O
porcine	O
intestinal	O
epithelial	O
cell	O
.	O

In	O
most	O
areas	O
of	O
Africa	O
,	O
P	O
.	O
vivax	O
infection	O
is	O
essentially	O
absent	O
because	O
of	O
the	O
inherited	O
lack	O
of	O
Duffy	O
antigen	B-CHED
receptor	O
for	O
chemokines	O
on	O
the	O
surface	O
of	O
red	O
blood	O
cells	O
that	O
is	O
involved	O
in	O
the	O
parasite	O
invasion	O
of	O
erythrocytes	O
.	O

TITLE	O
:	O
High	O
flow	O
nasal	O
cannula	O
oxygen	B-CHED
versus	O
noninvasive	O
ventilation	O
in	O
adult	O
acute	O
respiratory	O
failure	O
:	O
a	O
systematic	O
review	O
of	O
randomized	O
-	O
controlled	O
trials	O
.	O

In	O
the	O
latter	O
two	O
trials	O
,	O
only	O
one	O
reported	O
a	O
difference	O
in	O
the	O
lowest	O
peripheral	O
capillary	O
oxygen	B-CHED
saturation	O
between	O
NIV	O
+	O
HFNC	O
versus	O
the	O
NIV	O
group	O
during	O
intubation	O
[	O
100	O
%	O
(	O
interquartile	O
range	O
:	O
95	O
-	O
100	O
)	O
vs	O
.	O
96	O
%	O
(	O
interquartile	O
range	O
:	O
92	O
-	O
99	O
);	O
P	O
=	O
0	O
.	O
029	O
].	O

However	O
,	O
the	O
mechanisms	O
of	O
the	O
dimerization	O
and	O
nucleic	B-CHED
acid	I-CHED
binding	O
of	O
nsp9	O
remain	O
elusive	O
.	O

Here	O
,	O
we	O
report	O
four	O
crystal	O
structures	O
,	O
including	O
wild	O
-	O
type	O
porcine	O
delta	O
coronavirus	O
(	O
PDCoV	O
)	O
nsp9	O
,	O
PDCoV	O
nsp9	O
-	O
N7	O
(	O
N	O
-	O
terminal	O
7	O
amino	B-CHED
acids	I-CHED
deleted	O
),	O
wild	O
-	O
type	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
nsp9	O
,	O
and	O
PEDV	O
nsp9	O
-	O
C59A	O
mutant	O
.	O

In	O
addition	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
microscale	O
thermophoresis	O
analysis	O
indicate	O
that	O
the	O
monomeric	O
forms	O
of	O
PDCoV	O
nsp9	O
and	O
PEDV	O
nsp9	O
still	O
have	O
nucleic	B-CHED
acid	I-CHED
binding	O
affinity	O
,	O
although	O
it	O
is	O
lower	O
than	O
that	O
of	O
the	O
wild	O
type	O
.	O

TITLE	O
:	O
Breakthrough	O
infection	O
of	O
Geotrichum	O
capitatum	O
during	O
empirical	O
caspofungin	B-CHED
therapy	O
after	O
umbilical	O
cord	O
blood	O
transplantation	O
.	O

The	O
serum	O
levels	O
of	O
beta	B-CHED
-	I-CHED
D	I-CHED
-	I-CHED
glucan	I-CHED
were	O
elevated	O
to	O
747	O
pg	O
/	O
mL	O
.	O
Caspofungin	B-CHED
was	O
switched	O
to	O
liposomal	B-CHED
amphotericin	I-CHED
B	I-CHED
;	O
however	O
,	O
radiological	O
findings	O
revealed	O
pulmonary	O
,	O
splenic	O
,	O
and	O
central	O
nervous	O
system	O
involvement	O
.	O

Immunoblotting	O
and	O
magnetic	O
beads	O
immunoisolation	O
complemented	O
by	O
standardized	O
flow	O
cytometry	O
and	O
nanoparticles	B-CHED
tracking	O
analyses	O
identified	O
in	O
the	O
ARDS	O
patients	O
a	O
subset	O
of	O
EVs	O
with	O
mesenchymal	O
stem	O
cell	O
(	O
MSC	O
)	O
origin	O
(	O
CD73	O

The	O
factors	O
independently	O
related	O
to	O
mortality	O
were	O
prior	O
steroid	B-CHED
use	O
(	O
OR	O
20	O
.	O
2	O
,	O
95	O
%	O
CI	O
1	O
.	O
9	O
-	O
217	O
.	O
5	O
)	O
and	O
hemorrhage	O
(	O
OR	O
71	O
.	O
2	O
,	O
95	O
%	O
CI	O
4	O
.	O
9	O
-	O
>	O
999	O
.	O
9	O
).	O

In	O
view	O
of	O
the	O
later	O
identified	O
diagnostic	O
difference	O
in	O
this	O
very	O
part	O
of	O
the	O
S	O
protein	B-CHED
of	O
serotype	O
I	O
FCoV	O
pathotypes	O
,	O
the	O
present	O
study	O
aimed	O
to	O
further	O
define	O
the	O
contribution	O
of	O
the	O
earlier	O
observed	O
ten	O
amino	B-CHED
acids	I-CHED
difference	O
to	O
the	O
serotype	O
II	O
virus	O
phenotype	O
in	O
macrophages	O
.	O

Additionally	O
,	O
an	O
outbreak	O
of	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
may	O
have	O
occurred	O
in	O
Ras	B-CHED
Tanura	O
city	O
between	O
April	O
2015	O
and	O
February	O
2016	O
.	O

The	O
incidence	O
of	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
was	O
higher	O
in	O
Ras	B-CHED
Tanura	O
city	O
compared	O
to	O
other	O
locations	O
in	O
the	O
Eastern	O
Province	O
.	O

Treatment	O
with	O
cyclosporin	B-CHED
A	I-CHED
(	O
CsA	B-CHED
),	O
an	O
inhibitor	B-CHED
of	O
mitochondrial	O
permeability	O
transition	O
pore	O
(	O
MPTP	B-CHED
)	O
opening	O
,	O
significantly	O
suppressed	O
PDCoV	O
-	O
triggered	O
apoptosis	O
and	O
viral	O
replication	O
.	O

Moreover	O
,	O
cyt	B-CHED
c	O
release	O
was	O
completely	O
abrogated	O
in	O
PDCoV	O
-	O
infected	O
cells	O
in	O
the	O
presence	O
of	O
CsA	B-CHED
,	O
suggesting	O
the	O
critical	O
role	O
of	O
MPTP	B-CHED
in	O
intrinsic	O
apoptosis	O
in	O
response	O
to	O
PDCoV	O
infection	O
.	O

ABSTRACT	O
:	O
Multiple	O
Sclerosis	O
(	O
MS	O
)	O
is	O
a	O
chronic	O
inflammatory	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
characterized	O
by	O
demyelination	O
and	O
axonal	O
loss	O
.	O

While	O
gene	O
expression	O
in	O
CNS	B-CHED
infiltrating	O
BMDM	O
was	O
upregulated	O
early	O
following	O
infection	O
and	O
subsequently	O
sustained	O
,	O
microglia	O
expressed	O
a	O
more	O
dynamic	O
gene	O
profile	O
with	O
extensive	O
mRNA	B-CHED
upregulation	O
coinciding	O
with	O
peak	O
demyelination	O
after	O
viral	O
control	O
.	O

Nanobodies	O
(	O
Nbs	B-CHED
)	O
are	O
single	O
-	O
domain	O
antibodies	O
derived	O
from	O
camelids	O
and	O
sharks	O
and	O
are	O
potentially	O
cost	O
-	O
effective	O
antivirals	B-CHED
with	O
small	O
size	O
and	O
great	O
expression	O
yield	O
.	O

Clinical	O
presentation	O
ranges	O
from	O
asymptomatic	O
infection	O
to	O
severe	O
infection	O
including	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
disseminated	O
intravascular	O
coagulopathy	O
(	O
DIC	B-CHED
)	O
or	O
death	O
.	O

Although	O
all	O
anti	O
-	O
MDA5	O
-	O
positive	O
patients	O
with	O
CADM	O
had	O
ILD	O
,	O
the	O
MAA	B-CHED
-	O
positive	O
patients	O
showed	O
a	O
lower	O
risk	O
of	O
developing	O
RP	O
-	O
ILD	O
(	O
p	O
=	O
0	O
.	O
03	O
),	O
a	O
more	O
favorable	O
response	O
to	O
combination	O
therapy	O
of	O
corticosteroids	B-CHED
and	O
immunosuppressive	B-CHED
agents	I-CHED
,	O
and	O
a	O
lower	O
mortality	O
rate	O
than	O
patients	O
with	O
no	O
MAAs	O
(	O
p	O
=	O
0	O
.	O
03	O
).	O

In	O
the	O
present	O
study	O
,	O
to	O
mimic	O
the	O
native	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
,	O
a	O
stable	O
cell	O
line	O
producing	O
the	O
trimeric	O
ectodomain	O
of	O
S	O
glycoprotein	B-CHED
of	O
the	O
PEDV	O
Pintung	O
-	O
52	O
(	O
PEDV	O
-	O
PT	O
)	O
strain	O
was	O
successfully	O
established	O
by	O
incorporating	O
T4	O
bacteriophage	O
foldon	O
sequence	O
of	O
fibritin	O
trimerization	O
domains	O
at	O
the	O
C	O
-	O
terminal	O
end	O
and	O
replacing	O
the	O
signal	O
peptide	B-CHED
of	O
S	O
protein	B-CHED
with	O
the	O
tissue	O
plasminogen	O
activator	O
signal	O
peptide	B-CHED
sequence	O
at	O
the	O
N	O
terminal	O
end	O
.	O

Although	O
viral	O
RNA	O
was	O
detected	O
in	O
air	B-CHED
samples	O
with	O
both	O
strains	O
,	O
the	O
indirect	O
contact	O
pigs	O
remained	O
free	O
from	O
infection	O
with	O
the	O
InDel	O
strain	O
in	O
contrast	O
to	O
the	O
non	O
-	O
InDel	O
group	O
in	O
which	O
airborne	O
transmission	O
occurred	O
in	O
the	O
indirect	O
contact	O
pigs	O
.	O

The	O
newly	O
discovered	O
type	O
III	O
IFN	O
,	O
which	O
plays	O
a	O
crucial	O
role	O
in	O
antiviral	B-CHED
immunity	O
,	O
has	O
strong	O
antiviral	B-CHED
activity	O
against	O
PEDV	O
proliferation	O
in	O
IPEC	O
-	O
J2	O
cells	O
.	O

Anti	O
-	O
pneumococcal	O
vaccination	O
has	O
reduced	O
the	O
incidence	O
of	O
pneumonia	O
and	O
sepsis	O
caused	O
by	O
increasingly	O
antibiotic	B-CHED
-	O
resistant	O
Streptococcus	O
pneumoniae	O
in	O
all	O
age	O
groups	O
.	O

Although	O
the	O
formal	B-CHED
protocols	O
for	O
inter	O
-	O
sectoral	O
collaboration	O
were	O
not	O
always	O
up	O
to	O
date	O
,	O
good	O
personal	O
relations	O
were	O
reported	O
within	O
the	O
relevant	O
professional	O
networks	O
,	O
which	O
could	O
be	O
brought	O
into	O
play	O
in	O
the	O
event	O
of	O
a	O
public	O
health	O
emergency	O
.	O

Previously	O
,	O
groups	O
had	O
targeted	O
conserved	O
coronavirus	O
proteins	B-CHED
as	O
a	O
strategy	O
to	O
generate	O
live	O
attenuated	O
vaccine	O
strains	O
against	O
current	O
and	O
future	O
CoVs	O
.	O

Our	O
results	O
suggest	O
that	O
TMPRSS11A	O
could	O
promote	O
FLUAV	O
spread	O
in	O
target	O
cells	O
and	O
that	O
HA	O
-	O
activating	O
TTSPs	O
exhibit	O
differential	O
sensitivity	O
to	O
blockade	O
by	O
cellular	O
serine	B-CHED
protease	I-CHED
inhibitors	I-CHED
.	O

Three	O
unique	O
amino	B-CHED
acid	I-CHED
substitutions	O
(	O
L7	O
,	O
G8	O
,	O
and	O
V9	O
)	O
were	O
identified	O
in	O
the	O
SP	O
-	O
encoding	O
fragment	O
of	O
the	O
S1	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
PEDV	O
-	O
LY4	O
-	O
98	O
S	O
protein	B-CHED
compared	O
with	O
the	O
S	O
proteins	B-CHED
of	O
all	O
the	O
previous	O
PEDV	O
strains	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
PEDV	O
represents	O
a	O
new	O
vaccine	O
candidate	O
molecule	O
to	O
be	O
applied	O
via	O
the	O
mucosal	O
route	O
.	O

ABSTRACT	O
:	O
This	O
case	O
report	O
presents	O
a	O
46	O
-	O
year	O
old	O
man	B-CHED
with	O
a	O
failed	O
liver	O
transplant	O
who	O
presented	O
with	O
malaise	O
and	O
dyspnea	O
.	O

An	O
estimated	O
50	O
-	O
kDa	O
recombinant	O
protein	B-CHED
corresponding	O
to	O
the	O
expected	O
molecular	O
weight	O
of	O
IBV	O
N	O
including	O
the	O
6xHis	O
tag	O
was	O
detected	O
using	O
an	O
anti	O
-	O
His	O
monoclonal	O
antibody	O
.	O

These	O
include	O
an	O
infectious	O
model	O
of	O
ARDS	O
driven	O
by	O
direct	O
administration	O
of	O
Streptococcus	O
pneumoniae	O
and	O
a	O
sterile	O
inflammatory	O
model	O
mediated	O
by	O
intratracheal	O
administration	O
of	O
lipopolysaccharide	B-CHED
.	O

The	O
diagnostic	O
criteria	O
for	O
ARDS	O
are	O
mainly	O
clinical	O
and	O
lack	O
the	O
objectivity	O
of	O
a	O
laboratory	O
test	O
or	O
biomarker	B-CHED
.	O

Among	O
the	O
platforms	O
,	O
the	O
FilmArray	O
is	O
the	O
most	O
automated	O
but	O
is	O
of	O
the	O
lowest	O
-	O
throughput	O
and	O
has	O
the	O
highest	O
reagent	B-CHED
cost	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
nasal	O
spray	O
containing	O
xylometazoline	O
hydrochloride	B-CHED
and	O
iota	B-CHED
-	I-CHED
carrageenan	I-CHED
for	O
the	O
symptomatic	O
relief	O
of	O
nasal	O
congestion	O
caused	O
by	O
rhinitis	O
and	O
sinusitis	O
.	O

Also	O
the	O
involvement	O
of	O
the	O
FK	O
-	O
506	O
-	O
binding	O
proteins	B-CHED
and	O
parvulins	O
is	O
discussed	O
.	O

TITLE	O
:	O
StatPearls	O
ABSTRACT	O
:	O
Hypersensitivity	O
reactions	O
(	O
HR	O
)	O
are	O
immune	O
responses	O
that	O
are	O
exaggerated	O
or	O
inappropriate	O
against	O
an	O
antigen	B-CHED
or	O
allergen	B-CHED
.	O

A	O
previous	O
report	O
shows	O
that	O
furin	O
,	O
which	O
is	O
distributed	O
mainly	O
in	O
the	O
Golgi	O
apparatus	O
and	O
cycled	O
to	O
the	O
cell	O
surface	O
and	O
endosomes	O
,	O
proteolytically	O
activates	O
the	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
following	O
receptor	O
binding	O
to	O
mediate	O
fusion	O
between	O
the	O
viral	O
and	O
cellular	O
membranes	O
.	O

In	O
addition	O
,	O
dec	B-CHED
-	O
RVKR	O
-	O
CMK	O
inhibited	O
not	O
only	O
the	O
enzymatic	O
activity	O
of	O
furin	O
but	O
also	O
those	O
of	O
cathepsin	O
L	O
,	O
cathepsin	O
B	O
,	O
trypsin	O
,	O
papain	O
,	O
and	O
TMPRSS2	O
.	O

Here	O
we	O
mapped	O
33	O
host	O
protein	B-CHED
interactions	O
of	O
CD81	O
in	O
primary	O
human	O
liver	O
and	O
hepatoma	O
cells	O
using	O
high	O
-	O
resolution	O
quantitative	O
proteomics	O
.	O

This	O
literature	O
will	O
be	O
of	O
prime	O
interest	O
to	O
medicinal	O
chemists	O
in	O
getting	O
ideas	O
and	O
concepts	O
for	O
better	O
rational	O
development	O
of	O
potential	O
anti	O
-	O
infective	O
inhibitors	B-CHED
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
HCoV	O
-	O
OC43	O
to	O
antagonize	O
the	O
transcriptional	O
activation	O
of	O
antiviral	B-CHED
response	O
elements	O
.	O

The	O
antiviral	B-CHED
gene	O
expression	O
profile	O
in	O
HEK	O
-	O
293	O
cells	O
was	O
determined	O
by	O
PCR	O
array	O
.	O

Here	O
,	O
we	O
review	O
the	O
effect	O
of	O
cardiac	O
glycosides	B-CHED
on	O
viral	O
biology	O
and	O
the	O
mechanisms	O
by	O
which	O
these	O
drugs	O
impair	O
the	O
replication	O
of	O
this	O
array	O
of	O
different	O
viruses	O
.	O

TITLE	O
:	O
Chlorine	B-CHED
gas	O
inhalation	O
manifesting	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
successfully	O
treated	O
by	O
high	O
-	O
volume	O
hemofiltration	O
:	O
A	O
case	O
report	O
.	O

Interestingly	O
,	O
the	O
two	O
clades	O
,	O
both	O
pandemic	O
and	O
classical	O
,	O
consisted	O
of	O
clade	O
-	O
specific	O
amino	B-CHED
acid	I-CHED
sequences	O
in	O
five	O
genes	O
:	O
ORF1a	O
,	O
ORF1b	O
,	O
S	O
,	O
ORF3	O
,	O
and	O
N	O
.	O
Within	O
the	O
pandemic	O
clade	O
,	O
Group	O
1	O
and	O
Group	O
2	O
originated	O
from	O
North	O
America	O
,	O
whereas	O
Group	O
3	O
-	O
Group	O
5	O
were	O
derived	O
from	O
Asia	O
.	O

To	O
further	O
trace	O
PDCoV	O
in	O
the	O
period	O
of	O
2011	O
to	O
2015	O
,	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
used	O
to	O
detect	O
antibodies	O
against	O
PDCoV	O
.	O
The	O
results	O
showed	O
that	O
279	O
of	O
1	O
,	O
039	O
(	O
26	O
.	O
9	O
%)	O
sera	O
were	O
positive	O
for	O
the	O
PDCoV	O
nucleocapsid	O
protein	B-CHED
,	O
implying	O
that	O
PDCoV	O
might	O
have	O
existed	O
in	O
Taiwan	O
before	O
2011	O
.	O

Furthermore	O
,	O
the	O
pharmacological	O
sequestration	O
of	O
cellular	O
or	O
viral	O
cholesterol	B-CHED
efficiently	O
blocked	O
both	O
virus	O
attachment	O
and	O
internalization	O
.	O

A	O
/	O
H1N1pdm09	O
viruses	O
analyzed	O
by	O
gene	O
sequencing	O
fell	O
into	O
genetic	O
groups	O
6B	O
and	O
6B	O
.	O
1	O
;	O
A	O
/	O
H3N2	B-CHED
viruses	O
belonged	O
to	O
genetic	O
subclades	O
3C	O
.	O
3b	O
,	O
3C	O
.	O
3a	O
,	O
3C	O
.	O
2a	O
and	O
3C	O
.	O
2a1	O
;	O
B	O
/	O
Yamagata	O
lineage	O
viruses	O
were	O
of	O
clade	O
3	O
and	O
B	O
/	O
Victoria	O
lineage	O
viruses	O
fell	O
in	O
clade1A	O
.	O

Then	O
,	O
rice	O
hulls	O
treated	O
with	O
10	O
%	O
MCFA	B-CHED
were	O
mixed	O
and	O
discharged	O
through	O
a	O
production	O
scale	O
mixer	O
and	O
bucket	O
elevator	O
following	O
PEDV	O
-	O
positive	O
feed	O
.	O

However	O
,	O
one	O
10	O
%	O
MCFA	B-CHED
rice	O
hull	O
sample	O
collected	O
from	O
the	O
bucket	O
elevator	O
discharge	O
spout	O
had	O
detectible	O
PEDV	O
RNA	O
.	O

However	O
,	O
dust	O
collected	O
immediately	O
after	O
the	O
10	O
%	O
MCFA	B-CHED
rice	O
hull	O
flush	O
batch	O
had	O
a	O
reduced	O
quantity	O
of	O
PEDV	O
RNA	O
(	O
Ct	O
=	O
33	O
.	O
7	O
)	O
and	O
did	O
not	O
cause	O
infection	O
.	O

An	O
84	O
-	O
year	O
-	O
old	O
man	B-CHED
underwent	O
reperfusion	O
therapy	O
for	O
acute	O
left	O
internal	O
carotid	O
artery	O
occlusion	O
;	O
complete	O
reperfusion	O
was	O
achieved	O
.	O

Accordingly	O
,	O
surface	O
expression	O
of	O
DC	O
-	O
targeted	O
antigens	B-CHED
successfully	O
induced	O
cellular	O
,	O
mucosal	O
,	O
and	O
humoral	O
immunity	O
in	O
mice	O
and	O
could	O
be	O
used	O
as	O
a	O
vaccine	O
.	O

Overall	O
,	O
this	O
review	O
provides	O
informative	O
guidance	O
for	O
designing	O
and	O
developing	O
safe	O
and	O
effective	O
MERS	O
vaccines	O
based	O
on	O
viral	O
S	O
protein	B-CHED
.	O

Collectively	O
,	O
our	O
results	O
underscore	O
the	O
unprecedented	O
role	O
of	O
the	O
ORF3	O
,	O
which	O
involves	O
the	O
interaction	O
of	O
ORF3	O
with	O
S	O
and	O
,	O
possibly	O
,	O
other	O
structural	O
protein	B-CHED
during	O
PEDV	O
replication	O
.	O

Here	O
we	O
explored	O
the	O
possibilities	O
for	O
rationally	O
attenuating	O
IBV	O
to	O
improve	O
our	O
knowledge	O
regarding	O
the	O
function	O
of	O
IBV	O
accessory	O
proteins	B-CHED
and	O
for	O
the	O
development	O
of	O
next	O
-	O
generation	O
vaccines	O
with	O
the	O
recently	O
established	O
reverse	O
genetic	O
system	O
for	O
IBV	O
H52	O
based	O
on	O
targeted	O
RNA	O
recombination	O
and	O
selection	O
of	O
recombinant	O
viruses	O
in	O
embryonated	O
eggs	O
.	O

ABSTRACT	O
:	O
Multiple	O
sclerosis	O
(	O
MS	O
)	O
is	O
a	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
disease	O
characterized	O
by	O
chronic	O
neuroinflammation	O
,	O
demyelination	O
,	O
and	O
axonal	O
damage	O
.	O

The	O
present	O
study	O
examined	O
the	O
biological	B-CHED
role	I-CHED
of	O
SGs	O
in	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
CoV	O
replication	O
.	O

The	O
hemagglutination	O
inhibition	O
(	O
HI	O
)	O
titers	O
of	O
mice	O
immunized	O
with	O
the	O
JY	O
-	O
adjuvanted	O
vaccine	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
mice	O
immunized	O
with	O
the	O
vaccine	O
without	O
adjuvant	B-CHED
(	O
21	O
.	O
11	O
	O
9	O
.	O
58	O
vs	O
.	O
5	O
.	O
04	O
	O
3	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
human	O
	O
-	O
defensin	O
(	O
HBD	O
)	O
2	O
to	O
promote	O
antiviral	B-CHED
immunity	O
in	O
vitro	O
and	O
in	O
vivo	O
using	O
a	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
spike	O
protein	B-CHED
(	O
S	O
RBD	O
)	O
as	O
a	O
model	O
antigen	B-CHED
(	O
Ag	O
).	O

ABSTRACT	O
:	O
The	O
total	O
synthesis	O
of	O
reniochalistatins	O
A	O
-	O
E	O
,	O
along	O
with	O
a	O
reniochalistatin	O
E	O
analogue	O
(	O
inverso	O
-	O
E	O
)	O
was	O
successfully	O
achieved	O
through	O
Fmoc	B-CHED
-	O
based	O
solid	O
-	O
phase	O
peptide	B-CHED
synthesis	O
and	O
subsequent	O
macrolactamization	O
with	O
PyBOP	O
and	O
DIEA	O
.	O

In	O
addition	O
,	O
linear	O
reniochalistatin	O
B	O
was	O
found	O
to	O
have	O
antitubercular	B-CHED
activity	O
(	O
IC	O

In	O
addition	O
,	O
we	O
studied	O
the	O
structures	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	B-CHED
and	O
its	O
complexes	O
with	O
ACE2	O
in	O
different	O
in	O
vitro	O
conditions	O
,	O
which	O
may	O
mimic	O
different	O
conformational	O
states	O
of	O
the	O
S	O
glycoprotein	B-CHED
during	O
virus	O
entry	O
.	O

Moreover	O
,	O
macroscopic	O
and	O
microscopic	O
lesions	O
in	O
whole	O
intestinal	O
tract	O
were	O
observed	O
,	O
and	O
viral	O
antigen	B-CHED
could	O
be	O
detected	O
in	O
the	O
small	O
intestines	O
by	O
immunohistochemical	O
staining	O
and	O
electron	O
microscopy	O
.	O

Virus	O
-	O
specific	O
T	O
cells	O
are	O
recruited	O
to	O
the	O
CNS	B-CHED
,	O
and	O
control	O
viral	O
replication	O
through	O
release	O
of	O
antiviral	B-CHED
cytokines	O
and	O
cytolytic	O
activity	O
.	O

Variation	O
in	O
the	O
host	O
receptor	O
,	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
),	O
can	O
block	O
the	O
interaction	O
with	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
and	O
form	O
a	O
species	O
barrier	O
to	O
infection	O
.	O

Moreover	O
,	O
MAbs	O
were	O
induced	O
with	O
the	O
recombinant	O
S	O
protein	B-CHED
and	O
RBD	O
and	O
used	O
for	O
sandwich	O
ELISA	O
to	O
detect	O
the	O
MERS	O
-	O
CoV	O
S	O
protein	B-CHED
.	O

Structural	O
information	O
on	O
this	O
crucial	O
protein	B-CHED
from	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
CoV	O
(	O
MERS	O
-	O
CoV	O
),	O
which	O
is	O
lethally	O
pathogenic	O
and	O
has	O
caused	O
severe	O
respiratory	O
diseases	O
worldwide	O
,	O
is	O
lacking	O
.	O

Treatment	O
with	O
endocytosis	O
inhibitors	B-CHED
did	O
not	O
affect	O
syncytium	O
formation	O
by	O
infected	O
cells	O
.	O

Moreover	O
,	O
the	O
infectivity	O
of	O
scIAV	O
-	O
S	O
was	O
associated	O
with	O
the	O
degree	O
of	O
cell	O
adaptation	O
of	O
PEDV	O
-	O
S	O
.	O
Intriguingly	O
,	O
scIAV	O
-	O
S	O
lacking	O
functional	O
neuraminidase	O
(	O
NA	O
)	O
exhibited	O
substantially	O
higher	O
infectivity	O
,	O
suggesting	O
a	O
pivotal	O
role	O
of	O
the	O
sialic	B-CHED
acid	I-CHED
in	O
the	O
binding	O
/	O
entry	O
of	O
PEDV	O
.	O

In	O
addition	O
,	O
nonstructural	O
protein	B-CHED
4a	O
(	O
NSP4a	O
),	O
NSP4b	O
,	O
and	O
NSP15	O
inhibit	O
double	O
-	O
stranded	O
RNA	O
sensors	O
.	O

ABSTRACT	O
:	O
Modified	O
vaccinia	O
virus	O
Ankara	O
(	O
MVA	B-CHED
)	O
is	O
a	O
replication	O
-	O
deficient	O
poxvirus	O
,	O
attenuated	O
in	O
chick	O
embryo	O
fibroblast	O
primary	O
cells	O
.	O

However	O
,	O
due	O
to	O
the	O
complex	O
nature	O
of	O
many	O
pathogens	O
and	O
their	O
pathogenicity	O
,	O
MVA	B-CHED
vectored	O
vaccine	O
candidates	O
need	O
to	O
be	O
optimised	O
to	O
improve	O
their	O
immunogenicity	O
.	O

TITLE	O
:	O
Three	O
Main	O
Inducers	O
of	O
Alphacoronavirus	O
Infection	O
of	O
Enterocytes	O
:	O
Sialic	B-CHED
Acid	I-CHED
,	O
Proteases	O
,	O
and	O
Low	O
pH	O
.	O
ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
and	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
are	O
similar	O
coronaviruses	O
,	O
causing	O
diseases	O
characterized	O
by	O
vomiting	O
,	O
diarrhea	O
,	O
and	O
death	O
from	O
severe	O
dehydration	O
in	O
piglets	O
.	O

From	O
week	O
4	O
to	O
8	O
of	O
training	O
,	O
proper	O
neck	O
extension	O
,	O
positive	O
pressure	O
ventilation	O
(	O
PPV	B-CHED
)	O
with	O
chest	O
rise	O
,	O
and	O
assessment	O
of	O
heart	O
rate	O
increased	O
by	O
14	O
%,	O
19	O
%,	O
and	O
12	O
%	O
respectively	O
(	O
all	O
p	O
	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Chiral	O
zirconium	B-CHED
quantum	O
dots	O
:	O
A	O
new	O
class	O
of	O
nanocrystals	O
for	O
optical	O
detection	O
of	O
coronavirus	O
.	O

TITLE	O
:	O
DPP4	O
inhibition	O
by	O
sitagliptin	B-CHED
attenuates	O
LPS	B-CHED
-	O
induced	O
lung	O
injury	O
in	O
mice	O
.	O

Other	O
considerations	O
include	O
the	O
effects	O
of	O
cyanide	B-CHED
,	O
carbon	B-CHED
monoxide	I-CHED
,	O
and	O
fire	O
suppressants	O
.	O

Mice	O
received	O
intraperitoneal	O
injections	O
of	O
cerulein	B-CHED
7	O
times	O
(	O
100	O
g	O
/	O
kg	O
each	O
)	O
at	O
1	O
-	O
hour	O
intervals	O
to	O
induce	O
acute	O
pancreatitis	O
.	O

Moreover	O
,	O
HRG	O
suppressed	O
tumor	O
necrosis	O
factor	O
	O
,	O
inducible	O
nitric	B-CHED
oxide	I-CHED
synthase	O
,	O
interleukin	O
6	O
,	O
and	O
neutrophil	O
elastase	O
mRNA	B-CHED
expression	O
and	O
myeloperoxidase	O
activity	O
in	O
the	O
lung	O
.	O

Inhibition	O
of	O
coiled	O
coil	O
-	O
mediated	O
interactions	O
using	O
bioactive	O
peptides	B-CHED
that	O
replicate	O
an	O
	O
-	O
helical	O
chain	O
from	O
the	O
viral	O
fusion	O
machinery	O
has	O
significant	O
antiviral	B-CHED
potential	O
.	O

We	O
compared	O
drugs	O
administration	O
,	O
oxygen	B-CHED
delivery	O
,	O
and	O
laboratory	O
tests	O
between	O
those	O
patients	O
with	O
ultrasound	O
integrated	O
management	O
and	O
those	O
without	O
ultrasound	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
the	O
post	O
-	O
fusion	O
core	O
of	O
the	O
Human	O
coronavirus	O
229E	O
spike	O
protein	B-CHED
at	O
1	O
.	O
86	O
	O
resolution	O
.	O

A	O
pathogen	O
community	O
approach	O
including	O
both	O
virus	O
and	O
bacteria	O
at	O
a	O
larger	O
scale	O
becomes	O
crucial	O
for	O
a	O
better	O
understanding	O
of	O
transmission	O
dynamics	O
at	O
population	O
level	O
in	O
order	O
to	O
help	O
shape	O
ARI	B-CHED
control	O
strategies	O
.	O

TITLE	O
:	O
Clinical	O
features	O
and	O
outcome	O
of	O
patients	O
with	O
acute	O
respiratory	O
failure	O
revealing	O
anti	O
-	O
synthetase	O
or	O
anti	O
-	O
MDA	B-CHED
-	O
5	O
dermato	O
-	O
pulmonary	O
syndrome	O
:	O
a	O
French	O
multicenter	O
retrospective	O
study	O
.	O

To	O
evaluate	O
both	O
the	O
immediate	O
and	O
residual	O
effects	O
of	O
treatment	O
on	O
antibody	O
detection	O
,	O
samples	O
were	O
tested	O
immediately	O
post	O
-	O
treatment	O
,	O
then	O
stored	O
at	O
4	O
	O
C	O
and	O
retested	O
at	O
2	O
,	O
4	O
,	O
and	O
6	O
days	O
post	O
-	O
treatment	O
(	O
DPT	B-CHED
).	O

TITLE	O
:	O
Interplay	O
between	O
the	O
Poly	O
(	O
A	O
)	O
Tail	O
,	O
Poly	O
(	O
A	O
)-	O
Binding	O
Protein	B-CHED
,	O
and	O
Coronavirus	O
Nucleocapsid	O
Protein	B-CHED
Regulates	O
Gene	O
Expression	O
of	O
Coronavirus	O
and	O
the	O
Host	O
Cell	O
.	O

These	O
results	O
revealed	O
81	O
%	O
shared	O
nucleotide	B-CHED
identity	O
with	O
human	O
/	O
civet	O
SARS	O
CoVs	O
,	O
which	O
was	O
more	O
distant	O
than	O
that	O
observed	O
previously	O
for	O
bat	O
SL	O
-	O
CoVs	O
in	O
China	O
.	O

Reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
is	O
the	O
gold	B-CHED
standard	O
diagnostic	O
test	O
for	O
H7N9	O
avian	O
influenza	O
.	O

Like	O
cocaine	B-CHED
,	O
methamphetamine	B-CHED
blocks	O
reuptake	O
of	O
monoamine	B-CHED
transporters	O
,	O
but	O
also	O
stimulates	O
dopamine	B-CHED
release	O
and	O
has	O
a	O
longer	O
duration	O
of	O
action	O
.	O

In	O
this	O
vaccine	O
,	O
B	O
cell	O
epitopes	O
derived	O
from	O
the	O
second	O
heptad	O
repeat	O
(	O
HR2	O
)	O
region	O
of	O
IBV	O
spike	O
proteins	B-CHED
were	O
repetitively	O
presented	O
in	O
its	O
native	O
trimeric	O
conformation	O
.	O

RESULTS	O
:	O
We	O
have	O
developed	O
two	O
indirect	O
microarray	O
methods	O
to	O
detect	O
antibodies	O
against	O
IBV	O
:	O
a	O
chemiluminescent	O
immunoassay	O
test	O
(	O
CIT	B-CHED
)	O
and	O
a	O
rapid	O
diagnostic	O
test	O
(	O
RDT	O
).	O

In	O
addition	O
,	O
Caerin1	O
.	O
1	O
showed	O
powerful	O
antiviral	B-CHED
activity	O
without	O
interfering	O
with	O
the	O
binding	O
progress	O
between	O
PEDV	O
and	O
the	O
receptor	O
of	O
the	O
cells	O
,	O
therefore	O
,	O
it	O
could	O
be	O
used	O
as	O
a	O
potential	O
antiviral	B-CHED
drug	I-CHED
or	O
as	O
a	O
microbicide	B-CHED
compound	O
for	O
prevention	O
and	O
control	O
of	O
PEDV	O
.	O

RESULTS	O
:	O
Spearman	O
'	O
s	O
correlation	O
coefficient	O
for	O
comparison	O
between	O
EIT	O
-	O
derived	O
time	O
constants	O
and	O
those	O
from	O
flow	O
/	O
volume	O
curves	O
was	O
between	O
0	O
.	O
78	O
for	O
tau	B-CHED
(	O
	O
)	O
calculated	O
from	O
the	O
global	O
impedance	O
signal	O
up	O
to	O
0	O
.	O
83	O
for	O
the	O
mean	O
of	O
all	O
pixelwise	O
calculated	O
regional	O
impedance	O
changes	O
over	O
the	O
entire	O
PEEP	B-CHED
range	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
impact	O
of	O
TGEV	O
infection	O
on	O
arginine	B-CHED
uptake	O
using	O
the	O
porcine	O
small	O
intestinal	O
epithelial	O
cell	O
line	O
IPEC	O
-	O
J2	O
as	O
a	O
model	O
system	O
.	O

PEP	B-CHED
therapy	O
was	O
associated	O
with	O
a	O
40	O
%	O
decrease	O
in	O
the	O
risk	O
of	O
infection	O
.	O

There	O
were	O
no	O
severe	O
adverse	O
events	O
during	O
PEP	B-CHED
therapy	O
.	O

During	O
infection	O
,	O
MERS	O
-	O
CoV	O
regulates	O
several	O
host	O
cellular	O
processes	O
including	O
antiviral	B-CHED
response	O
genes	O
.	O

We	O
used	O
in	O
vivo	O
and	O
in	O
vitro	O
models	O
,	O
respectively	O
,	O
using	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)	O
to	O
induce	O
ALI	O
in	O
mice	O
and	O
exposing	O
J774	O
and	O
BEAS	O
-	O
2B	O
cells	O
to	O
LPS	B-CHED
.	O

In	O
addition	O
,	O
the	O
translocation	O
of	O
AIF	O
was	O
inhibited	O
by	O
Veliparib	B-CHED
(	O
ABT	B-CHED
-	I-CHED
888	I-CHED
),	O
an	O
inhibitor	B-CHED
of	O
poly	O
(	O
ADP	B-CHED
-	O
ribose	B-CHED
)	O
polymerase	O
(	O
PARP	B-CHED
).	O

And	O
the	O
reactive	B-CHED
oxygen	I-CHED
species	I-CHED
(	O
ROS	B-CHED
)	O
scavenger	O
,	O
pyrrolidinedithiocarbamic	O
(	O
PDTC	O
),	O
redistributed	O
AIF	O
in	O
the	O
mitochondria	O
and	O
nucleus	B-CHED
in	O
TGEV	O
-	O
infected	O
cells	O
.	O

RESULTS	O
:	O
During	O
the	O
study	O
period	O
,	O
336	O
patients	O
with	O
severe	O
influenza	O
pneumonia	O
were	O
screened	O
and	O
263	O
patients	O
met	B-CHED
the	O
diagnosis	O
of	O
ARDS	O
.	O

TITLE	O
:	O
First	O
identification	O
of	O
a	O
single	O
amino	B-CHED
acid	I-CHED
change	O
in	O
the	O
spike	O
protein	B-CHED
region	O
of	O
feline	O
coronavirus	O
detected	O
from	O
a	O
coronavirus	O
-	O
associated	O
cutaneous	O
nodule	O
in	O
a	O
cat	O
.	O

In	O
the	O
absence	O
of	O
an	O
available	O
vaccine	O
,	O
the	O
pregnant	O
sows	O
were	O
dosed	O
by	O
mouth	O
with	O
a	O
10	O
%	O
suspension	O
prepared	O
from	O
the	O
intestine	O
and	O
faeces	O
of	O
infected	O
piglets	O
in	O
warm	O
water	B-CHED
.	O

ABSTRACT	O
:	O
With	O
outbreaks	O
of	O
new	O
respiratory	O
viruses	O
such	O
as	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
swine	O
-	O
origin	O
influenza	O
A	O
/	O
H1N1	O
,	O
the	O
nucleic	B-CHED
acid	I-CHED
-	O
based	O
amplification	O
test	O
was	O
introduced	O
to	O
identify	O
causative	O
agents	O
.	O

ABSTRACT	O
:	O
Chlordecone	B-CHED
is	O
an	O
organochlorine	O
used	O
in	O
the	O
1970	O
'	O
s	O
as	O
a	O
pesticide	B-CHED
in	O
banana	O
plantations	O
.	O

Chlordecone	B-CHED
does	O
not	O
cause	O
liver	O
injuries	O
or	O
any	O
inflammation	O
by	O
itself	O
at	O
low	O
doses	O
,	O
but	O
it	O
can	O
potentiate	O
the	O
hepatotoxic	O
effects	O
of	O
other	O
chemicals	O
and	O
drugs	O
.	O

We	O
show	O
that	O
chlordecone	B-CHED
amplifies	O
the	O
auto	O
-	O
immune	O
hepatitis	O
induced	O
by	O
Concanavalin	O
A	O
by	O
increasing	O
the	O
number	O
of	O
liver	O
NKT	O
cells	O
,	O
which	O
are	O
involved	O
in	O
liver	O
damage	O
.	O

In	O
conclusion	O
,	O
chlordecone	B-CHED
potentiates	O
both	O
the	O
Concanavalin	O
A	O
-	O
induced	O
hepatitis	O
and	O
brain	O
damage	O
caused	O
by	O
an	O
hepatotropic	O
/	O
neurotropic	O
virus	O
.	O

Viral	O
diseases	O
are	O
highly	O
infectious	O
and	O
capable	O
of	O
causing	O
pandemics	O
as	O
evidenced	O
by	O
outbreaks	O
of	O
diseases	O
like	O
Ebola	O
,	O
Middle	O
East	O
Respiratory	O
Syndrome	O
,	O
West	O
Nile	O
,	O
SARS	O
-	O
Corona	B-CHED
,	O
Nipah	O
,	O
Hendra	O
,	O
Avian	O
influenza	O
and	O
Swine	O
influenza	O
.	O

Both	O
received	O
short	O
courses	O
of	O
intravenous	O
methylprednisolone	B-CHED
and	O
recovered	O
to	O
be	O
discharged	O
home	O
.	O

Both	O
received	O
short	O
courses	O
of	O
intravenous	O
methylprednisolone	B-CHED
and	O
recovered	O
to	O
be	O
discharged	O
home	O
.	O

A	O
statistically	O
significant	O
positive	O
correlation	O
was	O
found	O
between	O
L	O
-	O
US	O
TBS	B-CHED
and	O
an	O
EVLW	O
index	O
	O
10	O
mL	O
/	O
kg	O
(	O
L	O
-	O
US	O
is	O
feasible	O
in	O
patients	O
with	O
severe	O
sepsis	O
.	O

A	O
key	O
contribution	O
to	O
the	O
high	O
lethality	O
observed	O
during	O
EBOV	O
outbreaks	O
comes	O
from	O
viral	O
evasion	O
of	O
the	O
host	O
antiviral	B-CHED
innate	O
immune	O
response	O
in	O
which	O
viral	O
protein	B-CHED
VP35	O
plays	O
a	O
crucial	O
role	O
,	O
blocking	O
interferon	O
type	O
I	O
production	O
,	O
first	O
by	O
masking	O
the	O
viral	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	B-CHED
)	O
and	O
preventing	O
its	O
detection	O
by	O
the	O
pattern	O
recognition	O
receptor	O
RIG	O
-	O
I	O
.	O
Aiming	O
to	O
identify	O
inhibitors	B-CHED
of	O
the	O
interaction	O
of	O
VP35	O
with	O
the	O
viral	O
dsRNA	B-CHED
,	O
counteracting	O
the	O
VP35	O
viral	O
innate	O
immune	O
evasion	O
,	O
we	O
established	O
a	O
new	O
methodology	O
for	O
high	O
-	O
yield	O
recombinant	O
VP35	O
(	O
rVP35	O
)	O
expression	O
and	O
purification	O
and	O
a	O
novel	O
and	O
robust	O
fluorescence	O
-	O
based	O
rVP35	O
-	O
RNA	O
interaction	O
assay	O
(	O
Z	O
'	O
factor	O
of	O
0	O
.	O
69	O
).	O

A	O
bioguided	O
fractionation	O
led	O
to	O
the	O
identification	O
of	O
myricetin	B-CHED
as	O
the	O
component	O
that	O
can	O
inhibit	O
rVP35	O
-	O
dsRNA	B-CHED
interaction	O
with	O
an	O
IC	O

As	O
compared	O
to	O
the	O
survival	O
group	O
,	O
the	O
white	O
blood	O
cell	O
count	O
,	O
serum	O
bilirubin	B-CHED
,	O
aspartate	B-CHED
aminotransferase	O
,	O
alanine	B-CHED
aminotransferase	O
,	O
creatine	B-CHED
kinase	O
,	O
and	O
lactate	B-CHED
dehydrogenase	O
were	O
significantly	O
higher	O
,	O
and	O
serum	O
albumin	O
levels	O
were	O
significantly	O
lower	O
in	O
patients	O
who	O
died	O
.	O

A	O
man	B-CHED
in	O
his	O
50s	O
with	O
a	O
medical	O
history	O
notable	O
for	O
hypertension	O
was	O
transferred	O
to	O
our	O
institution	O
for	O
evaluation	O
of	O
refractory	O
hypoxemia	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggested	O
that	O
NF	O
-	O
B	O
activation	O
was	O
a	O
major	O
contributor	O
to	O
TGEV	O
infection	O
-	O
induced	O
inflammation	O
,	O
and	O
that	O
Nsp2	O
was	O
the	O
key	O
viral	O
protein	B-CHED
involved	O
in	O
the	O
regulation	O
of	O
inflammation	O
,	O
with	O
amino	B-CHED
acids	I-CHED
1	O
-	O
120	O
playing	O
a	O
critical	O
role	O
in	O
activating	O
NF	O
-	O
B	O
.	O
Abbreviations	O
:	O
TCID50	O
:	O
50	O
%	O
tissue	O
culture	O
infectious	O
dose	O
;	O
DMEM	O
:	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
Medium	O
;	O
eNOS	O
:	O
Endothelial	O
nitric	B-CHED
oxide	I-CHED
synthase	O
;	O
FBS	O
:	O
fetal	O
bovine	O
serum	O
;	O
IFA	O
:	O
Indirect	O
immunofluorescence	O
;	O
IB	O
:	O
inhibitor	B-CHED
of	O
nuclear	O
factor	O
kappa	O
-	O
B	O
;	O
IL	O
:	O
interleukin	O
;	O
IPEC	O
-	O
J2	O
:	O
intestinal	O
epithelial	O
cell	O
lines	O
J2	O
;	O
IKK	O
:	O
IB	O
kinase	O
;	O
Luc	O
:	O
luciferase	O
reporter	O
gene	O
;	O
mAbs	O
:	O
monoclonal	O
antibodies	O
;	O
MOI	O
:	O
multiple	O
of	O
infection	O
;	O
Nsp	O
:	O
nonstructural	O
protein	B-CHED
;	O
NF	O
-	O
B	O
:	O
nuclear	O
factor	O
-	O
kappa	O
;	O
ORFs	O
:	O
open	O
reading	O
frames	O
;	O
PBS	O
:	O
phosphate	B-CHED
-	O
buffered	O
saline	O
;	O
p65	O
p	O
-	O
p65	O
:	O
phosphorylated	O
;	O
RT	O
-	O
PCR	O
:	O
reverse	O
transcription	O
PC	O
;	O
SeV	O
:	O
Sendai	O
virus	O
;	O
ST	O
:	O
swine	O
testicular	O
;	O
TGEV	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
;	O
TNF	O
-	O
	O
:	O
tumor	O
necrosis	O
factor	O
	O
;	O
UV	O
-	O
TGEV	O
:	O
Ultraviolet	O
light	O
-	O
inactivated	O
TGEV	O
;	O
ZnF	O
:	O
zinc	B-CHED
finger	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
describes	O
the	O
association	O
between	O
inflammatory	O
cell	O
types	O
and	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
antigen	B-CHED
in	O
the	O
brain	O
of	O
4	O
cats	O
diagnosed	O
as	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

On	O
ICU	O
day	O
4	O
,	O
a	O
vancomycin	B-CHED
trough	O
serum	O
concentration	O
of	O
14	O
.	O
1	O
mg	O
/	O
L	O
was	O
obtained	O
before	O
the	O
fourth	O
dose	O
,	O
which	O
was	O
within	O
the	O
target	O
range	O
of	O
10	O
-	O
20	O
mg	O
/	O
L	O
.	O
By	O
ICU	O
day	O
7	O
,	O
vancomycin	B-CHED
dosage	O
was	O
elevated	O
to	O
1	O
.	O
0	O
g	O
every	O
12	O
hours	O
because	O
of	O
aggravated	O
infection	O
and	O
improved	O
kidney	O
function	O
.	O

Using	O
the	O
fluorescence	O
resonance	O
energy	O
transfer	O
assay	O
,	O
we	O
identified	O
potent	O
inhibitors	B-CHED
broadly	O
effective	O
against	O
feline	O
,	O
ferret	O
and	O
mink	O
coronavirus	O
3CLpro	O
.	O

During	O
the	O
initial	O
stages	O
of	O
the	O
MERS	O
outbreak	O
,	O
healthcare	O
workers	O
who	O
performed	O
MERS	O
-	O
related	O
tasks	O
scored	O
significantly	O
higher	O
on	O
the	O
total	O
IES	B-CHED
-	O
R	O
and	O
its	O
subscales	O
.	O

RESULTS	O
:	O
During	O
the	O
initial	O
stages	O
of	O
the	O
MERS	O
outbreak	O
,	O
healthcare	O
workers	O
who	O
performed	O
MERS	O
-	O
related	O
tasks	O
scored	O
significantly	O
higher	O
on	O
the	O
total	O
IES	B-CHED
-	O
R	O
and	O
its	O
subscales	O
.	O

We	O
benchmarked	O
this	O
approach	O
using	O
12	O
crystal	O
structures	O
and	O
showed	O
that	O
glycan	B-CHED
geometries	O
can	O
be	O
automatically	O
improved	O
while	O
maintaining	O
good	O
fit	O
to	O
the	O
crystallographic	O
data	O
.	O

Initial	O
laboratory	O
investigations	O
were	O
significant	O
for	O
a	O
lipase	O
level	O
of	O
4143	O
U	O
/	O
L	O
and	O
a	O
triglyceride	B-CHED
level	O
of	O
600	O
mg	O
/	O
dL	O
.	O
Computed	O
tomography	O
(	O
CT	O
)	O
of	O
the	O
abdomen	O
showed	O
diffuse	O
enlargement	O
of	O
the	O
pancreas	O
consistent	O
with	O
pancreatitis	O
.	O

TITLE	O
:	O
Structure	O
-	O
Activity	O
Relationships	O
in	O
Metal	B-CHED
-	O
Binding	O
Pharmacophores	O
for	O
Influenza	O
Endonuclease	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
uses	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
to	O
recognize	O
and	O
enter	O
target	O
cells	O
.	O

As	O
a	O
selected	O
viral	O
nucleic	B-CHED
acid	I-CHED
extraction	O
method	O
may	O
determine	O
the	O
sensitivity	O
and	O
reliability	O
of	O
NGS	O
,	O
it	O
is	O
still	O
valuable	O
to	O
evaluate	O
the	O
extraction	O
efficiency	O
of	O
different	O
extraction	O
kits	O
using	O
clinical	O
specimens	O
directly	O
.	O

Our	O
results	O
highlighted	O
the	O
importance	O
of	O
nucleic	B-CHED
acid	I-CHED
extraction	O
kit	O
selection	O
,	O
which	O
has	O
a	O
major	O
impact	O
on	O
the	O
yield	O
and	O
number	O
of	O
viral	O
reads	O
by	O
NGS	O
analysis	O
.	O

There	O
was	O
no	O
difference	O
in	O
relation	O
to	O
severity	O
outcomes	O
(	O
number	O
of	O
organic	O
dysfunctions	O
,	O
use	O
of	O
mechanical	O
ventilation	O
or	O
amines	B-CHED
,	O
hospital	O
/	O
PICU	O
length	O
of	O
stay	O
or	O
death	O
).	O

We	O
subsequently	O
identified	O
NF	O
-	O
B	O
-	O
inhibitor	B-CHED
	O
and	O
suppressor	O
of	O
cytokine	O
signaling	O
1	O
,	O
negative	O
regulators	O
of	O
the	O
NF	O
-	O
B	O
pathway	O
,	O
as	O
miR	O
-	O
221	O
-	O
5p	O
targets	O
.	O

TGF	O
-	O
1	O
should	O
not	O
be	O
used	O
as	O
a	O
biomarker	B-CHED
to	O
direct	O
anti	O
-	O
fibrotic	O
therapies	O
.	O

TITLE	O
:	O
Prospects	O
for	O
the	O
use	O
of	O
spherical	O
gold	B-CHED
nanoparticles	B-CHED
in	O
immunization	O
.	O

We	O
used	O
spherical	O
gold	B-CHED
nanoparticles	B-CHED
(	O
average	O
diameter	O
,	O
15	O
nm	O
)	O
as	O
a	O
platform	O
for	O
the	O
antigen	B-CHED
for	O
swine	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
).	O

The	O
overexpressing	O
plasmids	O
of	O
16	O
non	O
-	O
structural	O
proteins	B-CHED
(	O
Nsp1	O
-	O
16	O
)	O
and	O
6	O
structural	O
proteins	B-CHED
(	O
M	O
,	O
N	O
,	O
E	O
,	O
ORF3	O
,	O
S1	O
and	O
S2	O
)	O
were	O
constructed	O
by	O
cloning	O
.	O

Overexpression	O
of	O
S1	O
Spike	O
protein	B-CHED
of	O
PEDV	O
SM98	O
strain	O
effectively	O
induced	O
host	O
cell	O
apoptosis	O
,	O
while	O
the	O
expression	O
of	O
the	O
other	O
non	O
-	O
structure	O
proteins	B-CHED
(	O
Nsp1	O
-	O
16	O
)	O
and	O
structural	O
proteins	B-CHED
(	O
M	O
,	O
N	O
,	O
E	O
,	O
S2	O
and	O
ORF3	O
)	O
has	O
no	O
or	O
less	O
effect	O
on	O
cell	O
apoptosis	O
.	O

TITLE	O
:	O
Deletion	O
of	O
both	O
the	O
Tyrosine	B-CHED
-	O
Based	O
Endocytosis	O
Signal	O
and	O
the	O
Endoplasmic	O
Reticulum	O
Retrieval	O
Signal	O
in	O
the	O
Cytoplasmic	O
Tail	O
of	O
Spike	O
Protein	B-CHED
Attenuates	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
in	O
Pigs	O
.	O

Infection	O
of	O
Vero	O
cells	O
with	O
ic10aa	O
resulted	O
in	O
larger	O
syncytia	O
and	O
more	O
virions	O
,	O
with	O
reduced	O
numbers	O
of	O
S	O
protein	B-CHED
projections	O
on	O
the	O
surface	O
compared	O
with	O
icPC22A	O
.	O

The	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
binds	O
to	O
the	O
cellular	O
protein	B-CHED
DPP4	O
via	O
its	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
and	O
mediates	O
viral	O
entry	O
into	O
target	O
cells	O
.	O

We	O
confirm	O
that	O
changes	O
D510G	O
and	O
I529T	O
reduce	O
S	O
protein	B-CHED
binding	O
to	O
DPP4	O
but	O
show	O
that	O
this	O
reduction	O
only	O
translates	O
into	O
diminished	O
viral	O
entry	O
when	O
expression	O
of	O
DPP4	O
on	O
target	O
cells	O
is	O
low	O
.	O

Importantly	O
,	O
viral	O
RNA	O
can	O
be	O
reliably	O
detected	O
in	O
MLN	O
FNA	B-CHED
samples	O
in	O
saline	O
submitted	O
via	O
the	O
national	O
mail	O
service	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
association	O
between	O
initial	O
ARI	B-CHED
admission	O
because	O
of	O
viruses	O
including	O
human	O
rhinovirus	O
(	O
HRV	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
adenovirus	O
(	O
HAdV	O
)	O
and	O
human	O
metapneumovirus	O
(	O
hMPV	O
)	O
and	O
the	O
risk	O
of	O
ARI	B-CHED
readmission	O
in	O
children	O
.	O

During	O
the	O
follow	O
-	O
up	O
period	O
(	O
4572	O
.	O
7	O
person	O
-	O
years	O
),	O
277	O
children	O
were	O
readmitted	O
with	O
ARI	B-CHED
.	O

Virus	O
-	O
related	O
ARI	B-CHED
initial	O
admission	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
ARI	B-CHED
readmission	O
for	O
children	O
who	O
were	O
initially	O
admitted	O
before	O
6	O
months	O
of	O
age	O
(	O
adjusted	O
rate	O
ratio	O
,	O
1	O
.	O
6	O
;	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
1	O
-	O
2	O
.	O
5	O
).	O

Neutralizing	O
IL	O
-	O
33	O
in	O
culture	O
medium	O
with	O
specific	O
antibodies	O
suppressed	O
the	O
expression	O
and	O
secretion	O
of	O
MMP2	O
and	O
MMP9	O
in	O
LPS	B-CHED
-	O
treated	O
alveolar	O
macrophages	O
.	O

ABSTRACT	O
:	O
Central	O
Nervous	O
System	O
(	O
CNS	B-CHED
)	O
infections	O
are	O
one	O
of	O
the	O
most	O
critical	O
problems	O
in	O
public	O
health	O
,	O
as	O
frequently	O
patients	O
exhibit	O
neurologic	O
sequelae	O
.	O

However	O
,	O
nowadays	O
respiratory	O
viruses	O
have	O
placed	O
themselves	O
as	O
relevant	O
agents	O
responsible	O
for	O
CNS	B-CHED
pathologies	O
.	O

We	O
developed	O
a	O
sealed	O
air	B-CHED
-	O
tight	O
chamber	O
in	O
which	O
plates	O
with	O
human	O
alveolar	O
epithelial	O
immortalized	O
cells	O
could	O
be	O
exposed	O
to	O
a	O
precise	O
,	O
controlled	O
fraction	O
of	O
sevoflurane	B-CHED
or	O
isoflurane	B-CHED
using	O
a	O
continuous	O
gas	O
flow	O
provided	O
by	O
an	O
anesthetic	O
machine	O
circuit	O
.	O

In	O
patients	O
with	O
severe	O
pneumonia	O
who	O
experience	O
respiratory	O
failure	O
,	O
it	O
has	O
been	O
reported	O
that	O
nasal	O
high	O
-	O
flow	O
oxygen	B-CHED
therapy	O
is	O
not	O
inferior	O
to	O
noninvasive	O
positive	O
pressure	O
ventilation	O
therapy	O
regarding	O
intubation	O
rate	O
.	O

Here	O
we	O
report	O
the	O
presence	O
of	O
common	O
respiratory	O
viral	O
pathogens	O
in	O
returning	O
Hajj	O
and	O
Umrah	O
pilgrims	O
suffering	O
from	O
acute	O
respiratory	O
illness	O
(	O
ARI	B-CHED
)	O
in	O
2014	O
-	O
2015	O
.	O

Eighteen	O
influenza	O
positive	O
patients	O
were	O
treated	O
with	O
oseltamivir	B-CHED
.	O

Compared	O
with	O
the	O
non	O
-	O
ARDS	O
group	O
,	O
the	O
ARDS	O
group	O
had	O
older	O
age	O
,	O
higher	O
rates	O
of	O
traffic	O
injuries	O
,	O
endotracheal	O
intubation	O
and	O
infection	O
,	O
higher	O
blood	O
sugar	O
,	O
PaO	B-CHED
The	O
traumatic	O
patients	O
on	O
admission	O
with	O
hyperglycemia	O
,	O
abnormal	O
PaO	B-CHED
RESULTS	O
:	O
A	O
total	O
of	O
303	O
patients	O
with	O
severe	O
trauma	O
,	O
including	O
223	O
males	O
and	O
80	O
females	O
,	O
were	O
enrolled	O
.	O

During	O
the	O
late	O
phase	O
(	O
day	O
10	O
),	O
both	O
lung	O
mechanics	O
and	O
the	O
cell	O
/	O
cytokine	O
homeostasis	O
recovered	O
in	O
LPS	B-CHED
-	O
treated	O
wt	O
mice	O
.	O

ABSTRACT	O
:	O
Upon	O
viral	O
infection	O
,	O
the	O
interferon	O
(	O
IFN	O
)	O
system	O
triggers	O
potent	O
antiviral	B-CHED
mechanisms	O
limiting	O
viral	O
growth	O
and	O
spread	O
.	O

A	O
new	O
infectious	O
bronchitis	O
virus	O
serotype	O
can	O
emerge	O
from	O
only	O
very	O
few	O
amino	B-CHED
acid	I-CHED
changes	O
within	O
the	O
major	O
peplomer	O
glycoprotein	B-CHED
,	O
namely	O
in	O
its	O
S1	O
part	O
forming	O
the	O
virion	O
spike	O
.	O

TITLE	O
:	O
Improved	O
Detection	O
of	O
Culprit	O
Pathogens	O
by	O
Bacterial	O
DNA	O
Sequencing	O
Affects	O
Antibiotic	B-CHED
Management	O
Decisions	O
in	O
Severe	O
Pneumonia	O
.	O

Evidence	O
-	O
based	O
management	O
includes	O
early	O
administration	O
of	O
empiric	O
antibiotics	B-CHED
against	O
plausible	O
bacterial	O
pathogens	O
while	O
awaiting	O
results	O
of	O
microbiologic	O
cultures	O
.	O

An	O
empirical	O
systemic	O
anticoagulation	O
protocol	O
(	O
heparin	B-CHED
intravenous	O
infusion	O
)	O
was	O
initiated	O
when	O
autopsy	O
of	O
patients	O
with	O
severe	O
hypoxemia	O
confirmed	O
multiple	O
primary	O
pulmonary	O
thrombi	O
and	O
emboli	O
.	O

This	O
study	O
defined	O
three	O
groups	O
based	O
on	O
the	O
evolution	O
of	O
severity	O
in	O
the	O
first	O
week	O
:	O
""""	O
worsening	O
""""	O
if	O
moderate	O
or	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
criteria	O
were	O
met	B-CHED
,	O
""""	O
persisting	O
""""	O
if	O
mild	O
acute	O
respiratory	O
distress	O
syndrome	O
criteria	O
were	O
the	O
most	O
severe	O
category	O
,	O
and	O
""""	O
improving	O
""""	O
if	O
patients	O
did	O
not	O
fulfill	O
acute	O
respiratory	O
distress	O
syndrome	O
criteria	O
any	O
more	O
from	O
day	O
2	O
.	O

There	O
is	O
no	O
specific	O
treatment	O
for	O
the	O
MERS	O
-	O
CoV	O
till	O
now	O
,	O
but	O
drugs	O
are	O
in	O
pipeline	O
which	O
bind	O
with	O
the	O
spike	O
glycoprotein	B-CHED
and	O
inhibit	O
its	O
entrance	O
host	O
cells	O
.	O

MERS	O
-	O
CoV	O
and	O
SAR	B-CHED
-	O
CoV	O
are	O
from	O
the	O
same	O
genus	O
,	O
so	O
it	O
was	O
thought	O
that	O
the	O
drugs	O
which	O
inhibit	O
the	O
growth	O
of	O
SARS	O
-	O
CoV	O
can	O
also	O
inhibit	O
the	O
growth	O
of	O
MERS	O
-	O
CoV	O
but	O
those	O
drugs	O
are	O
not	O
completely	O
inhibiting	O
virus	O
activity	O
.	O

ABSTRACT	O
:	O
Nucleotide	B-CHED
skew	O
analysis	O
is	O
a	O
versatile	O
method	O
to	O
study	O
the	O
nucleotide	B-CHED
composition	O
of	O
RNA	O
/	O
DNA	O
molecules	O
,	O
in	O
particular	O
to	O
reveal	O
characteristic	O
sequence	O
signatures	O
.	O

Here	O
,	O
we	O
present	O
a	O
procedure	O
for	O
a	O
more	O
simple	O
identification	O
of	O
similarities	O
and	O
dissimilarities	O
between	O
nucleotide	B-CHED
skew	O
data	O
of	O
coronavirus	O
,	O
flavivirus	O
,	O
picornavirus	O
,	O
and	O
HIV	O
-	O
1	O
RNA	O
genomes	O
.	O

In	O
this	O
article	O
,	O
we	O
review	O
current	O
advances	O
in	O
neutralizing	O
mAbs	O
against	O
MERS	O
-	O
CoV	O
.	O
The	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
the	O
spike	O
protein	B-CHED
of	O
MERS	O
-	O
CoV	O
is	O
a	O
major	O
target	O
,	O
and	O
mouse	O
,	O
camel	O
,	O
or	O
human	O
-	O
derived	O
neutralizing	O
mAbs	O
targeting	O
RBD	O
have	O
been	O
developed	O
.	O

TITLE	O
:	O
A	O
Single	O
-	O
Step	O
Gold	B-CHED
Nanoparticle	I-CHED
-	O
Blood	O
Serum	O
Interaction	O
Assay	O
Reveals	O
Humoral	O
Immunity	O
Development	O
and	O
Immune	O
Status	O
of	O
Animals	O
from	O
Neonates	O
to	O
Adults	O
.	O

Such	O
interactions	O
cause	O
the	O
gold	B-CHED
nanoparticles	B-CHED
to	O
form	O
clusters	B-CHED
and	O
aggregates	O
.	O

The	O
average	O
particle	O
size	O
of	O
the	O
gold	B-CHED
nanoparticle	I-CHED
-	O
serum	O
mixture	B-CHED
,	O
measured	O
by	O
dynamic	O
light	O
scattering	O
,	O
corresponds	O
positively	O
to	O
the	O
immune	O
status	O
and	O
activity	O
of	O
the	O
subject	O
.	O

RESULTS	O
:	O
Although	O
whole	O
genome	O
sequencing	O
of	O
these	O
two	O
Mass	O
IBV	O
isolates	O
showed	O
low	O
similarity	O
with	O
the	O
M41	O
vaccinal	O
strain	O
,	O
they	O
had	O
an	O
identical	O
nucleotide	B-CHED
sequence	O
at	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
3a	O
,	O
3b	O
,	O
envelop	O
(	O
E	O
),	O
matrix	O
(	O
M	O
),	O
5a	O
and	O
5b	O
.	O

EVLWI	O
began	O
to	O
abnormally	O
increase	O
(>	O
7ml	O
/	O
kg	O
)	O
on	O
day	O
3	O
and	O
up	O
to	O
PBD	B-CHED
9	O
,	O
indicating	O
that	O
a	O
supranormal	O
EVLWI	O
developed	O
in	O
the	O
fluid	O
reabsorption	O
stage	O
.	O

Suppressing	O
TRIM8	O
markedly	O
ameliorated	O
LPS	B-CHED
-	O
elicited	O
inflammatory	O
response	O
,	O
as	O
evidenced	O
by	O
the	O
down	O
-	O
regulated	O
mRNA	B-CHED
levels	O
of	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
),	O
IL	O
-	O
6	O
and	O
tumor	O
necrosis	O
factor	O
-	O
	O
(	O
TNF	O
-	O
	O
)	O
in	O
cells	O
mainly	O
through	O
inactivating	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
B	O
)	O
signaling	O
pathway	O
;	O
however	O
,	O
over	O
-	O
expressing	O
TRIM8	O
markedly	O
promoted	O
inflammation	O
in	O
LPS	B-CHED
-	O
challenged	O
cells	O
.	O

Meanwhile	O
,	O
the	O
loss	O
of	O
TRIM8	O
markedly	O
lessened	O
IL	O
-	O
1	O
,	O
IL	O
-	O
6	O
and	O
TNF	O
-	O
	O
expression	O
in	O
lung	O
tissues	O
of	O
LPS	B-CHED
-	O
challenged	O
mice	O
,	O
and	O
reduced	O
NF	O
-	O
B	O
phosphorylation	O
.	O

The	O
combination	O
of	O
persistent	O
hypernatremia	O
(	O
150	O
-	O
160	O
mmol	O
/	O
l	O
),	O
polyuria	O
(	O
8	O
.	O
4	O
ml	O
/	O
kg	O
/	O
hr	O
),	O
high	O
plasma	O
osmolality	O
(	O
323	O
mosm	O
/	O
kg	O
),	O
hyposthenuria	O
(	O
75	O
mosm	O
/	O
kg	O
)	O
and	O
an	O
undetectable	O
serum	O
ADH	B-CHED
(<	O
0	O
.	O
8	O
pg	O
/	O
ml	O
)	O
confirmed	O
the	O
diagnosis	O
of	O
central	O
diabetes	O
insipidus	O
(	O
CDI	O
).	O

DPP4	O
was	O
expressed	O
in	O
the	O
five	O
bat	O
cells	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
,	O
with	O
significantly	O
higher	O
mRNA	B-CHED
expression	O
levels	O
than	O
those	O
in	O
non	O
-	O
susceptible	O
cells	O
(	O
P	O
=	O
0	O
.	O
0174	O
),	O
supporting	O
that	O
DPP4	O
expression	O
is	O
critical	O
for	O
MERS	O
-	O
CoV	O
infection	O
in	O
bats	O
.	O

We	O
present	O
the	O
first	O
tirofiban	B-CHED
-	O
related	O
diffuse	O
alveolar	O
hemorrhage	O
case	O
caused	O
with	O
half	O
of	O
the	O
recommended	O
dose	O
of	O
tirofiban	B-CHED
used	O
in	O
the	O
setting	O
of	O
non	O
-	O
ST	O
-	O
elevation	O
myocardial	O
infarction	O
.	O

A	O
portable	O
oxygen	B-CHED
concentrator	O
has	O
the	O
advantage	O
of	O
operating	O
solely	O
from	O
electrical	O
power	O
and	O
theoretically	O
is	O
a	O
never	O
-	O
exhausting	O
supply	O
of	O
oxygen	B-CHED
.	O

The	O
oxygen	B-CHED
bolus	O
was	O
delivered	O
from	O
the	O
concentrator	O
and	O
injected	O
into	O
the	O
ventilator	O
circuit	O
at	O
the	O
patient	O
connector	O
.	O

The	O
pigs	O
were	O
then	O
placed	O
on	O
the	O
ventilator	O
/	O
concentrator	O
system	O
and	O
allowed	O
to	O
adjust	O
the	O
oxygen	B-CHED
autonomously	O
to	O
determine	O
if	O
the	O
target	O
SpO2	O
could	O
be	O
maintained	O
.	O

In	O
extubation	O
day	O
an	O
association	O
between	O
driving	O
pressure	O
and	O
NT	O
-	O
PCP	B-CHED
-	O
III	O
was	O
observed	O
.	O

The	O
design	O
of	O
both	O
the	O
multi	O
-	O
epitope	B-CHED
vaccines	O
(	O
MEVs	O
)	O
are	O
composed	O
of	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
and	O
helper	O
T	O
lymphocyte	O
(	O
HTL	O
)	O
epitopes	O
,	O
screened	O
form	O
thirteen	O
different	O
proteins	B-CHED
of	O
MERS	O
-	O
CoV	O
.	O
Both	O
the	O
MEVs	O
also	O
carry	O
potential	O
B	O
-	O
cell	O
linear	O
epitope	B-CHED
regions	O
,	O
B	O
-	O
cell	O
discontinuous	O
epitopes	O
as	O
well	O
as	O
interferon	O
-	O
	O
-	O
inducing	O
epitopes	O
.	O

CTL	O
epitopes	O
were	O
also	O
found	O
to	O
have	O
favorable	O
molecular	O
interaction	O
within	O
the	O
cavity	O
of	O
transporter	O
associated	O
with	O
antigen	B-CHED
processing	O
.	O

A	O
soluble	O
recombinant	O
N	O
protein	B-CHED
(	O
rN	O
)	O
of	O
approximately	O
50	O
kDa	O
was	O
obtained	O
.	O

The	O
SDS	B-CHED
-	O
PAGE	O
results	O
demonstrated	O
the	O
presence	O
of	O
two	O
distinct	O
bands	O
that	O
had	O
a	O
molecular	O
mass	O
of	O
approximately	O
45	O
and	O
50	O
KDa	O
.	O

TITLE	O
:	O
Acute	O
left	O
ventricular	O
dysfunction	O
complicating	O
pregnancy	O
on	O
ECMO	O
:	O
Tri	O
-	O
iodothyronine	B-CHED
to	O
the	O
rescue	O
with	O
real	O
time	O
transesophageal	O
echocardiography	O
.	O

ABSTRACT	O
:	O
Anti	O
-	O
neutrophil	O
cytoplasmic	O
antibody	O
(	O
ANCA	B-CHED
)-	O
associated	O
vasculitis	O
(	O
AAV	O
)	O
is	O
a	O
systemic	O
vasculitis	O
resulting	O
in	O
severe	O
organ	O
injuries	O
.	O

Despite	O
the	O
treatment	O
with	O
cyclophosphamide	B-CHED
and	O
glucocorticoid	B-CHED
,	O
the	O
patient	O
presented	O
with	O
severe	O
respiratory	O
failure	O
due	O
to	O
alveolar	O
hemorrhage	O
and	O
heart	O
failure	O
.	O

A	O
56	O
-	O
year	O
-	O
old	O
Caucasian	O
man	B-CHED
with	O
multiple	O
comorbidities	O
and	O
severe	O
aortic	O
stenosis	O
underwent	O
transcatheter	O
aortic	O
valve	O
replacement	O
under	O
monitored	O
anesthesia	O
care	O
.	O

After	O
treatment	O
with	O
beta	O
blockers	O
,	O
fluid	O
resuscitation	O
,	O
and	O
alpha	O
-	O
1	O
agonists	B-CHED
,	O
he	O
stabilized	O
and	O
was	O
eventually	O
discharged	O
from	O
our	O
hospital	O
without	O
any	O
lasting	O
sequelae	O
.	O

Tracer	B-CHED
gas	O
experiments	O
conducted	O
on	O
the	O
eighth	O
floor	O
,	O
where	O
the	O
initial	O
patient	O
was	O
hospitalized	O
,	O
confirmed	O
that	O
the	O
tracer	B-CHED
gas	O
spread	O
to	O
adjacent	O
patient	O
rooms	O
and	O
rooms	O
across	O
corridors	O
.	O

In	O
contrast	O
,	O
the	O
tracer	B-CHED
gas	O
was	O
barely	O
detected	O
in	O
a	O
maternity	O
ward	O
to	O
the	O
south	O
of	O
room	O
8104	O
,	O
where	O
there	O
was	O
no	O
secondary	O
infected	O
patient	O
.	O

A	O
collection	O
of	O
worldwide	O
available	O
hypervariable	O
region	O
1	O
and	O
2	O
(	O
HVR12	O
)	O
and	O
3	O
(	O
HVR3	O
)	O
sequences	O
of	O
the	O
S1	O
protein	B-CHED
was	O
analysed	O
together	O
with	O
258	O
HVR3	O
sequences	O
obtained	O
from	O
samples	O
collected	O
in	O
Italy	O
(	O
the	O
country	O
where	O
this	O
genotype	O
was	O
initially	O
identified	O
)	O
since	O
1963	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
lung	O
compliance	O
,	O
the	O
applied	O
PEEP	B-CHED
and	O
the	O
plateau	O
pressures	O
across	O
trimesters	O
.	O

This	O
notion	O
is	O
supported	O
by	O
preclinical	O
animal	O
models	O
,	O
genome	O
-	O
wide	O
association	O
studies	O
(	O
GWAS	O
),	O
as	O
well	O
as	O
approved	O
disease	O
modifying	O
therapies	O
(	O
DMTs	O
)	O
that	O
suppress	O
clinical	O
relapse	O
and	O
are	O
designed	O
to	O
impede	O
infiltration	O
of	O
activated	O
lymphocytes	O
into	O
the	O
CNS	B-CHED
.	O

These	O
respiratory	O
problems	O
due	O
to	O
viral	O
infection	O
become	O
a	O
public	O
health	O
concern	O
due	O
to	O
rapid	O
transmission	O
through	O
air	B-CHED
/	O
aerosols	O
or	O
via	O
direct	O
-	O
indirect	O
contact	O
with	O
infected	O
persons	O
.	O

TITLE	O
:	O
MMI	B-CHED
-	O
0100	O
ameliorates	O
lung	O
inflammation	O
in	O
a	O
mouse	O
model	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
by	O
reducing	O
endothelial	O
expression	O
of	O
ICAM	O
-	O
1	O
.	O

We	O
found	O
that	O
the	O
level	O
of	O
phosphorylated	O
MK2	O
in	O
the	O
LPS	B-CHED
plus	O
MMI	B-CHED
-	O
0100	O
group	O
was	O
reduced	O
.	O

In	O
Vero	O
and	O
IPEC	O
-	O
DQ	O
cells	O
,	O
certain	O
concentrations	O
of	O
BM	O
,	O
PGM	B-CHED
,	O
bile	O
and	O
bile	B-CHED
acids	I-CHED
increased	O
significantly	O
the	O
infectivity	O
of	O
icPC22A	O
but	O
had	O
no	O
or	O
negative	O
effects	O
on	O
icPC22A	O
-	O
S1197	O
.	O

This	O
observation	O
may	O
be	O
explained	O
partially	O
by	O
the	O
fact	O
that	O
mucin	O
,	O
bile	O
and	O
bile	B-CHED
acids	I-CHED
in	O
gastrointestinal	O
tract	O
had	O
facilitating	O
effects	O
on	O
the	O
infection	O
of	O
S	O
-	O
intact	O
PEDV	O
,	O
but	O
no	O
/	O
inhibition	O
effects	O
on	O
S1	O
NTD	O
-	O
del	O
PEDV	O
.	O

We	O
assessed	O
exposures	O
and	O
determined	O
seropositivity	O
among	O
available	O
healthcare	O
personnel	O
(	O
HCP	B-CHED
)	O
cases	O
and	O
HCP	B-CHED
contacts	O
of	O
cases	O
.	O

Overall	O
,	O
4	O
(	O
24	O
%)	O
of	O
17	O
HCP	B-CHED
cases	O
and	O
3	O
(	O
3	O
%)	O
of	O
114	O
HCP	B-CHED
contacts	O
of	O
cases	O
were	O
seropositive	O
.	O

Prompt	O
contact	O
tracing	O
,	O
repeated	O
testing	O
,	O
HCP	B-CHED
furloughing	O
,	O
and	O
implementation	O
of	O
recommended	O
transmission	O
-	O
based	O
precautions	O
for	O
suspected	O
cases	O
ultimately	O
halted	O
transmission	O
.	O

ABSTRACT	O
:	O
We	O
used	O
Casd1	O
-	O
deficient	O
mice	O
to	O
confirm	O
that	O
this	O
enzyme	O
is	O
responsible	O
for	O
9	O
-	O
O	O
-	O
acetylation	O
of	O
sialic	B-CHED
acids	I-CHED
in	O
vivo	O
.	O

As	O
erythrocytes	O
mature	O
,	O
the	O
surfaces	O
of	O
Ery	O
-	O
C	O
cells	O
and	O
mature	O
erythrocytes	O
also	O
acquire	O
an	O
additional	O
distinct	O
CASD1	O
-	O
dependent	O
9	O
-	O
O	O
-	O
acetyl	B-CHED
sialic	B-CHED
acid	I-CHED
moiety	O
that	O
can	O
be	O
recognized	O
by	O
virolectins	O
from	O
both	O
influenza	O
C	O
and	O
bovine	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Rasburicase	O
is	O
a	O
recombinant	O
urate	B-CHED
-	O
oxidase	O
enzyme	O
and	O
is	O
a	O
very	O
important	O
medication	O
for	O
tumor	O
lysis	O
syndrome	O
.	O

We	O
were	O
aware	O
that	O
methylene	B-CHED
blue	I-CHED
is	O
a	O
contraindication	O
in	O
patients	O
with	O
G6PD	O
deficiency	O
but	O
considering	O
patient	O
being	O
Caucasian	O
and	O
low	O
risk	O
for	O
it	O
and	O
his	O
deteriorating	O
respiratory	O
condition	O
,	O
it	O
was	O
decided	O
to	O
offer	O
the	O
treatment	O
and	O
patient	O
received	O
1	O
dose	O
of	O
methylene	B-CHED
blue	I-CHED
which	O
failed	O
to	O
improve	O
his	O
methemoglobinemia	O
.	O

The	O
most	O
recent	O
randomized	O
clinical	O
trial	O
,	O
Conventional	O
Ventilation	O
or	O
ECMO	O
for	O
Severe	O
Adult	O
Respiratory	O
Failure	O
(	O
CESAR	O
),	O
showed	O
a	O
significant	O
mortality	O
reduction	O
in	O
ARDS	O
patients	O
who	O
were	O
treated	O
with	O
ECMO	O
[	O
Peek	B-CHED
2009	O
].	O

TITLE	O
:	O
Decoding	O
the	O
enigma	O
of	O
antiviral	B-CHED
crisis	O
:	O
Does	O
one	O
target	O
molecule	O
regulate	O
all	O
?	O

Interleukin	O
(	O
IL	O
)-	O
6	O
acts	O
as	O
a	O
mediator	O
between	O
pro	B-CHED
-	O
and	O
anti	O
-	O
inflammatory	O
reactivity	O
by	O
initiating	O
trans	O
-	O
and	O
classical	O
-	O
signaling	O
,	O
respectively	O
.	O

Hence	O
,	O
IL	O
-	O
6	O
is	O
assumed	O
to	O
provide	O
a	O
target	O
for	O
a	O
broad	O
range	O
of	O
antiviral	B-CHED
agents	I-CHED
.	O

Therefore	O
,	O
ADAM	O
-	O
17	O
should	O
be	O
considered	O
as	O
a	O
potential	O
target	O
molecule	O
for	O
novel	O
antiviral	B-CHED
drug	I-CHED
discovery	O
that	O
would	O
regulate	O
host	O
reactivity	O
to	O
infection	O
and	O
thereby	O
limit	O
or	O
prevent	O
fatal	O
outcomes	O
.	O

However	O
,	O
with	O
the	O
exception	O
of	O
neuraminidase	B-CHED
inhibitors	I-CHED
for	O
influenza	O
infection	O
,	O
there	O
are	O
no	O
accepted	O
treatments	O
.	O

We	O
describe	O
patients	O
with	O
dengue	O
infection	O
confirmed	O
by	O
dengue	O
serology	O
or	O
NS1	O
antigen	B-CHED
in	O
Cali	O
,	O
Colombia	O
.	O

ABSTRACT	O
:	O
Griffithsin	O
is	O
a	O
lectin	O
with	O
potent	O
antiviral	B-CHED
activity	O
against	O
enveloped	O
viruses	O
.	O

The	O
immune	O
-	O
enhancing	O
effect	O
of	O
IFN	O
-	O
	O
adjuvant	B-CHED
was	O
excellent	O
compared	O
with	O
pig	O
spleen	O
transfer	O
factor	O
and	O
IL	O
-	O
12	O
adjuvant	B-CHED
.	O

TITLE	O
:	O
Lactobacillus	O
acidophilus	O
S	O
-	O
layer	O
protein	B-CHED
-	O
mediated	O
inhibition	O
of	O
PEDV	O
-	O
induced	O
apoptosis	O
of	O
Vero	O
cells	O
.	O

Bats	O
,	O
like	O
all	O
mammals	O
,	O
rely	O
on	O
a	O
number	O
of	O
innate	O
immune	O
mechanisms	O
to	O
combat	B-CHED
invading	O
pathogens	O
,	O
including	O
the	O
interferon	O
type	O
I	O
,	O
II	O
and	O
III	O
responses	O
.	O

Together	O
with	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
,	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
is	O
one	O
of	O
the	O
immunodominant	O
regions	O
among	O
coronaviruses	O
.	O

Twenty	O
-	O
four	O
severe	O
ARDS	O
patients	O
(	O
arterial	O
oxygen	B-CHED
partial	O
pressure	O
to	O
fractional	O
inspired	O
oxygen	B-CHED
ratio	O
,	O
PaO	B-CHED
Patients	O
in	O
the	O
EIT	O
group	O
were	O
younger	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
their	O
mean	O
plateau	O
pressure	O
was	O
1	O
.	O
5	O
cmH	B-CHED
In	O
severe	O
ARDS	O
patients	O
,	O
it	O
was	O
feasible	O
and	O
safe	O
to	O
guide	O
PEEP	B-CHED
titration	O
with	O
EIT	O
at	O
the	O
bedside	O
.	O

As	O
compared	O
with	O
pressure	O
-	O
volume	O
curve	O
,	O
the	O
EIT	O
-	O
guided	O
PEEP	B-CHED
titration	O
may	O
be	O
associated	O
with	O
improved	O
oxygenation	O
,	O
compliance	O
,	O
driving	O
pressure	O
,	O
and	O
weaning	O
success	O
rate	O
.	O

RESULTS	O
:	O
Patients	O
in	O
the	O
EIT	O
group	O
were	O
younger	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
their	O
mean	O
plateau	O
pressure	O
was	O
1	O
.	O
5	O
cmH	B-CHED
CONCLUSIONS	O
:	O
In	O
severe	O
ARDS	O
patients	O
,	O
it	O
was	O
feasible	O
and	O
safe	O
to	O
guide	O
PEEP	B-CHED
titration	O
with	O
EIT	O
at	O
the	O
bedside	O
.	O

We	O
retrospectively	O
recorded	O
AE	O
reports	O
for	O
""""	O
paracetamol	B-CHED
""""	O
reported	O
from	O
1	O
January	O
2007	O
to	O
1	O
October	O
2018	O
which	O
fulfilled	O
the	O
category	O
of	O
""""	O
serious	O
""""	O
in	O
EV	O
.	O

ABSTRACT	O
:	O
Vascular	O
endothelial	O
cadherin	O
(	O
VE	O
-	O
cadherin	O
)	O
is	O
a	O
membrane	O
protein	B-CHED
that	O
is	O
the	O
major	O
component	O
of	O
adherens	O
junctions	O
between	O
endothelial	O
cells	O
.	O

We	O
measured	O
metrics	O
for	O
oxygenation	O
,	O
ventilation	O
,	O
and	O
haemodynamics	O
as	O
well	O
as	O
the	O
use	O
of	O
sedative	B-CHED
-	O
analgesic	B-CHED
medications	O
and	O
neuromuscular	O
blocking	O
agents	O
.	O

Here	O
,	O
we	O
developed	O
,	O
compared	O
and	O
evaluated	O
three	O
different	O
indirect	O
ELISAs	O
based	O
on	O
MERS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
),	O
spike	O
(	O
S	O
)	O
ectodomain	O
(	O
amino	B-CHED
acids	I-CHED
1	O
-	O
1297	O
)	O
and	O
S1	O
subunit	O
(	O
amino	B-CHED
acids	I-CHED
1	O
-	O
725	O
)	O
and	O
compared	O
them	O
with	O
MN	O
assay	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
45	O
studies	O
(	O
including	O
data	O
from	O
15	O
,	O
990	O
pigs	O
)	O
met	B-CHED
our	O
evaluation	O
criteria	O
.	O

ABSTRACT	O
:	O
Effective	O
antiviral	B-CHED
treatments	O
for	O
MERS	O
-	O
CoV	O
are	O
urgently	O
needed	O
.	O

Azithromycin	B-CHED
was	O
most	O
commonly	O
used	O
(	O
97	O
/	O
136	O
;	O
71	O
.	O
3	O
%).	O

On	O
admission	O
to	O
ICU	O
,	O
the	O
baseline	O
characteristics	O
of	O
patients	O
who	O
received	O
and	O
did	O
not	O
receive	O
macrolides	B-CHED
were	O
similar	O
,	O
including	O
demographic	O
data	O
and	O
sequential	O
organ	O
failure	O
assessment	O
score	O
.	O

TITLE	O
:	O
Structure	O
-	O
Based	O
Vaccine	O
Antigen	B-CHED
Design	O
.	O

ABSTRACT	O
:	O
Enabled	O
by	O
new	O
approaches	O
for	O
rapid	O
identification	O
and	O
selection	O
of	O
human	O
monoclonal	O
antibodies	O
,	O
atomic	O
-	O
level	O
structural	O
information	O
for	O
viral	O
surface	O
proteins	B-CHED
,	O
and	O
capacity	O
for	O
precision	O
engineering	O
of	O
protein	B-CHED
immunogens	O
and	O
self	O
-	O
assembling	O
nanoparticles	B-CHED
,	O
a	O
new	O
era	B-CHED
of	O
antigen	B-CHED
design	O
and	O
display	O
options	O
has	O
evolved	O
.	O

These	O
are	O
part	O
of	O
the	O
first	O
line	O
of	O
defence	O
and	O
suggest	O
a	O
response	O
to	O
both	O
viral	O
structural	O
proteins	B-CHED
and	O
viral	O
nucleic	B-CHED
acid	I-CHED
.	O

Given	O
that	O
a	O
false	O
-	O
positive	O
result	O
occurred	O
and	O
FIP	O
was	O
correctly	O
detected	O
in	O
only	O
approximately	O
half	O
of	O
the	O
cases	O
of	O
FIP	O
,	O
ICC	O
of	O
mesenteric	O
lymph	O
node	O
FNA	B-CHED
alone	O
cannot	O
reliably	O
confirm	O
or	O
exclude	O
FIP	O
,	O
but	O
can	O
be	O
a	O
helpful	O
test	O
in	O
conjunction	O
with	O
other	O
diagnostic	O
measures	O
.	O

Because	O
of	O
its	O
anti	O
-	O
inflammatory	O
and	O
immunomodulatory	O
properties	O
,	O
omega	O
-	O
3	O
polyunsaturated	B-CHED
fatty	I-CHED
acids	I-CHED
(	O
	O
-	O
3	O
PUFA	B-CHED
)	O
have	O
been	O
administered	O
to	O
ARDS	O
patients	O
,	O
mostly	O
by	O
the	O
enteral	O
route	O
,	O
as	O
immune	O
-	O
enhancing	O
diets	O
with	O
eicosapentaenoic	B-CHED
acid	I-CHED
,	O
	O
-	O
linolenic	B-CHED
acid	I-CHED
,	O
and	O
antioxidants	B-CHED
.	O

However	O
,	O
clinical	O
benefits	O
of	O
	O
-	O
3	O
PUFAs	B-CHED
in	O
ARDS	O
patients	O
remain	O
unclear	O
because	O
clinical	O
trials	O
have	O
found	O
conflicting	O
results	O
.	O

Three	O
months	O
beforehand	O
he	O
had	O
been	O
bitten	O
by	O
a	O
tick	O
and	O
developed	O
erythema	O
migrans	O
which	O
was	O
treated	O
with	O
Doxycycline	B-CHED
for	O
10	O
days	O
.	O

Host	O
-	O
based	O
antiviral	B-CHED
agents	I-CHED
target	O
host	O
cellular	O
machineries	O
essential	O
for	O
viral	O
infections	O
or	O
innate	O
immune	O
responses	O
to	O
interfere	O
with	O
viral	O
pathogenesis	O
.	O

Finally	O
,	O
several	O
approaches	O
to	O
minimize	O
P	O
-	O
SILI	O
while	O
maintaining	O
some	O
diaphragm	O
activity	O
(	O
e	O
.	O
g	O
.	O
partial	O
neuromuscular	O
blockade	O
,	O
high	O
PEEP	B-CHED
)	O
appear	O
promising	O
.	O

ABSTRACT	O
:	O
Identifying	O
viral	O
antagonists	B-CHED
of	O
innate	O
immunity	O
and	O
determining	O
if	O
they	O
contribute	O
to	O
pathogenesis	O
are	O
critical	O
for	O
developing	O
effective	O
strategies	O
to	O
control	O
emerging	O
viruses	O
.	O

The	O
scFv	O
gene	O
was	O
subcloned	O
into	O
the	O
pET	O
-	O
28a	O
(+),	O
and	O
the	O
constituted	O
plasmid	O
was	O
introduced	O
into	O
Escherichia	O
coli	O
BL21	O
(	O
DE3	O
)	O
for	O
protein	B-CHED
expression	O
.	O

TITLE	O
:	O
Successful	O
extracorporeal	O
membrane	O
oxygenation	O
support	O
for	O
severe	O
acute	O
diquat	B-CHED
and	O
glyphosate	B-CHED
poisoning	O
:	O
A	O
case	O
report	O
.	O

<	O
strong	O
>	O
MATERIAL	O
AND	O
METHODS	O
</	O
strong	O
>	O
We	O
used	O
an	O
LPS	B-CHED
-	O
induced	O
mouse	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
model	O
to	O
investigate	O
the	O
possible	O
role	O
of	O
HIPK1	O
in	O
ALI	O
pathophysiology	O
.	O

TITLE	O
:	O
The	O
3D8	O
single	O
chain	O
variable	O
fragment	O
protein	B-CHED
suppress	O
infectious	O
bronchitis	O
virus	O
transmission	O
in	O
the	O
transgenic	O
chickens	O
.	O

Multivariate	O
analyses	O
revealed	O
that	O
elevated	O
blood	O
lactate	B-CHED
level	O
(	O
2	O
.	O
0	O
mmol	O
/	O
L	O
)	O
and	O
increased	O
HRCT	O
scores	O
were	O
significantly	O
associated	O
with	O
weaning	O
failure	O
and	O
30	O
-	O
day	O
mortality	O
of	O
the	O
patients	O
with	O
ARDS	O
.	O

Multivariate	O
analyses	O
revealed	O
that	O
elevated	O
blood	O
lactate	B-CHED
level	O
(	O
2	O
.	O
0	O
mmol	O
/	O
L	O
)	O
and	O
increased	O
HRCT	O
scores	O
were	O
significantly	O
associated	O
with	O
weaning	O
failure	O
and	O
30	O
-	O
day	O
mortality	O
of	O
the	O
patients	O
with	O
ARDS	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
indicated	O
that	O
miR	O
	O
223	O
functioned	O
as	O
a	O
biological	O
indicator	B-CHED
by	O
regulating	O
inflammation	O
in	O
ALI	O
,	O
and	O
may	O
represent	O
a	O
novel	O
potential	O
therapeutic	O
target	O
and	O
prognostic	O
marker	O
of	O
ALI	O
.	O

He	O
was	O
switched	O
to	O
oral	O
anti	O
-	O
coagulation	O
by	O
vitamin	B-CHED
-	O
K	O
antagonists	B-CHED
and	O
was	O
referred	O
to	O
a	O
hematologist	O
,	O
a	O
vascular	O
-	O
surgeon	O
,	O
and	O
a	O
dentist	O
.	O

Duration	O
of	O
antibiotic	B-CHED
therapy	O
and	O
additional	O
anticoagulation	O
treatment	O
are	O
still	O
under	O
discussion	O
.	O

While	O
cells	O
uninfected	O
or	O
infected	O
with	O
a	O
lentivirus	O
expressing	O
a	O
3a	O
protein	B-CHED
defective	O
in	O
ion	O
channel	O
activity	O
expressed	O
NLRP3	O
uniformly	O
throughout	O
the	O
cytoplasm	O
,	O
NLRP3	O
was	O
redistributed	O
to	O
the	O
perinuclear	O
space	O
in	O
cells	O
infected	O
with	O
a	O
lentivirus	O
expressing	O
the	O
3a	O
protein	B-CHED
.	O

The	O
identified	O
mBALF	O
endotypes	O
(	O
isoleucine	B-CHED
,	O
leucine	B-CHED
,	O
valine	B-CHED
,	O
lysine	B-CHED
/	O
arginine	B-CHED
,	O
tyrosine	B-CHED
,	O
threonine	B-CHED
)	O
and	O
serum	O
endotypes	O
(	O
proline	O
,	O
glutamate	B-CHED
,	O
phenylalanine	B-CHED
,	O
valine	B-CHED
)	O
in	O
both	O
subphenotypes	O
by	O
statistical	O
analysis	O
were	O
tested	O
for	O
their	O
reproducibility	O
and	O
robustness	O
.	O

TITLE	O
:	O
Kaempferol	B-CHED
reduces	O
K63	O
-	O
linked	O
polyubiquitination	O
to	O
inhibit	O
nuclear	O
factor	O
-	O
B	O
and	O
inflammatory	O
responses	O
in	O
acute	O
lung	O
injury	O
in	O
mice	O
.	O

TITLE	O
:	O
Absence	O
of	O
neutralizing	O
activity	O
in	O
serum	O
1	O
year	O
after	O
successful	O
treatment	O
with	O
antivirals	B-CHED
and	O
recovery	O
from	O
MERS	O
in	O
South	O
Korea	O
.	O

ABSTRACT	O
:	O
Adjusting	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
to	O
offset	O
pleural	O
pressure	O
might	O
attenuate	O
lung	O
injury	O
and	O
improve	O
patient	O
outcomes	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Furthermore	O
,	O
four	O
metabolites	B-CHED
,	O
ornithine	B-CHED
,	O
caprylic	B-CHED
acid	I-CHED
,	O
azetidine	B-CHED
,	O
and	O
iminodiacetic	B-CHED
acid	I-CHED
,	O
could	O
serve	O
as	O
biomarkers	O
to	O
potentially	O
predict	O
the	O
severity	O
of	O
ARDS	O
.	O

Preliminary	O
insecticidal	O
activity	O
and	O
antiviral	B-CHED
activity	O
were	O
also	O
observed	O
for	O
some	O
title	O
compounds	O
.	O

Several	O
therapeutic	O
options	O
are	O
currently	O
available	O
including	O
fluid	O
management	O
,	O
neuromuscular	O
blocking	O
agents	O
,	O
prone	O
positioning	O
,	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
corticosteroids	B-CHED
,	O
and	O
inhaled	O
pulmonary	O
vasodilating	O
agents	O
(	O
prostacyclins	O
and	O
nitric	B-CHED
oxide	I-CHED
).	O

All	O
newly	O
synthesized	O
nucleosides	B-CHED
were	O
tested	O
for	O
their	O
antitumor	O
or	O
antiviral	B-CHED
activity	O
.	O

TITLE	O
:	O
Antigens	B-CHED
under	O
cover	O
-	O
The	O
preservation	O
and	O
demasking	O
of	O
selected	O
antigens	B-CHED
for	O
successful	O
poststaining	O
immunocytochemistry	O
of	O
effusion	O
,	O
brain	O
smears	O
,	O
and	O
lymph	O
node	O
aspirates	O
.	O

The	O
staining	O
intensity	O
reached	O
the	O
same	O
levels	O
as	O
that	O
of	O
the	O
controls	O
if	O
the	O
films	O
underwent	O
MWT	O
in	O
citrate	B-CHED
buffer	B-CHED
.	O

In	O
contrast	O
,	O
FCoV	O
antigen	B-CHED
detection	O
was	O
abolished	O
after	O
any	O
physicochemical	O
interference	O
.	O

Paired	O
untreated	O
samples	O
should	O
be	O
kept	O
in	O
case	O
the	O
workup	O
requires	O
testing	O
for	O
more	O
vulnerable	O
viral	O
antigens	B-CHED
.	O

RESULTS	O
:	O
Cellular	O
antigens	B-CHED
were	O
reliably	O
detected	O
with	O
immunocytochemistry	O
after	O
smears	O
were	O
stained	O
with	O
a	O
Romansky	O
stain	O
and	O
were	O
coverslipped	O
early	O
after	O
staining	O
and	O
stayed	O
coverslipped	O
until	O
immediately	O
before	O
immunolabeling	O
.	O

In	O
contrast	O
,	O
FCoV	O
antigen	B-CHED
detection	O
was	O
abolished	O
after	O
any	O
physicochemical	O
interference	O
.	O

There	O
are	O
no	O
approved	O
vaccines	O
or	O
licensed	O
antivirals	B-CHED
for	O
parainfluenza	O
,	O
rhinovirus	O
,	O
hMPV	O
,	O
and	O
coronavirus	O
.	O

Additionally	O
,	O
DON	O
led	O
to	O
earlier	O
expression	O
of	O
the	O
growth	O
factor	O
amphiregulin	O
and	O
more	O
rapid	O
recovery	O
of	O
LPS	B-CHED
-	O
induced	O
weight	O
loss	O
.	O

The	O
spike	O
glycoprotein	B-CHED
from	O
strain	O
RSA59	O
(	O
PP	O
)	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
contains	O
two	O
central	O
,	O
consecutive	O
prolines	O
in	O
the	O
FP	O
.	O

NOX	O
-	O
derived	O
ROS	B-CHED
is	O
involved	O
in	O
the	O
defense	O
function	O
of	O
lung	O
tissue	O
and	O
related	O
to	O
the	O
occurrence	O
and	O
development	O
of	O
ALI	O
/	O
ARDS	O
.	O

ABSTRACT	O
:	O
A	O
44	O
-	O
year	O
-	O
old	O
woman	O
intentionally	O
ingested	O
a	O
solution	O
of	O
copper	B-CHED
sulphate	B-CHED
.	O

Acute	O
copper	B-CHED
sulphate	B-CHED
poisoning	O
can	O
cause	O
severe	O
pulmonary	O
toxicity	O
even	O
in	O
the	O
absence	O
of	O
other	O
serious	O
symptoms	O
.	O

We	O
suggest	O
early	O
initiation	O
of	O
venovenous	O
ECMO	O
in	O
those	O
with	O
ARDS	O
following	O
copper	B-CHED
sulphate	B-CHED
poisoning	O
.	O

TITLE	O
:	O
Guinea	O
Fowl	O
Coronavirus	O
Diversity	O
Has	O
Phenotypic	O
Consequences	O
for	O
Glycan	B-CHED
and	O
Tissue	O
Binding	O
.	O

We	O
conducted	O
a	O
systematic	O
literature	O
review	O
(	O
across	O
7	O
databases	O
)	O
of	O
case	O
-	O
control	O
studies	O
published	O
from	O
1996	O
to	O
2017	O
that	O
investigated	O
the	O
viral	O
profile	O
of	O
older	O
adults	O
with	O
and	O
those	O
without	O
ARI	B-CHED
.	O

Expert	O
opinion	O
:	O
Treatment	O
of	O
SARS	O
and	O
MERS	O
in	O
outbreak	O
settings	O
has	O
focused	O
on	O
therapeutics	O
with	O
general	O
antiviral	B-CHED
activity	O
and	O
good	O
safety	O
profiles	O
rather	O
than	O
efficacy	O
data	O
provided	O
by	O
cellular	O
,	O
rodent	O
,	O
or	O
nonhuman	O
primate	O
models	O
of	O
highly	O
pathogenic	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
Type	O
-	O
I	O
IFNs	O
(	O
IFN	O
-	O
I	O
)	O
provide	O
a	O
key	O
mediator	O
of	O
innate	O
antiviral	B-CHED
response	O
during	O
virus	O
proliferation	O
.	O

Both	O
toxicological	O
analysis	O
of	O
deceased	O
blood	O
and	O
urine	O
samples	O
and	O
chemical	O
analysis	O
of	O
the	O
herbal	O
mixture	B-CHED
seized	O
revealed	O
presence	O
of	O
two	O
SCs	O
-	O
5F	O
-	O
ADB	O
and	O
FUB	O
-	O
AMB	B-CHED
.	O

The	O
present	O
case	O
can	O
be	O
discussed	O
as	O
an	O
example	O
of	O
both	O
drug	O
-	O
induced	O
and	O
drug	O
-	O
related	O
death	O
resulting	O
from	O
acute	O
intoxication	O
with	O
5F	O
-	O
ADB	O
and	O
FUB	O
-	O
AMB	B-CHED
as	O
well	O
as	O
from	O
systematic	O
use	O
of	O
both	O
synthetic	O
cannabinoids	B-CHED
.	O

Here	O
,	O
IBV	O
S1	O
and	O
the	O
ectodomain	O
of	O
NDV	O
F	O
proteins	B-CHED
were	O
separately	O
linked	O
with	O
the	O
trans	O
-	O
membrane	O
and	O
carboxy	B-CHED
-	O
terminal	O
domain	O
of	O
IBV	O
S	O
protein	B-CHED
(	O
S	O

The	O
use	O
of	O
interferon	O
-	O
ribavirin	B-CHED
was	O
not	O
associated	O
with	O
mortality	O
in	O
this	O
cohort	O
.	O

ABSTRACT	O
:	O
The	O
main	O
immunogenic	O
protein	B-CHED
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
is	O
the	O
spike	O
protein	B-CHED
(	O
S	O
protein	B-CHED
),	O
which	O
plays	O
an	O
important	O
role	O
in	O
receptor	O
binding	O
,	O
membrane	O
fusion	O
,	O
and	O
viral	O
invasion	O
of	O
the	O
host	O
.	O

We	O
performed	O
successful	O
treatment	O
for	O
both	O
mucormycosis	O
and	O
CMV	O
pneumonia	O
and	O
adjusted	O
the	O
tacrolimus	B-CHED
dose	O
accordingly	O
.	O

In	O
the	O
moderate	O
and	O
severe	O
groups	O
,	O
PAP	B-CHED
was	O
significantly	O
higher	O
in	O
neonates	O
with	O
pulmonary	O
ALI	O
/	O
ADDS	O
(	O
ALI	O
/	O
ARDSp	O
)	O
than	O
in	O
neonates	O
with	O
extrapulmonary	O
ALI	O
/	O
ARDS	O
(	O
ALI	O
/	O
ARDSexp	O
)	O
(	O
62	O
.	O
5	O
	O
5	O
.	O
4	O
vs	O
68	O
.	O
0	O
	O
6	O
.	O
5	O
,	O
54	O
.	O
7	O
	O
5	O
.	O
9	O
vs	O
64	O
.	O
2	O
	O
4	O
.	O
9	O
;	O
t	O
=	O
3	O
.	O
264	O
,	O
3	O
.	O
123	O
;	O
P	O
=	O
.	O
004	O
,.	O
039	O
).	O

This	O
can	O
be	O
used	O
as	O
a	O
monitoring	O
indicator	B-CHED
for	O
the	O
severity	O
of	O
illness	O
.	O

Liver	O
suture	O
was	O
performed	O
,	O
but	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
PaO2	O
/	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
,	O
50	O
)	O
necessitated	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

The	O
vast	O
majority	O
(	O
92	O
.	O
4	O
%)	O
of	O
patients	O
who	O
were	O
managed	O
initially	O
with	O
NIV	O
required	O
intubation	O
and	O
invasive	O
mechanical	O
ventilation	O
,	O
and	O
were	O
more	O
likely	O
to	O
require	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
compared	O
to	O
those	O
who	O
were	O
managed	O
initially	O
with	O
invasive	O
MV	O
.	O

Their	O
knowledge	O
was	O
evaluated	O
against	O
facts	O
published	O
by	O
Mayo	O
Clinic	O
Foundation	O
,	O
and	O
its	O
percentage	O
mean	O
score	O
(	O
PMS	B-CHED
)	O
	O
standard	O
deviation	O
was	O
calculated	O
.	O

Older	O
(>	O
40	O
years	O
of	O
age	O
)	O
and	O
more	O
experienced	O
(>	O
10	O
years	O
)	O
HCWs	O
had	O
the	O
highest	O
PMS	B-CHED
for	O
knowledge	O
(	O
73	O
.	O
4	O
	O
18	O
.	O
9	O
,	O
P	O
=	O
0	O
.	O
005	O
and	O
76	O
.	O
9	O
	O
15	O
.	O
7	O
,	O
P	O
<	O
0	O
.	O
001	O
respectively	O
).	O

Negative	O
perceptions	O
of	O
educational	O
programs	O
(	O
49	O
.	O
4	O
	O
20	O
.	O
7	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
knowledge	O
transfer	O
(	O
46	O
.	O
0	O
	O
19	O
.	O
7	O
;	O
P	O
=	O
0	O
.	O
001	O
)	O
were	O
associated	O
with	O
a	O
lower	O
knowledge	O
PMS	B-CHED
.	O

RESULTS	O
:	O
A	O
total	O
of	O
1	O
,	O
362	O
respiratory	O
samples	O
were	O
collected	O
from	O
733	O
(	O
53	O
.	O
8	O
%)	O
male	O
and	O
629	O
(	O
46	O
.	O
2	O
%)	O
female	O
patients	O
with	O
ARI	B-CHED
who	O
visited	O
the	O
SKSH	O
between	O
November	O
2015	O
and	O
February	O
2018	O
.	O

In	O
addition	O
,	O
neutralizing	O
activity	O
against	O
these	O
2	O
mutant	O
viruses	O
in	O
serum	O
samples	O
from	O
mice	O
immunized	O
with	O
wild	O
-	O
type	O
spike	O
antigen	B-CHED
were	O
gradually	O
reduced	O
,	O
suggesting	O
emergence	O
and	O
wide	O
spread	O
of	O
neutralization	O
escapers	O
during	O
the	O
outbreak	O
.	O

The	O
heavily	O
glycosylated	O
IBV	O
spike	O
protein	B-CHED
is	O
responsible	O
for	O
binding	O
to	O
host	O
tissues	O
.	O

Incorporation	O
of	O
CD40L	O
into	O
rAd5	O
-	O
based	O
MERS	O
-	O
CoV	O
S1	O
vaccine	O
targeting	O
molecule	O
and	O
molecular	O
adjuvants	B-CHED
not	O
only	O
enhances	O
immunogenicity	O
and	O
efficacy	O
but	O
also	O
prevents	O
inadvertent	O
pulmonary	O
pathology	O
after	O
viral	O
challenge	O
,	O
thereby	O
offering	O
a	O
promising	O
strategy	O
to	O
enhance	O
safety	O
and	O
potency	O
of	O
vaccines	O
.	O

After	O
the	O
reappearance	O
of	O
an	O
emerging	O
enteropathogen	O
,	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
in	O
Hungary	O
in	O
2016	O
,	O
an	O
extensive	O
survey	O
was	O
initiated	O
in	O
an	O
attempt	O
to	O
identify	O
diarrhoea	O
-	O
related	O
porcine	O
viruses	O
,	O
including	O
adeno	O
-,	O
astro	O
-,	O
boca	O
-,	O
calici	O
-,	O
circo	O
-,	O
corona	B-CHED
-,	O
kobu	O
-,	O
rota	O
-	O
and	O
Torque	B-CHED
teno	O
viruses	O
.	O

Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
highly	O
pathogenic	O
human	O
corona	B-CHED
virus	O
with	O
38	O
%	O
fatality	O
rate	O
of	O
infected	O
patients	O
.	O

ABSTRACT	O
:	O
First	O
-	O
line	O
management	O
of	O
severe	O
asthma	O
exacerbations	O
include	O
the	O
use	O
of	O
inhaled	O
short	O
-	O
acting	O
	O
-	O
agonists	B-CHED
,	O
anticholinergics	B-CHED
,	O
and	O
systemic	O
corticosteroids	B-CHED
.	O

Whole	O
blood	O
samples	O
were	O
obtained	O
for	O
pharmacokinetic	O
analysis	O
of	O
ketamine	B-CHED
during	O
ECMO	O
.	O

Our	O
technique	O
,	O
catheter	O
-	O
in	O
-	O
catheter	O
selective	O
lung	O
injury	O
(	O
CICSLI	O
),	O
involves	O
guiding	O
an	O
inner	O
catheter	O
to	O
a	O
particular	O
area	O
of	O
the	O
lung	O
and	O
delivering	O
an	O
injurious	O
agent	O
mixed	O
with	O
nanoparticles	B-CHED
(	O
fluorescently	O
and	O
/	O
or	O
radioactively	O
labeled	O
)	O
that	O
can	O
be	O
used	O
days	O
later	O
to	O
track	O
the	O
location	O
and	O
extent	O
of	O
where	O
the	O
initial	O
injury	O
occurred	O
.	O

SI	O
-	O
ALI	O
model	O
rats	O
had	O
a	O
high	O
mortality	O
rate	O
and	O
severe	O
lung	O
injury	O
with	O
proinflammatory	O
,	O
procoagulant	O
,	O
and	O
pro	B-CHED
-	O
fibrotic	O
changes	O
.	O

Pro	B-CHED
-	O
fibrotic	O
chemokine	O
levels	O
were	O
gradually	O
increased	O
,	O
followed	O
by	O
an	O
increase	O
in	O
collagen	O
and	O
fibrin	O
deposition	O
after	O
smoke	O
inhalation	O
.	O

Three	O
and	O
7	O
-	O
day	O
MP	O
treatments	O
significantly	O
attenuated	O
this	O
process	O
,	O
which	O
was	O
reflected	O
by	O
a	O
reduction	O
in	O
pro	B-CHED
-	O
fibrotic	O
chemokine	O
levels	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aims	O
to	O
determine	O
the	O
feasibility	O
of	O
using	O
oligodeoxynucleotides	O
with	O
unmethylated	O
cytosine	B-CHED
-	O
guanine	B-CHED
dinucleotide	B-CHED
sequences	O
(	O
CpG	O
ODN	O
)	O
as	O
an	O
immunity	O
protection	O
strategy	O
for	O
a	O
mouse	O
model	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

The	O
general	O
anesthetic	O
at	O
this	O
time	O
consisted	O
of	O
a	O
nonspecific	O
mixture	B-CHED
of	O
gas	O
,	O
oxygen	B-CHED
,	O
and	O
ether	B-CHED
.	O

Despite	O
this	O
,	O
the	O
64	O
nonfatal	O
cases	O
were	O
almost	O
all	O
liquid	O
aspirations	O
with	O
radiographic	O
resolution	O
within	O
seven	O
days	O
and	O
clinical	O
recovery	O
within	O
36	O
hours	O
without	O
the	O
use	O
of	O
antibiotic	B-CHED
treatment	O
.[	O
1	O
]	O
Mendelson	O
	O
s	O
study	O
led	O
to	O
a	O
number	O
of	O
recommendations	O
that	O
still	O
are	O
in	O
use	O
in	O
the	O
obstetric	O
population	O
to	O
this	O
day	O
.	O

Opaque	O
rubber	B-CHED
masks	O
that	O
can	O
conceal	O
regurgitation	O
and	O
vomitus	O
have	O
been	O
replaced	O
with	O
clear	O
plastic	O
masks	O
and	O
ingestion	O
of	O
solid	O
food	O
has	O
been	O
discouraged	O
during	O
labor	O
.	O

Like	O
surfactin	O
,	O
SLP5	O
has	O
a	O
direct	O
antiviral	B-CHED
effect	O
on	O
PEDV	O
.	O

For	O
comparative	O
analyses	O
,	O
two	O
eS770	O
proteins	B-CHED
lacking	O
the	O
IgG4	O
Fc	O
domain	O
were	O
generated	O
using	O
the	O
IdeS	O
protease	O
(	O
eS770	O
-	O
Fc	O
)	O
or	O
His	O
tag	O
attachment	O
(	O
eS770	O
-	O
His	O
)	O
and	O
the	O
immunogenicity	O
of	O
the	O
above	O
constructs	O
were	O
examined	O
following	O
intramuscular	O
immunization	O
in	O
mice	O
.	O

To	O
various	O
degrees	O
,	O
they	O
are	O
also	O
amenable	O
to	O
alternative	O
responses	O
,	O
ranging	O
from	O
clean	O
water	B-CHED
provision	O
to	O
regulation	O
to	O
biomedical	O
countermeasures	O
.	O

Here	O
,	O
we	O
describe	O
an	O
improved	O
procedure	O
of	O
affinity	O
selection	O
against	O
crude	O
or	O
non	O
-	O
purified	O
antigen	B-CHED
by	O
saturation	O
of	O
non	O
-	O
binders	O
with	O
blocking	O
agents	O
to	O
promote	O
positive	O
binder	O
enrichment	O
termed	O
as	O
Yin	O
-	O
Yang	O
panning	O
.	O

High	O
-	O
dose	O
intravenous	O
steroids	B-CHED
were	O
started	O
as	O
adjuvant	B-CHED
therapy	O
due	O
to	O
the	O
rapid	O
decline	O
,	O
presumably	O
due	O
to	O
a	O
dysregulated	O
host	O
immune	O
response	O
.	O

EK1	O
,	O
the	O
optimized	O
form	O
of	O
OC43	O
-	O
HR2P	O
,	O
showed	O
substantially	O
improved	O
pan	B-CHED
-	O
CoV	O
fusion	O
inhibitory	O
activity	O
and	O
pharmaceutical	B-CHED
properties	O
.	O

Fatty	B-CHED
acid	I-CHED
-	O
binding	O
protein	B-CHED
1	O
(	O
FABP1	O
)	O
and	O
fatty	B-CHED
acid	I-CHED
-	O
binding	O
protein	B-CHED
3	O
(	O
FABP3	O
)	O
were	O
found	O
to	O
be	O
regulated	O
by	O
PDCoV	O
.	O
These	O
two	O
genes	O
not	O
only	O
mediate	O
fatty	B-CHED
acid	I-CHED
transportation	O
to	O
different	O
cell	O
organelles	O
such	O
as	O
mitochondria	O
,	O
peroxisome	O
,	O
endoplasmic	O
reticulum	O
and	O
nucleus	B-CHED
,	O
but	O
also	O
modulate	O
fatty	B-CHED
acid	I-CHED
metabolism	O
and	O
storage	O
as	O
a	O
signaling	B-CHED
molecule	I-CHED
outside	O
the	O
cell	O
.	O

ABSTRACT	O
:	O
Pesticide	B-CHED
self	O
-	O
poisoning	O
is	O
rare	O
in	O
developed	O
countries	O
.	O

H3K4me3	O
expression	O
was	O
significantly	O
lower	O
in	O
QFS	O
patients	O
than	O
in	O
healthy	O
controls	O
on	O
the	O
promoter	O
regions	O
of	O
IL	O
-	O
1	O
(	O
p	O
=	O
0	O
.	O
004	O
),	O
MCP	B-CHED
-	O
1	O
(<	O
0	O
.	O
001	O
and	O
<	O
0	O
.	O
001	O
),	O
IP	O
-	O
10	O
(<	O
0	O
.	O
001	O
),	O
IL	O
-	O
10	O
(	O
0	O
.	O
041	O
),	O
and	O
IL	O
-	O
13	O
(<	O
0	O
.	O
001	O
,	O
<	O
0	O
.	O
001	O
,	O
and	O
0	O
.	O
001	O
).	O

After	O
ruling	O
out	O
other	O
causes	O
,	O
the	O
diagnosis	O
of	O
gabapentin	B-CHED
withdrawal	O
was	O
considered	O
.	O

Gabapentin	B-CHED
was	O
administered	O
by	O
a	O
nasogastric	O
tube	O
that	O
quickly	O
resulted	O
in	O
a	O
reversal	O
of	O
his	O
symptoms	O
.	O

We	O
concluded	O
that	O
severe	O
gabapentin	B-CHED
withdrawal	O
should	O
be	O
considered	O
in	O
patients	O
on	O
higher	O
doses	O
of	O
gabapentin	B-CHED
when	O
it	O
is	O
stopped	O
abruptly	O
.	O

Interestingly	O
,	O
the	O
ORF3	O
protein	B-CHED
expression	O
was	O
diminished	O
in	O
VPS36	O
-	O
overexpressing	O
cells	O
,	O
an	O
effect	O
that	O
could	O
not	O
be	O
restored	O
by	O
treatment	O
of	O
lysosomal	O
inhibitors	B-CHED
.	O

TITLE	O
:	O
Immunogenicity	O
of	O
Different	O
Forms	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
S	O
Glycoprotein	B-CHED
.	O

In	O
this	O
study	O
,	O
the	O
pro	B-CHED
-	O
apoptotic	O
effect	O
of	O
PEDV	O
was	O
examined	O
in	O
Vero	O
cells	O
and	O
we	O
observed	O
that	O
PEDV	O
infection	O
increased	O
MDM2	O
and	O
CBP	O
,	O
promoted	O
p53	O
phosphorylation	O
at	O
serine	B-CHED
20	O
and	O
,	O
promoted	O
p53	O
nuclear	O
translocation	O
,	O
leading	O
to	O
p53	O
activation	O
in	O
Vero	O
cells	O
.	O

Treatment	O
with	O
antioxidants	B-CHED
,	O
such	O
as	O
pyrrolidine	B-CHED
dithiocarbamate	O
(	O
PDTC	O
)	O
or	O
N	B-CHED
-	I-CHED
acetylcysteine	I-CHED
(	O
NAC	O
),	O
significantly	O
inhibited	O
PEDV	O
-	O
induced	O
apoptosis	O
.	O

However	O
,	O
treatment	O
with	O
the	O
p38	O
MAPK	O
inhibitor	B-CHED
SB203580	O
,	O
and	O
the	O
SAPK	O
/	O
JNK	O
inhibitor	B-CHED
SP600125	O
reversed	O
PEDV	O
-	O
induced	O
apoptosis	O
.	O

The	O
effectiveness	O
of	O
cisplatin	B-CHED
-	O
based	O
chemotherapy	O
secures	O
more	O
than	O
95	O
%	O
of	O
patients	O
'	O
5	O
-	O
years	O
survival	O
rate	O
.	O

SARS	O
-	O
CoV	O
and	O
its	O
ORF3a	O
protein	B-CHED
were	O
found	O
to	O
be	O
potent	O
activators	O
of	O
pro	B-CHED
-	O
IL	O
-	O
1	O
gene	O
transcription	O
and	O
protein	B-CHED
maturation	O
,	O
the	O
2	O
signals	O
required	O
for	O
activation	O
of	O
the	O
NLRP3	O
inflammasome	O
.	O

Commonest	O
Influenza	O
subtype	O
in	O
age	O
group	O
-	O
IV	O
was	O
H3N2	B-CHED
found	O
in	O
20	O
(	O
32	O
.	O
8	O
%)	O
patients	O
,	O
followed	O
by	O
H1N1	O
in	O
15	O
(	O
12	O
.	O
5	O
%)	O
patients	O
.	O

The	O
relationship	O
among	O
the	O
number	O
and	O
type	O
of	O
comorbidities	O
,	O
Charlson	O
comorbidity	O
index	O
(	O
CCI	O
),	O
clinical	O
characteristics	O
and	O
the	O
levels	O
of	O
plasma	O
inflammatory	O
markers	O
[	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
high	O
sensitivity	O
C	O
-	O
reaction	O
protein	B-CHED
(	O
hs	O
-	O
CRP	O
),	O
tumor	O
necrosis	O
factor	O
-	O
	O
(	O
TNF	O
-	O
	O
),	O
IL	O
-	O
8	O
]	O
were	O
studied	O
.	O

In	O
addition	O
,	O
healthcare	O
worker	O
participants	O
providing	O
care	O
to	O
infected	O
participants	O
were	O
recruited	O
to	O
wear	O
a	O
polytetrafluoroethylene	B-CHED
(	O
PTFE	B-CHED
)	O
filter	O
cassette	O
in	O
their	O
breathing	O
zones	O
.	O

Viral	O
RNA	O
was	O
detected	O
from	O
the	O
air	B-CHED
emitted	O
by	O
37	O
.	O
5	O
%	O
of	O
the	O
16	O
participants	O
infected	O
with	O
influenza	O
virus	O
and	O
distributed	O
both	O
in	O
near	O
and	O
far	O
fields	O
and	O
in	O
all	O
tested	O
particle	O
sizes	O
(<	O
1	O
m	O
,	O
1	O
-	O
4	O
m	O
,	O
and	O
>	O
4	O
m	O
).	O

Viral	O
RNA	O
was	O
recovered	O
in	O
droplet	O
nuclei	B-CHED
and	O
beyond	O
1	O
m	O
from	O
naturally	O
-	O
infected	O
participants	O
in	O
the	O
healthcare	O
setting	O
and	O
from	O
the	O
breathing	O
zone	O
of	O
one	O
healthcare	O
worker	O
.	O

To	O
analyze	O
lipid	B-CHED
peroxidation	O
we	O
used	O
a	O
spectrophotometric	O
determination	O
of	O
diene	O
conjugates	O
.	O

Conclusions	O
:	O
Changes	O
in	O
antioxidant	B-CHED
system	O
happend	O
due	O
to	O
the	O
activation	O
of	O
lipid	B-CHED
peroxidation	O
,	O
and	O
because	O
of	O
the	O
inability	O
to	O
neutralize	O
toxic	O
metabolites	B-CHED
in	O
the	O
children	O
`	O
body	O
the	O
intoxication	O
syndrome	O
developed	O
.	O

CONCLUSIONS	O
:	O
Conclusions	O
:	O
Changes	O
in	O
antioxidant	B-CHED
system	O
happend	O
due	O
to	O
the	O
activation	O
of	O
lipid	B-CHED
peroxidation	O
,	O
and	O
because	O
of	O
the	O
inability	O
to	O
neutralize	O
toxic	O
metabolites	B-CHED
in	O
the	O
children	O
`	O
body	O
the	O
intoxication	O
syndrome	O
developed	O
.	O

We	O
performed	O
a	O
multicenter	O
,	O
prospective	O
data	O
collection	O
study	O
and	O
retrospectively	O
analyzed	O
the	O
data	O
to	O
confirm	O
the	O
role	O
of	O
DIC	B-CHED
in	O
severe	O
sepsis	O
.	O

DIC	B-CHED
patients	O
also	O
showed	O
a	O
lower	O
survival	O
probability	O
than	O
non	O
-	O
DIC	B-CHED
patients	O
(	O
Log	O
rank	O
p	O
=	O
0	O
.	O
028	O
).	O

Full	O
-	O
length	O
genome	O
sizes	O
of	O
four	O
isolates	O
differed	O
from	O
that	O
of	O
the	O
G2b	O
epidemic	O
field	O
strain	O
due	O
to	O
insertion	O
or	O
deletion	O
(	O
DEL	O
)	O
mutations	O
in	O
the	O
non	O
-	O
structural	O
protein	B-CHED
(	O
nsp	O
)-	O
or	O
spike	O
(	O
S	O
)	O
protein	B-CHED
-	O
coding	O
regions	O
.	O

These	O
symptoms	O
were	O
associated	O
with	O
fevers	O
,	O
and	O
24	O
hours	O
prior	O
to	O
admission	O
,	O
he	O
developed	O
intermittent	O
chest	O
pain	O
at	O
rest	B-CHED
,	O
radiating	O
to	O
the	O
back	O
,	O
worsening	O
in	O
the	O
supine	O
position	O
.	O

Colorimetric	O
assays	O
are	O
a	O
representative	O
tool	O
to	O
simply	O
identify	O
the	O
target	O
molecules	O
in	O
specimens	O
through	O
color	O
changes	O
of	O
an	O
indicator	B-CHED
(	O
e	O
.	O
g	O
.,	O
nanosized	O
metallic	O
particle	O
,	O
and	O
dye	B-CHED
molecules	O
).	O

The	O
lowest	O
amino	B-CHED
acid	I-CHED
identity	O
of	O
16BO133	O
was	O
identified	O
at	O
the	O
spike	O
region	O
among	O
various	O
ORFs	O
.	O

Although	O
OA	O
reduced	O
SOD	O
,	O
CAT	O
,	O
and	O
GSH	B-CHED
levels	O
in	O
lung	O
tissue	O
,	O
the	O
vitamins	B-CHED
and	O
LDMP	O
markedly	O
enhanced	O
the	O
levels	O
except	O
for	O
HDMP	O
.	O

However	O
,	O
methylprednisolone	B-CHED
was	O
not	O
found	O
sufficient	O
for	O
being	O
a	O
therapeutic	O
agent	O
for	O
ARDS	O
.	O

Notably	O
,	O
IBV	O
-	O
induced	O
autophagy	O
was	O
dependent	O
on	O
autophagy	O
related	O
5	O
(	O
ATG5	O
)	O
but	O
not	O
beclin1	O
(	O
BECN1	O
),	O
although	O
both	O
are	O
essential	O
proteins	B-CHED
in	O
the	O
canonical	O
autophagy	O
pathway	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
series	O
of	O
dihydroquinazolin	O
-	O
2	O
-	O
amine	B-CHED
derivatives	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
in	O
MT	O
-	O
4	O
cell	O
cultures	O
.	O

T	O
cells	O
recognize	O
antigens	B-CHED
specifically	O
through	O
a	O
membrane	O
protein	B-CHED
T	O
cell	O
receptor	O
(	O
TCR	O
).	O

While	O
several	O
PARPs	B-CHED
have	O
known	O
antiviral	B-CHED
activities	O
,	O
these	O
activities	O
are	O
mostly	O
independent	O
of	O
ADP	B-CHED
-	O
ribosylation	O
.	O

Consequently	O
,	O
less	O
is	O
known	O
about	O
the	O
antiviral	B-CHED
effects	O
of	O
ADP	B-CHED
-	O
ribosylation	O
.	O

Secondly	O
,	O
using	O
Sanger	O
sequencing	O
,	O
this	O
study	O
recovered	O
a	O
complete	O
genome	O
(	O
28	O
005	O
nucleotides	B-CHED
long	O
)	O
of	O
NB1	O
strain	O
from	O
a	O
farm	O
severely	O
affected	O
by	O
PED	O
.	O

In	O
this	O
study	O
,	O
a	O
series	O
of	O
heptad	O
repeat	O
1	O
(	O
HR1	O
)	O
peptide	B-CHED
inhibitors	B-CHED
have	O
been	O
developed	O
to	O
inhibit	O
HR1	O
/	O
HR2	O
-	O
mediated	O
membrane	O
fusion	O
between	O
MERS	O
-	O
CoV	O
and	O
host	O
cells	O
,	O
which	O
is	O
the	O
major	O
pathway	O
of	O
MERS	O
-	O
CoV	O
-	O
induced	O
host	O
infections	O
.	O

Isavuconazole	O
is	O
an	O
alternative	O
in	O
case	O
of	O
intolerance	O
to	O
voriconazole	B-CHED
,	O
drug	O
-	O
drug	O
interactions	O
,	O
renal	O
impairment	O
,	O
or	O
if	O
a	O
spectrum	O
of	O
activity	O
including	O
the	O
majority	O
of	O
Mucorales	O
is	O
desired	O
.	O

Primary	O
anti	O
-	O
mould	O
prophylaxis	O
with	O
posaconazole	B-CHED
is	O
recommended	O
in	O
haematology	O
patients	O
at	O
high	O
-	O
risk	O
.	O

Nonsurvivors	O
had	O
a	O
more	O
intense	O
inflammatory	O
response	O
than	O
did	O
survivors	O
at	O
48	O
h	O
(	O
C	O
-	O
reactive	O
protein	B-CHED
:	O
31	O
.	O
0	O
	O
17	O
.	O
5	O
vs	O
.	O
14	O
.	O
6	O
	O
8	O
.	O
9	O
mg	O
/	O
dl	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
as	O
well	O
as	O
a	O
more	O
positive	O
fluid	O
balance	B-CHED
.	O

As	O
epidemiologic	O
and	O
etiopathologic	O
data	O
for	O
canine	O
myocarditis	O
are	O
lacking	O
,	O
we	O
performed	O
a	O
retrospective	O
study	O
using	O
nucleic	B-CHED
acid	I-CHED
extracted	O
from	O
archived	O
(	O
2007	O
to	O
2015	O
)	O
tissues	O
from	O
myocarditis	O
cases	O
and	O
control	O
dogs	O
without	O
myocardial	O
lesions	O
.	O

Diagnosis	O
of	O
mercury	B-CHED
poisoning	O
was	O
confirmed	O
by	O
blood	O
levels	O
,	O
and	O
despite	O
treatment	O
with	O
dimercaprol	B-CHED
(	O
mercury	B-CHED
chelator	B-CHED
)	O
and	O
high	O
-	O
frequency	O
ventilation	O
,	O
the	O
child	O
subsequently	O
succumbed	O
within	O
26	O
hours	O
.	O

TITLE	O
:	O
Characterization	O
of	O
antiviral	B-CHED
T	O
cell	O
responses	O
during	O
primary	O
and	O
secondary	O
challenge	O
of	O
laboratory	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
).	O

Differences	O
in	O
disease	O
outcome	O
provided	O
an	O
opportunity	O
to	O
investigate	O
the	O
role	O
of	O
T	O
cell	O
immunity	O
to	O
FIP	O
determined	O
by	O
T	O
cell	O
subset	O
proliferation	O
after	O
stimulation	O
with	O
different	O
viral	O
antigens	B-CHED
.	O

This	O
review	O
will	O
discuss	O
the	O
role	O
of	O
two	O
cellular	O
eukaryotic	O
processes	O
that	O
are	O
vital	O
for	O
maintenance	O
of	O
cellular	O
homeostasis	O
-	O
1	O
)	O
the	O
nonsense	O
-	O
mediated	O
mRNA	B-CHED
decay	O
(	O
NMD	O
)	O
pathway	O
and	O
2	O
)	O
the	O
transient	O
formation	O
of	O
stress	O
granules	O
(	O
SG	O
)	O
-	O
and	O
explore	O
the	O
current	O
literature	O
on	O
their	O
roles	O
in	O
antiviral	B-CHED
defence	O
.	O

Viral	O
envelope	O
proteins	B-CHED
from	O
a	O
variety	O
of	O
human	O
pathogens	O
including	O
HIV	O
-	O
1	O
,	O
influenza	O
virus	O
,	O
Lassa	O
virus	O
,	O
SARS	O
,	O
Zika	O
virus	O
,	O
dengue	O
virus	O
,	O
and	O
Ebola	O
virus	O
have	O
evolved	O
to	O
be	O
extensively	O
glycosylated	O
.	O

In	O
this	O
review	O
,	O
we	O
highlight	O
the	O
imperative	O
and	O
auxiliary	O
roles	O
glycans	B-CHED
play	O
,	O
and	O
how	O
specific	O
oligosaccharide	B-CHED
structures	O
facilitate	O
these	O
functions	O
during	O
viral	O
pathogenesis	O
.	O

A	O
translocation	O
model	O
is	O
proposed	O
for	O
the	O
Upf1	O
-	O
like	O
helicase	O
members	O
according	O
to	O
three	O
different	O
structural	O
conditions	O
in	O
solution	O
characterized	O
through	O
H	O
/	O
D	O
exchange	O
assay	O
,	O
including	O
substrate	O
state	O
(	O
SARS	O
-	O
Nsp13	O
-	O
dsDNA	O
bound	O
with	O
AMPPNP	B-CHED
),	O
transition	O
state	O
(	O
bound	O
with	O
ADP	B-CHED
-	O
AlF4	B-CHED
-)	O
and	O
product	O
state	O
(	O
bound	O
with	O
ADP	B-CHED
).	O

It	O
also	O
compares	O
E	O
to	O
other	O
viral	O
proteins	B-CHED
of	O
a	O
similar	O
nature	O
to	O
speculate	O
the	O
relevance	O
of	O
these	O
new	O
findings	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
corona	B-CHED
pre	O
-	O
coating	O
differentially	O
affects	O
viral	O
infectivity	O
and	O
immune	O
cell	O
activation	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
viruses	O
bind	O
amyloidogenic	O
peptides	B-CHED
in	O
their	O
corona	B-CHED
and	O
catalyze	O
amyloid	O
formation	O
via	O
surface	O
-	O
assisted	O
heterogeneous	O
nucleation	O
.	O

TITLE	O
:	O
Lessening	O
of	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
susceptibility	O
in	O
piglets	O
after	O
editing	O
of	O
the	O
CMP	B-CHED
-	O
N	B-CHED
-	I-CHED
glycolylneuraminic	I-CHED
acid	I-CHED
hydroxylase	O
gene	O
with	O
CRISPR	O
/	O
Cas9	O
to	O
nullify	O
N	B-CHED
-	I-CHED
glycolylneuraminic	I-CHED
acid	I-CHED
expression	O
.	O

ABSTRACT	O
:	O
The	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
devastates	O
the	O
health	O
of	O
piglets	O
but	O
may	O
not	O
infect	O
piglets	O
whose	O
CMP	B-CHED
-	O
N	B-CHED
-	I-CHED
glycolylneuraminic	I-CHED
acid	I-CHED
hydroxylase	O
(	O
CMAH	O
)	O
gene	O
is	O
mutated	O
(	O
knockouts	O
,	O
KO	O
)	O
by	O
using	O
CRISPR	O
/	O
Cas9	O
gene	O
editing	O
techniques	O
.	O

Two	O
single	O
-	O
guide	O
RNAs	O
targeting	O
the	O
CMAH	O
gene	O
and	O
Cas9	O
mRNA	B-CHED
were	O
microinjected	O
into	O
the	O
cytoplasm	O
of	O
newly	O
fertilized	O
eggs	O
.	O

Four	O
live	O
founders	O
generated	O
and	O
proven	O
to	O
be	O
biallelic	O
KO	O
,	O
lacking	O
detectable	O
N	B-CHED
-	I-CHED
glycolylneuraminic	I-CHED
acid	I-CHED
(	O
NGNA	B-CHED
).	O

Herein	O
,	O
we	O
generated	O
a	O
bacterial	O
outer	O
membrane	O
vesicles	O
(	O
OMVs	O
)-	O
based	O
vaccine	O
presenting	O
the	O
antigenic	O
stable	O
chimeric	O
fusion	O
protein	B-CHED
of	O
the	O
H1	O
-	O
type	O
haemagglutinin	O
(	O
HA	O
)	O
of	O
the	O
pandemic	O
influenza	O
A	O
virus	O
(	O
H1N1	O
)	O
strain	O
from	O
2009	O
(	O
H1N1pdm09	O
)	O
and	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
(	O
OMVs	O
-	O
H1	O
/	O
RBD	O
).	O

ABSTRACT	O
:	O
Viral	O
proteins	B-CHED
must	O
intimately	O
interact	O
with	O
the	O
host	O
cell	O
machinery	O
during	O
virus	O
replication	O
.	O

The	O
interferon	O
(	O
IFN	O
)-	O
mediated	O
antiviral	B-CHED
response	O
is	O
an	O
important	O
component	O
of	O
virus	O
-	O
host	O
interactions	O
and	O
plays	O
an	O
essential	O
role	O
in	O
inhibiting	O
virus	O
infection	O
.	O

PDCoV	O
N	O
protein	B-CHED
targeted	O
porcine	O
retinoic	B-CHED
acid	I-CHED
-	O
inducible	O
gene	O
I	O
(	O
pRIG	O
-	O
I	O
)	O
and	O
porcine	O
TNF	O
receptor	O
associated	O
factor	O
3	O
(	O
pTRAF3	O
)	O
by	O
directly	O
interacting	O
with	O
them	O
.	O

Positive	O
fluid	O
balance	B-CHED
(	O
a	O
cut	O
-	O
off	O
value	O
>	O
102	O
.	O
5	O
mL	O
/	O
kg	O
;	O
p	O
=	O
0	O
.	O
016	O
)	O
was	O
associated	O
with	O
higher	O
mortality	O
at	O
48	O
hours	O
.	O

Forty	O
-	O
nine	O
pregnant	O
,	O
buprenorphine	B-CHED
-	O
maintained	O
women	O
yielded	O
maternal	O
physiologic	O
information	O
(	O
heart	O
rate	O
and	O
variability	O
,	O
electrodermal	O
activity	O
,	O
and	O
respiratory	O
rate	O
)	O
at	O
24	O
,	O
28	O
,	O
32	O
and	O
36	O
weeks	O
gestation	O
.	O

Buprenorphine	B-CHED
administration	O
accelerated	O
maternal	O
heart	O
rate	O
and	O
reduced	O
variability	O
at	O
two	O
gestational	O
ages	O
(	O
24	O
and	O
36	O
weeks	O
)	O
and	O
suppressed	O
sympathetic	O
(	O
electrodermal	O
)	O
activation	O
at	O
24	O
,	O
28	O
and	O
32	O
weeks	O
at	O
times	O
of	O
peak	O
maternal	O
medication	O
levels	O
.	O

Larger	O
degree	O
of	O
maternal	O
heart	O
rate	O
reactivity	O
to	O
buprenorphine	B-CHED
administration	O
was	O
related	O
to	O
more	O
severe	O
NAS	O
expression	O
.	O

These	O
findings	O
detail	O
the	O
maternal	O
autonomic	O
response	O
to	O
buprenorphine	B-CHED
administration	O
but	O
also	O
illustrate	O
the	O
significant	O
effect	O
of	O
concurrent	O
cigarette	O
use	O
on	O
maternal	O
autonomic	O
regulation	O
.	O

TITLE	O
:	O
DL	O
-	O
3	O
-	O
n	O
-	O
butylphthalide	O
attenuates	O
lipopolysaccharide	B-CHED
-	O
induced	O
acute	O
lung	O
injury	O
via	O
SIRT1	O
-	O
dependent	O
and	O
-	O
independent	O
regulation	O
of	O
Nrf2	O
.	O

However	O
,	O
there	O
is	O
no	O
compelling	O
evidence	O
supporting	O
the	O
use	O
of	O
direct	O
oral	O
anticoagulant	B-CHED
in	O
individuals	O
who	O
are	O
intubated	O
or	O
have	O
a	O
percutaneous	O
endoscopic	O
gastrostomy	O
(	O
PEG	B-CHED
):	O
patients	O
with	O
several	O
co	O
-	O
morbidities	O
are	O
underrepresented	O
in	O
clinical	O
trials	O
,	O
so	O
the	O
best	O
long	O
-	O
term	O
strategy	O
for	O
anticoagulation	O
is	O
difficult	O
to	O
ascertain	O
.	O

A	O
71	O
-	O
year	O
-	O
old	O
man	B-CHED
with	O
atrial	O
fibrillation	O
,	O
advanced	O
ALS	O
,	O
type	O
II	O
diabetes	O
mellitus	O
,	O
and	O
hypertension	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
dyspnoea	O
and	O
tachycardia	O
.	O

We	O
compared	O
mean	O
SF	O
-	O
36	O
scores	O
of	O
MERS	O
and	O
non	O
-	O
MERS	O
SARI	O
survivors	O
using	O
independent	O
t	O
-	O
test	O
,	O
and	O
compared	O
categorical	O
variables	O
using	O
chi	B-CHED
-	O
square	O
test	O
.	O

Other	O
findings	O
during	O
the	O
initial	O
evaluation	O
of	O
the	O
patient	O
may	O
include	O
a	O
lack	O
of	O
acute	O
cardiac	O
disease	O
or	O
inappropriate	O
fluid	O
balance	B-CHED
,	O
flat	O
neck	O
veins	O
,	O
and	O
the	O
absence	O
of	O
peripheral	O
edema	O
.	O

Four	O
recommendations	O
(	O
low	O
tidal	O
volume	O
,	O
plateau	O
pressure	O
limitation	O
,	O
no	O
oscillatory	O
ventilation	O
,	O
and	O
prone	O
position	O
)	O
had	O
a	O
high	O
level	O
of	O
proof	O
(	O
GRADE	O
1	O
+	O
or	O
1	O
-);	O
four	O
(	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
[	O
PEEP	B-CHED
]	O
in	O
moderate	O
and	O
severe	O
ARDS	O
,	O
muscle	B-CHED
relaxants	I-CHED
,	O
recruitment	O
maneuvers	O
,	O
and	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
[	O
ECMO	O
])	O
a	O
low	O
level	O
of	O
proof	O
(	O
GRADE	O
2	O
+	O
or	O
2	O
-);	O
seven	O
(	O
surveillance	O
,	O
tidal	O
volume	O
for	O
non	O
ARDS	O
mechanically	O
ventilated	O
patients	O
,	O
tidal	O
volume	O
limitation	O
in	O
the	O
presence	O
of	O
low	O
plateau	O
pressure	O
,	O
PEEP	B-CHED
>	O
5	O
cmH2O	O
,	O
high	O
PEEP	B-CHED
in	O
the	O
absence	O
of	O
deleterious	O
effect	O
,	O
pressure	O
mode	O
allowing	O
spontaneous	O
ventilation	O
after	O
the	O
acute	O
phase	O
,	O
and	O
nitric	B-CHED
oxide	I-CHED
)	O
corresponded	O
to	O
a	O
level	O
of	O
proof	O
that	O
did	O
not	O
allow	O
use	O
of	O
the	O
GRADE	O
classification	O
and	O
were	O
expert	O
opinions	O
.	O

Lastly	O
,	O
for	O
three	O
aspects	O
of	O
ARDS	O
management	O
(	O
driving	O
pressure	O
,	O
early	O
spontaneous	O
ventilation	O
,	O
and	O
extracorporeal	O
carbon	B-CHED
dioxide	I-CHED
removal	O
),	O
the	O
experts	O
concluded	O
that	O
no	O
sound	O
recommendation	O
was	O
possible	O
given	O
current	O
knowledge	O
.	O

The	O
levels	O
of	O
EVLWI	O
,	O
Ang	O
-	O
2	O
and	O
PaO	B-CHED

Here	O
we	O
report	O
our	O
new	O
finding	O
that	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
,	O
similar	O
to	O
Vpu	O
,	O
is	O
capable	O
of	O
antagonizing	O
the	O
BST2	O
tethering	O
of	O
SARS	O
-	O
CoV	O
,	O
HCoV	O
-	O
229E	O
,	O
and	O
HIV	O
-	O
1	O
virus	O
-	O
like	O
particles	O
via	O
BST2	O
downregulation	O
.	O

During	O
the	O
course	O
of	O
time	O
,	O
this	O
scaffold	O
has	O
been	O
studied	O
extensively	O
for	O
its	O
antiviral	B-CHED
activities	O
and	O
provided	O
compounds	O
with	O
activity	O
in	O
the	O
nM	O
range	O
.	O

We	O
searched	O
the	O
SciFinder	O
database	O
(	O
excluding	O
patent	O
literature	O
)	O
with	O
keywords	O
like	O
""""	O
antiviral	B-CHED
""","	O
""""	O
anti	O
-	O
HIV	O
""""	O
and	O
""""	O
virus	O
"""."	O

There	O
is	O
further	O
scope	O
for	O
the	O
synthesis	O
and	O
evaluation	O
of	O
novel	O
thiazole	B-CHED
compounds	O
by	O
taking	O
the	O
most	O
active	O
compounds	O
as	O
lead	O
structures	O
.	O

ADP	B-CHED
-	O
ribosylation	O
plays	O
an	O
important	O
role	O
in	O
several	O
biological	O
processes	O
such	O
as	O
DNA	O
repair	O
,	O
transcription	O
,	O
chromatin	O
remodelling	O
,	O
host	O
-	O
virus	O
interactions	O
,	O
cellular	O
stress	O
response	O
and	O
many	O
more	O
.	O

Using	O
biochemical	O
methods	O
we	O
identify	O
RNA	O
as	O
a	O
novel	O
target	O
of	O
reversible	O
mono	O
-	O
ADP	B-CHED
-	O
ribosylation	O
.	O

Our	O
data	O
suggest	O
that	O
RNA	O
ADP	B-CHED
-	O
ribosylation	O
may	O
represent	O
a	O
widespread	O
and	O
physiologically	O
relevant	O
form	O
of	O
reversible	O
ADP	B-CHED
-	O
ribosylation	O
signalling	O
.	O

TITLE	O
:	O
Combined	O
adjuvant	B-CHED
effect	O
of	O
ginseng	O
stem	O
-	O
leaf	O
saponins	O
and	O
selenium	B-CHED
on	O
immune	O
responses	O
to	O
a	O
live	O
bivalent	O
vaccine	O
of	O
Newcastle	O
disease	O
virus	O
and	O
infectious	O
bronchitis	O
virus	O
in	O
chickens	O
.	O

TITLE	O
:	O
Modifications	O
in	O
the	O
branched	O
arms	O
of	O
a	O
class	O
of	O
dual	O
inhibitors	B-CHED
of	O
HIV	O
and	O
EV71	O
replication	O
expand	O
their	O
antiviral	B-CHED
spectrum	O
.	O

Our	O
findings	O
demonstrate	O
that	O
only	O
compounds	O
with	O
tetravalent	O
branched	O
arms	O
showed	O
the	O
same	O
anti	O
-	O
HIV	O
and	O
anti	O
-	O
EV71	O
activity	O
of	O
the	O
prototype	O
(	O
low	O
micromolar	O
)	O
and	O
even	O
gain	O
significant	O
antiviral	B-CHED
activity	O
against	O
new	O
pathogens	O
such	O
as	O
HSV	O
-	O
2	O
,	O
adenovirus	O
-	O
2	O
,	O
human	O
corona	B-CHED
virus	O
and	O
respiratory	O
syncytial	O
virus	O
,	O
being	O
the	O
first	O
members	O
of	O
the	O
Trp	B-CHED
dendrimer	B-CHED
family	O
that	O
showed	O
activity	O
against	O
those	O
viruses	O
.	O

These	O
results	O
support	O
the	O
interest	O
of	O
this	O
new	O
series	O
of	O
Trp	B-CHED
dendrimers	O
and	O
qualify	O
them	O
as	O
useful	O
prototypes	O
for	O
the	O
development	O
of	O
novel	O
inhibitors	B-CHED
of	O
viral	O
entry	O
with	O
broad	O
antiviral	B-CHED
spectrum	O
.	O

The	O
cat	O
was	O
treated	O
with	O
imidocarb	B-CHED
dipropionate	O
(	O
6	O
mg	O
/	O
kg	O
body	O
weight	O
,	O
repeated	O
after	O
14	O
days	O
)	O
and	O
doxycycline	B-CHED
monohydrate	I-CHED
(	O
5	O
mg	O
/	O
kg	O
body	O
weight	O
twice	O
a	O
day	O
,	O
p	O
.	O
o	O
.,	O
for	O
four	O
weeks	O
)	O
and	O
recovered	O
completely	O
.	O

We	O
show	O
that	O
ORF8b	O
forms	O
insoluble	O
intracellular	O
aggregates	O
dependent	O
on	O
a	O
valine	B-CHED
at	O
residue	O
77	O
.	O

In	O
addition	O
,	O
the	O
trial	O
registers	O
to	O
be	O
searched	O
will	O
include	O
:	O
World	O
Health	O
Organization	O
International	O
Clinical	O
Trials	O
Registry	O
Platform	O
(	O
ICTRP	O
),	O
U	O
.	O
S	O
.	O
National	O
Library	O
of	O
Medicine	B-CHED
Drug	O
Information	O
Portal	O
and	O
ClinicalTrials	O
.	O
gov	O
.	O

Eleven	O
common	O
respiratory	O
pathogens	O
were	O
tested	O
in	O
hospitalized	O
children	O
<	O
13	O
years	O
of	O
age	O
who	O
met	B-CHED
the	O
criteria	O
for	O
lower	O
respiratory	O
tract	O
infection	O
by	O
GeXP	O
-	O
based	O
multiplex	O
-	O
PCR	O
of	O
paired	O
OPS	O
and	O
sputum	O
.	O

Daily	O
injections	O
of	O
Clenbuterol	B-CHED
(	O
1	O
mg	O
/	O
kg	O
for	O
21	O
days	O
)	O
or	O
vehicle	O
control	O
were	O
also	O
carried	O
out	O
to	O
assess	O
the	O
effects	O
of	O
AAV	O
-	O
Pck2	O
overexpression	O
on	O
the	O
anabolic	O
response	O
to	O
a	O
beta	B-CHED
-	I-CHED
adrenergic	I-CHED
agonist	I-CHED
.	O

When	O
skeletal	O
muscle	O
growth	O
was	O
induced	O
by	O
daily	O
administration	O
of	O
Clenbuterol	B-CHED
(	O
for	O
21	O
days	O
),	O
overexpression	O
of	O
AAV	O
-	O
Pck2	O
had	O
no	O
effect	O
on	O
the	O
growth	O
response	O
,	O
nor	O
did	O
it	O
alter	O
the	O
expression	O
of	O
Phosphoserine	B-CHED
Aminotransferase	O
-	O
1	O
(	O
Psat1	O
)	O
or	O
Asparagine	B-CHED
Synthetase	O
(	O
Asns	O
)	O
mRNA	B-CHED
or	O
the	O
Clenbuterol	B-CHED
-	O
induced	O
decreases	O
in	O
MyHC	O
IIa	O
and	O
IIx	O
mRNA	B-CHED
expression	O
(	O
p	O
=	O
0	O
.	O
0065	O
and	O
p	O
=	O
0	O
.	O
0267	O
respectively	O
).	O

RSV	O
infection	O
can	O
be	O
associated	O
as	O
a	O
serious	O
disease	O
in	O
newborns	O
involving	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
and	O
causing	O
seizures	O
or	O
acute	O
encephalopathy	O
.	O

The	O
RSV	O
related	O
encephalopathy	O
could	O
be	O
caused	O
by	O
different	O
mechanisms	O
,	O
such	O
as	O
direct	O
viral	O
invasion	O
of	O
the	O
CNS	B-CHED
or	O
by	O
indirect	O
mechanism	O
mediated	O
by	O
inflammatory	O
cytokines	O
.	O

MBL	O
was	O
detectable	O
in	O
the	O
ellipsoid	O
-	O
associated	O
cells	O
(	O
EACs	O
)	O
and	O
cell	O
clusters	B-CHED
in	O
the	O
periarterial	O
lymphoid	O
sheath	O
(	O
PALS	O
)	O
by	O
7	O
days	O
post	O
infection	O
(	O
dpi	O
).	O

In	O
both	O
organs	O
,	O
the	O
MBL	O
-	O
positive	O
cells	O
occupy	O
antigen	B-CHED
-	O
exposed	O
areas	O
,	O
indicating	O
that	O
GC	O
formation	O
depends	O
on	O
resident	O
precursors	O
of	O
dendritic	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
6	O
'-	O
fluorinated	O
aristeromycins	O
were	O
designed	O
as	O
dual	O
-	O
target	O
antiviral	B-CHED
compounds	O
aimed	O
at	O
inhibiting	O
both	O
the	O
viral	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
and	O
the	O
host	O
cell	O

A	O
cross	O
-	O
sectional	O
study	O
was	O
performed	O
in	O
the	O
consultation	O
for	O
travel	O
medicine	B-CHED
and	O
international	O
vaccination	O
in	O
Reims	O
University	O
Hospital	O
between	O
July	O
2014	O
and	O
October	O
2015	O
.	O

Ribavirin	B-CHED
and	O
interferon	O
were	O
the	O
most	O
widely	O
used	O
combination	O
and	O
experience	O
comes	O
from	O
a	O
number	O
of	O
observational	O
studies	O
.	O

In	O
order	O
to	O
further	O
enhance	O
the	O
therapeutic	O
aroma	B-CHED
for	O
MERS	O
-	O
CoV	O
infection	O
,	O
repurposing	O
old	O
drugs	O
against	O
MERS	O
-	O
CoV	O
is	O
an	O
interesting	O
strategy	O
and	O
deserves	O
further	O
consideration	O
and	O
use	O
in	O
clinical	O
settings	O
.	O

Treatment	O
with	O
NET	O
inhibitors	B-CHED
significantly	O
inhibitor	B-CHED
NETs	O
generation	O
,	O
downregulated	O
M1	O
markers	O
and	O
upregulated	O
M2	O
markers	O
.	O

Compound	O
1	O
has	O
an	O
activating	O
methylene	B-CHED
group	I-CHED
,	O
so	O
it	O
was	O
directed	O
toward	O
some	O
specific	O
reactions	O
.	O

Arylhydrazono	O
derivatives	O
9a	O
,	O
b	O
were	O
produced	O
through	O
the	O
reaction	O
of	O
compound	O
7a	O
with	O
aryldiazonium	O
chlorides	B-CHED
.	O

Products	O
9a	O
,	O
b	O
underwent	O
cyclization	O
to	O
produce	O
pyridazine	B-CHED
derivatives	O
10a	O
,	O
b	O
.	O

Viral	O
nucleic	B-CHED
acids	I-CHED
,	O
and	O
in	O
some	O
instances	O
viable	O
viruses	O
,	O
have	O
been	O
detected	O
in	O
aerosols	O
in	O
the	O
air	B-CHED
in	O
healthcare	O
settings	O
for	O
some	O
respiratory	O
viruses	O
such	O
as	O
seasonal	O
and	O
avian	O
influenza	O
viruses	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
-	O
coronavirus	O
and	O
respiratory	O
syncytial	O
virus	O
.	O

The	O
primary	O
therapies	O
were	O
antibiotics	B-CHED
(	O
99	O
.	O
0	O
%),	O
immunoglobulin	O
(	O
88	O
.	O
3	O
%),	O
mechanical	O
ventilation	O
(	O
78	O
.	O
4	O
%),	O
vasoactive	O
infusions	O
(	O
59	O
.	O
6	O
%),	O
and	O
corticosteroids	B-CHED
(	O
46	O
.	O
1	O
%).	O

ABSTRACT	O
:	O
This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
viral	O
and	O
bacterial	O
etiology	O
and	O
epidemiology	O
of	O
patients	O
with	O
acute	O
febrile	O
respiratory	O
syndrome	O
(	O
AFRS	O
)	O
in	O
Qinghai	O
using	O
a	O
commercial	O
routine	O
multiplex	O
-	O
ligation	O
-	O
nucleic	B-CHED
acid	I-CHED
amplification	O
test	O
(	O
NAT	O
)-	O
based	O
assay	O
.	O

TITLE	O
:	O
Streptokinase	O
Versus	O
Unfractionated	O
Heparin	B-CHED
Nebulization	O
in	O
Patients	O
With	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
):	O

ABSTRACT	O
:	O
To	O
examine	O
and	O
compare	O
nebulizing	O
heparin	B-CHED
versus	O
streptokinase	O
for	O
reversing	O
alveolar	O
collapse	O
nonresponsive	O
to	O
recruitment	O
.	O

In	O
the	O
present	O
study	O
,	O
partial	O
nucleotide	B-CHED
sequences	O
of	O
the	O
S1	O
glycoprotein	B-CHED
gene	O
and	O
the	O
3	O
'-	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
2	O
Tunisian	O
isolates	O
,	O
TN1011	O
/	O
16	O
and	O
TN1012	O
/	O
16	O
,	O
identified	O
in	O
2016	O
,	O
were	O
determined	O
.	O

The	O
expression	O
of	O
six	O
tight	O
junction	O
protein	B-CHED
genes	O
was	O
lower	O
in	O
PEDV	O
-	O
infected	O
piglets	O
than	O
in	O
the	O
normal	O
animals	O
.	O

In	O
this	O
study	O
,	O
samples	O
from	O
bats	O
collected	O
from	O
caves	O
in	O
Ruhengeri	O
,	O
Rwanda	O
,	O
were	O
tested	O
for	O
the	O
presence	O
of	O
corona	B-CHED
-	O
and	O
paramyxoviral	O
RNA	O
using	O
reverse	O
transcription	O
PCR	O
assays	O
.	O

Original	O
clinical	O
randomized	O
controlled	O
trials	O
which	O
met	B-CHED
the	O
eligibility	O
criteria	O
were	O
included	O
.	O

RESULTS	O
:	O
No	O
difference	O
was	O
found	O
in	O
28	O
-	O
day	O
mortality	O
and	O
ICU	O
mortality	O
(	O
OR	O
=	O
0	O
.	O
97	O
,	O
95	O
%	O
CI	O
(	O
0	O
.	O
61	O
-	O
1	O
.	O
52	O
),	O
CONCLUSIONS	O
:	O
No	O
difference	O
was	O
observed	O
in	O
the	O
RM	O
between	O
the	O
titrated	O
PEEP	B-CHED
and	O
the	O
low	O
PEEP	B-CHED
in	O
28	O
-	O
day	O
mortality	O
and	O
ICU	O
mortality	O
on	O
patients	O
with	O
moderate	O
-	O
severe	O
ARDS	O
.	O

ASA	B-CHED
classification	O
	O
3	O
,	O
lower	O
BMI	O
,	O
presence	O
of	O
ILA	O
on	O
CT	O
,	O
and	O
larger	O
extent	O
of	O
resection	O
are	O
predictors	O
of	O
PPC	O
development	O
,	O
which	O
guide	O
treatment	O
decision	O
-	O
making	O
in	O
these	O
patients	O
.	O

Results	O
from	O
the	O
hematoxylin	B-CHED
and	O
eosin	O
staining	O
showed	O
that	O
fraxin	O
might	O
alleviate	O
pathological	O
changes	O
in	O
the	O
lung	O
tissues	O
of	O
mice	O
with	O
ARDS	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
the	O
S1	O
subunit	O
N	O
-	O
terminal	O
domain	O
from	O
DcCoV	O
UAE	O
-	O
HKU23	O
spike	O
protein	B-CHED
.	O

TITLE	O
:	O
A	O
48	O
-	O
Year	O
-	O
Old	O
Man	B-CHED
With	O
Excessive	O
Drooling	O
and	O
Descending	O
Paralysis	O
Requiring	O
Mechanical	O
Ventilation	O
.	O

Of	O
note	O
,	O
2	O
weeks	O
ago	O
,	O
the	O
patient	O
had	O
an	O
upper	O
respiratory	O
tract	O
infection	O
(	O
including	O
otitis	O
media	O
)	O
that	O
was	O
treated	O
with	O
amoxicillin	B-CHED
-	O
clavulanate	B-CHED
.	O

In	O
this	O
study	O
,	O
we	O
screened	O
seven	O
human	O
cell	O
lines	O
and	O
found	O
that	O
the	O
human	O
monocytic	O
cell	O
U937	O
supports	O
the	O
replication	O
of	O
different	O
subtypes	O
of	O
influenza	O
viruses	O
as	O
well	O
as	O
the	O
production	O
of	O
the	O
important	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
and	O
was	O
selected	O
to	O
develop	O
the	O
cell	O
-	O
based	O
model	O
.	O

Dendritic	O
cells	O
(	O
DCs	O
)	O
are	O
specialised	O
cells	O
responsible	O
for	O
sampling	O
antigens	B-CHED
and	O
presenting	O
them	O
to	O
T	O
cells	O
,	O
which	O
also	O
play	O
an	O
essential	O
role	O
in	O
recognising	O
and	O
neutralising	O
viruses	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
high	O
fat	O
diet	O
induced	O
obesity	O
increases	O
the	O
severity	O
of	O
hyperoxic	O
acute	O
lung	O
injury	O
in	O
mice	O
in	O
part	O
by	O
altering	O
fatty	B-CHED
acid	I-CHED
synthase	O
(	O
FASN	O
)	O
levels	O
in	O
the	O
lung	O
.	O

In	O
this	O
retrospective	O
cohort	O
study	O
,	O
serum	O
SP	O
-	O
D	O
levels	O
were	O
analyzed	O
in	O
37	O
CDH	B-CHED
infants	O
and	O
5	O
control	O
infants	O
using	O
a	O
commercially	O
available	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
kit	O
.	O

These	O
results	O
demonstrate	O
that	O
CDH	B-CHED
infants	O
experience	O
lung	O
injury	O
during	O
the	O
first	O
week	O
of	O
life	O
,	O
around	O
the	O
time	O
of	O
surgery	O
,	O
and	O
at	O
the	O
time	O
of	O
ECMO	O
termination	O
.	O

TITLE	O
:	O
Effects	O
of	O
environmental	O
disinfection	O
on	O
the	O
isolation	O
of	O
vancomycin	B-CHED
-	O
resistant	O
Enterococcus	O
after	O
a	O
hospital	O
-	O
associated	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
.	O

High	O
-	O
throughput	O
16S	B-CHED
rRNA	B-CHED
gene	O
sequencing	O
was	O
performed	O
to	O
explore	O
differences	O
.	O

The	O
most	O
likely	O
high	O
-	O
risk	O
MERS	O
-	O
CoV	O
annual	O
spatiotemporal	O
clusters	B-CHED
were	O
identified	O
for	O
a	O
group	O
of	O
cities	O
(	O

The	O
objectives	O
of	O
the	O
present	O
study	O
were	O
to	O
assess	O
the	O
effect	O
of	O
biosecurity	O
measures	O
and	O
intervention	O
practices	O
to	O
control	O
PED	O
on	O
time	O
to	O
absence	O
of	O
clinical	O
signs	O
(	O
TAC	B-CHED
)	O
and	O
number	O
of	O
dead	O
suckling	O
piglets	O
during	O
TAC	B-CHED
.	O

In	O
conclusion	O
,	O
variables	O
associated	O
with	O
long	O
TAC	B-CHED
were	O
Actinobacillus	O
pleuropneumoniae	O
-	O
positive	O
farms	O
,	O
farms	O
outsourcing	O
pig	O
transport	O
to	O
the	O
slaughterhouse	O
,	O
and	O
farms	O
performing	O
feedback	O
at	O
2	O
week	O
or	O
later	O
after	O
PED	O
outbreak	O
.	O

TITLE	O
:	O
Mechanism	O
of	O
Cxc	O
Chemokine	O
Ligand	B-CHED
5	O
(	O
CXCL5	O
)/	O
Cxc	O
Chemokine	O
Receptor	O
2	O
(	O
CXCR2	O
)	O
Bio	O
-	O
Axis	O
in	O
Mice	O
with	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

Pre	O
-	O
and	O
postfusion	O
structures	O
of	O
viral	O
fusion	O
proteins	B-CHED
have	O
been	O
characterized	O
,	O
but	O
conformational	O
changes	O
between	O
them	O
remain	O
poorly	O
understood	O
.	O

Western	O
blot	O
analysis	O
of	O
protease	O
digestion	O
products	O
revealed	O
that	O
two	O
subunits	O
(	O
67	O
and	O
69	O
kDa	O
)	O
are	O
produced	O
from	O
a	O
single	O
spike	O
protein	B-CHED
(	O
180	O
kDa	O
).	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
the	O
membrane	O
protein	B-CHED
(	O
M	O
)	O
of	O
HCoV	O
-	O
NL63	O
mediates	O
this	O
attachment	O
.	O

ABSTRACT	O
:	O
The	O
surface	O
of	O
proteins	B-CHED
is	O
heterogeneous	O
with	O
sophisticated	O
but	O
precise	O
hydrophobic	O
and	O
hydrophilic	O
patches	O
,	O
which	O
is	O
essential	O
for	O
their	O
diverse	O
biological	O
functions	O
.	O

In	O
this	O
study	O
,	O
an	O
oligonucleotide	B-CHED
microarray	O
system	O
was	O
developed	O
.	O

No	O
cross	O
-	O
reaction	O
was	O
observed	O
with	O
10	O
other	O
subtypes	O
of	O
AIV	O
and	O
infectious	O
bursal	O
disease	O
virus	O
,	O
indicating	O
that	O
the	O
oligonucleotide	B-CHED
microarray	O
assay	O
was	O
highly	O
specific	O
.	O

The	O
sensitivity	O
of	O
the	O
method	O
was	O
at	O
least	O
100	O
times	O
higher	O
than	O
that	O
of	O
the	O
conventional	O
PCR	O
,	O
and	O
the	O
detection	O
limit	O
of	O
NDV	O
,	O
AIV	O
,	O
H5	O
,	O
H7	O
,	O
and	O
H9	O
can	O
reach	O
0	O
.	O
1	O
EID	O
We	O
have	O
successfully	O
developed	O
an	O
approach	O
to	O
differentiate	O
AIV	O
,	O
NDV	O
,	O
IBV	O
,	O
H5	O
,	O
H7	O
,	O
and	O
H9	O
subtypes	O
of	O
AIV	O
using	O
oligonucleotide	B-CHED
microarray	O
.	O

Patients	O
admitted	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
severe	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
),	O
subarachnoid	O
hemorrhage	O
(	O
SAH	B-CHED
)	O
and	O
neurocritically	O
ill	O
patients	O
at	O
the	O
moment	O
of	O
brain	O
death	O
(	O
BD	O
)	O
diagnosis	O
were	O
included	O
in	O
the	O
present	O
post	O
-	O
hoc	O
analysis	O
.	O

The	O
included	O
patients	O
were	O
divided	O
into	O
the	O
ARDS	O
(	O
ARDS	O
patients	O
who	O
met	B-CHED
the	O
Berlin	O
definition	O
)	O
and	O
non	O
-	O
ARDS	O
groups	O
.	O

Postoperative	O
hemoglobin	B-CHED
level	O
(	O
odds	O
ratio	O
[	O
OR	O
]:	O
0	O
.	O
78	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]:	O
0	O
.	O
62	O
-	O
0	O
.	O
99	O
)	O
and	O
perioperative	O
blood	O
transfusion	O
volume	O
(	O
OR	O
:	O
1	O
.	O
07	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
03	O
-	O
1	O
.	O
12	O
)	O
were	O
associated	O
with	O
ARDS	O
risk	O
.	O

Treatment	O
with	O
intravenous	O
lipid	B-CHED
emulsion	O
(	O
ILE	B-CHED
)	O
therapy	O
was	O
instituted	O
to	O
accelerate	O
toxin	O
elimination	O
,	O
reduce	O
the	O
risk	O
of	O
complications	O
related	O
to	O
progressive	O
obtundation	O
and	O
shorten	O
hospitalization	O
time	O
.	O

The	O
complete	O
blood	O
count	O
is	O
the	O
most	O
ordered	O
clinical	O
test	O
in	O
the	O
United	O
States	O
serving	O
as	O
the	O
cornerstone	O
of	O
clinical	O
medicine	B-CHED
and	O
differential	O
diagnosis	O
.	O

The	O
levels	O
of	O
C	O
-	O
reactive	O
protein	B-CHED
,	O
however	O
,	O
were	O
similar	O
.	O

Our	O
earlier	O
studies	O
have	O
identified	O
that	O
3	O
-	O
O	O
-	O
	O
-	O
chacotriosyl	O
ursolic	B-CHED
acid	I-CHED
(	O
1	O
)	O
could	O
inhibit	O
H5N1	O
pseudovirus	O
by	O
targeting	O
hemagglutinin	O
(	O
HA	O
).	O

In	O
vitro	O
contractility	O
studies	O
determined	O
a	O
decreased	O
basal	O
detrusor	O
tone	O
and	O
reduced	O
amplitude	O
of	O
nerve	O
-	O
mediated	O
contractions	O
in	O
C	O
-	O
RELAP	O
group	O
,	O
whereas	O
C	O
-	O
PRO	B-CHED
group	O
had	O
elevated	O
muscle	O
-	O
mediated	O
contractions	O
.	O

Whole	O
-	O
genome	O
sequencing	O
of	O
the	O
Jeju	O
S	O
-	O
DEL	O
isolates	O
KNU	O
-	O
1829	O
and	O
KNU	O
-	O
1830	O
revealed	O
the	O
presence	O
of	O
a	O
continuous	O
9	O
-	O
nucleotide	B-CHED
deletion	O
within	O
the	O
nonstructural	O
protein	B-CHED
coding	O
region	O
.	O

It	O
is	O
observed	O
that	O
seven	O
putative	O
peptides	B-CHED
have	O
good	O
binding	O
score	O
based	O
on	O
cluster	O
size	O
cutoff	O
of	O
208	O
.	O

We	O
conclude	O
that	O
seven	O
peptides	B-CHED
,	O
namely	O
,	O
AP00225	O
,	O
AP00180	O
,	O
AP00549	O
,	O
AP00744	O
,	O
AP00729	O
,	O
AP00764	O
,	O
and	O
AP00223	O
,	O
could	O
possibly	O
have	O
binding	O
with	O
the	O
active	O
site	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
.	O

TITLE	O
:	O
Spike	O
proteins	B-CHED
of	O
novel	O
MERS	O
-	O
coronavirus	O
isolates	O
from	O
North	O
-	O
and	O
West	O
-	O
African	O
dromedary	O
camels	O
mediate	O
robust	O
viral	O
entry	O
into	O
human	O
target	O
cells	O
.	O

TITLE	O
:	O
Octreotide	B-CHED
and	O
Continuous	O
Hemofiltration	O
versus	O
Continuous	O
Hemofiltration	O
Alone	O
in	O
Severe	O
Acute	O
Pancreatitis	O
Complicated	O
with	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
effects	O
of	O
octreotide	B-CHED
and	O
continuous	O
hemofiltration	O
versus	O
continuous	O
hemofiltration	O
alone	O
in	O
the	O
treatment	O
of	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
)	O
complicated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

When	O
transmission	O
-	O
based	O
PPE	B-CHED
ensembles	O
are	O
not	O
appropriate	O
,	O
HCP	B-CHED
must	O
recognize	O
the	O
transmission	O
pathway	O
of	O
the	O
disease	O
and	O
anticipate	O
the	O
exposures	O
to	O
select	O
PPE	B-CHED
.	O

Participation	O
,	O
documentation	O
,	O
and	O
transparency	O
are	O
necessary	O
to	O
ensure	O
the	O
decisions	O
can	O
be	O
communicated	O
,	O
critiqued	O
,	O
and	O
understood	O
by	O
HCP	B-CHED
.	O

A	O
41	O
-	O
year	O
-	O
old	O
man	B-CHED
had	O
undergone	O
cervical	O
laminoplasty	O
for	O
ossification	O
of	O
the	O
posterior	O
longitudinal	O
ligament	O
and	O
thoracic	O
laminectomy	O
for	O
ossification	O
of	O
the	O
posterior	O
longitudinal	O
ligament	O
and	O
ossification	O
of	O
the	O
ligamentum	O
flavum	O
in	O
the	O
prone	O
position	O
.	O

Before	O
cardiac	O
arrest	O
due	O
to	O
the	O
massive	O
VAE	O
,	O
visible	O
air	B-CHED
bubbling	O
had	O
been	O
observed	O
at	O
the	O
operated	O
site	O
of	O
the	O
thoracic	O
laminectomy	O
,	O
and	O
this	O
phenomenon	O
had	O
been	O
incidentally	O
recorded	O
with	O
the	O
video	O
.	O

However	O
,	O
the	O
homology	O
of	O
ORF3	O
gene	O
was	O
97	O
.	O
7	O
%,	O
and	O
protein	B-CHED
of	O
ORF3	O
was	O
90	O
.	O
1	O
%.	O

In	O
addition	O
,	O
HLJBY	O
showed	O
the	O
highest	O
nucleotide	B-CHED
identity	O
(	O
99	O
.	O
9	O
%)	O
with	O
PEDV	O
-	O
SX	O
/	O
China	O
/	O
2017	O
strain	O
and	O
lowest	O
similarity	O
(	O
91	O
.	O
2	O
%)	O
to	O
PEDV	O
/	O
Belgorod	O
/	O
dom	O
/	O
2008	O
strain	O
.	O

The	O
length	O
of	O
deduced	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
S	O
proteins	B-CHED
varied	O
from	O
1	O
,	O
372	O
to	O
1	O
,	O
390	O
amino	B-CHED
acids	I-CHED
(	O
aa	O
).	O

We	O
revealed	O
that	O
the	O
length	O
of	O
deduced	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
ORF3	O
proteins	B-CHED
was	O
80	O
-	O
224	O
aa	O
among	O
tested	O
strains	O
and	O
the	O
identity	O
of	O
HLJBY	O
ORF3	O
amino	B-CHED
acids	I-CHED
with	O
other	O
PEDV	O
strains	O
was	O
71	O
.	O
4	O
%-	O
98	O
.	O
9	O
%.	O

This	O
work	O
not	O
only	O
provides	O
some	O
new	O
findings	O
for	O
the	O
biological	B-CHED
function	I-CHED
of	O
the	O
PEDV	O
ORF3	O
protein	B-CHED
,	O
but	O
also	O
help	O
us	O
for	O
the	O
further	O
understanding	O
the	O
molecular	O
interaction	O
between	O
PEDV	O
ORF3	O
protein	B-CHED
and	O
cells	O
.	O

In	O
the	O
control	O
group	O
,	O
patients	O
received	O
a	O
tidal	O
volume	O
of	O
6	O
mL	O
/	O
kg	O
per	O
predicted	O
bodyweight	O
and	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
was	O
selected	O
according	O
to	O
a	O
low	O
PEEP	B-CHED
and	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
table	O
,	O
and	O
early	O
prone	O
position	O
was	O
encouraged	O
.	O

The	O
regression	O
model	O
including	O
the	O
two	O
-	O
way	O
interaction	O
term	O
showed	O
significant	O
interaction	O
between	O
intervention	O
and	O
disease	O
severity	O
as	O
indicated	O
by	O
the	O
ISTH	O
overt	O
DIC	B-CHED
score	O
and	O
APACHE	O
II	O
score	O
(	O
CONCLUSIONS	O
:	O
Anticoagulant	B-CHED
therapy	O
was	O
associated	O
with	O
better	O
outcome	O
according	O
to	O
the	O
deterioration	O
of	O
both	O
DIC	B-CHED
and	O
disease	O
severity	O
,	O
suggesting	O
that	O
anticoagulant	B-CHED
therapy	O
should	O
be	O
restricted	O
to	O
patients	O
having	O
DIC	B-CHED
and	O
high	O
disease	O
severity	O
simultaneously	O
.	O

However	O
,	O
ITP	B-CHED
in	O
association	O
with	O
coronavirus	O
infection	O
has	O
not	O
previously	O
been	O
reported	O
.	O

Domain	O
mapping	O
of	O
antibody	O
epitopes	O
indicated	O
the	O
presence	O
of	O
conserved	O
epitope	B-CHED
(	O
s	O
)	O
particularly	O
in	O
the	O
CD	O
domains	O
of	O
S1	O
.	O

ABSTRACT	O
:	O
Guillain	O
-	O
Barre	O
syndrome	O
(	O
GBS	O
)	O
is	O
an	O
autoimmune	O
disease	O
on	O
the	O
injury	O
of	O
peripheral	O
nerve	O
myelin	O
proteins	B-CHED
or	O
axon	O
,	O
of	O
which	O
the	O
acute	O
motor	O
axonal	O
neuropathy	O
(	O
AMAN	O
)	O
as	O
a	O
subtype	O
is	O
of	O
infrequence	O
and	O
an	O
extremely	O
low	O
incidence	O
of	O
post	O
-	O
operation	O
.	O

People	O
with	O
acute	O
tetraplegia	O
require	O
less	O
pressure	O
to	O
treat	O
their	O
OSA	O
than	O
the	O
nondisabled	O
;	O
however	O
,	O
air	B-CHED
leak	O
is	O
high	O
.	O

Average	O
95th	O
percentile	O
pressure	O
was	O
low	O
(	O
9	O
.	O
3	O
	O
1	O
.	O
7	O
cmH	B-CHED
CONCLUSIONS	O
:	O
Adherence	O
to	O
CPAP	O
after	O
acute	O
,	O
traumatic	O
tetraplegia	O
is	O
low	O
.	O

Using	O
in	O
-	O
house	O
S1	O
ELISA	O
and	O
protein	B-CHED
microarray	O
,	O
we	O
demonstrate	O
that	O
most	O
PCR	O
-	O
confirmed	O
MERS	O
-	O
CoV	O
case	O
-	O
patients	O
with	O
mild	O
infections	O
seroconverted	O
;	O
nonetheless	O
,	O
some	O
of	O
these	O
samples	O
did	O
not	O
have	O
detectable	O
levels	O
of	O
virus	O
-	O
neutralizing	O
antibodies	O
.	O

After	O
conducting	O
univariate	O
analysis	O
of	O
risk	O
factors	O
,	O
statistically	O
significant	O
risk	O
factors	O
affecting	O
the	O
development	O
of	O
ROP	O
in	O
our	O
study	O
were	O
:	O
low	O
gestational	O
age	O
,	O
low	O
birth	O
weight	O
,	O
type	O
of	O
multiple	O
gestation	O
,	O
the	O
presence	O
of	O
affected	O
sibling	O
,	O
low	O
level	O
of	O
Hemoglobin	B-CHED
at	O
birth	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
low	O
Hemoglobin	B-CHED
level	O
,	O
blood	O
transfusion	O
and	O
days	O
on	O
oxygen	B-CHED
supplements	O
with	O
either	O
mechanical	O
,	O
non	O
-	O
mechanical	O
methods	O
or	O
both	O
combined	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
-	O
Encoded	O
Accessory	O
Proteins	B-CHED
Impair	O
MDA5	O
-	O
and	O
TBK1	O
-	O
Mediated	O
Activation	O
of	O
NF	O
-	O
B	O
.	O
ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
newly	O
emerging	O
coronavirus	O
which	O
is	O
zoonotic	O
from	O
bats	O
and	O
camels	O
.	O

Here	O
we	O
report	O
that	O
ORF4a	O
,	O
ORF4b	O
,	O
and	O
ORF8b	O
proteins	B-CHED
,	O
alone	O
or	O
in	O
combination	O
,	O
effectively	O
antagonize	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
B	O
)	O
activation	O
.	O

These	O
long	O
-	O
term	O
effects	O
are	O
likely	O
secondary	O
to	O
prolonged	O
hospitalizations	O
,	O
prolonged	O
mechanical	O
ventilation	O
,	O
utilization	O
of	O
prone	O
strategies	O
,	O
utilization	O
of	O
paralytic	O
drugs	O
,	O
and	O
occasionally	O
steroids	B-CHED
.	O

Steroids	B-CHED
and	O
extracorporeal	O
membrane	O
oxygenation	O
have	O
been	O
discussed	O
in	O
a	O
previous	O
article	O
.	O

Both	O
BCoV	O
lineages	O
were	O
estimated	O
to	O
have	O
entered	O
Uruguay	O
in	O
2013	O
:	O
one	O
of	O
them	O
from	O
Brazil	O
(	O
95	O
%	O
HPD	B-CHED
interval	O
:	O
2011	O
-	O
2014	O
)	O
and	O
the	O
other	O
from	O
Argentina	O
(	O
95	O
%	O
HPD	B-CHED
interval	O
:	O
2010	O
-	O
2014	O
).	O

The	O
lineages	O
differed	O
by	O
four	O
amino	B-CHED
acid	I-CHED
changes	O
,	O
and	O
both	O
were	O
divergent	O
from	O
the	O
Mebus	O
reference	O
strain	O
.	O

TITLE	O
:	O
Peptidoglycan	B-CHED
-	O
Associated	O
Cyclic	O
Lipopeptide	B-CHED
Disrupts	O
Viral	O
Infectivity	O
.	O

TITLE	O
:	O
Ambient	O
ammonia	B-CHED
does	O
not	O
appear	O
to	O
inhibit	O
the	O
immune	O
response	O
to	O
infectious	O
bronchitis	O
virus	O
vaccination	O
and	O
protection	O
from	O
homologous	O
challenge	O
in	O
broiler	O
chickens	O
.	O

In	O
that	O
regard	O
,	O
flexible	O
nucleoside	B-CHED
analogues	I-CHED
known	O
as	O
""""	O
fleximers	O
""""	O
have	O
garnered	O
attention	O
over	O
the	O
years	O
due	O
to	O
their	O
ability	O
to	O
survey	O
different	O
amino	B-CHED
acids	I-CHED
in	O
enzyme	O
binding	O
sites	O
,	O
thus	O
overcoming	O
the	O
potential	O
development	O
of	O
antiviral	B-CHED
resistance	O
.	O

Acyclic	O
fleximers	O
have	O
previously	O
demonstrated	O
antiviral	B-CHED
activity	O
against	O
numerous	O
viruses	O
including	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
Ebola	O
virus	O
(	O
EBOV	O
),	O
and	O
,	O
most	O
recently	O
,	O
flaviviruses	O
such	O
as	O
Dengue	O
(	O
DENV	O
)	O
and	O
Yellow	O
Fever	O
Virus	O
(	O
YFV	O
).	O

Prospective	O
,	O
multicenter	O
,	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
of	O
NIV	O
compared	O
with	O
conventional	O
administration	O
of	O
oxygen	B-CHED
through	O
a	O
Venturi	O
mask	O
.	O

In	O
the	O
NIV	O
group	O
,	O
PaO	B-CHED

Key	O
residues	O
required	O
for	O
activity	O
were	O
mapped	O
by	O
amino	B-CHED
acid	I-CHED
replacement	O
and	O
their	O
relevance	O
in	O
vitro	O
tested	O
by	O
their	O
introduction	O
into	O
recombinant	O
MERS	O
S	O
protein	B-CHED
expressed	O
in	O
mammalian	O
cells	O
.	O

The	O
structures	O
of	O
Ptal	B-CHED
-	O
N	O
*	O
01	O
:	O
01	O
display	O
unusual	O
peptide	B-CHED
presentation	O
features	O
in	O
that	O
the	O
bat	O
-	O
specific	O
3	O
-	O
amino	B-CHED
acid	I-CHED
(	O
aa	O
)	O
insertion	O
enables	O
the	O
tight	O
""""	O
surface	O
anchoring	O
""""	O
of	O
the	O
P1	O
-	O
Asp	B-CHED
in	O
pocket	O
A	O
of	O
bat	O
MHC	O
I	O
.	O
As	O
the	O
classical	O
primary	O
anchoring	O
positions	O
,	O
the	O
B	O
and	O
F	O
pockets	O
of	O
Ptal	B-CHED
-	O
N	O
*	O
01	O
:	O
01	O
also	O
show	O
unconventional	O
conformations	O
,	O
which	O
contribute	O
to	O
unusual	O
peptide	B-CHED
motifs	O
and	O
distinct	O
peptide	B-CHED
presentation	O
.	O

Prone	O
positioning	O
,	O
lung	O
-	O
protective	O
ventilation	O
and	O
corticosteroid	B-CHED
therapy	O
were	O
initiated	O
.	O

According	O
to	O
western	O
blots	O
,	O
serum	O
antibody	O
interactions	O
with	O
the	O
S1	O
protein	B-CHED
were	O
relatively	O
more	O
sensitive	O
and	O
specific	O
than	O
ORF3C	O
,	O
E	O
and	O
Ac	O
.	O

Stress	O
granules	O
(	O
SGs	O
)	O
are	O
sites	O
of	O
mRNA	B-CHED
storage	O
that	O
are	O
formed	O
under	O
various	O
stress	O
conditions	O
including	O
viral	O
infections	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
G3BP1	O
plays	O
an	O
antiviral	B-CHED
role	O
and	O
impairs	O
PEDV	O
replication	O
.	O

S2	O
protein	B-CHED
is	O
an	O
invariant	O
that	O
harbors	O
broad	O
neutralizing	O
epitopes	O
.	O

Despite	O
the	O
progress	O
that	O
has	O
been	O
made	O
in	O
the	O
mapping	O
and	O
characterization	O
of	O
some	O
packaging	O
signals	O
,	O
there	O
is	O
conflicting	O
evidence	O
as	O
to	O
whether	O
the	O
viral	O
nucleocapsid	O
protein	B-CHED
or	O
the	O
membrane	O
protein	B-CHED
plays	O
the	O
primary	O
role	O
in	O
packaging	O
signal	O
recognition	O
.	O

TITLE	O
:	O
Application	O
of	O
Chinese	O
Medicine	B-CHED
in	O
Acute	O
and	O
Critical	O
Medical	O
Conditions	O
.	O

In	O
order	O
to	O
promote	O
more	O
widespread	O
application	O
of	O
Chinese	O
medicine	B-CHED
,	O
well	O
-	O
designed	O
controlled	O
clinical	O
trials	O
are	O
urgently	O
needed	O
to	O
prove	O
its	O
safety	O
and	O
effectiveness	O
.	O

TITLE	O
:	O
Efficacy	O
and	O
immunogenicity	O
of	O
a	O
live	O
L	O
.	O
acidophilus	O
expressing	O
SAD	O
epitope	B-CHED
of	O
transmissible	O
gastroenteritis	O
virus	O
as	O
an	O
oral	O
vaccine	O
.	O

Despite	O
the	O
introduction	O
of	O
effective	O
antibiotics	B-CHED
and	O
intensive	O
supportive	O
care	O
in	O
the	O
20th	O
century	O
,	O
death	O
rates	O
from	O
community	O
-	O
acquired	O
pneumonia	O
among	O
patients	O
in	O
the	O
intensive	O
care	O
unit	O
remain	O
as	O
high	O
as	O
35	O
%.	O

The	O
results	O
suggest	O
that	O
the	O
current	O
design	O
of	O
the	O
PPE	B-CHED
gown	O
can	O
be	O
improved	O
in	O
usability	O
and	O
user	O
satisfaction	O
.	O

The	O
exposure	O
scenario	O
includes	O
a	O
single	O
index	O
patient	O
emitting	O
virus	O
-	O
containing	O
aerosols	O
into	O
the	O
air	B-CHED
by	O
coughing	O
,	O
leading	O
to	O
short	O
-	O
and	O
long	O
-	O
range	O
airborne	O
exposures	O
for	O
other	O
patients	O
in	O
the	O
same	O
room	O
,	O
nurses	O
,	O
healthcare	O
workers	O
,	O
and	O
family	O
visitors	O
.	O

RESULTS	O
:	O
Using	O
phage	O
display	O
technology	O
and	O
periplasmic	O
extraction	O
ELISA	O
(	O
PE	O
-	O
ELISA	O
),	O
anti	O
-	O
PEDV	O
N	O
protein	B-CHED
nanobodies	O
from	O
three	O
strains	O
of	O
PEDV	O
were	O
successfully	O
isolated	O
after	O
three	O
consecutive	O
rounds	O
of	O
bio	O
-	O
panning	O
from	O
a	O
high	O
quality	O
phage	O
display	O
VHH	O
library	O
.	O

A	O
similar	O
staining	O
was	O
obtained	O
by	O
two	O
other	O
mAbs	O
which	O
recognize	O
the	O
sialic	B-CHED
acid	I-CHED
-	O
binding	O
domain	O
and	O
the	O
ectodomain	O
of	O
the	O
membrane	O
fusion	O
subunit	O
S2	O
,	O
respectively	O
.	O

Five	O
mAbs	O
lacked	O
immunoreactivity	O
for	O
MERS	O
-	O
CoV	O
antigen	B-CHED
on	O
FFPE	O
tissue	O
,	O
even	O
though	O
they	O
belong	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
same	O
epitope	B-CHED
group	O
.	O

TITLE	O
:	O
Severe	O
ARDS	O
Complicating	O
an	O
Acute	O
Intentional	O
Cresol	B-CHED
Poisoning	O
.	O

This	O
shows	O
the	O
importance	O
of	O
intensive	O
care	O
in	O
the	O
management	O
of	O
cresol	B-CHED
poisoning	O
.	O

The	O
35	O
characterised	O
IBV	O
strains	O
belonged	O
to	O
Yamagata	O
lineage	O
clade	O
3	O
,	O
the	O
36	O
A	O
/	O
H1N1pdm09	O
strains	O
clustered	O
with	O
the	O
genetic	O
subgroup	O
6B	O
.	O
1	O
,	O
and	O
the	O
2	O
A	O
/	O
H3N2	B-CHED
strains	O
clustered	O
with	O
the	O
genetic	O
subgroup	O
3C	O
.	O
2a	O
.	O

TITLE	O
:	O
Distinct	O
mutation	O
in	O
the	O
feline	O
coronavirus	O
spike	O
protein	B-CHED
cleavage	O
activation	O
site	O
in	O
a	O
cat	O
with	O
feline	O
infectious	O
peritonitis	O
-	O
associated	O
meningoencephalomyelitis	O
.	O

ABSTRACT	O
:	O
In	O
general	O
,	O
heterocyclic	B-CHED
compounds	I-CHED
are	O
a	O
significant	O
source	O
of	O
pharmacologically	O
active	O
compounds	O
.	O

This	O
review	O
aimed	O
to	O
provide	O
a	O
clear	O
knowledge	O
on	O
the	O
recent	O
development	O
of	O
indoles	B-CHED
as	O
anti	O
-	O
cancer	O
agents	O
,	O
such	O
as	O
myeloid	O
cell	O
leukemia	O
-	O
1	O
(	O
Mcl	O
-	O
1	O
)	O
inhibitors	B-CHED
,	O
proviral	O
insertion	O
site	O
in	O
moloney	O
murine	O
leukemia	O
virus	O
(	O
Pim	B-CHED
)	O
inhibitors	B-CHED
,	O
histone	B-CHED
deacetylase	O
(	O
HDAC	O
)	O
inhibitors	B-CHED
,	O
silent	O
mating	O
type	O
information	O
regulation	O
2	O
homolog	O
(	O
SIRT	O
)	O
inhibitors	B-CHED
and	O
tubulin	O
inhibitors	B-CHED
,	O
and	O
made	O
an	O
insight	O
into	O
the	O
corresponding	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
).	O

As	O
a	O
first	O
step	O
toward	O
understanding	O
the	O
biology	O
of	O
the	O
PDCoV	O
accessory	O
proteins	B-CHED
,	O
we	O
established	O
a	O
stable	O
porcine	O
cell	O
line	O
constitutively	O
expressing	O
the	O
PDCoV	O
NS7	O
protein	B-CHED
in	O
order	O
to	O
investigate	O
the	O
functional	O
characteristics	O
of	O
NS7	O
for	O
viral	O
replication	O
.	O

The	O
affected	O
cellular	O
proteins	B-CHED
identified	O
in	O
this	O
study	O
were	O
classified	O
into	O
functional	O
groups	O
involved	O
in	O
various	O
cellular	O
processes	O
such	O
as	O
cytoskeleton	O
networks	O
and	O
cell	O
communication	O
,	O
metabolism	O
,	O
and	O
protein	B-CHED
biosynthesis	O
.	O

Although	O
RNase	O
H	O
inhibitors	B-CHED
have	O
not	O
been	O
developed	O
into	O
licensed	O
drugs	O
,	O
recent	O
progress	O
has	O
led	O
to	O
the	O
identification	O
of	O
a	O
number	O
of	O
small	O
molecules	O
with	O
inhibitory	O
activity	O
at	O
low	O
micromolar	O
or	O
even	O
nanomolar	O
concentrations	O
.	O

Among	O
them	O
,	O
	O
-	O
hydroxytropolones	O
,	O
N	O
-	O
hydroxyisoquinolinediones	O
and	O
N	O
-	O
hydroxypyridinediones	O
represent	O
chemotypes	O
active	O
against	O
both	O
HIV	O
and	O
HBV	O
RNases	O
H	O
.	O
In	O
this	O
review	O
we	O
summarize	O
recent	O
developments	O
in	O
the	O
field	O
including	O
the	O
identification	O
of	O
novel	O
RNase	O
H	O
inhibitors	B-CHED
,	O
compounds	O
with	O
dual	O
inhibitory	O
activity	O
,	O
broad	O
specificity	O
and	O
efforts	O
to	O
decrease	O
their	O
toxicity	O
.	O

The	O
cytokine	O
and	O
/	O
or	O
chemokine	O
induction	O
was	O
significantly	O
attenuated	O
by	O
siRNA	O
depletion	O
of	O
retinoic	B-CHED
acid	I-CHED
-	O
inducible	O
-	O
I	O
-	O
like	O
receptors	O
(	O
RLR	O
)	O
or	O
adaptor	O
,	O
indicating	O
that	O
RLR	O
signaling	O
also	O
contributed	O
to	O
MERS	O
-	O
CoV	O
-	O
induced	O
proinflammatory	O
response	O
.	O

We	O
will	O
search	O
the	O
following	O
electronic	O
databases	O
of	O
Ovid	O
MEDLINE	O
,	O
EMBASE	O
,	O
Web	O
of	O
Science	O
,	O
Cochrane	O
Library	O
,	O
Scopus	O
,	O
Cumulative	O
Index	O
to	O
Nursing	O
and	O
Allied	O
Health	O
Literature	O
,	O
the	O
Allied	O
and	O
Complementary	O
Medicine	B-CHED
Database	O
,	O
Chinese	O
Biomedical	O
Literature	O
Database	O
,	O
China	O
National	O
Knowledge	O
Infrastructure	O
,	O
and	O
WANGFANG	O
from	O
inception	O
to	O
the	O
present	O
without	O
language	O
restriction	O
.	O

The	O
S1	O
gene	O
has	O
1	O
,	O
620	O
nucleotides	B-CHED
and	O
encoded	O
a	O
polypeptide	B-CHED
of	O
540	O
amino	B-CHED
acids	I-CHED
with	O
typical	O
coronavirus	O
cleavage	O
recognition	O
sites	O
of	O
HRRR	O
.	O

ABSTRACT	O
:	O
Experimental	O
data	O
suggest	O
that	O
intravenous	O
vitamin	B-CHED
C	I-CHED
may	O
attenuate	O
inflammation	O
and	O
vascular	O
injury	O
associated	O
with	O
sepsis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

To	O
determine	O
the	O
effect	O
of	O
intravenous	O
vitamin	B-CHED
C	I-CHED
infusion	O
on	O
organ	O
failure	O
scores	O
and	O
biological	O
markers	O
of	O
inflammation	O
and	O
vascular	O
injury	O
in	O
patients	O
with	O
sepsis	O
and	O
ARDS	O
.	O

TITLE	O
:	O
GHRH	O
antagonists	B-CHED
support	O
lung	O
endothelial	O
barrier	O
function	O
.	O

In	O
contrast	O
,	O
both	O
GHRH	O
and	O
GHRH	O
agonist	B-CHED
MR409	O
exerted	O
the	O
opposite	O
effects	O
.	O

We	O
have	O
previously	O
reported	O
the	O
synthesis	O
of	O
potent	O
coronavirus	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
inhibitors	B-CHED
and	O
the	O
efficacy	O
of	O
a	O
protease	B-CHED
inhibitor	I-CHED
,	O
GC376	O
,	O
in	O
client	O
-	O
owned	O
cats	O
with	O
FIP	O
.	O

We	O
generated	O
recombinant	O
3CLpro	O
containing	O
the	O
identified	O
amino	B-CHED
acid	I-CHED
changes	O
(	O
N25S	O
,	O
A252S	O
or	O
K260	O
N	O
)	O
and	O
determined	O
their	O
susceptibility	O
to	O
protease	B-CHED
inhibitors	I-CHED
in	O
the	O
fluorescence	O
resonance	O
energy	O
transfer	O
assay	O
.	O

Modelling	O
of	O
3CLpro	O
carrying	O
the	O
amino	B-CHED
acid	I-CHED
changes	O
was	O
conducted	O
to	O
probe	O
the	O
structural	O
basis	O
for	O
these	O
findings	O
.	O

Mitochondrial	O
permeability	O
transition	O
pore	O
(	O
mPTP	B-CHED
)	O
opening	O
is	O
a	O
key	O
reason	O
for	O
mitochondrial	O
damage	O
.	O

Silencing	O
IL	O
-	O
6	O
promoted	O
TGEV	O
-	O
induced	O
mPTP	B-CHED
opening	O
and	O
inhibited	O
NF	O
-	O
B	O
pathway	O
.	O

The	O
data	O
revealed	O
that	O
TGEV	O
-	O
induced	O
mPTP	B-CHED
opening	O
was	O
regulated	O
via	O
two	O
pathways	O
:	O
circEZH2	O
/	O
miR	O
-	O
22	O
/	O
HK2	O
axis	O
and	O
circEZH2	O
/	O
miR	O
-	O
22	O
/	O
IL	O
-	O
6	O
/	O
NF	O
-	O
B	O
axis	O
.	O

While	O
recent	O
studies	O
have	O
uncovered	O
the	O
sequence	O
of	O
this	O
packaging	O
signal	O
,	O
little	O
is	O
known	O
about	O
the	O
specific	O
interaction	O
between	O
the	O
N	O
-	O
protein	B-CHED
and	O
the	O
packaging	O
signal	O
sequence	O
,	O
and	O
the	O
mechanisms	O
by	O
which	O
this	O
interaction	O
drives	O
viral	O
genome	O
packaging	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
novel	O
in	O
vivo	O
cell	O
-	O
based	O
assay	O
for	O
examining	O
this	O
interaction	O
between	O
the	O
N	O
-	O
protein	B-CHED
and	O
packaging	O
signal	O
RNA	O
for	O
SARS	O
-	O
CoV	O
,	O
as	O
well	O
as	O
other	O
viruses	O
within	O
the	O
coronaviridae	O
family	O
.	O

These	O
results	O
describe	O
,	O
for	O
the	O
first	O
time	O
,	O
in	O
vivo	O
evidence	O
for	O
an	O
interaction	O
between	O
the	O
SARS	O
-	O
CoV	O
N	O
-	O
protein	B-CHED
and	O
its	O
packaging	O
signal	O
RNA	O
,	O
and	O
demonstrate	O
the	O
feasibility	O
of	O
using	O
this	O
cell	O
-	O
based	O
assay	O
to	O
further	O
probe	O
viral	O
RNA	O
-	O
protein	B-CHED
interactions	O
in	O
future	O
studies	O
.	O

Surfaces	O
with	O
the	O
highest	O
rates	O
of	O
positive	O
samples	O
were	O
kitchen	O
tables	O
(	O
100	O
%),	O
water	B-CHED
fountain	O
faucet	O
(	O
73	O
.	O
3	O
%)	O
and	O
edge	O
of	O
water	B-CHED
coolers	O
lid	O
(	O
84	O
.	O
6	O
%).	O

We	O
compared	O
vaccination	O
status	O
of	O
2880	O
people	O
with	O
non	O
-	O
influenza	O
respiratory	O
viruses	O
to	O
3240	O
people	O
with	O
pan	B-CHED
-	O
negative	O
results	O
.	O

In	O
the	O
HCDRs	O
(	O
excluding	O
HCDR3	O
)	O
in	O
this	O
clone	O
,	O
two	O
hydrophobic	O
residues	O
were	O
replaced	O
with	O
Glu	B-CHED
,	O
two	O
residues	O
were	O
replaced	O
with	O
Asp	B-CHED
,	O
and	O
four	O
residues	O
were	O
replaced	O
with	O
positively	O
charged	O
amino	B-CHED
acids	I-CHED
.	O

In	O
LCDRs	O
,	O
only	O
two	O
Leu	B-CHED
residues	O
were	O
replaced	O
with	O
Val	B-CHED
.	O

Our	O
analysis	O
revealed	O
two	O
pathogenicity	O
-	O
related	O
gene	O
expression	O
clusters	B-CHED
;	O
these	O
results	O
were	O
corroborated	O
by	O
matching	O
proteomics	O
data	O
.	O

ABSTRACT	O
:	O
3	O
-	O
Acyl	O
-	O
2	O
-	O
phenylamino	B-CHED
-	O
1	O
,	O
4	O
-	O
dihydroquinolin	O
-	O
4	O
(	O
1H	O
)-	O
one	O
derivatives	O
were	O
synthesized	O
and	O
evaluated	O
to	O
show	O
high	O
anti	O
-	O
MERS	O
-	O
CoV	O
inhibitory	O
activities	O
.	O

TITLE	O
:	O
Use	O
of	O
glucocorticoids	B-CHED
in	O
the	O
critical	O
care	O
setting	O
:	O
Science	O
and	O
clinical	O
evidence	O
.	O

ABSTRACT	O
:	O
Glucocorticoids	B-CHED
(	O
GC	O
)	O
in	O
all	O
its	O
various	O
forms	O
and	O
formulations	O
are	O
likely	O
one	O
of	O
the	O
most	O
commonly	O
used	O
pharmacologic	O
agents	O
in	O
medicine	B-CHED
.	O

The	O
top	O
five	O
diseases	O
in	O
terms	O
of	O
the	O
number	O
of	O
entries	O
were	O
described	O
in	O
depth	O
to	O
determine	O
the	O
effectiveness	O
of	O
PHE	B-CHED
'	O
s	O
EI	O
surveillance	O
system	O
compared	O
to	O
other	O
sources	O
.	O

Overall	O
,	O
this	O
study	O
demonstrates	O
the	O
ability	O
of	O
PMO	O
to	O
deliver	O
life	O
-	O
sustaining	O
supplemental	O
oxygen	B-CHED
to	O
rats	O
suffering	O
from	O
ARDS	O
and	O
warrants	O
further	O
work	O
toward	O
clinical	O
translation	O
.	O

In	O
addition	O
,	O
the	O
trial	O
registers	O
to	O
be	O
searched	O
will	O
include	O
:	O
World	O
Health	O
Organization	O
International	O
Clinical	O
Trials	O
Registry	O
Platform	O
(	O
ICTRP	O
),	O
United	O
States	O
National	O
Library	O
of	O
Medicine	B-CHED
Drug	O
Information	O
Portal	O
and	O
ClinicalTrials	O
.	O
gov	O
.	O

The	O
BCoV	O
antigen	B-CHED
distribution	O
was	O
prominent	O
within	O
the	O
necrotic	O
crypts	O
in	O
the	O
jejunum	O
and	O
cryptic	O
micro	O
-	O
abscesses	O
in	O
the	O
colon	O
and	O
ileum	O
.	O

Finally	O
,	O
opioids	O
can	O
be	O
categorized	O
on	O
the	O
basis	O
of	O
their	O
action	O
as	O
full	O
agonists	B-CHED
,	O
partial	O
agonists	B-CHED
or	O
mixed	O
agonists	B-CHED
/	O
antagonists	B-CHED
,	O
and	O
antagonists	B-CHED
of	O
opiate	O
receptors	O
.	O

These	O
other	O
stresses	O
can	O
lower	O
hepatic	O
glutathione	B-CHED
levels	O
and	O
predispose	O
to	O
acetaminophen	B-CHED
hepatotoxicity	O
.	O

References	O
to	O
the	O
opioids	O
and	O
the	O
opiate	B-CHED
antagonists	I-CHED
used	O
to	O
treat	O
substance	O
abuse	O
are	O
given	O
separately	O
with	O
each	O
agent	O
(	O
buprenorphine	B-CHED
,	O
methadone	B-CHED
,	O
nalmefene	O
,	O
naloxone	B-CHED
,	O
naltrexone	B-CHED
).	O

Codeine	B-CHED
.	O

Diphenoxylate	B-CHED
.	O

Hydrocodone	B-CHED
.	O

Oxycodone	B-CHED
.	O

The	O
aminopenicillins	O
,	O
like	O
the	O
natural	O
first	O
generation	O
penicillins	B-CHED
,	O
bind	O
to	O
bacterial	O
proteins	B-CHED
and	O
inhibit	O
synthesis	O
of	O
the	O
bacterial	O
cell	O
wall	O
,	O
causing	O
cell	O
lysis	O
particularly	O
in	O
rapidly	O
growing	O
organisms	O
.	O

The	O
references	O
for	O
ampicillin	B-CHED
,	O
amoxicillin	B-CHED
and	O
ampicillin	B-CHED
/	O
sulbactam	B-CHED
are	O
given	O
together	O
at	O
the	O
end	O
of	O
this	O
Overview	O
section	O
,	O
because	O
they	O
are	O
rare	O
causes	O
of	O
acute	O
liver	O
injury	O
and	O
appear	O
to	O
share	O
a	O
common	O
pattern	O
of	O
associated	O
liver	O
injury	O
.	O

Typical	O
hepatotoxicity	O
due	O
to	O
the	O
aminopenicillins	O
resembles	O
that	O
of	O
the	O
first	O
generation	O
penicillins	B-CHED
.	O

TITLE	O
:	O
The	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
S	O
-	O
protein	B-CHED
structure	O
and	O
receptor	O
binding	O
.	O

Mutation	O
of	O
the	O
S2	O
'	O
site	O
of	O
QX	O
genotype	O
(	O
QX	O
-	O
type	O
)	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
spike	O
protein	B-CHED
(	O
S	O
)	O
in	O
a	O
recombinant	O
virus	O
background	O
results	O
in	O
higher	O
pathogenicity	O
,	O
pronounced	O
neural	O
symptoms	O
and	O
neurotropism	O
when	O
compared	O
with	O
conditions	O
in	O
wild	O
-	O
type	O
IBV	O
(	O
WT	O
-	O
IBV	O
)	O
infected	O
chickens	O
.	O

We	O
confirmed	O
that	O
DEV	O
infection	O
was	O
significantly	O
suppressed	O
in	O
MDA5	O
-	O
overexpressing	O
DEF	B-CHED
cells	O
,	O
while	O
knockdown	O
of	O
MDA5	O
by	O
siRNA	O
markedly	O
enhanced	O
DEV	O
growth	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
if	O
the	O
influence	O
of	O
Met	B-CHED
on	O
HEV	O
infected	O
turkeys	O
immune	O
response	O
can	O
be	O
differentiated	O
by	O
both	O
its	O
level	O
and	O
source	O
.	O

In	O
the	O
uninfected	O
turkeys	O
,	O
the	O
higher	O
by	O
40	O
%	O
(	O
than	O
recommended	O
by	O
NRC	O
)	O
level	O
of	O
Met	B-CHED
in	O
the	O
feeds	O
had	O
a	O
positive	O
effect	O
on	O
humoral	O
immunity	O
parameters	O
.	O

In	O
this	O
study	O
,	O
the	O
results	O
of	O
base	O
composition	O
analysis	O
showed	O
A	O
/	O
T	O
rich	O
and	O
G	O
/	O
C	O
poor	O
in	O
PEDV	O
orf3	O
genes	O
,	O
and	O
the	O
most	O
abundant	O
base	O
was	O
nucleotide	B-CHED
T	O
.	O
The	O
relative	O
synonymous	O
codon	O
usage	O
value	O
in	O
each	O
codon	O
revealed	O
that	O
codon	O
usage	O
bias	O
existed	O
.	O

The	O
parameters	O
including	O
prothrombin	O
time	O
(	O
PT	O
),	O
hematocrit	O
(	O
HCT	O
),	O
platelet	O
(	O
PLT	O
)	O
and	O
blood	O
lactate	B-CHED
(	O
BL	O
)	O
at	O
the	O
4th	O
hour	O
after	O
fluid	O
resuscitation	O
were	O
recorded	O
.	O

The	O
pseudotyped	O
vesicular	O
stomatitis	O
virus	O
coated	O
with	O
the	O
spike	O
protein	B-CHED
of	O
MERS	O
-	O
CoV	O
was	O
used	O
in	O
virus	O
neutralization	O
(	O
VN	O
)	O
tests	O
performed	O
in	O
a	O
biosafety	O
level	O
(	O
BSL	O
)-	O
2	O
laboratory	O
.	O

Whereas	O
similar	O
virus	O
titers	O
were	O
observed	O
in	O
the	O
control	O
animals	O
and	O
the	O
animals	O
immunized	O
with	O
S	O
protein	B-CHED
with	O
or	O
without	O
AuNPs	O
,	O
Type	O
1	O
interferon	O
and	O
pro	B-CHED
-	O
inflammatory	O
responses	O
were	O
moderate	O
in	O
the	O
mice	O
treated	O
with	O
S	O
protein	B-CHED
with	O
and	O
without	O
AuNPs	O
.	O

Our	O
patient	O
simultaneously	O
had	O
kidney	O
failure	O
,	O
rhabdomyolysis	O
,	O
and	O
permanent	O
hearing	O
loss	O
following	O
methadone	B-CHED
poisoning	O
.	O

CONCLUSIONS	O
:	O
Our	O
patient	O
simultaneously	O
had	O
kidney	O
failure	O
,	O
rhabdomyolysis	O
,	O
and	O
permanent	O
hearing	O
loss	O
following	O
methadone	B-CHED
poisoning	O
.	O

ABSTRACT	O
:	O
The	O
aryl	O
hydrocarbon	B-CHED
receptor	O
(	O
AhR	O
)	O
is	O
a	O
cytoplasmic	O
receptor	O
/	O
transcription	O
factor	O
that	O
modulates	O
several	O
cellular	O
and	O
immunological	O
processes	O
following	O
activation	O
by	O
pathogen	O
-	O
associated	O
stimuli	O
,	O
though	O
its	O
role	O
during	O
virus	O
infection	O
is	O
largely	O
unknown	O
.	O

Among	O
T	O
-	O
cell	O
epitopes	O
,	O
MHC	O
class	O
-	O
I	O
peptide	B-CHED
YKLQPLTFL	O
and	O
MHC	O
class	O
-	O
II	O
peptide	B-CHED
YCILEPRSG	O
were	O
identified	O
as	O
highly	O
antigenic	O
.	O

RESULTS	O
:	O
Many	O
conserved	O
cytotoxic	O
T	O
-	O
lymphocyte	O
epitopes	O
and	O
discontinuous	O
and	O
linear	O
B	O
-	O
cell	O
epitopes	O
were	O
predicted	O
for	O
the	O
MERS	O
-	O
COV	O
S	O
protein	B-CHED
,	O
and	O
their	O
antigenicity	O
and	O
interactions	O
with	O
the	O
human	O
leukocyte	O
antigen	B-CHED
(	O
HLA	O
)	O
B7	O
allele	O
were	O
estimated	O
.	O

ABSTRACT	O
:	O
MERS	O
-	O
CoV	O
seronegative	O
and	O
seropositive	O
camels	O
received	O
a	O
single	O
intramuscular	O
dose	O
of	O
ChAdOx1	O
MERS	O
,	O
a	O
replication	O
-	O
deficient	O
adenoviral	O
vectored	O
vaccine	O
expressing	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
,	O
with	O
further	O
groups	O
receiving	O
control	O
vaccinations	O
.	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
(	O
HCoVs	O
)	O
are	O
important	O
pathogens	O
that	O
cause	O
upper	O
respiratory	O
tract	O
infections	O
and	O
have	O
neuroinvasive	O
abilities	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
the	O
dynamic	O
infection	O
process	O
of	O
CoVs	O
in	O
vivo	O
,	O
and	O
there	O
are	O
currently	O
no	O
specific	O
antiviral	B-CHED
drugs	I-CHED
to	O
prevent	O
or	O
treat	O
HCoV	O
infection	O
.	O

Drug	O
-	O
induced	O
lymphocyte	O
stimulation	O
test	O
performed	O
six	O
months	O
after	O
withdrawing	O
methylprednisolone	B-CHED
was	O
positive	O
for	O
Sai	O
-	O
rei	O
-	O
to	O
.	O

Our	O
findings	O
demonstrate	O
that	O
in	O
cases	O
of	O
severe	O
acute	O
respiratory	O
failure	O
due	O
to	O
DLI	O
,	O
the	O
multi	O
-	O
modal	O
therapy	O
with	O
plasma	O
exchange	O
and	O
IVIG	O
in	O
addition	O
to	O
conventional	O
treatment	O
with	O
prednisolone	B-CHED
and	O
immunosuppressant	B-CHED
may	O
be	O
beneficial	O
.	O

Two	O
hundred	O
and	O
eighty	O
-	O
eight	O
pediatric	O
patients	O
admitted	O
between	O
January	O
1	O
,	O
2010	O
and	O
January	O
30	O
,	O
2017	O
,	O
who	O
met	B-CHED
the	O
inclusion	O
criteria	O
for	O
PARDS	O
were	O
retrospectively	O
analyzed	O
.	O

The	O
antiviral	B-CHED
activity	O
of	O
some	O
flavonoids	B-CHED
against	O
CoVs	O
is	O
presumed	O
directly	O
caused	O
by	O
inhibiting	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
).	O

In	O
children	O
with	O
severe	O
PARDS	O
,	O
further	O
research	O
is	O
needed	O
to	O
determine	O
if	O
factors	O
other	O
than	O
the	O
haemoglobin	B-CHED
level	O
might	O
guide	O
RBC	O
transfusion	O
decision	O
-	O
making	O
by	O
better	O
characterizing	O
the	O
presence	O
of	O
low	O
oxygen	B-CHED
delivery	O
(	O
DO	O

In	O
addition	O
,	O
similarities	O
to	O
the	O
human	O
toll	O
-	O
like	O
receptor	O
4	O
,	O
the	O
existence	O
of	O
intraalveolar	O
macrophages	O
,	O
the	O
sensitivity	O
to	O
lipopolysaccharide	B-CHED
,	O
and	O
the	O
production	O
of	O
nitric	B-CHED
oxide	I-CHED
make	O
the	O
piglet	O
indispensable	O
in	O
anti	O
-	O
inflammatory	O
research	O
.	O

Here	O
we	O
present	O
the	O
physiologic	O
and	O
immunologic	O
data	O
of	O
newborn	O
piglets	O
from	O
three	O
trials	O
involving	O
acute	O
lung	O
injury	O
secondary	O
to	O
repeated	O
airway	O
lavage	O
(	O
and	O
others	O
),	O
mechanical	O
ventilation	O
,	O
and	O
a	O
specific	O
anti	O
-	O
inflammatory	O
intervention	O
via	O
the	O
intratracheal	O
route	O
using	O
surfactant	B-CHED
as	O
a	O
carrier	O
substance	O
.	O

This	O
prospective	O
study	O
investigated	O
the	O
use	O
of	O
electromyography	O
of	O
the	O
diaphragm	O
(	O
EMGdi	O
)	O
for	O
monitoring	O
respiratory	O
drive	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	O
during	O
long	O
-	O
term	O
PPV	B-CHED
.	O

Ensuring	O
the	O
optimized	O
effective	O
dosing	O
of	O
antimicrobials	B-CHED
on	O
ECMO	O
remains	O
a	O
challenge	O
.	O

We	O
have	O
further	O
evaluated	O
the	O
effect	O
of	O
membrane	O
cholesterol	B-CHED
on	O
the	O
binding	O
and	O
organization	O
of	O
the	O
peptide	B-CHED
and	O
the	O
impact	O
of	O
peptide	B-CHED
binding	O
on	O
the	O
depth	O
-	O
dependent	O
physical	O
properties	O
of	O
the	O
membrane	O
at	O
various	O
cholesterol	B-CHED
concentrations	O
.	O

We	O
compared	O
the	O
characteristics	O
and	O
in	O
-	O
hospital	O
mortality	O
of	O
patients	O
administered	O
with	O
antibiotics	B-CHED
at	O
varying	O
durations	O
after	O
sepsis	O
recognition	O
,	O
i	O
.	O
e	O
.,	O
0	O
-	O
60	O
,	O
61	O
-	O
120	O
,	O
121	O
-	O
180	O
,	O
181	O
-	O
240	O
,	O
241	O
-	O
360	O
,	O
and	O
361	O
-	O
1440	O
min	O
,	O
and	O
estimated	O
the	O
impact	O
of	O
antibiotic	B-CHED
timing	O
on	O
risk	O
-	O
adjusted	O
in	O
-	O
hospital	O
mortality	O
using	O
the	O
generalized	O
estimating	O
equation	O
model	O
(	O
GEE	O
)	O
with	O
an	O
exchangeable	O
,	O
within	O
-	O
group	O
correlation	O
matrix	O
,	O
with	O
""""	O
hospital	O
""""	O
as	O
the	O
grouping	O
variable	O
.	O

Compared	O
with	O
patients	O
diagnosed	O
in	O
the	O
emergency	O
department	O
[	O
90	O
min	O
(	O
IQR	O
,	O
48	O
-	O
164	O
min	O
)],	O
time	O
to	O
antibiotic	B-CHED
administration	O
was	O
shortest	O
in	O
patients	O
diagnosed	O
in	O
ICUs	O
[	O
60	O
min	O
(	O
39	O
-	O
180	O
min	O
)]	O
and	O
longest	O
in	O
patients	O
transferred	O
from	O
wards	O
[	O
120	O
min	O
(	O
62	O
-	O
226	O
)].	O

Additionally	O
,	O
SOT	O
patients	O
had	O
higher	O
odds	O
of	O
hospital	O
readmission	O
within	O
30	O
days	O
(	O
OR	O
=	O
1	O
.	O
25	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
06	O
-	O
1	O
.	O
51	O
],	O
P	O
=	O
.	O
020	O
),	O
and	O
higher	O
odds	O
for	O
DIC	B-CHED
compared	O
with	O
non	O
-	O
SOT	O
patients	O
(	O
OR	O
=	O
1	O
.	O
76	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
10	O
-	O
2	O
.	O
86	O
],	O
P	O
=	O
.	O
021	O
).	O

A	O
24	O
-	O
year	O
-	O
old	O
man	B-CHED
was	O
admitted	O
to	O
our	O
Internal	O
Medicine	B-CHED
Department	O
due	O
to	O
dyspnea	O
,	O
ascites	O
,	O
and	O
leg	O
swelling	O
.	O

Sacubitril	O
/	O
valsartan	B-CHED
was	O
added	O
to	O
optimal	O
medical	O
therapy	O
after	O
hemodynamic	O
stabilization	O
allowing	O
progressive	O
clinical	O
,	O
laboratoristic	O
,	O
and	O
echocardiographic	O
improvement	O
.	O

This	O
study	O
indicates	O
that	O
the	O
absence	O
of	O
accessory	O
proteins	B-CHED
3a	O
and	O
3b	O
in	O
IBV	O
lead	O
to	O
attenuated	O
pathogenicity	O
in	O
chickens	O
.	O

A	O
41	O
-	O
year	O
-	O
old	O
man	B-CHED
presented	O
with	O
high	O
fever	O
,	O
general	O
malaise	O
,	O
myalgia	O
,	O
dyspnea	O
,	O
and	O
dark	O
-	O
colored	O
urine	O
,	O
and	O
then	O
progressed	O
to	O
anuria	O
.	O

He	O
was	O
then	O
administered	O
valsartan	B-CHED
tablets	O
at	O
a	O
dosage	O
of	O
80	O
mg	O
per	O
day	O
and	O
L	B-CHED
-	I-CHED
carnitine	I-CHED
supplements	O
.	O

In	O
the	O
absence	O
of	O
a	O
targeted	O
vaccine	O
or	O
a	O
pathogen	O
-	O
specific	O
antiviral	B-CHED
,	O
broad	O
-	O
spectrum	O
antivirals	B-CHED
would	O
function	O
to	O
limit	O
virus	O
spread	O
.	O

A	O
selective	O
N	O
protein	B-CHED
variant	O
carrying	O
point	O
mutations	O
in	O
these	O
two	O
regions	O
fails	O
to	O
bind	O
nsp3	O

Here	O
,	O
we	O
report	O
a	O
fatal	O
case	O
of	O
APS	B-CHED
type	O
1	O
with	O
hypotension	O
and	O
profound	O
hypoglycemia	O
in	O
a	O
24	O
-	O
year	O
-	O
old	O
man	B-CHED
who	O
was	O
found	O
unconsciousness	O
at	O
home	O
and	O
progressively	O
evolved	O
into	O
pulseless	O
electrical	O
activity	O
.	O

Two	O
clusters	B-CHED
of	O
patients	O
were	O
defined	O
from	O
chronological	O
data	O
and	O
phylogenetic	O
trees	O
.	O

Analyses	O
of	O
amino	B-CHED
acids	I-CHED
substitutions	O
of	O
the	O
S	O
protein	B-CHED
sequences	O
identified	O
substitutions	O
specific	O
for	O
genotype	O
F	O
strains	O
circulating	O
among	O
European	O
people	O
.	O

Analyses	O
of	O
amino	B-CHED
acids	I-CHED
substitutions	O
of	O
the	O
S	O
protein	B-CHED
sequences	O
identified	O
substitutions	O
specific	O
for	O
genotype	O
F	O
strains	O
circulating	O
among	O
European	O
people	O
.	O

Corticosteroids	B-CHED
were	O
prescribed	O
in	O
20	O
/	O
55	O
(	O
36	O
%).	O

Combining	O
rapid	O
viral	O
surveillance	O
and	O
PCT	O
test	O
is	O
a	O
useful	O
strategy	O
for	O
early	O
detection	O
of	O
potential	O
viral	O
epidemics	O
and	O
antibiotic	B-CHED
stewardship	O
.	O

To	O
understand	O
MERS	O
-	O
CoV	O
engagement	O
of	O
sialylated	O
receptors	O
,	O
we	O
determined	O
the	O
cryo	O
-	O
EM	O
structures	O
of	O
S	O
in	O
complex	O
with	O
5	O
-	O
N	O
-	O
acetyl	B-CHED
neuraminic	B-CHED
acid	I-CHED
,	O
5	O
-	O
N	O
-	O
glycolyl	B-CHED
neuraminic	B-CHED
acid	I-CHED
,	O
sialyl	O
-	O
Lewis	O

TITLE	O
:	O
A	O
Recombinant	O
Influenza	O
A	O
/	O
H1N1	O
Carrying	O
A	O
Short	O
Immunogenic	O
Peptide	B-CHED
of	O
MERS	O
-	O
CoV	O
as	O
Bivalent	O
Vaccine	O
in	O
BALB	O
/	O
c	O
Mice	O
.	O

In	O
this	O
study	O
,	O
a	O
chimeric	O
DNA	O
construct	O
was	O
designed	O
to	O
encode	O
an	O
influenza	O
A	O
/	O
H1N1	O
NA	O
protein	B-CHED
which	O
is	O
flanking	O
immunogenic	O
amino	B-CHED
acids	I-CHED
(	O
aa	O
)	O
736	O
-	O
761	O
of	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
.	O

TITLE	O
:	O
Choking	O
agents	O
and	O
chlorine	B-CHED
gas	O
-	O
History	O
,	O
pathophysiology	O
,	O
clinical	O
effects	O
and	O
treatment	O
.	O

In	O
this	O
work	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
5	B-CHED
,	I-CHED
6	I-CHED
-	I-CHED
dihydroxyindole	I-CHED
-	I-CHED
2	I-CHED
-	I-CHED
carboxylic	I-CHED
acid	I-CHED
(	O
DHICA	B-CHED
)	O
derivatives	O
on	O
both	O
HIV	O
-	O
1	O
Integrase	O
(	O
IN	O
)	O
and	O
Reverse	O
Transcriptase	O
associated	O
Ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
activities	O
.	O

As	O
one	O
of	O
the	O
potential	O
strategies	O
to	O
render	O
spontaneous	O
effort	O
less	O
injurious	O
in	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
the	O
role	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
is	O
now	O
discussed	O
.	O

The	O
amino	B-CHED
acid	I-CHED
sequences	O
variations	O
were	O
observed	O
in	O
28	O
/	O
35	O
samples	O
and	O
two	O
unique	O
amino	B-CHED
acid	I-CHED
sequences	O
variations	O
were	O
observed	O
in	O
all	O
samples	O
analyzed	O
while	O
total	O
19	O
nucleotides	B-CHED
sequences	O
variations	O
were	O
observed	O
in	O
the	O
Spike	O
protein	B-CHED
gene	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
PHEV	O
infection	O
upregulates	O
miR	O
-	O
142a	O
-	O
3p	O
RNA	O
expression	O
in	O
N2a	O
cells	O
and	O
in	O
the	O
CNS	B-CHED
of	O
mice	O
.	O

This	O
study	O
aimed	O
to	O
(	O
i	O
)	O
investigate	O
a	O
cross	O
-	O
sectional	O
incidence	O
of	O
canine	O
respiratory	O
viruses	O
,	O
including	O
influenza	O
(	O
CIV	O
),	O
parainfluenza	O
,	O
distemper	O
(	O
CDV	B-CHED
),	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
),	O
adenovirus	O
-	O
2	O
,	O
and	O
herpesvirus	O
,	O
in	O
respiratory	O
-	O
diseased	O
dogs	O
,	O
and	O
(	O
ii	O
)	O
analyze	O
the	O
possibly	O
related	O
risk	O
factors	O
.	O

We	O
postulated	O
that	O
the	O
effect	O
of	O
these	O
residues	O
in	O
enteric	O
tropism	O
may	O
be	O
mediated	O
by	O
the	O
modification	O
of	O
both	O
glycosaminoglycan	B-CHED
binding	O
and	O
S	O
protein	B-CHED
structure	O
.	O

Like	O
other	O
well	O
-	O
recognized	O
neuroinvasive	O
human	O
viruses	O
,	O
respiratory	O
viruses	O
may	O
damage	O
the	O
CNS	B-CHED
as	O
a	O
result	O
of	O
misdirected	O
host	O
immune	O
responses	O
that	O
could	O
be	O
associated	O
with	O
autoimmunity	O
in	O
susceptible	O
individuals	O
(	O
virus	O
-	O
induced	O
neuro	O
-	O
immunopathology	O
)	O
and	O
/	O
or	O
viral	O
replication	O
,	O
which	O
directly	O
causes	O
damage	O
to	O
CNS	B-CHED
cells	O
(	O
virus	O
-	O
induced	O
neuropathology	O
).	O

The	O
aims	O
of	O
medical	O
reform	O
by	O
Prof	O
.	O
Lin	B-CHED
are	O
(	O
1	O
)	O
to	O
eliminate	O
the	O
specialty	O
training	O
part	O
,	O
(	O
2	O
)	O
to	O
use	O
innovative	O
teaching	O
methods	O
to	O
motivate	O
students	O
to	O
learn	O
proactively	O
,	O
and	O
(	O
3	O
)	O
to	O
implement	O
competency	O
-	O
based	O
medical	O
education	O
.	O

With	O
the	O
aim	O
of	O
evaluating	O
the	O
selectivity	O
of	O
action	O
of	O
this	O
class	O
of	O
compounds	O
,	O
a	O
wide	O
spectrum	O
of	O
RNA	O
(	O
positive	O
-	O
and	O
negative	O
-	O
sense	O
),	O
double	O
-	O
stranded	O
(	O
dsRNA	B-CHED
)	O
or	O
DNA	O
viruses	O
were	O
also	O
assayed	O
.	O

The	O
worst	O
PaO	B-CHED
PPV	B-CHED
improves	O
oxygenation	O
when	O
started	O
early	O
with	O
adequate	O
duration	O
and	O
should	O
be	O
considered	O
in	O
all	O
severe	O
ARDS	O
cases	O
secondary	O
to	O
H1N1	O
viral	O
infection	O
.	O

Analysis	O
of	O
coronavirus	O
spike	O
proteins	B-CHED
by	O
western	O
blot	O
allows	O
the	O
visualization	O
and	O
assessment	O
of	O
proteolytic	O
processing	O
by	O
endogenous	O
or	O
exogenous	O
proteases	O
.	O

Such	O
analysis	O
enables	O
the	O
characterization	O
of	O
cleavage	O
patterns	O
produced	O
by	O
a	O
host	O
protease	O
on	O
a	O
coronavirus	O
spike	O
glycoprotein	B-CHED
.	O

TITLE	O
:	O
Crystallization	O
and	O
Structural	O
Determination	O
of	O
the	O
Receptor	O
-	O
Binding	O
Domain	O
of	O
MERS	O
-	O
CoV	O
Spike	O
Glycoprotein	B-CHED
.	O

TITLE	O
:	O
Metabolite	B-CHED
,	O
Protein	B-CHED
,	O
and	O
Lipid	B-CHED
Extraction	O
(	O
MPLEx	O
):	O
A	O
Method	O
that	O
Simultaneously	O
Inactivates	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
and	O
Allows	O
Analysis	O
of	O
Multiple	O
Host	O
Cell	O
Components	O
Following	O
Infection	O
.	O

TITLE	O
:	O
Massive	O
air	B-CHED
leak	O
secondary	O
to	O
influenza	O
B	O
in	O
a	O
7	O
-	O
year	O
-	O
old	O
:	O
A	O
case	O
report	O
.	O

This	O
case	O
report	O
describes	O
the	O
circumstances	O
surrounding	O
the	O
critical	O
illness	O
of	O
a	O
healthy	O
7	O
-	O
year	O
-	O
old	O
child	O
who	O
developed	O
a	O
massive	O
air	B-CHED
leak	O
syndrome	O
secondary	O
to	O
influenza	O
B	O
.	O
She	O
required	O
the	O
emergent	O
insertion	O
of	O
a	O
chest	O
tube	O
as	O
well	O
as	O
intubation	O
and	O
mechanical	O
ventilation	O
.	O

Intracellular	O
cholesterol	B-CHED
accumulation	O
was	O
reported	O
to	O
disrupt	O
late	O
endosome	O
function	O
.	O

ABSTRACT	O
:	O
The	O
MIRACLE	O
trial	O
(	O
MERS	O
-	O
CoV	O
Infection	O
tReated	O
with	O
A	O
Combination	O
of	O
Lopinavir	O
/	O
ritonavir	B-CHED
and	O
intErferon	O
-	O
1b	O
)	O
investigates	O
the	O
efficacy	O
of	O
a	O
combination	O
therapy	O
of	O
lopinavir	O
/	O
ritonavir	B-CHED
and	O
recombinant	O
interferon	O
-	O
1b	O
provided	O
with	O
standard	O
supportive	O
care	O
,	O
compared	O
to	O
placebo	O
provided	O
with	O
standard	O
supportive	O
care	O
,	O
in	O
hospitalized	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
MERS	O
.	O

ABSTRACT	O
:	O
RNA	O
viruses	O
encode	O
dedicated	O
protein	B-CHED
machinery	O
required	O
through	O
the	O
viral	O
life	O
cycle	O
.	O

The	O
selected	O
vitamin	B-CHED
E	I-CHED
coated	O
LPH	O
nanoparticles	B-CHED
enriched	O
with	O
lecithin	B-CHED
-	O
glyceryl	B-CHED
monostearate	O
lipid	B-CHED
shell	O
exhibited	O
high	O
entrapment	O
for	O
E	O
(	O
80	O
.	O
47	O
%),	O
a	O
size	O
	O
200	O
nm	O
for	O
liver	O
passive	O
targeting	O
,	O
extended	O
release	O
over	O
one	O
week	O
,	O
proven	O
serum	O
stability	O
,	O
retained	O
stability	O
after	O
refrigeration	O
storage	O
for	O
6	O
months	O
.	O

There	O
are	O
no	O
approved	O
treatments	O
for	O
MERS	O
-	O
CoV	O
infection	O
although	O
a	O
combination	O
of	O
lopinavir	O
,	O
ritonavir	B-CHED
and	O
interferon	O
beta	O
(	O
LPV	O
/	O
RTV	O
-	O
IFNb	O
)	O
is	O
currently	O
being	O
evaluated	O
in	O
humans	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
.	O

RESULTS	O
:	O
Of	O
349	O
MERS	O
patients	O
,	O
144	O
(	O
41	O
.	O
3	O
%)	O
patients	O
received	O
RBV	B-CHED
/	O
rIFN	O
(	O
RBV	B-CHED
and	O
/	O
or	O
rIFN	O
-	O
2a	O
,	O
rIFN	O
-	O
2b	O
,	O
or	O
rIFN	O
-	O
1a	O
;	O
none	O
received	O
rIFN	O
-	O
1b	O
).	O

Since	O
virus	O
replication	O
relies	O
on	O
the	O
host	O
translation	O
machinery	O
,	O
it	O
is	O
not	O
surprising	O
that	O
the	O
rocaglate	O
Silvestrol	B-CHED
has	O
broad	O
-	O
spectrum	O
antiviral	B-CHED
activity	O
.	O

Note	O
that	O
the	O
level	O
of	O
FcRn	O
mRNA	B-CHED
in	O
the	O
intestinal	O
mucosa	O
of	O
normal	O
piglets	O
is	O
positively	O
correlated	O
with	O
pIgR	O
and	O
NF	O
-	O
B	O
.	O
At	O
the	O
same	O
time	O
,	O
the	O
expressions	O
of	O
FcRn	O
,	O
pIgR	O
,	O
and	O
NF	O
-	O
B	O
mRNA	B-CHED
are	O
also	O
positively	O
correlated	O
in	O
infected	O
piglets	O
.	O

At	O
farm	O
A	O
,	O
20	O
calves	O
were	O
selected	O
and	O
sampled	O
weekly	O
for	O
12	O
weeks	O
(	O
184	O
samples	O
);	O
at	O
farm	O
B	O
,	O
10	O
calves	O
were	O
selected	O
and	O
sampled	O
for	O
five	O
weeks	O
(	O
50	O
samples	O
);	O
and	O
at	O
the	O
rest	B-CHED
of	O
the	O
46	O
farms	O
,	O
88	O
calves	O
were	O
sampled	O
once	O
.	O

With	O
the	O
development	O
of	O
modern	O
technologies	O
,	O
new	O
diagnostic	O
strategies	O
,	O
including	O
multiplex	O
nucleic	B-CHED
acid	I-CHED
amplification	O
and	O
microarray	O
-	O
based	O
assays	O
,	O
are	O
emerging	O
.	O

TITLE	O
:	O
Recombinant	O
adenovirus	O
carrying	O
a	O
core	O
neutralizing	O
epitope	B-CHED
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
and	O
heat	O
-	O
labile	O
enterotoxin	O
B	O
of	O
Escherichia	O
coli	O
as	O
a	O
mucosal	O
vaccine	O
.	O

To	O
conclude	O
,	O
the	O
detection	O
power	O
of	O
PCR	O
was	O
better	O
than	O
that	O
of	O
traditional	O
antigen	B-CHED
tests	O
and	O
virus	O
cultures	O
when	O
considering	O
the	O
detection	O
of	O
respiratory	O
viruses	O
.	O

Studies	O
of	O
convalescent	O
plasma	O
treatment	O
for	O
A	O
(	O
H7N9	O
)	O
patients	O
should	O
consider	O
collection	O
of	O
donor	B-CHED
plasma	O
from	O
survivors	O
of	O
severe	O
disease	O
between	O
1	O
and	O
11	O
months	O
after	O
illness	O
onset	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
SARs	O
of	O
dopamine	B-CHED
derivatives	O
as	O
potential	O
inhibitors	B-CHED
of	O
influenza	O
virus	O
PA	O
ABSTRACT	O
:	O
Currently	O
,	O
influenza	O
PA	O

SAR	B-CHED
studies	O
were	O
performed	O
.	O

We	O
also	O
found	O
NMBAs	O
did	O
not	O
affect	O
total	O
PEEP	B-CHED
,	O
plateau	O
pressure	O
,	O
days	O
free	O
of	O
ventilation	O
at	O
day	O
28	O
and	O
ICU	O
-	O
acquired	O
weakness	O
.	O

The	O
antibody	O
designated	O
4E88	O
had	O
highest	O
binding	O
affinity	O
with	O
the	O
N	O
protein	B-CHED
and	O
was	O
chosen	O
for	O
in	O
-	O
depth	O
examination	O
.	O

3D	O
structural	O
analysis	O
revealed	O
that	O
amino	B-CHED
acids	I-CHED
of	O
EP	O
-	O
4E88	O
were	O
in	O
close	O
proximity	O
and	O
may	O
be	O
exposed	O
on	O
the	O
surface	O
of	O
the	O
N	O
protein	B-CHED
.	O

Four	O
polymorphisms	O
(	O
K267E	O
,	O
K267N	O
,	O
A291P	O
and	O
346	O
-	O
348	O
)	O
strongly	O
reduced	O
binding	O
of	O
MERS	O
-	O
CoV	O
S	O
to	O
DPP4	O
and	O
S	O
protein	B-CHED
-	O
driven	O
host	O
cell	O
entry	O
,	O
as	O
determined	O
using	O
soluble	O
S	O
protein	B-CHED
and	O
S	O
protein	B-CHED
bearing	O
rhabdoviral	O
vectors	O
,	O
respectively	O
.	O

Nevertheless	O
,	O
there	O
is	O
the	O
need	O
for	O
urgent	O
development	O
of	O
specific	O
antiviral	B-CHED
drugs	I-CHED
.	O

In	O
the	O
search	O
for	O
new	O
RNA	O
virus	O
inhibitors	B-CHED
,	O
we	O
recently	O
identified	O
a	O
series	O
of	O
variously	O
substituted	O
5	O
,	O
6	O
-	O
dichloro	O
-	O
1	O
(	O
2	O
)-	O
phenyl	B-CHED
-	O
1	O
(	O
2	O
)	O
H	O
-	O
benzo	O
[	O
d	O
][	O
1	O
,	O
2	O
,	O
3	O
]	O
triazole	B-CHED
derivatives	O
active	O
against	O
the	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
HRSV	O
).	O

The	O
2019	O
-	O
nCoV	O
infection	O
caused	O
clusters	B-CHED
of	O
severe	O
respiratory	O
illness	O
similar	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
was	O
associated	O
with	O
ICU	O
admission	O
and	O
high	O
mortality	O
.	O

Phylogenetic	O
and	O
single	O
amino	B-CHED
acid	I-CHED
polymorphism	O
analyses	O
showed	O
that	O
this	O
outbreak	O
was	O
associated	O
with	O
two	O
subgenotypes	O
(	O
C3	O
and	O
B	O
)	O
of	O
HCoV	O
-	O
NL63	O
.	O

Nucleic	B-CHED
acids	I-CHED
of	O
the	O
BAL	B-CHED
were	O
extracted	O
and	O
subjected	O
to	O
next	O
-	O
generation	O
sequencing	O
.	O

Public	O
Health	O
England	O
(	O
PHE	B-CHED
)	O
Manchester	O
is	O
one	O
of	O
the	O
two	O
PHE	B-CHED
centres	O
in	O
the	O
UK	O
that	O
perform	O
testing	O
for	O
MERS	O
-	O
CoV	O
.	O
The	O
results	O
of	O
the	O
PHE	B-CHED
Manchester	O
MERS	O
surveillance	O
from	O
2012	O
to	O
2019	O
are	O
presented	O
in	O
this	O
report	O
.	O

Retrospective	O
data	O
were	O
collected	O
for	O
returning	O
travellers	O
from	O
the	O
Middle	O
East	O
fitting	O
the	O
PHE	B-CHED
MERS	O
case	O
definition	O
.	O

Although	O
no	O
cases	O
of	O
MERS	O
were	O
identified	O
,	O
the	O
majority	O
of	O
patients	O
had	O
Influenza	O
infection	O
for	O
which	O
oseltamivir	B-CHED
treatment	O
was	O
indicated	O
and	O
isolation	O
warranted	O
.	O

TITLE	O
:	O
Model	O
-	O
based	O
PEEP	B-CHED
titration	O
versus	O
standard	O
practice	O
in	O
mechanical	O
ventilation	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

The	O
Clinical	O
utilisation	O
of	O
respiratory	O
elastance	O
(	O
CURE	O
)	O
trial	O
is	O
a	O
two	O
-	O
arm	O
,	O
randomised	O
controlled	O
trial	O
(	O
RCT	O
)	O
investigating	O
the	O
performance	O
of	O
PEEP	B-CHED
selected	O
at	O
an	O
objective	O
,	O
model	O
-	O
based	O
minimal	O
respiratory	O
system	O
elastance	O
in	O
patients	O
with	O
ARDS	O
.	O

The	O
primary	O
outcome	O
is	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
ratio	O
of	O
arterial	O
blood	O
oxygenation	O
to	O
the	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
over	O
time	O
.	O

For	O
example	O
,	O
some	O
bats	O
have	O
an	O
antiviral	B-CHED
immune	O
response	O
called	O
the	O
interferon	O
pathway	O
perpetually	O
switched	O
on	O
.	O

TITLE	O
:	O
Isolated	O
Pauci	O
-	O
Immune	O
Pulmonary	O
Capillaritis	O
Associated	O
with	O
Hydrocarbon	B-CHED
Inhalation	O
and	O
Marijuana	O
Smoking	O
:	O
An	O
Unusual	O
Case	O
of	O
Severe	O
Hypoxemia	O
.	O

Median	O
(	O
IQR	O
)	O
optimal	O
PEEP	B-CHED
decreased	O
from	O
14	O
(	O
12	O
-	O
16	O
)	O
to	O
10	O
(	O
8	O
-	O
14	O
)	O
cmH	B-CHED
CONCLUSIONS	O
:	O
Although	O
baseline	O
tidal	O
volume	O
distribution	O
on	O
EIT	O
may	O
predict	O
static	O
compliance	O
improvement	O
after	O
PP	O
on	O
ECMO	O
,	O
our	O
results	O
support	O
physiological	O
benefits	O
of	O
PP	O
in	O
all	O
ECMO	O
patients	O
,	O
by	O
modifying	O
lung	O
mechanics	O
and	O
potentially	O
reducing	O
VILI	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
LPS	B-CHED
-	O
induced	O
Nox2	O
activation	O
by	O
VAS2870	O
protects	O
alveolar	O
epithelial	O
cells	O
through	O
eliminating	O
ROS	B-CHED
and	O
restoring	O
tight	O
junctions	O
.	O

According	O
to	O
current	O
observations	O
,	O
2019	O
-	O
nCoV	O
is	O
weaker	O
than	O
SARS	O
in	O
pathogenesis	O
,	O
but	O
has	O
stronger	O
transmission	O
competence	O
;	O
it	O
'	O
s	O
mechanism	O
of	O
cross	O
-	O
species	O
spread	O
might	O
be	O
related	O
with	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
	O
(	O
ACE2	O
),	O
which	O
is	O
consistent	O
with	O
the	O
receptor	O
SARS	O
-	O
CoV	O
.	O
After	O
the	O
outbreak	O
of	O
this	O
disease	O
,	O
Chinese	O
scientists	O
invested	O
a	O
lot	O
of	O
energy	O
to	O
carry	O
out	O
research	O
by	O
developing	O
rapid	O
diagnostic	O
reagents	B-CHED
,	O
identifying	O
the	O
characters	O
of	O
the	O
pathogen	O
,	O
screening	O
out	O
clinical	O
drugs	O
that	O
may	O
inhibit	O
the	O
virus	O
,	O
and	O
are	O
rapidly	O
developing	O
vaccines	O
.	O

This	O
guideline	O
includes	O
the	O
guideline	O
methodology	O
,	O
epidemiological	O
characteristics	O
,	O
disease	O
screening	O
and	O
population	O
prevention	O
,	O
diagnosis	O
,	O
treatment	O
and	O
control	O
(	O
including	O
traditional	O
Chinese	O
Medicine	B-CHED
),	O
nosocomial	O
infection	O
prevention	O
and	O
control	O
,	O
and	O
disease	O
nursing	O
of	O
the	O
2019	O
-	O
nCoV	O
.	O
Moreover	O
,	O
we	O
also	O
provide	O
a	O
whole	O
process	O
of	O
a	O
successful	O
treatment	O
case	O
of	O
the	O
severe	O
2019	O
-	O
nCoV	O
infected	O
pneumonia	O
and	O
experience	O
and	O
lessons	O
of	O
hospital	O
rescue	O
for	O
2019	O
-	O
nCoV	O
infections	O
.	O

On	O
July	O
7	O
,	O
2018	O
,	O
a	O
case	O
of	O
ARDS	O
caused	O
by	O
ammonia	B-CHED
inhalation	O
was	O
admitted	O
to	O
the	O
emergency	O
ICU	O
of	O
the	O
First	O
Affiliated	O
Hospital	O
of	O
Zhengzhou	O
University	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
whether	O
symptomatic	O
respiratory	O
viral	O
infections	O
after	O
lung	O
transplantation	O
induce	O
circulating	O
exosomes	O
that	O
contain	O
lung	O
-	O
associated	O
self	O
-	O
antigens	B-CHED
and	O
assessed	O
whether	O
these	O
exosomes	O
activate	O
immune	O
responses	O
to	O
self	O
-	O
antigens	B-CHED
.	O

Mice	O
immunized	O
with	O
exosomes	O
from	O
recipients	O
with	O
respiratory	O
viral	O
infections	O
developed	O
immune	O
responses	O
to	O
self	O
-	O
antigens	B-CHED
,	O
fibrosis	O
,	O
small	O
airway	O
occlusion	O
,	O
and	O
significant	O
cellular	O
infiltration	O
;	O
mice	O
immunized	O
with	O
exosomes	O
from	O
controls	O
did	O
not	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Systemic	O
corticosteroid	B-CHED
treatment	O
did	O
not	O
show	O
significant	O
benefits	O
.	O

TITLE	O
:	O
	O
-	O
Ketoamides	O
as	O
Broad	O
-	O
Spectrum	O
Inhibitors	B-CHED
of	O
Coronavirus	O
and	O
Enterovirus	O
Replication	O
:	O
Structure	O
-	O
Based	O
Design	O
,	O
Synthesis	O
,	O
and	O
Activity	O
Assessment	O
.	O

Because	O
of	O
their	O
unique	O
specificity	O
and	O
essential	O
role	O
in	O
viral	O
polyprotein	O
processing	O
,	O
these	O
proteases	O
are	O
suitable	O
targets	O
for	O
the	O
development	O
of	O
antiviral	B-CHED
drugs	I-CHED
.	O

Six	O
crystal	O
structures	O
of	O
protease	O
-	O
inhibitor	B-CHED
complexes	O
were	O
determined	O
as	O
part	O
of	O
this	O
study	O
.	O

The	O
best	O
near	O
-	O
equipotent	O
inhibitors	B-CHED
,	O

Several	O
CoV	O
strains	O
have	O
spike	O
proteins	B-CHED
with	O
two	O
receptor	O
-	O
binding	O
domains	O
,	O
an	O
S1A	O
that	O
engages	O
host	O
sialic	B-CHED
acids	I-CHED
and	O
an	O
S1B	O
that	O
recognizes	O
host	O
transmembrane	O
proteins	B-CHED
.	O

Focusing	O
on	O
two	O
betacoronaviruses	O
,	O
murine	O
JHM	O
-	O
CoV	O
and	O
human	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
we	O
found	O
that	O
virus	O
particle	O
binding	O
to	O
cells	O
was	O
mediated	O
by	O
sialic	B-CHED
acids	I-CHED
;	O
however	O
,	O
the	O
transmembrane	O
protein	B-CHED
receptors	O
were	O
required	O
for	O
a	O
subsequent	O
virus	O
infection	O
.	O

Age	O
,	O
viral	O
load	O
,	O
lung	O
injury	O
score	O
,	O
and	O
blood	O
biochemistry	O
indexes	O
,	O
albumin	O
(	O
ALB	O
),	O
CRP	O
,	O
LDH	O
,	O
LYM	O
(%),	O
LYM	O
,	O
and	O
NEU	B-CHED
(%),	O
may	O
be	O
predictors	O
of	O
disease	O
severity	O
.	O

Further	O
investigation	O
revealed	O
these	O
cases	O
to	O
result	O
from	O
infection	O
with	O
a	O
newly	O
identified	O
coronavirus	O
,	O
termed	O
the	O
2019	O
-	O
nCoV	O
.	O
The	O
infection	O
moved	O
rapidly	O
through	O
China	O
,	O
spread	O
to	O
Thailand	O
and	O
Japan	O
,	O
extended	O
into	O
adjacent	O
countries	O
through	O
infected	O
persons	O
travelling	O
by	O
air	B-CHED
,	O
eventually	O
reaching	O
multiple	O
countries	O
and	O
continents	O
.	O

Some	O
patients	O
who	O
received	O
rib	B-CHED
fixation	O
with	O
VATS	O
were	O
enrolled	O
as	O
group	O
1	O
,	O
and	O
the	O
others	O
who	O
received	O
only	O
VATS	O
were	O
designated	O
as	O
group	O
2	O
.	O

Here	O
,	O
we	O
have	O
conducted	O
an	O
online	O
search	O
for	O
all	O
treatment	O
options	O
related	O
to	O
coronavirus	O
infections	O
as	O
well	O
as	O
some	O
RNA	O
-	O
virus	O
infection	O
and	O
we	O
have	O
found	O
that	O
general	O
treatments	O
,	O
coronavirus	O
-	O
specific	O
treatments	O
,	O
and	O
antiviral	B-CHED
treatments	O
should	O
be	O
useful	O
in	O
fighting	O
COVID	O
-	O
19	O
.	O

After	O
multiple	O
antibiotic	B-CHED
courses	O
,	O
he	O
developed	O
acute	O
kidney	O
injury	O
,	O
a	O
hemophagocytic	O
syndrome	O
,	O
and	O
eventually	O
respiratory	O
failure	O
,	O
which	O
led	O
to	O
his	O
death	O
a	O
year	O
later	O
.	O

ABSTRACT	O
:	O
Through	O
literature	O
review	O
and	O
group	O
discussion	O
,	O
Special	O
Expert	O
Group	O
for	O
Control	O
of	O
the	O
Epidemic	O
of	O
Novel	O
Coronavirus	O
Pneumonia	O
of	O
the	O
Chinese	O
Preventive	O
Medicine	B-CHED
Association	O
formulated	O
an	O
update	O
on	O
the	O
epidemiological	O
characteristics	O
of	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	O
).	O

TITLE	O
:	O
2019_nCoV	O
/	O
SARS	O
-	O
CoV	O
-	O
2	O
:	O
rapid	O
classification	O
of	O
betacoronaviruses	O
and	O
identification	O
of	O
Traditional	O
Chinese	O
Medicine	B-CHED
as	O
potential	O
origin	O
of	O
zoonotic	O
coronaviruses	O
.	O

Chinese	O
bat	O
species	O
with	O
commercial	O
value	O
were	O
identified	O
as	O
natural	O
reservoirs	O
of	O
coronaviruses	O
and	O
are	O
used	O
in	O
Traditional	O
Chinese	O
Medicine	B-CHED
.	O

Increased	O
ACE	O
and	O
Ang	B-CHED
II	I-CHED
are	O
poor	O
prognostic	O
factors	O
for	O
severe	O
pneumonia	O
.	O

TITLE	O
:	O
Can	O
Chinese	O
Medicine	B-CHED
Be	O
Used	O
for	O
Prevention	O
of	O
Corona	B-CHED
Virus	O
Disease	O
2019	O
(	O
COVID	O
-	O
19	O
)?	O

An	O
in	O
ovo	O
model	O
was	O
employed	O
to	O
study	O
the	O
antiviral	B-CHED
activity	O
of	O
TLR	O
ligands	O
(	O
Pam3CSK4	O
,	O
LPS	B-CHED
and	O
CpG	O
ODN	O
)	O
on	O
replication	O
of	O
IBV	O
.	O

Further	O
,	O
the	O
mechanism	O
involved	O
in	O
the	O
TLR	O
-	O
mediated	O
antiviral	B-CHED
response	O
in	O
chorioallantoic	O
membrane	O
(	O
CAM	O
)	O
of	O
ECEs	O
was	O
investigated	O
.	O

TITLE	O
:	O
Important	O
roles	O
of	O
dietary	O
taurine	B-CHED
,	O
creatine	B-CHED
,	O
carnosine	B-CHED
,	O
anserine	B-CHED
and	O
4	B-CHED
-	I-CHED
hydroxyproline	I-CHED
in	O
human	O
nutrition	O
and	O
health	O
.	O

Recommending	O
laparoscopy	O
-	O
assisted	O
radical	B-CHED
surgery	O
for	O
colorectal	O
cancer	O
patients	O
.	O

Neoadjuvant	O
therapy	O
is	O
highly	O
recommended	O
for	O
gastrointestinal	O
cancer	O
at	O
advanced	O
stages	O
that	O
meet	O
the	O
indications	O
of	O
NCCN	B-CHED
guideline	O
(	O
gastric	O
cancer	O
T	O
stage	O
	O
2	O
/	O
rectal	O
cancer	O
T	O
stage	O
	O
3	O
/	O
unresectable	O
colon	O
cancer	O
).	O

Here	O
we	O
found	O
that	O
treating	O
the	O
patients	O
diagnosed	O
as	O
novel	O
coronavirus	O
pneumonia	O
with	O
chloroquine	B-CHED
might	O
improve	O
the	O
success	O
rate	O
of	O
treatment	O
,	O
shorten	O
hospital	O
stay	O
and	O
improve	O
patient	O
outcome	O
.	O

In	O
order	O
to	O
guide	O
and	O
regulate	O
the	O
use	O
of	O
chloroquine	B-CHED
in	O
patients	O
with	O
novel	O
coronavirus	O
pneumonia	O
,	O
the	O
multicenter	O
collaboration	O
group	O
of	O
Department	O
of	O
Science	O
and	O
Technology	O
of	O
Guangdong	O
Province	O
and	O
Health	O
Commission	O
of	O
Guangdong	O
Province	O
for	O
chloroquine	B-CHED
in	O
the	O
treatment	O
of	O
novel	O
coronavirus	O
pneumonia	O
developed	O
this	O
expert	O
consensus	O
after	O
extensive	O
discussion	O
.	O

The	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
is	O
a	O
key	O
target	O
for	O
vaccines	O
,	O
therapeutic	O
antibodies	O
,	O
and	O
diagnostics	O
.	O

Significantly	O
higher	O
levels	O
of	O
D	O
-	O
dimer	O
,	O
C	O
-	O
reactive	O
protein	B-CHED
,	O
and	O
procalcitonin	O
were	O
associated	O
with	O
severe	O
patients	O
compared	O
to	O
nonsevere	O
patients	O
(	O
all	O
P	O
<	O
.	O
001	O
).	O

Those	O
recommendations	O
include	O
:	O
(	O
1	O
)	O
Standard	O
prevention	O
and	O
protection	O
,	O
and	O
patient	O
isolation	O
;	O
(	O
2	O
)	O
Patient	O
wearing	O
mask	O
during	O
HFNC	O
treatment	O
;	O
(	O
3	O
)	O
Using	O
dual	O
limb	O
ventilator	O
with	O
filters	O
placed	O
at	O
the	O
ventilator	O
outlets	O
,	O
or	O
using	O
heat	O
-	O
moisture	O
exchanger	O
(	O
HME	O
)	O
instead	O
of	O
heated	O
humidification	O
in	O
single	O
limb	O
ventilator	O
with	O
HME	O
placed	O
between	O
exhalation	O
port	O
and	O
mask	O
;	O
avoid	O
using	O
mask	O
with	O
exhalation	O
port	O
on	O
the	O
mask	O
;	O
(	O
4	O
)	O
Placing	O
filter	O
between	O
resuscitator	O
and	O
mask	O
or	O
artificial	O
airway	O
;	O
(	O
5	O
)	O
For	O
spontaneous	O
breathing	O
patients	O
,	O
placing	O
mask	O
for	O
patients	O
during	O
bronchoscopy	O
examination	O
;	O
for	O
patients	O
receiving	O
noninvasive	O
ventilation	O
,	O
using	O
the	O
special	O
mask	O
with	O
bronchoscopy	O
port	O
to	O
perform	O
bronchoscopy	O
;	O
(	O
6	O
)	O
Using	O
sedation	O
and	O
paralytics	O
during	O
intubation	O
,	O
cuff	O
pressure	O
should	O
be	O
maintained	O
between	O
25	O
-	O
30	O
cmH	B-CHED
(	O
2	O
)	O
O	O
;	O
(	O
7	O
)	O
In	O
-	O
line	O
suction	O
catheter	O
is	O
recommended	O
and	O
it	O
can	O
be	O
used	O
for	O
one	O
week	O
;	O
(	O
8	O
)	O
Dual	O
-	O
limb	O
heated	O
wire	O
circuits	O
are	O
recommended	O
and	O
only	O
changed	O
with	O
visible	O
soiled	O
;	O
(	O
9	O
.	O

A	O
point	O
-	O
of	O
-	O
care	O
ultrasound	O
(	O
POCUS	O
)	O
examination	O
showed	O
increased	O
extravascular	O
lung	O
water	B-CHED
retention	O
during	O
a	O
hypovolemic	O
state	O
.	O

TITLE	O
:	O
Structure	O
analysis	O
of	O
the	O
receptor	O
binding	O
of	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
2019	O
-	O
nCoV	O
is	O
a	O
newly	O
identified	O
coronavirus	O
with	O
high	O
similarity	O
to	O
SARS	O
-	O
CoV	O
.	O
We	O
performed	O
a	O
structural	O
analysis	O
of	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
spike	O
glycoprotein	B-CHED
responsible	O
for	O
entry	O
of	O
coronaviruses	O
into	O
host	O
cells	O
.	O

Position	O
723	O
in	O
the	O
COVID	O
-	O
2019	O
has	O
a	O
serine	B-CHED
instead	O
a	O
glycine	B-CHED
residue	I-CHED
,	O
while	O
at	O
aminoacidic	O
position	O
1010	O
a	O
proline	O
instead	O
an	O
isoleucine	B-CHED
.	O

To	O
date	O
,	O
there	O
are	O
no	O
clinically	O
approved	O
vaccines	O
or	O
antiviral	B-CHED
drugs	I-CHED
available	O
for	O
these	O
human	O
coronavirus	O
infections	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
chest	O
computed	O
tomography	O
(	O
CT	O
)	O
findings	O
in	O
patients	O
with	O
confirmed	O
corona	B-CHED
virus	O
disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
and	O
to	O
evaluate	O
its	O
relationship	O
with	O
clinical	O
features	O
.	O

TITLE	O
:	O
Is	O
COVID	O
-	O
19	O
receiving	O
ADE	B-CHED
from	O
other	O
coronaviruses	O
?	O

Long	O
-	O
acting	O
muscarinic	B-CHED
antagonists	I-CHED
and	O
	O
Primary	O
human	O
nasal	O
(	O
HNE	B-CHED
)	O
and	O
tracheal	O
(	O
HTE	B-CHED
)	O
epithelial	O
cell	O
cultures	O
were	O
infected	O
with	O
HCoV	O
-	O
229E	O
.	O

Pretreatment	O
with	O
formoterol	B-CHED
increased	O
cAMP	B-CHED
levels	O
and	O
treatment	O
with	O
cAMP	B-CHED
decreased	O
viral	O
titers	O
,	O
CD13	O
expression	O
,	O
and	O
the	O
fluorescence	O
intensity	O
of	O
acidic	O
endosomes	O
.	O

RDV	O
is	O
a	O
nucleotide	B-CHED
analog	O
inhibitor	B-CHED
of	O
RNA	O
-	O
dependent	O
RNA	O
polymerases	O
(	O
RdRps	O
).	O

The	O
additional	O
three	O
nucleotides	B-CHED
may	O
protect	O
the	O
inhibitor	B-CHED
from	O
excision	O
by	O
the	O
viral	O
3	O
'-	O
5	O
'	O
exonuclease	O
activity	O
.	O

RNA	O
-	O
seq	O
profiling	O
data	O
of	O
13	O
organ	O
types	O
with	O
para	B-CHED
-	O
carcinoma	O
normal	O
tissues	O
from	O
TCGA	O
and	O
14	O
organ	O
types	O
with	O
normal	O
tissues	O
from	O
FANTOM5	O
CAGE	O
were	O
analyzed	O
in	O
order	O
to	O
explore	O
and	O
validate	O
the	O
expression	O
of	O
ACE2	O
on	O
the	O
mucosa	O
of	O
oral	O
cavity	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
dynamic	O
changes	O
of	O
chest	O
CT	O
images	O
of	O
patients	O
with	O
corona	B-CHED
virus	O
disease	O
-	O
19	O
(	O
COVID	O
-	O
19	O
).	O

The	O
""""	O
Four	O
-	O
Anti	O
and	O
Two	O
-	O
Balance	B-CHED
""""	O
strategy	O
included	O
antivirus	O
,	O
anti	O
-	O
shock	O
,	O
anti	O
-	O
hyoxemia	O
,	O
anti	O
-	O
secondary	O
infection	O
,	O
and	O
maintaining	O
of	O
water	B-CHED
,	O
electrolyte	O
and	O
acid	O
base	O
balance	B-CHED
and	O
microecological	O
balance	B-CHED
.	O

Conservative	O
oxygen	B-CHED
therapy	O
was	O
preferred	O
and	O
noninvasive	O
ventilation	O
was	O
not	O
recommended	O
.	O

CONCLUSIONS	O
:	O
The	O
median	O
with	O
95	O
%	O
CI	O
of	O
R0	O
of	O
COVID	O
-	O
19	O
was	O
about	O
2	O
.	O
28	O
(	O
2	O
.	O
06	O
-	O
2	O
.	O
52	O
)	O
during	O
the	O
early	O
stage	O
experienced	O
on	O
the	O
Diamond	B-CHED
Princess	O
cruise	O
ship	O
.	O

Many	O
nanoparticles	B-CHED
(	O
NPs	O
)	O
can	O
inhibit	O
the	O
biological	O
functions	O
of	O
tumours	O
by	O
modulating	O
tumour	O
-	O
associated	O
inflammation	O
,	O
which	O
provokes	O
angiogenesis	O
and	O
tumour	O
growth	O
.	O

TITLE	O
:	O
Structural	O
Basis	O
for	O
Inhibiting	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Replication	O
with	O
the	O
3C	O
-	O
Like	O
Protease	B-CHED
Inhibitor	I-CHED
GC376	O
.	O

In	O
pan	B-CHED
-	O
Europe	O
,	O
UK	O
,	O
France	O
,	O
Russia	O
,	O
Germany	O
and	O
Italy	O
;	O
in	O
North	O
America	O
,	O
USA	O
and	O
Canada	O
;	O
in	O
Oceania	O
,	O
Australia	O
had	O
high	O
risk	O
,	O
all	O
of	O
them	O
reported	O
at	O
least	O
one	O
case	O
.	O

The	O
temperature	O
profile	O
of	O
NPA	B-CHED
exhibits	O
30	O
cycles	O
between	O
98	O
and	O
60	O
	O
C	O
for	O
a	O
total	O
of	O
3	O
min	O
and	O
30	O
s	O
during	O
the	O
cyclic	O
excitation	O
of	O
white	O
LED	O
light	O
.	O

During	O
the	O
next	O
two	O
months	O
,	O
it	O
moved	O
rapidly	O
throughout	O
China	O
and	O
spread	O
to	O
multiple	O
countries	O
through	O
infected	O
persons	O
travelling	O
by	O
air	B-CHED
.	O

Clinicians	O
should	O
be	O
cautious	O
while	O
using	O
corticosteroid	B-CHED
treatment	O
in	O
this	O
patient	O
group	O
.	O

ABSTRACT	O
:	O
We	O
aim	O
to	O
summarize	O
reliable	O
evidence	O
of	O
evidence	O
-	O
based	O
medicine	B-CHED
for	O
the	O
treatment	O
and	O
prevention	O
of	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
2	O
(	O
SARS	O
-	O
CoV	O
-	O
2	O
)	O
by	O
analyzing	O
all	O
the	O
published	O
studies	O
on	O
the	O
clinical	O
characteristics	O
of	O
patients	O
with	O
SARS	O
-	O
CoV	O
-	O
2	O
.	O

TITLE	O
:	O
Development	O
of	O
epitope	B-CHED
-	O
based	O
peptide	B-CHED
vaccine	O
against	O
novel	O
coronavirus	O
2019	O
(	O
SARS	O
-	O
COV	O
-	O
2	O
):	O
Immunoinformatics	O
approach	O
.	O

https	O
://	O
www	O
.	O
genomedetective	O
.	O
com	B-CHED
/	O
app	B-CHED
/	O
typingtool	O
/	O
cov	O
.	O

9	O
patients	O
were	O
unconfirmed	O
until	O
a	O
third	O
-	O
time	O
nucleic	B-CHED
acid	I-CHED
test	O
.	O

Notably	O
,	O
infected	O
patients	O
may	O
be	O
falsely	O
excluded	O
based	O
on	O
two	O
consecutively	O
negative	O
respiratory	O
pathogenic	O
nucleic	B-CHED
acid	I-CHED
test	O
results	O
.	O

Mild	O
patients	O
had	O
low	O
to	O
moderate	O
fever	O
(<	O
39	O
.	O
1	O
	O
C	O
),	O
49	O
(	O
98	O
%)	O
patients	O
had	O
normal	O
or	O
slightly	O
reduced	O
leukocyte	O
count	O
,	O
14	O
(	O
28	O
%)	O
had	O
decreased	O
counts	O
of	O
lymphocytes	O
,	O
and	O
26	O
(	O
52	O
%)	O
patients	O
had	O
increased	O
C	O
-	O
reactive	O
protein	B-CHED
.	O

Therefore	O
,	O
we	O
developed	O
an	O
online	O
follow	O
-	O
up	O
program	O
for	O
convenient	O
monitoring	O
of	O
bilirubin	B-CHED
level	O
of	O
newborns	O
that	O
is	O
based	O
on	O
our	O
practical	O
experiences	O
.	O

It	O
might	O
be	O
better	O
to	O
make	O
a	O
diagnosis	O
combining	O
the	O
computed	O
tomography	O
scans	O
and	O
nucleic	B-CHED
acid	I-CHED
detection	O
.	O

At	O
90	O
days	O
,	O
the	O
overall	O
mortality	O
rate	O
was	O
higher	O
in	O
the	O
corticosteroid	B-CHED
-	O
treated	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
59	O
.	O
2	O
%	O
vs	O
.	O
48	O
.	O
4	O
%,	O
p	O
=	O
0	O
.	O
021	O
).	O

However	O
,	O
on	O
propensity	O
score	O
matching	O
,	O
corticosteroid	B-CHED
therapy	O
was	O
not	O
associated	O
with	O
a	O
higher	O
28	O
-	O
day	O
mortality	O
rate	O
(	O
odds	O
ratio	O
,	O
1	O
.	O
031	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
657	O
to	O
1	O
.	O
618	O
;	O
p	O
=	O
0	O
.	O
895	O
)	O
and	O
90	O
days	O
(	O
odds	O
ratio	O
,	O
1	O
.	O
435	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
877	O
to	O
2	O
.	O
348	O
;	O
p	O
=	O
0	O
.	O
151	O
).	O

Using	O
data	O
obtained	O
from	O
similar	O
coronaviruses	O
,	O
e	O
.	O
g	O
.	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
),	O
experts	O
are	O
confident	O
that	O
70	O
%	O
ethanol	B-CHED
and	O
0	O
.	O
1	O
%	O
sodium	O
hypochlorite	B-CHED
should	O
inactivate	O
the	O
virus	O
.	O

Formalin	B-CHED
fixation	O
and	O
heating	O
samples	O
to	O
56oC	O
,	O
as	O
used	O
in	O
routine	O
tissue	O
processing	O
,	O
were	O
found	O
to	O
inactivate	O
several	O
coronaviruses	O
and	O
it	O
is	O
believed	O
that	O
2019	O
-	O
nCoV	O
would	O
be	O
similarly	O
affected	O
.	O

Here	O
,	O
we	O
summarize	O
our	O
current	O
understanding	O
of	O
antiviral	B-CHED
immune	O
responses	O
in	O
bats	O
and	O
discuss	O
their	O
ability	O
to	O
co	O
-	O
exist	O
with	O
emerging	O
viruses	O
that	O
cause	O
serious	O
disease	O
in	O
other	O
mammals	O
.	O

The	O
proposal	O
is	O
a	O
biologic	O
that	O
blocks	O
2019	O
-	O
nCoV	O
entry	O
using	O
a	O
soluble	O
version	O
of	O
the	O
viral	O
receptor	O
,	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
fused	O
to	O
an	O
immunoglobulin	O
Fc	O
domain	O
,	O
providing	O
a	O
neutralizing	O
antibody	O
with	O
maximal	O
breath	O
to	O
avoid	O
any	O
viral	O
escape	O
,	O
while	O
also	O
helping	O
to	O
recruit	O
the	O
immune	O
system	O
to	O
build	O
lasting	O
immunity	O
.	O

The	O
duration	O
of	O
viral	O
RNA	O
detection	O
from	O
oropharyngeal	O
swabs	O
and	O
fecal	O
samples	O
in	O
the	O
glucocorticoid	B-CHED
treatment	O
group	O
was	O
longer	O
than	O
that	O
in	O
the	O
non	O
-	O
glucocorticoid	B-CHED
treatment	O
group	O
(	O
15	O
days	O
vs	O
.	O
8	O
.	O
0	O
days	O
,	O
respectively	O
;	O
t	O
=	O
2	O
.	O
550	O
,	O
P	O
=	O
0	O
.	O
013	O
)	O
and	O
the	O
duration	O
of	O
viral	O
RNA	O
detection	O
in	O
fecal	O
samples	O
in	O
the	O
glucocorticoid	B-CHED
treatment	O
group	O
was	O
longer	O
than	O
that	O
in	O
the	O
non	O
-	O
glucocorticoid	B-CHED
treatment	O
group	O
(	O
20	O
days	O
vs	O
.	O
11	O
days	O
,	O
respectively	O
;	O
t	O
=	O
4	O
.	O
631	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Because	O
of	O
the	O
delayed	O
clearance	O
of	O
viral	O
RNA	O
in	O
the	O
glucocorticoid	B-CHED
treatment	O
group	O
,	O
glucocorticoids	B-CHED
are	O
not	O
recommended	O
in	O
the	O
treatment	O
of	O
COVID	O
-	O
19	O
,	O
especially	O
for	O
mild	O
disease	O
.	O

Several	O
factors	O
that	O
led	O
to	O
the	O
progression	O
of	O
COVID	O
-	O
19	O
pneumonia	O
were	O
identified	O
,	O
including	O
age	O
,	O
history	O
of	O
smoking	O
,	O
maximum	O
body	O
temperature	O
on	O
admission	O
,	O
respiratory	O
failure	O
,	O
albumin	O
,	O
C	O
-	O
reactive	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
time	O
-	O
dependent	O
risk	O
of	O
infection	O
on	O
a	O
cruise	O
ship	O
,	O
the	O
Diamond	B-CHED
Princess	O
,	O
I	O
estimated	O
the	O
incidence	O
of	O
infection	O
with	O
novel	O
coronavirus	O
(	O
COVID	O
-	O
19	O
).	O

Third	O
,	O
universal	O
masking	O
,	O
hand	O
hygiene	O
,	O
and	O
appropriate	O
use	O
of	O
personal	O
protective	O
equipment	O
(	O
PPE	B-CHED
)	O
were	O
promoted	O
.	O

Through	O
a	O
series	O
of	O
drug	O
repurposing	O
screening	O
campaigns	O
,	O
niclosamide	O
,	O
an	O
FDA	O
-	O
approved	O
anthelminthic	B-CHED
drug	I-CHED
,	O
was	O
found	O
to	O
be	O
effective	O
against	O
various	O
viral	O
infections	O
with	O
nanomolar	O
to	O
micromolar	O
potency	O
such	O
as	O
SARS	O
-	O
CoV	O
,	O
MERS	O
-	O
CoV	O
,	O
ZIKV	O
,	O
HCV	O
,	O
and	O
human	O
adenovirus	O
,	O
indicating	O
its	O
potential	O
as	O
an	O
antiviral	B-CHED
agent	I-CHED
.	O

Dexamethasone	B-CHED
,	O
a	O
positive	O
reference	O
standard	O
as	O
expected	O
exhibited	O
potent	O
anti	O
-	O
inflammatory	O
activity	O
.	O

The	O
2019	O
-	O
nCoV	O
was	O
different	O
from	O
SARS	O
-	O
CoV	O
,	O
but	O
shared	O
the	O
same	O
host	O
receptor	O
the	O
human	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

This	O
idea	O
is	O
based	O
on	O
observations	O
that	O
the	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
very	O
likely	O
serves	O
as	O
the	O
binding	O
site	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
the	O
strain	O
implicated	O
in	O
the	O
current	O
COVID	O
-	O
19	O
epidemic	O
,	O
similarly	O
to	O
strain	O
SARS	O
-	O
CoV	O
implicated	O
in	O
the	O
2002	O
-	O
2003	O
SARS	O
epidemic	O
.	O

TITLE	O
:	O
[	O
Expert	O
consensus	O
on	O
Pulmonary	O
Function	O
Testing	O
during	O
the	O
epidemic	O
of	O
Corona	B-CHED
Virus	O
Disease	O
2019	O
].	O

ABSTRACT	O
:	O
Corona	B-CHED
virus	O
disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
is	O
mainly	O
transmitted	O
by	O
respiratory	O
droplets	O
and	O
close	O
contact	O
.	O

Here	O
we	O
present	O
cryo	O
-	O
EM	O
structures	O
of	O
full	O
-	O
length	O
human	O
ACE2	O
,	O
in	O
the	O
presence	O
of	O
a	O
neutral	O
amino	B-CHED
acid	I-CHED
transporter	O
B	O

The	O
9	O
healthcare	O
workers	O
were	O
protected	O
under	O
the	O
Personal	O
Protective	O
Equipment	O
(	O
PPE	B-CHED
)	O
with	O
positive	O
pressure	O
protective	O
hood	O
.	O

The	O
PPE	B-CHED
with	O
positive	O
pressure	O
protective	O
hood	O
should	O
be	O
needed	O
to	O
perform	O
bronchoscope	O
-	O
guided	O
endotracheal	O
intubation	O
in	O
patients	O
with	O
COVID	O
-	O
19	O
,	O
it	O
could	O
strengthen	O
to	O
protect	O
healthcare	O
workers	O
from	O
virus	O
exposure	O
.	O

The	O
mean	O
change	O
in	O
Pao	B-CHED
Fixed	O
-	O
dose	O
iEPO	O
was	O
comparable	O
to	O
iNO	O
in	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
for	O
oxygenation	O
and	O
ventilation	O
parameters	O
as	O
well	O
as	O
clinical	O
outcomes	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
SARS	O
-	O
CoV	O
-	O
2	O
uses	O
the	O
SARS	O
-	O
CoV	O
receptor	O
ACE2	O
for	O
entry	O
and	O
the	O
serine	B-CHED
protease	O
TMPRSS2	O
for	O
S	O
protein	B-CHED
priming	O
.	O

Asymptomatic	O
carriers	O
were	O
laboratory	O
-	O
confirmed	O
positive	O
for	O
the	O
COVID	O
-	O
19	O
virus	O
by	O
testing	O
the	O
nucleic	B-CHED
acid	I-CHED
of	O
the	O
pharyngeal	O
swab	O
samples	O
.	O

Further	O
isolation	O
recommendation	O
and	O
continuous	O
nucleic	B-CHED
acid	I-CHED
tests	O
may	O
also	O
be	O
recommended	O
to	O
the	O
patients	O
discharged	O
.	O

The	O
scientific	O
community	O
should	O
consider	O
this	O
information	O
in	O
light	O
of	O
previous	O
experiments	O
with	O
chloroquine	B-CHED
in	O
the	O
field	O
of	O
antiviral	B-CHED
research	O
.	O

ABSTRACT	O
:	O
The	O
current	O
corona	B-CHED
virus	O
disease	O
2019	O
outbreak	O
caused	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
2	O
started	O
in	O
Wuhan	O
,	O
China	O
in	O
December	O
2019	O
and	O
has	O
put	O
the	O
world	O
on	O
alert	O
.	O

The	O
role	O
of	O
fibrinolytic	O
components	O
such	O
as	O
Urokinase	O
Plasminogen	O
activator	O
(	O
uPA	O
),	O
uPA	O
receptor	O
(	O
uPAR	O
)	O
and	O
Plasminogen	O
activator	O
inhibitor	B-CHED
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
has	O
been	O
detailed	O
in	O
I	O
.	O
Curcumin	B-CHED
is	O
known	O
to	O
possess	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
fibrotic	O
effects	O
.	O

Whether	O
GX_P2X	O
uses	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
as	O
the	O
cell	O
receptor	O
was	O
investigated	O
by	O
using	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
-	O
mediated	O
silencing	O
of	O
ACE2	O
.	O

Furthermore	O
,	O
we	O
found	O
CEP	O
has	O
potent	O
antiviral	B-CHED
activities	O
against	O
both	O
viral	O
entry	O
(	O
1	O
.	O
00	O
	O
0	O
.	O
37	O
vs	O
.	O
0	O
.	O
46	O
	O
0	O
.	O
12	O
,	O
t	O
=	O
2	O
.	O
42	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
viral	O
replication	O
(	O
1	O
.	O
00	O
	O
0	O
.	O
43	O
vs	O
.	O
[	O
6	O
.	O
18	O
	O
0	O
.	O
95	O
]	O
	O
10	O
,	O
t	O
=	O
3	O
.	O
98	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

CEP	O
,	O
selamectin	O
and	O
mefloquine	B-CHED
hydrochloride	B-CHED
are	O
potential	O
drugs	O
for	O
treating	O
2019	O
-	O
nCoV	O
infection	O
.	O

The	O
effectiveness	O
of	O
adjunctive	O
glucocorticoid	B-CHED
therapy	O
uses	O
in	O
the	O
management	O
of	O
2019	O
-	O
nCoV	O
infected	O
patients	O
with	O
severe	O
lower	O
respiratory	O
tract	O
infections	O
is	O
not	O
clear	O
,	O
and	O
warrants	O
further	O
investigation	O
.	O

Each	O
eligible	O
subject	O
will	O
be	O
assigned	O
to	O
an	O
intervention	O
group	O
(	O
methylprednisolone	B-CHED
via	O
intravenous	O
injection	O
at	O
a	O
dose	O
of	O
1	O
-	O
2mg	O
/	O
kg	O
/	O
day	O
for	O
3	O
days	O
)	O
or	O
a	O
control	O
group	O
(	O
no	O
glucocorticoid	B-CHED
use	O
)	O
randomly	O
,	O
at	O
a	O
1	O
:	O
1	O
ratio	O
.	O

ABSTRACT	O
:	O
We	O
developed	O
and	O
validated	O
2	O
species	O
-	O
independent	O
protein	B-CHED
-	O
based	O
assays	O
to	O
detect	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
functional	O
antibodies	O
that	O
can	O
block	O
virus	O
receptor	O
-	O
binding	O
or	O
sialic	B-CHED
acid	I-CHED
-	O
attachment	O
.	O

MiRNAs	O
contribute	O
to	O
RNA	O
virus	O
pathogenesis	O
by	O
promoting	O
antiviral	B-CHED
immune	O
response	O
,	O
enhancing	O
viral	O
replication	O
,	O
or	O
altering	O
miRNA	O
-	O
mediated	O
host	O
gene	O
regulation	O
.	O

Pharyngeal	O
swab	O
specimens	O
were	O
collected	O
from	O
9	O
of	O
the	O
10	O
neonates	O
1	O
to	O
9	O
days	O
after	O
birth	O
for	O
nucleic	B-CHED
acid	I-CHED
amplification	O
tests	O
for	O
2019	O
-	O
nCoV	O
,	O
all	O
of	O
which	O
showed	O
negative	O
results	O
.	O

Three	O
days	O
later	O
,	O
levofloxacin	B-CHED
was	O
started	O
because	O
the	O
patient	O
	O
s	O
symptoms	O
did	O
not	O
improve	O
.	O

The	O
genome	O
composition	O
,	O
nucleotide	B-CHED
analysis	O
,	O
codon	O
usage	O
indices	O
,	O
relative	O
synonymous	O
codons	O
usage	O
,	O
and	O
effective	O
number	O
of	O
codons	O
(	O
ENc	O
)	O
were	O
analyzed	O
in	O
the	O
four	O
structural	O
genes	O
;	O
Spike	O
(	O
S	O
),	O
Envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
),	O
and	O
Nucleocapsid	O
(	O
N	O
)	O
genes	O
,	O
and	O
two	O
of	O
the	O
most	O
important	O
nonstructural	O
genes	O
comprising	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
and	O
main	O
protease	O
(	O
Mpro	O
)	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
Beta	O
-	O
CoV	O
from	O
pangolins	O
,	O
bat	O
SARS	O
,	O
MERS	O
,	O
and	O
SARS	O
CoVs	O
.	O

This	O
implies	O
higher	O
codon	O
bias	O
and	O
higher	O
gene	O
expression	O
efficiency	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
structural	O
proteins	B-CHED
.	O

Preparing	O
for	O
a	O
potential	O
infectious	O
disease	O
pandemic	O
from	O
influenza	O
or	O
a	O
novel	O
corona	B-CHED
virus	O
is	O
an	O
essential	O
component	O
of	O
a	O
business	O
continuity	O
plan	O
,	O
especially	O
for	O
businesses	O
that	O
provide	O
critical	O
healthcare	O
and	O
infrastructure	O
services	O
.	O

ABSTRACT	O
:	O
Studies	O
have	O
reminded	O
that	O
cardiovascular	O
metabolic	O
comorbidities	O
made	O
patients	O
more	O
susceptible	O
to	O
suffer	O
2019	O
novel	O
corona	B-CHED
virus	O
(	O
2019	O
-	O
nCoV	O
)	O
disease	O
(	O
COVID	O
-	O
19	O
),	O
and	O
exacerbated	O
the	O
infection	O
.	O

According	O
to	O
AllerHunter	O
results	O
,	O
all	O
those	O
selected	O
different	O
protein	B-CHED
showed	O
non	O
-	O
allergen	B-CHED
;	O
this	O
finding	O
makes	O
this	O
computational	O
vaccine	O
study	O
more	O
desirable	O
for	O
vaccine	O
synthesis	O
.	O

With	O
use	O
of	O
this	O
comprehensive	O
and	O
rapid	O
test	O
,	O
improved	O
patient	O
outcomes	O
and	O
antimicrobial	B-CHED
stewardship	O
may	O
potentially	O
be	O
achieved	O
.	O

Drugs	O
are	O
possibly	O
effective	O
for	O
2019	O
-	O
nCoV	O
include	O
:	O
remdesivir	O
,	O
lopinavir	O
/	O
ritonavir	B-CHED
,	O
lopinavir	O
/	O
ritonavir	B-CHED
combined	O
with	O
interferon	O
-	O
	O
,	O
convalescent	O
plasma	O
,	O
and	O
monoclonal	O
antibodies	O
.	O

TITLE	O
:	O
COVID	O
-	O
19	O
:	O
An	O
Update	O
on	O
the	O
Epidemiological	O
,	O
Clinical	O
,	O
Preventive	O
and	O
Therapeutic	O
Evidence	O
and	O
Guidelines	O
of	O
Integrative	O
Chinese	O
-	O
Western	O
Medicine	B-CHED
for	O
the	O
Management	O
of	O
2019	O
Novel	O
Coronavirus	O
Disease	O
.	O

In	O
China	O
,	O
Chinese	O
medicine	B-CHED
is	O
proposed	O
as	O
a	O
treatment	O
option	O
by	O
national	O
and	O
provincial	O
guidelines	O
with	O
substantial	O
utilization	O
.	O

We	O
here	O
report	O
the	O
case	O
of	O
an	O
81	O
-	O
year	O
-	O
old	O
male	O
subject	O
affected	O
by	O
a	O
multifactorial	O
DAH	O
,	O
in	O
which	O
the	O
bleeding	O
was	O
related	O
to	O
the	O
administration	O
of	O
clopidogrel	B-CHED
and	O
warfarin	B-CHED
,	O
both	O
implicated	O
in	O
the	O
context	O
of	O
a	O
polycythaemia	O
.	O

The	O
S1	O
domain	O
of	O
the	O
spike	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
attaches	O
the	O
virus	O
to	O
its	O
cellular	O
receptor	O
ACE2	O
on	O
the	O
host	O
cells	O
.	O

TITLE	O
:	O
An	O
exclusive	O
42	O
amino	B-CHED
acid	I-CHED
signature	O
in	O
pp1ab	O
protein	B-CHED
provides	O
insights	O
into	O
the	O
evolutive	O
history	O
of	O
the	O
2019	O
novel	O
human	O
-	O
pathogenic	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
-	O
2	O
).	O

Our	O
results	O
suggest	O
that	O
theaflavin	O
could	O
be	O
a	O
potential	O
SARS	O
-	O
CoV	O
-	O
2	O
RdRp	O
inhibitor	B-CHED
for	O
further	O
study	O
.	O

At	O
present	O
,	O
the	O
sensitivity	O
of	O
clinical	O
nucleic	B-CHED
acid	I-CHED
detection	O
is	O
limited	O
,	O
and	O
it	O
is	O
still	O
unclear	O
whether	O
it	O
is	O
related	O
to	O
genetic	O
variation	O
.	O

In	O
a	O
short	O
time	O
following	O
the	O
outbreak	O
,	O
it	O
has	O
been	O
shown	O
that	O
,	O
similar	O
to	O
SARS	O
-	O
CoV	O
,	O
COVID	O
-	O
19	O
virus	O
exploits	O
the	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
receptor	O
to	O
gain	O
entry	O
inside	O
the	O
cells	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
density	O
of	O
the	O
expression	O
levels	O
of	O
ACE2	O
in	O
the	O
CNS	B-CHED
,	O
the	O
host	O
-	O
virus	O
interaction	O
and	O
relate	O
it	O
to	O
the	O
pathogenesis	O
and	O
complications	O
seen	O
in	O
the	O
recent	O
cases	O
resulting	O
from	O
the	O
COVID	O
-	O
19	O
outbreak	O
.	O

Protein	B-CHED
-	O
protein	B-CHED
docking	O
was	O
performed	O
to	O
test	O
the	O
four	O
regions	O
of	O
the	O
spike	O
that	O
fit	O
tightly	O
in	O
the	O
GRP78	O
Substrate	O
Binding	O
Domain	O
	O
(	O
SBD	O
).	O

Here	O
we	O
report	O
the	O
first	O
family	O
case	O
of	O
coronavirus	O
disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
confirmed	O
in	O
Wuhan	O
and	O
treated	O
using	O
the	O
combination	O
of	O
western	O
medicine	B-CHED
and	O
Chinese	O
traditional	O
patent	O
medicine	B-CHED
Shuanghuanglian	O
oral	O
liquid	O
(	O
SHL	O
).	O

The	O
four	O
datasets	O
we	O
fitted	O
to	O
were	O
:	O
daily	O
number	O
of	O
new	O
internationally	O
exported	O
cases	O
(	O
or	O
lack	O
thereof	O
),	O
by	O
date	O
of	O
onset	O
,	O
as	O
of	O
Jan	O
26	O
,	O
2020	O
;	O
daily	O
number	O
of	O
new	O
cases	O
in	O
Wuhan	O
with	O
no	O
market	O
exposure	O
,	O
by	O
date	O
of	O
onset	O
,	O
between	O
Dec	B-CHED
1	O
,	O
2019	O
,	O
and	O
Jan	O
1	O
,	O
2020	O
;	O
daily	O
number	O
of	O
new	O
cases	O
in	O
China	O
,	O
by	O
date	O
of	O
onset	O
,	O
between	O
Dec	B-CHED
29	O
,	O
2019	O
,	O
and	O
Jan	O
23	O
,	O
2020	O
;	O
and	O
proportion	O
of	O
infected	O
passengers	O
on	O
evacuation	O
flights	O
between	O
Jan	O
29	O
,	O
2020	O
,	O
and	O
Feb	O
4	O
,	O
2020	O
.	O

The	O
binding	O
of	O
COVI	O
-	O
19	O
to	O
the	O
Toll	O
Like	O
Receptor	O
(	O
TLR	O
)	O
causes	O
the	O
release	O
of	O
pro	B-CHED
-	O
IL	O
-	O
1	O
which	O
is	O
cleaved	O
by	O
caspase	O
-	O
1	O
,	O
followed	O
by	O
inflammasome	O
activation	O
and	O
production	O
of	O
active	O
mature	O
IL	O
-	O
1	O
which	O
is	O
a	O
mediator	O
of	O
lung	O
inflammation	O
,	O
fever	O
and	O
fibrosis	O
.	O

The	O
efforts	O
of	O
international	O
health	O
authorities	O
have	O
since	O
focused	O
on	O
rapid	O
diagnosis	O
and	O
isolation	O
of	O
patients	O
as	O
well	O
as	O
the	O
search	O
for	O
therapies	O
able	O
to	O
counter	B-CHED
the	O
most	O
severe	O
effects	O
of	O
the	O
disease	O
.	O

TITLE	O
:	O
A	O
tug	O
-	O
of	O
-	O
war	O
between	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
2	O
and	O
host	O
antiviral	B-CHED
defence	O
:	O
lessons	O
from	O
other	O
pathogenic	O
viruses	O
.	O

Increasing	O
eosinophils	O
may	O
be	O
an	O
indicator	B-CHED
of	O
COVID	O
-	O
19	O
improvement	O
.	O

Compared	O
with	O
general	O
COVID	O
-	O
19	O
patients	O
(	O
45	O
.	O
2	O
%),	O
refractory	O
patients	O
had	O
an	O
older	O
age	O
,	O
male	O
sex	O
,	O
more	O
underlying	O
comorbidities	O
,	O
lower	O
incidence	O
of	O
fever	O
,	O
higher	O
levels	O
of	O
maximum	O
temperature	O
among	O
fever	O
cases	O
,	O
higher	O
incidence	O
of	O
breath	O
shortness	O
and	O
anorexia	O
,	O
severer	O
disease	O
assessment	O
on	O
admission	O
,	O
high	O
levels	O
of	O
neutrophil	O
,	O
aspartate	B-CHED
aminotransferase	O
(	O
AST	O
),	O
lactate	B-CHED
dehydrogenase	O
(	O
LDH	O
)	O
and	O
C	O
-	O
reactive	O
protein	B-CHED
,	O
lower	O
levels	O
of	O
platelets	O
and	O
albumin	O
,	O
and	O
higher	O
incidence	O
of	O
bilateral	O
pneumonia	O
and	O
pleural	O
effusion	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

After	O
adjustment	O
,	O
those	O
with	O
refractory	O
COVID	O
-	O
19	O
were	O
also	O
more	O
likely	O
to	O
have	O
a	O
male	O
sex	O
and	O
manifestations	O
of	O
anorexia	O
and	O
fever	O
on	O
admission	O
,	O
and	O
receive	O
oxygen	B-CHED
,	O
expectorant	O
and	O
adjunctive	O
agents	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
when	O
considering	O
the	O
factors	O
of	O
disease	O
severity	O
on	O
admission	O
,	O
mechanical	O
ventilation	O
,	O
and	O
ICU	O
transfer	O
.	O

ABSTRACT	O
:	O
The	O
Corona	B-CHED
Virus	O
Disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
outbroke	O
in	O
Wuhan	O
,	O
China	O
in	O
December	O
2019	O
and	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
outbroke	O
in	O
Guangzhou	O
,	O
China	O
in	O
2003	O
were	O
caused	O
by	O
highly	O
pathogenic	O
coronaviruses	O
with	O
high	O
homology	O
.	O

We	O
also	O
predict	O
the	O
unique	O
N	O
-	O
and	O
O	O
-	O
linked	O
glycosylation	O
sites	O
of	O
spike	O
glycoprotein	B-CHED
that	O
distinguish	O
it	O
from	O
the	O
SARS	O
and	O
underlines	O
shielding	O
and	O
camouflage	O
of	O
COVID	O
-	O
19	O
from	O
the	O
host	O
the	O
defence	O
system	O
.	O

Chloroquine	B-CHED
,	O
remdesivir	O
,	O
lopinavir	O
,	O
ribavirin	B-CHED
or	O
ritonavir	B-CHED
have	O
shown	O
efficacy	O
to	O
inhibit	O
coronavirus	O
in	O
vitro	O
.	O

Their	O
epidemiologic	O
history	O
,	O
chest	O
computed	O
tomography	O
scans	O
,	O
laboratory	O
measurements	O
,	O
and	O
SARS	O
-	O
CoV	O
-	O
2	O
nucleic	B-CHED
acid	I-CHED
positivity	O
were	O
evaluated	O
.	O

TITLE	O
:	O
Platelet	O
-	O
to	O
-	O
lymphocyte	O
ratio	O
is	O
associated	O
with	O
prognosis	O
in	O
patients	O
with	O
Corona	B-CHED
Virus	O
Disease	O
-	O
19	O
.	O

Single	O
-	O
center	O
case	O
series	O
of	O
the	O
30	O
hospitalized	O
patients	O
with	O
confirmed	O
Corona	B-CHED
Virus	O
Disease	O
(	O
COVID	O
)-	O
19	O
in	O
Huizhou	O
municipal	O
central	O
hospitalfrom	O
January	O
2020	O
to	O
February	O
2020	O
were	O
retrospectively	O
analysed	O
.	O

NETs	O
include	O
a	O
DNA	O
backbone	O
coated	O
with	O
cytoplasmic	O
proteins	B-CHED
,	O
which	O
drive	O
pulmonary	O
cytotoxic	O
effects	O
.	O

The	O
study	O
was	O
approved	O
by	O
both	O
the	O
Agence	O
Nationale	O
de	O
la	O
Scurit	O
du	O
Mdicament	O
et	O
des	B-CHED
Produits	O
de	O
Sant	O
(	O
ANSM	O
,	O
on	O
5	O
October	O
2018	O
)	O
and	O
a	O
National	O
Institutional	O
Review	O
Board	O
(	O
CPP	O
,	O
on	O
6	O
November	O
2018	O
).	O

Treatment	O
with	O
lopinavir	O
-	O
ritonavir	B-CHED
was	O
not	O
associated	O
with	O
a	O
difference	O
from	O
standard	O
care	O
in	O
the	O
time	O
to	O
clinical	O
improvement	O
(	O
hazard	O
ratio	O
for	O
clinical	O
improvement	O
,	O
1	O
.	O
24	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
0	O
.	O
90	O
to	O
1	O
.	O
72	O
).	O

ABSTRACT	O
:	O
The	O
reliable	O
detection	O
of	O
transcription	O
events	O
via	O
the	O
quantification	O
of	O
the	O
corresponding	O
mRNA	B-CHED
is	O
of	O
paramount	O
importance	O
for	O
the	O
diagnostics	O
of	O
infections	O
and	O
diseases	O
.	O

PLP2	O
acts	O
as	O
a	O
protease	O
that	O
cleaves	O
the	O
viral	O
replicase	O
polyprotein	O
,	O
and	O
a	O
deubiquitinating	O
(	O
DUB	O
)	O
enzyme	O
which	O
removes	O
ubiquitin	O
moieties	O
from	O
ubiquitin	O
-	O
conjugated	B-CHED
proteins	I-CHED
.	O

ABSTRACT	O
:	O
Coronaviruses	O
encode	O
multiple	O
interferon	O
antagonists	B-CHED
that	O
modulate	O
the	O
host	O
response	O
to	O
virus	O
replication	O
.	O

Departments	O
of	O
Anaesthesia	O
,	O
Intensive	O
Care	O
and	O
emergency	O
medicine	B-CHED
will	O
envisage	O
major	O
challenges	O
.	O

By	O
summarizing	O
the	O
research	O
progress	O
and	O
guidelines	O
in	O
recent	O
years	O
in	O
the	O
fields	O
of	O
colorectal	O
cancer	O
disease	O
screening	O
,	O
treatment	O
strategies	O
(	O
including	O
early	O
colorectal	O
cancer	O
,	O
locally	O
advanced	O
colorectal	O
cancer	O
,	O
obstructive	O
colorectal	O
cancer	O
,	O
metastatic	O
colorectal	O
cancer	O
and	O
the	O
treatment	O
of	O
patients	O
after	O
neoadjuvant	O
therapy	O
),	O
the	O
choice	O
of	O
medication	O
and	O
time	O
limit	O
for	O
adjuvant	B-CHED
therapy	O
,	O
the	O
protective	O
measures	O
for	O
patients	O
undergoing	O
emergency	O
surgery	O
,	O
the	O
re	O
-	O
examination	O
of	O
postoperative	O
patients	O
and	O
the	O
protection	O
of	O
medical	O
staff	O
,	O
etc	O
.,	O
authors	O
improve	O
treatment	O
strategies	O
in	O
order	O
to	O
provide	O
more	O
choices	O
for	O
patients	O
to	O
obtain	O
the	O
best	O
treatment	O
under	O
the	O
severe	O
epidemic	O
situation	O
of	O
new	O
coronavirus	O
pneumonia	O
.	O

Based	O
on	O
our	O
experience	O
with	O
laparoscopic	O
colorectal	O
operation	O
,	O
we	O
propose	O
some	O
surgery	O
strategies	O
for	O
colorectal	O
cancer	O
patients	O
under	O
the	O
corona	B-CHED
virus	O
disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
situation	O
:	O
the	O
screening	O
process	O
should	O
be	O
strictly	O
carried	O
out	O
before	O
surgery	O
to	O
reduce	O
the	O
risk	O
of	O
nosocomial	O
infection	O
in	O
the	O
later	O
stage	O
;	O
laparoscopic	O
-	O
assisted	O
surgery	O
is	O
recommended	O
for	O
radical	B-CHED
surgery	O
for	O
patients	O
with	O
colorectal	O
cancer	O
;	O
strict	O
aerosol	O
management	O
must	O
be	O
made	O
during	O
the	O
operation	O
;	O
natural	O
orifice	O
specimen	O
extraction	O
surgery	O
and	O
transanal	O
total	O
mesorectal	O
excision	O
are	O
should	O
be	O
performed	O
prudently	O
;	O
scientific	O
and	O
reasonable	O
prophylactic	O
stoma	O
should	O
be	O
done	O
;	O
personnel	O
protection	O
in	O
surgical	O
ward	O
and	O
operation	O
room	O
must	O
be	O
strengthened	O
.	O

TITLE	O
:	O
Investigation	O
of	O
three	O
clusters	B-CHED
of	O
COVID	O
-	O
19	O
in	O
Singapore	O
:	O
implications	O
for	O
surveillance	O
and	O
response	O
measures	O
.	O

Based	O
on	O
the	O
high	O
-	O
homology	O
between	O
the	O
Spike	O
protein	B-CHED
epitopes	O
of	O
taxonomically	O
-	O
related	O
coronaviruses	O
,	O
we	O
hypothesized	O
that	O
past	O
contact	O
with	O
infected	O
dogs	O
shield	O
humans	O
against	O
the	O
circulating	O
SARS	O
-	O
CoV	O
-	O
2	O
.	O

Path	O
analysis	O
was	O
performed	O
to	O
evaluate	O
the	O
relationships	O
between	O
a	O
dependent	O
variable	O
(	O
social	O
capital	O
)	O
and	O
two	O
or	O
more	O
independent	O
variables	O
,	O
using	O
Pearson	O
'	O
s	O
correlation	O
analysis	O
and	O
structural	O
equation	O
modeling	O
(	O
SEM	B-CHED
).	O

Phylogenetic	O
analyses	O
of	O
15	O
HCoV	O
whole	O
genomes	O
reveal	O
that	O
2019	O
-	O
nCoV	O
/	O
SARS	O
-	O
CoV	O
-	O
2	O
shares	O
the	O
highest	O
nucleotide	B-CHED
sequence	O
identity	O
with	O
SARS	O
-	O
CoV	O
(	O
79	O
.	O
7	O
%).	O

TITLE	O
:	O
Identifying	O
Septic	O
Shock	O
Populations	O
Benefitting	O
from	O
Polymyxin	B-CHED
B	I-CHED
Hemoperfusion	O
:	O
A	O
Prospective	O
Cohort	O
Study	O
Incorporating	O
a	O
Restricted	O
Cubic	O
Spline	O
Regression	O
Model	O
.	O

DIAGNOSIS	O
::	O
Three	O
patients	O
diagnosed	O
SJS	O
/	O
TEN	O
with	O
clinical	O
symptoms	O
that	O
were	O
triggered	O
by	O
antibiotics	B-CHED
,	O
nonsteroidal	O
anti	B-CHED
-	I-CHED
inflammatory	I-CHED
drugs	I-CHED
,	O
previous	O
infection	O
,	O
or	O
neoplasms	O
.	O

The	O
aim	O
of	O
the	O
present	O
review	O
of	O
the	O
European	O
Dialysis	O
(	O
EUDIAL	O
)	O
Working	O
Group	O
of	O
ERA	B-CHED
-	O
EDTA	B-CHED
is	O
to	O
provide	O
recommendations	O
for	O
the	O
prevention	O
,	O
mitigation	O
and	O
containment	O
in	O
haemodialysis	O
centres	O
of	O
the	O
emerging	O
COVID	O
-	O
19	O
pandemic	O
.	O

Three	O
patients	O
were	O
treated	O
with	O
glucocorticoids	B-CHED
including	O
two	O
treated	O
with	O
oral	O
glucocorticoids	B-CHED
.	O

Five	O
key	O
amino	B-CHED
acid	I-CHED
residues	O
involved	O
in	O
the	O
interaction	O
with	O
human	O
ACE2	O
are	O
completely	O
consistent	O
between	O
Pangolin	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
but	O
four	O
amino	B-CHED
acid	I-CHED
mutations	O
are	O
present	O
in	O
RaTG13	O
.	O

Angiotensin	B-CHED
receptor	O
blockers	O
and	O
statins	O
upregulate	O
ACE2	O
.	O

Current	O
method	O
of	O
detection	O
involves	O
qPCR	O
-	O
based	O
technique	O
,	O
which	O
identifies	O
the	O
viral	O
nucleic	B-CHED
acids	I-CHED
when	O
present	O
in	O
sufficient	O
quantity	O
.	O

It	O
is	O
suggested	O
that	O
patients	O
should	O
receive	O
Kaletra	O
early	O
and	O
should	O
be	O
treated	O
by	O
a	O
combination	O
of	O
western	O
and	O
Chinese	O
medicine	B-CHED
.	O

ABSTRACT	O
:	O
Since	O
2003	O
,	O
coronavirus	O
has	O
caused	O
multiple	O
major	O
public	O
health	O
events	O
that	O
resulted	O
in	O
global	O
epidemics	O
such	O
as	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
	O
SARS	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
	O
MERS	O
	O
and	O
corona	B-CHED
virus	O
disease	O
2019	O
	O
COVID	O
-	O
19	O
.	O

Angiotensin	B-CHED
I	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
is	O
the	O
host	O
receptor	O
by	O
SARS	O
-	O
CoV	O
-	O
2	O
to	O
infect	O
human	O
cells	O
.	O

We	O
identified	O
that	O
N82	O
in	O
ACE2	O
showed	O
a	O
closer	O
contact	O
with	O
SARS	O
-	O
CoV	O
-	O
2	O
S	O
protein	B-CHED
than	O
M82	O
in	O
human	O
ACE2	O
.	O

TITLE	O
:	O
Post	O
-	O
translational	O
modifications	O
of	O
coronavirus	O
proteins	B-CHED
:	O
roles	O
and	O
function	O
.	O

The	O
ability	O
of	O
some	O
CoV	O
proteins	B-CHED
to	O
interfere	O
with	O
PTMs	O
of	O
host	O
proteins	B-CHED
will	O
also	O
be	O
discussed	O
.	O

An	O
activated	O
STAT3	O
translocates	O
into	O
the	O
nucleus	B-CHED
and	O
combines	O
with	O
DNA	O
to	O
regulate	O
the	O
expression	O
of	O
target	O
genes	O
involved	O
in	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
apoptosis	O
and	O
metastasis	O
.	O

TITLE	O
:	O
Membrane	O
binding	O
proteins	B-CHED
of	O
coronaviruses	O
.	O

HCoVs	O
need	O
host	O
cell	O
proteins	B-CHED
to	O
successively	O
establish	O
infections	O
.	O

Based	O
on	O
our	O
collective	O
experience	O
,	O
we	O
discuss	O
mitigation	O
strategies	O
such	O
as	O
donor	B-CHED
screening	O
,	O
resource	O
planning	O
and	O
a	O
staged	O
approach	O
to	O
transplant	O
volume	O
considerations	O
as	O
local	O
resource	O
issues	O
demand	O
.	O

SARS	O
-	O
CoV	O
RBD	O
-	O
specific	O
antibodies	O
could	O
cross	O
-	O
react	O
with	O
SARS	O
-	O
CoV	O
-	O
2	O
RBD	O
protein	B-CHED
,	O
and	O
SARS	O
-	O
CoV	O
RBD	O
-	O
induced	O
antisera	O
could	O
cross	O
-	O
neutralize	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
suggesting	O
the	O
potential	O
to	O
develop	O
SARS	O
-	O
CoV	O
RBD	O
-	O
based	O
vaccines	O
for	O
prevention	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
and	O
SARS	O
-	O
CoV	O
infection	O
.	O

Approaching	O
to	O
treat	O
severe	O
respiratory	O
disease	O
in	O
infants	O
and	O
children	O
,	O
the	O
risks	O
related	O
to	O
the	O
development	O
of	O
atelectasis	O
starting	O
invasive	O
or	O
non	O
-	O
invasive	O
ventilation	O
support	O
and	O
the	O
risk	O
of	O
oxygen	B-CHED
toxicity	O
must	O
be	O
taken	O
into	O
serious	O
consideration	O
.	O

A	O
retrospective	O
analysis	O
was	O
performed	O
for	O
the	O
clinical	O
data	O
and	O
chest	O
CT	O
images	O
of	O
9	O
children	O
,	O
aged	O
0	O
to	O
3	O
years	O
,	O
who	O
were	O
diagnosed	O
with	O
COVID	O
-	O
19	O
by	O
nucleic	B-CHED
acid	I-CHED
detection	O
between	O
January	O
20	O
and	O
February	O
10	O
,	O
2020	O
.	O

Infants	O
and	O
young	O
children	O
with	O
COVID	O
-	O
19	O
tend	O
to	O
have	O
mild	O
clinical	O
symptoms	O
and	O
imaging	O
findings	O
not	O
as	O
typical	O
as	O
those	O
of	O
adults	O
,	O
and	O
therefore	O
,	O
the	O
diagnosis	O
of	O
COVID	O
-	O
19	O
should	O
be	O
made	O
based	O
on	O
imaging	O
findings	O
along	O
with	O
epidemiological	O
history	O
and	O
nucleic	B-CHED
acid	I-CHED
detection	O
.	O

Pro	B-CHED
-	O
inflammatory	O
cytokine	O
expression	O
levels	O
upon	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
in	O
Huh	O
-	O
7	O
cells	O
were	O
measured	O
by	O
real	O
-	O
time	O
quantitative	O
PCR	O
assays	O
.	O

RESULTS	O
:	O
LH	O
significantly	O
inhibited	O
SARS	O
-	O
CoV	O
-	O
2	O
replication	O
in	O
Vero	O
E6	O
cells	O
and	O
markedly	O
reduced	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
(	O
TNF	O
-	O
	O
,	O
IL	O
-	O
6	O
,	O
CCL	B-CHED
-	O
2	O
/	O
MCP	B-CHED
-	O
1	O
and	O
CXCL	O
-	O
10	O
/	O
IP	O
-	O
10	O
)	O
production	O
at	O
the	O
mRNA	B-CHED
levels	O
.	O

TITLE	O
:	O
Tilorone	O
:	O
A	O
Broad	O
-	O
Spectrum	O
Antiviral	B-CHED
For	O
Emerging	O
Viruses	O
.	O

CoV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
which	O
is	O
crucial	O
for	O
receptor	O
binding	O
,	O
membrane	O
fusion	O
via	O
conformational	O
changes	O
,	O
internalization	O
of	O
the	O
virus	O
,	O
host	O
tissue	O
tropism	O
and	O
comprises	O
crucial	O
targets	O
for	O
vaccine	O
development	O
,	O
remain	O
largely	O
uncharacterized	O
.	O

The	O
structural	O
divergence	O
was	O
determined	O
by	O
using	O
SuperPose	O
Version	O
1	O
.	O
0	O
based	O
on	O
cryo	O
-	O
EM	O
structure	O
of	O
the	O
SARS	O
coronavirus	O
spike	O
glycoprotein	B-CHED
.	O

Moreover	O
,	O
there	O
are	O
no	O
data	O
to	O
support	O
the	O
notion	O
that	O
ACE	B-CHED
inhibitor	I-CHED
or	O
angiotensin	B-CHED
II	I-CHED
type	O
1	O
receptor	O
blocker	O
administration	O
facilitates	O
coronavirus	O
entry	O
by	O
increasing	O
ACE2	O
expression	O
in	O
either	O
animals	O
or	O
humans	O
.	O

Neutralising	O
antibody	O
response	O
appeared	O
within	O
9	O
days	O
along	O
with	O
specific	O
IgM	O
and	O
IgG	O
response	O
,	O
targeting	O
particularly	O
nucleocapsid	O
and	O
spike	O
proteins	B-CHED
.	O

The	O
blood	O
oxygen	B-CHED
saturation	O
was	O
significantly	O
lower	O
in	O
the	O
death	O
group	O
(	O
85	O
[	O
77	O
,	O
91	O
]%	O
vs	O
.	O
97	O
[	O
95	O
,	O
98	O
]%,	O
Z	O
=	O
10	O
.	O
625	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Microscopic	O
analysis	O
revealed	O
diffuse	O
filamentous	O
fungi	O
throughout	O
the	O
lungs	O
,	O
heart	O
,	O
stomach	O
,	O
thyroid	O
gland	O
,	O
and	O
the	O
pulmonary	O
embolus	O
,	O
which	O
were	O
identified	O
as	O
Invasive	O
aspergillosis	O
should	O
also	O
be	O
considered	O
in	O
immunocompetent	O
patients	O
with	O
severe	O
respiratory	O
failure	O
after	O
non	O
-	O
fatal	O
drowning	O
who	O
do	O
not	O
respond	O
to	O
broad	O
-	O
spectrum	O
antibiotics	B-CHED
.	O

TITLE	O
:	O
Unrevealing	O
sequence	O
and	O
structural	O
features	O
of	O
novel	O
coronavirus	O
using	O
ABSTRACT	O
:	O
Direct	O
-	O
acting	O
antivirals	B-CHED
are	O
effective	O
tools	O
to	O
control	O
viral	O
infections	O
.	O

Changes	O
in	O
the	O
viral	O
proteins	B-CHED
that	O
function	O
as	O
ligands	O
of	O
the	O
host	O
receptor	O
may	O
promote	O
the	O
spillover	O
between	O
species	O
.	O

TITLE	O
:	O
Inflammatory	O
bowel	O
disease	O
care	O
in	O
the	O
COVID	O
-	O
19	O
pandemic	O
era	B-CHED
:	O
the	O
Humanitas	O
,	O
Milan	O
experience	O
.	O

As	O
the	O
number	O
of	O
imported	O
SARS	O
-	O
CoV	O
-	O
2	O
cases	O
is	O
on	O
the	O
rise	O
in	O
Brazil	O
,	O
we	O
use	O
incidence	O
and	O
historical	O
air	B-CHED
travel	O
data	O
to	O
estimate	O
the	O
most	O
important	O
routes	O
of	O
importation	O
into	O
the	O
country	O
.	O

Healthcare	O
personnel	O
(	O
HCP	B-CHED
)	O
nationwide	O
are	O
facing	O
heavy	O
workloads	O
and	O
high	O
risk	O
of	O
infection	O
,	O
especially	O
those	O
who	O
care	O
for	O
patients	O
at	O
the	O
epicenter	O
of	O
the	O
outbreak	O
,	O
Hubei	O
Province	O
.	O

TITLE	O
:	O
Coronavirus	O
(	O
Covid	O
-	O
19	O
)	O
outbreak	O
on	O
the	O
cruise	O
ship	O
Diamond	B-CHED
Princess	O
.	O

